<SEC-DOCUMENT>0001178913-26-001581.txt : 20260323
<SEC-HEADER>0001178913-26-001581.hdr.sgml : 20260323
<ACCEPTANCE-DATETIME>20260323070907
ACCESSION NUMBER:		0001178913-26-001581
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		111
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260323
DATE AS OF CHANGE:		20260323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioLineRx Ltd.
		CENTRAL INDEX KEY:			0001498403
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35223
		FILM NUMBER:		26779874

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		2 HAMAAYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		PROVINCE COUNTRY:   	L3
		ZIP:			ISRAEL
		BUSINESS PHONE:		972-8-642-9100

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		2 HAMAAYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		PROVINCE COUNTRY:   	L3
		ZIP:			ISRAEL

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioLineRX, Ltd.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>zk2634707.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" xmlns:amli="http://www.americanlithiumcorp.com/20250229" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:cyd-af="http://xbrl.sec.gov/cyd-af/2025" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2025" xmlns:blrx="http://biolinerx.com/20251231"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>BioLineRx Ltd. - 1498403 - 2026</title></head><body style="font-size:10pt;font-family:Times New Roman, Times, serif;"><div style="font-size: 10pt;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20250101to20251231" id="Fdei_EntityCentralIndexKey20211006175904255">0001498403</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20250101to20251231" id="Fdei_AmendmentFlag20211006180939012">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20250101to20251231" id="Fdei_DocumentFiscalPeriodFocus20211006181124979">FY</ix:nonNumeric><ix:nonFraction name="blrx:NumberOfSegments" contextRef="C_20250101to20251231" id="Fxbrl_20250327041154148" unitRef="Segment" scale="0" decimals="0">1</ix:nonFraction><ix:nonFraction name="blrx:CommitmentsAndContingentLiabilities" contextRef="C_20251231" id="Fxbrl_20260317100008074_20211006114529300_39" unitRef="USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="blrx:CommitmentsAndContingentLiabilities" contextRef="C_20241231" id="Fxbrl_20260317100008074_20211006114529300_38" unitRef="USD" xsi:nil="true"></ix:nonFraction></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="blrx-20251231.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20250101to20251231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260308"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-03-08</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AssetTransferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="blrx:CollaborationTransactionAxis">blrx:HemispherianAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:TetragonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AssetTransferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="blrx:CollaborationTransactionAxis">blrx:HemispherianAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:TetragonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AssetTransferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="blrx:CollaborationTransactionAxis">blrx:HemispherianAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:TetragonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:SeniorManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:SeniorManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:SeniorManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:DirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:DirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:DirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullBusinessCombinationsAxis_blrxAgalimmuneLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">blrx:AgalimmuneLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullBusinessCombinationsAxis_blrxBiokineTherapeuticsLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullBusinessCombinationsAxis_blrxBiokineTherapeuticsLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullBusinessCombinationsAxis_blrxGlix1Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">blrx:Glix1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_blrxBL8040Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">blrx:BL8040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:TradePayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:OtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:NisLinkedBalancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:EuroLinkedTradePayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:CashAndCashEquivalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:TradePayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:OtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:EuroLinkedTradePayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:DollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:NisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:OtherCurrenciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:DollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:NisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:OtherCurrenciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:NisLinkedBalancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:ShortTermDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_ifrsfullComputerSoftwareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220901to20220930_blrxTrancheAxis_blrxFirstTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:TrancheAxis">blrx:FirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220901to20220930_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210901to20220930_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210901to20220930_ifrsfullRangeAxis_ifrsfullTopOfRangeMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220901to20220930_blrxTrancheAxis_blrxSecondTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:TrancheAxis">blrx:SecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220901to20220930_blrxTrancheAxis_blrxThirdTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:TrancheAxis">blrx:ThirdTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240401to20240430_blrxTrancheAxis_blrxSecondTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:TrancheAxis">blrx:SecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241001to20241231_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxHighbridgeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:HighbridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxRegisteredDirectOfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_blrxPerformanceObligationAxis_blrxSingleMaterialPerformanceObligationMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="blrx:PerformanceObligationAxis">blrx:SingleMaterialPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241001to20241231_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231to20201231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-12-31</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231to20201231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-12-31</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240601to20240630_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullMaturityAxis_blrxFirstThreeYearsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">blrx:FirstThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullMaturityAxis_blrxThreeSubsequentYearsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">blrx:ThreeSubsequentYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullMaturityAxis_blrxSeventhYearMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">blrx:SeventhYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxShareIncentivePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:ShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxShareIncentivePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:ShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200930_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:HCWainwrightAndCoLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:HCWainwrightAndCoLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200901to20200930_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:HCWainwrightAndCoLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:PerformanceSharesUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:PerformanceSharesUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:PerformanceSharesUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:PlacementAgentsDesigneesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:PlacementAgentsDesigneesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-08-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullInitiallyAppliedIFRSsAxis_ifrsfullIncreaseDecreaseDueToApplicationOfIFRS15Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxHighbridgeCapitalManagementLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:HighbridgeCapitalManagementLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxHighbridgeCapitalManagementLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:HighbridgeCapitalManagementLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullCategoriesOfFinancialLiabilitiesAxis_ifrsfullFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250131_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250131_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:PlacementAgentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:PlacementAgentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:HCWainwrightAndCoLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:PerformanceSharesUnitTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:GloriaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-12</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:GloriaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-12</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:GloriaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-12</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:GloriaPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231001to20231231_blrxAgreementTypeAxis_blrxScmLicenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:ScmLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_blrxAgreementTypeAxis_blrxScmSupportServicesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:ScmSupportServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_blrxAgreementTypeAxis_blrxPDACPerformanceObligationMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:PDACPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_blrxAgreementTypeAxis_blrxLicenseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231_blrxAgreementTypeAxis_blrxLicenseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241001to20241231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231001to20231031_blrxAgreementTypeAxis_blrxPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001498403</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:GloriaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:unit id="ILS"><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unit>
<xbrli:unit id="ILS_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Segment"><xbrli:measure>blrx:Segment</xbrli:measure></xbrli:unit>
<xbrli:unit id="Share"><xbrli:measure>blrx:Share</xbrli:measure></xbrli:unit>
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Year"><xbrli:measure>blrx:Year</xbrli:measure></xbrli:unit>
</ix:resources></ix:header></div><div>
  <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/>
  <div>
    <div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">UNITED STATES</span><br/><span style="font-size:14pt">SECURITIES AND EXCHANGE COMMISSION</span></span></div>
    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>WASHINGTON, D.C. 20549</span></span></span></div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:100%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width:100%;vertical-align:top">
            <div style="text-align:center;line-height:1.25;font-weight:bold;font-size:14pt"><span style="font-size:14pt"><span><span style="font-family:Times New Roman,Times,serif"><span>FORM <ix:nonNumeric id="Fxbrl_20230321211828660" name="dei:DocumentType" contextRef="C_20250101to20251231">20-F</ix:nonNumeric></span></span></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:100%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Mark One)</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230321211839260" name="dei:DocumentRegistrationStatement" contextRef="C_20250101to20251231" format="ixt:fixed-false">&#9744;</ix:nonNumeric> REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>OR</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230321211845746" name="dei:DocumentAnnualReport" contextRef="C_20250101to20251231" format="ixt:fixed-true">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>For the fiscal year ended <ix:nonNumeric id="Fxbrl_20230321211855372" name="dei:DocumentPeriodEndDate" contextRef="C_20250101to20251231" format="ixt:date-monthname-day-year-en"><ix:nonNumeric id="Fxbrl_20230321211902964" name="dei:CurrentFiscalYearEndDate" contextRef="C_20250101to20251231" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20230321211913620" name="dei:DocumentFiscalYearFocus" contextRef="C_20250101to20251231">2025</ix:nonNumeric></ix:nonNumeric></span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>OR</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230321211921956" name="dei:DocumentTransitionReport" contextRef="C_20250101to20251231" format="ixt:fixed-false">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>OR</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230321211926964" name="dei:DocumentShellCompanyReport" contextRef="C_20250101to20251231" format="ixt:fixed-false">&#9744;</ix:nonNumeric> SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Date of event requiring this shell company report</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold">For the transition period from</span> __________ to __________</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Commission file number <ix:nonNumeric id="Fxbrl_20230321211936228" name="dei:EntityFileNumber" contextRef="C_20250101to20251231">001-35223</ix:nonNumeric></span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-weight:bold;font-size:16pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230321211942373" name="dei:EntityRegistrantName" contextRef="C_20250101to20251231">BioLineRx Ltd.</ix:nonNumeric></span></div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<span style="font-style:italic">Exact name of Registrant as specified in its charter</span>)</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Translation of Registrant&#8217;s name into English</span></span></span></div>
    <div style="text-align:center;line-height:1.25;font-style:italic">&#160;</div>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:49%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230321211948794" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20250101to20251231" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></span></span></div>
          </td>
          <td style="width:2%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:49%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230321211953973" name="dei:EntityAddressAddressLine1" contextRef="C_20250101to20251231">2 HaMa&#8217;ayan Street</ix:nonNumeric><br/><ix:nonNumeric id="Fxbrl_20230321212003751" name="dei:EntityAddressCityOrTown" contextRef="C_20250101to20251231">Modi&#8217;in</ix:nonNumeric>&#160;<ix:nonNumeric id="Fxbrl_20230321212009869" name="dei:EntityAddressPostalZipCode" contextRef="C_20250101to20251231">7177871</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20230321212015828" name="dei:EntityAddressCountry" contextRef="C_20250101to20251231" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:49%;vertical-align:top">
            <div style="text-align:center;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Jurisdiction of incorporation or organization)</span></span></span></div>
          </td>
          <td style="width:2%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:49%;vertical-align:top">
            <div style="text-align:center;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Address of principal executive offices)</span></span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230321212022686" name="dei:ContactPersonnelName" contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Philip A. Serlin</ix:nonNumeric><br/>+<ix:nonNumeric id="Fxbrl_20230321212032077" name="dei:CityAreaCode" contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">972</ix:nonNumeric> (8) <ix:nonNumeric id="Fxbrl_20230321212037083" name="dei:LocalPhoneNumber" contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">642-9100</ix:nonNumeric><br/>+<ix:nonNumeric id="Fxbrl_20230321212047709" name="dei:ContactPersonnelFaxNumber" contextRef="C_20250101to20251231">972 (8) 642-9101</ix:nonNumeric> (facsimile)<br/><ix:nonNumeric id="Fxbrl_20230321212053828" name="dei:ContactPersonnelEmailAddress" contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">phils@biolinerx.com</ix:nonNumeric><br/><ix:nonNumeric id="Fxbrl_20230321212100284" name="dei:EntityAddressAddressLine1" contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">2 HaMa&#8217;ayan Street</ix:nonNumeric><br/><ix:nonNumeric id="Fxbrl_20230321212105980" name="dei:EntityAddressCityOrTown" contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Modi&#8217;in</ix:nonNumeric>&#160;<ix:nonNumeric id="Fxbrl_20230321212116452" name="dei:EntityAddressPostalZipCode" contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">7177871</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20230321212122747" name="dei:EntityAddressCountry" contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></span></div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<span style="font-style:italic">Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person</span>)</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Securities registered or to be registered pursuant to Section 12(b) of the Act:</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:49%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Title of each class</span></span></span></div>
          </td>
          <td style="width:2%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:49%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Name of each exchange on which registered</span></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:49%;vertical-align:top">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>American Depositary Shares, each representing 600 ordinary shares, par value NIS 0.10 per share</span></span></span></div>
          </td>
          <td style="width:2%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:49%;vertical-align:top">
            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Nasdaq Capital Market</span></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:49%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:2%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:49%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width:49%;vertical-align:top">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Ordinary shares, par value NIS 0.10 per share</span></span></span></div>
          </td>
          <td style="width:2%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:49%;vertical-align:top">
            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Nasdaq Capital Market*</span></span></span></div>
          </td>
        </tr>

    </table>
    <div style="text-align:center;line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>*Not for trading; only in connection with the registration of American Depositary Shares.</span></span></span></div>
    <div style="text-align:center;line-height:1.25">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
      </div>
    </div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Securities registered or to be registered pursuant to Section 12(g) of the Act.</span></span></span></div>
    <div style="text-align:center;line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="text-decoration:underline">None</span><br/>(Title of Class)</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.</span></span></span></div>
    <div style="text-align:center;line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="text-decoration:underline">None</span><br/>(Title of Class)</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of March 8, 2026: <ix:nonFraction id="Fxbrl_20230321212139620" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20260308" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,610,814,390</ix:nonFraction> ordinary shares</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Yes &#9744;&#160;&#160;&#160; <ix:nonNumeric id="Fxbrl_20230321212144853" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_20250101to20251231">No</ix:nonNumeric> &#9746;</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Yes &#9744;&#160;&#160;&#160; <ix:nonNumeric id="Fxbrl_20230321212153388" name="dei:EntityVoluntaryFilers" contextRef="C_20250101to20251231">No</ix:nonNumeric> &#9746;</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Note - Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230321212201628" name="dei:EntityCurrentReportingStatus" contextRef="C_20250101to20251231">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160; No &#9744;</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230321212207485" name="dei:EntityInteractiveDataCurrent" contextRef="C_20250101to20251231">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160; No &#9744;</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25%;vertical-align:top">
            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Large accelerated filer &#9744;</span></span></span></div>
          </td>
          <td style="width:25%;vertical-align:top">
            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Accelerated filer &#9744;</span></span></span></div>
          </td>
          <td style="width:25%;vertical-align:top">
            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20250331155751411" name="dei:EntityFilerCategory" contextRef="C_20250101to20251231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric> &#9746;</span></span></span></div>
          </td>
          <td style="width:25%;vertical-align:top">
            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Emerging growth company <ix:nonNumeric id="Fxbrl_20230321212324757" name="dei:EntityEmergingGrowthCompany" contextRef="C_20250101to20251231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric id="Fxbrl_20230321212236424" name="dei:IcfrAuditorAttestationFlag" contextRef="C_20250101to20251231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <ix:nonNumeric id="Fxbrl_20240324220112714" name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="C_20250101to20251231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:15%;vertical-align:top">
            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>U.S. GAAP &#9744;</span></span></span></div>
          </td>
          <td style="width:70%;vertical-align:top">
            <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230321212256084" name="dei:DocumentAccountingStandard" contextRef="C_20250101to20251231">International Financial Reporting Standards</ix:nonNumeric> as issued by the International Accounting Standards Board &#9746;</span></span></span></div>
          </td>
          <td style="width:15%;vertical-align:top">
            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Other &#9744;</span></span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. N/A</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;Item 17 &#9744;&#160;&#160;&#160; Item 18 &#9744;</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Yes &#9744;&#160;&#160;&#160; No <ix:nonNumeric id="Fxbrl_20230321212304420" name="dei:EntityShellCompany" contextRef="C_20250101to20251231" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></span></div>
  </div>
  <div>
    <div style="line-height:1.25;font-weight:400;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
      </div>
    <!-- Field: Include-Text; File: pf\body.htm; Date: 2026%2D03%2D23T07:52:30; Size: 0x00109F4A; Options: XMLPreprocess -->
<div><br/>

<div>

<table cellspacing="0" cellpadding="0" id="za2d8fb5e653b476eb851642b3f12c5ba" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">TABLE OF CONTENTS</div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center"><br/> </td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center"><br/> </td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold"><a href="#PARTI">PART I.</a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">1<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM1"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 1</span></span><span style="text-decoration: underline">.
        IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">1<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM2"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 2.</span></span><span style="text-decoration: underline">
        OFFER STATISTICS AND EXPECTED TIMETABLE</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">1<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM3"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 3</span></span><span style="text-decoration: underline">.
        KEY INFORMATION</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">1<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM4"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 4. </span></span><span style="text-decoration: underline">INFORMATION
        ON THE COMPANY</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">35<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="#ITEM4A"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM
        4A </span></span><span style="text-decoration: underline">UNRESOLVED STAFF COMMENTS</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">68<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM5"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 5.</span></span><span style="text-decoration: underline">
        OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">68<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM6"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 6.</span></span><span style="text-decoration: underline">
        DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">79<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM7"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 7.</span></span><span style="text-decoration: underline">
        MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">101<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM8"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 8.</span></span><span style="text-decoration: underline">
        FINANCIAL INFORMATION</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">104<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM9"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 9.</span></span><span style="text-decoration: underline">
        THE OFFER AND LISTING</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">105<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM10"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 10.</span></span><span style="text-decoration: underline">
        ADDITIONAL INFORMATION</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">106<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM11"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 11.</span></span><span style="text-decoration: underline">
        QUANTITATIVE AND QUALITATIVE DISCLOSURE ON MARKET RISK</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">118<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM12"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 12.</span></span><span style="text-decoration: underline">
        DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">118<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM13"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 13.</span></span><span style="text-decoration: underline">
        DEFAULTS, DIVIDENDS ARREARAGES AND DELINQUENCIES</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">121<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM14"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 14.</span></span><span style="text-decoration: underline">
        MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">121<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM15"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 15.</span></span><span style="text-decoration: underline">
        CONTROLS AND PROCEDURES</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">121<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM 16.</span></span><span style="text-decoration: underline">
        [RESERVED]</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">122<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="#ITEM16A"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM
        16A.</span></span><span style="text-decoration: underline"> AUDIT COMMITTEE FINANCIAL EXPERTS</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">122<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="#ITEM16B"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM
        16B.</span></span><span style="text-decoration: underline"> CODE OF ETHICS</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">122<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="#ITEM16C"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM
        16C.</span></span><span style="text-decoration: underline"> PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">122<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="#ITEM16D"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM
        16D.</span></span><span style="text-decoration: underline"> EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></a></div>
        </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">123<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="#ITEM16E"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM
        16E.</span></span><span style="text-decoration: underline"> PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</span></a></div>
        </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">123<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="#ITEM16F"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM
        16F.</span></span><span style="text-decoration: underline"> CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">123<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="#ITEM16G"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM
        16G. </span></span><span style="text-decoration: underline">CORPORATE GOVERNANCE</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">123<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="#ITEM16H"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM
        16H.</span></span><span style="text-decoration: underline"> MINE SAFETY DISCLOSURE</span></a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">124<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="#ITEM16I"><span style="font-weight: bold"><span style="text-decoration: underline">ITEM
        16I.</span></span><span style="text-decoration: underline"> DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></div>
        </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">124<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold"><a href="#ITEM16J">ITEM 16J.</a></span>&#160;<a href="#ITEM16J">INSIDER TRADING POLICIES</a></div>
        </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold"><a href="#ITEM16K">ITEM 16K.</a></span>&#160;<a href="#ITEM16K">CYBERSECURITY</a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-weight: bold"><a href="#ITEM17">ITEM 17.</a>&#160;</span><a href="#ITEM17">FINANCIAL STATEMENTS</a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-weight: bold"><a href="#ITEM18">ITEM 18.</a></span>&#160;<a href="#ITEM18">FINANCIAL STATEMENTS</a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-weight: bold"><a href="#ITEM19">ITEM 19.</a></span>&#160;<a href="#ITEM19">EXHIBITS</a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">126<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95.36%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.64%; vertical-align: bottom; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 95.36%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"><a href="#SIGNATURES">SIGNATURES</a></div> </td>
    <td style="width: 4.64%; vertical-align: bottom; text-align: center">129<br/> </td> </tr>
  </table> <br/>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>
<!--PROfilePageNumberReset%LCR%1%%%-->

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span style="text-decoration: underline">INTRODUCTION</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are a biopharmaceutical company pursuing life-changing therapies
in oncology and rare diseases. Our first approved product, APHEXDA&#174; (motixafortide), a novel peptide for the treatment of stem-cell
mobilization and solid tumors, with an indication in the United States for stem cell mobilization for autologous transplantation in multiple
myeloma, is being developed and commercialized by Ayrmid Pharma Ltd., or Ayrmid (globally, excluding Asia) and Auspex Bioscience (Guangzhou)
Co., Ltd. (formerly Guangzhou Gloria Biosciences Co., Ltd.), or Gloria (in Asia). We are also advancing the development of motixafortide
for patients with pancreatic cancer and other solid tumors outside of Asia.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In September 2025, we entered into a collaboration transaction
with Hemispherian AS, or Hemispherian, a Norwegian biotech company focused on small molecule cancer therapeutics, for the development,
clinical evaluation and commercialization of GLIX1, Hemispherian&#8217;s lead drug candidate, a first-in-class, oral, small molecule targeting
DNA damage response in glioblastoma, or GBM, and other cancers.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;Our ordinary shares have been trading on the Tel Aviv Stock
Exchange, or TASE, under the symbol &#8220;BLRX&#8221; since February 2007, and our American Depositary Shares, or ADSs, have been traded
on the Nasdaq Capital Market, or Nasdaq, also under the symbol &#8220;BLRX,&#8221; since July 2011.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Unless otherwise indicated, all references to &#8220;BioLineRx,&#8221;
the &#8220;Company,&#8221; &#8220;us,&#8221; &#8220;we&#8221; and &#8220;our&#8221; refer to BioLineRx Ltd., an Israeli company, and its
consolidated subsidiaries. References to &#8220;ordinary shares&#8221;, &#8220;ADSs&#8221;, &#8220;warrants&#8221; and &#8220;share capital&#8221;
refer to the ordinary shares, ADSs, warrants and share capital, respectively, of BioLineRx.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We use &#8220;APHEXDA&#8221; when referring to our FDA approved
drug and &#8220;motixafortide&#8221; when referring to our development of APHEXDA for additional indications. We refer to the license
agreements with Ayrmid and Gloria as the Ayrmid License Agreement and Gloria License Agreement, respectively and the collaboration agreement
with Hemispherian, as the Collaboration Agreement.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">References to &#8220;U.S. dollars&#8221;, &#8220;dollars&#8221;,
&#8220;USD&#8221;, and &#8220;$&#8221; are to currency of the United States of America, and references to &#8220;NIS&#8221; are to New
Israeli Shekels. References to &#8220;ordinary shares&#8221; are to our ordinary shares, no par value. We report financial information
under IFRS Accounting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. The functional and presentation
currency of the Company in this annual report on Form 20-F for the year ended December 31, 2025, or the Annual Report on Form 20-F, is
the U.S. dollar.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Unless otherwise indicated, U.S. dollar translations of NIS amounts
presented in this Annual Report on Form 20-F are translated using the rate of NIS 3.19 to $1.00, the exchange rate reported by the Bank
of Israel on December 31, 2025.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On January 30, 2025,
we effected a change in the ratio of our ADSs to ordinary shares from one ADS representing 15 ordinary shares to a new ratio of one ADS
representing 600 ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-forty reverse ADS split. All ADS
and related option and warrant information presented in this Annual Report on Form 20-F have been retroactively adjusted to reflect the
reduced number of ADSs and the increase in the ADS price which resulted from this action. Unless otherwise indicated, in this Annual Report
on Form 20-F fractional ADSs have been rounded to the nearest whole number.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Forward-Looking Statements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 26pt; line-height: 1.25">Some of the statements under the sections entitled &#8220;Item
3. Key Information - Risk Factors,&#8221; &#8220;Item 4. Information on the Company&#8221; and &#8220;Item 5. Operating and Financial
Review and Prospects&#8221; and elsewhere in this Annual Report on Form 20-F constitute forward-looking statements. These include statements
regarding management's expectations, beliefs and intentions regarding, among other things, the potential benefits of GLIX1 and motixafortide,
the potential success of our out-licensing and collaboration agreements, expectations and commercial potential of GLIX1 and motixafortide,
as well as its potential investigational uses, expectations with regard to clinical trials of GLIX1 and motixafortide, the plans and objectives
of management for future operations, and statements as to results of operations or of financial condition, expected capital needs and
expenses. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements. In some cases, you can identify forward-looking statements by terms including &#8220;anticipates,&#8221; &#8220;believes,&#8221;
&#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221;
&#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions
intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and
are based on assumptions, and are subject to risks and uncertainties. In addition, the section of this Annual Report on Form 20-F entitled
&#8220;Item 4. Information on the Company&#8221; contains information obtained from independent industry and other sources that we have
not independently verified. You should not put undue reliance on any forward-looking statements. Our actual results could differ materially
from those discussed in the forward-looking statements. Unless we are required to do so under U.S. federal securities laws or other applicable
laws, we do not intend to update or revise any forward-looking statements. Readers are encouraged to consult the Company&#8217;s filings
made on Form 6-K, which are periodically filed with or furnished to the SEC.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">i</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Factors that could cause our actual results to differ materially
from those expressed or implied in such forward-looking statements include, but are not limited to:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="ze745e72fc8ba4c70a4d66e5183850fbc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the clinical development, commercialization and market acceptance of GLIX1 and motixafortide including the degree and pace of market
        uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z87dae8d8e04a4463b8c0d74201c1bc82" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the initiation, timing, progress and results of our preclinical studies, clinical trials and other therapeutic candidate development
        efforts;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z24dbd24fa2b340a6a0bd00b2021fdfd6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to advance GLIX1 and motixafortide into clinical trials or to successfully complete our preclinical studies or clinical
        trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z0d1f478bd51e4caa8b43d70aee41c23e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>whether the clinical trial results for GLIX1 and motixafortide will be predictive of real-world results;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zcb68f98688f6426db282458f8422236b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our receipt of regulatory approvals for GLIX1 and motixafortide and the timing of other regulatory filings and approvals;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z289bda4e78724f1796644539e0e25721" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>whether access to GLIX1 and motixafortide is achieved in a commercially viable manner and whether GLIX1 and motixafortide receives
        adequate reimbursement from third-party payors;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z8b831961c23f4bdeb64c3793b203f305" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to establish, manage, and maintain corporate collaborations, as well as the ability of our collaborators to execute on
        their development and commercialization plans;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z936afe1b8dae45a4ac90f5bf8691b845" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to integrate new therapeutic candidates and new personnel, as well as new collaborations;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z62f64decbf4e4594a118862a403aeaef" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the interpretation of the properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic
        candidates in preclinical studies or clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zfdf0e6cf8bea4cf78367f56783704342" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the implementation of our business model and strategic plans for our business and therapeutic candidates;</div> </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">ii</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<table cellspacing="0" cellpadding="0" id="zc3ed7bbbf8a741d88efb80d56c11e942" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the scope of protection that we are able to establish and maintain for intellectual property rights covering our therapeutic candidates
        and our ability to operate our business without infringing the intellectual property rights of others;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z7a0a4135a9d4414d85ec1cbd55105d71" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>estimates of our expenses, future revenues, capital requirements and our need for and ability to access sufficient additional financing;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z0a4c53e6cd87427ea844fd636ca96e75" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="za31ba022a2e14152bfca0c2b35def531" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>competitive companies, technologies and our industry;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zc6a71c2779c14828934b23034a1f4c15" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to maintain the listing of our ADSs on Nasdaq;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zc6e32d6019d441fbbff0135f635ec6dd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>statements as to the impact of the political and security situation in Israel on our business which may exacerbate the magnitude
        of the factors discussed above; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zbee7674a596349668345dd64b5ba196c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br/> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>those factors referred to in &#8220;Item 3.D. Risk Factors,&#8221; &#8220;Item 4. Information on the Company,&#8221; and &#8220;Item
        5. Operating and Financial Review and Prospects&#8221;, as well as in this Annual Report on Form 20-F generally.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">iii</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%1%%%-->

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span style="text-decoration: underline">PART I<span id="PARTI"><!--Anchor--></span>.</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 1<span id="ITEM1"><!--Anchor--></span>. IDENTITY OF DIRECTORS,
SENIOR MANAGEMENT AND ADVISERS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 2<span id="ITEM2"><!--Anchor--></span>. OFFER STATISTICS AND
EXPECTED TIMETABLE</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 3<span id="ITEM3"><!--Anchor--></span>. KEY INFORMATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. [Reserved]</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. Capitalization and Indebtedness</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">C. Reasons for the Offer and Use of Proceeds</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">D. Risk Factors</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">You should carefully consider the risks we describe below, in addition
to the other information set forth elsewhere in this Annual Report on Form 20-F, including our consolidated financial statements and the
related notes beginning on page F-1, before deciding to invest in our ordinary shares and ADSs. These material risks could adversely impact
our results of operations, possibly causing the trading price of our ordinary shares and ADSs to decline, and you could lose all or part
of your investment.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">1</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25; font-weight: bold">Summary Risk Factors</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Investing in our securities involves a high degree of risk, as
fully described below. The principal factors and uncertainties that make investing in our ordinary shares risky include, among others:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Risks Related to Our Financial Condition and Capital Requirements</div>

<div style="line-height: 1.25">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z2a1d529e9f434aba922ee4aecac4b1da" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">We have incurred significant losses since inception and expect to incur additional losses in the future
        and may never be profitable.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">We cannot assure investors that our existing cash and investment balances will be sufficient to meet our
        future capital requirements.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">If we default under our secured loan agreement with BlackRock EMEA Venture and Growth Lending (previously
        Kreos Capital VII Aggregator SCSP), or BlackRock, all or a portion of our assets could be subject to forfeiture.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Management has concluded that there is substantial doubt about our ability to continue as a going concern,
        which could prevent us from obtaining new financing on reasonable terms or at all.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Risks Related to Our Business and Regulatory Matters</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z34e5d2ab75df441c90f5f586d659d902" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">We have earned limited revenues to date and we may never achieve profitability.</div> </div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle"> <br/> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">GLIX1, motixafortide, or any other therapeutic candidate that may receive marketing
        approval in the future, may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in
        the medical community necessary for commercial success and the market opportunity for GLIX1, motixafortide or any other therapeutic candidate
        may be smaller than our estimates.</div> </td> </tr>
  </table> <br/>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">If we, our licensees or our collaborators are unable to obtain and/or maintain U.S.
        and/or foreign regulatory approval for our therapeutic candidates, in a timely manner or at all, we will be unable to commercialize our
        therapeutic candidates.</div> </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">2</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div>

<div>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">We, our licensees, and our collaborators may not obtain additional marketing approvals
        for motixafortide in other indications or initial approval for GLIX1 or any other therapeutic candidates we may develop in the future.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Clinical trials involve a lengthy and expensive process with an uncertain outcome,
        and results of earlier studies and trials may not be predictive of future trial results.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle"> <br/> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Even if we obtain regulatory approvals, GLIX1, motixafortide and any other therapeutic candidate that we
        may develop in the future will be subject to ongoing regulatory review and if we fail to comply with continuing U.S. and applicable foreign
        regulations, we could lose those approvals and our business would be seriously harmed.</div> </div>
        <div style="text-align: justify; line-height: 1.25"> <br/> </div> </td> </tr>
  </table> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">We generally rely on third parties to conduct our preclinical studies and clinical
        trials and to provide other services, and those third parties may not perform satisfactorily, including by failing to meet established
        deadlines for the completion of such services.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">We recently entered into and may in the future rely on out-licensing arrangements
        for late-stage development, marketing or commercialization of our therapeutic candidates.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160; <br/> </div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">If we cannot meet requirements under our in-license agreements, we could lose the
        rights to our therapeutic candidates, which could have a material adverse effect on our business.</div>
        <div style="text-align: justify; line-height: 1.25"> <br/> </div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">We have partnered with and may seek to partner with third-party collaborators with
        respect to the development and commercialization of motixafortide, and we may not succeed in establishing and maintaining collaborative
        relationships, which may significantly limit our ability to develop and commercialize our therapeutic candidates successfully, if at all.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" id="zbe79a81c74f54ba2ba3e91ce1e437468" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">If competitors develop and market therapeutics that are more effective, safer or less
        expensive than our current or future therapeutic candidates, our prospects will be negatively impacted.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">GLIX1, motixafortide, or any other therapeutic candidate that we, our licensees are
        able to commercialize, may become subject to unfavorable pricing regulations, third-party payor reimbursement practices or healthcare
        reform initiatives, any of which could harm our business.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">We rely upon third-party manufacturers to produce therapeutic supplies for the clinical
        trials, and commercialization, of GLIX1 and motixafortide. If we manufacture any therapeutic candidates in the future, we will be required
        to incur significant costs and devote significant efforts to establish and maintain manufacturing capabilities.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;<span style="font-weight: bold; font-style: italic">Risks Related to Our Industry</span></div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc14fdf56f7844616891ecb63d4af10cb" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Healthcare reforms and related reductions in pharmaceutical pricing, reimbursement and coverage by government
        authorities and third-party payors may adversely affect our business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">3</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<table cellspacing="0" cellpadding="0" id="z2b7fa086ec404c2a8c96650f3fffda2c" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">If third-party payors do not adequately reimburse customers for any of our therapeutic candidates that
        are approved for marketing, they might not be purchased or used, and our revenues and profits will not develop or increase.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Our business has a substantial risk of clinical trial and product liability claims. If we are unable to
        obtain and maintain appropriate levels of insurance, a claim could adversely affect our business.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Significant disruptions of our information technology systems or breaches of our data security could adversely
        affect our business.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">We deal with hazardous materials and must comply with environmental, health and safety laws and regulations,
        which can be expensive and restrict how we do business.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">We have in the past, and may in the future, become subject to litigation or claims arising in or outside
        the ordinary course of business that could negatively affect our business operations and financial condition.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Risks Related to Intellectual Property</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z05c25dbf6a08460ea26f186a3078db75" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Our access to most of the intellectual property associated with our therapeutic candidates
        results from in-license and collaboration agreements with biotechnology companies and a university, the termination of which would prevent
        us from commercializing the associated therapeutic candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Risks Related to our Ordinary Shares and ADSs</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze0d14801b86543dbadea76f1c5c7d874" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Our business, operating results and growth rates may be adversely affected by current or future unfavorable
        economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">The market prices of our ordinary shares and ADSs are subject to fluctuation, which could result in substantial
        losses by our investors.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Future sales of our ordinary shares or ADSs could reduce the market price of our ordinary shares and ADSs.</div>
        </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Raising additional capital by issuing securities may cause dilution to existing shareholders.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">If we fail to comply with the continued listing requirements of the Nasdaq, our ADSs may be delisted and
        the price of our ADSs and our ability to access the capital markets could be negatively impacted.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Risks Related to our Operations in Israel</div>

<div style="line-height: 1.25">&#160;&#160;&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z440fa462d4724ca394c2034d2077a201" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">We conduct a substantial part of our operations in Israel and therefore our results may be adversely affected
        by political, economic and military instability in Israel and its region.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Provisions of Israeli law may delay, prevent or otherwise impede a merger with, or an acquisition of, our
        company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zef458f30cd4745dab1dd995ad5b0d99a" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">It may be difficult to enforce a U.S. judgment against us and our officers and directors in Israel or the
        United States, or to serve process on our officers and directors.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Your rights and responsibilities as a shareholder will be governed by Israeli law, which may differ in
        some respects from the rights and responsibilities of shareholders of U.S. companies.</div> </td> </tr>
  </table>

<div style="text-align: center; line-height: 1.25; font-weight: bold"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">4</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">Risks Related to Our Financial Condition and Capital Requirements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We have incurred significant losses since inception
and expect to incur additional losses in the future and may never be profitable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are a biopharmaceutical company pursuing life-changing therapies
in oncology and rare diseases. Our first approved product is APHEXDA (motixafortide), a novel peptide for the treatment of stem-cell mobilization
and solid tumors which, on September 8, 2023, was approved by the FDA for use in combination with filgrastim (G-CSF) to mobilize hematopoietic
stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. In October
2023, we out-licensed the rights to motixafortide for all indications in substantially all of Asia and in November 2024, we out-licensed
the global rights (other than in Asia) to motixafortide for all indications, other than solid tumors. As a result of the November 2024
transaction, we shut down our independent commercialization activities in the United States and refocused our operations on development
activities in Israel in the fields of oncology and rare diseases, at a significantly reduced annual cash burn rate. In September 2025
we entered into a collaboration with Hemispherian for the development, clinical evaluation and commercialization of GLIX1, a first-in-class,
oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Since our incorporation, we have been mainly focused on research
and development. We have incurred losses since inception, principally as a result of research and development and general administrative
expenses and, between 2022 and 2024, sales and marketing in support of the launch and direct commercialization of APHEXDA. We recorded
net losses of $60.6 million in 2023, $9.2 million in 2024, and $2.0 million in 2025. As of December 31, 2025, we had an accumulated deficit
of $401 million. While we generate revenue from royalties on product sales of APHEXDA and have the potential to generate additional revenue
from milestone payments, these have not been at a level to sustain our operations and there can be no assurance that significant revenue
from product sales of APHEXDA will ever be generated or that milestones will be met. As a result, we expect to continue to incur significant
expenses and sustain net losses for the foreseeable future as we continue our planned development activities for GLIX1 and motixafortide
in other indications.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;&#160;&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We cannot assure investors
that our existing cash and investment balances will be sufficient to meet our future capital requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As of December 31, 2025, we held $20.9 million of cash, cash equivalents
and short-term bank deposits. Based on our current projected cash requirements, we believe that our existing cash and investment balances
will be sufficient to meet our capital requirements into the first half of 2027. We have funded our operations primarily through public
and private offerings of our securities, payments received under our strategic licensing and collaboration arrangements and interest earned
on investments. The adequacy of our available funds to meet our operating and capital requirements will depend on many factors, including:
royalty and milestone payments from our license agreements with Ayrmid and Gloria, the number, breadth, progress and results of our research,
product development and clinical programs; the costs and timing of obtaining regulatory approvals for any of our therapeutic candidates;
the terms and conditions of in-licensing and out-licensing therapeutic candidates; and costs incurred in enforcing and defending our patent
claims and other intellectual property rights.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">While we expect to continue to explore alternative financing sources,
including the possibility of future securities offerings and government funding, we cannot be certain that in the future these liquidity
sources will be available when needed on commercially reasonable terms or at all, or that our actual cash requirements will not be greater
than anticipated. We expect to also continue to seek to finance our operations through other sources, including out-licensing arrangements
for the development and commercialization of our therapeutic candidates or other partnerships or joint ventures, as well as grants from
government agencies and foundations. If we are unable to obtain future financing through the methods we describe above or through other
means, we may be unable to complete our business objectives and may be unable to continue operations, which would have a material adverse
effect on our business and financial condition.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">5</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">If we default under our
secured loan agreement with BlackRock, all or a portion of our assets could be subject to forfeiture.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In September 2022, we entered into a secured loan agreement, or
the Loan Agreement, with BlackRock, under which BlackRock agreed to provide the Company with access to term loans in an aggregate principal
amount of up to $40 million in three tranches as follows: (a) a loan in the aggregate principal amount of up to $10 million, (b) a loan
in the aggregate principal amount of up to $20 million, available for drawdown upon achievement of certain milestones and until April
1, 2024, and (c) a loan in the aggregate principal amount of up to $10 million, available for drawdown upon achievement of certain milestones
and until October 1, 2024. We drew down the initial tranche of $10 million following execution of the agreement in September 2022 and
we drew down the second tranche of $20 million in April 2024, following fulfilment of the requisite milestones. We did not draw down the
third tranche.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In November 2024, in connection with the Ayrmid License Agreement
(as defined below), we entered into an amendment, or the Amendment, to the Loan Agreement with BlackRock, pursuant to which, (i) we agreed
to make aggregate payments of $16.5 million, as partial repayment of the loan to BlackRock and in lieu of future revenue-based payments,
which were fully cancelled, (ii) effective December 1, 2024, we agreed to pay the remaining amounts outstanding under the loan (in principal
and interest) over a three year period ending December 1, 2027, and (iii) our minimum cash balance requirement under the Loan Agreement
was reduced to $4 million. In addition, pursuant to the Amendment, 10% of any future milestone payments received by us from the out-licensing
agreements through December 1, 2027 will be used to repay outstanding loan principal, and the repayments in (ii) above will be adjusted
accordingly. All other terms of the Loan Agreement remain the same.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our ability to make the scheduled payments under the Loan Agreement
or to refinance our debt obligations with BlackRock depends on numerous factors including, but not limited to, the amount of our cash
reserves, our capital requirements and our ability to raise additional capital. We may be unable to maintain a level of cash reserves
sufficient to permit us to pay the principal and accrued interest on the loan. If our cash reserves, cash flows and capital resources
are insufficient to fund our debt obligations to BlackRock, we may be required to seek additional capital, restructure or refinance our
indebtedness, or delay or abandon our research and development projects or other capital expenditures, which could have a material adverse
effect on our business, financial condition, prospects or results of operations. There is no assurance that we would be able to take any
of such actions, or that such actions would permit us meet our scheduled debt obligations under the BlackRock loan agreement. If we default
on the Loan Agreement and are unable to cure the default pursuant to the terms of the Loan Agreement or are unable to repay or refinance
the loan when due, BlackRock could take possession of any or all assets in which it holds a security interest, and dispose those assets
to the extent necessary to pay off the debts, which would have a material adverse effect on our business, financial condition, prospects
or results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Management has concluded
that there is substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing
on reasonable terms or at all.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have incurred significant losses and negative cash flows from
operations and have an accumulated deficit that raises substantial doubt about our ability to continue as a going concern. Our audited
consolidated financial statements for the year ended December 31, 2025 were prepared under the assumption that we would continue our operations
as a going concern. Our independent registered public accounting firm has included a &#8220;going concern&#8221; explanatory paragraph
in its report on our financial statements for the year ended December 31, 2025. If we are unable to improve our liquidity position, by,
among other things, raising capital through public or private offerings or reducing our expenses, we may exhaust our cash resources and
will be unable to continue our operations. If we cannot continue as a viable entity, our shareholders would likely lose most or all of
their investment in us.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">6</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">Risks Related to Our Business and Regulatory Matters</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We have earned limited revenues
to date. We may never achieve profitability.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are a biopharmaceutical company pursuing life-changing therapies
in oncology and rare diseases. To date, we have generated only limited revenues from sales of APHEXDA. Our ability to generate revenues
from sales of APHEXDA and achieve profitability will be dependent on the ability of the licensees under the Gloria License Agreement (as
defined below) and the Ayrmid License Agreement to successfully commercialize the licensed products and the ability of any future partners
or licenses to successfully commercialize any other product candidates that we may develop, in-license or acquire in the future.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our revenues from motixafortide or any product candidate for which
regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory
approval, the accepted price for the product, the ability to get reimbursement at any price, and the terms and conditions of our commercialization
agreement with our partner for that territory. While we retain the right to potentially meaningful milestones or royalty payments under
the Gloria License Agreement and the Ayrmid License Agreement, it could take many years before such milestones are achieved, resulting
in such royalty payments being made, if at all.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The timing and amount of any milestone and royalty payments we
may receive from our licensees, as well as the commercial success of our products will depend on, among other things, the efforts, allocation
of resources, negotiation of pricing and reimbursement and successful commercialization of our products by our licensees. As a result,
even if we generate product revenues, we may not become profitable and may need to obtain additional funding to continue operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">GLIX1, motixafortide, or
any other therapeutic candidate that may receive marketing approval in the future, may fail to achieve the degree of market acceptance
by physicians, patients, third-party payors and others in the medical community necessary for commercial success and the market opportunity
for GLIX1, motixafortide or any other therapeutic candidate may be smaller than our estimates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">GLIX1, motixafortide or any other therapeutic candidate that may
be approved in the future by the appropriate regulatory authorities for marketing and sale, may fail to gain sufficient market acceptance
by physicians, patients, third-party payors and others in the medical community. Physicians are often reluctant to switch their patients
from existing therapies even when new and potentially more effective or convenient treatments enter the market. APHEXDA competes with
the standard of care using stem cell mobilization and its generic versions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Efforts to educate the medical community and third-party payors
on the benefits of APHEXDA over its competition have required significant resources and may not ultimately be successful. If GLIX1, motixafortide,
or any other therapeutic candidate that may be approved in the future for marketing and sale in the future, does not achieve an adequate
level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance
of GLIX1, motixafortide, or any other therapeutic candidate that may be approved in the future, will depend on a number of factors, including:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z652a0c0051b943db8bbfda507f0f4419" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the advantages of the treatment compared to competitive therapies;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the number of competitors approved for similar uses;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the relative promotional effort and marketing success of us as compared with our competitors;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">7</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">how the product is positioned in physician treatment guidelines and pathways;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the prevalence and severity of any side effects;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div>

<table cellspacing="0" cellpadding="0" id="z64acdbb9373b4371bdff9ce0ec29b981" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">the efficacy and safety of the product;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">our ability to offer the product for sale at competitive reimbursement;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">the product&#8217;s tolerability, convenience and ease of administration compared to alternative treatments;</div>
        </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">the willingness of the target patient population to try, and of physicians to prescribe, the product;</div>
        </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">limitations or warnings, including use restrictions, contained in the product&#8217;s approved labeling;</div>
        </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">the strength of sales, marketing and distribution support;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">the timing of market introduction of our approved products as well as competitive products;</div> </td>
        </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">adverse publicity about the product or favorable publicity about competitive products;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">potential product liability claims;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">changes in the standard of care for the targeted indications of the product; and</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">availability and amount of coverage and reimbursement from government payors, managed care plans and other
        third-party payors.</div> </td> </tr>
  </table> </div>

<div><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, the potential market opportunities for GLIX1, motixafortide
and any other therapeutic are difficult to estimate precisely. Our estimates of the potential market opportunities are predicated on many
assumptions, including industry knowledge and publications, third-party research reports and other surveys. While we believe that our
internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are
inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions
prove to be inaccurate, the actual markets for our therapeutic candidate could be smaller than our estimates of the potential market opportunities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Even if a therapeutic candidate
receives marketing approval, we or others may later discover that the product is less effective than previously believed or causes undesirable
side effects that were not previously identified, which could compromise our ability or that of any collaborators to market the product,
and could cause regulatory authorities to take certain regulatory actions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">It is possible that our clinical trials may indicate an apparent
positive effect of a therapeutic candidate that is greater than the actual positive effect, if any, or alternatively fail to identify
undesirable side effects. For example, despite the recent FDA marketing approval of APHEXDA in the United States, we, or others, including
our licensees, may discover that APHEXDA is less effective or tolerable than previously believed. If we, or others, discover that a product
is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following
adverse events could occur:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze6935f87e194417bada2c2ae2bec720a" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">regulatory authorities may withdraw their approval of the product or seize the product;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">we, or any of our licensees or collaborators, may be required to recall the product,
        change the way the product is administered or conduct additional clinical trials;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">8</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">additional restrictions may be imposed on the marketing of, or the manufacturing processes
        for, the particular product;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">we, or any of our licensees or collaborators, may be subject to fines, injunctions
        or the imposition of civil or criminal penalties;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">regulatory authorities may require the addition of labeling or warning statements,
        such as a &#8220;black box&#8221; warning or a contraindication;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">we, or any of our collaborators, may be required to create a Medication Guide outlining
        the risks of the previously unidentified side effects for distribution to physicians, health care professionals and patients;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">we could be sued and held liable for harm caused to patients;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">physicians and patients may stop using our product; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226; <br/> </div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">our reputation may suffer.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Any of these events could harm our business and operations and could negatively impact
the market price of our ordinary shares and/or ADSs.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">If we, our licensees or
our collaborators are unable to obtain and/or maintain U.S. and/or foreign regulatory approval for our therapeutic candidates in a timely
manner or at all, we will be unable to commercialize our therapeutic candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">While we recently shut down our independent commercialization activities
in the United States and refocused our operations on development activities in Israel in the fields of oncology and rare diseases, we
continue to advance the development of motixafortide in solid tumors for all territories other than Asia and are advancing the development
of GLIX1 under the Collaboration Agreement. GLIX1, motixafortide, and any other therapeutic candidate we develop will require additional,
time-consuming and costly development efforts, by us or by our collaborators, prior to commercial sale, including preclinical studies,
clinical trials and approval by the FDA and/or applicable foreign regulatory authorities. All therapeutic candidates are prone to the
risks of failure that are inherent in pharmaceutical product development, including the possibility that the therapeutic candidate will
not be shown to be sufficiently safe and/or effective for approval by regulatory authorities. In addition, we cannot assure you that any
such products that are approved will be manufactured or produced economically, successfully commercialized or widely accepted in the marketplace,
or will be more effective than other commercially available alternatives.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the United States, we are required to submit a New Drug Application,
or NDA, to obtain FDA approval before marketing any of our current or future therapeutic candidates. An NDA must include extensive preclinical
and clinical data and supporting information to establish the therapeutic candidate&#8217;s safety, purity and potency, or efficacy, for
each desired indication. The NDA must also include information regarding the product&#8217;s pharmacology, toxicology, chemistry, manufacture
and manufacturing controls. Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and approval may not be obtained.
Upon submission of an NDA, the FDA must make an initial determination that the application is sufficiently complete to accept the submission
for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA, or ultimately be approved. The
FDA may require that we conduct additional clinical or preclinical trials, or take other actions before it will approve or reconsider
any application we make. If the FDA requires additional studies or data, we will incur increased costs and delays in the marketing approval
process, which may require us to expend more resources than we have available. In addition, the FDA may not consider any additional information
to be complete or sufficient to support approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">9</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Any delay in obtaining, or the failure to obtain, required regulatory
approvals will materially and adversely affect our ability to generate future revenues from a particular therapeutic candidate. Any regulatory
approval to market a product may be subject to limitations on the indicated uses for which we may market the product or may impose restrictive
conditions of use, including cautionary information, thereby limiting the size of the market for the product. We and our collaborators,
as applicable, also are, and will be, subject to numerous foreign regulatory requirements that govern the conduct of clinical trials,
manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process includes all
the risks associated with the FDA approval process that we describe above, as well as risks attributable to the satisfaction of foreign
requirements. Approval by the FDA does not ensure approval by regulatory authorities outside the United States. Foreign jurisdictions
may have different approval processes than those required by the FDA and may impose additional testing requirements for our therapeutic
candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We, our licensees and our
collaborators may not obtain additional marketing approvals for motixafortide or initial approval for GLIX1 or any other therapeutic candidates
we may develop in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We, our licensees or our collaborators may not obtain additional
marketing approvals for motixafortide or initial approval for GLIX1 or any other therapeutic candidate that we may develop in the future.
It is possible that the FDA or comparable foreign regulatory agencies may refuse to accept for substantive review any future application
that we, a licensee or a collaborator may submit to market and sell our therapeutic candidates, or that any such agency may conclude after
review of our, our licensee&#8217;s or collaborator&#8217;s data that such application is insufficient to obtain marketing approval of
our therapeutic candidate.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If the FDA or other comparable foreign regulatory agency does not
accept or approve any future application to market and sell any therapeutic candidate, such regulators may require that we conduct additional
clinical trials, preclinical studies or manufacturing validation studies and submit that data before they will reconsider our application.
Depending on the extent of these or any other required trials or studies, approval of any application that we submit may be delayed by
several years, or may require us, our licensee or our collaborator to expend more resources than we or they have available. It is also
possible that additional trials or studies, if performed and completed, may not be considered sufficient by the FDA or other foreign regulatory
agency to approve our applications for marketing and commercialization.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Any delay in obtaining, or an inability to obtain, marketing approvals
would prevent us, our licensees or collaborators from commercializing GLIX1 or motixafortide in other jurisdictions and indications or
any other therapeutic candidate that we may develop in the future and generating revenues. If any of these outcomes occur, we would not
be eligible for certain milestone and royalty revenue under our license agreements, our licensees could terminate our license agreements
and we may be forced to abandon our development efforts, any of which could significantly harm our business.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Clinical trials involve a lengthy and expensive
process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Clinical trials are expensive and complex, can take many years
and have uncertain outcomes. We cannot necessarily predict whether we or any licensee will encounter problems with any of the completed,
ongoing or planned clinical trials that will cause us, any licensee or regulatory authorities to delay or suspend clinical trials, or
to delay the analysis of data from completed or ongoing clinical trials. In addition, because some of our clinical trials are investigator-initiated
studies (i.e., we are not the study sponsor), we may have less control over these studies. We estimate that certain of our clinical trials
will continue for several years, but they may take significantly longer to complete. Failure can occur at any stage of the testing, and
we may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent commercialization
of our current or future therapeutic candidates, including, but not limited to:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z04070c8784824ac2a8dfbffe219717e3" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top"> <br/> </td>
    <td style="width: 36pt; vertical-align: bottom">
        <div style="line-height: 1.25">&#8226; <br/> </div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">delays in securing clinical investigators or trial sites for the clinical trials;</div>
        </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">10</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>

<table cellspacing="0" cellpadding="0" id="z2273cf0da6e543179f580f9cd581b124" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">delays in obtaining institutional review board and other regulatory approvals to commence a clinical trial;</div>
        </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">slower-than-anticipated patient recruitment and enrollment;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">negative or inconclusive results from clinical trials;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">unforeseen safety issues;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">uncertain dosing issues;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">an inability to monitor patients adequately during or after treatment; and</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">problems with investigator or patient compliance with the trial protocols.</div> </td> </tr>
  </table>

<div><br/> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A number of companies in the pharmaceutical and biotechnology industries,
including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after
seeing promising results in earlier clinical trials. Despite the results reported in earlier clinical trials for our therapeutic candidates,
we do not know whether any Phase 3 or other clinical trials we or our licensees may conduct will demonstrate adequate efficacy and safety
to result in regulatory approval to market any therapeutic candidate. For example, we previously investigated the treatment of motixafortide
for acute myeloid leukemia, AML, and following an interim analysis of a Phase 2b trial in which the investigational arm of motixafortide
combined with cytarabine did not demonstrate a statistically significant effect in the study&#8217;s primary endpoint, we terminated the
study. Nevertheless, we continue to believe in the relevance of CXCR4 as a viable target in other AML treatment lines, such as rr/AML
and induction treatment. If later-stage clinical trials of any therapeutic candidate do not produce favorable results, our ability to
obtain regulatory approval for the therapeutic candidate may be adversely impacted, which will have a material adverse effect on our business,
financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Even if we obtain regulatory
approvals, GLIX1, motixafortide and any other therapeutic candidate that we may develop in the future will be subject to ongoing regulatory
review and if we fail to comply with continuing U.S. and applicable foreign regulations, we could lose those approvals and our business
would be seriously harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Even if therapeutics we or any licensee or collaborator develops
receive regulatory approval, we or any licensee, as applicable, will be subject to ongoing reporting obligations, and any approved products
and the manufacturing operations for such products will be subject to continuing regulatory review, including FDA inspections. The outcome
of this ongoing review may result in the withdrawal of a product from the market, the interruption of the manufacturing operations and/or
the imposition of labeling and/or marketing limitations. Since many more patients are exposed to a drug product following its marketing
approval, serious but infrequent adverse reactions that were not observed in clinical trials may be observed during the commercial marketing
of the product. In addition, the manufacturer and the manufacturing facilities we or our licensees, as applicable, will use to produce
any therapeutic candidate will be subject to periodic review and inspection by the FDA and other similar foreign regulators. Later discovery
of previously unknown problems with any product, manufacturer or manufacturing process, or failure to comply with regulatory requirements,
may result in actions such as:</div>

<div style="line-height: 1.25">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd726ad9a652e40e7879c1f722a7c49a2" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">restrictions on such product, manufacturer or manufacturing process;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">warning letters from the FDA or other regulatory authorities;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">withdrawal of the product from the market;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">suspension or withdrawal of regulatory approvals;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">11</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>

<table cellspacing="0" cellpadding="0" id="z89d3668c782c43e1ae8d920cfc4fd07e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">refusal to approve pending applications or supplements to approved applications that we or our licensees
        submit;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">voluntary or mandatory recall;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">fines;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">refusal to permit the import or export of our products;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">product seizure or detentions;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">injunctions or the imposition of civil or criminal penalties; or</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">adverse publicity.</div> </td> </tr>
  </table> </div>

<div> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If we, or any licensee, supplier, third-party contractor, partner
or clinical investigator is slow to adapt, or are unable to adapt, to changes in existing regulatory requirements or the adoption of new
regulatory requirements or policies, we or any licensee may lose marketing approval for any of our products, if any of our therapeutic
products are approved, resulting in decreased or lost revenue from milestones, product sales or royalties.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We generally rely on third
parties to conduct our preclinical studies and clinical trials and to provide other services, and those third parties may not perform
satisfactorily, including by failing to meet established deadlines for the completion of such services.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We do not have the ability to conduct certain preclinical studies
and clinical trials independently for GLIX1 and motixafortide, and we rely on third parties, such as contract laboratories, contract research
organizations, medical institutions, clinical investigators and other collaborators to conduct these studies and clinical trials. Our
reliance on these third parties limits our control over these activities. The collaborators may not assign as great a priority to our
clinical development programs or pursue them as diligently as we would if we were undertaking such programs directly. Accordingly, these
collaborators may not complete activities on schedule, or may not conduct the studies or our clinical trials in accordance with regulatory
requirements or with our trial design. If these third parties do not successfully carry out their contractual duties or meet expected
deadlines, or if their performance is substandard, we may be required to replace them or add more sites to the studies. Although we believe
that there are a number of other third-parties that we could engage to continue these activities, replacement of these third parties will
result in delays and/or additional costs. As a result, our efforts to obtain regulatory approvals for, and to commercialize GLIX1, motixafortide
and any other therapeutic candidate that we may develop in the future may be delayed. The collaborators may also have relationships with
other commercial entities, some of whom may compete with us. If the collaborators assist our competitors, our competitive position may
be harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, our ability to bring future products to market depends
on the quality and integrity of data that we present to regulatory authorities in order to obtain marketing authorizations. Although we
attempt to audit and control the quality of third-party data, we cannot guarantee the authenticity or accuracy of such data, nor can we
be certain that such data has not been fraudulently generated. The failure of these third parties to carry out their obligations would
materially adversely affect our ability to develop and market new products and implement our strategies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We entered into out-licensing
arrangements with Gloria and Ayrmid and may in the future rely on additional out-licensing or collaboration arrangements for later-stage
development, marketing or commercialization.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We entered into out-licensing arrangements with Gloria and Ayrmid
and may in the future rely on additional<span style="font-weight: bold; font-style: italic">&#160;</span>out-licensing arrangements for
later-stage development, marketing or commercialization. Dependence on out-licensing arrangements subjects us to a number of risks, including
the risk that:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z92e5c4809cf44c039ebc556ad993321b" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">we have limited control over the amount and timing of resources that a licensee devotes
        to our therapeutic candidate;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">12</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a licensee or collaborator may experience financial difficulties;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a licensee may fail to secure adequate commercial supplies of our therapeutic candidate
        upon marketing approval, if at all;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">our future revenues depend heavily on the efforts of a licensee;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">business combinations or significant changes in a licensee&#8217;s business strategy
        may adversely affect the licensee&#8217;s willingness or ability to complete its obligations under any arrangement with us;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z017ca8b240684bffab17b369a3cf3c13" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a licensee could move forward with a competing therapeutic candidate developed either
        independently or in collaboration with others, including our competitors; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">out-licensing arrangements are often terminated or allowed to expire, which would
        delay the development and may increase the development costs of our therapeutic candidates.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Gloria License Agreement, the planned stud of motixafortide
in China under the Gloria License Agreement for PDAC is currently not advancing according to schedule and it is unclear when such study
will be initiated, if at all.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If we or any licensee breaches or terminates its agreement with
us, or if any licensee otherwise fails to conduct its development and commercialization activities in a timely manner or there is a dispute
about their obligations, we may need to seek other licensees or collaborators, or we may have to develop our own internal sales and marketing
capability.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our dependence on a licensee&#8217;s experience and the rights
of a licensee or collaborator will limit our flexibility in considering alternative out-licensing or collaborator arrangements for any
therapeutic candidate. Any failure to successfully develop these arrangements or failure by a licensee or collaborator to successfully
develop or commercialize any therapeutic candidate in a competitive and timely manner will have a material adverse effect on the commercialization
of any therapeutic candidate.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We have partnered with and
may seek to partner with third-party collaborators with respect to the development and commercialization of both GLIX1 and motixafortide
and for any other therapeutic candidate and we may not succeed in establishing and maintaining collaborative relationships, which may
significantly limit our ability to develop and commercialize our therapeutic candidates successfully, if at all.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We collaborate with third parties with respect to the development
of motixafortide for certain indications and may in the future seek a partner for other indications or other therapeutic candidates. In
September 2025, we entered into a collaboration with Hemispherian for the development, clinical evaluation and commercialization of GLIX1.
We may compete with many other companies if we seek additional partners for GLIX1 and motixafortide and for any other therapeutic candidate
and we may not be able to compete successfully against those companies. If we are not able to enter into additional collaboration arrangements
for GLIX1 and motixafortide and for any other therapeutic candidate, we would be required to undertake and fund further development, clinical
trials, manufacturing and commercialization activities solely at our own expense and risk. If we are unable to finance and/or successfully
execute those expensive activities, or we delay such activities due to capital availability, our business could be materially and adversely
affected, and potential future product launch could be materially delayed, be less successful, or we may be forced to discontinue clinical
development of these therapeutic candidates. Furthermore, if we are unable to enter into a commercial agreement for the development and
commercialization of GLIX1 and motixafortide and for any other therapeutic candidate, then this could have a material adverse effect on
our business, financial condition or results of operations.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">13</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The process of establishing and maintaining collaborative relationships
is difficult, time-consuming and involves significant uncertainty, including:</div>

<div style="line-height: 1.25">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2e1351abd9914cf79e860a1437221d65" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a collaboration partner may shift its priorities and resources away from our therapeutic
        candidates due to a change in business strategies, or a merger, acquisition, sale or downsizing;</div>
        <div style="text-align: justify; line-height: 1.25"> <br/> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z872ffb6c6f3640b28b75d193536b7960" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a collaboration partner may seek to renegotiate or terminate their relationships with
        us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a collaboration partner may cease development in therapeutic areas which are the subject
        of our strategic collaboration;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a collaboration partner may not devote sufficient capital or resources towards our
        therapeutic candidates;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a collaboration partner may change the success criteria for a therapeutic candidate,
        thereby delaying or ceasing development of such candidate;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a significant delay in initiation of certain development activities by a collaboration
        partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a collaboration partner could develop a product that competes, either directly or
        indirectly, with our therapeutic candidate;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a collaboration partner with commercialization obligations may not commit sufficient
        financial or human resources to the marketing, distribution or sale of a product;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a collaboration partner with manufacturing responsibilities may encounter regulatory,
        resource or quality issues and be unable to meet demand requirements;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a partner may exercise a contractual right to terminate a strategic alliance;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a dispute may arise between us and a partner concerning the research, development
        or commercialization of a therapeutic candidate resulting in a delay in milestones, royalty payments or termination of an alliance and
        possibly resulting in costly litigation or arbitration which may divert management attention and resources; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a partner may use our products or technology in such a way as to invite litigation
        from a third party.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Any collaborative partners may in the future shift their priorities
and resources away from our therapeutic candidates or seek to renegotiate or terminate their relationships with us. If any collaborator
fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing or commercialization
efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses
or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborative
relationships on acceptable terms or to successfully transition terminated collaborative agreements, we may have to delay or discontinue
further development of one or more of our therapeutic candidates, undertake development and commercialization activities at our own expense
or find alternative sources of capital.</div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">14</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">If we cannot meet requirements
under our in-license and collaboration agreements, we could lose the rights to any of our therapeutic candidates, which could have a material
adverse effect on our business.</div>

<div style="text-indent: 36pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We depend on in-licensing and collaboration agreements with third
parties to maintain the intellectual property rights to some of our therapeutic candidates. We have in-licensed rights from Biokine Therapeutics
Ltd., or Biokine, with respect to our motixafortide therapeutic candidate; and from Innovative Pharmaceutical Concepts, Inc., or IPC,
with respect to our BL-5010 therapeutic candidate. Additionally, we entered into a collaboration with Hemispherian for the development,
clinical evaluation and commercialization of GLIX1.&#160; See &#8220;Item 4.B. Information on the Company - Business Overview - In-Licensing
Agreements.&#8221; Our in-license and collaboration agreements require us to make payments and satisfy performance obligations in order
to maintain our rights under these agreements. For example, under the Collaboration Agreement with Hemispherian, we are required to invest
$5 million in Tetragon Biosciences Ltd., or Tetragon, a newly created company formed to develop GLIX1, within 36 months of the entry into
of the Collaboration Agreement, and failure to do so may result in a reduction of our equity interest or trigger repurchase rights in
favor of Hemispherian. Our in-license agreements generally remain in effect until the expiration, under the applicable agreement, of all
the licensing, royalty and sublicense revenue obligations to the applicable licensors, determined on a product-by-product and country-by-country
basis while our collaboration agreement with Hemispherian is based on specific business, financial, or procedural milestones. In addition,
we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents licensed
to us. Previously, in June 16, 2024, Biokine filed a complaint with the District Court of Jerusalem against us. The complaint alleged
breach of contract and a purported failure to make certain payments to Biokine under our in-licensing agreement with Biokine for motixafortide.
The lawsuit sought compensatory damages in the amount of approximately $7.2 million and declaratory judgment. The parties agreed to address
the matter through binding arbitration and in February 2026, the arbitrator issued a final award in our favor denying all claims asserted
against us and awarding us expenses, including legal fees. See &#8220;Item 8. Financial Information - Biokine Claim.&#8221; If we do not
meet our obligations under our in-license and collaboration agreements in a timely manner, we could lose the rights to our proprietary
technology, which could have a material adverse effect on our business, financial condition and results of operations. For more information,
see &#8220;Item 3.D - Key Information - Risks Related to our Intellectual Property - <span style="font-style: italic">Our access to most
of the intellectual property associated with our therapeutic candidates results from in-license and collaboration agreements with biotechnology
companies, the termination of which would prevent us from commercializing the associated therapeutic candidates.</span></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We depend on our ability
to identify and in-license technologies and therapeutic candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We employ a number of methods to identify therapeutic candidates
that we believe are likely to achieve commercial success. In certain instances, disease-specific third-party advisors evaluate therapeutic
candidates as we deem necessary. However, there can be no assurance that our internal research efforts or our screening system will accurately
or consistently select among various therapeutic candidates those that have the highest likelihood to achieve, and that ultimately achieve,
commercial success. As a result, we may spend substantial resources developing therapeutic candidates that will not achieve commercial
success, and we may not advance those therapeutic candidates with the greatest potential for commercial success. For example, we terminated
development of AGI-134 and in connection therewith, in June 2025, we sold our wholly-owned subsidiary, Agalimmune, to a third party for
future potential royalty consideration, in the event that such third party successfully brings an Agalimmune product to the market in
the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">An important element of our strategy is maintaining relationships
with universities, medical institutions and biotechnology companies in order to in-license potential therapeutic candidates. We may not
be able to maintain relationships with these entities, and they may elect not to enter into in-licensing agreements with us or to terminate
existing agreements. The existence of global companies with significantly greater resources than we have may increase the competition
with respect to the in-licensing of promising therapeutic candidates. We may not be able to acquire licenses on commercially reasonable
terms or at all. Failure to license or otherwise acquire necessary technologies could materially and adversely affect our business, financial
condition and results of operations.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">15</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">If competitors develop and
market products that are more effective, safer or less expensive than our current or future therapeutic candidates, our prospects will
be negatively impacted.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The life sciences industry is highly competitive, and we and our
licensees face significant competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching and
marketing products designed to address the indications for which we are currently developing GLIX1 or motixafortide or for which we may
develop therapeutic candidates in the future. Specifically, we are aware of other companies that currently market and/or are in the process
of developing products that address stem cell mobilization, solid malignancies and skin lesions. In particular, during 2023, the last
to expire patent for Mozobil and uses thereof, the standard of care for stem cell mobilization expired and as a consequence there are
several generic versions on the market. Successful commercialization of APHEXDA will in part require that our licensees are able to overcome
competition from Mozobil and its generic versions.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Any therapeutic candidates that we successfully develop and commercialize
will compete with existing therapies and new therapies that may become available in the future. The key competitive factors affecting
the success of each therapeutic candidate, if approved, is likely to be their safety, efficacy, convenience, price, the level of proprietary
and generic competition, and the availability of coverage and reimbursement from government and other third&#8209;party payors. APHEXDA
sales will suffer, or the commercial opportunity may be reduced or eliminated if competitors develop and commercialize products that are
safer or more effective, have fewer or less severe side effects, or are more convenient or less expensive than any products that we may
develop. Competitors may also obtain FDA or other regulatory approval for their therapeutic candidates more rapidly than we or our licensees
may be able to do so for any existing or new therapeutic candidates of ours, which could result in their establishing a strong market
position before we are able to enter the market.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Mergers and acquisitions in the biotechnology and pharmaceutical
industries may result in even more resources being concentrated in favor of our competitors. Additionally, many competitors have greater
experience in product discovery and development, obtaining FDA and other regulatory approvals and commercialization capabilities, which
may provide them with a competitive advantage. If we or our licensees are not able to compete effectively, our business will not grow
and our financial condition and operations will suffer.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">An important element of our strategy for identifying future products
is maintaining relationships with universities, medical institutions and biotechnology companies in order to in-license potential therapeutic
candidates, and we compete with respect to this in-licensing with a number of global pharmaceutical companies. The presence of these global
companies with significantly greater resources than we have may increase the competition with respect to the in-licensing of promising
therapeutic candidates. Our failure to license or otherwise acquire necessary technologies could materially and adversely affect our business,
financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">GLIX1, motixafortide or
any other therapeutic candidate that we or our licensees are able to commercialize, may become subject to unfavorable pricing regulations,
third-party payor reimbursement practices or healthcare reform initiatives, any of which could harm our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The commercial success of GLIX1, motixafortide and any other therapeutic
candidate will depend substantially, both domestically and abroad, on the extent to which product costs will be paid by third-party payors,
including government health care programs and private health insurers. There is significant uncertainty related to third-party payor coverage
and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country
to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review
period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains
subject to continuing governmental control even after initial approval is granted. As a result, we or our licensees might obtain marketing
approval for a product in a particular country but then be subject to price regulations that delay commercial launch of the product, possibly
for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country.
Adverse pricing limitations may hinder our ability to recoup our or their investment in one or more therapeutic candidates, even if our
therapeutic candidates obtain marketing approval.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">16</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Patients who are provided with medical treatment for their conditions
generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, our ability, and
the ability of any licensees to successfully commercialize any of our therapeutic candidates will depend in part on the extent to which
coverage and adequate reimbursement for these products and related treatments will be available from third-party payors. Third-party payors
decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment,
both in the United States and elsewhere. Government authorities and other third-party payors have attempted to control costs by limiting
coverage and the amount of reimbursement for particular medications, which could affect the ability to sell APHEXDA profitably. These
payors may not view APHEXDA as cost-effective, and coverage and reimbursement may not be available to customers or may not be sufficient
to allow our products to be marketed on a competitive basis. Cost-control initiatives could cause us or our licensees to decrease the
price we might establish, which could result in lower than anticipated product revenues. If the prices for our products, if any, decrease
or if governmental and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and profitability
will suffer.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">There may also be delays in obtaining coverage and reimbursement
for newly approved drugs, such as APHEXDA, and coverage may be more limited for APHEXDA than for other drug products with similar indications
approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any therapeutic
will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution.
Reimbursement rates may vary, for example, according to the use of the product and the clinical setting in which it is used. Reimbursement
rates may also be based on reimbursement levels already set for lower cost treatments or may be incorporated into existing payments for
other services.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, increasingly, third-party payors are requiring higher
levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We cannot be sure
that coverage will be available for any therapeutic candidate that we, or third parties, commercialize and, if available, that the reimbursement
rates will be adequate. Further, the net reimbursement for products may be subject to additional reductions if there are changes to laws
that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. An inability
to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any therapeutic candidate for
which we obtain regulatory approval could significantly harm our operating results and our overall financial condition.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We rely upon third-party
manufacturers to produce therapeutic supplies of GLIX1 and motixafortide. If we manufacture any therapeutic candidates in the future,
we will be required to incur significant costs and devote significant efforts to establish and maintain manufacturing capabilities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We do not currently have laboratories that are compliant with cGMP
and therefore cannot independently manufacture drug products for our current clinical trials or commercialization. We rely on third-party
manufacturers, including Ayrmid if it takes over manufacturing, to produce the therapeutic supplies that enable us to perform clinical
trials and supply commercial scale product. We have limited personnel with experience in drug product manufacturing and we lack the resources
and capabilities to manufacture any of our therapeutic candidates on a commercial scale. The manufacture of pharmaceutical products requires
significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers
of pharmaceutical products often encounter difficulties in production, particularly in scaling up initial production. These problems include
difficulties with production costs and yields and quality control, including stability of the therapeutic candidate.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We do not currently have any long-term agreements with third-party
manufacturers that guarantee the supply of therapeutic supplies and we rely on single source suppliers. When we require additional supplies
to complete our clinical trials or for commercialization, we may be unable to enter into agreements for clinical or commercial supply,
as applicable, with third-party manufacturers, or may be unable to do so on acceptable terms.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">17</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Reliance on third-party manufacturers entails risks to which we
would not be subject if we manufactured therapeutic candidates ourselves, including:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf1b25653568042858c30f88d1e66a69d" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">reliance on the third party for regulatory compliance and quality assurance;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">limitations on supply availability resulting from capacity and scheduling constraints
        of the third parties;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">impact on our reputation in the marketplace if manufacturers of our products, once
        commercialized, fail to meet customer demands;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the possible breach of the manufacturing agreement by the third party because of factors
        beyond our control; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the possible termination or nonrenewal of the agreement by the third party, based
        on its own business priorities, at a time that is costly or inconvenient for us.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25">The failure of any of our contract manufacturers to maintain high manufacturing standards
could result in injury or death of clinical trial participants or patients being treated with our products. Such failure could also result
in product liability claims, product recalls, product seizures or withdrawals, delays or failures in testing or delivery, cost overruns
or other problems, which would have a material adverse effect on our business, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Our contract manufacturers
are, and will be, subject to FDA and other comparable agency regulations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our contract manufacturers are, and will be, required to adhere
to FDA regulations setting forth current good manufacturing practices, or cGMP, for drugs. These regulations cover all aspects of the
manufacturing, testing, quality control and recordkeeping relating to our therapeutic candidates. Our manufacturers may not be able to
comply with applicable regulations. Our manufacturers are and will be subject to unannounced inspections by the FDA, state regulators
and similar regulators outside the United States. The failure of our third-party manufacturers to comply with applicable regulations could
result in the imposition of sanctions on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant
marketing approval of our therapeutic candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls
of our candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect
regulatory approval and supplies of our therapeutic candidates, and materially and adversely affect our business, financial condition
and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Our business could suffer
if we are unable to attract and retain key employees.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our success depends upon the continued service and performance
of our senior management and other key personnel. The loss of the services of these personnel could delay or prevent the successful completion
of our planned clinical trials or the commercialization of our therapeutic candidates or otherwise affect our ability to manage our company
effectively and to carry out our business plan. We do not maintain key-man life insurance. Although we have entered into employment agreements
with all of the members of our senior management team, members of our senior management team may resign at any time subject to prior notice
as applicable. High demand exists for senior management and other key personnel in the pharmaceutical industry. There can be no assurance
that we will be able to continue to retain and attract such personnel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our growth and success also depend on our ability to attract and
retain highly qualified scientific, technical, sales, managerial and finance personnel. We experience intense competition for qualified
personnel, and the existence of non-competition agreements between prospective employees and their former employers may prevent us from
hiring those individuals or subject us to suit from their former employers. While we attempt to provide competitive compensation packages
to attract and retain key personnel, many of our competitors are likely to have greater resources and more experience than we have, making
it difficult for us to compete successfully for key personnel. If we cannot attract and retain sufficiently qualified technical employees
on acceptable terms, we may not be able to develop competitive products. Further, any failure to effectively integrate new personnel could
prevent us from successfully growing our company.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">18</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Scrutiny of sustainability
and environmental, social, and governance, or ESG, initiatives could increase our costs or otherwise adversely impact our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Public companies have recently faced scrutiny related to ESG practices
and disclosures from certain investors, capital providers, shareholder advocacy groups, other market participants and other stakeholder
groups. Such scrutiny may result in increased costs, enhanced compliance or disclosure obligations, or other adverse impacts on our business,
financial condition or results of operations. If our ESG practices and reporting do not meet investor or other stakeholder expectations,
we may be subject to investor or regulator engagement regarding such matters. Our failure to comply with any applicable ESG rules or regulations
could lead to penalties and adversely impact our reputation, access to capital and employee retention. Such ESG matters may also impact
our third-party contract manufacturers and other third parties on which we rely, which may augment or cause additional impacts on our
business, financial condition, or results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">Risks Related to Our Industry</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Healthcare reforms and related
reductions in pharmaceutical pricing, reimbursement and coverage by governmental authorities and third-party payors may adversely affect
our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The continuing increase in expenditures for healthcare has been
the subject of considerable government attention, particularly as public resources have been stretched by financial and economic crises
in the United States, Western Europe and elsewhere. Both private health insurance funds and government health authorities continue to
seek ways to reduce or contain healthcare costs, including by reducing or eliminating coverage for certain products and lowering reimbursement
levels. In many countries and regions, including the United States, Western Europe, Israel, Russia, certain countries in Central and Eastern
Europe and several countries in Latin America, pharmaceutical prices are subject to new government policies designed to reduce healthcare
costs. These changes frequently adversely affect pricing and profitability and may cause delays in market entry. We cannot predict which
additional measures may be adopted or the impact of current and additional measures on the marketing, pricing and demand for our approved
products, if any of our therapeutic products are approved.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Significant developments that may adversely affect pricing in the
United States include (i) the enactment of federal healthcare reform laws and regulations, including the Medicare Prescription Drug Improvement
and Modernization Act of 2003 and the ACA, and (ii) trends in the practices of managed care groups and institutional and governmental
purchasers, including the impact of consolidation of our customers. In 2022, the IRA, established the Medicare Drug Price Negotiation
Program which permits the government to negotiate &#8220;maximum fair&#8221; drug prices for certain high expenditure, single source drugs
and biologics. As of January 1, 2026, 10 drugs now have Medicare-negotiated pricing with a second set of 15 drugs selected for price negotiation,
and whose prices will take effect in 2027. However, the IRA&#8217;s impact on the pharmaceutical industry in the United States remains
uncertain, in part because multiple large pharmaceutical companies and other stakeholders have initiated federal lawsuits against CMS
arguing the program is unconstitutional for a variety of reasons, among other complaints. Those lawsuits are currently ongoing.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">There have also been several recent U.S. Congressional inquiries
and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review
the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program
reimbursement methodologies for drugs. On September 24, 2020, the FDA released a final rule providing guidance for states to build and
submit importation plans for drugs from Canada. In 2025, HHS began implementation of &#8220;Most Favored Nation&#8221; drug pricing by
setting the Medicare price of single-source brand drugs without generic or biosimilar competition to the lowest price available in wealthy
countries with a per capita GDP of at least 60% of that in the United States.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">19</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Changes to the healthcare system enacted as part of healthcare
reform in the United States, as well as the increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and
private sector beneficiaries, may result in increased pricing pressure by influencing, for instance, the reimbursement policies of third-party
payors. Healthcare reform legislation has increased the number of patients who would have insurance coverage for our approved products,
if any of our therapeutic products are approved, but provisions such as the assessment of a branded pharmaceutical manufacturer fee and
an increase in the amount of the rebates that manufacturers pay for coverage of their drugs by Medicaid programs may have an adverse effect
on us. It is uncertain how current and future reforms in these areas will influence the future of our business operations and financial
condition, as federal, state and foreign governmental authorities are likely to continue efforts to control the price of drugs and reduce
overall healthcare costs. These efforts could have an adverse impact on our ability to market products and generate revenues in the United
States and foreign countries.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">If third-party payors do
not adequately reimburse customers for any of our therapeutic candidates that are approved for marketing, they might not be purchased
or used, and our revenues and profits will not develop or increase.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our revenues and profits will depend heavily upon the availability
of adequate reimbursement for the use of our approved candidates, if any, from governmental or other third-party payors, both in the United
States and in foreign markets. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s
determination that the use of an approved product is:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb4cf9d0d012c443b9712116c56d23e7b" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a covered benefit under its health plan;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">safe, effective and medically necessary;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">appropriate for the specific patient;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">cost-effective; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="text-align: right; line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">neither experimental nor investigational.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Obtaining reimbursement approval for a product from each government
or other third-party payor is a time-consuming and costly process that could require us or our licensees to provide supporting scientific,
clinical and cost-effectiveness data for the use of our products to each payor. Even when a payor determines that a product is eligible
for reimbursement, the payor may impose coverage limitations that preclude payment for some uses that are approved by the FDA or comparable
foreign regulatory authorities. Reimbursement rates may vary according to the use of the product and the clinical setting in which it
is used, may be based on payments allowed for lower-cost products that are already reimbursed, may be incorporated into existing payments
for other products or services, and may reflect budgetary constraints and/or imperfections in Medicare, Medicaid or other data used to
calculate these rates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Regardless of the impact of the ACA on us, the U.S. government,
other governments and commercial payors have shown significant interest in pursuing healthcare reform and reducing healthcare costs. Any
government-adopted reform measures could cause significant pressure on the pricing of healthcare products and services, including those
biopharmaceuticals currently being developed by us or our licensees, in the United States and internationally, as well as the amount of
reimbursement available from governmental agencies or other third-party payors. The continuing efforts of the U.S. and foreign governments,
insurance companies, managed care organizations and other payors to contain or reduce healthcare costs may compromise our ability to set
prices at commercially attractive levels for our products that we may develop, which in turn could adversely impact how much or under
what circumstances healthcare providers will prescribe or administer our products, if approved. Changes in healthcare policy, such as
the creation of broad limits for diagnostic products, could substantially diminish the sale of or inhibit the utilization of diagnostic
tests, increase costs, divert management&#8217;s attention and adversely affect our ability to generate revenues and achieve consistent
profitability. This could materially and adversely impact our business by reducing our ability to generate revenue, raise capital, obtain
additional collaborators and market our products, if approved.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">20</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Further, the Centers for Medicare and Medicaid Services, or CMS,
frequently change product descriptors, coverage policies, product and service codes, payment methodologies and reimbursement values. The
IRA will modify selected drugs and biologics through negotiation of a fair maximum pricing for CMS. Third-party payors often follow Medicare
coverage policy and payment limitations in setting their own reimbursement rates, and both CMS and other third-party payors may have sufficient
market power to demand significant price reductions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Our business has a substantial
risk of clinical trial and product liability claims. If we are unable to obtain and maintain appropriate levels of insurance, a claim
could adversely affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our business exposes us to significant potential clinical trial
and product liability risks that are inherent in the development, manufacturing and sales and marketing of human therapeutic products.
Claims could be made against us based on the use of our therapeutic candidates in clinical trials and in marketed products. In addition,
we have a cyber insurance policy with a coverage amount of $5.0 million per each claim and in the aggregate. However, our insurance may
not provide adequate coverage against potential liabilities. Furthermore, clinical trial and product liability insurance are becoming
increasingly expensive. As a result, we may be unable to maintain current amounts of insurance coverage or to obtain additional or sufficient
insurance at a reasonable cost to protect against losses that could have a material adverse effect on us. If a claim is brought against
us, we might be required to pay legal and other expenses to defend the claim, as well as damage awards beyond the coverage of our insurance
policies resulting from a claim brought successfully against us. Furthermore, whether or not we are ultimately successful in defending
any claims, we might be required to direct significant financial and managerial resources to such defense, and adverse publicity is likely
to result.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Significant disruptions
of our information technology systems or breaches of our data security could adversely affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A significant invasion, interruption, destruction or breakdown
of our information technology systems and/or infrastructure by persons with authorized or unauthorized access could negatively impact
our business and operations. We could experience business interruption, information theft and/or reputational damage from cyber-attacks
or cyber-intrusions over the Internet, computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical
failures, and attachments to emails. Any of the foregoing may compromise our systems and lead to data leakage either internally or at
our third-party providers. The risk of a security breach or disruption, particularly through cyber-attacks or cyber-intrusion, including
by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of
attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations,
it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed
or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to
recover or reproduce the data. Our systems have been, and are expected to continue to be, the target of malware and other cyber-attacks.
Although we have invested in measures to reduce these risks, we cannot assure you that these measures will be successful in preventing
compromise and/or disruption of our information technology systems and related data.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">21</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We deal with hazardous materials
and must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our activities and those of our third-party manufacturers on our
behalf involve the controlled storage, use and disposal of hazardous materials, including microbial agents, corrosive, explosive and flammable
chemicals, as well as cytotoxic, biologic, radio-labeled and other hazardous compounds. We and our manufacturers are subject to U.S. federal,
state, local, Israeli and other foreign laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous
materials. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed
by these laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In addition, if
we develop a manufacturing capacity, we may incur substantial costs to comply with environmental regulations and would be subject to the
risk of accidental contamination or injury from the use of hazardous materials in our manufacturing process.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the event of an accident, government authorities may curtail
our use of these materials and interrupt our business operations. In addition, we could be liable for any civil damages that result, which
may exceed our financial resources and may seriously harm our business. Although our Israeli insurance program covers certain unforeseen
sudden pollutions, we do not maintain a separate insurance policy for any of the foregoing types of risks. In addition, although the general
liability section of our life sciences policy covers certain unforeseen, sudden environmental issues, pollution in the United States and
Canada is excluded from the policy. In the event of environmental discharge or contamination or an accident, we may be held liable for
any resulting damages, and any liability could exceed our resources. In addition, we may be subject to liability and may be required to
comply with new or existing environmental laws regulating pharmaceuticals or other medical products in the environment.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We have in the past, and
may in the future, become subject to litigation or claims arising in or outside the ordinary course of business that could negatively
affect our business operations and financial condition.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have in the past, and may in the future, become subject to litigation
or claims arising in or outside the ordinary course of business (other than intellectual property infringement actions) that could negatively
affect our business operations and financial condition, including securities class actions which are typically expensive to defend. Such
claims and litigation proceedings may be brought by third parties, including our competitors, advisors, service providers, partners or
collaborators, employees, and governmental or regulatory bodies. Any claims and lawsuits, and the disposition of such claims and lawsuits,
could be time-consuming and expensive to resolve, divert management attention and resources, and lead to attempts on the part of other
parties to pursue similar claims. We may not be able to determine the amount of any potential losses and other costs we may incur due
to the inherent uncertainties of litigation and settlement negotiations. In the event we are required or decide to pay amounts in connection
with any claims or lawsuits, such amounts could be significant and could have a material adverse impact on our liquidity, business, financial
condition and results of operations. In addition, depending on the nature and timing of any such dispute, a resolution of a legal matter
could materially affect our future operating results, our cash flows or both. Additionally, we may be unable to maintain our existing
directors&#8217; and officers&#8217; liability insurance in the future at satisfactory rates or adequate coverage amounts and may incur
significant increases in insurance costs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">Risks Related to Intellectual Property</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Our access to most of the
intellectual property associated with our therapeutic candidates results from in-license and collaboration agreements with biotechnology
companies, the termination of which would prevent us from commercializing the associated therapeutic candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We do not conduct our own initial research with respect to the
identification of our therapeutic candidates. Instead, we rely upon research and development work conducted by third parties as the primary
source of our therapeutic candidates. As such, we have obtained our rights to our therapeutic candidates through in-licensing and collaboration
agreements entered into with biotechnology companies that invent and own or jointly own with us the intellectual property underlying our
candidates. There is no assurance that such agreements or rights will not be terminated or expire due to a material breach of the agreements,
such as a failure on our part to achieve certain progress milestones, funding obligations or other requirements set forth in the terms
of the agreements, or due to the loss of the rights to the underlying intellectual property by any of our licensors or collaborators.
For example, under the Collaboration Agreement with Hemispherian, we are required to invest $5 million in Tetragon within 36 months of
the entry into of the Collaboration Agreement, and failure to do so may result in a reduction of our equity interest or trigger repurchase
rights in favor of Hemispherian. There is no assurance that we will be able to renew or renegotiate an in-licensing agreement on acceptable
terms if and when the agreement terminates. We cannot guarantee that any agreement is enforceable or will not be terminated or converted
into a non-exclusive license in the future. The termination of any in-license or collaboration agreement or our inability to enforce our
rights under any such agreement would materially and adversely affect our ability to commercialize certain of our therapeutic candidates.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">22</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We currently have in-licensing and collaboration agreements relating
to our therapeutic candidates that are in development or are being commercialized. In 2012, we in-licensed the rights to motixafortide
under a license agreement from Biokine. Under the license agreement for motixafortide, we are obligated to make commercially reasonable,
good faith efforts to sublicense or commercialize motixafortide for fair consideration. In 2007, we in-licensed the rights to BL-5010
under a license agreement with IPC. Under the BL-5010 license agreement, we are obligated to use commercially reasonable efforts to develop
the licensed technology in accordance with a specified development plan, including meeting certain specified diligence goals. In 2025,
we entered into a Collaboration Agreement with Hemispherian for the development of GLIX1 via Tetragon. Under the Collaboration Agreement,
we are responsible for managing and implementing Tetragon&#8217;s activities and overseeing its operations, budget, and expenses.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Each of the foregoing in-licensing agreements, or the obligation
to pay royalties thereunder, will generally remain in effect until the expiration, under the applicable agreement, of all the licensing,
royalty and sublicense revenue obligations to the applicable licensors, determined on a product-by-product and country-by-country basis.
We may terminate the motixafortide in-licensing agreement upon 90 days&#8217; prior written notice to Biokine. We may terminate the BL-5010
in-licensing agreement upon 30 days&#8217; prior written notice to IPC. Any party to any of the foregoing in-licensing agreements may
terminate the respective agreement for material breach by the other party if the breaching party is unable to cure the breach within an
agreed-upon period, generally 30 days to 90 days, after receiving written notice of the breach from the non-breaching party.&#160;With
respect to GLIX1, the Collaboration Agreement may be terminated under certain circumstances, including cessation of operations or failure
to meet funding obligations. The termination or expiration of any of these agreements, or our inability to enforce our rights thereunder,
could prevent us from commercializing the associated therapeutic candidates and would have a material adverse effect on our business,
financial condition, and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Patent protection for our
products is important and uncertain.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our success depends, in part, on our ability, and the ability of
our licensees and licensors to obtain patent protection for any therapeutic candidate, maintain the confidentiality of our trade secrets
and know-how, operate without infringing on the proprietary rights of others and prevent others from infringing our proprietary rights.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We try to protect our proprietary position by, among other things,
filing U.S., European, Japanese, Chinese, Israeli and other patent applications related to our proprietary products, technologies, inventions
and improvements that may be important to the continuing development of our therapeutic candidates. As of March 8, 2026, we owned or exclusively
licensed for use within our field of business 20 patent families that collectively contain 141 granted patents, 3 allowed patent applications
and 97 pending patent applications relating to motixafortide, BL-5010 and GLIX1.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Because the patent position of biopharmaceutical companies involves
complex legal and factual questions, we cannot predict the validity and enforceability of patents with certainty. Our issued patents and
the issued patents of our licensees or licensors may not provide us with any competitive advantages or may be held invalid or unenforceable
as a result of legal challenges by third parties. Thus, any patents that we own or license from others may not provide any protection
against competitors. Our pending patent applications, those we may file in the future or those we may license from third parties may not
result in patents being issued. If these patents are issued, they may not provide us with proprietary protection or competitive advantages
against competitors with similar technology. The degree of future protection to be afforded by our proprietary rights is uncertain because
legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">23</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Patent rights are territorial; thus, the patent protection we do
have will only extend to those countries in which we have issued patents. Even so, the laws of certain countries do not protect our intellectual
property rights to the same extent as do the laws of the United States. For example, the patent laws of China and India are relatively
new and are not as developed as are older, more established patent laws of other countries. Competitors may successfully challenge our
patents, produce similar drugs or products that do not infringe our patents, or produce drugs in countries where we have not applied for
patent protection or that do not respect our patents. Furthermore, it is not possible to know the scope of claims that will be allowed
in published applications and it is also not possible to know which claims of granted patents, if any, will be deemed enforceable in a
court of law.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our technology may infringe the rights of third parties. The nature
of claims contained in unpublished patent filings around the world is unknown to us and it is not possible to know which countries patent
holders may choose for the extension of their filings under the Patent Cooperation Treaty, or other mechanisms. Any infringement by us
of the proprietary rights of third parties may have a material adverse effect on our business, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">If we are unable to protect the confidentiality of our trade secrets
or know-how, such proprietary information may be used by others to compete against us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We rely on a combination of patents, trade secrets, know-how, technology,
trademarks and regulatory exclusivity to maintain our competitive position. We generally try to protect trade secrets, know-how and technology
by entering into confidentiality or non-disclosure agreements with parties that have access to it, such as our licensees, employees, contractors
and consultants. We also enter into agreements that purport to require the disclosure and assignment to us of the rights to the ideas,
developments, discoveries and inventions of our employees, advisors, research collaborators, contractors and consultants while we employ
or engage them. However, these agreements can be difficult and costly to enforce or may not provide adequate remedies. Any of these parties
may breach the confidentiality agreements and willfully or unintentionally disclose our confidential information, or our competitors might
learn of the information in some other way. The disclosure to, or independent development by, a competitor of any trade secret, know-how
or other technology not protected by a patent could materially adversely affect any competitive advantage we may have over any such competitor.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">To the extent that any of our employees, advisors, research collaborators,
contractors or consultants independently develop, or use independently developed, intellectual property in connection with any of our
projects, disputes may arise as to the proprietary rights to this type of information. If a dispute arises with respect to any proprietary
right, enforcement of our rights can be costly and unpredictable, and a court may determine that the right belongs to a third party.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Legal proceedings or third-party
claims of intellectual property infringement may require us to spend substantial time and money and could prevent us from developing or
commercializing products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The development, manufacture, use, offer for sale, sale or importation
of therapeutic candidates may infringe on the claims of third-party patents. A party might file an infringement action against us. The
cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors
may be able to sustain the costs of such litigation or proceedings more effectively because of their substantially greater financial resources.
Uncertainties resulting from the initiation and continuation or defense of a patent litigation or other proceedings could have a material
adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management
time. Consequently, we are unable to guarantee that we will be able to manufacture, use, offer for sale, sell or import our therapeutic
candidates in the event of an infringement action. At present, we are not aware of pending or threatened patent infringement actions against
us.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">24</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the event of patent infringement claims, or to avoid potential
claims, we may choose or be required to seek a license from a third party and would most likely be required to pay license fees or royalties
or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may
be non-exclusive, which could potentially limit our competitive advantage. Ultimately, we could be prevented from commercializing a therapeutic
candidate or be forced to cease some aspect of our business operations if, as a result of actual or threatened patent infringement claims,
we are unable to enter into licenses on acceptable terms. This inability to enter into licenses could harm our business significantly.
At present, we have not received any written demands from third parties that we take a license under their patents nor have we received
any notice form a third party accusing us of patent infringement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our license agreements with our licensees contain, and any contract
that we enter into with licensees in the future will likely contain, indemnity provisions that obligate us to indemnify the licensee against
any losses arising from infringement of third-party intellectual property rights. In addition, our in-license agreements contain provisions
that obligate us to indemnify the licensors against any damages arising from the development, manufacture and use of products developed
on the basis of the in-licensed intellectual property.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We may be subject to other
patent-related litigation or proceedings that could be costly to defend and uncertain in their outcome.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition to infringement claims against us, we may in the future
become a party to other patent litigation or proceedings, including interference or re-examination proceedings filed with the U.S. Patent
and Trademark Office or opposition proceedings in other foreign patent offices regarding intellectual property rights with respect to
our products and technology, as well as other disputes regarding intellectual property rights with licensees, licensors or others with
whom we have contractual or other business relationships. Post-issuance oppositions are not uncommon and we, our licensee or our licensor
will be required to defend these opposition procedures as a matter of course. Opposition procedures may be costly, and there is a risk
that we may not prevail.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">We may be subject to damages resulting from claims that we or our
employees or contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Many of our employees and contractors were previously employed
at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims
against us are currently pending, we may be subject to claims that we or any employee or contractor has inadvertently or otherwise used
or disclosed trade secrets or other proprietary information of his or her former employers. Litigation may be necessary to defend against
these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel. A loss of key research personnel or their work product could hamper or prevent our ability to commercialize certain
therapeutic candidates, which could severely harm our business, financial condition and results of operations. Even if we are successful
in defending against these claims, litigation could result in substantial costs and be a distraction to management.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">25</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">Risks Related to Our Ordinary Shares and ADSs</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">There can be no assurance
that we will not be classified as a &#8220;passive foreign investment company,&#8221; or PFIC, for U.S. federal income tax purposes in
the current taxable year or may become one in any subsequent taxable year. There generally would be negative tax consequences for U.S.
taxpayers that are holders of our ordinary shares if we are or were to become a PFIC.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We will be treated as a PFIC for U.S. federal income tax purposes
in any taxable year in which either (i) at least 75% of our gross income is &#8220;passive income&#8221; or (ii) on average at least 50%
of our assets by value produce passive income or are held for the production of passive income. Passive income for this purpose generally
includes, among other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions and
from the sale or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of the
temporary investment of funds, including those raised in a public offering. In determining whether a non-U.S. corporation is a PFIC, a
proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by
value) is taken into account. We believe that we may have been a PFIC for the year ended December 31, 2025. Although we have not determined
whether we will be a PFIC for our taxable year ending December 31, 2026, or in any subsequent year, our operating results for any such
years may cause us to be a PFIC. Because PFIC status is determined annually and is based on our income, assets and activities for the
entire taxable year, it is not possible to determine with certainty whether we will be characterized as a PFIC for the 2026 taxable year
until after the close of the year, and there can be no assurance that we will not be classified as a PFIC in any future year. If we are
a PFIC for our taxable year ending December 31, 2025, or any subsequent year, and a U.S. Investor (as defined below) does not make an
election to treat us as a &#8220;qualified electing fund,&#8221; or QEF, or make a &#8220;mark-to-market&#8221; election, then &#8220;excess
distributions&#8221; to a U.S. Investor, and any gain realized on the sale or other disposition of our ordinary shares or ADSs will be
subject to special rules. Under these rules: (i) the excess distribution or gain would be allocated ratably over the U.S. Investor&#8217;s
holding period for the ordinary shares (or ADSs, as the case may be); (ii) the amount allocated to the current taxable year and any period
prior to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (iii) the amount allocated
to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for
that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each
such other taxable year. In addition, if the U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year with
respect to which we have determined that we were not a PFIC, it may be too late for a U.S. Investor to make a timely QEF or mark-to-market
election. U.S. Investors who hold our ordinary shares or ADSs during a period when we are a PFIC will be subject to the foregoing rules,
even if we cease to be a PFIC in subsequent years, subject to exceptions for U.S. Investors who made a timely QEF or mark-to-market election.
A U.S. Investor can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions
thereto. A QEF election generally may not be revoked without the consent of the IRS. Upon request, we intend to annually furnish U.S.
Investors with information needed in order to complete IRS Form 8621 (which form would be required to be filed with the IRS on an annual
basis by the U.S. Investor) and to make and maintain a valid QEF election for any year in which we are a PFIC. There is no assurance,
however, that we will have timely knowledge of our status as a PFIC, or that the information that we provide will be adequate to allow
U.S. Investors to make a QEF election. See also &#8220;Item 10. Additional Information-E. Taxation-Certain Material U.S. Federal Income
Tax Considerations.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Our business, operating
results and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments
with respect to financial institutions and associated liquidity risk.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our business depends on the economic health of the global economies.
If the conditions in the global economies remain uncertain or continue to be volatile, or if they deteriorate, including as a result of
the impact of military conflict, terrorism or other geopolitical events, our business, operating results and financial condition may be
materially adversely affected. Economic weakness, inflation and increases in interest rates, limited availability of credit, liquidity
shortages and constrained capital spending have at times in the past resulted, and may in the future result, in challenging and delayed
sales cycles, slower adoption of new technologies and increased price competition, and could negatively affect our ability to forecast
future periods, which could result in an inability to satisfy demand for our products and a loss of market share.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">26</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, increases in inflation raise our costs for commodities,
labor, materials and services and other costs required to grow and operate our business, and failure to secure these on reasonable terms
may adversely impact our financial condition. Additionally, increases in inflation, along with the uncertainties geopolitical developments
and global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest
rate environment, which may make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately
respond to these risks could have a material adverse impact on our financial condition, results of operations or cash flows.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">There can be no assurance that future credit and financial market
instability and a deterioration in confidence in economic conditions will not occur. Our general business strategy may be adversely affected
by any such economic downturn, liquidity shortages, volatile business environment or continued unpredictable and unstable market conditions.
If the current equity and credit markets deteriorate, or if adverse developments are experienced by financial institutions, it may cause
short-term liquidity risk and also make any necessary debt or equity financing more difficult, more costly, more onerous with respect
to financial and operating covenants and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable
terms could have a material adverse effect on our growth strategy, financial performance and market price of our ordinary shares and ADSs
and could require us to alter our operating plans. In addition, there is a risk that one or more of our service providers, financial institutions,
manufacturers, suppliers and other partners may be adversely affected by the foregoing risks, which could directly affect our ability
to attain our operating goals on schedule and on budget.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">The market prices of our
ordinary shares and ADSs are subject to fluctuation, which could result in substantial losses by our investors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The stock market in general and the market prices of our ordinary
shares on the TASE, and ADSs on Nasdaq, in particular, are subject to fluctuation, and changes in these prices may be unrelated to our
operating performance. We expect that the market prices of our ordinary shares and ADSs will continue to be subject to wide fluctuations.
The market price of our ordinary shares and ADSs are and will be subject to a number of factors, including:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" id="z1d862f1e977a462498b60ee90a8b0685" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">announcements of technological innovations or new products by us or others;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">announcements by us of significant acquisitions, strategic partnerships, in-licensing, out-licensing, joint
        ventures or capital commitments;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">expiration or terminations of licenses, research contracts or other collaboration agreements;</div> </td>
        </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">public concern as to the safety of drugs we, our licensees or others develop;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">general market conditions;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">the volatility of market prices for shares of biotechnology companies generally;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">success of research and development projects;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">departure of key personnel;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">developments concerning intellectual property rights or regulatory approvals;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">variations in our and our competitors&#8217; results of operations;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">27</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares or ADSs
        are covered by analysts;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">statements about the Company made in the financial media or by bloggers on the Internet;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">statements made about drug pricing and other industry-related issues by government officials;</div> </td>
        </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">changes in government regulations or patent decisions;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">developments by our licensees; and</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">general market conditions and other factors, including factors unrelated to our operating performance.</div>
        </td> </tr>
  </table> </div> <br/>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">These factors and any corresponding price fluctuations may materially
and adversely affect the market price of our ordinary shares and ADSs, and result in substantial losses by our investors. See also Risk
Factors-Risks Related to our Ordinary Shares and ADSs - &#8220;<span style="font-style: italic">Our business, operating results and growth
rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with respect
to financial institutions and associated liquidity risk.</span>&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Additionally, market prices for securities of biotechnology and
pharmaceutical companies historically have been very volatile. The market for these securities has from time to time experienced significant
price and volume fluctuations for reasons unrelated to the operating performance of any one company. Following periods of market volatility,
shareholders have often instituted securities class action litigation, and in the past, we have been party to securities class action
litigations. See &#8220;Item 8.A-Financial Information-Legal Proceedings&#8221; for additional information. Such securities litigation
or any additional securities litigation could have a substantial cost and divert resources and attention of management from our business,
even if we are successful.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our ordinary shares are traded on the TASE and our ADSs are listed
on Nasdaq. Trading in our securities on these markets takes place in different currencies (dollars on Nasdaq and NIS on the TASE), and
at different times (resulting from different time zones, and different public holidays in the United States and Israel). The trading prices
of our securities on these two markets may differ due to these factors, the factors listed above, or other factors. Any decrease in the
price of our securities on one of these markets could cause a decrease in the trading price of our securities on the other market.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Future sales of our ordinary
shares or ADSs could reduce the market price of our ordinary shares and ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Substantial sales of our ordinary shares or ADSs, either on the
TASE or on Nasdaq, may cause the market price of our ordinary shares or ADSs to decline. Sales by us or our securityholders of substantial
amounts of our ordinary shares or ADSs, or the perception that these sales may occur in the future, could cause a reduction in the market
price of our ordinary shares or ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As of March 8, 2026, as a result of previous financings, we had
(A) warrants outstanding (i) for the purchase of 1,596 ADSs at an exercise price of $564.00 per ADS, (ii) for the purchase of 277,273
ADSs at an exercise price of $46.00 per ADS, (iii) for the purchase of 17,045 ADSs at an exercise price of $55.00 per ADS, (iv) for the
purchase of 187,500 ADSs at an exercise price of $32.00 per ADS, (v) for the purchase of 205,893 ADSs at an exercise price of $23.60 per
ADS, (vi) for the purchase of 1,250,000 ADSs at an exercise price of $8.00 per ADS, and (vii) for the purchase of 62,500 ADSs at an exercise
price of $10.00 per ADS, and (B) pre-funded warrants outstanding for the purchase of 82,357 ADSs at an exercise price of $0.004 per ADS.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On September 3, 2021, we entered into an offering agreement, or
the HCW Offering Agreement, with H.C. Wainwright &amp; Co., LLC, or HCW, pursuant to which we may offer and sell, at our option, up to
$25.0 million of our ADSs through an &#8220;at-the-market&#8221; equity program under which HCW agreed to act as sales agent. As of March
8, 2026, we have sold 825,010 of our ADSs for total gross proceeds of approximately $9.6 million under the ATM program. Under General
Instruction I.B.5 to Form F-3 (also known as the baby shelf rule), we may currently sell up to $4.5 million under the ATM program.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">28</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As of March 8, 2026, in the framework of our Share Incentive Plan,
there are outstanding options, restricted share units, or RSUs, and performance share units, or PSUs, (granted to directors, employees
and consultants) for the purchase of 326,293,200 ordinary shares (equivalent to 543,822 ADSs) with a weighted average exercise price of
$0.03 per ordinary share (equivalent to $20.35 per ADS).</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The issuance of any additional ordinary shares, any additional
ADSs, or any securities that are exercisable for or convertible into our ordinary shares or ADSs, may have an adverse effect on the market
price of our ordinary shares and ADSs and will have a dilutive effect on our shareholders.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Raising additional capital
by issuing securities may cause dilution to existing shareholders.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We expect that we will need to raise substantial future capital
to continue to complete clinical development and commercialize our products and therapeutic candidates and to conduct the research and
development and clinical and regulatory activities necessary to bring our therapeutic candidates to market. Our future capital requirements
will depend on many factors, including:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z315a56047d2c4b3e8f25a6e0f945dd08" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the failure to obtain regulatory approval, in a timely manner or at all, or achieve
        commercial success of our therapeutic candidates;</div> </td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">our success in effecting out-licensing arrangements with third parties;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">our success in establishing other out-licensing or co-development arrangements;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the success of our licensees in selling products that utilize our technologies;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the results of our preclinical studies and clinical trials for our earlier-stage therapeutic
        candidates, and any decisions to initiate clinical trials if supported by the preclinical results;</div> </td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the costs, timing and outcome of regulatory review of our therapeutic candidates that
        progress to clinical trials;</div> </td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the costs of establishing or acquiring specialty sales, marketing and distribution
        capabilities, if any of our therapeutic candidates are approved, and we decide to commercialize them ourselves;</div> </td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the costs of preparing, filing and prosecuting patent applications, maintaining and
        enforcing our issued patents and defending intellectual property-related claims;</div> </td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the extent to which we acquire or invest in businesses, products or technologies and
        other strategic relationships; and</div> </td> </tr>
  <tr>
    <td rowspan="1" colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the costs of financing unanticipated working capital requirements and responding to
        competitive pressures.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If we raise additional funds through licensing arrangements with
third parties, we may have to relinquish valuable rights to our therapeutic candidates or grant licenses on terms that are not favorable
to us. If we raise additional funds by issuing equity or convertible debt securities, we will reduce the percentage ownership of our then-existing
shareholders, and these securities may have rights, preferences or privileges senior to those of our existing shareholders. See also &#8220;-
Future sales of our ordinary shares or ADSs could reduce the market price of our ordinary shares and ADSs.&#8221;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">29</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">As a foreign private issuer,
we follow certain home country corporate governance practices instead of applicable Nasdaq requirements, which may result in less protection
than is accorded to investors under rules applicable to domestic issuers.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As a foreign private issuer, we are permitted to follow certain
home country corporate governance practices instead of those otherwise required under the Listing Rules of the Nasdaq Stock Market, or
the Nasdaq Rules, for U.S. domestic issuers. For instance, we follow home country practice in Israel with regard to, among other things,
director nomination procedure, approval of compensation of officers, and quorum at shareholders&#8217; meetings. In addition, we will
follow our home country law, instead of the Nasdaq Rules, which require that we obtain shareholder approval for certain dilutive events,
such as for the establishment or amendment of certain equity-based compensation plans, an issuance that will result in a change of control
of the company, certain transactions other than a public offering involving issuances of a 20% or more interest in the company and certain
acquisitions of the stock or assets of another company. Following our home country governance practices as opposed to the requirements
that would otherwise apply to a U.S. company listed on Nasdaq may provide less protection than is accorded to investors under the Nasdaq
Rules applicable to U.S. domestic issuers. See &#8220;Item 16G - Corporate Governance - Nasdaq Listing Rules and Home Country Practices.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, as a foreign private issuer, we are exempt from the
rules and regulations under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, related to the furnishing and content
of proxy statements. While our officers and directors are, effective March 18, 2026, required to make insider reports under Section 16(a)
of the Exchange Act, our principal shareholders are exempt from the reporting under Section 16(a) of the Exchange Act, and our directors,
officers and principal shareholders continue to be exempt from the short-swing profit recovery provisions contained in Section 16(b) of
the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial
statements with the SEC as frequently or as promptly as domestic companies whose securities are registered under the Exchange Act.</div>

<div style="text-align: justify; line-height: 1.25"><br/> &#160;<span style="font-weight: bold; font-style: italic">If we fail to comply
with the continued listing requirements of the Nasdaq Capital Market, our ADSs may be delisted and the price of our ADSs and our ability
to access the capital markets could be negatively impacted.</span></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our ADSs are listed on the Nasdaq Capital Market. As such, we are
required to meet the continued listing requirements of the Nasdaq Capital Market and other Nasdaq rules, including minimum bid price,
minimum market value of publicly held shares, minimum shareholders&#8217; equity (or other financial metrics), corporate governance requirements,
and timely filing of periodic reports with the SEC. In particular, we are required to maintain a minimum bid price for our ADSs of $1.00
per ADS and in the past, we have fallen out of compliance with this listing standard although we subsequently regained compliance.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On January 26, 2026, Nasdaq filed a rule proposal with the SEC
that would permit the immediate suspension and delisting of a company listed on the Nasdaq Capital Market if its market value of listed
securities remains below $5 million for 30 consecutive business days. As of the date of this Annual Report, our market value of listed
securities is above $5 million; however, if this rule were to go into effect and we are unable to maintain our market value of listed
securities above $5 million, we would become subject to immediate suspension and delisting.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If we do not meet the minimum bid price requirement or other continued
listing requirements, our ADSs could be delisted. A delisting of our ADSs from Nasdaq could materially reduce the liquidity of our ADSs
and result in a corresponding material reduction in the price of our ADSs. In addition, delisting could harm our ability to raise capital
through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors,
employees and fewer business development opportunities and strategic alternatives. There can be no assurance that our ADSs, if delisted
from the Nasdaq Capital Market in the future, would be listed on a national securities exchange, a national quotation service, the Over-The-Counter
Markets or the pink sheets. Delisting from the Nasdaq Capital Market, or even the issuance of a notice of potential delisting, would also
result in negative publicity, make it more difficult for us to raise additional capital, adversely affect the market liquidity of our
ADSs, reduce security analysts&#8217; coverage of us and diminish investor, supplier and employee confidence. Additionally, the threat
of delisting or the delisting of our ADSs from the Nasdaq Capital Market could reduce the number of investors willing to hold or acquire
our ADSs, thereby further restricting our ability to obtain equity financing, and it could reduce our ability to retain, attract and motivate
our directors, officers and employees. In addition, as a consequence of any such delisting, our ADS price could be negatively affected
and our shareholders would likely find it more difficult to sell, or to obtain accurate quotations as to the prices of, our ADSs.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">30</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25; font-weight: bold">Risks Related to Our Operations in Israel</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">We conduct our operations
in Israel and therefore, may be adversely affected by political, geopolitical, economic and military instability in Israel and its region.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our headquarters and principal executive offices, development,
and some of our suppliers and third-party contractors are located in central Israel. In addition, all of our employees and officers and
the majority of our directors are residents of Israel. Accordingly, political, geopolitical, economic and military conditions in Israel
and the surrounding region may directly affect our business could harm our results of operations and could make it more difficult for
us to raise capital.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Since the establishment of the State of Israel in 1948, a number
of armed conflicts have occurred between Israel and its neighboring countries and militia groups, including Hamas (an Islamist terrorist
militia and political group that controls the Gaza Strip) and Hezbollah (an Islamist terrorist militia and political group based in Lebanon)
and other terrorist organizations active in the region. These conflicts have involved missile strikes, hostile infiltrations and terrorism
against civilian targets in various parts of Israel, which have negatively affected business conditions in Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In October 7, 2023, Hamas terrorists infiltrated Israel&#8217;s
southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive
rocket attacks on the Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas
within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the
attack, Israel&#8217;s security cabinet declared war against Hamas and, as a result of attacks by Hezbollah along Israel&#8217;s northern
border with Lebanon that commenced following the commencement of the war with Hamas, launched attacks against Hezbollah in Lebanon. Israel
was subsequently involved in military conflicts with Hamas, Hezbollah, and Iran, both directly and through Iranian proxies such as the
Houthi movement in Yemen and armed groups in Iraq and other terrorist organizations. Additionally, following the fall of the Assad regime
in Syria, Israel conducted limited military operations targeting the Assad-led Syrian army, Iranian military assets, and infrastructure
linked to Hezbollah and other Iran-supported groups. In November 2024, a ceasefire agreement was reached with Hezbollah in Lebanon.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In June 2025, in light of continued nuclear threats and intelligence
assessments, Israel launched a military operation directly targeting military and nuclear infrastructure inside Iran, aimed at disrupting
Iran's capacity to coordinate or launch further hostilities against Israel and to degrade its nuclear program. In response, Iran launched
multiple waves of drones and ballistic missiles at Israeli cities. While most of these attacks were intercepted, several caused civilian
deaths and casualties, as well as some damage to infrastructure and property. A ceasefire was declared between Israel and Iran in June
2025 after 12 days of hostilities.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In October 2025, a ceasefire in the conflict with Hamas came into
effect; however, the situation remains fragile, with isolated incidents of fighting.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On February 28, 2026, Israel and the United States commenced coordinated
military air strikes against targets in Iran, including military and strategic infrastructure in response to ongoing regional tensions
and recent escalations involving Iran&#8217;s nuclear and military activities.&#160; In response, Iran launched retaliatory attacks against
Israel, targeting major cities and strategic sites, which are ongoing. While most of these attacks have been intercepted to date, some
have resulted in civilian casualties and damage to property.&#160; Subsequently, Hezbollah launched attacks against Israel in retaliation
for the killing of Ali Hosseini Khamenei, the Supreme Leader of Iran, and in response, Israel launched attacks against Lebanon and Israeli
ground forces have entered into Southern Lebanon, and hostilities between Israel and Hezbollah are ongoing.&#160; Iran subsequently began
launching retaliatory strikes on U.S. and other targets in Kuwait, Qatar, Saudi Arabia, United Arab Emirates, Bahrain.&#160; The Israeli
government has declared a state of emergency, and the situation remains highly unstable, with ongoing exchanges of fire and heightened
risk of further escalation. Regional and international responses are ongoing, and the risk of broader conflict in the Middle East has
increased.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">31</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In connection with the Israeli security cabinet&#8217;s declaration
of war against Hamas, several hundred thousand Israeli military reservists were drafted to perform immediate military service. None of
our employees were called up for active duty; however, any renewed military actions, restrictions, or government-imposed measures could
adversely affect our business, prospects, financial condition and results of operations. As of March 8, 2026, we had 20 full-time and
4 part-time employees, all of whom are located in Israel.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our commercial insurance does not cover losses that may occur as
a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct
damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or
that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our
business and financial condition. Any armed conflicts or political instability in the region would likely negatively affect business conditions
and could harm our results of operations.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The continuation of the war and the recent conflicts also led to
a deterioration of certain indicators of Israel&#8217;s economic standing, for instance, international credit rating agencies have lowered
Israel&#8217;s credit rating. Credit rating agencies could further lower Israel&#8217;s credit rating in the future, which could disrupt
the business environment in Israel and make investors hesitant to invest or transact business in Israel.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, several organizations and countries may restrict doing
business with Israel and Israeli companies, including economic boycotts. The interruption or curtailment of trade between Israel and its
present trading partners could adversely affect our business, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Further, political instability in Israel or any negative changes
in the political environment, may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial
condition, results of operations and growth prospects.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The continued hostilities between Israel and its neighbors and
any future armed conflict, terrorist activity or political instability in Israel or the region could adversely affect our operations in
Israel and adversely affect the market price of our ordinary shares and ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Due to a significant portion
of our expenses and revenues being denominated in non-dollar currencies, our results of operations may be harmed by currency fluctuations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our reporting and functional currency is the U.S. dollar. However,
we pay a significant portion of our expenses in NIS, and we expect this to continue. If the dollar materially depreciates against the
NIS in the future, then the U.S. dollar cost of our operations in Israel would increase and our results of operations could be materially
and adversely affected. Although the revenues from our current out-licensing and co-development arrangements are payable in dollars and
we expect our revenues from any future licensing arrangements to be denominated primarily in dollars, we are exposed to currency fluctuation
risks relating to the recording of our revenues in currencies other than the U.S. dollar. From time to time, we engage in currency hedging
transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of the currencies mentioned above in relation
to the dollar. These measures, however, may not adequately protect us from material adverse effects.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">32</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Before we in-licensed motixafortide,
Biokine had received Israeli government grants for motixafortide research and development. Under our agreement with Biokine, we are required
to abide with terms of these grants, which require us, in addition to payment of royalties, to satisfy specified conditions in order to
transfer the manufacture of products and transfer technologies outside of Israel and to make additional payments in addition to repayment
of the grants.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Before we in-licensed motixafortide, Biokine had received $2.7
million in funding for the project from the Israel Innovation Authority, or the IIA (formerly the Office of the Chief Scientist of Israel&#8217;s
Ministry of Economy and Industry, or the OCS). As a condition for the IIA&#8217;s consent to our in-licensing of motixafortide, we were
required to agree to abide by any obligations resulting from such funding under the Israeli Encouragement of Industrial Research, Development
and Technological Innovation Law, 1984, and related regulations, as amended (the Research Law). Under the Research Law and the terms of
IIA grants, royalties on the revenues derived from sales of products (and associated services) developed with IIA funding are payable
to the Israeli government, generally at the rate of 3% (and at an increased rate under certain circumstances, as described below). The
obligation to make these royalty payments terminates upon repayment of the amount of grants, linked to the U.S. dollar, plus interest
(in accordance with IIA regulations), which amount may be increased under certain circumstances, as described below.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Research Law, the transfer or license to third parties
outside of Israel of know-how or technologies developed under IIA-funded programs, or the transfer to third parties outside of Israel
of manufacturing or rights to manufacture based on IIA-funded know-how, requires the consent of the IIA in certain circumstances, and
may result in increased payments to the IIA. Specifically, for the transfer of manufacturing outside of Israel, royalty payments can be
up to three times the amount of the IIA grants received, linked, plus interest, and the royalty repayment rate may increase. For the transfer
of IIA-funded know-how outside of Israel, the payment may be up to six times the amount of the IIA grants, linked, plus interest. In connection
with the IIA&#8217;s approval of the out-licensing transactions with Gloria and Ayrmid, the IIA determined that we are required to pay
the IIA 3.9% on any sub-license consideration, up to six times the IIA grant, linked, plus interest. Additionally, in December 2024, we
received IIA approval to transfer the manufacturing of motixafortide outside of Israel, which requires us to pay the IIA 4% of proceeds
on any direct product sales, up to three times the IIA grant, linked plus interest. As of December 31, 2025, $1.3 million in aggregate
royalties had been paid to the IIA on account of the motixafortide program and there was a contingent liability to the IIA (including
interest) of $2.5 million (without taking into account the potential repayment requirement of up to six times the amount as detailed above).
In any event, under our agreement with Biokine, we have a full right of offset for amounts payable to the IIA for the motixafortide program
from any payments that we may owe to Biokine in the future.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Should we wish to further out-license motixafortide in the future,
there is no assurance that we will be able to obtain the IIA&#8217;s consent on terms acceptable to us, or at all. Even following the
full repayment of IIA grants, we must nevertheless continue to comply with the requirements of the Research Law. If we fail to comply
with any of the conditions and restrictions imposed by the Research Law and regulations and guidelines thereunder, or by the specific
terms of the IIA grants, we may be required to refund any IIA grants that Biokine previously received together with interest and penalties,
and, in certain circumstances, may be subject to criminal charges. In any event, under our agreement with Biokine, we have a full right
of offset for amounts payable to the IIA for the motixafortide program from any payments that we may owe to Biokine in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Provisions of Israeli law
and our Articles of Association may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could prevent
a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Israeli corporate law regulates mergers, requires tender offers
for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant
shareholders and regulates other matters that may be relevant to these types of transactions. For example, a merger may not be consummated
unless at least 50 days have passed from the date that a merger proposal was filed by each merging company with the Israel Registrar of
Companies and at least 30 days from the date that the shareholders of both merging companies approved the merger. In addition, a majority
of each class of securities of the target company must approve a merger. Moreover, a tender offer for all of a company&#8217;s issued
and outstanding shares can only be completed if the acquirer receives the approval of at least 95% of the issued share capital (provided
that a majority of the offerees that do not have a personal interest in such tender offer shall have approved the tender offer, except
that if the total votes to reject the tender offer represent less than 2% of the company&#8217;s issued and outstanding share capital,
in the aggregate, approval by a majority of the offerees that do not have a personal interest in such tender offer is not required to
complete the tender offer). Furthermore, the shareholders, including those who indicated their acceptance of such a tender offer, may,
at any time within six months following the completion of the tender offer, claim that the consideration for the acquisition of the shares
did not reflect their fair market value and petition an Israeli court to alter the consideration for the acquisition accordingly (unless
the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek appraisal rights, and the acquirer
or the company published all required information with respect to the tender offer prior to the date indicated for response to the tender
offer).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">33</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Furthermore, Israeli tax considerations may make potential transactions
unappealing to us or to our shareholders, such as for those whose country of residence does not have a tax treaty with Israel exempting
such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S.
tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on
the fulfilment of numerous conditions, including, in some cases, a holding period of two years from the date of the transaction during
which sales and dispositions of shares of the participating companies are subject to certain restriction. Moreover, with respect to certain
share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable, even if no actual disposition
of the shares has occurred.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Further, our Articles of Association, as amended and currently
in effect, or our Articles of Association provide that our directors (other than external directors, if any) are elected on a staggered
basis, such that a potential acquirer cannot readily replace our entire board of directors at a single annual general shareholder meeting;
rather, at least two annual meetings of shareholders will generally be required to effect a change in a majority of our board of directors.
Any amendment to the provision in our Articles of Association dividing our directors into three classes and certain related provisions
requires a vote of the holders of at least 65% of the shares represented at the meeting and voting on the matter.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">These and other similar provisions could delay, prevent or impede
an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-style: italic">It may be difficult
to enforce a U.S. judgment against us and our officers and directors in Israel or the United States,</span>&#160;<span style="font-weight: bold; font-style: italic">to
assert U.S. securities laws claims in Israel or to serve process on our officers and directors.</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are incorporated in Israel. All of our executive officers and
the majority of our directors reside outside of the United States, and a significant portion of our assets and most of the assets of such
executive officers and directors are located outside of the United States. Therefore, a judgment obtained against us or any of our executive
officers and directors in the United States, including a judgment based on the civil liability provisions of the U.S. federal securities
laws, may not be collectible in the United States. It also may be difficult for you to effect service of process on these persons in the
United States or to assert U.S. securities law claims in original actions instituted in Israel or obtain a judgment based on the civil
liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim against us or our non-U.S. officers and
directors based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring
such a claim. In addition, even if an Israeli court agrees to hear such a claim, it may determine that Israeli law and not U.S. law is
applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert
witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There
is little binding case law in Israel that addresses the matters described above. Additionally, Israeli courts might not enforce judgments
obtained in the United States against us or our non-U.S. directors and executive officers, which may make it difficult to collect on judgments
rendered against us or our non-U.S. officers and directors.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">34</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Your rights and responsibilities
as a shareholder will be governed by Israeli law, which may differ in some respects from the rights and responsibilities of shareholders
of U.S. companies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are incorporated under Israeli law. The rights and responsibilities
of the holders of our ordinary shares are governed by our Articles of Association and Israeli law. These rights and responsibilities differ
in some respects from the rights and responsibilities of shareholders in typical U.S.-based corporations. In particular, pursuant to the
Companies Law, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner toward the company and other
shareholders, and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of
shareholders on amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers
and acquisitions and interested party transactions requiring shareholder approval under the Companies Law, as well as a general duty to
refrain from discriminating against other shareholders. In addition, a controlling shareholder and a shareholder who knows that it possesses
the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive officer in
the company or has other powers toward the company, has a duty of fairness toward the company. Israeli law does not define the substance
of this duty of fairness and there is limited case law available to assist us in understanding the nature of these duties or the implications
of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares
that are not typically imposed on shareholders of U.S. corporations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM4"><!--Anchor--></span>ITEM 4. INFORMATION ON THE
COMPANY</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. History and Development of the Company</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our legal and commercial name is BioLineRx Ltd. We are a company
limited by shares organized under the laws of the State of Israel. Our principal executive offices are located at 2 HaMa&#8217;ayan Street,
Modi&#8217;in 7177871, Israel, and our telephone number is +972 (8) 642-9100.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Following the entry into the collaboration with Hemispherian, we
currently own 40% of Tetragon, the newly created company formed to develop GLIX1, with the remaining 60% owned by Hemispherian. Tetragon
is considered our partially owned subsidiary.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our wholly owned subsidiary, BioLineRx USA, Inc., was incorporated
in Delaware on January 4, 2008, and is currently inactive.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We were founded in 2003 by leading institutions in the Israeli
life sciences industry. We completed our initial public offering in Israel in February 2007 and our ordinary shares are traded on the
TASE under the symbol &#8220;BLRX.&#8221; In July 2011, we listed our ADSs on Nasdaq and they are traded under the symbol &#8220;BLRX.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In March 2017, we acquired Agalimmune a private U.K.-based company
and in June 2025, we sold Agalimmune, to a third party for future potential royalty consideration.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our capital expenditures for each of the years ended December 31,
2024 and 2025 were immaterial and were $0.3 million for the year ended December 31, 2023. Our current capital expenditures involve acquisitions
of laboratory equipment, computers and communications equipment.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The SEC maintains an Internet site that contains reports, proxy
and information statements, and other information regarding issuers like BioLineRx that file electronically with the SEC. The address
of that site is <span style="font-style: italic"><span style="text-decoration: underline">www.sec.gov</span></span>. We maintain a corporate
website at <span style="font-style: italic"><span style="text-decoration: underline">www.biolinerx.com</span>. </span>Information contained
on or accessible through our website is not a part of this Annual Report on Form 20-F, and the inclusion of our website address herein
is an inactive textual reference only.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">35</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We use our website (<span style="text-decoration: underline">http://www.biolinerx.com</span>)
as a channel of distribution of Company information. The information we post through this channel may be deemed material. Accordingly,
investors should monitor our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.
The contents of our website are not, however, a part of this Annual Report on Form 20-F.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. Business Overview</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">General</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are a biopharmaceutical company pursuing life-changing therapies
in oncology and rare diseases. Our first approved product, APHEXDA&#174; (motixafortide), a novel peptide for the treatment of stem-cell
mobilization and solid tumors, with an indication in the United States for stem cell mobilization for&#160;autologous transplantation
in multiple myeloma, is being developed and commercialized by Ayrmid Pharma Ltd. (globally, excluding Asia) and Gloria, (in Asia). We
are also advancing the development of motixafortide for patients with pancreatic cancer and other solid tumors outside of Asia.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In October 2023, we out-licensed the rights to motixafortide for
all indications in substantially all of Asia to Gloria, and in November 2024, we out-licensed the global rights (other than in Asia) to
motixafortide for all indications, other than solid tumors, to Ayrmid. As a result of the November 2024 transaction, we shut down our
independent commercialization activities in the United States and refocused our operations on development activities in Israel in the
fields of oncology (including solid tumors) and rare diseases, at a significantly reduced annual cash burn rate.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have retained the rights to develop motixafortide across all
solid tumor indications, in all territories other than Asia, including in PDAC, for which an investigator-initiated Phase 2b trial, sponsored
by Columbia University, and supported equally by us and Regeneron, is ongoing at a relatively minimal cost to us. We expect this program
to continue to advance without any significant expense to us.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In September 2025, we entered into a collaboration transaction
with Hemispherian a Norwegian biotech company focused on small molecule cancer therapeutics,&#160;for the development, clinical evaluation
and commercialization&#160;of GLIX1, Hemispherian&#8217;s lead drug candidate, a first-in-class, oral, small molecule targeting DNA damage
response in glioblastoma, or GBM, and other cancers. Under the terms of the Collaboration Agreement, development of GLIX1 is being carried
out by Tetragon.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A key pillar of our growth strategy is to in-license additional
assets in the fields of oncology and rare diseases &#8211; areas where significant unmet medical needs remain and where innovative therapies
can have a transformative impact on patient lives. We are committed to identifying and advancing therapeutic candidates that demonstrate
clear differentiation from currently available treatments, offering the potential for superior efficacy, improved safety, and novel mechanisms
of action. We have generated our pipeline through a systematic process of asset identification, rigorous scientific and clinical validation,
and disciplined in-licensing. We believe this methodical approach allows us to select candidates with a high probability of both therapeutic
and commercial success. Drawing on our substantial experience in asset scouting and evaluation and executing transactions structured with
back-ended, success-based consideration, we are seeking to secure assets with modest upfront payments, while aligning incentives with
our partners and maintaining a focus on cost-effective clinical development programs. With our deep expertise, strategic focus, and prudent
financial management, we believe we are uniquely positioned to bring forward novel therapies that can redefine standards of care and deliver
significant value to patients, healthcare providers, and stakeholders.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our longer-term vision is to develop innovative assets with significant
potential value whose development costs have been offset by the royalties and milestones from our existing motixafortide partnerships.
We aim to continue pursuing new partnerships on these programs to create additional value for our shareholders.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">36</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Our Product Pipeline</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The table below summarizes key information about our products and
our clinical programs:</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25"><img src="image2.jpg" alt="" style="height: 376px; width: 698px; border: black 0px solid"/></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25"><img src="image3.jpg" alt="" style="height: 52px; width: 121px"/></div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">GLIX1</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In September 2025, we entered into a collaboration transaction
with Hemispherian for the development, clinical evaluation and commercialization of GLIX1, a first-in-class, oral, small molecule targeting
DNA damage response in glioblastoma and other solid tumors. GLIX1, Hemispherian&#8217;s lead drug candidate, is initially being developed
as a potential treatment for newly diagnosed and recurrent GBM.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">GBM is the most common and aggressive form of primary brain cancer&#8203;.
The current standard of care (SoC) treatment was established in 2005, with only limited further advancements since. Treatment includes
surgical resection, followed by radiotherapy, and concomitant and adjuvant chemotherapy (Temozolomide), yet most patients will succumb
to their disease within less than 18 months (median OS of 12-18 months). GBM occurs at all ages, but peaks in the fifth and sixth decades
of life, with an increasing incidence in light of the aging global population. The current standard of care (SoC) for newly diagnosed
GBM, established in 2005, consists of surgical resection followed by radiotherapy and treatment with temozolomide (TMZ). While the addition
of TMZ to radiotherapy has demonstrated a marginal improvement in overall survival&#8212;14.6 months with TMZ compared to 12.1 months
without&#8212;this benefit is primarily observed in patients whose tumors have a methylated MGMT promoter, a subgroup that comprises only
approximately 30% of GBM patients. There is currently no established standard of care for patients with recurrent GBM, further highlighting
the urgent need for new therapeutic options in this patient population. New and better treatments are desperately needed aiming at improving
survival, maintaining quality of life and delaying tumor progression and symptoms.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The annual incidence of GBM is expected to be approximately 18,500
patients in the U.S. and approximately 13,400 across the EU5 (France, Germany, Italy, Spain and the United Kingdom) by 2030.&#160; Based
on our estimates, we believe the total addressable market for newly diagnosed and recurrent GBM in the U.S., Germany, UK, France, Italy
and Spain will reach approximately $3.7 billion by 2030.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">37</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">GLIX1 is a first-in-class therapeutic agent with a novel mechanism
of action that targets DNA damage repair by restoring Ten-Eleven Translocation 2 (TET2) activity, making it applicable to a broad range
of cancers.&#160; DNA methylation and demethylation are essential processes for normal cellular function. TET2 is a key enzyme responsible
for initiating the DNA demethylation cycle, which results in the formation of single-stranded DNA breaks that are well tolerated in healthy
cells. In cancer cells, however, hypermethylation in certain regions is a common feature, and TET2 activity is frequently inhibited by
oncometabolites, leading to increased DNA methylation in close genomic proximity. Restoration of TET2 activity in these cancer cells generates
numerous single-stranded DNA breaks at heavily methylated regions, which are subsequently converted into double-stranded DNA breaks. This
overwhelms the DNA repair capacity of the cancer cells, ultimately resulting in cell death. This mechanism underpins the therapeutic rationale
for targeting TET2 activity in cancers characterized by reduced TET2 activity.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Preclinical studies of GLIX1 have demonstrated its ability to restore
TET2 activity in cancer cells, resulting in increased levels of 5-hydroxymethylcytosine (5hmC) and the induction of double-stranded DNA
breaks, ultimately leading to cancer cell death. In tumor tissue, GLIX1 treatment was associated with a significant increase in 5hmC levels
compared to controls (p&lt;0.001), confirming the compound&#8217;s on-target activity. Immunohistochemical analyses further showed that
restoration of 5hmC in cancer cells led to the accumulation of DNA damage markers and apoptosis. GLIX1 exhibited high potency, as reflected
by low IC50 values, across a variety of cancer cell lines. Importantly, GLIX1 demonstrated strong synergy with PARP inhibitors (PARPi),
sensitizing homologous recombination (HR)-proficient cancer cells to PARPi therapy. This finding suggests that GLIX1 may substantially
expand the population of patients who could benefit from PARP inhibitor-based regimens, beyond the small subset of HR-deficient cancers
currently addressed by these agents.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">GBM was selected as the initial clinical indication for GLIX1 based
on several lines of evidence. GBM and other high-grade gliomas are characterized by significantly reduced 5hmC levels and increased DNA
methylation compared to healthy brain tissue. GLIX1 demonstrated efficacy in orthotopic GBM xenograft models, with treated animals showing
marked tumor reduction compared to controls. Additionally, GLIX1 was effective in cell lines resistant to TMZ, the current standard of
care, addressing a critical unmet need as more than half of GBM patients are TMZ-resistant due to unmethylated MGMT promoter status. Pharmacokinetic
studies in healthy mice showed that GLIX1 achieves good blood-brain barrier penetration following oral administration, with favorable
brain and plasma exposure profiles. Collectively, we believe these results support the advancement of GLIX1 into clinical development
for GBM and potentially other cancers with reduced TET2 activity or high HR proficiency. GBM has been selected as the initial target indication,
with data from this setting expected to support further development of GLIX1 in central nervous system malignancies as well as additional
cancer types.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">An IND application was cleared by the FDA in August 2025, and a
Phase 1/2 study is expected to initiate in Q1 2026. GLIX1 has also been granted Orphan Drug Designation by both the FDA and the European
Medicines Agency, or EMA, underscoring the substantial unmet need in this indication. Further development in other solid tumors is being
planned.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The open-label dose escalation Phase 1 part of the trial is expected to recruit up to
30 patients with recurrent and progressive GBM and other high-grade gliomas. The objective of this part is to establish a maximum tolerated
dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy&#8203;. Data from the Phase 1 part of the trial is
anticipated in H1 2027. The Phase 2a expansion part of the trial is planned to include various population cohorts including GBM (newly
diagnosed and/or recurrent), as well as additional cancers with/without SOC (e.g., PARP inhibitors). These cohorts are planned to provide
preliminary efficacy, PD assessments and dose optimization to provide the basis for a rapid and effective advanced clinical development
program. Data from the Phase 2 part of the trial is planned in H1 2028.</div> </div> </div> </div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Motixafortide</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Motixafortide is a novel, short peptide that functions as a high-affinity
antagonist for CXCR4, for the treatment of stem cell mobilization and solid tumors. CXCR4 is expressed by normal hematopoietic cells and
overexpressed in various human cancers where its expression correlates with disease severity. CXCR4 is a chemokine receptor that mediates
the homing and retention of hematopoietic stem cells, or HSCs, in the bone marrow, and also mediates tumor progression, angiogenesis (growth
of new blood vessels in the tumor), metastasis (spread of tumor to other organs) and survival. Before &#8220;motixafortide&#8221; was
approved by the World Health Organization, or WHO, in 2019 as an International Nonproprietary Name, this therapeutic candidate was known
as &#8220;BL-8040.&#8221; In October 2021, we received WHO approval of the United States Adopted Name, or USAN, &#8220;motixafortide.&#8221;
The FDA-approved trade or brand name of motixafortide is APHEXDA.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">38</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div> <br/>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Inhibition of CXCR4 by motixafortide leads to the mobilization
of HSCs from the bone marrow to the peripheral blood, enabling their collection for subsequent autologous or allogeneic transplantation
in cancer and other patients requiring the mobilization of HSCs. Clinical data has demonstrated the ability of motixafortide to mobilize
higher numbers of long-term engrafting HSCs (CD34+CD38-CD45RA-CD90+CD49f+) as compared to G-CSF.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Motixafortide also mobilizes cancer cells from the bone marrow,
detaching them from their survival signals and sensitizing them to chemotherapy. In addition, motixafortide has demonstrated a direct
anti-cancer effect by inducing apoptosis (cell death) and inhibiting proliferation in various cancer cell models (multiple myeloma, non-Hodgkin&#8217;s
lymphoma, leukemia, non-small-cell lung carcinoma, neuroblastoma and melanoma).</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the field of immuno-oncology, motixafortide mediates infiltration
of effector T-cells while reducing immune suppressor cells (Tregs and MDSCs) in the tumor microenvironment, or TME.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The following is a summary of our motixafortide principal development activities.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Stem cell mobilization</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic">Multiple Myeloma</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In September 2023, the FDA approved motixafortide in combination
with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients
with multiple myeloma. In March 2025, marketing authorization with the FDA was transferred to Ayrmid.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In November 2023, we initiated pivotal bridging study preparation
activities with Gloria, our Asia partner, to support potential approval and commercialization of motixafortide in stem-cell mobilization
in China. In February 2024, an IND was filed with the Center for Drug Evaluation of the National Medical Products Administration, which
was approved in May 2024. The study in China was originally planned to commence in the first half of 2025 and was initiated in November
2025, with data approximately 18 months later.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Sickle Cell Disease</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In March 2023, we entered into a clinical collaboration with Washington
University School of Medicine in St. Louis to advance a Phase 1 clinical trial in which motixafortide would be evaluated as a monotherapy
and in combination with natalizumab (VLA-4 inhibitor), as novel regimens to mobilize CD34+ hematopoietic stem cells (HSC) for gene therapies
in Sickle Cell Disease. The proof-of-concept investigator-initiated study planned to enroll ten adults with a diagnosis of SCD that were
receiving automated red blood cell exchanges via apheresis. The trial&#8217;s primary objective was to assess the safety and tolerability
of motixafortide alone and in combination with natalizumab in SCD patients, defined by dose-limiting toxicities. Secondary objectives
included determining the number of CD34+ hematopoietic stem and progenitor cells (HSPCs) mobilized via leukapheresis; and determining
the pharmacokinetics of CD34+ HSPCs mobilization to peripheral blood in response to motixafortide alone and motixafortide plus natalizumab
in SCD patients. The study began in 2023 and was completed during 2025. Following the out-licensing of motixafortide to Ayrmid, the study
was continued under the Ayrmid License Agreement. Final results from the study were presented in a poster presentation at the 67th&#160;American
Society of Hematology (ASH) Annual Meeting in December 2025. A summary of the published abstract is set forth below.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Ten subjects were enrolled (median age 29.5 yrs, 50% male, 90%
SS). Motixafortide alone and in combination with natalizumab were safe and well tolerated. Common adverse events were transient and included
Grade 1-2 injection site and systemic reactions (pruritic &#8211; 90%; tingling/pain &#8211; 80%; urticaria &#8211; 40%). No Grade 4 adverse
events, dose limiting toxicities or complicated vaso-occlusive crises were observed.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">39</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Motixafortide alone, and in combination with natalizumab, resulted
in robust CD34+ HSC mobilization to the peripheral blood, or PB. Motixafortide alone mobilized a median of 189 CD34+ cells/&#956;l (range
77-690) to the PB at 10-14 hours post motixafortide administration, with a median 4.22x10<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">6</sup>&#160;CD34+
cells/kg as part of a single blood volume collection, projecting the collection of 16.9x10<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">6</sup>&#160;HSCs
in a normal, single-day four-blood-volume apheresis collection session. Motixafortide in combination with natalizumab mobilized a median
of 312 CD34+ cells/&#956;l (range 117-447) at 14 hours post motixafortide administration, with median 4.89x10<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">6</sup>&#160;CD34+
cells/kg collected as part of a single blood volume collection, projecting the collection of 19.6x10<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">6</sup>&#160;CD34+
HSCs in a single-day four-blood -volume apheresis collection session. In two subjects with prior plerixafor mobilization, motixafortide
alone, and in combination with natalizumab led to 2.7-2.8 fold higher PB CD34+ cells/&#956;l and 2.8-3.2 fold higher CD34+ cells/kg, respectively.
Moreover, while all SCD subjects mobilized well, two phenotypic SCD subgroups were identified with distinct mobilization kinetics, &#8220;super&#8221;
(n=4) and &#8220;standard&#8221; (n=6) mobilizers. Motixafortide mobilized significantly higher CD34+ HSCs in super vs standard mobilizers
(median 481 vs 132 CD34+ cells/&#956;l) (p&lt;0.0001), while with motixafortide in combination with natalizumab the difference in super
vs standard was not significant (p=0.1156).</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In conclusion, this first-in-human trial demonstrated the potential
of motixafortide alone, and in combination with natalizumab, as novel G-CSF-free regimens to safely optimize HSC mobilization in SCD (median
CD34+ cells/&#956;l: plerixafor=73, motixafortide=189, motixafortide+natalizumab=312).</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In May 2024, we announced that we entered into a multi-center Phase
1 clinical trial sponsored by St. Jude Children&#8217;s Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+
hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with SCD.&#160; Investigators in the trial from
St. Jude Children&#8217;s Research Hospital, Inc. and two other clinical sites have extensive SCD gene therapy clinical development experience
and are recognized leaders in the field. Following the out-licensing of motixafortide to Ayrmid, the study is being continued under the
Ayrmid License Agreement. The first patient in the study was dosed in February 2025 and data is expected in 2026.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Pancreatic Cancer</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In January 2016, we entered into a clinical collaboration with
MSD (a tradename of Merck &amp; Co., Inc., Kenilworth, New Jersey) in the field of cancer immunotherapy. Based on this collaboration,
in September 2016 we initiated a Phase 2a study, known as the COMBAT/KEYNOTE-202 study, focusing on evaluating the mechanism of action
and safety of motixafortide in combination with KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>&#160;(pembrolizumab),
MSD&#8217;s anti-PD-1 therapy, in 37 patients with metastatic PDAC. The study was an open-label, multicenter, single-arm trial designed
to evaluate the mechanism of action, safety and tolerability, and clinical response of the combination of these therapies. The mechanistic
evaluation consisted of multiple pharmacodynamic parameters, including the ability to improve infiltration of T-cells into the tumor and
their reactivity. Top-line results showed that the dual combination demonstrated encouraging disease control and overall survival in patients
with metastatic pancreatic cancer. In addition, assessment of patient biopsies supported motixafortide&#8217;s ability to induce infiltration
of tumor-reactive T-cells into the tumor, while reducing the number of immune regulatory cells.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In July 2018, we announced the expansion of the COMBAT/KEYNOTE-202
study under the collaboration to include a triple combination arm investigating the safety, tolerability and efficacy of motixafortide,
KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>&#160;and chemotherapy. We initiated this
arm of the trial in December 2018. In February 2020, we completed the recruiting of a total of 43 patients for the study and in December
2020, we announced the final results of the study. The results of the study showed substantial improvement as compared to comparable historical
results of other pancreatic cancer studies across all study endpoints. Of the 38 evaluable patients, median overall survival was 6.5 months,
median progression free survival was 4.0 months, confirmed overall response rate was 13.2%, overall response rate was 21.2% and disease
control rate was 63.2%. The combination was generally well tolerated, with a safety profile consistent with the individual safety profile
of each component alone; adverse event and severe adverse event profiles were as expected with chemotherapy-based treatment regimens.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In October 2020, we announced that motixafortide will be tested
in combination with the anti-PD-1 cemiplimab (LIBTAYO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>)
and standard-of-care chemotherapy (gemcitabine and nab-paclitaxel) in first-line PDAC. This investigator-initiated Phase 2, single-arm
study (CheMo4METPANC), led by Columbia University and supported equally by BioLineRx and Regeneron, initially enrolled 11 PDAC patients
in a pilot phase. In September 2023, we reported preliminary data from the pilot phase of the study. As of July 2023, of those 11 patients,
seven patients (64%) experienced a partial response (PR), of which six (55%) are now confirmed PRs, with one patient experiencing resolution
of the hepatic (liver) metastatic lesion.&#160;Three patients (27%) experienced stable disease, resulting in a disease control rate of
91%.&#160;These findings compare favorably to historic partial response and disease control rates of 23% and 48%, respectively, reported
with the chemotherapy combination of gemcitabine and nab-paclitaxel. In May 2025, we reported updated results from the pilot phase, indicating
that four of 11 patients remained progression free after more than one year. Two patients underwent definitive treatment for mPDAC &#8211;
one had complete resolution of all radiologically detected liver lesions and underwent definitive radiation to the primary pancreatic
tumor, and one had a sustained partial response and underwent pancreaticoduodenectomy with pathology demonstrating a complete response.
An analysis of pre- and on-treatment biopsies and peripheral blood mononuclear cells (PBMCs) also revealed that CD8+ T-cell tumor infiltration
increased across all eleven patients treated with the motixafortide combination.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">40</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Based on the preliminary data from the pilot phase, the planned
single-arm study was amended to a significantly larger, randomized multi-center study, with a new planned total of 108 patients. The amended
Phase 2b study is evaluating the combination of motixafortide, PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine
and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone. The trial's primary endpoint is progression free survival, and a pre-specified
interim futility analysis will be conducted when 40% of progression free survival events are observed, which is planned for 2026. Secondary
objectives include safety, response rate, disease control rate, duration of clinical benefit and overall survival. In February 2024, the
first patient was dosed, with full enrollment planned in 2027.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have also been advancing plans in collaboration with Gloria,
our Asia partner, for a Phase 2b randomized study assessing motixafortide in combination with the PD-1 inhibitor zimberelimab and standard-of-care
chemotherapy as first-line treatment in patients with metastatic pancreatic cancer. IND submission and protocol finalization was planned
for the first half of 2025. However, Gloria is not currently advancing this study according to schedule and it is unclear when such study
will be initiated, if at all. There can be no assurance that Gloria will meet its obligations under the Gloria License Agreement.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Other Studies</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition to the above, from time to time a number of Company-sponsored
and investigator-initiated studies may be conducted in a variety of indications, to support the interest of the scientific and medical
communities in exploring additional uses for motixafortide. These studies serve to potentially further elucidate the mechanism of action
for motixafortide, generate data about motixafortide&#8217;s potential use in other indications, and inform the life-cycle management
process of motixafortide. The results of studies such as these are presented from time to time at relevant professional conferences.&#160;&#160;</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Orphan Drug Designations</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Motixafortide has been granted three Orphan Drug Designations by
the FDA: for use to mobilize HSCs from the bone marrow to peripheral blood for collection in autologous or allogeneic transplantation
(granted in July 2012); for the treatment of AML (granted in September 2013); and for the treatment of pancreatic cancer (granted in February
2019). Orphan Drug Designation is granted to therapeutics intended to treat rare diseases or conditions that affect not more than 200,000
people in the United States (or diseases or conditions that affect more than 200,000 people but where there is no reasonable expectation
that the product development cost will be recovered from product sales in the United States). If an Orphan Drug-Designated product subsequently
receives FDA approval for the disease or condition for which it was designated, the product is entitled to a seven-year marketing exclusivity
period, which means that the FDA may not approve any other applications to market the same drug for the same indication, except in very
limited circumstances (such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness,
greater safety or providing a major contribution to patient care or in instances of drug supply issues), for seven years. In addition,
Orphan Drug Designation enables sponsors to apply for certain federal grants and tax credits for clinical trials and provides an exemption
from the Prescription Drug User Fee so long, as the sponsor&#8217;s annual revenue is below $50,000,000.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In January 2020, the EMA granted an Orphan Drug Designation to
motixafortide for the treatment of pancreatic cancer. In addition, in December 2023, the EMA granted Orphan Drug Designation to motixafortide
for treatment of patients undergoing hematopoietic stem cell transplantation. The EMA grants orphan medicinal product designation to investigational
drugs intended to treat, prevent or diagnose a life-threatening or chronically debilitating disease affecting fewer than five in 10,000
people in the EU and for which no satisfactory treatment is available or, if such treatment exists, the medicine must be of significant
benefit to those affected by the condition. Orphan medicinal product designation provides regulatory and financial incentives for companies
to develop and market therapies, including ten years of market exclusivity, protocol assistance, fee reductions and EU-funded research.</div>
</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">41</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">BL-5010</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our commercialized, legacy therapeutic product, BL-5010, is a customized,
proprietary pen-like applicator containing a novel, acidic, aqueous solution for the non-surgical removal of skin lesions. It offers an
alternative to painful, invasive and expensive removal treatments including cryotherapy, laser treatment and surgery. Since the treatment
is non-invasive, it poses minimal infection risk and eliminates the need for anesthesia, antiseptic precautions and bandaging. The pre-filled
device controls and standardizes the volume of solution applied to a lesion, ensuring accurate administration directly on the lesion and
preventing both accidental exposure of the healthy surrounding tissue and unintentional dripping. It has an ergonomic design, making it
easy to handle, and has been designed with a childproof cap. BL-5010 is applied topically on a skin lesion in a treatment lasting a few
minutes with the pen-like applicator and causes the lesion to gradually dry out and fall off within one to four weeks.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In December 2014, we entered into an exclusive out-licensing arrangement
with Perrigo Company plc, or Perrigo, for the rights to BL-5010 for over-the-counter, or OTC, indications in Europe, Australia and additional
selected countries. In March 2016, Perrigo received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal
of warts. The commercial launch of products for treatment of this first OTC indication (warts/verrucas) commenced in Europe in the second
quarter of 2016. Since then, Perrigo has invested in improving the product and during 2019 launched an improved version of the product
in several European countries. In March 2020, we agreed that Perrigo could relinquish its license rights for certain countries that had
been included in its territory according to the original license agreement, and was also no longer obligated to develop, obtain regulatory
approval for, and commercialize products for a second OTC indication. In turn, in March 2020, we agreed with our licensor of the rights
to BL-5010, Innovative Pharmaceutical Concepts (IPC) Inc., or IPC, to return to IPC those license rights no longer out-licensed to Perrigo
as a result of the agreement described in the preceding sentence, in consideration of the payment to us of royalties or fees on sublicense
receipts.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Expanding our Product Portfolio</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Following entry into the Gloria License Agreement and the Ayrmid
License Agreement as well as the shutdown of our U.S. commercial operations, we have refocused our operations on development activities
in Israel in the fields of oncology and rare diseases, at a significantly reduced annual cash burn rate.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are continuing to advance the development of motixafortide for
patients with pancreatic cancer and other solid tumors.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, as part of our future growth strategy, we intend to
pursue additional in-licensing opportunities as well as other strategic transactions such as co-development agreements, acquisitions,
and technology partnerships, to expand and diversify our product pipeline. We will specifically target innovative therapeutic candidates
that complement our existing portfolio and align with our core expertise in oncology and rare disease. Through these strategic in-licensing
efforts, we aim to enhance shareholder value while advancing our mission of bringing novel therapies to patients in need.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Out-Licensing Agreements</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Out Licensing of Motixafortide in All Territories Except Asia</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On November 20, 2024, we entered into a license agreement, or the
Ayrmid License Agreement with Ayrmid pursuant to which we granted to Ayrmid an exclusive, transferable, royalty-bearing, sublicensable
license with respect to the intellectual property rights and know-how associated with motixafortide, in order to commercialize motixafortide
across all indications, except solid tumor indications, in all territories other than Asia, or collectively, the Ayrmid Territory.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">42</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 35.9pt; line-height: 1.25">Pursuant to the terms of the Ayrmid License Agreement, Ayrmid
paid a non-refundable $10 million upfront payment and we are entitled to up to $87 million of certain commercial and sales milestones
based on defined sales targets of motixafortide in the Ayrmid Territory. Additionally, we are eligible to receive tiered double-digit
royalties (ranging from 18-23%) on aggregate net sales of motixafortide on a country-by-country basis until the longer of (i) fifteen
years from the date of the first sale of motixafortide by Ayrmid in such country, (ii) the last to expire of any licensed patents with
respect to motixafortide in such country, (iii) the expiration of regulatory exclusivity in such country and (iv) the expiration of motixafortide&#8217;s
orphan drug status, if any, in such country, it being noted that such royalties may be subject to reduction in certain specific circumstances.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 35.9pt; line-height: 1.25">In connection with the Ayrmid License Agreement, we and Ayrmid
also entered into a manufacturing and supply agreement, or the Supply Agreement, according to which we will supply motixafortide to Ayrmid
during the term of the Ayrmid License Agreement, on a cost-plus basis, for both commercial and development supply. Furthermore, the Supply
Agreement provides Ayrmid with &#8220;step-in rights&#8221; with respect to the manufacture and supply of motixafortide upon the occurrence
of certain trigger events. In addition, we and Ayrmid entered into a transition services agreement pursuant to which we agreed to provide
Ayrmid with certain services related to the development and commercialization of motixafortide within the Ayrmid Territory during a defined
transition period, on a cost basis.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 35.9pt; line-height: 1.25">The Ayrmid License Agreement will continue on a country-by-country
basis in the Ayrmid Territory until the expiration of the royalty term or earlier termination thereof. The Ayrmid License Agreement may
also be terminated by either party in the case of a material breach or bankruptcy. Further, if our license agreement with Biokine Therapeutics
Ltd., or the Upstream License, is terminated in whole or in part, the Ayrmid License Agreement will immediately terminate. In such event,
Ayrmid will have the right to enter into a direct license agreement with the licensor of such Upstream License on substantially similar
terms.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Following the Ayrmid License Agreement, we shut down our commercial
operations in the United States and undertook certain cost-cutting and workforce reduction measures. As a result, we have significantly
reduced our expenditures and as of the date of this Annual Report on Form 20-F have 24 full-time employees and 4 part-time employees.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Out Licensing of Motixafortide in Asia</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On August 27, 2023, we entered into the Gloria License Agreement,
with Hong Seng Technology Limited, or HST, and Gloria, and/or with HST, the Gloria Licensee, pursuant to which we granted HST an exclusive,
royalty-bearing, sublicensable license with respect to the intellectual property rights and know-how associated with motixafortide in
order to develop and commercialize motixafortide in Asia (other than Israel and certain other countries), or the Gloria Territory, and
to engage and authorize Gloria to perform services under the Gloria License Agreement in the Territory.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Pursuant to the terms of the Gloria License Agreement, the Gloria
Licensee made a $15 million upfront payment in October 2023, upon the closing of the transaction. We are entitled to up to $49 million
based on the achievement of certain development and regulatory milestones in China and Japan, and up to $197 million in sales milestones
based on defined sales targets of motixafortide in the Gloria Territory. Additionally, we are eligible to receive tiered, double-digit
royalties (ranging from 10-20%), on aggregate net sales of motixafortide in the Gloria Territory payable on a country-by-country basis
until the longer of (i) fifteen years from the date of the first sale of motixafortide by Licensee, (ii) the last to expire valid claim
of any licensed patents with respect to motixafortide in such country and (iii) the expiration of motixafortide&#8217;s orphan drug status
in such country. The royalties payable by Gloria Licensee to us are to be reduced by 50% following the end of the initial royalty term
and are also to be reduced upon the occurrence of certain events, including, on a country-by-country basis, the entry of a generic product
in such country.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">43</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Gloria License Agreement includes various development obligations
for the Gloria Licensee pursuant to an agreed-upon development plan, including the execution of a registrational study in stem-cell mobilization
and the execution of a randomized Phase 2b study in first-line pancreatic adenocarcinoma.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Out-Licensing Agreement with Perrigo</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">See &#8220;&#8212;Our Product Portfolio&#8212; BL-5010.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Collaboration Agreement with Hemispherian</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On September 29, 2025, we entered into a collaboration with Hemispherian
for the development, clinical evaluation and commercialization of GLIX1, a first-in-class, oral, small molecule targeting DNA damage response
in glioblastoma and other solid tumors. As part of the collaboration, (i) we and Hemispherian entered into a Collaboration and Shareholders
Agreement, or the Collaboration Agreement, which governs the ownership, governance, funding, administration, and related operational and
commercial terms of Tetragon Biosciences, Ltd, a newly-created company owned by us and Hemispherian, or Tetragon, and (ii) Hemispherian
and Tetragon entered into an Asset Transfer Agreement (the &#8220;ATA&#8221;), pursuant to which Hemispherian transferred to Tetragon
certain intellectual property, regulatory filings, know-how, and related assets primarily in respect of GLIX1, Hemispherian&#8217;s lead
compound, or the Transferred Assets. The transactions closed on the same day.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Pursuant to the Collaboration Agreement, Hemispherian will initially
hold 60% of the issued share capital of Tetragon, and we will hold the remaining 40%. As consideration for Hemispherian&#8217;s contribution
of the Transferred Assets, we agreed to invest $5 million in Tetragon, or the Threshold Amount, within 36 months as of the date of the
Collaboration Agreement, in tranches according to a development plan, which period may be extended by an additional six months upon the
occurrence of certain events as specified in the Collaboration Agreement, or the Threshold Term. If we do not invest the full Threshold
Amount by the end of the Threshold Term, Hemispherian will have the right to repurchase, for nominal consideration, a pro rata portion
of the Company&#8217;s shares in Tetragon corresponding to the unfunded portion of the Threshold Amount.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Following the investment of the Threshold Amount, we may make additional
investments in Tetragon. For each incremental $1 million invested by us beyond the Threshold Amount, we will be entitled to an additional
1% equity interest, up to an aggregate maximum ownership of 70%. Following the attainment of a 50% stake by us in Tetragon, Hemispherian
will have the right to co-invest alongside us on the same terms in order to maintain a 50% ownership stake in Tetragon.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Furthermore, under the terms of the Collaboration Agreement, we
will be responsible for managing and implementing Tetragon&#8217;s activities and overseeing Tetragon&#8217;s operations, budget, and
expenses. Following the closing, Tetragon will pay Hemispherian a monthly advisory fee of $80,000 for a period of 24 months or until the
termination of Tetragon, whichever occurs first.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Collaboration Agreement provides for the establishment of a
board of directors of Tetragon as well as a steering committee with joint representation from both us and Hemispherian. We hold the deciding
vote in the event of any deadlock on either of such corporate bodies. In addition, the Collaboration Agreement includes restrictions on
the transfer of shares of Tetragon by us and Hemispherian, requiring the consent of the other party, subject to certain exceptions, including
transfers to permitted transferees or transfers in connection with a merger or acquisition transaction. The Collaboration Agreement further
provides a bring-along right, which may be exercised by a simple majority of the shareholders and the board of directors, subject to the
consent rights described above.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Tetragon has a first look right, as well as a right of first refusal,
on other assets in Hemispherian&#8217;s pipeline for defined periods specified in the ATA.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The ATA and the Collaboration Agreement contain customary representations
and warranties, indemnification and other provisions customary for transactions of this nature. In addition, we have provided an indemnification
to Hemispherian in an amount of up to 50% of Hemispherian&#8217;s potential tax liability in Israel arising from the unlikely event of
the payment of future dividend distributions by Tetragon to its shareholders, net of amounts recoverable under any double tax treaties
available to Hemispherian.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">44</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>
<!--PROfilePageNumberReset%Num%1%%%-->

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Collaboration Agreement and the ATA include termination events,
including failure to fund the Threshold Amount within the Threshold Term, or prolonged inability of Tetragon to operate due to insufficient
financial resources.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">In-Licensing Agreements</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have in-licensed and intend to continue to in-license development,
production and marketing rights from selected research and academic institutions in order to capitalize on the capabilities and technology
developed by these entities. We also seek to obtain technologies that complement and expand our existing technology base by entering into
license agreements with pharmaceutical and biotechnology companies. When entering into in-license agreements, we generally seek to obtain
unrestricted sublicense rights consistent with our primarily partner-driven strategy. We are generally obligated under these agreements
to diligently pursue product development, make development milestone payments, pay royalties on any product sales and make payments upon
the grant of sublicense rights. We generally insist on the right to terminate any in-license for convenience upon prior written notice
to the licensor.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The scope of payments we are required to make under our in-licensing
agreements is comprised of various components that are paid commensurate with the progressive development and commercialization of our
drug products.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our in-licensing agreements generally provide for the following
types of payments:</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" border="0" id="z248ab3890013460dabd56a7af9710720" style="font: 10pt Times New Roman,Times,serif; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Revenue sharing payments. These are payments to be made to licensors with respect
        to revenue we receive from sub-licensing to third parties for further development and commercialization of our drug products. These payments
        are generally fixed at a percentage of the total revenues we earn from these sublicenses.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" border="0" id="z34ad58aa32c7491ebe3654c27561a9e0" style="font: 10pt Times New Roman,Times,serif; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Milestone payments. These payments are generally linked to the successful achievement
        of milestones in the development and approval of drugs, such Phases 1, 2 and 3 of clinical trials and approvals of NDAs, and achievement
        of sales milestones.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" border="0" id="z47a1df6ef1f648b88674196d5e5f1a97" style="font: 10pt Times New Roman,Times,serif; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Royalty payments. To the extent we elect to complete the development, licensing and
        marketing of a therapeutic candidate, we are generally required to pay our licensors royalties on the sales of the end drug product. These
        royalty payments are generally based on the net revenue from these sales. In certain instances, the rate of the royalty payments decreases
        upon the expiration of the drug&#8217;s underlying patent and its transition into a generic drug.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" border="0" id="zd5c02d6b8804425396db148546f4c06a" style="font: 10pt Times New Roman,Times,serif; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Additional payments. In addition to the above payments, certain of our in-license
        agreements provide for a one-time or periodic payment that is not linked to milestones. Periodic payments may be paid until the commercialization
        of the product, either by direct sales or sublicenses to third parties. Other agreements provide for the continuation of these payments
        even following the commercialization of the licensed drug product.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following are descriptions of our in-licensing agreements associated
with our therapeutic candidates. In addition to the in-licensing agreements discussed herein, we have entered into other in-licensing
arrangements in connection with our therapeutic candidates in clinical, advanced preclinical and feasibility stages.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Motixafortide</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In September 2012, we in-licensed the rights to motixafortide under
a license agreement with Biokine. Pursuant to the agreement, Biokine granted us an exclusive, worldwide, sublicensable license to develop,
manufacture, market and sell certain technology relating to a short peptide that functions as a high-affinity antagonist for CXCR4 and
the uses thereof.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">45</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">There were no upfront payments due under the agreement. We are
obligated to pay a monthly development fee of $27,500 for certain development services that Biokine has committed to provide to us under
the agreement. The payment of this monthly fee is required to continue until March 2029.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are responsible for paying all development costs incurred by
the parties in carrying out the development plan.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The agreement also grants us the right to grant sublicenses for
the licensed technology. In the case of a sublicense, we were initially required to pay Biokine a payment of 40% of the amounts we receive
as consideration in connection with a sublicense, including royalties, license fees, milestone payments, license maintenance fees and
equity, or the Sublicense Receipts. In October 2018, the agreement was amended to reduce the payments associated with sublicensing to
20% of Sublicense Receipts, in return for the payment by us of $10 million in cash plus $5 million in our restricted ADSs. Biokine is
also eligible to receive up to a total of $2.5 million in future milestone payments. In the case of self-commercialization, we are obligated
to make royalty payments of 10% of net sales, subject to certain limitations.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Before we in-licensed motixafortide, Biokine had received funding
for the project from the IIA, and as a condition to IIA giving its consent to our in-licensing of motixafortide, we were required to agree
to abide by any obligations resulting from such funding. However, we have the right to offset the full amount of any royalty payments
payable to the IIA from any payments otherwise due to Biokine as sublicensing royalties as described above.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are obligated under the agreement with Biokine to make commercially
reasonable, good faith efforts to sublicense or commercialize motixafortide for fair consideration.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have the first right to prepare, file, prosecute and maintain
any patent applications and patents, in respect of the licensed technology and any part thereof, at our expense, provided that we are
required to consult with Biokine regarding patent prosecution and patent maintenance. In addition, we have the right to take action in
the prosecution, prevention, or termination of any patent infringement of the licensed technology. We are responsible for all the expenses
of any patent infringement suit that we bring, including any expenses incurred by Biokine in connection with such suits, with such expenses
reimbursable from any sums recovered in such suit or in the settlement thereof for. After such reimbursement, if any funds remain, both
we and Biokine are each entitled to a certain percentage of any remaining sums.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The agreement will remain in effect until the expiration of all
of our royalty and sublicense revenue obligations to Biokine, determined on a product-by-product and country-by-country basis. We may
terminate the agreement for any reason on 90 days&#8217; prior written notice to Biokine. Either party may terminate the agreement for
a material breach by the other party if the breaching party is unable to cure the breach within 30 days after receiving written notice
of the breach from the non-breaching party. With respect to any termination for a material breach, if the breach is not susceptible to
cure within the stated period and the breaching party uses diligent, good faith efforts to cure such breach, the stated period will be
extended by an additional 30 days. In addition, either party may terminate the agreement upon the occurrence of certain bankruptcy events.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Termination of the agreement will result in a loss of all of our
rights to the drug and the licensed technology, which will revert to Biokine. In addition, any sublicense of ours will terminate provided
that, upon such termination and at the request of the sublicensee, Biokine will be required to enter into a separate license agreement
with the sublicensee on substantially the same terms as those contained in the applicable sublicense agreement.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">BL-5010</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In November 2007, we in-licensed the rights to develop and commercialize
BL-5010 under a license agreement with IPC. Under the agreement, IPC granted us an exclusive, worldwide, sublicensable license to develop,
manufacture, market and sell certain technology relating to an acid-based formulation for the non-surgical removal of skin lesions and
the uses thereof. We are obligated to use commercially reasonable efforts to develop the licensed technology in accordance with a specified
development plan, including meeting certain specified diligence goals. We are required to make low, single-digit royalty payments on the
net sales of the licensed technology if we manufacture and sell it on our own, subject to certain limitations. Our royalty payment obligations
are payable on a product-by-product and country-by-country basis, until the last to expire of any patent included within the licensed
technology in such country. We also have the right to grant sublicenses for the licensed technology and are required to pay IPC a payment,
within our standard range of sublicense receipt consideration, based on the revenues we receive as consideration in connection with any
sublicensing, development, manufacture, marketing, distribution or sale of the licensed technology.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">46</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The license agreement remains in effect until the expiration of
all of our license, royalty and sublicense revenue obligations to IPC, determined on a product-by-product and country-by-country basis,
unless we terminate the license agreement earlier. We may terminate the license agreement for any reason on 30 days&#8217; prior written
notice. Either party may terminate the agreement for material breach if the breach is not cured within 30 days after written notice from
the non-breaching party. If the breach is not susceptible to cure within the stated period and the breaching party uses diligent, good
faith efforts to cure such breach, the stated period will be extended by an additional 30 days. In addition, either party may terminate
the agreement upon the occurrence of certain bankruptcy events.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Termination of the agreement will result in a loss of all of our
rights to the licensed technology, which would revert to IPC. In addition, any sublicense of the licensed technology will terminate provided
that, upon termination, at the request of the sublicensee, IPC is required to enter into a license agreement with the sublicensee on substantially
the same terms as those contained in the sublicense agreement.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Intellectual Property</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our success depends in part on our ability to obtain and maintain
proprietary protection for our therapeutic candidates, technology and know-how, to operate without infringing the proprietary rights of
others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among
other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are
important to the development of our business. We also rely on trade secrets, know-how and continuing technological innovation, as well
as on regulatory exclusivity, such as Orphan Drug designation or new chemical entity, or NCE, protection to develop and maintain our proprietary
position.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Patents</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As of March 8, 2026, we owned or exclusively licensed for use within
our field of business 21 patent families that collectively contain 141 granted patents, 3 allowed patent applications and 97 pending patent
applications relating to the three candidates listed below. We are also pursuing patent protection for other drug candidates in our pipeline.
Patents related to our therapeutic candidates may provide future competitive advantages by providing exclusivity related to the composition
of matter, formulation, and method of administration of the applicable compounds and could materially improve the value of our therapeutic
candidates. The patent positions for our three therapeutic candidates are described below and include both issued patents and pending
patent applications we own or exclusively license. We vigorously defend our intellectual property to preserve our rights and gain the
benefit of our investment.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" border="0" id="z1ae52025f296482baad4e0a076c2d427" style="font: 10pt Times New Roman,Times,serif; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">The motixafortide drug product composition of matter and methods of manufacturing
        thereof are covered by a granted U.S. patent and patent applications pending in the USA (two applications received notice of allowance).
        Israel, Europe, Japan, Canada, Australia, China, India, Mexico, Brazil, Hong-Kong and Korea. The patents, if granted, will expire in December
        2041, not including any applicable patent term extension, which may add an additional term of up to five years for the U.S. patents. We
        also have an exclusive license to a patent family that covers motixafortide combined with a PD1 antagonist for the treatment of cancer.
        Patents of this family have been granted in the U.S., Israel, Australia, China, India, Mexico and Hong Kong; and member patent applications
        are pending in Australia, Hong Kong, Europe, China, Canada, India, Israel and Brazil. The granted U.S. patent and patents to issue in
        the future based on pending patent applications in this family will expire in 2036, not including any applicable patent term extension.
        In addition, we have an exclusive license to nineteen other patent families pending or granted worldwide directed to methods of synthesis
        of motixafortide and methods of use of motixafortide either alone or in combination with other drugs for the treatment of certain types
        of cancer and other indications. Furthermore, we have Orphan Drug status for AML, pancreatic cancer and stem cell mobilization, as well
        as data exclusivity protection afforded to motixafortide as an NCE.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">47</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" border="0" id="ze0062e759a2249218948a9fe4d280dbe" style="font: 10pt Times New Roman,Times,serif; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">With respect to BL-5010, we have an exclusive license to a patent family directed
        to a novel applicator uniquely configured for applying the BL-5010 composition to targeted skin tissue safely and effectively. Patents
        in this family have been granted in the U.S., Europe, Israel, Japan, China, Australia and New Zealand. The patents will expire in 2033-2034.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">With respect to GLIX1 Tetragon owns the following: (i) the use of GLIX1 for treating
        cancer of the central nervous system, e.g., glioblastoma, is covered by patents granted in the United States, Europe, China, Japan and
        eight other countries. The term of these patents will expire in 2040; (ii) the use of GLIX1 for treating cancer, in which cytidine deaminase
        (CDA) is not over-expressed, is covered by patents granted in Europe and Japan. A member patent application has been allowed in the United
        States, while other member applications are pending in China and other countries. The term of the patents, if granted, will expire in
        2040; (iii) the use of GLIX1 for treating chronic myelogenous leukemia (CML) is covered by member applications pending in Europe and Korea.
        The term of the patents, if granted, will expire in 2040; and (iv) the use of GLIX1 in combination with a PARP inhibitor, for treating
        HR-proficient cancers is covered by patent applications pending in the United States, Europe, Japan, China, Canada, Australia, Mexico,
        Brazil, Korea and Israel. The term of the patents, if granted, will expire in 2044.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The patent positions of companies like ours are generally uncertain
and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary position for our technology will
depend on our success in obtaining effective claims and enforcing those claims once granted. We do not know whether any of our patent
applications or those patent applications that we license will result in the issuance of any patents. Our issued patents and those that
may issue in the future, or those licensed to us, may be challenged, narrowed, circumvented or found to be invalid or unenforceable, which
could limit our ability to stop competitors from marketing related products or the length of term of patent protection that we may have
for our products. Neither we nor our licensors can be certain that we were the first to invent the inventions claimed in our owned or
licensed patents or patent applications. In addition, our competitors may independently develop similar technologies or duplicate any
technology developed by us, and the rights granted under any issued patents may not provide us with any meaningful competitive advantages
against these competitors. Furthermore, because of the extensive time required for development, testing and regulatory review of a potential
product, it is possible that, before any of our products can be commercialized, any related patent may expire or remain in force for only
a short period following commercialization, thereby reducing any advantage of the patent.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Trade Secrets</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We may rely, in some circumstances, on trade secrets to protect
our technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part,
by confidentiality agreements and assignment of invention agreements with our employees, consultants, scientific advisors and contractors.
We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises
and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations
and systems, such agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition,
our trade secrets may otherwise become known or be independently discovered by competitors.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Trademarks</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We also rely on protection available under trademark laws. As of
March 8, 2026, we have registered textual trademarks for &#8220;APHEXDA&#8221; in Israel, Australia, Brazil, Canada, China, EU, UK, Japan,
Republic of Korea and the USA, as well as registered logo marks for &#8220;APHEXDA&#8221; in Israel, Australia, Brazil, China, EU, UK,
Japan, Republic of Korea and the USA. We also have the same pending logo trademark in Canada. We further have registered textual trademarks
for &#8220;BioLineRx&#8221; in the USA and registered logo marks for &#8220;BioLineRx&#8221; in Israel and the USA, and a pending national
application for the textual trademark &#8220;BioLineRx&#8221; in the USA (subject to approval of a transformation request). We also claim
common law protections for other marks we use in our business. Competitors and other companies could adopt similar marks or try to prevent
us from using our marks, consequently impeding our ability to build brand identity and possibly leading to customer confusion.</div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">48</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Manufacturing</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">With respect to GLIX1, we rely on contract manufacturers for clinical
and pre-clinical development. For motixafortide, we also rely on contract manufacturers for clinical development and fulfillment of our
obligations under the Ayrmid License Agreement and Gloria License Agreement. We are currently in the process of transferring responsibility
for manufacturing of motixafortide to Ayrmid. In addition, under the Gloria License Agreement, the Gloria Licensee may in the future serve
as an additional source for the manufacture of motixafortide. Nevertheless, we will still retain the right to manufacture motixafortide
in the future for our own clinical development and future commercialization in the indications and territories where we have retained
rights. Given the long lead times and cost of establishing additional manufacturing sites, we expect that the manufacture of GLIX1 and
motixafortide will occur at single contract manufacturers for the foreseeable future. Our manufacturing partners have a limited number
of facilities in which our therapeutic candidates can be produced.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our laboratories are located in our headquarters in Modi&#8217;in,
Israel, and are in part compliant with FDA regulations setting forth current good laboratory practices, or GLP. While our bioanalytical
laboratory complies with these regulations, the chemistry and formulation laboratories, as well as the analytical laboratories, are limited
in manufacturing scale and resources and therefore are intended to support our projects for research and development activities only.
These laboratories are not compliant with current good manufacturing practices, or cGMP. Hence, we cannot independently manufacture drug
substances or drug products for our current clinical trials or for commercial distribution.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our current and any future third-party manufacturers, their facilities
and all lots of drug substance and drug products used in our clinical trials and commercial sales are required to be in compliance with
cGMP. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of
components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution,
laboratory controls, records and reports, and returned or salvaged products. The manufacturing facilities for our products must meet cGMP
requirements and FDA satisfaction before any product is approved and we can manufacture commercial products. Our current and any future
third-party manufacturers are also subject to periodic inspections of facilities by the FDA and other authorities, including procedures
and operations used in the testing and manufacture of our products to assess our compliance with applicable regulations.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Failure to comply with statutory and regulatory requirements subjects
a manufacturer to possible legal or regulatory action, including refusal to approve pending applications, license suspension or revocation,
withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters,
modification of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports,
total or partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, additional reporting requirements
and oversight if we become subject to a corporate integrity agreement or similar agreements to resolve allegations of&#160;non-compliance&#160;with
these laws, refusals of government contracts and new orders under existing contracts, exclusion from participation in federal and state
healthcare programs, restitution, disgorgement or civil or criminal penalties, including fines and individual imprisonments.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">49</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Contract Research Organizations</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We outsource certain preclinical and clinical development activities
to CROs, which meet FDA or European Medicines Agency regulatory standards. We create and implement the drug development plans and, during
the preclinical and clinical phases of development, manage the CROs according to the specific requirements of the therapeutic candidate
under development.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Competition</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The life science industry is intensely competitive. We face potential
competition from both large and small pharmaceutical and biotechnology companies, academic institutions, governmental and public and private
research institutions. Many of these organizations have substantially greater financial, technical, manufacturing and marketing resources
than we do. In certain cases, our competitors may also be able to use alternative technologies that do not infringe upon our patents to
formulate the active materials in our therapeutic candidates. They may, therefore, bring to market products that are able to compete with
our candidates, or other products that we may develop in the future.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Any therapeutic candidates that we successfully develop and commercialize
will compete with existing therapies and new therapies that may become available in the future. The key competitive factors affecting
the success of each therapeutic candidate, if approved, is likely to be their safety, efficacy, convenience, price, the level of proprietary
and generic competition, and the availability of coverage and reimbursement from government and other third&#8209;party payors. Our competitors
may also obtain FDA or other regulatory approval for their therapeutic candidates more rapidly than we may be able to do so for any existing
or new product candidates of ours, which could result in their establishing a strong market position before we are able to enter the market.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">GLIX1</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Glioblastoma</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the field of glioblastoma (GBM), therapeutic candidates compete
indirectly with a small number of established modalities. In newly diagnosed GBM, the backbone therapeutic regimen remains temozolomide
chemotherapy. In addition, Novocure&#8217;s Tumor Treating Fields (TTFields) device, Optune&#174;, is FDA-approved for maintenance in
combination with temozolomide. Oncologists have limited options for recurrent GBM. Bevacizumab (Avastin&#174; and biosimilars) is FDA-approved
for adult patients with GBM that has progressed following prior therapy. Local therapy with the GLIADEL&#174; wafer (carmustine implant)
is also indicated as an adjunct to surgery for recurrent GBM.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Blood-brain barrier constraints, profound heterogeneity, and an
immunosuppressive microenvironment have historically limited the impact of systemic immunotherapies, with mutational biomarkers such as
MSI-H being rare in GBM. Multiple agents are being evaluated, some in late-stage or pivotal development, including radiotherapeutics Reyobiq
by Plus Therapeutics and TLX-101 by Telix, cancer vaccines TVI-Brain-1 by TVAX Biomedical and IGV-001 by Imvax and GSK&#8217;s PARP inhibitor
niraparib. In addition, multiple agents are being evaluated within the GBM AGILE adaptive platform trial, such as AstraZeneca&#8217;s
ATM inhibitor AZD-1390, Vigeo Therapeutics&#8217; thrombospondin agonist VT-1021, Biohaven&#8217;s troriluzole, and Polaris&#8217; arginine-deprivation
therapy pegargiminase.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">GBM has shown a high attrition rate, with multiple failures across
mechanisms to improve survival endpoints. Examples include VAL-083 by Kintara Therapeutics and regorafenib by Bayer), which were evaluated
in the GBM AGILE trial, underscoring the persistent difficulty of converting early signals into registrational success.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">TET2 landscape</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The competitive landscape of TET2 agonists is sparse. Most notably,
GLIX1 competes mechanistically with ONR-001 by Oniria Therapeutics, a preclinical allosteric TET2 activator developed against treatment-resistant
colorectal cancer, melanoma and other hematologic and solid tumors. In addition, Vitamin C (ascorbic acid) is a co-factor of TET enzymes
and can enhance TET2-dependent activity. In the clinic, high-dose Vitamin C is explored in multiple cancer indications, largely by academic
investigators. Industry-sponsored clinical developments in oncology include General Oncology that combine low-dose Vitamin C with other
therapies in advanced BRCA or PALB2-mutated metastatic cancer pancreatic and breast cancer. In addition, Vitamin C treatment is tested
clinically in cancer-associated and other diseases. For instance, late-stage fixed-dose combinations that include Vitamin C are developed
by Quercis Pharma, testing isoquercetin-based Kinisoquin in preventing cancer-associated thrombosis, and Renovion, testing ARINA-1 to
prevent bronchiolitis obliterans syndrome.</div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">50</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Motixafortide</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Stem cell mobilization</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Motixafortide competes directly with Mozobil&#174; (plerixafor),
which is marketed by Sanofi Genzyme as a stem cell mobilizer for autologous stem cell transplantation. During the third quarter of 2023,
Mozobil&#8217;s last-to-expire U.S. listed patent expired. As a result, several companies have launched generic formulations of plerixafor
at prices substantially lower than Mozobil, including Dr. Reddy&#8217;s Laboratories Ltd., Teva Pharmaceuticals USA, Inc., MSN Laboratories
Private Ltd., Eugia Pharma Specialities Ltd., Amneal EU Ltd., Gland Pharma Ltd., Hetero Labs Ltd and Meitheal Pharmaceuticals, Inc.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The competitive development pipeline in stem cell mobilization
is currently limited, but we are aware of Exicure&#8217;s burixafor in combination with propranolol and G-CSF, which is under clinical
investigation for stem cell mobilization in multiple myeloma and may compete with motixafortide in the future.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">CXCR4 landscape</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A new CXCR4 inhibitor, XOLREMDI&#174;, was approved by the FDA
in 2024 for WHIM syndrome and has recently entered late-stage clinical trials for chronic neutropenia. We are also aware of other CXCR4
inhibitors in various stages of development, including burixafor being developed by Exicure for stem cell mobilization in multiple myeloma
and PTX-9908 being developed by TCM Biotech in hepatocellular carcinoma. Other approaches include radiotherapeutics targeting CXCR4-expressing
cells for various cancer indications, including those being developed by PentixaPharm.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Pancreatic cancer</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Immuno-oncology is an area of significant interest in the pharmaceutical
market, particularly immuno-oncology combination therapies. Thousands of immuno-oncology combination treatments are currently being tested
in clinical trials that aim to transform scientific innovation into practice-changing cancer drugs.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the field of pancreatic ductal adenocarcinoma (PDAC), motixafortide
competes indirectly with the few currently approved treatments for PDAC. Motixafortide is believed to modulate the effector/suppressor
cell ratio toward a proinflammatory profile, which may act synergistically with checkpoint inhibitor agents to enhance the anti-tumor
activity of infiltrated T cells. In the first-line setting, gemcitabine in combination with Abraxane&#174; or the FOLFIRINOX regimen are
the current standards of care. In February 2024, Ipsen&#8217;s Onivyde&#174; obtained approval in first-line metastatic PDAC as part of
the NALIRIFOX regimen based on the Phase III NAPOLI-3 trial.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Oncologists have limited options among existing therapies for second-line
metastatic patients. Onivyde&#174; is FDA-approved in combination with 5-FU and leucovorin for patients previously treated with gemcitabine-based
therapy. LYNPARZA&#174; is approved for maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer (approximately 7%
of all cases). Recently, BIZENGRI&#174; gained accelerated approval as a second-line treatment for patients with NRG1 fusions (less than
1% of all cases).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">51</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Multiple targeted, biomarker-specific treatments have been approved
across solid tumors. These include Merck&#8217;s KEYTRUDA&#174; for MSI-H/dMMR cancers (approximately 1% of all pancreatic cancer cases)
and ENHERTU&#174; for HER2-positive solid tumors (approximately 2-6% of PDAC) following prior systemic treatment.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are aware of late clinical-stage development in metastatic PDAC
by other companies, including daraxonrasib, a RAS inhibitor by Revolution Medicines, and quemliclustat from Arcus Biosciences. In China,
several advanced antibody modalities have entered late-stage development, including assets targeting Claudin 18.2-positive tumors and
PD-1-directed bispecifics.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In recent years, there have been multiple clinical failures of
compounds for advanced PDAC, most notably FibroGen&#8217;s pamrevlumab, Erytech&#8217;s eryaspase, and Astellas&#8217; zolbetuximab. Despite
a busy early-stage clinical pipeline, there are only a few Phase III and approved assets, demonstrating a high attrition rate in PDAC.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">BL-5010</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">BL-5010 competes with a variety of approved destructive and non-destructive
treatments for skin lesions. Both Endwarts<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>&#160;(Meda
Health) and Eskata<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;&#160;</sup>(Aclaris therapeutics) are
medical device-based treatments marketed for removal of warts.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Government Regulation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We operate in a highly controlled regulatory environment. Stringent
regulations establish requirements relating to analytical, toxicological and clinical standards and protocols in respect of the testing
of pharmaceuticals and medical devices. Regulations also cover research, development, manufacturing and reporting procedures, both pre-
and post-approval. In many markets, especially in Europe, marketing and pricing strategies are subject to national legislation or administrative
practices that include requirements to demonstrate not only the quality, safety and efficacy of a new product, but also its cost-effectiveness
relating to other treatment options. Failure to comply with regulations can result in stringent sanctions, including product recalls,
withdrawal of approvals, seizure of products and criminal prosecution.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Before obtaining regulatory approvals for the commercial sale of
our therapeutic candidates, we or our licensees must demonstrate through preclinical studies and clinical trials that our therapeutic
candidates are safe and effective. Historically, the results from nonclinical studies and early clinical trials often have not accurately
predicted results of later clinical trials. In addition, a number of pharmaceutical products have shown promising results in early clinical
trials but subsequently failed to establish sufficient safety and efficacy results to obtain necessary regulatory approvals. We have incurred
and will continue to incur substantial expense for, and devote a significant amount of time to, preclinical studies and clinical trials.
Many factors can delay the commencement and rate of completion of clinical trials, including the inability to recruit patients at the
expected rate, the inability to follow patients adequately after treatment, the failure to manufacture sufficient quantities of materials
used for clinical trials, and the emergence of unforeseen safety issues and governmental and regulatory delays. If a therapeutic candidate
fails to demonstrate safety and efficacy in clinical trials, this failure may delay development of other therapeutic candidates and hinder
our ability to conduct related preclinical studies and clinical trials. Additionally, as a result of these failures, we may also be unable
to find additional licensees or obtain additional financing.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Governmental authorities in all major markets require that a new
pharmaceutical product or medical device be approved or exempted from approval before it is marketed, and have established high standards
for technical appraisal, which can result in an expensive and lengthy approval process. The time to obtain approval varies by country.
In the past, it generally took from six months to four years from the application date, depending upon the quality of the results produced,
the degree of control exercised by the regulatory authority, the efficiency of the review procedure and the nature of the product. Some
products are never approved. In recent years, there has been a trend towards shorter regulatory review times in the United States as well
as certain European countries, despite increased regulation and higher quality, safety and efficacy standards.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">52</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Historically, different requirements by different countries&#8217;
regulatory authorities have influenced the submission of applications. However, a trend toward harmonization of drug and medical device
approval standards, starting in individual countries in Europe and then in the EU as a whole, in Japan, the United Kingdom and in the
United States under the aegis of what is now known as the International Council on Harmonisation, or ICH (created as the International
Conference on Harmonisation in 1990), is gradually narrowing these differences. In many cases, compliance with ICH standards can help
avoid duplication of non-clinical and clinical trials and enable companies to use the same basis for submissions to each of the respective
regulatory authorities. The adoption of the Common Technical Document format by the ICH has greatly facilitated use of a single regulatory
submission for seeking approval in the ICH regions and many other countries worldwide.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Summaries of the United States, EU, United Kingdom and Israeli regulatory processes
follow below.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span style="text-decoration: underline">United States</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the United States, drugs are subject to rigorous regulation
by the FDA. The U.S. Federal Food, Drug and Cosmetic Act, or FDCA, and other federal and state statutes and regulations govern, among
other things, the research, development, testing, manufacture, storage, record-keeping, packaging, labeling, adverse event reporting,
advertising, promotion, marketing, distribution and import and export of pharmaceutical products. Failure to comply with the applicable
U.S. requirements may subject us to stringent administrative or judicial sanctions, such as agency refusal to approve pending applications,
warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions or criminal
prosecution.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Unless a drug is exempt from the NDA process or the Biologics License
Application, or BLA, process or subject to another regulatory procedure, the steps required before a drug may be marketed in the United
States include:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8528ea5529924b508b475326b0baf2ab" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> <span style="line-height: 1.25">&#160;</span></div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">completion of preclinical laboratory tests, animal studies and formulation development;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">submission to the FDA of an Investigational New Drug, or IND, application to conduct human clinical testing;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">completion of adequate and well controlled clinical trials to determine the safety and efficacy of the
        drug for each indication as well as to establish the exposure levels;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">submission to the FDA of an application for marketing approval;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug
        is manufactured; and</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z2d77a2c3942e401ca5461486fa1dc3f9" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">FDA review and approval of the drug and drug labeling for marketing.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Preclinical studies include laboratory evaluation of product chemistry,
toxicity, formulation and stability, as well as animal studies. For preclinical studies conducted in the United States, and certain studies
carried out outside the United States, we submit the results of the nonclinical studies, together with manufacturing information and analytical
results, to the FDA as part of an IND, which must become effective before we may commence human clinical trials.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Clinical Trials (INDs)</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Clinical trials involve the administration of the investigational
drug to people under the supervision of qualified investigators in accordance with the principles of good clinical practice, or GCP. We
conduct clinical trials under protocols detailing the trial objectives, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated. We must submit each U.S. study protocol to the FDA as part of an IND. An IND will automatically become effective
30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about issues such as the conduct of the
trials as outlined in the IND. In such a case, the IND sponsor and the FDA must resolve any outstanding FDA concerns or questions before
clinical trials can proceed. Submission of an IND does not always result in the FDA allowing clinical trials to commence and the FDA may
halt a clinical trial if unexpected safety issues surface or the study is not being conducted in compliance with applicable requirements.</div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">53</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The FDA may refuse to accept an IND for review if applicable regulatory
requirements are not met. Moreover, the FDA may delay or prevent the start of clinical trials if the manufacturing of the study drug fails
to meet cGMP requirements or the clinical trials are not adequately designed. Such government regulation may delay or prevent the study
and marketing of potential products for a considerable time period and may impose costly procedures upon a manufacturer&#8217;s activities.
In addition, the FDA may, at any time, impose a clinical hold on ongoing clinical trials. If the FDA imposes a clinical hold, clinical
trials cannot continue without FDA authorization and then only under terms authorized by the FDA.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Success in early-stage clinical trials does not assure success
in later-stage clinical trials. Results obtained from clinical activities are not always conclusive and may be susceptible to varying
interpretations that could delay, limit or prevent regulatory approval. Even if a therapeutic candidate receives regulatory approval,
later discovery of previously unknown problems with a product may result in restrictions on the product or even withdrawal of marketing
approval for the product.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Foreign clinical trials may or may not be conducted under an IND.
However, their safety assessments should be submitted annually.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We conduct clinical trials typically in three sequential phases
(1-3), but the phases may overlap or be combined. An institutional review board, or IRB, must review and approve each trial before it
can begin. Phase 1 includes the initial administration of a tested drug to a small number of humans. These trials are closely monitored
and may be conducted in patients but are usually conducted in healthy volunteer subjects. These trials are designed to determine the metabolic
and pharmacologic actions of the drug in humans and the side effects associated with increasing doses as well as, if possible, to gain
early evidence of effectiveness. Phase 2 usually involves trials in a limited patient population to evaluate dosage tolerance and appropriate
dosage, identify possible adverse effects and safety risks and preliminarily evaluate the efficacy of the drug for specific indications.
Phase 3 trials are large trials used to further evaluate clinical efficacy and test further for safety by using the drug in its final
form in an expanded patient population. There can be no assurance that we or our licensees will successfully complete Phase 1, Phase 2
or Phase 3 testing with respect to any therapeutic candidate within any specified period of time, if at all. Furthermore, clinical trials
may be suspended at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable
health risk. We and our licensees perform some of our nonclinical and clinical testing outside of the United States. The acceptability
of the results of our preclinical and clinical testing by the FDA will be dependent upon adherence to applicable U.S. and foreign standards
and requirements, including GLP, GCP and the Declaration of Helsinki for protection of human subjects.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Marketing Applications (NDAs and BLAs)</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">After successful completion of the required clinical testing, an
NDA, or in the case of certain biological products, a BLA, is prepared and submitted to the FDA. FDA approval of the NDA or BLA is required
before product marketing may begin in the United States. The NDA/BLA must include the preclinical and clinical testing results and a compilation
of detailed information relating to the product&#8217;s pharmacology, toxicology, chemistry, manufacture and manufacturing controls. The
cost of preparing and submitting an NDA may be substantial. Under U.S. federal law, the submission of NDAs is generally subject to substantial
application user fees, and the manufacturer and/or sponsor under an NDA approved by the FDA is also subject to annual product and establishment
user fees. These fees are typically increased annually.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">54</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The FDA has 60 days from its receipt of an NDA/BLA to determine
whether the application will be accepted for filing based on the FDA threshold determination that the application is sufficiently complete
to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review of the submitted application.
Under U.S. federal law, the FDA has agreed to certain performance goals in the review of NDAs/BLAs. Most such applications for non-priority
drug products are to be reviewed within 10 months following acceptance of the application for filing. The review process may be significantly
extended by FDA requests for additional information or clarification or if the applicant submits a major amendment during the review.
The FDA may also refer applications to an advisory committee, typically a panel that includes clinicians and other experts, for review,
evaluation and a recommendation as to whether the application should be approved. This often, but not exclusively, occurs for novel drug
products or drug products that present difficult questions of safety or efficacy. The FDA is not bound by the recommendation of an advisory
committee.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Before approving an application, the FDA typically will inspect
the facility or facilities where the product is manufactured. The FDA will not approve the application unless the FDA determines that
the product is manufactured in substantial compliance with cGMP. If the FDA determines that the NDA or BLA is supported by adequate data
and information, the FDA may issue an approval letter. During review, the FDA may request additional information via an information request,
or IR letter, or state deficiencies via a deficiency letter, or DR letter. Upon compliance with the conditions stated, the FDA will typically
issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific
indications. As a condition of approval, the FDA may require additional trials or post-approval testing and surveillance to monitor the
drug&#8217;s safety or efficacy, the adoption of risk evaluation and mitigation strategies, and may impose other conditions, including
labeling and marketing restrictions on the use of the drug, which can materially affect its potential market and profitability. Once granted,
product approvals may be withdrawn if compliance with regulatory standards for manufacturing and quality control are not maintained or
if additional safety problems are identified following initial marketing.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If the FDA&#8217;s evaluation of the NDA or BLA submission or manufacturing
processes and facilities is not favorable, the FDA may refuse to approve the NDA or BLA and may issue a complete response letter. The
complete response letter, or CRL, indicates that the review cycle for an application is complete and that the application is not ready
for approval. The complete response letter will describe specific deficiencies and, when possible, will outline recommended actions the
applicant might take in order to place the application in condition for approval. Following receipt of a CRL, the company may submit additional
information and start a new review cycle, withdraw the application or request a hearing. Failure to take any of the above actions may
result in the FDA considering the application withdrawn following one year from issuance of the CRL. In such cases, the FDA will notify
the company and the company will have 30 days to respond and request an extension of time in which to resubmit the application. The FDA
may grant reasonable requests for extension. If the company does not respond within 30 days of the FDA&#8217;s notification, the application
will be considered withdrawn. Even with submission of additional information for a new review cycle, the FDA ultimately may decide that
the application does not satisfy the regulatory criteria for approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Pediatric Research Equity Act, or PREA, requires NDAs and BLAs
(or supplements) for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration to contain
results assessing the safety and efficacy for the claimed indication in all relevant pediatric subpopulations. Data to support dosing
and administration also must be provided for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant
deferrals for the submission of results or full or partial waivers from the PREA requirements (for example, if the product is ready for
approval in adults before pediatric studies are complete, if additional safety data is needed, among others). In addition, under the Best
Pharmaceuticals for Children Act, or BPCA, the FDA may issue a written request to the company to conduct clinical trials in the pediatric
population that are related to the moiety and expand on the claimed indication. The studies are voluntary but may award the company with
6 months of marketing exclusivity if conducted according to good scientific principles and address the written request. Finally, a sponsor
can request that a product that must be studied under PREA to be studied also under the BPCA to allow the sponsor to be eligible for six-months
of pediatric exclusivity. The pediatric studies requested under BPCA are usually more extensive and would generally also fulfill the PREA
requirement; however, even if the sponsor does not complete the studies outlined in the BPCA written request, it is still required to
complete any studies required under PREA.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">55</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25"><br/> &#160;<span style="font-weight: bold; font-style: italic">Post-Marketing Requirements</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Once an NDA or BLA is approved, the drug sponsor will be subject
to certain post-approval requirements, including requirements for adverse event reporting, submission of periodic reports, manufacturing,
labeling, packaging, advertising, promotion, distribution, record-keeping and other requirements. For example, the approval may be subject
to limitations on the uses for which the product may be marketed or conditions of approval, or contain requirements for costly post-marketing
testing and surveillance to monitor the safety or efficacy of the product or require the adoption of risk evaluation and mitigation strategies.
In addition, the FDA requires the reporting of any adverse effects observed after the approval or marketing of a therapeutic candidate
and such events could result in limitations on the use of such approved product or its withdrawal from the marketplace. Also, some types
of changes to the approved product, such as manufacturing changes and labeling claims, are subject to further FDA review and approval.
Additionally, the FDA strictly regulates the promotional claims that may be made about prescription drug products. In particular, the
FDA requires substantiation of any claims of superiority of one product over another including, in many cases, requirements that such
claims be proven by adequate and well controlled head-to-head clinical trials. To the extent that market acceptance of our therapeutic
candidates may depend on their superiority over existing products, any restriction on our ability to advertise or otherwise promote claims
of superiority, or any requirements to conduct additional expensive clinical trials to provide proof of such claims, could negatively
affect the sales of our therapeutic candidates and our costs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Orphan Drug Designation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Orphan Drug Act, or ODA, provides for granting special status
to a drug or biological product to treat a rare disease or condition (i.e., a disease or condition that affects fewer than 200,000 individuals
in the United States), or a disease or condition that affects more than 200,000 individuals in the United States but where there is no
reasonable expectation that the product development cost will be recovered from product sales in the United States, upon request of a
sponsor. This status is referred to as orphan designation (or sometimes &#8220;orphan status&#8221;). For a therapeutic candidate to qualify
for orphan designation, both the candidate and the disease or condition must meet certain criteria specified in the ODA&#8217;s implementing
regulations (set forth at 21 CFR Part 316). Orphan designation qualifies the sponsor of the candidate for various development incentives
of the ODA, including tax credits for qualified clinical testing, waiver of NDA/BLA user fees and eligibility for seven-year marketing
exclusivity, referred to as orphan exclusivity upon marketing approval. The granting of an orphan designation request does not alter the
standard regulatory requirements and process for obtaining marketing approval. Safety and effectiveness of a candidate must still be established
through adequate and well-controlled studies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Expedited Programs for Serious Conditions</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The FDA has put in place four programs intended to facilitate and
expedite development and review of a new drug intended to address an unmet medical need in the treatment of a serious or life-threatening
condition: fast track designation, breakthrough therapy designation, accelerated approval and priority review designation. Each program
offers the sponsor a defined set of opportunities such as expedited development and review, intensive FDA guidance during development,
marketing approval based on an effect on a surrogate endpoint or an intermediate clinical endpoint that is reasonably likely to predict
the drug&#8217;s clinical benefit, and a shorter time for review of marketing application. Fast Track and Breakthrough Therapy designations
may be requested during development, while Accelerated Approval and Priority Review relate to the marketing approval stage.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">56</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"><span style="text-decoration: underline">European
Union/European Economic Area</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Clinical Trials</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Within the European Union (EU) and the European Economic Area (EEA),
which is composed of the 27 member states of the EU plus Norway, Iceland and Liechtenstein, the authorization of clinical trials occurs
at member state level. The European Medicines Agency, or EMA, plays a key role in ensuring that GCP standards are applied across the European
Economic Area, or EEA, in cooperation with the member states. It also manages a database of clinical trials carried out in the EU.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Clinical trials in the EU are regulated under Regulation (EU) 536/2014
(CTR), as amended on April 5, 2022. As opposed to the previous Directive 2001/20/EC (CTD), which as an EU directive was not directly applicable
in the member states, the CTR (as an EU regulation) has immediate effect for the whole EU and did not have to be transposed into national
law. While national laws implementing the CTD varied to a great extent, the CTR provides for a significant further harmonization of the
law governing clinical trials in the EU. After significant delay, the CTR became applicable on January 31, 2022. The CTR now harmonizes
the assessment and supervision processes for clinical trials throughout the EU via the Clinical Trials Information System (CTIS), which
includes a centralized EU portal and database for clinical trials. From 31 January 2023 onwards, clinical trial sponsors need to apply
to start a clinical trial via CTIS. Additionally, CTIS is used to coordinate the assessment between Member States, handle regulatory queries,
and communicate the respective national decisions to the sponsor. Therefor CTIS ensures the harmonized and transparent approval system
envisaged by the CTR. In accordance with the CTR, the Data submitted, will be published in the EU database. From 31 January 2025, any
trials previously approved under the CTD that continue to run after such date will need to comply with CTR and their sponsors must have
recorded the required information on such trials in CTIS. The CTR provides inter alia:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z081b2bda5d3b46dfbc173fa0a63739b5" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Consistent rules for conducting clinical trials throughout the EU;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;<br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Making information on the authorization, conduct and results of each clinical trial carried out in the
        EU publicly available;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z502c79e336954b5caed15ae751849549" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Harmonized electronic submission and assessment process for clinical trials conducted in multiple member
        states;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Improved collaboration, information sharing and decision-making between and within member states;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Increased transparency of information on clinical trials; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Higher standards of safety for all participants in EU clinical trials, also ensured through compliance
        with Good Clinical Practice (GCP).</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The authorization of a clinical trial (Phase 1-3) in an EU member
state requires the submission of a clinical trial application (CTA) via the EU Portal, CTIS. The application will be reviewed by the competent
authorities of the member states where the trial is supposed to take place. The application and approval process is conducted by the member
states under the cooperation system set forth in the CTR. Particularities under member states&#8217; national law still apply to some
extent. In general, the CTA should include, among other documents, the study protocol, results of the nonclinical studies and manufacturing
information and analytical results. A detailed list is listed in Annex I of the CTR. Also, the sponsor has to suggest one of the concerned
member states as reporting member state. The concerned member state may, within three days of submission of the application, raise objections
to the proposal or declare their willingness to act as the reporting member state. The reporting member state is designated no later than
six days after submission. The reporting member state validates the application within ten days and requests additional documentation
if it is incomplete. The sponsor has ten days (max.) to supply the requested documents. The reporting Member State decides on the completeness
of the application within five days. Once validation has been successful, the evaluation phase begins. The CTR aims at speeding up the
validation and review of clinical trial applications and therefore provides strict deadlines.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">57</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Marketing Authorization Procedures</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A medicinal product may only be placed on the market in the EEA
if it has obtained a marketing authorization according to the applicable EU and/or member state law. A marketing authorization may either
be granted in a national procedure, or in a coordinated procedure of several member states pursuant to Directive 2001/83/EC, as amended
on January 1, 2025, or under the centralized EU procedure in accordance with Regulation (EC) No. 726/2004, as amended on January 28, 2022.
Depending on the nature of the medicinal product, several different legal frameworks of the EU and the member states may be relevant for
the market clearance.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Centralized Procedure (CP)</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Centralized Procedure according to Regulation 726/2004/EC (as
amended on January 28, 2022) allows a marketing authorization holder to market the medicine and make it available to patients and healthcare
professionals throughout the entire EEA on the basis of a single marketing authorization, granted by the European Commission based on
the opinion of the Committee for Medicinal Products for Human Use (CHMP), which is responsible for the scientific assessment, acting in
its capacity as the European Licensing Authority on the advice of the EMA. The EMA is the administrative body responsible for coordinating
the existing scientific resources available in the member states for evaluation, supervision and pharmacovigilance of medicinal products.
The marketing authorization needs to be renewed after 5 years, after which it is often valid indefinitely. Therefor a re-evaluation of
the risk-benefit balance is necessary for the renewal.&#160;A renewal application must be submitted to the Agency at the latest 9 months
before the expiry date of the MA. The MA validity period is calculated from the date of notification of the Commission Decision.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Certain medicinal products (e.g., products derived from biotechnology,
advanced-therapy medicinal products, orphan medicinal products and medicinal products for human use, which contain an active substance
authorized in the European Union after May 20, 2004 and which are intended for the treatment of AIDS, cancer, neurodegenerative disorders,
diabetes, auto-immune diseases and other immune dysfunctions or viral diseases) must be authorized centrally. The centralized authorization
procedure is optional for other medicinal products if they contain a new active substance which on May 20, 2002 was not authorized in
the European Union, or if the applicant shows that the medicinal product concerned constitutes a significant therapeutic, scientific or
technical innovation or that the granting of authorization is in the interest of patients in the European Union. For each application
submitted to the EMA for scientific assessment, the EMA is required to ensure that the opinion of the Committee for Medicinal Products
for Human Use, or CHMP, is given within 210 days after receipt of a valid application or within 150 days by means of an accelerated procedure
(excluding clock stops); the review period can be extended. If the opinion is positive, the EMA is required to send the opinion to the
European Commission, which is responsible for preparing the decision granting a marketing authorization. If the initial opinion of the
CHMP is negative, the applicant is afforded an opportunity to seek a re-examination of the opinion. The CHMP is required to re-examine
its opinion within 60 days following receipt of the request by the applicant. A refusal of a centralized marketing authorization constitutes
a prohibition on placing the given medicinal product on the market in the EU. The European Commission is further empowered to suspend,
revoke, or withdraw an authorization where safety concerns arise or where regulatory requirements have been breached.&#160;Any post&#8209;authorization
changes must be implemented in compliance with the procedural requirements laid down in Commission Regulation (EC) No 1234/2008.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The EMA&#8217;s Committee for Advanced Therapies (CAT) is responsible
for assessing the quality, safety and efficacy of advanced therapy medicinal products (ATMP). ATMP include gene therapy medicinal products,
somatic cell therapy medicinal products and tissue engineered medicinal products. The main responsibility of the CAT is to prepare a draft
opinion on an application for marketing authorization for an ATMP candidate that is submitted to the EMA. The EMA&#8217;s Committee for
Medicinal Products for Human Use (CHMP) then provides a final opinion regarding the application for marketing authorization. The European
Commission grants or refuses marketing authorization after the CHMP has delivered its opinion. ATMP are further regulated under Regulation
(EC) No 1394/2007 on advanced therapy medicinal products, as amended on July 26, 2024 and Directive 2001/83/EC on medicinal products for
human use, as amended on January 1, 2025.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">58</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">National Authorization Procedure</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A National Authorization Procedure is used when applying for a
marketing authorization in one individual EEA state. The national procedure can only be used if the medicinal product does not already
have a marketing authorization in another EEA state. The national authorization has validity for five years. After this period the authorization
can be renewed for another five years.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Mutual Recognition Procedure (MRP)</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The mutual recognition procedure (Art. 28 Directive 2004/27/EC)
can be used if a medicinal product already has a marketing authorization in one EEA member state, and the authorization holder would like
to extend the authorization to other member states. An application for mutual recognition may be addressed to one or more EEA countries.
The country in which the national marketing authorization has been granted acts as the &#8220;Reference Member State,&#8221; and the other
countries concerned (Concerned Member States) can, upon successful completion of the procedure, recognize the marketing authorization.
To this end, the marketing authorization holder shall request the Reference Member State either to prepare an assessment report on the
product or, if necessary, to update any existing assessment report. The assessment time is 180 days plus 30 days.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If the Member State concerned considers that the recognition of
an authorization would pose a risk to public health, it shall notify the other Member States so that, if necessary, with the involvement
of the Coordination Group for Mutual Recognition and Decentralised Procedures &#8211; Human (CMDh), measures can be taken to resolve the
conflict and enable the authorization to be recognized.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Decentralized Procedure (DCP)</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The decentralized procedure (introduced by Directive 2004/27/EU)
is used in cases where the medicinal product has not received a marketing authorization in the EU at the time of application. It allows
the common assessment of an application submitted simultaneously to several member states. One of the member states will take the lead
in evaluating the application as Reference Member State to facilitate agreement with the Concerned Member States and the grant of a national
marketing authorization in all of these member states. To this end, the Reference Member State conducts a detailed review and prepares
a draft assessment report, a draft assessment report, a draft summary of product characteristics and a draft of the labelling and package
leaflet and shall send these documents to the Concerned Member States to provide comments. The assessment time is 210 days plus 30 days.
Upon successful completion of the authorization procedure, the medicinal product will receive uniform national approval in the member
states concerned.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Manufacturing Requirements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Any medicinal product placed on the market in the EEA must be manufactured
in accordance with the principles of good manufacturing practice as set out in Directive EC2017/1572 supplementing Directive 2001/83/EC
of the European Parliament and of the Council as regards the principles and guidelines of good manufacturing practice for medicinal products
for human use for human use and Volume 4 of the &#8220;Rules Governing Medicinal Products in the European Community&#8221;. Directive
2017/1572/EU has replaced Directive 2003/94/EC. Directive 2003/94/EC will still be applicable to clinical trials conducted in accordance
with the former regime under transitional provisions. Furthermore, distribution of medicinal products in the EU is subject to Directive
2001/83/EC and current guidance on good distribution practice, or GDP. Additionally, an official manufacturing license is required before
production can commence. Moreover, EU law requires the clinical results in support of clinical safety and efficacy to be based upon clinical
trials conducted in the EU in compliance with the requirements of the CTR and Directive 2005/28/EC, which implement good clinical practice
in the conduct of clinical trials on medicinal products for human use. Clinical trials conducted outside the EU and used to support applications
for marketing within the EU must have been conducted in a way consistent with the principles set out in the CTR or if conducted prior
to 31 January 2022, its predecessor Directive 2001/20/EC. The conduct of a clinical trial in the EU requires, pursuant to the CTR, authorization
by the relevant national competent authority where a trial takes place, and an ethics committee to have issued a favorable opinion in
relation to the arrangements for the trial. It also requires that the sponsor of the trial, or a person authorized to act on his behalf
in relation to the trial, be established in the EU. The GMP requirements also apply tp investigational medicinal products and must be
released by a qualified person.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">59</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Law Relating to Pediatric Research</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Regulation (EC) 1901/2006 (as amended by Regulation (EC) 1902/2006
and Regulation (EU) 2019/5), or the Pediatric Regulation, was adopted on December 12, 2006. This Regulation governs the development of
medicinal products for human use in order to meet the specific therapeutic needs of the pediatric population (children aged 0 to 17 years).
It requires any application for marketing authorization made after July 26, 2008 in respect of a medicinal product not authorized in the
EU on January 26, 2007, the time the Regulation entered into force, to include studies in children conducted in accordance with a pediatric
investigation plan agreed to by the relevant European authorities. The approval authority may reject an application for approval or restrict
the approval if the paediatric investigation plan has not been complied with and no exemption applies. The results of the studies will
be published in the CTIS. This does not apply if the product is subject to an agreed waiver or deferral or if the product is excluded
from the scope of Regulation 1901/2006, which is the case for <span style="font-style: italic">inter alia</span> generics, homeopathic
and traditional (herbal) medicinal products. Waivers can be granted in certain circumstances where pediatric studies are not required
or desirable. Deferrals can be granted in certain circumstances where the initiation or completion of pediatric studies should be deferred
until appropriate studies in adults have been performed. Moreover, this regulation imposes the same obligation from January 26, 2009 on
an applicant seeking approval of a new indication, pharmaceutical form or route of administration for a product already authorized and
still protected by a supplementary protection certificate granted under Regulation (EC) no. 469/2009 or its precursor Regulation (EEC)
1768/92 by a patent that qualifies for the granting of such a supplementary protection certificate. The pediatric Regulation 1901/2006
also provides, subject to certain conditions, a reward for performing such pediatric studies, regardless of whether the pediatric results
provided resulted in the grant of a pediatric indication. This reward comes in the form of an extension of six months to the supplementary
protection certificate granted in respect of the product, unless the product is subject to Orphan Drug designation, in which case the
10-year market exclusivity period for such orphan products is extended to 12 years. If any of the non-centralized procedures for marketing
authorization have been used, the six-month extension of the supplementary protection certificate is only granted if the medicinal product
is authorized in all member states. Where the product is no longer covered by a patent or supplementary protection certificate, the applicant
may make a separate application for a Pediatric Use Marketing Authorization, or PUMA, which, on approval, will provide eight years&#8217;
protection for data and 10 years&#8217; marketing protection for the pediatric results.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Post-authorization Obligations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">An authorization to market a medicinal product in the EU carries
with it an obligation to comply with many post-authorization regulations relating to the marketing and other activities of authorization
holders. These may include requirements relating to provision of a risk management plan and provision of annual periodic safety update
reports, carrying out of post-authorization efficacy studies and/or post-authorization safety studies, maintenance of a pharmacovigilance
system master file, adverse event reporting, signal detection and management and other pharmacovigilance activities conducted under an
established quality system, advertising, packaging and labelling, patient package leaflets, and distribution. These obligations also include
reporting side effects via EudraVigilance. The regulations frequently operate within a criminal law framework, and failure to comply with
the requirements may not only affect the authorization, but also can lead to financial and other sanctions levied on the company in question
and responsible officers. As an example, the mandatory designation of a Qualified Person for Pharmacovigilance (QPPV) constitutes a requirement
whose breach can be subject to sanctions, EU pharmacovigilance legislation has been significantly modified by the Pharmacovigilance Directive,
Directive 2010/84/EU (as amended on January 20, 2011) which amended the legal framework of pharmacovigilance for medicines marketed within
the EU provided in Regulation (EC) No 726/2004 with respect to EU authorized medicinal products and in Directive 2001/83/EC with respect
to nationally authorized medicinal products (including those authorized through the mutual recognition and decentralized systems). Furthermore,
EU good pharmacovigilance practice (GVP) rules apply. With the amended pharmacovigilance requirements, the financial and organizational
burden on market authorization holders increased significantly, such as the obligation to maintain a pharmacovigilance system master file
that applies to all holders of marketing authorizations granted in accordance with Directive 2001/83/EC (as amended on January 1, 2025)
or Regulation (EC) No 726/2004 (as amended on January 28, 2022). Marketing authorization holders must furthermore collect data on adverse
events associated with use of the authorized product outside the scope of the authorization. Pharmacovigilance for biological products
and medicines with a new active substance is strengthened by subjecting their authorization to additional monitoring activities. The EMA
specifies the medicinal products concerned in the &#8220;List of Medicinal Products under Additional Monitoring&#8221;, which must be
regularly updated and reviewed. This ensures that safety&#8209;relevant information is collected more quickly and that risks can be identified
and managed at an early stage.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">60</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Another relevant aspect in the EU regulatory framework is the &#8220;sunset
clause&#8221;: a provision leading to the cessation of the validity of any marketing authorization if it is not followed by marketing
within three years or, if marketing is interrupted for a period of three consecutive years.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Data Privacy in the EU</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The EU has a strict regime on data privacy under the General Regulation
on Data Protection, Regulation 2016/679 (GDPR), as amended on May 4, 2016, that has become applicable on May 25, 2018. The GDPR as an
EU regulation does not have to be implemented into member states&#8217; national law but applies directly in all member states. It applies
to companies with an establishment in the European Economic Area (EEA) that includes the 27 member states of the EU and Norway, Iceland
and Liechtenstein. Furthermore, the GDPR applies to companies not located in the EEA but processing personal data of individuals located
in the EEA (e.g., through online business). The GDPR implements stringent operational requirements for controllers of personal data, including,
for example, obligations to justify the collection, use and other processing of personal data (e.g., based on the individual&#8217;s consent),
to notify the individuals concerned about data processing activities, to protect all processed personal data through appropriate technical
and organizational measures, and to implement a data protection compliance management. Furthermore, the GDPR defines high data security
and compliance standards for the transfer of personal data to third countries, including the U.S. In addition, the GDPR requires companies
to carry out a data protection impact assessment, appoint a data protection officer, report data breaches to the supervisory authority,
and notify the individuals affected. Where personal data is processed by third&#8209;party companies, these processors must be contractually
obligated to comply with the provisions of the GDPR. Data subjects also have the right to request the deletion of their data or the restriction
of processing, which has implications for data retention and overall compliance.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The operational requirements under the GDPR are even stricter in
case of sensitive personal data, such as health or genetic data, that typically have to be stored in a pseudonymized (i.e., key-coded)
manner. The GDPR provides that EU member states may in certain areas deviate from GDPR standards which results in varying laws and regulations
at member states level. The applicable data protection laws in the EEA may limit our ability to share and otherwise process personal data.
If our business falls below the GDPR standards, we may be subject to severe administrative fines up to 20,000,000 or up to 4 % of the
total worldwide annual turnover of our preceding financial year, if greater, and other administrative penalties including criminal liability,
which may be onerous and adversely affect our business, financial condition, results of operations and prospects. Failure to comply with
the GDPR and related laws may also give risk to increased risk of private actions, including a new form of class action that is available
under the GDPR.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">61</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold"><span style="text-decoration: underline">Israel</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Israel Ministry of the Environment - Toxin Permit</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In accordance with the Israeli Dangerous Substances Law - 1993,
the Israeli Ministry of the Environment is required to grant a permit in order to use toxic materials. Because we utilize toxic materials
in the course of operation of our laboratories, we were required to apply for a permit to use these materials. Our current toxin permit
will remain in effect until August 2031.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Clinical Testing in Israel</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In order to conduct clinical testing on humans in Israel, special
authorization must first be obtained from the ethics committee and the head of the medical center in which the clinical studies are planned
to be conducted, as required under the Guidelines for Clinical Trials in Human Subjects implemented pursuant to the Israeli Public Health
Regulations (Clinical Trials in Human Subjects), as amended from time to time, and other applicable legislation. These regulations require
authorization by the institutional ethics committee and the head of the medical center. Israeli Ministry of Health, except for certain
circumstances, is required to approve each trial as well. The institutional ethics committee must, among other things, evaluate the anticipated
benefits that are likely to be derived from the project to determine if it justifies the risks and inconvenience to be inflicted on the
human subjects, and the committee must ensure that adequate protection exists for the rights and safety of the participants as well as
the accuracy of the information gathered in the course of the clinical testing. Since we intend to perform a portion of the clinical studies
on certain of our therapeutic candidates in Israel, we will be required to obtain authorization from the ethics committee and head of
medical center of each institution in which we intend to conduct our clinical trials, and in most cases, from the Israeli Ministry of
Health.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Other Countries</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition to regulations in the United States, the EU and Israel,
we and our collaborators are subject to numerous and a variety of regulatory requirements of other countries and jurisdictions regarding
quality, safety and efficacy governing, among other things, clinical trials, marketing authorization, manufacturing, commercial sales
and distribution of drugs in other countries. Whether or not our products receive approval from the FDA, approval of such products must
be obtained by the comparable regulatory authorities of countries other than the United States before we or our collaborators can commence
clinical trials, manufacturing or marketing of the product in those countries. The approval process varies from country to country and
may involve additional product testing and additional administrative review periods. As a result, the time may be longer or shorter than
that required for FDA approval. The requirements governing the conduct of clinical trials and product licensing vary greatly from country
to country. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay
in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Related Matters</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">From time to time, legislation is drafted, introduced and passed
in governmental bodies that could significantly change the statutory provisions governing the approval, manufacturing and marketing of
products regulated by the FDA or EMA and other applicable regulatory bodies to which we are subject. In addition, regulations and guidance
are often revised or reinterpreted by the national agency in ways that may significantly affect our business and our therapeutic candidates.
It is impossible to predict whether such legislative changes will be enacted, whether FDA or EMA regulations, guidance or interpretations
will change, or what the impact of such changes, if any, may be. We may need to adapt our business and therapeutic candidates and products
to changes that occur in the future.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">62</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25"><br/> &#160;<span style="font-weight: bold">Pharmaceutical Coverage, Pricing and Reimbursement</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Significant uncertainty exists as to the coverage and reimbursement
status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which
third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers
and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process for determining
whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that
the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining
the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party
payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products
for a particular indication.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In order to secure coverage and reimbursement for any product that
might be approved for sale, a company may need to conduct expensive pharmacoeconomic, health outcome studies in order to demonstrate the
medical necessity, quality of life benefits, and cost-effectiveness of the product, in addition to the costs required to obtain FDA or
other comparable regulatory approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective in
light of cost-benefit analysis. Additionally, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate
reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that
other payors will also provide coverage for the drug product. Third-party reimbursement may not be sufficient to maintain price levels
high enough to realize an appropriate return on investment in product development.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The containment of healthcare costs also has become a priority
of federal, state and foreign governments and the prices of drugs have been a focus in this effort. Governments have shown significant
interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution
of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions
with existing controls and measures, could further limit our net revenue and results. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company
or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Outside the United States, ensuring adequate coverage and payment
for our therapeutic candidates will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many
countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for
a product and may require us to conduct studies that compare the cost effectiveness of our product candidates or products to other available
therapies. The conduct of such studies could be expensive and result in delays in our commercialization efforts.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Pricing and reimbursement schemes vary widely from country to country.
Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require
the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies
in order to obtain reimbursement. For example, the European Union provides options for its member states to restrict the range of drug
products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human
use. European Union member states may approve a specific price for a drug product, or it may instead adopt a system of direct or indirect
controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their
own prices for drug products but monitor and control company profits and issue guidance to prescribers. The downward pressure on health
care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected
to the entry of new products. In addition, reference pricing and cross-border imports from low-priced markets exert competitive pressure
that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow
favorable reimbursement and pricing arrangements.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">63</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25"><br/> &#160;<span style="font-weight: bold">Other Healthcare Laws and Regulation</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Healthcare providers and third-party payors play a primary role
in the recommendation and prescription of drug products that are granted regulatory approval. Arrangements with providers, consultants,
third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may
constrain our business and/or financial arrangements. Such restrictions under applicable federal and state healthcare laws and regulations
include the following:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z4693bba6187d44188d6e54b721f9596e" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle"> <br/> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the federal Anti-Kickback Statute, which prohibits, among other things, persons and
        entities from knowingly and willfully soliciting, offering, receiving or providing remuneration (including any kickback, bribe or rebate),
        directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease or order
        of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</div>
        <div style="text-align: justify; line-height: 1.25"> <br/> </div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the federal civil and criminal false claims laws, including the civil False Claims
        Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing
        to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease
        or conceal an obligation to pay money to the federal government;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA,
        which created additional federal criminal laws that prohibit, among other things, knowingly and willingly executing, or attempting to
        execute, a scheme or making false statements in connection with the delivery of or payment for health care benefits, items, or services;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health
        Act and its implementing regulations, which also imposes obligations, including mandatory contractual terms, with respect to safeguarding
        the privacy, security and transmission of individually identifiable health information on covered entities and their business associates
        that associates that perform certain functions or activities that involve the use or disclosure of protected health information on their
        behalf;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the Foreign Corrupt Practices Act, or FCPA, which prohibits companies and their intermediaries
        from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business
        or otherwise seeking favorable treatment;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25; text-align: justify">the Civil Monetary Penalty Act of 1981 imposes penalties against any person or entity
        that, among other things, is determined to have presented or caused to be presented a claim to a federal health care program that the
        person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or offering or transferring
        remuneration to a federal health care beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision
        to order or receive items or services reimbursable by the government from a particular provider or supplier;</div> </td> </tr>
  </table> <br/>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">64</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the federal transparency requirements known as the federal Physician Payments Sunshine
        Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or collectively
        the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare,
        Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp;
        Medicaid Services, or CMS, within HHS, information related to payments and other transfers of value to certain healthcare providers and
        teaching hospitals and information regarding ownership and investment interests held by physicians and their immediate family members;
        and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> </div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">analogous state and foreign laws and regulations, such as state anti-kickback and
        false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including
        private insurers.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Some state laws require pharmaceutical companies to comply with
the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government
in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or
marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many
of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">U.S. Healthcare Reform</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A primary trend in the U.S. healthcare industry and elsewhere is
cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount
of reimbursement for particular medical products. For example, in March 2010, the ACA was enacted, which, among other things, increased
the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which
rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted
or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care
plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#8217; outpatient drugs
coverage under Medicare Part D; subjected drug manufacturers to new annual fees based on pharmaceutical companies&#8217; share of sales
to federal healthcare programs; created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in and conduct
comparative clinical effectiveness research, along with funding for such research; and established the Center for Medicare &amp; Medicaid
Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We expect that future changes or additions to the ACA, the Medicare
and Medicaid programs, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing
or other legislation in individual states, could have a material adverse effect on the healthcare industry in the United States. For example,
the American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average
manufacturer price, beginning on January 1, 2024.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Additionally, on December 20, 2019, the Further Consolidated Appropriations
Act for 2020 was signed into law (P.L. 116-94) and includes a piece of bipartisan legislation called the Creating and Restoring Equal
Access to Equivalent Samples Act of 2019, or the CREATES Act. The CREATES Act aims to address the concern articulated by both the FDA
and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking
the existence of a REMS for certain products, to deny generic product developers access to samples of brand products. Because generic
product developers need samples of an RLD to conduct certain comparative testing required by the FDA, some have attributed the inability
to timely obtain samples as a cause of delay in the entry of generic products. To remedy this concern, the CREATES Act establishes a private
cause of action that permits a generic product developer to sue the brand manufacturer to compel it to furnish the necessary samples on
&#8220;commercially reasonable, market-based terms.&#8221; Whether and how generic product developments will use this new pathway, as
well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects
on any of our future commercial products are unknown.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">65</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In August 2022, President Biden signed into the law the Inflation
Reduction Act of 2022, or the IRA. The IRA has multiple provisions that may impact the prices of drug products that are both sold into
the Medicare program and throughout the United States. Starting in 2023, a manufacturer of a drug or biological product covered by Medicare
Parts B or D must pay a rebate to the federal government if the drug product&#8217;s price increases faster than the rate of inflation.
This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly
dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, CMS
will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will
also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for
negotiation, it is expected that the revenue generated from such drug will decrease. CMS has begun to implement these new authorities
and entered into the first set of agreements with pharmaceutical manufacturers for negotiated prices of 10 products, which became applicable
for payment year 2026. However, the IRA&#8217;s impact on the pharmaceutical industry in the United States remains uncertain, in part
because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits
against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. Those lawsuits are currently ongoing.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">To date, President Trump has signed an Executive Order to require
drug prices to be transparent. In addition, the President reversed certain policies by the Biden Administration. President Trump eliminated:
Medicare $2 drug list model, cell and gene therapy access model to improve high-cost drugs for Medicaid enrollees, and accelerate clinical
evidence model for new drug. Additionally, in 2025, HHS began implementation of &#8220;Most Favored Nation&#8221; drug pricing by setting
the Medicare price of single-source brand drugs without generic or biosimilar competition to the lowest price available in wealthy countries
with a per capita GDP of at least 60% of that in the United States. It is not clear what additional changes may be implemented, but President
Trump does want disclosure of transparency in prices.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Individual states in the United States have also increasingly passed
legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints,
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed
to encourage importation from other countries and bulk purchasing. For example, in recent years, several states have formed prescription
drug affordability boards (PDABs). Much like the IRA&#8217;s drug price negotiation program, these PDABs have attempted to implement upper
payment limits (UPLs) on drugs sold in their respective states in both public and commercial health plans. In August 2023, Colorado&#8217;s
PDAB announced a list of five prescription drugs that would undergo an affordability review. The effects of these efforts remain uncertain
pending the outcomes of several federal lawsuits challenging state authority to regulate prescription drug payment limits. In December
2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate pharmaceutical benefit
managers, or PBMs, and other members of the healthcare and pharmaceutical supply chain, an important decision that may lead to further
and more aggressive efforts by states in this area. The Federal Trade Commission (FTC) in mid-2022 also launched sweeping investigations
into the practices of the PBM industry that could lead to additional federal and state legislative or regulatory proposals targeting such
entities&#8217; operations, pharmacy networks, or financial arrangements. On February 3, 2026, Congress enacted the Consolidated Appropriations
Act of 2026, which limits the fees charged by PBMs, as well as requiring PBMs to fully pass through manufacturer rebates to a Medicare
Part D plan sponsor. Significant efforts to change the PBM industry as it currently exists in the U.S. may affect the entire pharmaceutical
supply chain and the business of other stakeholders, including pharmaceutical product developers like us.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We expect that additional foreign, federal and state healthcare
reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare
products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or
additional pricing pressures.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">66</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold">Israeli Government Programs</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Israel Innovation Authority</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Before we in-licensed motixafortide, Biokine had received $2.7
million in funding for the project from the IIA (formerly the OCS). As a condition for the IIA&#8217;s consent to our in-licensing of
motixafortide, we were required to agree to abide by any obligations resulting from such funding under the Israeli Encouragement of Industrial
Research, Development and Technological Innovation Law, 1984, and related regulations, as amended (the Research Law). Under the Research
Law and the terms of IIA grants, royalties on the revenues derived from sales of products (and associated services) developed with IIA
funding are payable to the Israeli government, generally at the rate of 3% (and at an increased rate under certain circumstances, as described
below). The obligation to make these royalty payments terminates upon repayment of the amount of grants, linked to the U.S. dollar, plus
interest (in accordance with IIA regulations), which amount may be increased under certain circumstances, as described below.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Research Law, the transfer or license to third parties
outside of Israel of know-how or technologies developed under IIA-funded programs, or the transfer to third parties outside of Israel
of manufacturing or rights to manufacture based on IIA-funded know-how, requires the consent of the IIA in certain circumstances, and
may result in increased payments to the IIA. Specifically, for the transfer of manufacturing outside of Israel, royalty payments can be
up to three times the amount of the IIA grants received, linked, plus interest, and the royalty repayment rate may increase. For the transfer
of IIA-funded know-how outside of Israel, the payment may be up to six times the amount of the IIA grants, linked, plus interest. In connection
with the IIA&#8217;s approval of the out-licensing transactions with Gloria and Ayrmid, the IIA determined that we are required to pay
the IIA 3.9% on any sub-license consideration, up to six times the IIA grant, linked, plus interest. Additionally, in December 2024, we
received IIA approval to transfer the manufacturing of motixafortide outside of Israel, which requires us to pay the IIA 4% of proceeds
on any direct product sales, up to three times the IIA grant, linked plus interest. As of December 31, 2025, $1.3 million in aggregate
royalties had been paid to the IIA on account of the motixafortide program and there was a contingent liability to the IIA (including
interest) of $2.5 million (without taking into account the potential repayment requirement of up to six times the amount as detailed above).
In any event, under our agreement with Biokine, we have a full right of offset for amounts payable to the IIA for the motixafortide program
from any payments that we may owe to Biokine in the future.</div>

<div style="line-height: 1.25">&#160;&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Should we wish to further out-license motixafortide in the future,
there is no assurance that we will be able to obtain the IIA&#8217;s consent on terms acceptable to us, or at all. Even following the
full repayment of IIA grants, we must nevertheless continue to comply with the requirements of the Research Law. If we fail to comply
with any of the conditions and restrictions imposed by the Research Law and regulations and guidelines thereunder, or by the specific
terms of the IIA grants, we may be required to refund any IIA grants that Biokine previously received together with interest and penalties,
and, in certain circumstances, may be subject to criminal charges. In any event, under our agreement with Biokine, we have a full right
of offset for amounts payable to the IIA for the motixafortide program from any payments that we may owe to Biokine in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Environmental Matters</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are subject to various environmental, health and safety laws
and regulations, including those governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal
of hazardous, radioactive and biological materials and wastes and the cleanup of contaminated sites. We believe that our business, operations
and facilities are being operated in compliance, in all material respects, with applicable environmental and health and safety laws and
regulations. Based on information currently available to us, we do not expect environmental costs and contingencies to have a material
adverse effect on us. The operation of our facilities, however, entails risks in these areas. Significant expenditures could be required
in the future if we are required to comply with new or more stringent environmental or health and safety laws, regulations or requirements.
See &#8220;Business - Government Regulation and Funding - Israel Ministry of Environment - Toxin Permit.&#8221;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">67</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">C. Organizational Structure</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our corporate structure consists of BioLineRx Ltd., one wholly
owned subsidiary, BioLineRx USA, Inc. and we own 40% of the shares of Tetragon.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">D. Property, Plant and Equipment</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are headquartered in Modi&#8217;in, Israel. We entered into
a lease agreement in August 2014, for an aggregate of 1,663 square meters (approximately 17,900 square feet) of space. Monthly rent is
NIS 137,000 (approximately $39,700), including maintenance fees and parking. The initial term of the lease expired in June 2020, and we
exercised our options to extend the lease through June 30, 2028. We have the option to extend the lease for one additional period of two
years, at a 5% increase to the preceding lease payment amount.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">This facility houses both our administrative and research operations
and our central laboratory. The central laboratory consists of approximately 380 square meters (approximately 4,200 square feet) and includes
a bioanalytical laboratory, a formulation laboratory and a tissue culture laboratory. Our bioanalytical laboratory has received GLP certification.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM4A"><!--Anchor--></span>ITEM 4A. UNRESOLVED STAFF
COMMENTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">None.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 5<span id="ITEM5"><!--Anchor--></span>. OPERATING AND FINANCIAL
REVIEW AND PROSPECTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">You should read the following discussion of our financial condition
and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Annual Report
on Form 20-F. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results
could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences
include those discussed below and elsewhere in this Annual Report on Form 20-F, particularly those in &#8220;Item 3. Key Information -
Risk Factors.&#8221; Our discussion and analysis for the year ended December 31, 2024 can be found in Item 5. &#8220;Operating and Financial
Review and Prospects&#8221; of our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the SEC on March
31, 2025 (File No. 001-35223).</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are a biopharmaceutical company pursuing life-changing therapies
in oncology and rare diseases. Our first approved product, APHEXDA&#174; (motixafortide), a novel peptide for the treatment of stem-cell
mobilization and solid tumors, with an indication in the United States for stem cell mobilization for&#160;autologous transplantation
in multiple myeloma, is being developed and commercialized by Ayrmid Pharma Ltd., or Ayrmid, (globally, excluding Asia) and Gloria, (in
Asia). We are also advancing the development of motixafortide for patients with pancreatic cancer and other solid tumors outside of Asia.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In October 2023, we out-licensed the rights to motixafortide for
all indications in substantially all of Asia to Gloria, and in November 2024, we out-licensed the global rights (other than in Asia) to
motixafortide for all indications, other than solid tumors, to Ayrmid. As a result of the November 2024 transaction, we shut down our
independent commercialization activities in the United States and refocused our operations on development activities in Israel in the
fields of oncology (including solid tumors) and rare diseases, at a significantly reduced annual cash burn rate.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">We have retained the rights to develop motixafortide across all solid tumor indications,
in all territories other than Asia, including in PDAC, for which an investigator-initiated Phase 2b trial, sponsored by Columbia University,
and supported equally by us and Regeneron, is ongoing at a relatively minimal cost to us. We expect this program to continue to advance
without any significant expense to us.</div>

<div style="text-indent: 36pt; line-height: 1.25"> <br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">68</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">In September 2025, we entered into a collaboration transaction with Hemispherian AS,
or Hemispherian, a Norwegian biotech company focused on small molecule cancer therapeutics,&#160;for the development, clinical evaluation
and commercialization&#160;of GLIX1, Hemispherian&#8217;s lead drug candidate, a first-in-class, oral, small molecule targeting DNA damage
response in GBM, and other cancers.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A key pillar of our growth strategy is to in-license additional
assets in the fields of oncology and rare diseases &#8211; areas where significant unmet medical needs remain and where innovative therapies
can have a transformative impact on patient lives. We are committed to identifying and advancing therapeutic candidates that demonstrate
clear differentiation from currently available treatments, offering the potential for superior efficacy, improved safety, and novel mechanisms
of action. We have generated our pipeline through a systematic process of asset identification, rigorous scientific and clinical validation,
and disciplined in-licensing. We believe this methodical approach allows us to select candidates with a high probability of both therapeutic
and commercial success. Drawing on our substantial experience in asset scouting and evaluation and executing transactions structured with
back-ended, success-based consideration, we are seeking to secure assets with modest upfront payments, while aligning incentives with
our partners and maintaining a focus on cost-effective clinical development programs. With our deep expertise, strategic focus, and prudent
financial management, we believe we are uniquely positioned to bring forward novel therapies that can redefine standards of care and deliver
significant value to patients, healthcare providers, and stakeholders.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our longer-term vision is to develop innovative assets with significant
potential value whose development costs have been offset by the royalties and milestones from our existing motixafortide partnerships.
We aim to continue pursuing new partnerships on these programs to create additional value for our shareholders.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. Operating Results</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">History of Losses</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Since our inception in 2003, we have generated significant losses.
As of December 31, 2025, we had an accumulated deficit of $401 million. We expect to continue to generate losses in connection with our
research and development activities relating to our pipeline of therapeutic candidates until we reach commercial profitability, if ever.
Such research and development activities are budgeted to expand over time and will require further resources if we are to be successful.
As a result, we expect to continue to incur operating losses and we expect to need to obtain additional funds to further pursue our research
and development programs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have funded our operations primarily through the sale of equity
securities (both in public and private offerings), payments received under our strategic licensing and collaboration arrangements, funding
received from the Israel Innovation Authority, or IIA, debt financing, and interest earned on investments. We expect to continue to fund
our operations over the next several years through our existing cash resources, potential future milestone and royalty payments that we
may receive from our existing out-licensing agreements, primarily royalties from the commercialization of APHEXDA by Ayrmid, potential
future upfront, milestone or royalty payments that we may receive from Gloria and any other out-licensing transaction, interest earned
on our investments, and additional capital to be raised through public or private equity offerings or debt financings.&#160;As of December
31, 2025, we had $20.9 million of cash, cash equivalents and short-term bank deposits.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;<span style="font-weight: bold">Revenues</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our revenues to date have been generated primarily from upfront
and milestone payments under out-licensing agreements and between the fourth quarter of 2023 and November 2024, and revenues from product
sales of APHEXDA.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We expect our revenues, if any, for the next several years to be
derived primarily from future royalties on product sales, primarily royalties paid by Ayrmid from the commercialization of APHEXDA in
stem cell mobilization in the U.S. and potential milestone payments from the license agreements with Ayrmid and Gloria.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Cost of Revenues</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our cost of revenues to date have consisted of sub-license payments
to the licensors in respect of upfront and milestone payments associated with out-licensing agreements, costs associated with the manufacture
of APHEXDA and royalty payments to the licensor with respect to direct product sales of APHEXDA. Prior to receiving FDA approval for APHEXDA
in September 2023, we expensed all manufacturing and material costs as research and development expenses.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We expect our cost of revenues, if any, for the next several years
to be derived primarily from sub-license payments to the licensors in respect of out-licensing agreements and other potential collaboration
arrangements, including future royalties on product sales from such out-licensing agreements.</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">69</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br/>

<div style="line-height: 1.25">&#160;<span style="font-weight: bold">Research and Development</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our research and development expenses consist primarily of salaries
and related personnel expenses, fees paid to external service providers, up-front and milestone payments under our license agreements,
patent-related legal fees, costs of preclinical studies and clinical trials, drug and laboratory supplies and costs for facilities and
equipment. We primarily use external service providers to manufacture our therapeutic candidates for clinical trials and for the majority
of our preclinical and clinical development work. We charge all research and development expenses to operations as they are incurred.
We expect our research and development expenses to remain one of our primary expenses in the near future as we continue to develop GLIX1,
motixafortide and additional assets we may in license.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">The following table identifies our current major research and development projects:</div>

<div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;</div>

<table cellspacing="0" cellpadding="3" border="0" id="z5860714194504d689d83449cb8fc68ff" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="border-top: #000000 2px solid; width: 13.56%; vertical-align: middle; border-left: #000000 2px solid">
        <div style="line-height: 1.25; font-weight: bold">Project</div> </td>
    <td colspan="2" style="border-top: #000000 2px solid; width: 58.68%; vertical-align: middle; border-left: #000000 2px solid">
        <div style="line-height: 1.25; font-weight: bold">Status</div> </td>
    <td colspan="2" style="border-top: #000000 2px solid; width: 27.76%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid">
        <div style="line-height: 1.25; font-weight: bold">Expected Near Term Milestones</div> </td> </tr>
  <tr>
    <td style="border-top: #000000 2px solid; width: 13.56%; vertical-align: middle; border-left: #000000 2px solid">
        <div style="line-height: 1.25">GLIX1&#160;</div> </td>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">1.</div> </td>
    <td style="border-top: #000000 2px solid; width: 56%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">IND cleared by the FDA in August 2025; preparations ongoing for upcoming initiation of Phase 1/2a study
        in GBM and other cancers</div> </td>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">1.</div> </td>
    <td style="border-top: #000000 2px solid; width: 25.08%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid">
        <div style="line-height: 1.25">Phase 1/2a study expected to initiate in Q1 2026</div> </td> </tr>
  <tr>
    <td rowspan="6" style="border-top: #000000 2px solid; width: 13.56%; vertical-align: middle; border-left: #000000 2px solid; border-bottom: #000000 2px solid">
        <div style="text-align: center; line-height: 1.25">Motixafortide</div> </td>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">2.</div> </td>
    <td style="border-top: #000000 2px solid; width: 56%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">FDA approval received on September 8, 2023 for stem-cell mobilization in multiple myeloma patients.</div>
        </td>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">2.</div> </td>
    <td style="border-top: #000000 2px solid; width: 25.08%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid">
        <div style="line-height: 1.25">Out-licensed to Ayrmid in November 2024; five-year long-term follow-up of GENESIS patients ongoing</div>
        </td> </tr>
  <tr>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">3.</div> </td>
    <td style="border-top: #000000 2px solid; width: 56%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">Reported preliminary data in September 2023 from single-arm pilot phase of the investigator-initiated Phase
        2 combination trial in first-line PDAC. Of 11 patients with metastatic pancreatic cancer enrolled, 7 patients (64%) experienced partial
        response (PR), of which 6 (55%) were confirmed PRs with one patient experiencing resolution of the hepatic (liver) metastatic lesion.
        3 patients (27%) experienced stable disease, resulting in a disease control rate of 91%. Based on these encouraging preliminary results,
        study was substantially revised to a multi-institution, randomized Phase 2b trial of 108 patients. In May 2025, reported updated results
        from the pilot phase indicating that four of 11 patients remained progression free after more than one year. Two patients underwent definitive
        treatment for mPDAC &#8211; one had complete resolution of all radiologically detected liver lesions and underwent definitive radiation
        to the primary pancreatic tumor, and one had a sustained partial response and underwent pancreaticoduodenectomy with pathology demonstrating
        a complete response. An analysis of pre- and on-treatment biopsies and peripheral blood mononuclear cells (PBMCs) also revealed that CD8+
        T-cell tumor infiltration increased across all eleven patients treated with the motixafortide combination.</div> </td>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">3.</div> </td>
    <td style="border-top: #000000 2px solid; width: 25.08%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">First patient dosed in randomized study in February 2024. Interim futility analysis&#160;planned for 2026
        and full enrollment projected for 2027*</div>
        <div style="line-height: 1.25">&#160;</div> </div>
        <div style="line-height: 1.25">&#160;</div> </div> </td> </tr>
  <tr>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">4.</div> </td>
    <td style="border-top: #000000 2px solid; width: 56%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">Phase 1 study for gene therapies in SCD (with Washington University School of Medicine in St. Louis)**,
        which was initiated in December 2023</div> </td>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">4.</div> </td>
    <td style="border-top: #000000 2px solid; width: 25.08%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid">
        <div style="line-height: 1.25">Study completed during 2025. Final results from the study were presented at ASH Annual Meeting in December
        2025. A summary of the published abstract is disclosed in this report above &#8211; see &#8220;Motixafortide&#8221;, &#8220;Stem cell
        mobilization&#8221;, &#8220;Sickle Cell Disease&#8221;</div> </td> </tr>
  <tr>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">5.</div> </td>
    <td style="border-top: #000000 2px solid; width: 56%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">Phase 1 study for gene therapies in SCD (with St. Jude Children&#8217;s Research Hospital, Inc.)**</div>
        </td>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">5.</div> </td>
    <td style="border-top: #000000 2px solid; width: 25.08%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid">
        <div style="line-height: 1.25">First patient dosed in February 2025, with data planned in 2026*</div> </td> </tr>
  <tr>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">6.</div> </td>
    <td style="border-top: #000000 2px solid; width: 56%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">IND approved in China for initiation of pivotal bridging study in SCM under license agreement with Gloria</div>
        </td>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid">
        <div style="line-height: 1.25">6.</div> </td>
    <td style="border-top: #000000 2px solid; width: 25.08%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid">
        <div style="line-height: 1.25">First patient dosed in December 2025</div> </td> </tr>
  <tr>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid; border-bottom: #000000 2px solid">
        <div style="line-height: 1.25">7.</div> </td>
    <td style="border-top: #000000 2px solid; width: 56%; vertical-align: top; border-left: #000000 2px solid; border-bottom: #000000 2px solid">
        <div style="line-height: 1.25">Phase 2b randomized study in first-line PDAC in China under license agreement with Gloria</div> </td>
    <td style="border-top: #000000 2px solid; width: 2.68%; vertical-align: top; border-left: #000000 2px solid; border-bottom: #000000 2px solid">
        <div style="line-height: 1.25">7.</div> </td>
    <td style="border: #000000 2px solid; width: 25.08%; vertical-align: top">
        <div style="line-height: 1.25">IND submission and protocol finalization is currently delayed***</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="za1bf0cf3087e4f6a9c41c797c42f1eb1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">*</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>These studies are investigator-initiated studies; therefore, the timelines are ultimately controlled by the independent investigators
        and are subject to change.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">**</td>
    <td style="width: auto; vertical-align: top; text-align: justify">Study to be continued under the Ayrmid License Agreement</td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z63018222d1fb44dcad14028e4dff9cee" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">***</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The planned study of motixafortide in China under the Gloria License Agreement is currently not advancing according to schedule and
        it is unclear when such study will be initiated, if at all.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We expect that a large percentage of our research and development
expenses in the future will be incurred in support of our current and future clinical and pre-clinical development projects. Clinical
development timelines, the probability of success and development costs can differ materially from expectations. We expect to continue
to test GLIX1, motixafortide and any other therapeutic candidates in preclinical studies for toxicology, safety and efficacy, and to conduct
additional clinical trials for each such candidate. If we are not able to enter into an out-licensing arrangement with respect to any
therapeutic candidate prior to the commencement of later stage clinical trials, we may fund the trials for the therapeutic candidate ourselves.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our future research and development expenses will depend on the
clinical success of GLIX1, motixafortide (in solid tumor indications) and on other potential therapeutic candidates, as well as ongoing
assessments of each therapeutic candidate&#8217;s commercial potential. In addition, we cannot forecast with any degree of certainty which
therapeutic candidates may be subject to future out-licensing arrangements, when such out-licensing arrangements will be secured, if at
all, and to what degree such arrangements would affect our development plans and capital requirements.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">70</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div> <br/>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As we obtain results from clinical trials, we may elect to discontinue
or delay clinical trials for certain therapeutic candidates or projects in order to focus our resources on more promising therapeutic
candidates or projects. Completion of clinical trials by us or our licensees may take several years or more, but the length of time generally
varies according to the type, complexity, novelty and intended use of a therapeutic candidate.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The cost of clinical trials may vary significantly over the life
of a project as a result of differences arising during clinical development, including, among others:</div> </div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zd14c95c5115e4b389d9e0f0dce5c0af5" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the number of sites included in the clinical trials;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the length of time required to enroll suitable patients;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the number of patients that participate, and are eligible to participate, in the clinical
        trials;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the duration of patient follow-up;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">whether the patients require hospitalization or can be treated on an outpatient basis;</div>
        </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the development stage of the therapeutic candidate; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the efficacy and safety pro&#64257;le of the therapeutic candidate.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The lengthy process of completing clinical trials and seeking regulatory
approval for our therapeutic candidates requires expenditure of substantial resources. Any failure or delay in completing clinical trials,
or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses
to increase and, in turn, have a material adverse effect on our operations. Due to the factors set forth above, we are not able to estimate
with any certainty when we would recognize any net cash inflows from our projects.</div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Sales and Marketing Expenses</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In 2023 and 2024, sales and marketing expenses consisted primarily
of compensation for employees in commercialization, marketing and business development functions. Other signi&#64257;cant costs included
marketing and communication materials, market access activities, professional fees for outside market research and consulting, and legal
services related to compliance and to potential business development transactions.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Following the license agreement with Ayrmid and the termination
of our commercialization activities in the U.S., we experienced a significant reduction in sales and marketing expenses and, during the
year ended December 31, 2025, we did not incur any sales and marketing expenses. We expect that any future sales and marketing expenses
will be primarily related to business development.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-weight: bold">General and Administrative Expenses</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">General and administrative expenses consist primarily of compensation
for employees in executive and operational functions, including accounting, finance, legal, investor relations, information technology,
and human resources. Other significant general and administration costs include facilities costs, professional fees for outside accounting
and legal services, travel costs, insurance premiums, depreciation and a provision for doubtful accounts receivable when relevant.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">71</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Non-Operating Expense and Income</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Non-operating expense and income includes fair-value adjustments
of liabilities on account of the warrants issued in equity financings we carried out in February 2019, September 2022 April 2024, November
2024 and January 2025. These fair-value adjustments are highly influenced by our share price at each period end (revaluation date). Non-operating
expense and income also includes issuance expenses under the &#8220;at-the-market&#8221; offering agreement, or ATM Agreement, between
us and HCW entered into in September 2021, and the pro-rata share of issuance expenses from the placements related to the warrants. Net
sales-based royalties from the license agreement with Perrigo have also been included as part of non-operating income, as the out-licensed
product is not an integral part of our strategy, and the amounts are not material.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Financial Expense and Income</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Financial expense and income consist of interest earned on our
cash, cash equivalents and short-term bank deposits; interest expense related to our loans from BlackRock, bank fees and other transactional
costs. In addition, it may also include gains/losses on foreign exchange hedging transactions, which we carry out from time to time to
protect against a portion of our NIS-denominated expenses (primarily compensation) in relation to the dollar.</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Critical Accounting Policies and Estimates</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our consolidated financial statements are prepared in conformity
with IFRS, as issued by the IASB. In preparing our consolidated financial statements, we make judgements, estimates and assumptions about
the application of our accounting policies which affect the reported amounts of assets, liabilities, revenue and expenses. Our critical
accounting judgements and sources of estimation uncertainty are described in Note to our consolidated financial statements, which are
included elsewhere in this Annual Report on Form 20-F.</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold"><span style="text-decoration: underline">Impairment
of indefinite-lived intangible assets</span></div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We perform impairment reviews of intangible assets not subject
to amortization on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The recoverable amount is determined using discounted cash flow calculations. The analysis
estimates the future cash flows we expect to derive from the asset, incorporates expectations about possible variations in the amount
or timing of those future cash flows, as well as the uncertainty inherent in the asset, and the risk-adjusted cash flows are then discounted
using our estimated post-tax weighted average cost of capital, or WACC. The main estimates used in calculating the recoverable amount
include the WACC estimation and the amounts and timing of projected future cash flows. Such amounts and timing are influenced by the expected
outcome of development activities, the probability of success and timing in gaining regulatory approval, size of the potential market
and our specific market share, either via direct sales or a potential out-licensing deal.</div> </div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">&#160;<span style="font-weight: bold">Accrued Expenses</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are required to estimate accrued expenses as part of our process
of preparing financial statements. This process involves estimating the level of service performed on our behalf and the associated cost
incurred in instances where we have not been invoiced or otherwise notified of actual costs. Examples of areas in which subjective judgments
may be required include costs associated with services provided by contract organizations for commercialization, clinical trials, and
preclinical development. We account for expenses associated with these external services by determining the total cost of a given study
based on the terms of the related contract. We accrue for costs incurred as the services are being provided by monitoring the status of
the trials and the invoices received from our external service providers. In the case of clinical trials, the estimated cost normally
relates to the projected costs of treating the patients in our trials, which we recognize over the estimated term of the trial according
to the number of patients enrolled in the trial on an ongoing basis, beginning with patient enrollment. As actual costs become known to
us, we adjust our accruals.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">72</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;<span style="font-weight: bold">Investments in Financial Assets</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The primary objective of our investment activities is to preserve
principal while maximizing the income that we receive from our investments without significantly increasing risk and loss. Our investments
are exposed to market risk due to fluctuations in interest rates, which may affect our interest income and the fair market value of our
investments. We manage this exposure by performing ongoing evaluations of our investments. Due to the short-term maturities of our investments
to date, their carrying value has always approximated their fair value.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A financial asset is classified in this category if our management
has designated it as a financial asset upon initial recognition, because it is managed, and its performance is evaluated, on a fair-value
basis in accordance with a documented risk management or investment strategy. Our investment policy with regard to excess cash, as adopted
by our board of directors, is composed of the following objectives: (i) preserving investment principal; (ii) providing liquidity; and
(iii) providing optimum yields pursuant to the policy guidelines and market conditions. The policy provides detailed guidelines as to
the securities and other financial instruments in which we are allowed to invest. In addition, in order to maintain liquidity, investments
are structured to provide flexibility to liquidate at least 50% of all investments within 15 business days. Information about these assets,
including details of the portfolio and income earned, is provided internally on a quarterly basis to our key management personnel and
on a semi-annual basis to the Investment Monitoring Committee of our board of directors. Any divergence from this investment policy requires
approval from our board of directors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Share-based Compensation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We account for share-based compensation arrangements in accordance
with the provisions of IFRS 2. IFRS 2 requires companies to recognize share compensation expense for awards of equity instruments based
on the grant-date fair value of those awards (with limited exceptions). The cost is recognized as compensation expense over the life of
the instruments, based upon the grant-date fair value of the equity or liability instruments issued. The fair value of our share-based
compensation grants is computed as of the grant date based on the Black-Scholes model, using the standard parameters established in that
model including estimates relating to volatility of our shares/ADSs, risk-free interest rates, estimated life of the equity instruments
issued and the market price of our shares/ADSs. As our ordinary shares/ADSs are publicly traded on the TASE or Nasdaq, we do not need
to estimate their fair market value. Rather, we use the actual closing market price of our ordinary shares/ADSs on the date of grant,
as reported by the TASE or Nasdaq.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Warrants</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In connection with a loan transaction entered into with BlackRock
in October 2018, we issued a warrant to purchase 1,596 ADSs at an exercise price of $564.00 per ADS. The warrant is exercisable for a
period of ten years from the date of issuance. Since the exercise price was not deemed to be fixed, the warrant is not qualified for classification
as an equity instrument and has therefore been classified as a non-current financial liability.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In connection with an underwritten public offering we completed
in January 2021, we issued warrants to purchase 17,989 ADSs at an exercise price of $120.00 per ADS. The warrants are exercisable for
a period of five years from the date of issuance. The warrants have been classified as shareholder&#8217;s equity and expired January
2026.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In connection with a registered direct offering we completed in
September 2022, we issued warrants to purchase 340,909 ADSs at an exercise price of $46.00 per ADS, of which warrants to purchase 63,637
have been exercised. The warrants are exercisable for a period of five years from the date of issuance. Since the exercise price of those
warrants were not deemed to be fixed, the warrants are not qualified for classification as an equity instrument and have therefore been
classified as a non-current financial liability. We also issued warrants to purchase 17,045 ADSs at an exercise price of $55.00 per ADS.
The warrants are exercisable for a period of five years from the date of issuance and have been classified as shareholder&#8217;s equity.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">73</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In connection with a registered direct offering we completed in
April 2024, we issued warrants to purchase 187,500 ADSs at an exercise price of $32.00 per ADS, of which none of these warrants have been
exercised to date. The warrants are exercisable for a period of five years from the date of issuance. Since the exercise price of those
warrants were not deemed to be fixed, the warrants are not qualified for classification as an equity instrument and have therefore been
classified as a non-current financial liability.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In connection with a registered direct offering we completed in
November 2024, we issued warrants to purchase 205,893 ADSs at an exercise price of $23.60 per ADS, of which none of these warrants have
been exercised to date, and pre-funded warrants to purchase 308,749 ADSs at an exercise price of $0.004 per ADS, of which warrants to
purchase 124,982 have been exercised. The warrants are exercisable for a period of four years from the date of issuance and the pre-funded
warrants will not expire until exercised in full. Since the exercise price of the warrants were not deemed to be fixed, the warrants are
not qualified for classification as an equity instrument and have therefore been classified as a non-current financial liability. The
pre-funded warrants have been classified as equity instruments.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In connection with a registered direct offering we completed in
January 2025, we issued warrants to purchase 1,250,000 ADSs at an exercise price of $8.00 per ADS, of which none of these warrants have
been exercised to date, and pre-funded warrants to purchase 391,697 ADSs at an exercise price of $7.996 per ADS, of which all of the warrants
had been exercised. The warrants are exercisable for a period of five years from the date of issuance and the pre-funded warrants will
not expire until exercised in full. We also issued placement agent warrants to purchase 62,500 ADSs at an exercise price of $10.00 per
ADS. The warrants are exercisable for a period of five years from the date of issuance. Since the exercise price of the warrants were
not deemed to be fixed, the warrants are not qualified for classification as an equity instrument and have therefore been classified as
a non-current financial liability. The pre-funded warrants have been classified as equity instruments.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Results of Operations - Overview</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Comparison of the Year Ended December 31, 2025 to the Year Ended
December 31, 2024</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Revenues</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Revenues for the year ended December 31, 2025 were $1.2 million,
a decrease of $27.7 million, compared to $28.9 million for the year ended December 31, 2024. The significant decrease in revenues in 2025
from 2024 reflects the one-time revenues recorded in 2024 relating to the out-licensing transaction with Gloria during the fourth quarter
of 2023, as well as the change in our operations following the out-licensing of APHEXDA to Ayrmid during the fourth quarter of 2024.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The revenues in 2025 reflect the royalties paid by Ayrmid from
the commercialization of APHEXDA in stem cell mobilization in the U.S. The revenues in 2024 primarily reflect a portion of the up-front
payment received by us under the Gloria License Agreement and a milestone payment achieved under the Gloria License Agreement, which collectively
amounted to $15.0 million, as well as the up-front payment received by us under the Ayrmid License Agreement and $6.0 million of net revenues
from product sales of APHEXDA in the United States.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Cost of revenues</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Cost of revenues for the year ended December 31, 2025 were $0.2
million, a decrease of $9.1, compared to $9.3 million for the year ended December 31, 2024. The cost of revenues in 2025 reflects sub-license
fees on royalties paid by Ayrmid from the commercialization of APHEXDA in stem cell mobilization in the U.S. The cost of revenues in 2024
primarily reflects the amortization of intangible assets, sub-license fees on the up-front payment received by us for the Ayrmid License
Agreement, sub-license fees accrued on a milestone payment recorded under the Gloria License Agreement, as well as royalties on net product
sales of APHEXDA in the U.S. and cost of goods sold on product sales.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">74</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Research and development expenses</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Research and development expenses for the year ended December 31, 2025 were $8.1 million,
a decrease of $1.1 million, or 11.5% compared to $9.2 million for the year ended December 31, 2024. The decrease resulted primarily from
lower expenses related to motixafortide due to the out-licensing of U.S. rights to Ayrmid, as well as a decrease in payroll and share-based
compensation, primarily due to a decrease in headcount, offset by expenses related to initiation of the GLIX1 project.</div> </div> </div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Sales and marketing expenses</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">There were no sales and marketing expenses in 2025 compared to $23.6 million for the
year ended December 31, 2024. The decrease resulted from the shutdown of U.S. commercial operations in the fourth quarter of 2024 following
the Ayrmid out-licensing transaction.</div> </div> </div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">General and administrative expenses</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">General and administrative expenses for the year ended December
31, 2025 were $3.1 million, a decrease of $3.2 million, or 50.3% compared to $6.3 million for the year ended December 31, 2024. The decrease
resulted primarily from the reversal of a provision for doubtful accounts following receipt of an overdue milestone payment from Gloria,
as well as a decrease in payroll and share-based compensation, primarily due to a decrease in headcount, and a decrease in a number of
general and administrative expenses.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Impairment of intangible assets</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We did not record an impairment of intangible assets in 2025, compared
to a $1.0 impairment of intangible assets&#160; for the year ended December 31, 2024. This non-cash expense in 2024 reflects the impairment
of the remaining rights related to motixafortide in solid tumor indications.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Non-operating income (expense), net</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We recognized net non-operating income of $8.1 million for the
year ended December 31, 2025 compared to net non-operating income of $18.4 million for the year ended December 31, 2024. Non-operating
income for the periods primarily relates to fair-value adjustments of warrant liabilities on our balance sheet, as a result of changes
in our share price, offset by warrant offering expenses.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Financial income (expense), net</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We recognized net financial income of $0.2 million for the year
ended December 31, 2025 compared to net financial expenses of $7.3 million for the year ended December 31, 2024. Net financial income
for 2025 relates to investment income earned on our bank deposits and gains on foreign currency (primarily NIS) cash balances due to the
appreciation of the NIS against the U.S. dollar during the period, partially offset by interest paid on loans. Net financial expenses
for 2024 primarily relate to interest paid on loans, which increased in 2024 due to a one-time $4.0 million charge to interest expense
in connection with the November 2024 amendment to our loan agreement with BlackRock (as described in Note 10 to our consolidated financial
statements), partially offset by investment income earned on our bank deposits.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. Liquidity and Capital Resources</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Since our inception, we have funded our operations primarily through
public and private offerings of our equity securities, payments received under our strategic licensing and collaboration arrangements,
interest earned on investments, debt financing and funding previously received from the IIA.&#160;As of December 31, 2025, we held $20.9
million of cash, cash equivalents and short-term bank deposits. We have invested substantially all our available cash funds in short-term
bank deposits.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">75</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In September 2021, we entered into the ATM Agreement with HCW pursuant
to which we may offer and sell, at our option, up to $25.0 million of our ADSs through an at-the-market equity program under which HCW
agreed to act as sales agent. As of the issuance date of this report, we have sold 825,010 of our ADSs for total gross proceeds of approximately
$9.6 million under the ATM program. Under General Instruction I.B.5 to Form F-3 (also known as the baby shelf rule), we may currently
sell up to $4.5 million under the ATM program.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Loan Agreements with BlackRock</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In September 2022, we entered into a secured Loan Agreement with
BlackRock EMEA Venture and Growth Lending (previously Kreos Capital VII Aggregator SCSP), or BlackRock, under which BlackRock agreed to
provide us with access to term loans in an aggregate principal amount of up to $40 million in three tranches, or the Loans. We drew down
the initial tranche of $10 million following execution of the agreement in September 2022 and we drew down the second tranche of $20 million
in April 2024, following fulfilment of the requisite milestones. The third tranche was available for drawdown until October 1, 2024, upon
achievement of certain milestones, but was not drawn down.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In November 2024, in connection with the Ayrmid License Agreement,
we entered into the Loan Amendment to the Loan Agreement with BlackRock, pursuant to which, (i) we agreed to make aggregate payments of
$16.5 million, as partial repayment of the Loans and in lieu of future revenue-based payments, which were fully cancelled, (ii) effective
December 1, 2024, we agreed to pay the remaining amounts outstanding under the Loans (in principal and interest) over a three year period
ending December 1, 2027, and (iii) our minimum cash balance requirement under the Loan Agreement was reduced from $10 million to $4 million.
In addition, pursuant to the Loan Amendment, 10% of any future milestone payments received by us from the out-licensing agreements through
December 1, 2027 will be used to repay principal of the Loans, and the repayments in (ii) above will be adjusted accordingly. All other
terms of the Loan Agreement remain the same.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Interest on each tranche of the Loans accrues at a fixed rate of
9.5% per annum from the drawdown date until repayment in full of the tranche.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We may prepay all, but not less than all, of the outstanding balance
of any of the Loans. In connection with any prepayment, we will also pay an end of loan payment equal to 5% of the amount of each tranche
drawn down upon the final repayment of each such tranche, or the End of Loan Payment, and any other unpaid fees or costs, if any.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Loans are subject to mandatory accelerated repayment provisions
that require repayment of the outstanding principal amount of the Loans, and all accrued and unpaid interest thereon, upon the occurrence
of an event of default, subject to certain limitations and cure rights. In addition, in the event of acceleration upon an event of default
(a) we will be required to pay the aggregate of the monthly interest payments scheduled to be paid by the Company for the period from
the date of acceleration to the expiry of the applicable Loan, in each case discounted from the applicable monthly repayment date to the
date of prepayment at the rate of 2% per annum and (b) the End of Loan Payment.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Outstanding borrowings under the Loan Agreement are secured by
(a) a first priority fixed charge over certain assets and intellectual property of the Company, as well as all shares held by the Company
in BioLineRx USA, Inc., or the Fixed Charge, (b) a first priority floating charge over all our assets as of the date of the Loan Agreement
or thereafter acquired, other than the assets charged under the Fixed Charge or as otherwise specifically excluded pursuant to the terms
of the floating charge, and (c) subject to the provisions of the Fixed Charge, a security interest in our intellectual property.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Loan Agreement contains customary representations and warranties,
indemnification provisions in favor of the Lender, events of default and affirmative and negative covenants, including, among others,
covenants that limit or restrict the Company&#8217;s ability to, among other things, incur additional indebtedness, merge or consolidate,
make acquisitions, pay dividends or other distributions or repurchase equity, and dispose of assets, in each case subject to certain exceptions.
The Company has also granted BlackRock certain information rights.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">76</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">&#160;<span style="font-weight: bold; font-style: italic">Cash Flows</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash used in operating activities was $8.1 million for the
year ended December 31, 2025, compared with net cash used in operating activities of $43.9 million for the year ended December 31, 2024.
The $35.8 million decrease in net cash used in operating activities in 2025&#160;was primarily the result of a&#160;significant decrease
in operating expenses following the transaction with Ayrmid in the fourth quarter of 2024.</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash used in investing activities was $8.6 million for the
year ended December 31, 2025, compared to net cash provided by investing activities of $29.4 million for the year ended December 31, 2024.
The changes in cash flows from investing activities relate primarily to investments in, and maturities of, short-term bank deposits.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash provided by financing activities was $8.9 million for
the year ended December 31, 2025, compared to net cash provided by financing activities of $20.7 million for the year ended December 31,
2024. The net cash provided by financing activities in 2025 primarily reflects the net proceeds of the registered direct offering&#160;and
net proceeds from the ATM facility, offset by&#160;repayments of the loan from BlackRock and the repayments of lease liabilities. Net
cash provided by financing activities in 2024 primarily reflects the net proceeds of a loan from BlackRock and the net proceeds of a registered
direct offering of our ADSs in April 2024, offset by repayments of the loan from BlackRock and the repayments of lease liabilities.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Funding Requirements</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We have incurred
accumulated losses in the amount of $401 million through December 31, 2025, and we expect to continue incurring losses and negative cash
flows from operations until the cash flows from our strategic partnerships and collaborations reach a level to offset our ongoing development
costs. In this regard, management monitors rolling forecasts of our liquidity reserves on the basis of anticipated cash flows and seeks
to maintain liquidity balances at levels that are sufficient to meet its needs. Our cash flow projections are subject to various risks
and uncertainties concerning their fulfilment, and these factors and the risk inherent in our operations, which management has concluded
indicate that a material uncertainty exists, may cast significant doubt on our ability to continue as a going concern. Similarly, our
independent registered public accounting firm included a &#8220;going concern&#8221; explanatory paragraph in its report on our financial
statements as of and for the year ended December 31, 2025.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Developing drugs and conducting clinical trials is expensive and
we will need to raise substantial additional funds to achieve our strategic objectives. Based on our current projected cash requirements,
we believe that our existing cash and investment balances and other sources of liquidity, including royalties received from Ayrmid from
product sales of APHEXDA and milestone payments from our license agreements with Ayrmid and Gloria, will be sufficient to meet our capital
requirements into the first half of 2027. We expect to also continue to seek to finance our operations through other sources, including
out-licensing arrangements for the development and commercialization of our therapeutic candidates or other partnerships or collaborations,
public and private offerings of our equity securities, as well as grants from government agencies and foundations. Our future capital
requirements will depend on many factors, including:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z60770e794057479aac87e9ba6a81f31c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the progress and costs of our preclinical studies, clinical trials and other research and development activities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z1f8dc1a7f74d4729b0b3984661309c62" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the scope, prioritization and number of our clinical trials and other research and development programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zcc3033bc39ac412583bda762e6887315" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the amount of revenues we receive, if any, under our collaboration or licensing arrangements;</div> </td> </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">77</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<table cellspacing="0" cellpadding="0" id="z0e23570600fe42558d14c76979867002" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the costs of the development and expansion of our operational infrastructure;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="ze62784cd393a4f52a2620f49f3729296" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the costs and timing of obtaining regulatory approval of our therapeutic candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z44700e9400374f5ea3c352eb8d9875a2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>our success in effecting out-licensing arrangements with third parties;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z875e4eff3ce54ed99e1687edeaa758d5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the ability of our collaborators and licensees to achieve development milestones, marketing approval and other events or developments
        under our collaboration and out-licensing agreements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zb27e80fc1957476e8d089455f512df52" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="za163c7201a064a7283095313cdce9d5e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the costs and timing of securing manufacturing arrangements for clinical or commercial production;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zdf9b7e855fb24b17ada981f94e579cc3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the costs of establishing sales and marketing capabilities or contracting with third parties to provide these capabilities for us;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z5ab3803afa334db49882a792f2069a5b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the costs of acquiring or undertaking development and commercialization efforts for any future therapeutic candidates;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zb2cd1ea62f014a04930273d0ca1f076c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>the magnitude of our general and administrative expenses;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z760c384263b040b7a76e6c0177423d0e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>interest and principal payments on the loan from BlackRock;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z120dfbb4a00948239bee51a9fd620f95" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>any cost that we may incur under current and future licensing arrangements relating to our therapeutic candidates; and</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zd31616ba499643259302bda1bc6fce58" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>market conditions.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">If funds are not available, we may be required to delay, reduce the scope of, or eliminate
one or more of our research or development programs.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Contractual Obligations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">We are party to contractual obligations involving commitments to make payments to third
parties. Our contractual obligations primarily consist of lease payments, a commitment to invest in Tetragon and purchase order obligations.
Premises leasing obligations represent our commitment for future lease payments under the lease agreement for our facilities in Modi&#8217;in,
Israel. The total future payments for our premises leasing obligations on December 31, 2025 were approximately $1.6 million which is due
through June 2030. Purchase order obligations amounted to $2.4 million as of December 31, 2025. Under the Collaboration Agreement, we
agreed to invest $5 million in Tetragon over 36 months (beginning September 2025) in tranches according to a development plan (subject
to extension for an additional six months in certain circumstances). As of December 31, 2025, we invested $1.2 million in Tetragon. For
additional details regarding our contractual obligations, see Note 14 to our audited financial statements included in this Annual Report
on Form 20-F.</div> </div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, under our in-licensing agreements, we are obligated
to make certain payments to our licensors upon the achievement of agreed-upon milestones and receipt of royalties. We are unable at this
time to estimate the actual amount or timing of the costs we will incur in the future under these agreements. Some of the in-licensing
agreements are accompanied by consulting, support and cooperation agreements, pursuant to which we are required to pay the licensors a
fixed monthly amount, over a period stipulated in the applicable agreement, for their assistance in the continued research and development
under the applicable license. All of our in-licensing agreements are terminable at-will by us upon prior written notice of 30 to 90 days.
We are unable at this time to estimate the actual amount or timing of the costs we will incur in the future under these agreements. See
&#8220;Item 4. Information on the Company - Business Overview - In-Licensing Agreements.&#8221;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">78</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">C. Research and Development, Patents and Licenses</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">For our research and development policies, see &#8220;Item 4.B.
- Information on the Company - Business Overview - Our Strategy.&#8221; For information regarding patents, see &#8220;Item 4.B. - Information
on the Company -Business Overview - Intellectual Property.&#8221; For information regarding licenses, see &#8220;Item 4.B. - Information
on the Company - Business Overview - Collaboration and Out-Licensing Arrangements&#8221; and &#8220;Item 4.B. - Information on the Company
- Business Overview - In-Licensing Agreements.&#8221;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">D. Trend Information</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are a biopharmaceutical company pursuing life-changing therapies
in oncology and rare diseases. To date, we have generated only limited direct product revenues from independent commercialization activities,
following the regulatory approval for APHEXDA (motixafortide) in September 2023. In October 2023, we out-licensed the rights to motixafortide
for all indications in substantially all of Asia, and in November 2024, we out-licensed the global rights (other than in Asia) to motixafortide
for all indications, other than solid tumors. As a result of the November 2024 transaction, we shut down our independent commercialization
activities in the United States and refocused our operations on development activities in Israel in the fields of oncology (including
solid tumors) and rare diseases, at a significantly reduced annual cash burn rate. Our ability to generate revenues from commercialization
and achieve profitability will be subject to Gloria License Agreement and the Ayrmid License Agreement and depend on our commercialization
partners&#8217; ability to successfully commercialize products, including any of our current product and product candidates, and other
product candidates that we may develop, in-license or acquire in the future. As such, it is not possible for us to predict with any degree
of accuracy any known trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our
net sales or revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported
financial information to not necessarily be indicative of future operating results or financial conditions. However, to the extent possible,
certain trends, uncertainties, demands, commitments and events are in this &#8220;Operating and Financial Review and Prospects.&#8221;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">E. Critical Accounting Estimates</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our consolidated financial statements are prepared in conformity
with IFRS, as issued by the IASB. In preparing our consolidated financial statements, we make judgements, estimates and assumptions about
the application of our accounting policies which affect the reported amounts of assets, liabilities, revenue and expenses. Our critical
accounting judgements and sources of estimation uncertainty are described in Note 2 to our consolidated financial statements, which are
included elsewhere in this Annual Report on Form 20-F.</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM6"><!--Anchor--></span>ITEM 6. DIRECTORS, SENIOR
MANAGEMENT AND EMPLOYEES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. Executive Officers and Directors</div> <br/>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following table sets forth information for our executive officers
and directors as of March 8, 2026. Unless otherwise stated, the address for our directors and officers is c/o BioLineRx Ltd., 2 HaMa&#8217;ayan
Street, Modi&#8217;in 7177871, Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">79</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<table cellspacing="0" cellpadding="0" id="zbafecfd7fdd1499184dd45b21b7abc36" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: #000000 2px solid; width: 36.07%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">Name</div> </td>
    <td style="width: 0.67%; vertical-align: top"><br/> </td>
    <td style="border-bottom: #000000 2px solid; width: 4.47%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Age</div> </td>
    <td style="width: 0.67%; vertical-align: top"><br/> </td>
    <td style="border-bottom: #000000 2px solid; width: 58.12%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">Position(s)</div> </td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top"><br/> </td>
    <td style="width: 0.67%; vertical-align: top"><br/> </td>
    <td style="width: 4.47%; vertical-align: top"><br/> </td>
    <td style="width: 0.67%; vertical-align: top"><br/> </td>
    <td style="width: 58.12%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25">Philip A. Serlin, CPA, MBA</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: #CCEEFF"><br/> </td>
    <td style="width: 4.47%; vertical-align: top; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25">65</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: #CCEEFF"><br/> </td>
    <td style="width: 58.12%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25">Chief Executive Officer</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 36.07%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.47%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 58.12%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Mali Zeevi, CPA</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 4.47%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">50</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 58.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Chief Financial Officer</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 36.07%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.47%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 58.12%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25">Ella Sorani, Ph.D.</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: #CCEEFF"><br/> </td>
    <td style="width: 4.47%; vertical-align: top; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25">58</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: #CCEEFF"><br/> </td>
    <td style="width: 58.12%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25">Chief Development Officer</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 36.07%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.47%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 58.12%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Aharon Schwartz, Ph.D. (1)</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 4.47%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">83</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 58.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Chairman of the Board of Directors, Class III Director</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 36.07%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.47%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 58.12%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Rami Dar, MBA (1)(2)(3)(4)</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 4.47%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">69</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 58.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Class I Director</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 36.07%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.47%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 58.12%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">B.J. Bormann, Ph.D. (1)(3)</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 4.47%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">67</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 58.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Class II Director</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 36.07%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.47%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 58.12%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Raphael Hofstein, Ph.D. (1)(2)(3)</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 4.47%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">76</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 58.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Class II Director</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 36.07%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.47%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 58.12%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Avraham Molcho, M.D. (1)(2)(3)</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 4.47%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">68</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 58.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Class I Director</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 36.07%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.47%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 58.12%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Sandra Panem, Ph.D. (1)(4)</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 4.47%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">79</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 58.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Class III Director</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 36.07%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.47%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 58.12%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Shaoyu Yan, Ph.D.</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 4.47%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">61</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 58.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Class III Director</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 36.07%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 4.47%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 0.67%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 58.12%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36.07%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Gal Cohen (1)</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 4.47%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">53</div> </td>
    <td style="width: 0.67%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="width: 58.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Class I Director</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z1f097ac3c1e3432b8230b25d7fb8ac88" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(1)</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Independent director under applicable Nasdaq Capital Market, as affirmatively determined by our board of
        directors.&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top"><br/> </td>
    <td style="width: 36pt; vertical-align: top"><br/> </td>
    <td style="width: auto; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(2)</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">A member of our audit committee.</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top"><br/> </td>
    <td style="width: 36pt; vertical-align: top"><br/> </td>
    <td style="width: auto; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(3)</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">A member of our compensation committee.</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top"><br/> </td>
    <td style="width: 36pt; vertical-align: top"><br/> </td>
    <td style="width: auto; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(4)</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">A member of our investment monitoring committee</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Philip A. Serlin, CPA, MBA,</span>
has served as our Chief Executive Officer since October 2016. From May 2009 to October 2016, Mr. Serlin served as our Chief Financial
and Operating Officer. From January 2008 to August 2008, Mr. Serlin served as the Chief Financial Officer and Chief Operating Officer
of Kayote Networks Inc. From January 2006 to December 2007, Mr. Serlin served as the Chief Financial Officer of Tescom Software Systems
Testing Ltd., an IT services company publicly traded in both Tel Aviv and London. Mr. Serlin&#8217;s background also includes senior positions
at Chiaro Networks Ltd. and at Deloitte, where he was head of the SEC and U.S. Accounting Department at the National Office in Tel Aviv,
as well as seven years at the SEC at its Washington, D.C., headquarters. Mr. Serlin is a certified public accountant and holds a B.Sc.
degree in accounting from Yeshiva University and a Master&#8217;s degree in economics and public policy from The George Washington University.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Mali Zeevi, CPA, </span>has served
as our Chief Financial Officer since October 2016. Prior to becoming Chief Financial Officer, Ms. Zeevi served as our Senior Director
of Finance and Reporting beginning in 2011 and as our Director of Finance and Reporting beginning in 2009.<span style="font-style: italic">&#160;</span>Before
joining BioLineRx, Ms. Zeevi was employed by Tescom Software Systems Testing Ltd., her last position there being Vice President Finance.
Ms. Zeevi also served as a certified public accountant at Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International
Limited. Ms. Zeevi is a certified public accountant and holds a B.A. degree in business and accountancy from the College of Management
Academic Studies in Israel.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">80</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Ella Sorani, Ph.D.,</span> has
served as our Chief Development Officer since January 2021. From February 2017 to December 2020, Dr. Sorani served as our Vice President
Research and Development. Before joining BioLineRx, from 2000 through 2016, Dr. Sorani served in a number of management positions in the
global R&amp;D division at Teva Pharmaceutical Industries Ltd. In her most recent position as Senior Director and Global Project Leader,
Dr. Sorani led the development of one of Teva&#8217;s leading innovative late-stage compounds. Dr. Sorani holds a B.Sc. degree in chemistry
and an M.Sc. degree and Ph.D. in pharmacology, all from Tel Aviv University.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Aharon Schwartz, Ph.D.,</span>
has served as the Chairman of our board of directors since 2004. Dr. Schwartz served in a number of positions at Teva from 1975 through
2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008. Dr. Schwartz is currently a member of the board
of directors of Protalix Ltd. (NYSE American:PLX). Dr. Schwartz also works as an independent consultant. Dr. Schwartz received his Ph.D.
in organic chemistry from the Weizmann Institute of Science, an M.Sc. degree in organic chemistry from the Technion - Institute of Technology
and a B.Sc. degree in chemistry and physics from the Hebrew University of Jerusalem. In addition, Dr. Schwartz holds a Ph.D. from the
Hebrew University of Jerusalem in the history and philosophy of science.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Rami Dar, MBA</span>, has served
on our board of directors (as an external director, within the meaning of the Companies Law, until March 25, 2024) since July 2022 and
as a member of our Audit Committee and Compensation Committee since such time and has served as a member of our Investment Monitoring
Committee since July 2022. Mr. Dar has served as a board member of BetterSeeds Ltd. since November 2023 and served as a board member of
Nordia Springs since March 2020. From 2018 to 2023, Mr. Dar served as chairman of Novolog Ltd. (TLV: NVLG). From 2002 to 2019, Mr. Dar
served as Chief Executive Officer of Hazera Seeds Ltd. (formerly Hazera Genetics), a leading global seed company, and prior to that, from
1998 to 2002, served in various management positions at Teva Pharmaceuticals Ltd., including as Business Development Executive from 2001
to 2002, Chief Executive Officer of Teva Medical Ltd., from 1998 to 2001, and Chief Executive Officer of Teva Pharmaceuticals Ltd. Israel
from 1995 to 1998. Mr. Dar holds a B.A. degree in economics and philosophy and an M.A. degree in economics, both from the Hebrew University
of Jerusalem, Israel, and an Executive M.B.A. from Columbia University, New York, USA.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">BJ Bormann, Ph.D.,</span> has
served on our board of directors since August 2013 and on our Compensation Committee since 2022. Dr. Bormann previously served as the
Vice President of Translational Science and Network Alliances at The Jackson Laboratory, a non-profit organization focused on the genetic
basis of disease. Dr. Bormann was previously the Chief Executive Officer of Supportive Therapeutics, LLC, a Boston-based company that
is developing two molecules for use in the supportive care of oncology patients. In the past several years Dr. Bormann has held executive
positions in several biotechnology companies including NanoMedical Systems (Austin, Texas), Harbour Antibodies (Rotterdam, The Netherlands)
and Pivot Pharmaceuticals (PVTF: OTC listed). Prior to these engagements, Dr. Bormann was Senior Vice President responsible for world-wide
alliances, licensing and business development at Boehringer Ingelheim Pharmaceuticals, Inc. from 2007 to 2013. From 1996 to 2007, Dr.
Bormann served in a number of positions at Pfizer, Inc., the last one being Vice President of Pfizer Global Research and Development and
world-wide Head of Strategic Alliances. Dr. Bormann serves on the board of directors of various companies, including Xeris BioPharma,
Inc (Nasdaq:XERS) and NanoMedical Systems (private). Dr. Bormann received her Ph.D. in biomedical science from the University of Connecticut
Health Center and her B.Sc. degree from Fairfield University in biology. Dr. Bormann completed postdoctoral training at Yale Medical School
in the department of pathology.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Raphael Hofstein, Ph.D.,</span>
has served on our board of directors since 2003, our Audit Committee since 2007 and our Compensation Committee since 2012. Dr. Hofstein
served as the President and Chief Executive Officer of MaRS Innovation (a commercialization company for 15 of Toronto&#8217;s universities,
institutions and research institutes plus the MaRS Discovery District) from June 2009 to March 2020. From 2000 through June 2009, Dr.
Hofstein was the President and Chief Executive Officer of Hadasit Medical Research Services and Development Ltd., or Hadasit, the technology
transfer company of Hadassah University Hospitals. Dr. Hofstein has served as chairman of the board of directors of Hadasit since 2006.
Prior to joining Hadasit, Dr. Hofstein was the President of Mindsense Biosystems Ltd. and the Business Unit Director of Ecogen Inc. and
has held a variety of other positions, including manager of R&amp;D and chief of immunochemistry at the International Genetic Science
Partnership. Dr. Hofstein serves on the board of directors of numerous companies. Dr. Hofstein received his Ph.D. and M.Sc. degree from
the Weizmann Institute of Science, and his B.Sc. degree in chemistry and physics from the Hebrew University of Jerusalem. Dr. Hofstein
completed postdoctoral training at Harvard Medical School in both the departments of biological chemistry and neurobiology.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">81</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Avraham Molcho, M.D.,</span> has
served on our board of directors since 2010 (as an external director, within the meaning of the Companies Law, until March 25, 2024) and
on our Audit Committee since 2010. In addition, Dr. Molcho has served on our Compensation Committee since 2012. Dr. Molcho is the co-founder
of Biolojic Design Ltd., a technology platform that encourages human antibody discovery. In 2012, Dr. Molcho became the co-founder of
Ayana Pharma Ltd. (formerly DoxoCure), a privately-held company engaged in the manufacturing of liposome-based therapeutics. Dr. Molcho
served as Ayana&#8217;s Chief Executive Officer and director until 2019. From 2006 through 2008, Dr. Molcho served as the Chief Executive
Officer and Chairman of Neovasc Medical, a privately-held Israeli medical device company. From 2006 until 2019, Dr. Molcho was a venture
partner at Forbion Capital Partners, a Dutch life sciences venture capital firm. From 2001 through 2006, Dr. Molcho was a managing director
and the head of life sciences of Giza Venture Capital and, in that capacity, was involved in the founding of our company. Dr. Molcho was
also the Deputy Director General of Abarbanel Mental Health Center, the largest acute psychiatric hospital in Israel, from 1999 to 2001.
Dr. Molcho holds an M.D. from Tel Aviv University School of Medicine and an MBA degree from Tel-Aviv University Recanati Business School.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Sandra Panem, Ph.D., </span>has
served on our board of directors since February 2014 and on our Investment Monitoring Committee since 2010. Dr. Panem served as a managing
partner at Cross Atlantic Partners, from 2000 2023. Dr. Panem is also co-founder and President of NeuroNetworks Fund, a not-for-profit
venture capital fund focusing on epilepsy, schizophrenia and autism. From 1994 to 1999, Dr. Panem was President of Vector Fund Management,
the then asset management affiliate of Vector Securities International. Prior thereto, Dr. Panem served as Vice President and Portfolio
Manager for the Oppenheimer Global BioTech Fund, a mutual fund that invested in public and private biotechnology companies. Previously,
Dr. Panem was Vice President at Salomon Brothers Venture Capital, a fund focused on early and later-stage life sciences and technology
investments. Dr. Panem was also a Science and Public Policy Fellow in economic studies at the Brookings Institution, and an Assistant
Professor of Pathology at the University of Chicago. Previously, Dr. Panem served on numerous boards of public and private companies,
including Acorda Therapeutics, Inc. (Nasdaq:ACOR). Martek Biosciences (Nasdaq:MATK), IBAH Pharmaceuticals (Nasdaq:IBAH), Confluent Surgical,
Molecular Informatics and Labcyte, Inc. Dr. Panem received a B.S. degree in biochemistry and a Ph.D. in microbiology from the University
of Chicago.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Shaoyu Yan, Ph.D.,</span> has
served on our board of directors since November 2023. Dr. Yan has over 30 years&#8217; experience in drug research and development, manufacturing,
and management, including more than 15 years working with pharmaceutical companies, contract research organizations and marketing authorization
holders under regulation of National Medical Products Administration of China (NMPA). Since March 2020, Dr. Yan has served as an executive
vice president and head of R&amp;D and manufacturing at Gloria Biosciences Co. Ltd. From February 2014 to December 2019, Dr. Yan served
as the senior director and senior research fellow of the oncology and immunology business unit at WuXi AppTec (Shanghai) Co., Ltd. (SHA:
603259). Prior to these roles, Dr. Yan held positions, including at various academic institutions, including: senior research scientist
at the department of thoracic and cardio surgery and pharmaceutical development center of the University of Texas&#8217;s MD Anderson
Cancer Center from June 2006 to December 2013; visiting scholar and research scientist of the faculty of pharmaceutical sciences at Kyushu
University from August 2001 to August 2002; deputy director in the institute of medical raw materials at Tianjin Pharmaceutical Group
Corp. and director and co-founder at the Shenyang Huiming Institute of Chinese Traditional Medicine from May 1995 to August 1998. Dr.
Yan received a Ph.D in pharmaceutical science and M.Sc. degree in pharmaceutics from Shenyang Pharmaceutical University, and a B.Sc. degree
from Jilin University in polymer chemistry. Dr. Yan completed his postdoctoral training in the field of pharmacology and biochemistry
from Michael E. DeBakey Department of Surgery at Baylor College of Medicine from February 2003 to June 2006. Dr. Yan was appointed to
serve as a Class III director by our board of directors pursuant to the securities purchase agreement that we entered into with HST and
Gloria in August 2023. See &#8220;Item 7B. Major Shareholders and Related Party Transactions - Related Party Transactions - Gloria License
Agreement and Securities Purchase Agreement.&#8221;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">82</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Gal Cohen, MBA,</span> has served
on our board of directors since December 2023. Mr. Cohen serves on the boards of directors of Ayana Pharma Ltd. and Silver Castle Holdings
Ltd (TASE: SLCL) and from April 2020 to February 2024, served as Chairman of the board of directors and Chief Executive Officer of Quark
Pharmaceuticals, Inc. From November 2006 to May 2019, Mr. Cohen served as President and Chief Executive Officer of MediWound Ltd., leading
the development of their innovative biological drug for burn treatment up to marketing authorization and commercialization in numerous
international markets, as well as their initial public offering on Nasdaq. Prior to that, from 2004 to 2006, Mr. Cohen served as Director
of Strategic Business Planning and New Ventures at Teva Pharmaceuticals Ltd. From 2000 to 2004, Mr. Cohen served at Teva&#8217;s Global
Products Division as Project Manager for the launch of Copaxone&#174; in Europe and numerous other countries, and from 1998 to 2000, he
led projects at Teva&#8217;s Corporate Industrial Engineering Department. Mr. Cohen holds a B.Sc. degree in Industrial Engineering and
Management (<span style="font-style: italic">cum laude</span>) from the Technion-Israel Institute of Technology and an M.B.A. degree (<span style="font-style: italic">cum
laude</span>) from Tel Aviv University.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. Compensation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Directors and Officer Agreements</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">&#160;</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have entered into written employment agreements with each of
our executive officers, the terms of which are consistent with the provisions of our Compensation Policy for Executives and Directors,
or Compensation Policy, which was approved most recently by our shareholders in June 2025. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, we have entered into agreements with each executive
officer and director exculpating them, to the fullest extent permitted by law, from liability to us for damages caused to us as a result
of a breach of duty of care, and undertaking to indemnify each of them to the fullest extent permitted by law, to the extent that these
liabilities are not covered by directors&#8217; and officers&#8217; liability insurance. The terms of these agreements and of our directors&#8217;
and officers&#8217; liability insurance are consistent with the provisions of the Compensation Policy. See &#8220;Item 6.C - Directors,
Senior Management and Employees - Board Practices - Exculpation, insurance and indemnification of office holders.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation of Directors and Senior Management</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following table presents in the aggregate all compensation
we paid to all of our directors and senior management as a group for the year ended December 31, 2025. The table does not include any
amounts we paid to reimburse any such persons for costs incurred in providing us with services during this period.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">83</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<table cellspacing="0" cellpadding="0" id="zafbf9145dfc749e6aaf2f213b949871c" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Salaries, fees,</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">commissions</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">and bonuses</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Pension,</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">retirement,</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">options and</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">other similar benefits</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-style: italic">(in thousands of U.S. dollars)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">All directors and senior management as a group, consisting of 13 persons</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,295</div>
        <div style="line-height: 1.25"></div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">577</div>
        <div style="line-height: 1.25"></div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 35.9pt; line-height: 1.25">The following table presents information regarding the compensation
costs of our three executive officers in the year ended December 31, 2025. All amounts reported reflect the cost to the Company as recognized
in our financial statements for the year ended December 31, 2025.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zcc21dcc8df3545b1ab011de05f1567e8" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Name and Position</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Salary<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Social Benefits<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Bonuses<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Value of</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Share-Based</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Compensation<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">All Other</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Compensation<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(5)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Total</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="22" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-style: italic">(in thousands of U.S. dollars)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 28%">
        <div style="line-height: 1.25">Philip A. Serlin</div>
        <div style="line-height: 1.25">Chief Executive Officer</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">296</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">93</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">148</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">81</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">23</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">641</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 28%">
        <div style="line-height: 1.25">Mali Zeevi</div>
        <div style="line-height: 1.25">Chief Financial Officer</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">195</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">57</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">73</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">12</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">23</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"></span></div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">360</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 28%">
        <div style="line-height: 1.25">Ella Sorani</div>
        <div style="line-height: 1.25">Chief Development Officer</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">221</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">59</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">83</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">12</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">23</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"></span></div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">397</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zb12e8c8fc9bb482e81ecc6771cb366e8" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(1)&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Amounts shown for 2025 reflect a 10% base salary reduction agreed to by management
        during the first three quarters of 2025; base salaries were reinstated to their prior levels effective as of the fourth quarter of 2025.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z344722c82c5b46dd910721a970f7f920" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(2)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8220;Social Benefits&#8221; include payments to the National Insurance Institute,
        advanced education funds, managers&#8217; insurance and pension funds, vacation pay and recuperation pay as mandated by Israeli law.</div>
        <div style="text-align: justify; line-height: 1.25"> <br/> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd3bc64c32d174fd7901419d84678d4a4" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(3)</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Does not include annual bonuses for 2025, which remain subject to the approval of
        the Company&#8217;s compensation committee and board of directors.</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(4)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Consists of amounts recognized as share-based compensation expense on the Company&#8217;s
        statement of comprehensive loss for the year ended December 31, 2025.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(5)</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">&#8220;All Other Compensation&#8221; includes automobile-related expenses pursuant to the Company&#8217;s
        automobile leasing program, telephone, basic health insurance and holiday presents.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As approved by our shareholders at the annual general meeting held
in 2022, our directors are entitled to cash compensation of $30,000 per annum, $1,200 for each board or committee meeting attended in
person, $720 for each board or committee meeting attended via telephone or videoconference, $600 for participation by written consent
and $3,000 for membership of each committee of the Board of Directors, and in the case of the Chairman of the Board of Directors, such
fees in amounts that are 50% higher than the foregoing fees, in each case provided that such fees do not exceed the maximum amounts payable
to external directors from time to time by us under the Israeli Companies Regulations (Rules Regarding Compensation and Expense Reimbursement
of External Directors), 2000 and the Israeli Companies Regulations (Relief for Companies whose Securities are Listed for Trading Outside
of Israel), 2000. During the first three quarters of 2025, directors&#8217; fees were reduced by 25% at the directors&#8217; initiative;
the directors&#8217; fees were reinstated to their prior levels effective as of the fourth quarter of 2025. For the year ended December
31, 2025, we recorded $45,000 on account of cash compensation paid to the Chairman of our Board of Directors, Dr. Aharon Schwartz, and
a $98,000&#160;equity-based compensation expense for equity-based compensation granted to Dr. Schwartz.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">84</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">For information concerning our equity compensation plan, see &#8220;-
Beneficial Ownership of Executive Officers and Directors - Equity Compensation Plan<span style="font-style: italic">.</span>&#8221;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">There are currently no arrangements or understandings between us,
on the one hand, and any of our directors, on the other hand, providing for benefits upon termination of their service as directors of
our Company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">C. Board Practices</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Board of Directors</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">According to the Companies Law, the management of our business
is vested in our board of directors. Our board of directors may exercise all powers and may take all actions that are not specifically
granted to our shareholders. Our executive officers are responsible for our day-to-day management and have individual responsibilities
established by our board of directors. Executive officers are appointed by and serve at the discretion of our board of directors, subject
to any applicable employment agreements we have entered into with the executive officers.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">According to our Articles of Association, our board of directors
must consist of at least five and not more than 10 directors, including external directors under Israeli law (if any). Currently, our
board of directors consists of eight directors. Our board of directors has determined that each of our directors other than Mr. Yan is
an &#8220;independent director&#8221; under Nasdaq Listing Rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under our Articles of Association, as amended at our annual general
meeting of shareholders held in August 2023, our directors (other than external directors, if any) are divided into three classes with
staggered three-year terms. Each class of directors consists, as nearly as possible, of one-third of the total number of directors constituting
the entire board of directors. At each annual general meeting of our shareholders beginning in 2024, the election or re-election of directors
following the expiration of the term of office of the directors of that class of directors will be for a term of office that expires on
the third annual general meeting following such election or re-election. Each director (other than external directors, if any) holds office
until the third annual general meeting of our shareholders and until his or her successor is duly appointed, unless the tenure of such
director expires earlier pursuant to the Companies Law, or unless removed from office as described below.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our directors are divided among three classes as follows:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z514738d0ecb04a84b893ef8fba473575" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;<br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">the Class I directors, consisting of Dr. Avraham Molcho, Mr. Rami Dar and Gal Cohen, will hold office until
        our annual general meeting of shareholders to be held in 2027;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;<br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">the Class II directors, consisting of Dr. B.J. Bormann and Dr. Raphael Hofstein, will hold office until
        our annual general meeting of shareholders to be held in 2028; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;<br/> &#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">the Class III directors, consisting of Dr. Sandra Panem, Dr. Aharon Schwartz and Dr. Shaoyu Yan, will hold
        office until our annual general meeting of shareholders to be held in 2026.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In accordance with the exemption available to foreign private issuers
under applicable Nasdaq Rules, we do not follow the requirements of the Nasdaq Rules with regard to the process of nominating directors,
and instead follow Israeli law and practice, in accordance with which our board of directors is authorized to recommend to our shareholders
director nominees for election, and, in some circumstances, our shareholders may nominate candidates for election as directors by the
shareholders&#8217; general meeting.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">85</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, our board of directors may appoint directors (other
than external directors) to fill vacancies on our board of directors, including if the number of directors is below the maximum number
of directors who may serve as provided in our Articles of Association, for a term of office equal to the remaining period of the term
of office of the director(s) whose office(s) has been vacated, or in case of a vacancy due to the number of directors serving being less
than the maximum number stated in our Articles of Association, until the next annual general meeting of our shareholders for the class
he or she has been assigned by our board of directors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, our board of directors must determine
the minimum number of directors who are required to have financial and accounting expertise. Under applicable regulations, a director
with financial and accounting expertise is a director who, by reason of his or her education, professional experience and skill, has a
high level of proficiency in and understanding of business accounting matters and financial statements. He or she must be able to thoroughly
comprehend the financial statements of the listed company and initiate debate regarding the manner in which financial information is presented.
In determining the number of directors required to have such expertise, a company&#8217;s board of directors must consider, among other
things, the type and size of the company and the scope and complexity of its operations. Our board of directors has determined that we
require at least one director with the requisite financial and accounting expertise. Our board of directors has determined that Rami Dar
has such financial and accounting expertise.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Chairperson of the Board.</span>
Under the Companies Law, a person cannot hold the role of both chairperson of the board of directors and chief executive officer of a
public company, without shareholder approval by a special majority and for periods of time not exceeding three years each. Furthermore,
a person who is directly or indirectly subordinate to a chief executive officer of a public company may not serve as the chairperson of
the board of directors of that company and the chairperson of the board of directors of a public company may not otherwise serve in any
other capacity in that company or a subsidiary of that company other than as a director or the chairperson of the board of directors of
such a subsidiary.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">External Directors</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, the board of directors of Israeli companies
whose shares are publicly traded, including companies with shares listed on Nasdaq, are required to include at least two external directors
who meet the qualification requirements in the Companies Law. However, pursuant to the Israeli Companies Regulations (Relief for Companies
whose Securities are Listed for Trading Outside of Israel) - 2000, or the Relief Regulations, companies that do not have a controlling
shareholder (within the meaning of the Companies Law), whose shares are listed on an exchange outside Israel or are dual listed on the
TASE and a foreign exchange referenced in the second or third addendum to the Israeli Securities Law, 5728-1968, or the Israeli Securities
Law (which include, among others, the Nasdaq), such as us, may, subject to certain conditions, &#8220;opt out&#8221; from the Companies
Law requirements to appoint external directors and related Companies Law rules concerning the composition of the audit committee and compensation
committee of the board of directors (other than the gender diversification rule under the Companies Law, which requires the appointment
of a director from the other gender if at the time of appointment of a director all members of the board of directors are of the same
gender).</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On March 25, 2024, in accordance with the Relief Regulations, our
board of directors elected to &#8220;opt out&#8221; from the Companies Law requirement to appoint external directors and related Companies
Law rules concerning the composition of the audit committee and compensation committee of the board of directors, effective immediately.
Under the Relief Regulations, the exemption from such Companies Law requirements will continue to be available to us so long as: (i) we
do not have a &#8220;controlling shareholder&#8221; (as such term is defined under the Companies Law), (ii) our shares are traded on an
exchange outside Israel or dual listed on the TASE and certain foreign stock exchanges, including the Nasdaq, and (iii) we comply with
the director independence requirements and the audit committee and compensation committee composition requirements under U.S. laws (including
applicable Nasdaq Rules) applicable to U.S. domestic issuers.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">86</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Audit Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In accordance with the Relief Regulations described above, on March
25, 2024, our board of directors elected to &#8220;opt out&#8221; from the Companies Law requirement to appoint external directors and
related rules concerning the composition of the audit committee and compensation committee, effective immediately. Under such exemption,
among other things, the composition of our audit committee must comply with the requirements of SEC and Nasdaq rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Nasdaq Rules require us to establish an audit committee comprised
of at least three members, all of whom must be independent directors under the respective &#8220;independence&#8221; requirements of the
SEC and Nasdaq, each of whom is financially literate and one of whom has accounting or related financial management expertise at senior
levels within a company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our Audit Committee is currently comprised of Mr. Rami Dar, Dr.
Avraham Molcho and Dr. Raphael Hofstein. Mr. Rami Dar serves as the Chairperson of the Audit Committee. Our board of directors has determined
that Mr. Rami Dar (Chairperson) qualifies as an audit committee financial expert as defined by the rules of the SEC and Nasdaq. Our board
of directors has determined that each member of our audit committee is &#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1)
under the Exchange Act, which is different from the test for independence of board and committee members under the Nasdaq Rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our board of directors adopted an audit committee charter that
added to the responsibilities of our Audit Committee under the Companies Law, setting forth the responsibilities of the audit committee
consistent with the rules of the SEC and the Nasdaq Rules, including the following:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z1170018e5fc848609c79545b1e0150c7" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">oversight of the company&#8217;s independent registered public accounting firm and
        recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to our board
        of directors in accordance with Israeli law;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">recommending the engagement or termination of the office of our internal auditor;
        and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">reviewing and pre-approving the terms of audit and non-audit services provided by
        our independent auditors.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our Audit Committee provides assistance to our board of directors
in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial reporting, internal control
and legal compliance functions by pre-approving the services performed by our independent accountants and reviewing their reports regarding
our accounting practices and systems of internal control over financial reporting. Our Audit Committee also oversees the audit efforts
of our independent accountants and takes those actions it deems necessary to satisfy itself that the accountants are independent of management.
Pursuant to the Companies Law, the audit committee of a company shall be responsible for: (i) determining whether there are delinquencies
in the business management practices of a company, including in consultation with an internal auditor or independent auditor, and making
recommendations to the company&#8217;s board of directors to improve such practices; (ii) determining whether to approve certain related
party transactions (including compensation of office holders or transactions in which an office holder has a personal interest and whether
such transaction is material or otherwise an extraordinary transaction); (iii) where the company&#8217;s board of directors approves the
work plan of the internal auditor, examining such work plan before its submission to the board of directors and proposing amendments thereto;
(iv) examining internal controls and the internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources
and tools to dispose of its responsibilities (taking into consideration the special needs and size of a company); (v) examining the scope
of the auditor&#8217;s work and compensation and submitting its recommendation with respect thereto to the corporate body considering
the appointment thereof (either the board of directors or the general meeting of shareholders); and (vi) establishing procedures for the
handling of employees&#8217; complaints as to the management of the business and the protection to be provided to such employees. The
responsibilities of the audit committee under the Companies Law also include the following matters: (i) the establishment of procedures
to be followed in respect of related party transactions with a controlling shareholder (whether or not it is an extraordinary transaction),
which may include, where applicable, the establishment of a competitive process for such transaction, under the supervision of the audit
committee, or individual, or other committee or body selected by the audit committee, in accordance with criteria determined by the audit
committee; and (ii) to determine procedures for approving certain related party transactions with a controlling shareholder, which having
been determined by the audit committee not to be extraordinary transactions, were also determined by the audit committee not to be negligible
transactions. Under the Companies Law, the approval of the audit committee is required for specified actions and transactions with office
holders and controlling shareholders. See &#8220;- Approval of Related Party Transactions under Israeli Law.&#8221;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">87</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In accordance with the Relief Regulations described above, on March
25, 2024, our board of directors elected to &#8220;opt out&#8221; from the Companies Law requirement to appoint external directors and
related rules concerning the composition of the audit committee and compensation committee, effective immediately. Under such exemption,
among other things, the composition of our compensation committee must comply with the requirements of the Nasdaq Rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Nasdaq Rules, we are required to maintain a compensation
committee consisting of at least two directors, each of whom is an independent director within the meaning of the Nasdaq Rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Our Compensation Committee is currently comprised of Mr. Rami Dar, Dr. Avraham Molcho,
Dr. Raphael Hofstein and Dr. B.J Bormann. Dr. Avraham Molcho serves as the Chairperson of our Compensation Committee. Our board of directors
has determined that each member of our compensation committee is independent under the Nasdaq Rules, including the additional independence
requirements applicable to the members of a compensation committee.</div>

<div style="text-indent: 36pt; line-height: 1.25"> <br/> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The responsibilities of the compensation committee include the
following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5d597fd707ed4a959686a8c738656e14" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">to make recommendations to the board of directors for its approval of (i) a compensation
        policy for office holders, (ii) once every three years whether to extend the then current compensation policy (approval of either a new
        compensation policy or the continuation of an existing compensation policy must, in any case, occur every three years); and (iii) periodic
        updates to the compensation policy which may be required from time to time. In addition, the compensation committee is required to periodically
        examine the implementation of the compensation policy; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z414337390e754fd0b4ac536f08e25ce1" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">to approve transactions relating to terms of office and employment of company office
        holders that require the approval of the compensation committee pursuant to the Companies Law (including determining whether the compensation
        terms of a candidate for chief executive officer of the company need not be brought to approval of the shareholders).</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, our Compensation Committee makes recommendations to
the board of directors regarding equity compensation (with the board also approving the compensation of our executive officers) and administers
our share incentive plan.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic">Compensation Policy</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, the board of directors of a publicly traded
company is required to adopt a compensation policy according to which the compensation of the company&#8217;s office holders will be determined.
The compensation policy must be approved at least once every three years by the board of directors, after considering the recommendations
of the compensation committee, and subject to limited exceptions, by the shareholders of the company by a majority vote of the shares
present and voting at a shareholder meeting on the matter, subject to a certain special majority requirement, or the Special Majority
for Compensation, as set forth in the Companies Law, pursuant to which one of the following must be met:</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle"> <br/> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the majority of the votes voted in favor includes at least a majority of all the votes
        of shareholders who are not controlling shareholders of the company and shareholders who do not have a personal interest in the compensation
        policy, present and voting on the matter (excluding abstentions); or</div> </td> </tr>
  </table>

<div><br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">88</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the total of opposing votes from among the shareholders who are non-controlling shareholders
        and shareholders who do not have a personal interest in the matter does not exceed 2% of all the voting rights in the company.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Nonetheless, even if the shareholders of the company do not approve
the compensation policy, the board of directors may still approve the compensation policy, provided that the compensation committee and,
thereafter, the board of directors determine, based on detailed, documented, reasons and after further discussion of the compensation
policy, that despite the objection of shareholders, the approval of the compensation policy is in the best interests of the company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our current Compensation Policy was approved at the annual general
meeting of our shareholders held in June 2025, and may be in effect for up to three years. Below is a summary discussion of the main provisions
of our Compensation Policy:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Compensation Policy includes (among other things) a framework
for establishing the terms of office and employment of our office holders, a recoupment policy and guidelines with respect to the structure
of the variable pay of our office holders.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Compensation is considered performance-based to the extent that
a direct link is maintained between compensation and performance and that rewards are consistent with long-term stakeholder value creation.
At the company level, we analyze the overall compensation trends of the market in order to make informed decisions about our compensation
approach.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">According to the Compensation Policy, the fixed components of our
office holder compensation will be examined at least every two years and compared to the market. Our board of directors may change the
amount of the fixed components for one or more of our executives after receiving a recommendation for such from our Compensation Committee,
provided such change is within the limits determined by the Compensation Policy and subject to applicable law. The change may be made
if our board of directors concludes that such a change would promote our goals, operating plans and objectives and after taking into account
the business and legal implications of the proposed change and its impact on our internal labor relations. Any such changes are subject
to formal approval by the relevant parties. Under Israeli law, our board of directors has the authority to approve a change in the incentive
structure of all executive officers, including the chief executive officer, up to an immaterial amount. The fixed component of compensation
remunerates the specific role covered and scope of responsibilities and reflects the experience and skills required for each position,
as well as the level of excellence demonstrated and the overall quality of the office holder&#8217;s contribution to our business. The
weighting of fixed compensation within the overall package is designed to reduce the risk of excessively risk-oriented behavior, to discourage
initiatives focused on short-term results which might jeopardize our mid and long-term business sustainability and value creation, and
to allow us a flexible compensation approach. We offer our employees benefit plans based on common practice in the local labor market
of the office holder.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Variable components of compensation are determined with an aim
at creating maximum alignment between the Compensation Policy and our operating plan and objectives. Variable components of compensation
are primarily based on measurable long-term criteria, except that a non-material portion of variable compensation may be based on qualitative
non-measurable criteria which focus on the office holder&#8217;s contribution to the Company. Our variable compensation aims to remunerate
for achievements by directly linking pay to performance outcomes in the short and long term. To strengthen the alignment of shareholder
interests and the interests of management and employees, performance measurements reflect our actual results overall, as well as that
of the individual office holder. To support the aforementioned principles, we provide two types of variable compensation: short-term -
annual bonuses; and long-term - equity compensation.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">89</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Annual bonuses are based on achievement of the business goals set
out in our annual operating plan approved by the board of directors at the beginning of each year. The operating plan encompasses all
aspects of our activities and as such sets the business targets for each member of the management team. Consequently, our Compensation
Committee and board of directors should be able to judge the suitability of a bonus payment by deliberating retrospectively at year end
and comparing actual performance and target achievements against the forecasted operating plan. The annual bonus mechanism will be directly
tied to meeting objectives - both our business objectives and the office holder&#8217;s personal objectives. The board of directors&#8217;
satisfaction with the officer&#8217;s performance will also affect the bonus amount. Annual bonus payments are subject to the limitations
set out in the Compensation Policy and are also subject to the discretion of our Compensation Committee and approval by the board of directors.
In order to maintain some measure of flexibility, after calculating the compensation amount, the board of directors may exercise discretion
about the final amount of the bonus but may not increase the recommended bonus amount by more than 25%.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Equity-based compensation may be granted in any form permitted
under our share incentive plan in effect from time to time and shall be made in accordance with the terms of such share incentive plan.
Equity-based compensation to office holders shall be granted from time to time and be individually determined and awarded according to
the performance, prior business experience, qualifications, role and the personal responsibilities of each officer. The vesting period
will generally be four years, with the vesting schedule to be determined in accordance with market compensation trends. Our policy is
to grant equity-based compensation with exercise prices at market value. Furthermore, in order to create a ceiling for the variable compensation:
(1) the aggregate value of annual grants to any one office holder (based on the Black Scholes calculation as of the date of grant) will
be no more than the higher of 2% of our market capitalization at the end of the measurement period or $1.5 million; and (2) it is our
intention that the maximum outstanding equity awards under our share incentive plan will not exceed 12% of our total fully-diluted share
capital. Our board of directors may, following approval by our Compensation Committee, make provisions with respect to the acceleration
of the vesting period of any office holder&#8217;s awards, including, without limitation, in connection with a corporate transaction involving
a change of control (subject to any other approvals required by applicable law).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have also established a defined ratio between the variable and
the fixed components of compensation, as well as a maximum amount for all variable components as of the date on which they are paid (or
as of the grant date for non-cash variable equity components), and subject to the limitations on variable compensation components which
are set out in the Compensation Policy. In all events, the weight of all the variable components (out of the total compensation amount
which is to be granted for any year) will not be greater than 80% for each office holder and may vary from one office holder to the other.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">According to the Companies Law, our Compensation Policy provides
that in the event of an accounting restatement, we shall be entitled to recover from office holders&#8217; bonus compensation granted,
earned or vested based on a pre-accounting restatement of our financial results in the amount of the excess over what would have been
paid under the accounting restatement, with a three-year look-back period. However, the compensation recovery will not be triggered in
the event of a financial restatement required due to changes in applicable financial reporting standards. In addition, in November 2023
we adopted an Executive Officer Clawback Policy in accordance with the rules of the SEC and Nasdaq, a copy of which is attached as Exhibit
97.1 to this Annual Report on Form 20-F.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">All compensation arrangements of office holders are to be approved
in the manner prescribed by applicable law. Our Compensation Committee will review the Compensation Policy on an annual basis, and monitor
its implementation, and recommend to our board of directors and shareholders to amend the Compensation Policy as it deems necessary from
time to time.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">90</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Investment Monitoring Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our board of directors has established an Investment Monitoring
Committee which currently consists of the following four members: our directors Dr. Sandra Panem (Chairperson) and Mr. Rami Dar; Ms. Mali
Zeevi, our Chief Financial Officer; and Mr. Raziel Fried, our Treasurer and Budgetary Control Director. The role of the Investment Monitoring
Committee includes providing recommendations to our board of directors regarding investment guidelines and performing an on-going review
of the fulfillment of established investment guidelines. The Investment Monitoring Committee convenes for meetings in accordance with
our needs, but in any event at least twice per year.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Internal Auditor</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, the board of directors of an Israeli public
company must appoint an internal auditor recommended by the audit committee and nominated by the board of directors. An internal auditor
may not be:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3e4a431a1019431e9cba89c85e9e8c0e" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a person (or a relative of a person) who holds more than 5% of the company&#8217;s
        shares;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a person (or a relative of a person) who has the power to appoint a director or the
        general manager of the company;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">an executive officer or director of the company (or a relative thereof); or</div>
        </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a member of the company&#8217;s independent accounting firm.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25">The role of the internal auditor is to examine, among other things, our compliance with
applicable law and orderly business procedures. The audit committee is required to oversee the activities and to assess the performance
of the internal auditor as well as to approve the internal auditor&#8217;s work plan. Our internal auditor is Dana Gottesman-Erlich, a
partner at BDO Israel.</div>

<div style="line-height: 1.25"><br/> &#160;<span style="font-weight: bold">Fiduciary Duties and Approval of Related Party Transactions
under Israeli Law</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Fiduciary duties of office holders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Companies Law imposes a duty of care and a duty of loyalty
on all office holders of a company. The duty of care of an office holder is based on the duty of care set forth in connection with the
tort of negligence under the Israeli Torts Ordinance (New Version) 5728-1968. This duty of care requires an office holder to act with
the degree of care with which a reasonable office holder in the same position would have acted under the same circumstances.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">91</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div> The duty of care includes a duty to use reasonable means, in light of the circumstances, to obtain:</div>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z12596993ceea4605839885c3023fd891" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">information on the advisability of a given action brought for his or her approval
        or performed by virtue of his or her position; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">all other important information pertaining to these actions.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25">The duty of loyalty requires an office holder to act in good faith and for the benefit
of the company, and includes the duty to:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z639c2b7d68314538bd30f0be8ce04ae7" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">refrain from any act involving a conflict of interest between the performance of his
        or her duties in the company and his or her other duties or personal affairs;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">refrain from any activity that is competitive with the business of the company;</div>
        </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">refrain from exploiting any business opportunity of the company for the purpose of
        gaining a personal advantage for himself or herself or others; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">disclose to the company any information or documents relating to the company&#8217;s
        affairs which the office holder received as a result of his or her position as an office holder.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We may approve an act performed in breach of the duty of loyalty
of an office holder provided that the office holder acted in good faith, the act or its approval does not harm the company, and the office
holder discloses his or her personal interest, as described below.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Disclosure of personal interests of an office holder</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Companies Law requires that an office holder promptly disclose
to the company any personal interest that he or she may have and all related material information or documents relating to any existing
or proposed transaction by the company, and in any event no later than the first meeting of the board of directors at which the transaction
is considered. An office holder is not, however, obliged to disclose a personal interest and related information if the personal interest
of the office holder derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary
transaction (as defined in the Companies Law).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The term personal interest is defined under the Companies Law to
include the personal interest of a person in an action or transaction of a company, including the personal interest of such person&#8217;s
relative or the interest of any entity in which the person or any of his/her relatives serves as a director or the chief executive officer,
owns at least 5% of its issued share capital or its voting rights or has the right to appoint a director or the chief executive officer,
but excluding a personal interest stemming solely from the ownership of shares in such entity. A personal interest includes the personal
interest of a person for whom the office holder holds a voting proxy and the personal interest of the office holder voting as a proxy,
even if the shareholder granting the proxy has no personal interest in the approval of the matter.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, an extraordinary transaction is defined
as any of the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2563adb3131e45748f37b79e2b586252" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a transaction other than in the ordinary course of business;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a transaction that is not on market terms; or</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a transaction that may have a material impact on the company&#8217;s profitability, assets or liabilities.</div>
        </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, once an office holder has complied with
the disclosure requirement described above, a company may approve a transaction between the company and the office holder or a third party
in which the office holder has a personal interest, or approve an action by the office holder that would otherwise be deemed a breach
of duty of loyalty. However, a company may not approve a transaction or action that is adverse to the company&#8217;s interest or that
is not performed by the office holder in good faith.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">92</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A director who has a personal interest in a matter that is considered
at a meeting of the board of directors or the audit committee may generally not be present at the meeting or vote on the matter unless
a majority of the directors or members of the audit committee have a personal interest in the matter, or, unless the chairman of the audit
committee or board of directors (as applicable) determines that he or she should be present to present the transaction that is subject
to approval. If a majority of the directors have a personal interest in the matter, such matter also requires approval of the shareholders
of the company.</div>

<div style="line-height: 1.25"> <br/> &#160;<span style="font-weight: bold; font-style: italic">Approval of transactions with officer
holders</span></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, unless the articles of association of
a company provide otherwise, a transaction with an office holder or with a third party in which the office holder has a personal interest
that is not an extraordinary transaction and an action of an office holder that would otherwise be deemed a breach of duty of loyalty
that may have a material impact on a company&#8217;s profitability, assets or liabilities, requires approval by the board of directors.
Our Articles of Association do not provide otherwise. If the transaction or action considered is (i) an extraordinary transaction or (ii)
an action of an office holder that would otherwise be deemed a breach of duty of loyalty and may have a material impact on a company&#8217;s
profitability, assets or liabilities, then audit committee approval is required prior to approval by the board of directors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Approval of compensation of office holders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Executive officers other than
the Chief Executive Officer</span>. The compensation of an office holder in a public company who is neither a director nor the chief executive
officer generally requires approval by the (i) compensation committee; and (ii) the board of directors. Approval of terms of office and
employment for such officers which do not comply with the compensation policy may nonetheless be approved, in special circumstances, subject
to two cumulative conditions: (i) the compensation committee and thereafter the board of directors, approved the terms after having taken
into account the various considerations and mandatory requirements set forth in the Companies Law with respect a compensation policy,
and (ii) the shareholders of the company have approved the terms by the Special Majority for Compensation . However, if the shareholders
do not approve a compensation arrangement with an executive officer that is inconsistent with the company&#8217;s compensation policy,
a company&#8217;s compensation committee and board of directors, may, in special circumstances approve the compensation despite shareholder
objection, provided that the compensation committee and thereafter the board of directors have determined to approve the compensation
based on detailed reasoning, after each having re- discussed the terms of compensation, and after examining the objection of the shareholders.</div>
</div>

<div style="line-height: 1.25"><br/>

<div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Chief Executive Officer</span>.
The compensation of a chief executive officer in a public company generally requires approval by the (i) compensation committee; (ii)
the board of directors; and (iii) the shareholders of the company by the Special Majority for Compensation. Approval of the compensation
terms of a chief executive officer which do not comply with the compensation policy may nonetheless be approved, in special circumstances,
subject to two cumulative conditions: (i) the compensation committee and thereafter the board of directors, approved the terms after having
taken into account the various considerations and mandatory requirements set forth in the Companies Law with respect to a compensation
policy and (ii) the shareholders of the company have approved the terms by means of the Special Majority for Compensation . However, a
company&#8217;s compensation committee and board of directors, may, in special circumstances approve the compensation of a chief executive
officer (who is not a director) that is not approved by shareholders despite shareholder objection, provided that the company&#8217;s
compensation committee and thereafter the board of directors have determined to approve the compensation, based on detailed reasoning,
after each having re-discussed the terms of office and employment, and after examining the objection of the shareholders. In addition,
the compensation committee may exempt from shareholder approval the compensation terms of a candidate for the office of chief executive
officer where such officer has no prior business relationship with the controlling shareholder or the company, if it has found, based
on detailed reasons, that bringing the compensation to the approval of the shareholders would impede the employment of such candidate
by the company, provided that the terms of office and employment are in accordance with the company&#8217;s compensation policy.</div>
</div>

<div><br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">93</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;

<div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Directors</span>. The <span style="font-style: italic">compensation</span>
of a director (who is not the chief executive officer) of a public company generally requires approval by the (i) compensation committee;
(ii) the board of directors; and (iii) unless exempted under regulations promulgated under the Companies Law, the shareholders of the
company. Approval of terms of the compensation of directors of a company which do not comply with the compensation policy may nonetheless
be approved, in special circumstances, subject to two cumulative conditions: (i) the compensation committee and thereafter the board of
directors, approved the terms after having taken into account the various considerations and mandatory requirements set forth in the Companies
Law with respect to a compensation policy and (ii) the shareholders of the company have approved the terms by means of the Special Majority
for Compensation.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;With respect to compensation of an officer (including a chief
executive officer) or director who is also a controlling shareholder, see &#8220;- <span style="font-style: italic">Disclosure of personal
interests of a controlling shareholder and approval of transactions</span>.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Disclosure of personal interests of a controlling shareholder and
approval of certain transactions</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, the disclosure requirements that apply
to an office holder also apply to a controlling shareholder of a public company. In the context of a transaction involving a shareholder
of the company, the definition of &#8220;controlling shareholder&#8221; also includes shareholders that hold 25% or more of the voting
rights if no other shareholder owns more than 50% of the voting rights in the company (and the holdings of two or more shareholders which
each have a personal interest in such matter will be aggregated for the purposes of determining such threshold), but excludes a shareholder
whose power derives solely from his or her position as a director of the company or from any other position with the company. For this
purpose, the holdings of all shareholders who have a personal interest in the approval of the same transaction will be aggregated.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, extraordinary transactions with a controlling
shareholder or in which a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder
has a personal interest, as well as transactions for the provision of services, whether directly or indirectly, by a controlling shareholder
or his or her relative, or a company such controlling shareholder controls, require the approval of the audit committee, the board of
directors and the shareholders, in that order. Transactions concerning the compensation terms of a controlling shareholder or a controlling
shareholder&#8217;s relative, whether as an office holder or an employee, require the approval of the compensation committee, the board
of directors and the shareholders, in that order. The shareholder approval must meet one of the following requirements:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z966db4b1c48a44ea815a359f8e7b4c89" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">at least a majority of the shares held by shareholders who have no personal interest in the matter who
        are present and voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">the shares voted by shareholders who have no personal interest in the matter who are present and vote against
        the transaction represent no more than 2% of the voting rights in the company.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">94</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The terms of service and employment of a controlling shareholder
approved by the compensation committee and board of directors shall be in accordance with the compensation policy of the company. Nonetheless,
the compensation committee and the board of directors may, in special circumstances, approve a compensation arrangement of a controlling
shareholder that does not comply with the company&#8217;s compensation policy, provided that (i) the compensation committee and, thereafter,
the board of directors approve such terms, based on, among other things, the considerations and mandatory requirements with respect to
a compensation policy set forth in the Companies Law and (ii) the shareholders have approved the terms by means of the Special Majority
for Compensation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">To the extent that any such transaction with a controlling shareholder
is for a period extending beyond three years, approval, in the same manner described above, is required once every three years, unless,
with respect to transactions not involving the receipt of services or compensation can be approved for a longer term, the audit committee
determines that the duration of the transaction for such longer term is reasonable given the related circumstances.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Pursuant to regulations promulgated under the Israeli Companies
Law, certain transactions, including with respect to compensation, with a controlling shareholder or his or her relative, or with directors
or other office holders, that would otherwise require approval of a company&#8217;s shareholders may be exempt from shareholder approval
under certain conditions.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Approval of Significant Private Placements</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, a significant private placement of securities
requires approval by the board of directors and the shareholders by a simple majority. A private placement is considered a significant
private placement if it will cause a person to become a controlling shareholder (within the meaning of the Companies Law) or if all of
the following conditions are met: (i) the securities issued amount to 20% or more of the company&#8217;s outstanding voting rights before
the issuance; (ii) some or all of the consideration is other than cash or listed securities or the transaction is not on market terms;
and (iii) the transaction will increase the relative holdings of a shareholder who holds 5% or more of the company&#8217;s outstanding
share capital or voting rights or that will cause any person to become, as a result of the issuance, a holder of more than 5% of the company&#8217;s
outstanding share capital or voting rights. However, pursuant to the Relief Regulations, the foregoing shareholder approval requirements
shall not apply to a company whose shares are listed on an exchange outside Israel or dual listed on the TASE and a foreign exchange referenced
in the second or third addendum to the Israeli Securities Law (which include, among others, the Nasdaq), if the law of the foreign jurisdiction
sets forth requirements regarding the approval of private placements and the company complies with such requirements as they apply to
companies incorporated in such foreign jurisdiction.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Duties of Shareholders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, a shareholder has a duty to act in good
faith and in an acceptable manner in exercising its rights and performing its obligations to the company and other shareholders, and must
refrain from abusing its power in the company, including, among other things, voting at general meetings of shareholders on the following
matters:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc999384c0ee64a3e9b1074f299c602cc" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">an amendment to the articles of association;</div> </td> </tr>
  </table>

<div style="margin-left: 36pt; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">95</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="zd1c6cfbb815d4360bcf45b7acdd8d2ea" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">an increase in the company&#8217;s authorized share capital;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a merger; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">the approval of related party transactions and acts of office holders that require shareholder approval
        under the Companies Law.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A shareholder also has a general duty to refrain from discriminating
against other shareholders.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The remedies generally available upon a breach of contract will
also apply to a breach of the above-mentioned duties, and in the event of discrimination against other shareholders, additional remedies
are available to the injured shareholder.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, a controlling shareholder, any shareholder that knows
that its vote can determine the outcome of a shareholder vote and any shareholder that, under a company&#8217;s articles of association,
has the power to appoint or prevent the appointment of an office holder, or has another power with respect to a company, is under a duty
to act with fairness towards the company. The Companies Law does not describe the substance of this duty of fairness except to state that
the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness,
taking the shareholder&#8217;s position in the company into account.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Exculpation, insurance and indemnification of office holders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, a company may not exculpate an office
holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability
to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care, but only if a provision
authorizing such exculpation is included in its articles of association. Our Articles of Association include such a provision. An Israeli
company may not exculpate a director from liability arising out of a prohibited dividend or distribution to shareholders.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">An Israeli company may indemnify an office holder in respect of
the following liabilities and expenses incurred for acts performed as an office holder, either pursuant to an undertaking given by the
company in advance of an event or following an event, provided a provision authorizing such indemnification is contained in its articles
of association:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z45b383bda1924f9ab6f674b0c1d6b91a" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle"><br/> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">monetary liability imposed on him or her in favor of another person pursuant to a
        judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office holder
        with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the
        board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount
        or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail
        the abovementioned foreseen events and amount or criteria;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">96</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office
        holder (i) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation
        or proceeding, provided that (1) no indictment was filed against such office holder as a result of such investigation or proceeding; and
        (2) no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or
        proceeding or, if such financial liability (such as a criminal penalty) was imposed, it was imposed with respect to an offense that does
        not require proof of criminal intent and (ii) in connection with a monetary sanction;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a monetary liability imposed on an office holder in favor of an injured party at an Administrative Procedure
        (as defined below) pursuant to Section 52(54)(a)(1)(a) of the Israeli Securities Law;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25; text-align: justify">expenses incurred by an office holder or certain compensation payments made to an
        injured party that were instituted against an office holder in connection with an Administrative Procedure under the Israeli Securities
        Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office
        holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf or by a third party or in connection
        with criminal proceedings in which the office holder was acquitted or as a result of a conviction for an offense that does not require
        proof of criminal intent.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">An &#8220;Administrative Procedure&#8221; is defined as a procedure
pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative
Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Israeli Securities
Law, which may result in sanctions, including monetary sanctions and certain restrictions on serving as a director or senior officer of
a public company for certain periods of time.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">An Israeli company may insure an office holder against the following
liabilities incurred for acts performed as an office holder if and to the extent provided in the company&#8217;s articles of association:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z59f55dec4c064d7292bb28fca629b4d6" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a breach of duty of loyalty to the company, provided that the office holder acted in good faith and had
        a reasonable basis to believe that the act would not prejudice the company;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a breach of duty of care to the company or to a third party, including a breach arising out of the negligent
        (but not intentional or reckless) conduct of the office holder;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a financial liability imposed on the office holder in favor of a third party;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a monetary liability imposed on the office holder in favor of an injured party in an Administrative Procedure
        pursuant to Section 52(54)(a)(1)(a) of the Israeli Securities Law; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">expenses, including reasonable litigation expenses and reasonable attorneys&#8217; fees, incurred by an
        office holder in connection with an Administrative Procedure instituted against him or her pursuant to certain provisions of the Israeli
        Securities Law.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">97</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">An Israeli company may not indemnify, exculpate or insure an office
holder against any of the following, and any provision in a company&#8217;s articles of association which allows for any of the following
is invalid:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7963990c31274d8dafecde6930f0115d" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a breach of duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty
        to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice
        the company;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent
        conduct of the office holder;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">an act or omission committed with intent to derive illegal personal benefit; or</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a fine, monetary sanction or forfeit levied against the office holder.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law and the regulations promulgated thereunder,
exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board of directors
and, with respect to the chief executive officer and a director, also by the shareholders. See &#8220;- Approval of Related Party Transactions
under Israeli Law.&#8221; However, under regulations promulgated under the Companies Law, the insurance of office holders shall not require
shareholder approval and may be approved by only the compensation committee, if the engagement terms are determined in accordance with
the company&#8217;s compensation policy, that compensation policy was approved by the shareholders by the same special majority required
to approve a compensation policy, and provided that the insurance policy is on market terms and the insurance policy is not likely to
materially impact the company&#8217;s profitability, assets or obligations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our Articles of Association permit us to exculpate, indemnify and
insure our office holders to the fullest extent permitted by law. We have entered into agreements with each of our directors and executive
officers exculpating them, to the fullest extent permitted by law, from liability to us for damages caused to us as a result of a breach
of duty of care, and undertaking to indemnify them to the fullest extent permitted by law. The indemnification for a monetary liability
imposed in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court, is
limited to events determined as foreseeable by the board of directors based on our activities, and to an amount determined by the board
of directors as reasonable under the circumstances. The maximum indemnification amount for all office holders, cumulatively, for one or
more of such events, shall be equal to the higher of (i) 25% of our total shareholders&#8217; equity as reflected in our audited annual
financial statements for the year preceding the year in which the event for which the indemnity is sought occurred, and (ii) $5 million.
The terms of such agreements are consistent with the provisions of our Compensation Policy that was approved by our shareholders in June
2025. However, in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against
public policy and therefore unenforceable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our office holders are currently covered by a directors&#8217;
and officers&#8217; liability insurance policy. The terms of such directors&#8217; and officers&#8217; insurance are consistent with the
provisions of our current Compensation Policy that was approved by our shareholders in June 2025.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As of the date of this Annual Report on Form 20-F, except as disclosed
in Item 8.A below, no claims have been filed under our directors&#8217; and officers&#8217; liability insurance policy, there is no pending
litigation or proceeding against any of our directors or officers as to which indemnification is being sought, nor are we aware of any
pending or threatened litigation that may result in claims for indemnification by any director or officer.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">D. Employees</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As of March 8, 2026, we had 20 full-time employees and 4 part-time
employees, all of whom are employed in Israel. Of our employees, 10 hold M.D. or Ph.D. degrees.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">98</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<table cellspacing="0" cellpadding="0" id="zf070fe9e0d9b40afb09f6293c475abfd" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">December 31,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2023</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2024</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2025</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 64%">
        <div style="line-height: 1.25">Management and administration</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">12</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">8</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">7</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%">
        <div style="line-height: 1.25">Research and development</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">29</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">19</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">17</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 64%; padding-bottom: 2px">
        <div style="line-height: 1.25">Commercialization and business development</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">38</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%">
        <div style="line-height: 1.25">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">79</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">28</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">24</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">While none of our employees are party to any collective bargaining
agreements, in Israel we are subject to certain labor statutes and national labor court precedent rulings, as well as to certain provisions
of the collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau of Economic
Organizations and/or the Industrialists&#8217; Association which are applicable to our employees by virtue of expansion orders issued
in accordance with relevant labor laws by the Israel Ministry of Labor and Welfare, and which apply such agreement provisions to our employees
even though they are not directly part of a union that has signed a collective bargaining agreement. The laws and labor court rulings
that apply to our employees principally concern the minimum wage laws, procedures for dismissing employees, determination of severance
pay, leaves of absence, sick pay and other conditions for employment. The expansion orders which apply to our employees principally concern
the requirement for length of the workday and work week, mandatory contributions to a pension fund, annual recreation allowance, travel
expenses payment and other conditions of employment. We generally provide our employees with benefits and working conditions beyond the
required minimums.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have never experienced any employment-related work stoppages
and believe our relationship with our employees is good.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">E. Share Ownership</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">See &#8220;Item 7.A. Major Shareholders&#8221; below.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Equity Compensation Plan</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">2003 Amended and Restated Share Incentive Plan</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In 2003, we adopted the BioLineRx Ltd. 2003 Share Incentive Plan,
or the Plan. In August 2013, our board of directors approved certain amendments to the Plan and extended the term of the Plan until November
2023, and the Plan was renamed as the BioLineRx Ltd. 2003 Amended and Restated Share Incentive Plan. In January 2016, our board of directors
approved amendments to the Plan in order to permit the granting RSUs and PSUs to eligible grantees. In November 2023, our board of directors
approved a six-month extension of the term of the Plan until May 2024 and, in May 2024, our board of directors approved a further extension
until May 2044. References below to the &#8220;Plan&#8221; refer to the Plan as amended in August 2013, January 2016, November 2023, and
May 2024.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Plan provides for the granting of options, ordinary shares,
RSUs and PSUs to our directors, employees, consultants and service providers, and to the directors, employees, consultants and service
providers of our subsidiaries and affiliates. The Plan provides for equity grants to be made at the determination of our board of directors
in accordance with applicable law. As of March 8, 2026, options to purchase 264,303,600 ordinary shares or 440,506 ADSs, an aggregate
29,366,400 PSUs or 48,944 ADSs and an aggregate of 32,623,200 RSUs or 54,372 ADSs were outstanding under the Plan.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">From time to time, our board of directors has approved an increase
in the number of shares reserved for the purpose of equity grants pursuant to the Plan. As of March 8, 2026, 233,830,200 million ordinary
shares, which may be represented by 0.4 million ADSs, were reserved for future issuance under the Plan.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">99</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Plan is administered by our board of directors for the purposes
of making equity grants and approving the terms of those grants, including, exercise price (in the case of options), vesting schedule,
acceleration of vesting and the other matters necessary in the administration of the Plan. Equity grants made under the Plan to eligible
employees and office holders who are Israeli residents are made under Section 102 of the Israeli Income Tax Ordinance [New Version], 5721-1961,
or the Israeli Tax Ordinance, pursuant to which the securities granted must be allocated or issued to a trustee and be held in trust for
two years from the date of grant. Under Section 102 of the Israeli Tax Ordinance, any tax payable by an employee from the grant of securities
or the exercise of options or vesting of RSUs or PSUs is deferred until the transfer of the securities (or ordinary shares issued upon
the exercise of options or the vesting of RSUs or PSUs) by the trustee to the employee or upon the sale of the securities or ordinary
shares, as the case may be, and gains may qualify to be taxed as capital gains at a rate equal to 25%, subject to compliance with specified
conditions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Options and RSUs granted under the Plan generally vest over four
years. Options generally expire 10 years from the grant date. If we terminate an employee&#8217;s employment or service for cause, all
of the grantee&#8217;s vested and unvested equity awards expire immediately from the time of delivery of the notice of discharge, unless
determined otherwise by the compensation committee or the board of directors. Upon termination of employment or service for any other
reason other than for cause, vested options may be exercised within three months of the termination date or if termination of employment
or service is due to death or disability of the employee, but in no event after the expiration date of the awards, within 12 months following
such death or disability, in each case unless otherwise determined by the compensation committee or the board of directors. Vested options
which are not exercised and unvested options, RSUs or PSUs return to the pool of reserved ordinary shares under the Plan for future grants.
The right to receive ordinary shares pursuant to PSUs granted under the Plan will vest upon the achievement of certain performance goals
to be established by the board of directors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In the event of a merger, consolidation, reorganization or similar
transaction or our voluntary liquidation or dissolution, all of our unexercised vested equity grants and any unvested equity grants will
be automatically terminated. However, in the event of a change of control, or merger, consolidation, reorganization or similar transaction
resulting in the acquisition of at least 50% of our voting power, or the sale or transfer of all or substantially all of our outstanding
shares assets, the equity grants then outstanding may be assumed or substituted for an appropriate number of shares of each class of shares
or other securities and/or assets of the successor company in such transaction (or a parent or subsidiary or another affiliate of such
successor company) as were distributed to our shareholders in respect of the transaction. In addition to the foregoing, our board of directors
has approved the inclusion in the option agreements of the Company&#8217;s officers of a provision for accelerated vesting of options
if both a change of control of the Company occurs and, following such change of control, the officer&#8217;s employment is terminated
or there is a significant demotion in the officer&#8217;s new job or position.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold"> <br/> F. Disclosure of a registrant&#8217;s
action to recover erroneously awarded compensation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">There was no erroneously awarded compensation that was required
to be recovered pursuant to the BioLineRx Ltd. Executive Officer Clawback Policy during the fiscal year ended December 31, 2025.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">100</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM7"><!--Anchor--></span>ITEM 7. MAJOR SHAREHOLDERS
AND RELATED PARTY TRANSACTIONS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. Major Shareholders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following table sets forth information with respect to the
beneficial ownership of our ordinary shares as of March 8, 2026 by:</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb3a43193721243de84bd9d488b0dd165" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#9679;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">each of our directors and senior management;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#9679;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">all of our directors and senior management as a group; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#9679;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">each person (or group of affiliated persons) known by us to be the beneficial owner
        of 5% or more of the outstanding ordinary shares.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following table sets forth information regarding the beneficial
ownership of our outstanding ordinary shares as of March 18, 2026 of each of our current directors and executive officers individually
and as a group. The percentages shown are based on 2,610,814,390 ordinary shares issued and outstanding as of March 18, 2026. Beneficial
ownership is determined in accordance with the rules of the SEC and generally includes voting power or investment power with respect to
securities. All ordinary shares subject to options currently exercisable or exercisable into ordinary shares within 60 days of March 18,
2026, and underlying RSUs and PSUs that shall vest within 60 days of March 18, 2026, are deemed to be outstanding and beneficially owned
by the shareholder holding such options, RSUs or PSUs for the purpose of computing the number of shares beneficially owned by such shareholder.
Such shares are also deemed outstanding for purposes of computing the percentage ownership of the person holding the option, RSU or PSU.
They are not, however, deemed to be outstanding and beneficially owned for the purpose of computing the percentage ownership of any other
shareholder.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="cfttable" id="z290fd0139cb14645b43a40c9caa22983" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Ordinary Shares</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Beneficially</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Percent of</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold"> Held</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Class</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-weight: bold">5% or Greater Shareholder</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Hong Seng Technology Limited<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">102,437,055</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3.9</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-weight: bold">Directors</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Aharon Schwartz<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,981,600</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">B.J. Bormann<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3,276,600</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Rami Dar<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,827,800</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Raphael Hofstein<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(5)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3,276,600</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Avraham Molcho<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(6)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3,276,600</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Sandra Panem<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(7)</sup></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3,267,600</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Shaoyu Yan</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Gal Cohen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;(8)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,027,800</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-weight: bold">Executive officers</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Philip A. Serlin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(9)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">18,226,800</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Mali Zeevi<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(10)</sup></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">4,746,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Ella Sorani<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(11)</sup></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">4,697,400</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold">All directors and executive officers as a group (11 persons)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(12)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">51,613,800</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1.94</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table> <br/> </div>

<div style="line-height: 1.25"> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">* Less than 1.0%.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">101</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 35.9pt; line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" id="z57d14c9b133742108e4f1fa3945829f9" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(1)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Based on Schedule 13D filed with the SEC on October 26, 2023. According to the Schedule 13D, includes 170,728
        ADS, representing 102,437,055 ordinary shares held by Hong Seng Technology Limited. Lepu (Hong Kong) Co., Limited holds 66.67% equity
        interest of Hong Seng Technology Limited. Lepu Holdings Limited holds 99.5% equity interest of Lepu (Hong Kong) Co., Limited. Lepu Medical
        (Europe) Cooperatief U.A. holds 100% equity interest of Lepu Holdings Limited. Lepu Medical Technology (Beijing) Co., Ltd. holds 99.95%
        equity interest of Lepu Medical (Europe) Cooperatief U.A. Lepu Medical Technology (Beijing) Co., Ltd. is a company publicly listed on
        Shenzhen Stock Exchange in the PRC (300003.SZ).</div> </div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(2)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Includes 3,705,000 ordinary shares and 3,276,600 ordinary shares issuable upon exercise of outstanding
        options currently exercisable or exercisable within 60 days of March 18, 2026. Does not include 1,027,200 ordinary shares issuable upon
        exercise of outstanding options that are not exercisable within 60 days of March 18, 2026.</div> </div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(3)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Includes 3,276,600 ordinary shares issuable upon exercise of outstanding options currently exercisable
        or exercisable within 60 days of March 18, 2026. Does not include 1,027,200 ordinary shares issuable upon exercise of outstanding options
        that are not exercisable within 60 days of March 18, 2026.</div> </div>
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(4)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Includes 2,827,800 ordinary shares issuable upon exercise of outstanding options currently exercisable
        or exercisable within 60 days of March 18, 2026. Does not include 1,027,200 ordinary shares issuable upon exercise of outstanding options
        that are not exercisable within 60 days of March 18, 2026.</div> </div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top"> <br/> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(5)</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Includes 3,276,600 ordinary shares issuable upon exercise of outstanding options currently exercisable
        or exercisable within 60 days of March 18, 2026. Does not include 1,027,200 ordinary shares issuable upon exercise of outstanding options
        that are not exercisable within 60 days of March 18, 2026. <br/> </div> </div> </td> </tr>
  </table> <br/>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">102</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(6)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Includes 3,276,600 ordinary shares issuable upon exercise of outstanding options currently exercisable
        or exercisable within 60 days of March 18, 2026. Does not include 1,027,200 ordinary shares issuable upon exercise of outstanding options
        that are not exercisable within 60 days of March 18, 2026.</div> </div> </td> </tr>
  </table>

<div> <br/> </div>

<div style="line-height: 1.25"> </div> </div>

<table cellspacing="0" cellpadding="0" id="z49925edb62b24e58bd7defcc2dc32ebb" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">(7)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Includes 3,276,600 ordinary shares issuable upon exercise of outstanding options currently exercisable
        or exercisable within 60 days of March 18, 2026. Does not include 1,027,200 ordinary shares issuable upon exercise of outstanding options
        that are not exercisable within 60 days of March 18, 2026. <br/> </div> </div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(8)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Includes 1,027,800 ordinary shares issuable upon exercise of outstanding options currently exercisable
        or exercisable within 60 days of March 18, 2026. Does not include 1,027,200 ordinary shares issuable upon exercise of outstanding options
        that are not exercisable within 60 days of March 18, 2026.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdcd3427480204a90843329a39cac7442" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(9)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Includes 171,600 ordinary shares and 18,055,200 ordinary shares issuable upon exercise of outstanding options
        and PSUs currently exercisable or exercisable within 60 days of March 18, 2026. Does not include 1,123,800 ordinary shares issuable upon
        exercise of outstanding options and PSUs that are not exercisable within 60 days of March 18, 2026.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z09ae3ee8115d4500b9aea01056636fd7" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(10)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">Includes 328,200 ordinary shares and 4,417,800 ordinary shares issuable upon exercise of outstanding options
        and PSUs currently exercisable or exercisable within 60 days of March 18, 2026. Does not include 24,570,600 ordinary shares issuable upon
        exercise of outstanding options and PSUs that are not exercisable within 60 days of March 18, 2026.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z32ecc092b38e4ce4866f6388f1b99d66" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(11)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Includes 66,600 ordinary shares and 4,631,400 ordinary shares issuable upon exercise
        of outstanding options and PSUs currently exercisable or exercisable within 60 days of March 18, 2026. Does not include 24,569,400 ordinary
        shares issuable upon exercise of outstanding options and PSUs that are not exercisable within 60 days of March 18, 2026. </div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(12)</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">
        <div style="line-height: 1.25">See footnotes (2)-(11) for certain information regarding beneficial ownership.</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">To our knowledge, other than as disclosed in the table above, our
other filings with the SEC and this Annual Report on Form 20-F, there has been no significant change in the percentage ownership held
by any major shareholder since January 1, 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">None of our shareholders has different voting rights from other shareholders. We are
not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Record Holders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Bank of New York Mellon, or BNY, is the holder of record for the Company&#8217;s American
Depositary Receipt program, pursuant to which each ADS represents 600 ordinary shares. As of March 8, 2026, BNY held 1,920,795,000 ordinary
shares representing 73.6% of our issued share capital held at that date. Certain of these ordinary shares were held by brokers or other
nominees. As a result, the number of holders of record or registered holders in the United States is not representative of the number
of beneficial holders or of the residence of beneficial holders.</div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. Related Party Transactions</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following is a description of the material terms of those transactions
with related parties to which we, or our subsidiaries, have been a party since January 1, 2025.</div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">103</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-style: normal">Agreements with Directors and Officers</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Employment Agreements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have entered into employment agreements with each of our executive
officers. See &#8220;Item 6.B. Directors, Senior Management and Employees - Compensation.&#8221;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Options, Restricted Share Units and Performance Share Units</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have granted, from time to time, options to purchase our ordinary
shares, RSUs and PSUs, to our executive officers and directors. We describe our share incentive plan under &#8220;Item 6.E. Directors,
Senior Management and Employees-Share Ownership-Equity Compensation Plan.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Exculpation, Insurance and Indemnification</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our Articles of Association and Compensation Policy approved by
our shareholders permit us to exculpate, indemnify and insure our directors and office holders to the fullest extent permitted by law.
We have entered into agreements with each of our office holders exculpating them, to the fullest extent permitted by law, from liability
to us for damages caused to us as a result of a breach of duty of care, and undertaking to indemnify them to the fullest extent permitted
by law, to the extent that these liabilities are not covered by insurance. We have obtained directors&#8217; and officers&#8217; liability
insurance for each of our officers and directors. See &#8220;Item 6. C - Directors, Senior Management and Employees - Board Practices
- Exculpation, insurance and indemnification of office holders.&#8221;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Gloria License Agreement and Securities Purchase Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On August 27, 2023, we entered into the Gloria License Agreement
with HST and Gloria, collectively, the Purchaser Party, pursuant to which we granted HST an exclusive, royalty-bearing, sublicensable
license with respect to the intellectual property rights and know-how associated with motixafortide in order to develop and commercialize
motixafortide in Asia (other than Israel and certain other countries) and to engage and authorize Gloria to perform services under the
Gloria License Agreement in such territory. In connection with the Gloria License Agreement, on August 27, 2023, we also entered into
a securities purchase agreement with HST and Gloria pursuant to which we agreed to sell and issue to HST, in a private placement, an aggregate
of 170,728 of our ADSs. Aggregate gross proceeds from the sale were approximately $14.6 million. In connection with the closing of the
private placement, Dr. Shaoyu Yan, a nominee of HST, was appointed to our board of directors to serve as one of our Class III directors
until our annual general meeting of shareholders to be held in 2026. The appointment was made effective in November 2023. In addition,
effective as of the annual general meeting to be held in 2026 and for so long as the Purchaser Party is the owner of at least 5% of our
issued and outstanding ordinary shares, the Purchaser Party shall have the right, but not the obligation, to nominate one person for election
by our shareholders to serve as a member of our board of directors, provided that such nominee provides the requisite certifications required
for appointment as a director of a public company under Israeli law.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">C. Interests of Experts and Counsel</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM8"><!--Anchor--></span>ITEM 8. FINANCIAL INFORMATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. Consolidated Statements and other Financial Information</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">See &#8220;Item 18. Financial Statements.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">104</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Legal Proceedings</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Biokine Claim</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On June 16, 2024, Biokine filed a complaint with the District Court
of Jerusalem against us. The complaint alleged breach of contract and a purported failure to make certain payments to Biokine under our
in-licensing agreement with Biokine for motixafortide. The lawsuit originally sought compensatory damages in the amount of approximately
$6.5 million and a declaratory judgment in favor of Biokine. We filed a statement of defense on November 17, 2024. In November 2024, the
parties entered into an agreement to refer the dispute to arbitration, and the claim was withdrawn. During the first quarter of 2025,
Biokine filed an updated complaint under the arbitration, increasing the damages to the amount of approximately $7.2 million.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In February 2026, the arbitrator issued a final award in favor
of us denying all claims asserted against us and awarding us expenses, including legal fees. </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Dividend Distributions</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have never declared or paid cash dividends to our shareholders.
Currently we do not intend to pay cash dividends. We currently intend to reinvest any future earnings in developing and expanding our
business. Any future determination relating to our dividend policy will be at the discretion of our board of directors and will depend
on a number of factors, including future earnings, our financial condition, operating results, contractual restrictions, capital requirements,
business prospects, applicable Israeli law and other factors our board of directors may deem relevant. Israeli law limits the distribution
of cash dividends to the greater of retained earnings or earnings generated over the two most recent years (referred to as the &#8220;profit
test&#8221;), in either case provided that we reasonably believe that the dividend will not render us unable to meet our existing and
foreseeable obligations when due (referred to as the &#8220;solvency test&#8221;). Notwithstanding the foregoing, in the event that a
company does meet the profit test, dividends may be paid with the approval of a court, provided that the court is convinced that the company
meets the solvency test. However, in accordance with the Relief Regulations, as a company whose shares are dual listed on the TASE and
a foreign exchange referenced in the second or third addendum to the Israeli Securities Law (which include, among others, the Nasdaq),
our board of directors may resolve to distribute a dividend by way of a share repurchase program (buy-back) if the company does not meet
the profit test without seeking the approval of the court, subject to the following: (i) the company meets the solvency test; and (ii)
we provide a notice to certain creditors regarding our intention to distribute a dividend by way of a share repurchase program in accordance
with the notice requirements set forth in the Relief Regulations and no such creditor submits an objection within 30 days of the notice
(otherwise, court approval would be required for such distribution in accordance with the requirements of the Companies Law). For information
regarding taxation of dividends, see &#8220;Item 10E. Additional Information - Taxation - Israeli Tax Considerations.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. Significant Changes</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">None.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM9"><!--Anchor--></span>ITEM 9. THE OFFER AND LISTING</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. Offer and Listing Details</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our ADSs have been trading on Nasdaq under the symbol &#8220;BLRX&#8221;
since July 2011. Our ordinary shares have been trading on the TASE under the symbol &#8220;BLRX&#8221; since February 2007.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">105</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. Plan of Distribution</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">C. Markets</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our ADSs trade on Nasdaq under the symbol &#8220;BLRX.&#8221; Our
ordinary shares trade on the TASE under the symbol &#8220;BLRX.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">D. Selling Shareholders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">E. Dilution</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">F. Expenses of the Issue</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM10"><!--Anchor--></span>ITEM 10. ADDITIONAL INFORMATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. Share Capital</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. Articles of Association</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A copy of our Articles of Association is attached as Exhibit 1.1
to this Annual Report on Form 20-F. Other than as set forth below, the information called for by this Item is set forth in Exhibit 2.2
to this Annual Report on Form 20-F and is incorporated by reference into this Annual Report on Form 20-F.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Board of Directors</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">See &#8220;Item 6. Directors, Senior Management and Employees - C. Board Practices.&#8221;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Borrowing Powers</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Pursuant to the Companies Law and our Articles of Association,
our board of directors may exercise all powers and take all actions that are not required under law or under our Articles of Association
to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">Shareholder Meetings</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, annual general meetings of shareholders
are required to be held at least once in every calendar year (within 15 months after the last preceding annual general meeting of shareholders).
All general meetings other than the annual meeting of shareholders are referred to in our Articles of Association as extraordinary meetings.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Companies Law provides that an extraordinary general meeting
of shareholders may be called by the board of directors as it deems fit. In addition, the board of directors is required to convene an
extraordinary general meeting of shareholders upon the written request of (i) two or more directors or 25% of the directors in office,
or (ii) one or more shareholders holding, in the aggregate, at least (a) 5% of the issued share capital and 1% of the voting rights; or
(b) 5% of the voting rights of the company.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">106</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Companies Law requires that resolutions regarding the following
matters must be passed at a general meeting of our shareholders:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0d329abae9ee435aa50d0ce56a97c20d" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">amendments to our Articles of Association;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">appointment, termination or the terms of service of our auditors;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">appointment of external directors (if applicable);</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">approval of certain related party transactions;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">increases or reductions of our authorized share capital;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">a merger; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the exercise of our board of directors&#8217; powers by a general meeting, if our
        board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.</div>
        </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Shareholders entitled to participate and vote at our general meetings
are the shareholders of record on a date to be determined by the board of directors, which, according to the Relief Regulations, as a
company dual listed on the TASE and the Nasdaq, may be between 4 and 60 days prior to the date of the meeting.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the Companies Law, shareholder meetings generally require
prior notice of not less than 21 days or, with respect to certain matters, such as election of directors and affiliated party transactions,
not less than 35 days. Only shareholders of record as reflected on our share register at the close of business on the date fixed by the
board of directors as the record date determining the then shareholders who will be entitled to vote, shall be entitled to notice of,
and to vote, in person or by proxy, at a general meeting and any postponement or adjournment thereof.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">C. Material Contracts</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have not entered into any material contract within the two years
prior to the date of this Annual Report on Form 20-F, other than contracts entered into in the ordinary course of business, or as otherwise
described elsewhere in this Annual Report on Form 20-F.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">D. Exchange Controls</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">There are currently no Israeli governmental laws, decrees or regulations
that restrict or affect our import or export of capital, including the availability of cash and cash equivalents for use by us and our
wholly owned subsidiaries, or the remittance of dividends, interest or other payments to non-resident holders of our securities, except
for shareholders who are subjects of countries that are, or have been, in a state of war with Israel or otherwise as set forth under &#8220;Item
10E. Additional Information - Taxation.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">E. Taxation</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic">The following description is not intended to constitute a complete
analysis of all tax consequences relating to the ownership or disposition of our ordinary shares or ADSs, both referred to in this Item
10E as the ordinary shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well
as any tax consequences that may arise under the laws of any state, local, non-U.S., including Israeli, or other taxing jurisdiction.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">107</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Israeli Tax Considerations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following is a summary of the material Israeli tax laws applicable
to us. This section also contains a discussion of material Israeli tax consequences concerning the ownership and disposition of our shares.
This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her
personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of this kind
of investor include residents of Israel or traders in securities who are subject to special tax regimes not covered in this discussion.
To the extent that this discussion is based on new tax legislation that has not yet been subject to judicial or administrative interpretation,
we cannot assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. The discussion
below is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations
of Israeli law, which change could affect the tax consequences described below.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">General Corporate Tax Structure in Israel</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Israeli companies are generally subject to corporate tax on their
taxable income. The regular corporate tax rate in Israel is 23% for the year 2018 and thereafter. Capital gains derived by an Israeli
company are now generally subject to tax at the same rate as the corporate tax rate.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As of December 31, 2025, the tax loss carryforwards of BioLineRx
were approximately $381 million with no expiration date.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Taxation of Israeli Individual
Shareholders on Receipt of Dividends.</span> Israeli residents who are individuals are generally subject to Israeli income tax for dividends
paid on our ordinary shares (other than a pro-rata distribution of bonus shares or share dividends) at a rate of either 25% or 30%, if
the recipient of such dividend is a substantial shareholder (as defined below) at the time of distribution or at any time during the preceding
12-month period.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Taxation of Israeli Resident Corporations
on Receipt of Dividends.</span> Israeli resident corporations are generally exempt from Israeli corporate tax for dividends paid on our
ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Taxation of Non-Israeli Shareholders
on Receipt of Dividends.</span> Non-residents of Israel (individuals or corporations) are generally subject to Israeli income tax on the
receipt of dividends paid on our ordinary shares at the rate of 25% (or 30% if such person is a &#8220;substantial shareholder&#8221;
at the time receiving the dividend or on any date in the 12 months preceding such date), which tax will be withheld at the source, unless
a lower rate is provided in the Israeli Tax Ordinance and/or regulations promulgated thereunder or under a tax treaty between Israel and
the shareholder&#8217;s country of residence and subject to the receipt in advance of a valid certificate from the Israeli Tax Authorities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the U.S.-Israel Tax Treaty (the &#8220;Treaty&#8221;), Israeli
withholding tax on dividends paid to a U.S. resident for treaty purposes may not, in general, exceed 25%. Where the recipient is a U.S.
corporation owning 10% or more of the voting stock of the paying corporation during the part of the paying corporation&#8217;s taxable
year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any) and the dividend is not
paid from the profits of a Benefited Enterprise, the Israeli tax withheld may not exceed 12.5%, subject to certain conditions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A &#8220;substantial shareholder&#8221; is generally a person who
alone, or together with his relative or another person who collaborates with him on a regular basis, holds, directly or indirectly, at
least 10% of any of the &#8220;means of control&#8221; of the corporation. &#8220;Means of control&#8221; generally include the right
to vote, receive profits, nominate a director, a general manager of the company or holders of similar offices in other bodies of persons,
receive assets upon liquidation, or instruct someone who holds any of the aforesaid rights regarding the manner in which he or she is
to exercise such right(s), and all regardless of the source of such right.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">108</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A non-resident of Israel who receives dividends from which tax
was withheld is generally exempt from the duty to file returns in Israel in respect of such income, provided that: (1) such income was
not derived from a business conducted in Israel by the taxpayer (2) the taxpayer has no other taxable sources of income in Israel with
respect to which a tax return is required to be filed and (3) the taxpayer is not obliged to pay excess tax.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Payers of dividends on our shares, including the Israeli stockbroker
effectuating the transaction or the financial institution through which the securities are held, are required, subject to any of the foregoing
exemptions, reduced tax rates and the demonstration of a shareholder of his, her or its foreign residency, to withhold taxes upon the
distribution of dividends at a rate of 25%, provided that the shares are registered with a nominee company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Taxation of Capital Gains</span>.
Israeli law imposes a capital gains tax on the sale or exchange of any capital assets by residents of Israel, as defined for Israeli tax
purposes, and on the sale or exchange of assets located in Israel, including shares in Israeli companies, by non-residents of Israel,
unless a specific exemption is available pursuant to the Israeli Tax Ordinance or the regulations thereunder or unless a tax treaty between
Israel and the shareholder&#8217;s country of residence provides otherwise and subject to the receipt in advance of a valid certificate
from the Israeli Tax Authorities. The law distinguishes between real capital gain and inflationary surplus. The inflationary surplus is
a portion of the total capital gain that is equivalent to the increase of the relevant asset&#8217;s purchase price which is attributable
to the increase in the Israeli consumer price index or, in certain circumstances, a foreign currency exchange rate, between the date of
purchase and the date of sale. The real capital gain is the excess of the total capital gain over the inflationary surplus. The inflationary
surplus is generally exempt from tax.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Capital Gains Taxes Applicable
to Israeli Resident Shareholders. </span>An individual is subject to a tax at a rate of 25% on real capital gains derived from the sale
of shares, as long as the individual is not a substantial shareholder at the time of sale or at any time during the 12-month period preceding
the company&#8217;s issuance of the shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">An individual who is a substantial shareholder at the time of sale
or at any time during the preceding 12-month period is subject to tax at a rate of 30% in respect of real capital gains derived from the
sale of shares issued by the company in which he or she is a substantial shareholder. Individual shareholders dealing in securities in
Israel are taxed at their marginal tax rates applicable to business income (up to 47% from 2017).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Real capital gains derived by an Israeli company are generally
subject to tax at the same rate as the corporate tax rate (currently 23%).</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Capital Gains Taxes Applicable
to Non-Israeli Resident Shareholders</span>. Shareholders that are not Israeli residents are generally exempt from Israeli capital gains
tax on any gains derived from the sale, exchange or disposition of our ordinary shares, provided that such shareholders did not acquire
their ordinary shares prior to our initial public offering on the TASE and such gains were not derived from a permanent establishment
or business activity of such shareholders in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemptions
if one or more Israeli residents (a) have a controlling interest of more than 25% in such non-Israeli corporation or (b) are the beneficiaries
of or are entitled to 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, under the Treaty, the sale, exchange or disposition
of our ordinary shares by a shareholder who is a U.S. resident (for purposes of the Treaty) holding the ordinary shares as a capital asset
is exempt from Israeli capital gains tax unless (1) the shareholder holds, directly or indirectly, shares representing 10% or more of
our voting capital during any part of the 12-month period preceding such sale, exchange or disposition; (2) the capital gains arising
from such sale are attributable to a permanent establishment of the shareholder located in Israel; (3) a shareholder who is an individual
and is present in Israel for a period or periods aggregating 183 days or more during a taxable year. In either case, the sale, exchange
or disposition of ordinary shares would be subject to Israeli tax, to the extent applicable (subject to the receipt in advance of a valid
certificate from the Israeli tax authorities); however, under the Treaty, the U.S. resident would be permitted to claim a credit for the
tax against the U.S. federal income tax imposed with respect to the sale, exchange or disposition, subject to the limitations in U.S.
laws applicable to foreign tax credits. The Treaty does not cover U.S. state or local taxes.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">109</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Shareholders may be required to demonstrate that they are exempt
from tax on their capital gains in order to avoid withholding at source at the time of sale.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The purchaser, the Israeli stockbrokers or financial institution
through which the shares are held are obliged, subject to the above mentioned exemptions, to withhold tax upon the sale of securities
on the amount of the consideration paid upon the sale of the securities (or on the real capital gain realized on the sale, if known),
at the rate of 25% in respect of an individual or at a corporate rate in respect of a corporation (23%).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Upon the sale of securities traded on a stock exchange, a detailed
return, including a computation of the tax due, must be filed and an advance payment must be paid on January 31 and July 31 of every tax
year in respect of sales of securities made within the previous six months (or within 30 days of the sale if the seller is not otherwise
required to file a tax return in Israel). However, if all tax due was withheld at source according to applicable provisions of the Israeli
Tax Ordinance and regulations promulgated thereunder, the aforementioned return need not be filed and no advance payment must be paid.
Capital gain is also reportable on the annual income tax returns.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Excess Tax</span>. Individuals
who are subject to tax in Israel (whether such individual is an Israeli resident or non-Israeli resident) are also subject to an additional
tax on taxable income exceeding a certain threshold in a tax year (NIS 721,560 for 2024, 2025 and 2026), at the rate of 3% on any such
taxable income prior to January 1, 2025 and commencing January 1, 2025, at the rate of 3% of any such active taxable income and 5% of
any such passive taxable income. For this purpose, passive taxable income includes taxable capital gains from the sale of securities and
taxable income from interest and dividends, subject to the provisions of an applicable double tax treaty.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Estate and gift tax</span>. Israeli
law presently does not impose estate or gift taxes.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Certain Material U.S. Federal Income Tax Considerations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following is a general summary of certain material U.S. federal
income tax considerations relating to the purchase, ownership and disposition of our ordinary shares and ADSs by U.S. Investors (as defined
below) that are initial purchasers of such ordinary shares or ADSs and that hold such ordinary shares or ADSs as capital assets for U.S.
federal income tax purposes (generally, property held for investment). This summary is based on the Internal Revenue Code of 1986, as
amended, or the Code, the regulations of the U.S. Department of the Treasury issued pursuant to the Code, or the Treasury Regulations,
the Treaty, and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject
to change, possibly with retroactive effect, or to different interpretation. No ruling has been sought from the IRS with respect to any
U.S. federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position.
This summary is for general information only and does not address all of the tax considerations that may be relevant to specific U.S.
Investors in light of their particular circumstances or to U.S. Investors subject to special treatment under U.S. federal income tax law
(such as, without limitation, banks, insurance companies, tax-exempt entities, retirement plans, regulated investment companies, partnerships,
dealers in securities, brokers, real estate investment trusts, grantor trusts, persons who acquire our ordinary shares through the exercise
or cancellation of employee stock options or otherwise as compensation for their services, certain former citizens or residents of the
United States, persons who acquire our ordinary shares or ADSs as part of a straddle, hedge, conversion transaction or other integrated
investment, persons that have a &#8220;functional currency&#8221; other than the Dollar, persons that own (or are deemed to own, indirectly
or by attribution) 10% or more of our ordinary shares or ADSs (by vote or value), persons subject to special tax accounting rules under
section 451(b), or persons that generally mark their securities to market for U.S. federal income tax purposes). This summary does not
address any U.S. state or local or non-U.S. tax considerations, any U.S. federal estate, gift or alternative minimum tax considerations
or any additional U.S. federal tax consequences other than U.S. federal income tax consequences.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">110</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As used in this summary, the term &#8220;U.S. Investor&#8221; means
a beneficial owner of our ordinary shares or ADSs that is, for U.S. federal income tax purposes, (i) an individual citizen or resident
of the United States, (ii) a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized
in or under the laws of the United States, any state thereof, or the District of Columbia, (iii) an estate the income of which is subject
to U.S. federal income tax regardless of its source or (iv) a trust with respect to which a court within the United States is able to
exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of its substantial
decisions, or a trust that has validly elected to be treated as a U.S. person for U.S. federal income tax purposes, whose status as a
U.S. person is not overwritten by an applicable tax treaty.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If an entity treated as a partnership for U.S. federal income tax
purposes holds our ordinary shares or ADSs, the tax treatment of such entity and each person treated as a partner thereof will generally
depend upon the status and activities of the entity and such person. An investor that is treated as a partnership for U.S. federal income
tax purposes should consult its own tax advisor regarding the U.S. federal income tax considerations applicable to it and its partners
of the purchase, ownership and disposition of its ordinary shares or ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Prospective investors should be aware that this summary does not
address the tax consequences to investors who are not U.S. Investors. Prospective investors should consult their own tax advisors as to
the particular tax considerations applicable to them relating to the purchase, ownership and disposition of their ordinary shares or ADSs,
including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.</div>

<div style="line-height: 1.25"> <br/> &#160;<span style="font-weight: bold; font-style: italic">Ownership of ADSs</span></div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold; font-style: italic">&#160;</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">For U.S. federal income tax purposes, we expect that a holder of
ADSs generally should be treated as the owner of the ordinary shares represented by such ADSs. As a result, gain or loss is generally
not expected to be recognized on account of exchanges of ordinary shares for ADSs, or of ADSs for ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Taxation of U.S. Investors</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The discussions under &#8220;- Distributions,&#8221; and under &#8220;- Sale, Exchange
or Other Disposition of Ordinary Shares or ADSs&#8221; below assumes that we will not be treated as a passive foreign investment company,
or PFIC, for U.S. federal income tax purposes. We believe that we may have been a PFIC for the year ended December 31, 2025. Although
we have not determined whether we will be a PFIC for our taxable year ending December 31, 2026, or in any subsequent year, our operating
results for any such years may cause us to be a PFIC.&#160;For a discussion of the rules that would apply if we are treated as a PFIC,
see the discussion under &#8220;- Passive Foreign Investment Company.&#8221;</div> </div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Distributions. </span>We have
no current plans to pay dividends. To the extent we pay any dividends, a U.S. Investor will be required to include in gross income as
a taxable dividend the amount of any distributions made on the ordinary shares or ADSs, including the amount of any Israeli taxes withheld,
when actually or constructively received, to the extent that those distributions are paid out of our current or accumulated earnings and
profits as determined for U.S. federal income tax purposes. Any distributions in excess of our earnings and profits will be applied against
and will reduce the U.S. Investor&#8217;s tax basis in its ordinary shares or ADSs and to the extent they exceed that tax basis, will
be treated as gain from the sale or exchange of those ordinary shares or ADSs. We do not intend to calculate our earnings and profits
under U.S. federal income tax principles. Therefore, a U.S. Investor should expect that a distribution will be treated as a dividend even
if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above.
If we were to pay dividends to holders of our ordinary shares, we expect to pay such dividends in NIS; however, dividends paid to holders
of our ADSs will be paid in dollars. A dividend paid in NIS, including the amount of any Israeli taxes withheld, will be includible in
a U.S. Investor&#8217;s income as a dollar amount calculated by reference to the exchange rate in effect on the date such dividend is
received, regardless of whether the payment is in fact converted into dollars. If the dividend is converted to dollars on the date of
receipt, a U.S. Investor generally will not recognize a foreign currency gain or loss. However, if the U.S. Investor converts the NIS
into dollars on a later date, the U.S. Investor must include, in computing its income, any gain or loss resulting from any exchange rate
fluctuations. The gain or loss will be equal to the difference between (i) the dollar value of the amount included in income when the
dividend was received and (ii) the amount received on the conversion of the NIS into dollars. Such gain or loss will generally be ordinary
income or loss and United States source for U.S. foreign tax credit purposes. U.S. Investors should consult their own tax advisors regarding
the tax consequences to them if we pay dividends in NIS or any other non-U.S. currency.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">111</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Subject to certain significant conditions and limitations, including
potential limitations under the Treaty, any Israeli taxes paid on or withheld from distributions from us and not refundable to a U.S.
Investor may be credited against the investor&#8217;s U.S. federal income tax liability or, alternatively, may be deducted from the investor&#8217;s
taxable income. This election is made on a year-by-year basis and applies to all foreign taxes paid by a U.S. Investor or withheld from
amounts paid to a U.S. Investor that year. Dividends paid on the ordinary shares or ADSs generally will constitute income from sources
outside the United States and be categorized as &#8220;passive category income&#8221; or, in the case of some U.S. Investors, as &#8220;general
category income&#8221; for U.S. foreign tax credit purposes.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As a result of recent changes to the U.S. foreign tax credit rules,
a withholding tax may need to satisfy certain additional requirements in orders to be considered a creditable tax for a U.S. investor.
We have not determined whether these requirements have been met and, accordingly, no assurance can be given that any withholding tax on
dividends paid by us will be creditable. Since the rules governing foreign tax credits are complex, U.S. Investors should consult their
own tax advisor regarding the availability of foreign tax credits in their particular circumstances.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Dividends paid on the ordinary shares and ADSs will not be eligible
for the &#8220;dividends-received&#8221; deduction generally allowed to corporate U.S. Investors with respect to dividends received from
U.S. corporations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Distributions treated as dividends that are received by an individual
U.S. Investor from &#8220;qualified foreign corporations&#8221; generally qualify for a reduced maximum tax rate so long as certain holding
period and other requirements are met. A non-U.S. corporation (other than a PFIC for the taxable year in which the dividend is paid or
the preceding taxable year) generally will be considered to be a qualified foreign corporation (i) if it is eligible for the benefits
of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for
purposes of this provision and which includes an exchange of information program, or (ii) with respect to any dividend it pays on stock
which is readily tradable on an established securities market in the United States. Any dividend paid by us in a taxable year in which
we are a PFIC (or with respect to which we were a PFIC in the preceding taxable year) will be subject to tax at regular ordinary income
rates. As mentioned above, we believe we may have been a PFIC for our 2025 taxable year and have not determined whether we will be a PFIC
for our 2026 taxable year. U.S. Investors should consult their own tax advisors regarding the availability of the lower rate for dividends
paid with respect to our ordinary shares and ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The additional 3.8% Medicare tax (described below) may apply to
dividends received by certain U.S. Investors who meet certain modified adjusted gross income thresholds.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Sale, Exchange or Other Disposition
of Ordinary Shares and ADSs. </span>Subject to the discussion under &#8220;- Passive Foreign Investment Company&#8221; below, a U.S. Investor
generally will recognize capital gain or loss upon the sale, exchange or other taxable disposition of ordinary shares or ADSs in an amount
equal to the difference between the amount realized on the sale, exchange or other taxable disposition and the U.S. Investor&#8217;s adjusted
tax basis in such ordinary shares or ADSs. This capital gain or loss will be long-term capital gain or loss if the U.S. Investor&#8217;s
holding period in the ordinary shares or ADSs exceeds one year. Preferential tax rates for long-term capital gain will apply to individual
U.S. Investors. The deductibility of capital losses is subject to limitations. The gain or loss will generally be income or loss from
sources within the United States for U.S. foreign tax credit purposes, subject to certain possible exceptions under the Treaty. The additional
3.8% Medicare tax (described below) may apply to gains recognized upon the sale, exchange, or other taxable disposition of our ordinary
shares or ADSs by certain U.S. Investors who meet certain modified adjusted gross income thresholds.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">112</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">U.S. Investors should consult their own tax advisors regarding
the U.S. federal income tax consequences of receiving currency other than Dollars upon the disposition of ordinary shares or ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Medicare Tax</span>. In addition,
certain U.S. persons, including individuals, estates and trusts, will be subject to an additional 3.8% Medicare tax, or net investment
income tax, on unearned income. For individuals, the additional Medicare tax applies to the lesser of (i) &#8220;net investment income&#8221;
or (ii) the excess of &#8220;modified adjusted gross income&#8221; over $200,000 ($250,000 if married and filing jointly or $125,000 if
married and filing separately). &#8220;Net investment income&#8221; generally equals the taxpayer&#8217;s gross investment income reduced
by the deductions that are allocable to such income. Investment income generally includes passive income such as interest, dividends,
annuities, royalties, rents, and capital gains. U.S. Investors are urged to consult their own tax advisors regarding the implications
of the additional Medicare tax resulting from their ownership and disposition of ordinary shares or ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Passive Foreign Investment Company</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In general, a corporation organized outside the United States will
be treated as a PFIC for U.S. federal income tax purposes in any taxable year in which either (i) at least 75% of its gross income is
&#8220;passive income&#8221; or (ii) on average at least 50% of its assets by value produce passive income or are held for the production
of passive income. Passive income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents
and gains from commodities and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive
income also includes amounts derived by reason of the temporary investment of funds, including those raised in the public offering. Assets
that produce or are held for the production of passive income may include cash, even if held as working capital or raised in a public
offering, as well as marketable debt securities and other assets that may produce passive income. In determining whether a non-U.S. corporation
is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25%
interest (by value) is taken into account.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Under the tests described above, whether or not we are a PFIC will
be determined annually based upon the composition of our income and the composition and valuation of our assets, all of which are subject
to change.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">We believe that we may have been a PFIC for the year ended December 31, 2025. Although
we have not determined whether we will be a PFIC for our taxable year ending December 31, 2026, or in any subsequent year, our operating
results for any such years may cause us to be a PFIC. Because the PFIC determination is highly fact intensive and made at the end of each
taxable year, there can be no assurance that we will not be a PFIC for taxable year ending December 31, 2026 or in any subsequent year.
[Upon request, we intend to annually inform U.S. Investors if we and any of our subsidiaries were a PFIC with respect to the preceding
year.]</div> </div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">U.S. Investors should be aware of certain tax consequences of investing
directly or indirectly in us if we are a PFIC. A U.S. Investor is subject to different rules depending on whether the U.S. Investor makes
an election to treat us as a &#8220;qualified electing fund,&#8221; known as a QEF election, for the first taxable year that the U.S.
Investor holds ordinary shares or ADSs, which is referred to in this disclosure as a &#8220;timely QEF election,&#8221; makes a &#8220;mark-to-market&#8221;
election with respect to the ordinary shares or ADSs (if such election is available) or makes neither election.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">QEF Election. </span>A U.S. Investor
who makes a timely QEF election, referred to in this disclosure as an &#8220;Electing U.S. Investor,&#8221; with respect to us must report
for U.S. federal income tax purposes his pro rata share of our ordinary earnings and net capital gain, if any, for our taxable year that
ends with or within the taxable year of the Electing U.S. Investor. The &#8220;net capital gain&#8221; of a PFIC is the excess, if any,
of the PFIC&#8217;s net long-term capital gains over its net short-term capital losses. The amount so included in income generally will
be treated as ordinary income to the extent of such Electing U.S. Investor&#8217;s allocable share of the PFIC&#8217;s ordinary earnings
and as long-term capital gain to the extent of such Electing U.S. Investor&#8217;s allocable share of the PFIC&#8217;s net capital gains.
Such Electing U.S. Investor generally will be required to translate such income into Dollars based on the average exchange rate for the
PFIC&#8217;s taxable year with respect to the PFIC&#8217;s functional currency. Such income generally will be treated as income from sources
outside the United States for U.S. foreign tax credit purposes. Amounts previously included in income by such Electing U.S. Investor under
the QEF rules generally will not be subject to tax when they are distributed to such Electing U.S. Investor. The Electing U.S. Investor&#8217;s
tax basis in ordinary shares or ADSs generally will increase by any amounts so included under the QEF rules and decrease by any amounts
not included in income when distributed.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">113</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">An Electing U.S. Investor will be subject to U.S. federal income
tax on such amounts for each taxable year in which we are a PFIC, regardless of whether such amounts are actually distributed to such
Electing U.S. Investor. However, an Electing U.S. Investor may, subject to certain limitations, elect to defer payment of current U.S.
federal income tax on such amounts, subject to an interest charge. If an Electing U.S. Investor is an individual, any such interest will
be treated as non-deductible &#8220;personal interest.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Any net operating losses or net capital losses of a PFIC will not
pass through to the Electing U.S. Investor and will not offset any ordinary earnings or net capital gain of a PFIC recognized by Electing
U.S. Investors in subsequent years.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">So long as an Electing U.S. Investor&#8217;s QEF election with
respect to us is in effect with respect to the entire holding period for ordinary shares or ADSs, any gain or loss recognized by such
Electing U.S. Investor on the sale, exchange or other disposition of such ordinary shares or ADSs generally will be long-term capital
gain or loss if such Electing U.S. Investor has held such ordinary shares or ADSs for more than one year at the time of such sale, exchange
or other disposition. Preferential tax rates for long-term capital gain will apply to individual U.S. Investors. The deductibility of
capital losses is subject to limitations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A U.S. Investor makes a QEF election by completing the relevant
portions of and filing IRS Form 8621 in accordance with the instructions thereto. A QEF election generally may not be revoked without
the consent of the IRS. [Upon request, we intend to annually furnish U.S. Investors with information needed in order to complete IRS Form
8621 (which form would be required to be filed with the IRS on an annual basis by the U.S. Investor) and to make and maintain a valid
QEF election for any year in which we are a PFIC.] There is no assurance, however, that we will have timely knowledge of our status as
a PFIC, or that the information that we provide will be adequate to allow U.S. Investors to make a QEF election. A QEF election will not
apply to any taxable year during which we are not a PFIC but will remain in effect with respect to any subsequent taxable year in which
we become a PFIC. Each U.S. Investor is encouraged to consult its own tax advisor with respect to tax consequences of a QEF election with
respect to us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Mark-to-Market Election</span>.
Alternatively, if our ordinary shares or ADSs are treated as &#8220;marketable stock,&#8221; a U.S. Investor would be allowed to make
a &#8220;mark-to-market&#8221; election with respect to our ordinary shares or ADSs, provided the U.S. Investor completes and files IRS
Form 8621 in accordance with the relevant instructions and related Treasury Regulations. If that election is made, the U.S. Investor generally
would include as ordinary income in each taxable year the excess, if any, of the fair market value of the ordinary shares or ADSs at the
end of the taxable year over such investor&#8217;s adjusted tax basis in the ordinary shares or ADSs. Thus, the U.S. Investor may recognize
taxable income without receiving any cash to pay its tax liability with respect to such income. The U.S. Investor would also be permitted
an ordinary loss in respect of the excess, if any, of the U.S. Investor&#8217;s adjusted tax basis in the ordinary shares or ADSs over
their fair market value at the end of the taxable year, but only to the extent of the net amount previously included in income as a result
of the mark-to-market election. A U.S. Investor&#8217;s tax basis in the ordinary shares or ADSs would be adjusted to reflect any such
income or loss amount. Gain realized on the sale, exchange or other disposition of the ordinary shares or ADSs would be treated as ordinary
income, and any loss realized on the sale, exchange or other disposition of the ordinary shares or ADSs would be treated as ordinary loss
to the extent that such loss does not exceed the net mark-to-market gains previously included in income by the U.S. Investor, and any
loss in excess of such amount will be treated as capital loss. Amounts treated as ordinary income will not be eligible for the favorable
tax rates applicable to qualified dividend income or long-term capital gains.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">114</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Generally, stock will be considered marketable stock if it is &#8220;regularly
traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning of applicable Treasury Regulations. A class of stock is regularly
traded on an exchange during any calendar year during which such class of stock is traded, other than in <span style="font-style: italic">de
minimis</span> quantities, on at least 15 days during each calendar quarter. To be marketable stock, our ordinary shares or ADSs must
be regularly traded on a qualifying exchange (i) in the United States that is registered with the SEC or a national market system established
pursuant to the Exchange Act or (ii) outside the United States that is properly regulated and meets certain trading, listing, financial
disclosure and other requirements. A mark-to-market election will not apply to our ordinary shares or ADSs held by a U.S. Investor for
any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become
a PFIC unless our ordinary shares or ADSs cease to be marketable. A mark-to-market election generally may not be revoked without the consent
of the IRS. Such election will not apply to any PFIC subsidiary that we own. Each U.S. Investor is encouraged to consult its own tax advisor
with respect to the availability and tax consequences of a mark-to-market election with respect to our ordinary shares or ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Default PFIC Rules</span>. A U.S.
Investor who does not make a timely QEF election or a mark-to-market election, referred to in this disclosure as a &#8220;Non-Electing
U.S. Investor,&#8221; will be subject to special rules with respect to (a) any &#8220;excess distribution&#8221; (generally, the portion
of any distributions received by the Non-Electing U.S. Investor on the ordinary shares or ADSs in a taxable year in excess of 125% of
the average annual distributions received by the Non-Electing U.S. Investor in the three preceding taxable years, or, if shorter, the
Non-Electing U.S. Investor&#8217;s holding period for the ordinary shares or ADSs), and (b) any gain realized on the sale or other disposition
of such ordinary shares or ADSs. Under these rules:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcc717d464c0d436397b33c03e7dc82e6" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the excess distribution or gain would be allocated ratably over the Non-Electing U.S.
        Investor&#8217;s holding period for the ordinary shares or ADSs;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the amount allocated to the current taxable year and any year prior to us becoming
        a PFIC would be taxed as ordinary income; and</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">the amount allocated to each of the other taxable years would be subject to tax at
        the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral benefit
        would be imposed with respect to the resulting tax attributable to each such other taxable year.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If a Non-Electing U.S. Investor who is an individual dies while
owning our ordinary shares or ADSs, the Non-Electing U.S. Investor&#8217;s successor would be ineligible to receive a step-up in tax basis
of the ordinary shares or ADSs. Non-Electing U.S. Investors are encouraged to consult their tax advisors regarding the application of
the PFIC rules to their specific situation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">A Non-Electing U.S. Investor who wishes to make a QEF election
for a subsequent year may be able to make a special &#8220;purging election&#8221; pursuant to Section 1291(d) of the Code. Pursuant to
this election, a Non-Electing U.S. Investor would be treated as selling his or her ordinary shares or ADSs for fair market value on the
first day of the taxable year for which the QEF election is made. Any gain on such deemed sale would be subject to tax under the rules
for Non-Electing U.S. Investors as discussed above. Non-Electing U.S. Investors are encouraged to consult their tax advisors regarding
the availability of a &#8220;purging election&#8221; as well as other available elections.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">To the extent a distribution on our ordinary shares or ADSs does
not constitute an excess distribution to a Non-Electing U.S. Investor, such Non-Electing U.S. Investor generally will be required to include
the amount of such distribution in gross income as a dividend to the extent of our current or accumulated earnings and profits (as determined
for U.S. federal income tax purposes) that are not allocated to excess distributions. The tax consequences of such distributions are discussed
above under &#8220;- Taxation of U.S. Investors - Distributions.&#8221; Each U.S. Investor is encouraged to consult its own tax advisor
with respect to the appropriate U.S. federal income tax treatment of any distribution on our ordinary shares or ADSs.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">115</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If we are treated as a PFIC for any taxable year during the holding
period of a Non-Electing U.S. Investor, we will continue to be treated as a PFIC for all succeeding years during which the Non-Electing
U.S. Investor is treated as a direct or indirect Non-Electing U.S. Investor even if we are not a PFIC for such years. A U.S. Investor
is encouraged to consult its tax advisor with respect to any available elections that may be applicable in such a situation, including
the &#8220;deemed sale&#8221; election of Section 1298(b)(1) of the Code. In addition, U.S. Investors should consult their tax advisors
regarding the IRS information reporting and filing obligations that may arise as a result of the ownership of shares in a PFIC, including
IRS Form 8621.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We may invest in the equity of foreign corporations that are PFICs
or may own subsidiaries that own PFICs. U.S. Investors will be subject to the PFIC rules with respect to their indirect ownership interests
in such PFICs, such that a disposition of the shares of the PFIC or receipt by us of a distribution from the PFIC generally will be treated
as a deemed disposition of such shares or the deemed receipt of such distribution by the U.S. Investor, subject to taxation under the
PFIC rules. There can be no assurance that a U.S. Investor will be able to make a QEF election or a mark-to-market election with respect
to PFICs in which we invest. Each U.S. Investor is encouraged to consult its own tax advisor with respect to tax consequences of an investment
by us in a corporation that is a PFIC.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold">The U.S. federal income tax rules relating to
PFICs are complex. U.S. Investors are urged to consult their own tax advisors with respect to the purchase, ownership and disposition
of ordinary shares or ADSs, any elections available with respect to such ordinary shares or ADSs and the IRS information reporting obligations
with respect to the purchase, ownership and disposition of ordinary shares or ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Certain Reporting Requirements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Certain U.S. Investors may be required to file IRS Form 926, Return
by U.S. Transferor of Property to a Foreign Corporation, reporting transfers of cash or other property to us and information relating
to the U.S. Investor and us. Substantial penalties may be imposed upon a U.S. Investor that fails to comply.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Certain U.S. Investors owning &#8220;specified foreign financial
assets&#8221; with an aggregate value in excess of $50,000 on the last day of the taxable year or $75,000 at any time during the taxable
year (or such higher dollar amount as may be prescribed by applicable IRS guidance) may be required to file IRS Form 8938, Statement of
Specified Foreign Financial Assets, with respect to such assets with their tax returns. &#8220;Specified foreign financial assets&#8221;
generally include any financial accounts maintained by foreign financial institutions, as well as any of the following held for investment
and not held in accounts maintained by financial institutions: (i) stocks and securities issued by non-U.S. persons, which may include
the ordinary shares or ADSs, (ii) financial instruments and contracts held for investment that have non-U.S. issuers or counterparties
and (iii) interests in foreign entities. The IRS has issued guidance exempting &#8220;specified foreign financial assets&#8221; held in
a financial account from reporting under this provision (although the financial account itself, if maintained by a foreign financial institution,
may remain subject to this reporting requirement). U.S. Investors are urged to consult their tax advisors regarding the application of
these requirements to their ownership of the ordinary shares or ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">If we are treated as a PFIC, U.S. Investors generally are required
to file annual tax returns (including on IRS Form 8621) containing such information as the U.S. Treasury requires (whether or not a mark-to-market
election is or has been made). A U.S. Investor that is not otherwise required to file a U.S. tax return must still file IRS Form 8621
in accordance with the instructions for the Form. Failure to file IRS Form 8621 for each applicable taxable year may result in substantial
penalties and the statute of limitations on the assessment and collection of U.S. federal income taxes of such U.S. Investor for the related
taxable year may not close until three years after the date on which the required information is filed. U.S. Investors should consult
their tax advisors regarding the IRS information reporting and filing obligations that may arise as a result of the ownership of shares
in a PFIC, including IRS Form 8621.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">116</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Backup Withholding Tax and Information Reporting Requirements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Generally, information reporting requirements will apply to distributions
on our ordinary shares or ADSs or proceeds on the disposition of our ordinary shares or ADSs paid within the United States (and, in certain
cases, outside the United States) to U.S. Investors other than certain exempt recipients, such as corporations. Furthermore, backup withholding
may apply to such amounts if the U.S. Investor fails to (i) provide a correct taxpayer identification number, (ii) report interest and
dividends required to be shown on its U.S. federal income tax return, or (iii) make other appropriate certifications in the required manner.
U.S. Investors who are required to establish their exempt status generally must provide such certification on IRS Form W-9.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Backup withholding is not an additional tax. Amounts withheld as
backup withholding from a payment may be credited against a U.S. Investor&#8217;s U.S. federal income tax liability and such U.S. Investor
may obtain a refund of any excess amounts withheld by timely filing the appropriate claim for refund with the IRS and furnishing any required
information in a timely manner.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">U.S. Investors should consult their own tax advisors concerning
the tax consequences relating to the purchase, ownership and disposition of the ordinary shares or ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">F. Dividends and Paying Agents</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">G. Statement by Experts</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">H. Documents on Display</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are currently subject to the information and periodic reporting
requirements of the Exchange Act, and file periodic reports and other information with the SEC through its electronic data gathering,
analysis and retrieval (EDGAR) system. Our filings with the SEC are available to the public through the SEC&#8217;s website at <span style="text-decoration: underline">www.sec.gov</span>.
Our SEC filings are also generally available on the ISA&#8217;s website at <span style="text-decoration: underline">wwyw.magna.isa.gov.il</span>
and the TASE&#8217;s website at http://www.maya.tase.co.il.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">As a foreign private issuer, we are exempt from the rules under
the Exchange Act related to the furnishing and content of proxy statements. In addition, while our officers and directors and are, effective
March&#160;18, 2026, required to make insider reports under Section&#160;16(a)&#160;of the Exchange&#160;Act, our principal shareholders
are exempt from the reporting under Section&#160;16(a)&#160;of the Exchange&#160;Act, and our directors, officers and principal shareholders
continue to be exempt from the short-swing profit recovery provisions contained in Section 16(b) of the Exchange&#160;Act. Furthermore,
we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently
or as promptly as U.S. companies whose securities are registered under the Exchange Act.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We maintain a corporate website at <span style="font-style: italic">www.biolinerx.com.</span>
Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 20-F.
We have included our website address in this Annual Report on Form 20-F solely as an inactive textual reference.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">I. Subsidiary Information</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">117</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">J. Annual Report to Security Holders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM11"><!--Anchor--></span>ITEM 11. QUANTITATIVE AND
QUALITATIVE DISCLOSURE ON MARKET RISK</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our consolidated financial statements are prepared in conformity
with IFRS, as issued by the IASB. We are exposed to a variety of risks in the ordinary course of our business, including, but not limited
to, interest rate risk, foreign exchange risk, liquidity risk and credit risk, as discussed below. We regularly assess each of these risks
to minimize any adverse effects on our business as a result of those factors. See Note 3 to our consolidated financial statements, which
are included elsewhere in this Annual Report on Form 20-F, for further discussion of our exposure to these risks.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risk of Interest Rate Fluctuation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our investments consist primarily of cash, cash equivalents and
short-term bank deposits. We may also invest in investment-grade marketable securities with maturities of up to three years, including
commercial paper, money market funds, and government/non-government debt securities. The primary objective of our investment activities
is to preserve principal, while maximizing the income that we receive from our investments without significantly increasing risk and loss.
Our investments are exposed to market risk due to fluctuation in interest rates, which may affect our interest income and the fair market
value of our investments. We manage this exposure by performing ongoing evaluations of our investments. Due to the short-term maturities
of our investments to date, their carrying value has always approximated their fair value. It is our policy to hold investments to maturity
in order to limit our exposure to interest rate fluctuations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Foreign Currency Exchange Risk</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our reporting and functional currency is the dollar. However, we
pay a significant portion of our expenses in NIS, and we expect this to continue. If the dollar materially depreciates against the NIS
in the future, then the U.S. dollar cost of our operations in Israel would increase and there may be a negative impact on our results
of operations. Although the revenues from our current out-licensing and co-development arrangements are payable in dollars and we expect
our revenues from future any licensing arrangements to be denominated primarily in dollars, we are exposed to the currency fluctuation
risks relating to the recording of our revenues in currencies other than dollars. To date, fluctuations in the exchange rates have not
materially affected our results of operations or financial condition for the periods under review.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">From time to time, we have engaged in currency hedging transactions
to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies, and we may continue
to do so in the future. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-weight: bold"><span id="ITEM12"><!--Anchor--></span>ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN
EQUITY SECURITIES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. Debt Securities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. Warrants and Rights</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">118</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">C. Other Securities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">D. American Depositary Shares</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Set forth below is a summary of some of the material terms of the
deposit agreement among BioLineRx, The Bank of New York Mellon as depositary, or the Depositary, and the owners and holders from time
to time of our ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Description of the ADSs</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Each of our ADSs represents 600 of our ordinary shares deposited
with the principal Tel Aviv office of Bank Leumi Le-Israel, as Custodian for the Depositary. Our ADSs trade on Nasdaq.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The form of the deposit agreement for the ADS and the form of American
Depositary Receipt (ADR) that represents an ADS have been incorporated by reference as exhibits to this Annual Report on Form 20-F. Copies
of the deposit agreement are available for inspection at the principal office of The Bank of New York Mellon, located at 101 Barclay Street,
New York, New York 10286.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Charges of Depositary</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We will pay the fees, reasonable expenses and out-of-pocket charges
of the Depositary and those of any registrar only in accordance with agreements in writing entered into between us and the Depositary
from time to time. The following charges shall be incurred by any party depositing or withdrawing ordinary shares or by any party surrendering
ADRs or to whom ADRs are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by us or
an exchange of stock regarding the ADRs or deposited ordinary shares or a distribution of ADRs pursuant to the terms of the deposit agreement):</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="zb17694369f6546a2ae46423dd218ef5a" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">taxes and other governmental charges;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">119</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>

<table cellspacing="0" cellpadding="0" id="z791eb0b20a2541a58d015d2e4f474057" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">any applicable transfer or registration fees;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">certain cable, telex and facsimile transmission charges as provided in the deposit agreement;</div> </td>
        </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">any expenses incurred in the conversion of foreign currency;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a fee of $5.00 or less per 100 ADSs (or a portion thereof) for the execution and delivery of ADRs and the
        surrender of ADRs, including if the deposit agreement terminates;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a fee of $.01 or less per ADS (or portion thereof) for any cash distribution made pursuant to the deposit
        agreement;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a fee for the distribution of securities pursuant to the deposit agreement;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">in addition to any fee charged for a cash distribution, a fee of $.01 or less per ADS (or portion thereof)
        per annum for depositary services;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">a fee for the distribution of proceeds of rights that the Depositary sells pursuant to the deposit agreement;
        and</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: auto; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">any other charges payable by the Depositary, any of the Depositary&#8217;s agents, or the agents of the
        Depositary&#8217;s agents in connection with the servicing of ordinary shares or other Deposited Securities.</div> </td> </tr>
  </table> </div>

<div> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Depositary may own and deal in our securities and in ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Depositary collects its fees for delivery and surrender of
ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them.
The Depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling
a portion of distributable property to pay the fees. The Depositary may collect its annual fee for depositary services by deduction from
cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The
Depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other
property distributable) to ADS holders that are obligated to pay those fees. The Depositary may generally refuse to provide fee-attracting
services until its fees for those services are paid.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">From time to time, the Depositary may make payments to us to reimburse
us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services
provided to us by the Depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit
agreement, the Depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated
with the Depositary and that may earn or share fees, spreads or commissions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Depositary may convert currency itself or through any of its
affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any
other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue
is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement
and the rate that the Depositary or its affiliate receives when buying or selling foreign currency for its own account. The Depositary
makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most
favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable
to ADS holders, subject to the Depositary&#8217;s obligations under the deposit agreement. The methodology used to determine exchange
rates used in currency conversions is available upon request.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">120</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Liability of Holders for Taxes, Duties or Other Charges</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Any tax or other governmental charge with respect to ADSs or any
deposited ordinary shares represented by any ADS shall be payable by the holder of such ADS to the Depositary. The Depositary may refuse
to effect transfer of such ADS or any withdrawal of deposited ordinary shares represented by such ADS until such payment is made, and
may withhold any dividends or other distributions or may sell for the account of the holder any part or all of the deposited ordinary
shares represented by such ADS and may apply such dividends or distributions or the proceeds of any such sale in payment of any such tax
or other governmental charge and the holder of such ADS shall remain liable for any deficiency.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM13"><!--Anchor--></span>ITEM 13. DEFAULTS, DIVIDENDS
ARREARAGES AND DELINQUENCIES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 14<span id="ITEM14"><!--Anchor--></span>. MATERIAL MODIFICATIONS
TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 15<span id="ITEM15"><!--Anchor--></span>. CONTROLS AND PROCEDURES</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z24572a575986452b8a9731a64797104d" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">a.</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold"><span style="text-decoration: underline">Disclosure Controls and Procedures</span></div>
        </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have performed an evaluation of the effectiveness of our disclosure
controls and procedures that are designed to ensure that the material financial and non-financial information required to be disclosed
to the SEC is recorded, processed, summarized and reported timely. Based on our evaluation, our Chief Executive Officer, or the CEO, and
the Chief Financial Officer, or the CFO, have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and
15d-15(e) of the Exchange Act) as of the end of the period covered by this report are effective. Notwithstanding the foregoing, there
can be no assurance that our disclosure controls and procedures will detect or uncover all failures of persons within the Company to disclose
material information otherwise required to be set forth in our reports.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze27b90e6fced4d3f8eb2ce84da21c1aa" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">b.</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold"><span style="text-decoration: underline">Management&#8217;s Annual Report on Internal
        Control over Financial Reporting</span></div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our management is responsible for establishing and maintaining
adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) promulgated under the Exchange Act. Our
internal control system was designed to provide reasonable assurance to our management and board of directors regarding the reliability
of financial reporting and the preparation and fair presentation of published financial statements for external purposes in accordance
with generally accepted accounting principles. All internal control systems, no matter how well designed, have inherent limitations. Therefore,
even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and
presentation and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures
may deteriorate.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our management, including the CEO and CFO, conducted an evaluation,
pursuant to Rule 13a-15(c) promulgated under the Exchange Act, of the effectiveness, as of the end of the period covered by this Annual
Report on Form 20-F, of its internal control over financial reporting based on the framework in <span style="font-style: italic">Internal
Control-Integrated Framework </span>issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013). Based on the
results of this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2025.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">121</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<table cellspacing="0" cellpadding="0" id="zafd84147e91e4bea9086833b9c4b19c3" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">c.</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold"><span style="text-decoration: underline">Attestation Report of Registered Public Accounting
        Firm</span></div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25">Not applicable (we are exempt from this requirement due to our status under the Exchange
Act as a non-accelerated filer as of the current time).</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z0fd98c32738a41cca4411920924f4f53" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">d.</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold"><span style="text-decoration: underline">Changes in Internal Control over Financial
        Reporting</span></div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">There were no changes in our internal control over financial reporting
that occurred during the year ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM16"><!--Anchor--></span>ITEM 16. [RESERVED]</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM16A"><!--Anchor--></span>ITEM 16A. AUDIT COMMITTEE
FINANCIAL EXPERTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our board of directors has determined that Mr. Rami Dar is an audit
committee financial expert. Mr. Dar is one of our independent directors for the purposes of the Nasdaq Rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16B<span id="ITEM16B"><!--Anchor--></span>. CODE OF ETHICS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In July 2011, our board of directors adopted a Code of Business
Conduct and Ethics, or the Code of Conduct, that applies to all our employees, including without limitation our CEO, CFO and controller.
Our Code of Conduct may be viewed on our website at <span style="font-style: italic"><span style="text-decoration: underline">www.biolinerx.com</span></span>.
The information contained on or through our website, or any other website referred to herein, is not incorporated by reference into this
Annual Report on Form 20-F. A copy of our Code of Conduct may be obtained, without charge, upon a written request addressed to our investor
relations department, 2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel (Telephone no. +972-8-642-9100) (e-mail: <span style="text-decoration: underline">info@BioLineRx.com</span>).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16C<span id="ITEM16C"><!--Anchor--></span>. PRINCIPAL ACCOUNTANT
FEES AND SERVICES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Fees Paid to Independent Registered Public Accounting Firm</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The following table sets forth, for each of the years indicated,
the fees billed by Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Ltd., our independent registered public
accounting firm.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="zd2a42cb224e84ed4a9165198c30ac613" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Year Ended December 31,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2024</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2025</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Services Rendered</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-style: italic">(in thousands of U.S. dollars)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Audit Fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">160</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">140</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">Audit-Related Fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">40</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">26</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25">Tax Fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">41</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">22</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">211</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">188</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<table cellspacing="0" cellpadding="0" id="z2c986525229f4cbfaa35955c78015630" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(1)</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Audit fees consist of services that would normally be provided in connection with statutory and regulatory
        filings or engagements, including services that generally only the independent accountant can reasonably provide.</div> </td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(2)</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Audit-related services relate to reports to the IIA and services in connection with a public listing or
        offering.</div> </td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td colspan="1" style="width: 36pt; vertical-align: top">&#160;</td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">(3)</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="line-height: 1.25">Tax fees relate to tax planning and advice in connection with certain transactions.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">122</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000; clear: both"/></div>

<div class="BRPFPageHeader"></div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our Audit Committee, in accordance with its charter, reviews and
pre-approves all audit services and permitted non-audit services (including the fees and other terms) to be provided by our independent
auditors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16D<span id="ITEM16D"><!--Anchor--></span>. EXEMPTIONS FROM
THE LISTING STANDARDS FOR AUDIT COMMITTEES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16E<span id="ITEM16E"><!--Anchor--></span>. PURCHASES OF EQUITY
SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16F<span id="ITEM16F"><!--Anchor--></span>. CHANGE IN REGISTRANT&#8217;S
CERTIFYING ACCOUNTANT</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16G<span id="ITEM16G"><!--Anchor--></span>. CORPORATE GOVERNANCE</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Nasdaq Rules permit listed companies that are foreign private
issuers, such as us, to follow home country practice in lieu of the corporate governance provisions specified by the Nasdaq Rules with
limited exceptions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In accordance with Israeli law and practice and subject to the
exemption set forth in Rule 5615 of the Nasdaq Rules, we have elected to follow the provisions of the Companies Law, rather than the Nasdaq
Rules, with respect to the following requirements:</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z1b066ca41873464fa0e77685c29c0231" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Distribution of periodic reports to shareholders</span>.
        Under Israeli law, a public company whose shares are traded on the TASE, is not required to distribute periodic reports directly to shareholders
        and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports publicly
        available through a public website. We will only mail such reports to shareholders upon request. In addition, we make our audited financial
        statements available to our shareholders at our offices.</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">123</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: collapse; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Quorum</span>. While the Nasdaq Rules require that
        the quorum for purposes of any meeting of the holders of a listed company&#8217;s common voting stock, as specified in the company&#8217;s
        bylaws, be no less than 33 1/3% of the company&#8217;s outstanding common voting stock, as permitted under the Companies Law, our Articles
        of Association provide that a quorum of two or more shareholders holding at least 25% of the voting rights in person or by proxy is required
        for commencement of business at a general meeting (and, with respect to an adjourned meeting, a quorum consists of any number of shareholders
        present in person or by proxy).</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25"><br/> &#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Nomination of Directors</span>. We follow Israeli
        corporate governance practices instead of the requirements of the Nasdaq Rules with regard to the nomination committee and director nomination
        procedures. Israeli law and practice does not require director nominations to be made by a nominating committee of our board of directors
        consisting solely of independent directors, as required under the Nasdaq Rules. In accordance with Israeli law and practice, directors
        are recommended by our board of directors for election by our shareholders (other than directors elected by our board of directors to
        fill a vacancy), and certain of our shareholders may nominate candidates for election as directors by the general meeting of shareholders
        in accordance with the Companies Law and our Articles of Association.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Compensation of Officers</span>. We follow Israeli
        law and practice with respect to the approval of officer compensation, pursuant to which transactions with office holders regarding their
        terms of office and employment generally require the approval of the compensation committee, the board of directors and under certain
        circumstances (such as if the officer is a director or controlling shareholder) the shareholders, either in accordance with our compensation
        policy or, in special circumstances in deviation therefrom, taking into account certain considerations set forth in the Companies Law.
        See &#8220;Item 6.C- Directors, Senior Management and Employees - Board Practices - Compensation Committee&#8221; for information regarding
        the Compensation Committee, and &#8220;Item 6.C - Directors, Senior Management and Employees - Approval of Related Party Transactions
        under Israeli Law&#8221; for information regarding the approvals required with respect to approval of terms of office and employment of
        office holders, pursuant to the Companies Law.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Approval of Related Party Transactions</span>. We
        follow Israeli law and practice with respect to the approval of interested party acts and transactions, as set forth in sections 268 to
        275 of the Companies Law, and the regulations promulgated thereunder, which generally require the approval of the audit committee, the
        board of directors and, under certain circumstances (such as if the transaction is with a controlling shareholder or another party in
        which the controlling shareholder has a personal interest) the shareholders, as may be applicable, for specified transactions. See &#8220;Item
        6.C- Directors, Senior Management and Employees -Board Practices - Approval of Related Party Transactions under Israeli Law&#8221; for
        information regarding the approvals required with respect to approval of related party transactions pursuant to the Companies Law.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Shareholder Approval</span>. We intend to seek shareholder
        approval for all corporate actions requiring such approval in accordance with the requirements of the Companies Law, which are different
        or in addition to the requirements for seeking shareholder approval under Nasdaq Listing Rule 5635, rather than seeking approval for corporation
        actions in accordance with such listing rules.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 36pt; vertical-align: middle">
        <div style="line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 36pt; vertical-align: top">
        <div style="line-height: 1.25">&#8226;</div> </td>
    <td style="width: auto; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Equity Compensation Plans</span>. We do not necessarily
        seek shareholder approval for the establishment of, and amendments to, stock option or equity compensation plans (as set forth in Nasdaq
        Listing Rule 5635(c)), as such matters are not subject to shareholder approval under Israeli law and practice. However, any equity-based
        compensation arrangement with a director or the chief executive officer or the material amendment of such an arrangement must be approved
        by our Compensation Committee, board of directors and shareholders, in that order.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Except as stated above, we currently intend to comply with the
rules generally applicable to U.S. domestic companies listed on Nasdaq. We may in the future decide to use the foreign private issuer
exemption with respect to some or all of the other Nasdaq corporate governance rules. Following our home country governance practices,
as opposed to the requirements that would otherwise apply to a company listed on Nasdaq, may provide less protection than is accorded
to investors under Nasdaq listing requirements applicable to domestic issuers. For more information, see &#8220;Item 3.D - Key Information
- Risks Related to our Ordinary Shares and ADSs - <span style="font-style: italic">As a foreign private issuer, we follow certain home
country corporate governance practices instead of applicable Nasdaq requirements, which may result in less protection than is accorded
to investors under rules applicable to domestic issuers.</span>&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16H<span id="ITEM16H"><!--Anchor--></span>. MINE SAFETY DISCLOSURE</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16I<span id="ITEM16I"><!--Anchor--></span>. DISCLOSURE REGARDING
FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">124</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <br/> </div>
  </div>
<!-- Field: /Include-Text -->
</div>
  </div>

  <div style="line-height:1.25;font-weight:400;font-family:'Times New Roman',Times,serif">&#160;</div>
  <div style="line-height:1.25;font-weight:400;font-family:'Times New Roman',Times,serif">
    <div style="line-height:1.25"><span id="ITEM16J"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span style="font-weight:bold">ITEM 16J. INSIDER TRADING POLICIES</span></span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have <ix:nonNumeric id="Fxbrl_20250327095952259" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" contextRef="C_20250101to20251231" format="ixt:fixed-true">adopted a statement of trading policies</ix:nonNumeric> that governs the trading in our securities by our directors, officers, employees and certain other covered persons, and which is reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and the Nasdaq Rules. A copy of the Insider Trading Policy is included as Exhibit 11.1 to this Annual Report on Form 20-F. In addition, with regard to any trading in our own securities, it is our policy to comply with the federal securities laws and the applicable exchange listing requirements.</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="line-height:1.25;font-weight:bold"><span id="ITEM16K"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM 16K. CYBERSECURITY</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <ix:nonNumeric id="Fxbrl_20260320004533678" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" contextRef="C_20250101to20251231" escape="true">
      <div>
        <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk management and strategy</span></span></div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have developed and maintain a cybersecurity risk management program that focuses primarily on securing and safeguarding computer systems, networks, cloud services, business applications and data and that is integrated in our overall risk management strategy and framework. We have implemented protocols to protect against cyber threats and ensure the containment and security of sensitive business data, including ongoing security reviews of critical systems, continuous monitoring of event data, and employee training programs, which processes are aligned with our overall business and operational goals and strategies. Our risk assessment occurs on an ongoing basis and covers identification of risks that could act against the company&#8217;s objectives as well as specific risks related to a compromise to the security of data.</span></span></div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20260320004838858" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" contextRef="C_20250101to20251231" format="ixt:fixed-true">We engage a <ix:nonNumeric id="Fxbrl_20260320004918603" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" contextRef="C_20250101to20251231" format="ixt:fixed-true">third party to provide operational support</ix:nonNumeric> for cybersecurity risks. This forms a critical part of our risk management strategy, facilitating effective management and mitigation of risks, and ensuring adherence to applicable regulatory and industry standards.</ix:nonNumeric></span></span></div>
        <div style="text-align:justify;line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20260320005006364" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" contextRef="C_20250101to20251231" escape="true">Overall, we believe that we have established a robust framework for confidentiality, <ix:nonNumeric id="Fxbrl_20260320005027903" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" contextRef="C_20250101to20251231" format="ixt:fixed-true">integrity</ix:nonNumeric>, and availability of information, adhering to relevant security standards, practices, and compliance requirements.</ix:nonNumeric> In addition, we maintain insurance to help protect against risks associated with cybersecurity threats. <ix:nonNumeric id="Fxbrl_20260320005108004" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" contextRef="C_20250101to20251231" escape="true">As of the date of this report, we do not believe that any risks from cybersecurity threats have materially affected, or are reasonably likely to materially affect, us, including our business strategy, results of operations, or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have <ix:nonNumeric id="Fxbrl_20260320005147955" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" contextRef="C_20250101to20251231" format="ixt:fixed-false">not experienced an undetected cybersecurity incident</ix:nonNumeric>.</ix:nonNumeric> For more information about these risks, please see &#8220;Item 3.D. Key Information - Risk Factors - Risks Related to Our Industry - Significant disruptions of our information technology systems or breaches of our data security could adversely affect our business.&#8221; in this Annual Report on Form 20-F.</span></span></div>
      </div>
    </ix:nonNumeric>
    <div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>
    <ix:nonNumeric id="Fxbrl_20260320004541710" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" contextRef="C_20250101to20251231" escape="true">
      <div>
        <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Governance</span></span></div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20260320004637955" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" contextRef="C_20250101to20251231" escape="true">Our audit committee oversees our cybersecurity program and helps guide our strategy for managing cybersecurity risks in the context of our overall risk management system.</ix:nonNumeric>&#160;<ix:nonNumeric id="Fxbrl_20260320004709368" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" contextRef="C_20250101to20251231" escape="true">Our cybersecurity program is managed by <ix:nonNumeric id="Fxbrl_20260320004744690" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" contextRef="C_20250101to20251231" format="ixt:fixed-true">our Chief Financial Officer and our internal IT team, who is responsible for leading enterprise-wide cybersecurity strategy</ix:nonNumeric>, protocols, framework, standards and processes.</ix:nonNumeric> The Chief Financial Officer reports to our board of directors, as well as our Chief Executive Officer and other members of senior management as appropriate.</span></span></div>
      </div>
    </ix:nonNumeric>
    <div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="ITEM17"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM 17. FINANCIAL STATEMENTS</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Registrant has responded to Item 18 in lieu of responding to this Item.</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="ITEM18"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM 18. FINANCIAL STATEMENTS</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">See the financial statements beginning on page F-1. The following financial statements are filed as part of this Annual Report on Form 20-F together with the report of the independent registered public accounting firm.</span></span></div>
    <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">125</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
      </div>
    </div>
    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="ITEM19"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM 19. EXHIBITS</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:7.84%;vertical-align:top;border-bottom:#000000 2px solid">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exhibit</span></span></div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:bottom;border-bottom:#000000 2px solid">
            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exhibit Description</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><a href="exhibit_1-1.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">1.1*</span></span></span></a></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><a href="exhibit_1-1.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Articles of Association, as amended June</span><span style="text-decoration:underline"> 2025</span></span></span></a></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><a href="exhibit_2-2.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">2.2*</span></span></span></a></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><a href="exhibit_2-2.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Description of Securities Registered under Section 12</span></span></span></a></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1201935/000101915517000191/biolinerxdepnrec.htm"><span style="text-decoration:underline">2.3</span><span style="text-decoration:underline">(2)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1201935/000101915517000191/biolinerxdepnrec.htm">Deposit Agreement dated as of July 21, 2011 among the Registrant, The Bank of New York Mellon, as Depositary, and all Owners and Holders from time to time of American Depositary Shares issued thereunder</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1201935/000101915517000191/biolinerxdepnrec.htm"><span style="text-decoration:underline">2.4</span><span style="text-decoration:underline">(2)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1201935/000101915517000191/biolinerxdepnrec.htm">Form of American Depositary Receipt; the Form is Exhibit A of the deposit agreement which is Exhibit 2.2 above.</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891317000871/exhibit_4-5.htm"><span style="text-decoration:underline">4.1</span><span style="text-decoration:underline">(3)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891317000871/exhibit_4-5.htm">Employment Agreement with Philip Serlin, dated May 24, 2009</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/exhibit_4-2.htm"><span style="text-decoration:underline">4.2</span><span style="text-decoration:underline">(1)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/exhibit_4-2.htm">Amendment to Employment Agreement between BioLineRx Ltd. and Philip Serlin, dated September 24, 2020</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891317000871/exhibit_4-43.htm"><span style="text-decoration:underline">4.3</span><span style="text-decoration:underline">(3)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891317000871/exhibit_4-43.htm">Employment Agreement with Mali Zeevi, dated September 16, 2009</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/exhibit_4-4.htm"><span style="text-decoration:underline">4.4</span><span style="text-decoration:underline">(1)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/exhibit_4-4.htm">Amendment to Employment Agreement between BioLineRx Ltd and Mali Zeevi, dated September 24, 2020</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891317000871/exhibit_4-45.htm"><span style="text-decoration:underline">4.5</span><span style="text-decoration:underline">(2)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891317000871/exhibit_4-45.htm">Employment Agreement with Ella Sorani, dated January 11, 2017</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/exhibit_4-8.htm"><span style="text-decoration:underline">4.6</span><span style="text-decoration:underline">(1)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/exhibit_4-8.htm">Amendment to Employment Agreement between BioLineRx Ltd and Ella Sorani, dated September 24, 2020</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-16.htm"><span style="text-decoration:underline">4.7&#8224;</span><span style="text-decoration:underline">(4)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-16.htm">License Agreement entered into as of November 25, 2007 between BioLine Innovations Jerusalem L.P. and Innovative Pharmaceutical Concepts, Inc.</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891316004649/exhibit_4-18.htm"><span style="text-decoration:underline">4.8</span><span style="text-decoration:underline">(5)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891316004649/exhibit_4-18.htm">BioLineRx Ltd. Amended and Restated 2003 Share Incentive Plan</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891316005577/exhibit_4-33.htm"><span style="text-decoration:underline">4.9</span><span style="text-decoration:underline">(6)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891316005577/exhibit_4-33.htm">License Agreement entered into as of September 2, 2012 by and between the Registrant and Biokine Therapeutics Ltd.</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891318002615/exhibit_10-1.htm"><span style="text-decoration:underline">4.10</span><span style="text-decoration:underline">(7)</span><span style="text-decoration:underline">&#8224;</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891318002615/exhibit_10-1.htm">Amendment Agreement entered into as of October 2, 2018 by and between the Registrant and Biokine Therapeutics Ltd.</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891318002615/exhibit_10-4.htm"><span style="text-decoration:underline">4.11</span><span style="text-decoration:underline">(7)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891318002615/exhibit_10-4.htm">Warrant issued to Kreos Capital V dated October 2, 2018</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891320000790/exhibit_4-36.htm"><span style="text-decoration:underline">4.12</span><span style="text-decoration:underline">(8)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891320000790/exhibit_4-36.htm">Compensation Policy for Executives and directors, as amended</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891315000957/exhibit_4-37.htm"><span style="text-decoration:underline">4.13</span><span style="text-decoration:underline">(10)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891315000957/exhibit_4-37.htm">Lease Agreement entered into as of August 7, 2014 between S.M.L. Solomon Industrial Buildings Ltd. and Infrastructure Management and Development Established by C.P.M. Ltd. as Lessor and the Registrant as Lessee, as amended (English summary of the Hebrew original)</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891315002925/exhibit_4-39.htm"><span style="text-decoration:underline">4.14</span><span style="text-decoration:underline">(11)</span><span style="text-decoration:underline">&#8224;</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891315002925/exhibit_4-39.htm">License Agreement entered into as of December 22, 2014 between the Registrant and Wartner Europe BV</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322001134/exhibit_4-20.htm">4.15&#8224;</a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322001134/exhibit_4-20.htm">Amendment No. 2 to Clinical Trial Collaboration and Supply Agreement entered into as of July 24, 2018 between the Registrant and Merck Sharp &amp; Dohme B.V.</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322001134/exhibit_4-24.htm">4.16&#8224;</a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322001134/exhibit_4-24.htm">Amendment No. 1 to License Agreement entered into as of June 18, 2018 between the Registrant and Wartner Europe BV</a></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:7.84%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891320000790/exhibit_4-51.htm"><span style="text-decoration:underline">4.17(</span><span style="text-decoration:underline">9)</span></a></span></span></div>
          </td>
          <td style="width:0.53%;vertical-align:top">&#160;</td>
          <td style="width:91.62%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891320000790/exhibit_4-51.htm">First Addendum to License Agreement entered into as of October 16, 2019 by and between the Registrant and Biokine Therapeutics Ltd., as amended.</a></span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">126</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
      </div>
    </div>
    <div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="text-align:center">
          <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;text-align:left;width:100%;color:rgb(0, 0, 0)">

              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891321002928/exhibit_10-1.htm"><span style="text-decoration-line:underline">4.18</span><span style="text-decoration-line:underline">(14)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891321002928/exhibit_10-1.htm">At-the-Market Sales Agreement, dated September 3, 2021, between BioLineRx Ltd. and H.C. Wainwright &amp; Co., LLC</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003437/exhibit_1.htm"><span style="text-decoration-line:underline">4.19</span><span style="text-decoration-line:underline">(15)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003437/exhibit_1.htm">Agreement for the Provision of a Loan Facility entered into as of September 14, 2022, by and between the Registrant and Kreos Capital VII Aggregator SCSP</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003482/exhibit_10-1.htm"><span style="text-decoration-line:underline">4.20</span><span style="text-decoration-line:underline">(16)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003482/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of September 18, 2022 between the Registrant and the investors listed therein</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003482/exhibit_10-2.htm"><span style="text-decoration-line:underline">4.22</span><span style="text-decoration-line:underline">(16)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003482/exhibit_10-2.htm">Form of Warrant issued by the Registrant on September 21, 2022</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003482/exhibit_10-3.htm"><span style="text-decoration-line:underline">4.23</span><span style="text-decoration-line:underline">16)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003482/exhibit_10-3.htm">Form of Placement Agent Warrant issued by the Registrant on September 21, 2022</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891323003014/exhibit_10-1.htm"><span style="text-decoration-line:underline">4.23</span><span style="text-decoration-line:underline">(18)</span><span style="text-decoration-line:underline">&#8224;</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891323003014/exhibit_10-1.htm">License Agreement dated as of August 27, 2023 between the BioLineRx Ltd., Guangzhou Gloria Biosciences Co., Ltd. and Hong Seng Technology Limited</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891323003014/exhibit_10-2.htm"><span style="text-decoration-line:underline">4.24</span><span style="text-decoration-line:underline">(18)</span><span style="text-decoration-line:underline">&#8224;</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891323003014/exhibit_10-2.htm">Securities Purchase Agreement dated as of August 27, 2023 between the BioLineRx Ltd., Hong Seng Technology Limited and Guangzhou Gloria Biosciences Co., Ltd.</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324001174/exhibit_10-1.htm"><span style="text-decoration-line:underline">4.25</span><span style="text-decoration-line:underline">(20)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324001174/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of March 28, 2024 between BioLineRx Ltd. and the investors listed therein</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324001174/exhibit_10-2.htm"><span style="text-decoration-line:underline">4.26</span><span style="text-decoration-line:underline">(20)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324001174/exhibit_10-2.htm">Form of Warrant issued by BioLineRx Ltd. on April 1, 2024</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-1.htm"><span style="text-decoration-line:underline">4.27</span><span style="text-decoration-line:underline">(21)&#8224;</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-1.htm">Form of License Agreement dated as of November 20, 2024, between BioLineRx Ltd. and Ayrmid Pharma Ltd.</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-2.htm"><span style="text-decoration-line:underline">4.28</span><span style="text-decoration-line:underline">(21)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-2.htm">Form of First Amendment dated as of November 14, 2024, to the Agreement for the Provision of a Loan Facility entered into as of September 14, 2022, by and between BioLineRx Ltd. and Kreos Capital VII Aggregator SCSP</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-3.htm"><span style="text-decoration-line:underline">4.29</span><span style="text-decoration-line:underline">(21)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-3.htm">Form of Securities Purchase Agreement dated as of November 20, 2024, between BioLineRx Ltd. and the Investors signatory thereto</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-4.htm"><span style="text-decoration-line:underline">4.30</span><span style="text-decoration-line:underline">(21)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-4.htm">Form of Pre-Funded Warrant issued by BioLineRx Ltd. on November 21, 2024</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-5.htm"><span style="text-decoration-line:underline">4.31</span><span style="text-decoration-line:underline">(21)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-5.htm">Form of Ordinary Warrant issued by BioLineRx Ltd. on November 21, 2024</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325000047/exhibit_10-1.htm"><span style="text-decoration-line:underline">4.32</span><span style="text-decoration-line:underline">(22)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325000047/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of January 6, 2025, between BioLineRx Ltd. and the investors signatory thereto</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325000047/exhibit_10-2.htm"><span style="text-decoration-line:underline">4.33</span><span style="text-decoration-line:underline">(22)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325000047/exhibit_10-2.htm">Form of Pre-Funded Warrant issued by BioLineRx Ltd. on January 7, 2025</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325000047/exhibit_10-3.htm"><span style="text-decoration-line:underline">4.34</span><span style="text-decoration-line:underline">(22)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325000047/exhibit_10-3.htm">Form of Ordinary Warrant issued by BioLineRx Ltd. on January 7, 2025</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/exhibit_4-40.htm"><span style="text-decoration-line:underline">4.35</span><span style="text-decoration-line:underline">(23)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/exhibit_4-40.htm"><span style="text-decoration-line:underline">Form of Placement Agent Warrant issued by BioLineRx Ltd. on January 7, 2025</span></a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325003403/exhibit_10-1.htm"><span style="text-decoration-line:underline">4.36(24)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325003403/exhibit_10-1.htm">Asset Transfer Agreement, dated as of September 29, 2025, between Hemispherian AS and Tetragon Biosciences Ltd.</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325003403/exhibit_10-2.htm"><span style="text-decoration-line:underline">4.37(24)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325003403/exhibit_10-2.htm">Collaboration and Shareholders Agreement, dated as of September 29, 2025, between BioLineRx Ltd., Tetragon Biosciences Ltd. and Hemispherian AS</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="exhibit_8-1.htm">8.1*</a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="exhibit_8-1.htm">List of Subsidiaries of BioLineRx Ltd.</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/exhibit_11-1.htm"><span style="text-decoration-line:underline">11.1(23)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/exhibit_11-1.htm"><span style="text-decoration-line:underline">Insider Trading Policy</span></a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="exhibit_12-1.htm">12.1*</a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="exhibit_12-1.htm">Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="exhibit_12-2.htm">12.2*</a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="exhibit_12-2.htm">Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width:7.91%;vertical-align:top"><span style="font-size:10pt"><span><a href="exhibit_13-1.htm">13.1*</a></span></span></td>
                <td rowspan="1" style="width:0.53%;vertical-align:top">&#160;</td>
                <td rowspan="1" style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="exhibit_13-1.htm">Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width:7.91%;vertical-align:top"><span style="font-size:10pt"><span><a href="exhibit_13-2.htm">13.2*</a></span></span></td>
                <td rowspan="1" style="width:0.53%;vertical-align:top">&#160;</td>
                <td rowspan="1" style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="exhibit_13-2.htm">Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="exhibit_15-1.htm">15.1</a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="exhibit_15-1.htm">Consent of Kesselman &amp; Kesselman, Certified Public Accountant (Isr.), a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Registrant</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324001075/exhibit_97-1.htm"><span style="text-decoration-line:underline">97.1</span><span style="text-decoration-line:underline">(19)</span></a></span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span><a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891324001075/exhibit_97-1.htm">BioLineRx Ltd. Executive Officer Clawback Policy</a></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:7.91%;vertical-align:top">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span>101</span></span></div>
                </td>
                <td style="width:0.53%;vertical-align:top">&#160;</td>
                <td style="width:91%;vertical-align:top">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span>The following financial information from BioLineRx Ltd.&#8217;s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 formatted in Inline XBRL (Extensible Business Reporting Language): (i) Consolidated Statements of Financial Position at December 31, 2025 and 2024; (ii) Consolidated Statements of Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023; (iii) Statements of Changes in Equity for the years ended December 31, 2025, 2024 and 2023; (iv) Consolidated Cash Flow Statements for the years ended December 31, 2025, 2024 and 2023; and (v) Notes to the Consolidated Financial Statements.</span></span></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Filed herewith.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">127</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
      </div>
      <div style="margin-top:0pt;margin-bottom:0pt">&#160;</div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8224;</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 20-F filed on February 23, 2021.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to Exhibit 1 of the Registration Statement on Form F-6EF (No. 333-218969) filed by the Bank of New York Mellon on June 26, 2017 with respect to the Registrant&#8217;s American Depositary Shares.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 20-F filed on March 23, 2017.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form 20-F (No. 001-35223) filed on July 1, 2011.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 20-F filed on March 10, 2016.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 20-F/A filed on May 31, 2016.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on October 3, 2018.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(8)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on May 23, 2025.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(9)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 20-F filed on March 12, 2020.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(10)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 20-F filed on March 23, 2015.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 20-F/A filed on September 22, 2015.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on February 7, 2019.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(13)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on January 21, 2021.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(14)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on September 3, 2021.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(15)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on September 15, 2022.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(16)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on September 21, 2022.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(17)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 20-F filed on March 16, 2022.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(18)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on August 30, 2023.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 20-F filed on March 26, 2024.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(20)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on April 1, 2024.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(21)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on November 21, 2024.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 20-F filed on March 31, 2025.</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:25pt;vertical-align:top">&#160;</td>
          <td style="width:auto;vertical-align:top">&#160;</td>
        </tr>
        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(23)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on January 7, 2025.</span></span></div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width:25pt;vertical-align:top">&#160;</td>
          <td rowspan="1" style="width:auto;vertical-align:top">&#160;</td>
        </tr>
        <tr>
          <td style="width:25pt;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;(24)</span></span></div>
          </td>
          <td style="width:auto;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Incorporated by reference to the Registrant&#8217;s Form 6-K filed on September 29, 2025.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">128</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="margin:4px 0px;width:100%;border-width:0;height:2px;color:#000000;background-color:#000000;clear:both"/>
      </div>
    </div>
    <div style="text-align:center;line-height:1.25;font-weight:bold"><span id="SIGNATURES"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SIGNATURES</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;color:#000000">

        <tr>
          <td style="width:50%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BIOLINERX LTD.</span></span></div>
          </td>
          <td style="width:21%;vertical-align:top">
            <div style="margin-left:17pt;line-height:1.25">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width:50%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:4%;vertical-align:top">
            <div style="margin-left:17pt;line-height:1.25">&#160;</div>
          </td>
          <td style="width:25%;vertical-align:top">
            <div style="margin-left:17pt;line-height:1.25">&#160;</div>
          </td>
          <td style="width:21%;vertical-align:top">
            <div style="margin-left:17pt;line-height:1.25">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width:50%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:4%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">By:</span></span></div>
          </td>
          <td style="width:25%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/ Philip A. Serlin</span></span></div>
          </td>
          <td style="width:21%;vertical-align:top">
            <div style="margin-left:17pt;line-height:1.25">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width:50%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:4%;vertical-align:top">
            <div style="margin-left:17pt;line-height:1.25">&#160;</div>
          </td>
          <td style="width:25%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Philip A. Serlin</span></span></div>
          </td>
          <td style="width:21%;vertical-align:top">
            <div style="margin-left:17pt;line-height:1.25">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width:50%;vertical-align:top">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:4%;vertical-align:top">
            <div style="margin-left:17pt;line-height:1.25">&#160;</div>
          </td>
          <td style="width:25%;vertical-align:top">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief Executive Officer</span></span></div>
          </td>
          <td style="width:21%;vertical-align:top">
            <div style="margin-left:17pt;line-height:1.25">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date: March 23, 2026</span></span></div>
    <div style="text-align:justify;line-height:1.25">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">129</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
      </div>
    </div>
    <div>&#160;</div>
  </div>

  <div>
    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INDEX TO FINANCIAL STATEMENTS:</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

        <tr>
          <td style="width:93.72%;vertical-align:middle">
            <div style="line-height:1.25">&#160;</div>
          </td>
          <td style="width:6.28%;vertical-align:middle">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:93.72%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ReportofIndependentRegist">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#160;</a></span></span></div>
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(PCAOB name: Kesselman &amp; Kesselman C.P.A.s and PCAOB ID No.&#160;<ix:nonNumeric id="Fxbrl_20230320174828660" name="dei:AuditorFirmId" contextRef="C_20250101to20251231">1309</ix:nonNumeric>)</span></span></span></div>
          </td>
          <td style="width:6.28%;vertical-align:middle">
            <div style="line-height:1.25">&#160;</div>
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-2</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:93.72%;vertical-align:middle">
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED FINANCIAL STATEMENTS:</span></span></div>
          </td>
          <td style="width:6.28%;vertical-align:middle">
            <div style="line-height:1.25">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width:93.72%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#FINANCIALPOSITION">CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</a></span></span></div>
          </td>
          <td style="width:6.28%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-4</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:93.72%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#COMPREHENSIVELOSS">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</a></span></span></div>
          </td>
          <td style="width:6.28%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-5</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:93.72%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CHANGESINEQUITY">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</a></span></span></div>
          </td>
          <td style="width:6.28%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-6</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:93.72%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CASHFLOWS">CONSOLIDATED STATEMENTS OF CASH FLOWS</a></span></span></div>
          </td>
          <td style="width:6.28%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-7</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:93.72%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#NOTES">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</a></span></span></div>
          </td>
          <td style="width:6.28%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-9</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
      </div>
    </div>
    <div style="line-height:1.25"><img src="image0.jpg" alt="image0.jpg" style="width:150px;height:126px"/></div>
    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="ReportofIndependentRegist"><!-- anchor --></span> Report of Independent Registered Public Accounting Firm</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To the Board of Directors and Shareholders of BioLineRx Ltd.</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <ix:nonNumeric id="Fxbrl_20260318131242326" name="dei:AuditorOpinionTextBlock" contextRef="C_20250101to20251231" escape="true">
      <div>
        <div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion on the Financial Statements</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have audited the accompanying consolidated statements of financial position of BioLineRx Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2025, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024 and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Substantial Doubt about the Company&#8217;s Ability to Continue as a Going Concern</span></span></div>
        <div style="text-align:justify;line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1(c) to the consolidated financial statements, the Company has suffered recurring losses from operations and has cash outflows from operating activities that indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&#160;1(c). The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></span></div>
      </div>
    </ix:nonNumeric>
    <div style="line-height:1.25">&#160;</div>
    <div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis for Opinion</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated<span style="font-weight:bold">&#160;</span>financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></span></div>
    <div>
      <div style="line-height:1.25">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 2</span></span></span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
        </div>
      </div>
      <div style="line-height:1.25">&#160;</div>
    </div>
    <div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Critical Audit Matters</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Intellectual Property Impairment Assessment</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As described in Notes 4 and 8 to the consolidated financial statements, the Company's intangible assets relating to its intellectual property associated with BL-8040 used for development services were $10.2 million as of December 31, 2025. Management conducts an annual impairment test, or more frequently if events or circumstances indicate that the carrying value of the intellectual property may be impaired. Potential impairment is identified by comparing the recoverable amount of the intellectual property to its carrying value. Value in use to the Company is estimated by management using a discounted cash flow model. Management's cash flow projections included significant judgments and assumptions relating to the weighted average cost of capital and the amount and timing of projected future cash flows.</span></span></div>
    <div style="line-height:1.25">
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The principal considerations for our determination that performing procedures relating to the intellectual property impairment assessment is a critical audit matter are (i) the significant judgment by management in developing the weighted average cost of capital and the amount and timing of projected future cash flows; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions related to the weighted average cost of capital and the amount and timing of projected future cash flows ; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.</span></span></div>
      <div style="text-align:justify;line-height:1.25">&#160;</div>
    </div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included among others: (i) testing management&#8217;s process for developing the value in use estimate; (ii) evaluating the appropriateness of the discounted cash flow model used by management; (iii) testing the completeness, accuracy, and relevance of underlying data used in the discounted cash flow model; and (iv) evaluating the reasonableness of the significant assumptions used by management, related to the weighted average cost of capital and the amount and timing of projected future cash flows. Evaluating management&#8217;s assumptions related to the weighted average cost of capital and the amount and timing of projected future cash flows involved evaluating whether the assumptions used by management were reasonable considering the consistency with external market and industry data. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the discounted cash flow model and (ii) the reasonableness of the weighted average cost of capital assumption.</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

        <tr>
          <td style="width:100%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/&#160;<ix:nonNumeric id="Fxbrl_20220305175717733" name="dei:AuditorName" contextRef="C_20250101to20251231">Kesselman &amp; Kesselman</ix:nonNumeric></span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:100%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certified Public Accountants (Isr.)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="width:100%;vertical-align:middle">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A member firm of PricewaterhouseCoopers International Ltd.</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25">&#160;</div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220305175738918" name="dei:AuditorLocation" contextRef="C_20250101to20251231">Tel Aviv, Israel</ix:nonNumeric>&#160;</span></span></div>
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March 23, 2026</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have served as the Company's auditor since 2003.</span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 3</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
      </div>
    </div>
  </div>
  <div style="line-height:1.25">&#160;</div>

  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>BioLineRx Ltd.</span></span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION<span id="FINANCIALPOSITION"><!-- anchor --></span></span></span></span></span></div>
  <div style="text-align:center;line-height:1.25">&#160;</div>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

      <tr>
        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2025</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>in USD thousands</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Assets</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CURRENT ASSETS</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cash and cash equivalents</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529288_0" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,436</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529288_1" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,250</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Short-term bank deposits</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529289_2" name="ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,126</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529289_3" name="ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,626</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Trade receivables</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323024550822_20211006114529289_2" name="ifrs-full:TradeReceivables" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323024550822_20211006114529289_3" name="ifrs-full:TradeReceivables" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Prepaid expenses</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529289_4" name="ifrs-full:CurrentPrepaidExpenses" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">443</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529290_5" name="ifrs-full:CurrentPrepaidExpenses" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">201</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other receivables</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20a</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529290_6" name="ifrs-full:OtherCurrentReceivables" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,478</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529290_7" name="ifrs-full:OtherCurrentReceivables" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Inventory</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323024552293_20211006114529289_2" name="ifrs-full:Inventories" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,145</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323024552293_20211006114529289_3" name="ifrs-full:Inventories" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,148</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total current assets</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529290_8" name="ifrs-full:CurrentAssets" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,104</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529291_9" name="ifrs-full:CurrentAssets" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,681</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NON-CURRENT ASSETS</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Property and equipment, net</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529291_10" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">386</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529291_11" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Right-of-use assets, net</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>9</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529291_12" name="ifrs-full:RightofuseAssets" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">967</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529292_13" name="ifrs-full:RightofuseAssets" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">696</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Intangible assets, net</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>8</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529292_14" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,449</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529292_15" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,368</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total non-current assets</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529292_16" name="ifrs-full:NoncurrentAssets" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,802</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529293_17" name="ifrs-full:NoncurrentAssets" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,224</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
          <div style="text-indent:28.35pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total assets</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529293_18" name="ifrs-full:Assets" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,906</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529293_19" name="ifrs-full:Assets" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,905</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Liabilities and equity</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CURRENT LIABILITIES</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Current maturities of long-term loan</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529293_20" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,479</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529294_21" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,479</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accounts payable and accruals:</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20b</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529294_22" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,583</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529294_23" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,493</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160; Other</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20b</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529294_24" name="ifrs-full:OtherCurrentPayables" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,131</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529295_25" name="ifrs-full:OtherCurrentPayables" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,743</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Current maturities of lease liabilities</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>9</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529295_26" name="ifrs-full:CurrentLeaseLiabilities" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529295_27" name="ifrs-full:CurrentLeaseLiabilities" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">234</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Warrants</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>11c</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529298_30" name="blrx:Warrants" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,691</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529299_31" name="blrx:Warrants" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,174</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529295_28" name="ifrs-full:CurrentLiabilities" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,406</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529298_29" name="ifrs-full:CurrentLiabilities" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,123</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NON-CURRENT LIABILITIES</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Long-term loan, net of current maturities</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529299_32" name="ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,958</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529299_33" name="ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,460</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Lease liabilities</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>9</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529299_34" name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,081</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529299_35" name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">977</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total non-current liabilities</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529300_36" name="ifrs-full:NoncurrentLiabilities" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,039</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529300_37" name="ifrs-full:NoncurrentLiabilities" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,437</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>COMMITMENTS AND CONTINGENT LIABILITIES</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20260317100008074_20211006114529300_38">&#160;&#160; </span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20260317100008074_20211006114529300_39">&#160;&#160; </span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
          <div style="text-indent:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total liabilities</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529300_38" name="ifrs-full:Liabilities" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,445</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529300_39" name="ifrs-full:Liabilities" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,560</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>EQUITY</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>11</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Equity attributable to owners of the Company:</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="text-indent:0pt;margin-left:15.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ordinary shares</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529300_40" name="ifrs-full:IssuedCapital" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,097</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529301_41" name="ifrs-full:IssuedCapital" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,428</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:0pt;margin-left:15.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share premium</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529301_42" name="ifrs-full:SharePremium" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353,693</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529301_43" name="ifrs-full:SharePremium" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">327,584</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="text-indent:0pt;margin-left:15.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Warrants</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304191450099" name="ifrs-full:WarrantReserve" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,367</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304191435587" name="ifrs-full:WarrantReserve" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,686</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:0pt;margin-left:15.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Capital reserve</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529301_44" name="ifrs-full:CapitalReserve" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,547</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529301_45" name="ifrs-full:CapitalReserve" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,916</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="text-indent:0pt;margin-left:15.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other comprehensive loss</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529302_46" name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,416</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529302_47" name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,416</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accumulated deficit</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20260318095808764_20211006114529302_46" name="ifrs-full:RetainedEarnings" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">399,827</ix:nonFraction></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20260318095808764_20211006114529302_47" name="ifrs-full:RetainedEarnings" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">401,002</ix:nonFraction></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="text-indent:12.55pt;margin-left:15.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total equity attributable to owners of the Company</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317095223548_20211006114529301_44" name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,461</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317095223548_20211006114529301_45" name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,196</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Non-controlling interest</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317095225412_20211006114529301_44" name="ifrs-full:NoncontrollingInterests" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317095225412_20211006114529301_45" name="ifrs-full:NoncontrollingInterests" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,149</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
          <div style="text-indent:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total equity</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529302_50" name="ifrs-full:Equity" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,461</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529303_51" name="ifrs-full:Equity" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,345</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:28.35pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total liabilities and equity</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529303_52" name="ifrs-full:EquityAndLiabilities" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,906</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529303_53" name="ifrs-full:EquityAndLiabilities" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,905</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>

  </table>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The accompanying notes are an integral part of the consolidated financial statements.</span></span></span></span></div>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:3pt;margin-top:10pt">F - 4</p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:20pt"/></div>

  <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>BioLineRx Ltd.</span></span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS<span id="COMPREHENSIVELOSS"><!-- anchor --></span></span></span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

      <tr>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Year ended December 31,</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2025</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>in USD thousands</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:top;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>REVENUES:</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
          <div style="text-indent:0pt;margin-left:13.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>License revenues</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>15, 16</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326131233828_xbrl_20240323025118703_20211006114529312_0" name="ifrs-full:LicenceFeeIncome" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,610</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326131233828_xbrl_20240323025118703_20211006114529313_1" name="ifrs-full:LicenceFeeIncome" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,917</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326131233828_xbrl_20240323025118703_20211006114529313_2" name="ifrs-full:LicenceFeeIncome" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,180</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:0pt;margin-left:13.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Product sales, net</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326131239004_xbrl_20240323025118703_20211006114529312_0" name="ifrs-full:RevenueFromSaleOfGoods" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326131239004_xbrl_20240323025118703_20211006114529313_1" name="ifrs-full:RevenueFromSaleOfGoods" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,023</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326131239004_xbrl_20240323025118703_20211006114529313_2" name="ifrs-full:RevenueFromSaleOfGoods" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;vertical-align:bottom">
          <div style="text-indent:14.85pt;margin-left:13.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total revenues</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323025118703_20211006114529312_0" name="ifrs-full:Revenue" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,800</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323025118703_20211006114529313_1" name="ifrs-full:Revenue" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,940</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323025118703_20211006114529313_2" name="ifrs-full:Revenue" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,180</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>COST OF REVENUES</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20c</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240323025120164_20211006114529312_0" name="ifrs-full:CostOfSales" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,692</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240323025120164_20211006114529313_1" name="ifrs-full:CostOfSales" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,263</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240323025120164_20211006114529313_2" name="ifrs-full:CostOfSales" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>GROSS PROFIT</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323025122020_20211006114529312_0" name="ifrs-full:GrossProfit" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,108</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323025122020_20211006114529313_1" name="ifrs-full:GrossProfit" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,677</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323025122020_20211006114529313_2" name="ifrs-full:GrossProfit" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">950</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>RESEARCH AND DEVELOPMENT EXPENSES</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20d</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529312_0" name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,519</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529313_1" name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,149</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529313_2" name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,093</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>SALES AND MARKETING EXPENSES</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20e</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529313_3" name="ifrs-full:SalesAndMarketingExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,270</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529313_4" name="ifrs-full:SalesAndMarketingExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,605</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529314_5" name="ifrs-full:SalesAndMarketingExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>GENERAL AND ADMINISTRATIVE EXPENSES</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20f</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529314_6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,310</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529314_7" name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,321</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529314_8" name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,144</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;padding-bottom:2px;vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>IMPAIRMENT OF INTANGIBLE ASSETS</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>8</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240323025125341_20211006114529312_0" name="blrx:ImpairmentLossOnIntangibleAssets" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,703</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240323025125341_20211006114529313_1" name="blrx:ImpairmentLossOnIntangibleAssets" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,010</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326130853146" name="blrx:ImpairmentLossOnIntangibleAssets" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>OPERATING LOSS</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529314_9" name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">49,694</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529315_10" name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20,408</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529315_11" name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,287</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NON-OPERATING INCOME (EXPENSES), NET</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20g</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311024658817" name="blrx:ProfitLossFromNonOperatingActivities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,819</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305101734013" name="blrx:ProfitLossFromNonOperatingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,435</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529316_14" name="blrx:ProfitLossFromNonOperatingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,077</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>FINANCIAL INCOME</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20h</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529316_15" name="ifrs-full:FinanceIncome" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,068</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529316_16" name="ifrs-full:FinanceIncome" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,871</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006114529316_17" name="ifrs-full:FinanceIncome" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,464</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;padding-bottom:2px;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>FINANCIAL EXPENSES</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20i</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529317_18" name="ifrs-full:FinanceCosts" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,169</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529317_19" name="ifrs-full:FinanceCosts" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,119</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529317_20" name="ifrs-full:FinanceCosts" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,280</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>LOSS AND COMPREHENSIVE LOSS</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529317_21" name="ifrs-full:ProfitLoss" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">60,614</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529317_22" name="ifrs-full:ProfitLoss" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,221</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006114529318_23" name="ifrs-full:ProfitLoss" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,026</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-14.4pt;margin-left:14.4pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ATTRIBUTION OF LOSS AND COMPREHENSIVE LOSS</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;vertical-align:bottom">
          <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>To owners of the Company</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260317100805907_20211006114529319_27" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">60,614</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260317100805907_20211006114529319_28" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,221</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260317100805907_20211006114529319_29" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,175</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>To non-controlling interests</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260317100808373_20211006114529319_27" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317100808373_20211006114529319_28" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260317100808373_20211006114529319_29" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">851</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260317100810085_20211006114529319_27" name="ifrs-full:ComprehensiveIncome" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">60,614</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260317100810085_20211006114529319_28" name="ifrs-full:ComprehensiveIncome" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,221</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260317100810085_20211006114529319_29" name="ifrs-full:ComprehensiveIncome" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,026</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="10" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>in USD</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>LOSS PER ORDINARY SHARE &#8211; BASIC AND DILUTED ATTRIBUTABLE</span></span></span></span></div>
          <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160; TO OWNERS OF THE COMPANY</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>13</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311025713314" name="ifrs-full:DilutedEarningsLossPerShare" contextRef="C_20230101to20231231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="F20211006114529318_24" name="ifrs-full:BasicEarningsLossPerShare" contextRef="C_20230101to20231231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.06</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311025731625" name="ifrs-full:DilutedEarningsLossPerShare" contextRef="C_20240101to20241231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="F20211006114529318_25" name="ifrs-full:BasicEarningsLossPerShare" contextRef="C_20240101to20241231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.01</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311025751753" name="ifrs-full:DilutedEarningsLossPerShare" contextRef="C_20250101to20251231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="F20211006114529318_26" name="ifrs-full:BasicEarningsLossPerShare" contextRef="C_20250101to20251231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.00</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION</span></span></span></span></div>
          <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160; OF BASIC AND DILUTED LOSS PER ORDINARY SHARE</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>13</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_s_20260317225120371" name="ifrs-full:AdjustedWeightedAverageShares" contextRef="C_20230101to20231231" unitRef="Shares" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20260317225120371" name="ifrs-full:WeightedAverageShares" contextRef="C_20230101to20231231" unitRef="Shares" scale="0" decimals="0" format="ixt:num-dot-decimal">963,365,525</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_s_20260317225107745" name="ifrs-full:AdjustedWeightedAverageShares" contextRef="C_20240101to20241231" unitRef="Shares" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20260317225107745" name="ifrs-full:WeightedAverageShares" contextRef="C_20240101to20241231" unitRef="Shares" scale="0" decimals="0" format="ixt:num-dot-decimal">1,198,107,761</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317105456167" name="ifrs-full:AdjustedWeightedAverageShares" contextRef="C_20250101to20251231" unitRef="Shares" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F20211006114529319_29" name="ifrs-full:WeightedAverageShares" contextRef="C_20250101to20251231" unitRef="Shares" scale="0" decimals="0" format="ixt:num-dot-decimal">2,465,272,604</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>

  </table>
  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The accompanying notes are an integral part of the consolidated financial statements.</span></span></span></span></div>
  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt">&#160;</div>
  <div style="margin-top:0pt;margin-bottom:0pt">
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:3pt;margin-top:10pt">F - 5</p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:20pt"/></div>
    </div>
  </div>

  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">STATEMENTS OF CHANGES IN EQUITY<span id="CHANGESINEQUITY"><!-- anchor --></span></span></span></div>
  <div style="text-align:center;line-height:1.25">&#160;</div>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

      <tr>
        <td style="vertical-align:top;font-size:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="26" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Equity attributable to owners of the Company</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;font-size:9pt;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;font-size:9pt;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;padding:0px 0px 2px;font-size:9pt">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
        <td colspan="6" style="border-bottom:2px solid;vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25">&#160;</div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ordinary shares</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
        <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share premium</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
        <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25">&#160;</div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Warrants</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
        <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Capital reserve</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
        <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other comprehensive<br/>loss</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
        <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accumulated deficit</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
        <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Non-controlling interest</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;padding-bottom:2px">&#160;</td>
        <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;font-size:9pt">
          <div style="line-height:1.25">
            <div style="line-height:1.25">&#160;</div>
            <div style="line-height:1.25">&#160;</div>
          </div>
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;font-size:9pt">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;font-size:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>in shares 000&#8217;s</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="30" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>in USD thousands</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>BALANCE AT JANUARY 1, 2023</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163203969" name="ifrs-full:NumberOfSharesOutstanding" contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">922,959</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200509259_20211006114529369_101" name="ifrs-full:Equity" contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,100</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200509259_20211006114529370_102" name="ifrs-full:Equity" contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">338,976</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304220723367" name="ifrs-full:Equity" contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,408</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200509259_20211006114529370_103" name="ifrs-full:Equity" contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,765</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220304200509259_20211006114529370_104" name="ifrs-full:Equity" contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,416</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220304200509259_20211006114529371_105" name="ifrs-full:Equity" contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">329,992</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172635551" name="ifrs-full:Equity" contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200509259_20211006114529371_106" name="ifrs-full:Equity" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,841</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CHANGES IN 2023:</span></span></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Issuance of share capital, net</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163510089" name="blrx:NumberOfNewSharesIssued" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,955</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529345_30" name="blrx:IssuanceOfShareCapital" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,242</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529345_31" name="blrx:IssuanceOfShareCapital" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,847</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304221454554" name="blrx:IssuanceOfShareCapital" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_32" name="blrx:IssuanceOfShareCapital" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_33" name="blrx:IssuanceOfShareCapital" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_34" name="blrx:IssuanceOfShareCapital" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172957489_xbrl_20260317172721088" name="blrx:IssuanceOfShareCapital" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529347_35" name="blrx:IssuanceOfShareCapital" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,089</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Warrants exercised</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163616374" name="blrx:IncreaseDecreaseThroughExerciseOfWarrantsShares" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,182</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529360_66" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529360_67" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,559</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172941629_xbrl_20220304221447611" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529361_68" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529361_69" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529361_70" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172941629_xbrl_20260317172727206" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529362_71" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,559</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Employee stock options exercised</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163627526" name="blrx:IncreaseDecreaseThroughExerciseOfOptionsShares" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">493</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200109668_20211006114529347_36" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200109668_20211006114529347_37" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304221441483" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220304200109668_20211006114529348_38" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">31</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200109668_20211006114529348_39" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200109668_20211006114529348_40" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172645381" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200109668_20211006114529349_41" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Employee stock options expired</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304194813627_20211006114529349_42" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304194813627_20211006114529349_43" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304221435852" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220304194813627_20211006114529350_44" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">55</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304194813627_20211006114529350_45" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304194813627_20211006114529350_46" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172652286" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304194813627_20211006114529350_47" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Share-based compensation</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304194756139_20211006114529351_48" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304194756139_20211006114529351_49" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304221424059" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304194756139_20211006114529351_50" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,321</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304194756139_20211006114529352_51" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304194756139_20211006114529352_52" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172657609" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304194756139_20211006114529352_53" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,321</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Comprehensive loss for the year</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220304194732539_20211006114529353_54" name="ifrs-full:ComprehensiveIncome" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220304194732539_20211006114529353_55" name="ifrs-full:ComprehensiveIncome" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220304221417995" name="ifrs-full:ComprehensiveIncome" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260317172604341" name="ifrs-full:ComprehensiveIncome" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220304194732539_20211006114529354_57" name="ifrs-full:ComprehensiveIncome" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220304194732539_20211006114529357_58" name="ifrs-full:ComprehensiveIncome" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">60,614</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260317172703408" name="ifrs-full:ComprehensiveIncome" contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220304194732539_20211006114529358_59" name="ifrs-full:ComprehensiveIncome" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">60,614</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:10%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>BALANCE AT DECEMBER 31, 2023</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163221672" name="ifrs-full:NumberOfSharesOutstanding" contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,086,589</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529371_107" name="ifrs-full:Equity" contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,355</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529372_108" name="ifrs-full:Equity" contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355,482</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031621434_xbrl_20220304220738543" name="ifrs-full:Equity" contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,408</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529372_109" name="ifrs-full:Equity" contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,000</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529372_110" name="ifrs-full:Equity" contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,416</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529373_111" name="ifrs-full:Equity" contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">390,606</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172712944" name="ifrs-full:Equity" contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529373_112" name="ifrs-full:Equity" contextRef="C_20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,223</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:10%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CHANGES IN 2024:</span></span></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-15.85pt;margin-left:15.85pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Issuance of share capital, pre-funded warrants and warrants, net</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163643048" name="blrx:NumberOfNewSharesIssued" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,322</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529345_30" name="ifrs-full:IssueOfEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,712</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529345_31" name="ifrs-full:IssueOfEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,060</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230311031510191_xbrl_20220304221454554" name="ifrs-full:IssueOfEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,650</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_32" name="ifrs-full:IssueOfEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_33" name="ifrs-full:IssueOfEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_34" name="ifrs-full:IssueOfEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260317172721088" name="ifrs-full:IssueOfEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529347_35" name="ifrs-full:IssueOfEquity" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,302</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Pre-funded warrants exercised</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163929824" name="blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,989</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200135612_20211006114529360_66" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,009</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200135612_20211006114529360_67" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220304221447611" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,691</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200135612_20211006114529361_68" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200135612_20211006114529361_69" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200135612_20211006114529361_70" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172727206" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304200135612_20211006114529362_71" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Employee stock options exercised</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163907944" name="blrx:IncreaseDecreaseThroughExerciseOfOptionsShares" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">770</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529347_36" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529347_37" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031521651_xbrl_20220304221441483" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529348_38" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">49</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529348_39" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529348_40" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172732879" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529349_41" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Employee stock options expired</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529349_42" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529349_43" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">539</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031541626_xbrl_20220304221435852" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529350_44" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">539</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529350_45" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529350_46" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172739750" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529350_47" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Share-based compensation</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529351_48" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529351_49" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031554946_xbrl_20220304221424059" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529351_50" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,135</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529352_51" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529352_52" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172754079" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529352_53" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,135</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;padding-bottom:2px;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Comprehensive loss for the year</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_54" name="ifrs-full:ComprehensiveIncome" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_55" name="ifrs-full:ComprehensiveIncome" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304221417995" name="ifrs-full:ComprehensiveIncome" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250326133054396_xbrl_20240323031148809" name="ifrs-full:ComprehensiveIncome" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529354_57" name="ifrs-full:ComprehensiveIncome" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529357_58" name="ifrs-full:ComprehensiveIncome" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,221</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260317172800990" name="ifrs-full:ComprehensiveIncome" contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529358_59" name="ifrs-full:ComprehensiveIncome" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,221</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>BALANCE AT DECEMBER 31, 2024</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163232247" name="ifrs-full:NumberOfSharesOutstanding" contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,336,670</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529371_107" name="ifrs-full:Equity" contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,097</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_108" name="ifrs-full:Equity" contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353,693</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031623889_xbrl_20220304220738543" name="ifrs-full:Equity" contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,367</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_109" name="ifrs-full:Equity" contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,547</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_110" name="ifrs-full:Equity" contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,416</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529373_111" name="ifrs-full:Equity" contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">399,827</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172816562" name="ifrs-full:Equity" contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529373_112" name="ifrs-full:Equity" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,461</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CHANGES IN 2025:</span></span></span></span></div>
        </td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="font-size:9pt;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;vertical-align:bottom">
          <div style="text-indent:-14.2pt;margin-left:15.85pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Issuance of share capital, pre-funded warrants and warrants, net</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163650647" name="blrx:NumberOfNewSharesIssued" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">978,340</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529345_30" name="ifrs-full:IssueOfEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,273</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529345_31" name="ifrs-full:IssueOfEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">22,260</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031504698_xbrl_20220304221454554" name="ifrs-full:IssueOfEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">501</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529346_32" name="ifrs-full:IssueOfEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529346_33" name="ifrs-full:IssueOfEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529346_34" name="ifrs-full:IssueOfEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172822424" name="ifrs-full:IssueOfEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529347_35" name="ifrs-full:IssueOfEquity" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,514</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="margin-left:5.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Pre-funded warrants exercised</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163953798" name="blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,804</ix:nonFraction></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_54" name="blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,058</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_55" name="blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,876</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304221417995" name="blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,182</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326133041525_xbrl_20240323031148809" name="blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529354_57" name="blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529357_58" name="blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172827962" name="blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529358_59" name="blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Employee stock options expired</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529349_42" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529349_43" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,027</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031545210_xbrl_20220304221435852" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529350_44" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,027</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529350_45" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529350_46" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172834685" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529350_47" name="blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Share-based compensation</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_48" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_49" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031558522_xbrl_20220304221424059" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_50" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_51" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_52" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317172841456" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_53" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Non-controlling interest</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_48" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_49" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304221424059" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_50" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_51" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_52" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317174334351_xbrl_20260317172841456" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_53" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:10%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;Comprehensive loss for the year</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_54" name="ifrs-full:ComprehensiveIncome" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_55" name="ifrs-full:ComprehensiveIncome" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230311031610458_xbrl_20220304221417995" name="ifrs-full:ComprehensiveIncome" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240323031148809" name="ifrs-full:ComprehensiveIncome" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230311031610458_xbrl_20220304194732539_20211006114529354_57" name="ifrs-full:ComprehensiveIncome" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311031610458_xbrl_20220304194732539_20211006114529357_58" name="ifrs-full:ComprehensiveIncome" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,175</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260317172846676" name="ifrs-full:ComprehensiveIncome" contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">851</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230311031610458_xbrl_20220304194732539_20211006114529358_59" name="ifrs-full:ComprehensiveIncome" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,026</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:10%;padding-bottom:4px;vertical-align:bottom">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:9pt;font-weight:bold"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>BALANCE AT DECEMBER 31, 2025</span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260319163250639" name="ifrs-full:NumberOfSharesOutstanding" contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,610,814</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529371_107" name="ifrs-full:Equity" contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,428</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_108" name="ifrs-full:Equity" contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">327,584</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304220738543" name="ifrs-full:Equity" contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,686</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_109" name="ifrs-full:Equity" contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,916</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_110" name="ifrs-full:Equity" contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,416</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529373_111" name="ifrs-full:Equity" contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">401,002</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260317172851782" name="ifrs-full:Equity" contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,149</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:7%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25;font-size:9pt">
            <div style="line-height:1.25"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:1.25"></span></span></span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:9pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529373_112" name="ifrs-full:Equity" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,345</ix:nonFraction></span></span></span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>

  </table>
  <div style="text-align:center;line-height:1.25">&#160;</div>
  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
  <div style="margin-top:0pt;margin-bottom:0pt">
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:3pt;margin-top:10pt">F - 6</p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:20pt"/></div>
  </div>

  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED STATEMENTS OF CASH FLOWS&#160;<span id="CASHFLOWS"><!-- anchor --></span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

      <tr>
        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH FLOWS - OPERATING ACTIVITIES</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555428_85" name="ifrs-full:ProfitLoss" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">60,614</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555428_84" name="ifrs-full:ProfitLoss" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,221</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555427_83" name="ifrs-full:ProfitLoss" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,026</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-16.4pt;margin-left:30.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments required to reflect net cash used in operating activities (see appendix below)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555389_0" name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,006</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555420_59" name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,652</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555440_112" name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,048</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
          <div style="text-indent:-14.15pt;margin-left:44.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash used in operating activities</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555390_1" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">22,608</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555391_2" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">43,873</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555391_3" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">8,074</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH FLOWS - INVESTING ACTIVITIES</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-30.6pt;margin-left:30.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;Investments in short-term deposits</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555392_4" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">47,588</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555392_5" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">26,350</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555393_6" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,644</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;Maturities of short-term deposits</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555393_7" name="blrx:MaturitiesOfShortTermDeposits" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">49,329</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555393_8" name="blrx:MaturitiesOfShortTermDeposits" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">55,778</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555394_9" name="blrx:MaturitiesOfShortTermDeposits" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,126</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555427_82" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555428_86" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555427_81" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
          <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of intangible assets</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555395_10" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555395_11" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555429_87" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-14.15pt;margin-left:44.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by (used in) investing activities</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555421_67" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,444</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555429_88" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,374</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555421_66" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">8,545</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH FLOWS - FINANCING ACTIVITIES</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="text-indent:-16.4pt;margin-left:30.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of share capital, pre-funded warrants and warrants, net of issuance costs</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555396_12" name="ifrs-full:ProceedsFromIssuingShares" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,089</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555396_13" name="ifrs-full:ProceedsFromIssuingShares" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,357</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555397_14" name="ifrs-full:ProceedsFromIssuingShares" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,894</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;Exercise of warrants</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305015204602_20230320171555396_12" name="ifrs-full:ProceedsFromExerciseOfWarrants" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,928</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305015204602_20230320171555396_13" name="ifrs-full:ProceedsFromExerciseOfWarrants" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305015204602_20230320171555397_14" name="ifrs-full:ProceedsFromExerciseOfWarrants" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="text-indent:-30.6pt;margin-left:30.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;Employee stock options exercised</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305015152596_20230320171555396_12" name="ifrs-full:ProceedsFromExerciseOfOptions" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305015152596_20230320171555396_13" name="ifrs-full:ProceedsFromExerciseOfOptions" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305015152596_20230320171555397_14" name="ifrs-full:ProceedsFromExerciseOfOptions" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-17.9pt;margin-left:30.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from long-term loan, net of issuance costs</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311040859398_xbrl_20220305015152596_20230320171555396_12" name="ifrs-full:ProceedsFromIssuingOtherEquityInstruments" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311040859398_xbrl_20220305015152596_20230320171555396_13" name="ifrs-full:ProceedsFromIssuingOtherEquityInstruments" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,223</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230311040859398_xbrl_20220305015152596_20230320171555397_14" name="ifrs-full:ProceedsFromIssuingOtherEquityInstruments" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="text-indent:-30.6pt;margin-left:30.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;Repayments of loan</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555397_15" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,543</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555397_16" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,433</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555398_17" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,498</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-30.6pt;margin-left:30.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;Repayments of lease liabilities</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555422_68" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">445</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555398_18" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">511</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555399_19" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">512</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
          <div style="text-indent:-14.15pt;margin-left:44.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by financing activities</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555399_20" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,056</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555400_21" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,658</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555400_22" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,884</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
          <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">INCREASE </span>(<span style="font-weight:bold">DECREASE)</span><span style="font-weight:bold">&#160;IN CASH AND CASH EQUIVALENTS</span></span></span></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555401_23" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,108</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555430_89" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,159</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555422_69" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,735</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555401_24" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,587</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555402_25" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,255</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555402_26" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,436</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
          <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555403_27" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">224</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555403_28" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555432_90" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">549</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH AND CASH EQUIVALENTS - END OF YEAR</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555403_29" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,255</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555404_30" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,436</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555404_31" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,250</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>

  </table>
  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
  <div style="line-height:1.25">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:3pt;margin-top:10pt">F - 7</p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:20pt"/></div>
  </div>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

      <tr>
        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:8.6pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:8.6pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:8.6pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:8.6pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
          <div style="line-height:1.25">
            <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:8.6pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">APPENDIX</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments required to reflect net cash used in operating activities:</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:22.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income and expenses not involving cash flows:</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation and amortization</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555405_32" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,384</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555405_33" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,065</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555406_34" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">523</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss on disposal of property and equipment</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317110115810_20230320171555405_32" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317110115810_20230320171555405_33" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317110115810_20230320171555406_34" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">25</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange differences on cash and cash equivalents</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555423_72" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555423_71" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">22</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555423_70" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">549</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value adjustments of warrants</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555406_35" name="ifrs-full:AdjustmentsForFairValueGainsLosses" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,054</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555406_36" name="ifrs-full:AdjustmentsForFairValueGainsLosses" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,965</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555438_106" name="ifrs-full:AdjustmentsForFairValueGainsLosses" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">8,599</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555407_37" name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,321</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555407_38" name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,135</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555408_39" name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest and exchange differences on short-term deposits</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555408_40" name="blrx:InterestAndExchangeDifferencesOnShortTermDeposits" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555409_41" name="blrx:InterestAndExchangeDifferencesOnShortTermDeposits" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555412_42" name="blrx:InterestAndExchangeDifferencesOnShortTermDeposits" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest on loan</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555413_43" name="blrx:InterestAndLinkageDifferencesOnBankLoan" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,148</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555413_44" name="blrx:InterestAndLinkageDifferencesOnBankLoan" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,126</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555414_45" name="blrx:InterestAndLinkageDifferencesOnBankLoan" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrant issuance costs</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555414_46" name="blrx:InterestAndExchangeDifferencesOnRestrictedDeposits" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555414_47" name="blrx:InterestAndExchangeDifferencesOnRestrictedDeposits" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">669</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555415_48" name="blrx:InterestAndExchangeDifferencesOnRestrictedDeposits" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">702</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange differences on lease liabilities</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555415_49" name="blrx:ExchangeDifferencesOnLeaseLiability" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">42</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555416_50" name="blrx:ExchangeDifferencesOnLeaseLiability" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">31</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555438_107" name="blrx:ExchangeDifferencesOnLeaseLiability" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">177</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Intangible assets impairment</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323031911019_20230320171555415_49" name="ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,703</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323031911019_20230320171555416_50" name="ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,010</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323031911019_20230320171555438_107" name="ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss on abandonment of right-of-use asset</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326142825154_20230320171555415_49" name="blrx:LossOnAbandonmentOfRightofuseAsset" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326142825154_20230320171555416_50" name="blrx:LossOnAbandonmentOfRightofuseAsset" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326142825154_20230320171555438_107" name="blrx:LossOnAbandonmentOfRightofuseAsset" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555426_80" name="blrx:TotalIncomeAndExpenseNotInvolvingCashFlows" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,807</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555424_73" name="blrx:TotalIncomeAndExpenseNotInvolvingCashFlows" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,834</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555439_108" name="blrx:TotalIncomeAndExpenseNotInvolvingCashFlows" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,307</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:22.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in operating asset and liability items:</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in trade receivables</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240323031913211_20230320171555415_49" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">358</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240323031913211_20230320171555416_50" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,118</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323031913211_20230320171555438_107" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,430</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in inventory</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240323031916787_20230320171555415_49" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,953</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240323031916787_20230320171555416_50" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,192</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323031916787_20230320171555438_107" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">997</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in prepaid expenses and other receivables</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555416_51" name="blrx:AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">959</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555417_52" name="blrx:AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555440_111" name="blrx:AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,310</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;vertical-align:bottom">
          <div style="text-indent:-9pt;margin-left:31.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in accounts payable and accruals</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555439_109" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,512</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555425_75" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,508</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555424_74" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,478</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:22.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in contract liabilities</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323031920060_20230320171555415_49" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,957</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240323031920060_20230320171555416_50" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,957</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323031920060_20230320171555438_107" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555439_110" name="blrx:TotalChangeInOperatingAssetAndLiability" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,199</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555425_77" name="blrx:TotalChangeInOperatingAssetAndLiability" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,818</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555425_76" name="blrx:TotalChangeInOperatingAssetAndLiability" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,259</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555426_79" name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,006</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220305021341935_20230320171555425_77" name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,652</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555441_113" name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,048</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
      </tr>

  </table>
  <div style="line-height:1.25">&#160;</div>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

      <tr>
        <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Supplemental information on interest received in cash</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555417_53" name="blrx:SupplementaryInformationOnInterestReceivedInCash" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,020</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555417_54" name="blrx:SupplementaryInformationOnInterestReceivedInCash" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,992</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555418_55" name="blrx:SupplementaryInformationOnInterestReceivedInCash" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,153</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Supplemental information on interest paid in cash</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240323031939880" name="blrx:SupplementalInformationOnInterestPaidInCash" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,111</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555419_57" name="blrx:SupplementalInformationOnInterestPaidInCash" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,387</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555419_58" name="blrx:SupplementalInformationOnInterestPaidInCash" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,268</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td rowspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>

  </table>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

      <tr>
        <td style="vertical-align:top;vertical-align:bottom">
          <div style="text-indent:-13.5pt;margin-left:13.5pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Supplemental information on non-cash transactions:</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="margin-left:22.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in right-of-use asset and lease liabilities</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555434_96" name="blrx:SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555434_95" name="blrx:SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">327</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20230320171555434_94" name="blrx:SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">57</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
          <div style="line-height:1.25">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
          <div style="margin-left:22.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value of exercised warrants (portion related to accumulated fair value adjustments)</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555437_105" name="blrx:SupplementaryInformationOnFairValueOfExercisedWarrants" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,631</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555437_104" name="blrx:SupplementaryInformationOnFairValueOfExercisedWarrants" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230320171555437_103" name="blrx:SupplementaryInformationOnFairValueOfExercisedWarrants" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="margin-left:22.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Intangible asset acquired in connection with GLIX1 collaboration transaction</span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317110118755_20230320171555405_32" name="blrx:SupplementaryInformationOnIntangibleAssetAcquired" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317110118755_20230320171555405_33" name="blrx:SupplementaryInformationOnIntangibleAssetAcquired" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317110118755_20230320171555406_34" name="blrx:SupplementaryInformationOnIntangibleAssetAcquired" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></span></div>
        </td>
        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
      </tr>

  </table>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
  <div>
    <div style="line-height:1.25">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:3pt;margin-top:10pt">F - 8</p><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:20pt"/></div>
    </div>
  </div>

  <div>
    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></div>
    <div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="NOTES"><!-- anchor --></span>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>
    <div style="text-align:center;line-height:1.25">&#160;</div>
  </div>
  <ix:nonNumeric id="Fxbrl_20250327032729591" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" contextRef="C_20250101to20251231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1 &#8211; GENERAL INFORMATION</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="vertical-align:top;width:24pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd. (&#8220;BioLineRx&#8221;), headquartered in Modi&#8217;in, Israel, was incorporated and commenced operations in April 2003. BioLineRx and its subsidiaries (collectively, the &#8220;Company&#8221;) are engaged in the development (primarily in clinical stages) and commercialization of therapeutics, with a focus on the fields of oncology and hematology.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) are traded on the NASDAQ Capital Market, and its ordinary shares are traded on the Tel Aviv Stock Exchange. <ix:nonNumeric id="Fxbrl_20260317182607060" name="blrx:DepositaryShareConversionDescription" contextRef="C_20250101to20251231">Each ADS represents 600 ordinary shares</ix:nonNumeric>.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has one wholly owned subsidiary, BioLineRx USA, Inc., incorporated in the U.S., which had been engaged in commercialization activities associated with the launch of motixafortide for stem-cell mobilization in the U.S., and which is now substantially inactive since the end of 2024 (see below). In addition, the Company is the controlling shareholder of Tetragon Biosciences Ltd. (&#8220;Tetragon&#8221;), a company incorporated in Israel in September 2025 for the development and commercialization of GLIX1, a clinical-stage, first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers (see below and Note 17).</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company began to independently commercialize motixafortide in the U.S.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, the Company out-licensed the rights to motixafortide for all indications in substantially all of Asia, and in November 2024, the Company out-licensed the global rights (other than in Asia) to motixafortide for all indications, other than solid tumors. In connection with the November 2024 transaction, the Company shut down its independent commercialization activities in the U.S., and entered into an agreement to repay a substantial portion of its outstanding debt, as well as restructure the remaining debt balance. Following these actions, the Company refocused its operations on development activities in Israel in the fields of oncology (including solid tumors) and rare diseases, at a significantly reduced annual cash burn rate.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"><ix:exclude>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 9</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 1 &#8211; GENERAL INFORMATION</span><span> (cont.)</span></span></span></div>
        <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="vertical-align:top;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
            <td style="vertical-align:top;text-align:justify;width:auto">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">War in Israel</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 7, 2023, an unprecedented invasion was launched against Israel from the Gaza Strip by terrorists from the Hamas terrorist organization that infiltrated Israel&#8217;s southern border and other areas within the country, attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli civilian population. These attacks resulted in extensive deaths, injuries and the kidnapping of civilians and soldiers. In response, the Security Cabinet of the State of Israel declared war against Hamas, with commencement of a military campaign against the terrorist organization, in parallel to its continued rocket and terror attacks. Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement controlling parts of Yemen, and with Iran. It is also possible that other terrorist organizations, including Palestinian military organizations in the West Bank, will join the hostilities. On October 9, 2025, Israel, Hamas, the US, and other counties in the region agreed to a framework for a ceasefire in Gaza between Israel and Hamas.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, in response to ongoing Iranian aggression and support of proxy attacks against Israel, on June 13, 2025, Israel conducted a series of preemptive defensive air strikes in Iran targeting Iran&#8217;s nuclear program and military commanders. While a ceasefire was reached in June 2025 following 12 days of hostilities, on February 28, 2026, the United States and Israel launched coordinated military strikes against Iran, including attacks on strategic military infrastructure and leadership targets, with the stated aim of degrading Iran&#8217;s capacity to conduct or support hostile operations against them. In response, Iran has fired missiles and drones toward population centers and military installations in Israel<span style="font-weight:bold">, </span>Europe and neighboring countries in the Gulf region, and also launched counter-strikes against U.S. forces and allied bases throughout the Gulf region. Continued military escalation, retaliatory actions, or broader regional involvement may adversely affect economic conditions, disrupt markets, and create uncertainty that could negatively impact our business, financial condition and results of operations.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The length and severity of the current conflicts in Gaza, Lebanon, Iran and the broader region is unknown at this time, and there can be no assurance that certain ceasefires will hold or that military activities and hostilities will not continue to exist at varying levels of intensity. Any or all of these situations may potentially escalate in the future to more violent events or a greater regional conflict.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s headquarters and principal development operations are located in the State of Israel. In addition, all of its key employees, officers and directors are residents of Israel. The ongoing war and other hostilities in Israel have not, to date, materially impacted the Company&#8217;s business or operations. Nevertheless, since these are events beyond the Company&#8217;s control, their continuation or cessation may affect the Company&#8217;s operations. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employees.</span></span></div>
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"><ix:exclude>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 10</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 1 &#8211; GENERAL INFORMATION</span><span> (cont.)</span></span></span></div>
        <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="vertical-align:top;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
            <td style="vertical-align:top;text-align:justify;width:auto">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Going concern</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred accumulated losses in the amount of $<ix:nonFraction id="Fxbrl_20260318094408173" name="ifrs-full:RetainedEarnings" contextRef="C_20251231" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal" sign="-">401</ix:nonFraction>&#160;million through December 31, 2025,&#160;and it expects to continue incurring losses and negative cash flows from operations until the cash flows from its strategic partnerships reach a level to offset its ongoing development costs. In this regard, Company management monitors rolling forecasts of the Company&#8217;s liquidity reserves on the basis of anticipated cash flows and seeks to maintain liquidity balances at levels that are sufficient to meet its needs. Management believes that the Company&#8217;s current cash and other resources will be sufficient to fund its projected cash requirements into the first half of 2027.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s cash flow projections are subject to various risks and uncertainties concerning their fulfilment, and these factors and the risks inherent in the Company&#8217;s operations indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) on the Company&#8217;s ability to continue as a going concern. These consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management&#8217;s plans include the realization of capital inflows from its strategic partnerships and, if and when required, raising capital through the issuance of debt or equity securities. There are no assurances, however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in realizing the potential cash flows from its strategic partnerships and/or in raising capital, it may need to reduce activities, or curtail or cease operations.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="vertical-align:top;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
            <td style="vertical-align:top;text-align:justify;width:auto">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in ratio of ADSs</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20260317174817980" name="blrx:DepositaryShareToOrdinaryShareRatioChangeDescription" contextRef="C_20250101to20251231">On January 30, 2025, the Company effected a change in the ratio of its ADSs to ordinary shares, from one ADS representing 15 ordinary shares to a new ratio of one ADS representing 600 ordinary shares.</ix:nonNumeric> All ADSs and per ADSs amounts in these financial statements have been retroactively adjusted as if the change in ratio had been effected at the earliest date of these financial statements.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="vertical-align:top;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
            <td style="vertical-align:top;text-align:justify;width:auto">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Approval of consolidated financial statements</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;text-indent:0pt;margin-left:70.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements of the Company for the year ended December 31, 2025 were approved by the Board of Directors on March 18, 2026, and signed on its behalf by the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer.</span></span></div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 11</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>

  <div>
    <ix:nonNumeric id="Fxbrl_20260317140533276" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" contextRef="C_20250101to20251231" escape="true">
      <div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 2 &#8211; MATERIAL ACCOUNTING POLICIES</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20250326162027979" name="blrx:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis of presentation and consolidation</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Basis of preparation</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s consolidated financial statements as of December 31, 2024 and 2025, and for each of the three years in the period ended December 31, 2025, have been prepared in accordance with IFRS<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#174;</sup> Accounting Standards as issued by the International Accounting Standards Board (&#8220;IASB<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#174;</sup>&#8221;) (hereinafter &#8220;IFRS&#8221;). The material<span style="font-weight:bold">&#160;</span>accounting policies described below have been applied on a consistent basis for all years presented.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements have been prepared on the basis of historical cost, subject to adjustment of warrant liabilities to their fair value through profit or loss.</span></span></div>
            <div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity and expenses, as well as the related disclosures of contingent assets and liabilities, in the process of applying the Company&#8217;s accounting policies.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are material<span style="font-weight:bold">&#160;</span>to the consolidated financial statements, are disclosed in Note 4. Actual results may differ materially from estimates and assumptions used by the Company&#8217;s management.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Basis of consolidation</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsidiaries are entities controlled by the Company. Control exists when the Company has power over the investee, is exposed or has rights to variable returns from its involvement with the investee, and has the ability to use its power to affect those returns. Subsidiaries are consolidated from the date on which control is obtained and are deconsolidated from the date control ceases. The financial statements of subsidiaries are prepared for the same reporting period as the parent company using consistent accounting policies.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All intercompany balances, transactions, income and expenses, and unrealized gains and losses arising from intra-group transactions are eliminated in full upon consolidation</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Non-controlling interests</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-controlling interests represent the portion of equity in subsidiaries not attributable, directly or indirectly, to the shareholders of the parent. Non-controlling interests are presented in the consolidated statement of financial position within equity, separately from the equity attributable to the owners of the parent.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in the Company&#8217;s ownership interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Any difference between the amount by which the non-controlling interests are adjusted, and the fair value of the consideration paid or received, is recognized directly in equity and attributed to the owners of the parent.</span></span></div>
          </div>
        </ix:nonNumeric>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 12</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
          <div style="line-height:1.25"><span style="font-weight:bold">NOTE 2 &#8211; MATERIAL ACCOUNTING POLICIES</span> (cont.)</div>
          <div style="line-height:1.25">&#160;</div>
        </ix:exclude></div>
        <ix:nonNumeric id="Fxbrl_20250326162040679" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Functional and reporting currency</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The functional and reporting currency in these financial statements is the U.S. dollar (&#8220;dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221;), which is the primary currency of the economic environment in which the Company operates. Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year-end exchange rates are generally recognized in profit or loss.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20250326162052843" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inventory</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inventory is measured at the lower of cost or net realizable value. The cost of inventories includes purchase costs, packaging and labeling costs, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price of the inventories in the ordinary course of business, less the estimated costs necessary to make the sale. Inventory is written down for estimated obsolescence based upon management assumptions about future demand, expiration due date and market conditions.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div>
          <ix:nonNumeric id="Fxbrl_20260317135930159" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" contextRef="C_20250101to20251231" escape="true">
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:43.9pt">&#160;</td>
                    <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment are stated at historical cost less depreciation. Historical cost includes expenditures that are directly attributable to acquisition of the items. Assets are depreciated by the straight-line method over the estimated useful lives of the assets, provided that Company management believes the residual values of the assets to be negligible, as follows:</span></span></div>
              <div style="text-align:justify;margin-left:69.85pt;line-height:1.25">&#160;</div>
              <ix:nonNumeric id="Fxbrl_20250326161520539" name="blrx:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory" contextRef="C_20250101to20251231" escape="true">
                <div>
                  <div style="margin-left:72pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="width:81.77%;vertical-align:middle">&#160;</td>
                          <td style="width:18.23%;vertical-align:middle;border-bottom:2px solid black">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers and communications equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20211006115502320_26" name="ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember">33</ix:nonNumeric></span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20211006115502321_27" name="ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember">6</ix:nonNumeric></span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20211006115502321_28" name="ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember">15</ix:nonNumeric></span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
              <div style="text-align:justify;line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful life of the improvements.</span></span></div>
            </div>
          </ix:nonNumeric>
        </div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 13</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
          <div style="line-height:1.25"><span style="font-weight:bold">NOTE 2 &#8211; MATERIAL ACCOUNTING POLICIES</span> (cont.)</div>
          <div style="line-height:1.25">&#160;</div>
        </ix:exclude></div>
        <ix:nonNumeric id="Fxbrl_20250326162206163" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="vertical-align:top;font-weight:bold;width:43.9pt">&#160;</td>
                    <td style="vertical-align:top;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                    <td style="vertical-align:top;text-align:justify;width:auto">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Intangible assets</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies the cost method of accounting for initial and subsequent measurements of intangible assets. Under this method of accounting, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Intellectual property</span></span></span></div>
              <div style="text-align:justify;margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes in its financial statements intellectual property developed by the Company to the extent that the conditions stipulated in paragraph j. below are met. Intellectual property acquired by the Company is initially measured at cost. Intellectual property used by the Company for development purposes and not yet generating revenues is not amortized and is tested annually for impairment. See f. below.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Computer software</span></span></span></div>
              <div style="text-align:justify;margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Acquired computer software licenses are capitalized based on the costs incurred&#160;to acquire and bring to use the specific software. These costs are amortized over the estimated useful lives of the software (<ix:nonNumeric id="Fxbrl_20250327102756586" name="ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_ifrsfullComputerSoftwareMember">5</ix:nonNumeric> years).</span></span></div>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20250326162222635" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Impairment of non-financial assets</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Impairment of intellectual property is required when the Company decides to terminate or suspend the development of a project based on such intellectual property. In addition, the Company performs impairment reviews on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment. Property and equipment, as well as computer software, are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized equal to the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value, less costs to sell and the asset&#8217;s value in use to the Company. See Note 8 for information about an impairment loss recorded in 2023 in connection with the decision to terminate the AGI-134 project, as well as an impairment loss recorded in 2024 in connection with the remaining rights to motixafortide in solid tumor indications.</span></span></div>
          </div>
        </ix:nonNumeric>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div><ix:exclude>
          <div style="line-height:1.25">
            <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
              <div>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 14</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
              </div>
            </div>
          </div>
          <div style="line-height:1.25"><span style="font-weight:bold">NOTE 2 &#8211; MATERIAL ACCOUNTING POLICIES</span> (cont.)</div>
          <div style="line-height:1.25">&#160;</div>
        </ix:exclude></div>
        <ix:nonNumeric id="Fxbrl_20250326162243307" name="blrx:DescriptionOfAccountingPolicyForWarrantExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Receipts in respect of ordinary warrants are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. In the event that the exercise price or the numbers of shares to be issued are not deemed to be fixed, the ordinary warrants are classified as a derivative financial liability. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value at each reporting date. The fair value changes are charged to non-operating income and expense on the statement of comprehensive loss. Issuance costs allocable to ordinary warrants classified as a liability are also recorded as non-operating expense on the statement of comprehensive loss.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pre-funded warrants are classified in shareholders&#8217; equity, with initial recognition at fair value on the date issued, using the same valuation assumptions as ordinary warrants.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20250326162306275" name="ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">h</span>.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Borrowings</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With respect to the long-term loan (see Note 10), a financial liability was recognized for each tranche upon drawdown. Upon initial recognition, the effective interest rate was calculated by estimating the future cash flows, including loan principal repayments, interest and royalties, if any. The royalty feature did not meet the definition of a derivative, was not classified separately, and was not measured separately, since it was an integral part of the loan terms and conditions and could not be transferred or settled separately from the loan.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Determining the weighted effective interest rate requires certain judgments and estimations regarding the timing and amount of the Company&#8217;s future revenues. The loans are subsequently measured at amortized cost. Furthermore, revisions to the estimated amounts or timing of future cash flows, if necessary, may result in an adjustment of the amortized cost of the loan to reflect the present value of actual and revised estimated contractual cash flows, discounted using the original effective interest rate. This adjustment was recognized in profit or loss as financial income or expense.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months subsequent to the reporting period.</span></span></div>
          </div>
        </ix:nonNumeric>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 15</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
          <div style="line-height:1.25"><span style="font-weight:bold">NOTE 2 &#8211; MATERIAL ACCOUNTING POLICIES</span> (cont.)</div>
          <div style="line-height:1.25">&#160;</div>
        </ix:exclude></div>
        <ix:nonNumeric id="Fxbrl_20250326162329517" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenues</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for contract revenue in accordance with IFRS 15, &#8220;Revenue from Contracts with Customers.&#8221;</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">IFRS 15 introduces a five-step model for recognizing revenue from contracts with customers, as follows:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">identify the contract with a customer;</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">identify the performance obligations in the contract;</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">determine the transaction price;</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">allocate the transaction price to the performance obligations in the contract; and</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">recognize revenue when (or as) the entity satisfies a performance obligation.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Revenues from selling products</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2023, the FDA approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and shortly thereafter, the Company began to independently commercialize motixafortide in the U.S. These activities terminated in November 2024, as a result of the out-licensing transaction entered into with Ayrmid Ltd. (see Note 16) and the shutdown of the Company&#8217;s U.S. commercial operations. The information below relates to the period during which the Company carried out direct sales activities.</span></span></div>
            <div style="text-align:justify;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company sells products mainly to wholesale distributors. Gross revenues are recognized at a point in time when control over the product is transferred to the distributors (upon delivery), at the gross selling price. The net revenues reflect gross revenues, reduced by amounts attributable to distributor fees, as well as accruals of chargebacks, rebates and returns.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The specific considerations the Company uses in estimating these amounts relating to variable consideration are as follows:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:85pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Distribution fees - The Company pays distribution fees to its three main distributors. The distribution fees are paid based on contractually determined rates from the gross consideration. When the service is received and the products sold to distributors, it is recognized as a reduction of revenues in the period the related revenues from the sale of products are recognized.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:85pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rebates and patient discount programs - The Company offers various rebate and patient discount programs, which results in discounted prescriptions to qualified patients. The Company estimates the allowance for these rebates, based on the estimated utilization of the rebate and discount programs, at the time the revenues are recognized. These estimates are recognized as a reduction of revenues.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:85pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Product returns - The Company offers customers a right of return as part of the distributor agreements. The Company estimates the amount of product sales that may be returned by its customers and records this estimate as a reduction of revenues at the time of sale, based on estimates of product returns based on its own sales information, its visibility into the inventory remaining in the distribution channel, and product dating.</span></span></div>
                  </td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 16</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
              </div>
              <div style="line-height:1.25"><span style="font-weight:bold">NOTE 2 &#8211; MATERIAL ACCOUNTING POLICIES</span> (cont.)</div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:43.9pt">&#160;</td>
                    <td style="width:24pt;vertical-align:top;font-weight:bold">i.</td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-weight:bold">Revenues (cont.)</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
            </ix:exclude></div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Revenues from</span><span style="text-decoration:underline"> licensing agreement</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">According to IFRS 15, performance obligations are a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service, either on its own or together with other resources that are readily available to the customer, and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">IFRS 15 defines the &#8216;Transaction Price&#8217; as the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services to a customer.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with IFRS 15, the Company identified a number of performance obligations (components) in the contract &#8211; in respect of which revenue will be recognized separately for each component.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following assumptions were taken into account, as part of the revenue recognition process:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Development milestones: Variable payments, contingent on achieving additional milestones, are included in the transaction price based on the most likely amount method. Amounts included in the transaction price are recognized only when it is highly probable that a material<span style="font-weight:bold">&#160;</span>reversal of cumulative revenues will not occur, usually upon achievement of the specific milestone, in accordance with the relevant agreement.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales-based royalties and sales-based milestones are recognized as the related sale occurs, due to the specific exception of IFRS 15 for sales-based royalties from licensing of intellectual properties.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For more information, see Notes 15 and 16.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20250326162345055" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">j.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research expenses are charged to profit or loss as incurred. As of December 31, 2025, the Company has not yet capitalized development expenses.</span></span></div>
          </div>
        </ix:nonNumeric>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div><ix:exclude>
          <div style="line-height:1.25">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 17</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
          <div style="line-height:1.25"><span style="font-weight:bold">NOTE 2 &#8211; MATERIAL ACCOUNTING POLICIES</span> (cont.)</div>
          <div style="line-height:1.25">&#160;</div>
        </ix:exclude></div>
        <ix:nonNumeric id="Fxbrl_20250326162401427" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">k.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based payments</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company operates an equity-settled, share-based compensation plan, under which it grants equity instruments (options, restricted stock units and performance stock units) of the Company as additional consideration for services from employees and service providers. The fair value of the employee services received in exchange for the grant of the equity instruments is recognized as an expense. The total amount to be expensed is determined by reference to the fair value of the equity instruments granted including any market performance conditions (for example, the Company&#8217;s share price).</span></span></div>
            <div style="text-align:justify;margin-right:0.55pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-market performance and service conditions are included in assumptions about the number of equity instruments that are expected to vest. Performance stock unit expenses are recognized only if it is probable that the performance condition will be achieved.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20250326162532956" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">l.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss per share</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
                  <td style="width:auto;vertical-align:top">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The basic loss per share is calculated by dividing the loss attributable to the holders of ordinary shares by the weighted average number of ordinary shares, including pre-funded warrants, outstanding during the year.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
                  <td style="width:auto;vertical-align:top">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Diluted</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The diluted loss per share is calculated by adjusting the weighted average number of outstanding ordinary shares, assuming conversion of all dilutive potential shares. The Company&#8217;s dilutive potential shares consist of warrants issued to investors, as well as equity instruments granted to employees and service providers. The dilutive potential shares were not taken into account in computing loss per share in 2023, 2024 and 2025, as their effect would have been anti-dilutive.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The calculation of diluted loss per share for the years ended December 31, 2023, 2024 and 2025 does not include <ix:nonFraction id="Fxbrl_20250326162459780" name="ifrs-full:AdjustedWeightedAverageShares" contextRef="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember" unitRef="Shares" scale="0" decimals="0" format="ixt:num-dot-decimal">369,484,579</ix:nonFraction>, <ix:nonFraction id="Fxbrl_20240324133220155" name="ifrs-full:AdjustedWeightedAverageShares" contextRef="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember" unitRef="Shares" scale="0" decimals="0" format="ixt:num-dot-decimal">568,205,319</ix:nonFraction> and <ix:nonFraction id="Fxbrl_20240324133441369" name="ifrs-full:AdjustedWeightedAverageShares" contextRef="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember" unitRef="Shares" scale="0" decimals="0" format="ixt:num-dot-decimal">1,538,622,579</ix:nonFraction> of shares underlying options and warrants, respectively, because the effect would be anti-dilutive.</span></span></div>
          </div>
        </ix:nonNumeric>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 18</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
            </div>
          </div>
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 2 &#8211; MATERIAL ACCOUNTING POLICIES</span> (cont.)</span></span></p>
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <ix:nonNumeric id="Fxbrl_20260317140445716" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:43.9pt">&#160;</td>
                    <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">m.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leases</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s leases include property and motor vehicle leases.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date. Simultaneously, the Company recognizes a right-of-use asset in the amount of the lease liability.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since the interest rate implicit in the lease cannot be readily determined, the Company uses the Company&#8217;s incremental borrowing rate.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The lease term is the non-cancellable period for which the Company has the right to use an underlying asset, together with both the periods covered by an option to extend the lease, if the Company is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the Company is reasonably certain not to exercise that option.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">After the commencement date, the Company measures the right-of-use asset applying the cost model, less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets are depreciated by the straight-line method over the estimated useful lives of the right of use assets or the lease period, whichever is shorter, as follows:</span></span></div>
            </div>
            <div>
              <div>
                <div>
                  <div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="margin-left:72pt">
                      <ix:nonNumeric id="Fxbrl_20260317140511131" name="blrx:DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory" contextRef="C_20250101to20251231" escape="true">
                        <div>
                          <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                              <tr>
                                <td style="width:76.27%;vertical-align:middle">&#160;</td>
                                <td style="width:23.73%;vertical-align:middle;border-bottom:2px solid black">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
                                </td>
                              </tr>
                              <tr>
                                <td style="width:76.27%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                                </td>
                                <td style="width:23.73%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20211006115502322_29" name="blrx:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">11</ix:nonNumeric></span></span></div>
                                </td>
                              </tr>
                              <tr>
                                <td style="width:76.27%;vertical-align:middle">
                                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                                </td>
                                <td style="width:23.73%;vertical-align:middle">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20211006115502322_30" name="blrx:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">3</ix:nonNumeric></span></span></div>
                                </td>
                              </tr>

                          </table>
                        </div>
                      </ix:nonNumeric>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20250326162724866" name="blrx:DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">New International Financial Reporting Standards, amendments to standards and new interpretations</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.85pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">New standards and interpretations not yet adopted</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.85pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">IFRS 18, Presentation and Disclosure in the Financial Statements</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">This standard replaces the international accounting standard IAS 1,&#160;&#8220;Presentation of Financial Statements.&#8221; As part of the new disclosure requirements, companies will be required to present new defined subtotals in the statements of income, as follows: (1) operating profit and (2) profit before financing and tax. In addition, income statement items will be classified into three defined categories: operating, investment and financing. The standard also includes a requirement to provide separate disclosure in the financial statements regarding the use of management-defined performance measures (&#8220;non-GAAP measures&#8221;), and specific instructions were added for the grouping and splitting of items in the financial statements and in the notes to the financial statements.&#160;IFRS 18&#160;is effective for annual reporting periods beginning on or after January 1, 2027, with an option for early adoption. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statement disclosures.</span></span></div>
          </div>
        </ix:nonNumeric>
      </div>
    </ix:nonNumeric>
  </div>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 19</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20240324113143639" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" contextRef="C_20250101to20251231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3 &#8211; FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin:0px 0px 0px 44.6pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Based on assessments by Company management, the Company&#8217;s exposure to credit risk as of December 31, 2025, is immaterial (see Note 3b). The activities of the Company expose it to market risk, primarily as a result of currency risk.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin:0px 0px 0px 44.6pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s Finance Department is responsible for carrying out risk management activities in accordance with policies approved by its Board of Directors. In this regard, the Finance Department identifies, defines and assesses financial risk in close cooperation with other Company departments. The Board of Directors provides written guidelines for overall risk management, as well as written policies dealing with specific areas, such as exchange rate risk, interest rate risk, credit risk, use of financial instruments and investment of excess cash.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Market risk</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Concentration of currency risk</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s activities are partly denominated in non-dollar currencies (primarily the New Israeli Shekel, or &#8220;NIS,&#8221; and the Euro), which exposes the Company to risks resulting from changes in exchange rates.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The effect of fluctuations in various exchange rates on the Company&#8217;s income and equity is as follows:</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250326191859313" name="blrx:DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div>
          <div style="margin-left:90pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Value on</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sensitive instrument</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">balance sheet</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS-linked balances:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317609_20211006115502390_8" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">179</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317609_20211006115502399_9" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">94</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317609_20211006115502405_10" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,974</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317609_20211006115502406_11" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317609_20211006115502408_12" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">219</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short term deposit</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20260317204521940_xbrl_20210923050317609_20211006115502390_8" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">86</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20260317204521940_xbrl_20210923050317609_20211006115502399_9" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">45</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20260317204521940_xbrl_20210923050317609_20211006115502405_10" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">943</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20260317204521940_xbrl_20210923050317609_20211006115502406_11" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20260317204521940_xbrl_20210923050317609_20211006115502408_12" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317629_20211006115502409_13" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317629_20211006115502410_14" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317629_20211006115502412_15" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317629_20211006115502428_16" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317629_20211006115502429_17" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317654_20211006115502430_18" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317654_20211006115502431_19" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317654_20211006115502433_20" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">206</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317654_20211006115502437_21" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317654_20211006115502438_22" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">23</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317678_20211006115502439_23" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317678_20211006115502440_24" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317678_20211006115502442_25" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">962</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317678_20211006115502443_26" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">51</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317678_20211006115502444_27" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">107</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total NIS-linked balances</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20260317101507687_xbrl_20210923050317678_20211006115502439_23" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">166</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20260317101507687_xbrl_20210923050317678_20211006115502440_24" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">86</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20260317101507687_xbrl_20210923050317678_20211006115502442_25" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,821</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20260317101507687_xbrl_20210923050317678_20211006115502443_26" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20260317101507687_xbrl_20210923050317678_20211006115502444_27" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Euro-linked trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317731_20211006115502463_33" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">107</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317731_20211006115502478_34" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">56</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20210923050317731_20211006115502479_35" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,177</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317731_20211006115502480_36" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210923050317731_20211006115502482_37" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20260317101621151_xbrl_20210923050317731_20211006115502463_33" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">273</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20260317101621151_xbrl_20210923050317731_20211006115502478_34" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">142</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317101621151_xbrl_20210923050317731_20211006115502479_35" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">644</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260317101621151_xbrl_20210923050317731_20211006115502480_36" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260317101621151_xbrl_20210923050317731_20211006115502482_37" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">333</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:90pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Value on</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sensitive instrument</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">balance sheet</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS-linked balances:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502390_8" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">87</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502399_9" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">45</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502405_10" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">955</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502406_11" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502408_12" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502409_13" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">52</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502410_14" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502412_15" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502428_16" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502429_17" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502430_18" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502431_19" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502433_20" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">933</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502437_21" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">67</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502438_22" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">141</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502439_23" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502440_24" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502442_25" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,495</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502443_26" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">89</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502444_27" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">188</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total NIS-linked balances</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502445_28" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502446_29" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502447_30" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">905</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502448_31" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">76</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502449_32" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">160</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Euro-linked trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502463_33" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">83</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502478_34" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">44</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502479_35" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">919</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502480_36" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502482_37" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324115437139_xbrl_20210923050317755_20211006115502483_38" name="blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324115437139_xbrl_20210923050317755_20211006115502484_39" name="blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240324115437139_xbrl_20210923050317755_20211006115502490_40" name="ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,824</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240324115437139_xbrl_20240324115048940" name="blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240324115437139_xbrl_20240324115058793" name="blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">58</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </ix:nonNumeric>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also maintains cash and cash equivalent balances in other currencies in amounts that are not material.</span></span></div>
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 20</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 3 &#8211; FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT </span><span>(cont.)</span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="font-family:Times New Roman, Times, serif;width:43.9pt">&#160;</td>
              <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="vertical-align:top;width:auto">
                <div style="color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Market risk</span><span> (cont.)</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:70.9pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:21.25pt;vertical-align:top;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
              <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">
                <div style="color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Concentration of currency risk (cont.)</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:70.9pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:21.25pt;vertical-align:top;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:auto;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
            </tr>

        </table>
      </ix:exclude></div>
      <div style="margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Set forth below is information on the linkage of monetary items:</span></span></div>
      <div style="margin-left:92.15pt;line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20240324120631670" name="blrx:DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div>
          <div style="margin-left:90pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding:0px 0px 2px">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dollar</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">currencies</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dollar</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currencies</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:middle;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD in thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:middle;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD in thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502512_88" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,428</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502513_89" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">955</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502514_90" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502515_91" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">973</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502516_92" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,974</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502517_93" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">303</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502520_94" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,126</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502521_95" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502522_96" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502523_97" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,683</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502524_98" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">943</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502524_99" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502525_100" name="ifrs-full:OtherReceivables" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">819</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502526_101" name="ifrs-full:OtherReceivables" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502527_102" name="ifrs-full:OtherReceivables" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502528_103" name="ifrs-full:OtherReceivables" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">338</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502529_104" name="ifrs-full:OtherReceivables" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502530_105" name="ifrs-full:OtherReceivables" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502533_106" name="ifrs-full:Assets" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,373</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502534_107" name="ifrs-full:Assets" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,523</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502535_108" name="ifrs-full:Assets" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502535_109" name="ifrs-full:Assets" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,994</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502536_110" name="ifrs-full:Assets" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,989</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502537_111" name="ifrs-full:Assets" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">303</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liabilities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current liabilities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current maturities of long-term loan</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502538_112" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,479</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502539_113" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502540_114" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502541_115" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,479</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502542_116" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502543_117" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accounts payable and accruals:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:0pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502546_118" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,549</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502547_119" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">933</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502548_120" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,101</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502549_121" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,993</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502550_122" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502550_123" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,294</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:0pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324174939473" name="ifrs-full:OtherPayables" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,636</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502551_124" name="ifrs-full:OtherPayables" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,495</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502552_125" name="ifrs-full:OtherPayables" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502554_127" name="ifrs-full:OtherPayables" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">781</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502555_128" name="ifrs-full:OtherPayables" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">962</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502556_129" name="ifrs-full:OtherPayables" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term loan, net of current maturities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502559_130" name="ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,958</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502560_131" name="ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502561_132" name="ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502562_133" name="ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,460</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502563_134" name="ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502564_135" name="ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502565_136" name="ifrs-full:Liabilities" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,622</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502566_137" name="ifrs-full:Liabilities" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,428</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502567_138" name="ifrs-full:Liabilities" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,101</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502568_139" name="ifrs-full:Liabilities" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,713</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502568_140" name="ifrs-full:Liabilities" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,168</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502570_141" name="ifrs-full:Liabilities" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,294</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net balance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502572_142" name="blrx:NetAssetValueOfLinkageMonetaryItems" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">751</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502573_143" name="blrx:NetAssetValueOfLinkageMonetaryItems" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">905</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502574_144" name="blrx:NetAssetValueOfLinkageMonetaryItems" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">957</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502575_145" name="blrx:NetAssetValueOfLinkageMonetaryItems" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,281</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502576_146" name="blrx:NetAssetValueOfLinkageMonetaryItems" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,821</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502577_147" name="blrx:NetAssetValueOfLinkageMonetaryItems" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">991</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 21</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 3 &#8211; FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT </span><span>(cont.)</span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="font-family:Times New Roman, Times, serif;width:43.9pt">&#160;</td>
              <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="vertical-align:top;width:auto">
                <div style="color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Market risk</span><span> (cont.)</span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="font-family:Times New Roman, Times, serif;width:43.9pt">&#160;</td>
              <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt">&#160;</td>
              <td style="vertical-align:top;width:auto">&#160;</td>
            </tr>

        </table>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value of financial instruments</span></span></div>
            </td>
          </tr>

      </table>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, the financial instruments of the Company consist of non-derivative assets and liabilities (primarily working capital items, deposits, and current and long-term loans), as well as warrants classified as a liability.</span></span></div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With regard to non-derivative assets and liabilities, given their nature, the fair value of the financial instruments included in working capital is generally close or identical to their carrying amount, as the effect of discounting is immaterial.</span></span></div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With regard to the warrants classified as a current financial liability, see Note 11c. With regard to long-term loans, see Note 10.</span></span></div>
      <div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exposure to market risk and management thereof</span></span></div>
            </td>
          </tr>

      </table>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In the opinion of Company management, the market risk to which the Company is exposed is primarily related to currency risk exposure, as mentioned above.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest rate risk</span></span></div>
            </td>
          </tr>

      </table>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Company management does not consider interest rate risk to be material, as the Company holds deposits whose fair value and/or cash flows are not materially affected by changes in interest rates.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Credit risk</span></span></div>
            </td>
          </tr>

      </table>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Credit risk is managed at the Company level. These risks relate to cash and cash equivalents, bank deposits, trade receivables, and other receivables.</span></span></div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s cash, cash equivalents and short-term bank deposits at December 31, 2024, and 2025 were deposited with highly rated major Israeli and U.S. banks. In the Company&#8217;s opinion, the credit risk associated with these balances is remote.</span></span></div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company considers its maximum exposure to credit risk to be as follows:</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20240324120639549" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div style="margin-left:72pt">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502578_148" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,436</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502579_149" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,250</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502580_150" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,126</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502581_151" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,626</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324113439146_20211006115502580_150" name="ifrs-full:TradeReceivables" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324113439146_20211006115502581_151" name="ifrs-full:TradeReceivables" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502582_152" name="ifrs-full:OtherReceivables" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,478</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502583_153" name="ifrs-full:OtherReceivables" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502585_154" name="ifrs-full:Assets" contextRef="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,516</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502586_155" name="ifrs-full:Assets" contextRef="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,332</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 22</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 3 &#8211; FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT </span><span>(cont.)</span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liquidity risk</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Company management monitors rolling forecasts of the Company&#8217;s liquidity reserves on the basis of anticipated cash flows and seeks to maintain the liquidity balances at a level that is sufficient to meet its needs.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Although the Company has succeeded in generating revenues from a number of out-licensing transactions, as well as the commercialization of its lead program, motixafortide, during 2024, it cannot determine with reasonable certainty if and when it will become profitable on a current basis. Management believes that the Company&#8217;s current cash and other resources will be sufficient to fund its projected cash requirements into the first half of 2027. However, in the event that the Company does not begin to generate sustainable cash flows from its operating activities in the future, the Company will need to carry out significant cost reductions and/or raise additional funding. See also Note 1c regarding the material uncertainty that may cast significant doubt about the Company&#8217;s ability to continue as a going concern.</span></span></div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value of financial instruments</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-indent:36pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The different levels of valuation of financial instruments are defined as follows:</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:72pt">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

            <tr>
              <td style="width:8%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1</span></span></div>
              </td>
              <td style="width:auto;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:8%;vertical-align:top">&#160;</td>
              <td style="width:auto;vertical-align:top">&#160;</td>
            </tr>
            <tr>
              <td style="width:8%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2</span></span></div>
              </td>
              <td style="width:auto;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inputs, other than quoted prices included within level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices).</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:8%;vertical-align:top">&#160;</td>
              <td style="width:auto;vertical-align:top">&#160;</td>
            </tr>
            <tr>
              <td style="width:8%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3</span></span></div>
              </td>
              <td style="width:auto;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inputs for the asset or liability that are not based on observable market data (unobservable inputs).</span></span></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk, in its assessment of fair value. The fair value of the financial instruments included in the working capital of the Company, as well as the long-term loan, is usually identical or close to their carrying value, as the effect of discounting is immaterial. The fair value of the warrants is based on Level 3 measurements.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the warrants, calculated based on the Black-Scholes model, was $<ix:nonFraction id="F20211006115502380_1" name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="C_20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,174,000</ix:nonFraction> as of December 31, 2025.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;text-indent:-0.05pt;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For more information on the parameters used to value the warrants, see Note 11c.</span></span></div>
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 23</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 3 &#8211; FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT </span><span>(cont.)</span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in financial liabilities with cash flows included in financing activities</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20240324120656358" name="ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div>
          <div style="margin-left:72pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Long-term loan</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                      <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Warrants</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                      <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Total</span></span></strong></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502587_156" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20221231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,168</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502588_157" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20221231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,509</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502589_158" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,677</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during the year 2023:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Principal and interest payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502590_159" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="C_20230101to20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,543</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502591_160" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502592_161" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,543</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts recognized through profit and loss</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502597_165" name="blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" contextRef="C_20230101to20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,148</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502599_166" name="blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" contextRef="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,054</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502601_167" name="blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,202</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share premium resulting from exercise of warrants</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324115004996" name="blrx:SharePremiumResultingFromExerciseOfWarrants" contextRef="C_20230101to20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240324114917970_xbrl_20220305103524791_xbrl_20220304191819962_20211006115502613_178" name="blrx:SharePremiumResultingFromExerciseOfWarrants" contextRef="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,631</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240324114917970_xbrl_20220305103524791_xbrl_20220304191819962_20211006115502614_179" name="blrx:SharePremiumResultingFromExerciseOfWarrants" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,631</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502602_168" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,773</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502603_169" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,932</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502604_170" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,705</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during the year 2024:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net proceeds</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250326192916872_20211006115502608_174" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" contextRef="C_20240101to20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,223</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250326192916872_20211006115502609_175" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" contextRef="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,724</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250326192916872_20211006115502610_176" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,947</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Principal and interest payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502611_177" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="C_20240101to20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,795</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502613_178" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502614_179" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,795</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts recognized through profit and loss</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502615_180" name="blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" contextRef="C_20240101to20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,236</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502616_181" name="blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" contextRef="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,965</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502617_182" name="blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,729</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502618_183" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,437</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502619_184" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,691</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502620_185" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,128</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during the year 2025:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net proceeds</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502608_174" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" contextRef="C_20250101to20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502609_175" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" contextRef="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,082</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502610_176" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,082</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Principal and interest payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240324114900770_20211006115502611_177" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="C_20250101to20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,568</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324114900770_20211006115502613_178" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240324114900770_20211006115502614_179" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,568</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts recognized through profit and loss</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324114908957_20211006115502615_180" name="blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" contextRef="C_20250101to20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,070</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240324114908957_20211006115502616_181" name="blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" contextRef="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">8,599</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240324114908957_20211006115502617_182" name="blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,529</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324114934398_20211006115502618_183" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,939</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324114934398_20211006115502619_184" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,174</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324114934398_20211006115502620_185" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,113</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value measurement of warrants using significant unobservable inputs (level 3)</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table presents the changes in level 3 instruments for the years ended December 31, 2023, 2024 and 2025:</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20260317101400566" name="ifrs-full:DisclosureOfFairValueMeasurementExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2023</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115502621_186" name="blrx:FairValueOfWarrants" contextRef="C_20221231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,509</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during 2023:</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercises</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20220304192105656" name="blrx:WarrantsExercises" contextRef="C_20230101to20231231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,631</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-14.15pt;margin-left:30.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value through profit and loss</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502623_188" name="blrx:ChangesInFairValueThroughProfitAndLossOfWarrants" contextRef="C_20230101to20231231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,054</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2023</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502628_192" name="blrx:FairValueOfWarrants" contextRef="C_20231231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,932</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during 2024:</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuances</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250326192810721_20211006115502622_187" name="blrx:IssuancesOfWarrants" contextRef="C_20240101to20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,724</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-14.15pt;margin-left:30.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value through profit and loss</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502627_191" name="blrx:ChangesInFairValueThroughProfitAndLossOfWarrants" contextRef="C_20240101to20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,965</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2024</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502632_196" name="blrx:FairValueOfWarrants" contextRef="C_20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,691</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during 2025:</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuances</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502622_187" name="blrx:IssuancesOfWarrants" contextRef="C_20250101to20251231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,082</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value through profit and loss</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502631_195" name="blrx:ChangesInFairValueThroughProfitAndLossOfWarrants" contextRef="C_20250101to20251231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">8,599</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2025</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324120123228" name="blrx:FairValueOfWarrants" contextRef="C_20251231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,174</ix:nonFraction></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>
  <div style="line-height:1.25">&#160;</div>
  <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
    <div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 24</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
    </div>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20240323034353643" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" contextRef="C_20250101to20251231" escape="true">
      <div>
        <div>
          <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4 &#8211; CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS</span></span></div>
          <div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the financial reporting process, Company management is required to make estimates that affect the value of assets, liabilities, income, expenses and certain disclosures included in the Company&#8217;s consolidated financial statements. By their very nature, such accounting estimates are subjective and complex and consequently may differ from actual results. The estimates are continually evaluated and adjusted based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances.</span></span></div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Below are the critical accounting estimates used in the preparation of the financial statements that required Company management to make assumptions involving significant uncertainty.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-indent:-21.25pt;margin-left:70.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Impairment of indefinite-lived intangible assets</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As mentioned in Notes 2e and 2f, the Company performs impairment reviews of intangible assets not subject to amortization on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The recoverable amount is determined using discounted cash flow calculations. The analysis estimates the future cash flows the Company expects to derive from the asset, incorporates expectations about possible variations in the amount or timing of those future cash flows, as well as the uncertainty inherent in the asset, and the risk-adjusted cash flows are then discounted using the Company&#8217;s estimated post-tax weighted average cost of capital (&#8220;WACC&#8221;). The main estimates used in calculating the recoverable amount include the WACC estimation and the amounts and timing of projected future cash flows. Such amounts and timing are influenced by the expected outcome of development activities, the probability of success and timing in gaining regulatory approval, size of the potential market and the Company&#8217;s specific market share, either via direct sales or a potential out-licensing deal.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In light of the Company&#8217;s decision to terminate AGI-134, the value of its intangible asset was written off in its entirety in 2023.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As a result of an impairment review of its remaining rights to motixafortide in solid tumor indications in the fourth quarter of 2024, the Company recorded an impairment loss (see Note 8).</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, the Company has concluded that the value of its intangible assets is higher than their carrying value.</span></span></div>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
    <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 25</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20240323034651084" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" contextRef="C_20250101to20251231" escape="true">
      <div>
        <div>
          <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 5 &#8211; CASH AND CASH EQUIVALENTS</span></span></div>
          <div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
            <div style="margin-left:54pt">
              <ix:nonNumeric id="Fxbrl_20250326163654597" name="blrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" contextRef="C_20250101to20251231" escape="true">
                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash on hand and in bank</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="F20211006115502655_1" name="ifrs-full:Cash" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">944</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="F20211006115502655_2" name="ifrs-full:Cash" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">632</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="F20211006115502655_3" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,492</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="F20211006115502655_4" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,618</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="F20211006115502656_5" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,436</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><ix:nonFraction id="F20211006115502656_6" name="ifrs-full:CashAndCashEquivalents" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,250</ix:nonFraction></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              </ix:nonNumeric>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The short-term bank deposits included in cash and cash equivalents bear interest at annual rates of between <ix:nonFraction id="Fxbrl_20230311051437007" name="blrx:InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents" contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.7</ix:nonFraction>% and <ix:nonFraction id="Fxbrl_20230311051447312" name="blrx:InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents" contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.9</ix:nonFraction>%.</span></span></div>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
  </div>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>

  <div>
    <ix:nonNumeric id="Fxbrl_20240323034902050" name="ifrs-full:DisclosureOfDepositsFromBanksExplanatory" contextRef="C_20250101to20251231" escape="true">
      <div>
        <div>
          <div>
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 6 &#8211; SHORT-TERM BANK DEPOSITS</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The short-term bank deposits are primarily in dollars and bear interest at annual rates of between <ix:nonFraction id="Fxbrl_20230311051710899" name="blrx:InterestRateOnShortTermDeposits" contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.20</ix:nonFraction>% and <ix:nonFraction id="Fxbrl_20230311051643701" name="blrx:InterestRateOnShortTermDeposits" contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.82</ix:nonFraction>%.</span></span></div>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
  </div>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 26</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260317141712300" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" contextRef="C_20250101to20251231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 7 &#8211; PROPERTY AND EQUIPMENT</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Set forth below are the composition of property and equipment and the related accumulated depreciation, grouped by major classifications:</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:54pt">
        <ix:nonNumeric id="Fxbrl_20260317141723430" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net book value</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:10%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502681_1" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502682_2" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502683_3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502684_4" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">209</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502685_5" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">191</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502686_6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502686_7" name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">41</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502681_11" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">177</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509500_20211006115502726_91" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509500_20211006115502726_92" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers and communications equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502689_11" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">467</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502689_12" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502690_13" name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502691_14" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">331</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502692_15" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">291</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502693_16" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502694_17" name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">138</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502689_111" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">223</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509525_20211006115502727_93" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509525_20211006115502727_94" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502698_21" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,571</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502699_22" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502699_23" name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502700_24" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,571</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502701_25" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,525</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502702_26" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502703_27" name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502698_211" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,551</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509556_20211006115502728_95" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509556_20211006115502729_96" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502705_31" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,036</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502705_32" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502706_33" name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502707_34" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,036</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502708_35" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,932</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502709_36" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502710_37" name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502705_311" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,036</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509587_20211006115502730_97" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024509587_20211006115502733_98" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502713_41" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,325</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502714_42" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502714_43" name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502715_44" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,147</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502716_45" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,939</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230314125758233" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502718_47" name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">179</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230314125810560" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,987</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024520812_20211006115502734_99" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">386</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20210923024520812_20211006115502734_100" name="ifrs-full:PropertyPlantAndEquipment" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </ix:nonNumeric>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 27</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20240323035623011" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" contextRef="C_20250101to20251231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 8 &#8211; INTANGIBLE ASSETS</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;Intellectual property included the following intangible assets acquired by the Company:</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:51.05pt">&#160;</td>
            <td style="width:19.85pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$<ix:nonFraction id="Fxbrl_20250326175306079" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="C_20251231_ifrsfullBusinessCombinationsAxis_blrxAgalimmuneLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.7</ix:nonFraction> million primarily related to AGI-134. In December 2023, the Company made a decision to terminate the development of AGI-134 and, accordingly, an impairment loss for the full amount of the related intellectual property was recorded in the 2023 financial statements.</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:51.05pt">&#160;</td>
            <td style="width:19.85pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$<ix:nonFraction id="Fxbrl_20250326175427881" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="C_20251231_ifrsfullBusinessCombinationsAxis_blrxBiokineTherapeuticsLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million associated with BL-8040 were recorded following an amendment to the in-licensing agreement with Biokine Therapeutics Ltd. (&#8220;Biokine&#8221;). This amendment reduced the payments owed by the Company on sublicense receipts (as defined in the license agreement) from <ix:nonNumeric id="Fxbrl_20250326175541026" name="blrx:PercentageOfPaymentToBeMade" contextRef="C_20250101to20251231_ifrsfullBusinessCombinationsAxis_blrxBiokineTherapeuticsLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">40% to 20%</ix:nonNumeric>. This intellectual property is amortized proportionally with the revenues recognized from the licensing transaction with HST and Gloria in Asia (see Note 15), and with Ayrmid for the rest of the world (excluding solid tumors) (see Note 16). During the period of self-commercialization in the U.S. of motixafortide in 2024, this intellectual property was amortized in accordance with the lifespan of the patents in the U.S. In addition, as a result of an impairment review of its remaining rights to motixafortide in solid tumor indications in the fourth quarter of 2024, the Company recorded an impairment loss of $<ix:nonFraction id="Fxbrl_20250326182401084" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="C_20250101to20251231_ifrsfullBusinessCombinationsAxis_blrxBiokineTherapeuticsLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million. Sensitivity tests on impairment of the remaining rights to motixafortide in solid tumor indications were carried out as of December 31, 2025, by increasing the WACC by <ix:nonFraction id="Fxbrl_20250328203717154" name="blrx:PercentageOfIncreasingWeightedAverageCostOfCapital" contextRef="C_20251231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction>% and by decreasing the annual growth rate of new cases by <ix:nonFraction id="Fxbrl_20250328203724794" name="blrx:PercentageOfDecreasingAnnualGrowthRate" contextRef="C_20251231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction>%. Such changes, if realized, would not have a material effect on the carrying amount of the motixafortide intellectual property. As of December 31, 2025, the net book value of the intangible assets associated with BL-8040 amounted to $<ix:nonFraction id="Fxbrl_20260319164858920" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_blrxBL8040Member" unitRef="USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">10.2</ix:nonFraction> million.</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:51.05pt">&#160;</td>
            <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$<ix:nonFraction id="Fxbrl_20260317113438748" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullBusinessCombinationsAxis_blrxGlix1Member" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction> million associated with the acquisition of GLIX1, pursuant to the collaboration transaction and asset transfer agreement with Hemispherian AS (see Note 17).</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;text-indent:-19.85pt;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, the Company has concluded that the value of its intangible assets is higher than their carrying value.</span></span></div>
      <div style="text-align:justify;text-indent:-19.85pt;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 28</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 8 &#8211; INTANGIBLE ASSETS </span>(cont.)</span></span></div>
        <div style="line-height:1.25">&#160;</div>
      </ix:exclude></div>
      <div style="text-align:justify;margin-left:51.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Set forth below are the composition of intangible assets and the related accumulated depreciation, grouped by major classifications:</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250326175052192" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Cost</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation and impairment</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Additions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Disposal</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Additions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Impairment</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Net book value</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">beginning</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">end of</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">beginning</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">end of</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">of year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">of year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">2024</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">2025</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Composition in 2024</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Intellectual property</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326180837730" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,342</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181014441" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326184206862" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181035360" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,323</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181108746" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,019</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181128651" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,799</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181334161" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326184431684" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181413186" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,010</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181436154" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,809</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181614360" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,210</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Computer software</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326180843674" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">982</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326180938994" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326184232596" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181042635" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181059298" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">798</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181122562" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">671</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181244586" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326184438035" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181358386" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181431017" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">559</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181601650" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326180851354" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,324</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326180858905" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326184301714" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181047651" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,323</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181054418" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,817</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181117137" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,470</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181154419" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326184452938" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181346674" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,010</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181420202" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">8,368</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326181453779" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,449</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Intellectual property</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137540_20211006115502773_1" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,019</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137540_20211006115502774_2" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250328205521418" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,700</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137540_20211006115502775_3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137540_20211006115502775_4" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,319</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137540_20211006115502776_5" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,809</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137540_20211006115502777_6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250328205547986" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,700</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137540_20211006115502777_7" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137540_20211006115502773_11" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,109</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137540_20211006115502773_15" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,210</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137540_20211006115502773_19" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,210</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Computer software</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137581_20211006115502782_11" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">798</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137581_20211006115502782_12" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326184313276" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137581_20211006115502783_13" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137581_20211006115502783_14" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">796</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137581_20211006115502784_15" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">559</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137581_20211006115502785_16" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326184501541" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137581_20211006115502785_17" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137581_20211006115502782_111" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">638</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137581_20211006115502782_115" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003137581_20211006115502782_119" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:16%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_21" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,817</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_22" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,002</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326184333780" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,704</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_23" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502788_24" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,115</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502789_25" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">8,368</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502789_26" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20250326184507195" name="blrx:DeletionsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,703</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502790_27" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_211" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,747</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_215" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,449</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt"><ix:nonFraction id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_219" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,368</ix:nonFraction></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>
  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 29</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20250326191254510" name="ifrs-full:DisclosureOfLeasesExplanatory" contextRef="C_20250101to20251231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 9 &#8211; LEASES</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right-of-use assets</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:72pt">
        <ix:nonNumeric id="Fxbrl_20250326191348973" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" contextRef="C_20250101to20251231" escape="true">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net book value</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:middle;width:20%;vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502851_26" name="ifrs-full:RightofuseAssets" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,551</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502852_27" name="ifrs-full:AdditionsToRightofuseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502853_28" name="blrx:DeletionsToRightOfUseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502853_29" name="ifrs-full:RightofuseAssets" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,551</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502854_30" name="ifrs-full:RightofuseAssets" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">810</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502855_31" name="ifrs-full:AdditionsToRightofuseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502856_32" name="blrx:DeletionsToRightOfUseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502851_261" name="ifrs-full:RightofuseAssets" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">945</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502851_265" name="ifrs-full:RightofuseAssets" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">741</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502851_269" name="ifrs-full:RightofuseAssets" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">606</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:middle;width:20%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502859_36" name="ifrs-full:RightofuseAssets" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">456</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502859_37" name="ifrs-full:AdditionsToRightofuseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502860_38" name="blrx:DeletionsToRightOfUseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502861_39" name="ifrs-full:RightofuseAssets" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">260</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502862_40" name="ifrs-full:RightofuseAssets" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">230</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502862_41" name="ifrs-full:AdditionsToRightofuseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502863_42" name="blrx:DeletionsToRightOfUseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502859_361" name="ifrs-full:RightofuseAssets" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">170</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502859_365" name="ifrs-full:RightofuseAssets" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502859_369" name="ifrs-full:RightofuseAssets" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:20%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502865_46" name="ifrs-full:RightofuseAssets" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,007</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502865_47" name="ifrs-full:AdditionsToRightofuseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502866_48" name="blrx:DeletionsToRightOfUseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502866_49" name="ifrs-full:RightofuseAssets" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,811</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502867_50" name="ifrs-full:RightofuseAssets" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,040</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502868_51" name="ifrs-full:AdditionsToRightofuseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502868_52" name="blrx:DeletionsToRightOfUseAssets" contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502865_461" name="ifrs-full:RightofuseAssets" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,115</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502865_465" name="ifrs-full:RightofuseAssets" contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">967</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><ix:nonFraction id="F20211006115502865_469" name="ifrs-full:RightofuseAssets" contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">696</ix:nonFraction></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </ix:nonNumeric>
      </div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">B.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:72pt">
        <ix:nonNumeric id="Fxbrl_20250326191404133" name="blrx:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest expense</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange differences</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="22" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:16%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024124710_20211006115502837_11" name="ifrs-full:LeaseLiabilities" contextRef="C_20241231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,409</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240326121702366" name="blrx:AdditionsLeaseLiabilities" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024124710_20211006115502836_9" name="blrx:DeletionsLeaseLiabilities" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024124710_20211006115502835_8" name="blrx:InterestExpenseLeaseLiabilities" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20230314032624262" name="blrx:ExchangeDifferencesDuringYear" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024124710_20211006115502833_6" name="blrx:PaymentsLeaseLiabilities" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">596</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024124710_20211006115502833_5" name="ifrs-full:LeaseLiabilities" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,163</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024124734_20211006115502845_18" name="ifrs-full:LeaseLiabilities" contextRef="C_20241231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024124734_20211006115502842_17" name="blrx:AdditionsLeaseLiabilities" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024124734_20211006115502841_16" name="blrx:DeletionsLeaseLiabilities" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024124734_20211006115502840_15" name="blrx:InterestExpenseLeaseLiabilities" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20230314032632460" name="blrx:ExchangeDifferencesDuringYear" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024124734_20211006115502839_13" name="blrx:PaymentsLeaseLiabilities" contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024124734_20211006115502838_12" name="ifrs-full:LeaseLiabilities" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:16%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024132837_20211006115502850_25" name="ifrs-full:LeaseLiabilities" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,603</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024132837_20211006115502850_24" name="blrx:AdditionsLeaseLiabilities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024132837_20211006115502849_23" name="blrx:DeletionsLeaseLiabilities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024132837_20211006115502848_22" name="blrx:InterestExpenseLeaseLiabilities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20230314032641700" name="blrx:ExchangeDifferencesDuringYear" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">191</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024132837_20211006115502847_20" name="blrx:PaymentsLeaseLiabilities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">698</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20210924024132837_20211006115502846_19" name="ifrs-full:LeaseLiabilities" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,211</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 30</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
        </div>
        <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 9 &#8211; LEASES</span><span> (cont.)</span></span></span></div>
        <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">C.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional disclosures</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:71.85pt">&#160;</td>
            <td style="width:21pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company leases its premises in Israel under a lease agreement entered into in August 2014. Payments under the lease commenced in June 2015, and the initial term of the lease expired in June 2020. The lease agreement includes <ix:nonNumeric id="Fxbrl_20230314033314848" name="blrx:AdditionalExtendLeasePeriod" contextRef="C_20250101to20251231_srtStatementGeographicalAxis_countryIL">three</ix:nonNumeric> options to extend the lease through June 30, 2030 in the aggregate, each at a <ix:nonFraction id="Fxbrl_20230314033321512" name="blrx:PercentageIncreasePrecedingLeasePaymentAmount" contextRef="C_20250101to20251231_srtStatementGeographicalAxis_countryIL" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% increase to the preceding lease payment amount. The Company exercised its first and second options to extend the lease through June 30, 2028, and is currently making monthly lease payments of approximately $<ix:nonFraction id="Fxbrl_20230314033341560" name="blrx:LeaseAgreementMonthlyFee" contextRef="C_20250101to20251231_srtStatementGeographicalAxis_countryIL" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,000</ix:nonFraction>. In addition to the monthly lease payments, the Company also pays building monthly maintenance charges of approximately $<ix:nonFraction id="Fxbrl_20230314033410465" name="ifrs-full:RepairsAndMaintenanceExpense" contextRef="C_20250101to20251231_srtStatementGeographicalAxis_countryIL" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,700</ix:nonFraction>.</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:71.85pt">&#160;</td>
            <td style="width:21pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has entered into lease agreements in connection with a number of vehicles. The lease periods are generally for <ix:nonNumeric id="Fxbrl_20230314035606134" name="blrx:LeasePeriod" contextRef="C_20250101to20251231" format="ixt-sec:durwordsen">three years</ix:nonNumeric>. The annual lease fees, linked to the CPI, are approximately $<ix:nonFraction id="Fxbrl_20230314035626037" name="blrx:AnnualLeaseFee" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215,000</ix:nonFraction>. To secure the terms of the lease agreements, the Company has prepaid two months of lease payments to the leasing companies.</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:71.85pt">&#160;</td>
            <td style="width:21pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3)</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, minimum future rental payments (taking into consideration the aforementioned extension periods) under the leases are as follows:</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:72pt">
        <ix:nonNumeric id="Fxbrl_20250326191426838" name="ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502888_121" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">332</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502889_122" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502890_123" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">438</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502891_124" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502891_125" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502894_126" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">369</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2028</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250326193055625" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502895_128" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502896_129" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2029-2030</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502899_133" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">523</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502900_134" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502900_135" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">523</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502901_136" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,551</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502902_137" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115502903_138" name="ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,678</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Extension and termination options are included in the property lease. These are used to maximize operational flexibility in terms of managing the assets used in the Company&#8217;s operations. The substantial majority of extension and termination options are exercisable solely by the Company and not by the lessors.</span></span></div>
    </div>
  </ix:nonNumeric>
  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
  <div>
    <div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 31</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
    </div>
  </div>

  <ix:nonNumeric id="Fxbrl_20260317115816245" name="ifrs-full:DisclosureOfBorrowingsExplanatory" contextRef="C_20250101to20251231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 10 </span></span>&#8211;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"> LONG-TERM LOAN</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2022, the Company entered into a loan agreement with BlackRock EMEA Venture and Growth Lending (previously Kreos Capital VII Aggregator SCSP) (&#8220;BlackRock&#8221;), with an aggregate principal amount of up to $<ix:nonFraction id="Fxbrl_20230314043327229" name="blrx:AmountOfLoanAgreement" contextRef="C_20220901to20220930_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">40</ix:nonFraction> million comprised of three tranches of up to $<ix:nonFraction id="Fxbrl_20230314043315425" name="blrx:AmountOfLoanAgreement" contextRef="C_20220901to20220930_blrxTrancheAxis_blrxFirstTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction> million, $<ix:nonFraction id="Fxbrl_20250327033702837" name="blrx:AmountOfLoanAgreement" contextRef="C_20220901to20220930_blrxTrancheAxis_blrxSecondTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction> million and $<ix:nonFraction id="Fxbrl_20250327033707132" name="blrx:AmountOfLoanAgreement" contextRef="C_20220901to20220930_blrxTrancheAxis_blrxThirdTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction> million. The Company drew down the initial tranche of $<ix:nonFraction id="Fxbrl_20250327033842837" name="blrx:AmountOfLoanAgreement" contextRef="C_20220901to20220930_blrxTrancheAxis_blrxFirstTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction> million following execution of the loan agreement in September 2022, and it drew down the second tranche of $<ix:nonFraction id="Fxbrl_20250327033853147" name="blrx:AmountOfLoanAgreement" contextRef="C_20240401to20240430_blrxTrancheAxis_blrxSecondTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction> million in April 2024, following fulfilment of the requisite milestones. The third tranche was available for drawdown until October 1, 2024, upon the achievement of certain milestones. No drawdown was made by the indicated date, and thus, availably of the third tranche under the facility was cancelled.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Each tranche of the loan carried a pre-defined interest-only payment period, followed by a loan principal amortization period of up to 36 months subsequent to the interest-only period. The interest-only periods were subject to possible extension based on certain pre-defined milestones. Borrowings under the financing bear interest at a fixed annual rate of <ix:nonFraction id="Fxbrl_20230314043952511" name="blrx:PercentageOfAnnualInterestOfCashFees" contextRef="C_20210901to20220930_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.5</ix:nonFraction>% (~<ix:nonFraction id="Fxbrl_20230314044017731" name="blrx:PercentageOfAnnualInterestOfCashFees" contextRef="C_20210901to20220930_ifrsfullRangeAxis_ifrsfullTopOfRangeMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.0</ix:nonFraction>%, including associated cash fees). As security for the loan, BlackRock received a first-priority secured interest in all Company assets, including intellectual property, and the Company undertook to maintain a $<ix:nonFraction id="Fxbrl_20250327034015884" name="blrx:AmountOfIntellectualPropertyAndCashBalance" contextRef="C_20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction> million minimum cash balance. In addition, BlackRock was entitled to mid-to-high single-digit revenue-based payments on motixafortide sales in the U.S., up to a pre-defined cap.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, in connection with the Ayrmid License Agreement, the Company entered into an amendment to the loan Agreement with BlackRock. Pursuant to the amendment: (i) the Company made a payment of $<ix:nonFraction id="Fxbrl_20250327034456542" name="ifrs-full:RepaymentsOfBondsNotesAndDebentures" contextRef="C_20241101to20241130_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.5</ix:nonFraction> million as partial repayment of the loan to BlackRock and in lieu of future revenue-based payments, which were fully cancelled, (ii) effective December 1, 2024, the Company began to pay the remaining amounts outstanding under the loan (in principal and interest) over a three-year period ending December 1, 2027, and (iii) the Company&#8217;s minimum cash balance requirement under the Loan Agreement was reduced to $<ix:nonFraction id="Fxbrl_20260317121137642" name="blrx:MinimumCashBalanceRequirementUnderLoanAgreement" contextRef="C_20241101to20241130_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">4</ix:nonFraction> million. In addition, pursuant to the amendment, <ix:nonFraction id="Fxbrl_20260317121151702" name="blrx:PercentageOfFutureMilestonePayments" contextRef="C_20241101to20241130_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction>% of any future milestone payments received by the Company from its out-licensing agreements through December 1, 2027 will be used to repay outstanding loan principal, and the repayments in (ii) above will be adjusted accordingly. All other terms of the Loan Agreement remain the same.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above amendment met the criteria in IFRS 9 regarding a substantial modification of the terms of a financial liability. In accordance with this paragraph, such modification is to be accounted for as the extinguishment of the original financial liability and the recognition of a new financial liability, with the&#160;difference between the carrying amount of the derecognized financial liability, versus any consideration paid plus any new liability undertaken, recorded as interest expense or income in the statement of comprehensive loss. Accordingly, the above amendment resulted in approximately $<ix:nonFraction id="Fxbrl_20260317121206469" name="ifrs-full:InterestExpenseOnBorrowings" contextRef="C_20241001to20241231_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction> million of interest expense in the fourth quarter of 2024.&#160;</span></span></div>
    </div>
  </ix:nonNumeric>
  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
  <div style="clear:both;margin-top:0pt;margin-bottom:10pt">
    <div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 32</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
    </div>
  </div>

  <ix:nonNumeric id="Fxbrl_20220304153940278" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" contextRef="C_20250101to20251231" escape="true">
    <div>
      <div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 11 &#8211; EQUITY</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share capital</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s share capital is composed of ordinary shares, par value NIS <ix:nonFraction id="Fxbrl_20260318014401116" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20251231" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.10</ix:nonFraction> per share, as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20250327035205202" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:90%;width:90%">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of Ordinary Shares</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Authorized share capital</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502956_7" name="ifrs-full:NumberOfSharesAuthorised" contextRef="C_20241231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000,000</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502957_8" name="ifrs-full:NumberOfSharesAuthorised" contextRef="C_20251231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">20,000,000,000</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and paid-up share capital</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502958_9" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="C_20241231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,336,670,575</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502959_10" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" contextRef="C_20251231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,610,814,390</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:90%;width:90%">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD and NIS Amounts</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Authorized share capital (in NIS)</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502960_11" name="blrx:AuthorizedShareCapitalValue" contextRef="C_20241231" unitRef="ILS" scale="0" decimals="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502961_12" name="blrx:AuthorizedShareCapitalValue" contextRef="C_20251231" unitRef="ILS" scale="0" decimals="0" format="ixt:num-dot-decimal">2,000,000,000</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and paid-up share capital (in NIS)</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502961_13" name="blrx:IssuedAndPaidUpShareCapitalValue" contextRef="C_20241231" unitRef="ILS" scale="0" decimals="0" format="ixt:num-dot-decimal">133,667,057</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502962_14" name="blrx:IssuedAndPaidUpShareCapitalValue" contextRef="C_20251231" unitRef="ILS" scale="0" decimals="0" format="ixt:num-dot-decimal">261,081,439</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and paid-up share capital (in USD)</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502963_15" name="blrx:IssuedAndPaidUpShareCapitalValue" contextRef="C_20241231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">38,096,940</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502964_16" name="blrx:IssuedAndPaidUpShareCapitalValue" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">73,428,375</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rights related to shares</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ordinary shares confer upon their holders voting and dividend rights and the right to receive assets of the Company upon its liquidation. As of December 31, 2024 and 2025, all outstanding share capital consisted of ordinary shares.</span></span></div>
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
        <div><ix:exclude>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 33</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 11 &#8211; EQUITY </span><span>(cont.)</span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in the Company&#8217;s equity</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;1)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2022, the Company completed a registered direct offering of <ix:nonFraction id="Fxbrl_20230314052424711" name="blrx:SharesIssuedRegisteredDirectOfferings" contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">340,909</ix:nonFraction> ADSs at a price of $<ix:nonFraction id="Fxbrl_20230314052436524" name="blrx:ExercisePriceOfShareIssued" contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">44.00</ix:nonFraction> per ADS. The Company also issued to investors in the offering unregistered warrants to purchase <ix:nonFraction id="Fxbrl_20230314052447987" name="blrx:WarrantsIssuedToPurchaseShares" contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">340,909</ix:nonFraction> ADSs. The warrants are exercisable immediately, expire <ix:nonNumeric id="Fxbrl_20230314052500179" name="blrx:WarrantsExpirationPeriod" contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"> five years</ix:nonNumeric> from the date of issuance and have an exercise price of $<ix:nonFraction id="Fxbrl_20230314052515116" name="blrx:ExercisePriceOfWarrants" contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">46.00</ix:nonFraction> per ADS. In addition, the Company granted to the placement agent in the offering, as part of the placement fee, warrants to purchase <ix:nonFraction id="Fxbrl_20230314052524982" name="blrx:WarrantsIssuedToPurchaseShares" contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">17,045</ix:nonFraction> ADSs. These warrants are exercisable immediately, expire <ix:nonNumeric id="Fxbrl_20230314052535780" name="blrx:WarrantsExpirationPeriod" contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember"> five years</ix:nonNumeric> from the date of issuance and have an exercise price of $<ix:nonFraction id="Fxbrl_20230314052545374" name="blrx:ExercisePriceOfWarrants" contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">55.00</ix:nonFraction> per ADS. Gross proceeds from the offering totaled $<ix:nonFraction id="Fxbrl_20230314052556205" name="blrx:AggregateOfferingPrice" contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million, with net proceeds of $<ix:nonFraction id="Fxbrl_20230314052604326" name="blrx:ProceedsFromWarrantIssue" contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.5</ix:nonFraction> million, after deducting fees and expenses. The offering consideration allocated to the placement agent warrants amounted to $<ix:nonFraction id="Fxbrl_20230314052615678" name="blrx:AmountAllocatedToWarrant" contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million.</span></span></div>
                <div>&#160;</div>
                <div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The warrants issued to the investors have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the warrants is computed using the Black-Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of <ix:nonFraction id="Fxbrl_20230314053247964" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.62</ix:nonFraction>%, and an average standard deviation of <ix:nonFraction id="Fxbrl_20230314053323669" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">82.5</ix:nonFraction>%. The gross consideration initially allocated to the investor warrants amounted to $<ix:nonFraction id="Fxbrl_20230314053502057" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.1</ix:nonFraction> million,</span></span></div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">with total issuance costs initially allocated to the warrants amounting to $<ix:nonFraction id="Fxbrl_20230314053603648" name="blrx:AmountAllocatedToWarrant" contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction> million.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the warrants amounted to $<ix:nonFraction id="Fxbrl_20230314053958904" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">24,000</ix:nonFraction> as of December 31, 2025 (December 31, 2024 - $<ix:nonFraction id="Fxbrl_20240324164651993" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">478,000</ix:nonFraction>), and was based on the then current price of an ADS, a risk-free interest rate of <ix:nonFraction id="Fxbrl_20230314053901242" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.47</ix:nonFraction>%, an average standard deviation of <ix:nonFraction id="Fxbrl_20230314053913105" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">101.32</ix:nonFraction>%, and on the remaining contractual life of the warrants.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The changes in fair value for the years ended December 31, 2024 and 2025 of $<ix:nonFraction id="Fxbrl_20230314054038616" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20240101to20241231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">11,427,000</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20240324164703256" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20250101to20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">454,000</ix:nonFraction> respectively, have been recorded as non-operating income in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, <ix:nonFraction id="Fxbrl_20240324164715248" name="blrx:WarrantsIssuedToPurchaseShares" contextRef="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">63,636</ix:nonFraction> of these warrants had been exercised.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The placement agent warrants have been classified in shareholders&#8217; equity, with initial recognition at fair value on the date issued, using the same assumptions as the investor warrants.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;2)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In August 2023, the Company entered into a securities purchase&#160;agreement, pursuant to which the Company sold in a private placement an aggregate of <ix:nonFraction id="Fxbrl_20240324165003117" name="ifrs-full:NumberOfSharesIssued" contextRef="C_20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">170,728</ix:nonFraction> ADSs of the Company, at a purchase price of $<ix:nonFraction id="Fxbrl_20240324165109745" name="blrx:ExercisePriceOfShareIssued" contextRef="C_20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">85.44</ix:nonFraction> per ADS. Aggregate gross proceeds from the sale amounted to $<ix:nonFraction id="Fxbrl_20240324165340844" name="ifrs-full:ProceedsFromIssuingShares" contextRef="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.6</ix:nonFraction> million, with related issuance costs amounting to approximately $<ix:nonFraction id="Fxbrl_20240324170202505" name="ifrs-full:ShareIssueRelatedCost" contextRef="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million. Pursuant to IFRS 15, approximately $<ix:nonFraction id="Fxbrl_20240324170219715" name="blrx:RecognizedAsEquity" contextRef="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullInitiallyAppliedIFRSsAxis_ifrsfullIncreaseDecreaseDueToApplicationOfIFRS15Member" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction> million of gross proceeds and $<ix:nonFraction id="Fxbrl_20240324170358812" name="ifrs-full:ShareIssueRelatedCost" contextRef="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullInitiallyAppliedIFRSsAxis_ifrsfullIncreaseDecreaseDueToApplicationOfIFRS15Member" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction> million of issuance costs were recognized as equity (see Note 15).</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 34</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 11 &#8211; EQUITY </span><span>(cont.)</span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
                <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                <td style="vertical-align:top;width:auto">
                  <div style="color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Changes in the Company&#8217;s equity</span><span> (cont.)</span></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
                <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt">&#160;</td>
                <td style="vertical-align:top;width:auto">&#160;</td>
              </tr>

          </table>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;3)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In April 2024, the Company completed a registered direct offering of <ix:nonFraction id="Fxbrl_20250327053040964" name="blrx:SharesIssuedRegisteredDirectOfferings" contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">187,500</ix:nonFraction> ADSs at a price of $<ix:nonFraction id="Fxbrl_20250327053051289" name="blrx:ExercisePriceOfShareIssued" contextRef="C_20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">32.00</ix:nonFraction> per ADS. The Company also issued to investors in the offering unregistered warrants to purchase <ix:nonFraction id="Fxbrl_20250327053107408" name="blrx:WarrantsIssuedToPurchaseShares" contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">187,500</ix:nonFraction> ADSs. The warrants are exercisable immediately, expire <ix:nonNumeric id="Fxbrl_20250327053120897" name="blrx:WarrantsExpirationPeriod" contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"> five years</ix:nonNumeric> from the date of issuance and have an exercise price of $<ix:nonFraction id="Fxbrl_20250327053135547" name="blrx:ExercisePriceOfWarrants" contextRef="C_20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">32.00</ix:nonFraction> per ADS. Gross proceeds from the offering totaled $<ix:nonFraction id="Fxbrl_20250327053205601" name="blrx:AggregateOfferingPrice" contextRef="C_20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction> million, with net proceeds of $<ix:nonFraction id="Fxbrl_20250327053215472" name="blrx:ProceedsFromWarrantIssue" contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.4</ix:nonFraction> million, after deducting fees and expenses.</span></span></div>&#160;<div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the warrants is computed using the Black-Scholes option pricing model and is determined by using a&#160;level 3&#160;valuation technique. The fair value of the warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of <ix:nonFraction id="Fxbrl_20250327053453803" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.21</ix:nonFraction>%, and an average standard deviation of <ix:nonFraction id="Fxbrl_20250327053512791" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">84.7</ix:nonFraction>%. The fair value initially allocated to the investor warrants amounted to $<ix:nonFraction id="Fxbrl_20250327053529465" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction>, with total issuance costs initially allocated to the warrants amounting to $<ix:nonFraction id="Fxbrl_20250327053547144" name="blrx:AmountAllocatedToWarrant" contextRef="C_20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">642,000</ix:nonFraction>.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Due to a difference between the fair value at initial recognition and the transaction price (&#8220;day 1 loss&#8221;),&#160;upon initial recognition, the fair value of the warrants was adjusted by the amount of $<ix:nonFraction id="Fxbrl_20260317140828916" name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="C_20251231_ifrsfullCategoriesOfFinancialLiabilitiesAxis_ifrsfullFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>, to reflect the unrecognized day 1 loss. Following initial recognition, the unrecognized day 1 loss of the warrants is being amortized over its contractual life.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the warrants amounted to $<ix:nonFraction id="Fxbrl_20250327053654403" name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">171,000</ix:nonFraction> as of December 31, 2025 (December 31, 2024 - $<ix:nonFraction id="Fxbrl_20260317140422075" name="ifrs-full:FinancialLiabilitiesAtFairValue" contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">679,000</ix:nonFraction>), and was based on the then current price of an ADS, a risk-free interest rate of <ix:nonFraction id="Fxbrl_20250327053715577" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.55</ix:nonFraction>%, an average standard deviation of <ix:nonFraction id="Fxbrl_20250327053730690" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">94</ix:nonFraction>%, and on the remaining contractual life of the warrants.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The changes in fair value for the years ended December 31, 2024 and 2025 of <ix:nonFraction id="Fxbrl_20260318021638236" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">5,571,000</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20250327054903591" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">298,000</ix:nonFraction> respectively, have been recorded as a non-operating income in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, none of these warrants had been exercised.</span></span>
                    <p style="margin:0pt">&#160;</p>
                  </div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div><ix:exclude>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 35</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 11 &#8211; EQUITY </span><span>(cont.)</span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
              <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="vertical-align:top;width:auto">
                <div style="color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Changes in the Company&#8217;s equity</span><span> (cont.)</span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
              <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt">&#160;</td>
              <td style="vertical-align:top;width:auto">&#160;</td>
            </tr>

        </table>
      </ix:exclude></div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;4)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, the Company completed a registered direct offering to certain funds associated with Highbridge Capital Management LLC (&#8220;Highbridge&#8221;) of <ix:nonFraction id="Fxbrl_20250327055310808" name="blrx:SharesIssuedRegisteredDirectOfferings" contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxHighbridgeCapitalManagementLlcMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">103,037</ix:nonFraction> ADSs and <ix:nonFraction id="Fxbrl_20250327055336152" name="blrx:SharesIssuedRegisteredDirectOfferings" contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">308,749</ix:nonFraction> pre-funded warrants to purchase ADSs. Each ADS and pre-funded warrant was sold at a purchase price of $<ix:nonFraction id="Fxbrl_20250327055414991" name="blrx:ExercisePriceOfShareIssued" contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxHighbridgeCapitalManagementLlcMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">21.86</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20250327055419007" name="blrx:ExercisePriceOfShareIssued" contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">21.85</ix:nonFraction>, respectively. The Company also issued to the investors unregistered ordinary warrants to purchase an aggregate of <ix:nonFraction id="Fxbrl_20250327055505325" name="blrx:WarrantsIssuedToPurchaseShares" contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">205,893</ix:nonFraction> ADSs. Gross proceeds from the offering totaled $<ix:nonFraction id="Fxbrl_20250327055518647" name="blrx:AggregateOfferingPrice" contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction> million, with net proceeds of $<ix:nonFraction id="Fxbrl_20250327055530087" name="blrx:ProceedsFromWarrantIssue" contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.9</ix:nonFraction> million, after deducting fees and expenses. See Note 16.</span></span></div>
                <div>&#160;</div>
                <div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The pre-funded warrants are exercisable immediately, do not expire until exercised in full, and have an exercise price of $<ix:nonFraction id="Fxbrl_20250327055706384" name="blrx:ExercisePriceOfShareIssued" contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember" unitRef="USD_per_Share" scale="0" decimals="3" format="ixt:num-dot-decimal">0.004</ix:nonFraction> per ADS. The ordinary warrants are exercisable immediately, expire <ix:nonNumeric id="Fxbrl_20250327055750895" name="blrx:WarrantsExpirationPeriod" contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"> four years</ix:nonNumeric> from the date of issuance, and have an exercise price of $<ix:nonFraction id="Fxbrl_20260317141350007" name="blrx:ExercisePriceOfWarrants" contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">23.60</ix:nonFraction> per ADS.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A holder of the pre-funded or ordinary warrants cannot exercise such warrants if the holder, together with its affiliates, would beneficially own in excess of <ix:nonFraction id="Fxbrl_20250327055923090" name="blrx:BeneficiallyOwnInExcess" contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.99</ix:nonFraction>% of the outstanding share capital of the Company immediately after giving effect to such exercise.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ordinary warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The pre-funded warrants have been classified in shareholders&#8217; equity, with initial recognition at fair value on the date issued, using the same assumptions as the ordinary warrants.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the ordinary warrants is computed using the Black-Scholes option pricing model. The fair value of the ordinary warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of <ix:nonFraction id="Fxbrl_20250327060326785" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.19</ix:nonFraction>%, and an average standard deviation of <ix:nonFraction id="Fxbrl_20250327060339417" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">84.5</ix:nonFraction>%. The gross consideration initially allocated to ordinary warrants amounted to $<ix:nonFraction id="Fxbrl_20250327060353217" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,721,000</ix:nonFraction>, with total issuance costs initially allocated to the ordinary warrants amounting to $<ix:nonFraction id="Fxbrl_20250327060405329" name="blrx:AmountAllocatedToWarrant" contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">27,000</ix:nonFraction>.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the ordinary warrants amounted to $<ix:nonFraction id="Fxbrl_20250327060452136" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">102,000</ix:nonFraction> as of December 31, 2025 (December 31,2024- $<ix:nonFraction id="Fxbrl_20260317135635140" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">745,000</ix:nonFraction>) and was based on the then current price of an ADS, a risk-free interest rate of <ix:nonFraction id="Fxbrl_20250327060524128" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.55</ix:nonFraction>%, an average standard deviation of <ix:nonFraction id="Fxbrl_20250327060611666" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">96</ix:nonFraction>%, and on the remaining contractual life of the ordinary warrants.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The changes in fair value for the years ended December 31, 2024 and 2025 of $<ix:nonFraction id="Fxbrl_20260317135618497" name="blrx:ChangesInFairValueRecordedAsANonoperatingIncome" contextRef="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,976,000</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20250327060654888" name="blrx:ChangesInFairValueRecordedAsANonoperatingIncome" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">643,000</ix:nonFraction> respectively, have been recorded as non-operating income in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, <ix:nonFraction id="Fxbrl_20250327060723548" name="blrx:WarrantsIssuedToPurchaseShares" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">226,392</ix:nonFraction> of the pre-funded warrants had been exercised, and none of the ordinary warrants had been exercised.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div><ix:exclude>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 36</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 11 &#8211; EQUITY </span><span>(cont.)</span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
              <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="vertical-align:top;width:auto">
                <div style="color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Changes in the Company&#8217;s equity</span><span> (cont.)</span></span></span></div>
              </td>
            </tr>
            <tr>
              <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
              <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt">&#160;</td>
              <td style="vertical-align:top;width:auto">&#160;</td>
            </tr>

        </table>
      </ix:exclude></div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;5)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2025, the Company completed a registered direct offering to certain institutional investors of <ix:nonFraction id="Fxbrl_20260317143223196" name="blrx:SharesIssuedRegisteredDirectOfferings" contextRef="C_20250101to20250131_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">858,303</ix:nonFraction> ADSs and <ix:nonFraction id="Fxbrl_20260317143257916" name="blrx:SharesIssuedRegisteredDirectOfferings" contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">391,697</ix:nonFraction> pre-funded warrants to purchase ADSs. Each ADS and pre-funded warrant was sold at a purchase price of $<ix:nonFraction id="Fxbrl_20260317144033649" name="blrx:ExercisePriceOfShareIssued" contextRef="C_20250131_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">8.00</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20260317144040498" name="blrx:ExercisePriceOfShareIssued" contextRef="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD_per_Share" scale="0" decimals="3" format="ixt:num-dot-decimal">7.996</ix:nonFraction>, respectively. The Company also issued to investors in the offering unregistered ordinary warrants to purchase an aggregate of <ix:nonFraction id="Fxbrl_20260317144348705" name="blrx:WarrantsIssuedToPurchaseShares" contextRef="C_20250101to20250131_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,250,000</ix:nonFraction> ADSs. The pre-funded warrants are exercisable immediately, do not expire until exercised in full, and have an exercise price of $<ix:nonFraction id="Fxbrl_20260317144336937" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" contextRef="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD_per_Share" scale="0" decimals="3" format="ixt:num-dot-decimal">0.004</ix:nonFraction> per ADS. The ordinary warrants are exercisable immediately, expire <ix:nonNumeric id="Fxbrl_20260317144423706" name="blrx:WarrantsExpirationPeriod" contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"> five years</ix:nonNumeric> from the date of issuance, and have an exercise price of $<ix:nonFraction id="Fxbrl_20260317144444209" name="blrx:ExercisePriceOfWarrants" contextRef="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">8.00</ix:nonFraction> per ADS. A holder of the pre-funded or ordinary warrants cannot exercise such warrants if the holder, together with its affiliates, would beneficially own in excess of <ix:nonFraction id="Fxbrl_20260317144524376" name="blrx:BeneficiallyOwnInExcess" contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.99</ix:nonFraction>% (or 9.99% at the election of the holder) of the outstanding share capital of the Company immediately after giving effect to such exercise.</span></span></div>
                <div>&#160;</div>
                <div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, the Company granted to the placement agent in the offering, as part of the placement fee, warrants to purchase <ix:nonFraction id="Fxbrl_20260317144642236" name="blrx:WarrantsIssuedToPurchaseShares" contextRef="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">62,500</ix:nonFraction> ADSs. These warrants are exercisable immediately, expire <ix:nonNumeric id="Fxbrl_20260317144727824" name="blrx:WarrantsExpirationPeriod" contextRef="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"> five years</ix:nonNumeric> from the date of issuance and have an exercise price of $<ix:nonFraction id="Fxbrl_20260317144745816" name="blrx:ExercisePriceOfWarrants" contextRef="C_20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per ADS. The offering consideration allocated to the placement agent warrants amounted to $<ix:nonFraction id="Fxbrl_20260317144815608" name="blrx:WarrantOfferingConsideration" contextRef="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross proceeds from the offering totaled $<ix:nonFraction id="Fxbrl_20260317145157752" name="blrx:ProceedsFromIssuanceOfInitialPublicOffering" contextRef="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction> million, with net proceeds of $<ix:nonFraction id="Fxbrl_20260317145543439" name="blrx:ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses" contextRef="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.9</ix:nonFraction> million, after deducting fees and expenses.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The investors&#8217; ordinary warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The pre-funded warrants have been classified in shareholders&#8217; equity. The fair value of the ordinary warrants is computed using the Black-Scholes option pricing model and is determined by using a level 3 valuation technique. The fair value of the ordinary warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of <ix:nonFraction id="Fxbrl_20260317145722430" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.41</ix:nonFraction>%, and an average standard deviation of <ix:nonFraction id="Fxbrl_20260317145815077" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">90.2</ix:nonFraction>%. The fair value initially allocated to the investor ordinary warrants amounted to $<ix:nonFraction id="Fxbrl_20260317145833957" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.4</ix:nonFraction> million, with total issuance costs initially allocated to the ordinary warrants amounting to $<ix:nonFraction id="Fxbrl_20260317145902029" name="blrx:AmountAllocatedToWarrant" contextRef="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction> million.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Due to a difference between the fair value at initial recognition and the transaction price (&#8220;Day 1 loss&#8221;), upon initial recognition, the fair value of the ordinary warrants was adjusted by the amount of $<ix:nonFraction id="Fxbrl_20260317150419004" name="blrx:FairValueOfOrdinaryWarrantsAdjustedAmount" contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction> million, to reflect the unrecognized day 1 loss. Following initial recognition, the unrecognized day 1 loss of the warrants is being amortized over its contractual life.</span></span></div>
                </div>
              </td>
            </tr>

        </table>&#160;<div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 37</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 11 &#8211; EQUITY </span><span>(cont.)</span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
                <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                <td style="vertical-align:top;width:auto">
                  <div style="color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Changes in the Company&#8217;s equity</span><span> (cont.)</span></span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="font-family:Times New Roman, Times, serif;width:67pt">&#160;</td>
                <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:18pt">5)</td>
                <td style="vertical-align:top;width:auto;text-align:justify">(cont.)</td>
              </tr>
              <tr>
                <td style="font-family:Times New Roman, Times, serif;width:67pt">&#160;</td>
                <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:18pt">&#160;</td>
                <td style="vertical-align:top;width:auto">&#160;</td>
              </tr>

          </table>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the ordinary warrants amounted to $<ix:nonFraction id="Fxbrl_20260317150511045" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,878,000</ix:nonFraction> as of December 31, 2025, and was based on the then current price of an ADS, a risk-free interest rate of <ix:nonFraction id="Fxbrl_20260317150548692" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.64</ix:nonFraction>%, an average standard deviation of <ix:nonFraction id="Fxbrl_20260317150614356" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">91.0</ix:nonFraction>%, and on the remaining contractual life of the warrants.</span></span></div>
                <div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The changes in fair value for the year ended December 31, 2025 of $<ix:nonFraction id="Fxbrl_20260317150659436" name="blrx:ChangesInFairValueRecordedAsANonoperatingIncome" contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">7,204,000</ix:nonFraction>, have been recorded as non-operating income in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, all of the pre-funded warrants had been exercised, and none of the ordinary warrants had been exercised.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with IFRS 2, the placement agent warrants have been classified in shareholders&#8217; equity, with initial recognition at fair value on the date issued, using the same assumptions as the investor warrants.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 38</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">NOTE 11 &#8211; EQUITY </span>(cont.)</span></span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share purchase agreement</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2021, the Company entered into an ATM sales agreement with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;), pursuant to which the Company is entitled, at its sole discretion, to offer and sell through HCW, acting as sales agent, ADSs having an aggregate offering price of up to $<ix:nonFraction id="Fxbrl_20220305140438613" name="blrx:AggregateOfferingPrice" contextRef="C_20200930_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction> million throughout the period during which the ATM facility remains in effect. The Company agreed to pay HCW a commission of <ix:nonFraction id="Fxbrl_20220304150237043" name="blrx:PercentageOfCommissionOnSalesAgreement" contextRef="C_20200930_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction>%&#160;of the gross proceeds from the sale of ADSs under the facility. During 2025, <ix:nonFraction id="Fxbrl_20260317150843891" name="blrx:SaleOfStockNumberOfSharesIssued" contextRef="C_20250101to20251231_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">772,264</ix:nonFraction> ADSs were sold under the program for total net proceeds of $<ix:nonFraction id="Fxbrl_20260317150912371" name="ifrs-full:ProceedsFromIssuingShares" contextRef="C_20250101to20251231_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction> million. From the effective date of the agreement through the issuance date of this report, <ix:nonFraction id="Fxbrl_20220304150321792" name="blrx:SaleOfStockNumberOfSharesIssued" contextRef="C_20200901to20200930_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">825,010</ix:nonFraction> ADSs have been sold under the program for total net proceeds of $<ix:nonFraction id="Fxbrl_20220304150309000" name="ifrs-full:ProceedsFromIssuingShares" contextRef="C_20240101to20241231_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.2</ix:nonFraction> million.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based payments</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:74pt">&#160;</td>
              <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
              <td style="vertical-align:top;text-align:justify;width:auto">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share Incentive plan &#8211; general</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In 2003, the Company adopted the 2003 Share Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the granting of stock options and ordinary shares to the Company&#8217;s employees, directors, consultants and other service providers. Options are issued at the determination of the Board of Directors in accordance with applicable law. The options are generally exercisable for a ten -year period, and the grants generally vest over a four -year period. In 2013, the Company&#8217;s Board of Directors approved amendments to the Plan to take into account changes in laws and regulations that had occurred since its adoption and to extend the term of the plan until November 2023. In 2016, the Board of Directors approved amendments to the Plan to allow for the grant of restricted stock units (&#8220;RSUs&#8221;) and performance stock units (&#8220;PSUs&#8221;). In 2022, the Board approved certain amendments to the Plan in order to conform the Plan to U.S. tax regulations for the benefit BioLineRx USA, Inc. employees.&#160;In November 2023, the Company&#8217;s Board of Directors approved extension of the Plan through May 2024, and subsequently further approved extension of the Plan through May 2044.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PSUs are RSUs that are linked to any one or more performance goals (in addition to, or in lieu of, time-based vesting terms) determined appropriate by the Board of Directors. The specific performance goals, as well as the time period associated with achieving such goals, are approved by the Board and are set forth in the grantee&#8217;s grant agreement. <ix:nonNumeric id="Fxbrl_20260318020210320" name="ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxShareIncentivePlanMember">To date, each PSU grant has had between three to five performance goals on which vesting is based, each such goal being either a specified Company milestone and or the success of a specific project, with vesting of 20-40% on the achievement of each goal.</ix:nonNumeric> The tranche of PSUs associated with a given milestone expires 12 months after the target date established for that milestone. As of December 31, 2025, <ix:nonFraction id="F20211006115503102_157" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxShareIncentivePlanMember" unitRef="Pure" decimals="INF" format="ixt:num-dot-decimal">8,787,600</ix:nonFraction> PSUs were vested in accordance with their original terms.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 39</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
          <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 11 &#8211; EQUITY </span><span>(cont.)</span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
                <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                <td style="vertical-align:top;width:auto">
                  <div style="color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Share-based payments </span><span>(cont.)</span></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
                <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt">&#160;</td>
                <td style="vertical-align:top;width:auto">&#160;</td>
              </tr>

          </table>
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="font-family:Times New Roman, Times, serif;width:74pt">&#160;</td>
                <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:18pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1)</span></td>
                <td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif;width:auto">
                  <div style="color:rgb(0, 0, 0)"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Share Incentive plan &#8211; general (cont.)</span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, there were <ix:nonFraction id="F20211006115503103_158" name="ifrs-full:NumberOfSharesIssued" contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxShareIncentivePlanMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">326,757,000</ix:nonFraction> ordinary shares issuable upon the exercise of outstanding equity instruments under the Plan.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Company employees and directors in Israel are granted options under Section 102 of the Israeli Income Tax Ordinance (the &#8220;Ordinance&#8221;), primarily under the &#8220;capital gains&#8221; track. Israeli non-employees of the Company (consultants and other service providers) are granted options under Section 3(i) of the Ordinance. All non-Israeli employees and non-employees of the Company are granted options as non-qualifies.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, there were <ix:nonFraction id="F20211006115503110_163" name="blrx:RemainingAuthorizedUnissuedOrdinaryShares" contextRef="C_20251231" unitRef="Shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">233.4</ix:nonFraction> million remaining authorized but unissued ordinary shares in the pool reserved for future share-based incentive grants.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:74pt">&#160;</td>
              <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
              <td style="vertical-align:top;width:auto">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee share incentive plan:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table contains additional information concerning equity instruments granted to employees and directors under the existing share incentive plans.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:99pt">
          <ix:nonNumeric id="Fxbrl_20250327041531143" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" contextRef="C_20250101to20251231" escape="true">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="22" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number<br/>of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise price</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number<br/>of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise price</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number<br/>of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise price</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at beginning of year</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502965_17" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20221231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">89,871,858</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502966_18" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20221231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.44</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502967_19" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">150,429,825</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502967_20" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.32</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502971_21" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">141,634,245</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502972_22" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.32</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502973_23" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">64,855,380</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502974_24" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.18</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502975_25" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">23,190,000</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502975_26" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.20</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502976_27" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">212,760,000</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502977_28" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expired</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20250327115544603_20211006115502973_23" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,379,640</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327115544603_20211006115502974_24" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.68</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20250327115544603_20211006115502975_25" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">3,825,990</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327115544603_20211006115502975_26" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.53</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20250327115544603_20211006115502976_27" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">24,310,920</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327115544603_20211006115502977_28" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.25</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502978_29" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,424,535</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502979_30" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.21</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502980_31" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,389,565</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502981_32" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.23</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502981_33" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">18,116,325</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502982_34" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.25</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(<ix:nonFraction id="F20211006115502983_35" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">493,238</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502986_36" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.22</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240324173832656" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">770,025</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502987_38" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.14</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324173750102" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324173515688" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at end of year*</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115502990_41" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">150,429,825</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115502991_42" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.32</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115502992_43" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">141,634,245</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115502993_44" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.32</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502993_45" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">311,967,000</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115502994_46" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.12</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable at end of year</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115502995_47" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">51,970,635</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115502996_48" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.54</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115502997_49" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">88,080,600</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115502998_50" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.40</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115503000_51" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">81,825,600</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503001_52" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.39</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:99pt">&#160;</td>
              <td style="width:7.05pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, 2024 and 2025 includes <ix:nonFraction id="Fxbrl_20220304152435700" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">12,219,465</ix:nonFraction>, <ix:nonFraction id="Fxbrl_20220304152442682" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">4,010,670</ix:nonFraction> and <ix:nonFraction id="Fxbrl_20220304152449442" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">8,126,400</ix:nonFraction> respectively, PSUs at an exercise price of <ix:nonFraction id="Fxbrl_20220305192307100" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220305192045655" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220304152502892" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.10</ix:nonFraction></ix:nonFraction></ix:nonFraction> NIS (par value of ordinary shares) for which performance obligations have not been met. As of December 31, 2025 includes additional <ix:nonFraction id="Fxbrl_20260317154353940" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitTwoMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">21,240,000</ix:nonFraction> PSUs at a <ix:nonFraction id="Fxbrl_20260317154421051" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitTwoMember" unitRef="ILS_per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen">zero</ix:nonFraction> exercise price, for which performance obligations have not been met.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 40</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
          <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 11 &#8211; EQUITY </span><span>(cont.)</span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
                <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                <td style="vertical-align:top;width:auto">
                  <div style="color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Share-based payments</span><span> (cont.)</span></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
                <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt">&#160;</td>
                <td style="vertical-align:top;width:auto">&#160;</td>
              </tr>

          </table>
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="font-family:Times New Roman, Times, serif;width:74pt">&#160;</td>
                <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:18pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2)</span></td>
                <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">
                  <div style="color:rgb(0, 0, 0)"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Employee share incentive plan (cont.):</span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The total consideration received from the exercise of equity instruments during 2023, 2024 and 2025 was not material.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Set forth below is data regarding the range of exercise prices and weighted-average remaining contractual life (in years) for the equity instruments outstanding at the end of each of the years indicated.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">
          <ix:nonNumeric id="Fxbrl_20250327041553087" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" contextRef="C_20250101to20251231" escape="true">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="14" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Range of</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise prices</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Number</span></span></span></span></strong></div>
                        <div style="line-height:1.25;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">of options outstanding</span></span></span></span></strong></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining contractual life (in&#160;yrs.)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Number</span></span></span></span></strong></div>
                        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">of options outstanding</span></span></span></span></strong></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining contractual life (in&#160;yrs.)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Up to 0.49</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324164459671_20211006115503003_55" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">114,352,425</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonNumeric id="Fxbrl_20240324164459671_20211006115503004_56" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember" format="ixt-sec:duryear">8.07</ix:nonNumeric></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324164459671_20211006115503005_57" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">288,520,200</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonNumeric id="Fxbrl_20240324164459671_20211006115503006_58" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember" format="ixt-sec:duryear">9.07</ix:nonNumeric></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.5-0.99</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115503003_55" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">15,104,100</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonNumeric id="F20211006115503004_56" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember" format="ixt-sec:duryear">6.54</ix:nonNumeric></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115503005_57" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">12,576,000</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonNumeric id="F20211006115503006_58" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember" format="ixt-sec:duryear">4.96</ix:nonNumeric></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.00-2.00</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115503015_67" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,727,795</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonNumeric id="F20211006115503016_68" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember" format="ixt-sec:duryear">4.57</ix:nonNumeric></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115503017_69" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">10,423,800</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonNumeric id="F20211006115503018_70" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember" format="ixt-sec:duryear">2.82</ix:nonNumeric></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.01-3.4</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324164501865_20211006115503003_55" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">449,925</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonNumeric id="Fxbrl_20240324164501865_20211006115503004_56" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember" format="ixt-sec:duryear">3.18</ix:nonNumeric></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240324164501865_20211006115503005_57" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">447,000</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonNumeric id="Fxbrl_20240324164501865_20211006115503006_58" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember" format="ixt-sec:duryear">1.17</ix:nonNumeric></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115503025_79" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20241231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">141,634,245</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonNumeric id="F20211006115503026_80" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="C_20240101to20241231" format="ixt-sec:duryear">7.60</ix:nonNumeric></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="F20211006115503028_81" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20251231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">311,967,000</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonNumeric id="F20211006115503029_82" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="C_20250101to20251231" format="ixt-sec:duryear">8.68</ix:nonNumeric></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of equity instruments granted to employees through December 31, 2025 has been determined using the Black-Scholes option-pricing model. These values are based on the following assumptions as of the applicable grant dates:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">
          <ix:nonNumeric id="Fxbrl_20250327041607903" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" contextRef="C_20250101to20251231" escape="true">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="width:41%;vertical-align:bottom;padding-bottom:2px">&#160;</td>
                    <td style="width:20.28%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;padding-bottom:2px">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;padding-bottom:2px">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected dividend yield</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503030_83" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503031_84" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503032_85" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="C_20250101to20251231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503032_86" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">69</ix:nonFraction>%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503033_87" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">73</ix:nonFraction>%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503034_88" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="C_20250101to20251231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">93</ix:nonFraction>%</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503035_89" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503035_90" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503036_91" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="C_20250101to20251231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>%</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life of options (in years)</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503037_92" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="C_20230101to20231231" unitRef="Year" scale="0" decimals="0" format="ixt:num-dot-decimal">6</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503038_93" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="C_20240101to20241231" unitRef="Year" scale="0" decimals="0" format="ixt:num-dot-decimal">6</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><ix:nonFraction id="F20211006115503039_94" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" contextRef="C_20250101to20251231" unitRef="Year" scale="0" decimals="0" format="ixt:num-dot-decimal">6</ix:nonFraction></div>
                    </td>
                  </tr>

              </table>
            </div>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The remaining unrecognized deferred compensation expense as of December 31, 2025 was $<ix:nonFraction id="F20211006115503113_166" name="blrx:RemainingUnrecognizedDeferredCompensationExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction> million. This amount will be expensed over the remaining vesting period of the equity instruments.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 41</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
          <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 11 &#8211; EQUITY </span><span>(cont.)</span></span></span></div>
          <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
          <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

                <tr>
                  <td style="font-family:Times New Roman, Times, serif;width:43pt">&#160;</td>
                  <td style="vertical-align:top;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-weight:bold;width:24pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">e.</span></td>
                  <td style="vertical-align:top;width:auto">
                    <div style="font-size:11pt;font-family:Times New Roman, serif;color:rgb(0, 0, 0)"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">Share-based payments</span> (cont.)</span></div>
                  </td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </div>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:74pt">&#160;</td>
              <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3)</span></span></td>
              <td style="vertical-align:top;width:auto">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock options to consultants</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">From inception through December 31, 2025, the Company has issued to consultants options for the purchase of <ix:nonFraction id="F20211006115503120_172" name="ifrs-full:NumberOfSharesIssued" contextRef="C_20231231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">17,836,200</ix:nonFraction> ordinary shares at a weighted average exercise price of <ix:nonFraction id="F20211006115503120_173" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="C_20230101to20231231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.36</ix:nonFraction> NIS per share.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20211006115503125_179" name="ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" contextRef="C_20250101to20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember">The options to consultants generally vest over four years and may be exercised for periods of between five and ten years.</ix:nonNumeric> As of December 31, 2025, <ix:nonFraction id="F20211006115503124_178" name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="C_20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">14,790,000</ix:nonFraction> options to consultants were outstanding with a weighted average exercise price of NIS <ix:nonFraction id="F20211006115503126_180" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="C_20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember" unitRef="ILS_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.03</ix:nonFraction> per share and a weighted average contractual life of <ix:nonNumeric id="Fxbrl_20211011164913211" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" contextRef="C_20250101to20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember" format="ixt-sec:duryear">9.8</ix:nonNumeric> years.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Company management estimates the fair value of the options granted to consultants based on the value of services received over the vesting period of the applicable options. The value of such services (primarily in respect of clinical advisory services) is estimated based on the additional cash compensation the Company would need to pay if such options were not granted. The value of services recorded in each of the years 2023, 2024 and 2025 was not material.</span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260317142207252" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" contextRef="C_20250101to20251231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 12 &#8211; TAXES ON INCOME</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Corporate taxation</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The taxable income of BioLineRx Ltd. and Tetragon is taxed at the standard Israeli corporate tax rate, which was <ix:nonFraction id="Fxbrl_s_20230320181509413" name="ifrs-full:ApplicableTaxRate" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230320181509414" name="ifrs-full:ApplicableTaxRate" contextRef="C_20250101to20251231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></ix:nonFraction>% for all years included in these financial statements.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax loss carryforwards</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, the tax loss carryforwards of BioLineRx Ltd. were approximately $<ix:nonFraction id="F20211006115503157_4" name="blrx:TaxLossCarryforwards" contextRef="C_20250101to20251231" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">381</ix:nonFraction> million. The tax loss carryforwards have no expiration date.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assessments</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with Israeli tax regulations, the tax returns filed by BioLineRx Ltd. through the 2020 tax year are considered final.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 42</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
        </div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 12 &#8211; TAXES ON INCOME</span> (cont.)</span></span></div>
        <div style="line-height:1.25">&#160;</div>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical taxes</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has not recognized any deferred tax assets in the financial statements, as it does not expect to generate taxable income in the foreseeable future. The reported tax on the Company&#8217;s income before taxes differs from the theoretical amount that would arise using the weighted average tax rate applicable to income of the consolidated entities as follows:</span></span></div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20260317142220573" name="blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div>
          <div style="margin-left:72pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="22" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503157_6" name="ifrs-full:ApplicableTaxRate" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">23.0</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115503158_9" name="ifrs-full:AccountingProfit" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">60,614</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503157_7" name="ifrs-full:ApplicableTaxRate" contextRef="C_20240101to20241231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">23.0</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115503158_10" name="ifrs-full:AccountingProfit" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,221</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503158_8" name="ifrs-full:ApplicableTaxRate" contextRef="C_20250101to20251231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">23.0</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115503158_11" name="ifrs-full:AccountingProfit" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,026</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical tax benefit</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115503159_12" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,941</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115503159_13" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,121</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="F20211006115503159_14" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">466</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Disallowed deductions (tax exempt income):</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss (gain) on adjustment of warrants to fair value</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503159_15" name="blrx:TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,542</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20240323053527621" name="blrx:TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,056</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20230314152311676" name="blrx:TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,978</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20260317142144620" name="blrx:TaxEffectOfShareBasedCompensationExemptFromTaxation" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">534</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503160_19" name="blrx:TaxEffectOfShareBasedCompensationExemptFromTaxation" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503160_20" name="blrx:TaxEffectOfShareBasedCompensationExemptFromTaxation" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Impairment of intangible asset</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240323053554820_20211006115503160_18" name="blrx:WriteoffOfIntangibleAsset" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,542</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240323053554820_20211006115503160_19" name="blrx:WriteoffOfIntangibleAsset" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">232</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20240323053554820_20211006115503160_20" name="blrx:WriteoffOfIntangibleAsset" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503161_21" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503161_22" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503161_23" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503161_24" name="blrx:IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,312</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503162_25" name="blrx:IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,673</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503162_26" name="blrx:IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,342</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income for the reported year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503162_27" name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="F20211006115503162_28" name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250326193719808" name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <div>
    <ix:nonNumeric id="Fxbrl_20250326194950231" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" contextRef="C_20250101to20251231" escape="true">
      <div>
        <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 13 &#8211; LOSS PER SHARE</span></span></div>
        <div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;text-indent:-21.25pt;margin-left:70.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table contains the data used in the computation of the basic loss per share:</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:54pt">
            <ix:nonNumeric id="Fxbrl_20250326193350587" name="blrx:DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory" contextRef="C_20250101to20251231" escape="true">
              <div>
                <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss attributed to ordinary shares</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(<ix:nonFraction id="F20211006115503174_1" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">60,614</ix:nonFraction></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(<ix:nonFraction id="F20211006115503174_2" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,221</ix:nonFraction></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(<ix:nonFraction id="F20211006115503174_3" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,026</ix:nonFraction></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in thousands</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of shares used in basic calculation</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220304172633227_20211006115503174_1" name="ifrs-full:WeightedAverageShares" contextRef="C_20230101to20231231" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">963,366</ix:nonFraction></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220304172633227_20211006115503174_2" name="ifrs-full:WeightedAverageShares" contextRef="C_20240101to20241231" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,198,108</ix:nonFraction></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20220304172633227_20211006115503174_3" name="ifrs-full:WeightedAverageShares" contextRef="C_20250101to20251231" unitRef="Shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,465,273</ix:nonFraction></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20230311055749004" name="ifrs-full:DilutedEarningsLossPerShare" contextRef="C_20230101to20231231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="F20211006115503174_7" name="ifrs-full:BasicEarningsLossPerShare" contextRef="C_20230101to20231231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.06</ix:nonFraction></ix:nonFraction></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20230311055803379" name="ifrs-full:DilutedEarningsLossPerShare" contextRef="C_20240101to20241231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="F20211006115503174_8" name="ifrs-full:BasicEarningsLossPerShare" contextRef="C_20240101to20241231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.01</ix:nonFraction></ix:nonFraction></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20230311055817891" name="ifrs-full:DilutedEarningsLossPerShare" contextRef="C_20250101to20251231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="F20211006115503175_9" name="ifrs-full:BasicEarningsLossPerShare" contextRef="C_20250101to20251231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.00</ix:nonFraction></ix:nonFraction></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                    </tr>

                </table>
              </div>
            </ix:nonNumeric>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The number of shares used in the 2024 and 2025 basic calculations includes <ix:nonFraction id="Fxbrl_20260317154957402" name="blrx:PreFundedWarrants" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,052</ix:nonFraction> and <ix:nonFraction id="Fxbrl_20250326194937641" name="blrx:PreFundedWarrants" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,279</ix:nonFraction> pre-funded warrants, respectively.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding options, RSUs, PSUs and ordinary warrants have been&#160;excluded from the calculation of the diluted loss per share for all years presented, since their effect was anti-dilutive.</span></span></div>
        </div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 43</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
  </div>

  <ix:nonNumeric id="Fxbrl_20260317145024567" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" contextRef="C_20250101to20251231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 14 &#8211; COMMITMENTS AND CONTINGENT LIABILITIES</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commitments</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Obligation to pay royalties to the State of Israel</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalties may be payable to the State of Israel (represented by the Israel Innovation Authority, or IIA), on proceeds from the sale or license of products whose development was supported by grants from&#160;the IIA. Such royalties are generally <ix:nonFraction id="Fxbrl_20240324071913871" name="blrx:RoyaltiesReceivedPercentage" contextRef="C_20250101to20251231_ifrsfullMaturityAxis_blrxFirstThreeYearsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>% in the first three years from initial repayment, <ix:nonFraction id="Fxbrl_20260317151021093" name="blrx:RoyaltiesReceivedPercentage" contextRef="C_20250101to20251231_ifrsfullMaturityAxis_blrxThreeSubsequentYearsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of sales in the three subsequent years and <ix:nonFraction id="Fxbrl_20260317151023551" name="blrx:RoyaltiesReceivedPercentage" contextRef="C_20250101to20251231_ifrsfullMaturityAxis_blrxSeventhYearMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of sales in the seventh year until repayment of <ix:nonFraction id="F20211006115503180_1" name="blrx:RoyaltiesReceivedPercentage" contextRef="C_20250101to20251231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the grants (linked to the dollar) received, plus annual interest at the 12-month SOFR rate as published on the first trading day of each calendar year. Under certain circumstances, the royalty rate is calculated according to a formula based on the ratio of participation by the IIA in the project to the project&#8217;s total accumulated costs.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other than motixafortide (see next paragraph), the Company does not have any royalty obligation in respect of products supported by the IIA.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the in-licensing of motixafortide from Biokine Therapeutics Ltd. (&#8220;Biokine&#8221;), and as a condition to IIA consent to the transaction, the Company agreed to abide by any obligations resulting from funds previously received by Biokine from the IIA. The contingent liability to the IIA assumed by the Company relating to this transaction amounts to $<ix:nonFraction id="Fxbrl_20230322125255995" name="blrx:ContingentLiability" contextRef="C_20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction> million as of December 31, 2025. In this regard, and in connection with the out-licensing transactions with Gloria (see Note 15) and with Ayrmid (see Note 16), as well as with the direct sales of motixafortide in the U.S. during the period from product launch through the transaction with Ayrmid, the royalty rate agreed with the IIA for motixafortide consideration received is <ix:nonFraction id="Fxbrl_20260317160834623" name="blrx:PercentageOfNetConsiderationReceivedForSubLicense" contextRef="C_20250101to20251231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.9</ix:nonFraction>% for sub-license consideration and <ix:nonFraction id="Fxbrl_20260317160847298" name="blrx:PercentageOfNetConsiderationReceivedForDirectProductSales" contextRef="C_20250101to20251231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>% for direct product sales. The Company has a full right of offset for amounts payable to the IIA from all payments due to Biokine in the future.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Licensing agreements</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the development of therapeutic compounds, the Company may enter into in-licensing agreements with academic institutions, research institutions and companies (the &#8220;licensors&#8221;). Pursuant to these licensing agreements, the Company generally obtains the rights for one or more therapeutic compounds in pre-clinical and early clinical stages of development, in order to continue development of the compounds through more advanced stages of development and, subsequently, to manufacture, distribute and market the drugs or to out-license the development, manufacturing and commercialization rights to third parties.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 44</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        </div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 14 &#8211; COMMITMENTS AND CONTINGENT LIABILITIES</span> (cont.)</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Commitments</span> (cont.)</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:70.9pt">&#160;</td>
              <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Licensing agreements (cont.)</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:70.9pt">&#160;</td>
              <td style="width:21.25pt;vertical-align:top">&#160;</td>
              <td style="width:auto;vertical-align:top">&#160;</td>
            </tr>

        </table>
      </ix:exclude></div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The licenses that have been granted to the Company are broad and comprehensive, and generally include various provisions and usage rights as follows: (i) territorial scope of the license (global); (ii) term of the license (unrestricted but not shorter than the life of the patent); and (iii) development of the therapeutic compound (allowing the Company to perform all development activities on its own, or by outsourcing under Company supervision, as well as out-licensing development under the license to other companies, subject to the provisions of the licensing agreements).</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">According to the provisions of the licensing agreements, the intellectual property rights in the development of any licensed technology, through the date the applicable license agreement is effective, remain with the licensor, while the rights in products and/or other deliverables developed by the Company after the license is granted belong to the Company. In cases where the licensor has a claim to an invention that was jointly developed with the Company, the licensor also co-owns the related intellectual property. In any event, the scope of the license also covers these intellectual property rights.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, the Company generally undertakes in the licensing agreements to protect registered patents resulting from developments under the various licenses, to promote the registration of patents covering new developments in cooperation with the licensor, and to bear responsibility for all related costs. Pursuant to the various agreements, the Company generally works to register the various patents on a broad basis worldwide, and if the Company decides not to initiate or continue a patent registration proceeding in a given country, the Company is required to notify the applicable licensor to this effect, and the licensor is entitled to take action for registration of the patent in such country.</span></span></div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consideration paid pursuant to the licensing agreements generally includes several components that may be payable over the license period and that relate, inter alia, to the progress made in research and development activities, as well as commercial success, as follows: (a) a one-time, up-front payment and/or periodic payments; (b) payments through the early stages of development (i.e., through the end of phase 2); (c) payments upon the achievement of milestones necessary for advancing to phase 3; (d) payments from the end of a successful phase 3 trial through approval of the therapeutic compound; and e) royalties on sales of the final product resulting from development under the license or including any component thereof, generally less than <ix:nonFraction id="Fxbrl_20260317151249446" name="blrx:RoyaltiesOnSale" contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of the Company&#8217;s net sales of the product, although in specific instances (for example, with regard to motixafortide, where the royalty rate on net sales directly commercialized by the Company payable to Biokine is <ix:nonFraction id="Fxbrl_20260317161352027" name="blrx:RoyaltiesOnSale" contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction>%) the royalty rate has been higher or lower than this range. In instances where the Company has out-licensed the product for further development, the Company pays a percentage of the net consideration received from the licensee (&#8220;Sublicense Receipts&#8221;) to the upstream licensor that generally range from <ix:nonFraction id="F20211006115503181_8" name="blrx:PercentageOfNetConsiderationReceivedFromLicensee" contextRef="C_20201231to20201231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction>% to <ix:nonFraction id="F20211006115503182_9" name="blrx:PercentageOfNetConsiderationReceivedFromLicensee" contextRef="C_20201231to20201231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">29.5</ix:nonFraction>% of such consideration, although in specific instances the percentage paid has been higher or lower than this range. These Sublicense Receipts generally take the place of most or all of the milestone and royalty payments set forth in (b) through (e) above.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 45</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        </div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 14 &#8211; COMMITMENTS AND CONTINGENT LIABILITIES</span> (cont.)</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Commitments</span> (cont.)</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:70.9pt">&#160;</td>
              <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Licensing agreements (cont.)</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:70.9pt">&#160;</td>
              <td style="width:21.25pt;vertical-align:top">&#160;</td>
              <td style="width:auto;vertical-align:top">&#160;</td>
            </tr>

        </table>
      </ix:exclude></div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The license agreements may be cancelled by the licensor only in specific circumstances, generally upon the occurrence of one of the following events: (a) the Company&#8217;s failure to meet certain milestones stipulated in the applicable license agreement and appended timetables; (b) default, insolvency, receivership, liquidation, etc., of the Company that is not imposed and/or lifted within the timeframe stipulated in the license agreement; and (c) fundamental breach of the license agreement that is not corrected within the stipulated timeframe. The Company may generally cancel a license agreement with prior notice of 30 to 90 days, due to unsuccessful development or any other cause.</span></span></div>
      <div style="text-align:justify;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Some of the license agreements have been accompanied by consulting, support and cooperation agreements, pursuant to which the Company may be committed to pay the various licensers a fixed monthly amount over the period stipulated in the agreement for their assistance in the continued research and development under the license.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commitments in respect of Biokine</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with the license agreement of motixafortide with Biokine (as amended), the Company is required to pay Biokine a payment of <ix:nonFraction id="Fxbrl_20220304151524036" name="blrx:RoyaltiesPaymentPercentage" contextRef="C_20250101to20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of amounts received as consideration in connection with any sublicensing or sale of the licensed technology. Biokine is also eligible to receive up to a total of $<ix:nonFraction id="Fxbrl_20240324072004311" name="blrx:MaximumFutureMilestonePayments" contextRef="C_20250101to20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction> million in future milestone payments. Subject to certain limitations, if the Company independently sells products related to motixafortide, the Company will pay Biokine a royalty payment of <ix:nonFraction id="Fxbrl_20220304151535337" name="blrx:RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts" contextRef="C_20250101to20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction>% of net sales.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase orders</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s outstanding open purchase order commitments as of December 31, 2025 amounted to $<ix:nonFraction id="F20211006115503182_10" name="blrx:OpenPurchaseOrderCommitments" contextRef="C_20251231" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction> million.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 46</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
          </div>
        </div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 14 &#8211; COMMITMENTS AND CONTINGENT LIABILITIES</span> (cont.)</span></span></div>
        <div style="line-height:1.25">&#160;</div>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Guarantees</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To secure the Company&#8217;s lease obligation on its Israeli premises, the Company has provided a bank guarantee in the amount of $<ix:nonFraction id="F20211006115503182_11" name="blrx:BankGuaranteeAmountForBenefitOfLessor" contextRef="C_20250101to20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction> for the benefit of the lessor, which remains outstanding as of December 31, 2025.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contingent liabilities</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2024, Biokine Therapeutics Ltd. (&#8220;Biokine&#8221;),&#160;filed a complaint with the District Court of Jerusalem against the Company. The complaint alleged breach of contract and a purported failure to make certain payments to Biokine under the Company&#8217;s in-licensing agreement with Biokine for motixafortide. The lawsuit sought compensatory damages in the amount of approximately $<ix:nonFraction id="Fxbrl_20230320180909657" name="blrx:LawsuitClaimAmount" contextRef="C_20240601to20240630_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction> million and a declaratory judgment in favor of Biokine. The Company filed a statement of defense in November 2024. In November 2024, the Company and Biokine entered into an agreement to refer the dispute to binding arbitration, and the claim was withdrawn. During the first quarter of 2025, Biokine filed an updated complaint under the arbitration, increasing the damages to the amount of approximately $<ix:nonFraction id="Fxbrl_20260317150140874" name="blrx:LawsuitClaimAmount" contextRef="C_20241101to20241130_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction> million.</span></span></div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In February 2026, the arbitrator issued a final decision in the case, denying all claims asserted by Biokine against the Company, and awarding the Company expenses, including legal fees.</span></span></div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 47</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>

  <div>
    <div>
      <ix:nonNumeric id="Fxbrl_20240324114158606" name="blrx:LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock" contextRef="C_20250101to20251231" escape="true">
        <div>
          <div>
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 15 &#8211; LICENSE AND SECURITIES PURCHASE AGREEMENTS &#8211; HST/GLORIA</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, the Company closed on a license agreement (the &#8220;Gloria License Agreement&#8221;) with Hong Seng Technology Limited (&#8220;HST&#8221;) and Auspex Bioscience (Guangzhou) Co., Ltd. (formerly Guangzhou Gloria Biosciences Co., Ltd.) (&#8220;Gloria&#8221; and together with HST, the &#8220;Gloria Licensee&#8221;), pursuant to which the Company granted HST an exclusive, royalty-bearing, sublicensable license to develop and commercialize motixafortide in Asia (other than Israel and certain other countries) (collectively, the &#8220;Gloria Territory&#8221;) and to engage and authorize Gloria to perform services under the Gloria License Agreement in the Gloria Territory. In addition, the Company granted the Gloria Licensee a first offer right with respect to the grant of certain rights in motixafortide outside of the Gloria Territory.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the terms of the Gloria License Agreement, the Gloria Licensee paid an upfront payment of $<ix:nonFraction id="Fxbrl_20240324114350435" name="blrx:UpfrontPayment" contextRef="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">15</ix:nonFraction> million, which was received by the Company at closing. The Company is also entitled to up to $<ix:nonFraction id="Fxbrl_20240324120125798" name="ifrs-full:PaymentsForDevelopmentProjectExpenditure" contextRef="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">49</ix:nonFraction> million based on the achievement of certain development and regulatory milestones in China and Japan, and up to $<ix:nonFraction id="Fxbrl_20240324120149766" name="blrx:SalesMilestoneAmount" contextRef="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">197</ix:nonFraction> million in sales milestones based on defined sales targets of motixafortide in the Gloria Territory. In addition, the Company is eligible to receive tiered double-digit royalties (ranging from <ix:nonFraction id="Fxbrl_20240324120208549" name="blrx:RoyaltiesEligibleMargin" contextRef="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction>-<ix:nonFraction id="Fxbrl_20240324120328382" name="blrx:RoyaltiesEligibleMargin" contextRef="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember_srtRangeAxis_srtMaximumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction>%), on a country-by-country basis until the longer of (i) fifteen years from the date of the first sale of motixafortide by the Gloria Licensee, (ii) the last to expire valid claim of any licensed patents with respect to motixafortide in such country and (iii) the expiration of motixafortide&#8217;s orphan drug status in such country. The royalties payable by Gloria Licensee are to be reduced by 50% following the end of the initial royalty term and are also to be reduced upon the occurrence of certain events, including, on a country-by-country basis, the entry of a generic product in such country.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, in October 2023, the Company closed on a securities purchase agreement (the &#8220;Gloria Purchase Agreement&#8221;) with HST and Gloria, pursuant to which the Company issued in a private placement an aggregate of <ix:nonFraction id="Fxbrl_20240324120750045" name="blrx:AggregateAmericanDepositaryShares" contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">170,728</ix:nonFraction> ADSs of the Company, at a purchase price of $<ix:nonFraction id="Fxbrl_20240324120850549" name="blrx:PurchasePricePerADS" contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">85.44</ix:nonFraction> per ADS. Aggregate gross proceeds from the sale were approximately $<ix:nonFraction id="Fxbrl_20240324120938500" name="ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares" contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.6</ix:nonFraction> million, with related issuance costs amounting to approximately $<ix:nonFraction id="Fxbrl_20240324121010839" name="ifrs-full:PaymentsForShareIssueCosts" contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million. No warrants were issued in the transaction.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with IFRS 15, both agreements have been treated as a single unit of account, with the consideration combined and subsequently allocated between the Gloria Purchase Agreement and the Gloria License Agreement. Of the total consideration amounting to $<ix:nonFraction id="Fxbrl_20250327102008077" name="ifrs-full:ConsiderationPaidReceived" contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.6</ix:nonFraction> million, $<ix:nonFraction id="Fxbrl_20250327102035988" name="ifrs-full:ConsiderationPaidReceived" contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxPurchaseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction> million were allocated to the Purchase Agreement, and $<ix:nonFraction id="Fxbrl_20250327102100125" name="ifrs-full:ConsiderationPaidReceived" contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.6</ix:nonFraction> million were allocated to the Gloria License Agreement. Costs in the amount of $<ix:nonFraction id="Fxbrl_20250327102118071" name="blrx:CostsIncurrentInOffering" contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction> million directly attributable to the Purchase Agreement were recognized as a reduction in equity.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company identified the following performance obligations in the contract, each to be recognized separately: (1) stem-cell mobilization (&#8220;SCM&#8221;) license; (2) SCM support services; and (3) pancreatic cancer (&#8220;PDAC&#8221;) license and related support services.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With regard to PDAC, the Company determined that the license, together with the associated support services, should be combined into a single performance obligation, since the Licensee cannot benefit from the license without the associated support services. The support services are highly specialized for the licensed product in this indication. Licensing rights for other indications and related support were deemed immaterial.</span></span>
              <p style="margin:0pt">&#160;</p>
            </div>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <div>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 48</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
                </div>
              </div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 15 &#8211; LICENSE AND SECURITIES PURCHASE AGREEMENTS &#8211; HST/GLORIA </span><span>(cont.)</span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
            </ix:exclude></div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fixed transaction price has been allocated among the performance obligations based on similar price offers received by the Company, with the assistance of a valuation specialist. The variable consideration&#160;related to the performance obligations&#160;was not taken into account in the fixed transaction price due to uncertainty.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue has been recognized in the Company&#8217;s financial statements as follows:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue for the SCM license was recognized in the fourth quarter of 2023, upon transfer of control over the license to the licensee, in the amount of $<ix:nonFraction id="Fxbrl_20240324122524826" name="ifrs-full:OtherRevenue" contextRef="C_20231001to20231231_blrxAgreementTypeAxis_blrxScmLicenseMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction> million.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue from providing the SCM support services has been recognized using the input method, which is based on costs incurred and labor hours expended, resulting in straight-line revenue recognition for the year ended December 31, 2024 totaling $<ix:nonFraction id="Fxbrl_20240324122550628" name="ifrs-full:OtherRevenue" contextRef="C_20240101to20241231_blrxAgreementTypeAxis_blrxScmSupportServicesMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue from the PDAC performance obligation has been recognized over time, with the percentage of completion determined based on support hours incurred, with a total amount of $<ix:nonFraction id="Fxbrl_20240324122622293" name="ifrs-full:OtherRevenue" contextRef="C_20240101to20241231_blrxAgreementTypeAxis_blrxPDACPerformanceObligationMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.5</ix:nonFraction> million recognized through the end of 2024.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Based on the above methodology, as well as the achievement of a specific regulatory milestone, the Company recognized revenues from the license agreement of $<ix:nonFraction id="Fxbrl_20250327094309125" name="ifrs-full:OtherRevenue" contextRef="C_20230101to20231231_blrxAgreementTypeAxis_blrxLicenseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction> million and $<ix:nonFraction id="Fxbrl_20250327094313532" name="ifrs-full:OtherRevenue" contextRef="C_20240101to20241231_blrxAgreementTypeAxis_blrxLicenseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million for the years ended December 31, 2023 and 2024, respectively. Due to a delay in payment of $<ix:nonFraction id="Fxbrl_20250328211831684" name="blrx:DelayInPayment" contextRef="C_20240101to20241231_blrxAgreementTypeAxis_blrxLicenseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction> million to be received from the Gloria Licensee during 2024, a provision for doubtful accounts receivable in the amount of $<ix:nonFraction id="Fxbrl_20250327100724372" name="blrx:ProvisionForDoubtfulAccountsReceivable" contextRef="C_20241001to20241231" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal" sign="-">0.8</ix:nonFraction> million was recorded in the fourth quarter of 2024. This amount was subsequently collected in 2025 and the provision was reversed.</span></span></div>
          </div>
        </div>
      </ix:nonNumeric>
      <p style="margin:0pt">&#160;</p>
    </div>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20250327055235567" name="blrx:DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory" contextRef="C_20250101to20251231" escape="true">
      <div>
        <div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 16 &#8211; LICENSE AND SECURITIES PURCHASE AGREEMENTS &#8211; AYRMID/HIGHBRIDGE</span></span><br/>&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, the Company entered into a license agreement (the &#8220;Ayrmid License Agreement&#8221;) with Ayrmid Pharma Ltd. (the &#8220;Ayrmid Licensee&#8221;), pursuant to which the Company granted the Ayrmid Licensee an exclusive, transferable, royalty-bearing, sublicensable license with respect to the intellectual property rights and know-how associated with motixafortide, to commercialize motixafortide across all indications, except solid tumor indications, in all territories other than Asia (collectively, the &#8220;Ayrmid Territory&#8221;).</span></span><br/>&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the terms of the Ayrmid License Agreement, the Company received a non-refundable $<ix:nonFraction id="Fxbrl_20250327055339574" name="blrx:UpfrontPayment" contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction> million upfront payment and is entitled to up to $<ix:nonFraction id="Fxbrl_20250327055352233" name="blrx:UpfrontPayment" contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">87</ix:nonFraction> million of certain commercial and sales milestones based on defined sales targets of motixafortide in the Ayrmid Territory. Additionally, the Company is eligible to receive tiered double-digit royalties (ranging from <ix:nonFraction id="Fxbrl_20250327055429844" name="blrx:PercentageOfRoyaltiesReceivableFromAggregateNetSales" contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">18</ix:nonFraction>-<ix:nonFraction id="Fxbrl_20250327055449918" name="blrx:PercentageOfRoyaltiesReceivableFromAggregateNetSales" contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction>%) on aggregate net sales of motixafortide&#160;on a country-by-country basis until the longer of (i) fifteen years from the date of the first sale of motixafortide by the Ayrmid Licensee in such country, (ii) the last to expire of any licensed patents with respect to motixafortide in such country, (iii) the expiration of regulatory exclusivity in such country and (iv) the expiration of motixafortide&#8217;s orphan drug status, if any, in such country, it being noted that such royalties may be subject to reduction in certain specific circumstances.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div><ix:exclude>
            <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
              <div>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 49</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
              </div>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 16 &#8211; LICENSE AND SECURITIES PURCHASE AGREEMENTS &#8211; AYRMID/HIGHBRIDGE </span><span>(cont.)</span></span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
          </ix:exclude></div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the Ayrmid License Agreement, the Company and the Ayrmid Licensee also entered into a manufacturing and supply agreement (the &#8220;Supply Agreement&#8221;), according to which the Company has committed to supply motixafortide to the Ayrmid Licensee during the term, on a cost-plus basis, for both commercial and development supply. Furthermore, the Supply Agreement provides the Ayrmid Licensee with &#8220;step-in rights&#8221; with respect to the manufacture and supply of motixafortide upon the occurrence of certain trigger events.</span></span><br/>&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Ayrmid License Agreement will continue on a country-by-country basis in the Ayrmid Territory until the expiration of the royalty term or earlier termination thereof. The Ayrmid License Agreement may also be terminated by either party in the case of a material breach or bankruptcy.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Concurrent with the above transaction, the Company completed a registered direct offering with gross proceeds of $<ix:nonFraction id="Fxbrl_20250327055641307" name="blrx:GrossProceedsFromOffering" contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxHighbridgeMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction> million to certain funds associated with&#160;Highbridge, a related party to Ayrmid&#160;(see Note 11c(4)).</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with IFRS 15, both transactions have been treated as a single unit of account, with the consideration combined and subsequently allocated between the Ayrmid License agreement and the registered direct offering. Of the total consideration amounting to $<ix:nonFraction id="Fxbrl_20250327055729114" name="ifrs-full:ConsiderationPaidReceived" contextRef="C_20241101to20241130" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.0</ix:nonFraction> million, $<ix:nonFraction id="Fxbrl_20250327055800636" name="ifrs-full:ConsiderationPaidReceived" contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.8</ix:nonFraction> million were allocated to the Ayrmid License Agreement, and $<ix:nonFraction id="Fxbrl_20250327055813830" name="ifrs-full:ConsiderationPaidReceived" contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxRegisteredDirectOfferingMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.2</ix:nonFraction> million were allocated to the registered direct offering. Costs in the amount of $<ix:nonFraction id="Fxbrl_20250327055844464" name="blrx:CostsIncurrentInOffering" contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxRegisteredDirectOfferingMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million directly attributable to the registered direct offering were recognized as a reduction in equity. The proceeds allocated to the ordinary warrants in the registered direct offering were measured with reference to their fair value as financial instruments issued to a customer.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consideration allocated to the Ayrmid License Agreement of $<ix:nonFraction id="Fxbrl_20250327055914455" name="ifrs-full:ConsiderationPaidReceived" contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_blrxPerformanceObligationAxis_blrxSingleMaterialPerformanceObligationMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.8</ix:nonFraction> million was attributed to a single material performance obligation &#8211; i.e., the granting of the license to commercialize and develop motixafortide in the Ayrmid Territory. Accordingly, revenue from the license of $<ix:nonFraction id="Fxbrl_20250327055951963" name="ifrs-full:LicenceFeeIncome" contextRef="C_20241001to20241231_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.8</ix:nonFraction> million was recognized during the fourth quarter of 2024, upon transfer of control over the Ayrmid License to the licensee. Sales-based milestone payments and royalties based on motixafortide net sales are subject to the &#8220;royalties exception&#8221; of IFRS 15 and are recognized as revenue when the related sale occurs. Total royalties based on motixafortide net sales in 2025 amounted to $<ix:nonFraction id="Fxbrl_20260317161059174" name="ifrs-full:RevenueFromRoyalties" contextRef="C_20250101to20251231_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction> million.</span></span></div>
        </div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 50</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20260317193423560" name="blrx:AgreementWithHemispherianForDevelopmentOfGlix1Explanatory" contextRef="C_20250101to20251231" escape="true">
      <div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 17 &#8211; AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2025, the Company entered into a collaboration transaction with Hemispherian AS, a Norwegian corporation (&#8220;Hemispherian&#8221;), for the development, clinical evaluation and commercialization of GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors. As part of the transaction, (i) the Company and Hemispherian entered into a Collaboration and Shareholders Agreement (the &#8220;Agreement with Hemispherian&#8221;), which governs the ownership, governance, funding, administration, and related operational and commercial terms of a new company (Tetragon) established by the Company and Hemispherian, and (ii) Hemispherian and Tetragon entered into an Asset Transfer Agreement (the &#8220;ATA&#8221;), pursuant to which Hemispherian transferred to Tetragon certain intellectual property, regulatory filings, know-how, and related assets primarily in respect of GLIX1, Hemispherian&#8217;s lead compound (the &#8220;Transferred Assets&#8221;).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In consideration for the transfer of the Transferred Assets, Hemispherian received <ix:nonFraction id="Fxbrl_20260317193503072" name="blrx:PercentageOfIssuedShareCapitalReceived" contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">60</ix:nonFraction>% of the issued share capital of Tetragon. In consideration for the Company&#8217;s commitment to invest $<ix:nonFraction id="Fxbrl_20260317193508882" name="ifrs-full:InvestmentProperty" contextRef="C_20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">5</ix:nonFraction> million in Tetragon (the &#8220;Threshold Amount&#8221;) within 36 months as of the date of the Agreement with Hemispherian, the Company received <ix:nonFraction id="Fxbrl_20260317193533712" name="blrx:PercentageOfIssuedShareCapitalReceivedWithinMonths" contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">40</ix:nonFraction>% of the issued share capital of Tetragon. Such threshold amount is to be paid in tranches according to a development plan, and the 36-month period may be extended by an additional six months upon the occurrence of certain events as specified in the Agreement with Hemispherian (the &#8220;Threshold Term&#8221;). If the Company does not invest the full Threshold Amount by the end of the Threshold Term, Hemispherian will have the right to repurchase, for nominal consideration, a pro rata portion of the Company&#8217;s shares in Tetragon corresponding to the unfunded portion of the Threshold Amount. As of December 31, 2025, the Company had invested $<ix:nonFraction id="Fxbrl_20260317193602468" name="ifrs-full:InvestmentProperty" contextRef="C_20251231_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction> million of the Threshold Amount.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Following the investment of the Threshold Amount, the Company may make additional investments in Tetragon. For each incremental $<ix:nonFraction id="Fxbrl_20260317193635912" name="blrx:IncrementalInvestment" contextRef="C_20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">1</ix:nonFraction> million invested by the Company beyond the Threshold Amount, the Company will be entitled to an additional <ix:nonFraction id="Fxbrl_20260317193701920" name="blrx:PercentageOfAdditionalEquityInterest" contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction>% equity interest, up to an aggregate maximum ownership of <ix:nonFraction id="Fxbrl_20260317193721402" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction>%. Following the attainment of a <ix:nonFraction id="Fxbrl_20260317193732807" name="blrx:PercentageOfOwnershipStake" contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction>% stake by the Company in Tetragon, Hemispherian will have the right to co-invest alongside the Company on the same terms in order to maintain a <ix:nonFraction id="Fxbrl_20260317193747080" name="blrx:PercentageOfOwnershipStake" contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction>% ownership stake in Tetragon.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furthermore, under the terms of the Agreement with Hemispherian, the Company will be responsible for managing and implementing Tetragon&#8217;s activities and overseeing its operations, budget, and expenses. Following the closing, Tetragon will pay Hemispherian a monthly advisory fee of $<ix:nonFraction id="Fxbrl_20260317193756880" name="blrx:MonthlyAdvisoryFee" contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">80,000</ix:nonFraction> for a period of 24 months or until the termination of the collaboration, whichever occurs first.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Agreement with Hemispherian provides for the establishment of a board of directors of Tetragon as well as a steering committee with joint representation from both the Company and Hemispherian. The Company holds the deciding vote in the event of any deadlock on either of such corporate bodies and, accordingly, is the controlling shareholder of Tetragon. Tetragon has a first-look right, as well as a right of first refusal, on other assets in Hemispherian&#8217;s pipeline for defined periods specified in the ATA.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ATA and the Agreement with Hemispherian contain customary representations and warranties, indemnification and other provisions customary for transactions of this nature. The ATA and Agreement with Hemispherian also include termination events, including failure to fund the Threshold Amount within the Threshold Term, or prolonged inability of Tetragon to operate due to insufficient financial resources.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the ATA and Agreement with Hemispherian, an intangible asset in the amount of $<ix:nonFraction id="Fxbrl_20260317193833840" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction> million was recorded in respect of the GLIX1 molecule at fair value, against a minority interest in the same amount.</span></span></div>
      </div>
    </ix:nonNumeric>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div>
      <div>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 51</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
      </div>
    </div>
  </div>

  <div>
    <div>
      <div>
        <ix:nonNumeric id="Fxbrl_20250326173517101" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" contextRef="C_20250101to20251231" escape="true">
          <div>
            <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 18 &#8211; TRANSACTIONS AND BALANCES WITH RELATED PARTIES</span></span></div>
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-indent:-12.35pt;margin-left:70.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions with related parties</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-indent:-12.35pt;margin-left:70.85pt;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expenses:</span></span></div>
              <div style="margin-left:70.9pt;line-height:1.25">&#160;</div>
              <div style="margin-left:63pt">
                <ix:nonNumeric id="Fxbrl_20250326173412246" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" contextRef="C_20250101to20251231" escape="true">
                  <div>
                    <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-14.6pt;margin-left:14.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Benefits to related parties:</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                            <div style="text-indent:-13.5pt;margin-left:28.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation and benefits to senior management, including benefit component of equity instrument grants</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503191_2" name="ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity" contextRef="C_20230101to20231231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,155</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503194_3" name="ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity" contextRef="C_20240101to20241231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,396</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503194_4" name="ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity" contextRef="C_20250101to20251231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,398</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-13.5pt;margin-left:28.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation and benefits to directors, including benefit component of equity instrument grants</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503195_8" name="ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity" contextRef="C_20230101to20231231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">587</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503195_9" name="ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity" contextRef="C_20240101to20241231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">415</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503196_10" name="ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity" contextRef="C_20250101to20251231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">473</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                </ix:nonNumeric>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;font-weight:normal;margin-left:60pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Regarding transactions and balances related to Gloria, see Note 15.</span></span></div>
              <div style="text-align:justify;line-height:1.25;margin-left:70pt">&#160;</div>
              <div style="line-height:1.25;font-weight:bold;margin-left:60pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Key management compensation</span></span></div>
              <div style="line-height:1.25;font-weight:bold;margin-left:70pt">&#160;</div>
              <div style="line-height:1.25;font-weight:normal;text-align:justify;margin-left:60pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Key management includes directors and executive officers. The compensation paid or payable to key management for services during each of the years indicated is presented below.</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:63pt">
                <ix:nonNumeric id="Fxbrl_20250326173500950" name="ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" contextRef="C_20250101to20251231" escape="true">
                  <div>
                    <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-16.35pt;margin-left:16.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and other short-term employee benefits</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503197_15" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,425</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503197_16" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,018</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503197_17" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,425</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Post-employment benefits</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503197_18" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503197_19" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">394</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503197_20" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other long-term benefits</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503198_21" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503198_22" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503198_23" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503198_24" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,030</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503198_25" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">370</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503199_26" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503199_27" name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,742</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503199_28" name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,811</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><ix:nonFraction id="F20211006115503199_29" name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,871</ix:nonFraction></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                </ix:nonNumeric>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
        <p style="margin:0pt">&#160;</p>
      </div>
    </div>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20250327040723759" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" contextRef="C_20250101to20251231" escape="true">
      <div>
        <div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 19 &#8211; SEGMENT REPORTING</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company operates in a <span style="-sec-ix-hidden:Fxbrl_20250327041154148">single</span> reportable operating segment &#8211; the development and commercialization of therapeutics. Its corporate headquarters and development activities are in Israel, while its revenues stem from activities carried out in the U.S. and Asia (primarily Greater China). In this regard, product sales relate to the Company&#8217;s direct commercialization activities in the U.S. from October 2023 through November 2024, while license revenues relate to outlicensing agreements entered into in Asia and in the U.S. in October 2023 and November 2024, respectively. Set forth below is a breakdown of revenues from external parties by geographic region.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:54pt">
            <ix:nonNumeric id="Fxbrl_20260317170227955" name="ifrs-full:DisclosureOfGeographicalAreasExplanatory" contextRef="C_20250101to20251231" escape="true">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">China</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327040836299_33" name="ifrs-full:Revenue" contextRef="C_20230101to20231231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,610</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327040836299_37" name="ifrs-full:Revenue" contextRef="C_20240101to20241231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,957</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327040836299_311" name="ifrs-full:Revenue" contextRef="C_20250101to20251231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327040836299_43" name="ifrs-full:Revenue" contextRef="C_20230101to20231231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327040836299_47" name="ifrs-full:Revenue" contextRef="C_20240101to20241231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,983</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327040836299_411" name="ifrs-full:Revenue" contextRef="C_20250101to20251231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,180</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327040836299_53" name="ifrs-full:Revenue" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,800</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327040836299_57" name="ifrs-full:Revenue" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,940</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20250327040836299_511" name="ifrs-full:Revenue" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,180</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </ix:nonNumeric>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Substantially all of the Company&#8217;s non-current assets are located in Israel. See Notes 15 and 16 for information on customers representing 10% or more of total revenues.</span></span></div>
        </div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 52</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
  </div>

  <ix:nonNumeric id="Fxbrl_20240324122047540" name="blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory" contextRef="C_20250101to20251231" escape="true">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE 20 &#8211; SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other receivables</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250326205132294" name="blrx:DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2025</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>in USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">Government institutions</div>
                </td>
                <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503214_4" name="blrx:InstitutionsCurrentReceivables" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">455</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503214_5" name="blrx:InstitutionsCurrentReceivables" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Advance payments</span></p>
                </td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"><ix:nonFraction id="Fxbrl_20260319170221167_20211006115503214_4" name="blrx:AdvancePayments" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"><ix:nonFraction id="Fxbrl_20260319170221167_20211006115503214_5" name="blrx:AdvancePayments" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503215_6" name="blrx:Others" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">932</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503216_7" name="blrx:Others" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">377</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503216_8" name="ifrs-full:OtherCurrentReceivables" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,478</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503217_9" name="ifrs-full:OtherCurrentReceivables" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>b.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accounts payable and accruals</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250326205152300" name="blrx:DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2025</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>in USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Accounts payable:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160; Overseas</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503217_10" name="blrx:TradeAndOtherPayablesToForeignTradeSuppliers" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,250</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503218_11" name="blrx:TradeAndOtherPayablesToForeignTradeSuppliers" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,814</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160; In Israel</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503218_12" name="blrx:TradeAndOtherPayablesToLocalTradeSuppliers" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,333</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503219_13" name="blrx:TradeAndOtherPayablesToLocalTradeSuppliers" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">679</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503223_14" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,583</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503223_15" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,493</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Payroll and related expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503224_16" name="blrx:PayrollAndRelatedExpenses" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,993</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503225_17" name="blrx:PayrollAndRelatedExpenses" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">523</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Accrued expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503225_18" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">707</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503226_19" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">372</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:0pt;margin-left:23.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160; Accrual for vacation and recreation pay</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503226_20" name="ifrs-full:CurrentProvisionsForEmployeeBenefits" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">431</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503227_21" name="ifrs-full:CurrentProvisionsForEmployeeBenefits" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Other</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503227_22" name="ifrs-full:OtherPayables" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503228_23" name="ifrs-full:OtherPayables" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">538</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503228_24" name="ifrs-full:OtherCurrentPayables" contextRef="C_20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,131</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20211006115503229_25" name="ifrs-full:OtherCurrentPayables" contextRef="C_20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,743</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The carrying amounts of accounts payable and accruals approximate their fair value, as the effect of discounting is not material.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 53</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        </div>
        <div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <div style="line-height:1.25">
              <div style="line-height:1.25">
                <div style="line-height:1.25">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 20 &#8211; SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION </span>(cont.)</span></div>
                        <div style="line-height:1.25">&#160;</div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenues</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250326205236196" name="blrx:DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">License fees and royalties payable to licensor</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326213035798" name="blrx:LicenseFeesAndRoyaltiesPayableToLicensor" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,027</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326213052598" name="blrx:LicenseFeesAndRoyaltiesPayableToLicensor" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,024</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326213103518" name="blrx:LicenseFeesAndRoyaltiesPayableToLicensor" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Direct costs related to license revenues</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324142706720_xbrl_20220304172035907_20211006115503242_44" name="blrx:CostRelatedToLicenseRevenues" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324142706720_xbrl_20220304172035907_20211006115503242_45" name="blrx:CostRelatedToLicenseRevenues" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,605</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324142706720_xbrl_20220304172035907_20211006115503243_46" name="blrx:CostRelatedToLicenseRevenues" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of intangible asset</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260317202838350" name="ifrs-full:AmortisationExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">450</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324142859214_xbrl_20240324142702400_xbrl_20220304172035907_20211006115503242_45" name="ifrs-full:AmortisationExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,323</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324142859214_xbrl_20240324142702400_xbrl_20220304172035907_20211006115503243_46" name="ifrs-full:AmortisationExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of product sales</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324142700553_xbrl_20220304172035907_20211006115503242_44" name="blrx:CostOfProductSales" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324142700553_xbrl_20220304172035907_20211006115503242_45" name="blrx:CostOfProductSales" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324142700553_xbrl_20220304172035907_20211006115503243_46" name="blrx:CostOfProductSales" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324142658592_xbrl_20220304172035907_20211006115503242_44" name="ifrs-full:CostOfSales" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,692</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324142658592_xbrl_20220304172035907_20211006115503242_45" name="ifrs-full:CostOfSales" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,263</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324142658592_xbrl_20220304172035907_20211006115503243_46" name="ifrs-full:CostOfSales" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <div style="text-indent:-21.25pt;margin-left:70.85pt;line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250326205320884" name="blrx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development services</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035875_20211006115503229_26" name="ifrs-full:ServicesExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,603</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035875_20211006115503230_27" name="ifrs-full:ServicesExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,170</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035875_20211006115503231_28" name="ifrs-full:ServicesExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,118</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payroll and related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035879_20211006115503231_29" name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,452</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035879_20211006115503232_30" name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,524</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035879_20211006115503232_31" name="ifrs-full:ShorttermEmployeeBenefitsExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,982</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lab, occupancy and telephone</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035890_20211006115503233_32" name="ifrs-full:CommunicationExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">969</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035890_20211006115503233_33" name="ifrs-full:CommunicationExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,102</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035890_20211006115503234_34" name="ifrs-full:CommunicationExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">855</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional fees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035894_20211006115503234_35" name="blrx:ProfessionalFee" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">935</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035894_20211006115503235_36" name="blrx:ProfessionalFee" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035894_20211006115503238_37" name="blrx:ProfessionalFee" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">390</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240326125243135_xbrl_20220304172035894_20211006115503234_35" name="blrx:ShareBasedCompensationRelatedToResearchAndDevelopment" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">760</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240326125243135_xbrl_20220304172035894_20211006115503235_36" name="blrx:ShareBasedCompensationRelatedToResearchAndDevelopment" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">451</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240326125243135_xbrl_20220304172035894_20211006115503238_37" name="blrx:ShareBasedCompensationRelatedToResearchAndDevelopment" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation and amortization</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035899_20211006115503239_38" name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">583</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035899_20211006115503239_39" name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">431</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035899_20211006115503240_40" name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">495</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035903_20211006115503240_41" name="ifrs-full:OtherExpenseByNature" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035903_20211006115503241_42" name="ifrs-full:OtherExpenseByNature" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035903_20211006115503241_43" name="ifrs-full:OtherExpenseByNature" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035907_20211006115503242_44" name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,519</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035907_20211006115503242_45" name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,149</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172035907_20211006115503243_46" name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,093</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales and marketing expenses</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20260317172622660" name="blrx:DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payroll and related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122600862_20211006115503243_47" name="blrx:SalesAndMarketingExpensesRelatedToSales" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,868</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122600862_20211006115503244_48" name="blrx:SalesAndMarketingExpensesRelatedToSales" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,224</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122600862_20211006115503245_49" name="blrx:SalesAndMarketingExpensesRelatedToSales" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Medical Affairs</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122557657_20211006115503243_47" name="blrx:MedicalAffairs" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,824</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122557657_20211006115503244_48" name="blrx:MedicalAffairs" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,891</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122557657_20211006115503245_49" name="blrx:MedicalAffairs" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503243_47" name="blrx:MarketingExpenses" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,091</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503244_48" name="blrx:MarketingExpenses" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,041</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503245_49" name="blrx:MarketingExpenses" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Travel</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503247_53" name="ifrs-full:TravelExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">986</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503247_54" name="ifrs-full:TravelExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,506</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503248_55" name="ifrs-full:TravelExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office-related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122605063_20211006115503243_47" name="blrx:SalesAndMarketingPayrollExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,923</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122605063_20211006115503244_48" name="blrx:SalesAndMarketingPayrollExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,477</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122605063_20211006115503245_49" name="blrx:SalesAndMarketingPayrollExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Business Analytics</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240326130835955" name="blrx:BusinessAnalyticsExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,005</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240326130857435" name="blrx:BusinessAnalyticsExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,264</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240326130914203" name="blrx:BusinessAnalyticsExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Market Access</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240326130818740" name="blrx:MarketAccessExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,606</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240326130848771" name="blrx:MarketAccessExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">701</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240326130904171" name="blrx:MarketAccessExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional fees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122611470_20211006115503243_47" name="blrx:SalesAndMarketingProfessionalFees" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">745</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122611470_20211006115503244_48" name="blrx:SalesAndMarketingProfessionalFees" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">627</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122611470_20211006115503245_49" name="blrx:SalesAndMarketingProfessionalFees" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122607991_20211006115503243_47" name="blrx:SalesAndMarketingShareBasedCompensation" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">751</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122607991_20211006115503244_48" name="blrx:SalesAndMarketingShareBasedCompensation" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122607991_20211006115503245_49" name="blrx:SalesAndMarketingShareBasedCompensation" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation and amortization</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122613792_20211006115503243_47" name="blrx:SalesAndMarketingDepreciationAndAmortization" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">314</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122613792_20211006115503244_48" name="blrx:SalesAndMarketingDepreciationAndAmortization" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">330</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122613792_20211006115503245_49" name="blrx:SalesAndMarketingDepreciationAndAmortization" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss on abandonment of right-of-use asset</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326213653806" name="blrx:LossOnAbandonmentOfRightofuseAsset" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326213702631" name="blrx:LossOnAbandonmentOfRightofuseAsset" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326213724679" name="blrx:LossOnAbandonmentOfRightofuseAsset" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122616608_20211006115503243_47" name="blrx:SalesAndMarketingExpensesOther" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122616608_20211006115503244_48" name="blrx:SalesAndMarketingExpensesOther" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240324122616608_20211006115503245_49" name="blrx:SalesAndMarketingExpensesOther" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503248_56" name="ifrs-full:SalesAndMarketingExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,270</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503249_57" name="ifrs-full:SalesAndMarketingExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,605</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503249_58" name="ifrs-full:SalesAndMarketingExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <div><ix:exclude>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0pt;margin-top:10pt">F - 54</p><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:10pt;margin-top:3pt"/><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd.</span></span></strong></p><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></span></p><p style="margin:0pt">&#160;</p>
        </div>
        <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 20 &#8211; SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION </span><span>(cont.)</span></span></span></div>
        <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:11pt">&#160;</div>
      </ix:exclude></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250326205430333" name="blrx:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payroll and related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054808_20211006115503250_59" name="ifrs-full:WagesAndSalaries" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,117</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054808_20211006115503252_60" name="ifrs-full:WagesAndSalaries" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054808_20211006115503253_61" name="ifrs-full:WagesAndSalaries" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,407</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional fees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054813_20211006115503254_62" name="ifrs-full:ProfessionalFeesExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,028</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054813_20211006115503254_63" name="ifrs-full:ProfessionalFeesExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,991</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054813_20211006115503255_64" name="ifrs-full:ProfessionalFeesExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,290</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Insurance</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054815_20211006115503255_65" name="ifrs-full:InsuranceExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">939</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054815_20211006115503256_66" name="ifrs-full:InsuranceExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">808</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054815_20211006115503256_67" name="ifrs-full:InsuranceExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">603</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054810_xbrl_20220304164546030_20211006115503254_62" name="blrx:ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">780</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054810_xbrl_20220304164546030_20211006115503254_63" name="blrx:ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">585</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054810_xbrl_20220304164546030_20211006115503255_64" name="blrx:ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054818_20211006115503257_68" name="ifrs-full:DepreciationExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054818_20211006115503257_69" name="ifrs-full:DepreciationExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054818_20211006115503258_70" name="ifrs-full:DepreciationExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Provision for doubtful accounts receivable</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326221617246" name="blrx:ProvisionForDoubtfulAccountsReceivable" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250326221623649" name="blrx:ProvisionForDoubtfulAccountsReceivable" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">800</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250326221807521" name="blrx:ProvisionForDoubtfulAccountsReceivable" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">800</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054822_20211006115503258_71" name="ifrs-full:OtherExpenseByFunction" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">409</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054822_20211006115503259_72" name="ifrs-full:OtherExpenseByFunction" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054822_20211006115503259_73" name="ifrs-full:OtherExpenseByFunction" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">324</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054824_20211006115503260_74" name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,310</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054824_20211006115503260_75" name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,321</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304172054824_20211006115503261_76" name="ifrs-full:SellingGeneralAndAdministrativeExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,144</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-operating income (expenses), net</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250326205450620" name="blrx:DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value of warrants</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230314130955334" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,054</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304165334042" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,965</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503264_82" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,599</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance costs</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503261_77" name="ifrs-full:ShareIssueRelatedCost" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20211006115503262_78" name="ifrs-full:ShareIssueRelatedCost" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">669</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230314112239673" name="ifrs-full:ShareIssueRelatedCost" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">702</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304165312882" name="blrx:OtherNonoperatingIncomeExpenses" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503269_87" name="blrx:OtherNonoperatingIncomeExpenses" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503269_88" name="blrx:OtherNonoperatingIncomeExpenses" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230314130616343" name="blrx:ProfitLossFromNonOperatingActivities" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,819</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220304165326367" name="blrx:ProfitLossFromNonOperatingActivities" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,435</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503271_91" name="blrx:ProfitLossFromNonOperatingActivities" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,077</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">h.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial income</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250326205511453" name="blrx:DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230314105745668_20211006115503273_95" name="ifrs-full:RevenueFromInterest" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,007</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230314105745668_20211006115503273_96" name="ifrs-full:RevenueFromInterest" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,820</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230314105745668_20211006115503274_97" name="ifrs-full:RevenueFromInterest" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,124</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange differences, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230314105743628_20211006115503273_95" name="ifrs-full:NetForeignExchangeGain" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230314105743628_20211006115503273_96" name="ifrs-full:NetForeignExchangeGain" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230314105743628_20211006115503274_97" name="ifrs-full:NetForeignExchangeGain" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">340</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503273_95" name="ifrs-full:FinanceIncome" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,068</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503273_96" name="ifrs-full:FinanceIncome" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,871</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503274_97" name="ifrs-full:FinanceIncome" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,464</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial expenses</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <ix:nonNumeric id="Fxbrl_20250326205529363" name="blrx:DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory" contextRef="C_20250101to20251231" escape="true">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest expense</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230314105810997_20211006115503281_107" name="ifrs-full:InterestExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,144</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230314105810997_20211006115503281_108" name="ifrs-full:InterestExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,074</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230314105810997_20211006115503282_109" name="ifrs-full:InterestExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,251</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank commissions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503277_104" name="ifrs-full:FeeAndCommissionExpense" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503278_105" name="ifrs-full:FeeAndCommissionExpense" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503280_106" name="ifrs-full:FeeAndCommissionExpense" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503281_107" name="ifrs-full:FinanceCosts" contextRef="C_20230101to20231231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,169</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503281_108" name="ifrs-full:FinanceCosts" contextRef="C_20240101to20241231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,119</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20211006115503282_109" name="ifrs-full:FinanceCosts" contextRef="C_20250101to20251231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,280</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <p style="margin:10pt 0pt 0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 55</span></span></p>
  <hr style="border:none;border-bottom:4px solid #000000;border-top:1px solid #000000;height:10px;width:100%;color:#000000;text-align:center;text-align:center"/>
</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>exhibit_1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 1.1</font></u><br>
  </div>
  <br>
  <div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;" id="z16795d18e4fa4bacb766b63ffd05cde6">

          <tr>
            <td style="width: 100%; background-color: rgb(219, 219, 219); border-color: rgb(0, 0, 0); border-style: solid; border-width: 2px;">
              <div style="text-align: center; margin-right: 0.9pt; margin-left: 0.2pt; line-height: 1.25; font-size: 12pt; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; margin-right: 0.9pt; margin-left: 0.2pt; line-height: 1.25; font-size: 12pt; font-weight: bold;">BioLineRx Ltd.</div>
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
              <div style="text-align: center; margin-right: 0.9pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Articles of Association of a Public Company</div>
              <div style="text-align: center; margin-right: 0.9pt; margin-left: 0.1pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">In accordance with</div>
              <div style="text-align: center; margin-right: 0.9pt; margin-left: 0.2pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">The Companies Law, 5759-1999</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-align: center; margin-right: 0.9pt; margin-left: 0.3pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">As of June 29, 2025</div>
              <br>
              <div style="text-align: center; margin-right: 0.9pt; margin-left: 0.2pt; line-height: 1.25; font-size: 12pt; font-weight: bold;">BioLineRx Ltd.</div>
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%%%-->
    <div> <br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">1.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Name of Company</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 28.35pt; line-height: 1.25;">The name of the Company is BioLineRx Ltd.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">2.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Goals of the Company</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 28.35pt; line-height: 1.25;">The goal of the Company is to engage in any lawful business.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">3.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Interpretation</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">3.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">Any statement in the singular shall also include the plural and vice versa; any statement in the masculine shall also include the feminine and vice versa.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">3.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Except insofar as these Articles include special definitions of certain terms, any word and expression in these Articles shall have the meaning attributed thereto in
                    the Companies Law, 5759-1999 (in these Articles &#8211; &#8220;<font style="font-weight: bold;">the Companies Law</font>,&#8221;) unless this contradicts the written matter or the content thereof.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">3.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To prevent doubt it is clarified that regarding matters regulated in the Companies Law in such manner that the arrangements in these matters may be conditioned in
                    the Articles, and in cases in which these Articles do not include different provisions from those in the Companies Law, the provisions of the Companies Law shall apply.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">3.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">It is hereby clarified that the provisions of the Articles of Association of the Company as detailed below are subject to the provisions of the Companies Law, the
                    Securities Law, and any law.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">4.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>The Share Capital of the Company and the Rights Attached to Shares</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">4.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">The registered capital of the Company is NIS 2,000,000,000, divided into 20,000,000,000 ordinary shares with a nominal value of NIS 0.10 each.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 28.35pt;"><br>
                </td>
                <td style="width: 28.35pt; vertical-align: top;">4.2</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>The ordinary shares shall entitle their owners to &#8211;</div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 56.7pt;"><br>
                </td>
                <td style="width: 35.45pt; vertical-align: top;">4.2.1</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">An equal right to participate in and vote at the general meetings of the Company, whether ordinary meetings or extraordinary meetings. Each of the shares in the
                      Company shall entitle its owner present at the meeting and participating in the vote in person, by proxy, or by means of a letter of voting, to one vote;</div>
                  </div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 56.7pt;"><br>
                </td>
                <td style="width: 35.45pt; vertical-align: top;">4.2.2</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">An equal right to participate in the distribution of dividends, whether in cash or in benefit shares, in the distribution of assets, or in any other distribution,
                      according to the proportionate nominal value of the shares held thereby;</div>
                  </div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 56.7pt;"><br>
                </td>
                <td style="width: 35.45pt; vertical-align: top;">4.2.3</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">An equal right to participate in the distribution of the surplus assets of the Company in the event of its liquidation in accordance with the proportionate nominal
                      value of the shares held thereby.</div>
                  </div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">1</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <br>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">4.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Board of Directors is entitled to issue shares and other convertible securities or securities that may be realized as shares up to the limit of the Company&#8217;s
                    registered capital. For the purpose of calculating the limit of the registered capital, convertible securities or securities that may be realized as shares shall be considered to have been converted or realized as of their date of
                    issue.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">5.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Limited Liability</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 28.35pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The liability of the shareholders for the Company&#8217;s debts shall be limited to the full amount (nominal value with the addition of premium) they shall be required to pay the
            Company for the shares and which they have not yet paid.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">6.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Joint Shares and Share Certificates</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">6.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The owner of a share registered in the registry of shareholders is entitled to receive from the Company, without payment and within a period of three months
                    following the allocation or the registration of transfer, one share certificate stamped with the Company&#8217;s stamp regarding all the shares registered in his name, which certificate shall detail the number of shares. In the event of a
                    jointly owned share, the Company shall issue one share certificate for all the joint owners of the share, and the delivery of such a certificate to one of the partners shall be considered delivery to them all.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Each share certificate shall bear the signature of at least one director, the Chief Executive Officer or the Chief Financial and Operating Officer, together with the Company
            stamp or its printed name.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">6.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">A share certificate that has been defaced, destroyed, or lost may be renewed on the basis of such proof and guarantees as shall be required by the Company from time
                    to time.</div>
                </div>
              </td>
            </tr>

        </table>
        <br>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">7.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>The Company&#8217;s Reliefs relating to Shares that Have Not Been Fully Paid</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">7.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">If any or all of the remuneration the shareholder undertook to pay the Company in return for his shares has not been paid by such date and on such conditions as
                    established in the conditions for the allocation of his shares and/or in the payment request as stated in section 7.2 below, the Company is entitled, by way of a decision of the Board of Directors, to forfeit the shares whose
                    remuneration has not been fully paid. The forfeiture of shares shall take place provided that the Company has sent the shareholder written warning of its intention to forfeit the shares after at least 7 days from the date of receipt of
                    the warning, insofar as payment shall not be made during the period determined in the letter of warning.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Board of Directors is entitled, at any time prior to the date on which the forfeited share is sold, reallocated, or otherwise transferred, to nullify the forfeiture on
            such conditions as it shall see fit.</div>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">The forfeited shares shall be held by the Company as retired shares or shall be sold to another.</div>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">2</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 28.35pt;"><br>
                </td>
                <td style="width: 28.35pt; vertical-align: top;">7.2</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>If, in accordance with the conditions of allocation of the shares, there is no fixed date for the payment of any part of the price to be paid on account thereof, the Board of Directors is entitled, from time to time, to present
                    payment requests to the shareholders on account of monies not yet removed for the shares they hold, and each shareholder shall be obliged to pay the Company the amount requested on the date determined as stated, provided that he shall
                    receive prior notice of 14 days of the date and place of payment (hereinafter &#8211; &#8220;<font style="font-weight: bold;">the Payment Request</font>.&#8221;) The notification shall specify that non-payment by or before the determined date and in the
                    specified place may lead to the forfeiture of the shares regarding which payment is requested. A Payment Request may be nullified or postponed to another date, all as shall be decided by the Board of Directors.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">7.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Unless otherwise determined in the conditions of allocations of the shares, a shareholder shall not be entitled to receive a dividend or to exercise any right as a
                    shareholder on account of shares that have not yet been fully paid.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">7.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">Persons who are the joint owners of a share shall be liable jointly and severally for payment of the amounts due to the Company on account of the share.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">7.5</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The content of this section shall not derogate from any other relief of the Company vis-&#224;-vis a shareholder who fails to pay his debt to the Company on account of his
                    shares.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">8.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Transfer of Shares</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">8.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The Company&#8217;s shares are transferable.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">8.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The transfer of shares must be made in writing, and it shall be recorded only if &#8211;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">8.2.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">A proper certificate for the transfer of shares, together with the certificates of the share intended for transfer, if such were issued, is delivered to the Company
                    at its registered office. The certificate of transfer shall be signed by the transferor and by a witness confirming the signature of the transferor. In the event of the transfer of shares that are not fully paid as of the date of
                    transfer, the certificate of transfer shall also be signed by the recipient of the share and by a witness testifying to the signature of the recipient; or</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">8.2.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">A court order for the amendment of the registration shall be delivered to the Company; or</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">8.2.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">It shall be proved to the Company that lawful conditions pertain for the transfer of the right to the share.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">8.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The transfer of shares that have not been fully paid requires the authorization of the Board of Directors, which is entitled to refuse to grant its authorization at
                    its absolute discretion and without stating grounds therefore.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">8.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The recipient of the transfer shall be considered the shareholder regarding the transferred shares from the moment of the registration of his name in the registry of
                    shareholders.</div>
                </div>
              </td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">3</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">9.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Changes in Capital</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">9.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The general meeting is entitled to increase the Company&#8217;s registered share capital by creating new shares of an existing type or a new type, all as shall be
                    determined in the decision of the general meeting.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">9.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The general meeting is entitled to nullify registered share capital that has not yet been allocated, provided that there is no commitment, including a conditioned
                    commitment, by the Company to allocate the shares.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">9.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">The general meeting shall be entitled, subject to the provisions of any law:</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">9.3.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">To unify and redivide its share capital, or any part thereof, into shares of a nominal value greater than the nominal value of the existing shares.</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">9.3.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">To divide, by way of the redivision of any or all of the existing shares, its share capital into shares of a nominal value smaller than the nominal value of the
                    existing shares.</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">9.3.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.95pt; margin-left: 1pt; line-height: 1.25;">To reduce its share capital and any reserved fund for the repayment of capital in such manner and on such conditions and with the receipt of such authorization as
                    shall be required by the Companies Law.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">10.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Changes in the Rights of Share Types</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">10.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Unless otherwise stated in the conditions of issue of the shares, and subject to the provisions of any law, the rights of any share type may be changed following a
                    decision of the Company&#8217;s Board of Directors, and with the authorization of the general meeting of shareholders of that type, or with the written consent of all the shareholders of that type. The provisions of the Company&#8217;s Articles of
                    Association regarding general meetings shall apply, <font style="font-style: italic;">mutatis mutandis</font>, to a general meeting of type shareholders.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">10.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The rights granted to the holders of shares of a specific type issued with special rights shall not be considered to have been changed by virtue of the creation or
                  issue of additional shares of equal grade, unless otherwise conditioned in the conditions of issue of the said shares.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">11.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>General Meetings</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">11.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Company decisions on the following matters shall be taken at the general meeting &#8211;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">11.1.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Changes to the Articles;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">11.1.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Exercising the authorities of the Board of Directors in the event that the Board of Directors is unable to perform its function;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">11.1.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Appointment of the auditing accountant of the Company and the cessation of employment thereof;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">11.1.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Appointment of directors, including external directors;</div>
              </td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">11.1.5</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Authorization of actions and transactions requiring the authorization of the general meeting in accordance with the provisions of the Companies Law and any other law;</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">11.1.6</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">Increasing and decreasing the registered share capital;</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">11.1.7</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">Merger as defined in the Companies Law.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">11.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Subject to the provisions of the law, the general meeting is entitled to assume authorities granted to another organ in the Company, including the Board of Directors,
                    for a particular matter or for a given period of time.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">If the general meeting has assumed authorities granted to the Board of Directors in accordance with the Companies Law, the shareholders shall bear the same rights,
            obligations, and liability as apply to the Board of Directors regarding the exercising of those same authorities, as detailed in Article 50 of the Companies Law, as this shall be amended from time to time.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">12.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Convening of General Meetings</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">12.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">General meetings shall be convened at least once a year at such a venue and on such a date as shall be determined by the Board of Directors, and subject to the
                    provisions of the law, but not later than 15 months after the previous general meeting. These general meetings shall be called &#8220;annual meetings.&#8221; The remaining meetings of the Company shall be called &#8220;extraordinary meetings.&#8221;</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">12.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The agenda at the annual meeting shall include discussion of the report of the Board of Directors and financial statements as required by law. The annual meeting
                    shall appoint an auditing accountant; shall appoint the directors in accordance with these Articles; and shall discuss all other matters to be discussed at the annual meeting of the Company in accordance with these Articles or in
                    accordance with the Companies Law, as well as any other matter as shall be determined by the Board of Directors.</div>
                </div>
              </td>
            </tr>

        </table>
        <br>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">12.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Board of Directors is entitled to convene an extraordinary meeting in accordance with its decision, and must convene a general meeting if a written request is
                    received from any of the following (hereinafter &#8211; &#8220;<font style="font-weight: bold;">Request to Convene</font>&#8221;)</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">12.3.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">Two directors or one-fourth of the incumbent directors; and/or</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">12.3.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">One or more shareholders holding at least five percent of the issued capital and at least one percent of the voting rights in the Company; and/or</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">12.3.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">One or more shareholders holding at least five percent of the voting rights in the Company.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">12.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Any Request to Convene must specify the goals for whose purpose the meeting is to be convened, and shall be signed by those requesting the convening and delivered at
                    the Company&#8217;s registered office. The request may consist of a number of documents of identical format, each signed by one or more individuals making the request.</div>
                </div>
              </td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">12.5</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>A Board of Directors required to convene an extraordinary meeting shall convene such meeting within twenty-one days from the date on which the Request to Convene was submitted thereto, for a date determined in an invitation in
                  accordance with section 12.6 below and subject to any law.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">12.6</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Notification of the members of the Company regarding the convening of a general meeting shall be published or delivered to all the shareholders registered in the registry of shareholders in the Company in accordance with the
                  requirements of the law. The notification shall include the agenda, the proposed decisions, and arrangements regarding voting in writing.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">13.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Discussion at General Meetings</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">13.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The discussion at the general meeting shall be opened only if a legal quorum is present at the time the discussion begins. A legal quorum is the presence of at least
                    two shareholders holding at least 25 percent of the voting rights (including presence by means of proxy or through a letter of voting) within one half-hour from the time specified for the opening of the meeting.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">13.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">If, at the end of one half-hour from the time specified for the opening of the meeting, no legal quorum is present, the meeting shall be postponed by one week, to the
                    same day, the same hour, and the same venue, or to a later date, if specified on the invitation to the meeting or in the notification of the meeting (hereinafter &#8211; &#8220;<font style="font-weight: bold;">the Postponed Meeting</font>.&#8221;)
                    Notification and invitation regarding a Postponed Meeting postponed for a period of not more than 21 days shall be made not later than seventy-two hours prior to the Postponed Meeting. Notification of a Postponed Meeting shall be made
                    as stated in section 12.6, <font style="font-style: italic;">mutatis mutandis</font>.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">13.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">The legal quorum for commencing a Postponed Meeting shall be any number of participants.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">13.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The chairperson of the Board of Directors shall serve as the chairperson of the general meeting. If the chairperson of the Board of Directors is absent from the
                    meeting after 15 minutes from the time specified for the meeting, or if he refuses to serve as the chairperson of the meeting, the chairperson shall be elected by the general meeting.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">13.5</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">A general meeting with a legal quorum is entitled to decide on the postponement of the meeting to another date and to such venue as shall be determined and, in this
                    case, notifications and invitations to the Postponed Meeting shall be made as stated in section 13.2 above.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">14.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Voting at a General Meeting</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">14.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>A shareholder in the Company shall be entitled to vote at general meetings in person or by means of a proxy or a letter of voting.</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Shareholders entitled to participate in and vote at the general meeting are the shareholders as of such date as shall be determined by the Board of Directors in the decision
            to convene the general meeting, and subject to any law.</div>
        </div>
        <div style="line-height: 1.25;"></div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">14.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">In any vote, each shareholder shall have a number of votes equivalent to the number of shares in their possession entitling the holder to a vote.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">14.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">A decision at the general meeting shall be taken by an ordinary majority unless another majority is determined in the Companies Law or in these Articles.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">14.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The declaration by the chairperson of the meeting that a decision has been adopted unanimously or by a given majority, or rejected or not adopted by a given majority,
                    shall constitute prima facie evidence of the content thereof.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">14.5</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">If the votes at the meeting are equally divided, the chairperson of the meeting shall not have an additional or casting opinion and the decision presented for voting
                    shall be rejected.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">14.6</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Subject to any law, the shareholders in the Company are entitled to vote in any matter on the agenda of a general meeting (including type meetings) by means of a
                    letter of voting, provided that the Board of Directors, subject to any law, has not negated in its decision to convene the general meeting the possibility of voting by means of a letter of voting on that matter.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">If the Board of Directors has prohibited voting by means of a letter of voting, the fact of the negation of the possibility of voting by means of a letter of voting shall be
            stated in the notification of the convening of the meeting in accordance with section 12.6 above.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">14.7</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">A shareholder is entitled to state the manner of his vote in the letter of voting and to deliver this to the Company up to 48 hours prior to the time of commencement
                    of the meeting. A letter of voting stating the manner of voting of the shareholder reaching the Company at least 48 hours prior to the time of commencement of the meeting shall be considered tantamount to presence at the meeting,
                    including for the matter of the presence of the legal quorum as stated in section 13.1 above.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">14.8</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Appointment of a proxy shall be in writing, signed by the appointer (hereinafter &#8211; &#8220;<font style="font-weight: bold;">Power of Attorney</font>.&#8221;) A corporation shall
                    vote by means of its representatives, who shall be appointed in a document signed properly by the corporation (hereinafter &#8211; &#8220;<font style="font-weight: bold;">Letter of Appointment</font>.&#8221;)</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">14.9</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">A vote in accordance with the conditions of a Power of Attorney shall be lawful even if the appointer dies before the voting, or becomes legally incompetent, is
                    liquidated, becomes bankrupt, nullifies the Letter of Appointment, or transfers the share regarding which it was given, unless written notification is received at the Company&#8217;s office prior to the meeting that the shareholder has died,
                    become legally incompetent, been liquidated, become bankrupt, or has nullified the Letter of Appointment or transferred the shares as stated.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">14.10</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Letter of Appointment and the Power of Attorney, or a copy authorized by anattorney, shall be deposited at the Company&#8217;s registered offices at least forty
                    eight (48) hours prior to the time determined for the meeting or for the Postponed Meeting at which the person mentioned in the document intends to vote in accordance therewith.</div>
                </div>
              </td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">14.11</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">A shareholder in the Company shall be entitled to vote at the Company&#8217;s meetings by means of several proxies appointed thereby, provided that each proxy shall be appointed on account of
                    different sections of the shares held by the said shareholder. There shall be no impediment to each proxy as stated voting in a different manner in the Company&#8217;s meetings.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">14.12</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">If a shareholder is legally incompetent, he is entitled to vote by means of his trustees, the recipient of his assets, his natural guardian or other legal guardian, and these are entitled
                    to vote in person or by proxy or a Letter of Voting.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">14.13</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">When two or more persons are the joint owners of a share, in a vote on any matter the vote of the person whose name is registered first in the registry of shareholders as the owner of that
                    share shall be accepted, whether in person or by proxy, and he is entitled to deliver Letters of Voting to the Company.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">15.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>The Board of Directors</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 28.35pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Board of Directors shall set the Company&#8217;s policy, supervise the execution of the functions and actions of the general director, and, within this, shall act and shall
            enjoy all the authorities detailed in Article 92 of the Companies Law. In addition, any authority not granted in the Companies Law or in these Articles to another organ may be exercised by the Board of Directors, in addition to the authorities
            and functions of the Board of Directors in accordance with the content of any law.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">16.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Appointment of the Board of Directors and Cessation of Office Thereof</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">16.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">The number of directors in the Company shall be determined from time to time by the annual general meeting, provided that this shall not be fewer than 5 and not more than 10 directors,
                    including external directors (if any were elected). The number of external directors in the Company shall not be less than the number determined in the Companies Law.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 28.35pt;">
                  <div>&#160;</div>
                </td>
                <td style="width: 28.35pt; text-align: left; vertical-align: top;">
                  <div><font style="font-family: 'Times New Roman',Times,serif;">16.2</font> <br>
                  </div>
                </td>
                <td style="width: 21.25pt; text-align: left; vertical-align: top;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font></td>
                <td style="width: auto;">
                  <div>
                    <div style="text-align: justify; margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Directors shall be elected at the annual general meeting by vote of a shareholders&#8217; resolution. The directors, excluding the external directors
                      (if any were elected), shall be classified, with respect to the term for which they each severally hold office, into three classes, as nearly equal in number as practicable, hereby designated as Class I, Class II and Class III.</div>
                  </div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" border="0" id="cc8b3b4eee1440929315c7cfb84dc72a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 77.95pt;">&#160;</td>
              <td style="width: 18pt; text-align: left; vertical-align: top;">(i)</td>
              <td rowspan="1" style="vertical-align: top; width: auto; text-align: left; text-indent: 18pt;">The term of office of the initial Class I directors shall expire when their successors are elected and qualified at the first annual general
                meeting to be held following the approval of this provision;</td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" border="0" id="ccd6b8e1f3a247aaadb4672d2d3cc5fa" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 77.95pt;">&#160;</td>
              <td style="width: 18pt; text-align: left; vertical-align: top;">(ii)</td>
              <td rowspan="1" style="vertical-align: top; text-align: left; text-indent: 18pt;">The term of office of the initial Class II directors shall expire when their successors are elected and qualified at the first annual general meeting following
                the annual general meeting referred to in clause (i) above; and<br>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" border="0" id="5f4fb4a80e474cc28357cb19e1fe7fe4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 77.95pt;">&#160;</td>
              <td style="width: 18pt; text-align: left; vertical-align: top;">(iii)</td>
              <td rowspan="1" style="vertical-align: top; text-align: left; text-indent: 18pt;">The term of office of the initial Class III directors shall expire when their successors are elected and qualified at the first annual general meeting following
                the annual general meeting referred to in clause (ii) above.</td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 21.25pt; vertical-align: top;">(b)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">At each annual general meeting, commencing with the annual general meeting to be held following the approval of this provision (anticipated to be in 2024), each of
                    the successors elected to replace the directors of a Class whose term shall have expired at such annual general meeting shall be elected to hold office until the third annual general meeting next succeeding his or her election (or
                    re-election) and until his or her respective successor shall have been elected and qualified. Notwithstanding anything to the contrary, each director shall serve subject to section 16 hereof until his or her successor is elected and
                    qualified or until such earlier time as such director&#8217;s office is vacated, or his earlier removal pursuant to this section 16.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 21.25pt; vertical-align: top;">(c)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">If the number of directors (excluding external directors, if any were elected) that comprise the Board of Directors is hereafter changed, any newly created
                    directorships or decrease in directorships shall be so apportioned by the Board of Directors among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of directors
                    constituting the Board of Directors shall shorten the term of any incumbent director.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">16.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">In addition to the content of section 16.2 above, the Board of Directors is entitled to appoint a director in place of a director whose position has become vacant
                    and/or by way of an addition to the Board of Directors, subject to the maximum number of directors on the Board of Directors as stated in section 16.1 above. The appointment of a director by the Board of Directors to fill any vacancy
                    shall only be for the remaining period of time during which the director whose service has ended would have held office, or in case of a vacancy due to the number of directors serving being less than the maximum number stated in section
                    16.1 above, the Board of Directors shall determine at the time of appointment the class, pursuant to section 16.2, to which the additional director is assigned.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">16.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">A director whose period of office has expired may be reelected, with the exception of an external director, who may be reelected for an additional period of office
                    subject to the provisions of the law.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">16.5</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The office of a director shall commence on the date of his/her appointment by the annual meeting and/or the Board of Directors, or on a later date if this date is
                    determined in the decision of appointment at the annual meeting and/or the Board of Directors.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">16.6</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Board of Directors shall elect one of its members as the chairperson of the Board of Directors. The elected chairperson shall run the meetings of the Board of
                    Directors and shall sign the minutes of the discussion. If no chairperson is elected, or if the chairperson of the Board of Directors is not present after 15 minutes from the time set for the meeting, the directors present shall choose
                    one of their number to serve as the chairperson at that meeting, and the chosen member shall run the meeting and sign the minutes of the discussion.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The chairperson of the Board of Directors shall not be the general director of the Company unless the conditions stipulated in Article 121(C) of the Companies Law apply.</div>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">16.7</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The general meeting is entitled to remove any director from their office prior to the end of the period of their office, inter alia whether the director was appointed
                    thereby in accordance with section 16.2 above or was appointed by the Board of Directors in accordance with section 16.3 above, provided that the director shall be given a reasonable opportunity to state their case before the general
                    meeting.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">16.8</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Any director is entitled, with the agreement of the Board of Directors, to appoint a substitute for themselves (hereinafter &#8211; a &#8220;<font style="font-weight: bold;">Substitute
                      Director</font>&#8221;), provided that a person who is not competent shall not be appointed to serve as a Substitute Director, nor a person who has been appointed as a Substitute Director for another director and/or a person who is already
                    serving as a director in the Company.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The appointment or cessation of office of a Substitute Director shall be made in a written document signed by the director who appointed him; in any case, however, the office
            of a Substitute Director shall be terminated if one of the cases stipulated in the paragraphs in section 16.9 below shall apply, or if the office of the member of the Board of Directors for whom he serves as a substitute shall become vacant for
            any reason.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">A Substitute Director is considered tantamount to a director and all the legal provisions and the provisions of these Articles shall apply, with the exception of the
            provisions regarding the appointment and/or dismissal of a director as established in these Articles.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">16.9</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">The office of a director shall become vacant in any of the following cases:</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">16.9.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">The director resigns from office by means of a letter signed in his hand, submitted to the Company and detailing the reasons for his resignation;</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">16.9.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The director is removed from office by the general meeting;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">16.9.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">The director is convicted of an offense as stated in Article 232 of the Companies Law;</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">16.9.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">In accordance with a court decision as stated in Article 233 of the Companies Law;</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">16.9.5</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">The director is declared legally incompetent or died;</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">16.9.6</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">The director is declared bankrupt and, if the director is a corporation &#8211; it opted for voluntary liquidation or a liquidation order was issued against it.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">16.10</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">In the event that the position of a director becomes vacant, the remaining directors shall be entitled to continue to act, provided the number of directors remaining shall not be less than
                    the minimum number of directors as stated above in section 16.1 above. If the number of directors falls below the above-mentioned minimum number, the remaining directors shall be entitled to act solely in order to fill the place of the
                    director that has become vacant as stated in section 16.3 above, or in order to convene a general meeting of the Company, and pending the convening of the general meeting of the Company as stated they may act to manage the Company&#8217;s
                    affairs solely in matters that cannot be delayed.</div>
                </div>
              </td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">16.11</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; text-indent: -28.35pt; margin-left: 29.3pt; line-height: 1.25;">The terms and conditions of the office of the members of the Board of Directors shall be authorized in accordance with the provisions of the
                    Companies Law.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">16.12</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">Notwithstanding anything to the contrary herein, clauses 16.1, 16.2 and 16.3 above may only be amended, replaced or suspended by a resolution adopted at an annual general meeting by a
                    majority of at least 65% of the ordinary shares represented at such meeting (in person, by proxy, by voting instruction form or via the electronic voting system of the Israel Securities Authority) voting on the proposal.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">16.13</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">Notwithstanding anything to the contrary in these Articles, the election, qualification, removal or dismissal of external directors, if so elected, shall be only in accordance with the
                    applicable provisions set forth in the Companies Law.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">17.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Meetings of the Board of Directors</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">17.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">The Board of Directors shall convene for a meeting in accordance with the needs of the Company, and at least once every three months.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">17.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The chairperson of the Board of Directors is entitled to convene the Board at any time. In addition, the Board of Directors shall hold a meeting on such subject as
                  shall be specified in the following cases:</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">17.2.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">In accordance with the request of two directors; however, if at the time the Board of Directors comprises five directors or less &#8211; in accordance with the request of
                    one director;</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">17.2.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">In accordance with the request of one director if, in his request to convene the Board, he states that he has learned of a matter in the Company ostensibly entailing
                    a violation of the law or infringement of proper business practice;</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">17.2.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">If a general director has been appointed in the Company or if a notification or report by the general director require an action on the part of the Board of
                    Directors;</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">17.2.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">If the auditing accountant has informed the chairperson of the Board of Directors &#8211; or, in the event that no chairperson was appointed for the Board of Directors, has
                    informed the Board of Directors &#8211; of substantial defects in the accounting control of the Company.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">17.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Notification of the meeting of the Board of Directors shall be delivered to all members of the Board at least three days prior to the date of convening of the Board,
                    or with shorter prior notice insofar as the chairperson of the Board decided that, in the circumstances of the matter, it is vital and reasonable to convene the Board of Directors with notice shorter than three days. Notification shall
                    be delivered to the address of the director as forwarded to the Company in advance, and shall stipulate the time of the meeting and the venue at which it shall convene, as well as reasonable detail of all subjects on the agenda.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">Notwithstanding the above, the Board of Directors is entitled to convene a meeting without notification, with the consent of all the directors.</div>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">11</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">17.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The agenda of the meetings of the Board of Directors shall be determined by the chairperson of the Board and shall include: Subjects determined by the chairperson of
                    the Board; subjects deriving from the report of the general director and/or the auditing accountant; any subject a director of the general director have requested of the chairperson of the Board to include on the agenda, at least two
                    days prior to the convening of the meeting of the Board.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">If no chairperson has been appointed for the Board of Directors, the agenda for the meetings of the Board shall be determined by the directors in such manner that each
            director shall send to the Company, at least two days before the convening of the meeting of the Board, the subjects that, in his opinion, should be included in the meeting of the Board. The agenda for the meetings of the Board shall also
            include subjects deriving from the report of the general director and/or the auditing accountant.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">17.5</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The details of the subjects on the agenda as stated in section 17.4 above do not prevent discussion of a subject or subjects not mentioned in the notification of the
                    meeting of the Board of Directors (hereinafter: &#8220;<font style="font-weight: bold;">a New Subject</font>.&#8221;)</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">If a New Subject is discussed at the meeting of the Board of Directors, a director not present at the meeting of the Board of Directors at which the New Subject was discussed
            may express in writing his opposition to the decision and/or request that the subject be discussed again, within three days from the date on which he received a copy of the decision. If a further discussion is requested as stated, this shall be
            held by the Board of Directors on such date as shall determined by the chairperson of the Board of Directors or, in his absence, by the Board of Directors, and not later than seven days after the receipt of the request. However, the objection
            of the director to the decision on the New Subject shall not impair the validity of actions regarding third parties undertaken on the basis thereof.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">17.6</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The legal quorum for the commencement of a meeting of the Board of Directors shall be a majority of the members of the Board of Directors. If, at the end of one
                    half-hour from the time set for the commencement of the meeting, no quorum is present, the meeting shall be postponed to another date as decided by the chairperson of the Board, or, in his absence, by the directors present at the
                    convened meeting, provided that prior notification of three days shall be given to all directors regarding the date of the Postponed Meeting. The legal quorum for the opening of a Postponed Meeting shall be any number of participants.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">17.7</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Board of Directors is entitled to hold meetings by use of any means of communication, providing that all the participating directors can hear each other
                    simultaneously.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">17.8</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Board of Directors is entitled to take decisions without actually convening, provided that all the directors entitled to participate in the discussion and to vote
                    on the subject brought for decision agree thereto. If decisions are made as stated in this section, the chairperson of the Board of Directors shall record minutes of the decisions stating the manner of voting of each director on the
                    subjects brought for decision, as well as the fact that all the directors agreed to take the decision without convening.</div>
                </div>
              </td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">18.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Voting on the Board of Directors</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">18.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">Each director shall have one vote when voting on the Board of Directors.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">18.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">Decisions of the Board of Directors shall be taken by a majority vote. The chairperson of the Board of Directors shall not have any additional or casting opinion, and in the event of a tie
                    vote, the decision brought for voting shall be rejected.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">19.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Committees of the Board of Directors</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">19.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Board of Directors is entitled to establish committees and to appoint members thereto (hereinafter &#8211; &#8220;<font style="font-weight: bold;">the Committees of the Board
                      of Directors</font>.&#8221;) If Committees of the Board of Directors are established, the Board of Directors shall determine, in the conditions of empowerment thereof, whether specific authorities of the Board of Directors shall be
                    delegated to the Committees of the Board of Directors, in such manner that the decision of the Committee of the Board of Directors shall be considered tantamount to a decision of the Board of Directors, or whether the decision of the
                    Committee of the Board of Directors shall merely constitute a recommendation, subject to the authorization of the Board of Directors; provided that authorities to make decisions in the matters stated in Article 112 of the Companies Law
                    shall not be delegated to a committee.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">19.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">A person who is not a director shall not serve in a Committee of the Board of Directors to which the Board of Directors has delegated authorities. Persons who are not
                    members of the Board of Directors may serve in a Committee of the Board of Director whose function is merely to advise or submit recommendations to the Board of Directors.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">19.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The provisions included in these Articles relating to the meetings of the Board of Directors and voting therein shall apply, <font style="font-style: italic;">mutatis
                      mutandis </font>and subject to the decisions of the Board of Directors regarding the procedures for the meetings of the committee (if any), to any Committee of the Board of Directors comprising two or more members.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">20.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Audit Committee</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">20.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="text-align: left; line-height: 1.25;">The Board of Directors of the Company shall appoint an audit committee from among its members. The number of members of the audit committee shall be not less than three, and any external
                  director may be a member thereof. The chairperson of the Board of Directors or any director employed by the Company, or providing it with services on a regular basis, or a controlling shareholder in the Company, or a relative thereof
                  shall not be appointed to the committee.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">20.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The functions of the audit committee shall be &#8211;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">20.2.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">To identify defects in the business management of the Company, inter alia through consultation with the internal auditor of the Company or the auditing accountant, and to propose methods
                    to the Board of Directors for correcting these;</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">20.2.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">To decide whether to authorize actions and transactions requiring the authorization of the audit committee in accordance with the Companies Law.</div>
                </div>
              </td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">13</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">21.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>General Director</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 28.35pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Board of Directors of the Company shall appoint a general director, and is entitled to appoint more than one general director. The general director shall be responsible
            for the routine management of the Company&#8217;s affairs within the framework of the policy set by the Board of Directors and subject to its guidelines.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">22.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Exemption, Insurance, and Indemnification</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="text-align: justify; margin-left: 28.35pt; line-height: 1.25;">&#160;Subject to the provisions of the Companies Law and the Israeli Securities law, 5728-1968 (the &#8220;Israeli Securities Law&#8221;), the Company may:</div>
        <div style="text-align: justify; margin-left: 28.35pt; line-height: 1.25;"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">22.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">enter into a contract for the insurance of the liability, in whole or in part, of any of its &#8220;Office Holders&#8221; (as defined in the Companies Law) with respect to an
                    obligation imposed on such Office Holder due to an act performed by the Office Holder in the Office Holder&#8217;s capacity as an Office Holder of the Company arising from any of the following:</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
        </div>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 56.7pt;"><br>
                </td>
                <td style="width: 35.45pt; vertical-align: top;">22.1.1</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>a breach of duty of care to the Company or to any other person;</div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">22.1.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="text-align: left; line-height: 1.25;">a breach of the duty of loyalty to the Company provided that the Office Holder acted in good faith and had reasonable grounds to assume that the act would not harm the interests of the
                  Company;</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">22.1.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">a financial liability imposed on such Office Holder in favor of any other person:</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">22.1.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">reasonable litigation expenses, including attorneys fees, incurred by the Office Holder as a result of an ongoing administrative enforcement proceeding instituted
                  against him in accordance with the Israeli Securities Law. Without derogating from the generality of the foregoing, such expenses will include, and the Company may procure insurance for, a payment imposed on the Office Holder in favor of
                  an injured party as set forth in Section 52CIV(a)(1)(a) of the Israeli Securities Law and expenses that the Office Holder incurred in connection with a proceeding under Chapters VIII&#8221;3, VIII&#8221;4 or IX&#8221;1 of the Israeli Securities Law,
                  including reasonable legal expenses, which term includes attorney fees; and</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 56.7pt;"><br>
              </td>
              <td style="width: 35.45pt; vertical-align: top;">22.1.5</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="text-align: left; line-height: 1.25;">any other incident for which it is or shall be permitted to insure the liability of an officer.</div>
              </td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">14</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">22.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">undertake, in advance to indemnify, or may indemnify retroactively, an Office Holder of the Company with respect to any of the following
                    liabilities or expenses that arise from an act performed by the Office Holder by virtue of being an Office Holder of the Company:</div>
                </div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 56.7pt;"><br>
                </td>
                <td style="width: 35.45pt; vertical-align: top;">22.2.1</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="line-height: 1.25;">a financial liability imposed on an Office Holder in favor of another person by any judgment, including a judgment given as a result of a settlement or an arbitrator&#8217;s award which has
                      been confirmed by a court;</div>
                  </div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 56.7pt;"><br>
                </td>
                <td style="width: 35.45pt; vertical-align: top;">22.2.2</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="line-height: 1.25;">reasonable litigation expenses including attorney&#8217;s fees, incurred by him as a result of an investigation or proceeding instituted against him by an authority empowered to conduct an
                      investigation or proceedings, which are concluded without the filing of an indictment against the Office Holder and without the levying of a monetary obligation in lieu of criminal proceedings upon the Office Holder, or which are
                      concluded without the filing of an indictment against the Office Holder but with levying a monetary obligation in substitute of such criminal proceedings upon the Office Holder for a crime that does not require proof of criminal
                      intent; or in connection with an administrative enforcement proceeding or a financial sanction. Without derogating from the generality of the foregoing, such expenses will include, and the Company may undertake to indemnify an Office
                      Holder of the Company as aforesaid, for a payment imposed on the Office Holder in favor of an injured party as set forth in Section 52LIV(a)(1)(a) of the Israeli Securities Law and expenses that the Office Holder incurred in
                      connection with a proceeding under Chapters VIII&#8221;3, VIII&#8221;4 or IX&#8217;1 of the Israeli Securities Law, including reasonable legal expenses, which term includes attorney fees; and</div>
                  </div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
        </div>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 56.7pt;"><br>
                </td>
                <td style="width: 35.45pt; vertical-align: top;">22.2.3</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="line-height: 1.25;">reasonable litigation expenses, including attorney&#8217;s fees, expended by an Office Holder or which were imposed on an Office Holder by a court in proceedings filed against the Office
                      Holder by the Company or in its name or by any other person or in a criminal charge on which the Office Holder was acquitted or in a criminal charge on which the Office Holder was convicted for an offense which did not require proof
                      of criminal intent; and</div>
                  </div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
        </div>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 56.7pt;"><br>
                </td>
                <td style="width: 35.45pt; vertical-align: top;">22.2.4</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="line-height: 1.25;">any other obligation or expense for which it is or shall be permitted to indemnify an officer, provided however, that in the event the Company wishes to indemnify an Office Holder in
                      advance for financial liabilities under Article 22 it may only do so if the undertaking to indemnify the Office Holder for such liabilities was restricted to those events that the Board may deem foreseeable in light of the Company&#8217;s
                      actual activities, at the time of giving of such undertaking, and to a specific sum or a reasonable criterion under such circumstances as determined by the Board.</div>
                  </div>
                </td>
              </tr>

          </table>
        </div>
        <br>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">23.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="line-height: 1.25;">
                  <div style="margin-left: 1pt; line-height: 1.25;">Subject to the provisions of the Law and the Israeli Securities Law, the Company hereby releases, in advance, its Office Holders from liability to the Company for
                    damage that arises from the breach of the Office Holder&#8217;s duty of care to the Company.</div>
                </div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">24.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="line-height: 1.25;">The provisions of Articles 22 and 23 are not intended, and shall not be interpreted, to restrict the Company in any manner in respect of the procurement of insurance or in respect of
                  indemnification (i) in connection with any person who is not an Office Holder, including, without limitation, any employee, agent, consultant or contractor of the Company who is not an Office Holder, or (ii) in connection with any Office
                  Holder to the extent that such insurance and/ or indemnification is not specifically prohibited under the Companies Law; provided that the procurement of any such insurance or the provision of any such indemnification shall be approved by
                  the Board. Any modification of Articles 22 through 24, and any amendment to the Companies Law, the Israeli Securities Law or any other applicable law, shall be prospective in effect and shall not affect the Company&#8217;s obligation or ability
                  to indemnify an Office Holder for any act or omission occurring prior to such modification or amendment, unless otherwise provided by the Companies Law, the Israeli Securities Law or such applicable law.</div>
              </td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <br>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">25.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Internal Auditor</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">25.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Board of Directors of the Company shall appoint an internal auditor in accordance with the proposal of the audit committee. A person who is an interested party in
                    the Company, an office holder therein, or the relative or either of the above, as well as the auditing accountant or any person on his behalf, shall not serve as an internal auditor in the Company.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">25.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Board of Directors shall determine which office holder shall be organizationally accountable for the internal auditor and, in the absence of such determination;
                    this shall be the chairperson of the Board of Directors.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">25.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The internal audit plan prepared by the auditor shall be submitted to the audit committee for authorization; however, the Board of Directors is permitted to determine
                    that the plan shall be submitted to the Board of Directors for authorization.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">26.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Auditing Accountant</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">26.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">The general meeting shall appoint an auditing accountant for the Company. The auditing accountant shall service in his office through the end of the following annual meeting, or for a
                    longer period as determined by the annual meeting, provided that the period of office shall not be extended beyond the end of the third annual meeting following that at which he was appointed.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">26.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">The fee of the auditing accountant for the auditing operations shall be determined by the Board of Directors. The Board of Directors shall report to the annual meeting on the fee of the
                    auditing accountant.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">27.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Signing in the Company&#8217;s Name</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">27.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The rights to sign in the Company&#8217;s name shall be determined from time to time by the Board of Directors of the Company.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">27.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Company&#8217;s authorized signatory shall do so together with the Company&#8217;s stamp, or alongside its printed name.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">28.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Dividend and Benefit Shares</u></div>
              </td>
            </tr>

        </table>
        <br>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">28.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The decision by the Company to allocate a dividend and/or to allocate benefit shares shall be taken by the Company&#8217;s Board of Directors.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">28.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Unless determined otherwise by the Board of Directors, it shall be permitted to pay any dividend by way of check or payment order
                    to be sent by mail in accordance with the registered address of the shareholder or the personal eligible thereto or, in the case of joint registered owners of the same share, to that shareholder whose name is mentioned first in the
                    registry of shareholders with regard to the joint ownership. Any such check shall be made out to order of the person to whom it is sent. A receipt from a person whose name, as of the date of declaration of the&#160; dividend, is registered
                    in the registry of shareholders as the owner of any share or, in the case of joint owners, of one of the joint owners, shall serve as authorization regarding all payments made in connection with that share and regarding which the
                    receipt was received.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">28.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">For the purpose of executing any decision in accordance with the provisions of this section, the Board of Directors is entitled to resolve as it
                    sees fit any difficulty that emerges regarding distribution of the dividend and/or the benefit shares, including determining the value for the purpose of the said division of certain assets, and to determine that payments in cash shall
                    be made to members on the basis of the value so determined; to determine provisions regarding fractions of shares; or to determine that sums of less than NIS 50 shall not be paid to a shareholder.</div>
                </div>
              </td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">16</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">29.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Redeemable Securities</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 28.35pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Company is entitled, subject to any law, to issue redeemable securities on such conditions as shall be determined by the Board of Directors, provided that the general
            meeting shall approve the recommendation of the Board of Directors and the conditions established thereby.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">30.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Donations</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 28.35pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">The Company is entitled to donate a reasonable sum of money for a fit purpose. The Board of Directors of the Company is entitled to determine, at its discretion, rules for
            the making of donations by the Company.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">31.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Accounts</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">31.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">The Company shall maintain accounts and shall prepare financial statements in accordance with the Securities Law and in accordance with any law.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">31.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">The account ledgers shall be held at the Company&#8217;s registered offices or in any other place as the directors shall see fit, and shall always be open for inspection by the directors.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt; vertical-align: top;">32.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-weight: bold;"><u>Notifications</u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">32.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="line-height: 1.25;">Subject to any law, a notification or any other document that shall be delivered by the Company, and which it is entitled or required to issue in accordance with the provisions of the
                    Articles and/or the Companies Law, the Securities Law, or any law, shall be delivered by the Company to any person in one of the following manners as decided by the Company in each individual case: (A) By dispatch by registered mail in
                    a letter addressed in accordance with the registered address of that shareholder in the registry of shareholders, or in accordance with such address as stated by the shareholder in a letter to the Company as the letter for the delivery
                    of notifications or other documents; or (B) By dispatch by facsimile in accordance with the number stated by the shareholder as the number for the delivery of facsimile notifications; or (C) By way of publication in two daily newspapers
                    appearing in Israel; or (D) By way of publication in the distribution site of the Securities Authority and the Tel Aviv Stock Exchange Ltd.</div>
                </div>
              </td>
            </tr>

        </table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">17</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">32.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Any notification to be made to shareholders shall be made, regarding jointly owned shares, to that person whose name is mentioned first in the registry of
                    shareholders as the holder of that share, and any notification made in this manner shall be sufficient notification for the holders of that share.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">32.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">Any notification or other document sent in accordance with the provisions of section 30.1 above shall be considered to have reached its destination: (A) Within 3
                    business days &#8211; if sent by registered mail in Israel; or (B) On the first business day after its dispatch, if delivered by hand or sent by facsimile; or (C) On the date of publication, if published in a newspaper or on the distribution
                    site of the Securities Authority and the Tel Aviv Stock Exchange Ltd.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 0pt; margin-left: 56.7pt; line-height: 1.25;">
          <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">In proving delivery, it shall be sufficient to prove that the letter sent by mail included the notification and that the document was addressed properly and was delivered to
            the post office as a letter bearing stamps, or as a registered letter bearing stamps, and, regarding a facsimile, it shall be sufficient to produce a dispatch confirmation sheet from the dispatching facsimile machine.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">32.4</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; margin-left: 1pt; line-height: 1.25;">Any record made in an ordinary manner in the company&#8217;s registry shall be considered prima facie evidence of dispatch as recorded in that registry.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 28.35pt; vertical-align: top;">32.5</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25;">When it is necessary to provide prior notification of a certain number of days, or when notification is valid for a certain period, the date of delivery shall be
                    included in reckoning the number of days or the period.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25;">**************</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; margin-right: 0.85pt; margin-left: 1pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Articles were adopted on November 29, 2007 and amended by approval of the shareholders at the Annual General
          Meeting held on September 24, 2020 and were further amended by approval of the shareholders at the Annual General Meetings held on August 7, 2023, October 1, 2024 and June 29, 2025</div>
        <div style="text-align: center; line-height: 1.25;"> <br>
        </div>
      </div>
    </div>
    <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;">18</font>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.2
<SEQUENCE>3
<FILENAME>exhibit_2-2.htm
<DESCRIPTION>EXHIBIT 2.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 2.2</font></u><br>
  </div>
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">DESCRIPTION OF SECURITIES</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As of December 31, 2025, BioLineRx Ltd. had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or Exchange Act: our
        ordinary shares and American Depositary Shares, or ADSs. References herein to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to BioLineRx Ltd. and its subsidiary.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">General</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We were incorporated under the laws of the State of Israel in 2003 under the name &#8220;BioLineRx Ltd.&#8221; Our registration number with the Israeli Registrar of Companies is 513398750.
        Our purpose is set forth in Section 2 of our Articles of Association and includes every lawful purpose.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">Listing</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our ADSs have been trading on Nasdaq under the symbol &#8220;BLRX&#8221; since July 2011.&#160; Our ordinary shares have been trading on the Tel Aviv Stock Exchange, or the TASE, under the symbol
        &#8220;BLRX&#8221; since February 2007.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Ordinary Shares</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our authorized share capital consists of 2,000,000,000 ordinary shares, par value NIS 0.1 per share.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Transfer of Shares</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our ordinary shares that are fully paid for are issued in registered form and may be freely transferred under our Articles of Association, unless the transfer is restricted or
        prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are traded. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our Articles of Association
        or the laws of the State of Israel, except under certain circumstances with respect to subjects of some countries which are, or have been, in a state of war with Israel.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="margin-left: 36pt; line-height: 1.25; font-style: italic;"><font style="font-weight: bold;">Changes in Capital</font>&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Articles of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies Law, 1999, or the Companies
        Law, and must be approved by a resolution duly passed by our shareholders at a general or extraordinary meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and
        payment of dividends in the absence of sufficient retained earnings and profits, require a resolution of our Board of Directors and court approval (subject to limited exceptions, see below under &#8220;&#8212;<font style="font-style: italic;">Dividends and
          Liquidation Rights</font>&#8221;).</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="margin-left: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Dividends and Liquidation Rights</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are
        determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide otherwise. Our Articles of Association do not require shareholder approval of a dividend
        distribution and provide that dividend distributions may be determined by our board of directors.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Companies Law, we may only distribute dividends out of the higher of (a) retained earnings and (b) earnings generated over the two most recent fiscal years years,
        as such terms are defined in the Companies Law, according to our then last reviewed or audited financial reports, provided that the date of the financial reports is not more than six months prior to the date of distribution (referred to as the
        &#8220;profit test&#8221;), provided that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due (referred to as the &#8220;solvency test&#8221;).&#160; Notwithstanding the
        foregoing, in the event that a company does meet the profit test, dividends may be paid with the approval of a court, provided that the court is convinced that the company meets the solvency test.&#160; However, in accordance with the (Relief for
        Companies the Shares of which are Registered for Trading Outside of Israel) &#8211; 2000, or the Relief Regulations, as a company whose shares are dual listed on the TASE and a foreign (non-Israeli) exchange referenced in the second or third addendum to
        the Israeli Securities Law, 1968 (which include, among others, the NASDAQ Capital Market), our board of directors may resolve to distribute a dividend by way of a share repurchase program if the company does not meet the profit test without seeking
        the approval of the court, subject to the following: (i) the company meets the solvency test; and (ii) we provided a notice to certain creditors regarding our intention to distribute a dividend by way of a share repurchase program in accordance
        with the notice requirements set forth in the Relief Regulations and no such creditor submits an objection within 30 days of the notice (otherwise, court approval would be required for such distribution in accordance with the requirements of the
        Companies Law).</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their
        shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential dividend or distribution rights that may be
        authorized in the future.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="margin-left: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Election of Directors</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under our Articles of Association, our board of directors must consist of at least five and not more than 10 directors (including external directors under Israeli law, if any).&#160;
        Our ordinary shares do not have cumulative voting rights in the election of directors. As a result, the holders of a majority of the voting power represented at a shareholders meeting and voting on the matter have the power to elect all of our
        directors (other than with respect to the special approval requirements for the election of external directors, if applicable).</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to our Articles of Association, other than the external directors (if any), for whom special election requirements apply under the Companies Law, our directors are divided into three
        classes, one class being elected each year at the annual general meeting of our shareholders, and serve on our board of directors until the third annual general meeting following such election or re-election or until they are removed by a vote of
        65% of the total voting power of our shareholders or upon the occurrence of certain events, in accordance with the Companies Law and our Articles of Association. In addition, our Articles of Association allow our board of directors to appoint
        directors (who are not external directors) to fill vacancies on the board of directors up to the maximum number of directors permitted under our Articles of Association. Any director so appointed serves for a term of office equal to the remaining
        period of the term of office of the director whose office has been vacated (or in the case of any new director, for a term of office according to the class to which such director was assigned upon appointment).</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Quorum</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The quorum required for our general meetings of shareholders consists of at least two shareholders present in person, by proxy or written ballot who hold or represent between
        them at least 25% of the total outstanding voting rights.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A meeting adjourned for lack of a quorum is adjourned to the same day in the following week at the same time and place or on a later date if so specified in the summons or notice
        of the meeting. At the reconvened meeting, any number of our shareholders present in person or by proxy shall constitute a lawful quorum.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="margin-left: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Vote Requirements</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Holders of ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of shareholders.&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Articles of Association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by applicable law or by our Articles of
        Association. Under the Companies Law, certain actions require a special majority, including: (i) the approval of an extraordinary transaction with a controlling shareholder or in which the controlling shareholder has a personal interest, (ii) the
        terms of employment or other engagement of a controlling shareholder of the company or a controlling shareholder&#8217;s relative (even if such terms are not extraordinary) and (iii) approval of certain compensation-related matters, such as approval of a
        compensation policy, approval of executive officer compensation inconsistent with our compensation policy or the compensation of our chief executive officer (subject to limited exceptions). Under our Articles of Association, the alteration of the
        rights, privileges, preferences or obligations of any class of our shares (to the extent there are classes other than ordinary shares) may require a simple majority of the class so affected (or such other percentage of the relevant class that may
        be set forth in the governing documents relevant to such class), in addition to the ordinary majority vote of all classes of shares voting together as a single class at a shareholder meeting. Our Articles of Association also provide that the
        removal of any director from office or the amendment of such provision, or certain other provisions regarding our staggered board, require the vote of at least 65% of the total voting power of our shareholders. Another exception to the simple
        majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law, which requires the approval of a majority of the
        holders holding at least 75% of the voting rights represented at the meeting and voting on the resolution.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Access to Corporate Records</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, all shareholders of a company generally have the right to review minutes of the company&#8217;s general meetings, its shareholders register and principal
        shareholders register, articles of association, financial statements and any document it is required by law to file publicly with the Israeli Companies Registrar and the Israel Securities Authority. Furthermore, any of our shareholders may request
        access to review any document in our possession that relates to any action or transaction with a related party, interested party or office holder that requires shareholder approval under the Companies Law. However, we may deny such a request to
        review a document if we determine that the request was not made in good faith, that the document contains a trade secret or a patent or that the document&#8217;s disclosure may otherwise prejudice our interests.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">Acquisitions under Israeli Law</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Full Tender Offer</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A person wishing to acquire shares of a public Israeli company and who would as a result hold over 90% of the target company&#8217;s voting rights or issued and outstanding share
        capital (or a class thereof), is required by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of the issued and outstanding shares of the company (or the applicable class). If (a) the
        shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company (or of the applicable class) and the shareholders who accept the offer constitute a majority of the offerees that do not have a
        personal interest in the acceptance of the tender offer, or (b) the shareholders who did not accept the tender offer hold less than 2% of the issued and outstanding share capital of the company (or of the applicable class), all of the shares that
        the acquirer offered to purchase will be transferred to the acquirer by operation of law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">However, a shareholder that had its shares so transferred may petition the court within six months from the date of acceptance of the full tender offer, regardless of whether
        such shareholder agreed to the tender, to determine whether the tender offer was for less than fair value and whether the fair value should be paid as determined by the court unless the acquirer stipulated in the tender offer that a shareholder
        that accepts the offer may not seek appraisal rights. If the full tender offer was not accepted in accordance with any of the above alternatives, the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of
        the company&#8217;s issued and outstanding share capital (or of the applicable class) from shareholders who accepted the tender offer. Shares purchased in contradiction to the special tender offer rules under the Companies Law will have no rights and
        will become dormant shares.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Special Tender Offer</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law provides that an acquisition of shares of a public Israeli company must be made by means of a special tender offer if as a result of the acquisition, the
        purchaser would become a holder of 25% or more of the voting rights in the company, unless one of the exemptions in the Companies Law is met. This rule does not apply if there is already another holder of at least 25% of the voting rights in the
        company. Similarly, the Companies Law provides that an acquisition of shares in a public company must be made by means of a tender offer if as a result of the acquisition the purchaser would become a holder of 45% or more of the voting rights in
        the company, if there is no other shareholder of the company who holds 45% or more of the voting rights in the company. These requirements do not apply if the acquisition (i) occurs in the context of a private placement that received shareholder
        approval as a private placement whose purpose is to give the acquirer at least 25% of the voting rights in the company if there is no person who holds at least 25% of the voting rights in the company, or as a private offering whose purpose is to
        give the acquirer 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company; (ii) was from a shareholder holding at least 25% of the voting rights in the company and resulted in the acquirer
        becoming a holder of at least 25% of the voting rights in the company; or (iii) was from a holder of more than 45% of the voting rights in the company and resulted in the acquirer becoming a holder of more than 45% of the voting rights in the
        company.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A special tender offer must be extended to all shareholders of a company. A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the
        company&#8217;s outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event that a special tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the offer or shall abstain from
        expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. The board of directors shall also disclose any personal interest that any of the directors has with respect to the special tender offer or in
        connection therewith. An office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing or foreseeable special tender offer or to impair the chances
        of its acceptance, is liable to the potential purchaser and shareholders for damages resulting from his acts, unless such office holder acted in good faith and had reasonable grounds to believe he or she was acting for the benefit of the company.
        However, office holders of the target company may negotiate with the potential purchaser in order to improve the terms of the special tender offer, and may further negotiate with third parties in order to obtain a competing offer.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a special tender offer was accepted by a majority of the shareholders who announced their stand on such offer, then shareholders who did not respond to the special tender
        offer or objected to the special tender offer may accept the offer within four days of the last day set for the acceptance of the offer and they will be considered to have accepted the offer from the first day it was made.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may
      not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook
      to effect such an offer or merger in the initial special tender offer. Shares purchased in contradiction to the special tender offer rules under the Companies Law will have no rights and will become dormant shares.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Merger</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under the Companies Law are met, a
        majority of each party&#8217;s shares voted on the proposed merger at a shareholders&#8217; meeting called with at least 35 days&#8217; prior notice.&#160; The board of directors of a merging company is required pursuant to the Companies Law to discuss and determine
        whether in its opinion there exists a reasonable concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors, taking into account the financial condition of the merging
        companies. If the board of directors determines that such a concern exists, it may not approve a proposed merger. Following the approval of the board of directors of each of the merging companies, the boards of directors must jointly prepare a
        merger proposal for submission to the Israeli Registrar of Companies.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For purposes of the shareholder vote of a merging company whose shares are held by the other merging company, or by a person or entity holding 25% or more of the voting rights at
      the general meeting of shareholders of the other merging company, or by a person or entity holding the right to appoint 25% or more of the directors of the other merging company (referred to as &#8220;Affiliated Parties&#8221;), unless a court rules otherwise,
      the merger will not be deemed approved if a majority of the shares represented at the shareholders meeting that are held by parties other than Affiliated Parties or any one on their behalf including their relatives or corporations controlled by any
      of them, vote against the merger.&#160; In addition, if the non-surviving entity of the merger has more than one class of shares, the merger must be approved by each class of shareholders.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If the transaction would have been approved but for the separate approval of each class of shares or the exclusion of the votes of certain shareholders as provided above, a court
      may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the valuation of the merging companies and the consideration
      offered to the shareholders. If a merger is with a company&#8217;s controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority approval that governs all
      extraordinary transactions with controlling shareholders.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law and the regulations promulgated thereunder, each merging company must deliver a copy of the proposed merger proposal to its secured creditors and inform
        unsecured creditors of the merger proposal and its content. Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of
        the merger, the surviving company will be unable to satisfy the obligations of any of the parties to the merger, and may further give instructions to secure the rights of creditors.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, a merger may not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed by each party with the Israeli
        Registrar of Companies and 30 days have passed from the date the merger was approved by the shareholders of each party.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Antitakeover Measures</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights
        with respect to voting, distributions or other matters and shares having preemptive rights. As of the date hereof, we do not have any authorized or issued shares other than our ordinary shares. In the future, if we do create and issue a class of
        shares other than ordinary shares, such class of shares, depending on the specific rights that may be attached to them, may delay or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value
        of their ordinary shares. The authorization of a new class of shares will require an amendment to our Articles of Association which requires the prior approval of the holders of a majority of our shares at a general meeting. The convening of the
        meeting, the shareholders entitled to participate and the vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law and our articles of association. In addition, the Israeli Securities Law,
        1968 and the rules and regulations of the TASE, also limit the terms permitted with respect to a new class of shares created by a public company whose shares are traded on the TASE and prohibit any such new class of shares from having voting
        rights. In addition, as disclosed above under &#8220;&#8212;Election of Directors,&#8221; we have a classified board structure, which will effectively limit the ability of any investor or potential investor or group of investors or potential investors to gain
        control of our board of directors.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">American Depositary Shares</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="margin-left: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Description of the ADSs</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each of our ADSs represents 600 of our ordinary shares deposited with the principal Tel Aviv office of either Bank Hapoalim B.M. or Bank Leumi Le-Israel, as Custodian for the
        Depositary. Our ADSs trade on Nasdaq.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The form of the deposit agreement for the ADS and the form of American Depositary Receipt (ADR) that represents an ADS have been incorporated by reference as exhibits to our most
        recent Annual Report on Form 20-F. Copies of the deposit agreement are available for inspection at the principal office of The Bank of New York Mellon, located at 101 Barclay Street, New York, New York 10286.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="margin-left: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Charges of Depositary</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will pay the fees, reasonable expenses and out-of-pocket charges of the Depositary and those of any registrar only in accordance with agreements in writing entered into
        between us and the Depositary from time to time. The following charges shall be incurred by any party depositing or withdrawing ordinary shares or by any party surrendering ADRs or to whom ADRs are issued (including, without limitation, issuance
        pursuant to a stock dividend or stock split declared by us or an exchange of stock regarding the ADRs or deposited ordinary shares or a distribution of ADRs pursuant to the terms of the deposit agreement):</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"> </div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z5fcda2120cd549c7bc57718395cb6d8e">

            <tr>
              <td style="width: 2.7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
              </td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">taxes and other governmental charges;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 2.7%; vertical-align: top; text-align: center;">&#160;</td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 2.7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
              </td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">any applicable transfer or registration fees;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 2.7%; vertical-align: top; text-align: center;">&#160;</td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 2.7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
              </td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">certain cable, telex and facsimile transmission charges as provided in the deposit agreement;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 2.7%; vertical-align: top; text-align: center;">&#160;</td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 2.7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
              </td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">any expenses incurred in the conversion of foreign currency;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 2.7%; vertical-align: top; text-align: center;">&#160;</td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 2.7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
              </td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">a fee of $5.00 or less per 100 ADSs (or a portion thereof) for the execution and delivery of ADRs and the surrender of ADRs, including if the deposit agreement terminates;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 2.7%; vertical-align: top; text-align: center;">&#160;</td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 2.7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
              </td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">a fee of $.05 or less per ADS (or portion thereof) for any cash distribution made pursuant to the deposit agreement;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 2.7%; vertical-align: top; text-align: center;">&#160;</td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 2.7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
              </td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">a fee for the distribution of securities pursuant to the deposit agreement;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 2.7%; vertical-align: top; text-align: center;">&#160;</td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 2.7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
              </td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">in addition to any fee charged for a cash distribution, a fee of $.05 or less per ADS (or portion thereof) per annum for depositary services;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 2.7%; vertical-align: top; text-align: center;">&#160;</td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 2.7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
              </td>
              <td rowspan="1" style="width: auto; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">a fee for the distribution of proceeds of rights that the Depositary sells pursuant to the deposit agreement; and</div>
              </td>
              <td style="width: 0.23%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 2.7%; vertical-align: top; text-align: center;">&#160;</td>
              <td rowspan="1" style="width: auto; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 0.23%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 2.7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
              </td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">any other charges payable by the Depositary, any of the Depositary&#8217;s agents, or the agents of the Depositary&#8217;s agents in connection with the servicing of ordinary shares or other
                  Deposited Securities.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> </div>
        </div>
      </div>
      <div style="line-height: 1.25;"> <br>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary may own and deal in our securities and in ADSs.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from
        intermediaries acting for them. The Depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The Depositary may collect
        its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The Depositary may collect any of its fees by deduction from
        any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The Depositary may generally refuse to provide fee-attracting services until its fees for
        those services are paid.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">From time to time, the Depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive
        fees and expenses for services provided to us by the Depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the Depositary may use brokers, dealers, foreign currency dealers or
        other service providers that are owned by or affiliated with the Depositary and that may earn or share fees, spreads or commissions.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or
        fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned
        to the currency conversion made under the deposit agreement and the rate that the Depositary or its affiliate receives when buying or selling foreign currency for its own account. The Depositary makes no representation that the exchange rate used
        or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the
        Depositary&#8217;s obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="margin-left: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Liability of Holders for Taxes, Duties or Other Charges</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Any tax or other governmental charge with respect to ADSs or any deposited ordinary shares represented by any ADS shall be payable by the holder of such ADS to the Depositary.
        The Depositary may refuse to effect transfer of such ADS or any withdrawal of deposited ordinary shares represented by such ADS until such payment is made, and may withhold any dividends or other distributions or may sell for the account of the
        holder any part or all of the deposited ordinary shares represented by such ADS and may apply such dividends or distributions or the proceeds of any such sale in payment of any such tax or other governmental charge and the holder of such ADS shall
        remain liable for any deficiency.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>4
<FILENAME>exhibit_8-1.htm
<DESCRIPTION>EXHIBIT 8.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    </div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 8.1</u></div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: center; margin-right: 217.45pt; margin-left: 218.45pt; line-height: 1.25; font-weight: bold;">Subsidiaries of BioLineRx Ltd.</div>
    <div style="text-align: center; margin-right: 217.45pt; margin-left: 218.45pt; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="margin-left: 49.95pt; line-height: 1.25;">The following table sets forth the name and jurisdiction of incorporation of our subsidiaries:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zea6ad4d69dd1409b832fcf2335de988a">

        <tr>
          <td style="width: 49.02%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-weight: bold;">Name of Subsidiary</div>
          </td>
          <td style="width: 2.04%; vertical-align: top;">&#160;</td>
          <td style="width: 48.94%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-weight: bold;">Jurisdiction of Incorporation</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.02%; vertical-align: top;">&#160;</td>
          <td style="width: 2.04%; vertical-align: top;">&#160;</td>
          <td style="width: 48.94%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.02%; vertical-align: top;">
            <div style="line-height: 1.25;">BioLineRx USA Inc.</div>
            <div style="line-height: 1.25;"> <br>
            </div>
            <div style="line-height: 1.25;">Tetragon Biosciences Ltd.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td style="width: 2.04%; vertical-align: top;">&#160;</td>
          <td style="width: 48.94%; vertical-align: top;">
            <div style="line-height: 1.25;">Delaware</div>
            <div style="line-height: 1.25;"> <br>
            </div>
            <div style="line-height: 1.25;">Israel</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0a660ccea8374896ad3510da1c13ab3b">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 54pt; vertical-align: top;">(1)</td>
          <td style="width: auto; vertical-align: top;">
            <div>BioLineRx Ltd. holds 40% of the share capital of Tetragon Biosciences Ltd.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>exhibit_12-1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 12.1</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF</div>
    <div style="text-align: center; line-height: 1.25;">THE SARBANES-OXLEY ACT</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">I, Philip A. Serlin, certify that:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z9d8b7b73f03e4f379f1f8a5b95781a2d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.53%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.6%; vertical-align: top;">
            <div style="line-height: 1.25;">1.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="line-height: 1.25;">I have reviewed this annual report on Form 20-F of BioLineRx Ltd.;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z0de5a14410df4f1a8ddabb906a15b45b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.53%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.6%; vertical-align: top;">
            <div style="line-height: 1.25;">2.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
              necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z13f2aebd83cc4b4d81f20be9a6d277b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.53%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.6%; vertical-align: top;">
            <div style="line-height: 1.25;">3.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
              material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z96d681f018cc439893ce78e9340aca72" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.53%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.6%; vertical-align: top;">
            <div style="line-height: 1.25;">4.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
              procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z7430246d49c049b592f1616948686961" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">a)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
              supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z957726fefd954eff9c684c690d4347c1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">b)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
              under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zeda0f66228554f6f8680d8b021406f4f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">c)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions
              about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z3e54cd4ae9e5432e907b155033ebb2e2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">d)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period
              covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z78ceae0225c94884baac2a8f4132adef" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.53%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.6%; vertical-align: top;">
            <div style="line-height: 1.25;">5.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="line-height: 1.25;">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
              financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zec33a8c7c33e4ff0b862496d80e9fac9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">a)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
              which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zb3c135137d774be78847d45b15f04abd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">b)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s
              internal control over financial reporting.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Date: March 23, 2026</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><u>/s/ Philip A. Serlin</u></div>
    <div style="line-height: 1.25;">Philip A. Serlin</div>
    <div style="line-height: 1.25;">Chief Executive Officer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>6
<FILENAME>exhibit_12-2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit 12.2</u></font><br>
    </div>
    <div style="text-align: right; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF</div>
    <div style="text-align: center; line-height: 1.25;">THE SARBANES-OXLEY ACT</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">I, Mali Zeevi, certify that:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z544432bd69bf46d28e9bb17ec8338d3e">

        <tr>
          <td style="width: 0.53%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.6%; vertical-align: top;">
            <div style="line-height: 1.25;">1.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">I have reviewed this annual report on Form 20-F of BioLineRx Ltd.;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7406a6b13a2a480c9d5f7badcb19f6cc">

        <tr>
          <td style="width: 0.53%; vertical-align: middle;">&#160;</td>
          <td style="width: 1.6%; vertical-align: top;">
            <div style="line-height: 1.25;">2.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
              circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z87acc415dc534e77b4372ca693bf6218">

        <tr>
          <td style="width: 0.53%; vertical-align: middle;">&#160;</td>
          <td style="width: 1.6%; vertical-align: top;">
            <div style="line-height: 1.25;">3.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
              operations and cash flows of the company as of, and for, the periods presented in this report;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z90a596499a97493c8261d15a756f4069">

        <tr>
          <td style="width: 0.53%; vertical-align: middle;">&#160;</td>
          <td style="width: 1.6%; vertical-align: top;">
            <div style="line-height: 1.25;">4.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
              and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc9e4b4dc464842d8b2a9795597f26794">

        <tr>
          <td style="width: 3%; vertical-align: middle;"><br>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">a)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
              company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5cea5d9e93dd4faf96025ad38e074a2c">

        <tr>
          <td style="width: 3%; vertical-align: middle;"><br>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">b)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
              regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3d02a3ec92434873a0db36d00571e006">

        <tr>
          <td style="width: 3%; vertical-align: middle;"><br>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">c)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
              as of the end of the period covered by this report based on such evaluation; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z10883774b46d46c4bbf7672779dc72e3">

        <tr>
          <td style="width: 3%; vertical-align: middle;"><br>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">d)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is
              reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zadc0ed500c38492d934036039723507f">

        <tr>
          <td style="width: 0.53%; vertical-align: middle;">&#160;</td>
          <td style="width: 1.6%; vertical-align: top;">
            <div style="line-height: 1.25;">5.</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit
              committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z266448e2650e4d35a7f5d9fba6ea4794">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">a)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s
              ability to record, process, summarize and report financial information; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z59abdc19083346f9864c142b9471c627">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.67%; vertical-align: top;">
            <div style="line-height: 1.25;">b)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Date: March 23, 2026</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><u>/s/ Mali Zeevi</u></div>
    <div style="line-height: 1.25;">Mali Zeevi</div>
    <div style="line-height: 1.25;">Chief Financial Officer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>7
<FILENAME>exhibit_13-1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 13.1</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF</div>
    <div style="text-align: center; line-height: 1.25;">THE SARBANES-OXLEY ACT</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; text-align: justify; text-indent: 2%;">Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the &#8220;Company&#8221;) hereby certifies to such
      officer&#8217;s knowledge that:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5c0c0c3e093a4d54b1fba2f62397dce1">

        <tr>
          <td style="width: 2.05%; vertical-align: top;">
            <div style="line-height: 1.25;">(i)</div>
          </td>
          <td style="width: 97.95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2025 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as
              applicable, of the Securities Exchange Act of 1934, as amended; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z61a44730c942453780f5a12a574f0b6a">

        <tr>
          <td style="width: 2.05%; vertical-align: top;">
            <div style="line-height: 1.25;">(ii)</div>
          </td>
          <td style="width: 97.95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Date: March 23, 2026</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><u>/s/ Philip A. Serlin</u></div>
    <div style="line-height: 1.25;">Philip A. Serlin</div>
    <div style="line-height: 1.25;">Chief Executive Officer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section 18 of the Securities Exchange Act
      of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>8
<FILENAME>exhibit_13-2.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 13.2</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF</div>
    <div style="text-align: center; line-height: 1.25;">THE SARBANES-OXLEY ACT</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; text-align: justify; text-indent: 2%;">Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the &#8220;Company&#8221;) hereby certifies to such
      officer&#8217;s knowledge that:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5c0c0c3e093a4d54b1fba2f62397dce1">

        <tr>
          <td style="width: 2.05%; vertical-align: top;">
            <div style="line-height: 1.25;">(i)</div>
          </td>
          <td style="width: 97.95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2025 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as
              applicable, of the Securities Exchange Act of 1934, as amended; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z61a44730c942453780f5a12a574f0b6a">

        <tr>
          <td style="width: 2.05%; vertical-align: top;">
            <div style="line-height: 1.25;">(ii)</div>
          </td>
          <td style="width: 97.95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Date: March 23, 2026</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><u>/s/ Mali Zeevi</u></div>
    <div style="line-height: 1.25;">Mali Zeevi</div>
    <div style="line-height: 1.25;">Chief Financial Officer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section 18 of the Securities Exchange Act
      of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>9
<FILENAME>exhibit_15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 15.1</font></u><br>
  </div>
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><img height="89" width="105" src="image00001.jpg"></div>
    </div>
    <div style="text-align: center; line-height: 1.25;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-176419, 333-183976, 333-201326, 333-208865, 333-269334,333-276325, 333-284059 and 333-292922) and Form F-3 (Nos.
      333-229021 and 333-276323)&#160; of BioLineRx Ltd. of our report dated December 31, 2025 relating to the financial statements, which appears in this Form 20-F.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z056c9ca1d5a94e0da134ea5b37945fb0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-indent: -28.35pt; margin-left: 28.35pt; line-height: 1.25;">/s/ Kesselman &amp; Kesselman</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Tel-Aviv, Israel</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Certified Public Accountants (Isr.)</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">March 23, 2026</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">A member firm of PricewaterhouseCoopers</div>
            <div style="line-height: 1.25;">International Limited</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>blrx-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:blrx="http://biolinerx.com/20251231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2025" xmlns:cyd-af="http://xbrl.sec.gov/cyd-af/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" targetNamespace="http://biolinerx.com/20251231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/cyd-af/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd"/>
  <import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://biolinerx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" id="ConsolidatedStatementsOfFinancialPosition">
        <link:definition>0002 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>0003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/StatementsOfChangesInEquity" id="StatementsOfChangesInEquity">
        <link:definition>0004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/ConsolidatedCashFlowStatements" id="ConsolidatedCashFlowStatements">
        <link:definition>0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/GeneralInformation" id="GeneralInformation">
        <link:definition>0006 - Disclosure - GENERAL INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
        <link:definition>0007 - Disclosure - MATERIAL ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagement" id="FinancialInstrumentsAndFinancialRiskManagement">
        <link:definition>0008 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/CriticalAccountingEstimatesAndJudgments" id="CriticalAccountingEstimatesAndJudgments">
        <link:definition>0009 - Disclosure - CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
        <link:definition>0010 - Disclosure - CASH AND CASH EQUIVALENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/Short-termBankDeposits" id="Short-termBankDeposits">
        <link:definition>0011 - Disclosure - SHORT-TERM BANK DEPOSITS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>0012 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>0013 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/Leases" id="Leases">
        <link:definition>0014 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/Long-termLoans" id="Long-termLoans">
        <link:definition>0015 - Disclosure - LONG-TERM LOAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/Equity" id="Equity">
        <link:definition>0016 - Disclosure - EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/TaxesOnIncome" id="TaxesOnIncome">
        <link:definition>0017 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LOSSPERSHARE" id="LOSSPERSHARE">
        <link:definition>0018 - Disclosure - LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
        <link:definition>0019 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTS" id="LICENSEANDSECURITIESPURCHASEAGREEMENTS">
        <link:definition>0020 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGE" id="LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGE">
        <link:definition>0021 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1" id="AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1">
        <link:definition>0022 - Disclosure - AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedParties" id="TransactionsAndBalancesWithRelatedParties">
        <link:definition>0023 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SEGMENTREPORTING" id="SEGMENTREPORTING">
        <link:definition>0024 - Disclosure - SEGMENT REPORTING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformation" id="SupplementaryFinancialStatementInformation">
        <link:definition>0025 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SUBSEQUENTEVENTREGISTEREDDIRECTOFFERING" id="SUBSEQUENTEVENTREGISTEREDDIRECTOFFERING">
        <link:definition>0026 - Disclosure - SUBSEQUENT EVENT (if relevant)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
        <link:definition>9960701 - Disclosure - MATERIAL ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
        <link:definition>9960702 - Disclosure - MATERIAL ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables" id="FinancialInstrumentsAndFinancialRiskManagementTables">
        <link:definition>9960703 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
        <link:definition>9960704 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <link:definition>9960705 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <link:definition>9960706 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LeasesTables" id="LeasesTables">
        <link:definition>9960707 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/EquityTables" id="EquityTables">
        <link:definition>9960708 - Disclosure - EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/TaxesOnIncomeTables" id="TaxesOnIncomeTables">
        <link:definition>9960709 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LossPerShareTables" id="LossPerShareTables">
        <link:definition>9960710 - Disclosure - LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables" id="TransactionsAndBalancesWithRelatedPartiesTables">
        <link:definition>9960711 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SEGMENTREPORTINGTables" id="SEGMENTREPORTINGTables">
        <link:definition>9960712 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables" id="SupplementaryFinancialStatementInformationTables">
        <link:definition>9960713 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/GeneralInformationDetails" id="GeneralInformationDetails">
        <link:definition>9960714 - Disclosure - GENERAL INFORMATION (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails" id="SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9960715 - Disclosure - MATERIAL ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" id="SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails">
        <link:definition>9960716 - Disclosure - MATERIAL ACCOUNTING POLICIES (Schedule of Depreciation Rates) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" id="SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails">
        <link:definition>9960717 - Disclosure - MATERIAL ACCOUNTING POLICIES (Schedule of Useful Life of Right of Use Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails" id="FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails">
        <link:definition>9960718 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" id="FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails">
        <link:definition>9960719 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails" id="FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails">
        <link:definition>9960720 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Concentration of Currency Risk) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" id="FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails">
        <link:definition>9960721 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Linkage of Monetary Items) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails" id="FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails">
        <link:definition>9960722 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Credit Risk) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" id="FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails">
        <link:definition>9960723 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Changes in Financial Liabilities With Cash Flows) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" id="FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails">
        <link:definition>9960724 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Value Measurement of Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails" id="CashAndCashEquivalentsNarrativeDetails">
        <link:definition>9960725 - Disclosure - CASH AND CASH EQUIVALENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" id="CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails">
        <link:definition>9960726 - Disclosure - CASH AND CASH EQUIVALENTS (Schedule of Cash And Cash Equivalents) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails" id="Short-termBankDepositsNarrativeDetails">
        <link:definition>9960727 - Disclosure - SHORT-TERM BANK DEPOSITS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" id="PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails">
        <link:definition>9960728 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Composition of Property and Equipment and Related Accumulated Depreciation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails" id="INTANGIBLEASSETSNarrativeDetails">
        <link:definition>9960729 - Disclosure - INTANGIBLE ASSETS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" id="IntangibleAssetsScheduleOfIntangibleAssetsDetails">
        <link:definition>9960730 - Disclosure - INTANGIBLE ASSETS (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LeasesNarrativeDetails" id="LeasesNarrativeDetails">
        <link:definition>9960731 - Disclosure - LEASES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails" id="LeasesScheduleOfRight-of-useAssetsDetails">
        <link:definition>9960732 - Disclosure - LEASES (Schedule of Right-of-use assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails" id="LeasesScheduleOfLeaseLiabilitiesDetails">
        <link:definition>9960733 - Disclosure - LEASES (Schedule of Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails" id="LeasesScheduleOfMinimumFutureRentalPaymentsDetails">
        <link:definition>9960734 - Disclosure - LEASES (Schedule of Minimum Future Rental Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/Long-termLoansNarrativeDetails" id="Long-termLoansNarrativeDetails">
        <link:definition>9960735 - Disclosure - LONG-TERM LOAN (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/EquityNarrativeDetails" id="EquityNarrativeDetails">
        <link:definition>9960736 - Disclosure - EQUITY (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails" id="EquityScheduleOfShareCapitalDetails">
        <link:definition>9960737 - Disclosure - EQUITY (Schedule of Share Capital) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" id="EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails">
        <link:definition>9960738 - Disclosure - EQUITY (Schedule of Amounts Outstanding Under Employee Share Incentive Plan) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" id="EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails">
        <link:definition>9960739 - Disclosure - EQUITY (Schedule of Options Outstanding by Exercise Price Range) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails" id="EquityScheduleOfAssumptionsUsedToValueOptionsDetails">
        <link:definition>9960740 - Disclosure - EQUITY (Schedule of Assumptions Used to Value Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" id="TaxesOnIncomeNarrativeDetails">
        <link:definition>9960741 - Disclosure - TAXES ON INCOME (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" id="TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails">
        <link:definition>9960742 - Disclosure - TAXES ON INCOME (Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LOSSPERSHARENarrativeDetails" id="LOSSPERSHARENarrativeDetails">
        <link:definition>9960743 - Disclosure - LOSS PER SHARE (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" id="LossPerShareScheduleOfBasicLossPerShareDetails">
        <link:definition>9960744 - Disclosure - LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" id="CommitmentsAndContingentLiabilitiesDetails">
        <link:definition>9960745 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails" id="LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails">
        <link:definition>9960746 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails" id="LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails">
        <link:definition>9960747 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" id="AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails">
        <link:definition>9960748 - Disclosure - AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1 (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" id="TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails">
        <link:definition>9960749 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Transactions With Related Parties) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails" id="TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails">
        <link:definition>9960750 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Key Management Compensation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SEGMENTREPORTINGNarrativeDetails" id="SEGMENTREPORTINGNarrativeDetails">
        <link:definition>9960751 - Disclosure - SEGMENT REPORTING (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SEGMENTREPORTINGDetails" id="SEGMENTREPORTINGDetails">
        <link:definition>9960752 - Disclosure - SEGMENT REPORTING (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails" id="SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails">
        <link:definition>9960753 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Receivables) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" id="SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails">
        <link:definition>9960754 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Payable and Accruals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails" id="SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails">
        <link:definition>9960755 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Cost of revenues) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails" id="SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails">
        <link:definition>9960756 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Research and Development Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails" id="SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails">
        <link:definition>9960757 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Sales and Marketing Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails" id="SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails">
        <link:definition>9960758 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of General and Administrative Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails" id="SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails">
        <link:definition>9960759 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Non-Operating Income (Expenses), Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails" id="SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails">
        <link:definition>9960760 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails" id="SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails">
        <link:definition>9960761 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/InsiderTradingArrangementsNarrativeDetails" id="InsiderTradingArrangementsNarrativeDetails">
        <link:definition>0089 - Disclosure - Insider Trading Policies and Procedures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss__1" id="ConsolidatedStatementsOfComprehensiveLoss__1">
        <link:definition>0091 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Additional Calculation 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="blrx-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="blrx-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="blrx-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="blrx-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccountsPayableAbstract" id="blrx_AccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AdditionalCommitmentFee" id="blrx_AdditionalCommitmentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AdditionalExtendLeasePeriod" id="blrx_AdditionalExtendLeasePeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate" id="blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdditionalImpairmentChargesOfWeightedAverageCostOfCapital" id="blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdditionalSharesMember" id="blrx_AdditionalSharesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AdditionsLeaseLiabilities" id="blrx_AdditionsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables" id="blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract" id="blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AdvancePayments" id="blrx_AdvancePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AgalimmuneLtdMember" id="blrx_AgalimmuneLtdMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AggregateAmericanDepositaryShares" id="blrx_AggregateAmericanDepositaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AggregateOfferingPrice" id="blrx_AggregateOfferingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AgreementTypeAxis" id="blrx_AgreementTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="AgreementTypeDomain" id="blrx_AgreementTypeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementTypeMember" id="blrx_AgreementTypeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementWithCompaniesForDevelopmentAbstract" id="blrx_AgreementWithCompaniesForDevelopmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementWithHemispherianForDevelopmentOfGlix1Explanatory" id="blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmericanDepositarySharesMember" id="blrx_AmericanDepositarySharesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmericanDepositarySharesPurchasePricePerShare" id="blrx_AmericanDepositarySharesPurchasePricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmericanStockExchangeMember" id="blrx_AmericanStockExchangeMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmountAllocatedToWarrant" id="blrx_AmountAllocatedToWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AmountGrantOfEquityInstruments" id="blrx_AmountGrantOfEquityInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmountOfIntellectualPropertyAndCashBalance" id="blrx_AmountOfIntellectualPropertyAndCashBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmountOfLoanAgreement" id="blrx_AmountOfLoanAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmountOfPaymentInFutrueMilestone" id="blrx_AmountOfPaymentInFutrueMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AnnualLeaseFee" id="blrx_AnnualLeaseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AssetTransferAgreementMember" id="blrx_AssetTransferAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AuthorizedShareCapitalValue" id="blrx_AuthorizedShareCapitalValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AvailableBalanceUnderFacility" id="blrx_AvailableBalanceUnderFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AyrmidLicenseAgreementMember" id="blrx_AyrmidLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BankGuaranteeAmountForBenefitOfLessor" id="blrx_BankGuaranteeAmountForBenefitOfLessor" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BankLoanMember" id="blrx_BankLoanMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BasicAndDilutedEarningsLossPerShare" id="blrx_BasicAndDilutedEarningsLossPerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BeneficiallyOwnInExcess" id="blrx_BeneficiallyOwnInExcess" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BenefitsToRelatedPartiesAbstract" id="blrx_BenefitsToRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BiokineMember" id="blrx_BiokineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BiokineTherapeuticsLtdMember" id="blrx_BiokineTherapeuticsLtdMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BioLineRxMember" id="blrx_BioLineRxMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BL8040Member" id="blrx_BL8040Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BostonMember" id="blrx_BostonMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BtigLlcMember" id="blrx_BtigLlcMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BusinessAnalyticsExpense" id="blrx_BusinessAnalyticsExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BvfPartnersLpMember" id="blrx_BvfPartnersLpMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashAndCashEquivalentMember" id="blrx_CashAndCashEquivalentMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChangesInFairValueRecordedAsANonoperatingIncome" id="blrx_ChangesInFairValueRecordedAsANonoperatingIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ChangesInFairValueThroughProfitAndLossOfWarrants" id="blrx_ChangesInFairValueThroughProfitAndLossOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ChangesInOperatingAssetsAndLiabilitiesAbstract" id="blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborationAndShareholdersAgreementLineItems" id="blrx_CollaborationAndShareholdersAgreementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborationAndShareholdersAgreementTable" id="blrx_CollaborationAndShareholdersAgreementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="CollaborationTransactionAxis" id="blrx_CollaborationTransactionAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="CollaborationTransactionDomain" id="blrx_CollaborationTransactionDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommitmentsAndContingentLiabilities" id="blrx_CommitmentsAndContingentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConsultantsMember" id="blrx_ConsultantsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate" id="blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ContingentLiability" id="blrx_ContingentLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CostOfProductSales" id="blrx_CostOfProductSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CostRelatedToLicenseRevenues" id="blrx_CostRelatedToLicenseRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CostsIncurrentInOffering" id="blrx_CostsIncurrentInOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DelayInPayment" id="blrx_DelayInPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DeletionsIntangibleAssetsOtherThanGoodwill" id="blrx_DeletionsIntangibleAssetsOtherThanGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DeletionsLeaseLiabilities" id="blrx_DeletionsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeletionsToRightOfUseAssets" id="blrx_DeletionsToRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DepositaryShareConversionDescription" id="blrx_DepositaryShareConversionDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DepositaryShareToOrdinaryShareRatioChangeDescription" id="blrx_DepositaryShareToOrdinaryShareRatioChangeDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" id="blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory" id="blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory" id="blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory" id="blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory" id="blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfAccountingPolicyForWarrantExplanatory" id="blrx_DescriptionOfAccountingPolicyForWarrantExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets" id="blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DirectorsMember" id="blrx_DirectorsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DirectPlacementMember" id="blrx_DirectPlacementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisallowedDeductionsTaxExemptIncomeAbstract" id="blrx_DisallowedDeductionsTaxExemptIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract" id="blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfAgalimmuneAcquisitionAbstract" id="blrx_DisclosureOfAgalimmuneAcquisitionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfAgreementWithOmegaPharmaAbstract" id="blrx_DisclosureOfAgreementWithOmegaPharmaAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfAgreementWithOmegaPharmaExplanatory" id="blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfAmendmentToLicenseAbstract" id="blrx_DisclosureOfAmendmentToLicenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory" id="blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfCommitmentsAndContingentLiabilitiesAbstract" id="blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory" id="blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory" id="blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" id="blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory" id="blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory" id="blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory" id="blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory" id="blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory" id="blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory" id="blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory" id="blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock" id="blrx_DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory" id="blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory" id="blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory" id="blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutRevenuesExplanatory" id="blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory" id="blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory" id="blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory" id="blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfEventsSubsequentToBalanceSheetDateAbstract" id="blrx_DisclosureOfEventsSubsequentToBalanceSheetDateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfGeneralInformationAbstract" id="blrx_DisclosureOfGeneralInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfIncomeTaxesAbstract" id="blrx_DisclosureOfIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfLeasesLineItems" id="blrx_DisclosureOfLeasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfLeasesTable" id="blrx_DisclosureOfLeasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract" id="blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory" id="blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfLongTermInvestmentAbstract" id="blrx_DisclosureOfLongTermInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory" id="blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" id="blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable" id="blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="DisclosureOfShortTermBankDepositsAbstract" id="blrx_DisclosureOfShortTermBankDepositsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfSignificantAccountingPoliciesAbstract" id="blrx_DisclosureOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract" id="blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory" id="blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfSupplementaryFinancialStatementInformationAbstract" id="blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfSupplementaryFinancialStatementInformationExplanatory" id="blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory" id="blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DisclsoureOfAmendmentToLicenseExplanatory" id="blrx_DisclsoureOfAmendmentToLicenseExplanatory" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DollarMember" id="blrx_DollarMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesAndDirectorsMember" id="blrx_EmployeesAndDirectorsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesMember" id="blrx_EmployeesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EuroLinkedTradePayablesMember" id="blrx_EuroLinkedTradePayablesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EuroPerDollarMember" id="blrx_EuroPerDollarMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExchangeDifferences" id="blrx_ExchangeDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ExchangeDifferencesDuringYear" id="blrx_ExchangeDifferencesDuringYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ExchangeDifferencesOnLeaseLiability" id="blrx_ExchangeDifferencesOnLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ExercisableTermOfWarrant" id="blrx_ExercisableTermOfWarrant" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExerciseOfPricePerAds" id="blrx_ExerciseOfPricePerAds" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePriceOfShareIssued" id="blrx_ExercisePriceOfShareIssued" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePriceOfWarrants" id="blrx_ExercisePriceOfWarrants" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePriceRangeFourMember" id="blrx_ExercisePriceRangeFourMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePriceRangeMember" id="blrx_ExercisePriceRangeMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePriceRangeOneMember" id="blrx_ExercisePriceRangeOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePriceRangeSixMember" id="blrx_ExercisePriceRangeSixMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePriceRangeThreeMember" id="blrx_ExercisePriceRangeThreeMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePriceRangeTwoMember" id="blrx_ExercisePriceRangeTwoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfOrdinaryWarrantsAdjustedAmount" id="blrx_FairValueOfOrdinaryWarrantsAdjustedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfWarrants" id="blrx_FairValueOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FirstThreeYearsMember" id="blrx_FirstThreeYearsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FirstTrancheMember" id="blrx_FirstTrancheMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FivePercentDecreaseEffectOnNetIncomeLossAndEquity" id="blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FivePercentIncreaseEffectOnNetIncomeLossAndEquity" id="blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GainOnRealizationOfLongtermInvestment" id="blrx_GainOnRealizationOfLongtermInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="Glix1Member" id="blrx_Glix1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GloriaLicenseAgreementMember" id="blrx_GloriaLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GloriaPurchaseAgreementMember" id="blrx_GloriaPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrossProceedsFromOffering" id="blrx_GrossProceedsFromOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="HCWainwrightAndCoLlcMember" id="blrx_HCWainwrightAndCoLlcMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HemispherianAsMember" id="blrx_HemispherianAsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HighbridgeCapitalManagementLlcMember" id="blrx_HighbridgeCapitalManagementLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HighbridgeMember" id="blrx_HighbridgeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IBridgeCapitalMember" id="blrx_IBridgeCapitalMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IfrsStatementLineItems" id="blrx_IfrsStatementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IfrsStatementTable" id="blrx_IfrsStatementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="ImpairmentLossOnIntangibleAssets" id="blrx_ImpairmentLossOnIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncomeAndExpensesNotInvolvingCashFlowsAbstract" id="blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" id="blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseThroughExerciseOfOptionsShares" id="blrx_IncreaseDecreaseThroughExerciseOfOptionsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" id="blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares" id="blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncreaseDecreaseThroughExerciseOfWarrantsShares" id="blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities" id="blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities" id="blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" id="blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated" id="blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncrementalInvestment" id="blrx_IncrementalInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InitialRoyaltyTerm" id="blrx_InitialRoyaltyTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InstitutionsCurrentReceivables" id="blrx_InstitutionsCurrentReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InterestAndExchangeDifferencesOnRestrictedDeposits" id="blrx_InterestAndExchangeDifferencesOnRestrictedDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InterestAndExchangeDifferencesOnShortTermDeposits" id="blrx_InterestAndExchangeDifferencesOnShortTermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InterestAndLinkageDifferencesOnBankLoan" id="blrx_InterestAndLinkageDifferencesOnBankLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InterestExpenseAndExchangeDifferencesOnFinancialExpenses" id="blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InterestExpenseLeaseLiabilities" id="blrx_InterestExpenseLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="InterestExpenses" id="blrx_InterestExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InterestIncomeAndExchangeDifferences" id="blrx_InterestIncomeAndExchangeDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="InterestRateOnLongTermBankLoan" id="blrx_InterestRateOnLongTermBankLoan" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InterestRateOnShortTermDeposits" id="blrx_InterestRateOnShortTermDeposits" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents" id="blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InvestorsMember" id="blrx_InvestorsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfAdsValue" id="blrx_IssuanceOfAdsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IssuanceOfShareCapital" id="blrx_IssuanceOfShareCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuancesOfWarrants" id="blrx_IssuancesOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuedAndPaidUpShareCapitalValue" id="blrx_IssuedAndPaidUpShareCapitalValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="January2025OfferingMember" id="blrx_January2025OfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="KreosLoanMember" id="blrx_KreosLoanMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LaboratoryEquipmentMember" id="blrx_LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LawsuitClaimAmount" id="blrx_LawsuitClaimAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LeaseAgreementMonthlyFee" id="blrx_LeaseAgreementMonthlyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LeasePeriod" id="blrx_LeasePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAgreementMember" id="blrx_LicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAndSecuritiesPurchaseAgreementsAbstract" id="blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock" id="blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAndSecuritiesPurchaseAgreementsLineItems" id="blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAndSecuritiesPurchaseAgreementsTable" id="blrx_LicenseAndSecuritiesPurchaseAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="LicenseFeesAndRoyaltiesPayableToLicensor" id="blrx_LicenseFeesAndRoyaltiesPayableToLicensor" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LicenseRevenues" id="blrx_LicenseRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LincolnParkCapitalFundMember" id="blrx_LincolnParkCapitalFundMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanAgreementWithKreosCapitalMember" id="blrx_LoanAgreementWithKreosCapitalMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LoanTakenForPaymentOfAgreementValue" id="blrx_LoanTakenForPaymentOfAgreementValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LongTermPrepaidExpenses" id="blrx_LongTermPrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LossOnAbandonmentOfRightofuseAsset" id="blrx_LossOnAbandonmentOfRightofuseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MarketAccessExpense" id="blrx_MarketAccessExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MarketingExpenses" id="blrx_MarketingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MarketSharePrice" id="blrx_MarketSharePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaturitiesOfRestrictedDeposits" id="blrx_MaturitiesOfRestrictedDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MaturitiesOfShortTermDeposits" id="blrx_MaturitiesOfShortTermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MaturityDate" id="blrx_MaturityDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaximumFutureMilestonePayments" id="blrx_MaximumFutureMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MedicalAffairs" id="blrx_MedicalAffairs" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MinimumCashBalanceRequirementUnderLoanAgreement" id="blrx_MinimumCashBalanceRequirementUnderLoanAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MonthlyAdvisoryFee" id="blrx_MonthlyAdvisoryFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NetAssetValueOfLinkageMonetaryItems" id="blrx_NetAssetValueOfLinkageMonetaryItems" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NetBookValueMember" id="blrx_NetBookValueMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NetMember" id="blrx_NetMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NisLinkedBalancesMember" id="blrx_NisLinkedBalancesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NisMember" id="blrx_NisMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NisPerDollarMember" id="blrx_NisPerDollarMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonOperatingExpense" id="blrx_NonOperatingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NovartisPharmaMember" id="blrx_NovartisPharmaMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAmericanDepositarySharesIssuedToInvestors" id="blrx_NumberOfAmericanDepositarySharesIssuedToInvestors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfNewSharesIssued" id="blrx_NumberOfNewSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOptionsAbstract" id="blrx_NumberOfOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOrdinarySharesAbstract" id="blrx_NumberOfOrdinarySharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfPreFundedWarrantsIssuedToPurchaseAds" id="blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfPremises" id="blrx_NumberOfPremises" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfSegments" id="blrx_NumberOfSegments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantPurchase" id="blrx_NumberOfWarrantPurchase" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OberonSecuritiesMember" id="blrx_OberonSecuritiesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OfferingToInstitutionalInvestorsMember" id="blrx_OfferingToInstitutionalInvestorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OpenPurchaseOrderCommitments" id="blrx_OpenPurchaseOrderCommitments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="OrbiMedAdvisorsMember" id="blrx_OrbiMedAdvisorsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherComprehensiveIncomeLossMember" id="blrx_OtherComprehensiveIncomeLossMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherCurrenciesMember" id="blrx_OtherCurrenciesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherNonoperatingIncomeExpenses" id="blrx_OtherNonoperatingIncomeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="OtherPayablesAbstract" id="blrx_OtherPayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherPayablesMember" id="blrx_OtherPayablesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherReceivablesMember" id="blrx_OtherReceivablesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Others" id="blrx_Others" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PaymentsLeaseLiabilities" id="blrx_PaymentsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PayrollAndRelatedExpenses" id="blrx_PayrollAndRelatedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PDACPerformanceObligationMember" id="blrx_PDACPerformanceObligationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageIncreaseDecreaseInExchangeRate" id="blrx_PercentageIncreaseDecreaseInExchangeRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageIncreasePrecedingLeasePaymentAmount" id="blrx_PercentageIncreasePrecedingLeasePaymentAmount" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfAdditionalEquityInterest" id="blrx_PercentageOfAdditionalEquityInterest" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfAnnualInterestOfCashFees" id="blrx_PercentageOfAnnualInterestOfCashFees" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfCommissionOnSalesAgreement" id="blrx_PercentageOfCommissionOnSalesAgreement" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfDecreasingAnnualGrowthRate" id="blrx_PercentageOfDecreasingAnnualGrowthRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfFutureMilestonePayments" id="blrx_PercentageOfFutureMilestonePayments" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfIncreasingWeightedAverageCostOfCapital" id="blrx_PercentageOfIncreasingWeightedAverageCostOfCapital" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfIssuedShareCapitalReceived" id="blrx_PercentageOfIssuedShareCapitalReceived" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfIssuedShareCapitalReceivedWithinMonths" id="blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfNetConsiderationReceivedForDirectProductSales" id="blrx_PercentageOfNetConsiderationReceivedForDirectProductSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfNetConsiderationReceivedForSubLicense" id="blrx_PercentageOfNetConsiderationReceivedForSubLicense" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfNetConsiderationReceivedFromLicensee" id="blrx_PercentageOfNetConsiderationReceivedFromLicensee" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfOwnershipStake" id="blrx_PercentageOfOwnershipStake" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfPaymentToBeMade" id="blrx_PercentageOfPaymentToBeMade" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfReducePaymentOwedOnSublicenseReceipts" id="blrx_PercentageOfReducePaymentOwedOnSublicenseReceipts" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRoyaltiesReceivableFromAggregateNetSales" id="blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PerformanceObligationAxis" id="blrx_PerformanceObligationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="PerformanceObligationDomain" id="blrx_PerformanceObligationDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PerformanceSharesUnitMember" id="blrx_PerformanceSharesUnitMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PerformanceSharesUnitTwoMember" id="blrx_PerformanceSharesUnitTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PerformanceStockUnitsMember" id="blrx_PerformanceStockUnitsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PhaseThreeMember" id="blrx_PhaseThreeMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PhaseTwoMember" id="blrx_PhaseTwoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PlacementAgentMember" id="blrx_PlacementAgentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PlacementAgentOfferingMember" id="blrx_PlacementAgentOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PlacementAgentsDesigneesMember" id="blrx_PlacementAgentsDesigneesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreFundedOrOrdinaryWarrantsExerciseTerms" id="blrx_PreFundedOrOrdinaryWarrantsExerciseTerms" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreFundedWarrantPurchasePricePerShare" id="blrx_PreFundedWarrantPurchasePricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreFundedWarrants" id="blrx_PreFundedWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PreFundedWarrantsExercisablePricePerAds" id="blrx_PreFundedWarrantsExercisablePricePerAds" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreFundedWarrantsExercisePricePerAds" id="blrx_PreFundedWarrantsExercisePricePerAds" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreFundedWarrantsMember" id="blrx_PreFundedWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses" id="blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromExerciseWarrants" id="blrx_ProceedsFromExerciseWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromIssuanceOfInitialPublicOffering" id="blrx_ProceedsFromIssuanceOfInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromIssuanceOfInitialPublicOfferingNet" id="blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromWarrantIssue" id="blrx_ProceedsFromWarrantIssue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProductSalesNet" id="blrx_ProductSalesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ProfessionalFee" id="blrx_ProfessionalFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProfitLossFromNonOperatingActivities" id="blrx_ProfitLossFromNonOperatingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ProvisionForDoubtfulAccountsReceivable" id="blrx_ProvisionForDoubtfulAccountsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PublicOfferingMember" id="blrx_PublicOfferingMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseAgreementMember" id="blrx_PurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseAgreementPeriod" id="blrx_PurchaseAgreementPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchasePricePerADS" id="blrx_PurchasePricePerADS" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RecognizedAsEquity" id="blrx_RecognizedAsEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RegisteredDirectOfferingMember" id="blrx_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RemainingAuthorizedUnissuedOrdinaryShares" id="blrx_RemainingAuthorizedUnissuedOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RemainingUnrecognizedDeferredCompensationExpense" id="blrx_RemainingUnrecognizedDeferredCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RepaymentOfLongTermDebtAfterOneYear" id="blrx_RepaymentOfLongTermDebtAfterOneYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RepaymentOfLongTermDebtYearsTwo" id="blrx_RepaymentOfLongTermDebtYearsTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019" id="blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RightOfUseAssetWrittenOff" id="blrx_RightOfUseAssetWrittenOff" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RoyaltiesEligibleMargin" id="blrx_RoyaltiesEligibleMargin" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltiesOnSale" id="blrx_RoyaltiesOnSale" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltiesPaymentPercentage" id="blrx_RoyaltiesPaymentPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts" id="blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltiesRateOnNetSales" id="blrx_RoyaltiesRateOnNetSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltiesReceivedPercentage" id="blrx_RoyaltiesReceivedPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStockNumberOfSharesIssued" id="blrx_SaleOfStockNumberOfSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SalesAndMarketingDepreciationAndAmortization" id="blrx_SalesAndMarketingDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SalesAndMarketingExpensesOther" id="blrx_SalesAndMarketingExpensesOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SalesAndMarketingExpensesRelatedToSales" id="blrx_SalesAndMarketingExpensesRelatedToSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SalesAndMarketingPayrollExpense" id="blrx_SalesAndMarketingPayrollExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SalesAndMarketingProfessionalFees" id="blrx_SalesAndMarketingProfessionalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SalesAndMarketingShareBasedCompensation" id="blrx_SalesAndMarketingShareBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SalesMilestoneAmount" id="blrx_SalesMilestoneAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ScmLicenseMember" id="blrx_ScmLicenseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScmSupportServicesMember" id="blrx_ScmSupportServicesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecondTrancheMember" id="blrx_SecondTrancheMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeniorManagementMember" id="blrx_SeniorManagementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SensitivityTestsDecreasingAnnualGrowthRate" id="blrx_SensitivityTestsDecreasingAnnualGrowthRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SensitivityTestsIncreasingAnnualGrowthRate" id="blrx_SensitivityTestsIncreasingAnnualGrowthRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesAWarrantsMember" id="blrx_SeriesAWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBWarrantMember" id="blrx_SeriesBWarrantMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeventhYearMember" id="blrx_SeventhYearMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses" id="blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedCompensationRelatedToResearchAndDevelopment" id="blrx_ShareBasedCompensationRelatedToResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareIncentivePlanMember" id="blrx_ShareIncentivePlanMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareIssuedAsAdditionalCommitmentFee" id="blrx_ShareIssuedAsAdditionalCommitmentFee" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareIssuedOfPublicOffering" id="blrx_ShareIssuedOfPublicOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareIssuedToPurchaseWarrant" id="blrx_ShareIssuedToPurchaseWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharePremiumResultingFromExerciseOfWarrants" id="blrx_SharePremiumResultingFromExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SharePurchaseAgreement" id="blrx_SharePurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SharePurchaseAgreementMember" id="blrx_SharePurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharePurchaseAgreementShares" id="blrx_SharePurchaseAgreementShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharesIssuedRegisteredDirectOfferings" id="blrx_SharesIssuedRegisteredDirectOfferings" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermDepositMember" id="blrx_ShortTermDepositMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SingleMaterialPerformanceObligationMember" id="blrx_SingleMaterialPerformanceObligationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedPricePerShare" id="blrx_StockIssuedPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplementalInformationOnInterestPaidInCash" id="blrx_SupplementalInformationOnInterestPaidInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SupplementalInformationOnNoncashTransactionsAbstract" id="blrx_SupplementalInformationOnNoncashTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities" id="blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SupplementaryInformationOnFairValueOfExercisedWarrants" id="blrx_SupplementaryInformationOnFairValueOfExercisedWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SupplementaryInformationOnIntangibleAssetAcquired" id="blrx_SupplementaryInformationOnIntangibleAssetAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SupplementaryInformationOnInterestReceivedInCash" id="blrx_SupplementaryInformationOnInterestReceivedInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract" id="blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplementaryInformationOnPurchaseOfPropertyAndEquipment" id="blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SupplementaryInformationOnWarrantIssuanceCosts" id="blrx_SupplementaryInformationOnWarrantIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation" id="blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TaxEffectOfShareBasedCompensationExemptFromTaxation" id="blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TaxLossCarryforwards" id="blrx_TaxLossCarryforwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TelAvivStockExchangeMember" id="blrx_TelAvivStockExchangeMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TenPercentDecreaseEffectOnNetIncomeLossAndEquity" id="blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TenPercentIncreaseEffectOnNetIncomeLossAndEquity" id="blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="Test" id="blrx_Test" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TetragonMember" id="blrx_TetragonMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThirdTrancheMember" id="blrx_ThirdTrancheMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThreeSubsequentYearsMember" id="blrx_ThreeSubsequentYearsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TotalChangeInOperatingAssetAndLiability" id="blrx_TotalChangeInOperatingAssetAndLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalIncomeAndExpenseNotInvolvingCashFlows" id="blrx_TotalIncomeAndExpenseNotInvolvingCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TradeAndOtherPayablesToForeignTradeSuppliers" id="blrx_TradeAndOtherPayablesToForeignTradeSuppliers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TradeAndOtherPayablesToLocalTradeSuppliers" id="blrx_TradeAndOtherPayablesToLocalTradeSuppliers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TradePayablesAbstract" id="blrx_TradePayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TradePayablesMember" id="blrx_TradePayablesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TrancheAxis" id="blrx_TrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="TrancheDomain" id="blrx_TrancheDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TransferFromLicenseToTheLicenseeAmount" id="blrx_TransferFromLicenseToTheLicenseeAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="UnderwaterEmployeeStockOptionsMember" id="blrx_UnderwaterEmployeeStockOptionsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnderwritersMember" id="blrx_UnderwritersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniformTaxRate" id="blrx_UniformTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UpfrontPayment" id="blrx_UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ValueOfServicesRecorded" id="blrx_ValueOfServicesRecorded" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="WarrantFiveMember" id="blrx_WarrantFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantFourMember" id="blrx_WarrantFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantOfferingConsideration" id="blrx_WarrantOfferingConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantOneMember" id="blrx_WarrantOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Warrants" id="blrx_Warrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantsExercisableTerm" id="blrx_WarrantsExercisableTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsExercises" id="blrx_WarrantsExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantsExpirationPeriod" id="blrx_WarrantsExpirationPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsIssuedToPurchaseAds" id="blrx_WarrantsIssuedToPurchaseAds" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsIssuedToPurchaseShares" id="blrx_WarrantsIssuedToPurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantSixMember" id="blrx_WarrantSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsReserve" id="blrx_WarrantsReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantThreeMember" id="blrx_WarrantThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantTwoMember" id="blrx_WarrantTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageExercisePriceAbstract" id="blrx_WeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WithholdingApplicableTaxRate" id="blrx_WithholdingApplicableTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WriteoffOfIntangibleAsset" id="blrx_WriteoffOfIntangibleAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>blrx-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#ConsolidatedStatementsOfFinancialPosition" roleURI="http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#ConsolidatedCashFlowStatements" roleURI="http://biolinerx.com/role/ConsolidatedCashFlowStatements"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" roleURI="http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" roleURI="http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails" roleURI="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#ConsolidatedStatementsOfComprehensiveLoss__1" roleURI="http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss__1"/>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-full_Inventories_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Warrants" xlink:label="loc_blrx_Warrants_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CommitmentsAndContingentLiabilities" xlink:label="loc_blrx_CommitmentsAndContingentLiabilities_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-full_NoncontrollingInterests_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalReserve" xlink:label="loc_ifrs-full_CapitalReserve_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantReserve" xlink:label="loc_ifrs-full_WarrantReserve_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-full_SharePremium_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_31"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_0" xlink:to="loc_ifrs-full_CurrentAssets_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1" xlink:to="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1" xlink:to="loc_ifrs-full_TradeReceivables_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1" xlink:to="loc_ifrs-full_OtherCurrentReceivables_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_1" xlink:to="loc_ifrs-full_Inventories_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_0" xlink:to="loc_ifrs-full_NoncurrentAssets_8" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_8" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_8" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_8" xlink:to="loc_ifrs-full_RightofuseAssets_10" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_12" xlink:to="loc_ifrs-full_Liabilities_13" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_13" xlink:to="loc_ifrs-full_CurrentLiabilities_13" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_13" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_13" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_13" xlink:to="loc_ifrs-full_CurrentContractLiabilities_14" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_13" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_15" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_13" xlink:to="loc_ifrs-full_OtherCurrentPayables_16" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_13" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_17" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_13" xlink:to="loc_blrx_Warrants_18" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_13" xlink:to="loc_ifrs-full_NoncurrentLiabilities_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_20" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_20" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_20" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_21" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_12" xlink:to="loc_blrx_CommitmentsAndContingentLiabilities_24" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_12" xlink:to="loc_ifrs-full_Equity_25" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_25" xlink:to="loc_ifrs-full_NoncontrollingInterests_25" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_25" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_26" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent_26" xlink:to="loc_ifrs-full_RetainedEarnings_26" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent_26" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_27" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent_26" xlink:to="loc_ifrs-full_CapitalReserve_28" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent_26" xlink:to="loc_ifrs-full_WarrantReserve_29" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent_26" xlink:to="loc_ifrs-full_SharePremium_30" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent_26" xlink:to="loc_ifrs-full_IssuedCapital_31" order="50" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossProfit" xlink:label="loc_ifrs-full_GrossProfit_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="loc_ifrs-full_LicenceFeeIncome_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ImpairmentLossOnIntangibleAssets" xlink:label="loc_blrx_ImpairmentLossOnIntangibleAssets_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfitLossFromNonOperatingActivities" xlink:label="loc_blrx_ProfitLossFromNonOperatingActivities_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_14"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_1" xlink:to="loc_ifrs-full_GrossProfit_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_1" xlink:to="loc_ifrs-full_Revenue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_1" xlink:to="loc_ifrs-full_LicenceFeeIncome_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_1" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_1" xlink:to="loc_ifrs-full_CostOfSales_4" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_1" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_6" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_1" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_7" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_1" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_8" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_1" xlink:to="loc_blrx_ImpairmentLossOnIntangibleAssets_9" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_blrx_ProfitLossFromNonOperatingActivities_11" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_ifrs-full_FinanceIncome_12" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_ifrs-full_FinanceCosts_13" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_14" order="40" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/ConsolidatedCashFlowStatements">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TotalIncomeAndExpenseNotInvolvingCashFlows" xlink:label="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndLinkageDifferencesOnBankLoan" xlink:label="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndExchangeDifferencesOnShortTermDeposits" xlink:label="loc_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndExchangeDifferencesOnRestrictedDeposits" xlink:label="loc_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferencesOnLeaseLiability" xlink:label="loc_blrx_ExchangeDifferencesOnLeaseLiability_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LossOnAbandonmentOfRightofuseAsset" xlink:label="loc_blrx_LossOnAbandonmentOfRightofuseAsset_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TotalChangeInOperatingAssetAndLiability" xlink:label="loc_blrx_TotalChangeInOperatingAssetAndLiability_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables" xlink:label="loc_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_22"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturitiesOfShortTermDeposits" xlink:label="loc_blrx_MaturitiesOfShortTermDeposits_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_32"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" xlink:to="loc_ifrs-full_ProfitLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_2" xlink:to="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xlink:to="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_3" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xlink:to="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_4" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_5" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xlink:to="loc_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_6" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xlink:to="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_7" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xlink:to="loc_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_8" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xlink:to="loc_blrx_ExchangeDifferencesOnLeaseLiability_9" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_10" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_11" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xlink:to="loc_blrx_LossOnAbandonmentOfRightofuseAsset_12" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_2" xlink:to="loc_blrx_TotalChangeInOperatingAssetAndLiability_14" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalChangeInOperatingAssetAndLiability_14" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_14" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalChangeInOperatingAssetAndLiability_14" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_15" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalChangeInOperatingAssetAndLiability_14" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_16" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalChangeInOperatingAssetAndLiability_14" xlink:to="loc_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_17" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_TotalChangeInOperatingAssetAndLiability_14" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_18" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_22" xlink:to="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_22" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_22" xlink:to="loc_blrx_MaturitiesOfShortTermDeposits_23" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_22" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_24" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_22" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_25" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_27" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_27" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_27" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_27" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_28" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_27" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_29" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_27" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_30" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_27" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_31" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_27" xlink:to="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_32" order="50" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_0" xlink:to="loc_ifrs-full_Cash_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_0" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation" xlink:label="loc_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WriteoffOfIntangibleAsset" xlink:label="loc_blrx_WriteoffOfIntangibleAsset_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation" xlink:label="loc_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated" xlink:label="loc_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_6"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xlink:to="loc_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xlink:to="loc_blrx_WriteoffOfIntangibleAsset_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xlink:to="loc_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xlink:to="loc_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_6" order="50" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InstitutionsCurrentReceivables" xlink:label="loc_blrx_InstitutionsCurrentReceivables_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdvancePayments" xlink:label="loc_blrx_AdvancePayments_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Others" xlink:label="loc_blrx_Others_3"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentReceivables_0" xlink:to="loc_blrx_InstitutionsCurrentReceivables_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentReceivables_0" xlink:to="loc_blrx_AdvancePayments_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentReceivables_0" xlink:to="loc_blrx_Others_3" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradeAndOtherPayablesToForeignTradeSuppliers" xlink:label="loc_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradeAndOtherPayablesToLocalTradeSuppliers" xlink:label="loc_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PayrollAndRelatedExpenses" xlink:label="loc_blrx_PayrollAndRelatedExpenses_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherPayables" xlink:label="loc_ifrs-full_OtherPayables_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPayable" xlink:label="loc_ifrs-full_InterestPayable_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_8"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_0" xlink:to="loc_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_0" xlink:to="loc_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentPayables_3" xlink:to="loc_blrx_PayrollAndRelatedExpenses_4" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentPayables_3" xlink:to="loc_ifrs-full_OtherPayables_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentPayables_3" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_6" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentPayables_3" xlink:to="loc_ifrs-full_InterestPayable_7" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentPayables_3" xlink:to="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_8" order="40" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ServicesExpense" xlink:label="loc_ifrs-full_ServicesExpense_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareBasedCompensationRelatedToResearchAndDevelopment" xlink:label="loc_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CommunicationExpense" xlink:label="loc_ifrs-full_CommunicationExpense_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfessionalFee" xlink:label="loc_blrx_ProfessionalFee_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherExpenseByNature" xlink:label="loc_ifrs-full_OtherExpenseByNature_7"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_0" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_0" xlink:to="loc_ifrs-full_ServicesExpense_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_0" xlink:to="loc_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_0" xlink:to="loc_ifrs-full_CommunicationExpense_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_0" xlink:to="loc_blrx_ProfessionalFee_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_0" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpense_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_0" xlink:to="loc_ifrs-full_OtherExpenseByNature_7" order="60" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingDepreciationAndAmortization" xlink:label="loc_blrx_SalesAndMarketingDepreciationAndAmortization_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LossOnAbandonmentOfRightofuseAsset" xlink:label="loc_blrx_LossOnAbandonmentOfRightofuseAsset_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingExpensesOther" xlink:label="loc_blrx_SalesAndMarketingExpensesOther_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingShareBasedCompensation" xlink:label="loc_blrx_SalesAndMarketingShareBasedCompensation_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingProfessionalFees" xlink:label="loc_blrx_SalesAndMarketingProfessionalFees_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BusinessAnalyticsExpense" xlink:label="loc_blrx_BusinessAnalyticsExpense_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketingExpenses" xlink:label="loc_blrx_MarketingExpenses_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketAccessExpense" xlink:label="loc_blrx_MarketAccessExpense_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MedicalAffairs" xlink:label="loc_blrx_MedicalAffairs_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingPayrollExpense" xlink:label="loc_blrx_SalesAndMarketingPayrollExpense_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingExpensesRelatedToSales" xlink:label="loc_blrx_SalesAndMarketingExpensesRelatedToSales_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TravelExpense" xlink:label="loc_ifrs-full_TravelExpense_12"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_blrx_SalesAndMarketingDepreciationAndAmortization_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_blrx_LossOnAbandonmentOfRightofuseAsset_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_blrx_SalesAndMarketingExpensesOther_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_blrx_SalesAndMarketingShareBasedCompensation_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_blrx_SalesAndMarketingProfessionalFees_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_blrx_BusinessAnalyticsExpense_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_blrx_MarketingExpenses_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_blrx_MarketAccessExpense_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_blrx_MedicalAffairs_9" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_blrx_SalesAndMarketingPayrollExpense_10" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_blrx_SalesAndMarketingExpensesRelatedToSales_11" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_0" xlink:to="loc_ifrs-full_TravelExpense_12" order="110" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-full_WagesAndSalaries_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InsuranceExpense" xlink:label="loc_ifrs-full_InsuranceExpense_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses" xlink:label="loc_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationExpense" xlink:label="loc_ifrs-full_DepreciationExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="loc_ifrs-full_OtherExpenseByFunction_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProvisionForDoubtfulAccountsReceivable" xlink:label="loc_blrx_ProvisionForDoubtfulAccountsReceivable_7"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0" xlink:to="loc_ifrs-full_WagesAndSalaries_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0" xlink:to="loc_ifrs-full_InsuranceExpense_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0" xlink:to="loc_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0" xlink:to="loc_ifrs-full_DepreciationExpense_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0" xlink:to="loc_ifrs-full_OtherExpenseByFunction_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_0" xlink:to="loc_blrx_ProvisionForDoubtfulAccountsReceivable_7" order="60" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfitLossFromNonOperatingActivities" xlink:label="loc_blrx_ProfitLossFromNonOperatingActivities_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GainOnRealizationOfLongtermInvestment" xlink:label="loc_blrx_GainOnRealizationOfLongtermInvestment_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherNonoperatingIncomeExpenses" xlink:label="loc_blrx_OtherNonoperatingIncomeExpenses_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_ProfitLossFromNonOperatingActivities_0" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_ProfitLossFromNonOperatingActivities_0" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_ProfitLossFromNonOperatingActivities_0" xlink:to="loc_blrx_GainOnRealizationOfLongtermInvestment_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_blrx_ProfitLossFromNonOperatingActivities_0" xlink:to="loc_blrx_OtherNonoperatingIncomeExpenses_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-full_RevenueFromInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-full_NetForeignExchangeGain_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_0" xlink:to="loc_ifrs-full_RevenueFromInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_0" xlink:to="loc_ifrs-full_NetForeignExchangeGain_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-full_InterestExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-full_FeeAndCommissionExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_3"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_0" xlink:to="loc_ifrs-full_InterestExpense_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_0" xlink:to="loc_ifrs-full_FeeAndCommissionExpense_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_0" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_3" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss__1">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_0" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_0" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2" order="10" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>blrx-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#DocumentAndEntityInformation" roleURI="http://biolinerx.com/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#StatementsOfChangesInEquity" roleURI="http://biolinerx.com/role/StatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SignificantAccountingPoliciesNarrativeDetails" roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#CashAndCashEquivalentsNarrativeDetails" roleURI="http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#Short-termBankDepositsNarrativeDetails" roleURI="http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" roleURI="http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#INTANGIBLEASSETSNarrativeDetails" roleURI="http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#IntangibleAssetsScheduleOfIntangibleAssetsDetails" roleURI="http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LeasesNarrativeDetails" roleURI="http://biolinerx.com/role/LeasesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LeasesScheduleOfRight-of-useAssetsDetails" roleURI="http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LeasesScheduleOfLeaseLiabilitiesDetails" roleURI="http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LeasesScheduleOfMinimumFutureRentalPaymentsDetails" roleURI="http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#Long-termLoansNarrativeDetails" roleURI="http://biolinerx.com/role/Long-termLoansNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#EquityNarrativeDetails" roleURI="http://biolinerx.com/role/EquityNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" roleURI="http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" roleURI="http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TaxesOnIncomeNarrativeDetails" roleURI="http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#CommitmentsAndContingentLiabilitiesDetails" roleURI="http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails" roleURI="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails" roleURI="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" roleURI="http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" roleURI="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SEGMENTREPORTINGDetails" roleURI="http://biolinerx.com/role/SEGMENTREPORTINGDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_dei_AuditorOpinionTextBlock_47"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentInformationTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="loc_dei_BusinessContactMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentType_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityRegistrantName_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityFilerCategory_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AmendmentFlag_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentRegistrationStatement_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentAnnualReport_14" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_15" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentShellCompanyReport_16" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentAccountingStandard_17" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_18" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_19" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_20" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_21" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_ContactPersonnelName_22" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_ContactPersonnelEmailAddress_23" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_ContactPersonnelFaxNumber_24" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_25" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_26" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_27" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_28" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_CityAreaCode_29" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_30" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressCountry_31" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_32" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_33" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_34" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_35" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityPublicFloat_36" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_37" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_38" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityShellCompany_39" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityFileNumber_40" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_41" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_42" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorName_43" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorLocation_44" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorFirmId_45" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AmendmentDescription_46" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorOpinionTextBlock_47" order="420" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/StatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IfrsStatementLineItems" xlink:label="loc_blrx_IfrsStatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IfrsStatementTable" xlink:label="loc_blrx_IfrsStatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-full_WarrantReserveMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalReserveMember" xlink:label="loc_ifrs-full_CapitalReserveMember_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherComprehensiveIncomeLossMember" xlink:label="loc_blrx_OtherComprehensiveIncomeLossMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInEquityAbstract" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_14"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfNewSharesIssued" xlink:label="loc_blrx_NumberOfNewSharesIssued_15"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuanceOfShareCapital" xlink:label="loc_blrx_IssuanceOfShareCapital_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_22"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" xlink:label="loc_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_27"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blrx_IfrsStatementLineItems_0" xlink:to="loc_blrx_IfrsStatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blrx_IfrsStatementTable_1" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_1" xlink:to="loc_ifrs-full_IssuedCapitalMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_1" xlink:to="loc_ifrs-full_SharePremiumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_1" xlink:to="loc_ifrs-full_WarrantReserveMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_1" xlink:to="loc_ifrs-full_CapitalReserveMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_1" xlink:to="loc_blrx_OtherComprehensiveIncomeLossMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_1" xlink:to="loc_ifrs-full_RetainedEarningsMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_1" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_IfrsStatementLineItems_0" xlink:to="loc_ifrs-full_Equity_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_IfrsStatementLineItems_0" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_IfrsStatementLineItems_0" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_ifrs-full_IssueOfEquity_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_blrx_NumberOfNewSharesIssued_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_blrx_IssuanceOfShareCapital_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_20" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_21" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_22" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_23" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_24" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_25" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_26" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_14" xlink:to="loc_ifrs-full_ComprehensiveIncome_27" order="130" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOptionsMember" xlink:label="loc_ifrs-full_ShareOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-full_WarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" xlink:to="loc_ifrs-full_ShareOptionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" xlink:to="loc_ifrs-full_WarrantsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_6" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_6" xlink:to="loc_ifrs-full_ComputerSoftwareMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_6" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_14" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LaboratoryEquipmentMember" xlink:label="loc_blrx_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1" xlink:to="loc_ifrs-full_ComputerEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1" xlink:to="loc_ifrs-full_OfficeEquipmentMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1" xlink:to="loc_blrx_LaboratoryEquipmentMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7" xlink:to="loc_ifrs-full_CarryingAmountMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_7" xlink:to="loc_blrx_NetBookValueMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7" xlink:to="loc_ifrs-full_CarryingAmountMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0" xlink:to="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_12" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="loc_ifrs-full_MotorVehiclesMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets" xlink:label="loc_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_1" xlink:to="loc_ifrs-full_LandAndBuildingsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_1" xlink:to="loc_ifrs-full_MotorVehiclesMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xlink:to="loc_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_7" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-full_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" xlink:to="loc_ifrs-full_WarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_0" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CashAndCashEquivalentMember" xlink:label="loc_blrx_CashAndCashEquivalentMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShortTermDepositMember" xlink:label="loc_blrx_ShortTermDepositMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherReceivablesMember" xlink:label="loc_blrx_OtherReceivablesMember_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradePayablesMember" xlink:label="loc_blrx_TradePayablesMember_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherPayablesMember" xlink:label="loc_blrx_OtherPayablesMember_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisLinkedBalancesMember" xlink:label="loc_blrx_NisLinkedBalancesMember_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EuroLinkedTradePayablesMember" xlink:label="loc_blrx_EuroLinkedTradePayablesMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" xlink:label="loc_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads_14"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_15"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_CashAndCashEquivalentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_ShortTermDepositMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_OtherReceivablesMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_TradePayablesMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_OtherPayablesMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_NisLinkedBalancesMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_EuroLinkedTradePayablesMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_16" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-full_TypesOfRisksDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisPerDollarMember" xlink:label="loc_blrx_NisPerDollarMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EuroPerDollarMember" xlink:label="loc_blrx_EuroPerDollarMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-full_TypesOfRisksDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageIncreaseDecreaseInExchangeRate" xlink:label="loc_blrx_PercentageIncreaseDecreaseInExchangeRate_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_blrx_NisPerDollarMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_blrx_EuroPerDollarMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0" xlink:to="loc_blrx_PercentageIncreaseDecreaseInExchangeRate_8" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-full_TypesOfRisksDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DollarMember" xlink:label="loc_blrx_DollarMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisMember" xlink:label="loc_blrx_NisMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherCurrenciesMember" xlink:label="loc_blrx_OtherCurrenciesMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-full_TypesOfRisksDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="loc_ifrs-full_LiabilitiesAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherPayables" xlink:label="loc_ifrs-full_OtherPayables_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetAssetValueOfLinkageMonetaryItems" xlink:label="loc_blrx_NetAssetValueOfLinkageMonetaryItems_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_blrx_DollarMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_blrx_NisMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_blrx_OtherCurrenciesMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0" xlink:to="loc_ifrs-full_AssetsAbstract_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_8" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_8" xlink:to="loc_ifrs-full_CashAndCashEquivalents_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_8" xlink:to="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_8" xlink:to="loc_ifrs-full_OtherReceivables_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_8" xlink:to="loc_ifrs-full_Assets_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0" xlink:to="loc_ifrs-full_LiabilitiesAbstract_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesAbstract_14" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_14" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesAbstract_14" xlink:to="loc_ifrs-full_TradeAndOtherPayablesAbstract_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_16" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_16" xlink:to="loc_ifrs-full_OtherPayables_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesAbstract_14" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_19" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_19" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesAbstract_14" xlink:to="loc_ifrs-full_Liabilities_21" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesAbstract_14" xlink:to="loc_blrx_NetAssetValueOfLinkageMonetaryItems_22" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-full_TypesOfRisksDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-full_TypesOfRisksDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_ifrs-full_CreditRiskMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0" xlink:to="loc_ifrs-full_AssetsAbstract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_6" xlink:to="loc_ifrs-full_CashAndCashEquivalents_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_6" xlink:to="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_6" xlink:to="loc_ifrs-full_TradeReceivables_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_6" xlink:to="loc_ifrs-full_OtherReceivables_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0" xlink:to="loc_ifrs-full_Assets_11" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-full_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" xlink:label="loc_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePremiumResultingFromExerciseOfWarrants" xlink:label="loc_blrx_SharePremiumResultingFromExerciseOfWarrants_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" xlink:to="loc_ifrs-full_WarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_5" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_5" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_5" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0" xlink:to="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_11" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_11" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_11" xlink:to="loc_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_11" xlink:to="loc_blrx_SharePremiumResultingFromExerciseOfWarrants_14" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfWarrants" xlink:label="loc_blrx_FairValueOfWarrants_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuancesOfWarrants" xlink:label="loc_blrx_IssuancesOfWarrants_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExercises" xlink:label="loc_blrx_WarrantsExercises_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInFairValueThroughProfitAndLossOfWarrants" xlink:label="loc_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_1" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0" xlink:to="loc_blrx_FairValueOfWarrants_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0" xlink:to="loc_blrx_IssuancesOfWarrants_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0" xlink:to="loc_blrx_WarrantsExercises_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0" xlink:to="loc_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_9" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents" xlink:label="loc_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_1" xlink:to="loc_ifrs-full_RangeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_BottomOfRangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_TopOfRangeMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_1" xlink:to="loc_ifrs-full_RangeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_7" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnShortTermDeposits" xlink:label="loc_blrx_InterestRateOnShortTermDeposits_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_1" xlink:to="loc_ifrs-full_RangeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_BottomOfRangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_TopOfRangeMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_1" xlink:to="loc_ifrs-full_RangeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xlink:to="loc_blrx_InterestRateOnShortTermDeposits_7" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LaboratoryEquipmentMember" xlink:label="loc_blrx_LaboratoryEquipmentMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="loc_ifrs-full_CarryingAmountMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_blrx_NetBookValueMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="loc_ifrs-full_CarryingAmountMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_7" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7" xlink:to="loc_ifrs-full_OfficeEquipmentMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7" xlink:to="loc_ifrs-full_ComputerEquipmentMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7" xlink:to="loc_blrx_LaboratoryEquipmentMember_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_7" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_17" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgalimmuneLtdMember" xlink:label="loc_blrx_AgalimmuneLtdMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BiokineTherapeuticsLtdMember" xlink:label="loc_blrx_BiokineTherapeuticsLtdMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Glix1Member" xlink:label="loc_blrx_Glix1Member_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BL8040Member" xlink:label="loc_blrx_BL8040Member_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfPaymentToBeMade" xlink:label="loc_blrx_PercentageOfPaymentToBeMade_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIncreasingWeightedAverageCostOfCapital" xlink:label="loc_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_22"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfDecreasingAnnualGrowthRate" xlink:label="loc_blrx_PercentageOfDecreasingAnnualGrowthRate_23"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital" xlink:label="loc_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_24"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate" xlink:label="loc_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_27"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_1" xlink:to="loc_blrx_AgalimmuneLtdMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_1" xlink:to="loc_blrx_BiokineTherapeuticsLtdMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_1" xlink:to="loc_blrx_Glix1Member_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_7" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_7" xlink:to="loc_blrx_BL8040Member_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_12" xlink:to="loc_ifrs-full_CarryingAmountMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_12" xlink:to="loc_blrx_NetBookValueMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_12" xlink:to="loc_ifrs-full_CarryingAmountMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_CashTransferred_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_blrx_PercentageOfPaymentToBeMade_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_21" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_22" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_blrx_PercentageOfDecreasingAnnualGrowthRate_23" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_24" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_25" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_26" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_27" order="110" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_14"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="loc_ifrs-full_CarryingAmountMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_blrx_NetBookValueMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="loc_ifrs-full_CarryingAmountMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_7" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_7" xlink:to="loc_ifrs-full_ComputerSoftwareMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_16" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_17" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LeasesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLeasesLineItems" xlink:label="loc_blrx_DisclosureOfLeasesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLeasesTable" xlink:label="loc_blrx_DisclosureOfLeasesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL" xlink:label="loc_country_IL_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BostonMember" xlink:label="loc_blrx_BostonMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfPremises" xlink:label="loc_blrx_NumberOfPremises_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LeaseAgreementMonthlyFee" xlink:label="loc_blrx_LeaseAgreementMonthlyFee_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalExtendLeasePeriod" xlink:label="loc_blrx_AdditionalExtendLeasePeriod_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageIncreasePrecedingLeasePaymentAmount" xlink:label="loc_blrx_PercentageIncreasePrecedingLeasePaymentAmount_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RightOfUseAssetWrittenOff" xlink:label="loc_blrx_RightOfUseAssetWrittenOff_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LeasePeriod" xlink:label="loc_blrx_LeasePeriod_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AnnualLeaseFee" xlink:label="loc_blrx_AnnualLeaseFee_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepairsAndMaintenanceExpense" xlink:label="loc_ifrs-full_RepairsAndMaintenanceExpense_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_0" xlink:to="loc_blrx_DisclosureOfLeasesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blrx_DisclosureOfLeasesTable_1" xlink:to="loc_srt_StatementGeographicalAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1" xlink:to="loc_srt_SegmentGeographicalDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_IL_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_blrx_BostonMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1" xlink:to="loc_srt_SegmentGeographicalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_0" xlink:to="loc_blrx_NumberOfPremises_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_0" xlink:to="loc_blrx_LeaseAgreementMonthlyFee_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_0" xlink:to="loc_blrx_AdditionalExtendLeasePeriod_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_0" xlink:to="loc_blrx_PercentageIncreasePrecedingLeasePaymentAmount_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_0" xlink:to="loc_blrx_RightOfUseAssetWrittenOff_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_0" xlink:to="loc_blrx_LeasePeriod_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_0" xlink:to="loc_blrx_AnnualLeaseFee_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_0" xlink:to="loc_ifrs-full_RepairsAndMaintenanceExpense_14" order="80" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="loc_ifrs-full_MotorVehiclesMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_14"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsToRightOfUseAssets" xlink:label="loc_blrx_DeletionsToRightOfUseAssets_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="loc_ifrs-full_CarryingAmountMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_blrx_NetBookValueMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="loc_ifrs-full_CarryingAmountMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_7" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_7" xlink:to="loc_ifrs-full_LandAndBuildingsMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_7" xlink:to="loc_ifrs-full_MotorVehiclesMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_7" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xlink:to="loc_ifrs-full_RightofuseAssets_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xlink:to="loc_blrx_DeletionsToRightOfUseAssets_15" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" xlink:label="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable" xlink:label="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="loc_ifrs-full_MotorVehiclesMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionsLeaseLiabilities" xlink:label="loc_blrx_AdditionsLeaseLiabilities_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsLeaseLiabilities" xlink:label="loc_blrx_DeletionsLeaseLiabilities_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestExpenseLeaseLiabilities" xlink:label="loc_blrx_InterestExpenseLeaseLiabilities_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferencesDuringYear" xlink:label="loc_blrx_ExchangeDifferencesDuringYear_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PaymentsLeaseLiabilities" xlink:label="loc_blrx_PaymentsLeaseLiabilities_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_0" xlink:to="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable_1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_1" xlink:to="loc_ifrs-full_LandAndBuildingsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_1" xlink:to="loc_ifrs-full_MotorVehiclesMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_0" xlink:to="loc_ifrs-full_LeaseLiabilities_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_0" xlink:to="loc_blrx_AdditionsLeaseLiabilities_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_0" xlink:to="loc_blrx_DeletionsLeaseLiabilities_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_0" xlink:to="loc_blrx_InterestExpenseLeaseLiabilities_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_0" xlink:to="loc_blrx_ExchangeDifferencesDuringYear_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_0" xlink:to="loc_blrx_PaymentsLeaseLiabilities_12" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="loc_ifrs-full_MaturityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="loc_ifrs-full_MaturityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="loc_ifrs-full_MotorVehiclesMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived" xlink:label="loc_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_1" xlink:to="loc_ifrs-full_MaturityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_1" xlink:to="loc_ifrs-full_MaturityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_1" xlink:to="loc_ifrs-full_MaturityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_9" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_9" xlink:to="loc_ifrs-full_LandAndBuildingsMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_9" xlink:to="loc_ifrs-full_MotorVehiclesMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_9" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_0" xlink:to="loc_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived_15" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/Long-termLoansNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyAxis" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyDomain" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LoanAgreementWithKreosCapitalMember" xlink:label="loc_blrx_LoanAgreementWithKreosCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyDomain" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TrancheAxis" xlink:label="loc_blrx_TrancheAxis_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TrancheDomain" xlink:label="loc_blrx_TrancheDomain_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FirstTrancheMember" xlink:label="loc_blrx_FirstTrancheMember_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SecondTrancheMember" xlink:label="loc_blrx_SecondTrancheMember_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ThirdTrancheMember" xlink:label="loc_blrx_ThirdTrancheMember_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TrancheDomain" xlink:label="loc_blrx_TrancheDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnLongTermBankLoan" xlink:label="loc_blrx_InterestRateOnLongTermBankLoan_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LoanTakenForPaymentOfAgreementValue" xlink:label="loc_blrx_LoanTakenForPaymentOfAgreementValue_18"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfLoanAgreement" xlink:label="loc_blrx_AmountOfLoanAgreement_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfAnnualInterestOfCashFees" xlink:label="loc_blrx_PercentageOfAnnualInterestOfCashFees_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfIntellectualPropertyAndCashBalance" xlink:label="loc_blrx_AmountOfIntellectualPropertyAndCashBalance_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_22"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MinimumCashBalanceRequirementUnderLoanAgreement" xlink:label="loc_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_23"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfFutureMilestonePayments" xlink:label="loc_blrx_PercentageOfFutureMilestonePayments_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1" xlink:to="loc_ifrs-full_TypesOfInvestmentPropertyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyAxis_1" xlink:to="loc_ifrs-full_TypesOfInvestmentPropertyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_1" xlink:to="loc_blrx_LoanAgreementWithKreosCapitalMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyAxis_1" xlink:to="loc_ifrs-full_TypesOfInvestmentPropertyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1" xlink:to="loc_blrx_TrancheAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_blrx_TrancheAxis_5" xlink:to="loc_blrx_TrancheDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_TrancheDomain_5" xlink:to="loc_blrx_FirstTrancheMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_TrancheDomain_5" xlink:to="loc_blrx_SecondTrancheMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_TrancheDomain_5" xlink:to="loc_blrx_ThirdTrancheMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_blrx_TrancheAxis_5" xlink:to="loc_blrx_TrancheDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1" xlink:to="loc_ifrs-full_RangeAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_11" xlink:to="loc_ifrs-full_RangeDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_11" xlink:to="loc_ifrs-full_BottomOfRangeMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_11" xlink:to="loc_ifrs-full_TopOfRangeMember_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_11" xlink:to="loc_ifrs-full_RangeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0" xlink:to="loc_blrx_InterestRateOnLongTermBankLoan_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0" xlink:to="loc_blrx_LoanTakenForPaymentOfAgreementValue_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0" xlink:to="loc_blrx_AmountOfLoanAgreement_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0" xlink:to="loc_blrx_PercentageOfAnnualInterestOfCashFees_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0" xlink:to="loc_blrx_AmountOfIntellectualPropertyAndCashBalance_21" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0" xlink:to="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_22" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0" xlink:to="loc_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_23" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0" xlink:to="loc_blrx_PercentageOfFutureMilestonePayments_24" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_25" order="90" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/EquityNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-full_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyAxis" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyDomain" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyDomain_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BvfPartnersLpMember" xlink:label="loc_blrx_BvfPartnersLpMember_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DirectPlacementMember" xlink:label="loc_blrx_DirectPlacementMember_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ConsultantsMember" xlink:label="loc_blrx_ConsultantsMember_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LoanAgreementWithKreosCapitalMember" xlink:label="loc_blrx_LoanAgreementWithKreosCapitalMember_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InvestorsMember" xlink:label="loc_blrx_InvestorsMember_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PlacementAgentsDesigneesMember" xlink:label="loc_blrx_PlacementAgentsDesigneesMember_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HighbridgeCapitalManagementLlcMember" xlink:label="loc_blrx_HighbridgeCapitalManagementLlcMember_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_January2025OfferingMember" xlink:label="loc_blrx_January2025OfferingMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyDomain" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeriesAWarrantsMember" xlink:label="loc_blrx_SeriesAWarrantsMember_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeriesBWarrantMember" xlink:label="loc_blrx_SeriesBWarrantMember_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantOneMember" xlink:label="loc_blrx_WarrantOneMember_18"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantTwoMember" xlink:label="loc_blrx_WarrantTwoMember_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantThreeMember" xlink:label="loc_blrx_WarrantThreeMember_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantFourMember" xlink:label="loc_blrx_WarrantFourMember_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantFiveMember" xlink:label="loc_blrx_WarrantFiveMember_22"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantSixMember" xlink:label="loc_blrx_WarrantSixMember_23"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantsMember" xlink:label="loc_blrx_PreFundedWarrantsMember_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_28"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIncentivePlanMember" xlink:label="loc_blrx_ShareIncentivePlanMember_28"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceSharesUnitMember" xlink:label="loc_blrx_PerformanceSharesUnitMember_29"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UnderwaterEmployeeStockOptionsMember" xlink:label="loc_blrx_UnderwaterEmployeeStockOptionsMember_30"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceSharesUnitTwoMember" xlink:label="loc_blrx_PerformanceSharesUnitTwoMember_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_35"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BtigLlcMember" xlink:label="loc_blrx_BtigLlcMember_35"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HCWainwrightAndCoLlcMember" xlink:label="loc_blrx_HCWainwrightAndCoLlcMember_36"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PlacementAgentMember" xlink:label="loc_blrx_PlacementAgentMember_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_41"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmericanDepositarySharesMember" xlink:label="loc_blrx_AmericanDepositarySharesMember_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsAxis_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsDomain" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsDomain_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsDomain" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketSharePrice" xlink:label="loc_blrx_MarketSharePrice_54"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedToPurchaseWarrant" xlink:label="loc_blrx_ShareIssuedToPurchaseWarrant_55"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceOfShareIssued" xlink:label="loc_blrx_ExercisePriceOfShareIssued_56"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountAllocatedToWarrant" xlink:label="loc_blrx_AmountAllocatedToWarrant_57"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_58"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturityDate" xlink:label="loc_blrx_MaturityDate_59"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisableTermOfWarrant" xlink:label="loc_blrx_ExercisableTermOfWarrant_60"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedOfPublicOffering" xlink:label="loc_blrx_ShareIssuedOfPublicOffering_61"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_StockIssuedPricePerShare" xlink:label="loc_blrx_StockIssuedPricePerShare_62"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromIssuanceOfInitialPublicOffering" xlink:label="loc_blrx_ProceedsFromIssuanceOfInitialPublicOffering_63"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet" xlink:label="loc_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_64"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreement" xlink:label="loc_blrx_SharePurchaseAgreement_65"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreementShares" xlink:label="loc_blrx_SharePurchaseAgreementShares_66"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchaseAgreementPeriod" xlink:label="loc_blrx_PurchaseAgreementPeriod_67"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_68"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedAsAdditionalCommitmentFee" xlink:label="loc_blrx_ShareIssuedAsAdditionalCommitmentFee_69"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFeeAndCommissionExpense" xlink:label="loc_ifrs-full_OtherFeeAndCommissionExpense_70"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalCommitmentFee" xlink:label="loc_blrx_AdditionalCommitmentFee_71"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NonOperatingExpense" xlink:label="loc_blrx_NonOperatingExpense_72"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_73"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_74"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AvailableBalanceUnderFacility" xlink:label="loc_blrx_AvailableBalanceUnderFacility_75"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SaleOfStockNumberOfSharesIssued" xlink:label="loc_blrx_SaleOfStockNumberOfSharesIssued_76"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_77"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RemainingAuthorizedUnissuedOrdinaryShares" xlink:label="loc_blrx_RemainingAuthorizedUnissuedOrdinaryShares_78"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_79"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_80"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_81"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_82"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_83"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_84"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019" xlink:label="loc_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_85"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_86"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ValueOfServicesRecorded" xlink:label="loc_blrx_ValueOfServicesRecorded_87"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountGrantOfEquityInstruments" xlink:label="loc_blrx_AmountGrantOfEquityInstruments_88"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_89"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_90"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_91"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AggregateOfferingPrice" xlink:label="loc_blrx_AggregateOfferingPrice_92"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfCommissionOnSalesAgreement" xlink:label="loc_blrx_PercentageOfCommissionOnSalesAgreement_93"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditExposure" xlink:label="loc_ifrs-full_CreditExposure_94"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RemainingUnrecognizedDeferredCompensationExpense" xlink:label="loc_blrx_RemainingUnrecognizedDeferredCompensationExpense_95"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharesIssuedRegisteredDirectOfferings" xlink:label="loc_blrx_SharesIssuedRegisteredDirectOfferings_96"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsIssuedToPurchaseShares" xlink:label="loc_blrx_WarrantsIssuedToPurchaseShares_97"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_98"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExpirationPeriod" xlink:label="loc_blrx_WarrantsExpirationPeriod_99"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceOfWarrants" xlink:label="loc_blrx_ExercisePriceOfWarrants_100"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantOfferingConsideration" xlink:label="loc_blrx_WarrantOfferingConsideration_101"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromExerciseWarrants" xlink:label="loc_blrx_ProceedsFromExerciseWarrants_102"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses" xlink:label="loc_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_103"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromWarrantIssue" xlink:label="loc_blrx_ProceedsFromWarrantIssue_104"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfOrdinaryWarrantsAdjustedAmount" xlink:label="loc_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_105"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_106"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_107"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RecognizedAsEquity" xlink:label="loc_blrx_RecognizedAsEquity_108"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInFairValueRecordedAsANonoperatingIncome" xlink:label="loc_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_109"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BeneficiallyOwnInExcess" xlink:label="loc_blrx_BeneficiallyOwnInExcess_110"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" xlink:to="loc_ifrs-full_WarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_TypesOfInvestmentPropertyAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyAxis_5" xlink:to="loc_ifrs-full_TypesOfInvestmentPropertyDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_5" xlink:to="loc_blrx_BvfPartnersLpMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_5" xlink:to="loc_blrx_DirectPlacementMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_5" xlink:to="loc_blrx_ConsultantsMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_5" xlink:to="loc_blrx_LoanAgreementWithKreosCapitalMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_5" xlink:to="loc_blrx_InvestorsMember_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_5" xlink:to="loc_blrx_PlacementAgentsDesigneesMember_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_5" xlink:to="loc_blrx_HighbridgeCapitalManagementLlcMember_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_5" xlink:to="loc_blrx_January2025OfferingMember_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyAxis_5" xlink:to="loc_ifrs-full_TypesOfInvestmentPropertyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_16" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_16" xlink:to="loc_blrx_SeriesAWarrantsMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_16" xlink:to="loc_blrx_SeriesBWarrantMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_16" xlink:to="loc_blrx_WarrantOneMember_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_16" xlink:to="loc_blrx_WarrantTwoMember_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_16" xlink:to="loc_blrx_WarrantThreeMember_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_16" xlink:to="loc_blrx_WarrantFourMember_21" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_16" xlink:to="loc_blrx_WarrantFiveMember_22" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_16" xlink:to="loc_blrx_WarrantSixMember_23" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_16" xlink:to="loc_blrx_PreFundedWarrantsMember_24" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_16" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_28" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_28" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_28" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_28" xlink:to="loc_blrx_ShareIncentivePlanMember_28" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_28" xlink:to="loc_blrx_PerformanceSharesUnitMember_29" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_28" xlink:to="loc_blrx_UnderwaterEmployeeStockOptionsMember_30" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_28" xlink:to="loc_blrx_PerformanceSharesUnitTwoMember_31" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_28" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_35" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_35" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_35" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_35" xlink:to="loc_blrx_BtigLlcMember_35" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_35" xlink:to="loc_blrx_HCWainwrightAndCoLlcMember_36" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_35" xlink:to="loc_blrx_PlacementAgentMember_37" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_35" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_41" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_41" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_41" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_41" xlink:to="loc_blrx_AmericanDepositarySharesMember_41" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_41" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_45" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_45" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_45" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_45" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_45" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_45" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_InitiallyAppliedIFRSsAxis_49" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsAxis_49" xlink:to="loc_ifrs-full_InitiallyAppliedIFRSsDomain_49" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsDomain_49" xlink:to="loc_ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_49" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsAxis_49" xlink:to="loc_ifrs-full_InitiallyAppliedIFRSsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_MarketSharePrice_54" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ShareIssuedToPurchaseWarrant_55" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ExercisePriceOfShareIssued_56" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_AmountAllocatedToWarrant_57" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_58" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_MaturityDate_59" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ExercisableTermOfWarrant_60" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ShareIssuedOfPublicOffering_61" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_StockIssuedPricePerShare_62" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ProceedsFromIssuanceOfInitialPublicOffering_63" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_64" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_SharePurchaseAgreement_65" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_SharePurchaseAgreementShares_66" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_PurchaseAgreementPeriod_67" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_68" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ShareIssuedAsAdditionalCommitmentFee_69" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_OtherFeeAndCommissionExpense_70" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_AdditionalCommitmentFee_71" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_NonOperatingExpense_72" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_73" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_74" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_AvailableBalanceUnderFacility_75" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_SaleOfStockNumberOfSharesIssued_76" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_NumberOfSharesIssued_77" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_RemainingAuthorizedUnissuedOrdinaryShares_78" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_79" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_80" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_81" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_82" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_83" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_84" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_85" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_86" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ValueOfServicesRecorded_87" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_AmountGrantOfEquityInstruments_88" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_89" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_90" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_91" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_AggregateOfferingPrice_92" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_PercentageOfCommissionOnSalesAgreement_93" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_CreditExposure_94" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_RemainingUnrecognizedDeferredCompensationExpense_95" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_SharesIssuedRegisteredDirectOfferings_96" order="430" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_WarrantsIssuedToPurchaseShares_97" order="440" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_98" order="450" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_WarrantsExpirationPeriod_99" order="460" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ExercisePriceOfWarrants_100" order="470" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_WarrantOfferingConsideration_101" order="480" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ProceedsFromExerciseWarrants_102" order="490" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_103" order="500" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ProceedsFromWarrantIssue_104" order="510" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_105" order="520" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_106" order="530" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_107" order="540" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_RecognizedAsEquity_108" order="550" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_109" order="560" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_BeneficiallyOwnInExcess_110" order="570" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EmployeesAndDirectorsMember" xlink:label="loc_blrx_EmployeesAndDirectorsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfOptionsAbstract" xlink:label="loc_blrx_NumberOfOptionsAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WeightedAverageExercisePriceAbstract" xlink:label="loc_blrx_WeightedAverageExercisePriceAbstract_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_18"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1" xlink:to="loc_blrx_EmployeesAndDirectorsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_NumberOfOptionsAbstract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_NumberOfOptionsAbstract_6" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_NumberOfOptionsAbstract_6" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_NumberOfOptionsAbstract_6" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_NumberOfOptionsAbstract_6" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_NumberOfOptionsAbstract_6" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_NumberOfOptionsAbstract_6" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xlink:to="loc_blrx_WeightedAverageExercisePriceAbstract_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_13" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_13" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_13" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_13" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_13" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_17" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_13" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_18" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeMember" xlink:label="loc_blrx_ExercisePriceRangeMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeOneMember" xlink:label="loc_blrx_ExercisePriceRangeOneMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeTwoMember" xlink:label="loc_blrx_ExercisePriceRangeTwoMember_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeFourMember" xlink:label="loc_blrx_ExercisePriceRangeFourMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1" xlink:to="loc_blrx_ExercisePriceRangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1" xlink:to="loc_blrx_ExercisePriceRangeOneMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1" xlink:to="loc_blrx_ExercisePriceRangeTwoMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1" xlink:to="loc_blrx_ExercisePriceRangeFourMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_0" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_0" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_10" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="loc_ifrs-full_GeographicalAreasDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL" xlink:label="loc_country_IL_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="loc_ifrs-full_GeographicalAreasDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember" xlink:label="loc_ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UniformTaxRate" xlink:label="loc_blrx_UniformTaxRate_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WithholdingApplicableTaxRate" xlink:label="loc_blrx_WithholdingApplicableTaxRate_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxLossCarryforwards" xlink:label="loc_blrx_TaxLossCarryforwards_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1" xlink:to="loc_ifrs-full_GeographicalAreasDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_1" xlink:to="loc_country_IL_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1" xlink:to="loc_ifrs-full_GeographicalAreasDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_5" xlink:to="loc_ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xlink:to="loc_ifrs-full_ApplicableTaxRate_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xlink:to="loc_blrx_UniformTaxRate_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xlink:to="loc_blrx_WithholdingApplicableTaxRate_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xlink:to="loc_blrx_TaxLossCarryforwards_13" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems" xlink:label="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="loc_ifrs-full_MaturityDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FirstThreeYearsMember" xlink:label="loc_blrx_FirstThreeYearsMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ThreeSubsequentYearsMember" xlink:label="loc_blrx_ThreeSubsequentYearsMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeventhYearMember" xlink:label="loc_blrx_SeventhYearMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="loc_ifrs-full_MaturityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BiokineTherapeuticsLtdMember" xlink:label="loc_blrx_BiokineTherapeuticsLtdMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesReceivedPercentage" xlink:label="loc_blrx_RoyaltiesReceivedPercentage_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesPaymentPercentage" xlink:label="loc_blrx_RoyaltiesPaymentPercentage_18"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaximumFutureMilestonePayments" xlink:label="loc_blrx_MaximumFutureMilestonePayments_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ContingentLiability" xlink:label="loc_blrx_ContingentLiability_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts" xlink:label="loc_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedForDirectProductSales" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_23"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesOnSale" xlink:label="loc_blrx_RoyaltiesOnSale_24"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedForSubLicense" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedForSubLicense_25"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedFromLicensee" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedFromLicensee_26"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesRateOnNetSales" xlink:label="loc_blrx_RoyaltiesRateOnNetSales_27"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BankGuaranteeAmountForBenefitOfLessor" xlink:label="loc_blrx_BankGuaranteeAmountForBenefitOfLessor_28"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OpenPurchaseOrderCommitments" xlink:label="loc_blrx_OpenPurchaseOrderCommitments_29"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LawsuitClaimAmount" xlink:label="loc_blrx_LawsuitClaimAmount_30"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1" xlink:to="loc_ifrs-full_MaturityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_1" xlink:to="loc_ifrs-full_MaturityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_blrx_FirstThreeYearsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_blrx_ThreeSubsequentYearsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_blrx_SeventhYearMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_1" xlink:to="loc_ifrs-full_MaturityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1" xlink:to="loc_ifrs-full_RangeAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_7" xlink:to="loc_ifrs-full_RangeDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_7" xlink:to="loc_ifrs-full_BottomOfRangeMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_7" xlink:to="loc_ifrs-full_TopOfRangeMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_7" xlink:to="loc_ifrs-full_RangeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1" xlink:to="loc_dei_LegalEntityAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_12" xlink:to="loc_blrx_BiokineTherapeuticsLtdMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_RoyaltiesReceivedPercentage_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_RoyaltiesPaymentPercentage_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_MaximumFutureMilestonePayments_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_ContingentLiability_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_21" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_22" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_23" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_RoyaltiesOnSale_24" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_PercentageOfNetConsiderationReceivedForSubLicense_25" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_PercentageOfNetConsiderationReceivedFromLicensee_26" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_RoyaltiesRateOnNetSales_27" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_BankGuaranteeAmountForBenefitOfLessor_28" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_OpenPurchaseOrderCommitments_29" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xlink:to="loc_blrx_LawsuitClaimAmount_30" order="140" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsTable" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeAxis" xlink:label="loc_blrx_AgreementTypeAxis_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeDomain" xlink:label="loc_blrx_AgreementTypeDomain_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchaseAgreementMember" xlink:label="loc_blrx_PurchaseAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreementMember" xlink:label="loc_blrx_SharePurchaseAgreementMember_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ScmLicenseMember" xlink:label="loc_blrx_ScmLicenseMember_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ScmSupportServicesMember" xlink:label="loc_blrx_ScmSupportServicesMember_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PDACPerformanceObligationMember" xlink:label="loc_blrx_PDACPerformanceObligationMember_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GloriaLicenseAgreementMember" xlink:label="loc_blrx_GloriaLicenseAgreementMember_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GloriaPurchaseAgreementMember" xlink:label="loc_blrx_GloriaPurchaseAgreementMember_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAgreementMember" xlink:label="loc_blrx_LicenseAgreementMember_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeDomain" xlink:label="loc_blrx_AgreementTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UpfrontPayment" xlink:label="loc_blrx_UpfrontPayment_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForDevelopmentProjectExpenditure" xlink:label="loc_ifrs-full_PaymentsForDevelopmentProjectExpenditure_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesMilestoneAmount" xlink:label="loc_blrx_SalesMilestoneAmount_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesEligibleMargin" xlink:label="loc_blrx_RoyaltiesEligibleMargin_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InitialRoyaltyTerm" xlink:label="loc_blrx_InitialRoyaltyTerm_22"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AggregateAmericanDepositaryShares" xlink:label="loc_blrx_AggregateAmericanDepositaryShares_23"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchasePricePerADS" xlink:label="loc_blrx_PurchasePricePerADS_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:label="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-full_ConsiderationPaidReceived_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_29"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TransferFromLicenseToTheLicenseeAmount" xlink:label="loc_blrx_TransferFromLicenseToTheLicenseeAmount_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="loc_ifrs-full_OtherRevenue_31"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DelayInPayment" xlink:label="loc_blrx_DelayInPayment_32"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProvisionForDoubtfulAccountsReceivable" xlink:label="loc_blrx_ProvisionForDoubtfulAccountsReceivable_33"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostsIncurrentInOffering" xlink:label="loc_blrx_CostsIncurrentInOffering_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="loc_ifrs-full_LicenceFeeIncome_35"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales" xlink:label="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_36"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_blrx_AgreementTypeAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_blrx_AgreementTypeAxis_6" xlink:to="loc_blrx_AgreementTypeDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_6" xlink:to="loc_blrx_PurchaseAgreementMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_6" xlink:to="loc_blrx_SharePurchaseAgreementMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_6" xlink:to="loc_blrx_ScmLicenseMember_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_6" xlink:to="loc_blrx_ScmSupportServicesMember_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_6" xlink:to="loc_blrx_PDACPerformanceObligationMember_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_6" xlink:to="loc_blrx_GloriaLicenseAgreementMember_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_6" xlink:to="loc_blrx_GloriaPurchaseAgreementMember_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_6" xlink:to="loc_blrx_LicenseAgreementMember_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_blrx_AgreementTypeAxis_6" xlink:to="loc_blrx_AgreementTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_UpfrontPayment_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_ifrs-full_PaymentsForDevelopmentProjectExpenditure_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_SalesMilestoneAmount_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_RoyaltiesEligibleMargin_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_InitialRoyaltyTerm_22" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_AggregateAmericanDepositaryShares_23" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_PurchasePricePerADS_24" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_25" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_26" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_ifrs-full_ConsiderationPaidReceived_27" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_28" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_29" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_TransferFromLicenseToTheLicenseeAmount_30" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_ifrs-full_OtherRevenue_31" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_DelayInPayment_32" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_ProvisionForDoubtfulAccountsReceivable_33" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_CostsIncurrentInOffering_34" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_ifrs-full_LicenceFeeIncome_35" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_36" order="190" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsTable" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeAxis" xlink:label="loc_blrx_AgreementTypeAxis_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeDomain" xlink:label="loc_blrx_AgreementTypeDomain_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AyrmidLicenseAgreementMember" xlink:label="loc_blrx_AyrmidLicenseAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HighbridgeMember" xlink:label="loc_blrx_HighbridgeMember_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RegisteredDirectOfferingMember" xlink:label="loc_blrx_RegisteredDirectOfferingMember_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeDomain" xlink:label="loc_blrx_AgreementTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceObligationAxis" xlink:label="loc_blrx_PerformanceObligationAxis_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceObligationDomain" xlink:label="loc_blrx_PerformanceObligationDomain_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SingleMaterialPerformanceObligationMember" xlink:label="loc_blrx_SingleMaterialPerformanceObligationMember_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceObligationDomain" xlink:label="loc_blrx_PerformanceObligationDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UpfrontPayment" xlink:label="loc_blrx_UpfrontPayment_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales" xlink:label="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_18"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GrossProceedsFromOffering" xlink:label="loc_blrx_GrossProceedsFromOffering_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-full_ConsiderationPaidReceived_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostsIncurrentInOffering" xlink:label="loc_blrx_CostsIncurrentInOffering_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="loc_ifrs-full_LicenceFeeIncome_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="loc_ifrs-full_RevenueFromRoyalties_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_ifrs-full_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_1" xlink:to="loc_ifrs-full_RangeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_BottomOfRangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_TopOfRangeMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_1" xlink:to="loc_ifrs-full_RangeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_blrx_AgreementTypeAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_blrx_AgreementTypeAxis_6" xlink:to="loc_blrx_AgreementTypeDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_6" xlink:to="loc_blrx_AyrmidLicenseAgreementMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_6" xlink:to="loc_blrx_HighbridgeMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_6" xlink:to="loc_blrx_RegisteredDirectOfferingMember_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_blrx_AgreementTypeAxis_6" xlink:to="loc_blrx_AgreementTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_blrx_PerformanceObligationAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_blrx_PerformanceObligationAxis_12" xlink:to="loc_blrx_PerformanceObligationDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_PerformanceObligationDomain_12" xlink:to="loc_blrx_SingleMaterialPerformanceObligationMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_blrx_PerformanceObligationAxis_12" xlink:to="loc_blrx_PerformanceObligationDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_UpfrontPayment_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_GrossProceedsFromOffering_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_ifrs-full_ConsiderationPaidReceived_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_blrx_CostsIncurrentInOffering_21" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_ifrs-full_LicenceFeeIncome_22" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xlink:to="loc_ifrs-full_RevenueFromRoyalties_23" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationAndShareholdersAgreementLineItems" xlink:label="loc_blrx_CollaborationAndShareholdersAgreementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationAndShareholdersAgreementTable" xlink:label="loc_blrx_CollaborationAndShareholdersAgreementTable_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationTransactionAxis" xlink:label="loc_blrx_CollaborationTransactionAxis_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationTransactionDomain" xlink:label="loc_blrx_CollaborationTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HemispherianAsMember" xlink:label="loc_blrx_HemispherianAsMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationTransactionDomain" xlink:label="loc_blrx_CollaborationTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeAxis" xlink:label="loc_blrx_AgreementTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeDomain" xlink:label="loc_blrx_AgreementTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AssetTransferAgreementMember" xlink:label="loc_blrx_AssetTransferAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeDomain" xlink:label="loc_blrx_AgreementTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TetragonMember" xlink:label="loc_blrx_TetragonMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIssuedShareCapitalReceived" xlink:label="loc_blrx_PercentageOfIssuedShareCapitalReceived_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentProperty" xlink:label="loc_ifrs-full_InvestmentProperty_15"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths" xlink:label="loc_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncrementalInvestment" xlink:label="loc_blrx_IncrementalInvestment_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfAdditionalEquityInterest" xlink:label="loc_blrx_PercentageOfAdditionalEquityInterest_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfOwnershipStake" xlink:label="loc_blrx_PercentageOfOwnershipStake_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MonthlyAdvisoryFee" xlink:label="loc_blrx_MonthlyAdvisoryFee_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_0" xlink:to="loc_blrx_CollaborationAndShareholdersAgreementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementTable_1" xlink:to="loc_blrx_CollaborationTransactionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_blrx_CollaborationTransactionAxis_1" xlink:to="loc_blrx_CollaborationTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_CollaborationTransactionDomain_1" xlink:to="loc_blrx_HemispherianAsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_blrx_CollaborationTransactionAxis_1" xlink:to="loc_blrx_CollaborationTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementTable_1" xlink:to="loc_blrx_AgreementTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_blrx_AgreementTypeAxis_5" xlink:to="loc_blrx_AgreementTypeDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_AssetTransferAgreementMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_blrx_AgreementTypeAxis_5" xlink:to="loc_blrx_AgreementTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementTable_1" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_9" xlink:to="loc_blrx_TetragonMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_0" xlink:to="loc_blrx_PercentageOfIssuedShareCapitalReceived_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_0" xlink:to="loc_ifrs-full_InvestmentProperty_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_0" xlink:to="loc_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_0" xlink:to="loc_blrx_IncrementalInvestment_17" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_0" xlink:to="loc_blrx_PercentageOfAdditionalEquityInterest_18" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_0" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_19" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_0" xlink:to="loc_blrx_PercentageOfOwnershipStake_20" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_0" xlink:to="loc_blrx_MonthlyAdvisoryFee_21" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_0" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_22" order="90" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SeparateManagementEntitiesAxis" xlink:label="loc_ifrs-full_SeparateManagementEntitiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SeparateManagementEntitiesDomain" xlink:label="loc_ifrs-full_SeparateManagementEntitiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeniorManagementMember" xlink:label="loc_blrx_SeniorManagementMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DirectorsMember" xlink:label="loc_blrx_DirectorsMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SeparateManagementEntitiesDomain" xlink:label="loc_ifrs-full_SeparateManagementEntitiesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BenefitsToRelatedPartiesAbstract" xlink:label="loc_blrx_BenefitsToRelatedPartiesAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity" xlink:label="loc_ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfEmployees" xlink:label="loc_ifrs-full_NumberOfEmployees_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_1" xlink:to="loc_ifrs-full_SeparateManagementEntitiesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SeparateManagementEntitiesAxis_1" xlink:to="loc_ifrs-full_SeparateManagementEntitiesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SeparateManagementEntitiesDomain_1" xlink:to="loc_blrx_SeniorManagementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SeparateManagementEntitiesDomain_1" xlink:to="loc_blrx_DirectorsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SeparateManagementEntitiesAxis_1" xlink:to="loc_ifrs-full_SeparateManagementEntitiesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_0" xlink:to="loc_blrx_BenefitsToRelatedPartiesAbstract_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_BenefitsToRelatedPartiesAbstract_7" xlink:to="loc_ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blrx_BenefitsToRelatedPartiesAbstract_7" xlink:to="loc_ifrs-full_NumberOfEmployees_8" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SEGMENTREPORTINGDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="loc_ifrs-full_GeographicalAreasDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="loc_ifrs-full_ForeignCountriesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="loc_ifrs-full_CountryOfDomicileMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="loc_ifrs-full_GeographicalAreasDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_0" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_1" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1" xlink:to="loc_ifrs-full_GeographicalAreasDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_1" xlink:to="loc_ifrs-full_ForeignCountriesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_1" xlink:to="loc_ifrs-full_CountryOfDomicileMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1" xlink:to="loc_ifrs-full_GeographicalAreasDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_0" xlink:to="loc_ifrs-full_Revenue_7" order="10" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>blrx-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ImpairmentLossOnIntangibleAssets" xlink:label="loc_blrx_ImpairmentLossOnIntangibleAssets_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ImpairmentLossOnIntangibleAssets" xlink:label="loc_blrx_ImpairmentLossOnIntangibleAssets_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ImpairmentLossOnIntangibleAssets" xlink:label="loc_blrx_ImpairmentLossOnIntangibleAssets_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ImpairmentLossOnIntangibleAssets" xlink:label="loc_blrx_ImpairmentLossOnIntangibleAssets_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ImpairmentLossOnIntangibleAssets" xlink:label="loc_blrx_ImpairmentLossOnIntangibleAssets_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AccountsPayableAbstract" xlink:label="loc_blrx_AccountsPayableAbstract_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AccountsPayableAbstract" xlink:label="loc_blrx_AccountsPayableAbstract_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AccountsPayableAbstract" xlink:label="loc_blrx_AccountsPayableAbstract_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalCommitmentFee" xlink:label="loc_blrx_AdditionalCommitmentFee_14"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalCommitmentFee" xlink:label="loc_blrx_AdditionalCommitmentFee_15"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalExtendLeasePeriod" xlink:label="loc_blrx_AdditionalExtendLeasePeriod_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalExtendLeasePeriod" xlink:label="loc_blrx_AdditionalExtendLeasePeriod_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalExtendLeasePeriod" xlink:label="loc_blrx_AdditionalExtendLeasePeriod_18"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate" xlink:label="loc_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate" xlink:label="loc_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate" xlink:label="loc_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital" xlink:label="loc_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_22"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital" xlink:label="loc_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_23"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital" xlink:label="loc_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_24"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalSharesMember" xlink:label="loc_blrx_AdditionalSharesMember_25"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionsLeaseLiabilities" xlink:label="loc_blrx_AdditionsLeaseLiabilities_26"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionsLeaseLiabilities" xlink:label="loc_blrx_AdditionsLeaseLiabilities_27"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionsLeaseLiabilities" xlink:label="loc_blrx_AdditionsLeaseLiabilities_28"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables" xlink:label="loc_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_29"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables" xlink:label="loc_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_30"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables" xlink:label="loc_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_31"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdvancePayments" xlink:label="loc_blrx_AdvancePayments_32"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdvancePayments" xlink:label="loc_blrx_AdvancePayments_33"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdvancePayments" xlink:label="loc_blrx_AdvancePayments_34"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgalimmuneLtdMember" xlink:label="loc_blrx_AgalimmuneLtdMember_35"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgalimmuneLtdMember" xlink:label="loc_blrx_AgalimmuneLtdMember_36"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AggregateAmericanDepositaryShares" xlink:label="loc_blrx_AggregateAmericanDepositaryShares_37"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AggregateAmericanDepositaryShares" xlink:label="loc_blrx_AggregateAmericanDepositaryShares_38"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AggregateAmericanDepositaryShares" xlink:label="loc_blrx_AggregateAmericanDepositaryShares_39"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AggregateOfferingPrice" xlink:label="loc_blrx_AggregateOfferingPrice_40"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AggregateOfferingPrice" xlink:label="loc_blrx_AggregateOfferingPrice_41"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeAxis" xlink:label="loc_blrx_AgreementTypeAxis_42"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeAxis" xlink:label="loc_blrx_AgreementTypeAxis_43"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeMember" xlink:label="loc_blrx_AgreementTypeMember_44"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeMember" xlink:label="loc_blrx_AgreementTypeMember_45"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory" xlink:label="loc_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_46"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory" xlink:label="loc_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_47"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory" xlink:label="loc_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_48"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmericanDepositarySharesMember" xlink:label="loc_blrx_AmericanDepositarySharesMember_49"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmericanDepositarySharesMember" xlink:label="loc_blrx_AmericanDepositarySharesMember_50"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmericanDepositarySharesMember" xlink:label="loc_blrx_AmericanDepositarySharesMember_51"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmericanDepositarySharesPurchasePricePerShare" xlink:label="loc_blrx_AmericanDepositarySharesPurchasePricePerShare_52"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmericanDepositarySharesPurchasePricePerShare" xlink:label="loc_blrx_AmericanDepositarySharesPurchasePricePerShare_53"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmericanDepositarySharesPurchasePricePerShare" xlink:label="loc_blrx_AmericanDepositarySharesPurchasePricePerShare_54"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmericanStockExchangeMember" xlink:label="loc_blrx_AmericanStockExchangeMember_55"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountAllocatedToWarrant" xlink:label="loc_blrx_AmountAllocatedToWarrant_56"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountAllocatedToWarrant" xlink:label="loc_blrx_AmountAllocatedToWarrant_57"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountGrantOfEquityInstruments" xlink:label="loc_blrx_AmountGrantOfEquityInstruments_58"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountGrantOfEquityInstruments" xlink:label="loc_blrx_AmountGrantOfEquityInstruments_59"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountGrantOfEquityInstruments" xlink:label="loc_blrx_AmountGrantOfEquityInstruments_60"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfIntellectualPropertyAndCashBalance" xlink:label="loc_blrx_AmountOfIntellectualPropertyAndCashBalance_61"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfIntellectualPropertyAndCashBalance" xlink:label="loc_blrx_AmountOfIntellectualPropertyAndCashBalance_62"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfIntellectualPropertyAndCashBalance" xlink:label="loc_blrx_AmountOfIntellectualPropertyAndCashBalance_63"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfLoanAgreement" xlink:label="loc_blrx_AmountOfLoanAgreement_64"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfLoanAgreement" xlink:label="loc_blrx_AmountOfLoanAgreement_65"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfLoanAgreement" xlink:label="loc_blrx_AmountOfLoanAgreement_66"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfPaymentInFutrueMilestone" xlink:label="loc_blrx_AmountOfPaymentInFutrueMilestone_67"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfPaymentInFutrueMilestone" xlink:label="loc_blrx_AmountOfPaymentInFutrueMilestone_68"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AnnualLeaseFee" xlink:label="loc_blrx_AnnualLeaseFee_69"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AnnualLeaseFee" xlink:label="loc_blrx_AnnualLeaseFee_70"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AuthorizedShareCapitalValue" xlink:label="loc_blrx_AuthorizedShareCapitalValue_71"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AuthorizedShareCapitalValue" xlink:label="loc_blrx_AuthorizedShareCapitalValue_72"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AuthorizedShareCapitalValue" xlink:label="loc_blrx_AuthorizedShareCapitalValue_73"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AvailableBalanceUnderFacility" xlink:label="loc_blrx_AvailableBalanceUnderFacility_74"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AvailableBalanceUnderFacility" xlink:label="loc_blrx_AvailableBalanceUnderFacility_75"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AyrmidLicenseAgreementMember" xlink:label="loc_blrx_AyrmidLicenseAgreementMember_76"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AyrmidLicenseAgreementMember" xlink:label="loc_blrx_AyrmidLicenseAgreementMember_77"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BankGuaranteeAmountForBenefitOfLessor" xlink:label="loc_blrx_BankGuaranteeAmountForBenefitOfLessor_78"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BankGuaranteeAmountForBenefitOfLessor" xlink:label="loc_blrx_BankGuaranteeAmountForBenefitOfLessor_79"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BankLoanMember" xlink:label="loc_blrx_BankLoanMember_80"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BankLoanMember" xlink:label="loc_blrx_BankLoanMember_81"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_blrx_BasicAndDilutedEarningsLossPerShare_82"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_blrx_BasicAndDilutedEarningsLossPerShare_83"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_blrx_BasicAndDilutedEarningsLossPerShare_84"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_blrx_BasicAndDilutedEarningsLossPerShare_85"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BeneficiallyOwnInExcess" xlink:label="loc_blrx_BeneficiallyOwnInExcess_86"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BeneficiallyOwnInExcess" xlink:label="loc_blrx_BeneficiallyOwnInExcess_87"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BenefitsToRelatedPartiesAbstract" xlink:label="loc_blrx_BenefitsToRelatedPartiesAbstract_88"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BenefitsToRelatedPartiesAbstract" xlink:label="loc_blrx_BenefitsToRelatedPartiesAbstract_89"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BenefitsToRelatedPartiesAbstract" xlink:label="loc_blrx_BenefitsToRelatedPartiesAbstract_90"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BiokineMember" xlink:label="loc_blrx_BiokineMember_91"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BiokineMember" xlink:label="loc_blrx_BiokineMember_92"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BiokineTherapeuticsLtdMember" xlink:label="loc_blrx_BiokineTherapeuticsLtdMember_93"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BiokineTherapeuticsLtdMember" xlink:label="loc_blrx_BiokineTherapeuticsLtdMember_94"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BiokineTherapeuticsLtdMember" xlink:label="loc_blrx_BiokineTherapeuticsLtdMember_95"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BioLineRxMember" xlink:label="loc_blrx_BioLineRxMember_96"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BL8040Member" xlink:label="loc_blrx_BL8040Member_97"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BL8040Member" xlink:label="loc_blrx_BL8040Member_98"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BL8040Member" xlink:label="loc_blrx_BL8040Member_99"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BostonMember" xlink:label="loc_blrx_BostonMember_100"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BostonMember" xlink:label="loc_blrx_BostonMember_101"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BostonMember" xlink:label="loc_blrx_BostonMember_102"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BtigLlcMember" xlink:label="loc_blrx_BtigLlcMember_103"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BtigLlcMember" xlink:label="loc_blrx_BtigLlcMember_104"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BusinessAnalyticsExpense" xlink:label="loc_blrx_BusinessAnalyticsExpense_105"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BusinessAnalyticsExpense" xlink:label="loc_blrx_BusinessAnalyticsExpense_106"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BusinessAnalyticsExpense" xlink:label="loc_blrx_BusinessAnalyticsExpense_107"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BvfPartnersLpMember" xlink:label="loc_blrx_BvfPartnersLpMember_108"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BvfPartnersLpMember" xlink:label="loc_blrx_BvfPartnersLpMember_109"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BvfPartnersLpMember" xlink:label="loc_blrx_BvfPartnersLpMember_110"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CashAndCashEquivalentMember" xlink:label="loc_blrx_CashAndCashEquivalentMember_111"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CashAndCashEquivalentMember" xlink:label="loc_blrx_CashAndCashEquivalentMember_112"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CashAndCashEquivalentMember" xlink:label="loc_blrx_CashAndCashEquivalentMember_113"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInFairValueRecordedAsANonoperatingIncome" xlink:label="loc_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_114"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInFairValueRecordedAsANonoperatingIncome" xlink:label="loc_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_115"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInFairValueThroughProfitAndLossOfWarrants" xlink:label="loc_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_116"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInFairValueThroughProfitAndLossOfWarrants" xlink:label="loc_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_117"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInFairValueThroughProfitAndLossOfWarrants" xlink:label="loc_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_118"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CommitmentsAndContingentLiabilities" xlink:label="loc_blrx_CommitmentsAndContingentLiabilities_119"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CommitmentsAndContingentLiabilities" xlink:label="loc_blrx_CommitmentsAndContingentLiabilities_120"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ConsultantsMember" xlink:label="loc_blrx_ConsultantsMember_121"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ConsultantsMember" xlink:label="loc_blrx_ConsultantsMember_122"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_123"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_124"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_125"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ContingentLiability" xlink:label="loc_blrx_ContingentLiability_126"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ContingentLiability" xlink:label="loc_blrx_ContingentLiability_127"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ContingentLiability" xlink:label="loc_blrx_ContingentLiability_128"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostOfProductSales" xlink:label="loc_blrx_CostOfProductSales_129"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostOfProductSales" xlink:label="loc_blrx_CostOfProductSales_130"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostOfProductSales" xlink:label="loc_blrx_CostOfProductSales_131"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostRelatedToLicenseRevenues" xlink:label="loc_blrx_CostRelatedToLicenseRevenues_132"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostRelatedToLicenseRevenues" xlink:label="loc_blrx_CostRelatedToLicenseRevenues_133"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostRelatedToLicenseRevenues" xlink:label="loc_blrx_CostRelatedToLicenseRevenues_134"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostsIncurrentInOffering" xlink:label="loc_blrx_CostsIncurrentInOffering_135"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostsIncurrentInOffering" xlink:label="loc_blrx_CostsIncurrentInOffering_136"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostsIncurrentInOffering" xlink:label="loc_blrx_CostsIncurrentInOffering_137"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DelayInPayment" xlink:label="loc_blrx_DelayInPayment_138"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DelayInPayment" xlink:label="loc_blrx_DelayInPayment_139"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DelayInPayment" xlink:label="loc_blrx_DelayInPayment_140"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_141"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_142"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_143"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_144"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsLeaseLiabilities" xlink:label="loc_blrx_DeletionsLeaseLiabilities_145"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsLeaseLiabilities" xlink:label="loc_blrx_DeletionsLeaseLiabilities_146"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsLeaseLiabilities" xlink:label="loc_blrx_DeletionsLeaseLiabilities_147"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsLeaseLiabilities" xlink:label="loc_blrx_DeletionsLeaseLiabilities_148"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsToRightOfUseAssets" xlink:label="loc_blrx_DeletionsToRightOfUseAssets_149"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsToRightOfUseAssets" xlink:label="loc_blrx_DeletionsToRightOfUseAssets_150"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsToRightOfUseAssets" xlink:label="loc_blrx_DeletionsToRightOfUseAssets_151"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DepositaryShareConversionDescription" xlink:label="loc_blrx_DepositaryShareConversionDescription_152"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DepositaryShareConversionDescription" xlink:label="loc_blrx_DepositaryShareConversionDescription_153"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DepositaryShareConversionDescription" xlink:label="loc_blrx_DepositaryShareConversionDescription_154"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DepositaryShareToOrdinaryShareRatioChangeDescription" xlink:label="loc_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_155"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DepositaryShareToOrdinaryShareRatioChangeDescription" xlink:label="loc_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_156"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DepositaryShareToOrdinaryShareRatioChangeDescription" xlink:label="loc_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_157"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_158"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_159"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_160"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_161"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_162"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_163"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_164"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_165"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_166"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_167"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_168"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_169"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_170"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_171"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_172"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForWarrantExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_173"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForWarrantExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_174"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForWarrantExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_175"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets" xlink:label="loc_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_176"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets" xlink:label="loc_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_177"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets" xlink:label="loc_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_178"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DirectorsMember" xlink:label="loc_blrx_DirectorsMember_179"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DirectorsMember" xlink:label="loc_blrx_DirectorsMember_180"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DirectorsMember" xlink:label="loc_blrx_DirectorsMember_181"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DirectPlacementMember" xlink:label="loc_blrx_DirectPlacementMember_182"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DirectPlacementMember" xlink:label="loc_blrx_DirectPlacementMember_183"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisallowedDeductionsTaxExemptIncomeAbstract" xlink:label="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_184"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisallowedDeductionsTaxExemptIncomeAbstract" xlink:label="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_185"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisallowedDeductionsTaxExemptIncomeAbstract" xlink:label="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_186"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory" xlink:label="loc_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_187"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory" xlink:label="loc_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_188"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory" xlink:label="loc_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_189"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory" xlink:label="loc_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_190"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory" xlink:label="loc_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_191"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory" xlink:label="loc_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_192"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_193"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_194"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_195"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_196"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_197"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_198"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_199"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_200"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_201"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_202"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_203"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_204"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_205"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_206"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_207"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_208"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_209"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_210"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_211"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_212"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_213"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_214"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_215"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_216"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_217"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_218"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_219"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_220"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_221"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_222"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_223"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_224"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_225"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_226"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_227"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_228"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_229"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_230"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_231"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_232"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_233"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_234"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_235"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_236"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_237"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_238"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_239"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_240"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_241"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_242"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_243"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_244"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLeasesLineItems" xlink:label="loc_blrx_DisclosureOfLeasesLineItems_245"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLeasesLineItems" xlink:label="loc_blrx_DisclosureOfLeasesLineItems_246"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLeasesTable" xlink:label="loc_blrx_DisclosureOfLeasesTable_247"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLeasesTable" xlink:label="loc_blrx_DisclosureOfLeasesTable_248"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory" xlink:label="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_249"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory" xlink:label="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_250"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory" xlink:label="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_251"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory" xlink:label="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_252"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory" xlink:label="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_253"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory" xlink:label="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_254"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory" xlink:label="loc_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_255"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory" xlink:label="loc_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_256"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory" xlink:label="loc_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_257"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_258"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_259"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_260"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_261"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_262"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_263"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_264"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory" xlink:label="loc_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_265"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory" xlink:label="loc_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_266"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory" xlink:label="loc_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_267"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclsoureOfAmendmentToLicenseExplanatory" xlink:label="loc_blrx_DisclsoureOfAmendmentToLicenseExplanatory_268"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclsoureOfAmendmentToLicenseExplanatory" xlink:label="loc_blrx_DisclsoureOfAmendmentToLicenseExplanatory_269"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclsoureOfAmendmentToLicenseExplanatory" xlink:label="loc_blrx_DisclsoureOfAmendmentToLicenseExplanatory_270"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DollarMember" xlink:label="loc_blrx_DollarMember_271"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DollarMember" xlink:label="loc_blrx_DollarMember_272"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EmployeesAndDirectorsMember" xlink:label="loc_blrx_EmployeesAndDirectorsMember_273"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EmployeesAndDirectorsMember" xlink:label="loc_blrx_EmployeesAndDirectorsMember_274"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EmployeesMember" xlink:label="loc_blrx_EmployeesMember_275"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EuroLinkedTradePayablesMember" xlink:label="loc_blrx_EuroLinkedTradePayablesMember_276"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EuroLinkedTradePayablesMember" xlink:label="loc_blrx_EuroLinkedTradePayablesMember_277"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EuroLinkedTradePayablesMember" xlink:label="loc_blrx_EuroLinkedTradePayablesMember_278"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EuroPerDollarMember" xlink:label="loc_blrx_EuroPerDollarMember_279"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EuroPerDollarMember" xlink:label="loc_blrx_EuroPerDollarMember_280"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EuroPerDollarMember" xlink:label="loc_blrx_EuroPerDollarMember_281"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferences" xlink:label="loc_blrx_ExchangeDifferences_282"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferences" xlink:label="loc_blrx_ExchangeDifferences_283"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferencesDuringYear" xlink:label="loc_blrx_ExchangeDifferencesDuringYear_284"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferencesDuringYear" xlink:label="loc_blrx_ExchangeDifferencesDuringYear_285"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferencesDuringYear" xlink:label="loc_blrx_ExchangeDifferencesDuringYear_286"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferencesDuringYear" xlink:label="loc_blrx_ExchangeDifferencesDuringYear_287"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferencesOnLeaseLiability" xlink:label="loc_blrx_ExchangeDifferencesOnLeaseLiability_288"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferencesOnLeaseLiability" xlink:label="loc_blrx_ExchangeDifferencesOnLeaseLiability_289"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferencesOnLeaseLiability" xlink:label="loc_blrx_ExchangeDifferencesOnLeaseLiability_290"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisableTermOfWarrant" xlink:label="loc_blrx_ExercisableTermOfWarrant_291"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisableTermOfWarrant" xlink:label="loc_blrx_ExercisableTermOfWarrant_292"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExerciseOfPricePerAds" xlink:label="loc_blrx_ExerciseOfPricePerAds_293"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExerciseOfPricePerAds" xlink:label="loc_blrx_ExerciseOfPricePerAds_294"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceOfShareIssued" xlink:label="loc_blrx_ExercisePriceOfShareIssued_295"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceOfShareIssued" xlink:label="loc_blrx_ExercisePriceOfShareIssued_296"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceOfShareIssued" xlink:label="loc_blrx_ExercisePriceOfShareIssued_297"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceOfWarrants" xlink:label="loc_blrx_ExercisePriceOfWarrants_298"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceOfWarrants" xlink:label="loc_blrx_ExercisePriceOfWarrants_299"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeFourMember" xlink:label="loc_blrx_ExercisePriceRangeFourMember_300"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeFourMember" xlink:label="loc_blrx_ExercisePriceRangeFourMember_301"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeFourMember" xlink:label="loc_blrx_ExercisePriceRangeFourMember_302"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeMember" xlink:label="loc_blrx_ExercisePriceRangeMember_303"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeMember" xlink:label="loc_blrx_ExercisePriceRangeMember_304"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeMember" xlink:label="loc_blrx_ExercisePriceRangeMember_305"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeOneMember" xlink:label="loc_blrx_ExercisePriceRangeOneMember_306"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeOneMember" xlink:label="loc_blrx_ExercisePriceRangeOneMember_307"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeOneMember" xlink:label="loc_blrx_ExercisePriceRangeOneMember_308"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeSixMember" xlink:label="loc_blrx_ExercisePriceRangeSixMember_309"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeThreeMember" xlink:label="loc_blrx_ExercisePriceRangeThreeMember_310"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeTwoMember" xlink:label="loc_blrx_ExercisePriceRangeTwoMember_311"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeTwoMember" xlink:label="loc_blrx_ExercisePriceRangeTwoMember_312"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeTwoMember" xlink:label="loc_blrx_ExercisePriceRangeTwoMember_313"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfOrdinaryWarrantsAdjustedAmount" xlink:label="loc_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_314"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfOrdinaryWarrantsAdjustedAmount" xlink:label="loc_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_315"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfOrdinaryWarrantsAdjustedAmount" xlink:label="loc_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_316"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfWarrants" xlink:label="loc_blrx_FairValueOfWarrants_317"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfWarrants" xlink:label="loc_blrx_FairValueOfWarrants_318"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfWarrants" xlink:label="loc_blrx_FairValueOfWarrants_319"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfWarrants" xlink:label="loc_blrx_FairValueOfWarrants_320"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FirstThreeYearsMember" xlink:label="loc_blrx_FirstThreeYearsMember_321"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FirstThreeYearsMember" xlink:label="loc_blrx_FirstThreeYearsMember_322"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FirstThreeYearsMember" xlink:label="loc_blrx_FirstThreeYearsMember_323"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FirstTrancheMember" xlink:label="loc_blrx_FirstTrancheMember_324"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FirstTrancheMember" xlink:label="loc_blrx_FirstTrancheMember_325"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FirstTrancheMember" xlink:label="loc_blrx_FirstTrancheMember_326"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_327"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_328"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_329"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_330"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_331"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_332"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GainOnRealizationOfLongtermInvestment" xlink:label="loc_blrx_GainOnRealizationOfLongtermInvestment_333"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GainOnRealizationOfLongtermInvestment" xlink:label="loc_blrx_GainOnRealizationOfLongtermInvestment_334"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GainOnRealizationOfLongtermInvestment" xlink:label="loc_blrx_GainOnRealizationOfLongtermInvestment_335"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GainOnRealizationOfLongtermInvestment" xlink:label="loc_blrx_GainOnRealizationOfLongtermInvestment_336"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GloriaLicenseAgreementMember" xlink:label="loc_blrx_GloriaLicenseAgreementMember_337"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GloriaLicenseAgreementMember" xlink:label="loc_blrx_GloriaLicenseAgreementMember_338"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GloriaPurchaseAgreementMember" xlink:label="loc_blrx_GloriaPurchaseAgreementMember_339"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GloriaPurchaseAgreementMember" xlink:label="loc_blrx_GloriaPurchaseAgreementMember_340"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GrossProceedsFromOffering" xlink:label="loc_blrx_GrossProceedsFromOffering_341"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GrossProceedsFromOffering" xlink:label="loc_blrx_GrossProceedsFromOffering_342"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GrossProceedsFromOffering" xlink:label="loc_blrx_GrossProceedsFromOffering_343"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HCWainwrightAndCoLlcMember" xlink:label="loc_blrx_HCWainwrightAndCoLlcMember_344"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HCWainwrightAndCoLlcMember" xlink:label="loc_blrx_HCWainwrightAndCoLlcMember_345"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HCWainwrightAndCoLlcMember" xlink:label="loc_blrx_HCWainwrightAndCoLlcMember_346"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HighbridgeCapitalManagementLlcMember" xlink:label="loc_blrx_HighbridgeCapitalManagementLlcMember_347"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HighbridgeCapitalManagementLlcMember" xlink:label="loc_blrx_HighbridgeCapitalManagementLlcMember_348"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HighbridgeMember" xlink:label="loc_blrx_HighbridgeMember_349"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HighbridgeMember" xlink:label="loc_blrx_HighbridgeMember_350"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IBridgeCapitalMember" xlink:label="loc_blrx_IBridgeCapitalMember_351"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IBridgeCapitalMember" xlink:label="loc_blrx_IBridgeCapitalMember_352"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IfrsStatementLineItems" xlink:label="loc_blrx_IfrsStatementLineItems_353"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IfrsStatementLineItems" xlink:label="loc_blrx_IfrsStatementLineItems_354"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IfrsStatementTable" xlink:label="loc_blrx_IfrsStatementTable_355"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IfrsStatementTable" xlink:label="loc_blrx_IfrsStatementTable_356"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" xlink:label="loc_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_357"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" xlink:label="loc_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_358"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" xlink:label="loc_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_359"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_360"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_361"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_362"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_363"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_364"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_365"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_366"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_367"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_368"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_369"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_370"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_371"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities" xlink:label="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_372"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities" xlink:label="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_373"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities" xlink:label="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_374"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities" xlink:label="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_375"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities" xlink:label="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_376"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities" xlink:label="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_377"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" xlink:label="loc_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_378"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" xlink:label="loc_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_379"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" xlink:label="loc_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_380"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated" xlink:label="loc_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_381"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated" xlink:label="loc_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_382"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncrementalInvestment" xlink:label="loc_blrx_IncrementalInvestment_383"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncrementalInvestment" xlink:label="loc_blrx_IncrementalInvestment_384"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncrementalInvestment" xlink:label="loc_blrx_IncrementalInvestment_385"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InitialRoyaltyTerm" xlink:label="loc_blrx_InitialRoyaltyTerm_386"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InitialRoyaltyTerm" xlink:label="loc_blrx_InitialRoyaltyTerm_387"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InitialRoyaltyTerm" xlink:label="loc_blrx_InitialRoyaltyTerm_388"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InstitutionsCurrentReceivables" xlink:label="loc_blrx_InstitutionsCurrentReceivables_389"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InstitutionsCurrentReceivables" xlink:label="loc_blrx_InstitutionsCurrentReceivables_390"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InstitutionsCurrentReceivables" xlink:label="loc_blrx_InstitutionsCurrentReceivables_391"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndExchangeDifferencesOnRestrictedDeposits" xlink:label="loc_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_392"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndExchangeDifferencesOnRestrictedDeposits" xlink:label="loc_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_393"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndExchangeDifferencesOnRestrictedDeposits" xlink:label="loc_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_394"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndExchangeDifferencesOnShortTermDeposits" xlink:label="loc_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_395"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndExchangeDifferencesOnShortTermDeposits" xlink:label="loc_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_396"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndExchangeDifferencesOnShortTermDeposits" xlink:label="loc_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_397"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndLinkageDifferencesOnBankLoan" xlink:label="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_398"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndLinkageDifferencesOnBankLoan" xlink:label="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_399"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndLinkageDifferencesOnBankLoan" xlink:label="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_400"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndLinkageDifferencesOnBankLoan" xlink:label="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_401"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses" xlink:label="loc_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_402"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses" xlink:label="loc_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_403"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses" xlink:label="loc_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_404"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestExpenseLeaseLiabilities" xlink:label="loc_blrx_InterestExpenseLeaseLiabilities_405"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestExpenseLeaseLiabilities" xlink:label="loc_blrx_InterestExpenseLeaseLiabilities_406"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestExpenseLeaseLiabilities" xlink:label="loc_blrx_InterestExpenseLeaseLiabilities_407"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestExpenses" xlink:label="loc_blrx_InterestExpenses_408"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestExpenses" xlink:label="loc_blrx_InterestExpenses_409"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestExpenses" xlink:label="loc_blrx_InterestExpenses_410"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestIncomeAndExchangeDifferences" xlink:label="loc_blrx_InterestIncomeAndExchangeDifferences_411"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestIncomeAndExchangeDifferences" xlink:label="loc_blrx_InterestIncomeAndExchangeDifferences_412"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnLongTermBankLoan" xlink:label="loc_blrx_InterestRateOnLongTermBankLoan_413"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnLongTermBankLoan" xlink:label="loc_blrx_InterestRateOnLongTermBankLoan_414"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnShortTermDeposits" xlink:label="loc_blrx_InterestRateOnShortTermDeposits_415"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnShortTermDeposits" xlink:label="loc_blrx_InterestRateOnShortTermDeposits_416"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnShortTermDeposits" xlink:label="loc_blrx_InterestRateOnShortTermDeposits_417"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents" xlink:label="loc_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_418"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents" xlink:label="loc_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_419"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents" xlink:label="loc_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_420"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InvestorsMember" xlink:label="loc_blrx_InvestorsMember_421"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InvestorsMember" xlink:label="loc_blrx_InvestorsMember_422"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuanceOfAdsValue" xlink:label="loc_blrx_IssuanceOfAdsValue_423"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuanceOfAdsValue" xlink:label="loc_blrx_IssuanceOfAdsValue_424"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuanceOfShareCapital" xlink:label="loc_blrx_IssuanceOfShareCapital_425"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuanceOfShareCapital" xlink:label="loc_blrx_IssuanceOfShareCapital_426"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuanceOfShareCapital" xlink:label="loc_blrx_IssuanceOfShareCapital_427"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuancesOfWarrants" xlink:label="loc_blrx_IssuancesOfWarrants_428"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuancesOfWarrants" xlink:label="loc_blrx_IssuancesOfWarrants_429"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuancesOfWarrants" xlink:label="loc_blrx_IssuancesOfWarrants_430"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuedAndPaidUpShareCapitalValue" xlink:label="loc_blrx_IssuedAndPaidUpShareCapitalValue_431"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuedAndPaidUpShareCapitalValue" xlink:label="loc_blrx_IssuedAndPaidUpShareCapitalValue_432"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuedAndPaidUpShareCapitalValue" xlink:label="loc_blrx_IssuedAndPaidUpShareCapitalValue_433"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_KreosLoanMember" xlink:label="loc_blrx_KreosLoanMember_434"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_KreosLoanMember" xlink:label="loc_blrx_KreosLoanMember_435"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_KreosLoanMember" xlink:label="loc_blrx_KreosLoanMember_436"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LaboratoryEquipmentMember" xlink:label="loc_blrx_LaboratoryEquipmentMember_437"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LaboratoryEquipmentMember" xlink:label="loc_blrx_LaboratoryEquipmentMember_438"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LawsuitClaimAmount" xlink:label="loc_blrx_LawsuitClaimAmount_439"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LawsuitClaimAmount" xlink:label="loc_blrx_LawsuitClaimAmount_440"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LawsuitClaimAmount" xlink:label="loc_blrx_LawsuitClaimAmount_441"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LeaseAgreementMonthlyFee" xlink:label="loc_blrx_LeaseAgreementMonthlyFee_442"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LeaseAgreementMonthlyFee" xlink:label="loc_blrx_LeaseAgreementMonthlyFee_443"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LeasePeriod" xlink:label="loc_blrx_LeasePeriod_444"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LeasePeriod" xlink:label="loc_blrx_LeasePeriod_445"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAgreementMember" xlink:label="loc_blrx_LicenseAgreementMember_446"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAgreementMember" xlink:label="loc_blrx_LicenseAgreementMember_447"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_448"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_449"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_450"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseFeesAndRoyaltiesPayableToLicensor" xlink:label="loc_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_451"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseFeesAndRoyaltiesPayableToLicensor" xlink:label="loc_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_452"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseFeesAndRoyaltiesPayableToLicensor" xlink:label="loc_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_453"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseRevenues" xlink:label="loc_blrx_LicenseRevenues_454"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseRevenues" xlink:label="loc_blrx_LicenseRevenues_455"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseRevenues" xlink:label="loc_blrx_LicenseRevenues_456"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LincolnParkCapitalFundMember" xlink:label="loc_blrx_LincolnParkCapitalFundMember_457"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LoanAgreementWithKreosCapitalMember" xlink:label="loc_blrx_LoanAgreementWithKreosCapitalMember_458"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LoanAgreementWithKreosCapitalMember" xlink:label="loc_blrx_LoanAgreementWithKreosCapitalMember_459"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LoanTakenForPaymentOfAgreementValue" xlink:label="loc_blrx_LoanTakenForPaymentOfAgreementValue_460"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LoanTakenForPaymentOfAgreementValue" xlink:label="loc_blrx_LoanTakenForPaymentOfAgreementValue_461"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LoanTakenForPaymentOfAgreementValue" xlink:label="loc_blrx_LoanTakenForPaymentOfAgreementValue_462"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LongTermPrepaidExpenses" xlink:label="loc_blrx_LongTermPrepaidExpenses_463"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LongTermPrepaidExpenses" xlink:label="loc_blrx_LongTermPrepaidExpenses_464"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LongTermPrepaidExpenses" xlink:label="loc_blrx_LongTermPrepaidExpenses_465"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LossOnAbandonmentOfRightofuseAsset" xlink:label="loc_blrx_LossOnAbandonmentOfRightofuseAsset_466"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LossOnAbandonmentOfRightofuseAsset" xlink:label="loc_blrx_LossOnAbandonmentOfRightofuseAsset_467"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LossOnAbandonmentOfRightofuseAsset" xlink:label="loc_blrx_LossOnAbandonmentOfRightofuseAsset_468"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketAccessExpense" xlink:label="loc_blrx_MarketAccessExpense_469"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketAccessExpense" xlink:label="loc_blrx_MarketAccessExpense_470"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketAccessExpense" xlink:label="loc_blrx_MarketAccessExpense_471"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketingExpenses" xlink:label="loc_blrx_MarketingExpenses_472"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketingExpenses" xlink:label="loc_blrx_MarketingExpenses_473"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketingExpenses" xlink:label="loc_blrx_MarketingExpenses_474"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketSharePrice" xlink:label="loc_blrx_MarketSharePrice_475"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketSharePrice" xlink:label="loc_blrx_MarketSharePrice_476"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketSharePrice" xlink:label="loc_blrx_MarketSharePrice_477"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturitiesOfRestrictedDeposits" xlink:label="loc_blrx_MaturitiesOfRestrictedDeposits_478"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturitiesOfRestrictedDeposits" xlink:label="loc_blrx_MaturitiesOfRestrictedDeposits_479"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturitiesOfRestrictedDeposits" xlink:label="loc_blrx_MaturitiesOfRestrictedDeposits_480"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturitiesOfShortTermDeposits" xlink:label="loc_blrx_MaturitiesOfShortTermDeposits_481"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturitiesOfShortTermDeposits" xlink:label="loc_blrx_MaturitiesOfShortTermDeposits_482"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturitiesOfShortTermDeposits" xlink:label="loc_blrx_MaturitiesOfShortTermDeposits_483"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturityDate" xlink:label="loc_blrx_MaturityDate_484"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturityDate" xlink:label="loc_blrx_MaturityDate_485"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturityDate" xlink:label="loc_blrx_MaturityDate_486"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaximumFutureMilestonePayments" xlink:label="loc_blrx_MaximumFutureMilestonePayments_487"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaximumFutureMilestonePayments" xlink:label="loc_blrx_MaximumFutureMilestonePayments_488"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaximumFutureMilestonePayments" xlink:label="loc_blrx_MaximumFutureMilestonePayments_489"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MedicalAffairs" xlink:label="loc_blrx_MedicalAffairs_490"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MedicalAffairs" xlink:label="loc_blrx_MedicalAffairs_491"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MinimumCashBalanceRequirementUnderLoanAgreement" xlink:label="loc_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_492"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MinimumCashBalanceRequirementUnderLoanAgreement" xlink:label="loc_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_493"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MinimumCashBalanceRequirementUnderLoanAgreement" xlink:label="loc_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_494"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MonthlyAdvisoryFee" xlink:label="loc_blrx_MonthlyAdvisoryFee_495"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MonthlyAdvisoryFee" xlink:label="loc_blrx_MonthlyAdvisoryFee_496"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MonthlyAdvisoryFee" xlink:label="loc_blrx_MonthlyAdvisoryFee_497"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetAssetValueOfLinkageMonetaryItems" xlink:label="loc_blrx_NetAssetValueOfLinkageMonetaryItems_498"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetAssetValueOfLinkageMonetaryItems" xlink:label="loc_blrx_NetAssetValueOfLinkageMonetaryItems_499"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetAssetValueOfLinkageMonetaryItems" xlink:label="loc_blrx_NetAssetValueOfLinkageMonetaryItems_500"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetAssetValueOfLinkageMonetaryItems" xlink:label="loc_blrx_NetAssetValueOfLinkageMonetaryItems_501"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_502"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_503"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_504"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetMember" xlink:label="loc_blrx_NetMember_505"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetMember" xlink:label="loc_blrx_NetMember_506"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetMember" xlink:label="loc_blrx_NetMember_507"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisLinkedBalancesMember" xlink:label="loc_blrx_NisLinkedBalancesMember_508"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisLinkedBalancesMember" xlink:label="loc_blrx_NisLinkedBalancesMember_509"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisLinkedBalancesMember" xlink:label="loc_blrx_NisLinkedBalancesMember_510"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisMember" xlink:label="loc_blrx_NisMember_511"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisMember" xlink:label="loc_blrx_NisMember_512"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisPerDollarMember" xlink:label="loc_blrx_NisPerDollarMember_513"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisPerDollarMember" xlink:label="loc_blrx_NisPerDollarMember_514"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisPerDollarMember" xlink:label="loc_blrx_NisPerDollarMember_515"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NonOperatingExpense" xlink:label="loc_blrx_NonOperatingExpense_516"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NonOperatingExpense" xlink:label="loc_blrx_NonOperatingExpense_517"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NovartisPharmaMember" xlink:label="loc_blrx_NovartisPharmaMember_518"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfAmericanDepositarySharesIssuedToInvestors" xlink:label="loc_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_519"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfAmericanDepositarySharesIssuedToInvestors" xlink:label="loc_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_520"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfAmericanDepositarySharesIssuedToInvestors" xlink:label="loc_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_521"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfNewSharesIssued" xlink:label="loc_blrx_NumberOfNewSharesIssued_522"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfNewSharesIssued" xlink:label="loc_blrx_NumberOfNewSharesIssued_523"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfNewSharesIssued" xlink:label="loc_blrx_NumberOfNewSharesIssued_524"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfNewSharesIssued" xlink:label="loc_blrx_NumberOfNewSharesIssued_525"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfOptionsAbstract" xlink:label="loc_blrx_NumberOfOptionsAbstract_526"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfOptionsAbstract" xlink:label="loc_blrx_NumberOfOptionsAbstract_527"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfOptionsAbstract" xlink:label="loc_blrx_NumberOfOptionsAbstract_528"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfOrdinarySharesAbstract" xlink:label="loc_blrx_NumberOfOrdinarySharesAbstract_529"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfOrdinarySharesAbstract" xlink:label="loc_blrx_NumberOfOrdinarySharesAbstract_530"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfOrdinarySharesAbstract" xlink:label="loc_blrx_NumberOfOrdinarySharesAbstract_531"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds" xlink:label="loc_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_532"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds" xlink:label="loc_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_533"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds" xlink:label="loc_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_534"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfPremises" xlink:label="loc_blrx_NumberOfPremises_535"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfPremises" xlink:label="loc_blrx_NumberOfPremises_536"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfPremises" xlink:label="loc_blrx_NumberOfPremises_537"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfSegments" xlink:label="loc_blrx_NumberOfSegments_538"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfSegments" xlink:label="loc_blrx_NumberOfSegments_539"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfSegments" xlink:label="loc_blrx_NumberOfSegments_540"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfWarrantPurchase" xlink:label="loc_blrx_NumberOfWarrantPurchase_541"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfWarrantPurchase" xlink:label="loc_blrx_NumberOfWarrantPurchase_542"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OberonSecuritiesMember" xlink:label="loc_blrx_OberonSecuritiesMember_543"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OfferingToInstitutionalInvestorsMember" xlink:label="loc_blrx_OfferingToInstitutionalInvestorsMember_544"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OfferingToInstitutionalInvestorsMember" xlink:label="loc_blrx_OfferingToInstitutionalInvestorsMember_545"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OpenPurchaseOrderCommitments" xlink:label="loc_blrx_OpenPurchaseOrderCommitments_546"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OpenPurchaseOrderCommitments" xlink:label="loc_blrx_OpenPurchaseOrderCommitments_547"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OpenPurchaseOrderCommitments" xlink:label="loc_blrx_OpenPurchaseOrderCommitments_548"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OrbiMedAdvisorsMember" xlink:label="loc_blrx_OrbiMedAdvisorsMember_549"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherComprehensiveIncomeLossMember" xlink:label="loc_blrx_OtherComprehensiveIncomeLossMember_550"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherComprehensiveIncomeLossMember" xlink:label="loc_blrx_OtherComprehensiveIncomeLossMember_551"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherComprehensiveIncomeLossMember" xlink:label="loc_blrx_OtherComprehensiveIncomeLossMember_552"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherCurrenciesMember" xlink:label="loc_blrx_OtherCurrenciesMember_553"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherCurrenciesMember" xlink:label="loc_blrx_OtherCurrenciesMember_554"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherCurrenciesMember" xlink:label="loc_blrx_OtherCurrenciesMember_555"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherNonoperatingIncomeExpenses" xlink:label="loc_blrx_OtherNonoperatingIncomeExpenses_556"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherNonoperatingIncomeExpenses" xlink:label="loc_blrx_OtherNonoperatingIncomeExpenses_557"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherNonoperatingIncomeExpenses" xlink:label="loc_blrx_OtherNonoperatingIncomeExpenses_558"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherPayablesAbstract" xlink:label="loc_blrx_OtherPayablesAbstract_559"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherPayablesAbstract" xlink:label="loc_blrx_OtherPayablesAbstract_560"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherPayablesAbstract" xlink:label="loc_blrx_OtherPayablesAbstract_561"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherPayablesMember" xlink:label="loc_blrx_OtherPayablesMember_562"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherPayablesMember" xlink:label="loc_blrx_OtherPayablesMember_563"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherPayablesMember" xlink:label="loc_blrx_OtherPayablesMember_564"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherReceivablesMember" xlink:label="loc_blrx_OtherReceivablesMember_565"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherReceivablesMember" xlink:label="loc_blrx_OtherReceivablesMember_566"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherReceivablesMember" xlink:label="loc_blrx_OtherReceivablesMember_567"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Others" xlink:label="loc_blrx_Others_568"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Others" xlink:label="loc_blrx_Others_569"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Others" xlink:label="loc_blrx_Others_570"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PaymentsLeaseLiabilities" xlink:label="loc_blrx_PaymentsLeaseLiabilities_571"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PaymentsLeaseLiabilities" xlink:label="loc_blrx_PaymentsLeaseLiabilities_572"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PaymentsLeaseLiabilities" xlink:label="loc_blrx_PaymentsLeaseLiabilities_573"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PaymentsLeaseLiabilities" xlink:label="loc_blrx_PaymentsLeaseLiabilities_574"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PayrollAndRelatedExpenses" xlink:label="loc_blrx_PayrollAndRelatedExpenses_575"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PayrollAndRelatedExpenses" xlink:label="loc_blrx_PayrollAndRelatedExpenses_576"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PayrollAndRelatedExpenses" xlink:label="loc_blrx_PayrollAndRelatedExpenses_577"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PDACPerformanceObligationMember" xlink:label="loc_blrx_PDACPerformanceObligationMember_578"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PDACPerformanceObligationMember" xlink:label="loc_blrx_PDACPerformanceObligationMember_579"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PDACPerformanceObligationMember" xlink:label="loc_blrx_PDACPerformanceObligationMember_580"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageIncreaseDecreaseInExchangeRate" xlink:label="loc_blrx_PercentageIncreaseDecreaseInExchangeRate_581"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageIncreaseDecreaseInExchangeRate" xlink:label="loc_blrx_PercentageIncreaseDecreaseInExchangeRate_582"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageIncreaseDecreaseInExchangeRate" xlink:label="loc_blrx_PercentageIncreaseDecreaseInExchangeRate_583"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageIncreasePrecedingLeasePaymentAmount" xlink:label="loc_blrx_PercentageIncreasePrecedingLeasePaymentAmount_584"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageIncreasePrecedingLeasePaymentAmount" xlink:label="loc_blrx_PercentageIncreasePrecedingLeasePaymentAmount_585"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfAdditionalEquityInterest" xlink:label="loc_blrx_PercentageOfAdditionalEquityInterest_586"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfAdditionalEquityInterest" xlink:label="loc_blrx_PercentageOfAdditionalEquityInterest_587"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfAdditionalEquityInterest" xlink:label="loc_blrx_PercentageOfAdditionalEquityInterest_588"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfAnnualInterestOfCashFees" xlink:label="loc_blrx_PercentageOfAnnualInterestOfCashFees_589"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfAnnualInterestOfCashFees" xlink:label="loc_blrx_PercentageOfAnnualInterestOfCashFees_590"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfAnnualInterestOfCashFees" xlink:label="loc_blrx_PercentageOfAnnualInterestOfCashFees_591"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfCommissionOnSalesAgreement" xlink:label="loc_blrx_PercentageOfCommissionOnSalesAgreement_592"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfCommissionOnSalesAgreement" xlink:label="loc_blrx_PercentageOfCommissionOnSalesAgreement_593"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfDecreasingAnnualGrowthRate" xlink:label="loc_blrx_PercentageOfDecreasingAnnualGrowthRate_594"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfDecreasingAnnualGrowthRate" xlink:label="loc_blrx_PercentageOfDecreasingAnnualGrowthRate_595"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfDecreasingAnnualGrowthRate" xlink:label="loc_blrx_PercentageOfDecreasingAnnualGrowthRate_596"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfFutureMilestonePayments" xlink:label="loc_blrx_PercentageOfFutureMilestonePayments_597"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfFutureMilestonePayments" xlink:label="loc_blrx_PercentageOfFutureMilestonePayments_598"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfFutureMilestonePayments" xlink:label="loc_blrx_PercentageOfFutureMilestonePayments_599"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIncreasingWeightedAverageCostOfCapital" xlink:label="loc_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_600"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIncreasingWeightedAverageCostOfCapital" xlink:label="loc_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_601"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIncreasingWeightedAverageCostOfCapital" xlink:label="loc_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_602"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIssuedShareCapitalReceived" xlink:label="loc_blrx_PercentageOfIssuedShareCapitalReceived_603"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIssuedShareCapitalReceived" xlink:label="loc_blrx_PercentageOfIssuedShareCapitalReceived_604"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIssuedShareCapitalReceived" xlink:label="loc_blrx_PercentageOfIssuedShareCapitalReceived_605"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths" xlink:label="loc_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_606"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths" xlink:label="loc_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_607"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths" xlink:label="loc_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_608"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedForDirectProductSales" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_609"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedForDirectProductSales" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_610"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedForSubLicense" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedForSubLicense_611"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedForSubLicense" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedForSubLicense_612"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedFromLicensee" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedFromLicensee_613"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedFromLicensee" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedFromLicensee_614"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfOwnershipStake" xlink:label="loc_blrx_PercentageOfOwnershipStake_615"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfOwnershipStake" xlink:label="loc_blrx_PercentageOfOwnershipStake_616"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfOwnershipStake" xlink:label="loc_blrx_PercentageOfOwnershipStake_617"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfPaymentToBeMade" xlink:label="loc_blrx_PercentageOfPaymentToBeMade_618"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfPaymentToBeMade" xlink:label="loc_blrx_PercentageOfPaymentToBeMade_619"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfPaymentToBeMade" xlink:label="loc_blrx_PercentageOfPaymentToBeMade_620"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfReducePaymentOwedOnSublicenseReceipts" xlink:label="loc_blrx_PercentageOfReducePaymentOwedOnSublicenseReceipts_621"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfReducePaymentOwedOnSublicenseReceipts" xlink:label="loc_blrx_PercentageOfReducePaymentOwedOnSublicenseReceipts_622"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales" xlink:label="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_623"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales" xlink:label="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_624"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales" xlink:label="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_625"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceSharesUnitMember" xlink:label="loc_blrx_PerformanceSharesUnitMember_626"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceSharesUnitMember" xlink:label="loc_blrx_PerformanceSharesUnitMember_627"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceStockUnitsMember" xlink:label="loc_blrx_PerformanceStockUnitsMember_628"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PhaseThreeMember" xlink:label="loc_blrx_PhaseThreeMember_629"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PhaseTwoMember" xlink:label="loc_blrx_PhaseTwoMember_630"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PlacementAgentOfferingMember" xlink:label="loc_blrx_PlacementAgentOfferingMember_631"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PlacementAgentOfferingMember" xlink:label="loc_blrx_PlacementAgentOfferingMember_632"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PlacementAgentsDesigneesMember" xlink:label="loc_blrx_PlacementAgentsDesigneesMember_633"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PlacementAgentsDesigneesMember" xlink:label="loc_blrx_PlacementAgentsDesigneesMember_634"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedOrOrdinaryWarrantsExerciseTerms" xlink:label="loc_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_635"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedOrOrdinaryWarrantsExerciseTerms" xlink:label="loc_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_636"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedOrOrdinaryWarrantsExerciseTerms" xlink:label="loc_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_637"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantPurchasePricePerShare" xlink:label="loc_blrx_PreFundedWarrantPurchasePricePerShare_638"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantPurchasePricePerShare" xlink:label="loc_blrx_PreFundedWarrantPurchasePricePerShare_639"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantPurchasePricePerShare" xlink:label="loc_blrx_PreFundedWarrantPurchasePricePerShare_640"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrants" xlink:label="loc_blrx_PreFundedWarrants_641"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrants" xlink:label="loc_blrx_PreFundedWarrants_642"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantsExercisablePricePerAds" xlink:label="loc_blrx_PreFundedWarrantsExercisablePricePerAds_643"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantsExercisablePricePerAds" xlink:label="loc_blrx_PreFundedWarrantsExercisablePricePerAds_644"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantsExercisablePricePerAds" xlink:label="loc_blrx_PreFundedWarrantsExercisablePricePerAds_645"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantsExercisePricePerAds" xlink:label="loc_blrx_PreFundedWarrantsExercisePricePerAds_646"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantsExercisePricePerAds" xlink:label="loc_blrx_PreFundedWarrantsExercisePricePerAds_647"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantsExercisePricePerAds" xlink:label="loc_blrx_PreFundedWarrantsExercisePricePerAds_648"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantsMember" xlink:label="loc_blrx_PreFundedWarrantsMember_649"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantsMember" xlink:label="loc_blrx_PreFundedWarrantsMember_650"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses" xlink:label="loc_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_651"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses" xlink:label="loc_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_652"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses" xlink:label="loc_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_653"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromExerciseWarrants" xlink:label="loc_blrx_ProceedsFromExerciseWarrants_654"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromExerciseWarrants" xlink:label="loc_blrx_ProceedsFromExerciseWarrants_655"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromExerciseWarrants" xlink:label="loc_blrx_ProceedsFromExerciseWarrants_656"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromIssuanceOfInitialPublicOffering" xlink:label="loc_blrx_ProceedsFromIssuanceOfInitialPublicOffering_657"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromIssuanceOfInitialPublicOffering" xlink:label="loc_blrx_ProceedsFromIssuanceOfInitialPublicOffering_658"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromIssuanceOfInitialPublicOffering" xlink:label="loc_blrx_ProceedsFromIssuanceOfInitialPublicOffering_659"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet" xlink:label="loc_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_660"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet" xlink:label="loc_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_661"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet" xlink:label="loc_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_662"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromWarrantIssue" xlink:label="loc_blrx_ProceedsFromWarrantIssue_663"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromWarrantIssue" xlink:label="loc_blrx_ProceedsFromWarrantIssue_664"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromWarrantIssue" xlink:label="loc_blrx_ProceedsFromWarrantIssue_665"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProductSalesNet" xlink:label="loc_blrx_ProductSalesNet_666"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProductSalesNet" xlink:label="loc_blrx_ProductSalesNet_667"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProductSalesNet" xlink:label="loc_blrx_ProductSalesNet_668"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfessionalFee" xlink:label="loc_blrx_ProfessionalFee_669"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfessionalFee" xlink:label="loc_blrx_ProfessionalFee_670"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfessionalFee" xlink:label="loc_blrx_ProfessionalFee_671"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfitLossFromNonOperatingActivities" xlink:label="loc_blrx_ProfitLossFromNonOperatingActivities_672"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfitLossFromNonOperatingActivities" xlink:label="loc_blrx_ProfitLossFromNonOperatingActivities_673"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfitLossFromNonOperatingActivities" xlink:label="loc_blrx_ProfitLossFromNonOperatingActivities_674"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfitLossFromNonOperatingActivities" xlink:label="loc_blrx_ProfitLossFromNonOperatingActivities_675"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProvisionForDoubtfulAccountsReceivable" xlink:label="loc_blrx_ProvisionForDoubtfulAccountsReceivable_676"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProvisionForDoubtfulAccountsReceivable" xlink:label="loc_blrx_ProvisionForDoubtfulAccountsReceivable_677"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProvisionForDoubtfulAccountsReceivable" xlink:label="loc_blrx_ProvisionForDoubtfulAccountsReceivable_678"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProvisionForDoubtfulAccountsReceivable" xlink:label="loc_blrx_ProvisionForDoubtfulAccountsReceivable_679"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PublicOfferingMember" xlink:label="loc_blrx_PublicOfferingMember_680"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PublicOfferingMember" xlink:label="loc_blrx_PublicOfferingMember_681"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchaseAgreementMember" xlink:label="loc_blrx_PurchaseAgreementMember_682"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchaseAgreementMember" xlink:label="loc_blrx_PurchaseAgreementMember_683"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchaseAgreementPeriod" xlink:label="loc_blrx_PurchaseAgreementPeriod_684"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchaseAgreementPeriod" xlink:label="loc_blrx_PurchaseAgreementPeriod_685"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchasePricePerADS" xlink:label="loc_blrx_PurchasePricePerADS_686"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchasePricePerADS" xlink:label="loc_blrx_PurchasePricePerADS_687"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchasePricePerADS" xlink:label="loc_blrx_PurchasePricePerADS_688"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RecognizedAsEquity" xlink:label="loc_blrx_RecognizedAsEquity_689"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RecognizedAsEquity" xlink:label="loc_blrx_RecognizedAsEquity_690"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RecognizedAsEquity" xlink:label="loc_blrx_RecognizedAsEquity_691"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RegisteredDirectOfferingMember" xlink:label="loc_blrx_RegisteredDirectOfferingMember_692"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RegisteredDirectOfferingMember" xlink:label="loc_blrx_RegisteredDirectOfferingMember_693"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RemainingAuthorizedUnissuedOrdinaryShares" xlink:label="loc_blrx_RemainingAuthorizedUnissuedOrdinaryShares_694"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RemainingAuthorizedUnissuedOrdinaryShares" xlink:label="loc_blrx_RemainingAuthorizedUnissuedOrdinaryShares_695"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RemainingUnrecognizedDeferredCompensationExpense" xlink:label="loc_blrx_RemainingUnrecognizedDeferredCompensationExpense_696"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RemainingUnrecognizedDeferredCompensationExpense" xlink:label="loc_blrx_RemainingUnrecognizedDeferredCompensationExpense_697"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RepaymentOfLongTermDebtAfterOneYear" xlink:label="loc_blrx_RepaymentOfLongTermDebtAfterOneYear_698"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RepaymentOfLongTermDebtAfterOneYear" xlink:label="loc_blrx_RepaymentOfLongTermDebtAfterOneYear_699"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RepaymentOfLongTermDebtAfterOneYear" xlink:label="loc_blrx_RepaymentOfLongTermDebtAfterOneYear_700"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RepaymentOfLongTermDebtYearsTwo" xlink:label="loc_blrx_RepaymentOfLongTermDebtYearsTwo_701"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RepaymentOfLongTermDebtYearsTwo" xlink:label="loc_blrx_RepaymentOfLongTermDebtYearsTwo_702"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RepaymentOfLongTermDebtYearsTwo" xlink:label="loc_blrx_RepaymentOfLongTermDebtYearsTwo_703"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019" xlink:label="loc_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_704"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019" xlink:label="loc_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_705"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019" xlink:label="loc_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_706"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RightOfUseAssetWrittenOff" xlink:label="loc_blrx_RightOfUseAssetWrittenOff_707"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RightOfUseAssetWrittenOff" xlink:label="loc_blrx_RightOfUseAssetWrittenOff_708"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RightOfUseAssetWrittenOff" xlink:label="loc_blrx_RightOfUseAssetWrittenOff_709"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesEligibleMargin" xlink:label="loc_blrx_RoyaltiesEligibleMargin_710"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesEligibleMargin" xlink:label="loc_blrx_RoyaltiesEligibleMargin_711"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesEligibleMargin" xlink:label="loc_blrx_RoyaltiesEligibleMargin_712"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesOnSale" xlink:label="loc_blrx_RoyaltiesOnSale_713"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesOnSale" xlink:label="loc_blrx_RoyaltiesOnSale_714"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesPaymentPercentage" xlink:label="loc_blrx_RoyaltiesPaymentPercentage_715"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesPaymentPercentage" xlink:label="loc_blrx_RoyaltiesPaymentPercentage_716"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesPaymentPercentage" xlink:label="loc_blrx_RoyaltiesPaymentPercentage_717"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts" xlink:label="loc_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_718"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts" xlink:label="loc_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_719"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts" xlink:label="loc_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_720"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesRateOnNetSales" xlink:label="loc_blrx_RoyaltiesRateOnNetSales_721"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesRateOnNetSales" xlink:label="loc_blrx_RoyaltiesRateOnNetSales_722"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesReceivedPercentage" xlink:label="loc_blrx_RoyaltiesReceivedPercentage_723"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesReceivedPercentage" xlink:label="loc_blrx_RoyaltiesReceivedPercentage_724"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SaleOfStockNumberOfSharesIssued" xlink:label="loc_blrx_SaleOfStockNumberOfSharesIssued_725"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SaleOfStockNumberOfSharesIssued" xlink:label="loc_blrx_SaleOfStockNumberOfSharesIssued_726"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SaleOfStockNumberOfSharesIssued" xlink:label="loc_blrx_SaleOfStockNumberOfSharesIssued_727"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingDepreciationAndAmortization" xlink:label="loc_blrx_SalesAndMarketingDepreciationAndAmortization_728"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingDepreciationAndAmortization" xlink:label="loc_blrx_SalesAndMarketingDepreciationAndAmortization_729"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingDepreciationAndAmortization" xlink:label="loc_blrx_SalesAndMarketingDepreciationAndAmortization_730"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingExpensesOther" xlink:label="loc_blrx_SalesAndMarketingExpensesOther_731"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingExpensesOther" xlink:label="loc_blrx_SalesAndMarketingExpensesOther_732"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingExpensesOther" xlink:label="loc_blrx_SalesAndMarketingExpensesOther_733"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingExpensesRelatedToSales" xlink:label="loc_blrx_SalesAndMarketingExpensesRelatedToSales_734"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingExpensesRelatedToSales" xlink:label="loc_blrx_SalesAndMarketingExpensesRelatedToSales_735"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingExpensesRelatedToSales" xlink:label="loc_blrx_SalesAndMarketingExpensesRelatedToSales_736"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingPayrollExpense" xlink:label="loc_blrx_SalesAndMarketingPayrollExpense_737"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingPayrollExpense" xlink:label="loc_blrx_SalesAndMarketingPayrollExpense_738"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingPayrollExpense" xlink:label="loc_blrx_SalesAndMarketingPayrollExpense_739"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingProfessionalFees" xlink:label="loc_blrx_SalesAndMarketingProfessionalFees_740"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingProfessionalFees" xlink:label="loc_blrx_SalesAndMarketingProfessionalFees_741"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingProfessionalFees" xlink:label="loc_blrx_SalesAndMarketingProfessionalFees_742"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingShareBasedCompensation" xlink:label="loc_blrx_SalesAndMarketingShareBasedCompensation_743"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingShareBasedCompensation" xlink:label="loc_blrx_SalesAndMarketingShareBasedCompensation_744"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingShareBasedCompensation" xlink:label="loc_blrx_SalesAndMarketingShareBasedCompensation_745"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesMilestoneAmount" xlink:label="loc_blrx_SalesMilestoneAmount_746"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesMilestoneAmount" xlink:label="loc_blrx_SalesMilestoneAmount_747"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesMilestoneAmount" xlink:label="loc_blrx_SalesMilestoneAmount_748"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ScmLicenseMember" xlink:label="loc_blrx_ScmLicenseMember_749"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ScmLicenseMember" xlink:label="loc_blrx_ScmLicenseMember_750"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ScmLicenseMember" xlink:label="loc_blrx_ScmLicenseMember_751"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ScmSupportServicesMember" xlink:label="loc_blrx_ScmSupportServicesMember_752"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ScmSupportServicesMember" xlink:label="loc_blrx_ScmSupportServicesMember_753"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ScmSupportServicesMember" xlink:label="loc_blrx_ScmSupportServicesMember_754"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SecondTrancheMember" xlink:label="loc_blrx_SecondTrancheMember_755"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SecondTrancheMember" xlink:label="loc_blrx_SecondTrancheMember_756"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SecondTrancheMember" xlink:label="loc_blrx_SecondTrancheMember_757"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeniorManagementMember" xlink:label="loc_blrx_SeniorManagementMember_758"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeniorManagementMember" xlink:label="loc_blrx_SeniorManagementMember_759"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SensitivityTestsDecreasingAnnualGrowthRate" xlink:label="loc_blrx_SensitivityTestsDecreasingAnnualGrowthRate_760"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SensitivityTestsDecreasingAnnualGrowthRate" xlink:label="loc_blrx_SensitivityTestsDecreasingAnnualGrowthRate_761"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SensitivityTestsDecreasingAnnualGrowthRate" xlink:label="loc_blrx_SensitivityTestsDecreasingAnnualGrowthRate_762"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SensitivityTestsIncreasingAnnualGrowthRate" xlink:label="loc_blrx_SensitivityTestsIncreasingAnnualGrowthRate_763"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SensitivityTestsIncreasingAnnualGrowthRate" xlink:label="loc_blrx_SensitivityTestsIncreasingAnnualGrowthRate_764"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SensitivityTestsIncreasingAnnualGrowthRate" xlink:label="loc_blrx_SensitivityTestsIncreasingAnnualGrowthRate_765"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeriesAWarrantsMember" xlink:label="loc_blrx_SeriesAWarrantsMember_766"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeriesAWarrantsMember" xlink:label="loc_blrx_SeriesAWarrantsMember_767"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeriesBWarrantMember" xlink:label="loc_blrx_SeriesBWarrantMember_768"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeriesBWarrantMember" xlink:label="loc_blrx_SeriesBWarrantMember_769"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeriesBWarrantMember" xlink:label="loc_blrx_SeriesBWarrantMember_770"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeventhYearMember" xlink:label="loc_blrx_SeventhYearMember_771"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeventhYearMember" xlink:label="loc_blrx_SeventhYearMember_772"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeventhYearMember" xlink:label="loc_blrx_SeventhYearMember_773"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses" xlink:label="loc_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_774"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses" xlink:label="loc_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_775"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses" xlink:label="loc_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_776"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareBasedCompensationRelatedToResearchAndDevelopment" xlink:label="loc_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_777"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareBasedCompensationRelatedToResearchAndDevelopment" xlink:label="loc_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_778"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareBasedCompensationRelatedToResearchAndDevelopment" xlink:label="loc_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_779"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIncentivePlanMember" xlink:label="loc_blrx_ShareIncentivePlanMember_780"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIncentivePlanMember" xlink:label="loc_blrx_ShareIncentivePlanMember_781"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIncentivePlanMember" xlink:label="loc_blrx_ShareIncentivePlanMember_782"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedAsAdditionalCommitmentFee" xlink:label="loc_blrx_ShareIssuedAsAdditionalCommitmentFee_783"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedAsAdditionalCommitmentFee" xlink:label="loc_blrx_ShareIssuedAsAdditionalCommitmentFee_784"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedOfPublicOffering" xlink:label="loc_blrx_ShareIssuedOfPublicOffering_785"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedOfPublicOffering" xlink:label="loc_blrx_ShareIssuedOfPublicOffering_786"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedOfPublicOffering" xlink:label="loc_blrx_ShareIssuedOfPublicOffering_787"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedToPurchaseWarrant" xlink:label="loc_blrx_ShareIssuedToPurchaseWarrant_788"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedToPurchaseWarrant" xlink:label="loc_blrx_ShareIssuedToPurchaseWarrant_789"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedToPurchaseWarrant" xlink:label="loc_blrx_ShareIssuedToPurchaseWarrant_790"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePremiumResultingFromExerciseOfWarrants" xlink:label="loc_blrx_SharePremiumResultingFromExerciseOfWarrants_791"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePremiumResultingFromExerciseOfWarrants" xlink:label="loc_blrx_SharePremiumResultingFromExerciseOfWarrants_792"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePremiumResultingFromExerciseOfWarrants" xlink:label="loc_blrx_SharePremiumResultingFromExerciseOfWarrants_793"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreement" xlink:label="loc_blrx_SharePurchaseAgreement_794"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreement" xlink:label="loc_blrx_SharePurchaseAgreement_795"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreementMember" xlink:label="loc_blrx_SharePurchaseAgreementMember_796"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreementMember" xlink:label="loc_blrx_SharePurchaseAgreementMember_797"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreementShares" xlink:label="loc_blrx_SharePurchaseAgreementShares_798"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreementShares" xlink:label="loc_blrx_SharePurchaseAgreementShares_799"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharesIssuedRegisteredDirectOfferings" xlink:label="loc_blrx_SharesIssuedRegisteredDirectOfferings_800"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharesIssuedRegisteredDirectOfferings" xlink:label="loc_blrx_SharesIssuedRegisteredDirectOfferings_801"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharesIssuedRegisteredDirectOfferings" xlink:label="loc_blrx_SharesIssuedRegisteredDirectOfferings_802"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShortTermDepositMember" xlink:label="loc_blrx_ShortTermDepositMember_803"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShortTermDepositMember" xlink:label="loc_blrx_ShortTermDepositMember_804"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShortTermDepositMember" xlink:label="loc_blrx_ShortTermDepositMember_805"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SingleMaterialPerformanceObligationMember" xlink:label="loc_blrx_SingleMaterialPerformanceObligationMember_806"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SingleMaterialPerformanceObligationMember" xlink:label="loc_blrx_SingleMaterialPerformanceObligationMember_807"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_StockIssuedPricePerShare" xlink:label="loc_blrx_StockIssuedPricePerShare_808"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_StockIssuedPricePerShare" xlink:label="loc_blrx_StockIssuedPricePerShare_809"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_StockIssuedPricePerShare" xlink:label="loc_blrx_StockIssuedPricePerShare_810"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementalInformationOnInterestPaidInCash" xlink:label="loc_blrx_SupplementalInformationOnInterestPaidInCash_811"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementalInformationOnInterestPaidInCash" xlink:label="loc_blrx_SupplementalInformationOnInterestPaidInCash_812"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementalInformationOnInterestPaidInCash" xlink:label="loc_blrx_SupplementalInformationOnInterestPaidInCash_813"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementalInformationOnNoncashTransactionsAbstract" xlink:label="loc_blrx_SupplementalInformationOnNoncashTransactionsAbstract_814"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementalInformationOnNoncashTransactionsAbstract" xlink:label="loc_blrx_SupplementalInformationOnNoncashTransactionsAbstract_815"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementalInformationOnNoncashTransactionsAbstract" xlink:label="loc_blrx_SupplementalInformationOnNoncashTransactionsAbstract_816"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities" xlink:label="loc_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_817"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities" xlink:label="loc_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_818"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities" xlink:label="loc_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_819"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnFairValueOfExercisedWarrants" xlink:label="loc_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_820"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnFairValueOfExercisedWarrants" xlink:label="loc_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_821"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnFairValueOfExercisedWarrants" xlink:label="loc_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_822"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnIntangibleAssetAcquired" xlink:label="loc_blrx_SupplementaryInformationOnIntangibleAssetAcquired_823"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnIntangibleAssetAcquired" xlink:label="loc_blrx_SupplementaryInformationOnIntangibleAssetAcquired_824"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnIntangibleAssetAcquired" xlink:label="loc_blrx_SupplementaryInformationOnIntangibleAssetAcquired_825"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnInterestReceivedInCash" xlink:label="loc_blrx_SupplementaryInformationOnInterestReceivedInCash_826"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnInterestReceivedInCash" xlink:label="loc_blrx_SupplementaryInformationOnInterestReceivedInCash_827"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnInterestReceivedInCash" xlink:label="loc_blrx_SupplementaryInformationOnInterestReceivedInCash_828"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment" xlink:label="loc_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_829"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment" xlink:label="loc_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_830"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment" xlink:label="loc_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_831"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnWarrantIssuanceCosts" xlink:label="loc_blrx_SupplementaryInformationOnWarrantIssuanceCosts_832"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnWarrantIssuanceCosts" xlink:label="loc_blrx_SupplementaryInformationOnWarrantIssuanceCosts_833"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnWarrantIssuanceCosts" xlink:label="loc_blrx_SupplementaryInformationOnWarrantIssuanceCosts_834"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation" xlink:label="loc_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_835"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation" xlink:label="loc_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_836"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation" xlink:label="loc_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_837"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation" xlink:label="loc_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_838"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation" xlink:label="loc_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_839"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation" xlink:label="loc_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_840"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxLossCarryforwards" xlink:label="loc_blrx_TaxLossCarryforwards_841"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxLossCarryforwards" xlink:label="loc_blrx_TaxLossCarryforwards_842"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxLossCarryforwards" xlink:label="loc_blrx_TaxLossCarryforwards_843"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TelAvivStockExchangeMember" xlink:label="loc_blrx_TelAvivStockExchangeMember_844"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_845"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_846"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_847"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_848"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_849"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_850"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ThirdTrancheMember" xlink:label="loc_blrx_ThirdTrancheMember_851"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ThirdTrancheMember" xlink:label="loc_blrx_ThirdTrancheMember_852"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ThreeSubsequentYearsMember" xlink:label="loc_blrx_ThreeSubsequentYearsMember_853"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ThreeSubsequentYearsMember" xlink:label="loc_blrx_ThreeSubsequentYearsMember_854"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ThreeSubsequentYearsMember" xlink:label="loc_blrx_ThreeSubsequentYearsMember_855"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TotalChangeInOperatingAssetAndLiability" xlink:label="loc_blrx_TotalChangeInOperatingAssetAndLiability_856"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TotalChangeInOperatingAssetAndLiability" xlink:label="loc_blrx_TotalChangeInOperatingAssetAndLiability_857"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TotalChangeInOperatingAssetAndLiability" xlink:label="loc_blrx_TotalChangeInOperatingAssetAndLiability_858"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TotalIncomeAndExpenseNotInvolvingCashFlows" xlink:label="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_859"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TotalIncomeAndExpenseNotInvolvingCashFlows" xlink:label="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_860"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TotalIncomeAndExpenseNotInvolvingCashFlows" xlink:label="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_861"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradeAndOtherPayablesToForeignTradeSuppliers" xlink:label="loc_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_862"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradeAndOtherPayablesToForeignTradeSuppliers" xlink:label="loc_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_863"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradeAndOtherPayablesToForeignTradeSuppliers" xlink:label="loc_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_864"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradeAndOtherPayablesToLocalTradeSuppliers" xlink:label="loc_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_865"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradeAndOtherPayablesToLocalTradeSuppliers" xlink:label="loc_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_866"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradeAndOtherPayablesToLocalTradeSuppliers" xlink:label="loc_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_867"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradePayablesAbstract" xlink:label="loc_blrx_TradePayablesAbstract_868"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradePayablesAbstract" xlink:label="loc_blrx_TradePayablesAbstract_869"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradePayablesAbstract" xlink:label="loc_blrx_TradePayablesAbstract_870"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradePayablesMember" xlink:label="loc_blrx_TradePayablesMember_871"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradePayablesMember" xlink:label="loc_blrx_TradePayablesMember_872"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradePayablesMember" xlink:label="loc_blrx_TradePayablesMember_873"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TrancheAxis" xlink:label="loc_blrx_TrancheAxis_874"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TrancheAxis" xlink:label="loc_blrx_TrancheAxis_875"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TrancheDomain" xlink:label="loc_blrx_TrancheDomain_876"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TrancheDomain" xlink:label="loc_blrx_TrancheDomain_877"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TransferFromLicenseToTheLicenseeAmount" xlink:label="loc_blrx_TransferFromLicenseToTheLicenseeAmount_878"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TransferFromLicenseToTheLicenseeAmount" xlink:label="loc_blrx_TransferFromLicenseToTheLicenseeAmount_879"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TransferFromLicenseToTheLicenseeAmount" xlink:label="loc_blrx_TransferFromLicenseToTheLicenseeAmount_880"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UnderwaterEmployeeStockOptionsMember" xlink:label="loc_blrx_UnderwaterEmployeeStockOptionsMember_881"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UnderwaterEmployeeStockOptionsMember" xlink:label="loc_blrx_UnderwaterEmployeeStockOptionsMember_882"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UnderwritersMember" xlink:label="loc_blrx_UnderwritersMember_883"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UnderwritersMember" xlink:label="loc_blrx_UnderwritersMember_884"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UniformTaxRate" xlink:label="loc_blrx_UniformTaxRate_885"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UniformTaxRate" xlink:label="loc_blrx_UniformTaxRate_886"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UniformTaxRate" xlink:label="loc_blrx_UniformTaxRate_887"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UpfrontPayment" xlink:label="loc_blrx_UpfrontPayment_888"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UpfrontPayment" xlink:label="loc_blrx_UpfrontPayment_889"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ValueOfServicesRecorded" xlink:label="loc_blrx_ValueOfServicesRecorded_890"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ValueOfServicesRecorded" xlink:label="loc_blrx_ValueOfServicesRecorded_891"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantFiveMember" xlink:label="loc_blrx_WarrantFiveMember_892"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantFiveMember" xlink:label="loc_blrx_WarrantFiveMember_893"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantFiveMember" xlink:label="loc_blrx_WarrantFiveMember_894"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantFourMember" xlink:label="loc_blrx_WarrantFourMember_895"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantFourMember" xlink:label="loc_blrx_WarrantFourMember_896"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantFourMember" xlink:label="loc_blrx_WarrantFourMember_897"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantOfferingConsideration" xlink:label="loc_blrx_WarrantOfferingConsideration_898"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantOfferingConsideration" xlink:label="loc_blrx_WarrantOfferingConsideration_899"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantOfferingConsideration" xlink:label="loc_blrx_WarrantOfferingConsideration_900"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantOneMember" xlink:label="loc_blrx_WarrantOneMember_901"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantOneMember" xlink:label="loc_blrx_WarrantOneMember_902"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantOneMember" xlink:label="loc_blrx_WarrantOneMember_903"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Warrants" xlink:label="loc_blrx_Warrants_904"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Warrants" xlink:label="loc_blrx_Warrants_905"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExercisableTerm" xlink:label="loc_blrx_WarrantsExercisableTerm_906"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExercisableTerm" xlink:label="loc_blrx_WarrantsExercisableTerm_907"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExercisableTerm" xlink:label="loc_blrx_WarrantsExercisableTerm_908"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExercises" xlink:label="loc_blrx_WarrantsExercises_909"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExercises" xlink:label="loc_blrx_WarrantsExercises_910"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExercises" xlink:label="loc_blrx_WarrantsExercises_911"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExpirationPeriod" xlink:label="loc_blrx_WarrantsExpirationPeriod_912"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExpirationPeriod" xlink:label="loc_blrx_WarrantsExpirationPeriod_913"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsIssuedToPurchaseAds" xlink:label="loc_blrx_WarrantsIssuedToPurchaseAds_914"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsIssuedToPurchaseAds" xlink:label="loc_blrx_WarrantsIssuedToPurchaseAds_915"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsIssuedToPurchaseAds" xlink:label="loc_blrx_WarrantsIssuedToPurchaseAds_916"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsIssuedToPurchaseShares" xlink:label="loc_blrx_WarrantsIssuedToPurchaseShares_917"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsIssuedToPurchaseShares" xlink:label="loc_blrx_WarrantsIssuedToPurchaseShares_918"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantSixMember" xlink:label="loc_blrx_WarrantSixMember_919"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantSixMember" xlink:label="loc_blrx_WarrantSixMember_920"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantSixMember" xlink:label="loc_blrx_WarrantSixMember_921"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsReserve" xlink:label="loc_blrx_WarrantsReserve_922"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsReserve" xlink:label="loc_blrx_WarrantsReserve_923"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsReserve" xlink:label="loc_blrx_WarrantsReserve_924"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantThreeMember" xlink:label="loc_blrx_WarrantThreeMember_925"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantThreeMember" xlink:label="loc_blrx_WarrantThreeMember_926"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantThreeMember" xlink:label="loc_blrx_WarrantThreeMember_927"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantTwoMember" xlink:label="loc_blrx_WarrantTwoMember_928"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantTwoMember" xlink:label="loc_blrx_WarrantTwoMember_929"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantTwoMember" xlink:label="loc_blrx_WarrantTwoMember_930"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WeightedAverageExercisePriceAbstract" xlink:label="loc_blrx_WeightedAverageExercisePriceAbstract_931"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WeightedAverageExercisePriceAbstract" xlink:label="loc_blrx_WeightedAverageExercisePriceAbstract_932"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WeightedAverageExercisePriceAbstract" xlink:label="loc_blrx_WeightedAverageExercisePriceAbstract_933"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WithholdingApplicableTaxRate" xlink:label="loc_blrx_WithholdingApplicableTaxRate_934"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WithholdingApplicableTaxRate" xlink:label="loc_blrx_WithholdingApplicableTaxRate_935"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WithholdingApplicableTaxRate" xlink:label="loc_blrx_WithholdingApplicableTaxRate_936"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WriteoffOfIntangibleAsset" xlink:label="loc_blrx_WriteoffOfIntangibleAsset_937"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WriteoffOfIntangibleAsset" xlink:label="loc_blrx_WriteoffOfIntangibleAsset_938"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WriteoffOfIntangibleAsset" xlink:label="loc_blrx_WriteoffOfIntangibleAsset_939"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_940"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_941"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_942"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_943"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_944"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_945"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_946"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_947"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_948"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_949"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_950"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_951"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_952"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_953"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_954"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_955"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_956"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_957"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_958"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_959"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_960"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_961"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_962"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_963"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_964"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_965"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_966"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_967"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_968"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossOnFinancialAssets" xlink:label="loc_ifrs-full_ImpairmentLossOnFinancialAssets_969"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossOnFinancialAssets" xlink:label="loc_ifrs-full_ImpairmentLossOnFinancialAssets_970"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_971"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_972"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_973"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_974"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_975"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_976"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_977"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_978"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_979"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_980"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_981"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_982"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_983"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_984"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_985"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_986"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_987"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_988"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_989"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_990"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_991"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_992"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_993"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_994"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_995"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_996"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_997"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_998"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_999"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_1000"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_1001"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1002"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1003"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1004"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_1005"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_1006"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_1007"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_1008"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_1009"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_1010"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1011"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1012"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1013"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_1014"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_1015"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_1016"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1017"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1018"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1019"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1020"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1021"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1022"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1023"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1024"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1025"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1026"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1027"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1028"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1029"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1030"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1031"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_1032"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_1033"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_1034"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_1035"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1036"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1037"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1038"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_1039"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_1040"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_1041"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_1042"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1043"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1044"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1045"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1046"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1047"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_1048"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_1049"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_1050"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_1051"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_1052"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_1053"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_1054"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_1055"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1056"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1057"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1058"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1059"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings_1060"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings_1061"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings_1062"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-full_Borrowings_1063"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_1064"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_1065"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_1066"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_1067"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_1068"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_1069"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_1070"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_1071"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_1072"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1073"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1074"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1075"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1076"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1077"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract" xlink:label="loc_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_1078"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract" xlink:label="loc_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_1079"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeDomain" xlink:label="loc_blrx_AgreementTypeDomain_1080"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementWithCompaniesForDevelopmentAbstract" xlink:label="loc_blrx_AgreementWithCompaniesForDevelopmentAbstract_1081"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AssetTransferAgreementMember" xlink:label="loc_blrx_AssetTransferAgreementMember_1082"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:label="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_1083"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:label="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_1084"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationAndShareholdersAgreementLineItems" xlink:label="loc_blrx_CollaborationAndShareholdersAgreementLineItems_1085"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationAndShareholdersAgreementTable" xlink:label="loc_blrx_CollaborationAndShareholdersAgreementTable_1086"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationTransactionAxis" xlink:label="loc_blrx_CollaborationTransactionAxis_1087"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationTransactionDomain" xlink:label="loc_blrx_CollaborationTransactionDomain_1088"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract" xlink:label="loc_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract_1089"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract" xlink:label="loc_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract_1090"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfAgalimmuneAcquisitionAbstract" xlink:label="loc_blrx_DisclosureOfAgalimmuneAcquisitionAbstract_1091"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfAgreementWithOmegaPharmaAbstract" xlink:label="loc_blrx_DisclosureOfAgreementWithOmegaPharmaAbstract_1092"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfAgreementWithOmegaPharmaAbstract" xlink:label="loc_blrx_DisclosureOfAgreementWithOmegaPharmaAbstract_1093"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfAmendmentToLicenseAbstract" xlink:label="loc_blrx_DisclosureOfAmendmentToLicenseAbstract_1094"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfAmendmentToLicenseAbstract" xlink:label="loc_blrx_DisclosureOfAmendmentToLicenseAbstract_1095"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract" xlink:label="loc_blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract_1096"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock_1097"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock_1098"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfEventsSubsequentToBalanceSheetDateAbstract" xlink:label="loc_blrx_DisclosureOfEventsSubsequentToBalanceSheetDateAbstract_1099"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfEventsSubsequentToBalanceSheetDateAbstract" xlink:label="loc_blrx_DisclosureOfEventsSubsequentToBalanceSheetDateAbstract_1100"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfGeneralInformationAbstract" xlink:label="loc_blrx_DisclosureOfGeneralInformationAbstract_1101"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfIncomeTaxesAbstract" xlink:label="loc_blrx_DisclosureOfIncomeTaxesAbstract_1102"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfIncomeTaxesAbstract" xlink:label="loc_blrx_DisclosureOfIncomeTaxesAbstract_1103"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfIncomeTaxesAbstract" xlink:label="loc_blrx_DisclosureOfIncomeTaxesAbstract_1104"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract" xlink:label="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract_1105"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLongTermInvestmentAbstract" xlink:label="loc_blrx_DisclosureOfLongTermInvestmentAbstract_1106"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" xlink:label="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_1107"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable" xlink:label="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable_1108"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfShortTermBankDepositsAbstract" xlink:label="loc_blrx_DisclosureOfShortTermBankDepositsAbstract_1109"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfShortTermBankDepositsAbstract" xlink:label="loc_blrx_DisclosureOfShortTermBankDepositsAbstract_1110"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_1111"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract" xlink:label="loc_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract_1112"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract" xlink:label="loc_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract_1113"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Glix1Member" xlink:label="loc_blrx_Glix1Member_1114"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Glix1Member" xlink:label="loc_blrx_Glix1Member_1115"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HemispherianAsMember" xlink:label="loc_blrx_HemispherianAsMember_1116"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract" xlink:label="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_1117"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract" xlink:label="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_1118"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_January2025OfferingMember" xlink:label="loc_blrx_January2025OfferingMember_1119"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract_1120"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_1121"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsTable" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1122"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceObligationAxis" xlink:label="loc_blrx_PerformanceObligationAxis_1123"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceObligationDomain" xlink:label="loc_blrx_PerformanceObligationDomain_1124"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceSharesUnitTwoMember" xlink:label="loc_blrx_PerformanceSharesUnitTwoMember_1125"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceSharesUnitTwoMember" xlink:label="loc_blrx_PerformanceSharesUnitTwoMember_1126"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PlacementAgentMember" xlink:label="loc_blrx_PlacementAgentMember_1127"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract" xlink:label="loc_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_1128"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract" xlink:label="loc_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_1129"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Test" xlink:label="loc_blrx_Test_1130"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Test" xlink:label="loc_blrx_Test_1131"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TetragonMember" xlink:label="loc_blrx_TetragonMember_1132"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL" xlink:label="loc_country_IL_1133"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL" xlink:label="loc_country_IL_1134"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_ILS" xlink:label="loc_currency_ILS_1135"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_ILS" xlink:label="loc_currency_ILS_1136"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1137"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1138"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1139"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_1140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_1141"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_1142"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_dei_AuditorOpinionTextBlock_1143"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1144"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_1145"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_1146"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_1147"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1148"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_1149"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_1150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_1151"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_1152"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_1153"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_1154"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1155"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1156"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1157"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1158"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_1159"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_1160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_1161"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_1162"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1163"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_1164"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_1165"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1166"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_1167"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1168"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_1169"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1171"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_1172"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1173"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_1174"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_1175"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_1176"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1177"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1178"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_1179"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_1180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1181"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_1182"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_1183"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_1184"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1185"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1186"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_1187"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_1188"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_1189"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccountingProfit" xlink:label="loc_ifrs-full_AccountingProfit_1190"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccountingProfit" xlink:label="loc_ifrs-full_AccountingProfit_1191"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_1192"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_1193"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_1194"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_1195"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_1196"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_1197"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1198"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1199"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1201"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_1202"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_1203"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_1204"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_1205"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_1206"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_1207"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_1208"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_1209"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_1210"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_1211"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_1212"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_1213"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_1214"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_1215"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_1216"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_1217"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_1218"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_1219"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_1220"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1221"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity" xlink:label="loc_ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity_1222"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_1223"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_1224"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_1225"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_1226"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_1227"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_1228"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_1229"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_1230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_1231"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_1232"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1233"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1234"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-full_BorrowingsInterestRate_1235"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_1236"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_1237"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1238"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1239"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_1240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalReserve" xlink:label="loc_ifrs-full_CapitalReserve_1241"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalReserveMember" xlink:label="loc_ifrs-full_CapitalReserveMember_1242"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1243"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1244"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1245"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_1246"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_1247"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_1248"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_1249"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_1250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1251"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1252"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1253"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_1254"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1255"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1256"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1257"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred_1258"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred_1259"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1260"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_1261"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1262"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1263"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_1264"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInEquityAbstract" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_1265"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_1266"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember" xlink:label="loc_ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember_1267"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_1268"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_1269"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1271"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1272"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1273"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1274"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1275"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_1276"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_1277"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1278"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1279"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_1281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_1282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CommunicationExpense" xlink:label="loc_ifrs-full_CommunicationExpense_1283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_1285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_1286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_1287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_1288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_1289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_1290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_1291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember_1292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-full_ConsiderationPaidReceived_1293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-full_ConsiderationPaidReceived_1294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="loc_ifrs-full_CountryOfDomicileMember_1295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="loc_ifrs-full_CountryOfDomicileMember_1296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditExposure" xlink:label="loc_ifrs-full_CreditExposure_1297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_1298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_1299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_1300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_1301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_1302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_1303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_1304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_1305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_1306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_1307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_1308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_1309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_1310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_1311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_1312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_1313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_1314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:label="loc_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_1315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:label="loc_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_1316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_1317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationExpense" xlink:label="loc_ifrs-full_DepreciationExpense_1318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_1319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_1320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_1321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_1322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_1323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_1324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_1325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_1326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_1327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_1328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_1329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_1330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_1331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_1332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_1333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_1334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_1335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_1336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_1337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_1338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_1339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_1342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_1345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_1346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_1347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_1348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_1349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_1350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory_1351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_1352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_1353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_1354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems" xlink:label="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_1355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_1357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_1358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_1361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_1362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_1363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_1364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_1366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_1367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_1368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDepositsFromBanksExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDepositsFromBanksExplanatory_1369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_1370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_1371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_1374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_1375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_1376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_1380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory_1381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_1383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_1384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_1386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_1387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_1388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_1389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_1390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_1391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_1392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_1395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_1396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_1397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_1398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory_1400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory_1401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfInvestmentPropertyExplanatory_1402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfJointVenturesLineItems" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesLineItems_1403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfJointVenturesTable" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesTable_1404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_1405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_1406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_1407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_1408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_1409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_1410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_1411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_1412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_1415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_1418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_1419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_1420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_1421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_1422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_1423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_1425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_1426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_1428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_1432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_1434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_1435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_1438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_1440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_1442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_1443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_1444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_1445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_1446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_1447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_1448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_1449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_1450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_1451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_1452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-full_FeeAndCommissionExpense_1453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_1454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_1455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_1456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_1457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_1458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinishedGoods" xlink:label="loc_ifrs-full_FinishedGoods_1459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinishedGoods" xlink:label="loc_ifrs-full_FinishedGoods_1460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="loc_ifrs-full_ForeignCountriesMember_1461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="loc_ifrs-full_ForeignCountriesMember_1462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeGain" xlink:label="loc_ifrs-full_ForeignExchangeGain_1463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeGain" xlink:label="loc_ifrs-full_ForeignExchangeGain_1464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeLoss" xlink:label="loc_ifrs-full_ForeignExchangeLoss_1465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignExchangeLoss" xlink:label="loc_ifrs-full_ForeignExchangeLoss_1466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_1467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="loc_ifrs-full_GeographicalAreasDomain_1469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossProfit" xlink:label="loc_ifrs-full_GrossProfit_1472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossProfit" xlink:label="loc_ifrs-full_GrossProfit_1473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_1474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_1475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_1476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_1477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_1478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_1481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_1484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsAxis_1489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsDomain" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsDomain_1490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InsuranceExpense" xlink:label="loc_ifrs-full_InsuranceExpense_1491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_1495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-full_InterestExpense_1496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-full_InterestExpense_1497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-full_InterestExpense_1498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_1499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_1500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPayable" xlink:label="loc_ifrs-full_InterestPayable_1501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPayable" xlink:label="loc_ifrs-full_InterestPayable_1502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-full_Inventories_1503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-full_Inventories_1504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-full_Inventories_1505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentProperty" xlink:label="loc_ifrs-full_InvestmentProperty_1506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentProperty" xlink:label="loc_ifrs-full_InvestmentProperty_1507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentPropertyMember" xlink:label="loc_ifrs-full_InvestmentPropertyMember_1508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_1509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_1510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_1511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_1512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_1513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_JointVenturesAxis" xlink:label="loc_ifrs-full_JointVenturesAxis_1514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_1515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_1516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_1517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_1518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_1521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_1522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_1523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_1524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_1525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_1530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_1531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_1532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_1533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_1534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_1535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_1537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_1538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_1539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_1540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="loc_ifrs-full_LiabilitiesAbstract_1541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_1543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="loc_ifrs-full_LicenceFeeIncome_1544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="loc_ifrs-full_LicenceFeeIncome_1545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_1546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="loc_ifrs-full_MaturityDomain_1548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="loc_ifrs-full_MotorVehiclesMember_1549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="loc_ifrs-full_MotorVehiclesMember_1550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-full_NetForeignExchangeGain_1551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-full_NetForeignExchangeGain_1552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_1554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-full_NoncontrollingInterests_1555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_1556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_1557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_1558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_1559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_1560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_1561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_1562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_1563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_1564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_1565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_1566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_1567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_1568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfEmployees" xlink:label="loc_ifrs-full_NumberOfEmployees_1569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_1570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_1571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_1572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_1573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_1574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_1576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_1577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_1578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_1579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables_1580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables_1581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_1582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_1583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherEquityInterest" xlink:label="loc_ifrs-full_OtherEquityInterest_1584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="loc_ifrs-full_OtherExpenseByFunction_1585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="loc_ifrs-full_OtherExpenseByFunction_1586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherExpenseByNature" xlink:label="loc_ifrs-full_OtherExpenseByNature_1587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherExpenseByNature" xlink:label="loc_ifrs-full_OtherExpenseByNature_1588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFeeAndCommissionExpense" xlink:label="loc_ifrs-full_OtherFeeAndCommissionExpense_1589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_1590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_1591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherPayables" xlink:label="loc_ifrs-full_OtherPayables_1592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherPayables" xlink:label="loc_ifrs-full_OtherPayables_1593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_1594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_1595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="loc_ifrs-full_OtherRevenue_1596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="loc_ifrs-full_OtherRevenue_1597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_1598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_1599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForDevelopmentProjectExpenditure" xlink:label="loc_ifrs-full_PaymentsForDevelopmentProjectExpenditure_1600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForDevelopmentProjectExpenditure" xlink:label="loc_ifrs-full_PaymentsForDevelopmentProjectExpenditure_1601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_1602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_1603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_1604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_1605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_1606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_1607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_1608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_1609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_1610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_1611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_1612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_1613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_1614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_1618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_1619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:label="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_1620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:label="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_1621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_1622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_1623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract_1624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract_1625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_1628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_1629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_1630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_1631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_1632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_1635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_1638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_1639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepairsAndMaintenanceExpense" xlink:label="loc_ifrs-full_RepairsAndMaintenanceExpense_1640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_1641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_1642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" xlink:label="loc_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads_1643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_1644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_1645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_1646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_1647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_1648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="loc_ifrs-full_RevenueAbstract_1649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="loc_ifrs-full_RevenueAbstract_1650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-full_RevenueFromInterest_1651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-full_RevenueFromInterest_1652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="loc_ifrs-full_RevenueFromRoyalties_1653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="loc_ifrs-full_RevenueFromRoyalties_1654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_1655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_1656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_1657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SeparateManagementEntitiesAxis" xlink:label="loc_ifrs-full_SeparateManagementEntitiesAxis_1658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SeparateManagementEntitiesAxis" xlink:label="loc_ifrs-full_SeparateManagementEntitiesAxis_1659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ServicesExpense" xlink:label="loc_ifrs-full_ServicesExpense_1660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOptionsMember" xlink:label="loc_ifrs-full_ShareOptionsMember_1661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-full_SharePremium_1662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_1663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_1664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_1665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_1666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_1667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_1668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_1669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_1670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_1671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_1672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_1674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_1675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_1676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_1681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TravelExpense" xlink:label="loc_ifrs-full_TravelExpense_1682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TravelExpense" xlink:label="loc_ifrs-full_TravelExpense_1683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyAxis" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyAxis_1686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyAxis" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyAxis_1687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyDomain" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyDomain_1688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-full_TypesOfRisksDomain_1691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived" xlink:label="loc_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived_1694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnobservableInputsDomain" xlink:label="loc_ifrs-full_UnobservableInputsDomain_1695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-full_WagesAndSalaries_1696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-full_WagesAndSalaries_1697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantReserve" xlink:label="loc_ifrs-full_WarrantReserve_1698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantReserve" xlink:label="loc_ifrs-full_WarrantReserve_1699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-full_WarrantReserveMember_1700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-full_WarrantReserveMember_1701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-full_WarrantsMember_1702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember" xlink:label="loc_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_1703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember" xlink:label="loc_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_1704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_1705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_1706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_1707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_1708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_1709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_1710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_1713"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_1714"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1715"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1716"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_1717"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_1718"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_1719"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WorkInProgress" xlink:label="loc_ifrs-full_WorkInProgress_1720"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WorkInProgress" xlink:label="loc_ifrs-full_WorkInProgress_1721"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1722"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1723"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1724"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1725"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1726"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1727"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract_1728"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/commentaryGuidance" xlink:label="lab_blrx_ImpairmentLossOnIntangibleAssets_0" xml:lang="en-US">This element should be used to tag non-restated comparative information only.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ImpairmentLossOnIntangibleAssets_1" xml:lang="en-US">Represent the amount of impairment loss on intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_blrx_ImpairmentLossOnIntangibleAssets_2" xml:lang="en-US">IMPAIRMENT OF INTANGIBLE ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ImpairmentLossOnIntangibleAssets_3" xml:lang="en-US">Impairment Loss On Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_ImpairmentLossOnIntangibleAssets_4" xml:lang="en-US">IMPAIRMENT OF INTANGIBLE ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/commentaryGuidance" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares_0" xml:lang="en-US">The reported value should be tagged twice, with both this element and the element &#8216;Basic earnings (loss) per share&#8217; when: (a) basic and diluted earnings per share are equal; and (b) an entity presents one line item to accomplish the dual presentation requirement of paragraph 67 of IAS 33.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares_1" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares_2" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF DILUTED LOSS PER ORDINARY SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares_3" xml:lang="en-US">Total diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares_4" xml:lang="en-US">Diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AccountsPayableAbstract_0" xml:lang="en-US">Accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AccountsPayableAbstract_1" xml:lang="en-US">Accounts Payable Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_AccountsPayableAbstract_2" xml:lang="en-US">Accounts payable:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AdditionalCommitmentFee_0" xml:lang="en-US">Additional commitment fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AdditionalCommitmentFee_1" xml:lang="en-US">Additional commitment fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AdditionalExtendLeasePeriod_0" xml:lang="en-US">Additional extend the lease period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AdditionalExtendLeasePeriod_1" xml:lang="en-US">Additional Extend Lease Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_AdditionalExtendLeasePeriod_2" xml:lang="en-US">Additional extension period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_0" xml:lang="en-US">It represents additional impairment charges of decreasing annual growth rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_1" xml:lang="en-US">Additional Impairment Charges Of Decreasing Annual Growth Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_2" xml:lang="en-US">Additional impairment charges of decreasing annual growth rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_0" xml:lang="en-US">It represnts additional impairment charges of weighted average cost of capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_1" xml:lang="en-US">Additional Impairment Charges Of Weighted Average Cost Of Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_2" xml:lang="en-US">Additional impairment charges of weighted average cost of capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AdditionalSharesMember_0" xml:lang="en-US">Additional Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AdditionsLeaseLiabilities_0" xml:lang="en-US">Addition in lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AdditionsLeaseLiabilities_1" xml:lang="en-US">Additions Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_AdditionsLeaseLiabilities_2" xml:lang="en-US">Additions during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_0" xml:lang="en-US">Adjustments for decrease (increase) in prepaid expense other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_1" xml:lang="en-US">Decrease (increase) in prepaid expenses and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_2" xml:lang="en-US">Adjustments For Decrease Increase In Prepaid Expenses And Other Operating Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AdvancePayments_0" xml:lang="en-US">Advance payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AdvancePayments_1" xml:lang="en-US">Advance Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_AdvancePayments_2" xml:lang="en-US">Advance payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AgalimmuneLtdMember_0" xml:lang="en-US">Agalimmune Ltd. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AgalimmuneLtdMember_1" xml:lang="en-US">Agalimmune Ltd. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AggregateAmericanDepositaryShares_0" xml:lang="en-US">Represents about aggregate American depositary shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AggregateAmericanDepositaryShares_1" xml:lang="en-US">Aggregate American Depositary Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_AggregateAmericanDepositaryShares_2" xml:lang="en-US">Aggregate American depositary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AggregateOfferingPrice_0" xml:lang="en-US">Aggregate offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AggregateOfferingPrice_1" xml:lang="en-US">Aggregate offering price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AgreementTypeAxis_0" xml:lang="en-US">Represents about agreement type .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AgreementTypeAxis_1" xml:lang="en-US">Agreement Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AgreementTypeMember_0" xml:lang="en-US">Represents about agreement type.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AgreementTypeMember_1" xml:lang="en-US">Agreement Type [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_0" xml:lang="en-US">The disclosure of agreement with hemispherian for development of Glix1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_1" xml:lang="en-US">Agreement With Hemispherian For Development Of Glix1 Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_2" xml:lang="en-US">AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AmericanDepositarySharesMember_0" xml:lang="en-US">ADSs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AmericanDepositarySharesMember_1" xml:lang="en-US">American Depositary Shares Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_AmericanDepositarySharesMember_2" xml:lang="en-US">ADSs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AmericanDepositarySharesPurchasePricePerShare_0" xml:lang="en-US">American Depositary Shares purchase price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AmericanDepositarySharesPurchasePricePerShare_1" xml:lang="en-US">American Depositary Shares Purchase Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_AmericanDepositarySharesPurchasePricePerShare_2" xml:lang="en-US">American Depositary Shares purchase price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AmericanStockExchangeMember_0" xml:lang="en-US">American stock exchange [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AmountAllocatedToWarrant_0" xml:lang="en-US">Amount allocated to warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AmountAllocatedToWarrant_1" xml:lang="en-US">Amount allocated to warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AmountGrantOfEquityInstruments_0" xml:lang="en-US">Amount granted for equity instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AmountGrantOfEquityInstruments_1" xml:lang="en-US">Amount Grant Of Equity Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_AmountGrantOfEquityInstruments_2" xml:lang="en-US">Amount granted for equity instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AmountOfIntellectualPropertyAndCashBalance_0" xml:lang="en-US">It represents amount of intellectual property and cash balance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AmountOfIntellectualPropertyAndCashBalance_1" xml:lang="en-US">Amount Of Intellectual Property And Cash Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_AmountOfIntellectualPropertyAndCashBalance_2" xml:lang="en-US">Amount of intellectual property and cash balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AmountOfLoanAgreement_0" xml:lang="en-US">It represents amount of loan agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AmountOfLoanAgreement_1" xml:lang="en-US">Amount Of Loan Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_AmountOfLoanAgreement_2" xml:lang="en-US">Amount of loan agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AmountOfPaymentInFutrueMilestone_0" xml:lang="en-US">Amount of payment in futrue milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AmountOfPaymentInFutrueMilestone_1" xml:lang="en-US">Amount of payment in futrue milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AnnualLeaseFee_0" xml:lang="en-US">Annual Lease fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AnnualLeaseFee_1" xml:lang="en-US">Annual Lease fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AuthorizedShareCapitalValue_0" xml:lang="en-US">Amount of authorized share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AuthorizedShareCapitalValue_1" xml:lang="en-US">Authorized Share Capital Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_AuthorizedShareCapitalValue_2" xml:lang="en-US">Authorized share capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AvailableBalanceUnderFacility_0" xml:lang="en-US">Available balance under the facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AvailableBalanceUnderFacility_1" xml:lang="en-US">Available balance under the facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_AyrmidLicenseAgreementMember_0" xml:lang="en-US">This member stands for Ayrmid License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AyrmidLicenseAgreementMember_1" xml:lang="en-US">Ayrmid License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BankGuaranteeAmountForBenefitOfLessor_0" xml:lang="en-US">Bank guarantee amount for benefit of Lessor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BankGuaranteeAmountForBenefitOfLessor_1" xml:lang="en-US">Bank guarantee amount for benefit of lessor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BankLoanMember_0" xml:lang="en-US">Bank Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BankLoanMember_1" xml:lang="en-US">Bank Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BasicAndDilutedEarningsLossPerShare_0" xml:lang="en-US">Represent the Basic and Diluted earnings (loss) per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BasicAndDilutedEarningsLossPerShare_1" xml:lang="en-US">Basic And Diluted Earnings Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_BasicAndDilutedEarningsLossPerShare_2" xml:lang="en-US">Basic and diluted loss per ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_BasicAndDilutedEarningsLossPerShare_3" xml:lang="en-US">LOSS PER ORDINARY SHARE - BASIC AND DILUTED</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BeneficiallyOwnInExcess_0" xml:lang="en-US">Beneficially Own In Excess</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BeneficiallyOwnInExcess_1" xml:lang="en-US">Beneficially Own In Excess</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BenefitsToRelatedPartiesAbstract_0" xml:lang="en-US">Benefits to related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BenefitsToRelatedPartiesAbstract_1" xml:lang="en-US">Benefits To Related Parties Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_BenefitsToRelatedPartiesAbstract_2" xml:lang="en-US">Benefits to related parties:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BiokineMember_0" xml:lang="en-US">This member stands for Biokine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BiokineMember_1" xml:lang="en-US">Biokine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BiokineTherapeuticsLtdMember_0" xml:lang="en-US">Biokine Therapeutics Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BiokineTherapeuticsLtdMember_1" xml:lang="en-US">Biokine Therapeutics Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_BiokineTherapeuticsLtdMember_2" xml:lang="en-US">Biokine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BioLineRxMember_0" xml:lang="en-US">Available balance under the facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BL8040Member_0" xml:lang="en-US">B L-8040 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BL8040Member_1" xml:lang="en-US">B L-8040 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_BL8040Member_2" xml:lang="en-US">BL-8040 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BostonMember_0" xml:lang="en-US">This member stands for Boston</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BostonMember_1" xml:lang="en-US">Boston [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_BostonMember_2" xml:lang="en-US">Boston [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BtigLlcMember_0" xml:lang="en-US">BTIG, LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BtigLlcMember_1" xml:lang="en-US">BTIG, LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BusinessAnalyticsExpense_0" xml:lang="en-US">Business analytics expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BusinessAnalyticsExpense_1" xml:lang="en-US">Business Analytics Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_BusinessAnalyticsExpense_2" xml:lang="en-US">Business Analytics</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_BvfPartnersLpMember_0" xml:lang="en-US">BVF Partners L.P. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_BvfPartnersLpMember_1" xml:lang="en-US">Bvf Partners Lp Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_BvfPartnersLpMember_2" xml:lang="en-US">BVF Partners L.P. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_CashAndCashEquivalentMember_0" xml:lang="en-US">Cash and cash equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_CashAndCashEquivalentMember_1" xml:lang="en-US">Cash And Cash Equivalent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_CashAndCashEquivalentMember_2" xml:lang="en-US">Cash and cash equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_0" xml:lang="en-US">The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_1" xml:lang="en-US">Changes In Fair Value Recorded As A Non-operating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_0" xml:lang="en-US">Changes in fair value through profit and loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_1" xml:lang="en-US">Changes In Fair Value Through Profit And Loss Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_2" xml:lang="en-US">Changes in fair value through profit and loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_CommitmentsAndContingentLiabilities_0" xml:lang="en-US">Commitment and contingent liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_CommitmentsAndContingentLiabilities_1" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ConsultantsMember_0" xml:lang="en-US">Consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ConsultantsMember_1" xml:lang="en-US">Consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_0" xml:lang="en-US">The amount recognised as of the acquisition date for contingent consideration arrangements assumed and indemnification assets acquired in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_1" xml:lang="en-US">Contingent Consideration Arrangements And Indemnification Assets Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_2" xml:lang="en-US">Total costs associated with bringing assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ContingentLiability_0" xml:lang="en-US">Represents the value of contingent liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ContingentLiability_1" xml:lang="en-US">Contingent Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_ContingentLiability_2" xml:lang="en-US">Value of contingent liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_CostOfProductSales_0" xml:lang="en-US">Cost of product sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_CostOfProductSales_1" xml:lang="en-US">Cost Of Product Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_CostOfProductSales_2" xml:lang="en-US">Cost of product sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_CostRelatedToLicenseRevenues_0" xml:lang="en-US">Cost related to license revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_CostRelatedToLicenseRevenues_1" xml:lang="en-US">Cost Related To License Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_CostRelatedToLicenseRevenues_2" xml:lang="en-US">Direct costs related to license revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_CostsIncurrentInOffering_0" xml:lang="en-US">Amount of costs incurrent in offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_CostsIncurrentInOffering_1" xml:lang="en-US">Costs Incurrent In Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_CostsIncurrentInOffering_2" xml:lang="en-US">Costs incurrent in offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DelayInPayment_0" xml:lang="en-US">It represents delay in payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DelayInPayment_1" xml:lang="en-US">Delay In Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DelayInPayment_2" xml:lang="en-US">Delay in payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_0" xml:lang="en-US">The decrease in intangible assets other than goodwill resulting from deletions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_1" xml:lang="en-US">Deletions during the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_2" xml:lang="en-US">Deletions during the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_3" xml:lang="en-US">Deletions during the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DeletionsLeaseLiabilities_0" xml:lang="en-US">Deletions in lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_blrx_DeletionsLeaseLiabilities_1" xml:lang="en-US">Deletions during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DeletionsLeaseLiabilities_2" xml:lang="en-US">Deletions Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DeletionsLeaseLiabilities_3" xml:lang="en-US">Deletions during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DeletionsToRightOfUseAssets_0" xml:lang="en-US">The amount of deletions to right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DeletionsToRightOfUseAssets_1" xml:lang="en-US">Deletions To Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DeletionsToRightOfUseAssets_2" xml:lang="en-US">Deletions during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DepositaryShareConversionDescription_0" xml:lang="en-US">Describes the conversion relationship between one depositary share and the number of ordinary shares it represents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DepositaryShareConversionDescription_1" xml:lang="en-US">Depositary Share Conversion Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DepositaryShareConversionDescription_2" xml:lang="en-US">Depositary share conversion description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_0" xml:lang="en-US">Describes the change in the ratio of depositary shares to ordinary shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_1" xml:lang="en-US">Depositary Share To Ordinary Share Ratio Change Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_2" xml:lang="en-US">Depositary share ratio change description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_0" xml:lang="en-US">The description of the entity's material accounting policy information for basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_1" xml:lang="en-US">Description Of Accounting Policy For Basis Of Presentation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_2" xml:lang="en-US">Basis of presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_0" xml:lang="en-US">The description of the entity's accounting policy for changes in accounting policies and disclosures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_1" xml:lang="en-US">Description Of Accounting Policy For Change In Accounting Policy And Disclosures Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_2" xml:lang="en-US">New International Financial Reporting Standards, amendments to standards and new interpretations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_0" xml:lang="en-US">The description of the entity's accounting policy for Changes in accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_1" xml:lang="en-US">Description Of Accounting Policy For Change In Accounting Policy Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_2" xml:lang="en-US">Changes in accounting policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_0" xml:lang="en-US">The description of the entity's accounting policy for consolidation of the financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_1" xml:lang="en-US">Description Of Accounting Policy For Consolidation Of Financial Statements Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_2" xml:lang="en-US">Consolidation of the financial statements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_0" xml:lang="en-US">The description of the entity's accounting policy for principles of consolidation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_1" xml:lang="en-US">Description Of Accounting Policy For Principles Of Consolidation And Equity Accounting Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_2" xml:lang="en-US">Principles of consolidation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_0" xml:lang="en-US">The description of the entity's accounting policy for warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_1" xml:lang="en-US">Description Of Accounting Policy For Warrant Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_2" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_0" xml:lang="en-US">Description of useful life or lease period of right of use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_1" xml:lang="en-US">Description Of Useful Life Or Lease Period Of Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_2" xml:lang="en-US">Estimated useful lives or lease period of right of use assets (in Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DirectorsMember_0" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DirectorsMember_1" xml:lang="en-US">Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DirectorsMember_2" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DirectPlacementMember_0" xml:lang="en-US">Direct Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DirectPlacementMember_1" xml:lang="en-US">Direct Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_0" xml:lang="en-US">Disallowed deductions tax exempt income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_1" xml:lang="en-US">Disallowed Deductions Tax Exempt Income Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_2" xml:lang="en-US">Disallowed deductions (tax exempt income):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_0" xml:lang="en-US">The entire disclosure for agreement with Omega Pharma.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_1" xml:lang="en-US">Disclosure Of Agreement With Omega Pharma Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_2" xml:lang="en-US">AGREEMENT WITH OMEGA PHARMA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_0" xml:lang="en-US">The disclosure detailed information about classification of financial assets and liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_1" xml:lang="en-US">Disclosure Of Classification Of Financial Assets And Liabilities Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_2" xml:lang="en-US">Schedule of Linkage of Monetary Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_0" xml:lang="en-US">The disclosure of detailed information about accounts payable and accruals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Accounts Payable And Accruals Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_2" xml:lang="en-US">Schedule of Accounts Payable and Accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_0" xml:lang="en-US">The disclosure of detailed information about basic loss per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Basic Loss Per Share Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_2" xml:lang="en-US">Schedule of Basic Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_3" xml:lang="en-US">LOSS PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_0" xml:lang="en-US">The disclosure of detailed information about cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Cash And Cash Equivalents Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_2" xml:lang="en-US">Schedule of Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_0" xml:lang="en-US">The disclosure of detailed information about concentration of currency risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Concentration Of Currency Risk Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_2" xml:lang="en-US">Schedule of Concentration of Currency Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_0" xml:lang="en-US">The disclosure of detailed information about cost of revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Cost Of Revenues Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_2" xml:lang="en-US">Schedule of Cost of Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_0" xml:lang="en-US">The disclosure of detailed information about financial expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Financial Expenses Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_2" xml:lang="en-US">Schedule of Financial Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_0" xml:lang="en-US">The disclosure of detailed information about fnancial income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Financial Income Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_2" xml:lang="en-US">Schedule of Financial Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_0" xml:lang="en-US">The disclosure of detailed information about future repayments of long term bank loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Future Repayments Of Long Term Bank Loan Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_2" xml:lang="en-US">Schedule of Future Repayments of Long-Term Bank Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_0" xml:lang="en-US">The disclosure of detailed information about general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About General And Administrative Expenses Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_2" xml:lang="en-US">Schedule of General and Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_0" xml:lang="en-US">The disclosure of detailed information about income and expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Income And Expenses Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_2" xml:lang="en-US">Schedule of Income and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_0" xml:lang="en-US">The disclosure of detailed information about non-operating income expenses net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Non-operating Income Expenses Net Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_2" xml:lang="en-US">Schedule of Non-Operating Income (Expenses), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_0" xml:lang="en-US">The disclosure of detailed information about other receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Other Receivables Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_2" xml:lang="en-US">Schedule of Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_0" xml:lang="en-US">The disclosure of detailed information about research and development expenses..</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Research And Development Expenses Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_2" xml:lang="en-US">Schedule of Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_0" xml:lang="en-US">The disclosure of detailed information about revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Revenues Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_2" xml:lang="en-US">Schedule of Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_0" xml:lang="en-US">The disclosure of detailed information about sales and marketing expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Sales And Marketing Expenses Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_2" xml:lang="en-US">Schedule of Sales and Marketing Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_0" xml:lang="en-US">The disclosure of detailed information about useful lives for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Useful Life Of Property Plant And Equipment Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_2" xml:lang="en-US">Schedule of Depreciation Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_0" xml:lang="en-US">The disclosure of detailed information about weighted average tax rate applicable to income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_1" xml:lang="en-US">Disclosure Of Detailed Information About Weighted Average Tax Rate Applicable To Income Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_2" xml:lang="en-US">Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfLeasesLineItems_0" xml:lang="en-US">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfLeasesLineItems_1" xml:lang="en-US">Disclosure Of Leases [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfLeasesTable_0" xml:lang="en-US">Schedule disclosing information related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfLeasesTable_1" xml:lang="en-US">Disclosure Of Leases [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_0" xml:lang="en-US">Disclosure of license and securities purchase agreements Ayrmid And Highbridge explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_1" xml:lang="en-US">Disclosure Of License And Securities Purchase Agreements Ayrmid And Highbridge Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_2" xml:lang="en-US">LICENSE AND SECURITIES PURCHASE AGREEMENTS &#8211; AYRMID/HIGHBRIDGE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_0" xml:lang="en-US">The disclosure of quantitative information about lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_1" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_2" xml:lang="en-US">Schedule of Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_0" xml:lang="en-US">The entire disclosure for stratgic collaboration agreement with Novartis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_1" xml:lang="en-US">Disclosure Of Strategic Collaboration Agreement With Novartis Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_2" xml:lang="en-US">STRATEGIC COLLABORATION AGREEMENT WITH NOVARTIS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xml:lang="en-US">Disclosure of supplimentry financial statements information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_1" xml:lang="en-US">Disclosure of supplementary financial statement information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_2" xml:lang="en-US">Supplementary Financial Statement Information Schedule Of Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_3" xml:lang="en-US">Supplementary Financial Statement Information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_0" xml:lang="en-US">The entire disclosure for supplementary financial statement information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_1" xml:lang="en-US">Disclosure Of Supplementary Financial Statement Information Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_2" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_0" xml:lang="en-US">The disclosure of detailed information of useful life of right of use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_1" xml:lang="en-US">Disclosure Of Useful Life Of Right Of Use Assets Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_2" xml:lang="en-US">Schedule of Useful Life of Right of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DisclsoureOfAmendmentToLicenseExplanatory_0" xml:lang="en-US">The entire disclosure for amendment to license and long-term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclsoureOfAmendmentToLicenseExplanatory_1" xml:lang="en-US">Disclsoure Of Amendment To License Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclsoureOfAmendmentToLicenseExplanatory_2" xml:lang="en-US">AMENDMENT TO BL-8040 LICENSE AND LONG-TERM LOAN</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_DollarMember_0" xml:lang="en-US">Dollar [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DollarMember_1" xml:lang="en-US">Dollar [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_EmployeesAndDirectorsMember_0" xml:lang="en-US">Employees and Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_EmployeesAndDirectorsMember_1" xml:lang="en-US">Employees and Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_EmployeesMember_0" xml:lang="en-US">Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_EuroLinkedTradePayablesMember_0" xml:lang="en-US">Euro-linked trade payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_EuroLinkedTradePayablesMember_1" xml:lang="en-US">Euro Linked Trade Payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_EuroLinkedTradePayablesMember_2" xml:lang="en-US">Euro-linked trade payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_EuroPerDollarMember_0" xml:lang="en-US">Euro Per Dollar [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_EuroPerDollarMember_1" xml:lang="en-US">Euro Per Dollar Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_EuroPerDollarMember_2" xml:lang="en-US">Euro per $1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExchangeDifferences_0" xml:lang="en-US">Exchange differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ExchangeDifferences_1" xml:lang="en-US">Exchange differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExchangeDifferencesDuringYear_0" xml:lang="en-US">Excahnge difference in lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_blrx_ExchangeDifferencesDuringYear_1" xml:lang="en-US">Exchange differences during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ExchangeDifferencesDuringYear_2" xml:lang="en-US">Exchange differences during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ExchangeDifferencesDuringYear_3" xml:lang="en-US">Exchange differences during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExchangeDifferencesOnLeaseLiability_0" xml:lang="en-US">Adjustments for exchange differences on lease liability to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ExchangeDifferencesOnLeaseLiability_1" xml:lang="en-US">Exchange differences on lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ExchangeDifferencesOnLeaseLiability_2" xml:lang="en-US">Exchange differences on lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExercisableTermOfWarrant_0" xml:lang="en-US">Exercisable term of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ExercisableTermOfWarrant_1" xml:lang="en-US">Exercisable term of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExerciseOfPricePerAds_0" xml:lang="en-US">Exercise of price per ADS.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ExerciseOfPricePerAds_1" xml:lang="en-US">Exercise of price per ADS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExercisePriceOfShareIssued_0" xml:lang="en-US">Exercise price of shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ExercisePriceOfShareIssued_1" xml:lang="en-US">Exercise Price Of Share Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ExercisePriceOfShareIssued_2" xml:lang="en-US">Exercise price of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExercisePriceOfWarrants_0" xml:lang="en-US">Exercise price of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ExercisePriceOfWarrants_1" xml:lang="en-US">Exercise price of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExercisePriceRangeFourMember_0" xml:lang="en-US">Over 40.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ExercisePriceRangeFourMember_1" xml:lang="en-US">Exercise Price Range Four Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ExercisePriceRangeFourMember_2" xml:lang="en-US">2.01-3.4 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExercisePriceRangeMember_0" xml:lang="en-US">Up to 10.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ExercisePriceRangeMember_1" xml:lang="en-US">Exercise Price Range Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ExercisePriceRangeMember_2" xml:lang="en-US">Up to 0.49 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExercisePriceRangeOneMember_0" xml:lang="en-US">10.01-20.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ExercisePriceRangeOneMember_1" xml:lang="en-US">Exercise Price Range One Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ExercisePriceRangeOneMember_2" xml:lang="en-US">0.5- 0.99 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExercisePriceRangeSixMember_0" xml:lang="en-US">Range six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExercisePriceRangeThreeMember_0" xml:lang="en-US">30.01-40.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ExercisePriceRangeTwoMember_0" xml:lang="en-US">20.01-30.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ExercisePriceRangeTwoMember_1" xml:lang="en-US">Exercise Price Range Two Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ExercisePriceRangeTwoMember_2" xml:lang="en-US">1.00-2.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_0" xml:lang="en-US">Represents amount fair value of ordinary warrants adjusted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_1" xml:lang="en-US">Fair Value Of Ordinary Warrants Adjusted Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_2" xml:lang="en-US">Fair value of the ordinary warrants was adjusted amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_FairValueOfWarrants_0" xml:lang="en-US">Balance as of January 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_blrx_FairValueOfWarrants_1" xml:lang="en-US">Balance as of December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_blrx_FairValueOfWarrants_2" xml:lang="en-US">Balance as of January 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_FairValueOfWarrants_3" xml:lang="en-US">Fair Value Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_FirstThreeYearsMember_0" xml:lang="en-US">First three years.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_FirstThreeYearsMember_1" xml:lang="en-US">First Three Years [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_FirstThreeYearsMember_2" xml:lang="en-US">First three years [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_FirstTrancheMember_0" xml:lang="en-US">This member stands for first tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_FirstTrancheMember_1" xml:lang="en-US">First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_FirstTrancheMember_2" xml:lang="en-US">First tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_0" xml:lang="en-US">The effect of a five percent decrease in the given metric on net income (loss) and equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_1" xml:lang="en-US">Five Percent Decrease Effect On Net Income Loss And Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_2" xml:lang="en-US">5% decrease effect on net income (loss) and equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_0" xml:lang="en-US">The effect of a five percent increase in the given metric on net income (loss) and equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_1" xml:lang="en-US">Five Percent Increase Effect On Net Income Loss And Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_2" xml:lang="en-US">5% increase effect on net income (loss) and equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_GainOnRealizationOfLongtermInvestment_0" xml:lang="en-US">Gain on realization of long-term investment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_blrx_GainOnRealizationOfLongtermInvestment_1" xml:lang="en-US">Gain on realization of long-term investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_GainOnRealizationOfLongtermInvestment_2" xml:lang="en-US">Gain On Realization Of Longterm Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_GainOnRealizationOfLongtermInvestment_3" xml:lang="en-US">Gain from realization of long-term investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_GloriaLicenseAgreementMember_0" xml:lang="en-US">Represents the member information related to Gloria License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_GloriaLicenseAgreementMember_1" xml:lang="en-US">Gloria License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_GloriaPurchaseAgreementMember_0" xml:lang="en-US">This member is stand for Gloria Purchase Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_GloriaPurchaseAgreementMember_1" xml:lang="en-US">Gloria Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_GrossProceedsFromOffering_0" xml:lang="en-US">Amount of gross proceeds from offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_GrossProceedsFromOffering_1" xml:lang="en-US">Gross Proceeds From Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_GrossProceedsFromOffering_2" xml:lang="en-US">Gross proceeds from offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_HCWainwrightAndCoLlcMember_0" xml:lang="en-US">H.C. Wainwright &amp; Co., LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_HCWainwrightAndCoLlcMember_1" xml:lang="en-US">H C Wainwright And Co Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_HCWainwrightAndCoLlcMember_2" xml:lang="en-US">H.C. Wainwright &amp; Co., LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_HighbridgeCapitalManagementLlcMember_0" xml:lang="en-US">Highbridge Capital Management LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_HighbridgeCapitalManagementLlcMember_1" xml:lang="en-US">Highbridge Capital Management Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_HighbridgeMember_0" xml:lang="en-US">Highbridge [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_HighbridgeMember_1" xml:lang="en-US">Highbridge [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IBridgeCapitalMember_0" xml:lang="en-US">I-Bridge Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IBridgeCapitalMember_1" xml:lang="en-US">I-Bridge Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IfrsStatementLineItems_0" xml:lang="en-US">Ifrs Statement [LineItems]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IfrsStatementLineItems_1" xml:lang="en-US">Ifrs Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IfrsStatementTable_0" xml:lang="en-US">ifrs Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IfrsStatementTable_1" xml:lang="en-US">Ifrs Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_0" xml:lang="en-US">The increase (decrease) in liabilities arising from financing activities resulting from amounts recognized through profit and loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_1" xml:lang="en-US">Increase Decrease Through Amounts Recognized Through Profit And Loss Arising From Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_2" xml:lang="en-US">Amounts recognized through profit and loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_0" xml:lang="en-US">The increase (decrease) in equity resulting from the exercise of options, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_1" xml:lang="en-US">Increase (Decrease) Through Exercise Of Options, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_2" xml:lang="en-US">Employee stock options exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_0" xml:lang="en-US">Represents the increase (decrease) in equity resulting from the exercise of pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_1" xml:lang="en-US">Increase (Decrease) Through Exercise Of Pre-funded Warrants Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_2" xml:lang="en-US">Pre-funded warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_0" xml:lang="en-US">Represents the increase (decrease) in equity resulting from the exercise of pre-funded warrants, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_1" xml:lang="en-US">Increase (Decrease) Through Exercise Of Pre-funded Warrants Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_2" xml:lang="en-US">Pre-funded warrants exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_0" xml:lang="en-US">The increase (decrease) in equity resulting from the exercise of warrants, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_1" xml:lang="en-US">Increase (Decrease) Through Exercise Of Warrants, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_2" xml:lang="en-US">Warrants exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_0" xml:lang="en-US">The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_1" xml:lang="en-US">Increase Decrease Through Financing Cash Flows Paid Liabilities Arising From Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_2" xml:lang="en-US">Cash flows paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_0" xml:lang="en-US">The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_1" xml:lang="en-US">Increase Decrease Through Financing Cash Flows Received Liabilities Arising From Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_2" xml:lang="en-US">Cash flows received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_0" xml:lang="en-US">Employee stock options forfeited and expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_1" xml:lang="en-US">Increase Decrease Through Forfeited And Expired Of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_2" xml:lang="en-US">Employee stock options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_0" xml:lang="en-US">Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_1" xml:lang="en-US">Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IncrementalInvestment_0" xml:lang="en-US">Represents amount of incremental investment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IncrementalInvestment_1" xml:lang="en-US">Incremental Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_IncrementalInvestment_2" xml:lang="en-US">Incremental investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InitialRoyaltyTerm_0" xml:lang="en-US">Represents about initial royalty term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InitialRoyaltyTerm_1" xml:lang="en-US">Initial Royalty Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_InitialRoyaltyTerm_2" xml:lang="en-US">Initial royalty term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InstitutionsCurrentReceivables_0" xml:lang="en-US">Institutions other receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InstitutionsCurrentReceivables_1" xml:lang="en-US">Institutions Current Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_InstitutionsCurrentReceivables_2" xml:lang="en-US">Government institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_0" xml:lang="en-US">Interest and exchange differences on restricted deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_1" xml:lang="en-US">Interest And Exchange Differences On Restricted Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_2" xml:lang="en-US">Warrant issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_0" xml:lang="en-US">Interest and exchange differences on short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_1" xml:lang="en-US">Interest And Exchange Differences On Short Term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_2" xml:lang="en-US">Interest and exchange differences on short-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InterestAndLinkageDifferencesOnBankLoan_0" xml:lang="en-US">Interest and linkage differences on bank loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InterestAndLinkageDifferencesOnBankLoan_1" xml:lang="en-US">Interest And Linkage Differences On Bank Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_InterestAndLinkageDifferencesOnBankLoan_2" xml:lang="en-US">Interest accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_InterestAndLinkageDifferencesOnBankLoan_3" xml:lang="en-US">Interest on loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_0" xml:lang="en-US">Represent the amount of Interest expense and exchange differences on Financial expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_1" xml:lang="en-US">Interest Expense And Exchange Differences On Financial Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_2" xml:lang="en-US">Interest expense and exchange differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InterestExpenseLeaseLiabilities_0" xml:lang="en-US">Interest expense on lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InterestExpenseLeaseLiabilities_1" xml:lang="en-US">Interest Expense Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_InterestExpenseLeaseLiabilities_2" xml:lang="en-US">Interest expense during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InterestExpenses_0" xml:lang="en-US">Interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InterestExpenses_1" xml:lang="en-US">Interest Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_InterestExpenses_2" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InterestIncomeAndExchangeDifferences_0" xml:lang="en-US">Interest income and exchange differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InterestIncomeAndExchangeDifferences_1" xml:lang="en-US">Interest income and exchange differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InterestRateOnLongTermBankLoan_0" xml:lang="en-US">Interest rate on long term bank loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InterestRateOnLongTermBankLoan_1" xml:lang="en-US">Interest rate on long term bank loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InterestRateOnShortTermDeposits_0" xml:lang="en-US">Interest rate on short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InterestRateOnShortTermDeposits_1" xml:lang="en-US">Interest Rate On Short Term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_InterestRateOnShortTermDeposits_2" xml:lang="en-US">Interest rate on short-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_0" xml:lang="en-US">Interest rate on short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_1" xml:lang="en-US">Interest Rate On Short Term Deposits Includes Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_2" xml:lang="en-US">Interest rate on short-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_InvestorsMember_0" xml:lang="en-US">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_InvestorsMember_1" xml:lang="en-US">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IssuanceOfAdsValue_0" xml:lang="en-US">Issuance of ADS, value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IssuanceOfAdsValue_1" xml:lang="en-US">Issuance of ADS, value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IssuanceOfShareCapital_0" xml:lang="en-US">This represents the issuance of share capital, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IssuanceOfShareCapital_1" xml:lang="en-US">Issuance Of Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_IssuanceOfShareCapital_2" xml:lang="en-US">Issuance of share capital, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IssuancesOfWarrants_0" xml:lang="en-US">Issuances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IssuancesOfWarrants_1" xml:lang="en-US">Issuances Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_IssuancesOfWarrants_2" xml:lang="en-US">Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_IssuedAndPaidUpShareCapitalValue_0" xml:lang="en-US">Amount of issued and paid up share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IssuedAndPaidUpShareCapitalValue_1" xml:lang="en-US">Issued And Paid Up Share Capital Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_IssuedAndPaidUpShareCapitalValue_2" xml:lang="en-US">Issued and paid-up share capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_KreosLoanMember_0" xml:lang="en-US">Kreos Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_KreosLoanMember_1" xml:lang="en-US">Kreos Loan Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_KreosLoanMember_2" xml:lang="en-US">Loan from Kreos Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LaboratoryEquipmentMember_0" xml:lang="en-US">Laboratory equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LaboratoryEquipmentMember_1" xml:lang="en-US">Laboratory equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LawsuitClaimAmount_0" xml:lang="en-US">lawsuit claim amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LawsuitClaimAmount_1" xml:lang="en-US">Lawsuit Claim Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_LawsuitClaimAmount_2" xml:lang="en-US">Lawsuit claim amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LeaseAgreementMonthlyFee_0" xml:lang="en-US">Lease agreement monthly fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LeaseAgreementMonthlyFee_1" xml:lang="en-US">Lease agreement monthly fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LeasePeriod_0" xml:lang="en-US">Lease Period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LeasePeriod_1" xml:lang="en-US">Lease Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LicenseAgreementMember_0" xml:lang="en-US">This member stands for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LicenseAgreementMember_1" xml:lang="en-US">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_0" xml:lang="en-US">The disclosure of license and securities purchase agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_1" xml:lang="en-US">License And Securities Purchase Agreements Explanatory [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_2" xml:lang="en-US">LICENSE AND SECURITIES PURCHASE AGREEMENTS &#8211; HST/GLORIA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_0" xml:lang="en-US">License fees and royalties payable to licensor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_1" xml:lang="en-US">License Fees And Royalties Payable To Licensor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_2" xml:lang="en-US">License fees and royalties payable to licensor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LicenseRevenues_0" xml:lang="en-US">License revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LicenseRevenues_1" xml:lang="en-US">License Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_LicenseRevenues_2" xml:lang="en-US">License revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LincolnParkCapitalFundMember_0" xml:lang="en-US">Oberon Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LoanAgreementWithKreosCapitalMember_0" xml:lang="en-US">Loan Agreement With Kreos Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LoanAgreementWithKreosCapitalMember_1" xml:lang="en-US">Loan Agreement With BlackRock EMEA Venture and Growth Lending [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LoanTakenForPaymentOfAgreementValue_0" xml:lang="en-US">Represents amount of loan taken for payment of agreement value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LoanTakenForPaymentOfAgreementValue_1" xml:lang="en-US">Loan Taken For Payment Of Agreement Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_LoanTakenForPaymentOfAgreementValue_2" xml:lang="en-US">Loan taken from Kreos Capital for the payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LongTermPrepaidExpenses_0" xml:lang="en-US">Long-term prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LongTermPrepaidExpenses_1" xml:lang="en-US">Long Term Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_LongTermPrepaidExpenses_2" xml:lang="en-US">Long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_LossOnAbandonmentOfRightofuseAsset_0" xml:lang="en-US">Represents the amount of loss on abandonment of rightofuse asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LossOnAbandonmentOfRightofuseAsset_1" xml:lang="en-US">Loss On Abandonment Of Rightofuse Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_LossOnAbandonmentOfRightofuseAsset_2" xml:lang="en-US">Loss on abandonment of right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_MarketAccessExpense_0" xml:lang="en-US">Market access expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_MarketAccessExpense_1" xml:lang="en-US">Market Access Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_MarketAccessExpense_2" xml:lang="en-US">Market Access</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_MarketingExpenses_0" xml:lang="en-US">Marketing Expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_MarketingExpenses_1" xml:lang="en-US">Marketing Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_MarketingExpenses_2" xml:lang="en-US">Marketing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_MarketSharePrice_0" xml:lang="en-US">Market price of ordinary shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_MarketSharePrice_1" xml:lang="en-US">Market Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_MarketSharePrice_2" xml:lang="en-US">Market price of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_MaturitiesOfRestrictedDeposits_0" xml:lang="en-US">Maturities of restricted deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_blrx_MaturitiesOfRestrictedDeposits_1" xml:lang="en-US">Maturities of restricted deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_MaturitiesOfRestrictedDeposits_2" xml:lang="en-US">Maturities Of Restricted Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_MaturitiesOfShortTermDeposits_0" xml:lang="en-US">Maturities of short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_blrx_MaturitiesOfShortTermDeposits_1" xml:lang="en-US">Maturities of short-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_MaturitiesOfShortTermDeposits_2" xml:lang="en-US">Maturities Of Short Term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_MaturityDate_0" xml:lang="en-US">Maturity date of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_MaturityDate_1" xml:lang="en-US">Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_MaturityDate_2" xml:lang="en-US">Maturity date of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_MaximumFutureMilestonePayments_0" xml:lang="en-US">Represent the maximum future milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_MaximumFutureMilestonePayments_1" xml:lang="en-US">Maximum Future Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_MaximumFutureMilestonePayments_2" xml:lang="en-US">Maximum future milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_MedicalAffairs_0" xml:lang="en-US">Medical Affairs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_MedicalAffairs_1" xml:lang="en-US">Medical Affairs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_0" xml:lang="en-US">Represents amount of minimum cash balance requirement under the Loan Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_1" xml:lang="en-US">Minimum Cash Balance Requirement Under Loan Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_2" xml:lang="en-US">Minimum cash balance requirement under the Loan Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_MonthlyAdvisoryFee_0" xml:lang="en-US">Represents amount of monthly advisory fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_MonthlyAdvisoryFee_1" xml:lang="en-US">Monthly Advisory Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_MonthlyAdvisoryFee_2" xml:lang="en-US">Monthly advisory fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NetAssetValueOfLinkageMonetaryItems_0" xml:lang="en-US">Net asset value of linkage monetary items.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NetAssetValueOfLinkageMonetaryItems_1" xml:lang="en-US">Net Asset Value Of Linkage Monetary Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_blrx_NetAssetValueOfLinkageMonetaryItems_2" xml:lang="en-US">Net asset value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_NetAssetValueOfLinkageMonetaryItems_3" xml:lang="en-US">Net asset value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NetBookValueMember_0" xml:lang="en-US">Net book value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NetBookValueMember_1" xml:lang="en-US">Net Book Value [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_NetBookValueMember_2" xml:lang="en-US">Net book value [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NetMember_0" xml:lang="en-US">Net [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NetMember_1" xml:lang="en-US">Net Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_NetMember_2" xml:lang="en-US">Total [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NisLinkedBalancesMember_0" xml:lang="en-US">NIS-linked balances [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NisLinkedBalancesMember_1" xml:lang="en-US">Nis Linked Balances Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_NisLinkedBalancesMember_2" xml:lang="en-US">Total NIS-linked balances [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NisMember_0" xml:lang="en-US">NIS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NisMember_1" xml:lang="en-US">NIS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NisPerDollarMember_0" xml:lang="en-US">Nis Per Dollar [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NisPerDollarMember_1" xml:lang="en-US">Nis Per Dollar Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_NisPerDollarMember_2" xml:lang="en-US">NIS per $1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NonOperatingExpense_0" xml:lang="en-US">Non-operating expense incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NonOperatingExpense_1" xml:lang="en-US">Non operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NovartisPharmaMember_0" xml:lang="en-US">Novartis pharma [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_0" xml:lang="en-US">Number of American Depositary Shares issued to investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_1" xml:lang="en-US">Number Of American Depositary Shares Issued To Investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_2" xml:lang="en-US">Number of ADS issued to institutional investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NumberOfNewSharesIssued_0" xml:lang="en-US">The number of new shares issued by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NumberOfNewSharesIssued_1" xml:lang="en-US">Number Of New Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_blrx_NumberOfNewSharesIssued_2" xml:lang="en-US">Total number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_NumberOfNewSharesIssued_3" xml:lang="en-US">Issuance of share capital, pre-funded warrants and warrants, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NumberOfOptionsAbstract_0" xml:lang="en-US">Number of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NumberOfOptionsAbstract_1" xml:lang="en-US">Number Of Options Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_NumberOfOptionsAbstract_2" xml:lang="en-US">Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NumberOfOrdinarySharesAbstract_0" xml:lang="en-US">Number of ordinary shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NumberOfOrdinarySharesAbstract_1" xml:lang="en-US">Number of Ordinary Shares Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_NumberOfOrdinarySharesAbstract_2" xml:lang="en-US">Number of Ordinary Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_0" xml:lang="en-US">Number of pre funded warrants issued to purchase ADS.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_1" xml:lang="en-US">Number Of Pre Funded Warrants Issued To Purchase Ads</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_2" xml:lang="en-US">Number of pre funded warrants issued to purchase ADS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NumberOfPremises_0" xml:lang="en-US">It represents number of premises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NumberOfPremises_1" xml:lang="en-US">Number Of Premises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_NumberOfPremises_2" xml:lang="en-US">Number of premises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NumberOfSegments_0" xml:lang="en-US">Number of segments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NumberOfSegments_1" xml:lang="en-US">Number Of Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_NumberOfSegments_2" xml:lang="en-US">Number of segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_NumberOfWarrantPurchase_0" xml:lang="en-US">Number of warrant purchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_NumberOfWarrantPurchase_1" xml:lang="en-US">Number of warrant purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_OberonSecuritiesMember_0" xml:lang="en-US">Oberon Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_OfferingToInstitutionalInvestorsMember_0" xml:lang="en-US">This member stands for offering to institutional investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_OfferingToInstitutionalInvestorsMember_1" xml:lang="en-US">Offering To Institutional Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_OpenPurchaseOrderCommitments_0" xml:lang="en-US">Total outstanding open purchase order commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_OpenPurchaseOrderCommitments_1" xml:lang="en-US">Open Purchase Order Commitments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_OpenPurchaseOrderCommitments_2" xml:lang="en-US">Company's outstanding open purchase order commitments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_OrbiMedAdvisorsMember_0" xml:lang="en-US">OrbiMed Advisors LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_OtherComprehensiveIncomeLossMember_0" xml:lang="en-US">Other comprehensive income loss [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_OtherComprehensiveIncomeLossMember_1" xml:lang="en-US">Other Comprehensive Income Loss [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_OtherComprehensiveIncomeLossMember_2" xml:lang="en-US">Other comprehensive loss [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_OtherCurrenciesMember_0" xml:lang="en-US">OrbiMed Advisors LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_OtherCurrenciesMember_1" xml:lang="en-US">Other Currencies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_OtherCurrenciesMember_2" xml:lang="en-US">Other currencies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_OtherNonoperatingIncomeExpenses_0" xml:lang="en-US">Other nonoperating income (expense).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_OtherNonoperatingIncomeExpenses_1" xml:lang="en-US">Other Nonoperating Income Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_OtherNonoperatingIncomeExpenses_2" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_OtherPayablesAbstract_0" xml:lang="en-US">Other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_OtherPayablesAbstract_1" xml:lang="en-US">Other Payables Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_OtherPayablesAbstract_2" xml:lang="en-US">Other:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_OtherPayablesMember_0" xml:lang="en-US">Other payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_OtherPayablesMember_1" xml:lang="en-US">Other Payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_OtherPayablesMember_2" xml:lang="en-US">Other payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_OtherReceivablesMember_0" xml:lang="en-US">Other receivables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_OtherReceivablesMember_1" xml:lang="en-US">Other Receivables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_OtherReceivablesMember_2" xml:lang="en-US">Other receivables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_Others_0" xml:lang="en-US">The amount of other receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_Others_1" xml:lang="en-US">Others</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_Others_2" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PaymentsLeaseLiabilities_0" xml:lang="en-US">Payments of lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_blrx_PaymentsLeaseLiabilities_1" xml:lang="en-US">Payments during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PaymentsLeaseLiabilities_2" xml:lang="en-US">Payments Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PaymentsLeaseLiabilities_3" xml:lang="en-US">Payments during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PayrollAndRelatedExpenses_0" xml:lang="en-US">Payroll and related expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PayrollAndRelatedExpenses_1" xml:lang="en-US">Payroll And Related Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PayrollAndRelatedExpenses_2" xml:lang="en-US">Payroll and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PDACPerformanceObligationMember_0" xml:lang="en-US">This member stands for PDAC performance obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PDACPerformanceObligationMember_1" xml:lang="en-US">P D A C Performance Obligation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PDACPerformanceObligationMember_2" xml:lang="en-US">PDAC performance obligation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageIncreaseDecreaseInExchangeRate_0" xml:lang="en-US">Percentage increase (decrease) in exchange rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageIncreaseDecreaseInExchangeRate_1" xml:lang="en-US">Percentage Increase Decrease In Exchange Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PercentageIncreaseDecreaseInExchangeRate_2" xml:lang="en-US">Percentage increase (decrease) in USD exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageIncreasePrecedingLeasePaymentAmount_0" xml:lang="en-US">Percentage Increase preceding lease payment amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageIncreasePrecedingLeasePaymentAmount_1" xml:lang="en-US">Percentage Increase preceding lease payment amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfAdditionalEquityInterest_0" xml:lang="en-US">Represents percentage of additional equity interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfAdditionalEquityInterest_1" xml:lang="en-US">Percentage Of Additional Equity Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PercentageOfAdditionalEquityInterest_2" xml:lang="en-US">Percentage of additional equity interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfAnnualInterestOfCashFees_0" xml:lang="en-US">It represents percentage of annual interest of cash fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfAnnualInterestOfCashFees_1" xml:lang="en-US">Percentage Of Annual Interest Of Cash Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_PercentageOfAnnualInterestOfCashFees_2" xml:lang="en-US">Percentage of annual interest of cash fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfCommissionOnSalesAgreement_0" xml:lang="en-US">Percentage of commission on sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfCommissionOnSalesAgreement_1" xml:lang="en-US">Percentage of commission on sales agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfDecreasingAnnualGrowthRate_0" xml:lang="en-US">It represets percentage of decreasing annual growth rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfDecreasingAnnualGrowthRate_1" xml:lang="en-US">Percentage Of Decreasing Annual Growth Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_PercentageOfDecreasingAnnualGrowthRate_2" xml:lang="en-US">Percentage of decreasing annual growth rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfFutureMilestonePayments_0" xml:lang="en-US">Represents future milestone payments percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfFutureMilestonePayments_1" xml:lang="en-US">Percentage Of Future Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PercentageOfFutureMilestonePayments_2" xml:lang="en-US">Percentage of future milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_0" xml:lang="en-US">It represents percentage of increasing weighted average cost of capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_1" xml:lang="en-US">Percentage Of Increasing Weighted Average Cost Of Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_2" xml:lang="en-US">Percentage of increasing weighted average cost of capital (WACC)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfIssuedShareCapitalReceived_0" xml:lang="en-US">Represents percentage of issued share capital received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfIssuedShareCapitalReceived_1" xml:lang="en-US">Percentage Of Issued Share Capital Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PercentageOfIssuedShareCapitalReceived_2" xml:lang="en-US">Percentage of issued share capital received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_0" xml:lang="en-US">Represents percentage of issued share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_1" xml:lang="en-US">Percentage Of Issued Share Capital Received Within Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_2" xml:lang="en-US">Percentage of issued share capital received within 36 months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_0" xml:lang="en-US">Percentage of net consideration received from the for direct product sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_1" xml:lang="en-US">Percentage Of Net Consideration Received For Direct Product Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfNetConsiderationReceivedForSubLicense_0" xml:lang="en-US">Percentage of net consideration received from the for sub license</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfNetConsiderationReceivedForSubLicense_1" xml:lang="en-US">Percentage Of Net Consideration Received For Sub License</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfNetConsiderationReceivedFromLicensee_0" xml:lang="en-US">Percentage of net consideration received from the licensee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfNetConsiderationReceivedFromLicensee_1" xml:lang="en-US">Percentage of net consideration received from the licensee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfOwnershipStake_0" xml:lang="en-US">Perpresents percentage of ownership.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfOwnershipStake_1" xml:lang="en-US">Percentage Of Ownership Stake</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PercentageOfOwnershipStake_2" xml:lang="en-US">Percentage of ownership stake</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfPaymentToBeMade_0" xml:lang="en-US">Represents percentage of payment to be made.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfPaymentToBeMade_1" xml:lang="en-US">Percentage Of Payment To Be Made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_PercentageOfPaymentToBeMade_2" xml:lang="en-US">Percentage of payment to be made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfReducePaymentOwedOnSublicenseReceipts_0" xml:lang="en-US">Percentage of Reduce payment owed on sublicense receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfReducePaymentOwedOnSublicenseReceipts_1" xml:lang="en-US">Percentage of Reduce payment owed on sublicense receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_0" xml:lang="en-US">Percentage of royalties receivable from aggregate net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_1" xml:lang="en-US">Percentage Of Royalties Receivable From Aggregate Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_2" xml:lang="en-US">Percentage of royalties receivable from aggregate net sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PerformanceSharesUnitMember_0" xml:lang="en-US">Performance Shares Unit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PerformanceSharesUnitMember_1" xml:lang="en-US">Performance Shares Unit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PerformanceStockUnitsMember_0" xml:lang="en-US">PSU [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PhaseThreeMember_0" xml:lang="en-US">Phase three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PhaseTwoMember_0" xml:lang="en-US">Phase two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PlacementAgentOfferingMember_0" xml:lang="en-US">This member stands for placement agent offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PlacementAgentOfferingMember_1" xml:lang="en-US">Placement Agent Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PlacementAgentsDesigneesMember_0" xml:lang="en-US">Placement Agent's Designees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PlacementAgentsDesigneesMember_1" xml:lang="en-US">Placement Agent's Designees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_0" xml:lang="en-US">Pre funded or ordinary warrants exercise terms.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_1" xml:lang="en-US">Pre Funded Or Ordinary Warrants Exercise Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_2" xml:lang="en-US">Pre funded or ordinary warrants exercise terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PreFundedWarrantPurchasePricePerShare_0" xml:lang="en-US">Pre-funded warrant purchase price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PreFundedWarrantPurchasePricePerShare_1" xml:lang="en-US">Pre Funded Warrant Purchase Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PreFundedWarrantPurchasePricePerShare_2" xml:lang="en-US">Pre-funded warrant purchase price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PreFundedWarrants_0" xml:lang="en-US">Amount represnts of pre funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PreFundedWarrants_1" xml:lang="en-US">Pre Funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PreFundedWarrantsExercisablePricePerAds_0" xml:lang="en-US">Pre funded warrants exercisable price per ADS.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PreFundedWarrantsExercisablePricePerAds_1" xml:lang="en-US">Pre Funded Warrants Exercisable Price Per Ads</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PreFundedWarrantsExercisablePricePerAds_2" xml:lang="en-US">Pre funded warrants exercisable price per AD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PreFundedWarrantsExercisePricePerAds_0" xml:lang="en-US">Pre funded warrants exercise price per ADS.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PreFundedWarrantsExercisePricePerAds_1" xml:lang="en-US">Pre Funded Warrants Exercise Price Per Ads</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PreFundedWarrantsExercisePricePerAds_2" xml:lang="en-US">Pre funded warrants exercise price per ADS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PreFundedWarrantsMember_0" xml:lang="en-US">Pre Funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PreFundedWarrantsMember_1" xml:lang="en-US">Pre Funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_0" xml:lang="en-US">Represents amount of proceeds from exercise of warrants after deducting fees and expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_1" xml:lang="en-US">Proceeds From Exercise Of Warrants After Deducting Fees And Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_2" xml:lang="en-US">Proceeds from exercise of warrants after deducting fees and expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ProceedsFromExerciseWarrants_0" xml:lang="en-US">The cash inflow from the exercise share purchase warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ProceedsFromExerciseWarrants_1" xml:lang="en-US">Proceeds From Exercise Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ProceedsFromExerciseWarrants_2" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ProceedsFromIssuanceOfInitialPublicOffering_0" xml:lang="en-US">Proceeds from public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ProceedsFromIssuanceOfInitialPublicOffering_1" xml:lang="en-US">Proceeds From Issuance Of Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ProceedsFromIssuanceOfInitialPublicOffering_2" xml:lang="en-US">Proceeds from public offering, gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_0" xml:lang="en-US">Proceeds from public offering, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_1" xml:lang="en-US">Proceeds From Issuance Of Initial Public Offering Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_2" xml:lang="en-US">Proceeds from public offering, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ProceedsFromWarrantIssue_0" xml:lang="en-US">Proceeds from warrant issue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ProceedsFromWarrantIssue_1" xml:lang="en-US">Proceeds From Warrant Issue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ProceedsFromWarrantIssue_2" xml:lang="en-US">Proceeds from warrant issue, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ProductSalesNet_0" xml:lang="en-US">Product sales, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ProductSalesNet_1" xml:lang="en-US">Product Sales, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_ProductSalesNet_2" xml:lang="en-US">Product sales, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ProfessionalFee_0" xml:lang="en-US">Fee expense related to professional.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ProfessionalFee_1" xml:lang="en-US">Professional Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ProfessionalFee_2" xml:lang="en-US">Professional fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ProfitLossFromNonOperatingActivities_0" xml:lang="en-US">Non operating profit (loss) from operating activities of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ProfitLossFromNonOperatingActivities_1" xml:lang="en-US">Profit Loss From Non Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ProfitLossFromNonOperatingActivities_2" xml:lang="en-US">NON-OPERATING INCOME (EXPENSES), NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_blrx_ProfitLossFromNonOperatingActivities_3" xml:lang="en-US">Non-operating income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ProvisionForDoubtfulAccountsReceivable_0" xml:lang="en-US">Represents amount for provision for doubtful accounts receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_blrx_ProvisionForDoubtfulAccountsReceivable_1" xml:lang="en-US">Provision for doubtful accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ProvisionForDoubtfulAccountsReceivable_2" xml:lang="en-US">Provision For Doubtful Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ProvisionForDoubtfulAccountsReceivable_3" xml:lang="en-US">Provision for doubtful accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PublicOfferingMember_0" xml:lang="en-US">Public offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PublicOfferingMember_1" xml:lang="en-US">Public offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PurchaseAgreementMember_0" xml:lang="en-US">Represents bout purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PurchaseAgreementMember_1" xml:lang="en-US">Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PurchaseAgreementPeriod_0" xml:lang="en-US">Purchase agreement period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PurchaseAgreementPeriod_1" xml:lang="en-US">Purchase agreement period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_PurchasePricePerADS_0" xml:lang="en-US">Represent about purchase price per ADS.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PurchasePricePerADS_1" xml:lang="en-US">Purchase Price Per A D S</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PurchasePricePerADS_2" xml:lang="en-US">Purchase price per ADS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RecognizedAsEquity_0" xml:lang="en-US">Amount of recognized as equity Pursuant to IFRS 15.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RecognizedAsEquity_1" xml:lang="en-US">Recognized As Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_RecognizedAsEquity_2" xml:lang="en-US">Recognized as equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RegisteredDirectOfferingMember_0" xml:lang="en-US">This member stands for registered direct offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RegisteredDirectOfferingMember_1" xml:lang="en-US">Registered Direct Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RemainingAuthorizedUnissuedOrdinaryShares_0" xml:lang="en-US">Remaining authorized unissued ordinary shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RemainingAuthorizedUnissuedOrdinaryShares_1" xml:lang="en-US">Remaining authorized unissued ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RemainingUnrecognizedDeferredCompensationExpense_0" xml:lang="en-US">Remaining unrecognized deferred compensation expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RemainingUnrecognizedDeferredCompensationExpense_1" xml:lang="en-US">Remaining unrecognized deferred compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RepaymentOfLongTermDebtAfterOneYear_0" xml:lang="en-US">The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RepaymentOfLongTermDebtAfterOneYear_1" xml:lang="en-US">Repayment Of Long Term Debt After One Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_RepaymentOfLongTermDebtAfterOneYear_2" xml:lang="en-US">2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RepaymentOfLongTermDebtYearsTwo_0" xml:lang="en-US">The cash outflow for debt initially having maturity due year two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RepaymentOfLongTermDebtYearsTwo_1" xml:lang="en-US">Repayment Of Long Term Debt Years Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_RepaymentOfLongTermDebtYearsTwo_2" xml:lang="en-US">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_0" xml:lang="en-US">The revised weighted average exercise price of share options exercised in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_1" xml:lang="en-US">Revised Weighted Average Exercise Price Of Share Options Exercised In Share Based Payment Arrangement 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_2" xml:lang="en-US">Revised weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RightOfUseAssetWrittenOff_0" xml:lang="en-US">Right Of Use Asset Written Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RightOfUseAssetWrittenOff_1" xml:lang="en-US">Right Of Use Asset Written Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_RightOfUseAssetWrittenOff_2" xml:lang="en-US">Right of use of asset written off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RoyaltiesEligibleMargin_0" xml:lang="en-US">Represents about royalties eligible margins.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RoyaltiesEligibleMargin_1" xml:lang="en-US">Royalties Eligible Margin</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_RoyaltiesEligibleMargin_2" xml:lang="en-US">Royalties eligible margin</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RoyaltiesOnSale_0" xml:lang="en-US">Royalties on sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RoyaltiesOnSale_1" xml:lang="en-US">Royalties on sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RoyaltiesPaymentPercentage_0" xml:lang="en-US">Represent the royalties payment percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RoyaltiesPaymentPercentage_1" xml:lang="en-US">Royalties Payment Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_RoyaltiesPaymentPercentage_2" xml:lang="en-US">Royalties payment percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_0" xml:lang="en-US">Represent the royalties payment percentage if the company independently sell products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_1" xml:lang="en-US">Royalties Payment Percentage If Company Independently Sell Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_2" xml:lang="en-US">Royalties payment percentage if the company independently sell products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RoyaltiesRateOnNetSales_0" xml:lang="en-US">Represent the royalties rate on net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RoyaltiesRateOnNetSales_1" xml:lang="en-US">Royalties Rate On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_RoyaltiesReceivedPercentage_0" xml:lang="en-US">Royalties received percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_RoyaltiesReceivedPercentage_1" xml:lang="en-US">Royalties received percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SaleOfStockNumberOfSharesIssued_0" xml:lang="en-US">Sale of stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SaleOfStockNumberOfSharesIssued_1" xml:lang="en-US">Sale Of Stock Number Of Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_SaleOfStockNumberOfSharesIssued_2" xml:lang="en-US">Sale of stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SalesAndMarketingDepreciationAndAmortization_0" xml:lang="en-US">Depreciation and amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SalesAndMarketingDepreciationAndAmortization_1" xml:lang="en-US">Sales And Marketing Depreciation And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SalesAndMarketingDepreciationAndAmortization_2" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SalesAndMarketingExpensesOther_0" xml:lang="en-US">Sales and marketing expenses Other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SalesAndMarketingExpensesOther_1" xml:lang="en-US">Sales And Marketing Expenses Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SalesAndMarketingExpensesOther_2" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SalesAndMarketingExpensesRelatedToSales_0" xml:lang="en-US">Sales and marketing expenses related to sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SalesAndMarketingExpensesRelatedToSales_1" xml:lang="en-US">Sales And Marketing Expenses Related To Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SalesAndMarketingExpensesRelatedToSales_2" xml:lang="en-US">Payroll and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SalesAndMarketingPayrollExpense_0" xml:lang="en-US">Payroll and related expenses, including vehicles.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SalesAndMarketingPayrollExpense_1" xml:lang="en-US">Sales And Marketing Payroll Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SalesAndMarketingPayrollExpense_2" xml:lang="en-US">Office-related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SalesAndMarketingProfessionalFees_0" xml:lang="en-US">Sales and marketing professional fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SalesAndMarketingProfessionalFees_1" xml:lang="en-US">Sales And Marketing Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_SalesAndMarketingProfessionalFees_2" xml:lang="en-US">Professional fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SalesAndMarketingShareBasedCompensation_0" xml:lang="en-US">Sales and marketing Share-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SalesAndMarketingShareBasedCompensation_1" xml:lang="en-US">Sales And Marketing Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SalesAndMarketingShareBasedCompensation_2" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SalesMilestoneAmount_0" xml:lang="en-US">Amount of sales milestone amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SalesMilestoneAmount_1" xml:lang="en-US">Sales Milestone Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_SalesMilestoneAmount_2" xml:lang="en-US">Sales milestone amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ScmLicenseMember_0" xml:lang="en-US">This member stands for SCM license.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ScmLicenseMember_1" xml:lang="en-US">Scm License [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ScmLicenseMember_2" xml:lang="en-US">SCM license [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ScmSupportServicesMember_0" xml:lang="en-US">This member stands for SCM support services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ScmSupportServicesMember_1" xml:lang="en-US">Scm Support Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ScmSupportServicesMember_2" xml:lang="en-US">SCM support services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SecondTrancheMember_0" xml:lang="en-US">This member stands for second tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SecondTrancheMember_1" xml:lang="en-US">Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SecondTrancheMember_2" xml:lang="en-US">Second tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SeniorManagementMember_0" xml:lang="en-US">Senior Management [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SeniorManagementMember_1" xml:lang="en-US">Senior Management [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SensitivityTestsDecreasingAnnualGrowthRate_0" xml:lang="en-US">It repreesnts sensitivity tests decreasing annual growth rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SensitivityTestsDecreasingAnnualGrowthRate_1" xml:lang="en-US">Sensitivity Tests Decreasing Annual Growth Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SensitivityTestsDecreasingAnnualGrowthRate_2" xml:lang="en-US">Sensitivity tests decreasing annual growth rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SensitivityTestsIncreasingAnnualGrowthRate_0" xml:lang="en-US">It represents sensitivity tests increasing annual growth rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SensitivityTestsIncreasingAnnualGrowthRate_1" xml:lang="en-US">Sensitivity Tests Increasing Annual Growth Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SensitivityTestsIncreasingAnnualGrowthRate_2" xml:lang="en-US">Sensitivity tests increasing annual growth rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SeriesAWarrantsMember_0" xml:lang="en-US">Series A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SeriesAWarrantsMember_1" xml:lang="en-US">Series A Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SeriesBWarrantMember_0" xml:lang="en-US">Series B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SeriesBWarrantMember_1" xml:lang="en-US">Series B Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_SeriesBWarrantMember_2" xml:lang="en-US">Series B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SeventhYearMember_0" xml:lang="en-US">Seventh year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SeventhYearMember_1" xml:lang="en-US">Seventh Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_SeventhYearMember_2" xml:lang="en-US">Seventh year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_0" xml:lang="en-US">Represent the amount of share based compensation related to general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_1" xml:lang="en-US">Share Based Compensation Related To General And Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_2" xml:lang="en-US">Share based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_0" xml:lang="en-US">Represent the amount of share based compensation related to research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_1" xml:lang="en-US">Share Based Compensation Related To Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_2" xml:lang="en-US">Share based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ShareIncentivePlanMember_0" xml:lang="en-US">2003 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ShareIncentivePlanMember_1" xml:lang="en-US">Share Incentive Plan Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ShareIncentivePlanMember_2" xml:lang="en-US">2003 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ShareIssuedAsAdditionalCommitmentFee_0" xml:lang="en-US">Share issued as additional commitment fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ShareIssuedAsAdditionalCommitmentFee_1" xml:lang="en-US">Share issued as additional commitment fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ShareIssuedOfPublicOffering_0" xml:lang="en-US">Underwritten public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ShareIssuedOfPublicOffering_1" xml:lang="en-US">Share Issued Of Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ShareIssuedOfPublicOffering_2" xml:lang="en-US">Underwritten public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ShareIssuedToPurchaseWarrant_0" xml:lang="en-US">Shares issued to purchase warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ShareIssuedToPurchaseWarrant_1" xml:lang="en-US">Share Issued To Purchase Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ShareIssuedToPurchaseWarrant_2" xml:lang="en-US">Shares issued to purchase warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SharePremiumResultingFromExerciseOfWarrants_0" xml:lang="en-US">Share premium resulting from exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SharePremiumResultingFromExerciseOfWarrants_1" xml:lang="en-US">Share Premium Resulting From Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_SharePremiumResultingFromExerciseOfWarrants_2" xml:lang="en-US">Share premium resulting from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SharePurchaseAgreement_0" xml:lang="en-US">Share purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SharePurchaseAgreement_1" xml:lang="en-US">Share purchase agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SharePurchaseAgreementMember_0" xml:lang="en-US">This member stands for share purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SharePurchaseAgreementMember_1" xml:lang="en-US">Share Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SharePurchaseAgreementShares_0" xml:lang="en-US">Share purchase agreement, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SharePurchaseAgreementShares_1" xml:lang="en-US">Share purchase agreement, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SharesIssuedRegisteredDirectOfferings_0" xml:lang="en-US">Registered direct offerings sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SharesIssuedRegisteredDirectOfferings_1" xml:lang="en-US">Shares Issued Registered Direct Offerings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_SharesIssuedRegisteredDirectOfferings_2" xml:lang="en-US">Registered direct offerings sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ShortTermDepositMember_0" xml:lang="en-US">Short term deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ShortTermDepositMember_1" xml:lang="en-US">Short Term Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ShortTermDepositMember_2" xml:lang="en-US">Short term deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SingleMaterialPerformanceObligationMember_0" xml:lang="en-US">This member stands for single material performance obligation .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SingleMaterialPerformanceObligationMember_1" xml:lang="en-US">Single Material Performance Obligation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_StockIssuedPricePerShare_0" xml:lang="en-US">Public offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_StockIssuedPricePerShare_1" xml:lang="en-US">Stock Issued Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_StockIssuedPricePerShare_2" xml:lang="en-US">Public offering price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SupplementalInformationOnInterestPaidInCash_0" xml:lang="en-US">Supplemental information on interest paid in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SupplementalInformationOnInterestPaidInCash_1" xml:lang="en-US">Supplemental Information On Interest Paid In Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_SupplementalInformationOnInterestPaidInCash_2" xml:lang="en-US">Supplemental information on interest paid in cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SupplementalInformationOnNoncashTransactionsAbstract_0" xml:lang="en-US">Supplementary non-cash investment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SupplementalInformationOnNoncashTransactionsAbstract_1" xml:lang="en-US">Supplemental Information On Non-cash Transactions: [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_SupplementalInformationOnNoncashTransactionsAbstract_2" xml:lang="en-US">Supplemental information on non-cash transactions:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_0" xml:lang="en-US">Supplementary information on Changes In Right-of-use Asset And Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_1" xml:lang="en-US">Supplementary Information On Changes In Right Of Use Asset And Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_2" xml:lang="en-US">Changes in right-of-use asset and lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_0" xml:lang="en-US">Represent the amount of Supplementary information on Fair Value Of Exercised Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_1" xml:lang="en-US">Supplementary Information On Fair Value Of Exercised Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_2" xml:lang="en-US">Fair value of exercised warrants (portion related to accumulated fair value adjustments)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SupplementaryInformationOnIntangibleAssetAcquired_0" xml:lang="en-US">Represent the amount of supplementary information on intangible asset acquired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SupplementaryInformationOnIntangibleAssetAcquired_1" xml:lang="en-US">Supplementary Information On Intangible Asset Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SupplementaryInformationOnIntangibleAssetAcquired_2" xml:lang="en-US">Intangible asset acquired in connection with GLIX1 collaboration transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SupplementaryInformationOnInterestReceivedInCash_0" xml:lang="en-US">Supplementary information on interest received in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SupplementaryInformationOnInterestReceivedInCash_1" xml:lang="en-US">Supplementary Information On Interest Received In Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_SupplementaryInformationOnInterestReceivedInCash_2" xml:lang="en-US">Supplemental information on interest received in cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_0" xml:lang="en-US">Represent the amount of Supplementary Information On Purchase Of Property And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_1" xml:lang="en-US">Supplementary Information On Purchase Of Property And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_2" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_SupplementaryInformationOnWarrantIssuanceCosts_0" xml:lang="en-US">Represent the amount of Supplementary Information On Warrant issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SupplementaryInformationOnWarrantIssuanceCosts_1" xml:lang="en-US">Supplementary Information On Warrant Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_SupplementaryInformationOnWarrantIssuanceCosts_2" xml:lang="en-US">Warrant issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_0" xml:lang="en-US">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to gains on adjustments of warrants to fair value, that are exempt from taxation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_1" xml:lang="en-US">Tax Effect Of Gain On Adjustment Of Warrants Fair Value Exempt From Taxation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_2" xml:lang="en-US">Loss (gain) on adjustment of warrants to fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_0" xml:lang="en-US">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to share-based compensation that are exempt from taxation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_1" xml:lang="en-US">Tax Effect Of Share Based Compensation Exempt From Taxation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_2" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TaxLossCarryforwards_0" xml:lang="en-US">Tax loss carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TaxLossCarryforwards_1" xml:lang="en-US">Tax Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_TaxLossCarryforwards_2" xml:lang="en-US">Tax loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TelAvivStockExchangeMember_0" xml:lang="en-US">Tel Aviv Stock Exchange [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_0" xml:lang="en-US">The effect of a ten percent decrease in the given metric on net income (loss) and equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_1" xml:lang="en-US">Ten Percent Decrease Effect On Net Income Loss And Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_2" xml:lang="en-US">10% decrease effect on net income (loss) and equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_0" xml:lang="en-US">The effect of a ten percent increase in the given metric on net income (loss) and equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_1" xml:lang="en-US">Ten Percent Increase Effect On Net Income Loss And Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_2" xml:lang="en-US">10% increase effect on net income (loss) and equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ThirdTrancheMember_0" xml:lang="en-US">This member stands for thied tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ThirdTrancheMember_1" xml:lang="en-US">Third Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ThreeSubsequentYearsMember_0" xml:lang="en-US">Three subsequent year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ThreeSubsequentYearsMember_1" xml:lang="en-US">Three Subsequent Years Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ThreeSubsequentYearsMember_2" xml:lang="en-US">Three subsequent years [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TotalChangeInOperatingAssetAndLiability_0" xml:lang="en-US">Total Change in operating asset and liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TotalChangeInOperatingAssetAndLiability_1" xml:lang="en-US">Total Change In Operating Asset And Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_blrx_TotalChangeInOperatingAssetAndLiability_2" xml:lang="en-US">Total change in operating asset and liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_0" xml:lang="en-US">Total income and expense not involving cash flows.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_1" xml:lang="en-US">Total Income And Expense Not Involving Cash Flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2" xml:lang="en-US">Total income and expense not involving cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_0" xml:lang="en-US">The amount of payment due to foreign suppliers for goods and services used in the entity's business.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_1" xml:lang="en-US">Trade And Other Payables To Foreign Trade Suppliers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_2" xml:lang="en-US">Overseas</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_0" xml:lang="en-US">The amount of payment due to local suppliers for goods and services used in the entity's business.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_1" xml:lang="en-US">Trade And Other Payables To Local Trade Suppliers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_2" xml:lang="en-US">In Israel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TradePayablesAbstract_0" xml:lang="en-US">Trade payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TradePayablesAbstract_1" xml:lang="en-US">Trade Payables Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_TradePayablesAbstract_2" xml:lang="en-US">Trade:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TradePayablesMember_0" xml:lang="en-US">Trade payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TradePayablesMember_1" xml:lang="en-US">Trade Payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_TradePayablesMember_2" xml:lang="en-US">Trade payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TrancheAxis_0" xml:lang="en-US">The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TrancheAxis_1" xml:lang="en-US">Tranche [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TrancheDomain_0" xml:lang="en-US">This member stands for tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TrancheDomain_1" xml:lang="en-US">Tranche [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_TransferFromLicenseToTheLicenseeAmount_0" xml:lang="en-US">Transfer from license to the licensee amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TransferFromLicenseToTheLicenseeAmount_1" xml:lang="en-US">Transfer From License To The Licensee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_TransferFromLicenseToTheLicenseeAmount_2" xml:lang="en-US">Transfer from license to the licensee amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_UnderwaterEmployeeStockOptionsMember_0" xml:lang="en-US">Underwater Employee Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_UnderwaterEmployeeStockOptionsMember_1" xml:lang="en-US">Underwater Employee Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_UnderwritersMember_0" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_UnderwritersMember_1" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_UniformTaxRate_0" xml:lang="en-US">Uniform tax rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_UniformTaxRate_1" xml:lang="en-US">Uniform Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_UniformTaxRate_2" xml:lang="en-US">Uniform tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_UpfrontPayment_0" xml:lang="en-US">Amount of upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_UpfrontPayment_1" xml:lang="en-US">Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_ValueOfServicesRecorded_0" xml:lang="en-US">Value of services recorded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ValueOfServicesRecorded_1" xml:lang="en-US">Value of services recorded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantFiveMember_0" xml:lang="en-US">Warrant Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantFiveMember_1" xml:lang="en-US">Warrant Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_WarrantFiveMember_2" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantFourMember_0" xml:lang="en-US">Warrant Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantFourMember_1" xml:lang="en-US">Warrant Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_WarrantFourMember_2" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantOfferingConsideration_0" xml:lang="en-US">Tha amount of warrant offering consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantOfferingConsideration_1" xml:lang="en-US">Warrant Offering Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_WarrantOfferingConsideration_2" xml:lang="en-US">Warrants offering consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantOneMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantOneMember_1" xml:lang="en-US">Warrant One Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_WarrantOneMember_2" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_Warrants_0" xml:lang="en-US">The non-current portion of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_Warrants_1" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantsExercisableTerm_0" xml:lang="en-US">Warrants exercisable term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantsExercisableTerm_1" xml:lang="en-US">Warrants Exercisable Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_WarrantsExercisableTerm_2" xml:lang="en-US">Warrants exercisable term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantsExercises_0" xml:lang="en-US">Exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantsExercises_1" xml:lang="en-US">Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_WarrantsExercises_2" xml:lang="en-US">Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantsExpirationPeriod_0" xml:lang="en-US">Warrants expiration period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantsExpirationPeriod_1" xml:lang="en-US">Warrants expiration period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantsIssuedToPurchaseAds_0" xml:lang="en-US">Warrants issued to purchase ADS.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantsIssuedToPurchaseAds_1" xml:lang="en-US">Warrants Issued To Purchase Ads</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_WarrantsIssuedToPurchaseAds_2" xml:lang="en-US">Warrants issued to purchase ADS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantsIssuedToPurchaseShares_0" xml:lang="en-US">Warrants issued to purchase shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantsIssuedToPurchaseShares_1" xml:lang="en-US">Warrants issued to purchase shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantSixMember_0" xml:lang="en-US">Warrant six.[Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantSixMember_1" xml:lang="en-US">Warrant Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_WarrantSixMember_2" xml:lang="en-US">Warrantt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantsReserve_0" xml:lang="en-US">Represents amount related to warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantsReserve_1" xml:lang="en-US">Warrants Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_WarrantsReserve_2" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantThreeMember_0" xml:lang="en-US">Warrant Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantThreeMember_1" xml:lang="en-US">Warrant Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_WarrantThreeMember_2" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WarrantTwoMember_0" xml:lang="en-US">Warrant One[Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WarrantTwoMember_1" xml:lang="en-US">Warrant Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_WarrantTwoMember_2" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WeightedAverageExercisePriceAbstract_0" xml:lang="en-US">Weighted average exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WeightedAverageExercisePriceAbstract_1" xml:lang="en-US">Weighted Average Exercise Price Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_WeightedAverageExercisePriceAbstract_2" xml:lang="en-US">Weighted average exercise price (in NIS)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WithholdingApplicableTaxRate_0" xml:lang="en-US">The applicable withholding income tax rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WithholdingApplicableTaxRate_1" xml:lang="en-US">Withholding Applicable Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_WithholdingApplicableTaxRate_2" xml:lang="en-US">Withholding income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blrx_WriteoffOfIntangibleAsset_0" xml:lang="en-US">Represent the amount of write-off of intangible asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_WriteoffOfIntangibleAsset_1" xml:lang="en-US">Write-off Of Intangible Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_WriteoffOfIntangibleAsset_2" xml:lang="en-US">Impairment of intangible asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_0" xml:lang="en-US">Loss on disposal of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_1" xml:lang="en-US">Adjustments for gain (loss) on disposals, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_2" xml:lang="en-US">Loss on disposal of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_AmortisationExpense_0" xml:lang="en-US">Depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmortisationExpense_1" xml:lang="en-US">Amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AmortisationExpense_2" xml:lang="en-US">Amortization of intangible asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_AmortisationExpense_3" xml:lang="en-US">Total depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AmortisationExpense_4" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CostOfSales_0" xml:lang="en-US">COST OF REVENUES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_CostOfSales_1" xml:lang="en-US">Cost of sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CostOfSales_2" xml:lang="en-US">Cost of sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CostOfSales_3" xml:lang="en-US">Cost of sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CostOfSales_4" xml:lang="en-US">Cost of sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_0" xml:lang="en-US">Less current maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_1" xml:lang="en-US">Current maturities of long-term loans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_2" xml:lang="en-US">Current maturities of long-term loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpense_0" xml:lang="en-US">Depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpense_1" xml:lang="en-US">Depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpense_2" xml:lang="en-US">Total depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpense_3" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_0" xml:lang="en-US">Disposal during the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_1" xml:lang="en-US">Disposals, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_2" xml:lang="en-US">Disposal during the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_0" xml:lang="en-US">Deletions during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_1" xml:lang="en-US">Disposals, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_2" xml:lang="en-US">Deletions during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_FinanceCosts_0" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinanceCosts_1" xml:lang="en-US">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_FinanceCosts_2" xml:lang="en-US">Financial expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ImpairmentLossOnFinancialAssets_0" xml:lang="en-US">IMPAIRMENT OF INTANGIBLE ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ImpairmentLossOnFinancialAssets_1" xml:lang="en-US">Impairment loss on financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_0" xml:lang="en-US">Impairment during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_1" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_2" xml:lang="en-US">Impairment during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0" xml:lang="en-US">Employee stock options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_1" xml:lang="en-US">Increase (decrease) through exercise of options, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_2" xml:lang="en-US">Employee stock options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NetForeignExchangeLoss_0" xml:lang="en-US">Foreign exchange loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetForeignExchangeLoss_1" xml:lang="en-US">Net foreign exchange loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NetForeignExchangeLoss_2" xml:lang="en-US">Exchange differences, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_0" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_1" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_2" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_0" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_1" xml:lang="en-US">Number of share options expired in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_2" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_0" xml:lang="en-US">Repayments of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_1" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_0" xml:lang="en-US">Purchase of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_1" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_1" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_0" xml:lang="en-US">Repayments of loans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_1" xml:lang="en-US">Principal and interest payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_2" xml:lang="en-US">Repayments of borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_3" xml:lang="en-US">Repayment of loan and Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_0" xml:lang="en-US">Repayments of loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_1" xml:lang="en-US">Repayments of borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_2" xml:lang="en-US">Repayments of non-current borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_3" xml:lang="en-US">Repayment of loan and Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense_0" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense_2" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_RetainedEarnings_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarnings_1" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_SalesAndMarketingExpense_0" xml:lang="en-US">SALES AND MARKETING EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SalesAndMarketingExpense_1" xml:lang="en-US">Sales and marketing expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_SalesAndMarketingExpense_2" xml:lang="en-US">Sales and marketing expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_SalesAndMarketingExpense_3" xml:lang="en-US">Sales and marketing expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_0" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_1" xml:lang="en-US">Selling, general and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_2" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_0" xml:lang="en-US">Issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_1" xml:lang="en-US">Share issue related cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_2" xml:lang="en-US">Costs related to share purchase agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1" xml:lang="en-US">Forfeited and expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_2" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents_0" xml:lang="en-US">CASH AND CASH EQUIVALENTS - END OF YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents_1" xml:lang="en-US">CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalents_2" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashAndCashEquivalents_3" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_Equity_0" xml:lang="en-US">BALANCE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_Equity_1" xml:lang="en-US">BALANCE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Equity_2" xml:lang="en-US">Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Equity_3" xml:lang="en-US">Total equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_0" xml:lang="en-US">Balance at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_1" xml:lang="en-US">Balance at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_2" xml:lang="en-US">Intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_3" xml:lang="en-US">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_LeaseLiabilities_0" xml:lang="en-US">Balance at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_LeaseLiabilities_1" xml:lang="en-US">Balance at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LeaseLiabilities_2" xml:lang="en-US">Lease liabilities [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_LeaseLiabilities_3" xml:lang="en-US">Total lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_0" xml:lang="en-US">Balance as of December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_1" xml:lang="en-US">Balance as of January 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_2" xml:lang="en-US">Liabilities arising from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_0" xml:lang="en-US">Outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_1" xml:lang="en-US">Outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_2" xml:lang="en-US">Option outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_3" xml:lang="en-US">Number of options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_0" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding_0" xml:lang="en-US">BALANCE, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding_1" xml:lang="en-US">BALANCE, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding_2" xml:lang="en-US">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment_0" xml:lang="en-US">Balance at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment_1" xml:lang="en-US">Balance at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment_2" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_RightofuseAssets_0" xml:lang="en-US">Balance at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_RightofuseAssets_1" xml:lang="en-US">Balance at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RightofuseAssets_2" xml:lang="en-US">Right-of-use assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_0" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_1" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" xml:lang="en-US">Outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1" xml:lang="en-US">Outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3" xml:lang="en-US">Weighted average exercise price outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_Borrowings_0" xml:lang="en-US">Total loan balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Borrowings_1" xml:lang="en-US">Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Borrowings_2" xml:lang="en-US">Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Borrowings_3" xml:lang="en-US">Future repayments of long-term loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_0" xml:lang="en-US">Long-term loan, net of current maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_1" xml:lang="en-US">Long-term loans, net of current maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_2" xml:lang="en-US">Long-term portion of loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_3" xml:lang="en-US">Long-term bank loan, net of current maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome_0" xml:lang="en-US">Comprehensive loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncome_1" xml:lang="en-US">Comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome_2" xml:lang="en-US">Comprehensive loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome_3" xml:lang="en-US">Total comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncome_4" xml:lang="en-US">Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_ifrs-full_ProfitLoss_0" xml:lang="en-US">Comprehensive loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLoss_1" xml:lang="en-US">Comprehensive loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLoss_2" xml:lang="en-US">Comprehensive loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLoss_3" xml:lang="en-US">LOSS AND COMPREHENSIVE LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLoss_4" xml:lang="en-US">Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments Required To Reflect Net Cash Used In Operating Activities Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Adjustments required to reflect net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AgreementTypeDomain_0" xml:lang="en-US">Agreement Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AgreementWithCompaniesForDevelopmentAbstract_0" xml:lang="en-US">Agreement With Companies For Development [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_AssetTransferAgreementMember_0" xml:lang="en-US">Asset Transfer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_0" xml:lang="en-US">Changes In Operating Assets And Liabilities Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_1" xml:lang="en-US">Changes in operating asset and liability items:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_CollaborationAndShareholdersAgreementLineItems_0" xml:lang="en-US">Collaboration And Shareholders Agreement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_CollaborationAndShareholdersAgreementTable_0" xml:lang="en-US">Collaboration And Shareholders Agreement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_CollaborationTransactionAxis_0" xml:lang="en-US">Collaboration Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_CollaborationTransactionDomain_0" xml:lang="en-US">Collaboration Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract_0" xml:lang="en-US">Disclosure Of Accounting Judgements And Estimates Explanatory Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract_1" xml:lang="en-US">Disclosure of critical accounting estimates and judgments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfAgalimmuneAcquisitionAbstract_0" xml:lang="en-US">Disclosure of Agalimmune Acquisition [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfAgreementWithOmegaPharmaAbstract_0" xml:lang="en-US">Disclosure Of Agreement With Omega Pharma [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfAgreementWithOmegaPharmaAbstract_1" xml:lang="en-US">Disclosure of agreement with omega pharma [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfAmendmentToLicenseAbstract_0" xml:lang="en-US">Disclosure Of Amendment To License Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfAmendmentToLicenseAbstract_1" xml:lang="en-US">Disclosure of amendment to license [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract_0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock_0" xml:lang="en-US">Disclosure Of Detailed Information About Inventory Explanatory [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock_1" xml:lang="en-US">Schedule of Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfEventsSubsequentToBalanceSheetDateAbstract_0" xml:lang="en-US">Disclosure Of Events Subsequent To Balance Sheet Date Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfEventsSubsequentToBalanceSheetDateAbstract_1" xml:lang="en-US">Disclosure of event subsequent to the balance sheet date [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfGeneralInformationAbstract_0" xml:lang="en-US">Disclosure of general information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfIncomeTaxesAbstract_0" xml:lang="en-US">Disclosure Of Income Taxes [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfIncomeTaxesAbstract_1" xml:lang="en-US">Taxes On Income Schedule Of Reconciliation Of Weighted Average Tax Rate Applicable To Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blrx_DisclosureOfIncomeTaxesAbstract_2" xml:lang="en-US">Taxes On Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract_0" xml:lang="en-US">Disclosure Of License And Securities Purchase Agreements Ayrmid And Highbridge [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfLongTermInvestmentAbstract_0" xml:lang="en-US">Disclosure of Long-term investment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_0" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable_0" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfShortTermBankDepositsAbstract_0" xml:lang="en-US">Disclosure Of Short Term Bank Deposits Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfShortTermBankDepositsAbstract_1" xml:lang="en-US">Disclosure of short-term bank deposits [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xml:lang="en-US">Disclosure of significant accounting policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract_0" xml:lang="en-US">Disclosure Of Strategic Collaboration Agreement With Novartis Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract_1" xml:lang="en-US">Disclosure of strategic collaboration agreement with novartis [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_Glix1Member_0" xml:lang="en-US">Glix1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_Glix1Member_1" xml:lang="en-US">GLIX1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_HemispherianAsMember_0" xml:lang="en-US">Hemispherian As [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_0" xml:lang="en-US">Income And Expenses Not Involving Cash Flows Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_1" xml:lang="en-US">Income and expenses not involving cash flows:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_January2025OfferingMember_0" xml:lang="en-US">January 2025 Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract_0" xml:lang="en-US">License And Securities Purchase Agreements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0" xml:lang="en-US">License And Securities Purchase Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_0" xml:lang="en-US">License And Securities Purchase Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PerformanceObligationAxis_0" xml:lang="en-US">Performance Obligation [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PerformanceObligationDomain_0" xml:lang="en-US">Performance Obligation [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PerformanceSharesUnitTwoMember_0" xml:lang="en-US">Performance Shares Unit Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_PerformanceSharesUnitTwoMember_1" xml:lang="en-US">Performance Shares Unit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_PlacementAgentMember_0" xml:lang="en-US">Placement Agent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_0" xml:lang="en-US">Supplementary Information On Investing And Financing Activities Not Involving Cash Flows Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_1" xml:lang="en-US">Supplementary information on investing and financing activities not involving cash flows:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_Test_0" xml:lang="en-US">Test</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blrx_Test_1" xml:lang="en-US">Loss on abandonment of right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blrx_TetragonMember_0" xml:lang="en-US">Tetragon [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL_0" xml:lang="en-US">ISRAEL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_IL_1" xml:lang="en-US">Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_ILS_0" xml:lang="en-US">Israel, New Shekels</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_currency_ILS_1" xml:lang="en-US">NIS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain_0" xml:lang="en-US">Address Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription_0" xml:lang="en-US">Amendment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId_0" xml:lang="en-US">Auditor Firm ID</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation_0" xml:lang="en-US">Auditor Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName_0" xml:lang="en-US">Auditor Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorOpinionTextBlock_0" xml:lang="en-US">Auditor Opinion [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember_0" xml:lang="en-US">Business Contact [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelEmailAddress_0" xml:lang="en-US">Contact Personnel Email Address</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelFaxNumber_0" xml:lang="en-US">Contact Personnel Fax Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName_0" xml:lang="en-US">Contact Personnel Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CoverAbstract_1" xml:lang="en-US">Document And Entity Information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard_0" xml:lang="en-US">Document Accounting Standard</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag_0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems_0" xml:lang="en-US">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable_0" xml:lang="en-US">Document Information [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement_0" xml:lang="en-US">Document Registration Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport_0" xml:lang="en-US">Document Shell Company Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis_0" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity's Reporting Status Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain_0" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation State Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity a Voluntary Filer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity a Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag_0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis_0" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Security Exchange Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccountingProfit_0" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AccountingProfit_1" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_0" xml:lang="en-US">Accumulated depreciation and impairment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_0" xml:lang="en-US">Accumulated depreciation [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_1" xml:lang="en-US">Accumulated depreciation and amortisation [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_0" xml:lang="en-US">Other comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_0" xml:lang="en-US">Initial consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_1" xml:lang="en-US">Cash payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_0" xml:lang="en-US">Acquisitions through business combinations, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1" xml:lang="en-US">Intangible asset amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_0" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1" xml:lang="en-US">Additions during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_0" xml:lang="en-US">Additions during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets_0" xml:lang="en-US">Additions to right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets_1" xml:lang="en-US">Additions during year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_0" xml:lang="en-US">Adjustments for decrease (increase) in inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_1" xml:lang="en-US">Decrease (increase) in inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_0" xml:lang="en-US">Adjustments for decrease (increase) in trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_1" xml:lang="en-US">Decrease (increase) in trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_0" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForFairValueGainsLosses_0" xml:lang="en-US">Fair value adjustments of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_0" xml:lang="en-US">Adjustments for impairment loss recognised in profit or loss, goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_1" xml:lang="en-US">Intangible assets impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_0" xml:lang="en-US">Adjustments for increase (decrease) in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_1" xml:lang="en-US">Increase (decrease) in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_0" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLoss_0" xml:lang="en-US">Adjustments required to reflect net cash used in operating activities (see appendix below)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLoss_1" xml:lang="en-US">Total adjustments required to reflect net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLoss_2" xml:lang="en-US">Adjustments required to reflect net cash used in operating activities (see appendix below)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments_0" xml:lang="en-US">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_0" xml:lang="en-US">Exchange differences on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity_0" xml:lang="en-US">Compensation and benefits to management, including benefit component of equity instrument grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ApplicableTaxRate_0" xml:lang="en-US">Corporate tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ApplicableTaxRate_1" xml:lang="en-US">Loss before taxes (Percentage)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Assets_0" xml:lang="en-US">Assets [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Assets_2" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_AssetsAbstract_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_AssetsAbstract_1" xml:lang="en-US">Assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare_0" xml:lang="en-US">Basic earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare_1" xml:lang="en-US">LOSS PER ORDINARY SHARE &#8211; BASIC ATTRIBUTABLE TO OWNERS OF THE COMPANY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare_2" xml:lang="en-US">Basic and diluted loss per ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsByNameAxis_0" xml:lang="en-US">Borrowings by name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_BorrowingsByNameAxis_1" xml:lang="en-US">Borrowings by name [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BorrowingsInterestRate_0" xml:lang="en-US">Interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BottomOfRangeMember_0" xml:lang="en-US">Bottom of range [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_BottomOfRangeMember_1" xml:lang="en-US">Bottom of range [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BusinessCombinationsAxis_0" xml:lang="en-US">Business combinations [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_BusinessCombinationsAxis_1" xml:lang="en-US">Business combinations [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_BusinessCombinationsDomain_0" xml:lang="en-US">Business combinations [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CapitalReserve_0" xml:lang="en-US">Capital reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CapitalReserveMember_0" xml:lang="en-US">Capital reserve [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_0" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CarryingAmountMember_0" xml:lang="en-US">Carrying amount [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Cash_0" xml:lang="en-US">Cash on hand and in bank</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract_0" xml:lang="en-US">Cash and cash equivalents [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_0" xml:lang="en-US">Investments in short-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">CASH FLOWS - FINANCING ACTIVITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">CASH FLOWS - INVESTING ACTIVITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_0" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">CASH FLOWS - OPERATING ACTIVITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CashTransferred_0" xml:lang="en-US">Cash transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CashTransferred_1" xml:lang="en-US">Cash consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_0" xml:lang="en-US">Categories of financial liabilities [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_0" xml:lang="en-US">Categories of financial liabilities [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_0" xml:lang="en-US">Categories of related parties [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_1" xml:lang="en-US">Categories of related parties [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesDomain_0" xml:lang="en-US">Categories of related parties [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ChangesInEquityAbstract_0" xml:lang="en-US">CHANGES IN</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_0" xml:lang="en-US">Changes during the year:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember_0" xml:lang="en-US">Changes in tax rates or tax laws enacted or announced [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis_0" xml:lang="en-US">Classes of assets [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfAssetsDomain_0" xml:lang="en-US">Classes of assets [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_0" xml:lang="en-US">Classes of financial instruments [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xml:lang="en-US">Classes of financial instruments [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain_0" xml:lang="en-US">Classes of financial instruments [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0" xml:lang="en-US">Classes of intangible assets other than goodwill [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_0" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract_0" xml:lang="en-US">Classes of current inventories [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract_1" xml:lang="en-US">INVENTORY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_0" xml:lang="en-US">Classes of property, plant and equipment [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" xml:lang="en-US">Classes of property, plant and equipment [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis_0" xml:lang="en-US">Classes of share capital [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate_0" xml:lang="en-US">Exchange rate per dollar</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CommunicationExpense_0" xml:lang="en-US">Lab, occupancy and telephone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis_0" xml:lang="en-US">Components of equity [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_0" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_1" xml:lang="en-US">Total comprehensive income, attributable to non-controlling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2" xml:lang="en-US">To non-controlling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_0" xml:lang="en-US">Comprehensive income, attributable to owners of parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_1" xml:lang="en-US">Total comprehensive income, attributable to owners of parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_2" xml:lang="en-US">To owners of the Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComputerEquipmentMember_0" xml:lang="en-US">Computers and communications equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ComputerSoftwareMember_0" xml:lang="en-US">Computer software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ConsiderationPaidReceived_0" xml:lang="en-US">Consideration paid (received)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ConsiderationPaidReceived_1" xml:lang="en-US">Consideration received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CountryOfDomicileMember_0" xml:lang="en-US">Country of domicile [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CountryOfDomicileMember_1" xml:lang="en-US">U.S. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CreditExposure_0" xml:lang="en-US">Line of credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CreditRiskMember_0" xml:lang="en-US">Credit risk [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_0" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssets_0" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentAssets_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentAssetsAbstract_0" xml:lang="en-US">CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentAssetsAbstract_1" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentContractLiabilities_0" xml:lang="en-US">Current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentContractLiabilities_1" xml:lang="en-US">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities_0" xml:lang="en-US">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities_1" xml:lang="en-US">Current maturities of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities_2" xml:lang="en-US">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilities_0" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CurrentLiabilities_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract_0" xml:lang="en-US">CURRENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract_1" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentProvisionsForEmployeeBenefits_0" xml:lang="en-US">Accrual for vacation and recreation pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_0" xml:lang="en-US">Current raw materials and current production supplies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_1" xml:lang="en-US">Raw materials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_0" xml:lang="en-US">Total increase in intangibles</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DepreciationExpense_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_0" xml:lang="en-US">Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_0" xml:lang="en-US">Deferred taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_0" xml:lang="en-US">Loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_0" xml:lang="en-US">Employee benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_0" xml:lang="en-US">Financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_0" xml:lang="en-US">Functional and reporting currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_0" xml:lang="en-US">Impairment of non-amortized non-financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_1" xml:lang="en-US">Impairment of non-financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_0" xml:lang="en-US">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_0" xml:lang="en-US">Share capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_0" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_0" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_1" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_0" xml:lang="en-US">Property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_0" xml:lang="en-US">Revenue from contracts with customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_1" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_0" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_1" xml:lang="en-US">Share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_0" xml:lang="en-US">Cash equivalents and short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_0" xml:lang="en-US">Expected volatility (%)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1" xml:lang="en-US">Average standard deviation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_0" xml:lang="en-US">Expected life of options (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_0" xml:lang="en-US">Risk-free interest rate (%)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_0" xml:lang="en-US">Estimated useful lives of intangible assets (In years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_0" xml:lang="en-US">Depreciation rates (in %)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_0" xml:lang="en-US">Option vested and exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare_0" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare_1" xml:lang="en-US">LOSS PER ORDINARY SHARE &#8211; DILUTED ATTRIBUTABLE TO OWNERS OF THE COMPANY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_0" xml:lang="en-US">CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory_0" xml:lang="en-US">Schedule of Composition of Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_0" xml:lang="en-US">Schedule of Key Management Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_0" xml:lang="en-US">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_0" xml:lang="en-US">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0" xml:lang="en-US">Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_0" xml:lang="en-US">Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory_0" xml:lang="en-US">LONG-TERM LOANS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_0" xml:lang="en-US">AGALIMMUNE ACQUISITION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_0" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_0" xml:lang="en-US">Disclosure of detailed information about business combination [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_0" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_1" xml:lang="en-US">CASH AND CASH EQUIVALENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_0" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_1" xml:lang="en-US">MATERIAL ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xml:lang="en-US">Disclosure of classes of share capital [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_0" xml:lang="en-US">Schedule of Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_1" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDepositsFromBanksExplanatory_0" xml:lang="en-US">SHORT-TERM BANK DEPOSITS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_0" xml:lang="en-US">Disclosure of detailed information about borrowings [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_0" xml:lang="en-US">Schedule of Composition of Long-Term Bank Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_0" xml:lang="en-US">Schedule of Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_0" xml:lang="en-US">Schedule of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_0" xml:lang="en-US">Schedule of Composition of Property and Equipment and Related Accumulated Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_0" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1" xml:lang="en-US">Schedule of Basic Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_2" xml:lang="en-US">LOSS PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_0" xml:lang="en-US">EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementExplanatory_0" xml:lang="en-US">Schedule of Fair Value Measurement of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_0" xml:lang="en-US">FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_0" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_0" xml:lang="en-US">Disclosure of financial liabilities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_0" xml:lang="en-US">Disclosure of financial liabilities [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_0" xml:lang="en-US">GENERAL INFORMATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_0" xml:lang="en-US">Disclosure of geographical areas [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_1" xml:lang="en-US">Schedule of revenues from external parties by geographic region</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_0" xml:lang="en-US">Disclosure of geographical areas [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable_0" xml:lang="en-US">Disclosure of geographical areas [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_1" xml:lang="en-US">TAXES ON INCOME</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_0" xml:lang="en-US">Schedule of Assumptions Used to Value Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract_0" xml:lang="en-US">Disclosure of detailed information about intangible assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_0" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_0" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory_0" xml:lang="en-US">Disclosure of inventories [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory_1" xml:lang="en-US">INVENTORY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfInvestmentPropertyExplanatory_0" xml:lang="en-US">LONG-TERM INVESTMENT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesLineItems_0" xml:lang="en-US">Disclosure of joint ventures [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesTable_0" xml:lang="en-US">Disclosure of joint ventures [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory_0" xml:lang="en-US">LEASES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_0" xml:lang="en-US">Schedule of Minimum Future Rental Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_0" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_0" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_0" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_0" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_1" xml:lang="en-US">SUBSEQUENT EVENT (if relevant)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_0" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_0" xml:lang="en-US">Schedule of Amounts Outstanding Under Employee Share Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_0" xml:lang="en-US">Schedule of Options Outstanding by Exercise Price Range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_0" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_0" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0" xml:lang="en-US">Disclosure of operating segments [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_0" xml:lang="en-US">Disclosure of operating segments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_1" xml:lang="en-US">SEGMENT REPORTING</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_0" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_0" xml:lang="en-US">Schedule of Right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_0" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_0" xml:lang="en-US">Schedule of Changes in Financial Liabilities With Cash Flows Included in Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_0" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_0" xml:lang="en-US">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0" xml:lang="en-US">Disclosure of risk management strategy related to hedge accounting [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_0" xml:lang="en-US">Disclosure of risk management strategy related to hedge accounting [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_0" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_1" xml:lang="en-US">EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_0" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_0" xml:lang="en-US">Schedule of Transactions With Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings per share [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_0" xml:lang="en-US">EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense_0" xml:lang="en-US">Employee benefit expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAbstract_0" xml:lang="en-US">EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAndLiabilities_0" xml:lang="en-US">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_EquityAndLiabilities_1" xml:lang="en-US">Total liabilities and equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract_0" xml:lang="en-US">Liabilities and equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent_0" xml:lang="en-US">Equity attributable to owners of parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent_1" xml:lang="en-US">Total equity attributable to owners of the Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer_0" xml:lang="en-US">Equity interests of acquirer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer_1" xml:lang="en-US">Equity consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_0" xml:lang="en-US">Contingent liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_0" xml:lang="en-US">Expected dividend yield (%)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FeeAndCommissionExpense_0" xml:lang="en-US">Bank commissions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinanceIncome_0" xml:lang="en-US">FINANCIAL INCOME</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_FinanceIncome_1" xml:lang="en-US">Financial income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue_0" xml:lang="en-US">Fair value of the warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_0" xml:lang="en-US">Financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently, category [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_1" xml:lang="en-US">Initial recognition [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_FinishedGoods_0" xml:lang="en-US">Current finished goods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_FinishedGoods_1" xml:lang="en-US">Finished goods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ForeignCountriesMember_0" xml:lang="en-US">Foreign countries [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ForeignCountriesMember_1" xml:lang="en-US">China [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ForeignExchangeGain_0" xml:lang="en-US">Foreign exchange gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ForeignExchangeGain_1" xml:lang="en-US">Exchange differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ForeignExchangeLoss_0" xml:lang="en-US">Foreign exchange loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ForeignExchangeLoss_1" xml:lang="en-US">Exchange differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_0" xml:lang="en-US">Change in fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeographicalAreasAxis_0" xml:lang="en-US">Geographical areas [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GeographicalAreasDomain_0" xml:lang="en-US">Geographical areas [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GrossCarryingAmountMember_0" xml:lang="en-US">Cost [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_GrossCarryingAmountMember_1" xml:lang="en-US">Gross carrying amount [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_GrossProfit_0" xml:lang="en-US">Gross profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_GrossProfit_1" xml:lang="en-US">GROSS PROFIT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_0" xml:lang="en-US">Identifiable intangible assets recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_1" xml:lang="en-US">Intangible assets acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_0" xml:lang="en-US">Impairment loss recognised in profit or loss, goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_1" xml:lang="en-US">Impairment loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeStatementAbstract_0" xml:lang="en-US">Profit or loss [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xml:lang="en-US">Tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_1" xml:lang="en-US">Taxes on income for the reported year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_0" xml:lang="en-US">IFRS 15 [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1" xml:lang="en-US">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_0" xml:lang="en-US">Changes in fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_0" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_0" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InitiallyAppliedIFRSsAxis_0" xml:lang="en-US">Initially applied IFRSs [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InitiallyAppliedIFRSsDomain_0" xml:lang="en-US">Initially applied IFRSs [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InsuranceExpense_0" xml:lang="en-US">Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0" xml:lang="en-US">Intangible assets other than goodwill [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_0" xml:lang="en-US">Intangible assets with indefinite useful life [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1" xml:lang="en-US">Intangible assets with indefinite useful life [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_0" xml:lang="en-US">Intangible assets with indefinite useful life [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestExpense_0" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestExpense_1" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_InterestExpense_2" xml:lang="en-US">Interest expense, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings_0" xml:lang="en-US">Interest expense on borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings_1" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InterestPayable_0" xml:lang="en-US">Interest payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InterestPayable_1" xml:lang="en-US">Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Inventories_0" xml:lang="en-US">Current inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Inventories_1" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Inventories_2" xml:lang="en-US">Total Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InvestmentProperty_0" xml:lang="en-US">Investment property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_InvestmentProperty_1" xml:lang="en-US">Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_InvestmentPropertyMember_0" xml:lang="en-US">Investment property [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapital_0" xml:lang="en-US">Ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssuedCapitalMember_0" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_IssueOfEquity_0" xml:lang="en-US">Issuance of share capital, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_IssueOfEquity_1" xml:lang="en-US">Issuance of share capital, pre-funded warrants and warrants, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_JointVenturesAxis_0" xml:lang="en-US">Joint ventures [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_JointVenturesAxis_1" xml:lang="en-US">Joint ventures [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation_0" xml:lang="en-US">Compensation cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation_1" xml:lang="en-US">Benefits to key executive personnel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_0" xml:lang="en-US">Other long-term benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_0" xml:lang="en-US">Post-employment benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_0" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0" xml:lang="en-US">Salaries and other short-term employee benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LandAndBuildingsMember_0" xml:lang="en-US">Property [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LandAndBuildingsMember_1" xml:lang="en-US">Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_0" xml:lang="en-US">2027-2030 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_1" xml:lang="en-US">2029-2030 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0" xml:lang="en-US">2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1" xml:lang="en-US">2027 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_0" xml:lang="en-US">2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1" xml:lang="en-US">2029 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_0" xml:lang="en-US">2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_1" xml:lang="en-US">2028 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember_0" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract_0" xml:lang="en-US">Composition of lease liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember_0" xml:lang="en-US">Level 3 of fair value hierarchy [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember_1" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_0" xml:lang="en-US">Levels of fair value hierarchy [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyDomain_0" xml:lang="en-US">Levels of fair value hierarchy [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Liabilities_2" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesAbstract_0" xml:lang="en-US">Liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_0" xml:lang="en-US">Liabilities arising from financing activities [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_0" xml:lang="en-US">Liabilities arising from financing activities [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LicenceFeeIncome_0" xml:lang="en-US">Licence fee income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_LicenceFeeIncome_1" xml:lang="en-US">License revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_LongtermBorrowingsMember_0" xml:lang="en-US">Long-term loans [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaturityAxis_0" xml:lang="en-US">Maturity [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MaturityDomain_0" xml:lang="en-US">Maturity [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_MotorVehiclesMember_0" xml:lang="en-US">Motor vehicles [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_MotorVehiclesMember_1" xml:lang="en-US">Motor vehicles [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NetForeignExchangeGain_0" xml:lang="en-US">Net foreign exchange gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NetForeignExchangeGain_1" xml:lang="en-US">Exchange differences, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" xml:lang="en-US">Non-adjusting events after reporting period [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncontrollingInterests_0" xml:lang="en-US">Non-controlling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember_0" xml:lang="en-US">Non-controlling interests [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember_1" xml:lang="en-US">Non-controlling interest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssets_0" xml:lang="en-US">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NoncurrentAssets_1" xml:lang="en-US">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract_0" xml:lang="en-US">NON-CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities_0" xml:lang="en-US">Non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities_1" xml:lang="en-US">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLiabilities_0" xml:lang="en-US">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_NoncurrentLiabilities_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract_0" xml:lang="en-US">NON-CURRENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract_1" xml:lang="en-US">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember_0" xml:lang="en-US">2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember_1" xml:lang="en-US">2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfEmployees_0" xml:lang="en-US">Number of individuals to which this benefit related</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_0" xml:lang="en-US">Option vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_0" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesAuthorised_0" xml:lang="en-US">Authorized share capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesIssued_0" xml:lang="en-US">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_NumberOfSharesIssued_1" xml:lang="en-US">Issuance of share capital and warrants, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid_0" xml:lang="en-US">Issued and paid-up share capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OfficeEquipmentMember_0" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_0" xml:lang="en-US">Cash consideration to joint venture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherComprehensiveIncome_0" xml:lang="en-US">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherComprehensiveIncome_1" xml:lang="en-US">Other comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentPayables_0" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherCurrentPayables_1" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherCurrentReceivables_0" xml:lang="en-US">Other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_OtherCurrentReceivables_1" xml:lang="en-US">Other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherEquityInterest_0" xml:lang="en-US">Other equity interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherExpenseByFunction_0" xml:lang="en-US">Other expense, by function</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherExpenseByFunction_1" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherExpenseByNature_0" xml:lang="en-US">Other expenses, by nature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherExpenseByNature_1" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherFeeAndCommissionExpense_0" xml:lang="en-US">Commitment fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherIntangibleAssetsMember_0" xml:lang="en-US">Intellectual property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense_0" xml:lang="en-US">Non-operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherPayables_0" xml:lang="en-US">Other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherPayables_1" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherReceivables_0" xml:lang="en-US">Other receivables [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherReceivables_1" xml:lang="en-US">Other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherRevenue_0" xml:lang="en-US">Other revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_OtherRevenue_1" xml:lang="en-US">Revenue recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_0" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_1" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PaymentsForDevelopmentProjectExpenditure_0" xml:lang="en-US">Payments for development project expenditure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PaymentsForDevelopmentProjectExpenditure_1" xml:lang="en-US">Development and regulatory entitled amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts_0" xml:lang="en-US">Payments for share issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts_1" xml:lang="en-US">Share issue related costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xml:lang="en-US">Presentation of leases for lessee [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_0" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_1" xml:lang="en-US">Net proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions_0" xml:lang="en-US">Proceeds from exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions_1" xml:lang="en-US">Employee stock options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants_0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants_1" xml:lang="en-US">Exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants_2" xml:lang="en-US">Gross proceeds from offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_0" xml:lang="en-US">Net proceeds from transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_0" xml:lang="en-US">Proceeds from issuing other equity instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_1" xml:lang="en-US">Proceeds from long-term loan, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares_0" xml:lang="en-US">Issuance of share capital and warrants, net of issuance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares_1" xml:lang="en-US">Issuance of share capital, pre-funded warrants and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares_2" xml:lang="en-US">Gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_0" xml:lang="en-US">Realization of long-term investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_1" xml:lang="en-US">Net gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_0" xml:lang="en-US">Proceeds from sale or issue of treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_1" xml:lang="en-US">Aggregate gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfessionalFeesExpense_0" xml:lang="en-US">Professional fees expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfessionalFeesExpense_1" xml:lang="en-US">Professional fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossAttributableToAbstract_0" xml:lang="en-US">Profit (loss), attributable to [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToAbstract_1" xml:lang="en-US">ATTRIBUTION OF LOSS AND COMPREHENSIVE LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_0" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1" xml:lang="en-US">Non-controlling interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_0" xml:lang="en-US">Loss attributed to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities_0" xml:lang="en-US">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities_1" xml:lang="en-US">OPERATING LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_0" xml:lang="en-US">Proportion of ownership interest in associate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_1" xml:lang="en-US">Percentage of aggregate maximum ownership</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangeAxis_0" xml:lang="en-US">Range [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RangeAxis_1" xml:lang="en-US">Range [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangeDomain_0" xml:lang="en-US">Range [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_0" xml:lang="en-US">Ranges of exercise prices for outstanding share options [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReductionOfIssuedCapital_0" xml:lang="en-US">Reduction of issued capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_ReductionOfIssuedCapital_1" xml:lang="en-US">Reduction in equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RepairsAndMaintenanceExpense_0" xml:lang="en-US">Building maintenance charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures_0" xml:lang="en-US">Repayments of bonds, notes and debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures_1" xml:lang="en-US">Repayment of loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads_0" xml:lang="en-US">Value on balance sheet</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RetainedEarningsMember_0" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_Revenue_0" xml:lang="en-US">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_Revenue_1" xml:lang="en-US">Total revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Revenue_2" xml:lang="en-US">Total revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_Revenue_3" xml:lang="en-US">Rvenues from external parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueAbstract_0" xml:lang="en-US">Revenue [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RevenueAbstract_1" xml:lang="en-US">REVENUES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueFromInterest_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RevenueFromInterest_1" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueFromRoyalties_0" xml:lang="en-US">Royalty income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_RevenueFromRoyalties_1" xml:lang="en-US">Total royalties based on motixafortide net sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods_0" xml:lang="en-US">Revenue from sale of goods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods_1" xml:lang="en-US">Product sales, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_0" xml:lang="en-US">Schedule of Sensitivity Analysis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SeparateManagementEntitiesAxis_0" xml:lang="en-US">Separate management entities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_SeparateManagementEntitiesAxis_1" xml:lang="en-US">Separate management entities [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ServicesExpense_0" xml:lang="en-US">Research and development services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShareOptionsMember_0" xml:lang="en-US">Share options [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharePremium_0" xml:lang="en-US">Share premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_SharePremiumMember_0" xml:lang="en-US">Share premium [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_0" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_1" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_0" xml:lang="en-US">Short term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_1" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpense_0" xml:lang="en-US">Short-term employee benefits expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpense_1" xml:lang="en-US">Payroll and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_0" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of financial position [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_0" xml:lang="en-US">Theoretical tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TopOfRangeMember_0" xml:lang="en-US">Top of range [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TopOfRangeMember_1" xml:lang="en-US">Top of range [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0" xml:lang="en-US">Accounts payable and accruals:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0" xml:lang="en-US">Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_0" xml:lang="en-US">Trade payables [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1" xml:lang="en-US">Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_2" xml:lang="en-US">Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TradeReceivables_0" xml:lang="en-US">Trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TravelExpense_0" xml:lang="en-US">Overseas travel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TravelExpense_1" xml:lang="en-US">Travel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_0" xml:lang="en-US">Types of antidilutive instruments [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xml:lang="en-US">Types of antidilutive instruments [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfInvestmentPropertyAxis_0" xml:lang="en-US">Types of investment property [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TypesOfInvestmentPropertyAxis_1" xml:lang="en-US">Types of investment property [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfInvestmentPropertyDomain_0" xml:lang="en-US">Types of investment property [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksAxis_0" xml:lang="en-US">Types of risks [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TypesOfRisksAxis_1" xml:lang="en-US">Types of risks [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfRisksDomain_0" xml:lang="en-US">Types of risks [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0" xml:lang="en-US">Types of share-based payment arrangements [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived_0" xml:lang="en-US">Minimum future rental payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_UnobservableInputsDomain_0" xml:lang="en-US">Unobservable inputs [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WagesAndSalaries_0" xml:lang="en-US">Wages and salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WagesAndSalaries_1" xml:lang="en-US">Payroll and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WarrantReserve_0" xml:lang="en-US">Warrant reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WarrantReserve_1" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WarrantReserveMember_0" xml:lang="en-US">Warrant reserve [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WarrantReserveMember_1" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WarrantsMember_0" xml:lang="en-US">Warrants [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_0" xml:lang="en-US">Weighted average cost of capital, measurement input [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_1" xml:lang="en-US">Weighted average cost of capital (&#8220;WACC&#8221;) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_0" xml:lang="en-US">Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_1" xml:lang="en-US">Exercise price of other equity instruments exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_0" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_1" xml:lang="en-US">Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_0" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_1" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_0" xml:lang="en-US">Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_0" xml:lang="en-US">Fair value of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_0" xml:lang="en-US">Weighted average incremental borrowing rate on lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_0" xml:lang="en-US">Weighted average contractual life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1" xml:lang="en-US">Weighted average remaining contractual (in yrs.)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WeightedAverageShares_0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WeightedAverageShares_1" xml:lang="en-US">Number of shares used in basic calculation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_WeightedAverageShares_2" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF BASIC LOSS PER ORDINARY SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ifrs-full_WorkInProgress_0" xml:lang="en-US">Current work in progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ifrs-full_WorkInProgress_1" xml:lang="en-US">Work-in-progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain_0" xml:lang="en-US">Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis_0" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ifrs-full_TradeAndOtherPayablesAbstract_0" xml:lang="en-US">Accounts payable and accruals:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ImpairmentLossOnIntangibleAssets_1" xlink:to="lab_blrx_ImpairmentLossOnIntangibleAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ImpairmentLossOnIntangibleAssets_2" xlink:to="lab_blrx_ImpairmentLossOnIntangibleAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ImpairmentLossOnIntangibleAssets_3" xlink:to="lab_blrx_ImpairmentLossOnIntangibleAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ImpairmentLossOnIntangibleAssets_4" xlink:to="lab_blrx_ImpairmentLossOnIntangibleAssets_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ImpairmentLossOnIntangibleAssets_5" xlink:to="lab_blrx_ImpairmentLossOnIntangibleAssets_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_6" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_7" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_8" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_9" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_10" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AccountsPayableAbstract_11" xlink:to="lab_blrx_AccountsPayableAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AccountsPayableAbstract_12" xlink:to="lab_blrx_AccountsPayableAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AccountsPayableAbstract_13" xlink:to="lab_blrx_AccountsPayableAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalCommitmentFee_14" xlink:to="lab_blrx_AdditionalCommitmentFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalCommitmentFee_15" xlink:to="lab_blrx_AdditionalCommitmentFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalExtendLeasePeriod_16" xlink:to="lab_blrx_AdditionalExtendLeasePeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalExtendLeasePeriod_17" xlink:to="lab_blrx_AdditionalExtendLeasePeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalExtendLeasePeriod_18" xlink:to="lab_blrx_AdditionalExtendLeasePeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_19" xlink:to="lab_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_20" xlink:to="lab_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_21" xlink:to="lab_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_22" xlink:to="lab_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_23" xlink:to="lab_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_24" xlink:to="lab_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionalSharesMember_25" xlink:to="lab_blrx_AdditionalSharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionsLeaseLiabilities_26" xlink:to="lab_blrx_AdditionsLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionsLeaseLiabilities_27" xlink:to="lab_blrx_AdditionsLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdditionsLeaseLiabilities_28" xlink:to="lab_blrx_AdditionsLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_29" xlink:to="lab_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_30" xlink:to="lab_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_31" xlink:to="lab_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdvancePayments_32" xlink:to="lab_blrx_AdvancePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdvancePayments_33" xlink:to="lab_blrx_AdvancePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdvancePayments_34" xlink:to="lab_blrx_AdvancePayments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AgalimmuneLtdMember_35" xlink:to="lab_blrx_AgalimmuneLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AgalimmuneLtdMember_36" xlink:to="lab_blrx_AgalimmuneLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AggregateAmericanDepositaryShares_37" xlink:to="lab_blrx_AggregateAmericanDepositaryShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AggregateAmericanDepositaryShares_38" xlink:to="lab_blrx_AggregateAmericanDepositaryShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AggregateAmericanDepositaryShares_39" xlink:to="lab_blrx_AggregateAmericanDepositaryShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AggregateOfferingPrice_40" xlink:to="lab_blrx_AggregateOfferingPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AggregateOfferingPrice_41" xlink:to="lab_blrx_AggregateOfferingPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AgreementTypeAxis_42" xlink:to="lab_blrx_AgreementTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AgreementTypeAxis_43" xlink:to="lab_blrx_AgreementTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AgreementTypeMember_44" xlink:to="lab_blrx_AgreementTypeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AgreementTypeMember_45" xlink:to="lab_blrx_AgreementTypeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_46" xlink:to="lab_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_47" xlink:to="lab_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_48" xlink:to="lab_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmericanDepositarySharesMember_49" xlink:to="lab_blrx_AmericanDepositarySharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmericanDepositarySharesMember_50" xlink:to="lab_blrx_AmericanDepositarySharesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmericanDepositarySharesMember_51" xlink:to="lab_blrx_AmericanDepositarySharesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmericanDepositarySharesPurchasePricePerShare_52" xlink:to="lab_blrx_AmericanDepositarySharesPurchasePricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmericanDepositarySharesPurchasePricePerShare_53" xlink:to="lab_blrx_AmericanDepositarySharesPurchasePricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmericanDepositarySharesPurchasePricePerShare_54" xlink:to="lab_blrx_AmericanDepositarySharesPurchasePricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmericanStockExchangeMember_55" xlink:to="lab_blrx_AmericanStockExchangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountAllocatedToWarrant_56" xlink:to="lab_blrx_AmountAllocatedToWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountAllocatedToWarrant_57" xlink:to="lab_blrx_AmountAllocatedToWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountGrantOfEquityInstruments_58" xlink:to="lab_blrx_AmountGrantOfEquityInstruments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountGrantOfEquityInstruments_59" xlink:to="lab_blrx_AmountGrantOfEquityInstruments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountGrantOfEquityInstruments_60" xlink:to="lab_blrx_AmountGrantOfEquityInstruments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountOfIntellectualPropertyAndCashBalance_61" xlink:to="lab_blrx_AmountOfIntellectualPropertyAndCashBalance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountOfIntellectualPropertyAndCashBalance_62" xlink:to="lab_blrx_AmountOfIntellectualPropertyAndCashBalance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountOfIntellectualPropertyAndCashBalance_63" xlink:to="lab_blrx_AmountOfIntellectualPropertyAndCashBalance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountOfLoanAgreement_64" xlink:to="lab_blrx_AmountOfLoanAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountOfLoanAgreement_65" xlink:to="lab_blrx_AmountOfLoanAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountOfLoanAgreement_66" xlink:to="lab_blrx_AmountOfLoanAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountOfPaymentInFutrueMilestone_67" xlink:to="lab_blrx_AmountOfPaymentInFutrueMilestone_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AmountOfPaymentInFutrueMilestone_68" xlink:to="lab_blrx_AmountOfPaymentInFutrueMilestone_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AnnualLeaseFee_69" xlink:to="lab_blrx_AnnualLeaseFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AnnualLeaseFee_70" xlink:to="lab_blrx_AnnualLeaseFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AuthorizedShareCapitalValue_71" xlink:to="lab_blrx_AuthorizedShareCapitalValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AuthorizedShareCapitalValue_72" xlink:to="lab_blrx_AuthorizedShareCapitalValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AuthorizedShareCapitalValue_73" xlink:to="lab_blrx_AuthorizedShareCapitalValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AvailableBalanceUnderFacility_74" xlink:to="lab_blrx_AvailableBalanceUnderFacility_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AvailableBalanceUnderFacility_75" xlink:to="lab_blrx_AvailableBalanceUnderFacility_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AyrmidLicenseAgreementMember_76" xlink:to="lab_blrx_AyrmidLicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AyrmidLicenseAgreementMember_77" xlink:to="lab_blrx_AyrmidLicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BankGuaranteeAmountForBenefitOfLessor_78" xlink:to="lab_blrx_BankGuaranteeAmountForBenefitOfLessor_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BankGuaranteeAmountForBenefitOfLessor_79" xlink:to="lab_blrx_BankGuaranteeAmountForBenefitOfLessor_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BankLoanMember_80" xlink:to="lab_blrx_BankLoanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BankLoanMember_81" xlink:to="lab_blrx_BankLoanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BasicAndDilutedEarningsLossPerShare_82" xlink:to="lab_blrx_BasicAndDilutedEarningsLossPerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BasicAndDilutedEarningsLossPerShare_83" xlink:to="lab_blrx_BasicAndDilutedEarningsLossPerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BasicAndDilutedEarningsLossPerShare_84" xlink:to="lab_blrx_BasicAndDilutedEarningsLossPerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BasicAndDilutedEarningsLossPerShare_85" xlink:to="lab_blrx_BasicAndDilutedEarningsLossPerShare_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BeneficiallyOwnInExcess_86" xlink:to="lab_blrx_BeneficiallyOwnInExcess_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BeneficiallyOwnInExcess_87" xlink:to="lab_blrx_BeneficiallyOwnInExcess_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BenefitsToRelatedPartiesAbstract_88" xlink:to="lab_blrx_BenefitsToRelatedPartiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BenefitsToRelatedPartiesAbstract_89" xlink:to="lab_blrx_BenefitsToRelatedPartiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BenefitsToRelatedPartiesAbstract_90" xlink:to="lab_blrx_BenefitsToRelatedPartiesAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BiokineMember_91" xlink:to="lab_blrx_BiokineMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BiokineMember_92" xlink:to="lab_blrx_BiokineMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BiokineTherapeuticsLtdMember_93" xlink:to="lab_blrx_BiokineTherapeuticsLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BiokineTherapeuticsLtdMember_94" xlink:to="lab_blrx_BiokineTherapeuticsLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BiokineTherapeuticsLtdMember_95" xlink:to="lab_blrx_BiokineTherapeuticsLtdMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BioLineRxMember_96" xlink:to="lab_blrx_BioLineRxMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BL8040Member_97" xlink:to="lab_blrx_BL8040Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BL8040Member_98" xlink:to="lab_blrx_BL8040Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BL8040Member_99" xlink:to="lab_blrx_BL8040Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BostonMember_100" xlink:to="lab_blrx_BostonMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BostonMember_101" xlink:to="lab_blrx_BostonMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BostonMember_102" xlink:to="lab_blrx_BostonMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BtigLlcMember_103" xlink:to="lab_blrx_BtigLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BtigLlcMember_104" xlink:to="lab_blrx_BtigLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BusinessAnalyticsExpense_105" xlink:to="lab_blrx_BusinessAnalyticsExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BusinessAnalyticsExpense_106" xlink:to="lab_blrx_BusinessAnalyticsExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BusinessAnalyticsExpense_107" xlink:to="lab_blrx_BusinessAnalyticsExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BvfPartnersLpMember_108" xlink:to="lab_blrx_BvfPartnersLpMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BvfPartnersLpMember_109" xlink:to="lab_blrx_BvfPartnersLpMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_BvfPartnersLpMember_110" xlink:to="lab_blrx_BvfPartnersLpMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CashAndCashEquivalentMember_111" xlink:to="lab_blrx_CashAndCashEquivalentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CashAndCashEquivalentMember_112" xlink:to="lab_blrx_CashAndCashEquivalentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CashAndCashEquivalentMember_113" xlink:to="lab_blrx_CashAndCashEquivalentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_114" xlink:to="lab_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_115" xlink:to="lab_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_116" xlink:to="lab_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_117" xlink:to="lab_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_118" xlink:to="lab_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CommitmentsAndContingentLiabilities_119" xlink:to="lab_blrx_CommitmentsAndContingentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CommitmentsAndContingentLiabilities_120" xlink:to="lab_blrx_CommitmentsAndContingentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ConsultantsMember_121" xlink:to="lab_blrx_ConsultantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ConsultantsMember_122" xlink:to="lab_blrx_ConsultantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_123" xlink:to="lab_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_124" xlink:to="lab_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_125" xlink:to="lab_blrx_ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ContingentLiability_126" xlink:to="lab_blrx_ContingentLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ContingentLiability_127" xlink:to="lab_blrx_ContingentLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ContingentLiability_128" xlink:to="lab_blrx_ContingentLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CostOfProductSales_129" xlink:to="lab_blrx_CostOfProductSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CostOfProductSales_130" xlink:to="lab_blrx_CostOfProductSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CostOfProductSales_131" xlink:to="lab_blrx_CostOfProductSales_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CostRelatedToLicenseRevenues_132" xlink:to="lab_blrx_CostRelatedToLicenseRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CostRelatedToLicenseRevenues_133" xlink:to="lab_blrx_CostRelatedToLicenseRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CostRelatedToLicenseRevenues_134" xlink:to="lab_blrx_CostRelatedToLicenseRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CostsIncurrentInOffering_135" xlink:to="lab_blrx_CostsIncurrentInOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CostsIncurrentInOffering_136" xlink:to="lab_blrx_CostsIncurrentInOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CostsIncurrentInOffering_137" xlink:to="lab_blrx_CostsIncurrentInOffering_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DelayInPayment_138" xlink:to="lab_blrx_DelayInPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DelayInPayment_139" xlink:to="lab_blrx_DelayInPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DelayInPayment_140" xlink:to="lab_blrx_DelayInPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_141" xlink:to="lab_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_142" xlink:to="lab_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_143" xlink:to="lab_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_144" xlink:to="lab_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DeletionsLeaseLiabilities_145" xlink:to="lab_blrx_DeletionsLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DeletionsLeaseLiabilities_146" xlink:to="lab_blrx_DeletionsLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DeletionsLeaseLiabilities_147" xlink:to="lab_blrx_DeletionsLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DeletionsLeaseLiabilities_148" xlink:to="lab_blrx_DeletionsLeaseLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DeletionsToRightOfUseAssets_149" xlink:to="lab_blrx_DeletionsToRightOfUseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DeletionsToRightOfUseAssets_150" xlink:to="lab_blrx_DeletionsToRightOfUseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DeletionsToRightOfUseAssets_151" xlink:to="lab_blrx_DeletionsToRightOfUseAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DepositaryShareConversionDescription_152" xlink:to="lab_blrx_DepositaryShareConversionDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DepositaryShareConversionDescription_153" xlink:to="lab_blrx_DepositaryShareConversionDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DepositaryShareConversionDescription_154" xlink:to="lab_blrx_DepositaryShareConversionDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_155" xlink:to="lab_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_156" xlink:to="lab_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_157" xlink:to="lab_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_158" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_159" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_160" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_161" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_162" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_163" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_164" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_165" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_166" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_167" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_168" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_169" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForConsolidationOfFinancialStatementsExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_170" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_171" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_172" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_173" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_174" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_175" xlink:to="lab_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_176" xlink:to="lab_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_177" xlink:to="lab_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_178" xlink:to="lab_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DirectorsMember_179" xlink:to="lab_blrx_DirectorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DirectorsMember_180" xlink:to="lab_blrx_DirectorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DirectorsMember_181" xlink:to="lab_blrx_DirectorsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DirectPlacementMember_182" xlink:to="lab_blrx_DirectPlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DirectPlacementMember_183" xlink:to="lab_blrx_DirectPlacementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_184" xlink:to="lab_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_185" xlink:to="lab_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_186" xlink:to="lab_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_187" xlink:to="lab_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_188" xlink:to="lab_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_189" xlink:to="lab_blrx_DisclosureOfAgreementWithOmegaPharmaExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_190" xlink:to="lab_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_191" xlink:to="lab_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_192" xlink:to="lab_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_193" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_194" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_195" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_196" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_197" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_198" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_199" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_200" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_201" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_202" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_203" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_204" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_205" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_206" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_207" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_208" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_209" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_210" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_211" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_212" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_213" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_214" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_215" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_216" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_217" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_218" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_219" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_220" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_221" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_222" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_223" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_224" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_225" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_226" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_227" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_228" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_229" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_230" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_231" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_232" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_233" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_234" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_235" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_236" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_237" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_238" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_239" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_240" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_241" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_242" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_243" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_244" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_245" xlink:to="lab_blrx_DisclosureOfLeasesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_246" xlink:to="lab_blrx_DisclosureOfLeasesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfLeasesTable_247" xlink:to="lab_blrx_DisclosureOfLeasesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfLeasesTable_248" xlink:to="lab_blrx_DisclosureOfLeasesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_249" xlink:to="lab_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_250" xlink:to="lab_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_251" xlink:to="lab_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_252" xlink:to="lab_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_253" xlink:to="lab_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_254" xlink:to="lab_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_255" xlink:to="lab_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_256" xlink:to="lab_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_257" xlink:to="lab_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_258" xlink:to="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_259" xlink:to="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_260" xlink:to="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_261" xlink:to="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_262" xlink:to="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_263" xlink:to="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_264" xlink:to="lab_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_265" xlink:to="lab_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_266" xlink:to="lab_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_267" xlink:to="lab_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclsoureOfAmendmentToLicenseExplanatory_268" xlink:to="lab_blrx_DisclsoureOfAmendmentToLicenseExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclsoureOfAmendmentToLicenseExplanatory_269" xlink:to="lab_blrx_DisclsoureOfAmendmentToLicenseExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclsoureOfAmendmentToLicenseExplanatory_270" xlink:to="lab_blrx_DisclsoureOfAmendmentToLicenseExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DollarMember_271" xlink:to="lab_blrx_DollarMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DollarMember_272" xlink:to="lab_blrx_DollarMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_EmployeesAndDirectorsMember_273" xlink:to="lab_blrx_EmployeesAndDirectorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_EmployeesAndDirectorsMember_274" xlink:to="lab_blrx_EmployeesAndDirectorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_EmployeesMember_275" xlink:to="lab_blrx_EmployeesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_EuroLinkedTradePayablesMember_276" xlink:to="lab_blrx_EuroLinkedTradePayablesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_EuroLinkedTradePayablesMember_277" xlink:to="lab_blrx_EuroLinkedTradePayablesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_EuroLinkedTradePayablesMember_278" xlink:to="lab_blrx_EuroLinkedTradePayablesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_EuroPerDollarMember_279" xlink:to="lab_blrx_EuroPerDollarMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_EuroPerDollarMember_280" xlink:to="lab_blrx_EuroPerDollarMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_EuroPerDollarMember_281" xlink:to="lab_blrx_EuroPerDollarMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExchangeDifferences_282" xlink:to="lab_blrx_ExchangeDifferences_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExchangeDifferences_283" xlink:to="lab_blrx_ExchangeDifferences_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExchangeDifferencesDuringYear_284" xlink:to="lab_blrx_ExchangeDifferencesDuringYear_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExchangeDifferencesDuringYear_285" xlink:to="lab_blrx_ExchangeDifferencesDuringYear_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExchangeDifferencesDuringYear_286" xlink:to="lab_blrx_ExchangeDifferencesDuringYear_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExchangeDifferencesDuringYear_287" xlink:to="lab_blrx_ExchangeDifferencesDuringYear_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExchangeDifferencesOnLeaseLiability_288" xlink:to="lab_blrx_ExchangeDifferencesOnLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExchangeDifferencesOnLeaseLiability_289" xlink:to="lab_blrx_ExchangeDifferencesOnLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExchangeDifferencesOnLeaseLiability_290" xlink:to="lab_blrx_ExchangeDifferencesOnLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisableTermOfWarrant_291" xlink:to="lab_blrx_ExercisableTermOfWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisableTermOfWarrant_292" xlink:to="lab_blrx_ExercisableTermOfWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExerciseOfPricePerAds_293" xlink:to="lab_blrx_ExerciseOfPricePerAds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExerciseOfPricePerAds_294" xlink:to="lab_blrx_ExerciseOfPricePerAds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceOfShareIssued_295" xlink:to="lab_blrx_ExercisePriceOfShareIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceOfShareIssued_296" xlink:to="lab_blrx_ExercisePriceOfShareIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceOfShareIssued_297" xlink:to="lab_blrx_ExercisePriceOfShareIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceOfWarrants_298" xlink:to="lab_blrx_ExercisePriceOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceOfWarrants_299" xlink:to="lab_blrx_ExercisePriceOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeFourMember_300" xlink:to="lab_blrx_ExercisePriceRangeFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeFourMember_301" xlink:to="lab_blrx_ExercisePriceRangeFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeFourMember_302" xlink:to="lab_blrx_ExercisePriceRangeFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeMember_303" xlink:to="lab_blrx_ExercisePriceRangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeMember_304" xlink:to="lab_blrx_ExercisePriceRangeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeMember_305" xlink:to="lab_blrx_ExercisePriceRangeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeOneMember_306" xlink:to="lab_blrx_ExercisePriceRangeOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeOneMember_307" xlink:to="lab_blrx_ExercisePriceRangeOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeOneMember_308" xlink:to="lab_blrx_ExercisePriceRangeOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeSixMember_309" xlink:to="lab_blrx_ExercisePriceRangeSixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeThreeMember_310" xlink:to="lab_blrx_ExercisePriceRangeThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeTwoMember_311" xlink:to="lab_blrx_ExercisePriceRangeTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeTwoMember_312" xlink:to="lab_blrx_ExercisePriceRangeTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ExercisePriceRangeTwoMember_313" xlink:to="lab_blrx_ExercisePriceRangeTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_314" xlink:to="lab_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_315" xlink:to="lab_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_316" xlink:to="lab_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FairValueOfWarrants_317" xlink:to="lab_blrx_FairValueOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FairValueOfWarrants_318" xlink:to="lab_blrx_FairValueOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FairValueOfWarrants_319" xlink:to="lab_blrx_FairValueOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FairValueOfWarrants_320" xlink:to="lab_blrx_FairValueOfWarrants_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FirstThreeYearsMember_321" xlink:to="lab_blrx_FirstThreeYearsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FirstThreeYearsMember_322" xlink:to="lab_blrx_FirstThreeYearsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FirstThreeYearsMember_323" xlink:to="lab_blrx_FirstThreeYearsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FirstTrancheMember_324" xlink:to="lab_blrx_FirstTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FirstTrancheMember_325" xlink:to="lab_blrx_FirstTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FirstTrancheMember_326" xlink:to="lab_blrx_FirstTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_327" xlink:to="lab_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_328" xlink:to="lab_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_329" xlink:to="lab_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_330" xlink:to="lab_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_331" xlink:to="lab_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_332" xlink:to="lab_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_GainOnRealizationOfLongtermInvestment_333" xlink:to="lab_blrx_GainOnRealizationOfLongtermInvestment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_GainOnRealizationOfLongtermInvestment_334" xlink:to="lab_blrx_GainOnRealizationOfLongtermInvestment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_GainOnRealizationOfLongtermInvestment_335" xlink:to="lab_blrx_GainOnRealizationOfLongtermInvestment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_GainOnRealizationOfLongtermInvestment_336" xlink:to="lab_blrx_GainOnRealizationOfLongtermInvestment_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_GloriaLicenseAgreementMember_337" xlink:to="lab_blrx_GloriaLicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_GloriaLicenseAgreementMember_338" xlink:to="lab_blrx_GloriaLicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_GloriaPurchaseAgreementMember_339" xlink:to="lab_blrx_GloriaPurchaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_GloriaPurchaseAgreementMember_340" xlink:to="lab_blrx_GloriaPurchaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_GrossProceedsFromOffering_341" xlink:to="lab_blrx_GrossProceedsFromOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_GrossProceedsFromOffering_342" xlink:to="lab_blrx_GrossProceedsFromOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_GrossProceedsFromOffering_343" xlink:to="lab_blrx_GrossProceedsFromOffering_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_HCWainwrightAndCoLlcMember_344" xlink:to="lab_blrx_HCWainwrightAndCoLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_HCWainwrightAndCoLlcMember_345" xlink:to="lab_blrx_HCWainwrightAndCoLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_HCWainwrightAndCoLlcMember_346" xlink:to="lab_blrx_HCWainwrightAndCoLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_HighbridgeCapitalManagementLlcMember_347" xlink:to="lab_blrx_HighbridgeCapitalManagementLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_HighbridgeCapitalManagementLlcMember_348" xlink:to="lab_blrx_HighbridgeCapitalManagementLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_HighbridgeMember_349" xlink:to="lab_blrx_HighbridgeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_HighbridgeMember_350" xlink:to="lab_blrx_HighbridgeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IBridgeCapitalMember_351" xlink:to="lab_blrx_IBridgeCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IBridgeCapitalMember_352" xlink:to="lab_blrx_IBridgeCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IfrsStatementLineItems_353" xlink:to="lab_blrx_IfrsStatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IfrsStatementLineItems_354" xlink:to="lab_blrx_IfrsStatementLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IfrsStatementTable_355" xlink:to="lab_blrx_IfrsStatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IfrsStatementTable_356" xlink:to="lab_blrx_IfrsStatementTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_357" xlink:to="lab_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_358" xlink:to="lab_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_359" xlink:to="lab_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_360" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_361" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_362" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_363" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_364" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_365" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_366" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_367" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_368" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_369" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_370" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_371" xlink:to="lab_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_372" xlink:to="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_373" xlink:to="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_374" xlink:to="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_375" xlink:to="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_376" xlink:to="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_377" xlink:to="lab_blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_378" xlink:to="lab_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_379" xlink:to="lab_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_380" xlink:to="lab_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_381" xlink:to="lab_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_382" xlink:to="lab_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncrementalInvestment_383" xlink:to="lab_blrx_IncrementalInvestment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncrementalInvestment_384" xlink:to="lab_blrx_IncrementalInvestment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncrementalInvestment_385" xlink:to="lab_blrx_IncrementalInvestment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InitialRoyaltyTerm_386" xlink:to="lab_blrx_InitialRoyaltyTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InitialRoyaltyTerm_387" xlink:to="lab_blrx_InitialRoyaltyTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InitialRoyaltyTerm_388" xlink:to="lab_blrx_InitialRoyaltyTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InstitutionsCurrentReceivables_389" xlink:to="lab_blrx_InstitutionsCurrentReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InstitutionsCurrentReceivables_390" xlink:to="lab_blrx_InstitutionsCurrentReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InstitutionsCurrentReceivables_391" xlink:to="lab_blrx_InstitutionsCurrentReceivables_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_392" xlink:to="lab_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_393" xlink:to="lab_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_394" xlink:to="lab_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_395" xlink:to="lab_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_396" xlink:to="lab_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_397" xlink:to="lab_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_398" xlink:to="lab_blrx_InterestAndLinkageDifferencesOnBankLoan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_399" xlink:to="lab_blrx_InterestAndLinkageDifferencesOnBankLoan_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_400" xlink:to="lab_blrx_InterestAndLinkageDifferencesOnBankLoan_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_401" xlink:to="lab_blrx_InterestAndLinkageDifferencesOnBankLoan_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_402" xlink:to="lab_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_403" xlink:to="lab_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_404" xlink:to="lab_blrx_InterestExpenseAndExchangeDifferencesOnFinancialExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestExpenseLeaseLiabilities_405" xlink:to="lab_blrx_InterestExpenseLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestExpenseLeaseLiabilities_406" xlink:to="lab_blrx_InterestExpenseLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestExpenseLeaseLiabilities_407" xlink:to="lab_blrx_InterestExpenseLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestExpenses_408" xlink:to="lab_blrx_InterestExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestExpenses_409" xlink:to="lab_blrx_InterestExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestExpenses_410" xlink:to="lab_blrx_InterestExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestIncomeAndExchangeDifferences_411" xlink:to="lab_blrx_InterestIncomeAndExchangeDifferences_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestIncomeAndExchangeDifferences_412" xlink:to="lab_blrx_InterestIncomeAndExchangeDifferences_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestRateOnLongTermBankLoan_413" xlink:to="lab_blrx_InterestRateOnLongTermBankLoan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestRateOnLongTermBankLoan_414" xlink:to="lab_blrx_InterestRateOnLongTermBankLoan_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestRateOnShortTermDeposits_415" xlink:to="lab_blrx_InterestRateOnShortTermDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestRateOnShortTermDeposits_416" xlink:to="lab_blrx_InterestRateOnShortTermDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestRateOnShortTermDeposits_417" xlink:to="lab_blrx_InterestRateOnShortTermDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_418" xlink:to="lab_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_419" xlink:to="lab_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_420" xlink:to="lab_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InvestorsMember_421" xlink:to="lab_blrx_InvestorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_InvestorsMember_422" xlink:to="lab_blrx_InvestorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IssuanceOfAdsValue_423" xlink:to="lab_blrx_IssuanceOfAdsValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IssuanceOfAdsValue_424" xlink:to="lab_blrx_IssuanceOfAdsValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IssuanceOfShareCapital_425" xlink:to="lab_blrx_IssuanceOfShareCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IssuanceOfShareCapital_426" xlink:to="lab_blrx_IssuanceOfShareCapital_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IssuanceOfShareCapital_427" xlink:to="lab_blrx_IssuanceOfShareCapital_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IssuancesOfWarrants_428" xlink:to="lab_blrx_IssuancesOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IssuancesOfWarrants_429" xlink:to="lab_blrx_IssuancesOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IssuancesOfWarrants_430" xlink:to="lab_blrx_IssuancesOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IssuedAndPaidUpShareCapitalValue_431" xlink:to="lab_blrx_IssuedAndPaidUpShareCapitalValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IssuedAndPaidUpShareCapitalValue_432" xlink:to="lab_blrx_IssuedAndPaidUpShareCapitalValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IssuedAndPaidUpShareCapitalValue_433" xlink:to="lab_blrx_IssuedAndPaidUpShareCapitalValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_KreosLoanMember_434" xlink:to="lab_blrx_KreosLoanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_KreosLoanMember_435" xlink:to="lab_blrx_KreosLoanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_KreosLoanMember_436" xlink:to="lab_blrx_KreosLoanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LaboratoryEquipmentMember_437" xlink:to="lab_blrx_LaboratoryEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LaboratoryEquipmentMember_438" xlink:to="lab_blrx_LaboratoryEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LawsuitClaimAmount_439" xlink:to="lab_blrx_LawsuitClaimAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LawsuitClaimAmount_440" xlink:to="lab_blrx_LawsuitClaimAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LawsuitClaimAmount_441" xlink:to="lab_blrx_LawsuitClaimAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LeaseAgreementMonthlyFee_442" xlink:to="lab_blrx_LeaseAgreementMonthlyFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LeaseAgreementMonthlyFee_443" xlink:to="lab_blrx_LeaseAgreementMonthlyFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LeasePeriod_444" xlink:to="lab_blrx_LeasePeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LeasePeriod_445" xlink:to="lab_blrx_LeasePeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseAgreementMember_446" xlink:to="lab_blrx_LicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseAgreementMember_447" xlink:to="lab_blrx_LicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_448" xlink:to="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_449" xlink:to="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_450" xlink:to="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_451" xlink:to="lab_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_452" xlink:to="lab_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_453" xlink:to="lab_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseRevenues_454" xlink:to="lab_blrx_LicenseRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseRevenues_455" xlink:to="lab_blrx_LicenseRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseRevenues_456" xlink:to="lab_blrx_LicenseRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LincolnParkCapitalFundMember_457" xlink:to="lab_blrx_LincolnParkCapitalFundMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LoanAgreementWithKreosCapitalMember_458" xlink:to="lab_blrx_LoanAgreementWithKreosCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LoanAgreementWithKreosCapitalMember_459" xlink:to="lab_blrx_LoanAgreementWithKreosCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LoanTakenForPaymentOfAgreementValue_460" xlink:to="lab_blrx_LoanTakenForPaymentOfAgreementValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LoanTakenForPaymentOfAgreementValue_461" xlink:to="lab_blrx_LoanTakenForPaymentOfAgreementValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LoanTakenForPaymentOfAgreementValue_462" xlink:to="lab_blrx_LoanTakenForPaymentOfAgreementValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LongTermPrepaidExpenses_463" xlink:to="lab_blrx_LongTermPrepaidExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LongTermPrepaidExpenses_464" xlink:to="lab_blrx_LongTermPrepaidExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LongTermPrepaidExpenses_465" xlink:to="lab_blrx_LongTermPrepaidExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LossOnAbandonmentOfRightofuseAsset_466" xlink:to="lab_blrx_LossOnAbandonmentOfRightofuseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LossOnAbandonmentOfRightofuseAsset_467" xlink:to="lab_blrx_LossOnAbandonmentOfRightofuseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LossOnAbandonmentOfRightofuseAsset_468" xlink:to="lab_blrx_LossOnAbandonmentOfRightofuseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MarketAccessExpense_469" xlink:to="lab_blrx_MarketAccessExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MarketAccessExpense_470" xlink:to="lab_blrx_MarketAccessExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MarketAccessExpense_471" xlink:to="lab_blrx_MarketAccessExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MarketingExpenses_472" xlink:to="lab_blrx_MarketingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MarketingExpenses_473" xlink:to="lab_blrx_MarketingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MarketingExpenses_474" xlink:to="lab_blrx_MarketingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MarketSharePrice_475" xlink:to="lab_blrx_MarketSharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MarketSharePrice_476" xlink:to="lab_blrx_MarketSharePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MarketSharePrice_477" xlink:to="lab_blrx_MarketSharePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaturitiesOfRestrictedDeposits_478" xlink:to="lab_blrx_MaturitiesOfRestrictedDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaturitiesOfRestrictedDeposits_479" xlink:to="lab_blrx_MaturitiesOfRestrictedDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaturitiesOfRestrictedDeposits_480" xlink:to="lab_blrx_MaturitiesOfRestrictedDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaturitiesOfShortTermDeposits_481" xlink:to="lab_blrx_MaturitiesOfShortTermDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaturitiesOfShortTermDeposits_482" xlink:to="lab_blrx_MaturitiesOfShortTermDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaturitiesOfShortTermDeposits_483" xlink:to="lab_blrx_MaturitiesOfShortTermDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaturityDate_484" xlink:to="lab_blrx_MaturityDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaturityDate_485" xlink:to="lab_blrx_MaturityDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaturityDate_486" xlink:to="lab_blrx_MaturityDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaximumFutureMilestonePayments_487" xlink:to="lab_blrx_MaximumFutureMilestonePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaximumFutureMilestonePayments_488" xlink:to="lab_blrx_MaximumFutureMilestonePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MaximumFutureMilestonePayments_489" xlink:to="lab_blrx_MaximumFutureMilestonePayments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MedicalAffairs_490" xlink:to="lab_blrx_MedicalAffairs_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MedicalAffairs_491" xlink:to="lab_blrx_MedicalAffairs_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_492" xlink:to="lab_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_493" xlink:to="lab_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_494" xlink:to="lab_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MonthlyAdvisoryFee_495" xlink:to="lab_blrx_MonthlyAdvisoryFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MonthlyAdvisoryFee_496" xlink:to="lab_blrx_MonthlyAdvisoryFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_MonthlyAdvisoryFee_497" xlink:to="lab_blrx_MonthlyAdvisoryFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NetAssetValueOfLinkageMonetaryItems_498" xlink:to="lab_blrx_NetAssetValueOfLinkageMonetaryItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NetAssetValueOfLinkageMonetaryItems_499" xlink:to="lab_blrx_NetAssetValueOfLinkageMonetaryItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NetAssetValueOfLinkageMonetaryItems_500" xlink:to="lab_blrx_NetAssetValueOfLinkageMonetaryItems_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NetAssetValueOfLinkageMonetaryItems_501" xlink:to="lab_blrx_NetAssetValueOfLinkageMonetaryItems_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NetBookValueMember_502" xlink:to="lab_blrx_NetBookValueMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NetBookValueMember_503" xlink:to="lab_blrx_NetBookValueMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NetBookValueMember_504" xlink:to="lab_blrx_NetBookValueMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NetMember_505" xlink:to="lab_blrx_NetMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NetMember_506" xlink:to="lab_blrx_NetMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NetMember_507" xlink:to="lab_blrx_NetMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NisLinkedBalancesMember_508" xlink:to="lab_blrx_NisLinkedBalancesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NisLinkedBalancesMember_509" xlink:to="lab_blrx_NisLinkedBalancesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NisLinkedBalancesMember_510" xlink:to="lab_blrx_NisLinkedBalancesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NisMember_511" xlink:to="lab_blrx_NisMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NisMember_512" xlink:to="lab_blrx_NisMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NisPerDollarMember_513" xlink:to="lab_blrx_NisPerDollarMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NisPerDollarMember_514" xlink:to="lab_blrx_NisPerDollarMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NisPerDollarMember_515" xlink:to="lab_blrx_NisPerDollarMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NonOperatingExpense_516" xlink:to="lab_blrx_NonOperatingExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NonOperatingExpense_517" xlink:to="lab_blrx_NonOperatingExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NovartisPharmaMember_518" xlink:to="lab_blrx_NovartisPharmaMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_519" xlink:to="lab_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_520" xlink:to="lab_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_521" xlink:to="lab_blrx_NumberOfAmericanDepositarySharesIssuedToInvestors_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfNewSharesIssued_522" xlink:to="lab_blrx_NumberOfNewSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfNewSharesIssued_523" xlink:to="lab_blrx_NumberOfNewSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfNewSharesIssued_524" xlink:to="lab_blrx_NumberOfNewSharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfNewSharesIssued_525" xlink:to="lab_blrx_NumberOfNewSharesIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfOptionsAbstract_526" xlink:to="lab_blrx_NumberOfOptionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfOptionsAbstract_527" xlink:to="lab_blrx_NumberOfOptionsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfOptionsAbstract_528" xlink:to="lab_blrx_NumberOfOptionsAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfOrdinarySharesAbstract_529" xlink:to="lab_blrx_NumberOfOrdinarySharesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfOrdinarySharesAbstract_530" xlink:to="lab_blrx_NumberOfOrdinarySharesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfOrdinarySharesAbstract_531" xlink:to="lab_blrx_NumberOfOrdinarySharesAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_532" xlink:to="lab_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_533" xlink:to="lab_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_534" xlink:to="lab_blrx_NumberOfPreFundedWarrantsIssuedToPurchaseAds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfPremises_535" xlink:to="lab_blrx_NumberOfPremises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfPremises_536" xlink:to="lab_blrx_NumberOfPremises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfPremises_537" xlink:to="lab_blrx_NumberOfPremises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfSegments_538" xlink:to="lab_blrx_NumberOfSegments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfSegments_539" xlink:to="lab_blrx_NumberOfSegments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfSegments_540" xlink:to="lab_blrx_NumberOfSegments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfWarrantPurchase_541" xlink:to="lab_blrx_NumberOfWarrantPurchase_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_NumberOfWarrantPurchase_542" xlink:to="lab_blrx_NumberOfWarrantPurchase_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OberonSecuritiesMember_543" xlink:to="lab_blrx_OberonSecuritiesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OfferingToInstitutionalInvestorsMember_544" xlink:to="lab_blrx_OfferingToInstitutionalInvestorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OfferingToInstitutionalInvestorsMember_545" xlink:to="lab_blrx_OfferingToInstitutionalInvestorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OpenPurchaseOrderCommitments_546" xlink:to="lab_blrx_OpenPurchaseOrderCommitments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OpenPurchaseOrderCommitments_547" xlink:to="lab_blrx_OpenPurchaseOrderCommitments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OpenPurchaseOrderCommitments_548" xlink:to="lab_blrx_OpenPurchaseOrderCommitments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OrbiMedAdvisorsMember_549" xlink:to="lab_blrx_OrbiMedAdvisorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherComprehensiveIncomeLossMember_550" xlink:to="lab_blrx_OtherComprehensiveIncomeLossMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherComprehensiveIncomeLossMember_551" xlink:to="lab_blrx_OtherComprehensiveIncomeLossMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherComprehensiveIncomeLossMember_552" xlink:to="lab_blrx_OtherComprehensiveIncomeLossMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherCurrenciesMember_553" xlink:to="lab_blrx_OtherCurrenciesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherCurrenciesMember_554" xlink:to="lab_blrx_OtherCurrenciesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherCurrenciesMember_555" xlink:to="lab_blrx_OtherCurrenciesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherNonoperatingIncomeExpenses_556" xlink:to="lab_blrx_OtherNonoperatingIncomeExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherNonoperatingIncomeExpenses_557" xlink:to="lab_blrx_OtherNonoperatingIncomeExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherNonoperatingIncomeExpenses_558" xlink:to="lab_blrx_OtherNonoperatingIncomeExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherPayablesAbstract_559" xlink:to="lab_blrx_OtherPayablesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherPayablesAbstract_560" xlink:to="lab_blrx_OtherPayablesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherPayablesAbstract_561" xlink:to="lab_blrx_OtherPayablesAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherPayablesMember_562" xlink:to="lab_blrx_OtherPayablesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherPayablesMember_563" xlink:to="lab_blrx_OtherPayablesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherPayablesMember_564" xlink:to="lab_blrx_OtherPayablesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherReceivablesMember_565" xlink:to="lab_blrx_OtherReceivablesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherReceivablesMember_566" xlink:to="lab_blrx_OtherReceivablesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_OtherReceivablesMember_567" xlink:to="lab_blrx_OtherReceivablesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_Others_568" xlink:to="lab_blrx_Others_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_Others_569" xlink:to="lab_blrx_Others_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_Others_570" xlink:to="lab_blrx_Others_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PaymentsLeaseLiabilities_571" xlink:to="lab_blrx_PaymentsLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PaymentsLeaseLiabilities_572" xlink:to="lab_blrx_PaymentsLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PaymentsLeaseLiabilities_573" xlink:to="lab_blrx_PaymentsLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PaymentsLeaseLiabilities_574" xlink:to="lab_blrx_PaymentsLeaseLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PayrollAndRelatedExpenses_575" xlink:to="lab_blrx_PayrollAndRelatedExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PayrollAndRelatedExpenses_576" xlink:to="lab_blrx_PayrollAndRelatedExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PayrollAndRelatedExpenses_577" xlink:to="lab_blrx_PayrollAndRelatedExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PDACPerformanceObligationMember_578" xlink:to="lab_blrx_PDACPerformanceObligationMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PDACPerformanceObligationMember_579" xlink:to="lab_blrx_PDACPerformanceObligationMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PDACPerformanceObligationMember_580" xlink:to="lab_blrx_PDACPerformanceObligationMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageIncreaseDecreaseInExchangeRate_581" xlink:to="lab_blrx_PercentageIncreaseDecreaseInExchangeRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageIncreaseDecreaseInExchangeRate_582" xlink:to="lab_blrx_PercentageIncreaseDecreaseInExchangeRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageIncreaseDecreaseInExchangeRate_583" xlink:to="lab_blrx_PercentageIncreaseDecreaseInExchangeRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageIncreasePrecedingLeasePaymentAmount_584" xlink:to="lab_blrx_PercentageIncreasePrecedingLeasePaymentAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageIncreasePrecedingLeasePaymentAmount_585" xlink:to="lab_blrx_PercentageIncreasePrecedingLeasePaymentAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfAdditionalEquityInterest_586" xlink:to="lab_blrx_PercentageOfAdditionalEquityInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfAdditionalEquityInterest_587" xlink:to="lab_blrx_PercentageOfAdditionalEquityInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfAdditionalEquityInterest_588" xlink:to="lab_blrx_PercentageOfAdditionalEquityInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfAnnualInterestOfCashFees_589" xlink:to="lab_blrx_PercentageOfAnnualInterestOfCashFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfAnnualInterestOfCashFees_590" xlink:to="lab_blrx_PercentageOfAnnualInterestOfCashFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfAnnualInterestOfCashFees_591" xlink:to="lab_blrx_PercentageOfAnnualInterestOfCashFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfCommissionOnSalesAgreement_592" xlink:to="lab_blrx_PercentageOfCommissionOnSalesAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfCommissionOnSalesAgreement_593" xlink:to="lab_blrx_PercentageOfCommissionOnSalesAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfDecreasingAnnualGrowthRate_594" xlink:to="lab_blrx_PercentageOfDecreasingAnnualGrowthRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfDecreasingAnnualGrowthRate_595" xlink:to="lab_blrx_PercentageOfDecreasingAnnualGrowthRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfDecreasingAnnualGrowthRate_596" xlink:to="lab_blrx_PercentageOfDecreasingAnnualGrowthRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfFutureMilestonePayments_597" xlink:to="lab_blrx_PercentageOfFutureMilestonePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfFutureMilestonePayments_598" xlink:to="lab_blrx_PercentageOfFutureMilestonePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfFutureMilestonePayments_599" xlink:to="lab_blrx_PercentageOfFutureMilestonePayments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_600" xlink:to="lab_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_601" xlink:to="lab_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_602" xlink:to="lab_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfIssuedShareCapitalReceived_603" xlink:to="lab_blrx_PercentageOfIssuedShareCapitalReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfIssuedShareCapitalReceived_604" xlink:to="lab_blrx_PercentageOfIssuedShareCapitalReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfIssuedShareCapitalReceived_605" xlink:to="lab_blrx_PercentageOfIssuedShareCapitalReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_606" xlink:to="lab_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_607" xlink:to="lab_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_608" xlink:to="lab_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_609" xlink:to="lab_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_610" xlink:to="lab_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfNetConsiderationReceivedForSubLicense_611" xlink:to="lab_blrx_PercentageOfNetConsiderationReceivedForSubLicense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfNetConsiderationReceivedForSubLicense_612" xlink:to="lab_blrx_PercentageOfNetConsiderationReceivedForSubLicense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfNetConsiderationReceivedFromLicensee_613" xlink:to="lab_blrx_PercentageOfNetConsiderationReceivedFromLicensee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfNetConsiderationReceivedFromLicensee_614" xlink:to="lab_blrx_PercentageOfNetConsiderationReceivedFromLicensee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfOwnershipStake_615" xlink:to="lab_blrx_PercentageOfOwnershipStake_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfOwnershipStake_616" xlink:to="lab_blrx_PercentageOfOwnershipStake_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfOwnershipStake_617" xlink:to="lab_blrx_PercentageOfOwnershipStake_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfPaymentToBeMade_618" xlink:to="lab_blrx_PercentageOfPaymentToBeMade_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfPaymentToBeMade_619" xlink:to="lab_blrx_PercentageOfPaymentToBeMade_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfPaymentToBeMade_620" xlink:to="lab_blrx_PercentageOfPaymentToBeMade_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfReducePaymentOwedOnSublicenseReceipts_621" xlink:to="lab_blrx_PercentageOfReducePaymentOwedOnSublicenseReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfReducePaymentOwedOnSublicenseReceipts_622" xlink:to="lab_blrx_PercentageOfReducePaymentOwedOnSublicenseReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_623" xlink:to="lab_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_624" xlink:to="lab_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_625" xlink:to="lab_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PerformanceSharesUnitMember_626" xlink:to="lab_blrx_PerformanceSharesUnitMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PerformanceSharesUnitMember_627" xlink:to="lab_blrx_PerformanceSharesUnitMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PerformanceStockUnitsMember_628" xlink:to="lab_blrx_PerformanceStockUnitsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PhaseThreeMember_629" xlink:to="lab_blrx_PhaseThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PhaseTwoMember_630" xlink:to="lab_blrx_PhaseTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PlacementAgentOfferingMember_631" xlink:to="lab_blrx_PlacementAgentOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PlacementAgentOfferingMember_632" xlink:to="lab_blrx_PlacementAgentOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PlacementAgentsDesigneesMember_633" xlink:to="lab_blrx_PlacementAgentsDesigneesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PlacementAgentsDesigneesMember_634" xlink:to="lab_blrx_PlacementAgentsDesigneesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_635" xlink:to="lab_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_636" xlink:to="lab_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_637" xlink:to="lab_blrx_PreFundedOrOrdinaryWarrantsExerciseTerms_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrantPurchasePricePerShare_638" xlink:to="lab_blrx_PreFundedWarrantPurchasePricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrantPurchasePricePerShare_639" xlink:to="lab_blrx_PreFundedWarrantPurchasePricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrantPurchasePricePerShare_640" xlink:to="lab_blrx_PreFundedWarrantPurchasePricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrants_641" xlink:to="lab_blrx_PreFundedWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrants_642" xlink:to="lab_blrx_PreFundedWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrantsExercisablePricePerAds_643" xlink:to="lab_blrx_PreFundedWarrantsExercisablePricePerAds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrantsExercisablePricePerAds_644" xlink:to="lab_blrx_PreFundedWarrantsExercisablePricePerAds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrantsExercisablePricePerAds_645" xlink:to="lab_blrx_PreFundedWarrantsExercisablePricePerAds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrantsExercisePricePerAds_646" xlink:to="lab_blrx_PreFundedWarrantsExercisePricePerAds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrantsExercisePricePerAds_647" xlink:to="lab_blrx_PreFundedWarrantsExercisePricePerAds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrantsExercisePricePerAds_648" xlink:to="lab_blrx_PreFundedWarrantsExercisePricePerAds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrantsMember_649" xlink:to="lab_blrx_PreFundedWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PreFundedWarrantsMember_650" xlink:to="lab_blrx_PreFundedWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_651" xlink:to="lab_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_652" xlink:to="lab_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_653" xlink:to="lab_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromExerciseWarrants_654" xlink:to="lab_blrx_ProceedsFromExerciseWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromExerciseWarrants_655" xlink:to="lab_blrx_ProceedsFromExerciseWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromExerciseWarrants_656" xlink:to="lab_blrx_ProceedsFromExerciseWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromIssuanceOfInitialPublicOffering_657" xlink:to="lab_blrx_ProceedsFromIssuanceOfInitialPublicOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromIssuanceOfInitialPublicOffering_658" xlink:to="lab_blrx_ProceedsFromIssuanceOfInitialPublicOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromIssuanceOfInitialPublicOffering_659" xlink:to="lab_blrx_ProceedsFromIssuanceOfInitialPublicOffering_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_660" xlink:to="lab_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_661" xlink:to="lab_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_662" xlink:to="lab_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromWarrantIssue_663" xlink:to="lab_blrx_ProceedsFromWarrantIssue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromWarrantIssue_664" xlink:to="lab_blrx_ProceedsFromWarrantIssue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProceedsFromWarrantIssue_665" xlink:to="lab_blrx_ProceedsFromWarrantIssue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProductSalesNet_666" xlink:to="lab_blrx_ProductSalesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProductSalesNet_667" xlink:to="lab_blrx_ProductSalesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProductSalesNet_668" xlink:to="lab_blrx_ProductSalesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProfessionalFee_669" xlink:to="lab_blrx_ProfessionalFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProfessionalFee_670" xlink:to="lab_blrx_ProfessionalFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProfessionalFee_671" xlink:to="lab_blrx_ProfessionalFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProfitLossFromNonOperatingActivities_672" xlink:to="lab_blrx_ProfitLossFromNonOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProfitLossFromNonOperatingActivities_673" xlink:to="lab_blrx_ProfitLossFromNonOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProfitLossFromNonOperatingActivities_674" xlink:to="lab_blrx_ProfitLossFromNonOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProfitLossFromNonOperatingActivities_675" xlink:to="lab_blrx_ProfitLossFromNonOperatingActivities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProvisionForDoubtfulAccountsReceivable_676" xlink:to="lab_blrx_ProvisionForDoubtfulAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProvisionForDoubtfulAccountsReceivable_677" xlink:to="lab_blrx_ProvisionForDoubtfulAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProvisionForDoubtfulAccountsReceivable_678" xlink:to="lab_blrx_ProvisionForDoubtfulAccountsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ProvisionForDoubtfulAccountsReceivable_679" xlink:to="lab_blrx_ProvisionForDoubtfulAccountsReceivable_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PublicOfferingMember_680" xlink:to="lab_blrx_PublicOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PublicOfferingMember_681" xlink:to="lab_blrx_PublicOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PurchaseAgreementMember_682" xlink:to="lab_blrx_PurchaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PurchaseAgreementMember_683" xlink:to="lab_blrx_PurchaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PurchaseAgreementPeriod_684" xlink:to="lab_blrx_PurchaseAgreementPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PurchaseAgreementPeriod_685" xlink:to="lab_blrx_PurchaseAgreementPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PurchasePricePerADS_686" xlink:to="lab_blrx_PurchasePricePerADS_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PurchasePricePerADS_687" xlink:to="lab_blrx_PurchasePricePerADS_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PurchasePricePerADS_688" xlink:to="lab_blrx_PurchasePricePerADS_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RecognizedAsEquity_689" xlink:to="lab_blrx_RecognizedAsEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RecognizedAsEquity_690" xlink:to="lab_blrx_RecognizedAsEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RecognizedAsEquity_691" xlink:to="lab_blrx_RecognizedAsEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RegisteredDirectOfferingMember_692" xlink:to="lab_blrx_RegisteredDirectOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RegisteredDirectOfferingMember_693" xlink:to="lab_blrx_RegisteredDirectOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RemainingAuthorizedUnissuedOrdinaryShares_694" xlink:to="lab_blrx_RemainingAuthorizedUnissuedOrdinaryShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RemainingAuthorizedUnissuedOrdinaryShares_695" xlink:to="lab_blrx_RemainingAuthorizedUnissuedOrdinaryShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RemainingUnrecognizedDeferredCompensationExpense_696" xlink:to="lab_blrx_RemainingUnrecognizedDeferredCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RemainingUnrecognizedDeferredCompensationExpense_697" xlink:to="lab_blrx_RemainingUnrecognizedDeferredCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RepaymentOfLongTermDebtAfterOneYear_698" xlink:to="lab_blrx_RepaymentOfLongTermDebtAfterOneYear_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RepaymentOfLongTermDebtAfterOneYear_699" xlink:to="lab_blrx_RepaymentOfLongTermDebtAfterOneYear_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RepaymentOfLongTermDebtAfterOneYear_700" xlink:to="lab_blrx_RepaymentOfLongTermDebtAfterOneYear_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RepaymentOfLongTermDebtYearsTwo_701" xlink:to="lab_blrx_RepaymentOfLongTermDebtYearsTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RepaymentOfLongTermDebtYearsTwo_702" xlink:to="lab_blrx_RepaymentOfLongTermDebtYearsTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RepaymentOfLongTermDebtYearsTwo_703" xlink:to="lab_blrx_RepaymentOfLongTermDebtYearsTwo_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_704" xlink:to="lab_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_705" xlink:to="lab_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_706" xlink:to="lab_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RightOfUseAssetWrittenOff_707" xlink:to="lab_blrx_RightOfUseAssetWrittenOff_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RightOfUseAssetWrittenOff_708" xlink:to="lab_blrx_RightOfUseAssetWrittenOff_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RightOfUseAssetWrittenOff_709" xlink:to="lab_blrx_RightOfUseAssetWrittenOff_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesEligibleMargin_710" xlink:to="lab_blrx_RoyaltiesEligibleMargin_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesEligibleMargin_711" xlink:to="lab_blrx_RoyaltiesEligibleMargin_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesEligibleMargin_712" xlink:to="lab_blrx_RoyaltiesEligibleMargin_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesOnSale_713" xlink:to="lab_blrx_RoyaltiesOnSale_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesOnSale_714" xlink:to="lab_blrx_RoyaltiesOnSale_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesPaymentPercentage_715" xlink:to="lab_blrx_RoyaltiesPaymentPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesPaymentPercentage_716" xlink:to="lab_blrx_RoyaltiesPaymentPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesPaymentPercentage_717" xlink:to="lab_blrx_RoyaltiesPaymentPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_718" xlink:to="lab_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_719" xlink:to="lab_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_720" xlink:to="lab_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesRateOnNetSales_721" xlink:to="lab_blrx_RoyaltiesRateOnNetSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesRateOnNetSales_722" xlink:to="lab_blrx_RoyaltiesRateOnNetSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesReceivedPercentage_723" xlink:to="lab_blrx_RoyaltiesReceivedPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_RoyaltiesReceivedPercentage_724" xlink:to="lab_blrx_RoyaltiesReceivedPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SaleOfStockNumberOfSharesIssued_725" xlink:to="lab_blrx_SaleOfStockNumberOfSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SaleOfStockNumberOfSharesIssued_726" xlink:to="lab_blrx_SaleOfStockNumberOfSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SaleOfStockNumberOfSharesIssued_727" xlink:to="lab_blrx_SaleOfStockNumberOfSharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingDepreciationAndAmortization_728" xlink:to="lab_blrx_SalesAndMarketingDepreciationAndAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingDepreciationAndAmortization_729" xlink:to="lab_blrx_SalesAndMarketingDepreciationAndAmortization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingDepreciationAndAmortization_730" xlink:to="lab_blrx_SalesAndMarketingDepreciationAndAmortization_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingExpensesOther_731" xlink:to="lab_blrx_SalesAndMarketingExpensesOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingExpensesOther_732" xlink:to="lab_blrx_SalesAndMarketingExpensesOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingExpensesOther_733" xlink:to="lab_blrx_SalesAndMarketingExpensesOther_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingExpensesRelatedToSales_734" xlink:to="lab_blrx_SalesAndMarketingExpensesRelatedToSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingExpensesRelatedToSales_735" xlink:to="lab_blrx_SalesAndMarketingExpensesRelatedToSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingExpensesRelatedToSales_736" xlink:to="lab_blrx_SalesAndMarketingExpensesRelatedToSales_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingPayrollExpense_737" xlink:to="lab_blrx_SalesAndMarketingPayrollExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingPayrollExpense_738" xlink:to="lab_blrx_SalesAndMarketingPayrollExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingPayrollExpense_739" xlink:to="lab_blrx_SalesAndMarketingPayrollExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingProfessionalFees_740" xlink:to="lab_blrx_SalesAndMarketingProfessionalFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingProfessionalFees_741" xlink:to="lab_blrx_SalesAndMarketingProfessionalFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingProfessionalFees_742" xlink:to="lab_blrx_SalesAndMarketingProfessionalFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingShareBasedCompensation_743" xlink:to="lab_blrx_SalesAndMarketingShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingShareBasedCompensation_744" xlink:to="lab_blrx_SalesAndMarketingShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesAndMarketingShareBasedCompensation_745" xlink:to="lab_blrx_SalesAndMarketingShareBasedCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesMilestoneAmount_746" xlink:to="lab_blrx_SalesMilestoneAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesMilestoneAmount_747" xlink:to="lab_blrx_SalesMilestoneAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SalesMilestoneAmount_748" xlink:to="lab_blrx_SalesMilestoneAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ScmLicenseMember_749" xlink:to="lab_blrx_ScmLicenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ScmLicenseMember_750" xlink:to="lab_blrx_ScmLicenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ScmLicenseMember_751" xlink:to="lab_blrx_ScmLicenseMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ScmSupportServicesMember_752" xlink:to="lab_blrx_ScmSupportServicesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ScmSupportServicesMember_753" xlink:to="lab_blrx_ScmSupportServicesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ScmSupportServicesMember_754" xlink:to="lab_blrx_ScmSupportServicesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SecondTrancheMember_755" xlink:to="lab_blrx_SecondTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SecondTrancheMember_756" xlink:to="lab_blrx_SecondTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SecondTrancheMember_757" xlink:to="lab_blrx_SecondTrancheMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SeniorManagementMember_758" xlink:to="lab_blrx_SeniorManagementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SeniorManagementMember_759" xlink:to="lab_blrx_SeniorManagementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SensitivityTestsDecreasingAnnualGrowthRate_760" xlink:to="lab_blrx_SensitivityTestsDecreasingAnnualGrowthRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SensitivityTestsDecreasingAnnualGrowthRate_761" xlink:to="lab_blrx_SensitivityTestsDecreasingAnnualGrowthRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SensitivityTestsDecreasingAnnualGrowthRate_762" xlink:to="lab_blrx_SensitivityTestsDecreasingAnnualGrowthRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SensitivityTestsIncreasingAnnualGrowthRate_763" xlink:to="lab_blrx_SensitivityTestsIncreasingAnnualGrowthRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SensitivityTestsIncreasingAnnualGrowthRate_764" xlink:to="lab_blrx_SensitivityTestsIncreasingAnnualGrowthRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SensitivityTestsIncreasingAnnualGrowthRate_765" xlink:to="lab_blrx_SensitivityTestsIncreasingAnnualGrowthRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SeriesAWarrantsMember_766" xlink:to="lab_blrx_SeriesAWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SeriesAWarrantsMember_767" xlink:to="lab_blrx_SeriesAWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SeriesBWarrantMember_768" xlink:to="lab_blrx_SeriesBWarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SeriesBWarrantMember_769" xlink:to="lab_blrx_SeriesBWarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SeriesBWarrantMember_770" xlink:to="lab_blrx_SeriesBWarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SeventhYearMember_771" xlink:to="lab_blrx_SeventhYearMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SeventhYearMember_772" xlink:to="lab_blrx_SeventhYearMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SeventhYearMember_773" xlink:to="lab_blrx_SeventhYearMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_774" xlink:to="lab_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_775" xlink:to="lab_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_776" xlink:to="lab_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_777" xlink:to="lab_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_778" xlink:to="lab_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_779" xlink:to="lab_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareIncentivePlanMember_780" xlink:to="lab_blrx_ShareIncentivePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareIncentivePlanMember_781" xlink:to="lab_blrx_ShareIncentivePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareIncentivePlanMember_782" xlink:to="lab_blrx_ShareIncentivePlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareIssuedAsAdditionalCommitmentFee_783" xlink:to="lab_blrx_ShareIssuedAsAdditionalCommitmentFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareIssuedAsAdditionalCommitmentFee_784" xlink:to="lab_blrx_ShareIssuedAsAdditionalCommitmentFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareIssuedOfPublicOffering_785" xlink:to="lab_blrx_ShareIssuedOfPublicOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareIssuedOfPublicOffering_786" xlink:to="lab_blrx_ShareIssuedOfPublicOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareIssuedOfPublicOffering_787" xlink:to="lab_blrx_ShareIssuedOfPublicOffering_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareIssuedToPurchaseWarrant_788" xlink:to="lab_blrx_ShareIssuedToPurchaseWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareIssuedToPurchaseWarrant_789" xlink:to="lab_blrx_ShareIssuedToPurchaseWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShareIssuedToPurchaseWarrant_790" xlink:to="lab_blrx_ShareIssuedToPurchaseWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharePremiumResultingFromExerciseOfWarrants_791" xlink:to="lab_blrx_SharePremiumResultingFromExerciseOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharePremiumResultingFromExerciseOfWarrants_792" xlink:to="lab_blrx_SharePremiumResultingFromExerciseOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharePremiumResultingFromExerciseOfWarrants_793" xlink:to="lab_blrx_SharePremiumResultingFromExerciseOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharePurchaseAgreement_794" xlink:to="lab_blrx_SharePurchaseAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharePurchaseAgreement_795" xlink:to="lab_blrx_SharePurchaseAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharePurchaseAgreementMember_796" xlink:to="lab_blrx_SharePurchaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharePurchaseAgreementMember_797" xlink:to="lab_blrx_SharePurchaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharePurchaseAgreementShares_798" xlink:to="lab_blrx_SharePurchaseAgreementShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharePurchaseAgreementShares_799" xlink:to="lab_blrx_SharePurchaseAgreementShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharesIssuedRegisteredDirectOfferings_800" xlink:to="lab_blrx_SharesIssuedRegisteredDirectOfferings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharesIssuedRegisteredDirectOfferings_801" xlink:to="lab_blrx_SharesIssuedRegisteredDirectOfferings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SharesIssuedRegisteredDirectOfferings_802" xlink:to="lab_blrx_SharesIssuedRegisteredDirectOfferings_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShortTermDepositMember_803" xlink:to="lab_blrx_ShortTermDepositMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShortTermDepositMember_804" xlink:to="lab_blrx_ShortTermDepositMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ShortTermDepositMember_805" xlink:to="lab_blrx_ShortTermDepositMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SingleMaterialPerformanceObligationMember_806" xlink:to="lab_blrx_SingleMaterialPerformanceObligationMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SingleMaterialPerformanceObligationMember_807" xlink:to="lab_blrx_SingleMaterialPerformanceObligationMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_StockIssuedPricePerShare_808" xlink:to="lab_blrx_StockIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_StockIssuedPricePerShare_809" xlink:to="lab_blrx_StockIssuedPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_StockIssuedPricePerShare_810" xlink:to="lab_blrx_StockIssuedPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementalInformationOnInterestPaidInCash_811" xlink:to="lab_blrx_SupplementalInformationOnInterestPaidInCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementalInformationOnInterestPaidInCash_812" xlink:to="lab_blrx_SupplementalInformationOnInterestPaidInCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementalInformationOnInterestPaidInCash_813" xlink:to="lab_blrx_SupplementalInformationOnInterestPaidInCash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementalInformationOnNoncashTransactionsAbstract_814" xlink:to="lab_blrx_SupplementalInformationOnNoncashTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementalInformationOnNoncashTransactionsAbstract_815" xlink:to="lab_blrx_SupplementalInformationOnNoncashTransactionsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementalInformationOnNoncashTransactionsAbstract_816" xlink:to="lab_blrx_SupplementalInformationOnNoncashTransactionsAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_817" xlink:to="lab_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_818" xlink:to="lab_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_819" xlink:to="lab_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_820" xlink:to="lab_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_821" xlink:to="lab_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_822" xlink:to="lab_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnIntangibleAssetAcquired_823" xlink:to="lab_blrx_SupplementaryInformationOnIntangibleAssetAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnIntangibleAssetAcquired_824" xlink:to="lab_blrx_SupplementaryInformationOnIntangibleAssetAcquired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnIntangibleAssetAcquired_825" xlink:to="lab_blrx_SupplementaryInformationOnIntangibleAssetAcquired_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnInterestReceivedInCash_826" xlink:to="lab_blrx_SupplementaryInformationOnInterestReceivedInCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnInterestReceivedInCash_827" xlink:to="lab_blrx_SupplementaryInformationOnInterestReceivedInCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnInterestReceivedInCash_828" xlink:to="lab_blrx_SupplementaryInformationOnInterestReceivedInCash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_829" xlink:to="lab_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_830" xlink:to="lab_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_831" xlink:to="lab_blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnWarrantIssuanceCosts_832" xlink:to="lab_blrx_SupplementaryInformationOnWarrantIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnWarrantIssuanceCosts_833" xlink:to="lab_blrx_SupplementaryInformationOnWarrantIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnWarrantIssuanceCosts_834" xlink:to="lab_blrx_SupplementaryInformationOnWarrantIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_835" xlink:to="lab_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_836" xlink:to="lab_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_837" xlink:to="lab_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_838" xlink:to="lab_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_839" xlink:to="lab_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_840" xlink:to="lab_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TaxLossCarryforwards_841" xlink:to="lab_blrx_TaxLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TaxLossCarryforwards_842" xlink:to="lab_blrx_TaxLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TaxLossCarryforwards_843" xlink:to="lab_blrx_TaxLossCarryforwards_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TelAvivStockExchangeMember_844" xlink:to="lab_blrx_TelAvivStockExchangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_845" xlink:to="lab_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_846" xlink:to="lab_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_847" xlink:to="lab_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_848" xlink:to="lab_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_849" xlink:to="lab_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_850" xlink:to="lab_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ThirdTrancheMember_851" xlink:to="lab_blrx_ThirdTrancheMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ThirdTrancheMember_852" xlink:to="lab_blrx_ThirdTrancheMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ThreeSubsequentYearsMember_853" xlink:to="lab_blrx_ThreeSubsequentYearsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ThreeSubsequentYearsMember_854" xlink:to="lab_blrx_ThreeSubsequentYearsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ThreeSubsequentYearsMember_855" xlink:to="lab_blrx_ThreeSubsequentYearsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TotalChangeInOperatingAssetAndLiability_856" xlink:to="lab_blrx_TotalChangeInOperatingAssetAndLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TotalChangeInOperatingAssetAndLiability_857" xlink:to="lab_blrx_TotalChangeInOperatingAssetAndLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TotalChangeInOperatingAssetAndLiability_858" xlink:to="lab_blrx_TotalChangeInOperatingAssetAndLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_859" xlink:to="lab_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_860" xlink:to="lab_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_861" xlink:to="lab_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_862" xlink:to="lab_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_863" xlink:to="lab_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_864" xlink:to="lab_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_865" xlink:to="lab_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_866" xlink:to="lab_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_867" xlink:to="lab_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradePayablesAbstract_868" xlink:to="lab_blrx_TradePayablesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradePayablesAbstract_869" xlink:to="lab_blrx_TradePayablesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradePayablesAbstract_870" xlink:to="lab_blrx_TradePayablesAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradePayablesMember_871" xlink:to="lab_blrx_TradePayablesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradePayablesMember_872" xlink:to="lab_blrx_TradePayablesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TradePayablesMember_873" xlink:to="lab_blrx_TradePayablesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TrancheAxis_874" xlink:to="lab_blrx_TrancheAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TrancheAxis_875" xlink:to="lab_blrx_TrancheAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TrancheDomain_876" xlink:to="lab_blrx_TrancheDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TrancheDomain_877" xlink:to="lab_blrx_TrancheDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TransferFromLicenseToTheLicenseeAmount_878" xlink:to="lab_blrx_TransferFromLicenseToTheLicenseeAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TransferFromLicenseToTheLicenseeAmount_879" xlink:to="lab_blrx_TransferFromLicenseToTheLicenseeAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TransferFromLicenseToTheLicenseeAmount_880" xlink:to="lab_blrx_TransferFromLicenseToTheLicenseeAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_UnderwaterEmployeeStockOptionsMember_881" xlink:to="lab_blrx_UnderwaterEmployeeStockOptionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_UnderwaterEmployeeStockOptionsMember_882" xlink:to="lab_blrx_UnderwaterEmployeeStockOptionsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_UnderwritersMember_883" xlink:to="lab_blrx_UnderwritersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_UnderwritersMember_884" xlink:to="lab_blrx_UnderwritersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_UniformTaxRate_885" xlink:to="lab_blrx_UniformTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_UniformTaxRate_886" xlink:to="lab_blrx_UniformTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_UniformTaxRate_887" xlink:to="lab_blrx_UniformTaxRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_UpfrontPayment_888" xlink:to="lab_blrx_UpfrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_UpfrontPayment_889" xlink:to="lab_blrx_UpfrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ValueOfServicesRecorded_890" xlink:to="lab_blrx_ValueOfServicesRecorded_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ValueOfServicesRecorded_891" xlink:to="lab_blrx_ValueOfServicesRecorded_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantFiveMember_892" xlink:to="lab_blrx_WarrantFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantFiveMember_893" xlink:to="lab_blrx_WarrantFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantFiveMember_894" xlink:to="lab_blrx_WarrantFiveMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantFourMember_895" xlink:to="lab_blrx_WarrantFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantFourMember_896" xlink:to="lab_blrx_WarrantFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantFourMember_897" xlink:to="lab_blrx_WarrantFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantOfferingConsideration_898" xlink:to="lab_blrx_WarrantOfferingConsideration_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantOfferingConsideration_899" xlink:to="lab_blrx_WarrantOfferingConsideration_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantOfferingConsideration_900" xlink:to="lab_blrx_WarrantOfferingConsideration_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantOneMember_901" xlink:to="lab_blrx_WarrantOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantOneMember_902" xlink:to="lab_blrx_WarrantOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantOneMember_903" xlink:to="lab_blrx_WarrantOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_Warrants_904" xlink:to="lab_blrx_Warrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_Warrants_905" xlink:to="lab_blrx_Warrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsExercisableTerm_906" xlink:to="lab_blrx_WarrantsExercisableTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsExercisableTerm_907" xlink:to="lab_blrx_WarrantsExercisableTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsExercisableTerm_908" xlink:to="lab_blrx_WarrantsExercisableTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsExercises_909" xlink:to="lab_blrx_WarrantsExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsExercises_910" xlink:to="lab_blrx_WarrantsExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsExercises_911" xlink:to="lab_blrx_WarrantsExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsExpirationPeriod_912" xlink:to="lab_blrx_WarrantsExpirationPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsExpirationPeriod_913" xlink:to="lab_blrx_WarrantsExpirationPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsIssuedToPurchaseAds_914" xlink:to="lab_blrx_WarrantsIssuedToPurchaseAds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsIssuedToPurchaseAds_915" xlink:to="lab_blrx_WarrantsIssuedToPurchaseAds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsIssuedToPurchaseAds_916" xlink:to="lab_blrx_WarrantsIssuedToPurchaseAds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsIssuedToPurchaseShares_917" xlink:to="lab_blrx_WarrantsIssuedToPurchaseShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsIssuedToPurchaseShares_918" xlink:to="lab_blrx_WarrantsIssuedToPurchaseShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantSixMember_919" xlink:to="lab_blrx_WarrantSixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantSixMember_920" xlink:to="lab_blrx_WarrantSixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantSixMember_921" xlink:to="lab_blrx_WarrantSixMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsReserve_922" xlink:to="lab_blrx_WarrantsReserve_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsReserve_923" xlink:to="lab_blrx_WarrantsReserve_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantsReserve_924" xlink:to="lab_blrx_WarrantsReserve_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantThreeMember_925" xlink:to="lab_blrx_WarrantThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantThreeMember_926" xlink:to="lab_blrx_WarrantThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantThreeMember_927" xlink:to="lab_blrx_WarrantThreeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantTwoMember_928" xlink:to="lab_blrx_WarrantTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantTwoMember_929" xlink:to="lab_blrx_WarrantTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WarrantTwoMember_930" xlink:to="lab_blrx_WarrantTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_931" xlink:to="lab_blrx_WeightedAverageExercisePriceAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_932" xlink:to="lab_blrx_WeightedAverageExercisePriceAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_933" xlink:to="lab_blrx_WeightedAverageExercisePriceAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WithholdingApplicableTaxRate_934" xlink:to="lab_blrx_WithholdingApplicableTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WithholdingApplicableTaxRate_935" xlink:to="lab_blrx_WithholdingApplicableTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WithholdingApplicableTaxRate_936" xlink:to="lab_blrx_WithholdingApplicableTaxRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WriteoffOfIntangibleAsset_937" xlink:to="lab_blrx_WriteoffOfIntangibleAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WriteoffOfIntangibleAsset_938" xlink:to="lab_blrx_WriteoffOfIntangibleAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_WriteoffOfIntangibleAsset_939" xlink:to="lab_blrx_WriteoffOfIntangibleAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_940" xlink:to="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_941" xlink:to="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_942" xlink:to="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense_943" xlink:to="lab_ifrs-full_AmortisationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense_944" xlink:to="lab_ifrs-full_AmortisationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense_945" xlink:to="lab_ifrs-full_AmortisationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense_946" xlink:to="lab_ifrs-full_AmortisationExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense_947" xlink:to="lab_ifrs-full_AmortisationExpense_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales_948" xlink:to="lab_ifrs-full_CostOfSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales_949" xlink:to="lab_ifrs-full_CostOfSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales_950" xlink:to="lab_ifrs-full_CostOfSales_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales_951" xlink:to="lab_ifrs-full_CostOfSales_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales_952" xlink:to="lab_ifrs-full_CostOfSales_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_953" xlink:to="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_954" xlink:to="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_955" xlink:to="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationAndAmortisationExpense_956" xlink:to="lab_ifrs-full_DepreciationAndAmortisationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationAndAmortisationExpense_957" xlink:to="lab_ifrs-full_DepreciationAndAmortisationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationAndAmortisationExpense_958" xlink:to="lab_ifrs-full_DepreciationAndAmortisationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationAndAmortisationExpense_959" xlink:to="lab_ifrs-full_DepreciationAndAmortisationExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_960" xlink:to="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_961" xlink:to="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_962" xlink:to="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_963" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_964" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_965" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts_966" xlink:to="lab_ifrs-full_FinanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts_967" xlink:to="lab_ifrs-full_FinanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts_968" xlink:to="lab_ifrs-full_FinanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossOnFinancialAssets_969" xlink:to="lab_ifrs-full_ImpairmentLossOnFinancialAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossOnFinancialAssets_970" xlink:to="lab_ifrs-full_ImpairmentLossOnFinancialAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_971" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_972" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_973" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_974" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_975" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_976" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss_977" xlink:to="lab_ifrs-full_NetForeignExchangeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss_978" xlink:to="lab_ifrs-full_NetForeignExchangeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss_979" xlink:to="lab_ifrs-full_NetForeignExchangeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_980" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_981" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_982" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_983" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_984" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_985" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_986" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_987" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_988" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_989" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_990" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_991" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_992" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_993" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_994" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_995" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_996" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_997" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_998" xlink:to="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_999" xlink:to="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_1000" xlink:to="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_1001" xlink:to="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_1002" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_1003" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_1004" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings_1005" xlink:to="lab_ifrs-full_RetainedEarnings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings_1006" xlink:to="lab_ifrs-full_RetainedEarnings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_1007" xlink:to="lab_ifrs-full_SalesAndMarketingExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_1008" xlink:to="lab_ifrs-full_SalesAndMarketingExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_1009" xlink:to="lab_ifrs-full_SalesAndMarketingExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesAndMarketingExpense_1010" xlink:to="lab_ifrs-full_SalesAndMarketingExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1011" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1012" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1013" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost_1014" xlink:to="lab_ifrs-full_ShareIssueRelatedCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost_1015" xlink:to="lab_ifrs-full_ShareIssueRelatedCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost_1016" xlink:to="lab_ifrs-full_ShareIssueRelatedCost_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1017" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1018" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_1020" xlink:to="lab_ifrs-full_CashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_1021" xlink:to="lab_ifrs-full_CashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_1022" xlink:to="lab_ifrs-full_CashAndCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_1023" xlink:to="lab_ifrs-full_CashAndCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_1024" xlink:to="lab_ifrs-full_Equity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_1025" xlink:to="lab_ifrs-full_Equity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_1026" xlink:to="lab_ifrs-full_Equity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_1027" xlink:to="lab_ifrs-full_Equity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1028" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1029" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1030" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1031" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities_1032" xlink:to="lab_ifrs-full_LeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities_1033" xlink:to="lab_ifrs-full_LeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities_1034" xlink:to="lab_ifrs-full_LeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities_1035" xlink:to="lab_ifrs-full_LeaseLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1036" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1037" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1038" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_1039" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_1040" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_1041" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_1042" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1043" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1044" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding_1045" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding_1046" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding_1047" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment_1048" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment_1049" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment_1050" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets_1051" xlink:to="lab_ifrs-full_RightofuseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets_1052" xlink:to="lab_ifrs-full_RightofuseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets_1053" xlink:to="lab_ifrs-full_RightofuseAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_1054" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_1055" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1056" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1057" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1058" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1059" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings_1060" xlink:to="lab_ifrs-full_Borrowings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings_1061" xlink:to="lab_ifrs-full_Borrowings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings_1062" xlink:to="lab_ifrs-full_Borrowings_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings_1063" xlink:to="lab_ifrs-full_Borrowings_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_1064" xlink:to="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_1065" xlink:to="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_1066" xlink:to="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_1067" xlink:to="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome_1068" xlink:to="lab_ifrs-full_ComprehensiveIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome_1069" xlink:to="lab_ifrs-full_ComprehensiveIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome_1070" xlink:to="lab_ifrs-full_ComprehensiveIncome_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome_1071" xlink:to="lab_ifrs-full_ComprehensiveIncome_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome_1072" xlink:to="lab_ifrs-full_ComprehensiveIncome_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_1073" xlink:to="lab_ifrs-full_ProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_1074" xlink:to="lab_ifrs-full_ProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_1075" xlink:to="lab_ifrs-full_ProfitLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_1076" xlink:to="lab_ifrs-full_ProfitLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_1077" xlink:to="lab_ifrs-full_ProfitLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_1078" xlink:to="lab_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_1079" xlink:to="lab_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AgreementTypeDomain_1080" xlink:to="lab_blrx_AgreementTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AgreementWithCompaniesForDevelopmentAbstract_1081" xlink:to="lab_blrx_AgreementWithCompaniesForDevelopmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_AssetTransferAgreementMember_1082" xlink:to="lab_blrx_AssetTransferAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_1083" xlink:to="lab_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_1084" xlink:to="lab_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_1085" xlink:to="lab_blrx_CollaborationAndShareholdersAgreementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementTable_1086" xlink:to="lab_blrx_CollaborationAndShareholdersAgreementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CollaborationTransactionAxis_1087" xlink:to="lab_blrx_CollaborationTransactionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_CollaborationTransactionDomain_1088" xlink:to="lab_blrx_CollaborationTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract_1089" xlink:to="lab_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract_1090" xlink:to="lab_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfAgalimmuneAcquisitionAbstract_1091" xlink:to="lab_blrx_DisclosureOfAgalimmuneAcquisitionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfAgreementWithOmegaPharmaAbstract_1092" xlink:to="lab_blrx_DisclosureOfAgreementWithOmegaPharmaAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfAgreementWithOmegaPharmaAbstract_1093" xlink:to="lab_blrx_DisclosureOfAgreementWithOmegaPharmaAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfAmendmentToLicenseAbstract_1094" xlink:to="lab_blrx_DisclosureOfAmendmentToLicenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfAmendmentToLicenseAbstract_1095" xlink:to="lab_blrx_DisclosureOfAmendmentToLicenseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract_1096" xlink:to="lab_blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock_1097" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock_1098" xlink:to="lab_blrx_DisclosureOfDetailedInformationAboutInventoryExplanatoryTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfEventsSubsequentToBalanceSheetDateAbstract_1099" xlink:to="lab_blrx_DisclosureOfEventsSubsequentToBalanceSheetDateAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfEventsSubsequentToBalanceSheetDateAbstract_1100" xlink:to="lab_blrx_DisclosureOfEventsSubsequentToBalanceSheetDateAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfGeneralInformationAbstract_1101" xlink:to="lab_blrx_DisclosureOfGeneralInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfIncomeTaxesAbstract_1102" xlink:to="lab_blrx_DisclosureOfIncomeTaxesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfIncomeTaxesAbstract_1103" xlink:to="lab_blrx_DisclosureOfIncomeTaxesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfIncomeTaxesAbstract_1104" xlink:to="lab_blrx_DisclosureOfIncomeTaxesAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract_1105" xlink:to="lab_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfLongTermInvestmentAbstract_1106" xlink:to="lab_blrx_DisclosureOfLongTermInvestmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_1107" xlink:to="lab_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable_1108" xlink:to="lab_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfShortTermBankDepositsAbstract_1109" xlink:to="lab_blrx_DisclosureOfShortTermBankDepositsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfShortTermBankDepositsAbstract_1110" xlink:to="lab_blrx_DisclosureOfShortTermBankDepositsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_1111" xlink:to="lab_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract_1112" xlink:to="lab_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract_1113" xlink:to="lab_blrx_DisclosureOfStrategicCollaborationAgreementWithNovartisAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_Glix1Member_1114" xlink:to="lab_blrx_Glix1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_Glix1Member_1115" xlink:to="lab_blrx_Glix1Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_HemispherianAsMember_1116" xlink:to="lab_blrx_HemispherianAsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_1117" xlink:to="lab_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_1118" xlink:to="lab_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_January2025OfferingMember_1119" xlink:to="lab_blrx_January2025OfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract_1120" xlink:to="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_1121" xlink:to="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1122" xlink:to="lab_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PerformanceObligationAxis_1123" xlink:to="lab_blrx_PerformanceObligationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PerformanceObligationDomain_1124" xlink:to="lab_blrx_PerformanceObligationDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PerformanceSharesUnitTwoMember_1125" xlink:to="lab_blrx_PerformanceSharesUnitTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PerformanceSharesUnitTwoMember_1126" xlink:to="lab_blrx_PerformanceSharesUnitTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_PlacementAgentMember_1127" xlink:to="lab_blrx_PlacementAgentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_1128" xlink:to="lab_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_1129" xlink:to="lab_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_Test_1130" xlink:to="lab_blrx_Test_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_Test_1131" xlink:to="lab_blrx_Test_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blrx_TetragonMember_1132" xlink:to="lab_blrx_TetragonMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_1133" xlink:to="lab_country_IL_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_1134" xlink:to="lab_country_IL_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_ILS_1135" xlink:to="lab_currency_ILS_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_ILS_1136" xlink:to="lab_currency_ILS_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain_1137" xlink:to="lab_dei_AddressTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription_1138" xlink:to="lab_dei_AmendmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1139" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId_1140" xlink:to="lab_dei_AuditorFirmId_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation_1141" xlink:to="lab_dei_AuditorLocation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName_1142" xlink:to="lab_dei_AuditorName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorOpinionTextBlock_1143" xlink:to="lab_dei_AuditorOpinionTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember_1144" xlink:to="lab_dei_BusinessContactMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_1145" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress_1146" xlink:to="lab_dei_ContactPersonnelEmailAddress_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelFaxNumber_1147" xlink:to="lab_dei_ContactPersonnelFaxNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName_1148" xlink:to="lab_dei_ContactPersonnelName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_1149" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_1150" xlink:to="lab_dei_CoverAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_1151" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard_1152" xlink:to="lab_dei_DocumentAccountingStandard_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_1153" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag_1154" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_1155" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_1156" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_1157" xlink:to="lab_dei_DocumentInformationLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable_1158" xlink:to="lab_dei_DocumentInformationTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_1159" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement_1160" xlink:to="lab_dei_DocumentRegistrationStatement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport_1161" xlink:to="lab_dei_DocumentShellCompanyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_1162" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_1163" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_1164" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_1165" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_1166" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_1167" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1168" xlink:to="lab_dei_EntityAddressesAddressTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_1169" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_1170" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_1171" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_1172" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_1173" xlink:to="lab_dei_EntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_1174" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_1175" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_1176" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_1177" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_1178" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_1179" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_1180" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_1181" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_1182" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_1183" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_1184" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag_1185" xlink:to="lab_dei_IcfrAuditorAttestationFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_1186" xlink:to="lab_dei_LegalEntityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_1187" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_1188" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_1189" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit_1190" xlink:to="lab_ifrs-full_AccountingProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit_1191" xlink:to="lab_ifrs-full_AccountingProfit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_1192" xlink:to="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_1193" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_1194" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_1195" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_1196" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_1197" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1198" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1199" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1200" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1201" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_1202" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets_1203" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets_1204" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_1205" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_1206" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_1207" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_1208" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_1209" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_1210" xlink:to="lab_ifrs-full_AdjustmentsForFairValueGainsLosses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_1211" xlink:to="lab_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_1212" xlink:to="lab_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_1213" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_1214" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_1215" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_1216" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_1217" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_1218" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments_1219" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments_1220" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1221" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity_1222" xlink:to="lab_ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate_1223" xlink:to="lab_ifrs-full_ApplicableTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate_1224" xlink:to="lab_ifrs-full_ApplicableTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets_1225" xlink:to="lab_ifrs-full_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets_1226" xlink:to="lab_ifrs-full_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets_1227" xlink:to="lab_ifrs-full_Assets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract_1228" xlink:to="lab_ifrs-full_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract_1229" xlink:to="lab_ifrs-full_AssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare_1230" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare_1231" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare_1232" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1233" xlink:to="lab_ifrs-full_BorrowingsByNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1234" xlink:to="lab_ifrs-full_BorrowingsByNameAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate_1235" xlink:to="lab_ifrs-full_BorrowingsInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember_1236" xlink:to="lab_ifrs-full_BottomOfRangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember_1237" xlink:to="lab_ifrs-full_BottomOfRangeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1238" xlink:to="lab_ifrs-full_BusinessCombinationsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1239" xlink:to="lab_ifrs-full_BusinessCombinationsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_1240" xlink:to="lab_ifrs-full_BusinessCombinationsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalReserve_1241" xlink:to="lab_ifrs-full_CapitalReserve_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalReserveMember_1242" xlink:to="lab_ifrs-full_CapitalReserveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1243" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1244" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember_1245" xlink:to="lab_ifrs-full_CarryingAmountMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash_1246" xlink:to="lab_ifrs-full_Cash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_1247" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_1248" xlink:to="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_1249" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_1250" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1251" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1252" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_1253" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_1254" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1255" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1256" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1257" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashTransferred_1258" xlink:to="lab_ifrs-full_CashTransferred_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashTransferred_1259" xlink:to="lab_ifrs-full_CashTransferred_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1260" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_1261" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1262" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1263" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_1264" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_1265" xlink:to="lab_ifrs-full_ChangesInEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_1266" xlink:to="lab_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember_1267" xlink:to="lab_ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1268" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_1269" xlink:to="lab_ifrs-full_ClassesOfAssetsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1270" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1271" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1272" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1273" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1274" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1275" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_1276" xlink:to="lab_ifrs-full_ClassesOfInventoriesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_1277" xlink:to="lab_ifrs-full_ClassesOfInventoriesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1278" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1279" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1280" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_1281" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate_1282" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommunicationExpense_1283" xlink:to="lab_ifrs-full_CommunicationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1284" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_1285" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_1286" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_1287" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_1288" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_1289" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_1290" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember_1291" xlink:to="lab_ifrs-full_ComputerEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember_1292" xlink:to="lab_ifrs-full_ComputerSoftwareMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ConsiderationPaidReceived_1293" xlink:to="lab_ifrs-full_ConsiderationPaidReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ConsiderationPaidReceived_1294" xlink:to="lab_ifrs-full_ConsiderationPaidReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CountryOfDomicileMember_1295" xlink:to="lab_ifrs-full_CountryOfDomicileMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CountryOfDomicileMember_1296" xlink:to="lab_ifrs-full_CountryOfDomicileMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditExposure_1297" xlink:to="lab_ifrs-full_CreditExposure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditRiskMember_1298" xlink:to="lab_ifrs-full_CreditRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_1299" xlink:to="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets_1300" xlink:to="lab_ifrs-full_CurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets_1301" xlink:to="lab_ifrs-full_CurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1302" xlink:to="lab_ifrs-full_CurrentAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1303" xlink:to="lab_ifrs-full_CurrentAssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities_1304" xlink:to="lab_ifrs-full_CurrentContractLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities_1305" xlink:to="lab_ifrs-full_CurrentContractLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities_1306" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities_1307" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities_1308" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities_1309" xlink:to="lab_ifrs-full_CurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities_1310" xlink:to="lab_ifrs-full_CurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1311" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1312" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses_1313" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_1314" xlink:to="lab_ifrs-full_CurrentProvisionsForEmployeeBenefits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_1315" xlink:to="lab_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_1316" xlink:to="lab_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_1317" xlink:to="lab_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationExpense_1318" xlink:to="lab_ifrs-full_DepreciationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_1319" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_1320" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_1321" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_1322" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_1323" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_1324" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_1325" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_1326" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_1327" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_1328" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_1329" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_1330" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_1331" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_1332" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_1333" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_1334" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_1335" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_1336" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_1337" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_1338" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_1339" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1340" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1341" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_1342" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1343" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1344" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_1345" xlink:to="lab_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_1346" xlink:to="lab_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_1347" xlink:to="lab_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare_1348" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare_1349" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_1350" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory_1351" xlink:to="lab_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_1352" xlink:to="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_1353" xlink:to="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_1354" xlink:to="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_1355" xlink:to="lab_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1356" xlink:to="lab_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_1357" xlink:to="lab_ifrs-full_DisclosureOfBorrowingsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_1358" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_1359" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1360" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_1361" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_1362" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_1363" xlink:to="lab_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_1364" xlink:to="lab_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1365" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_1366" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_1367" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_1368" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDepositsFromBanksExplanatory_1369" xlink:to="lab_ifrs-full_DisclosureOfDepositsFromBanksExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_1370" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_1371" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1372" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1373" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_1374" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_1375" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_1376" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1377" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1378" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1379" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_1380" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory_1381" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1382" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_1383" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_1384" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1385" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_1386" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_1387" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_1388" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_1389" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_1390" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_1391" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_1392" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1393" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1394" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_1395" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_1396" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_1397" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_1398" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1399" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInventoriesExplanatory_1400" xlink:to="lab_ifrs-full_DisclosureOfInventoriesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInventoriesExplanatory_1401" xlink:to="lab_ifrs-full_DisclosureOfInventoriesExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInvestmentPropertyExplanatory_1402" xlink:to="lab_ifrs-full_DisclosureOfInvestmentPropertyExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_1403" xlink:to="lab_ifrs-full_DisclosureOfJointVenturesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_1404" xlink:to="lab_ifrs-full_DisclosureOfJointVenturesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory_1405" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_1406" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_1407" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_1408" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_1409" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_1410" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_1411" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_1412" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1413" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_1414" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_1415" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1416" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1417" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_1418" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_1419" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_1420" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_1421" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_1422" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_1423" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1424" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_1425" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_1426" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1427" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_1428" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1429" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1430" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1431" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_1432" xlink:to="lab_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1433" xlink:to="lab_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_1434" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_1435" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1436" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1437" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_1438" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1439" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_1440" xlink:to="lab_ifrs-full_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1441" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_1442" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract_1443" xlink:to="lab_ifrs-full_EquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities_1444" xlink:to="lab_ifrs-full_EquityAndLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities_1445" xlink:to="lab_ifrs-full_EquityAndLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_1446" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent_1447" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent_1448" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityInterestsOfAcquirer_1449" xlink:to="lab_ifrs-full_EquityInterestsOfAcquirer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityInterestsOfAcquirer_1450" xlink:to="lab_ifrs-full_EquityInterestsOfAcquirer_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_1451" xlink:to="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_1452" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FeeAndCommissionExpense_1453" xlink:to="lab_ifrs-full_FeeAndCommissionExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome_1454" xlink:to="lab_ifrs-full_FinanceIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome_1455" xlink:to="lab_ifrs-full_FinanceIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValue_1456" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_1457" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_1458" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinishedGoods_1459" xlink:to="lab_ifrs-full_FinishedGoods_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinishedGoods_1460" xlink:to="lab_ifrs-full_FinishedGoods_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignCountriesMember_1461" xlink:to="lab_ifrs-full_ForeignCountriesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignCountriesMember_1462" xlink:to="lab_ifrs-full_ForeignCountriesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignExchangeGain_1463" xlink:to="lab_ifrs-full_ForeignExchangeGain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignExchangeGain_1464" xlink:to="lab_ifrs-full_ForeignExchangeGain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignExchangeLoss_1465" xlink:to="lab_ifrs-full_ForeignExchangeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignExchangeLoss_1466" xlink:to="lab_ifrs-full_ForeignExchangeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_1467" xlink:to="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1468" xlink:to="lab_ifrs-full_GeographicalAreasAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasDomain_1469" xlink:to="lab_ifrs-full_GeographicalAreasDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember_1470" xlink:to="lab_ifrs-full_GrossCarryingAmountMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember_1471" xlink:to="lab_ifrs-full_GrossCarryingAmountMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossProfit_1472" xlink:to="lab_ifrs-full_GrossProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossProfit_1473" xlink:to="lab_ifrs-full_GrossProfit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_1474" xlink:to="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_1475" xlink:to="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_1476" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_1477" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract_1478" xlink:to="lab_ifrs-full_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1479" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1480" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_1481" xlink:to="lab_ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1482" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1483" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_1484" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1485" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1486" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1487" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1488" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsAxis_1489" xlink:to="lab_ifrs-full_InitiallyAppliedIFRSsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsDomain_1490" xlink:to="lab_ifrs-full_InitiallyAppliedIFRSsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InsuranceExpense_1491" xlink:to="lab_ifrs-full_InsuranceExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1492" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1493" xlink:to="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1494" xlink:to="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_1495" xlink:to="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpense_1496" xlink:to="lab_ifrs-full_InterestExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpense_1497" xlink:to="lab_ifrs-full_InterestExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpense_1498" xlink:to="lab_ifrs-full_InterestExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings_1499" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings_1500" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPayable_1501" xlink:to="lab_ifrs-full_InterestPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPayable_1502" xlink:to="lab_ifrs-full_InterestPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories_1503" xlink:to="lab_ifrs-full_Inventories_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories_1504" xlink:to="lab_ifrs-full_Inventories_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories_1505" xlink:to="lab_ifrs-full_Inventories_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentProperty_1506" xlink:to="lab_ifrs-full_InvestmentProperty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentProperty_1507" xlink:to="lab_ifrs-full_InvestmentProperty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentPropertyMember_1508" xlink:to="lab_ifrs-full_InvestmentPropertyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital_1509" xlink:to="lab_ifrs-full_IssuedCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember_1510" xlink:to="lab_ifrs-full_IssuedCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity_1511" xlink:to="lab_ifrs-full_IssueOfEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity_1512" xlink:to="lab_ifrs-full_IssueOfEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesAxis_1513" xlink:to="lab_ifrs-full_JointVenturesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesAxis_1514" xlink:to="lab_ifrs-full_JointVenturesAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_1515" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_1516" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_1517" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_1518" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1519" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1520" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_1521" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LandAndBuildingsMember_1522" xlink:to="lab_ifrs-full_LandAndBuildingsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LandAndBuildingsMember_1523" xlink:to="lab_ifrs-full_LandAndBuildingsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_1524" xlink:to="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_1525" xlink:to="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1526" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1527" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1528" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1529" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_1530" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_1531" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseholdImprovementsMember_1532" xlink:to="lab_ifrs-full_LeaseholdImprovementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_1533" xlink:to="lab_ifrs-full_LeaseLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level3OfFairValueHierarchyMember_1534" xlink:to="lab_ifrs-full_Level3OfFairValueHierarchyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level3OfFairValueHierarchyMember_1535" xlink:to="lab_ifrs-full_Level3OfFairValueHierarchyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1536" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_1537" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities_1538" xlink:to="lab_ifrs-full_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities_1539" xlink:to="lab_ifrs-full_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities_1540" xlink:to="lab_ifrs-full_Liabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesAbstract_1541" xlink:to="lab_ifrs-full_LiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1542" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_1543" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicenceFeeIncome_1544" xlink:to="lab_ifrs-full_LicenceFeeIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicenceFeeIncome_1545" xlink:to="lab_ifrs-full_LicenceFeeIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowingsMember_1546" xlink:to="lab_ifrs-full_LongtermBorrowingsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis_1547" xlink:to="lab_ifrs-full_MaturityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityDomain_1548" xlink:to="lab_ifrs-full_MaturityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MotorVehiclesMember_1549" xlink:to="lab_ifrs-full_MotorVehiclesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MotorVehiclesMember_1550" xlink:to="lab_ifrs-full_MotorVehiclesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeGain_1551" xlink:to="lab_ifrs-full_NetForeignExchangeGain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeGain_1552" xlink:to="lab_ifrs-full_NetForeignExchangeGain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1553" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_1554" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterests_1555" xlink:to="lab_ifrs-full_NoncontrollingInterests_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterestsMember_1556" xlink:to="lab_ifrs-full_NoncontrollingInterestsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterestsMember_1557" xlink:to="lab_ifrs-full_NoncontrollingInterestsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets_1558" xlink:to="lab_ifrs-full_NoncurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets_1559" xlink:to="lab_ifrs-full_NoncurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_1560" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities_1561" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities_1562" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities_1563" xlink:to="lab_ifrs-full_NoncurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities_1564" xlink:to="lab_ifrs-full_NoncurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_1565" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_1566" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember_1567" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember_1568" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfEmployees_1569" xlink:to="lab_ifrs-full_NumberOfEmployees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_1570" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_1571" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesAuthorised_1572" xlink:to="lab_ifrs-full_NumberOfSharesAuthorised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued_1573" xlink:to="lab_ifrs-full_NumberOfSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued_1574" xlink:to="lab_ifrs-full_NumberOfSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_1575" xlink:to="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember_1576" xlink:to="lab_ifrs-full_OfficeEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_1577" xlink:to="lab_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_1578" xlink:to="lab_ifrs-full_OtherComprehensiveIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_1579" xlink:to="lab_ifrs-full_OtherComprehensiveIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentPayables_1580" xlink:to="lab_ifrs-full_OtherCurrentPayables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentPayables_1581" xlink:to="lab_ifrs-full_OtherCurrentPayables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables_1582" xlink:to="lab_ifrs-full_OtherCurrentReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables_1583" xlink:to="lab_ifrs-full_OtherCurrentReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEquityInterest_1584" xlink:to="lab_ifrs-full_OtherEquityInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherExpenseByFunction_1585" xlink:to="lab_ifrs-full_OtherExpenseByFunction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherExpenseByFunction_1586" xlink:to="lab_ifrs-full_OtherExpenseByFunction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherExpenseByNature_1587" xlink:to="lab_ifrs-full_OtherExpenseByNature_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherExpenseByNature_1588" xlink:to="lab_ifrs-full_OtherExpenseByNature_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFeeAndCommissionExpense_1589" xlink:to="lab_ifrs-full_OtherFeeAndCommissionExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIntangibleAssetsMember_1590" xlink:to="lab_ifrs-full_OtherIntangibleAssetsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense_1591" xlink:to="lab_ifrs-full_OtherOperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherPayables_1592" xlink:to="lab_ifrs-full_OtherPayables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherPayables_1593" xlink:to="lab_ifrs-full_OtherPayables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReceivables_1594" xlink:to="lab_ifrs-full_OtherReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReceivables_1595" xlink:to="lab_ifrs-full_OtherReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRevenue_1596" xlink:to="lab_ifrs-full_OtherRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRevenue_1597" xlink:to="lab_ifrs-full_OtherRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_1598" xlink:to="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_1599" xlink:to="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForDevelopmentProjectExpenditure_1600" xlink:to="lab_ifrs-full_PaymentsForDevelopmentProjectExpenditure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForDevelopmentProjectExpenditure_1601" xlink:to="lab_ifrs-full_PaymentsForDevelopmentProjectExpenditure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts_1602" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts_1603" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_1604" xlink:to="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_1605" xlink:to="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_1606" xlink:to="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions_1607" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions_1608" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfWarrants_1609" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfWarrants_1610" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfWarrants_1611" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_1612" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_1613" xlink:to="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_1614" xlink:to="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares_1615" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares_1616" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares_1617" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_1618" xlink:to="lab_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_1619" xlink:to="lab_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_1620" xlink:to="lab_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_1621" xlink:to="lab_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfessionalFeesExpense_1622" xlink:to="lab_ifrs-full_ProfessionalFeesExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfessionalFeesExpense_1623" xlink:to="lab_ifrs-full_ProfessionalFeesExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_1624" xlink:to="lab_ifrs-full_ProfitLossAttributableToAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_1625" xlink:to="lab_ifrs-full_ProfitLossAttributableToAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1626" xlink:to="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1627" xlink:to="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_1628" xlink:to="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_1629" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_1630" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_1631" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_1632" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis_1633" xlink:to="lab_ifrs-full_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis_1634" xlink:to="lab_ifrs-full_RangeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeDomain_1635" xlink:to="lab_ifrs-full_RangeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1636" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1637" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReductionOfIssuedCapital_1638" xlink:to="lab_ifrs-full_ReductionOfIssuedCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReductionOfIssuedCapital_1639" xlink:to="lab_ifrs-full_ReductionOfIssuedCapital_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepairsAndMaintenanceExpense_1640" xlink:to="lab_ifrs-full_RepairsAndMaintenanceExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_1641" xlink:to="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_1642" xlink:to="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads_1643" xlink:to="lab_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember_1644" xlink:to="lab_ifrs-full_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue_1645" xlink:to="lab_ifrs-full_Revenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue_1646" xlink:to="lab_ifrs-full_Revenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue_1647" xlink:to="lab_ifrs-full_Revenue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue_1648" xlink:to="lab_ifrs-full_Revenue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract_1649" xlink:to="lab_ifrs-full_RevenueAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract_1650" xlink:to="lab_ifrs-full_RevenueAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromInterest_1651" xlink:to="lab_ifrs-full_RevenueFromInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromInterest_1652" xlink:to="lab_ifrs-full_RevenueFromInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromRoyalties_1653" xlink:to="lab_ifrs-full_RevenueFromRoyalties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromRoyalties_1654" xlink:to="lab_ifrs-full_RevenueFromRoyalties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromSaleOfGoods_1655" xlink:to="lab_ifrs-full_RevenueFromSaleOfGoods_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromSaleOfGoods_1656" xlink:to="lab_ifrs-full_RevenueFromSaleOfGoods_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_1657" xlink:to="lab_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SeparateManagementEntitiesAxis_1658" xlink:to="lab_ifrs-full_SeparateManagementEntitiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SeparateManagementEntitiesAxis_1659" xlink:to="lab_ifrs-full_SeparateManagementEntitiesAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ServicesExpense_1660" xlink:to="lab_ifrs-full_ServicesExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOptionsMember_1661" xlink:to="lab_ifrs-full_ShareOptionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremium_1662" xlink:to="lab_ifrs-full_SharePremium_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember_1663" xlink:to="lab_ifrs-full_SharePremiumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_1664" xlink:to="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_1665" xlink:to="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_1666" xlink:to="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_1667" xlink:to="lab_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_1668" xlink:to="lab_ifrs-full_ShorttermEmployeeBenefitsExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_1669" xlink:to="lab_ifrs-full_ShorttermEmployeeBenefitsExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_1670" xlink:to="lab_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_1671" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_1672" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_1673" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember_1674" xlink:to="lab_ifrs-full_TopOfRangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember_1675" xlink:to="lab_ifrs-full_TopOfRangeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_1676" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_1677" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1678" xlink:to="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1679" xlink:to="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_1680" xlink:to="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivables_1681" xlink:to="lab_ifrs-full_TradeReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TravelExpense_1682" xlink:to="lab_ifrs-full_TravelExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TravelExpense_1683" xlink:to="lab_ifrs-full_TravelExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1684" xlink:to="lab_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1685" xlink:to="lab_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyAxis_1686" xlink:to="lab_ifrs-full_TypesOfInvestmentPropertyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyAxis_1687" xlink:to="lab_ifrs-full_TypesOfInvestmentPropertyAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_1688" xlink:to="lab_ifrs-full_TypesOfInvestmentPropertyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1689" xlink:to="lab_ifrs-full_TypesOfRisksAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1690" xlink:to="lab_ifrs-full_TypesOfRisksAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1691" xlink:to="lab_ifrs-full_TypesOfRisksDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1692" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1693" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived_1694" xlink:to="lab_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsDomain_1695" xlink:to="lab_ifrs-full_UnobservableInputsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WagesAndSalaries_1696" xlink:to="lab_ifrs-full_WagesAndSalaries_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WagesAndSalaries_1697" xlink:to="lab_ifrs-full_WagesAndSalaries_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantReserve_1698" xlink:to="lab_ifrs-full_WarrantReserve_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantReserve_1699" xlink:to="lab_ifrs-full_WarrantReserve_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantReserveMember_1700" xlink:to="lab_ifrs-full_WarrantReserveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantReserveMember_1701" xlink:to="lab_ifrs-full_WarrantReserveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantsMember_1702" xlink:to="lab_ifrs-full_WarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_1703" xlink:to="lab_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_1704" xlink:to="lab_ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_1705" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_1706" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_1707" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_1708" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_1709" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_1710" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1711" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1712" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_1713" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_1714" xlink:to="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1715" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1716" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares_1717" xlink:to="lab_ifrs-full_WeightedAverageShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares_1718" xlink:to="lab_ifrs-full_WeightedAverageShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares_1719" xlink:to="lab_ifrs-full_WeightedAverageShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WorkInProgress_1720" xlink:to="lab_ifrs-full_WorkInProgress_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WorkInProgress_1721" xlink:to="lab_ifrs-full_WorkInProgress_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_1722" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_1723" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_1724" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_1725" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_1726" xlink:to="lab_srt_SegmentGeographicalDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_1727" xlink:to="lab_srt_StatementGeographicalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_1728" xlink:to="lab_ifrs-full_TradeAndOtherPayablesAbstract_0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>blrx-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#DocumentAndEntityInformation" roleURI="http://biolinerx.com/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#ConsolidatedStatementsOfFinancialPosition" roleURI="http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#StatementsOfChangesInEquity" roleURI="http://biolinerx.com/role/StatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#ConsolidatedCashFlowStatements" roleURI="http://biolinerx.com/role/ConsolidatedCashFlowStatements"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#GeneralInformation" roleURI="http://biolinerx.com/role/GeneralInformation"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SignificantAccountingPolicies" roleURI="http://biolinerx.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagement" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagement"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#CriticalAccountingEstimatesAndJudgments" roleURI="http://biolinerx.com/role/CriticalAccountingEstimatesAndJudgments"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#CashAndCashEquivalents" roleURI="http://biolinerx.com/role/CashAndCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#Short-termBankDeposits" roleURI="http://biolinerx.com/role/Short-termBankDeposits"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#PropertyAndEquipment" roleURI="http://biolinerx.com/role/PropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#IntangibleAssets" roleURI="http://biolinerx.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#Leases" roleURI="http://biolinerx.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#Long-termLoans" roleURI="http://biolinerx.com/role/Long-termLoans"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#Equity" roleURI="http://biolinerx.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TaxesOnIncome" roleURI="http://biolinerx.com/role/TaxesOnIncome"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LOSSPERSHARE" roleURI="http://biolinerx.com/role/LOSSPERSHARE"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#CommitmentsAndContingentLiabilities" roleURI="http://biolinerx.com/role/CommitmentsAndContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LICENSEANDSECURITIESPURCHASEAGREEMENTS" roleURI="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTS"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGE" roleURI="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGE"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1" roleURI="http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TransactionsAndBalancesWithRelatedParties" roleURI="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SEGMENTREPORTING" roleURI="http://biolinerx.com/role/SEGMENTREPORTING"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformation" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformation"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SUBSEQUENTEVENTREGISTEREDDIRECTOFFERING" roleURI="http://biolinerx.com/role/SUBSEQUENTEVENTREGISTEREDDIRECTOFFERING"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SignificantAccountingPoliciesTables" roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementTables" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#CashAndCashEquivalentsTables" roleURI="http://biolinerx.com/role/CashAndCashEquivalentsTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#PropertyAndEquipmentTables" roleURI="http://biolinerx.com/role/PropertyAndEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#IntangibleAssetsTables" roleURI="http://biolinerx.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LeasesTables" roleURI="http://biolinerx.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#EquityTables" roleURI="http://biolinerx.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TaxesOnIncomeTables" roleURI="http://biolinerx.com/role/TaxesOnIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LossPerShareTables" roleURI="http://biolinerx.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TransactionsAndBalancesWithRelatedPartiesTables" roleURI="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SEGMENTREPORTINGTables" roleURI="http://biolinerx.com/role/SEGMENTREPORTINGTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationTables" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#GeneralInformationDetails" roleURI="http://biolinerx.com/role/GeneralInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SignificantAccountingPoliciesNarrativeDetails" roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" roleURI="http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" roleURI="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#CashAndCashEquivalentsNarrativeDetails" roleURI="http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" roleURI="http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#Short-termBankDepositsNarrativeDetails" roleURI="http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" roleURI="http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#INTANGIBLEASSETSNarrativeDetails" roleURI="http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#IntangibleAssetsScheduleOfIntangibleAssetsDetails" roleURI="http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LeasesNarrativeDetails" roleURI="http://biolinerx.com/role/LeasesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LeasesScheduleOfRight-of-useAssetsDetails" roleURI="http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LeasesScheduleOfLeaseLiabilitiesDetails" roleURI="http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LeasesScheduleOfMinimumFutureRentalPaymentsDetails" roleURI="http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#Long-termLoansNarrativeDetails" roleURI="http://biolinerx.com/role/Long-termLoansNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#EquityNarrativeDetails" roleURI="http://biolinerx.com/role/EquityNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#EquityScheduleOfShareCapitalDetails" roleURI="http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" roleURI="http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" roleURI="http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#EquityScheduleOfAssumptionsUsedToValueOptionsDetails" roleURI="http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TaxesOnIncomeNarrativeDetails" roleURI="http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" roleURI="http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LOSSPERSHARENarrativeDetails" roleURI="http://biolinerx.com/role/LOSSPERSHARENarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LossPerShareScheduleOfBasicLossPerShareDetails" roleURI="http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#CommitmentsAndContingentLiabilitiesDetails" roleURI="http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails" roleURI="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails" roleURI="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" roleURI="http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" roleURI="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails" roleURI="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SEGMENTREPORTINGNarrativeDetails" roleURI="http://biolinerx.com/role/SEGMENTREPORTINGNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SEGMENTREPORTINGDetails" roleURI="http://biolinerx.com/role/SEGMENTREPORTINGDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails" roleURI="http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails" roleURI="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="blrx-20251231.xsd#ConsolidatedStatementsOfComprehensiveLoss__1" roleURI="http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss__1"/>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_dei_AuditorOpinionTextBlock_45"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentInformationTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="loc_dei_BusinessContactMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_dei_DocumentInformationLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_7" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_9" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_10" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentRegistrationStatement_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentAnnualReport_12" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentTransitionReport_13" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentShellCompanyReport_14" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentAccountingStandard_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_16" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_17" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_18" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_19" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_ContactPersonnelName_20" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_ContactPersonnelEmailAddress_21" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_ContactPersonnelFaxNumber_22" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine1_23" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine2_24" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressCityOrTown_25" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressPostalZipCode_26" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CityAreaCode_27" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_LocalPhoneNumber_28" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityAddressCountry_29" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityInteractiveDataCurrent_30" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_31" order="270" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_32" order="280" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_33" order="290" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityPublicFloat_34" order="300" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityEmergingGrowthCompany_35" order="310" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityExTransitionPeriod_36" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityShellCompany_37" order="330" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFileNumber_38" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_39" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_40" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AuditorName_41" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AuditorLocation_42" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AuditorFirmId_43" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentDescription_44" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AuditorOpinionTextBlock_45" order="410" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-full_Inventories_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Warrants" xlink:label="loc_blrx_Warrants_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_27"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CommitmentsAndContingentLiabilities" xlink:label="loc_blrx_CommitmentsAndContingentLiabilities_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-full_SharePremium_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantReserve" xlink:label="loc_ifrs-full_WarrantReserve_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalReserve" xlink:label="loc_ifrs-full_CapitalReserve_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-full_NoncontrollingInterests_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_41"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0" xlink:to="loc_ifrs-full_AssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_1" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1" xlink:to="loc_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1" xlink:to="loc_ifrs-full_TradeReceivables_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1" xlink:to="loc_ifrs-full_OtherCurrentReceivables_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1" xlink:to="loc_ifrs-full_Inventories_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1" xlink:to="loc_ifrs-full_CurrentAssets_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_1" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_9" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_9" xlink:to="loc_ifrs-full_RightofuseAssets_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_9" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_9" xlink:to="loc_ifrs-full_NoncurrentAssets_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_1" xlink:to="loc_ifrs-full_Assets_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_16" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_16" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_16" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_16" xlink:to="loc_ifrs-full_CurrentContractLiabilities_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_16" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_18" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_18" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesAbstract_18" xlink:to="loc_ifrs-full_OtherCurrentPayables_19" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_16" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_16" xlink:to="loc_blrx_Warrants_22" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_16" xlink:to="loc_ifrs-full_CurrentLiabilities_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_16" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_25" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_25" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_25" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_25" xlink:to="loc_ifrs-full_NoncurrentLiabilities_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_16" xlink:to="loc_blrx_CommitmentsAndContingentLiabilities_29" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_16" xlink:to="loc_ifrs-full_Liabilities_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_16" xlink:to="loc_ifrs-full_EquityAbstract_31" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31" xlink:to="loc_ifrs-full_IssuedCapital_31" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31" xlink:to="loc_ifrs-full_SharePremium_32" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31" xlink:to="loc_ifrs-full_WarrantReserve_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31" xlink:to="loc_ifrs-full_CapitalReserve_34" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_35" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31" xlink:to="loc_ifrs-full_RetainedEarnings_36" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_37" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31" xlink:to="loc_ifrs-full_NoncontrollingInterests_38" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31" xlink:to="loc_ifrs-full_Equity_39" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_16" xlink:to="loc_ifrs-full_EquityAndLiabilities_41" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="loc_ifrs-full_RevenueAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="loc_ifrs-full_LicenceFeeIncome_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossProfit" xlink:label="loc_ifrs-full_GrossProfit_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ImpairmentLossOnIntangibleAssets" xlink:label="loc_blrx_ImpairmentLossOnIntangibleAssets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfitLossFromNonOperatingActivities" xlink:label="loc_blrx_ProfitLossFromNonOperatingActivities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_RevenueAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_1" xlink:to="loc_ifrs-full_LicenceFeeIncome_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_1" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_1" xlink:to="loc_ifrs-full_Revenue_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_CostOfSales_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_GrossProfit_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_blrx_ImpairmentLossOnIntangibleAssets_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_blrx_ProfitLossFromNonOperatingActivities_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_FinanceIncome_13" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_FinanceCosts_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_ProfitLoss_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_ProfitLossAttributableToAbstract_16" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_16" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_16" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_16" xlink:to="loc_ifrs-full_ComprehensiveIncome_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_21" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_WeightedAverageShares_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_23" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/StatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IfrsStatementTable" xlink:label="loc_blrx_IfrsStatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-full_WarrantReserveMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CapitalReserveMember" xlink:label="loc_ifrs-full_CapitalReserveMember_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherComprehensiveIncomeLossMember" xlink:label="loc_blrx_OtherComprehensiveIncomeLossMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IfrsStatementLineItems" xlink:label="loc_blrx_IfrsStatementLineItems_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInEquityAbstract" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfNewSharesIssued" xlink:label="loc_blrx_NumberOfNewSharesIssued_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuanceOfShareCapital" xlink:label="loc_blrx_IssuanceOfShareCapital_14"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_15"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="loc_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions" xlink:label="loc_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_blrx_IfrsStatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IfrsStatementTable_1" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_IssuedCapitalMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_SharePremiumMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_WarrantReserveMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_CapitalReserveMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_blrx_OtherComprehensiveIncomeLossMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_RetainedEarningsMember_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IfrsStatementTable_1" xlink:to="loc_blrx_IfrsStatementLineItems_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IfrsStatementLineItems_10" xlink:to="loc_ifrs-full_Equity_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IfrsStatementLineItems_10" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IfrsStatementLineItems_10" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_ifrs-full_IssueOfEquity_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_blrx_NumberOfNewSharesIssued_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_blrx_IssuanceOfShareCapital_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares_20" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions_21" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_22" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_23" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_24" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_12" xlink:to="loc_ifrs-full_ComprehensiveIncome_25" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IfrsStatementLineItems_10" xlink:to="loc_ifrs-full_Equity_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IfrsStatementLineItems_10" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/ConsolidatedCashFlowStatements">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturitiesOfShortTermDeposits" xlink:label="loc_blrx_MaturitiesOfShortTermDeposits_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_22"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract" xlink:label="loc_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_23"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract" xlink:label="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_27"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndExchangeDifferencesOnShortTermDeposits" xlink:label="loc_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_28"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndLinkageDifferencesOnBankLoan" xlink:label="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_29"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestAndExchangeDifferencesOnRestrictedDeposits" xlink:label="loc_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_30"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferencesOnLeaseLiability" xlink:label="loc_blrx_ExchangeDifferencesOnLeaseLiability_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_32"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LossOnAbandonmentOfRightofuseAsset" xlink:label="loc_blrx_LossOnAbandonmentOfRightofuseAsset_33"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TotalIncomeAndExpenseNotInvolvingCashFlows" xlink:label="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_34"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:label="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_37"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables" xlink:label="loc_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_40"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TotalChangeInOperatingAssetAndLiability" xlink:label="loc_blrx_TotalChangeInOperatingAssetAndLiability_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_42"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract" xlink:label="loc_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_45"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnInterestReceivedInCash" xlink:label="loc_blrx_SupplementaryInformationOnInterestReceivedInCash_45"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementalInformationOnInterestPaidInCash" xlink:label="loc_blrx_SupplementalInformationOnInterestPaidInCash_46"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementalInformationOnNoncashTransactionsAbstract" xlink:label="loc_blrx_SupplementalInformationOnNoncashTransactionsAbstract_47"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities" xlink:label="loc_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_47"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnFairValueOfExercisedWarrants" xlink:label="loc_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_48"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SupplementaryInformationOnIntangibleAssetAcquired" xlink:label="loc_blrx_SupplementaryInformationOnIntangibleAssetAcquired_49"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1" xlink:to="loc_ifrs-full_ProfitLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_5" xlink:to="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_5" xlink:to="loc_blrx_MaturitiesOfShortTermDeposits_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_5" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_5" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_5" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_11" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_11" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_11" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_11" xlink:to="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_11" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_11" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_11" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_21" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_22" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_23" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_23" xlink:to="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_23" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_25" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_26" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_blrx_InterestAndExchangeDifferencesOnShortTermDeposits_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_blrx_InterestAndLinkageDifferencesOnBankLoan_29" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_blrx_ExchangeDifferencesOnLeaseLiability_31" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_32" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_blrx_LossOnAbandonmentOfRightofuseAsset_33" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract_23" xlink:to="loc_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows_34" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract_23" xlink:to="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_36" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_36" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_36" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_36" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_37" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_36" xlink:to="loc_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables_38" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_36" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_39" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_36" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_40" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_36" xlink:to="loc_blrx_TotalChangeInOperatingAssetAndLiability_41" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_36" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLoss_42" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_0" xlink:to="loc_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_45" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_45" xlink:to="loc_blrx_SupplementaryInformationOnInterestReceivedInCash_45" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_45" xlink:to="loc_blrx_SupplementalInformationOnInterestPaidInCash_46" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract_45" xlink:to="loc_blrx_SupplementalInformationOnNoncashTransactionsAbstract_47" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_SupplementalInformationOnNoncashTransactionsAbstract_47" xlink:to="loc_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities_47" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_SupplementalInformationOnNoncashTransactionsAbstract_47" xlink:to="loc_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants_48" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_SupplementalInformationOnNoncashTransactionsAbstract_47" xlink:to="loc_blrx_SupplementaryInformationOnIntangibleAssetAcquired_49" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/GeneralInformation">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfGeneralInformationAbstract" xlink:label="loc_blrx_DisclosureOfGeneralInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfGeneralInformationAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagement">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/CriticalAccountingEstimatesAndJudgments">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract" xlink:label="loc_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/CashAndCashEquivalents">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/Short-termBankDeposits">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfShortTermBankDepositsAbstract" xlink:label="loc_blrx_DisclosureOfShortTermBankDepositsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDepositsFromBanksExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDepositsFromBanksExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfShortTermBankDepositsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfDepositsFromBanksExplanatory_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/PropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/Leases">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/Long-termLoans">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TaxesOnIncome">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfIncomeTaxesAbstract" xlink:label="loc_blrx_DisclosureOfIncomeTaxesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfIncomeTaxesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LOSSPERSHARE">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/CommitmentsAndContingentLiabilities">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract" xlink:label="loc_blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTS">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract_0" xlink:to="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGE">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract" xlink:label="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory" xlink:label="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract_0" xlink:to="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementWithCompaniesForDevelopmentAbstract" xlink:label="loc_blrx_AgreementWithCompaniesForDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory" xlink:label="loc_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementWithCompaniesForDevelopmentAbstract_0" xlink:to="loc_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedParties">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SEGMENTREPORTING">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformation">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SUBSEQUENTEVENTREGISTEREDDIRECTOFFERING">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForWarrantExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory" xlink:label="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_16" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_18" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_19" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_20" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory_21" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory_22" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory" xlink:label="loc_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory" xlink:label="loc_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementExplanatory_6" order="50" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/CashAndCashEquivalentsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/PropertyAndEquipmentTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory" xlink:label="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xlink:to="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_4" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/EquityTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_4" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TaxesOnIncomeTables">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfIncomeTaxesAbstract" xlink:label="loc_blrx_DisclosureOfIncomeTaxesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfIncomeTaxesAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LossPerShareTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SEGMENTREPORTINGTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory" xlink:label="loc_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/GeneralInformationDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfGeneralInformationAbstract" xlink:label="loc_blrx_DisclosureOfGeneralInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DepositaryShareConversionDescription" xlink:label="loc_blrx_DepositaryShareConversionDescription_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DepositaryShareToOrdinaryShareRatioChangeDescription" xlink:label="loc_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfGeneralInformationAbstract_0" xlink:to="loc_ifrs-full_RetainedEarnings_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfGeneralInformationAbstract_0" xlink:to="loc_blrx_DepositaryShareConversionDescription_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfGeneralInformationAbstract_0" xlink:to="loc_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOptionsMember" xlink:label="loc_ifrs-full_ShareOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-full_WarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" xlink:to="loc_ifrs-full_ShareOptionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" xlink:to="loc_ifrs-full_WarrantsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis_5" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain_5" xlink:to="loc_ifrs-full_ComputerSoftwareMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8" xlink:to="loc_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LaboratoryEquipmentMember" xlink:label="loc_blrx_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1" xlink:to="loc_ifrs-full_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1" xlink:to="loc_ifrs-full_OfficeEquipmentMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_1" xlink:to="loc_blrx_LaboratoryEquipmentMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_6" xlink:to="loc_ifrs-full_CarryingAmountMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_6" xlink:to="loc_blrx_NetBookValueMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9" xlink:to="loc_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment_9" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="loc_ifrs-full_MotorVehiclesMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets" xlink:label="loc_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSignificantAccountingPoliciesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_1" xlink:to="loc_ifrs-full_LandAndBuildingsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_1" xlink:to="loc_ifrs-full_MotorVehiclesMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_5" xlink:to="loc_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-full_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" xlink:to="loc_ifrs-full_WarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_1" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_4" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_4" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CashAndCashEquivalentMember" xlink:label="loc_blrx_CashAndCashEquivalentMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShortTermDepositMember" xlink:label="loc_blrx_ShortTermDepositMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherReceivablesMember" xlink:label="loc_blrx_OtherReceivablesMember_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradePayablesMember" xlink:label="loc_blrx_TradePayablesMember_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherPayablesMember" xlink:label="loc_blrx_OtherPayablesMember_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisLinkedBalancesMember" xlink:label="loc_blrx_NisLinkedBalancesMember_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EuroLinkedTradePayablesMember" xlink:label="loc_blrx_EuroLinkedTradePayablesMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads" xlink:label="loc_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity" xlink:label="loc_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_CashAndCashEquivalentMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_ShortTermDepositMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_OtherReceivablesMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_TradePayablesMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_OtherPayablesMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_NisLinkedBalancesMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_1" xlink:to="loc_blrx_EuroLinkedTradePayablesMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_10" xlink:to="loc_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_10" xlink:to="loc_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_10" xlink:to="loc_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_10" xlink:to="loc_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_10" xlink:to="loc_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-full_TypesOfRisksDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisPerDollarMember" xlink:label="loc_blrx_NisPerDollarMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EuroPerDollarMember" xlink:label="loc_blrx_EuroPerDollarMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageIncreaseDecreaseInExchangeRate" xlink:label="loc_blrx_PercentageIncreaseDecreaseInExchangeRate_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_blrx_NisPerDollarMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_blrx_EuroPerDollarMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" xlink:to="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_5" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_5" xlink:to="loc_blrx_PercentageIncreaseDecreaseInExchangeRate_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-full_TypesOfRisksDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DollarMember" xlink:label="loc_blrx_DollarMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NisMember" xlink:label="loc_blrx_NisMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherCurrenciesMember" xlink:label="loc_blrx_OtherCurrenciesMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="loc_ifrs-full_LiabilitiesAbstract_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="loc_ifrs-full_TradeAndOtherPayablesAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherPayables" xlink:label="loc_ifrs-full_OtherPayables_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetAssetValueOfLinkageMonetaryItems" xlink:label="loc_blrx_NetAssetValueOfLinkageMonetaryItems_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_blrx_DollarMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_blrx_NisMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_blrx_OtherCurrenciesMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" xlink:to="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_6" xlink:to="loc_ifrs-full_AssetsAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_6" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_6" xlink:to="loc_ifrs-full_CashAndCashEquivalents_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_6" xlink:to="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_6" xlink:to="loc_ifrs-full_OtherReceivables_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_6" xlink:to="loc_ifrs-full_Assets_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_6" xlink:to="loc_ifrs-full_LiabilitiesAbstract_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_12" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_12" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_12" xlink:to="loc_ifrs-full_TradeAndOtherPayablesAbstract_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_14" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherPayablesAbstract_14" xlink:to="loc_ifrs-full_OtherPayables_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_12" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_17" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_12" xlink:to="loc_ifrs-full_Liabilities_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_12" xlink:to="loc_blrx_NetAssetValueOfLinkageMonetaryItems_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-full_TypesOfRisksDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-full_CreditRiskMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems" xlink:label="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-full_TradeReceivables_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" xlink:to="loc_ifrs-full_TypesOfRisksAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_1" xlink:to="loc_ifrs-full_TypesOfRisksDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksDomain_1" xlink:to="loc_ifrs-full_CreditRiskMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable_1" xlink:to="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_4" xlink:to="loc_ifrs-full_AssetsAbstract_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_4" xlink:to="loc_ifrs-full_CashAndCashEquivalents_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_4" xlink:to="loc_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_4" xlink:to="loc_ifrs-full_TradeReceivables_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_4" xlink:to="loc_ifrs-full_OtherReceivables_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems_4" xlink:to="loc_ifrs-full_Assets_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-full_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities" xlink:label="loc_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePremiumResultingFromExerciseOfWarrants" xlink:label="loc_blrx_SharePremiumResultingFromExerciseOfWarrants_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" xlink:to="loc_ifrs-full_WarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_4" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_4" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_7" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_7" xlink:to="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_8" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_8" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_8" xlink:to="loc_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_8" xlink:to="loc_blrx_SharePremiumResultingFromExerciseOfWarrants_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_7" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfWarrants" xlink:label="loc_blrx_FairValueOfWarrants_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuancesOfWarrants" xlink:label="loc_blrx_IssuancesOfWarrants_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExercises" xlink:label="loc_blrx_WarrantsExercises_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInFairValueThroughProfitAndLossOfWarrants" xlink:label="loc_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfWarrants" xlink:label="loc_blrx_FairValueOfWarrants_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_1" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_1" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_4" xlink:to="loc_blrx_FairValueOfWarrants_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_4" xlink:to="loc_blrx_IssuancesOfWarrants_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_4" xlink:to="loc_blrx_WarrantsExercises_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_4" xlink:to="loc_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_4" xlink:to="loc_blrx_FairValueOfWarrants_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents" xlink:label="loc_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_RangeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_1" xlink:to="loc_ifrs-full_RangeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_BottomOfRangeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_TopOfRangeMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_5" xlink:to="loc_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-full_Cash_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_0" xlink:to="loc_ifrs-full_Cash_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_0" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfShortTermBankDepositsAbstract" xlink:label="loc_blrx_DisclosureOfShortTermBankDepositsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnShortTermDeposits" xlink:label="loc_blrx_InterestRateOnShortTermDeposits_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfShortTermBankDepositsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_RangeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_1" xlink:to="loc_ifrs-full_RangeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_BottomOfRangeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_TopOfRangeMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_1" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_5" xlink:to="loc_blrx_InterestRateOnShortTermDeposits_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LaboratoryEquipmentMember" xlink:label="loc_blrx_LaboratoryEquipmentMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="loc_ifrs-full_CarryingAmountMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_blrx_NetBookValueMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_6" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_6" xlink:to="loc_ifrs-full_OfficeEquipmentMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_6" xlink:to="loc_ifrs-full_ComputerEquipmentMember_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_6" xlink:to="loc_blrx_LaboratoryEquipmentMember_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_6" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_9" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_12" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_12" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_13" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_12" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_12" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgalimmuneLtdMember" xlink:label="loc_blrx_AgalimmuneLtdMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BiokineTherapeuticsLtdMember" xlink:label="loc_blrx_BiokineTherapeuticsLtdMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Glix1Member" xlink:label="loc_blrx_Glix1Member_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BL8040Member" xlink:label="loc_blrx_BL8040Member_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-full_CashTransferred_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_15"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfPaymentToBeMade" xlink:label="loc_blrx_PercentageOfPaymentToBeMade_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIncreasingWeightedAverageCostOfCapital" xlink:label="loc_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_18"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfDecreasingAnnualGrowthRate" xlink:label="loc_blrx_PercentageOfDecreasingAnnualGrowthRate_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital" xlink:label="loc_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate" xlink:label="loc_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_1" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_1" xlink:to="loc_blrx_AgalimmuneLtdMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_1" xlink:to="loc_blrx_BiokineTherapeuticsLtdMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_1" xlink:to="loc_blrx_Glix1Member_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_6" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_6" xlink:to="loc_blrx_BL8040Member_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_10" xlink:to="loc_ifrs-full_CarryingAmountMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_10" xlink:to="loc_blrx_NetBookValueMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" xlink:to="loc_ifrs-full_CashTransferred_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" xlink:to="loc_blrx_PercentageOfPaymentToBeMade_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" xlink:to="loc_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" xlink:to="loc_blrx_PercentageOfDecreasingAnnualGrowthRate_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" xlink:to="loc_blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" xlink:to="loc_blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate_21" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_22" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_23" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember" xlink:label="loc_ifrs-full_ComputerSoftwareMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="loc_ifrs-full_CarryingAmountMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_blrx_NetBookValueMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_6" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_6" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_6" xlink:to="loc_ifrs-full_ComputerSoftwareMember_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_1" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_10" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_10" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_10" xlink:to="loc_blrx_DeletionsIntangibleAssetsOtherThanGoodwill_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_10" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_10" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_10" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LeasesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLeasesTable" xlink:label="loc_blrx_DisclosureOfLeasesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL" xlink:label="loc_country_IL_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BostonMember" xlink:label="loc_blrx_BostonMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLeasesLineItems" xlink:label="loc_blrx_DisclosureOfLeasesLineItems_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfPremises" xlink:label="loc_blrx_NumberOfPremises_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LeaseAgreementMonthlyFee" xlink:label="loc_blrx_LeaseAgreementMonthlyFee_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalExtendLeasePeriod" xlink:label="loc_blrx_AdditionalExtendLeasePeriod_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageIncreasePrecedingLeasePaymentAmount" xlink:label="loc_blrx_PercentageIncreasePrecedingLeasePaymentAmount_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RightOfUseAssetWrittenOff" xlink:label="loc_blrx_RightOfUseAssetWrittenOff_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LeasePeriod" xlink:label="loc_blrx_LeasePeriod_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AnnualLeaseFee" xlink:label="loc_blrx_AnnualLeaseFee_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepairsAndMaintenanceExpense" xlink:label="loc_ifrs-full_RepairsAndMaintenanceExpense_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xlink:to="loc_blrx_DisclosureOfLeasesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLeasesTable_1" xlink:to="loc_srt_StatementGeographicalAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1" xlink:to="loc_srt_SegmentGeographicalDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_country_IL_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1" xlink:to="loc_blrx_BostonMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLeasesTable_1" xlink:to="loc_blrx_DisclosureOfLeasesLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_5" xlink:to="loc_blrx_NumberOfPremises_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_5" xlink:to="loc_blrx_LeaseAgreementMonthlyFee_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_5" xlink:to="loc_blrx_AdditionalExtendLeasePeriod_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_5" xlink:to="loc_blrx_PercentageIncreasePrecedingLeasePaymentAmount_8" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_5" xlink:to="loc_blrx_RightOfUseAssetWrittenOff_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_5" xlink:to="loc_blrx_LeasePeriod_10" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_5" xlink:to="loc_blrx_AnnualLeaseFee_11" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLeasesLineItems_5" xlink:to="loc_ifrs-full_RepairsAndMaintenanceExpense_12" order="70" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NetBookValueMember" xlink:label="loc_blrx_NetBookValueMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="loc_ifrs-full_MotorVehiclesMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsToRightOfUseAssets" xlink:label="loc_blrx_DeletionsToRightOfUseAssets_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="loc_ifrs-full_CarryingAmountMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1" xlink:to="loc_blrx_NetBookValueMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_6" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_6" xlink:to="loc_ifrs-full_LandAndBuildingsMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_6" xlink:to="loc_ifrs-full_MotorVehiclesMember_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_10" xlink:to="loc_ifrs-full_RightofuseAssets_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_10" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_10" xlink:to="loc_blrx_DeletionsToRightOfUseAssets_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_10" xlink:to="loc_ifrs-full_RightofuseAssets_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable" xlink:label="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="loc_ifrs-full_MotorVehiclesMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" xlink:label="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionsLeaseLiabilities" xlink:label="loc_blrx_AdditionsLeaseLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DeletionsLeaseLiabilities" xlink:label="loc_blrx_DeletionsLeaseLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestExpenseLeaseLiabilities" xlink:label="loc_blrx_InterestExpenseLeaseLiabilities_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExchangeDifferencesDuringYear" xlink:label="loc_blrx_ExchangeDifferencesDuringYear_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PaymentsLeaseLiabilities" xlink:label="loc_blrx_PaymentsLeaseLiabilities_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xlink:to="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable_1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_1" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_1" xlink:to="loc_ifrs-full_LandAndBuildingsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_1" xlink:to="loc_ifrs-full_MotorVehiclesMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable_1" xlink:to="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_5" xlink:to="loc_ifrs-full_LeaseLiabilities_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_5" xlink:to="loc_blrx_AdditionsLeaseLiabilities_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_5" xlink:to="loc_blrx_DeletionsLeaseLiabilities_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_5" xlink:to="loc_blrx_InterestExpenseLeaseLiabilities_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_5" xlink:to="loc_blrx_ExchangeDifferencesDuringYear_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_5" xlink:to="loc_blrx_PaymentsLeaseLiabilities_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_5" xlink:to="loc_ifrs-full_LeaseLiabilities_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="loc_ifrs-full_MaturityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LandAndBuildingsMember" xlink:label="loc_ifrs-full_LandAndBuildingsMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="loc_ifrs-full_MotorVehiclesMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived" xlink:label="loc_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_1" xlink:to="loc_ifrs-full_MaturityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_1" xlink:to="loc_ifrs-full_MaturityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_8" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_8" xlink:to="loc_ifrs-full_LandAndBuildingsMember_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_8" xlink:to="loc_ifrs-full_MotorVehiclesMember_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_1" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_12" xlink:to="loc_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived_12" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/Long-termLoansNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyAxis" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyDomain" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LoanAgreementWithKreosCapitalMember" xlink:label="loc_blrx_LoanAgreementWithKreosCapitalMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TrancheAxis" xlink:label="loc_blrx_TrancheAxis_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TrancheDomain" xlink:label="loc_blrx_TrancheDomain_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FirstTrancheMember" xlink:label="loc_blrx_FirstTrancheMember_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SecondTrancheMember" xlink:label="loc_blrx_SecondTrancheMember_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ThirdTrancheMember" xlink:label="loc_blrx_ThirdTrancheMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InterestRateOnLongTermBankLoan" xlink:label="loc_blrx_InterestRateOnLongTermBankLoan_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LoanTakenForPaymentOfAgreementValue" xlink:label="loc_blrx_LoanTakenForPaymentOfAgreementValue_14"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfLoanAgreement" xlink:label="loc_blrx_AmountOfLoanAgreement_15"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfAnnualInterestOfCashFees" xlink:label="loc_blrx_PercentageOfAnnualInterestOfCashFees_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountOfIntellectualPropertyAndCashBalance" xlink:label="loc_blrx_AmountOfIntellectualPropertyAndCashBalance_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_18"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MinimumCashBalanceRequirementUnderLoanAgreement" xlink:label="loc_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfFutureMilestonePayments" xlink:label="loc_blrx_PercentageOfFutureMilestonePayments_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1" xlink:to="loc_ifrs-full_TypesOfInvestmentPropertyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyAxis_1" xlink:to="loc_ifrs-full_TypesOfInvestmentPropertyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_1" xlink:to="loc_blrx_LoanAgreementWithKreosCapitalMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1" xlink:to="loc_blrx_TrancheAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_TrancheAxis_4" xlink:to="loc_blrx_TrancheDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_TrancheDomain_4" xlink:to="loc_blrx_FirstTrancheMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_TrancheDomain_4" xlink:to="loc_blrx_SecondTrancheMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_TrancheDomain_4" xlink:to="loc_blrx_ThirdTrancheMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1" xlink:to="loc_ifrs-full_RangeAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_9" xlink:to="loc_ifrs-full_RangeDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_9" xlink:to="loc_ifrs-full_BottomOfRangeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_9" xlink:to="loc_ifrs-full_TopOfRangeMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13" xlink:to="loc_blrx_InterestRateOnLongTermBankLoan_13" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13" xlink:to="loc_blrx_LoanTakenForPaymentOfAgreementValue_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13" xlink:to="loc_blrx_AmountOfLoanAgreement_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13" xlink:to="loc_blrx_PercentageOfAnnualInterestOfCashFees_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13" xlink:to="loc_blrx_AmountOfIntellectualPropertyAndCashBalance_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13" xlink:to="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13" xlink:to="loc_blrx_MinimumCashBalanceRequirementUnderLoanAgreement_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13" xlink:to="loc_blrx_PercentageOfFutureMilestonePayments_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_21" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/EquityNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-full_WarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyAxis" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfInvestmentPropertyDomain" xlink:label="loc_ifrs-full_TypesOfInvestmentPropertyDomain_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BvfPartnersLpMember" xlink:label="loc_blrx_BvfPartnersLpMember_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DirectPlacementMember" xlink:label="loc_blrx_DirectPlacementMember_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ConsultantsMember" xlink:label="loc_blrx_ConsultantsMember_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LoanAgreementWithKreosCapitalMember" xlink:label="loc_blrx_LoanAgreementWithKreosCapitalMember_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InvestorsMember" xlink:label="loc_blrx_InvestorsMember_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PlacementAgentsDesigneesMember" xlink:label="loc_blrx_PlacementAgentsDesigneesMember_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HighbridgeCapitalManagementLlcMember" xlink:label="loc_blrx_HighbridgeCapitalManagementLlcMember_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_January2025OfferingMember" xlink:label="loc_blrx_January2025OfferingMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_14"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeriesAWarrantsMember" xlink:label="loc_blrx_SeriesAWarrantsMember_14"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeriesBWarrantMember" xlink:label="loc_blrx_SeriesBWarrantMember_15"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantOneMember" xlink:label="loc_blrx_WarrantOneMember_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantTwoMember" xlink:label="loc_blrx_WarrantTwoMember_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantThreeMember" xlink:label="loc_blrx_WarrantThreeMember_18"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantFourMember" xlink:label="loc_blrx_WarrantFourMember_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantFiveMember" xlink:label="loc_blrx_WarrantFiveMember_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantSixMember" xlink:label="loc_blrx_WarrantSixMember_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrantsMember" xlink:label="loc_blrx_PreFundedWarrantsMember_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_25"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIncentivePlanMember" xlink:label="loc_blrx_ShareIncentivePlanMember_25"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceSharesUnitMember" xlink:label="loc_blrx_PerformanceSharesUnitMember_26"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UnderwaterEmployeeStockOptionsMember" xlink:label="loc_blrx_UnderwaterEmployeeStockOptionsMember_27"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceSharesUnitTwoMember" xlink:label="loc_blrx_PerformanceSharesUnitTwoMember_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_31"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BtigLlcMember" xlink:label="loc_blrx_BtigLlcMember_31"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HCWainwrightAndCoLlcMember" xlink:label="loc_blrx_HCWainwrightAndCoLlcMember_32"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PlacementAgentMember" xlink:label="loc_blrx_PlacementAgentMember_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_36"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmericanDepositarySharesMember" xlink:label="loc_blrx_AmericanDepositarySharesMember_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsAxis_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsDomain" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsDomain_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketSharePrice" xlink:label="loc_blrx_MarketSharePrice_45"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedToPurchaseWarrant" xlink:label="loc_blrx_ShareIssuedToPurchaseWarrant_46"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceOfShareIssued" xlink:label="loc_blrx_ExercisePriceOfShareIssued_47"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountAllocatedToWarrant" xlink:label="loc_blrx_AmountAllocatedToWarrant_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_49"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaturityDate" xlink:label="loc_blrx_MaturityDate_50"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisableTermOfWarrant" xlink:label="loc_blrx_ExercisableTermOfWarrant_51"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedOfPublicOffering" xlink:label="loc_blrx_ShareIssuedOfPublicOffering_52"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_StockIssuedPricePerShare" xlink:label="loc_blrx_StockIssuedPricePerShare_53"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromIssuanceOfInitialPublicOffering" xlink:label="loc_blrx_ProceedsFromIssuanceOfInitialPublicOffering_54"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet" xlink:label="loc_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_55"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreement" xlink:label="loc_blrx_SharePurchaseAgreement_56"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreementShares" xlink:label="loc_blrx_SharePurchaseAgreementShares_57"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchaseAgreementPeriod" xlink:label="loc_blrx_PurchaseAgreementPeriod_58"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_59"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareIssuedAsAdditionalCommitmentFee" xlink:label="loc_blrx_ShareIssuedAsAdditionalCommitmentFee_60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFeeAndCommissionExpense" xlink:label="loc_ifrs-full_OtherFeeAndCommissionExpense_61"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdditionalCommitmentFee" xlink:label="loc_blrx_AdditionalCommitmentFee_62"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NonOperatingExpense" xlink:label="loc_blrx_NonOperatingExpense_63"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_64"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_65"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AvailableBalanceUnderFacility" xlink:label="loc_blrx_AvailableBalanceUnderFacility_66"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SaleOfStockNumberOfSharesIssued" xlink:label="loc_blrx_SaleOfStockNumberOfSharesIssued_67"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_68"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RemainingAuthorizedUnissuedOrdinaryShares" xlink:label="loc_blrx_RemainingAuthorizedUnissuedOrdinaryShares_69"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_71"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_72"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_73"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_74"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_75"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019" xlink:label="loc_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_76"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_77"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ValueOfServicesRecorded" xlink:label="loc_blrx_ValueOfServicesRecorded_78"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AmountGrantOfEquityInstruments" xlink:label="loc_blrx_AmountGrantOfEquityInstruments_79"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_80"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_81"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_82"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AggregateOfferingPrice" xlink:label="loc_blrx_AggregateOfferingPrice_83"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfCommissionOnSalesAgreement" xlink:label="loc_blrx_PercentageOfCommissionOnSalesAgreement_84"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CreditExposure" xlink:label="loc_ifrs-full_CreditExposure_85"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RemainingUnrecognizedDeferredCompensationExpense" xlink:label="loc_blrx_RemainingUnrecognizedDeferredCompensationExpense_86"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharesIssuedRegisteredDirectOfferings" xlink:label="loc_blrx_SharesIssuedRegisteredDirectOfferings_87"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsIssuedToPurchaseShares" xlink:label="loc_blrx_WarrantsIssuedToPurchaseShares_88"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_89"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantsExpirationPeriod" xlink:label="loc_blrx_WarrantsExpirationPeriod_90"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceOfWarrants" xlink:label="loc_blrx_ExercisePriceOfWarrants_91"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WarrantOfferingConsideration" xlink:label="loc_blrx_WarrantOfferingConsideration_92"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromExerciseWarrants" xlink:label="loc_blrx_ProceedsFromExerciseWarrants_93"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses" xlink:label="loc_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_94"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProceedsFromWarrantIssue" xlink:label="loc_blrx_ProceedsFromWarrantIssue_95"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FairValueOfOrdinaryWarrantsAdjustedAmount" xlink:label="loc_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_96"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_97"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_98"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RecognizedAsEquity" xlink:label="loc_blrx_RecognizedAsEquity_99"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ChangesInFairValueRecordedAsANonoperatingIncome" xlink:label="loc_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_100"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BeneficiallyOwnInExcess" xlink:label="loc_blrx_BeneficiallyOwnInExcess_101"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsAxis_1" xlink:to="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfAntidilutiveInstrumentsDomain_1" xlink:to="loc_ifrs-full_WarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_TypesOfInvestmentPropertyAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyAxis_4" xlink:to="loc_ifrs-full_TypesOfInvestmentPropertyDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_4" xlink:to="loc_blrx_BvfPartnersLpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_4" xlink:to="loc_blrx_DirectPlacementMember_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_4" xlink:to="loc_blrx_ConsultantsMember_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_4" xlink:to="loc_blrx_LoanAgreementWithKreosCapitalMember_7" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_4" xlink:to="loc_blrx_InvestorsMember_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_4" xlink:to="loc_blrx_PlacementAgentsDesigneesMember_9" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_4" xlink:to="loc_blrx_HighbridgeCapitalManagementLlcMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInvestmentPropertyDomain_4" xlink:to="loc_blrx_January2025OfferingMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_14" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_14" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_14" xlink:to="loc_blrx_SeriesAWarrantsMember_14" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_14" xlink:to="loc_blrx_SeriesBWarrantMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_14" xlink:to="loc_blrx_WarrantOneMember_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_14" xlink:to="loc_blrx_WarrantTwoMember_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_14" xlink:to="loc_blrx_WarrantThreeMember_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_14" xlink:to="loc_blrx_WarrantFourMember_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_14" xlink:to="loc_blrx_WarrantFiveMember_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_14" xlink:to="loc_blrx_WarrantSixMember_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_14" xlink:to="loc_blrx_PreFundedWarrantsMember_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_25" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_25" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_25" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_25" xlink:to="loc_blrx_ShareIncentivePlanMember_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_25" xlink:to="loc_blrx_PerformanceSharesUnitMember_26" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_25" xlink:to="loc_blrx_UnderwaterEmployeeStockOptionsMember_27" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_25" xlink:to="loc_blrx_PerformanceSharesUnitTwoMember_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_31" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_31" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_31" xlink:to="loc_blrx_BtigLlcMember_31" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_31" xlink:to="loc_blrx_HCWainwrightAndCoLlcMember_32" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_31" xlink:to="loc_blrx_PlacementAgentMember_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_36" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_36" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_36" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_36" xlink:to="loc_blrx_AmericanDepositarySharesMember_36" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_39" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_39" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_39" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_39" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_39" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_InitiallyAppliedIFRSsAxis_42" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsAxis_42" xlink:to="loc_ifrs-full_InitiallyAppliedIFRSsDomain_42" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsDomain_42" xlink:to="loc_ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_42" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_MarketSharePrice_45" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ShareIssuedToPurchaseWarrant_46" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ExercisePriceOfShareIssued_47" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_AmountAllocatedToWarrant_48" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_49" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_MaturityDate_50" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ExercisableTermOfWarrant_51" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ShareIssuedOfPublicOffering_52" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_StockIssuedPricePerShare_53" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ProceedsFromIssuanceOfInitialPublicOffering_54" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet_55" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_SharePurchaseAgreement_56" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_SharePurchaseAgreementShares_57" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_PurchaseAgreementPeriod_58" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_59" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ShareIssuedAsAdditionalCommitmentFee_60" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_OtherFeeAndCommissionExpense_61" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_AdditionalCommitmentFee_62" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_NonOperatingExpense_63" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_64" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_65" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_AvailableBalanceUnderFacility_66" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_SaleOfStockNumberOfSharesIssued_67" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_NumberOfSharesIssued_68" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_RemainingAuthorizedUnissuedOrdinaryShares_69" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_70" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_71" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_72" order="270" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_73" order="280" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_74" order="290" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_75" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019_76" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_77" order="320" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ValueOfServicesRecorded_78" order="330" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_AmountGrantOfEquityInstruments_79" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_80" order="350" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_81" order="360" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_82" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_AggregateOfferingPrice_83" order="380" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_PercentageOfCommissionOnSalesAgreement_84" order="390" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_CreditExposure_85" order="400" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_RemainingUnrecognizedDeferredCompensationExpense_86" order="410" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_SharesIssuedRegisteredDirectOfferings_87" order="420" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_WarrantsIssuedToPurchaseShares_88" order="430" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_89" order="440" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_WarrantsExpirationPeriod_90" order="450" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ExercisePriceOfWarrants_91" order="460" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_WarrantOfferingConsideration_92" order="470" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ProceedsFromExerciseWarrants_93" order="480" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses_94" order="490" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ProceedsFromWarrantIssue_95" order="500" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount_96" order="510" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_97" order="520" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_98" order="530" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_RecognizedAsEquity_99" order="540" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_ChangesInFairValueRecordedAsANonoperatingIncome_100" order="550" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_45" xlink:to="loc_blrx_BeneficiallyOwnInExcess_101" order="560" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfOrdinarySharesAbstract" xlink:label="loc_blrx_NumberOfOrdinarySharesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AuthorizedShareCapitalValue" xlink:label="loc_blrx_AuthorizedShareCapitalValue_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IssuedAndPaidUpShareCapitalValue" xlink:label="loc_blrx_IssuedAndPaidUpShareCapitalValue_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_blrx_NumberOfOrdinarySharesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_NumberOfOrdinarySharesAbstract_1" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_NumberOfOrdinarySharesAbstract_1" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_blrx_AuthorizedShareCapitalValue_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_blrx_IssuedAndPaidUpShareCapitalValue_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_EmployeesAndDirectorsMember" xlink:label="loc_blrx_EmployeesAndDirectorsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfOptionsAbstract" xlink:label="loc_blrx_NumberOfOptionsAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WeightedAverageExercisePriceAbstract" xlink:label="loc_blrx_WeightedAverageExercisePriceAbstract_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1" xlink:to="loc_blrx_EmployeesAndDirectorsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_1" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4" xlink:to="loc_blrx_NumberOfOptionsAbstract_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_NumberOfOptionsAbstract_4" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_NumberOfOptionsAbstract_4" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_NumberOfOptionsAbstract_4" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_NumberOfOptionsAbstract_4" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_NumberOfOptionsAbstract_4" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_NumberOfOptionsAbstract_4" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_NumberOfOptionsAbstract_4" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4" xlink:to="loc_blrx_WeightedAverageExercisePriceAbstract_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_12" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_12" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_12" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_12" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_12" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_16" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_12" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_WeightedAverageExercisePriceAbstract_12" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeMember" xlink:label="loc_blrx_ExercisePriceRangeMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeOneMember" xlink:label="loc_blrx_ExercisePriceRangeOneMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeTwoMember" xlink:label="loc_blrx_ExercisePriceRangeTwoMember_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ExercisePriceRangeFourMember" xlink:label="loc_blrx_ExercisePriceRangeFourMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1" xlink:to="loc_blrx_ExercisePriceRangeMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1" xlink:to="loc_blrx_ExercisePriceRangeOneMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1" xlink:to="loc_blrx_ExercisePriceRangeTwoMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_1" xlink:to="loc_blrx_ExercisePriceRangeFourMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_0" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_4" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfIncomeTaxesAbstract" xlink:label="loc_blrx_DisclosureOfIncomeTaxesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="loc_ifrs-full_GeographicalAreasDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL" xlink:label="loc_country_IL_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember" xlink:label="loc_ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UniformTaxRate" xlink:label="loc_blrx_UniformTaxRate_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WithholdingApplicableTaxRate" xlink:label="loc_blrx_WithholdingApplicableTaxRate_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxLossCarryforwards" xlink:label="loc_blrx_TaxLossCarryforwards_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfIncomeTaxesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1" xlink:to="loc_ifrs-full_GeographicalAreasDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_1" xlink:to="loc_country_IL_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_4" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_4" xlink:to="loc_ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_1" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7" xlink:to="loc_ifrs-full_ApplicableTaxRate_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7" xlink:to="loc_blrx_UniformTaxRate_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7" xlink:to="loc_blrx_WithholdingApplicableTaxRate_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7" xlink:to="loc_blrx_TaxLossCarryforwards_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfIncomeTaxesAbstract" xlink:label="loc_blrx_DisclosureOfIncomeTaxesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccountingProfit" xlink:label="loc_ifrs-full_AccountingProfit_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisallowedDeductionsTaxExemptIncomeAbstract" xlink:label="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation" xlink:label="loc_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation" xlink:label="loc_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_WriteoffOfIntangibleAsset" xlink:label="loc_blrx_WriteoffOfIntangibleAsset_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated" xlink:label="loc_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfIncomeTaxesAbstract_0" xlink:to="loc_ifrs-full_ApplicableTaxRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfIncomeTaxesAbstract_0" xlink:to="loc_ifrs-full_AccountingProfit_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfIncomeTaxesAbstract_0" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfIncomeTaxesAbstract_0" xlink:to="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_4" xlink:to="loc_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_4" xlink:to="loc_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_4" xlink:to="loc_blrx_WriteoffOfIntangibleAsset_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_4" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisallowedDeductionsTaxExemptIncomeAbstract_4" xlink:to="loc_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfIncomeTaxesAbstract_0" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LOSSPERSHARENarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PreFundedWarrants" xlink:label="loc_blrx_PreFundedWarrants_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_0" xlink:to="loc_blrx_PreFundedWarrants_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_0" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_0" xlink:to="loc_ifrs-full_WeightedAverageShares_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_0" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_0" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract" xlink:label="loc_blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="loc_ifrs-full_MaturityDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_FirstThreeYearsMember" xlink:label="loc_blrx_FirstThreeYearsMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ThreeSubsequentYearsMember" xlink:label="loc_blrx_ThreeSubsequentYearsMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeventhYearMember" xlink:label="loc_blrx_SeventhYearMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BiokineTherapeuticsLtdMember" xlink:label="loc_blrx_BiokineTherapeuticsLtdMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems" xlink:label="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesReceivedPercentage" xlink:label="loc_blrx_RoyaltiesReceivedPercentage_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesPaymentPercentage" xlink:label="loc_blrx_RoyaltiesPaymentPercentage_14"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MaximumFutureMilestonePayments" xlink:label="loc_blrx_MaximumFutureMilestonePayments_15"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ContingentLiability" xlink:label="loc_blrx_ContingentLiability_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts" xlink:label="loc_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedForDirectProductSales" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesOnSale" xlink:label="loc_blrx_RoyaltiesOnSale_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedForSubLicense" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedForSubLicense_21"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfNetConsiderationReceivedFromLicensee" xlink:label="loc_blrx_PercentageOfNetConsiderationReceivedFromLicensee_22"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesRateOnNetSales" xlink:label="loc_blrx_RoyaltiesRateOnNetSales_23"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BankGuaranteeAmountForBenefitOfLessor" xlink:label="loc_blrx_BankGuaranteeAmountForBenefitOfLessor_24"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OpenPurchaseOrderCommitments" xlink:label="loc_blrx_OpenPurchaseOrderCommitments_25"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LawsuitClaimAmount" xlink:label="loc_blrx_LawsuitClaimAmount_26"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1" xlink:to="loc_ifrs-full_MaturityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_1" xlink:to="loc_ifrs-full_MaturityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_blrx_FirstThreeYearsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_blrx_ThreeSubsequentYearsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_1" xlink:to="loc_blrx_SeventhYearMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1" xlink:to="loc_ifrs-full_RangeAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_6" xlink:to="loc_ifrs-full_RangeDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_6" xlink:to="loc_ifrs-full_BottomOfRangeMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_6" xlink:to="loc_ifrs-full_TopOfRangeMember_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1" xlink:to="loc_dei_LegalEntityAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_10" xlink:to="loc_dei_EntityDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_blrx_BiokineTherapeuticsLtdMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_1" xlink:to="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_RoyaltiesReceivedPercentage_13" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_RoyaltiesPaymentPercentage_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_MaximumFutureMilestonePayments_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_ContingentLiability_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_19" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_RoyaltiesOnSale_20" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_PercentageOfNetConsiderationReceivedForSubLicense_21" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_PercentageOfNetConsiderationReceivedFromLicensee_22" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_RoyaltiesRateOnNetSales_23" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_BankGuaranteeAmountForBenefitOfLessor_24" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_OpenPurchaseOrderCommitments_25" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems_13" xlink:to="loc_blrx_LawsuitClaimAmount_26" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsTable" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeAxis" xlink:label="loc_blrx_AgreementTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeDomain" xlink:label="loc_blrx_AgreementTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchaseAgreementMember" xlink:label="loc_blrx_PurchaseAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SharePurchaseAgreementMember" xlink:label="loc_blrx_SharePurchaseAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ScmLicenseMember" xlink:label="loc_blrx_ScmLicenseMember_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ScmSupportServicesMember" xlink:label="loc_blrx_ScmSupportServicesMember_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PDACPerformanceObligationMember" xlink:label="loc_blrx_PDACPerformanceObligationMember_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GloriaLicenseAgreementMember" xlink:label="loc_blrx_GloriaLicenseAgreementMember_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GloriaPurchaseAgreementMember" xlink:label="loc_blrx_GloriaPurchaseAgreementMember_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAgreementMember" xlink:label="loc_blrx_LicenseAgreementMember_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UpfrontPayment" xlink:label="loc_blrx_UpfrontPayment_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForDevelopmentProjectExpenditure" xlink:label="loc_ifrs-full_PaymentsForDevelopmentProjectExpenditure_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesMilestoneAmount" xlink:label="loc_blrx_SalesMilestoneAmount_17"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RoyaltiesEligibleMargin" xlink:label="loc_blrx_RoyaltiesEligibleMargin_18"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InitialRoyaltyTerm" xlink:label="loc_blrx_InitialRoyaltyTerm_19"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AggregateAmericanDepositaryShares" xlink:label="loc_blrx_AggregateAmericanDepositaryShares_20"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PurchasePricePerADS" xlink:label="loc_blrx_PurchasePricePerADS_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:label="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-full_ConsiderationPaidReceived_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_26"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TransferFromLicenseToTheLicenseeAmount" xlink:label="loc_blrx_TransferFromLicenseToTheLicenseeAmount_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="loc_ifrs-full_OtherRevenue_28"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DelayInPayment" xlink:label="loc_blrx_DelayInPayment_29"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProvisionForDoubtfulAccountsReceivable" xlink:label="loc_blrx_ProvisionForDoubtfulAccountsReceivable_30"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostsIncurrentInOffering" xlink:label="loc_blrx_CostsIncurrentInOffering_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="loc_ifrs-full_LicenceFeeIncome_32"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales" xlink:label="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_33"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract_0" xlink:to="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_blrx_AgreementTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeAxis_5" xlink:to="loc_blrx_AgreementTypeDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_PurchaseAgreementMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_SharePurchaseAgreementMember_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_ScmLicenseMember_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_ScmSupportServicesMember_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_PDACPerformanceObligationMember_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_GloriaLicenseAgreementMember_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_GloriaPurchaseAgreementMember_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_LicenseAgreementMember_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_blrx_UpfrontPayment_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_ifrs-full_PaymentsForDevelopmentProjectExpenditure_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_blrx_SalesMilestoneAmount_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_blrx_RoyaltiesEligibleMargin_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_blrx_InitialRoyaltyTerm_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_blrx_AggregateAmericanDepositaryShares_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_blrx_PurchasePricePerADS_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_23" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_ifrs-full_ConsiderationPaidReceived_24" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_25" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_26" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_blrx_TransferFromLicenseToTheLicenseeAmount_27" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_ifrs-full_OtherRevenue_28" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_blrx_DelayInPayment_29" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_blrx_ProvisionForDoubtfulAccountsReceivable_30" order="150" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_blrx_CostsIncurrentInOffering_31" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_ifrs-full_LicenceFeeIncome_32" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_15" xlink:to="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_33" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract" xlink:label="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsTable" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-full_RangeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeAxis" xlink:label="loc_blrx_AgreementTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeDomain" xlink:label="loc_blrx_AgreementTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AyrmidLicenseAgreementMember" xlink:label="loc_blrx_AyrmidLicenseAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HighbridgeMember" xlink:label="loc_blrx_HighbridgeMember_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_RegisteredDirectOfferingMember" xlink:label="loc_blrx_RegisteredDirectOfferingMember_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceObligationAxis" xlink:label="loc_blrx_PerformanceObligationAxis_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PerformanceObligationDomain" xlink:label="loc_blrx_PerformanceObligationDomain_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SingleMaterialPerformanceObligationMember" xlink:label="loc_blrx_SingleMaterialPerformanceObligationMember_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems" xlink:label="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_UpfrontPayment" xlink:label="loc_blrx_UpfrontPayment_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales" xlink:label="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_14"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GrossProceedsFromOffering" xlink:label="loc_blrx_GrossProceedsFromOffering_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-full_ConsiderationPaidReceived_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostsIncurrentInOffering" xlink:label="loc_blrx_CostsIncurrentInOffering_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="loc_ifrs-full_LicenceFeeIncome_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="loc_ifrs-full_RevenueFromRoyalties_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract_0" xlink:to="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_ifrs-full_RangeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_1" xlink:to="loc_ifrs-full_RangeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_BottomOfRangeMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_1" xlink:to="loc_ifrs-full_TopOfRangeMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_blrx_AgreementTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeAxis_5" xlink:to="loc_blrx_AgreementTypeDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_AyrmidLicenseAgreementMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_HighbridgeMember_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_5" xlink:to="loc_blrx_RegisteredDirectOfferingMember_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_blrx_PerformanceObligationAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_PerformanceObligationAxis_10" xlink:to="loc_blrx_PerformanceObligationDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_PerformanceObligationDomain_10" xlink:to="loc_blrx_SingleMaterialPerformanceObligationMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsTable_1" xlink:to="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_13" xlink:to="loc_blrx_UpfrontPayment_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_13" xlink:to="loc_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_13" xlink:to="loc_blrx_GrossProceedsFromOffering_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_13" xlink:to="loc_ifrs-full_ConsiderationPaidReceived_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_13" xlink:to="loc_blrx_CostsIncurrentInOffering_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_13" xlink:to="loc_ifrs-full_LicenceFeeIncome_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems_13" xlink:to="loc_ifrs-full_RevenueFromRoyalties_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementWithCompaniesForDevelopmentAbstract" xlink:label="loc_blrx_AgreementWithCompaniesForDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationAndShareholdersAgreementTable" xlink:label="loc_blrx_CollaborationAndShareholdersAgreementTable_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationTransactionAxis" xlink:label="loc_blrx_CollaborationTransactionAxis_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationTransactionDomain" xlink:label="loc_blrx_CollaborationTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_HemispherianAsMember" xlink:label="loc_blrx_HemispherianAsMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeAxis" xlink:label="loc_blrx_AgreementTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AgreementTypeDomain" xlink:label="loc_blrx_AgreementTypeDomain_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AssetTransferAgreementMember" xlink:label="loc_blrx_AssetTransferAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TetragonMember" xlink:label="loc_blrx_TetragonMember_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CollaborationAndShareholdersAgreementLineItems" xlink:label="loc_blrx_CollaborationAndShareholdersAgreementLineItems_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIssuedShareCapitalReceived" xlink:label="loc_blrx_PercentageOfIssuedShareCapitalReceived_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentProperty" xlink:label="loc_ifrs-full_InvestmentProperty_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths" xlink:label="loc_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_12"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_IncrementalInvestment" xlink:label="loc_blrx_IncrementalInvestment_13"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfAdditionalEquityInterest" xlink:label="loc_blrx_PercentageOfAdditionalEquityInterest_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_15"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PercentageOfOwnershipStake" xlink:label="loc_blrx_PercentageOfOwnershipStake_16"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MonthlyAdvisoryFee" xlink:label="loc_blrx_MonthlyAdvisoryFee_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementWithCompaniesForDevelopmentAbstract_0" xlink:to="loc_blrx_CollaborationAndShareholdersAgreementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementTable_1" xlink:to="loc_blrx_CollaborationTransactionAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationTransactionAxis_1" xlink:to="loc_blrx_CollaborationTransactionDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationTransactionDomain_1" xlink:to="loc_blrx_HemispherianAsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementTable_1" xlink:to="loc_blrx_AgreementTypeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeAxis_4" xlink:to="loc_blrx_AgreementTypeDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AgreementTypeDomain_4" xlink:to="loc_blrx_AssetTransferAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementTable_1" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_7" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_7" xlink:to="loc_blrx_TetragonMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementTable_1" xlink:to="loc_blrx_CollaborationAndShareholdersAgreementLineItems_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_10" xlink:to="loc_blrx_PercentageOfIssuedShareCapitalReceived_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_10" xlink:to="loc_ifrs-full_InvestmentProperty_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_10" xlink:to="loc_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_10" xlink:to="loc_blrx_IncrementalInvestment_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_10" xlink:to="loc_blrx_PercentageOfAdditionalEquityInterest_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_10" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_10" xlink:to="loc_blrx_PercentageOfOwnershipStake_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_10" xlink:to="loc_blrx_MonthlyAdvisoryFee_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_CollaborationAndShareholdersAgreementLineItems_10" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SeparateManagementEntitiesAxis" xlink:label="loc_ifrs-full_SeparateManagementEntitiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SeparateManagementEntitiesDomain" xlink:label="loc_ifrs-full_SeparateManagementEntitiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SeniorManagementMember" xlink:label="loc_blrx_SeniorManagementMember_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DirectorsMember" xlink:label="loc_blrx_DirectorsMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BenefitsToRelatedPartiesAbstract" xlink:label="loc_blrx_BenefitsToRelatedPartiesAbstract_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity" xlink:label="loc_ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfEmployees" xlink:label="loc_ifrs-full_NumberOfEmployees_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_1" xlink:to="loc_ifrs-full_SeparateManagementEntitiesAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SeparateManagementEntitiesAxis_1" xlink:to="loc_ifrs-full_SeparateManagementEntitiesDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SeparateManagementEntitiesDomain_1" xlink:to="loc_blrx_SeniorManagementMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SeparateManagementEntitiesDomain_1" xlink:to="loc_blrx_DirectorsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_1" xlink:to="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_5" xlink:to="loc_blrx_BenefitsToRelatedPartiesAbstract_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_BenefitsToRelatedPartiesAbstract_5" xlink:to="loc_ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_BenefitsToRelatedPartiesAbstract_5" xlink:to="loc_ifrs-full_NumberOfEmployees_6" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SEGMENTREPORTINGNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_NumberOfSegments" xlink:label="loc_blrx_NumberOfSegments_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0" xlink:to="loc_blrx_NumberOfSegments_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SEGMENTREPORTINGDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="loc_ifrs-full_GeographicalAreasDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="loc_ifrs-full_ForeignCountriesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="loc_ifrs-full_CountryOfDomicileMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-full_Revenue_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_1" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1" xlink:to="loc_ifrs-full_GeographicalAreasDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_1" xlink:to="loc_ifrs-full_ForeignCountriesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_1" xlink:to="loc_ifrs-full_CountryOfDomicileMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_1" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_5" xlink:to="loc_ifrs-full_Revenue_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_InstitutionsCurrentReceivables" xlink:label="loc_blrx_InstitutionsCurrentReceivables_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AdvancePayments" xlink:label="loc_blrx_AdvancePayments_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_Others" xlink:label="loc_blrx_Others_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_InstitutionsCurrentReceivables_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_AdvancePayments_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_Others_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_OtherCurrentReceivables_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradePayablesAbstract" xlink:label="loc_blrx_TradePayablesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_AccountsPayableAbstract" xlink:label="loc_blrx_AccountsPayableAbstract_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradeAndOtherPayablesToForeignTradeSuppliers" xlink:label="loc_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_TradeAndOtherPayablesToLocalTradeSuppliers" xlink:label="loc_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherPayablesAbstract" xlink:label="loc_blrx_OtherPayablesAbstract_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_PayrollAndRelatedExpenses" xlink:label="loc_blrx_PayrollAndRelatedExpenses_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPayable" xlink:label="loc_ifrs-full_InterestPayable_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherPayables" xlink:label="loc_ifrs-full_OtherPayables_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="loc_ifrs-full_OtherCurrentPayables_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_TradePayablesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_TradePayablesAbstract_1" xlink:to="loc_blrx_AccountsPayableAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AccountsPayableAbstract_1" xlink:to="loc_blrx_TradeAndOtherPayablesToForeignTradeSuppliers_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_AccountsPayableAbstract_1" xlink:to="loc_blrx_TradeAndOtherPayablesToLocalTradeSuppliers_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_OtherPayablesAbstract_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_OtherPayablesAbstract_6" xlink:to="loc_blrx_PayrollAndRelatedExpenses_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_OtherPayablesAbstract_6" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_OtherPayablesAbstract_6" xlink:to="loc_ifrs-full_CurrentProvisionsForEmployeeBenefits_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_OtherPayablesAbstract_6" xlink:to="loc_ifrs-full_InterestPayable_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_OtherPayablesAbstract_6" xlink:to="loc_ifrs-full_OtherPayables_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_OtherCurrentPayables_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LicenseFeesAndRoyaltiesPayableToLicensor" xlink:label="loc_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostRelatedToLicenseRevenues" xlink:label="loc_blrx_CostRelatedToLicenseRevenues_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_CostOfProductSales" xlink:label="loc_blrx_CostOfProductSales_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales" xlink:label="loc_ifrs-full_CostOfSales_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_LicenseFeesAndRoyaltiesPayableToLicensor_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_CostRelatedToLicenseRevenues_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_AmortisationExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_CostOfProductSales_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_CostOfSales_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ServicesExpense" xlink:label="loc_ifrs-full_ServicesExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CommunicationExpense" xlink:label="loc_ifrs-full_CommunicationExpense_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfessionalFee" xlink:label="loc_blrx_ProfessionalFee_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareBasedCompensationRelatedToResearchAndDevelopment" xlink:label="loc_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherExpenseByNature" xlink:label="loc_ifrs-full_OtherExpenseByNature_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_ServicesExpense_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_CommunicationExpense_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_ProfessionalFee_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_OtherExpenseByNature_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingExpensesRelatedToSales" xlink:label="loc_blrx_SalesAndMarketingExpensesRelatedToSales_1"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MedicalAffairs" xlink:label="loc_blrx_MedicalAffairs_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketingExpenses" xlink:label="loc_blrx_MarketingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TravelExpense" xlink:label="loc_ifrs-full_TravelExpense_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingPayrollExpense" xlink:label="loc_blrx_SalesAndMarketingPayrollExpense_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_BusinessAnalyticsExpense" xlink:label="loc_blrx_BusinessAnalyticsExpense_6"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_MarketAccessExpense" xlink:label="loc_blrx_MarketAccessExpense_7"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingProfessionalFees" xlink:label="loc_blrx_SalesAndMarketingProfessionalFees_8"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingShareBasedCompensation" xlink:label="loc_blrx_SalesAndMarketingShareBasedCompensation_9"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingDepreciationAndAmortization" xlink:label="loc_blrx_SalesAndMarketingDepreciationAndAmortization_10"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_LossOnAbandonmentOfRightofuseAsset" xlink:label="loc_blrx_LossOnAbandonmentOfRightofuseAsset_11"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_SalesAndMarketingExpensesOther" xlink:label="loc_blrx_SalesAndMarketingExpensesOther_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_SalesAndMarketingExpensesRelatedToSales_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_MedicalAffairs_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_MarketingExpenses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_TravelExpense_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_SalesAndMarketingPayrollExpense_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_BusinessAnalyticsExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_MarketAccessExpense_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_SalesAndMarketingProfessionalFees_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_SalesAndMarketingShareBasedCompensation_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_SalesAndMarketingDepreciationAndAmortization_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_LossOnAbandonmentOfRightofuseAsset_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_SalesAndMarketingExpensesOther_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-full_WagesAndSalaries_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InsuranceExpense" xlink:label="loc_ifrs-full_InsuranceExpense_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses" xlink:label="loc_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DepreciationExpense" xlink:label="loc_ifrs-full_DepreciationExpense_5"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProvisionForDoubtfulAccountsReceivable" xlink:label="loc_blrx_ProvisionForDoubtfulAccountsReceivable_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="loc_ifrs-full_OtherExpenseByFunction_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_WagesAndSalaries_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_InsuranceExpense_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_DepreciationExpense_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_ProvisionForDoubtfulAccountsReceivable_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_OtherExpenseByFunction_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_2"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_GainOnRealizationOfLongtermInvestment" xlink:label="loc_blrx_GainOnRealizationOfLongtermInvestment_3"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_OtherNonoperatingIncomeExpenses" xlink:label="loc_blrx_OtherNonoperatingIncomeExpenses_4"/>
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_ProfitLossFromNonOperatingActivities" xlink:label="loc_blrx_ProfitLossFromNonOperatingActivities_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_GainOnRealizationOfLongtermInvestment_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_OtherNonoperatingIncomeExpenses_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_blrx_ProfitLossFromNonOperatingActivities_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-full_RevenueFromInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="loc_ifrs-full_NetForeignExchangeGain_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-full_FinanceIncome_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_RevenueFromInterest_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_NetForeignExchangeGain_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_FinanceIncome_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails">
    <loc xlink:type="locator" xlink:href="blrx-20251231.xsd#blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract" xlink:label="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-full_InterestExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-full_FeeAndCommissionExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-full_FinanceCosts_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_InterestExpense_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_FeeAndCommissionExpense_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_ifrs-full_FinanceCosts_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss__1">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_0"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +J W(# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **\_^*?Q(T/X1^ ]=^(?B2TU:]T7
MP]_9GVVUT."SN=4E_M;6=/T.V^RP7]]IMH^R[U*"2?S;V#;;I,\?F2JD,GQ[
M_P /(/@?_P!"K\5O_!'X0_\ FYKX'BKQ2\/N",PHY5Q9Q7E619CB,'3S"CA,
M=4JPJU,%5KXC#4\3%0I37LYU\)B:2=T^:C/2R3?UV0<!<8<4X.IF'#_#^/S7
M!4<3/!U<1A84Y4X8JG2HUIT9.52+YXTL10J-6MRU(N^]OT"HK\_?^'D'P/\
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MR%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'PO_P4I_Y,I^-/_=.?_5L^!*_E'K^KC_@I3_R93\:?^Z<_^K9\"5_*
M/7^9/TT/^3HY#_V0.5_^M%Q2?Z=_0L_Y-;G_ /V7^:_^L[PJ%%%%?R*?UZ%%
M%% !1110 4444 %%%% !1110!^[%%%%?V@?P.?5?[('_ "4O7/\ L1M3_P#3
M_P"&:_1VOSB_9 _Y*7KG_8C:G_Z?_#-?H[7]C>"G_)#8?_L99C_Z<@?R?XO_
M /)9U_\ L7X#_P!-S"BBBOUH_+PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _/7_ (*K7]WIG[!/QXOK&7R+J#_A
M5_E2^7')M\SXS?#N%_DF22-MT<CK\R'&<C# $?QO_P#"=^*_^@K_ .2.F_\
MR'7]BG_!63_E']\??^Z5_P#JZ_AQ7\7M?YB_33;7BED%FU_Q@&5=?^JBXJ/]
M8OH)8>A5\(N(Y5:%&I)>(^;Q4JE.$Y**X9X0:2<HMV3;=MKMOJ==_P )WXK_
M .@K_P"2.F__ "'1_P )WXK_ .@K_P"2.F__ "'7(T5_(5WW?WL_M7ZE@_\
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M1_; 4444 %%%% !1110 4444 %%%% 'Z84445^+G\_GM/P*_Y&[4?^Q<O/\
MTYZ17U?7RA\"O^1NU'_L7+S_ -.>D5]7U\;G7^_S_P"O=/\ ])/R'C+_ )'=
M3_L'P_\ Z0PHHHKR3Y4**** "OV,_96_Y(+X#_[FC_U,_$5?CG7[&?LK?\D%
M\!_]S1_ZF?B*O[__ &<7_)[^*O\ LU6>?^M=P,?A7T@_^2,RS_LI\%_ZJLZ/
MH2BBBO\ :D_CP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#3GI%?5]?*'P*_Y&[4?^Q<O/\ TYZ17U?7QN=?[_/_ *]T_P#TD_(>,O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _.3_@K5/#;?\$^OC_-<3100I_PJK?+-(D4:;OC9\-T7=(Y55W,RJ,D9
M8@#D@5_%?_;6C?\ 06TS_P #[7_X[7]E_P#P65_Y1M_M'?\ =(/_ %?/PNK^
M$NO\X/I@933Q_B7D=:=:=-QX&RRG:,8M-+/^)I7UUO[[7R/]7?H*XF5'PDXB
MBHJ5_$;-Y7;:WX9X05M/0^A?[:T;_H+:9_X'VO\ \=H_MK1O^@MIG_@?:_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA1110 5^QG[*W_)!? ?_ '-'_J9^(J_'.OV,_96_Y(+X#_[FC_U,_$5?W_\
MLXO^3W\5?]FJSS_UKN!C\*^D'_R1F6?]E/@O_55G1]"4445_M2?QX%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7EW_ (18;_Y4</\ 8V3_ /0JRW_PAPO_ ,J/2_\ A='QB_Z*Q\2__"[\4_\
MRUH_X71\8O\ HK'Q+_\ "[\4_P#RUKS2BC^Q\I_Z%>7?^$6&_P#E0?V-D_\
MT*LM_P#"'"__ "H]+_X71\8O^BL?$O\ \+OQ3_\ +6ONGX-_M$?M 6/PW\.6
MME\=/C%9VT7]K^5;VOQ-\:V\$>_7M4D?RX8M;2--\CO(VU1N=F8Y9B3^9=?:
M7PE_Y)]X?_[BO_I[U*OZS^AOEV7X?Q.SV>'P.#H3? >9Q<Z.&HTI.+XAX7DX
MN4(1;BW&+LW:\4[72/B./L@R*MD^&A6R7*:L5F5&2C5R[!U(J2PN,2DE.BTF
MDVKVO9M=6?6'_#2?[1?_ $7WXU?^'3\<_P#R]H_X:3_:+_Z+[\:O_#I^.?\
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M;_TIM*]5KSL3_%?I'\CP\?\ [Q+_  P_(****P.,**** "OM+X2_\D^\/_\
M<5_]/>I5\6U]I?"7_DGWA_\ [BO_ *>]2K^KOH>_\G,SS_LA<S_]:#A@^,XY
M_P"13A_^QC1_]1L6>C4445_I$?E1^GW_  2<_P"3B_&G_9%?$?\ ZG/PXK^A
M*OY[?^"3G_)Q?C3_ +(KXC_]3GX<5_0E7S&:?[W+_!3_ /23_,#Z5G_)W,9_
MV(LD_P#3%4****\X_FX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^'3-/_D?7^EK_EQ?\._/V]/^C(_VN_\ Q&SXR_\ S%T?\._/V]/^C(_VN_\
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M\)[3E\.N&)^TY+\V:YJK<G-M:/7F?X'^9?\ \,%_MS?]&8?M8?\ B.OQ?_\
MF.H_X8+_ &YO^C,/VL/_ !'7XO\ _P QU?Z:%%<G_$M.1_\ 139M_P"$F#_S
M]?Z6O9_Q4>XV_P"C;\+?^';-O_D3_,O_ .&"_P!N;_HS#]K#_P 1U^+_ /\
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M]_T5N=?^$6!_S]?Z6N7_ !4&XQ_Z-[PS_P"'3-/_ )'U_I:_P2?\,=_M<?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ_\ 6</B_7^C%7]<^ ?_ "1^9?\ 92XS_P!5>3'^1'T^_P#D\7#7_9M,F_\
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M_6KB?_HH\^_\/&8?_-!\N?\ ##O[%7_1G_[+G_B/_P )_P#YDJ/^&'?V*O\
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M,_\ V7/_ !'_ .$__P R5?4=%']G9?\ ] .#_P#":A_\@'^M7$__ $4>??\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?D/_P %PO\
M@H5\3O\ @F)^P#XX_:H^#_@SP1XY\?:5XS\$>!=$TGXA_P!MR>%K.X\<WEYI
M4.N:A9>']1T?4]531[M+:\;28=7TH:E DUK_ &E8O(ES& ?KQ7QM^TU_P4,_
M8@_8VL#>_M-_M2?!;X/W#074]IX?\4^.-&3QCJJV42S7$>B^";&XO/%NL3(C
MQCR=-T:Z<M+&N,NH/^4'^UE_P</_ /!6[]K_ /M73?&7[5OBKX6^"]5\@/X
M_9X@C^#&@6\<#AS FN>%I$^(E];7!4+=VVM^.-5@NH2]O-&T$TT4GXM:GJ>I
M:UJ6H:SK.H7VK:OJU]=ZGJNJZG=SW^I:GJ5_/)=7VH:A?74DMU>WU[=2RW-W
M=W,LD]Q/))--(\CLQ /]+[]K7_@\_P#V'?AC'J6C?LD_!/XL_M0^(XH+9]-\
M3^*-GP,^%T\DUX8;E6O/$&G:]\2I)K*S22^6WE^&^G6]Z\EG9+J=JTUY<:=_
M,Y^UC_P=C_\ !6/]HN34=*^&WCCP)^R=X+N;R9K72_@CX3MKGQ>=+D@EA73M
M5^(7CUO%6KR3*THF;4O#%EX/N3+##Y20Q^?'<?S+44 >D_%'XR_%_P".'B(^
M+_C5\5OB3\7_ !:83;GQ1\4?'/BCX@>(C 9#*8#K?BS5-6U,PF5FD,?VG89&
M+E=Q)KS:BB@#_6+_ .#1K_E#)\,_^RW_ ![_ /4R%?N=^U?^VA^RY^P[\,=1
M^+_[57QI\%?!SP18Q7;6MSXFU'.M^)+VTLKF_;1/!?A33X[SQ1XU\17%O:3F
MST#POI&JZM=LA6&T8]/\SG]A?_@Y/\8_\$V_^"6OA+]C+]F'X/V^J?M(0?$3
MXG>)]9^,/Q1CM-0^&?@_1?&?B6+5M/?PEX0TC6(M8\8>)1IHGMG?Q+/X=T/1
M-2:&[>P\66D4EA-_/=^TK^U9^T=^V)\2M2^+_P"T[\8_''QH^(>I[D?7_&FK
M-=QZ=:G9_P 2SP[HMLEIX?\ "FBHT:O%H?AC2M(T>&3=)%8I([LP!_:M_P %
M ?\ @]$\2W]WKW@/_@G#\"[70]*AGNK"V^/G[0=JNH:QJ"07MW;'5/"/PBT7
M4!8:9:7UG':ZAH^H^,_$M]?JER(M8\$:?<P26Q_D+_::_P""F'[?O[8]]J-Y
M^TG^UM\;OB?9ZK9G3[[PM>^,[[P_\/I;-FF:2!/AIX0_X1_X>VZS">2.X-MX
M9A>XA$4$[20P01Q_#=% !5[3-3U+1=2T_6=&U"^TG5])OK34]*U73+N>PU+3
M-2L)X[JQU#3[ZUDBNK*^LKJ**YM+NVECGMYXXYH9$D16%&B@#]POV(O^#B'_
M (*H?L/ZKI,'A[]HKQ'\<OAK93#[=\)?VC;W4_BKX;N[1YK<S0:7XCUF_P#^
M%@>%Y([>*2#3U\/^+;/2K1IC+/H]\L<<(_T*/^"0W_!Q/^R!_P %2UTWX7Z@
MH_9T_:Q\@+/\#/&^N65W8>.I;?3UOK_4/@UXR*6$'C>T@6.]:?P_>:?HOC:Q
M@L+N\E\/W&D1QZO<?Y"M:N@Z]KGA;7-&\3^&-9U;PYXE\.:MIVO>'O$.@ZC>
M:1KF@ZYH]Y#J&DZSHVK:?-;W^EZMI=_;V]]IVHV-Q!>65Y!#<VTT4T2.H!_O
MQT5_*%_P;8_\%Z;K_@HUX&N/V3?VIM7M(?VS?A)X:CU+2O&4K6%C;_M'_#O3
ML6UQXIAT^W%NEG\3/"*_98OB!IEG:QZ?K5G=V/C'1%03^(](\.?U>T %4-3U
M72]$LI]2UG4K#2-.MD:2YO\ 4[RWL+*WC52S//=74D4$2*JLS-)(JA5))P":
M_CS_ .#K?_@JM^W!_P $[I_V1O ?['WQ:M_A!;?'70/C-JGCKQ%9^#O"/B/Q
M7YO@#4_AK:Z-!H6I^+M'UVUT6">W\7:JFH/:Z=]MD9;26TO+.6#>_P#GA_'_
M /;:_; _:IO=0O/VC?VFOCC\9TU.\CO[C2?'_P 2O%6O>&8KJ%TDA?3O"5UJ
M9\+Z0D,L:30P:3H]E;Q3@SQQ+*S.0#_7U_:3_P""Y?\ P2@_92&MVOQ8_;:^
M#5QXB\/3Q6FJ>"?AIK4_QB\<VM[.T2Q6=QX6^%UKXLU6SG(GAED^WPVD5M:R
M"]NY(+)7N$_ O]I3_@]9_8]\%?VUI7[+G[,'QI^.VKV4MO#I?B+XBZOX=^"W
M@/5DE^S/<7EL\ ^(/C@0VD4MPJV^I^#M&GNKVT-L#;V=Q'JB_P":[10!_5?^
MTG_P>"?\%5/C&->TKX.0?!#]EOPYJ$EN-'NO 7@3_A.OB%H]K&+5[B*X\6_%
M"]\3>&[^XNIHKJ/[79_#W1GM[&[$,$:WUO'J9_+74/\ @NS_ ,%?]4OKK4;O
M_@H+^T6+F\F:>86?BNVTZU#OU%O8:=IMK8VD0Z)!:6T$$8X2-1Q7Y-44 ?JP
M?^"Y/_!7<@@_\%!OVD\$8/\ Q7$@Z^XM<C\*_P!D#]GG5-3USX _ [6]:U"[
MU;6-8^#_ ,,]4U;5-0G>YO\ 4M3U#P7HEW?ZA>W,A,EQ=WEU-+<7,\A+RS2/
M(Q+,37^#/7^\3^S+_P FW?L^?]D0^%'_ *@>@4 >WT444 %9.O:[HWA?0]9\
M3>(]3LM$\/\ A[2M0US7=9U*XCM-.TG1])M)K_4M2O[J4K%;V=C9P37-S/(P
M2*&)W8A5)K6K^*__ (.\_P#@JU)\"/@;HW_!.+X,>)([;XJ?M&Z+_;_[0-]I
M\@>\\)? !I;BUM/!SRPWD,EAJOQ<UFV>VNUEM[R.3P%H7B.PNK> >)],O% /
MYJ_^"G'_  <@_MS_ +0_[9OQ;\<?L@_M._%WX$?LRZ;J4?@WX,>#_!.IW?A6
M/5_!OAEIK6W\>^(]-NX3>#Q+XZO9+WQ'/%>065WI6E7ND>'[JTCN-'EDE^!/
M^'Y7_!7?_I(-^TG_ .%Q)_\ (M?E-10!^K/_  _*_P""N_\ TD&_:3_\+B3_
M .1:_L#_ .#13]O7]LK]LOXR?MI:5^U-^T?\4_CGIG@/X9?"34/!^G_$#Q%+
MK%GX?OM=\4^,+?5KS3K<QQ1Q7-];Z;9033%6?RH BE59PW^='7]TG_!CW_R7
M/]O_ /[)/\#?_4P\?4 ?Z*E%%% '+>./$\7@GP5XP\9SV<FH0^$?"WB#Q/-8
M0RI!-?1:!I-WJLEG%/(KQPR7*6AA25T9(V<.RLH(/^.9_P %//\ @NM^W5_P
M4^\7:[!\0/B!J_PG^ $\]W!X9_9J^&7B#4M,^']AHTTD@AA\;WMJNF7_ ,4]
M<:W,4=_JWBN$Z8T\33:'X<\/03/9U_L"?'K_ )(9\:/^R3_$7_U#]8K_  7Z
M "MGP[XC\0^$-=TKQ1X3U[6?"_B70KZ#4]#\1>'=4OM%UW1M2M7$EKJ&E:MI
ML]M?Z=?6T@$D%W9W$,\+@-'(K &L:B@#_0B_X-P?^#D7X@?%3X@^"/\ @G__
M ,%!?&[^+/$_B^:#PU^SI^T9XCEBBU[7/$)5ETGX4_%74@D4.K:OK*JNG^!_
M&UYLU/5]56U\.>(KC4]:U/3M2NO[UJ_P'=!U[6O"VNZ+XG\-ZK?Z%XB\.:MI
MVO:!K>E74MEJFCZUI%Y#J&EZKIM[;LD]I?Z??6\%W9W4+I+;W$,<L;*Z*1_N
M8?L&_'V\_:H_8I_91_:/U*U^PZO\;?V?_A3\2-;LMXD%IKWBGP;I&IZ];+(H
M576#6)[V-'"@,J@@#- 'UE117X#_ /!;+_@O7\ O^"27@VU\$:;9V7QD_; \
M=:++J7@#X)V.HI%8>$]'G2YALOB)\7]1MI?M/ASPC)>P/;Z'H]LK>)O&EY%/
M#HUM;:/8ZWXBT8 _7K]I+]J?]GC]D#X9ZK\8?VF/B]X(^#?P[TA2LWB'QIK-
MOIJWUV0/)TG0M/S)JGB+7+MBL5EHFA66H:K>2ND=M:2,P%?Q-_M_?\'H^E:7
M<ZSX&_X)P? >V\2-#*]I!\>OVBK34[/0YUBN;4M?>%?@_H.IZ5KU[;WED;U+
M*^\8^*?#ES87?V:>]\(W\ DM'_BJ_;6_;S_:I_X*$_%_4/C5^U9\5M<^(_BF
M2;44\.Z1*PT[P3\/M%U&Z6Y/ACX>^$+1ETCPMH4"PV=NR6D+ZGJJV-I=^(=3
MUG5$DU"7X^H _5']I[_@MK_P5/\ VNK^\E^+_P"VE\9H-#N;[4+N#P1\,_$3
M_![P/96U_,TBZ3_PCOPPC\*V^L:=81>7:V)\3OKVH+#"DMU?W5Z\]W-^6][>
MWFI7EWJ.HW=S?ZA?W,][?7U[/+=7E[>74KSW-W=W,[R3W%S<3R/-//,[RS2N
M\DCL[$FM6IHFB:UXFUK2/#?AO2-4\0>(O$&J6&B:#H.B6%WJNM:WK6JW<5AI
M>D:1I=A%<7VI:IJ5]<065A864$UW>7<T5O;Q232(C &717]B?_!.C_@SY_:Z
M_:*TK0?B9^VUX[M/V0OAWJL=M?VOPUT_3[7QK^T!JVG3-?*PU;33<Q^#OAK)
M-%'IM_9C6-0\5:\L%W-9ZUX1T.^MV2OLC_@N%_P;U?\ !.K_ ()J?\$H?B'\
M<_@EX<^*/BGX]>%/''P9\.V/Q8^)/Q,UO5-0DL_$WCG2]#\1-)X/\/+X:^'>
M_5-.N)XFW>$W:SD<3:>]JZ*0 ?P3*S(RNC,CHP9'4E65E.596!!5E(!!!!!&
M0<U^KW[)G_!<+_@J3^QAJ=C/\(?VOOBEK'AFUN[6XN?AS\7-:N/C#\/M0M[5
M60:9_8/Q DUN;0K"96*S_P#"(:AX;O6.'2]CD&^OR?HH _TN_P#@ES_P=]_L
M_?M#:IX=^#__  4(\):'^RU\2]1BAL;3XX>'K^YN/V=?$.IQP:?$S>)%UJ[N
MO$GPAFU*[EOYK9]7OO%?@^QM+3=JWC72Y9K>WE_LQT[4=/UC3['5M(O[+5-*
MU.TM[_3=3TZZ@OM/U"QNXDN+2]L;RVDEMKNTNH)(YK>Y@DDAFB=)(W9&#'_
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M .R3_ W_ -3#Q]7\+=?W2?\ !CW_ ,ES_;__ .R3_ W_ -3#Q]0!_HJ4444
M>3_'K_DAGQH_[)/\1?\ U#]8K_!?K_>@^/7_ "0SXT?]DG^(O_J'ZQ7^"_0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M18P3VTP\$^!O@7X0E6 +YEO/'\*/#/B.6"\(EDS<AO$?F@E8F%K+; Q<"20
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M/%5 '^'91110 4444 ?ZQ?\ P:-?\H9/AG_V6_X]_P#J9"OZ;:_F2_X-&O\
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MZU7\2?\ P>Z_\FA_L6?]G(>,/_58ZA7]ME?Q)_\ ![K_ ,FA_L6?]G(>,/\
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MXTT:.5E2TU>VM7>T\0>%]39H;@C1O%_AN\U?PMK1CB:?^R=8O?L[1S^7(O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?#7_!3K_E''^WA_P!FA?M$_P#JJ/%5?<M?#7_!3K_E''^WA_V:%^T3
M_P"JH\54 ?X=E%%% !1110!_K%_\&C7_ "AD^&?_ &6_X]_^ID*_IMK^5C_@
MTT^*/PR\-_\ !'SX;>'O$/Q%\":#K\?QH^.]U)H>L^+_  ]IFL16TWC 217$
MFF7NHP7L<,L?[R.5X%22,AU8H03_ $:^*?VGOV;/!%A=:IXR_:#^"7A73K*%
MKB\O?$/Q4\#:/;6T"(9&FFEO]=@2.-8P9"[$*$!8G:": /<JKW=W:6%K<W]_
M<V]E8V5O-=WEY=S1VUK:6EM&TUQ<W-Q,R0P6\$*/+--*Z1Q1HSNRJI(_!O\
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MACPWI<-WK?B+5Y(95T_2;&ZG6&>98K>7^PW_ (@@OVDO^C[?@?\ ^&J\>_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5\-?\ !3K_ )1Q_MX?]FA?M$_^JH\55]RU
M\-?\%.O^4<?[>'_9H7[1/_JJ/%5 '^'91110 4444 ?ZQ?\ P:-?\H9/AG_V
M6_X]_P#J9"OZ;:_F2_X-&O\ E#)\,_\ LM_Q[_\ 4R%?TVT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7PU_P4Z_Y1Q_MX?]FA?M$_^JH\55]RU^3O
M_!8#]JO]F3X0?L#?MA>#OBI^T%\&_A[XO\??LT_'+P5X'\)^+?B+X5T7Q1XN
M\7Z]\,/$]IHOAKPWX=N]336M9UK5+EUBLM/T^QN+F9B66/8CLH!_BTT444 %
M%%% '^L7_P &C7_*&3X9_P#9;_CW_P"ID*_IMK^0C_@TS_:]_96\.?\ !,CP
M#^SOXC_:-^"?AWX\:=\5?C5XCO/@_P"(?B7X2T+XBQZ#JWBZ&;3=83PEJVJV
M>LW.FWD=Q;-#>VMI-;DW,"-(LDJ(?Z\;>YM[R"*YM+B&ZMID$D-Q;RQSP2HP
MRKQ2Q,T<B,.0RL01R#0!-1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E_QO\
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )T!(P# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBBN<
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ML10G*E6H5Z-6,:E&M1J1E3JTJD8SISC*$XJ2:11114F(4444 %%%% !1110
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M*=.G6G3>0YHIPI5JN(H4JLXO"\T:=6MA,51IS:49U<-B*<6YT:BC]H45\?\
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MX6_%N^\16.@Z9)IT-OJ7A'4K&%H]9637VU&ZGT^:W_2K1_&'QL^(?@30;/\
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M?$LU]X.\*Z3X8M/B1IMK$EQIED=6G_H4^%'[0WP!^//]O_\ "C?CE\'OC/\
M\(I_97_"4?\ "J/B9X+^(O\ PC?]N_VC_8G]O_\ "(:WK']C_P!L?V/J_P#9
M7]H_9O[0_LK4?LGG?8;GRK/_  M_P[_S[C_PK_A?_P#-_1_PM_P[_P ^X_\
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M /YOZ/J]?_GS5_\  )?Y>?Y]F'M(?SP_\"7^?FOO/5Z*\H_X6_X=_P"?<?\
MA7_"_P#^;^C_ (6_X=_Y]Q_X5_PO_P#F_H^KU_\ GS5_\ E_EY_GV8>TA_/#
M_P "7^?FOO/5Z*\H_P"%O^'?^?<?^%?\+_\ YOZ/^%O^'?\ GW'_ (5_PO\
M_F_H^KU_^?-7_P  E_EY_GV8>TA_/#_P)?Y^:^\]7HKRC_A;_AW_ )]Q_P"%
M?\+_ /YOZZB/Q_X'=$=O&'A:)F16:*3Q'HADC+ $QN8K^2(NA.UC')(A(.QV
M7#$]A7_Y\U?_  7+_(/:0_GA_P"!+_/S7WG7T5R?_">^!?\ H=/"?_A1Z/\
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M<-X.>"PE/*<O>#>,C6K8O$.MB<?4I\\,+0JPI^WGB?5Z*\H_X62/^@E\*/\
MPZH_^8^C_A9(_P"@E\*/_#JC_P"8^O'^KU_^?-7_ , E_EY_GV9\%[2'\\/_
M  )?Y^:^\]7HKAM/^(/A>2V#:KXI\#65WO<-!I_C+3M3M@@/R,+JYATF4NPR
M70V:A#P)).HN_P#">^!?^AT\)_\ A1Z/_P#)E'L*_P#SYJ_^"Y_Y![2'\\/_
M  )?Y^:^\ZRBN3_X3WP+_P!#IX3_ /"CT?\ ^3*/^$]\"_\ 0Z>$_P#PH]'_
M /DRCV%?_GS5_P#!<_\ (/:0_GA_X$O\_-?>=91116184444 %%%% !1110
M4444 ?/?[2?_ "(ND_\ 8V6/_IGUVOB.OMS]I/\ Y$72?^QLL?\ TSZ[7\TO
M[6'[5/[5?CC]IEOV(?V&++PQH'Q&\.^&-*\8_%KXQ^-+:PU#2_A_I^IIHNLZ
M=:6MEJ>E^(M)MK632=5T:+5;R\\+>+=6U(^*K>R\/Z'IUSI<NM2?H?"F!K8_
M"^RI2I4U3=>O6KUZGLJ%"A"45.K5G:34%*48VC&<Y2E&,8MNQZ_"G V;\?<0
M8G*LKQ.4Y;1R_*L3G>=9WGV.66Y'D.28%T*>+S7-<8J6(K4\+2KXG"X:,,+A
M<7BZ^)Q6'P^&PU:K5C$_7ZBOR _9O\4?\%3_ (7_ +2WAWX0_M3Z9X8_:!^$
MOCK0-0UF[^,_P\T+0M'T7X:S:3:72PP'6;#PK\+K.::[U6?2[75O#/B+PU<Z
M_J5C=#6O ]Y?1:!K^F7G>?LD_M%?&3XG?MO?MS_"#QQXQ_MOX=_!W6?#]I\.
M/#W_  C_ (6TW_A'+>^U#58+J/\ M;2-#L-<U?S8K:%=^NZGJCILW1LC,Y;Z
M.MD]:DL3.&*P.)I8;"4L;*KAJ\JL*E*KB(891A^[C.-6-6:YZ=>%%J,7)73C
MS>]G'@YG.5TN)<7A>*.!N(\LX9X1RSC2OFO#.>XC-,#F.4YIQ#@N&:5# K^S
M:&+P^:8?-,;&.+R_.\+D]6EAZ%:O!U8RPRQ'ZAT5^9/_  53_:$^+_[-WP.^
M%?C#X+^+_P#A#/$?B3]HGP/X$UK4?[ \+^(OMOA76/"'Q#U34=*^R>*]%UVQ
MMOM-]H6E3_;K2U@U*'[+Y4%Y%#/<QS<'^UG^U'\<_P!B+]J/X>_$;XC^)M2\
M:?L-?%FTD\':OH\/@[PL+_X._$);,74=SI^M:#H%EXKUU;JTT:;7M.T_7=9U
M4ZEI-UX[LK/3Y+WP[H5U"L-D^*Q5+#U*4Z#EBXXQX:C*=15JT\"J3JT8)4G!
MUJD:O-1@YI5.2<>:,^2,XX:\&N*.*\LX=Q^4X[(9XGBW#<:5>&LEK8K'T\XS
MG&\#0RVKF>38*E'+*F"GF^/H9DJV2X6>.A3QZPF*H2KX?%RP>&Q?ZY45^4W[
M#W[0?[17Q=\!?'K]LGXYZWJ>E_ &[?QGK/P)^">G^%O!L&J:1\/O!OV_5+[Q
M%+XBCT;2=?\ $FIW%KIW_".:1)JOB:'2M2U6T\1ZI)9V>FWGAY[#QO\ 9K_;
MK_:;^//_  4!T7X=^-O!6I_ WX)^(_@CK/CGP?\ !_Q#I6@7/BS5--MKB:/0
MOB#XKURZT:+Q7I>K^()DO9K?P];7&BZ+::%!HPBT[63(_BSQ'I+(\8IX^*J8
M62RVBZN*G&L^53C!3GAJ:<%.K7IWE&IR1=&$X24JR7*Y=]7P)XQIXKC_  \<
M?PO7AX:9/7S+BG%T,YD\/2Q^$P$,=C^&LNA/"4\7FN?9<OK&%S".!PM;*,)B
M\'B(5LWC2EAJV(_;VBN:\9>,/#?P_P#"VN^-/%^J1Z-X:\-Z=/J>KZC)!=7;
M0VT  $5K8:?!=ZEJFHW<S1V>F:1I=G>ZMJ^HW%KIFEV5YJ%W;6TN9X*^(_@[
MXAR^,+?PEJLVHW'@'Q8W@?Q?;W.CZWHUQHGBM/#?AOQ;)H\\&N:;ILTTT7A_
MQ=X?OI9K-+BTB>_:QDN%U&RO[2U\E4ZC@ZBA-TXZ2FHR<(M.*:<DN56<X+5[
MSBOM*_Y%#+LPJX.KF-/ XRIE]"4H5\=#"UYX.C.,\-3E"KBHP="G*,\;@X2C
M.::GB\-%J]>DI]Q1114'&%%<5\.OB+X.^+'@S1/B#\/]8_M_PAXCCO)=&U?^
MS]5TK[9'8:C>:3=M]@UJQTW5+?RM0L+NWQ=64#2>5YL0>&2.1P_$7P<OQ&3X
M2G6,?$&3P3+\14\/_P!GZKSX.AUV'PU)K']J_8?[$&W6YXK+^SSJ0U4[_M*V
M)M%:<6Z512G!TYJ=/F]I!PDI4^1VGSQM>'(])<R7*]'8[IY7F=/%8[!5,NQT
M,9E?UK^TL)/"8B.*R[ZC-TL;]>P\J:JX3ZG43IXKZQ"G]7FG"KR231VM%%%0
M<(45QVL>/_".@>,?!G@#5M6^R>+?B%;^*+KP?I/V#4Y_[7@\&6>GW_B63[?;
M64VF:?\ V;::I8R[=4O;)[SS_+L%NI(IDC[&J<9147*,DIQYH-II3BI2@Y1;
MTE%3C*-U=<T91W32VJX;$T*>&JU\/7HTL;0EB<'4JTJE.GB\-#$XC!RQ&&G.
M*C7H1Q>$Q6%E5I.=-8G#8B@Y*K1J1B4445)B%%%% !17&^ OB!X1^)WAJ/Q?
MX&U;^W/#LVL^*O#\>H?8-3TW=J_@GQ5K7@GQ/:?9-7LM/OA_9GB?P]K&F?:&
MMA:WOV/[;I\UWI]Q:W<_954HRA*4)QE"<9.,HR3C*,HNTHRB[-233332::L]
M3;$X;$X+$XC!XS#U\)B\)7JX;%87$TJE#$X;$T*DJ5?#XBA5C"K1KT:L)4ZM
M*I&-2G4C*$XJ2:11114F(45QOB'X@>$?"OB7P#X0U[5OL'B+XGZSK/A_P-I_
MV#4[K^W-7\/^%=;\;:O:?:[*RN+'3/LGACP[K&I_:-8N=/M;C[']BM9IM0N+
M6TGE\$>.O"OQ%T"/Q-X.U3^U=(?4-9T>9Y;'4=)O]/UKPYJU[H/B#0]9T76;
M/3]:T+7="UO3K_2=9T76=/L=4TS4+2XM+VT@GC9!;IU%!5'":@[-3<9*#4I3
MBFI6L[RI5(JSUE3FEK"5NR>79A3PE/'U,!C:>!K1I2I8V>%KPPE6->MC\-1E
M3Q,J:HSC6Q&5YG0I.,VJE;+L?2A>>#Q$:?6T445!QA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?K!1117Y>?4!1110 4444 %%%% !1110!\]_
MM)_\B+I/_8V6/_IGUVOY2OVE/%?Q _8 _;W\>?MIZG\)_%?Q,_9P^.WPW\'>
M%/B7XE\&6ZW>H?#75_#R^#/"%K->&>2#2]/FN9= \-QZ/!XDO] T;Q1=>))-
M,TW7HM8TZ:W']6O[2?\ R(ND_P#8V6/_ *9]=K\'O&G[.O[>.M^,?%FM>#_^
M"C?_  @_A+5_$NNZIX6\%?\ #(7P;\3?\(?X=U#5+J[T3PM_PD>J:Y#J?B#_
M (1_3)K72?[;U&**^U7[)]ONXTN+B11^G<$UZ-##5?K%3"QPU>G7PV(I8IXV
M*KT:E2G-PI5<#A<74I583I4ZD:DZ?*G%74[N)^B^$^>9/D7$>?\ ^L69\*X;
MAS/>&J_#?$65<4U.-L)3S[)\?C,!C:N$RK,^!^%.+<?E6:8/'97E^8X;'8O+
MWA:=3#1C*EBU*=!_BS^R]\0_VC?VC_VROAWXO^ /QW_;;^)7P6@^,]SXQ^,6
MD?$U=;\!?"KX=^"6\06NOV?@LWFE?'SXH>%/%,=QHL^I:7%X8OK'PQ<W-KIU
MBND:%JMI>7R:)U_A+]N7X3?L1_\ !0_]OO6_BMX>^(GB"T\?^--.TK1H_A[I
M/AK5;BVN-"N[V[NWU-/$GB[PG'##)'J$*VS6LMZ[NLHECA549_U2_P"&8?\
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M>'%E.-Q&6T<0L/0J9ACL)BZJBLK5#&>2?\$N?COXRT%?'?[ W[0,O]F?'/\
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M\/\ QM^&/C/X4>*[S6=/\.^.=&ET/5KWP]<65IK5O:2S0S-)IUSJ6G:M8PW
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT\L6FZ(NB:9:W+7GV?0-.+N9_8IOVV_&W[-6@?\ !63XI:1X7^'^J^)OA_\
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M_P!"G+/_  @PO_RH/^((^#'_ $:+PP_\0'A3_P"=)^E7_#W[_@HG_P!'#?\
MF)?@;_\ .SH_X>_?\%$_^CAO_,2_ W_YV=?FK11_8N3?]"G+/_"#"_\ RH/^
M((^#'_1HO##_ ,0'A3_YTGZ5?\/?O^"B?_1PW_F)?@;_ /.SH_X>_?\ !1/_
M *.&_P#,2_ W_P"=G7YJT4?V+DW_ $*<L_\ "#"__*@_X@CX,?\ 1HO##_Q
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M@*N6SQ%:<ZU>%#&97BJF&J5I2K+!UL-"M4K583K5"BBBOG#^;PHHHH ****
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M@ HHHH **** "OY&?^"\QS^U5X%/]WX2:7'^6N:S)C_R+^HK^N:G'HO^Z?\
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M\'J5*NX25&K7X^GB*-.HU[DZM"GP;AIU81=G*G'$4926BJ0;NOQ,_P""2_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4?\ @C#?_-/G^?9G[?T5^('_  _S_8\_Z)M^TK_X1WPN_P#GQT?\/\_V//\
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M\_V//^B;?M*_^$=\+O\ Y\='_#_/]CS_ *)M^TK_ .$=\+O_ )\='^K.??\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGS4ZDXR_-/\ X= _\$[/^C>?_,M?'+_YYE'_  Z!_P""=G_1O/\ YEKXY?\
MSS*_2JBO2_MK.?\ H;9G_P"%^*_^6GW/_$;O&?\ Z.[XG_\ B?<5_P#SV/S5
M_P"'0/\ P3L_Z-Y_\RU\<O\ YYE'_#H'_@G9_P!&\_\ F6OCE_\ /,K]*J*/
M[:SG_H;9G_X7XK_Y:'_$;O&?_H[OB?\ ^)]Q7_\ /8_-7_AT#_P3L_Z-Y_\
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M>91_PZ!_X)V?]&\_^9:^.7_SS*_2JBC^VLY_Z&V9_P#A?BO_ ):'_$;O&?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** /U@HHHK\O/J HHHH **** "BBB@ HHHH ^>_VD_\
MD1=)_P"QLL?_ $SZ[7Q'7VY^TG_R(ND_]C98_P#IGUVOYU_BA^U[^T]\2/VF
MO'/[+G[#/PZ^#^MZM\$M*T/4/CE\8/V@;[QG'\-O#FL^)K&\OM$\#:5I?@":
MU\13ZS=00(T.K)-J:7%]9^(=,DT&QM-!GU^?]$X4P%?'X*<:+I0A05;$8BOB
M*L*-"A152G3YZM6;27-5J4Z4(Q4ISJ5(0A&39\EQ!F>&RRI2G75:I4Q56GA<
M+AL+1GB,3B<1*G.K[.C1IIM\E&E5K5)R<:=.E2G.<XJ)^IE%?CWIW_!3/Q9\
M$K+]HWX>_ML?#OP?X(^/7[.OPS;XIV<_PQUCQ'>_"?XY>'M=\3V?A3P(W@>2
M^TOQ-XP\'_VSXI\4>!_!MV^O6VOO8W&HZGXKUBW\/:?IFKZ#HGC7AC_@L-/X
MM\$?L6^+K.[^#VD#XL_&K5?AE^U)+XBTKQMH/A_X0V%E/I&JB70/$OB+Q%H&
MCV\MCX-UJSU;5/$]_>>*O#44A>6:*Q\BYL(/KH<*YW44IT\+[2BIJ$,33G&K
MAJJEA*F.A.E6I\\9TYX>$7&6G[RM1HR4:L^1?,3XVX=I.%.KC72Q#INI4P=:
MG.CBZ#CCZ.65*5>A5Y)TZM/%U91E'5.E0Q&(@Y4*?M)?O317R?\  S]N;]D[
M]I#1_'6O?!_XT^&_$6D_#/33K7CV[UFP\1^ O^$6T%+6YO9O$6JP?$/1?"MS
M#X;M;:SNI+[Q"D,FBV'V>5+R^@D0H,#X,?\ !0S]C;]H3Q!XB\*?"'XX:)XK
M\1^%]%U'Q%JFC2^'O&_AJ_FT72$GEU2_T*'Q;X8T(^*HM.@MY;F]3PN=8FMK
M3R[N6-;::&63S)95FD/K"GEN/@\(H/%J6#Q$?JJJ).F\1>FO8*HFG#VO+S)I
MQNCV89WDU181T\WRR:Q[J+ N&/PLEC72?+56$Y:K^L.E).-14>?D:M*S/L^B
MOB[X(?\ !0W]CW]H_P =:7\-?@I\8%\=^-M8T+5?$MIHEGX#^)VEF#1=%N)[
M74KO5M0U_P %Z3I6@M#-!B.TUR^TZ]NTNM-FL[:XAU;2Y+SS?]J+]KCXQ>'?
MCWX"_8__ &3/ ?@+QQ^T+XR\'7'Q-\1>(OBQJ>MV?PI^%?P\L]6?3$U;Q7:^
M$Y(?$NK7NL7%G?V<-CI=[9WNDO<:!??8-<BUJ"S72GDV92Q?U.KA:N#KQHSQ
M-58Z$L'&CAJ:DZF(K/$*FX48*,ES6;E)>S@IU&H/&IG^41P/]H4,;0Q^&EB*
M>$I2RVI#,)8C&5I0C2PE".%E5]I7FZD'R72A"7M:CA24IK]&:*^!/V:OC=^V
M!-X[^,/PX_;,^"WP\\#:;\+] L/&=E^T?\*]8UK2_@'XFT75+6WG&@:?#\2+
MUO$TNKZ##9>)-3\2Z_'=_P!FZ':Z:MIXGTCPK]L\*:EXVZ'X)_\ !1K]B[]H
MKXCV_P )/@[\<=*\6?$*^L]7OM-\.S>%/B#X8?6(=!@>\U9-#U+Q?X2T#1M;
MO+33XKG5#I^DZC>W\VD6.I:O;VTNF:;?W=LJN48^G+$>SH2QE+"TJ=?$8G 7
MQN%HT:U/VU.I5KX=3IT8RIWDU6=.44I<\8M.SH9[E=6.%]KB8X"MC:U7#87!
MYG;+\;7Q%"K["K1H8;%.G5Q$HU6H*6'56$W*/LYS4DW]M45^<7_#W#_@G:)-
M#B;]I70HY/$%_<:99)-X)^*4+6EU;7\>FRGQ")? R'PG:?:9%>/4?%/]CZ?/
M9++J<%U)IL$UW'[%\?OV\_V1OV7]1\-Z/\;OC9X?\)ZQXLTMM=T/1].TKQ5X
MXU:XT,F);;6[S3/A_H'BF^TC1M3:1TT35=8M["PUY[34DT6XOWTK4UM'+)<X
MC5I4)93F<:U=5'0HRP&*56LJ-O:NE3=+GJ*E=>T<$^2ZYK7"/$.02HUL3'/,
MGEA\,Z2Q%>.9X)T<.Z_\!5JJKN%)UO\ EU[24?:?8YCZ[HKY,^*7[=/[)7P8
M^&WP^^+OQ$^-_A71_A_\5E,GPYUK3;?7O%EUXPMX[6.\O;W1?#_@_2->\2W.
MGZ.D]I;^(-1.CI8^'-1O],TG7;C3M4U33[.YS-?_ ."@/['GACX5?#OXW:S\
M<- @^%?Q4U]?"W@OQC:Z+XOU2QN_$7V>:ZGT?6K72O#M[J?@Z]T^""9]7B\9
M6.@?V*8WCU8V4@V5G'*LSG&G.&78^<*M:>'I3C@\1*-2O3Y_:4*<E3:G6I^S
MJ<].+<X\D^:*Y96UGG634YU:=3-LLA.A0IXJM">/PL9T<-6]G[+$58RJITZ%
M7VM+V=::5.?M*?+)\\;_ &-17YY:K_P5:_8!T/P=X3\>:K^T'96GAOQQ<Z[;
M^%IF^'GQ;DU;5%\-W<>GZO?CPQ#X!D\3V>B1:B\NF6FOZAH]IH>JZG8:OINE
M:A>WVBZO;V7VM\-OB3X$^,'@3PQ\3?AEXGTOQEX$\9:7%K'ASQ'H\KR6>H6<
MCR0R*T<T<-W8:A8W<-QIVKZ1J-O::MHNK6E[I&KV5EJ=C=VD,XG+<QP=.-7%
MX#&X6E*I.C&IB<+7H4Y5:;DITHSJTXQ=2#A)3@GS1<9)I-.UX3-\JQ]65# Y
MGE^-K0I0KSHX3&X;$U8T*JC*G6E3HU9SC2J1G!PJ-*$U.+C)J2OV]%?'.I_M
M_?LC:-\&M0_: U3XN167PFTKXA7?PIU'Q--X(^) N[3XA6/F-=^%Y?"H\'MX
MQ%]!'%)/)*- -D+9#="Z-O\ O:T_BG^V7\$/AY+X]\+6_C2RU3XE^#_V<O$_
M[347AB+1/%-YIK?#31-/OY;'Q!JWB:PT=_#&E6NIZG;6EA;Z9?Z]8Z]=-J>E
M?9-/<:OI;W=+*\R<U#ZAC%)SJ4_>PU:*4Z+IJM&3E!*+HNM2]MS->R]I#GY>
M>-X>=90H.I_:F7RBJ=&K[F,P\VZ>(55X>45&HW)8A4*WU=Q3]LZ514^9PE;Z
MSHK\(?#'[<'_  46^*OQD^$OP'^&7A3]CS1/'WC3]DOP3^TOXHE^*>A?&K3=
M#TUO%=ZAFT+39?"?CGQ!J5O+::?K'AY$L;_3[IUO(M8>XU:,?9;-/3_AA_P4
M?^)WAG2OVZ/"G[5?A7X2Z?\ %/\ 8N\,VWBFYU_X)ZKXAU#X6>./[?TB9O"_
MA2T3Q%?ZEKFF>(;KQ(VC:&_V_5+:>:]UZ;2M5T;PIJ7AG4A>>G5X7S.G%N+P
ME>HH4*KP]#$PJ8CV.)Q-/!T:RI63E3J8BK3IIQ<FN>,G%1NUXU'C/)JLESK'
M8:C*IB**Q6)P=2EA?K&$P=3,,1AW6O)0JTL)1K59*:C']U.*DY6B_P!CZ*_)
MW_@G1^W5\:?VD_&'Q%^%'[2_@KX?> /BEH/P[^%/QH\$Z=\/K'7]/T[Q#\*O
MBCX9TOQ!;:E=V_B'Q=XNNUU/1QXB\+1:G''=V@L;O7#I-W9Q:AIMT6\M^$/[
M5'_!33]IOQI^T59_ G1_V$](\&_ [X\>._@[$WQ;T_\ : L/$VH)X9U:YBTV
M^D/@[Q#K^E7;S:4+0WUTJZ2)-0^TF#2[>V\H5$^',?2KXVA7J8*@L!3PM6O7
MJXF*PSIXU1>'G2K1C*-6-3F2O'1-.+LTT:4^+<LK8;+\1AJ.88EYE5QM'#X:
MC@Y/%QJY>Y+%TZ]"<H2HRI<K;4GK&TE=--_MI17X!1_\%5/VD/'W[/?[+/B_
MX5_#_P"!^D_&/XX?M0S_ ++'B*/QTGC37/A.WB@_V'::=XN\+7?A/Q9:>(+'
MPK?7_B+39KEIKKQ==6%M#J-O9?VXT%M>WGN%A^V;^V;\%/VG_AG^SE^UUX:_
M95O_ /A=_@/Q[K_@3Q7^SU>_%62/PAJW@O1-:UI;OQ[HGC:YOO$5]X>NSHLE
MG(-'T73B8I[F^TO6-4N-%U;1X=:G"V:TE453ZI&M3CCI_57B8/$5(9=*:Q<Z
M4%>-2-*-.=1<LW*<(MQBY6B\J7&N2UG2=/Z]+#U99;#ZY]3JK"TJN;1I2P-*
MO4?O4IUI5J=-\T.6%25IRC%.2_8VBOE']B?XX>(?VBOV=/!OQ9\4^)_A1XQU
MOQ!J'BRUNM?^">B_%'P]\.KM-#\4ZMHMO'HVE?&32=#^(%O<6MO8QVVK-J^F
MPP3ZI%=S:6TVF/:RO]75X6)P]7"8BOA:RY:V'K5*%6-I*U2E-PFK3C&2M)/2
M48R[I/0^DP>*HX["8;&X>7-0Q="EB:,KQES4JU.-2#O"4X.\9)WA.47TDU9A
M7S9^T1^U_P#LZ_LI+X._X7[\0_\ A CX]/B+_A$_^*2\<^*?[6'A;^PO[=_Y
M$OPSXB^P?8?^$BT?_D)?8_M7VS_0_M'V>Z\CZ3K^:W_@X=^[^R!]?V@<#_PR
M7/XG^5=F29?1S3.,NP&(E5A1Q%7$<\J,H1J+V6 Q=:/*ZD*D=9TXIW@_=;M9
MZK]O^C]X>Y+XJ^+7"_ 7$.*S3!Y/GT,]^N8G)JV$P^94_P"R^'<VSG#_ %:M
MCL%F.%ASXK+J%.M[7!UN;#SJPA[.I*%6'Z4?\/?O^"=G_1PW_F)?CE_\[.C_
M (>_?\$[/^CAO_,2_'+_ .=G7\0-%?IG_$/\F_Z"<S_\'87_ .8C_27_ (I[
M>#'_ $4_B?\ ^'KA3_Z"C^W[_A[]_P $[/\ HX;_ ,Q+\<O_ )V='_#W[_@G
M9_T<-_YB7XY?_.SK^(&BC_B'^3?]!.9_^#L+_P#,0?\ %/;P8_Z*?Q/_ /#U
MPI_]!1_;]_P]^_X)V?\ 1PW_ )B7XY?_ #LZ/^'OW_!.S_HX;_S$OQR_^=G7
M\0-%'_$/\F_Z"<S_ /!V%_\ F(/^*>W@Q_T4_B?_ .'KA3_Z"C^W[_A[]_P3
ML_Z.&_\ ,2_'+_YV='_#W[_@G9_T<-_YB7XY?_.SK^(&BC_B'^3?]!.9_P#@
M["__ #$'_%/;P8_Z*?Q/_P##UPI_]!1_;]_P]^_X)V?]'#?^8E^.7_SLZ/\
MA[]_P3L_Z.&_\Q+\<O\ YV=?Q T4?\0_R;_H)S/_ ,'87_YB#_BGMX,?]%/X
MG_\ AZX4_P#H*/[?O^'OW_!.S_HX;_S$OQR_^=G1_P /?O\ @G9_T<-_YB7X
MY?\ SLZ_B!HH_P"(?Y-_T$YG_P"#L+_\Q!_Q3V\&/^BG\3__  ]<*?\ T%']
MOW_#W[_@G9_T<-_YB7XY?_.SH_X>_?\ !.S_ *.&_P#,2_'+_P"=G7\0-%'_
M !#_ ";_ *"<S_\ !V%_^8@_XI[>#'_13^)__AZX4_\ H*/[@HO^"O/_  3N
MFD2)/VAXU9VVJ9?A7\;8(P3_ 'YI_AM'#&OJTCJH[FONGX;?%'X=?&'PK9^.
M/A=XS\/>._"=]++;P:YX;U&#4;-;NW$;7%C<F)C+8ZA;++$;G3[V.WO;82Q&
M>",2)N_SE*^V_P!@G]KCQ;^R/\??"?C&RU2^?P#K6H6/ASXF>%FN[O\ L?6O
M"6H78AN[R33XF,3ZUX=^TS:UX<O%1)K;4HC;RROI6HZO8W_!F/ .&AA:M3+<
M3BI8FG&4XTL3*C4A6Y4W[.,J5&BZ<Y6M&3YX\UDTD^9?!>(_[/[AG!<+9EF/
MAKQ-Q5B.(\NPN(QN'RKB:MD^887.?J]*=7^SL/6RS*,DJ8'&8CEY,-7K?6Z$
MJSA2JTZ4*DL12_O-HHHK\O/\L0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSW^TK#IGCC_@H=X:^+OCSX?_ !:UF'XX>-M#\!ZGINB:+K/CSXG#P?\ "7P
M/A_:^)K.PDF\5Z'XPTR_N=):(7&MZ_\ :;^>PLOZFZ*UAQGBX4L-3C@Z$5AI
MS<7&OBW>DY8N=.F_:5JDISIRQ;_?U9U:LE2@VU4E6J5<*GA]@:M;%59X_$3^
MMTZ:FIX; IQJJ.7PJU(^RP]&%.G6A@(_[-0IT:,)5JB472AAZ5'\./\ @I-\
M-_$$G[1WP[^,&E?!C]M9=1TOX0ZMX(\,_M!?L.:YI?CSQ/;:J-9U/6]-\ _%
MGX!:EX6MIM6\!Z=J%_>ZM>W<7Q#\/:/XQT[7KSPQJ?\ :$R0IH7UW_P2^T'X
MW>'/V2?"]A\>OAYH'PR\6R^)_%FIZ-X9T3X:^"/@]=_\(=JU]%J.B:AXH^&?
MP\T;P_X9\'>*+N:YU!=0TB+1=/U2.VAL)=>B?6Y;^>7]#**\G$9W/$91A\IE
MA:*5"5)K%.=6I7Y:+K\D*;J2DZ4)?6)>TIQFZ#<8NG1I.]_<PO#=/"9]BL]A
MC<0Y8J%=2P484:6'Y\0L*IU*JHPA&O.'U6/LJLX?6+3FJU>LK6_F.^,/[ OQ
MA^)_[<OQ7_9L_P"$2\8Z;^R#\4?'7CS]JM/'L/ASQ+#\/=-^*WBWX+>(- L(
M9-?M(G\.1ZWHWQ)U>3R=(-Z-2.BJ[Q::MC="U?SSX/?L]?M9^/OV=_C)K7Q5
M^$'Q6T3XN?'SQ/\ LG?L*Z-::KX"\3Z=KG@OX$?#FW\'Q?$+XC:K;7&BQ76F
M^!M<TK0+9=>\<7\@\-2ZU%J+F^:8VY?^K2BO7CQKCE0HT)87#2]C2R^G&H^=
M3=3 UHUZE:36]3'5*.$^M=)QPM."M&4T_!EX=Y8\3B,1'&8N'UBOFE2=)*#I
MJEF-"6&I8:*>U++:5?'?4?M4YXVI-MRA!K\)/B_^PUX,_:)_X*E-8_&7X$^+
M?%7[-VB_LBZ#I^A:]%!\1O"OP_M?&WA[Q-;V6CZ%;>//"%_X?MI-9L-#O=0"
M>'6U^21[1FN9M/D^SQ319?[;W[$.@>'?AO\ !3]AG]C+X&Z]\/O!'[1GQLT/
M6_CU\4_#7@_QU\0])\%>"?!EQ!-;:E\0_&^N:C>SWBV>HZP^O^%_#WB'QO81
M%O#-[I>E2:.NM?:)?WOHKBI<59E2JY=)5*LJ&6X:C2H8*6)KO!RQ.&IU%A\;
M4P[DZ4J]*M*&(5X6E4I03;5STJW!645J.;0=*C'$YQBZ];$YA#"8>./A@\55
MI2Q674L7&*KPP]:A3J85VJ)QI5IN,>9(_GV\8?LS?M@_LK_MC?LH_M3:S\2_
M$O[8ME>:@?V??B?%\,OV7]&^'5YX#^$.JV=S;:7?:MX9^#]QK4&K>'/#TVKZ
MEKT6L7]AIHT.\\+>'='EO+^QO+'3;7PWP#_P2DTW]I[0?V_M9^)'PZ\<?"_X
MZ77[3_Q8U+X ?$+Q;8^-_"VFZOX=FU6\US1?*T+5FL_#?B;P)XIU&XEMKCQ5
M8Z1?WUM;W?VS2=5D6T6RG_I[HK>'&6:4J<71C1P^-C1P^'^N86G3PG-0PN,G
MBZ-*6%PM.CA>1>UJ4*D%34*M%J-2,FFY<M3@#)JU6<<1+$8K+YXC%8I9?C:M
M7'<F)QN I8#$5XXW&U<1C?:OV%/$TJDJTIT*Z<J4H)I+^7KQ)\+?B/\ M&_L
M]?\ !/'X(^//V+/B3\-8OA7^UYX3^'G[0G@7P]\&O'?@GP;??#VZNM)L/%GQ
M9@U7PQHFE66F^&/&>E7FLWOBWQII&L01V'B8:[JPUFVM[K2-2NOV/\ ?\$\O
MV1?V;+#X@>,/@)\"]-\-^/=4\!>)]"M-:DUWQUX\UZ&*]T74;=[+PX_CCQ+X
MJN-%N=4%PUE>-X>6PN]5MY%L;M[FWV0#[VHKEQ_$N-Q=..'H2K8'!^UQ5:M@
MZ&,Q+H8B6+Q+Q515X2G:K&-24HP513:A9.4FKOMRWA#+<#6GBL3'#YECO88*
MA0Q^*P&#6*PL,#@XX*E+#U8TW*C.=.$9U'2=.+J<THQBG9?F=_P2%\!>.?AI
M^P;\)_!_Q'\&>+/A_P"+=.UOXF2ZAX6\;>'=8\*^(["*_P#B/XGOK&6]T37;
M.PU.UCO;*X@O+1Y[6-;FUGAN(2\,B.WZ8T45Y&8XR>8X_&8^<(TYXS%5\5*G
M!MQA*O4E4<8MZM1<K)O5I:GO95@(95EF7Y93J2JT\OP6&P4*LTHSJ1PU&%&,
MY*/NJ4E!2:6B;L@K^:W_ (.'?N_L@<=_V@/QX^"7_P!;^?<U_2E7Q%^V7^P-
M\'OVXE^&W_"V/$GQ*\/?\*O/C+^P/^%=ZQX6TG[7_P )K_PBO]J_VQ_PDG@W
MQ;]H^S_\(EIO]GFR_L_RO/OA<?:_,@^S=60X[#Y;G>6XW%.2H4:F)YW"+G)>
MTP&,I1M%:OWYQOV5WTL?O_T<>.L@\-/&/A+C;BBIBJ619+#B#Z]4P6&EC,3'
M^TN&<XRG#>SPT)1E4OC,?AU.S7)3<ZCNHM/^#2BOZZ?^'!G['G_12?VE?_"Q
M^%W_ ,YRC_AP9^QY_P!%)_:5_P#"Q^%W_P YROU/_7C(?^?F*_\ ":7_ ,E_
M5GY7_P!0_P#B>KP"_P"AAQ1_XC6)_P#EW]6?E?\ D6HK^NG_ (<&?L>?]%)_
M:5_\+'X7?_.<H_X<&?L>?]%)_:5_\+'X7?\ SG*/]>,A_P"?F*_\)I?_ "7]
M6?E<_P")ZO +_H8<4?\ B-8G_P"7?U9^5_Y%J*_KI_X<&?L>?]%)_:5_\+'X
M7?\ SG*/^'!G['G_ $4G]I7_ ,+'X7?_ #G*/]>,A_Y^8K_PFE_\E_5GY7/^
M)ZO +_H8<4?^(UB?_EW]6?E?^1:BOZZ?^'!G['G_ $4G]I7_ ,+'X7?_ #G*
M/^'!G['G_12?VE?_  L?A=_\YRC_ %XR'_GYBO\ PFE_\E_5GY7/^)ZO +_H
M8<4?^(UB?_EW]6?E?^1:BOZZ?^'!G['G_12?VE?_  L?A=_\YRC_ (<&?L>?
M]%)_:5_\+'X7?_.<H_UXR'_GYBO_  FE_P#)?U9^5S_B>KP"_P"AAQ1_XC6)
M_P#EW]6?E?\ D6HK^NG_ (<&?L>?]%)_:5_\+'X7?_.<H_X<&?L>?]%)_:5_
M\+'X7?\ SG*/]>,A_P"?F*_\)I?_ "7]6?E<_P")ZO +_H8<4?\ B-8G_P"7
M?U9^5_Y%J*_KI_X<&?L>?]%)_:5_\+'X7?\ SG*/^'!G['G_ $4G]I7_ ,+'
MX7?_ #G*/]>,A_Y^8K_PFE_\E_5GY7/^)ZO +_H8<4?^(UB?_EW]6?E?^1:O
MI']DK]G?Q3^U)\>O ?P?\+VDLRZUJD%]XHU%1BW\/>"],G@G\3^(+V9T>"&*
MPTXNMK'<-'_:6J3Z?HUH9-2U*RMYOZ6XO^"!_P"QU'(CM\1/VDIE4@F*7QC\
M,Q'(/[KF'X012@'OLD1O1A7Z9?LZ?LI? G]E7PO)X7^"_@:Q\.K>[6UOQ#=,
MVJ^+_$;HQ>/^W/$MX'U&[MH)'DEL]+CDM]&T^6>YET[3K1[JY:7@S'CO+XX6
MHLNA7JXJ<91I.I25.E2DU95)N4G*7(W=0C%\[5G*"=SX+Q'^GKX>8?A;,J/A
MUA<^S;BK&X7$87+*V8Y;'+,LRJO6I2IT\RQ<ZU>=?$_5)RC6I8+#T']:G3]E
M5Q.%A+VI]%4445^2G^1(4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M *^/_P!,U2X_#4_P+_TY3&T445H0%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!^L%%%%?EY]0%%%% !1110 4444 %%%% !117.W7BC3+.XFM9K
M7Q$\L+E':U\'^+;ZW9A@YAN[+1+BTN$YXD@GDC)R Q(- '145RO_  F.D?\
M/GXJ_P#"%\;_ /S/4?\ "8Z1_P ^?BK_ ,(7QO\ _,]19]G_ %_PZ^\#JJ*Y
M7_A,=(_Y\_%7_A"^-_\ YGJ/^$QTC_GS\5?^$+XW_P#F>HL^S_K_ (=?>!U5
M%<K_ ,)CI'_/GXJ_\(7QO_\ ,]1_PF.D?\^?BK_PA?&__P SU%GV?]?\.OO
MZJBN5_X3'2/^?/Q5_P"$+XW_ /F>H_X3'2/^?/Q5_P"$+XW_ /F>HL^S_K_A
MU]X'545RO_"8Z1_SY^*O_"%\;_\ S/4?\)CI'_/GXJ_\(7QO_P#,]19]G_7_
M  Z^\#JJ*Y7_ (3'2/\ GS\5?^$+XW_^9ZC_ (3'2/\ GS\5?^$+XW_^9ZBS
M[/\ K_AU]X'545RO_"8Z1_SY^*O_  A?&_\ \SU'_"8Z1_SY^*O_  A?&_\
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M_AU]X'545RO_  F.D?\ /GXJ_P#"%\;_ /S/4?\ "8Z1_P ^?BK_ ,(7QO\
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M46?9_P!?\.OO ZJBN5_X3'2/^?/Q5_X0OC?_ .9ZC_A,=(_Y\_%7_A"^-_\
MYGJ+/L_Z_P"'7W@=517*_P#"8Z1_SY^*O_"%\;__ #/4?\)CI'_/GXJ_\(7Q
MO_\ ,]19]G_7_#K[P.JHKE?^$QTC_GS\5?\ A"^-_P#YGJ/^$QTC_GS\5?\
MA"^-_P#YGJ+/L_Z_X=?>!U5%<K_PF.D?\^?BK_PA?&__ ,SU'_"8Z1_SY^*O
M_"%\;_\ S/46?9_U_P .OO ZJBN5_P"$QTC_ )\_%7_A"^-__F>H_P"$QTC_
M )\_%7_A"^-__F>HL^S_ *_X=?>!U5%<K_PF.D?\^?BK_P (7QO_ /,]1_PF
M.D?\^?BK_P (7QO_ /,]19]G_7_#K[P.JHKE?^$QTC_GS\5?^$+XW_\ F>H_
MX3'2/^?/Q5_X0OC?_P"9ZBS[/^O^'7W@=517*_\ "8Z1_P ^?BK_ ,(7QO\
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M[^6;2/$>CZ[?V^N)J4]EI_AZ&ZTE[-+K4TO?<R_A_'9EE>:YMAI4'0RCZO\
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M*KX+#8"I3JYM@_9X6IEV+S"G5EBL+@Y3IYI.IE]+]9:*_GM_8#_X*N7>B?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9ODT\!G_ (C<&8G'YCPIFG"&>8[+:7BGE^$Q&7YQXF97XCXG$9=EU7P<QE3
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MWQ8@^%7[-O[=?Q2\5?&[7O@9J,ND_%?X=^"]:O\ X=7 ^+'@K5DM=0AT#7?
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ME&<)Q4H3BU*,HR5XRC)-J49)IIIM-.Z=@HHHI%!1110 4444 %%%% !1110
M4444 %%%% !1110 5RL'_([ZI[^%=!_35_$G\L_AGWKJJY6'_D=]2]_"NB?I
MJ^O_ .-'?\/O7Z7 ZJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_C'4M(N]:\)V%]%I>J:D9]&TRVBOI+*74HDMK5;:='M[?9\,_'+3OB#\4O\
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M_P#12>)7_AXX7_\ H.]?Z6O^D/\ \/[O^"3?_1UP_P##&?M)?_.=H_X?W?\
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MA?\ ^@[U_I:_Z0__  _N_P""3?\ T=</_#&?M)?_ #G:/^']W_!)O_HZX?\
MAC/VDO\ YSM?YO%%'_$'N&?^@[/?_"G+_P#YV!_Q(/X/_P#12>)7_AXX7_\
MH.]?Z6O^D/\ \/[O^"3?_1UP_P##&?M)?_.=H_X?W?\ !)O_ *.N'_AC/VDO
M_G.U_F\44?\ $'N&?^@[/?\ PIR__P"=@?\ $@_@_P#]%)XE?^'CA?\ ^@[U
M_I:_Z0__  _N_P""3?\ T=</_#&?M)?_ #G:/^']W_!)O_HZX?\ AC/VDO\
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M_P##&?M)?_.=H_X?W?\ !)O_ *.N'_AC/VDO_G.U_F\44?\ $'N&?^@[/?\
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M/VDO_G.U_F\44?\ $'N&?^@[/?\ PIR__P"=@?\ $@_@_P#]%)XE?^'CA?\
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M->.7^$_Q%_;)_9I^+7[*>I^"-7\'Z7^RO^TU:?M&^*/A?-I*^#+CX,:IX/\
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MI?Q0L-2^*^O?&W_!,SX>6.@>,?VDO"NHZ['XML_V./BOXH_8Z_9Y:_C6;5O
MO[/]I:^&OBMINB27DDTTUWJ'F^,M'^'-[K"+ NH^'/@WX.M)$^W:=JC3?KW7
M'CL/#"8B="G4E548P?/*')S1J156FU%MM7I3IN2>L:G.DW%*4NS XF>+PT*]
M2FJ4IN4734N?DE2DZ51.224K5H5.64=)4^1NTFTBBBBN,[ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !&?P>_Z.OX:_P#B=<,?_/3S_/LS\?**_8/_ (<'_P#!63_HU,?^'T_9M_\
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M_/3S_/LS\?**_8/_ (<'_P#!63_HU,?^'T_9M_\ GPT?\.#_ /@K)_T:F/\
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M_P##OE__ ,T!_P 1G\'O^CK^&O\ XG7#'_ST\_S[,_'T L0J@EB0  "223@
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M_$F?P/-%K$3GQCJ8\+R:'_PA%LLEBR>)$U7[?<,MSI?E1 TM._8OT6Q_9?\
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M^$UC\)O&VL^//%6K^--)TZ74_"6J)XJU+0?;OV[?AA\3].^-_P"Q=^VK\,/
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MZ<)U)NUHPC*<FHQ;7JE%>)6?[3'[.&HP:C=:?^T#\$;^VTBV\-WFK7%G\5O
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M+P^ZZ[)I$KIJ":,RZFUN+(B<GU3%_P#0-B/_  34_P#D0_L/.UOD^:*UK_\
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MVESLE]>Z7#+J%M!+:1O,*MQ^U!^S1::7I>MW?[1'P,M=%UO2H==T75[CXM^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW&M:)"D\.M:5=7-II\.EBXNM!M[*&YTW4I)?Z"/%'_!0/]NO]I'XT?&CX?\
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M2:U^WYINK/:6&J:A=VEJ^L:=8:F8(HVU&QM;OSK>/]DOVE_V,?VE?C]\%/V
MOBMXE_9*\6+^T;JG[$G[1G[.W[2'PZ^%]MX'MM.\):O\6O OPY\.Z9X?UKPW
M\2/BAI/PXTF+Q%KFDR0>+_',WBC4];TKP[I4UYI^I:W)X?\ #VBW7Z19=O/Y
M]S^+3SK_ ()E?\%K_CS^TCX0\4>"/C]^UY^RW\)?%'PR^/\ \#OAOX6^+OQD
M^"^A6E_^TKX7^(*_$/PKJ7@F/PY\*?VI[_P5X/\ CGKWQ&^%WB]?#=QH.H7_
M (;_ .$-'AK7[+PAJMOXC@-G]<_M-?\ !4;]MG_A OVAOC)^S/\ LO\ BSQC
M^RQIWQW_ &8_A3^S5^TGX?\ $'P0T*V\<P1_M > _AC\?M<E\.?%3X@VOB/Q
M'X,^)WBG7M2^$?PB\7Z-X#A\-M9P_P#"Q8?$IT+4+?6]+_/W]B'_ ()4?MG_
M +'7B'PM\'_B3\/M7^*OB?Q1^W3^PG\=_$'Q7^'5AIM[\%M)^&'PQ\;>/_C]
M\0M0USXC>.?&<?CX:O\ "[QCXJ^)?P_M_#,7A:.+Q5<ZYX,\6:993WOC/6WT
M/ZA_;V_9.\3_ +4/A/QK%X+_ ."/_P"V3H_Q0U_XE_!37AXD?]L_X0^%OAV_
MACX9?%OX<:YXEMM&^'GAO]N./P?X>76/AGX-U;1O"MII/@72?[*UV_TK58VT
M#5[<ZU8JR[+O_P '\@/M/]NG]OS_ (*"?"C]D_XF^._AA_P3Y^)/PT^)^G0>
M*EL;[QM\2?V>/']EX9^'GASX*_&#XD?$#XR0W'@'XJ>(_#&E7/PP/@/PZ-,T
MCQY,MGXQUSQ-I>@:'HWBG49AH]QX#X _X*6_M\^/?VB?!GA7P3\'_A;!H,O[
M'/A36KSX:?M+?%*_^#.I^+?C+X<L_AMX@^./Q8\/^*OA?\"_C;H6L^#M.UCX
ML^ /@MX&2+Q-X:T#Q=X[M/B2GA33_$'_  C%_-HG:^+/V0-<^+G[%/[9_P #
M?A=^RQ^WA^PSJ'B'X5>./$NB:?J7[6/@SXAZQ^T7XW?X5?$7PQX9^%4NO6'[
M07[17BC1?!]YJ>HZ4_BKPW9:Q\.--\527.EV=]J^IZ>NL64GDGQ!_P"">7BG
M]GW5/V9/C/X0^"'QN^.^B^!_@W\-M,M?@=X*U+2?'/C_ $#XX_#+X%ZUX,_9
M[^']UJWQ0\>^&-,\'?L^?#/XE^/OCO\ 'WX@^+=;\8>(=<U;X]^/?A_>W%I<
M^'/ ]@FG%EM9?AZ_\$#]YOV0OCK=_M0?LL?L\?M&W_A>'P3>?'/X-_#SXK7/
MA"WU=]?M_#4OCKPQIOB)]%@UN33])?5X=..H?9HM1?3-/:\2-9S:6^_RU^BZ
M^8OV*/@]XA_9[_8Z_96^!'BXV)\6_!S]G?X-_#/Q5_9EP+S31XF\$_#[P_X>
MU\:?> *+RR75M/O%M;L*GVF 1S[$\S:/IVL7N[=V 4444@"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OQ3_X+">"_ 'C_P .?#WPW\3/AQHWC;P8]KK>
MO^(M231++Q+\3['2O!MU8>*H_ ?P*T*:RO\ 5KOXG?&?7],\/_#FYU'PE:S^
M+?#7PTU/XB^)--C&GZ7K$T/[65^/_P#P56FM(=/^'<MKKE_X!\76>F^,-7\/
M?&_>UMH7[.&@:-8&\^*?QPN-3^>'2O&NG_##_A*/A=\*+F6WN7NO'_Q9TG2K
M6.*\U""ZM_;X<E*&=X"4'*,U4FXS@Y*4)*C4:J)P]Y*F[5&XQJNT7^XK_P &
M?Z-X2U:U#Q$X7K8>I6HUZ6,K3HU\/4KTJN&JQP6*=/%QJ89NO!82?+B9NC2Q
M<U"E+ER_,_\ D7XK\)[CX)?!O7K_ $)-6_9O_9G\(ZS#KPT7P;K'A;P7\.M6
M\!Z3XK_:'\/Z9JWB'XH?'(Q:7)HEI\%?V#/"5YH_PT\+6GB^:U\"_%_XX>&/
M']SXFN9/'1\1VL->U^&GP7M]3_X3_3/V*?V>6\7ZAH7A+QU/\(_%6@>$+?X2
M:%H'@G4;+X:?"O\ 9XMO&&H:2EC=_%GQC<Z];?M,_M:^(Y;C_A/_  =X6^'W
MB#P;X[M].\':AKKQ^LVS^$KB^TNR\&_#G7?"1U+Q'\/O#NH_"GQ98SV>G?M/
M^(?'OAS2_$'[%?[+EW:33R_VK\/YM$U*U_:J_;;L$>W30_'7Q@\0ZAK,U\UT
ML$>/'J_P<DTZWU#4=$^+?C?X+3^#8/%VD?!N'3[VY^+2?"N;QCI'A#XQ_M-:
MUHZ7,=]'\<OVZOCEJWA?X1>!YS>&Z\4_L]>/O'4EBNFV+O&O[#&O7=E?%.+4
M(^S52O=PJ/VDJ$>3%?%B*B^M4%"KR\BD\)BJ2YL ?WI'-,SDH0=3.Y4Y0H4G
MAJ>-S)2J4,2WB*F74E0SRW/FF*BL[R^.&QZ@L/&I+),\P257A=^9)^SI^SQ%
MI.M?#NW^"/PUE\$W\GC7X?\ B_XP7_PO\(Q_&MK;3%M/B=\3?CM\%O!,N@C5
M=4E^+>K:[:?LZ_LA>$O"EM<Z3_8W@#Q!XV^$?]HZGJ.N%+,OPA^">LKX?U34
M/V2O@'X86UUCPGXM\%^%]"\)>#M4ET_QG\:='?PKX8\%?'B]31FO=.^"G["_
M@Z^D\9?'SQ1XT-KX?\??&?1;;PS\8KBRUZ[DMF]:Q*U_>V-SK<6J?'*T\0^,
M?#_AWX[Q2!_A#^SA\9?"?AG2_$>H:3/K@"V&E?!;_@G3\!-6\,_\*[NI[&ZL
M=!^/_COQO8>1>W[27(I6]]\/+BTTN]\+:3X_T+0M33X6/KNI^);6YMO$7[5'
MPN^)C1)^S1^SW.DT\CZQXV_;B^)<VE?'[]LG1HA9WEQX-BU76-0O1:1/9EK$
M8AV?M<3)NTG)5:MIRJ-1J5(VJ17+BXKV%-QC!.K%^SI8*O>K*EF^;22D\?G%
M:4^6I.M''9CR8BIBJJH8G&4_9XRC#V6=THK+L$Z>&PU-XVE/ZG@.'<S4L?5\
MO?X0? ZQO3XD_P"&2/@AKGB&W\*W&SP;'X1\)VW@"^^'OP&U^XCT?PFVO6^A
MFPA_:;_;>\6ZG>>)]1LQ(?B/\*_@AH6B3>&+$^#+]+R2=/@!\#@_B#PE!\"O
M@%'!XFUOQ3X,\?\ Q7O_ (=> 0WA[7OBYHEWX_\ BO\ 'C]GGP]-HXT[Q)\*
M_@-HL%[^SE^R7H7A+[7X%^)OQ0U?P[XF\)W&H>/%TRW?T>YU#X?V]O+-JJ?$
M"Q^'Z>'_ !_KM]\--'@N&\9#4/ VM1:3^U_^V_9:>D_V@Z]H"2Z!^R_^QOKH
MN5BU30M"UO2M)LK-[:2XDU42SDUB31SX:EU7XE0^++'PI\-],>%G^&7[*/Q'
MOO!MYXO_ &8/V;O$]QO%MH/P:_8H^$=K<?M&_'>WNHKVW\(_'GP7ILNK/JMU
M"=P\37LVJN)5E*5Y5JMER24(RDY5N3DP]_8UN=.E[5I8GVU=1J)2S?-5"4EC
M,WBXTJTU4GCL?[.E]7J1H4:M55LP>'=#*X/ZAF"Q"E@EC)1_MC^T<S]EBSQ=
M_A5\ [C1],U2X_8O^$EKX;T,^#_BOX7^'MCX8\/S?%G7=8BFU/X7?"[]F3XI
MW::*?%^C^'_"5K9:Q^TQ^UUX^UFW@U6PD\5> / WQ0?3] 'AP36KWX'_  .L
M[]9]2_9K^ OB+6M"T?QA\/;*;PGX&\$1>!/&'@GX*ZC>^._&?Q=U2;1M'DTG
M2_C;^WGXJL;WX3?LV>"HY5U7P!\+/$OAGQ?\$K6]LX]&N)/0!K?PQ;0UUNRU
M[XHZ?HK>%_#GBCQC^T-<P7<?C/XT_L[>(?%>J>%=5BT"\:4OJ?[1G_!0;]H#
M3;WP_K>FPQ0:CXA_9X^#_AR]CN;'3[8P2ZM_/X8L;B\M[_1=?^'EE:7OQ7L?
M%GPNT.WFA_M#XW?"W3]0U#]IGX^>$K02,;CX3?\ !/SX.6.H?";]C'78I4L;
M3XJ> ?#VCZ?9/>PF[<]OB+M<V+23E%)U<1S+E@I.,N;$N?/3OSUG.];V+2Q?
M^R)2*>:9K&3BL1GE-1J8B"C4QV<>TI>PPT:SI576S.6)^L8:[Q&/==3Q\L!.
M$<_4,B]G5AYI;_!7X/KJVLI8?LU_LP0>(O%^NV\GC/7_ !!X-^'"?"WP+XP_
M: T&^;5=9^"KWVE+X9\3_ _]@_P=X=N_#=I=:)<7/@_XM?'+XE>&H?%]T?&N
MF:!:OSY^#?[.=MX5AB7]D'P;?_#OPWI>D>.M,\,MX(TR+]I[QSIWP7\23^"_
MA_\  #Q)81^'_P#A8^B^.?VH?$^E3?M _'CQ+]B3QC\+O@AXKT[1;V&U^'%G
MIMY7MT3>"Y=2BT^7X9>(O%JR:K\.],^%WP(?3[F72?V?K#X@Z/K6K?L:_LP^
M.K'[0C:+8>*Y]'\7_M2_MK:3=37;Z5K'P[^'^J:S<W:K';'&EUGP9%H5YKEY
M\4OB"NK6?A/Q#XI\;_MPV,DIU?Q!\*= \9WWA#]JWXU^"M>'[J[^-OQ[^(UA
MKG[)'[,[0V,=UXC^"7AWPW9:1_9L/ER%QQ&(O%<^*5Y44E&KB$[N/-'EY*TY
M<R?[R@Z2G5C2O_9L<91YHQ*>:YJY4TL5GBYJF7I*&.S:,OWE*56DJ;P^85ZZ
MJTY+ZUESPD:^+I81S_U2H\09:Z]*GPU[\!?@M)J]E::O\ _V<Y]?TRY\9_"S
M0_%?@OP!\.Y_ACJEM<64/Q&^*'[3WCH:1H\GAC3(O$QTFR_9T_9$\#:I<)X<
MU75_$>M>+_A:VH^)=.:.)MA\+?A#;ZM=^*M&_8^_9F'C+Q'<>"/'>M^#O'/A
MSP):_!KP9KGQ!LHOAS\/_@[X,\2:KH\.@:[X/_93\,V5O\</VL/%EG.[:_\
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M^S;%VC&J[$:A=:=>>(&O?CU;ZUXZT70_VA+:0M\&/@5\7_!.@:+KOC&ZF\0
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M\J4O[(O[>!#Z-;_L@?&.#1WT?7O%2^)IOB)^Q9>^.(?BWKFIG0O#_AM;J?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KB_!WP\\(> )?&,_A/26TR?Q_XTU7XA^+YY=2U;5)]:\7ZU9Z9IU_J
MTLVKW]_+;*=-T72=-L]-L6M=)TS3M.L[#3+"SM((X5[2O@74_B-\0O$OQR_:
M+M+G]H+3/@/X'_9R\0? ?2M-TS6?#GP]OO OBW3/'?AO0?&.OZO\3-1\9Z?9
M^*O+\4WVNWGPW\)2^!?B/X @TO5-%2[=->U076GW32O?^NJ73S ]*TG]A_\
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MF6>C:%++>OH=EIS:C?FY^D**5WW8!1110 4444 %%%% !1110 4444 %%%%
M!7.W7C#PE8W$UI>^*/#MG=V[F.>UNM;TRWN(9!@E)H)KI)8W ()5U5AD<5T5
M% '*_P#"=>"/^AQ\*_\ A0Z1_P#)E'_"=>"/^AQ\*_\ A0Z1_P#)E=511IY_
M?_P/7^EJ'*_\)UX(_P"AQ\*_^%#I'_R91_PG7@C_ *''PK_X4.D?_)E=511I
MY_?_ ,#U_I:ARO\ PG7@C_H<?"O_ (4.D?\ R91_PG7@C_H<?"O_ (4.D?\
MR97544:>?W_\#U_I:ARO_"=>"/\ H<?"O_A0Z1_\F4?\)UX(_P"AQ\*_^%#I
M'_R97544:>?W_P# ]?Z6H<K_ ,)UX(_Z''PK_P"%#I'_ ,F4?\)UX(_Z''PK
M_P"%#I'_ ,F5U5%&GG]__ ]?Z6H<K_PG7@C_ *''PK_X4.D?_)E'_"=>"/\
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MIY_?_P #U_I:ARO_  G7@C_H<?"O_A0Z1_\ )E'_  G7@C_H<?"O_A0Z1_\
M)E=511IY_?\ \#U_I:ARO_"=>"/^AQ\*_P#A0Z1_\F4?\)UX(_Z''PK_ .%#
MI'_R97544:>?W_\  ]?Z6H<K_P )UX(_Z''PK_X4.D?_ "91_P )UX(_Z''P
MK_X4.D?_ "97544:>?W_ / ]?Z6H<K_PG7@C_H<?"O\ X4.D?_)E'_"=>"/^
MAQ\*_P#A0Z1_\F5U5%&GG]__  /7^EJ'*_\ "=>"/^AQ\*_^%#I'_P F4?\
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MG7@C_H<?"O\ X4.D?_)E=511IY_?_P #U_I:ARO_  G7@C_H<?"O_A0Z1_\
M)E'_  G7@C_H<?"O_A0Z1_\ )E=511IY_?\ \#U_I:ARO_"=>"/^AQ\*_P#A
M0Z1_\F4?\)UX(_Z''PK_ .%#I'_R97544:>?W_\  ]?Z6H<K_P )UX(_Z''P
MK_X4.D?_ "91_P )UX(_Z''PK_X4.D?_ "97544:>?W_ / ]?Z6H<K_PG7@C
M_H<?"O\ X4.D?_)E'_"=>"/^AQ\*_P#A0Z1_\F5U5%&GG]__  /7^EJ'*_\
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M%%N=%AT+X?>#=6\7>([/7+J::Y/B[Q!X?N=,MH;KPZUXGS)\2?V)?VI(K/\
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MRT_4;[PWK:6LLC:;K5I8:MIEY<:=="*ZBMM0LYGB$=Q$S1RZ7MIWMIT7YV_
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MMZ?>0>IP^,OBKXTN/A_XP^(?Q+\3^";>U_:S^&WA&X\*Z9:>%O#NA^%K.]^
MR:_?:%JMY?\ A^ZU#4CJ_CWQ6^@F+7=0GB$CZ/I=E#'K$5O>OZ+??MK>#]&-
MS?3Z%K.OV7B2[\*Z[H'AZYC\.Z1>:9X/G^$7PI^(VI'3%C^TS^)]>M'^(FDC
M3?#TA.I:EK<UY9:;=V^G6%M.W:ZM^T5XNU:_^'=QX/\ AMI\W@+Q[\5O&W@:
M'Q)KGB*PBU75]'\">$?B-JNI>*])T%+.:/3VCU[P!/=:/%K%Q=3ZMH]I$LMK
MI5UJUM)I[K3Q;Y*KR/"X=5,+[.G7J5<'!*E1PL>:%.5;#QE[:%&C*"5I7C1:
MI1Y%7G4=:6)?+4>4X>BI8?DA5J5,+&U.EAHWC3=2C&2JQHTW%*TGRTVH+D5:
M4_ABR^+?CZXT[X+WD&L6W_"5_#W2-'\1_#;X*Z7X:\.Z7I?B$W'['GQA\3CQ
MY;Z/I6CVNN-"WCR:Z\$06FC7EIX<MAIQT9=,.LWBSG]*?V8_$7C'Q5\-3K?C
M#QKX;\?M>Z[=3>'?$7AWQ!H7B5W\/3:7H]RECX@U/PUX:\(Z+_;UCK,^M0O9
MVF@6<EAI/]DVE^USJ,-W<S>%Z=^VCH>E>"--\5:EX&\1:_IUA\.K6\D\6++X
M7TS4->\?Z=\%= ^.6K>#X]#MV2#2I)_!NN"ZBU:&XCT$:_#?Z/%#!;Q07UQ]
M4_"7X@#XA:%KMS/X6E\&:QX7\:>)O!7B+P^]]8:I%::WH%VGVB>TU/38X;74
M+6_M;NSOTN!!!*LES+;SQB6!V;ASN=>6%7M,HHX.*E3C&O&KAZDTHU*LYJG"
M%*G5C&=2KS5)2BI*<^6LVYTXPY,VG5GAUSY;2PT8N"C656C.27/4G)0C&$*B
MC.=1.<I1YE.355WE",/5$^\/Q_D:^ _%/[5GQW\7_&GXJ_"?]E?X >$?BKIO
MP NM"T3XO>.?B3\7)?A7H\WCO7M T[Q=#\-OAW::?X&\<WFOZ_8^&-7TN]UC
M7-;7P]X;TO4-1MM+>ZG<33Q??B?>'X_R-?CO$WC_ ,#?MA_MCV7[+/Q@^"G@
MB\\177P^\=_M _#/]I[P_P"*;*/PKXFN/ASI=C9?'KX,ZCX:\2Z8/%O@KQ#X
M4TRPL?&%CK0L-'@\8>$[NS'B'176\MU^7I1C)SNDVHW7-S*"?-%-R<+-:-I:
MI<S2>Z1\O4;7+9M)RL[<O-\,FDN;3=*_6WE<[SPK_P %)M9\7_LX_#?XHZ1\
M =8?XW?&[]H#Q]^SO\)?V>[OQA9:=J-[XO\  WBSQEI&JWGC7QC<:0^G>%-)
M\,^&?!&M^*_'%Y#IVLQZ0EE-IFDG7+B6REN>S^'G[8'[0,7[5O@_]D[X^_LY
M^%?A]K_BKX.^/_B_8?$?P'\6+GQ[X#UW3_!VJ^&M+32/#T6H^!_"FOQZG;7&
MNRV_B6WU^QTI]/>+2[S23K5AJXELOC#]D#]FCQW\<OV%O@?XZ\ ?%5="^-'P
MO_:N^//[17P,^,WC#PG/J/ASXD6WB+XJ_%32I]7\6>%;#4M*O9? ?QK\#^*-
M3GG&D:E#=65IJ^G:OI$MVMI;"X^OOA]^S%^UGX@_:[\#?M6?M%_%#X+7,/@S
MX+?$KX1:5\)_A!X;\:VF@:&WC;6?"NK+XDMO$?C#4KK4]=U/4WT%TUUKRPTF
MWLK:ST6RTJTE*:A>W.TXT(NI&T5R^U5FZG,IIR5-1ULX[?%=WYN9_"C*,JK5
M-^\[JD[I0Y7%J/M'+=\V[]UVLUR]6?/OA3_@IY^TQXB^'7P ^+G_  Q=X>E\
M#_M1>-)O@]\&[?2OC[#<^*)/BI/=>(K70=1\<V-[\.K#3?#'PLUAO"FOW$WB
M"SU+7/$^EZ;IPO[CPK+)?6UC6[\:_P!K)/&?[(_[='AS]JW]F3P7XA\4?LQ>
M(O GA3XJ_!BR^(.K:U\+_B3I'C"?P!XP\">(?#_CF3PIHFOVUC/;Z[:ZC)9W
MOAB#4=/U70?)E#0W4<J>Q>"/V%O&GA7X!?L'_""Y\=^&+O5?V2/C9X8^*7BC
M6(--U5-/\7:;H-E\2+6;2M @D;[38WT[>-[-HIM1+6Z+8W(<9DBQ4^./[!OC
M7XK>'/\ @H1HNF>/?"VDS?MDZE\$;[PG/?Z;JT\7@Q/A9X7\%Z#J<?B);=@]
M^VJS^&+FXL3INT0174"W&723+4L/SKW8Q2J)\T75ORQJP2L^9M7I.4FTN:ZN
MFG9 E6Y7=RD^6UFH6=Z5WI97_>62NVK-IW6IZ+\0?VG_ (Q7/QI\1?LY_LJ?
M OPG\3/%'PI\">"?&/Q7\3_$CXDW7PN^'7@J+QW'J4W@?P#I-UHW@OQUKNO^
M--<T;1+S6##%HMAH>A:.^GW5_J<L]VE@/B+]EG]J[4/@]\%?VQ_BUXF^#OBB
M/XJ_$/\ X*4^//AAX0^ $6N:$_B#4OC5XXTSX9>%]$\!3>,(W;PY!I:ZM;7E
M]?>,\2:=!X6L[C7DLI6"6#_:7C[]G+]HSP1^T'XT_:(_93\=_"6WU'XR>"?
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MX4F\5S>(O&NJ7NIR:Z+T68CT=K6VTK1M$BNH8;S6-2O9+Q/+OCIXHL_V+/\
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M0TP16MU-<0)&1Y?\;/@-HOQ _;(\7_$+]GGQC^R1X]^.4?PC\'^$/CQ^S_\
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M2>!7_0!Q+_XD6(_^4G]XO_$4-^P'_P!$A_;!_P#" ^"W_P!$#1_Q%#?L!_\
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M2']L'_P@/@M_]$#1_P 10W[ ?_1(?VP?_" ^"W_T0-?P=44?\0IX1_Y\X_\
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M4G]XO_$4-^P'_P!$A_;!_P#" ^"W_P!$#1_Q%#?L!_\ 1(?VP?\ P@/@M_\
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M_9_\?_LV?$*3X>_$ ^']0DO=#T7QGX,\8^#=;M_$W@/XE_#CQ9;'4?!'Q,\
M>(;=(3JW@WQIHQBU?1)K^RTK7+2*5],\1Z'H/B&QU31K'Q&NVCX8\'5Z5.M0
MCC*M&I",Z=2&.G*,X-74DU&S37^3U/;P/T,OH_9G@\-F&7T<_P 9@L91IXC"
MXK#\2UZE&O1JQ4H5*<XTK.,D_5.ZDDTTO[X_"G_!S/\ \$\_$>N6.DZIX0_:
M=\#V5Y.D,WB3Q7\.O $^B::KYS<7T?@[XM^+=>,$>!O^PZ'>S<C9"W./VD\+
M^,O@9^V/\%&USX=^.]$^)GPE\?6@M/\ A(/!FLGE[2XM;RXTRZ9434= UW3K
MF*"+5M#U>SL=;TF??9ZG86ER'B7_ ">*_<#_ ((,?MI>+_V:/VV? 'PIDU6Z
MG^$_[3/B+0OA1XM\,2.\EF/%NOWATSX<>*+")0!;ZSI/BG4;739+F1VMF\-Z
M[XCM7MGO;FPO+'P>)?#' X/+JV9</U\70QN7TY8M4*U55H5XX?\ >S5.?+&I
M2Q$8Q<Z4N:4)2BH.,7)5(?EOC)]"SA+*.#LVXG\-,;G6"SOAS XC-YY3F6-C
MF.$S;"8"G+$XJEAZTJ-+%8/,84*=2KA)^UK8>O5IQPLZ%)UEBJ/]X/\ PS%\
M,3XBO_$TD?B*:\NO%5AXPTZSF\074FE>&M5MOB+IWQ9U2/PU8M&5TS3_ !3\
M0M*LO$OB:T+SC4+F%;:%[2P"VJ]/K_P/\#>)?'"_$+5(-4;Q&LGA^3S(-4F@
ML]WAKP[\2?"^EG[&J&/"Z5\5O%RSC=^_N)=/G;#6$0;V"BOPQYECI.[Q59OV
M<J5W.5_9S5/G@]=I^R@Y_P THJ4KRU/\S7C,4W=XBJWR.G\<O@ER<T=]I>S@
MY?S.*E*[NW\A> ?V5]/\,ZAJ&IW.M:IX?O='\5:7_P *YO/!/B"]35=(^'GA
MWX9_#[X6VGAOQ'J>J:4L6N-XITKX>:3K'BFRETR2VM-32Q&E:A)=:5#K$W>1
M?LW^!K8VD=EJOC.QL=)^(>H_$KPYI5MXD;^S?"VN:]:>*+'Q3IN@036<SVOA
MKQ5;^-/$ZZSH5Q+=VL9U1_['.E+;6:V_T#16M3-\QJMN6)GK&,.5.T5"$>2,
M;:MKE<TVVVU5K7;]M4YKGF&,F[RKS^&,+)JW+&/(E;6_NN2=[M^TJMMNK4YO
ME8_L=?!IM/FT<V_B@Z)+X,3P:NB_\)->?V9 1X"TGX7S^++>V,1\KQI>?#_0
M],\+W>MARLEA!)*EG%>W=Y=3^\^%?!&B>#3XF.B)<QGQ;XMUCQKK'VFZ>YWZ
M[KB6B7[V^]1]GM66R@\JV7*Q$.0QW&NPHJ*N8XW$Q4,3BJU6"5E&I.4EHX]-
M>L4_57,ZN+Q5>*A6KU:D4K*,YN22]UZ)OO&+]5<C5""#Q_D?2OSN_:)D_9<^
M,OB7Q6GC?]C?4/VNY?@'')9^-/&FC?#CX1^*K'P!J<.G#Q1J7@>PU3XE>-O!
MNN>,]?TW27L]7U_P7\-++QM-IUQJ6FZ1JMC%XEOX='?]%:_,C2I?%/P#L_VB
M?A[XB@_:4\,:CXG^/?Q,^/?PY^('[./P4?XT3?$#PM\3=0N?%<7@Z"]O/A5\
M6_!GA+Q1HVLO=^#M8T[XE:3X-3;::!K.A^)9/#E]>:E:<\:EG>,FGT:NG\K:
M_<<S2:LTFGNFKK[F?6?P+^//PD^+MQXJ\*?"""8^&_AEH_PO:QU&RTFPT?PA
MJ/AWXC^ -+\=>##X.L[:Y6^MM/LO#6H65G>:=JNA^'KC2;Z*33H[%DMS(.S@
M^+?ANX^-6J_ A++6QXNTCX7:!\6[G47MK >''\-^(_%GB7P=8V4%X-2;4VUN
M+4_"VH3W=M)H\5@EA-9RPZE/<23VMO\ AU\/_A?^T;<_&23QI^V?\(O'_C_P
M)<>/_ FH?'G0+?X8I\1]%\8:];_LX'PYX!\2S^ ?A-H.N^'?B=X<\%^)HSIV
MMP^!M"\3:7X;\27>GZAJ=G!<Z;<36N?HGP6UW3KKQ'_PO7]G;XQ>.[.__8I\
M1>%/V>()/A1XZ^*-]\/M5OOC?\?]9^"W@&>_T;0=7;X<_%7PQ\.=;\&0:)XB
MUS4/#][\(=->/1M<\5>"IK^"RF+KOO\ C?\ K]1G]".NZQ;>'M#UG7[U)Y;/
M0]*U'6+N*U6-[F2VTVTFO9TMTEE@B>=XH'6%99H8VD*AY8U)<<C\)/B7H7QE
M^&/@/XK^%[35[#P[\0_"VC^+=%LM>@L[76K73=;LX[VU@U2WT^_U2Q@OHXI5
M6XCM-1O8$D#".YE4!S^#7Q%^&7QYU#5/#MQXE^">M2?&CP5\9O@7!XO\8:!\
M"?B_\2OB5XM\&6/PL^'WA/QO\0C^UC?^)M=\"W?PXU_5]6US3=5^!/PST&&^
M\/2F[UK6[(0:9\1-?N/L&3X<>.5_8/\ V(/"WB/X=^,M8\.>"O$?[.][^T=\
M*?\ A#]:UCQ+J'PRT/2[V#Q!HOB#X81Z?<^(_%UCH/B^7PCX@\3^!+?P_K.J
MZEI.@W\*^']2:%[1SF7??3\O\T!^BWPT^+?AOXIW_P 4M/\ #UEK=G-\(_BC
MJ_PD\2-K-M86\5[XDT7PYX5\3W5[H;6.I:B]SHDEAXOTV&WN;]--OWO(+Z.3
M38H8K>XN?4:_FWL?@;XIC^*'Q-UB\^ _B33?V6=7^*_QZOOAOX#\=?L??&?X
MS:!IFJZ_X#^!\/AGQ+IO[/\ X,\5_##QEX.M]>\*Z7KOAKX;^,+VVDTGX;7-
MAJ7@V;1_ .MHSZ+]&>"/V=?CI:7O@;X&W=CX_P!8\ ?%O2?@[^T%X]\=_$#P
MC9:%:Z7\0O@KX6U72;SPA\5O#VCZ]\1O"$GBCXA^)_"?[/&O>);&[\3^(-0\
M3OI_CK5O$4'BC5;75KFX.9=_Z_S\MP/UJ^-'Q;\-_ OX:^(?BEXMLM;U'P_X
M:ET&&^L_#EM87>LRMXB\2:/X7LC:6^IZEI%E(L6H:U:S71FU" I9QW$D(GG2
M.WEZWQCX-\)?$+POKG@GQWX:T/QAX/\ $VGSZ3XA\,>)=,L]9T/6=-N5VSV6
MI:9?PSVEW;R#!V31,%=5D3:Z*P_G U3]GSXUS?"JTLT\#?$@?&#3_#6IV'QZ
MTOP?^RA\1_#>I?$GQ0WQJ^'NHZKJ?Q=^/?B7XM:[H?[2>N3>)K;5/'7@;QE\
M)/!WC!7T6+Q#JNHR^#/"UU$B>G_$3X7^/-+^%_BZ>+X9^/\ PW^TAX<T?]M[
M6OVJOC=JOA'Q%HOA/XB?!?6_ /Q1;1](G^*5_HP\*_%?2/$4][\'W^''@?0]
M=UG4/ 3^%+FZ;P_X8'AW4=7L!271ZWT]?ZM9^:#?<^R%_P""1O[/FBM=:;\-
M/C%^V/\ !7P!>2W#O\(_A+^U#\0_#'PQMH;I@9[#2M NI]6O=#TY@9(UL=$U
M;3X(XIGBC1(T@6'[(_9V_95^ ?[*?A>_\*? KX=Z5X,M=;NTU+Q3K7G7VM>,
M/&FL(KK_ &SXT\9:[=:CXF\4ZH3+,RW6LZG=^09YEM4MXY&C/XM'X$_\)_K/
M[+<OPF^!/Q'TKX-WFF?LJZ=^TG8W7PV\>^%=-\=_$"X^)5CJNM>*_$1U.RLG
M^)G_  C_ (-NOB"OC?XUZ:_B;PK=Z'XNTZV/Q$U?3KR"*#T'Q1^R[XQ\/^'/
M%NM_!KX-:SX0^*^B?\%"M>T;X/>(]&\&:IH]WX%^!VJ:1J[63>"[M-,%OX,^
M!TWB#Q5KFHZG+H$6G_#^>]U&_P!0U!9YU,B:2KSDN6=236C:;>KTLY+J]M9:
MK5]R(TX1=XPBGW26GDNR\E9'[TUQ/B#XC>#?"WB[P#X$UW6?L/BOXH7?B.Q\
M"Z5_9^JW7]N77A+0+CQ/X@B^W6=C<:;IG]GZ':SWV_6+S3X[OR_LUD]S>,EN
MW\\)_9_^)]_\)3H>A?#SXFZ9K-Q\/_@;H/QM\$^%/V1OB5\*[7QUXHTK]I7X
M1:SJ.J_$GXC^+?B]XKO_ (Y?$SPHMEXZ\26GQ/\ ACX.U/3H_".J>*=4U/Q/
MX8T74;;2*^DH?V;K+P1_P4.T'Q)I?[/,ND? WPO\=- F\+3^%O@K?W/@/P[J
M/B;]EC3;&P\2:!:>&O"EUH^AZ'9?%W1M(NM=\7V4-GX>\)^-[.UU[Q#JNDZG
M;R:C%GS+O^?E_FO4L_<*BOQ"_;Z\)?$;QA\1OB^WASX':EK'B/0/#/P.U'X2
M>/=%_9^^+OQB\?ZT_AWQ#J'B_P 377PQ^,-IXI;X9?L]2^#KNSDBUWPSH_A&
M;QW\2EN6CM(=5U75/#DVG<%JO[-OQ5TSX7:5XU^$OPH\4>$OVFM7_;9_:<L]
M.^(=KX3U?0O&^F_#[QIX7_:(L_"VI:QXFFL[74-(^%-_KUYX-OK/4;^[M/!@
MOM2L]5MYTN]8DNKR9--6OOM^#_77^D!^U,_Q;\-V_P :M*^!#V6MGQ=J_P +
MM?\ BW;:BMM8'PXGAOPYXL\->#KZRGO#J2ZFNMRZGXIT^>UMH]'EL'L(;R6;
M4H+B."UN/4:_(G]D3X=:#H'[3/PM\0^ _@'X_P#A+H6E_L,ZCX)^)VK^(O@_
MXN^&>E7OQH7Q_P#!V^U;2]9U#7M!T/3_ !IX_EL]/O;G5_'NG_VU;>.;:P:?
M3?%_BF#PY>?V+^NU9M6?R7XJX!1112 **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K^8G_@Z-Y_9(^!0]/VB-'D_P"^?AQ\3H__ &K7].U?E?\ \%3/^">O_#R'
MX?\ PU^"O_"WO^%-?\(WXMOOB5_PDO\ P@'_  L3[:= TBX\-#1O['_X37P-
M]G^U#QL;S^T?[5G\C^S?L_V";[9Y]K]%PGC\+EG$658_'5?8X3#8J-2O5Y*E
M3D@HR3ER4H5*DK-K2$)/LC]5\$.),EX0\5^!^)>(L;_9V29/G5'%YCC?JV+Q
M?U?#QIU8RJ?5L#0Q.+K6<HKDH4*LW?2+29_FCT5_8)_Q"A_]7[?^:M__ )1=
M'_$*'_U?M_YJW_\ E%U_1G_$2N"?^AU_YCLV_P#F _UG_P")OOH[?]'#_P#-
M2XY_^AD_C[HK^P3_ (A0_P#J_;_S5O\ _*+H_P"(4/\ ZOV_\U;_ /RBZ/\
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MT</_ ,U+CG_Z&3^/NBO[!/\ B%#_ .K]O_-6_P#\HNC_ (A0_P#J_;_S5O\
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M_P"AU_YCLV_^8 _XF^^CM_T</_S4N.?_ *&3^/NBO[!/^(4/_J_;_P U;_\
MRBZ/^(4/_J_;_P U;_\ RBZ/^(E<$_\ 0Z_\QV;?_, ?\3??1V_Z.'_YJ7'/
M_P!#)_'W17]@G_$*'_U?M_YJW_\ E%T?\0H?_5^W_FK?_P"471_Q$K@G_H=?
M^8[-O_F /^)OOH[?]'#_ /-2XY_^AD_C[HK^P3_B%#_ZOV_\U;__ "BZ/^(4
M/_J_;_S5O_\ *+H_XB5P3_T.O_,=FW_S '_$WWT=O^CA_P#FI<<__0R?Q]T5
M_8)_Q"A_]7[?^:M__E%T?\0H?_5^W_FK?_Y1='_$2N"?^AU_YCLV_P#F /\
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MN"?^AU_YCLV_^8 _XF^^CM_T</\ \U+CG_Z&3^/NBO[!/^(4/_J_;_S5O_\
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MWT=O^CA_^:EQS_\ 0R?Q]T5_8)_Q"A_]7[?^:M__ )1='_$*'_U?M_YJW_\
ME%T?\1*X)_Z'7_F.S;_Y@#_B;[Z.W_1P_P#S4N.?_H9/X^Z*_L$_XA0_^K]O
M_-6__P HNC_B%#_ZOV_\U;__ "BZ/^(E<$_]#K_S'9M_\P!_Q-]]';_HX?\
MYJ7'/_T,G\?=%?V"?\0H?_5^W_FK?_Y1='_$*'_U?M_YJW_^471_Q$K@G_H=
M?^8[-O\ Y@#_ (F^^CM_T</_ ,U+CG_Z&3^/NBO[!/\ B%#_ .K]O_-6_P#\
MHNC_ (A0_P#J_;_S5O\ _*+H_P"(E<$_]#K_ ,QV;?\ S '_ !-]]';_ *.'
M_P":EQS_ /0R?@S_ ,$V/&'PK^!?Q*^(O[7'Q3U[36/[,OPVU;Q!\+_AG8^.
M?#/A'XC?%+XS?$(2?#7P':>!+;Q!H/BN>X7P$/$.L?$K6O$NG^%_$,/@>Y\+
M>']8U?1]4T^9]+O_ ->_^">GQ&_9V_:(\1_L,WWPJU+6?@U\7OV*/B3\8/AC
MH_A+XU?'+P5\2_B;XR^ WQF^#WQC\;Z)XM\.:II7PB^#.I^.++X/_%*WU73(
MO!O@OP;K5U\/_"?B235M9,FFZGI9LO:_^(4/_J_;_P U;_\ RBZ]+^#_ /P;
M1_$7X"?$7P[\6?A-_P %%_\ A%/B!X4_M?\ L#7_ /AD30M=^P?V[H6I^&M5
M_P")5XE^/&LZ)=?:M$UG4K+_ $W3;GR/M/VFV\F[A@GB^8SKBC@C-(8^M3XB
MG#'U\.Z&$G/ YU'#4::P6+PBP]6C' RIU:=18_'N=:=&I6I_6FZ:DJ4(2_'?
M$/QG^CEQEAN)\?AO%?$X;B?,LKJ9=D>)K\-^(5/*<!A8\/YWDD<KQN7T>&JV
M%Q>$Q<>)N))8C'5\!BL=A?[9E/#0J+ T*-3Y&_8:OM8^'_A/PK^S?K?[3OPD
MU_\ :FO_ !!_P4+^-_@;XH^"/C=X7^.7A?X#>#O$/[&WCSP@/'?B?XM>"]7\
M7^&_#4WC#XJZ?'\6-0\,6>L7GB--.T!/&'CC0]'UC4[.VN_'O@Q\5/ OP!_9
M%G^ 7CKX\?""?XW^%_V*?^"F<FFGP7\<?A]XYT;P/I?QUU7X%67PW^#'A[XC
M> /%/B+X;^*_'?C_ %OP1\1OB#:>"/!'C'7?$6@V^MB6[TZQU7Q'J%M'^BWP
MM_X-G_B%\%O$>H>+?AG_ ,%%O^$:\0:IX/\ &_@&_P!0_P"&1=$UGS_"7Q&\
M*ZKX)\9Z3]DU_P"/.JV47]L^&-;U33/M\-M'J>G?:OMNE7ECJ$-O=Q><?\0H
M?_5^W_FK?_Y1=<LN(."JN)KU*_$M-T:U3#XM^RR7-(5)XNG+-545G@7&EA%3
MS*2A14ZLYS4ISJQYJZQ/B5/%'Z.^-S?,\3F/B[AWE^/Q.69S-8+P_P",L/BJ
MV>X:IQK#%04)<-3IX+(UA.+ZL*& A7QF(KXF-2O6Q=&-7,*>;?GW^S]\1O!6
MI>,O^"67[07AS]HOX3?"#X*?L8?#/4?"_P"T7X"\5?$SPAX<^('A;Q'X8^(/
MQ+\?_'!?"_P"UO6;#QC\6X_VMOAWXQT+P?IWB7X-^&?']YK^I:K=^'/'0T2Z
M\%R6UMN-^U5^S!>_L5S_ +2=YXDTH?M'0?"[5/\ @FO'\ #K.EP>);O]G/4_
MC':?$2#QA9>'=,O;;Q)I6E:/^RY/J?P!LOB'!>6FA/K[RZ/<FXU(6H?[H_XA
M0_\ J_;_ ,U;_P#RBZ/^(4/_ *OV_P#-6_\ \HNNFIQ%P#5K1JSXDK+V>(IU
M(*GE>9TY2P\<7CL;5PN(J+ .=>%>MCZBJ3;BW"E1:BJ_MJ];V,5XL?1@QN.H
MXS$>+>8Q^K9IAL71AA>#>,,-5K972SOB3B#%Y+F>*CPQ.OF&'S+'<3XR&+K3
ME1D\-A,!.%..8K'YCC_ OB5^U5X"\)?M(_'S]HW2[7_@G9XD_9D^-'BSX2^)
M/$/BT_&OXW?$/]H3XU?"6Q^(GPT^)'A3P!9_LGS_ +3?Q&7P!\;/A3I_AK3]
M$L+_ .(_[.OPA^&O@+6O!&I67AO5/"GAC6-%T?5O"_CYK-IX?_9K_P""N.J>
M(?VM/@/\4]._:C_:#^"WQ*^!'@[PG^T7X%^(GCGQOH%E\;+WQ/>^.)/AQIGB
M74_%7@B^L? VO^&=$UGPYXGTK0_&>F1>%[JPU?0;?0_"FEWS_>/_ !"A_P#5
M^W_FK?\ ^471_P 0H?\ U?M_YJW_ /E%UG0S_@.@\,X<2S?L)Y=SN>4YM4E5
MI97B,!B,*N:IA9NE5<L!2IUJE.U*5*3A2P]"-.DJ?'EOBA]&C+)Y3.CXOXBH
M\NK\+>WGB.!N.,56QN#X.S3AK-<EA[;%Y-B)X+'3J<,X/#9ABL'[/!5L'4^K
M8'*LMHX7 PPWYZ_L _';X:_#3X3?L4RZG\8/ /@;Q7X ^+'_  5'\1Z@-6\>
M>&_#^M^#Y/&?["ND>&OAEK.I0W^J6MWHB^+_ !O;#P[X(O;V.WC\1^)X/[&T
M-[W5$-L/A7]HGQKX,UW_ ()\_P#!.'PAI'B_PUK/C;P)KW[:<7C/PIIWB'3-
M2\3^#--\2?$WX>ZQX27Q+H%M>3:GX;M/$*?VYJGA\ZG9V46LQIJ5YIYN4BN)
M%_?3_B%#_P"K]O\ S5O_ /*+H_XA0_\ J_;_ ,U;_P#RBZ[Z7%O =+'1QZXA
MFZD<5+%<CRO-$FY?V[:FY+ <W+%Y[6:Z_N8?SS/IL%XY_1GP7$U+B:'BGB9X
MFEG-7.?82X,XR4)SJ/Q,:PTJBX9]I[*F_$S,7!ZM/+\-9)UZ[/QK^*_@/1?V
MVO!W[#GB?X;_ !G_ &>/!&G?#3]F_P"'G[+GQETWXV?'WX1?!?Q=\+?%/PQ\
M9^*)]5\:W?@[XG>,?"FO?$#X>ZWX5\<:3XK\,ZS\([7Q]?7RV'B#PO?:5IGC
M+2&T"X^J/B+^T?>?&GXO_M&?&/\ 97^.O[,?Q'\!^+?VOM.\;>)OV-OV[?#'
M[-OA+X:>+?#'@_PC#X;\#_'CP1J?[7?BC1_#<L?Q&T;3_$?@?X@6/PUU?X4_
MM ^%M U#PQ:ZH\MA)I6L^&ONS_B%#_ZOV_\ -6__ ,HNC_B%#_ZOV_\ -6__
M ,HNLI\5\#SY%+B*%2GAUB886C7R+,:U*-+%XNEC*]/$QG@N>M*-2A06'K4)
MX.M05&$N><W4E/CQ'C;]'#$+#4ZGBOA\3ALJIYMALEP&9>&W%F8X*E@L\SO"
M9[F6&S>G7X?5;,)PQ679;'*\=EN(R''Y<L!0J_6<3B*F*JXC^=3]O:T^ =M\
M9?#D_P !]-^'_AZ;5?A%\.]9^.7A#X/^(]0\8?!CP3^T7J=A=W/Q5\*?"#Q1
M>^(/&%KK7@+2[Y].^PS>'/&OC3P7::I/J^F>"?%.K^%;'2)Z^)J_L$_XA0_^
MK]O_ #5O_P#*+H_XA0_^K]O_ #5O_P#*+KVL)XA\%87#4<.\_JUW1IQA[6M@
M,XG4G;K*4L#*3[)RE.7*ES3G*\G^A9']*OZ/&391E^52\4,7F4L!A:>'>.Q_
M#''E?%XAP7QU:M7ARK6G;X8.M5K5E3C"-6O7J*56?\?=?K;_ ,$3/V7O&/[2
M/_!03X%ZEHNG7G_"(_ CQIX<^._COQ&(&_LS1;+X:ZYI_B+P]97-RZ"![WQ'
MXLL]#T&QT^&1M0=+ZYU2.W;3=(U6YM/VZ\*?\&IWA.RURQN?&W[;.O\ B/P[
M%.C:CI'AKX!6'@_5[RW&=\-IKVI?&#QI:6$K\;9Y?#]^J8.8'R,?T<?LC_L7
M?L[_ +$/PW'PS_9[\"V_AC3;Q[6[\4>([Z4:KXU\=:M:),D6K^,?$DL4=SJ<
M\375[)8:;;16/A[0OM][;^'=%T>SN9+8^#Q5XGY&\JQ>$R.M4Q^,QE"IAXU?
MJV(P]##1K1=.=6;Q5.A4G4C"4G2A"G.+G;VDE%-/\T\:OID^'$N"<[R/PWS#
M%\3<09_EN+RFCC?[(S3*LMR>CCZ,\+B<;B)9U@\OQ.(Q5+#U:DL%0PV%KT9X
MCDEB:L*4)0J?5-%%%?SN?Y1A1110 4444 %<!'\6/A9-X^G^%,7Q*\ 2_%&U
MMA>77PVC\9>'7\?6UHVGPZLMU/X.74CXAAMFTJYM]3$\FG+$=/GAO0WV:5)6
M[^ORUB^ _P 8H/ /QJ_9WN/@MIGB>_\ B'\5OVA?'/A;]ICQ#XK\"P>#_"2_
M&/PYXT/ASXBV%E-?^*?C#'\7/!\7BV+X>MIMG\/M*TUM/@U&2R^(Z:(Z-J32
MOY?-:??OZ ?>>C_'GX&^(M)\1:_X?^,WPHUW0O"%]IVF>+-:T?XB>$-3TGPO
MJ6KWHTW2=.\1:E9:Q/9Z)?:GJ++8:=::E-;7%[>D6MM'+.1'63I/[2_[..O3
M>';?0OV@/@EK5QXOUR7PQX3@TGXK>!-1F\4>)8'TM)O#WAV*SUZ9];UR%]<T
M1)=)TU;F_C?6-+5[<'4+03?E]\2/V7?CU\6/ FI0V_P,;P->>'/V1_@M^S<O
M@S6O%?PPN7^(.O>%/C;\/_&^LW>@3^'_ !OKGAY/ASX-\-^%=>'A^;QO?>%_
M$NHGQ3?VD'A*R>2XAN?7OC9^S/\ %GQ5>?MYZAX8\"6UY?\ QM\>_L;:S\/;
MZ/6O"-C>>*M)^#LOPSG\4W$MS>:S:3:6OA2;1/$,UE;^(7TR>YEAFDT"&]>]
M@-R[+O\ D_Y?\W]P'V]-^T]^S5;S:G;W'[0WP-@GT6RN-2UF";XL^ 8IM)TZ
MTU--$NK_ %.)]?5["RMM9DCTBXNKI8H(=3D2PDD6Z98CM:M\>O@9H.E^#M<U
MWXT?"?1=$^(BN_P_UC5OB+X/T[2_'21-9I(_@[4+S6(;3Q.L;ZCIZ.VB37P1
MKZS5B#<P!_S[^#'[*OQ(\,7G[%%QXH^&FDVK?"GXS_MC^/OB;+-J'@J_?15^
M).I_$N?X6^(IFM-6NWUO4M1M[[P6;*;1O[5U70!;Z:FJ+I3:.RV7SEX9_8U_
M:7\&:'))J7A7XI:M9>./@#\7/@OK?@7X4>,?V7K34M(36/CG\5?%UCX8\9ZW
M\=-+\::+I?PT^(_A'Q[I%Y=:W\)'U/Q;H%YI5S#K?A#4+NTTB(%EWZ^7=I^F
MBO\ -+U#]G]0^,_P>TGQ+J_@S5?BO\-=,\8:!I^H:OKWA34/'7A>R\2Z)I6D
MZ%9^*-4U/5]"N=5CU33=/TWPSJ%AXBU"]O+6&VL]"OK/5[F6/3[F&X?A[']H
M;P=XL\9_"G1/A=KWPS^*'@_XBW'Q%LM2\<^%?C'X!O1H&I> M"TK6ET[0_#5
MG?W^J?$"[O#JL46N0^&IFE\%V;6FK:^B66H6I;X4U']D'XN?\*^_;#\(:=X<
MLY[GQO=?L>7?P];7/&>DZS_PLS2OV>OAS\%X/%OA;4O$L%GH-X9/$.I^ ?$O
M@I-6\6>&/!=CJ]YJSZU=:/I.@:A</%UGQ'^&WQO^*OQH\(?%CPS^S!H?PP;1
M/"W[1>DW]_X_\1?"'6?$OC7Q%XL^!>@^$? 5_P#%?P_X*UKQ1HE_X?EUZSC\
M&:5;P>-/B!>/X:TRY?Q#8>$-+;3[.\++OT_&R?==79>G74#Z0^)?[8/PE\,?
M"WQE\2/AAXN^'7QRF\"^)_A7X:\1^'O ?Q-\-:G+H\OQ2^)GA[X<Z?/K=_X>
M'BE]%DMWU?4M6LK6_P!.1M9;0+[3H);8BXO;/K_VAOB3\&O#G@+QIX&^)_BO
MX;1W7CCP)XFT2Q^&_C;XJ^&OA=??$6#Q#HVL:1%X5T_6M9UK2+O2AXKDCO-!
MM]=LW5M/F:XNX9EEL9#'^3FJ?LM_M;^-8M5OM<^'?CJ>[F^!/[-_PYM(/&WB
M;]EW0CI^L?"S]I[X2_$OQ+X<\*^&/@=<>&O ^@?#W1/#EIXRU7P*;U=4\2W6
MGZ9?Z3J^HVMW+X1\-O\ =_QW^"'Q"\;_ !V\=>-]!\*0ZMH6H_L)?&7X.:#J
M\FI^';>4_$[Q=XJTN]T7P];V^HZG;:C9/J>E0W9?6I+>WT*"+?;7VJP/*(G+
M)-:K1]_\/^;U\@/9_"GQS^!O@?P/\)O#_BWXA_"/X2ZMK7PJ\'^(] ^'FN?&
M3P5J-W8^&3X=C:$:%KEWKD;>./#ND1:;?V%OXWTS[7I6N0Z1=:I!>21>:Z\A
M\//VS_A#XL;XKZ=XL\5^ /A]XL^%GQ ^.7A>X\$:K\2_#$OBW6/"'P/USQ%I
MNK?$6+0M2;P_J5CHE]IOAC5];NM]K<Z9H5M87ZW.OW5OI]U>I^47QC\%>,/A
M5\!_VA? ?B'P)X?\::EXR\%_L)Z+K6L:?\0/AAJ$GP3\9^!_AY\-O!"_#WQS
MX>G\8OXXB\57>N^'Y/$?PS3P3X5\1Z'XD'C_ /M%M;TRQCU:_7ZYE_96^+%W
MHVC6G_"$6MAJ3?\ !37XM_'S4=2CU7PA)=V?P;\:7/Q/M;+QPTL>N1R79OM*
MUSPU'/X;BN#XJ-M]FL[W1X!8S):%EU>__P!J_P FP/L'X:_ME_LW?$SP1\,O
M&UK\6? 7A'_A;=I#-X-\(^._'?@/0/&][?RZ@NDR>'_[!C\47_VGQ#::L\>E
M7FE:5=ZE-!J4L=BQ-RZQGW3QKX_\"?#70Y/$_P 1O&OA+P!X:BN;>RE\0^-?
M$FC^%=#CO+QF2TM)-6UV]L+!+FZ966W@:X$L[*RQ(Q!%?BUH/[,_[27AWX/^
M!= T7X#>.O#WQ5TG]GCPM\%]4O[7QK^RKX]^$/CR_P#!GC#5=<T:P^/?PQ^*
M$NNQ?\(1HNH7LNL^&/&'PKU/5_B3<Z'KNKV&J:1H6H:7H^DR_<'[6GPB^,'C
MC7?V9?B)X)7Q)JFJ?!WQ5XEU/QCH_P *[GX2V/C)IO%O@I_#R>*? %M^T-I^
ML_"RYNO#>I>?LM/%;6FK)HNKWLFA:S9ZQ$DLBLK[]>Z[+JK][7^=N@'U=;_%
M[X37<=U-:_%#X=W,-EX$M/BE>RV_C7PU-':?#*_MI+RQ^(MU)'J;+;^!+VTA
MENK3Q=*4\/W-M%)/#J#Q(S"K9?&SX-:EXKT+P)IWQ;^&-_XX\4Z1;>(/#/@V
MR\>^%;KQ7XCT"\T>?Q#9ZYH7AV#59-7U?2+O0+:XURVU+3[.XLI]'MY]3BG>
MRBDG7\A=8_8V^-GB7P+\/?#FF?!"723\([GQU\7[NW^+?Q4\!^+=1^,]SXO^
M)5MXWNOV4[RX^$+?#/PCX=\$>)I8;CQGXFM=2\(3_#;P_P#$&P\)Z%H-YX@\
M,?\ "2^);GZ,TKX5?&"VD^-_@:__ &<E\0_\+Z^..I_&#P_\8/$OB[X5Q:5\
M(+/QAX*T:PL=3U^UC\2>*/'C?%GX)W6GW.D^%K/X?^']:\-:E=PZ8=#^)?AS
M2[B[UJP=EW_+35>>NCO9>@'W#I_Q^^!&K)XLETKXU_"34X_ 4]M;>.9-/^)'
M@Z]3P7<WNI/HUG;^+'MM9D7P[/=ZQ%)I5M%K!LY)]2C>QB5[I&B'F7C/]M/]
MFKP;IG@+7%^+/@3Q;H?Q"^*MA\(-,UOP3X[\ Z]I&D>*+JRBU'4+KQ#J0\56
MMG8:/X:L[S1Y_%$]O->ZAHT?B+P])/IC1:O:NWXX?&']G+XP>!_V7[Z?XC>"
M_B9I!^"O[/=G\)FU'Q-X]_9FM?AEJPUGXG_"V&Z\-^"_#7P2^%\/Q)\;>"=<
MOO#%GXQM]2^-OB#1-<\,7I%Q/I'BCQ)J.MZA<?77C#X ?'+QE\7-*_:!TGX'
M:MX!TO1/BS^R;<M\#[;Q1\(&\5:OH'P/T_XBP^)?' N='\<Q_#F*WTVW^(-A
MX5\&:=/XRC\0WN@>&;V2]TC0XWT72267?K;=>6WWW?W>8'Z%_M#?&6?X&_#F
M3Q;I/A&X^(?B_5?$?ACP7X"^'EEJ;:+>^-O&'BO6+;3=/T2VU9=*UL:<(+-M
M1UN]O'TN[6#3-(OI!"[JBF&S_:7^!\7PS^&_Q5\7_%'X>_#CPM\4O#NE>(/"
MMU\0/&_ACPE'>_VCI5IJEQI5O<:_J6G0W>JZ0EVMMJUE;LUQ8W,<D5U#"ZE1
MYS\9/A)\2/C#\>?A>8/$?C'X9_#'X1^$_$7C[1O'W@N?X7ZEJ>J_&SQ)._@G
M2]+/AKXC^%OB+IY@\)?#>Z\;3OJUYX(@VW7CNP&@^(DN['5K1/AJ?]EWX]?#
MK5/%/AC1O!7QG\;Z9X/D^,FD?!KXT?#OQW^RV=<\2?#_ .-MMX9\6ZQ\)OBM
M\%?C1I6@_"W6?AS;_$ ^);G6IK#2]%N].NM+\/6O@KPBFAWDU_I(DG;57Z_\
M/M^NKTTLP_2=OC]X5T#Q)\9[/XFZQ\.?AEX-^$_B+P/X?MO''B/XO^!$M]8D
M\9^#-$\3H?$^C37UE>?#+4(M0U9]'T;1O%T\=_XJL8+7Q-HR2:3JEGGSSQ[^
MV-X(\+>-?@UX5\(Z*_Q8TGXR/#-HOC3P-XW^&K^&/[,O=2N_#5C>Z7JVL^+M
M,TC5&D\9-X?\-,U_JN@:7J.I^)M&\.>$]8\4_$75= ^'^N?#MA\ OVPO"^OZ
MIXF?P#I8GU?XG?LX>)_$M[\&M,_9SG\6Z;!X#_8^TWX9^(]6^ ^C?':>^^&O
M@L>'?B/%>^$GN=8L?#VOR^$Y;H^#;6#0]3NH6^V_V$_AE\2/@_\  &#P!\4]
M&N]#\3:7\2/B[J4%K=>(=#\3I<:'XH^)'B3Q5H^I6FJ^'Y?L4D&IVNM?;9(Y
M=.T&^%[-=R7F@:5+(8*-%KH]M+_W=^^C_P M .C_ &;OVG]-_:.G^($6F>!=
M=\(1>!M:BTX7&K^(_ VL?VG9W;WD-E<&S\-^)-3U*TG>XTS5(7OK:RU3P'?S
M65U:^%/'WBG4-+\1V6@_4=%%2[7T5O+< HHHH **** "OY__ -CC]HWXVZ7_
M ,%,_P!JGX<_$#XF>,_&WP3^*W[3_P"T)\%_AMX5\5:_?:YI7PN^(WP6^$WP
M@^,GA?1/ \>JRWDWA_0O&'PYUOXR7=]X=T66PT.*Z\"6=_\ 8OMD[R2?T 5^
M*/C7_@G-^T+>>#_VQ=5^'GQ ^%OA?XX?$']OWPO^VU^RMXKO]3\8W'ASP?>>
M'- ^'_A*YTGXHQ6/A2VU:UN/$/@W3OB1X5U2P\)_V];+I_BBRGBUIG-U;V_U
M7#5;+8TLYPN95,-1CF."H8*A6Q,.98>M6QE&,,6FH3J0C@I\F+K.E:I*A1J0
M5U)QE\IQ-1S*57)L5EM/$UI9=C:^.KT<-/EEB*-#!UI3P;3G"G.6-ASX.BJM
MZ<:]:G-\K@IQ\<B_:Z^+G_#R3XB_%)O&OB_Q#^SSH'[&?[9_C#X7?!.S\7WN
MA_#KQ'I_[*_Q-\#_  YNO&=WIEI;W6CZAXF\:_$OPO\ %ZY\.?$B]T?6KD?#
M;7_"*:%]KT.**;5_T/D_;J\OX)_\$[/C%_PJW/\ PWUXX_9^\&_\([_PF^/^
M%3_\+U^!GC#XT?VE_:__  B!_P"$[_X1;_A%/^$:^Q_V9X-_MO[?_;/VK2/L
MO]E7/D]S_P $Z-1M?CA\)=2\.Z_X6T_X%_#S_@G-\3?V(+Z"9]4D^(-SK/C?
M5O!_V3Q=!HDND76@:G83:3H6J:AK][JOBY-8O/$%XIFL]26[O-23R;PS^Q9^
MW%=^$_\ @F[\'_'-Y^RSI/PP_P""?WQ7^$OB#4/$GA+QW\5M=\9_&OPE\'_A
M5XR^$7A'Q!!X:UKX0>'](^%_BFR\-:Q;SZWX*/B[XBZ+XKUGQ%J%_:^._!=G
MX,L=)\:^YBGPQF$,%.,\'26#P:HR4ZM3"U'A:6'SF.%C.G3E#V^,EB(9:Z\H
M1G7E5K1J5FL.Z\H>'A5Q1E]3&P<,95>,QCK0E"E3Q5-8FKB,D>*E"I4C-T,'
M'#SS-8>,Y0H1IT90I)XA4(S^,_V4OVE/VS-:US_@F5HFE^*I/B1H?Q)_:=_X
M*0V/C2?XG?M _$+1]5\>V_PVUCXYZ?I7AGQC,GPO^)-Y>>$OA7X*%IXB^&VE
M7&LZKI6M>+]+T+PW>:!X'L_#F@^.[#Z]\!_\%(O$MIJGP_\ AQ\%_P!EWQ-\
M0/&GQV_;9_;-_9[TO3O'W[5_CC7M/T#6/V?;V?4];^(VJ^,?'W@?Q_K7A3X8
M:C9Q7VM77P^\(:9=Z?\ "OPUIUSIGPZ\,^,;S^S/#-\_X+?\$\/VE?@7I/[$
M>NZ1J/P-\:^-OV7?VBOVSOB)XJ\,ZEX_\?>$/"WB/P!^U=<_$FVL+KP_XTM?
M@[XNU9?&'@K3/%VD7MWX9U+P'::+KE]'J.FP^,],M[:VU6^^:]3_ &=OVE?V
M4_VG/V%_#?@^]^"OBGXH?$/]N;_@IU\=O#.CZ]XC\:Z=\/M:^'/Q4^'>I>-?
M^$/\4>+;+P#>^)O!GBU_"(O+=-<T/P7XWTOPWXNCTRY>P\::!%J&G:A[.)?#
M6;XS%JC3RVORX;/:U"G#%8O!T<14PN(XQS.E/%PP^)H?N:5#^R:\*THTHJC4
M=&%54X5*=+QL,N)<HP>#=:IF5'FKY%0Q%2>%PF,K8>&*PW!N65882>(PU?\
M?5:_]KT9T8RJRE6IJM.E*I.E4J^O?MI_MN?%?7O@;\4_AU=Z-XD_9C_:7_9Y
M_:\_8F\(_$K3/A?\6M<\2>'M;^'/QM^+/AR\\(>)? GQ4TSPW\+=?\3^ _B5
MX4L_$6B:]I&N^"?"M]::EI/B3PIKNBW$5JTUU];>*/\ @H!\49V_:6\>_!S]
MEN+XI_L[_LA^-_$?@'XQ_$#4?C3;>!/BAXIUWX53&Y^/\/[/WP@E^&GB70/B
M3_PJ715F2$^//B_\&HO'7C'3M8\&>'9EFTXZK/X#\7/^"</[0_QQ\._'OXD>
M,?%?P=T/]H7]H[]H7]C[Q]KO@W0O$?CC4_@Y\+_@Y^Q_X];4?!W@?PYX\U#P
M!I_C#X@>-M:\.7_B;Q-K_BC4OAK\/](O_&7B<>&[/0M%T#0(/$.J\GXD_P""
M4?B'PSXH_:4TSX;_ +//_!.GXOZ+^T'\4_%OQ8\'?M _M0_#6R\5_'?]G36O
MBUK=UJ/Q"TJ'P3JGP)^)OA[]H/0/!%Y<3^*/A%IGB+XK?"2 7][+X4\8+J&C
MVO\ ;%]YT(\'U<+A\/4J8)5:%>525!U,4\-"=?#\/+-%#%+'X2O4HT<53S&&
M E+%XI5,-"O/#T\;6>'=3T9SXPI8JOB:<,:Z5>A&FJZIX98J<*.)X@_LMSPO
MU#%T*=:OA:N73S",<'A'3Q,Z%/$5,%16(]E^I/QD^)UCXL_8M^*OQF^%_B/4
M(=,\2_LO>.?B=\._%VC7-YH^J16.L_"C5/%7A+Q'I5Y;R6^H:7J"6]SI^IV-
MS!+!>65P(I8I(IXE9?S&_P"";'[9'CWP5^P7X^U?]IGQCXJ^+OQ _9Y^!_P+
M^.5EXBU_4Y]9\;?%'X:_M%_LY>"/C)\,-,GUVZBN]9UWQA??$O4OB+\%=.N]
M6BU+5]5U+PCIMQ->:M-?B1OU.\2_!"\/[)/B#]F[PGJ&A_;S^SIJOP0\,ZK<
M:!H/@;PW]L_X5I<> ]&U"?PO\/?#UAX8\':'YWV:YET#P/X4LM!\/V&[3O#/
MAZVT^TLM-3\\/"__  36^*.E^(?^"=5YJ'CGP GACX ?LO\ P&^ ?[7OA>UG
M\4WUO\5;W]EG_A$_B-\!KCX>O+I&E6VIZ/X9^/.E:_K5W+XUL=#ED\*:O(T>
MC/JET]E8^-E57(7EF98#&U:4:=3-(8K#5)Q;Q*P^!IU*_+3JQI1JQEC<-"O@
M*<;4Z<L7BL/.K"*IIP]G-:6?+-,LQ^!I5ISI974PN)ITYI85XC'U:5!2J4I5
M94I1P6(G1Q]25ZE2.$PF(A2G)U&I^!?L1_M=?'SX#:;\2-#_ &FM6\1?'Q_%
M?_!6_P 7_LF?$+XM>(?B1=VUG\$=?\8_!'X*:CX2C\%^#M1T;5=)M/@]J?QB
MU+6?#6C>#=$U[P7HG@%?%VF2Z3::O)>7%L_V[\3?^"DMCX'\3_M ^&?"_P &
M=8^)EU\,?C;\'/V3/A OA[QA:Z=+\=?VNOB]X33Q<_PC^T:QX;M_#GP\\+?#
M;3-5\,W_ ,3/B1>^)/$TOAK1KGQ+J;>#+B;PY9Z=XB^9?V@?V>?"7P!_8N_X
M*D:7^TW\6/ASX*TK]K+]IKXU?M _ 34M*\420>(SXVNOAE\.?%/P-\):#I?B
M33O#=UXE^.EI\0_@5)XCT#X=>!6\2ZGKK:78Q>&M2O=0:Y33KEK_ ,$V_&OQ
MJ_X)W? _P9\3+?X?3_M56'QGL/V^?'6A_&OPF_C/X1_$+]IOQ;<^,?%7BWX7
M?'/PJ8YKF3X>:KH_Q$U3X/ZX^B6FI7G@O2M-TK6M$TGQ3-X:M])UKVL33X7Q
ME6&;8ZG2HTL5F%#+I.@L31PM2U#!8VIF-.G1J4H^RP[CB,HQE#"NG&C2KT*\
M5'%259>+AJG%&#I3RG U*M6KA<!7S&*KRPU;%T[XC&X*GEU2I6IUI>UQ$94,
MWP=?%*I.M5H5\/)O"Q=%P_MW_MI_&OPY^S9^W'\$?'W@Q_V:?VF?!'[)VL?M
M!?"GQE\"_CEK_P 0?#'B7X<P>)= \%ZMXI\%_$]OA[\"_B!X5\;>"O&NK6VA
M>)- O_ 6E&TL]7\/ZSH?B36[76+B+3?I#P]^V;\:_&/B+Q?\'_V8_@!X=_:!
M\3_LZ_";X4ZM\;_$_P 3?C_-\%K.^^(/Q#^'6F^.O#'PT^'=[!\)_B^WCCQ[
MJGAR5=4\0ZCXRN_AOX1\/:AJVC66K>+6GO=1FTGY5\?_ /!+?XC_ !(^&O[6
M6F^%_@G_ ,$_?V2M;^+W[..J_ ;X6?#3]GCP'X<N=$36=?U[0/$>N_$OXJ_M
M)67[+WPD^+[BY;0X/#FF_#;PEX&/@FRTR(Z[KD/BOQ&^DW/ASZ+\*_LM?M;?
MLQ_%/XW?$+]ER#]F_P ?Z7^TCX+^&-]XR\+?&[Q[\3_AQ;_##XZ_##X::-\,
M8/&_AB]\"_"OXG2_$SP+XOTS2;/5O$_@S4T^%NN)JFF(-)\964&KS#2\*L>&
M/[.6%H?V;5QM.>(KT<+7Q.(HX*6+J4^'Z=2-;%TL=.<:2PU/,JM.$<VK8=XR
M%2-'$3YJ6&GO2EQ/_:#Q5?\ M*E@JD,-0K8JAAL/6QL<)3J<05*<J.$JX"$)
M57BJF6TJLY910Q*P=2G.MAX<M7$PK>%/^"G&M_'OXD? ;X?_ +(WP L_BC#\
M>_V8==_:7L/%'Q>^*VI_ _2OAU:>$_B4/A=XO\!?$RS\/?"+XUZKIGB/P[XK
MCN_"US<^&;3Q99W/C.W&E6BR^&&F\;6W%^#_ /@JG\2M>^#G@C]I7Q+^R18^
M"O@#??'CP[^S=\3-8O/V@+?6?B?X.^(NH_$^#X+^(/$G@GX>Z3\(I/#7Q(^$
MWASXG7MMX<C\3:C\3_A[X]UF&SUW5X/A7::?8Z9+KOH/[(W_  3KU_\ 9+^-
M?P.\1Z/X[T7QM\.?A/\ L.>+OV<M<UG4K>XT'QWXN^+OCG]H;2_CMXK\;V_A
M#3M*NO#.A>"M8U.3Q-<6>G?\)CJ6LZ%)>Z9HDG]OI;W7B2?SK_AW5\;/^'?_
M /PRG_PE'PL_X6'_ ,-?_P##0']L_P!M^+?^$,_X0W_AM#_AHO\ LS^T?^$(
M_MS_ (2;_A"?^)7]B_X1W^RO^$J_T'^VO[(_XGE9RCP4L1&C0HX:I@Y8_+:"
MQE?%9I#%/+\3BLVCC,54A'%4:,*^'PM/+96>%C"G.5YT)\\X&D9<;/#RK5JV
M)I8N.7YE7E@Z&%RN>%688?#9/+!86G.6%K5IT,1B:F:1;6*E.I"%H5X<D)OO
M/VG?^"DWC7]F[3_B_P#$+7O@)X \+_!;X0>)]<\(VNN?M$_M(1_LV_%SX_ZM
MX+T>#Q%XXD_92^$?B7X.>*-'^-&GP://)%X!GNOBEX)NOB?KUAJ.D^&[%+5+
M#5M1_3CP+XPTCXA^"?!WC_P_]H_L'QSX5\/>,-$^V)%'=_V1XFTBSUK3?M4=
MO/<P1W'V*]A\](;FXB27<L<\J!9&_#KXA_\ !-']HV\MOV_O#G@CPC^Q=XA\
M6_MC>,OC]J'A+]M7XFWGBX_M)?#3X2_'WP9I&B:Q\"+SP5:_ _Q-/J/AWPS8
M1^(_A9X3U_1/VC]"T;1O!^HZ%X['PUNM6T"]^'WB']EO@'X)U[X:? OX+?#C
MQ2^D2^)_A_\ ";X<^"?$<F@7MYJ.@R:]X4\'Z-H6KOHFH:CIFB:A?Z0^H6%P
MVFWM]HVD7EU9F&>ZTRPGD>TB\?/,/D-++<!++)T)8SVW+B)T:]:<L1AYX/#3
MA6J8>KB,2L.XXGV]-Q;PU=U%5=7!8:D\-&7LY%B,^JYECXYG#$1P7L>;#PK8
M>C".'Q$<9B83HT\12P^&>(4L-]7J*26)H1INFJ6.Q558F4?6:***^3/K HHH
MH **** "BBB@ KE;[CQIX;/KX=\7+^=_X//_ ++755RM_P#\CEX:/_4!\6#\
M[SPH?_9?YT =51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-W;V7B'4;+3U62?6=9%O(5OF2/[9J-IK,MVUY"EC::;Q'['7P3\8_"[X\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"A#@?_  &I_P#+ _XEM\"O^C9<-?\ @C$?_-)_2'_Q%#?M^?\ 1(?V/O\
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M_P"A#@?_  &I_P#+ _XEM\"O^C9<-?\ @C$?_-)_2'_Q%#?M^?\ 1(?V/O\
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M_P"A#@?_  &I_P#+ _XEM\"O^C9<-?\ @C$?_-)_2'_Q%#?M^?\ 1(?V/O\
MP@/C3_\ 1 U-;_\ !S]_P4$N[B"UM?@U^R)<W5S-%;VUM;_#SXV37%Q<3.L<
M,$$,?Q_:26:61ECBBC5GD=E1%+$ _P VU?T+_P#!NW^SOX&^*W[2/Q.^+OC/
M3;+6;OX >&/"VH^"M/O6M98[/QCXVU'6[6R\2)8SJ\L\^A:=X<U06=S$JKIV
MH:A97)E2?[*'\O.^&>#,ERK&YI6X>P=6&$I*:IQ52+J5)SA2I4^9S?*IU:D(
MRE:7*FY<KM9_%^(GA#]'[P[X*XAXSQ_A5P]C,/D6"C76$I4Z]*>+Q.(Q%#!8
M'"JK*O-48XC&XG#T9UG"I[&$Y5/9U'#DE^I?P\_X*)?\'"_Q1\/V7BCPE_P3
M_P#V;$T;4K.UO[&;Q=HGB7X<WES9WL*SVMQ%I/Q$_:Q\*ZN8YH725<V((1U+
M!=PSWO\ PV1_P<??]&"?L??^%5H7_P!&S7[HU^<O[:7[4_Q6^!WQM_98^$WP
MYN/#>D:7\=-)^/VI>*?$FH_LX_'+]J/Q)I$GPFTKX<:CH,'AKX7? 3QOX.\7
MWD&J2>+]3@U[4774[73((K+4)#96UI>&Z_'L+F6&Q^+^KX3A+AB+E#$581JX
M;-*LHT\-0JXFK=T<?SU)*E1FU&E0YIR2C"#DTC^!<EXQRGBG/%E.1^!G@S1E
M6P^:XVC2QF3\98VK2P>499C<XQGM)Y?Q+[?%UJ>!P&(E"G@\M=;$55"E1P[G
M.,3Y(_X;(_X./O\ HP3]C[_PJM"_^C9H_P"&R/\ @X^_Z,$_8^_\*K0O_HV:
M]]_9X_X*177Q#T/]G?PAXQ^$_B7QO\=OCE;_ !AO'TGX&1>"+/PGX;TCX/?$
M.?PAK.L^-K+XJ_%OP_K/PTU5]"GT;Q7JOPYU75?$WC+PW]MF\,WZ3>+8XM!E
MX.__ ."J<'_#,UYXY\"> /'7Q=^,9_95^,'[3!N-%^%>A^"?AYX$\,^"O%WC
MCX>>$?$_Q4\*:M^T1XDURP\,:IXU\)7EIJ&A_#GXC?$GQA/X<\.^)_%DUOX8
MTV,)I_=[/$^UE2_U-X5YHXB.'O[''\EY5,5155S>;*,*+JX.O"$ZC@ZDH\M*
M,VI*/T[PN=+&U,!_Q+]X)^WIYI3RKG_LWB58=SJXS.LOAC)8E\<*CA\OJ8S(
M,SPV'Q.+GAWC:U!T\#3Q,XU(T_/O^&R/^#C[_HP3]C[_ ,*K0O\ Z-FC_ALC
M_@X^_P"C!/V/O_"JT+_Z-FOH>V_X*D?#K1/#6A7_ (H^%OQ>\4/IJ_LW^$OB
MGX_^&7A_P+<?"SPC\7?VB?"7A+Q-H7@J%_%'Q5TKQG.NGP>++&ZUJ[L= US2
MO#<4]KHFJ:_-XIN+72KS/\/?\%0O!EI90Z?JW@'XM_%?Q;J_B/\ :H&CZ?\
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M3Q1\+/CCH]S>6;B*3[3I=W/\>IK'4+22.5!'J&GO?V8=Q\TA4QU^S7_!+/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB:U3A'+LXP.?9?D4\76H3Q<L'@<TRS+Z^#O7=;#4<'0P5"K# TUAC\'/"O\
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M<P_\(I?_ "S^K/RN?\3M^!?_ $'\3?\ B.XC_P"7?U9^5_X-J*_O)_XA?/V
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M_B%\_8!_Z*Q^U[_X<#X.?_.#H_XBOPE_S]S#_P (I?\ RS^K/RN?\3M^!?\
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M*7_RS^K/RN?\3M^!?_0?Q-_XCN(_^7?U9^5_X-J*_O)_XA?/V ?^BL?M>_\
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M#P7XETG6KOPA>:_HMWK>CC2_%^E:')X=6[2ZN+*"QUE%U 6T<=U%!\\?%?\
M9S_:4^,'QR\7_'C2O@[XN^$]M%XM_9+\;VFA6_C#]GS4?BCXIF^#US\2-+\7
M'18[[7?'GPF'C;PTOBC0/$_@P?$.]F\+ZO9^&M CN-8T36]VF^'?VPHI)V[;
MW_%/]$!^/FJ?LN?'VP^&DOQ!^&7AWQA8?'C4_CM\:/$G]F?%[Q[\'M8\3GP5
M\?/ %M\)/%_BCQ"?A'X<\ ?"[PM?V>HZ)X4^-"^!O NO^*4:Y\/R&7Q1K?B/
MQ!<>'-&Q/BW^Q5\1M#\5_%+PA\.?"/Q.\5_!KXF_!/X+_"/P[IOPX\9_LT>#
M[;2-+^&FFR^&;KP_\3_$'QK^'WC#QQX<TCYXO'%AXF^".CZMJ3:S)J5S<^%I
M]>32[R+]GJX3XA>.O^%?:/IFK_\ "'>._&_]I>*?#'A?^R_A[X>_X276-/\
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M?;/&_P#T+WA7_P +'5__ )A:+>GWK^NOY]F!U5%<K]L\;_\ 0O>%?_"QU?\
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M%HMZ?>OZZ_GV8'545ROVSQO_ -"]X5_\+'5__F%H^V>-_P#H7O"O_A8ZO_\
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MVSQO_P!"]X5_\+'5_P#YA:+>GWK^NOY]F!U5%<K]L\;_ /0O>%?_  L=7_\
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M*_\ A8ZO_P#,+1]L\;_]"]X5_P#"QU?_ .86BWI]Z_KK^?9@=517*_;/&_\
MT+WA7_PL=7_^86C[9XW_ .A>\*_^%CJ__P PM%O3[U_77\^S ZJBN5^V>-_^
MA>\*_P#A8ZO_ /,+1]L\;_\ 0O>%?_"QU?\ ^86BWI]Z_KK^?9@=517*_;/&
M_P#T+WA7_P +'5__ )A:/MGC?_H7O"O_ (6.K_\ S"T6]/O7]=?S[,#JJ*Y7
M[9XW_P"A>\*_^%CJ_P#\PM'VSQO_ -"]X5_\+'5__F%HMZ?>OZZ_GV8'545R
MOVSQO_T+WA7_ ,+'5_\ YA:/MGC?_H7O"O\ X6.K_P#S"T6]/O7]=?S[,#JJ
M*Y7[9XW_ .A>\*_^%CJ__P PM'VSQO\ ]"]X5_\ "QU?_P"86BWI]Z_KK^?9
M@=517*_;/&__ $+WA7_PL=7_ /F%H^V>-_\ H7O"O_A8ZO\ _,+1;T^]?UU_
M/LP.JHKE?MGC?_H7O"O_ (6.K_\ S"T?;/&__0O>%?\ PL=7_P#F%HMZ?>OZ
MZ_GV8'545ROVSQO_ -"]X5_\+'5__F%H^V>-_P#H7O"O_A8ZO_\ ,+1;T^]?
MUU_/LP.JHKE?MGC?_H7O"O\ X6.K_P#S"T?;/&__ $+WA7_PL=7_ /F%HMZ?
M>OZZ_GV8'545ROVSQO\ ]"]X5_\ "QU?_P"86C[9XW_Z%[PK_P"%CJ__ ,PM
M%O3[U_77\^S ZJBN5^V>-_\ H7O"O_A8ZO\ _,+1]L\;_P#0O>%?_"QU?_YA
M:+>GWK^NOY]F!U5%<K]L\;_]"]X5_P#"QU?_ .86C[9XW_Z%[PK_ .%CJ_\
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M?;/&_P#T+WA7_P +'5__ )A:+>GWK^NOY]F!U5%<K]L\;_\ 0O>%?_"QU?\
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MTG3O@%XP3QR=(\3:AXP\1^-_AO;7^DI974GBUK#2;BVM?T8^V>-_^A>\*_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!X'\%>#O!_@C0=(L[O6=>U!-!\.^'/#OA[0DENKV=KJYSOO[Y?I+Q7_P4<^
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M72K2T%S%H'AK2=*\.Z+','32]"TS3])L5@T^RMK>/J: "BBB@ HHHH ****
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MO_@M_P#0_4?\16X1_P"?V/\ _"*?_P E_5GY7/\ B=OP*_Z#^)?_ !'<1_\
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M ,(I_P#R7]6?E<_XG;\"O^@_B7_Q'<1_\N/X.J*_O%_XA>?V _\ HKW[8/\
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M_0_4?\14X3_Y^YA_X0U/_DOZL_*Y_P 3M^!7_0?Q+_XCN(_^7'\'5%?WB_\
M$+S^P'_T5[]L'_PO_@M_]#]1_P 0O/[ ?_17OVP?_"_^"W_T/U'_ !%3A/\
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MPU^,'@#2_"?B[4?"7P7U7]GCXA^!O#7A34_&_B72M(^-7Q__ &:_''COXV^
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MW5]X@M;6VB\(,9[:#1O$X:.ZC^E_%O[&GQ@US]I+]LWXY^%?C#H?P[;]J/\
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M1?#]C??#B;QGH.AW.B^(3K5YX*\4Q7/BUV'A[4=0U;2HK;6HM.%K]'_M-?\
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MW5SIEKHTEV^DZ=;3S#3K*U>1W/AO[8_P#^,]G\6?A7^VS^RAI>D^)?CQ\'-
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MC?M2>-OVA-6_9_\ B?\ !3PO8?!5?@IX/N_VGOVKOBO^U%^TOXIEUGQ?X?\
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M=\&_A[\0/@3X/F^%W@*[^'GB#X!:KI'C+X0:-HGBSPGXV\'Q^!/BE'H_QC^
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M+ES3<IR****X3O"BBB@ HHHH *^2_P!K7]K']G_]C;0/ 'Q6_:1\??\ "N/
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M7^HV7@.+4M?\=_#:XO/"=CXA@U?X;3?%&XBT?4?^$"MX=8;PGJ-QHRIVM_\
ML?\ QVE\.MXK\#:1XQ\.^//C%\4OCAX+^,<?Q1\;?!K5_'D/P)_:$T/PIX=\
M6>/]9F^$7AGP7\,]$US0-;^&^A^/]$^&_@:;Q^;6\\3ZUJT/BJX\0:QK.AZ<
M<RTU6OFG;U_S _3)OVA_@?=7EIH>@_%_X4^(_%^M>%[GQ?X5\&Z1\1_"-[XD
M\6Z%%H-]XD@U7P_I%EJEWJ>JZ3=Z+IUYJD6JZ=8WMF=+MKG4D>2TMY9%X;X,
M_M8?"_XG?#WX(^)_%'BGP#\,?''QS\)Z/XH\*?"K7_B-X>D\5WW]LSS6EM8^
M'K341X?U?Q5NO8);."YTWP_%]INHY(([<2QL@_//7OV,_B]I?B[XD^ M&\(?
M$[5/AQXG_:(\*?%_P-JG@?Q_^S;X,^&>@>'_  UIV@-X93Q/JOC'P#XK_:7M
M_%'P\7PY'X8TKP]X1N9/"WB#1I+33[;Q%X/L;[7;T<1\._V./VD_"WP!^(GP
M1UCX4O>^(/CWX _9<T>U\:)XQ^'<N@?!+5OA)!I.E>(+7QPQ\9P^)+G_ (1.
M_P!'G^(?@NY^%VB>/XM1UO7)H'N-%NXY;D',ORZ]';\5=Z>0'[!VO[0_P OM
M2U/1K+XY_!Z\U?1=*\0:[K&E6OQ-\%7&I:3H?A.2_A\5:SJ=C%K;W5AI7AJ7
M2]3B\0:C=116FC2:=?IJ,ULUI<"/)?\ :E_9CCBNIY/VC/@0D%CK,/AR]F?X
MO?#]8K/Q#<+=O;Z%=2-XA"6^LSII]^\.ERLE]*ME=LD#"VF*?BOX<^"?Q7_:
M%_9A\0?#?X;_  ;%E/HW[1'[7_Q!C^+\WB'X<Z?8>)[V9?C#X&LO VG6DVN0
M>-H_%OB_5]7TCP?JEYKVD:1X.L?".C66H77C*Y$4&A6'USXH_91^)E]9_%5-
M-^&>E-<:]_P2K\/?LU>&C'J/@B!YOC'IT7Q!$O@B!Y-7B%@EN]SX*V:_<-:^
M$B;32S#KC?V/FR.=?U;R\_/\'V _1R^^,_P>TSQ??_#W4OBO\-=/\?:5I=QK
M>J>![[QUX7M/%^FZ+::2=?N]7O\ PU<:K'K5GI=KH0.M7&H7%E':0Z2#J,DR
MV8,U>*?$?]N7]EKX<^"?$'CEOC/\-_&]KX9U+PQI>J:%\//B+\._$OB:.Y\5
MZ]9Z%8;=+/BZQC1+47%UK6H_:+NWD@T#1M;U*&.Y_LZ2%OS-L_V*OVCH_!WB
M#X7^(?#?Q8U];[XU>)OCIHM]HOQ&_9E\.?!RUU#5?!-Y?:1+K>J:CX,\2?M&
MZOX\TZYNF^$>I>%(+S3O &NZ:D30?$GPYX1D-U9=M\3/V/\ X[:E\/OA%HGA
M;X:1-=^#OV$?AC\+M>TC3O$7@'3R?BMX0^/7[./Q+UGPA ;KQ-INF76H76E^
M!/'-Y#X@^V#PK/J*2B7Q"MQJMN;LYEW_ !7EY^?X,#]</%OQ:^%7@#PSI/C7
MQW\3/A]X*\&Z]/86NA^+?%OC/PYX<\,ZU<ZII]SJVF6^DZ]K&I6>E:C/J.E6
M5YJ=A#9W<TEWI]I<WENLEM!+(G-ZI^T;^SUHE_I.E:U\=_@UI&J:_!HUUH6F
MZI\4/!&GW^M6OB.TM;_P]<Z39W>N17&I0:]8WUE>:--9QS1ZI:7EK<6+3PW$
M3O\ /?[4OA;XX^,?$7P-UOX:^"_%4FBVN@_%.U\??\(>?V<;3XM>%M0\7:!X
M5L_#.B6OB_XSVWBK1?#'A349(_$.E_$W4OAA)K7B:2WM-*FT--<BM;=)OSX^
M&O[$O[1VA?LN_M3>!-=^%L$'Q(\=?LZ_ 'X:?#^!_%GP]N[O6-=^'\OC,>)-
M,L]<@\43V>CV-K-/X=OK:;6-0TFSNP;!X"UW830V:;4H[I7:TOKNK_UVU _4
MKXK?M9?#7X=^./AY\,]%\0>!O'/Q$\7_ !A\#_"SQ)X#TOXB:!!XT\ 6'C.W
MO9QXQUSPK:1ZSKBV>G&/2XQ8W]CHT-X=;L#_ &O:F:W6Y^IJ_(:W_9W^.NDZ
MM\(_AO-\&O\ A)[?X:_MUZM^T7K7[1C>+OAXEAXL\!^*_%'B'Q--J:Z3J?BC
M_A9">.K2S\86GAOQ?H\OAG3]*,/@2.70=:\617&FO/\ KS6;2LOGUOV^[KH]
M>X!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^;K_ (.AU4_L"_"!RJEU
M_:_\!*KD#<JO\%_C\74-C(5BB%@#ABBD@E1C^D6OS>_X*A_\$^?^'DOP!\(?
M W_A;G_"F/\ A%/C#H'Q8_X2C_A ?^%B_;_[#\%_$#PA_8']B?\ ":>!?LOV
MK_A.O[1_M7^U[GR/[*^R?V=-]N^TV?T'"F.PN6\191C\;5]CA,+BXU:]7DJ5
M.2FHR3ER4H5*DM6M(0D_(_4_!'B3)>$/%C@7B7B+&_V=DF39Y2QF98WZOB\7
M]6PT:->$JGU; T,3BZUI3BN2AAZM1WNHV3:_S&**_L$_XA0_^K]O_-6__P H
MNC_B%#_ZOV_\U;__ "BZ_H[_ (B5P3_T.O\ S'9M_P#,!_K3_P 3??1V_P"C
MA_\ FI<<_P#T,G\?=%?V"?\ $*'_ -7[?^:M_P#Y1='_ !"A_P#5^W_FK?\
M^471_P 1*X)_Z'7_ )CLV_\ F /^)OOH[?\ 1P__ #4N.?\ Z&3^/NBO[!/^
M(4/_ *OV_P#-6_\ \HNC_B%#_P"K]O\ S5O_ /*+H_XB5P3_ -#K_P QV;?_
M # '_$WWT=O^CA_^:EQS_P#0R?Q]T5_8)_Q"A_\ 5^W_ )JW_P#E%T?\0H?_
M %?M_P":M_\ Y1='_$2N"?\ H=?^8[-O_F /^)OOH[?]'#_\U+CG_P"AD_C[
MHK^P3_B%#_ZOV_\ -6__ ,HNC_B%#_ZOV_\ -6__ ,HNC_B)7!/_ $.O_,=F
MW_S '_$WWT=O^CA_^:EQS_\ 0R?Q]T5_8)_Q"A_]7[?^:M__ )1='_$*'_U?
MM_YJW_\ E%T?\1*X)_Z'7_F.S;_Y@#_B;[Z.W_1P_P#S4N.?_H9/X^Z*_L$_
MXA0_^K]O_-6__P HNC_B%#_ZOV_\U;__ "BZ/^(E<$_]#K_S'9M_\P!_Q-]]
M';_HX?\ YJ7'/_T,G\?=%?V"?\0H?_5^W_FK?_Y1='_$*'_U?M_YJW_^471_
MQ$K@G_H=?^8[-O\ Y@#_ (F^^CM_T</_ ,U+CG_Z&3^/NBO[!/\ B%#_ .K]
MO_-6_P#\HNC_ (A0_P#J_;_S5O\ _*+H_P"(E<$_]#K_ ,QV;?\ S '_ !-]
M]';_ *.'_P":EQS_ /0R?Q]T5_8)_P 0H?\ U?M_YJW_ /E%TH_X-1!D9_;U
M)&1D#]EO!([@$_M%$ XZ'!QZ'I1_Q$K@G_H=?^8[-O\ Y@#_ (F^^CM_T</_
M ,U+CG_Z&3^02RLKS4KRVT_3[:>]OKR>.VM+2VC>:XN)YF"10PQ("[R.Q"JJ
M@DDU_J"?\$NOV??%?[+?[ G[-'P1\=6\UCXS\+^"M2UKQ3I=RJ)=Z%KWQ$\7
M^)/B5JGAR]6.6>$7_AR\\7RZ%?\ D3SVYO-/G,$TL)21OBO]@S_@@G^RI^QC
MXOTGXK>+=8U;]H[XP>';VSU/PIXD\<:#INA>#O!>L:=<27.G^(O"OP_M;S6X
MXO$MG,T-Q9ZQXB\1>)6TF_L=/U;P];Z)J]I'?U^YQX__ %9_2OR;Q$XWP7$:
MPF694JE3 X7$?6JF*JTY4GB,0J<Z5)4:<U&K"E3IU:O,ZL(3G.:]R,8*4_X:
M^EC](WA[Q;H9+P?P3'%8CAK)<S>=XS.<;A:N"EFN:0PF(P.#6 PF(4,70P6$
MPN.QRJ3QE'#U\17Q"2P]*GAXU,05#(1N X)(QC/J?P'KU./:O.?%_BSQQ9R3
M:7X!^'TWBG653'V_Q!J\7@_P=9NRJR-=ZS+::KK%\ &!,>@>'=57(:.6X@=6
MV?,GB3X-?MH_$J:5O$/[6'A_X*Z1*WR>'_@#\(-'U#5X8&4JT4_Q!^+5[XHG
MN)ER2+O3_!VB*3@_9!]T_F5_*_E=+MW:VNC^0,!E-'%VGC<YRK)J#Y6JN.GC
M,14DG9^[@\IP>98Z.FJE5P]*F]/WEFK_ ,:/_!07_A6FM?\ !2G]LC4OC5XJ
M\8Q^'-#\>ZF=.T[P/IUG?>*/%M]IVG^'M+T?P9IFI:P[Z)X6M+6U\PZAXAU2
MWU"&PLM,F6STG4;ZYM[<_1W_  2S_P""GOPN_8:TO]IS1_%6E_$*^^'7BB'P
M]XL^"WPMCU.'Q3K#^.8#>:7JFFW/B:/2M!T;31J^GR:9/J^MG1]/@:/2X#!I
MM[?(D4_[I>(/^"#/['?C_P 3Z]X\^*GC7]H;XC^/O%NJ7&N>+/%VM?$71].U
M#Q#K-X0UUJ-[;:)X0L+.*:8J R6D5O"BA5CC0# JQ?\ !O\ _L&Z9J%CK/A^
MZ^.WA_6-*O;34M*U#3_B;%-+8:C83QW5E>PI?^&KU#-:W,44\0<-&'C4E2 5
MKQXX7&0Q'MJ;PZ?M*DI2<IN4XU'?WE9*7*FG&-XQYDF^[_OS'^/G@!Q!X?9?
MP!Q3/CG-,!A^'^%\HKTL)EF'PF74<5PW1R^2KY8HXJGB<,LPQ>#G'$8ZKA:F
M90P6)K4:$J$6J9]H?L(?M$_M*?M)> /$'CW]H/\ 9O?]G*UEU'3$^'FD:CJU
M_<Z_XIT:YLI;W4-9O]&U*TM;W1[" S:=:Z5/=B&;6"+R[6SM(%B0^6?M!_ K
MXZ^)?VL=-^,_P[\*6VH^&O"OA#X5)9W7]JZ)I&M:EXL\.ZO\6K@G1M3GUVUO
MK/0](OO$_@N[^(>@WEE:VWQ!\%0:MH%GJ+7]A9VEWZ'I'[,G[5_P\=Y?AW^W
M9XW\76D8'D>'/VB_A9X$^)FGR*&#"*;Q'X13X:^+T7:/+\[^T[B;!+2>:P!K
MZ \'>+?COH[6NE_%[X=>&M09V2!O&WP=UF^U70G9B%%QJ7@OQ1;Z;XKT2-CD
MM'I=YXQCAZR700;Z]BDY045K*27*Y3=/WMM;1Y4OE&+M>Z3T/X=XJPF49AFF
M/S/AROP[0RVO557#Y)E%;.\/_9M*-*$(T81XHHT,9BJC4/:5?88K&N=>=25&
M-.DZ=&'Q:++_ (*)6_A73;JSN=2U?Q!/X4FN-9T?7H/AEH6H:%KTEW)+KEGH
MNHZ/XDUO0_%T[VD-WI_@Q-9D\,)9W5WX=U>\U>WL[?6M*K0O+']O>7Q%8Z19
MWGCI/#$D?PZTG5?%,H^!MIJDUG!XZ^&4OC'Q#8Z0M[JT&CZI/\.K_P")EGJ5
MFTNN.WB#2;6ZTN=A-I5O7Z@*=RJ>1E0<$%3R,\@@$'U! (Z$ \4M:>U_NTVW
M;6R3Z:^?1^;MY'Q:BEJF_P"N^A^3?C?X<_MG7WB3P'X\TFQ\7W/Q+^'MC\9-
M);6/[9^#UQX5U1=9\6^ SX4MM"M+QK2__P"$1\6>#=#N#K=MK=K9:YI^L64I
MADTVXN&N[V_\8_@-^T-KWQ,^,_BKP/HCMI&N_M&?LK>/?"6E7TWA7^S];T3X
M<>&O"MKXQUV[O9?$<&J:5IFEZMI6H+J>B?9(M0UZ)I&L;._&ISLOZJT5/M7=
M-0@M+:>;B^_39>6VZ#E7>7W^GYV_K0_*'Q!??MY>$/!^K^+M;UJ_M='\/^#M
M8\0ZTFJ/\/!K.E:YIOPQTN?Q5K,>KZ,FH:7>>'M,^(%IX@O_  /X3G\.7\VN
M^'KD6]]JF@WEOI<+\GHOA?\ ;6\=7_PG^)\.I>+-5T#4M&\!Z['K]M<?"+0/
M'\7@C5/'7[/OBSQ9X4U.YL%L[:>#7+#3OBQ?VVDVN;&Z\,0>%]*UR9M=7[/)
M^Q#*K=1GI^0.?\^W%*JJHPH 'H/R_I5*K;11A]RMT\[W??S]!<G9O^K?=M^7
M8_-SX-^$OVH]<^/_ (,\>_&GPEJUGH7A:7XP66CZGJ>L?#V[O-%\-^-_!'P8
MDT_1;P^$;^)M34^/?#GCXVKPZ44LK)].WNEK);LOZ2445A4ES).R6VBVT7S[
MV_'J4E96NWZA11160PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU:*R^'VJM;7TFD>);^'3[Z2W^6]0_8D^(WCGPY\3? 7BC2_AQX&\'_M!^(_
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M[9VC8I(J3V[R1,4=2CA7)5@5;!!%7*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !/ +8# 2(  A$! Q$!_\0
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M'=6.H:??6KRVM[8WMK+%<VEW;2RV]S!+'-#(\;JQ7UC*?^@/,?\ PY87RO\
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MG_H#S'_PY87RO_S*O7[_ "!8;-O^@S+^G_,MQ/7E_P"IMUN_O\M/D#_AX/\
ML"?]'Q_L?_\ B2WP7_\ FVH_X>#_ + G_1\?['__ (DM\%__ )MJ^PO[7T7^
MW/\ A&?[7TG_ (23^RO[=_X1_P"WVG]N?V)]K_L_^V?[)\W[?_97V_\ T+^T
M?L_V3[7_ *-YWG?)5R\FM=.M+K4-0N+6QL+&VGO+V^O)H[6TL[2UB:>YNKJY
MG*0V]M;PH\T\\SI%%$C22,J*2#V^4_\ 0'F/_ARPOE_U*O7[_(/JV;:?[9E_
M3_F6XG^[_P!3;S?W^6GQC_P\'_8$_P"CX_V/_P#Q);X+_P#S;4?\/!_V!/\
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MN_X*-5Z.!G+ZKG/_ &+:73_J;Y2>9CHQ^M9-I_S,JO\ ZI\U*'A#_D4O"_\
MV+NB?^FRUHH\(?\ (I>%_P#L7=$_]-EK17EGMQV7HOR+_P#P4:_Y1[?MW_\
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MQF$S#A_+N)/KZ+_@HI^V'XQDM[#4?$7AGX+:=\83+XR\2WVGV'@;Q?\ $O\
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M_P _<M_\/.3_ /S<?/\ ]K87_GUF?_AESC_Y@\_S[,^RZ*^-/^$X_P""A/\
MT:_^QI_XG?\ &[_Z7+1_PG'_  4)_P"C7_V-/_$[_C=_]+EH_LK%?\_<M_\
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M_P!C3_Q._P"-W_TN6C_A./\ @H3_ -&O_L:?^)W_ !N_^ERT?V5BO^?N6_\
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G6M%/\'?\BCX6_P"Q<T/_ --EK17E<L5T^_\ K^OF?11V7HOR/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image00001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +J W(# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **\_^*?Q(T/X1^ ]=^(?B2TU:]T7
MP]_9GVVUT."SN=4E_M;6=/T.V^RP7]]IMH^R[U*"2?S;V#;;I,\?F2JD,GQ[
M_P /(/@?_P!"K\5O_!'X0_\ FYKX'BKQ2\/N",PHY5Q9Q7E619CB,'3S"CA,
M=4JPJU,%5KXC#4\3%0I37LYU\)B:2=T^:C/2R3?UV0<!<8<4X.IF'#_#^/S7
M!4<3/!U<1A84Y4X8JG2HUIT9.52+YXTL10J-6MRU(N^]OT"HK\_?^'D'P/\
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MR%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _/7_ (*K7]WIG[!/QXOK&7R+J#_A
M5_E2^7')M\SXS?#N%_DF22-MT<CK\R'&<C# $?QO_P#"=^*_^@K_ .2.F_\
MR'7]BG_!63_E']\??^Z5_P#JZ_AQ7\7M?YB_33;7BED%FU_Q@&5=?^JBXJ/]
M8OH)8>A5\(N(Y5:%&I)>(^;Q4JE.$Y**X9X0:2<HMV3;=MKMOJ==_P )WXK_
M .@K_P"2.F__ "'1_P )WXK_ .@K_P"2.F__ "'7(T5_(5WW?WL_M7ZE@_\
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M1_; 4444 %%%% !1110 4444 %%%% 'Z84445^+G\_GM/P*_Y&[4?^Q<O/\
MTYZ17U?7RA\"O^1NU'_L7+S_ -.>D5]7U\;G7^_S_P"O=/\ ])/R'C+_ )'=
M3_L'P_\ Z0PHHHKR3Y4**** "OV,_96_Y(+X#_[FC_U,_$5?CG7[&?LK?\D%
M\!_]S1_ZF?B*O[__ &<7_)[^*O\ LU6>?^M=P,?A7T@_^2,RS_LI\%_ZJLZ/
MH2BBBO\ :D_CP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#3GI%?5]?*'P*_Y&[4?^Q<O/\ TYZ17U?7QN=?[_/_ *]T_P#TD_(>,O\
MD=U/^P?#_P#I#"BBBO)/E0HHHH *_8S]E;_D@O@/_N:/_4S\15^.=?L9^RM_
MR07P'_W-'_J9^(J_O_\ 9Q?\GOXJ_P"S59Y_ZUW Q^%?2#_Y(S+/^RGP7_JJ
MSH^A****_P!J3^/ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _.3_@K5/#;?\$^OC_-<3100I_PJK?+-(D4:;OC9\-T7=(Y55W,RJ,D9
M8@#D@5_%?_;6C?\ 06TS_P #[7_X[7]E_P#P65_Y1M_M'?\ =(/_ %?/PNK^
M$NO\X/I@933Q_B7D=:=:=-QX&RRG:,8M-+/^)I7UUO[[7R/]7?H*XF5'PDXB
MBHJ5_$;-Y7;:WX9X05M/0^A?[:T;_H+:9_X'VO\ \=H_MK1O^@MIG_@?:_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA1110 5^QG[*W_)!? ?_ '-'_J9^(J_'.OV,_96_Y(+X#_[FC_U,_$5?W_\
MLXO^3W\5?]FJSS_UKN!C\*^D'_R1F6?]E/@O_55G1]"4445_M2?QX%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7EW_ (18;_Y4</\ 8V3_ /0JRW_PAPO_ ,J/2_\ A='QB_Z*Q\2__"[\4_\
MRUH_X71\8O\ HK'Q+_\ "[\4_P#RUKS2BC^Q\I_Z%>7?^$6&_P#E0?V-D_\
MT*LM_P#"'"__ "H]+_X71\8O^BL?$O\ \+OQ3_\ +6ONGX-_M$?M 6/PW\.6
MME\=/C%9VT7]K^5;VOQ-\:V\$>_7M4D?RX8M;2--\CO(VU1N=F8Y9B3^9=?:
M7PE_Y)]X?_[BO_I[U*OZS^AOEV7X?Q.SV>'P.#H3? >9Q<Z.&HTI.+XAX7DX
MN4(1;BW&+LW:\4[72/B./L@R*MD^&A6R7*:L5F5&2C5R[!U(J2PN,2DE.BTF
MDVKVO9M=6?6'_#2?[1?_ $7WXU?^'3\<_P#R]H_X:3_:+_Z+[\:O_#I^.?\
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M;_TIM*]5KSL3_%?I'\CP\?\ [Q+_  P_(****P.,**** "OM+X2_\D^\/_\
M<5_]/>I5\6U]I?"7_DGWA_\ [BO_ *>]2K^KOH>_\G,SS_LA<S_]:#A@^,XY
M_P"13A_^QC1_]1L6>C4445_I$?E1^GW_  2<_P"3B_&G_9%?$?\ ZG/PXK^A
M*OY[?^"3G_)Q?C3_ +(KXC_]3GX<5_0E7S&:?[W+_!3_ /23_,#Z5G_)W,9_
MV(LD_P#3%4****\X_FX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^'3-/_D?7^EK_EQ?\._/V]/^C(_VN_\ Q&SXR_\ S%T?\._/V]/^C(_VN_\
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M\)[3E\.N&)^TY+\V:YJK<G-M:/7F?X'^9?\ \,%_MS?]&8?M8?\ B.OQ?_\
MF.H_X8+_ &YO^C,/VL/_ !'7XO\ _P QU?Z:%%<G_$M.1_\ 139M_P"$F#_S
M]?Z6O9_Q4>XV_P"C;\+?^';-O_D3_,O_ .&"_P!N;_HS#]K#_P 1U^+_ /\
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M]_T5N=?^$6!_S]?Z6N7_ !4&XQ_Z-[PS_P"'3-/_ )'U_I:_P2?\,=_M<?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ_\ 6</B_7^C%7]<^ ?_ "1^9?\ 92XS_P!5>3'^1'T^_P#D\7#7_9M,F_\
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M_6KB?_HH\^_\/&8?_-!\N?\ ##O[%7_1G_[+G_B/_P )_P#YDJ/^&'?V*O\
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M,_\ V7/_ !'_ .$__P R5?4=%']G9?\ ] .#_P#":A_\@'^M7$__ $4>??\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?D/_P %PO\
M@H5\3O\ @F)^P#XX_:H^#_@SP1XY\?:5XS\$>!=$TGXA_P!MR>%K.X\<WEYI
M4.N:A9>']1T?4]531[M+:\;28=7TH:E DUK_ &E8O(ES& ?KQ7QM^TU_P4,_
M8@_8VL#>_M-_M2?!;X/W#074]IX?\4^.-&3QCJJV42S7$>B^";&XO/%NL3(C
MQCR=-T:Z<M+&N,NH/^4'^UE_P</_ /!6[]K_ /M73?&7[5OBKX6^"]5\@/X
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MU.TM[_3=3TZZ@OM/U"QNXDN+2]L;RVDEMKNTNH)(YK>Y@DDAFB=)(W9&#'_
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M .R3_ W_ -3#Q]7\+=?W2?\ !CW_ ,ES_;__ .R3_ W_ -3#Q]0!_HJ4444
M>3_'K_DAGQH_[)/\1?\ U#]8K_!?K_>@^/7_ "0SXT?]DG^(O_J'ZQ7^"_0
M4444 %?[>O\ P2A^%WB'X*_\$SOV#OA;XNL?[,\5>#OV4_@EIWB732<MI^OS
M> ]&O]8L7)529+34+RXMY254F2-B0#Q7^3U_P1"_X)\:Q_P4B_X*(?!'X)W&
MBRZC\)O"NM6GQ9^/]_):I<:78_"/P+J-C?ZUI&H><5@9O'6I/I7@*SM\O.TO
MB-[M(9;>QNC'_LX:A?Z)X3T"]U34;BRT/PYX9T>YO[ZZF*6NG:/HFC63W%S<
M2MA8[:RT^PMGD<X"0P0DX"K0!^./_!<3_@KKX#_X)+?LHWOCBWFT+Q%^TI\5
M8M9\*_LV_#/4Y//&L>)K2VMQJWCSQ#IEO-#>R> ?ATFI:=J7B*59;2/4M1O=
M!\+17UI>^(;:>+_'W^,7QB^*'[07Q1\<_&KXU>./$'Q)^*GQ)\07OBCQOXW\
M3WAO=9U[6KXJ))YW"QV]K:6L$<%AI6E:?!::3HNDVECH^CV-CI5C9V<'Z+?\
M%H?^"DOBC_@J#^W;\4OCS)J.H+\'_#^H7GPY_9T\,7,UXMKH'P=\-:C=PZ#J
MO]FWEGITNGZ]X^E:?QSXGAN;%-0M-2UP:%<7-U:Z%8.GY/T %%%% $D,,UQ-
M%;V\4D\\\B0P00HTLTTTK!(XHHT#/))([*B(BEG8A5!) K_4V_X-QO\ @@9X
M._8,^%/@_P#:Z_:A\%Z7KO[;OQ)T*/7-&TK6H(-4M_V:_".NV[2:=X9T*.>'
MR+;XH:GHUQ"WC_Q% KW&B3W5WX*T&^?3K75=4\1?R*_\&LO[ FG?MJ?\%,?#
M?CSQYX>77/@[^R#H47QW\5PWD-E<Z/J?Q!@U2'2_@UX9U*WN)?.D,_BC[=XX
MA$5M/;2Q?#R[L[UXDNXHY_\ 6HH *_FI_P"#M/\ Y0K_ !L_[*Q^S]_ZM#1*
M_I6K^:G_ (.T_P#E"O\ &S_LK'[/W_JT-$H _P EVBBB@ JQ:7=W87=M?V%S
M<65]97$-W9WEI-);7=I=VTBS6]S;7$+)-!<03(DL,T3I)%(BNC*R@BO10!_M
M[_\ !*O]I?5?VPO^"='['7[1OB*\M;_Q=\2?@9X,N_'5W9;Q;3_$#0;(^%?'
MDL:22SR1"3Q=H>LR>3)-+)$7\MY&923^@-?B9_P;G>!]<\ ?\$7?V$M*\01+
M!>ZS\-->\<6L2[O^0'\0/B'XP\9^')6+ $M=:!K>FW9P-H\\*I90';]LZ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *^&O^"G7_*./]O#_LT+]HG_ -51
MXJK[EKX:_P""G7_*./\ ;P_[-"_:)_\ 54>*J /\.RBBB@ HHHH _P!8O_@T
M:_Y0R?#/_LM_Q[_]3(5_3;7\R7_!HU_RAD^&?_9;_CW_ .ID*_IMH **** /
MR/\ ^"WG_!/30/\ @I+_ ,$\/C=\$AI-E=?%GPKH=[\5_P!GW6YH[5+S1/B_
MX&T^\U+0K"WU">PU&73].\<V(U+X?^(Y+6W,[:%XFO9("EW!:S1?XO<T,UO-
M+;W$4D$\$CPSP3(T4T,T3%)(I8W"O')&ZLCHZAD8%6 ((K_?TZ]:_P 3O_@L
MS\"+']FO_@JA^W7\(-+(&CZ-^T+XT\3Z' L,=O'9:#\3I;?XI:%ID,,2JB6^
MEZ1XSLM.M]JC,%K&QR220#\RZ*** "OVK_X-W_V@I?V<O^"Q'[%7B>?7I-"\
M/>/OB-<? _Q5@H+;5]-^,VA:IX!T;2;W<CDP/XVUCPGJ$6PHZWVGV;E]BNK?
MBI7T)^R/XO'P^_:M_9C\>F1X1X(_:$^"_B\RQH\CQ#PU\2/#6LF1(XE:1W3[
M%N5(U9V8 (I8@$ _W=**:CB1$<='57&>N& (S^!IU !7^&%_P4$_Y/T_;<_[
M.[_:3_\ 5R^-*_W/:_PPO^"@G_)^G[;G_9W?[2?_ *N7QI0!\B4444 %?[Q/
M[,O_ ";=^SY_V1#X4?\ J!Z!7^#M7^\3^S+_ ,FW?L^?]D0^%'_J!Z!0![?7
MX6_\' __  5-LO\ @E[^PIXH\3>#=5LD_:7^.!O_ (6?L\:2\Z?:],UW4+/'
MBCXG2VOV>[+Z;\,M N)-9@-Q MC?>*[CPKH-S<6Z:P9H_P!M_$OB30/!OAS7
MO%WBK5[#P_X8\+Z-J?B'Q%KNJ7$=IIFC:'HUE-J.JZIJ%U*5CM[*PL;>>ZN9
MY"$BAB=V.!7^-%_P6\_X*=>(/^"IO[='COXT65]JD/P,\#"X^&?[-_A:\?4+
M:#2OAAHFH74D?BBYT:\,2Z?XG^(VIR7'BWQ"SV-KJ4-O=:)X<OVGB\,6)0 _
M(S4M2U'6=1U#6-8O[W5=6U6]NM2U35-2NI[[4=2U&^GDNKZ_U"^NI);F\O;R
MYEEN+JZN)9)[B>22::1Y'9C2HK]NOVM?^"4]_P#L:?\ !)/]CK]L7XO:;K.D
M?'[]L'XYZW?:-X:OI;NQC\$?L_Q?#BXU?P1I^K:*]P\+^)_&=Y$OCFXN[FWM
MK[2M#U+1-"EMK6\@U7SP#\1:*** "O[I/^#'O_DN?[?_ /V2?X&_^IAX^K^%
MNO[I/^#'O_DN?[?_ /V2?X&_^IAX^H _T5**** /)_CU_P D,^-'_9)_B+_Z
MA^L5_@OU_O'?M)ZUH_AW]G?X\:[X@U73M#T32?@Y\2[_ %76-7O;?3M+TVQM
M_!NLR7%Y?WUW)%;6EM"@+RSSR)&B@EF%?X.- !5[3-,U+6]2T_1M&T^^U;6-
M6OK33-*TK3+2XO\ 4M3U*_N([6QT_3[&UCENKV^O;J6*VM+2VBEN+FXECAAC
M>1U4T:_NJ_X-/O\ @B3+\0/$FA_\%0?VI/!4B^!O!^IR2?LA^"O$5N1#XP\7
M6#S6E_\ '+4=(F3$_A[PE="73_AN;]3'J/BF"^\76]HL7A[POJM^ ?T=_P#!
MN=_P21C_ ."8'[&=KK'Q.T5+?]K']I.'0/B!\<WNHM,EU#P#IZ:=YG@SX*6U
M_IXF62V\"6M]>W?B,IJ&HV]WX[UOQ++9WLVD6^C1VV5_P=%_MCWG[)/_  29
M^+ND>&M7&D_$']J#6]%_9K\)RHERUPFD>-8-0U7XFW$$EK-;R6DG_"K_  _X
MLTRVOVE"6FI:KI[E)G9()/Z**_SQO^#WSXTW]Y\3OV%?V>+/6I%TG0/ _P 5
MOC%XA\/1M&89M4\3ZYX>\&>$]6NUVF43V5EX6\86MEAU01:E?%D<LC( ?P@4
M444 %%%% '^F]_P9>?L\V_@'_@GY\;_VA;[2K&'7_P!H+]H*_P!'T[64B7^T
M+WP%\'_#VFZ%I-E<3D;S;6?C77OB%)!"&\M7N)9,;W-?V-5^ W_!L%X-A\&_
M\$2OV.8XG\Q_$L7QB\97$A*EFF\1?'#XB701MJJ/W$"PVR Y810Q[F8Y-?OS
M0 5_.I_P=1^!/''Q#_X(U?';1? '@WQ3XXUBP\?_  4\1WND^$/#^J^)-3M/
M#^@?$32-1U[7;G3]'M+R[AT?1-/BEO\ 5]2>$6>FV,4MY>S06T4DJ?T5TUT2
M1'CD19(Y%9'1U#(Z,"K(ZL"K*RDAE((()!!!H _P":*_V+_VY/\ @W7_ ."6
M7[>&I:UXQ\<? E?A#\6-;CU)[OXL_L]ZA%\,?$MYJFI)&)-<U[0+2QO_ (?>
M+=8BEBBFCU'Q5X.UB]W(T3W#6\]Q%+^%WB__ (,@_P!G^YU%I/ /[=/QBT;2
M6=REGXO^%_@KQ-J,49'[M&U+1=6\)VT[J?ORC2K96'"Q)UH _P Z&OU0_P""
M1W_!*[XV?\%5_P!J;PI\'/ NC>(M'^$&B:E8:S^T%\:+2P4:#\+OA]%,);_9
MJM_#)I4_CKQ+%&^C^!?#834+_4-5N#J]QI4OAG0_$5_I_P#</\ O^#+C]@3P
M%KVG:[\>/CS^T!\?[6S;?<^#;.;PY\)_"6JDH!Y6I7'ANTU3QKY(D&Y3I'B_
M19BA*&0G$@_JN_9V_9F^ 7[)7PPT7X-?LW?";P5\'/AIH/F/8^%?!.C6^E6<
MMY.QDN]5U6X16OM;UN_E+3ZCK>L75]JM_.S37=W-(2U 'H7P\\ ^$_A5X!\$
M_#'P'H]IX>\$?#SPGX>\$>$-!L(DAL]'\->%M)M-$T33+:*-41(;+3;*VMT"
MJHQ'G&2:[&BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M18P3VTP\$^!O@7X0E6 +YEO/'\*/#/B.6"\(EDS<AO$?F@E8F%K+; Q<"20
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M/%5 '^'91110 4444 ?ZQ?\ P:-?\H9/AG_V6_X]_P#J9"OZ;:_F2_X-&O\
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MZU7\2?\ P>Z_\FA_L6?]G(>,/_58ZA7]ME?Q)_\ ![K_ ,FA_L6?]G(>,/\
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MXTT:.5E2TU>VM7>T\0>%]39H;@C1O%_AN\U?PMK1CB:?^R=8O?L[1S^7(O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<V]E8V5O-=WEY=S1VUK:6EM&TUQ<W-Q,R0P6\$*/+--*Z1Q1HSNRJI(_!O\
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MACPWI<-WK?B+5Y(95T_2;&ZG6&>98K>7^PW_ (@@OVDO^C[?@?\ ^&J\>_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5\-?\ !3K_ )1Q_MX?]FA?M$_^JH\55]RU
M\-?\%.O^4<?[>'_9H7[1/_JJ/%5 '^'91110 4444 ?ZQ?\ P:-?\H9/AG_V
M6_X]_P#J9"OZ;:_F2_X-&O\ E#)\,_\ LM_Q[_\ 4R%?TVT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E_QO\
M$^L^"?@O\7O&?AV>&U\0>$?A?X_\3Z%<W%O'=P6^LZ!X4U;5=,GGM)OW5U#%
M>VD$DEO+^[G16B?Y6->H5Y[\7/!]]\0_A1\3O &EWEII^I^.?AYXT\'Z=?WZ
M326-C?>)O#>I:+:7E[';@W#VEM<7L<URD ,S0HZQ N5H _QI_P!H_P#X+D?\
M%8/VJ?M5M\5OVWOC5:Z%<:C=Z@GA7X8:Y;_!?PU!'<^<B:7)I_PGL_!SZOI-
MI!-Y%O:>(KC668107-W+=7T8NS^5E_?WVJWU[JFJ7MWJ6IZE=W-_J.HW]S->
M7U_?7DSW%W>WMW</)<75W=7$DD]S<SR233S2/+*[.S,?[>_^((/]IK_H^CX$
M_P#AL?B!_P#+2C_B"#_::_Z/H^!/_AL?B!_\M* /X>:*_N&_X@@_VFO^CZ/@
M3_X;'X@?_+2C_B"#_::_Z/H^!/\ X;'X@?\ RTH _AYHK^X;_B"#_::_Z/H^
M!/\ X;'X@?\ RTH_X@@_VFO^CZ/@3_X;'X@?_+2@#^'FOL'X!_\ !07]N3]E
MRYT.;]GW]K7]H+X4V?APD:1X<\*_%3Q?;>"88S%+"+>Y\!7.J7/@K4K-%F=X
M[+4] O+2*<1W44*7,,,L?]8O_$$'^TU_T?1\"?\ PV/Q _\ EI1_Q!!_M-?]
M'T? G_PV/Q _^6E 'ZR_\&I'_!53]M[_ (*+Q?MA>#/VQ/BQ:_%Y/@/IGP-U
M#P'XDN?!?@_POXH#?$:^^+,&NVVNWW@W1O#]AK,$$7@K1DTV2XTM;Z$F[>ZO
M+QYPT?\ 8;7\V/\ P0!_X(9?%+_@C?K?[4NJ?$7X[^ ?C1#^T%I7P>L-*C\%
M>&/$7AR3P[)\,KOXE7%V^H?VY<W*WB:JOCRW6V^S&-K=M/F\T.)T*?TG4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 08, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioLineRx Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001498403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity's Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity a Voluntary Filer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">L3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">972 (8) 642-9101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 HaMa&#8217;ayan Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Modi&#8217;in<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">7177871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,610,814,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity a Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Kesselman & Kesselman<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel Aviv, Israel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text">
      <div>
        <div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion on the Financial Statements</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have audited the accompanying consolidated statements of financial position of BioLineRx Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2025, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024 and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Substantial Doubt about the Company&#8217;s Ability to Continue as a Going Concern</span></span></div>
        <div style="text-align:justify;line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1(c) to the consolidated financial statements, the Company has suffered recurring losses from operations and has cash outflows from operating activities that indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&#160;1(c). The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></span></div>
      </div>
    <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Philip A. Serlin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">phils@biolinerx.com<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 HaMa&#8217;ayan Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Modi&#8217;in<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">7177871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">642-9100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="nump">$ 10,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents', window );">Short-term bank deposits</a></td>
<td class="nump">17,626<span></span>
</td>
<td class="nump">9,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">2,148<span></span>
</td>
<td class="nump">3,145<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">23,681<span></span>
</td>
<td class="nump">27,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>NON-CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, net</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">16,368<span></span>
</td>
<td class="nump">10,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">17,224<span></span>
</td>
<td class="nump">11,802<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">40,905<span></span>
</td>
<td class="nump">38,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Current maturities of long-term loan</a></td>
<td class="nump">4,479<span></span>
</td>
<td class="nump">4,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade</a></td>
<td class="nump">3,493<span></span>
</td>
<td class="nump">5,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Other</a></td>
<td class="nump">1,743<span></span>
</td>
<td class="nump">3,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current maturities of lease liabilities</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_Warrants', window );">Warrants</a></td>
<td class="nump">2,174<span></span>
</td>
<td class="nump">1,691<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">12,123<span></span>
</td>
<td class="nump">15,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>NON-CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived', window );">Long-term loan, net of current maturities</a></td>
<td class="nump">4,460<span></span>
</td>
<td class="nump">8,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">977<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">5,437<span></span>
</td>
<td class="nump">10,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_CommitmentsAndContingentLiabilities', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">17,560<span></span>
</td>
<td class="nump">25,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Ordinary shares</a></td>
<td class="nump">73,428<span></span>
</td>
<td class="nump">38,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">327,584<span></span>
</td>
<td class="nump">353,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantReserve', window );">Warrants</a></td>
<td class="nump">3,686<span></span>
</td>
<td class="nump">5,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalReserve', window );">Capital reserve</a></td>
<td class="nump">15,916<span></span>
</td>
<td class="nump">17,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Other comprehensive loss</a></td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(1,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(401,002)<span></span>
</td>
<td class="num">(399,827)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Total equity attributable to owners of the Company</a></td>
<td class="nump">18,196<span></span>
</td>
<td class="nump">13,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">5,149<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">23,345<span></span>
</td>
<td class="nump">13,461<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 40,905<span></span>
</td>
<td class="nump">$ 38,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_CommitmentsAndContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment and contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_CommitmentsAndContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_Warrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_Warrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the capital reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 164<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_164_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 164<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_164_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2025-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current loans received. [Refer: Loans received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LicenceFeeIncome', window );">License revenues</a></td>
<td class="nump">$ 1,180<span></span>
</td>
<td class="nump">$ 22,917<span></span>
</td>
<td class="nump">$ 4,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Product sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,023<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenues</a></td>
<td class="nump">1,180<span></span>
</td>
<td class="nump">28,940<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">COST OF REVENUES</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(9,263)<span></span>
</td>
<td class="num">(3,692)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">19,677<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="num">(8,093)<span></span>
</td>
<td class="num">(9,149)<span></span>
</td>
<td class="num">(12,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">SALES AND MARKETING EXPENSES</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,605)<span></span>
</td>
<td class="num">(25,270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="num">(3,144)<span></span>
</td>
<td class="num">(6,321)<span></span>
</td>
<td class="num">(6,310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ImpairmentLossOnIntangibleAssets', window );">IMPAIRMENT OF INTANGIBLE ASSETS</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,010)<span></span>
</td>
<td class="num">(6,703)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">OPERATING LOSS</a></td>
<td class="num">(10,287)<span></span>
</td>
<td class="num">(20,408)<span></span>
</td>
<td class="num">(49,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ProfitLossFromNonOperatingActivities', window );">NON-OPERATING INCOME (EXPENSES), NET</a></td>
<td class="nump">8,077<span></span>
</td>
<td class="nump">18,435<span></span>
</td>
<td class="num">(10,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">1,871<span></span>
</td>
<td class="nump">2,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(1,280)<span></span>
</td>
<td class="num">(9,119)<span></span>
</td>
<td class="num">(2,169)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">LOSS AND COMPREHENSIVE LOSS</a></td>
<td class="num">(2,026)<span></span>
</td>
<td class="num">(9,221)<span></span>
</td>
<td class="num">(60,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>ATTRIBUTION OF LOSS AND COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">To owners of the Company</a></td>
<td class="num">(1,175)<span></span>
</td>
<td class="num">(9,221)<span></span>
</td>
<td class="num">(60,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">To non-controlling interests</a></td>
<td class="num">(851)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="num">$ (2,026)<span></span>
</td>
<td class="num">$ (9,221)<span></span>
</td>
<td class="num">$ (60,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">LOSS PER ORDINARY SHARE &#8211; BASIC ATTRIBUTABLE TO OWNERS OF THE COMPANY</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">LOSS PER ORDINARY SHARE &#8211; DILUTED ATTRIBUTABLE TO OWNERS OF THE COMPANY</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF BASIC LOSS PER ORDINARY SHARE</a></td>
<td class="nump">2,465,272,604<span></span>
</td>
<td class="nump">1,198,107,761<span></span>
</td>
<td class="nump">963,365,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF DILUTED LOSS PER ORDINARY SHARE</a></td>
<td class="nump">2,465,272,604<span></span>
</td>
<td class="nump">1,198,107,761<span></span>
</td>
<td class="nump">963,365,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ImpairmentLossOnIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of impairment loss on intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ImpairmentLossOnIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ProfitLossFromNonOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non operating profit (loss) from operating activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ProfitLossFromNonOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LicenceFeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LicenceFeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2025-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Share premium [Member]</div></th>
<th class="th"><div>Warrants [Member]</div></th>
<th class="th"><div>Capital reserve [Member]</div></th>
<th class="th"><div>Other comprehensive loss [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Non-controlling interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">BALANCE at Dec. 31, 2022</a></td>
<td class="nump">$ 27,100<span></span>
</td>
<td class="nump">$ 338,976<span></span>
</td>
<td class="nump">$ 1,408<span></span>
</td>
<td class="nump">$ 14,765<span></span>
</td>
<td class="num">$ (1,416)<span></span>
</td>
<td class="num">$ (329,992)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,841<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">BALANCE, shares at Dec. 31, 2022</a></td>
<td class="nump">922,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>CHANGES IN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_NumberOfNewSharesIssued', window );">Issuance of share capital, pre-funded warrants and warrants, net, shares</a></td>
<td class="nump">124,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IssuanceOfShareCapital', window );">Issuance of share capital, net</a></td>
<td class="nump">$ 3,242<span></span>
</td>
<td class="nump">10,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Warrants exercised</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">5,559<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares', window );">Warrants exercised, shares</a></td>
<td class="nump">38,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Employee stock options exercised</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares', window );">Employee stock options exercised, shares</a></td>
<td class="nump">493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions', window );">Employee stock options expired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,321<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive loss for the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(60,614)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(60,614)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">BALANCE at Dec. 31, 2023</a></td>
<td class="nump">$ 31,355<span></span>
</td>
<td class="nump">355,482<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(390,606)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,223<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">BALANCE, shares at Dec. 31, 2023</a></td>
<td class="nump">1,086,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>CHANGES IN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital, pre-funded warrants and warrants, net</a></td>
<td class="nump">$ 4,712<span></span>
</td>
<td class="num">(3,060)<span></span>
</td>
<td class="nump">6,650<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_NumberOfNewSharesIssued', window );">Issuance of share capital, pre-funded warrants and warrants, net, shares</a></td>
<td class="nump">174,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares', window );">Pre-funded warrants exercised, shares</a></td>
<td class="nump">74,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Warrants exercised</a></td>
<td class="nump">$ 2,009<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="num">(2,691)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Employee stock options exercised</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares', window );">Employee stock options exercised, shares</a></td>
<td class="nump">770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions', window );">Employee stock options expired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">539<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(539)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive loss for the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,221)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,221)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">BALANCE at Dec. 31, 2024</a></td>
<td class="nump">$ 38,097<span></span>
</td>
<td class="nump">353,693<span></span>
</td>
<td class="nump">5,367<span></span>
</td>
<td class="nump">17,547<span></span>
</td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(399,827)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,461<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">BALANCE, shares at Dec. 31, 2024</a></td>
<td class="nump">1,336,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>CHANGES IN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital, pre-funded warrants and warrants, net</a></td>
<td class="nump">$ 27,273<span></span>
</td>
<td class="num">(22,260)<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_NumberOfNewSharesIssued', window );">Issuance of share capital, pre-funded warrants and warrants, net, shares</a></td>
<td class="nump">978,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity', window );">Pre-funded warrants exercised</a></td>
<td class="nump">$ 8,058<span></span>
</td>
<td class="num">(5,876)<span></span>
</td>
<td class="num">(2,182)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares', window );">Pre-funded warrants exercised, shares</a></td>
<td class="nump">295,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions', window );">Employee stock options expired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,027)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive loss for the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,175)<span></span>
</td>
<td class="num">(851)<span></span>
</td>
<td class="num">(2,026)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">BALANCE at Dec. 31, 2025</a></td>
<td class="nump">$ 73,428<span></span>
</td>
<td class="nump">$ 327,584<span></span>
</td>
<td class="nump">$ 3,686<span></span>
</td>
<td class="nump">$ 15,916<span></span>
</td>
<td class="num">$ (1,416)<span></span>
</td>
<td class="num">$ (401,002)<span></span>
</td>
<td class="nump">$ 5,149<span></span>
</td>
<td class="nump">$ 23,345<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">BALANCE, shares at Dec. 31, 2025</a></td>
<td class="nump">2,610,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IncreaseDecreaseThroughExerciseOfOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IncreaseDecreaseThroughExerciseOfOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) in equity resulting from the exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) in equity resulting from the exercise of pre-funded warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee stock options forfeited and expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IssuanceOfShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the issuance of share capital, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IssuanceOfShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_NumberOfNewSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_NumberOfNewSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS - OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="num">$ (2,026)<span></span>
</td>
<td class="num">$ (9,221)<span></span>
</td>
<td class="num">$ (60,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Adjustments required to reflect net cash used in operating activities (see appendix below)</a></td>
<td class="num">(6,048)<span></span>
</td>
<td class="num">(34,652)<span></span>
</td>
<td class="nump">38,006<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,074)<span></span>
</td>
<td class="num">(43,873)<span></span>
</td>
<td class="num">(22,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS - INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Investments in short-term deposits</a></td>
<td class="num">(36,644)<span></span>
</td>
<td class="num">(26,350)<span></span>
</td>
<td class="num">(47,588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_MaturitiesOfShortTermDeposits', window );">Maturities of short-term deposits</a></td>
<td class="nump">28,126<span></span>
</td>
<td class="nump">55,778<span></span>
</td>
<td class="nump">49,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property and equipment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(8,545)<span></span>
</td>
<td class="nump">29,374<span></span>
</td>
<td class="nump">1,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS - FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Issuance of share capital, pre-funded warrants and warrants, net of issuance costs</a></td>
<td class="nump">13,894<span></span>
</td>
<td class="nump">16,357<span></span>
</td>
<td class="nump">14,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Employee stock options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingOtherEquityInstruments', window );">Proceeds from long-term loan, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,223<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of loan</a></td>
<td class="num">(4,498)<span></span>
</td>
<td class="num">(14,433)<span></span>
</td>
<td class="num">(1,543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayments of lease liabilities</a></td>
<td class="num">(512)<span></span>
</td>
<td class="num">(511)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">8,884<span></span>
</td>
<td class="nump">20,658<span></span>
</td>
<td class="nump">15,056<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(7,735)<span></span>
</td>
<td class="nump">6,159<span></span>
</td>
<td class="num">(6,108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR</a></td>
<td class="nump">10,436<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
<td class="nump">10,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">CASH AND CASH EQUIVALENTS - END OF YEAR</a></td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">10,436<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract', window );"><strong>Income and expenses not involving cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">4,065<span></span>
</td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Exchange differences on cash and cash equivalents</a></td>
<td class="num">(549)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFairValueGainsLosses', window );">Fair value adjustments of warrants</a></td>
<td class="num">(8,599)<span></span>
</td>
<td class="num">(18,965)<span></span>
</td>
<td class="nump">11,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">2,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_InterestAndExchangeDifferencesOnShortTermDeposits', window );">Interest and exchange differences on short-term deposits</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_InterestAndLinkageDifferencesOnBankLoan', window );">Interest on loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,126)<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits', window );">Warrant issuance costs</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExchangeDifferencesOnLeaseLiability', window );">Exchange differences on lease liabilities</a></td>
<td class="nump">177<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill', window );">Intangible assets impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">6,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LossOnAbandonmentOfRightofuseAsset', window );">Loss on abandonment of right-of-use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows', window );">Total income and expense not involving cash flows</a></td>
<td class="num">(7,307)<span></span>
</td>
<td class="num">(12,834)<span></span>
</td>
<td class="nump">22,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract', window );"><strong>Changes in operating asset and liability items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Decrease (increase) in trade receivables</a></td>
<td class="nump">2,430<span></span>
</td>
<td class="num">(2,118)<span></span>
</td>
<td class="num">(358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease (increase) in inventory</a></td>
<td class="nump">997<span></span>
</td>
<td class="num">(1,192)<span></span>
</td>
<td class="num">(1,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables', window );">Decrease (increase) in prepaid expenses and other receivables</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="num">(959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="num">(3,478)<span></span>
</td>
<td class="num">(5,508)<span></span>
</td>
<td class="nump">5,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities', window );">Increase (decrease) in contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,957)<span></span>
</td>
<td class="nump">12,957<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TotalChangeInOperatingAssetAndLiability', window );">Total change in operating asset and liability</a></td>
<td class="nump">1,259<span></span>
</td>
<td class="num">(21,818)<span></span>
</td>
<td class="nump">15,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total adjustments required to reflect net cash used in operating activities</a></td>
<td class="num">(6,048)<span></span>
</td>
<td class="num">(34,652)<span></span>
</td>
<td class="nump">38,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract', window );"><strong>Supplementary information on investing and financing activities not involving cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SupplementaryInformationOnInterestReceivedInCash', window );">Supplemental information on interest received in cash</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
<td class="nump">2,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SupplementalInformationOnInterestPaidInCash', window );">Supplemental information on interest paid in cash</a></td>
<td class="nump">1,268<span></span>
</td>
<td class="nump">10,387<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SupplementalInformationOnNoncashTransactionsAbstract', window );"><strong>Supplemental information on non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities', window );">Changes in right-of-use asset and lease liabilities</a></td>
<td class="num">(57)<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants', window );">Fair value of exercised warrants (portion related to accumulated fair value adjustments)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SupplementaryInformationOnIntangibleAssetAcquired', window );">Intangible asset acquired in connection with GLIX1 collaboration transaction</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in prepaid expense other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ExchangeDifferencesOnLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for exchange differences on lease liability to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ExchangeDifferencesOnLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_InterestAndExchangeDifferencesOnRestrictedDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and exchange differences on restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_InterestAndExchangeDifferencesOnRestrictedDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_InterestAndExchangeDifferencesOnShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and exchange differences on short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_InterestAndExchangeDifferencesOnShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_InterestAndLinkageDifferencesOnBankLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and linkage differences on bank loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_InterestAndLinkageDifferencesOnBankLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_LossOnAbandonmentOfRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of loss on abandonment of rightofuse asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_LossOnAbandonmentOfRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_MaturitiesOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturities of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_MaturitiesOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SupplementalInformationOnInterestPaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental information on interest paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SupplementalInformationOnInterestPaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SupplementalInformationOnNoncashTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplementary non-cash investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SupplementalInformationOnNoncashTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplementary information on Changes In Right-of-use Asset And Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SupplementaryInformationOnFairValueOfExercisedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of Supplementary information on Fair Value Of Exercised Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SupplementaryInformationOnFairValueOfExercisedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SupplementaryInformationOnIntangibleAssetAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of supplementary information on intangible asset acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SupplementaryInformationOnIntangibleAssetAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SupplementaryInformationOnInterestReceivedInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplementary information on interest received in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SupplementaryInformationOnInterestReceivedInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TotalChangeInOperatingAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Change in operating asset and liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TotalChangeInOperatingAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TotalIncomeAndExpenseNotInvolvingCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total income and expense not involving cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TotalIncomeAndExpenseNotInvolvingCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFairValueGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFairValueGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfGeneralInformationAbstract', window );"><strong>Disclosure of general information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">GENERAL INFORMATION</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1 &#8211; GENERAL INFORMATION</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="vertical-align:top;width:24pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BioLineRx Ltd. (&#8220;BioLineRx&#8221;), headquartered in Modi&#8217;in, Israel, was incorporated and commenced operations in April 2003. BioLineRx and its subsidiaries (collectively, the &#8220;Company&#8221;) are engaged in the development (primarily in clinical stages) and commercialization of therapeutics, with a focus on the fields of oncology and hematology.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) are traded on the NASDAQ Capital Market, and its ordinary shares are traded on the Tel Aviv Stock Exchange. Each ADS represents 600 ordinary shares.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has one wholly owned subsidiary, BioLineRx USA, Inc., incorporated in the U.S., which had been engaged in commercialization activities associated with the launch of motixafortide for stem-cell mobilization in the U.S., and which is now substantially inactive since the end of 2024 (see below). In addition, the Company is the controlling shareholder of Tetragon Biosciences Ltd. (&#8220;Tetragon&#8221;), a company incorporated in Israel in September 2025 for the development and commercialization of GLIX1, a clinical-stage, first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers (see below and Note 17).</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company began to independently commercialize motixafortide in the U.S.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, the Company out-licensed the rights to motixafortide for all indications in substantially all of Asia, and in November 2024, the Company out-licensed the global rights (other than in Asia) to motixafortide for all indications, other than solid tumors. In connection with the November 2024 transaction, the Company shut down its independent commercialization activities in the U.S., and entered into an agreement to repay a substantial portion of its outstanding debt, as well as restructure the remaining debt balance. Following these actions, the Company refocused its operations on development activities in Israel in the fields of oncology (including solid tumors) and rare diseases, at a significantly reduced annual cash burn rate.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="vertical-align:top;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
            <td style="vertical-align:top;text-align:justify;width:auto">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">War in Israel</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 7, 2023, an unprecedented invasion was launched against Israel from the Gaza Strip by terrorists from the Hamas terrorist organization that infiltrated Israel&#8217;s southern border and other areas within the country, attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli civilian population. These attacks resulted in extensive deaths, injuries and the kidnapping of civilians and soldiers. In response, the Security Cabinet of the State of Israel declared war against Hamas, with commencement of a military campaign against the terrorist organization, in parallel to its continued rocket and terror attacks. Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement controlling parts of Yemen, and with Iran. It is also possible that other terrorist organizations, including Palestinian military organizations in the West Bank, will join the hostilities. On October 9, 2025, Israel, Hamas, the US, and other counties in the region agreed to a framework for a ceasefire in Gaza between Israel and Hamas.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, in response to ongoing Iranian aggression and support of proxy attacks against Israel, on June 13, 2025, Israel conducted a series of preemptive defensive air strikes in Iran targeting Iran&#8217;s nuclear program and military commanders. While a ceasefire was reached in June 2025 following 12 days of hostilities, on February 28, 2026, the United States and Israel launched coordinated military strikes against Iran, including attacks on strategic military infrastructure and leadership targets, with the stated aim of degrading Iran&#8217;s capacity to conduct or support hostile operations against them. In response, Iran has fired missiles and drones toward population centers and military installations in Israel<span style="font-weight:bold">, </span>Europe and neighboring countries in the Gulf region, and also launched counter-strikes against U.S. forces and allied bases throughout the Gulf region. Continued military escalation, retaliatory actions, or broader regional involvement may adversely affect economic conditions, disrupt markets, and create uncertainty that could negatively impact our business, financial condition and results of operations.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The length and severity of the current conflicts in Gaza, Lebanon, Iran and the broader region is unknown at this time, and there can be no assurance that certain ceasefires will hold or that military activities and hostilities will not continue to exist at varying levels of intensity. Any or all of these situations may potentially escalate in the future to more violent events or a greater regional conflict.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s headquarters and principal development operations are located in the State of Israel. In addition, all of its key employees, officers and directors are residents of Israel. The ongoing war and other hostilities in Israel have not, to date, materially impacted the Company&#8217;s business or operations. Nevertheless, since these are events beyond the Company&#8217;s control, their continuation or cessation may affect the Company&#8217;s operations. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employees.</span></span></div>
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="vertical-align:top;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
            <td style="vertical-align:top;text-align:justify;width:auto">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Going concern</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred accumulated losses in the amount of $401&#160;million through December 31, 2025,&#160;and it expects to continue incurring losses and negative cash flows from operations until the cash flows from its strategic partnerships reach a level to offset its ongoing development costs. In this regard, Company management monitors rolling forecasts of the Company&#8217;s liquidity reserves on the basis of anticipated cash flows and seeks to maintain liquidity balances at levels that are sufficient to meet its needs. Management believes that the Company&#8217;s current cash and other resources will be sufficient to fund its projected cash requirements into the first half of 2027.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s cash flow projections are subject to various risks and uncertainties concerning their fulfilment, and these factors and the risks inherent in the Company&#8217;s operations indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) on the Company&#8217;s ability to continue as a going concern. These consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management&#8217;s plans include the realization of capital inflows from its strategic partnerships and, if and when required, raising capital through the issuance of debt or equity securities. There are no assurances, however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in realizing the potential cash flows from its strategic partnerships and/or in raising capital, it may need to reduce activities, or curtail or cease operations.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="vertical-align:top;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
            <td style="vertical-align:top;text-align:justify;width:auto">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in ratio of ADSs</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 30, 2025, the Company effected a change in the ratio of its ADSs to ordinary shares, from one ADS representing 15 ordinary shares to a new ratio of one ADS representing 600 ordinary shares. All ADSs and per ADSs amounts in these financial statements have been retroactively adjusted as if the change in ratio had been effected at the earliest date of these financial statements.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="vertical-align:top;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
            <td style="vertical-align:top;text-align:justify;width:auto">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Approval of consolidated financial statements</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;text-indent:0pt;margin-left:70.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements of the Company for the year ended December 31, 2025 were approved by the Board of Directors on March 18, 2026, and signed on its behalf by the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer.</span></span></div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfGeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfGeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 128<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_128&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure of significant accounting policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory', window );">MATERIAL ACCOUNTING POLICIES</a></td>
<td class="text">
      <div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 2 &#8211; MATERIAL ACCOUNTING POLICIES</span></span></div>
        <div style="line-height:1.25">&#160;</div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis of presentation and consolidation</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Basis of preparation</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s consolidated financial statements as of December 31, 2024 and 2025, and for each of the three years in the period ended December 31, 2025, have been prepared in accordance with IFRS<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#174;</sup> Accounting Standards as issued by the International Accounting Standards Board (&#8220;IASB<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#174;</sup>&#8221;) (hereinafter &#8220;IFRS&#8221;). The material<span style="font-weight:bold">&#160;</span>accounting policies described below have been applied on a consistent basis for all years presented.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements have been prepared on the basis of historical cost, subject to adjustment of warrant liabilities to their fair value through profit or loss.</span></span></div>
            <div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity and expenses, as well as the related disclosures of contingent assets and liabilities, in the process of applying the Company&#8217;s accounting policies.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are material<span style="font-weight:bold">&#160;</span>to the consolidated financial statements, are disclosed in Note 4. Actual results may differ materially from estimates and assumptions used by the Company&#8217;s management.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Basis of consolidation</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsidiaries are entities controlled by the Company. Control exists when the Company has power over the investee, is exposed or has rights to variable returns from its involvement with the investee, and has the ability to use its power to affect those returns. Subsidiaries are consolidated from the date on which control is obtained and are deconsolidated from the date control ceases. The financial statements of subsidiaries are prepared for the same reporting period as the parent company using consistent accounting policies.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All intercompany balances, transactions, income and expenses, and unrealized gains and losses arising from intra-group transactions are eliminated in full upon consolidation</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Non-controlling interests</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-controlling interests represent the portion of equity in subsidiaries not attributable, directly or indirectly, to the shareholders of the parent. Non-controlling interests are presented in the consolidated statement of financial position within equity, separately from the equity attributable to the owners of the parent.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in the Company&#8217;s ownership interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Any difference between the amount by which the non-controlling interests are adjusted, and the fair value of the consideration paid or received, is recognized directly in equity and attributed to the owners of the parent.</span></span></div>
          </div>

        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div></div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Functional and reporting currency</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The functional and reporting currency in these financial statements is the U.S. dollar (&#8220;dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221;), which is the primary currency of the economic environment in which the Company operates. Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year-end exchange rates are generally recognized in profit or loss.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inventory</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inventory is measured at the lower of cost or net realizable value. The cost of inventories includes purchase costs, packaging and labeling costs, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price of the inventories in the ordinary course of business, less the estimated costs necessary to make the sale. Inventory is written down for estimated obsolescence based upon management assumptions about future demand, expiration due date and market conditions.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div>

            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:43.9pt">&#160;</td>
                    <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment are stated at historical cost less depreciation. Historical cost includes expenditures that are directly attributable to acquisition of the items. Assets are depreciated by the straight-line method over the estimated useful lives of the assets, provided that Company management believes the residual values of the assets to be negligible, as follows:</span></span></div>
              <div style="text-align:justify;margin-left:69.85pt;line-height:1.25">&#160;</div>

                <div>
                  <div style="margin-left:72pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="width:81.77%;vertical-align:middle">&#160;</td>
                          <td style="width:18.23%;vertical-align:middle;border-bottom:2px solid black">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers and communications equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15</span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                </div>

              <div style="text-align:justify;line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful life of the improvements.</span></span></div>
            </div>

        </div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div></div>

          <div>
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="vertical-align:top;font-weight:bold;width:43.9pt">&#160;</td>
                    <td style="vertical-align:top;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                    <td style="vertical-align:top;text-align:justify;width:auto">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Intangible assets</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies the cost method of accounting for initial and subsequent measurements of intangible assets. Under this method of accounting, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Intellectual property</span></span></span></div>
              <div style="text-align:justify;margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes in its financial statements intellectual property developed by the Company to the extent that the conditions stipulated in paragraph j. below are met. Intellectual property acquired by the Company is initially measured at cost. Intellectual property used by the Company for development purposes and not yet generating revenues is not amortized and is tested annually for impairment. See f. below.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Computer software</span></span></span></div>
              <div style="text-align:justify;margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Acquired computer software licenses are capitalized based on the costs incurred&#160;to acquire and bring to use the specific software. These costs are amortized over the estimated useful lives of the software (5 years).</span></span></div>
            </div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Impairment of non-financial assets</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Impairment of intellectual property is required when the Company decides to terminate or suspend the development of a project based on such intellectual property. In addition, the Company performs impairment reviews on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment. Property and equipment, as well as computer software, are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized equal to the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value, less costs to sell and the asset&#8217;s value in use to the Company. See Note 8 for information about an impairment loss recorded in 2023 in connection with the decision to terminate the AGI-134 project, as well as an impairment loss recorded in 2024 in connection with the remaining rights to motixafortide in solid tumor indications.</span></span></div>
          </div>

        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div></div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Receipts in respect of ordinary warrants are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. In the event that the exercise price or the numbers of shares to be issued are not deemed to be fixed, the ordinary warrants are classified as a derivative financial liability. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value at each reporting date. The fair value changes are charged to non-operating income and expense on the statement of comprehensive loss. Issuance costs allocable to ordinary warrants classified as a liability are also recorded as non-operating expense on the statement of comprehensive loss.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pre-funded warrants are classified in shareholders&#8217; equity, with initial recognition at fair value on the date issued, using the same valuation assumptions as ordinary warrants.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">h</span>.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Borrowings</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With respect to the long-term loan (see Note 10), a financial liability was recognized for each tranche upon drawdown. Upon initial recognition, the effective interest rate was calculated by estimating the future cash flows, including loan principal repayments, interest and royalties, if any. The royalty feature did not meet the definition of a derivative, was not classified separately, and was not measured separately, since it was an integral part of the loan terms and conditions and could not be transferred or settled separately from the loan.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Determining the weighted effective interest rate requires certain judgments and estimations regarding the timing and amount of the Company&#8217;s future revenues. The loans are subsequently measured at amortized cost. Furthermore, revisions to the estimated amounts or timing of future cash flows, if necessary, may result in an adjustment of the amortized cost of the loan to reflect the present value of actual and revised estimated contractual cash flows, discounted using the original effective interest rate. This adjustment was recognized in profit or loss as financial income or expense.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months subsequent to the reporting period.</span></span></div>
          </div>

        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div></div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenues</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for contract revenue in accordance with IFRS 15, &#8220;Revenue from Contracts with Customers.&#8221;</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">IFRS 15 introduces a five-step model for recognizing revenue from contracts with customers, as follows:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">identify the contract with a customer;</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">identify the performance obligations in the contract;</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">determine the transaction price;</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">allocate the transaction price to the performance obligations in the contract; and</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">recognize revenue when (or as) the entity satisfies a performance obligation.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Revenues from selling products</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2023, the FDA approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and shortly thereafter, the Company began to independently commercialize motixafortide in the U.S. These activities terminated in November 2024, as a result of the out-licensing transaction entered into with Ayrmid Ltd. (see Note 16) and the shutdown of the Company&#8217;s U.S. commercial operations. The information below relates to the period during which the Company carried out direct sales activities.</span></span></div>
            <div style="text-align:justify;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company sells products mainly to wholesale distributors. Gross revenues are recognized at a point in time when control over the product is transferred to the distributors (upon delivery), at the gross selling price. The net revenues reflect gross revenues, reduced by amounts attributable to distributor fees, as well as accruals of chargebacks, rebates and returns.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The specific considerations the Company uses in estimating these amounts relating to variable consideration are as follows:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:85pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Distribution fees - The Company pays distribution fees to its three main distributors. The distribution fees are paid based on contractually determined rates from the gross consideration. When the service is received and the products sold to distributors, it is recognized as a reduction of revenues in the period the related revenues from the sale of products are recognized.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:85pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rebates and patient discount programs - The Company offers various rebate and patient discount programs, which results in discounted prescriptions to qualified patients. The Company estimates the allowance for these rebates, based on the estimated utilization of the rebate and discount programs, at the time the revenues are recognized. These estimates are recognized as a reduction of revenues.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:85pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Product returns - The Company offers customers a right of return as part of the distributor agreements. The Company estimates the amount of product sales that may be returned by its customers and records this estimate as a reduction of revenues at the time of sale, based on estimates of product returns based on its own sales information, its visibility into the inventory remaining in the distribution channel, and product dating.</span></span></div>
                  </td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
            <div></div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Revenues from</span><span style="text-decoration:underline"> licensing agreement</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">According to IFRS 15, performance obligations are a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service, either on its own or together with other resources that are readily available to the customer, and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">IFRS 15 defines the &#8216;Transaction Price&#8217; as the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services to a customer.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with IFRS 15, the Company identified a number of performance obligations (components) in the contract &#8211; in respect of which revenue will be recognized separately for each component.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following assumptions were taken into account, as part of the revenue recognition process:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Development milestones: Variable payments, contingent on achieving additional milestones, are included in the transaction price based on the most likely amount method. Amounts included in the transaction price are recognized only when it is highly probable that a material<span style="font-weight:bold">&#160;</span>reversal of cumulative revenues will not occur, usually upon achievement of the specific milestone, in accordance with the relevant agreement.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales-based royalties and sales-based milestones are recognized as the related sale occurs, due to the specific exception of IFRS 15 for sales-based royalties from licensing of intellectual properties.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For more information, see Notes 15 and 16.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">j.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research expenses are charged to profit or loss as incurred. As of December 31, 2025, the Company has not yet capitalized development expenses.</span></span></div>
          </div>

        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div></div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">k.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based payments</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company operates an equity-settled, share-based compensation plan, under which it grants equity instruments (options, restricted stock units and performance stock units) of the Company as additional consideration for services from employees and service providers. The fair value of the employee services received in exchange for the grant of the equity instruments is recognized as an expense. The total amount to be expensed is determined by reference to the fair value of the equity instruments granted including any market performance conditions (for example, the Company&#8217;s share price).</span></span></div>
            <div style="text-align:justify;margin-right:0.55pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-market performance and service conditions are included in assumptions about the number of equity instruments that are expected to vest. Performance stock unit expenses are recognized only if it is probable that the performance condition will be achieved.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">l.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss per share</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
                  <td style="width:auto;vertical-align:top">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The basic loss per share is calculated by dividing the loss attributable to the holders of ordinary shares by the weighted average number of ordinary shares, including pre-funded warrants, outstanding during the year.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
                  <td style="width:auto;vertical-align:top">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Diluted</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The diluted loss per share is calculated by adjusting the weighted average number of outstanding ordinary shares, assuming conversion of all dilutive potential shares. The Company&#8217;s dilutive potential shares consist of warrants issued to investors, as well as equity instruments granted to employees and service providers. The dilutive potential shares were not taken into account in computing loss per share in 2023, 2024 and 2025, as their effect would have been anti-dilutive.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The calculation of diluted loss per share for the years ended December 31, 2023, 2024 and 2025 does not include 369,484,579, 568,205,319 and 1,538,622,579 of shares underlying options and warrants, respectively, because the effect would be anti-dilutive.</span></span></div>
          </div>

        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
        <div></div>

          <div>
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:43.9pt">&#160;</td>
                    <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">m.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leases</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s leases include property and motor vehicle leases.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date. Simultaneously, the Company recognizes a right-of-use asset in the amount of the lease liability.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since the interest rate implicit in the lease cannot be readily determined, the Company uses the Company&#8217;s incremental borrowing rate.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The lease term is the non-cancellable period for which the Company has the right to use an underlying asset, together with both the periods covered by an option to extend the lease, if the Company is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the Company is reasonably certain not to exercise that option.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">After the commencement date, the Company measures the right-of-use asset applying the cost model, less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets are depreciated by the straight-line method over the estimated useful lives of the right of use assets or the lease period, whichever is shorter, as follows:</span></span></div>
            </div>
            <div>
              <div>
                <div>
                  <div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="margin-left:72pt">

                        <div>
                          <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                              <tr>
                                <td style="width:76.27%;vertical-align:middle">&#160;</td>
                                <td style="width:23.73%;vertical-align:middle;border-bottom:2px solid black">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
                                </td>
                              </tr>
                              <tr>
                                <td style="width:76.27%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                                </td>
                                <td style="width:23.73%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div>
                                </td>
                              </tr>
                              <tr>
                                <td style="width:76.27%;vertical-align:middle">
                                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                                </td>
                                <td style="width:23.73%;vertical-align:middle">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></div>
                                </td>
                              </tr>

                          </table>
                        </div>

                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">New International Financial Reporting Standards, amendments to standards and new interpretations</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.85pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">New standards and interpretations not yet adopted</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.85pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">IFRS 18, Presentation and Disclosure in the Financial Statements</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">This standard replaces the international accounting standard IAS 1,&#160;&#8220;Presentation of Financial Statements.&#8221; As part of the new disclosure requirements, companies will be required to present new defined subtotals in the statements of income, as follows: (1) operating profit and (2) profit before financing and tax. In addition, income statement items will be classified into three defined categories: operating, investment and financing. The standard also includes a requirement to provide separate disclosure in the financial statements regarding the use of management-defined performance measures (&#8220;non-GAAP measures&#8221;), and specific instructions were added for the grouping and splitting of items in the financial statements and in the notes to the financial statements.&#160;IFRS 18&#160;is effective for annual reporting periods beginning on or after January 1, 2027, with an option for early adoption. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statement disclosures.</span></span></div>
          </div>

      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes made to accounting policies by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3 &#8211; FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin:0px 0px 0px 44.6pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Based on assessments by Company management, the Company&#8217;s exposure to credit risk as of December 31, 2025, is immaterial (see Note 3b). The activities of the Company expose it to market risk, primarily as a result of currency risk.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin:0px 0px 0px 44.6pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s Finance Department is responsible for carrying out risk management activities in accordance with policies approved by its Board of Directors. In this regard, the Finance Department identifies, defines and assesses financial risk in close cooperation with other Company departments. The Board of Directors provides written guidelines for overall risk management, as well as written policies dealing with specific areas, such as exchange rate risk, interest rate risk, credit risk, use of financial instruments and investment of excess cash.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Market risk</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Concentration of currency risk</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s activities are partly denominated in non-dollar currencies (primarily the New Israeli Shekel, or &#8220;NIS,&#8221; and the Euro), which exposes the Company to risks resulting from changes in exchange rates.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The effect of fluctuations in various exchange rates on the Company&#8217;s income and equity is as follows:</span></span></div>
      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="margin-left:90pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Value on</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sensitive instrument</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">balance sheet</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS-linked balances:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(179</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(94</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,974</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">104</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">219</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short term deposit</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(86</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(45</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">943</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">50</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">105</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(7</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(3</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">72</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">4</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">8</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">19</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">10</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(206</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(11</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(23</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">87</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">46</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(962</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(51</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(107</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total NIS-linked balances</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(166</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(86</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,821</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">96</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">202</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Euro-linked trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(107</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(56</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(1,177</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">62</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">131</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(273</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(142</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">644</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>158</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>333</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:90pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Value on</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sensitive instrument</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">balance sheet</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS-linked balances:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(87</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(45</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">955</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">50</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">106</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(52</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(27</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">568</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">30</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">63</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">115</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">60</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(933</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(67</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(141</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">154</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">81</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(1,495</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(89</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(188</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total NIS-linked balances</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">130</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">69</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(905</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(76</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(160</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Euro-linked trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(83</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(44</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(919</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">48</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">102</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">47</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(1,824</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(28</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(58</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>

      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also maintains cash and cash equivalent balances in other currencies in amounts that are not material.</span></span></div>
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"></div>
      <div style="margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Set forth below is information on the linkage of monetary items:</span></span></div>
      <div style="margin-left:92.15pt;line-height:1.25">&#160;</div>

        <div>
          <div style="margin-left:90pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding:0px 0px 2px">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dollar</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">currencies</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dollar</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currencies</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:middle;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD in thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:middle;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD in thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">9,428</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">955</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">53</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">973</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,974</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">303</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">9,126</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">16,683</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">943</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">819</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">568</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">91</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">338</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">72</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">19,373</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">1,523</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">144</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">17,994</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">2,989</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">303</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liabilities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current liabilities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current maturities of long-term loan</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">4,479</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">4,479</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accounts payable and accruals:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:0pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">3,549</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">933</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,101</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,993</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">206</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,294</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:0pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,636</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,495</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">781</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">962</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term loan, net of current maturities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">8,958</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">4,460</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">18,622</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,428</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,101</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">11,713</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,168</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,294</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net balance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">751</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(905</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(957</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">6,281</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">1,821</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(991</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>

      <div style="line-height:1.25">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value of financial instruments</span></span></div>
            </td>
          </tr>

      </table>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, the financial instruments of the Company consist of non-derivative assets and liabilities (primarily working capital items, deposits, and current and long-term loans), as well as warrants classified as a liability.</span></span></div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With regard to non-derivative assets and liabilities, given their nature, the fair value of the financial instruments included in working capital is generally close or identical to their carrying amount, as the effect of discounting is immaterial.</span></span></div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With regard to the warrants classified as a current financial liability, see Note 11c. With regard to long-term loans, see Note 10.</span></span></div>
      <div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exposure to market risk and management thereof</span></span></div>
            </td>
          </tr>

      </table>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In the opinion of Company management, the market risk to which the Company is exposed is primarily related to currency risk exposure, as mentioned above.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest rate risk</span></span></div>
            </td>
          </tr>

      </table>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Company management does not consider interest rate risk to be material, as the Company holds deposits whose fair value and/or cash flows are not materially affected by changes in interest rates.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Credit risk</span></span></div>
            </td>
          </tr>

      </table>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Credit risk is managed at the Company level. These risks relate to cash and cash equivalents, bank deposits, trade receivables, and other receivables.</span></span></div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s cash, cash equivalents and short-term bank deposits at December 31, 2024, and 2025 were deposited with highly rated major Israeli and U.S. banks. In the Company&#8217;s opinion, the credit risk associated with these balances is remote.</span></span></div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company considers its maximum exposure to credit risk to be as follows:</span></span></div>
      <div style="line-height:1.25">&#160;</div>

        <div style="margin-left:72pt">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">10,436</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">3,250</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">9,126</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">17,626</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">2,476</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">46</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,478</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">410</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">23,516</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">21,332</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>

      <div style="line-height:1.25">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liquidity risk</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Company management monitors rolling forecasts of the Company&#8217;s liquidity reserves on the basis of anticipated cash flows and seeks to maintain the liquidity balances at a level that is sufficient to meet its needs.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Although the Company has succeeded in generating revenues from a number of out-licensing transactions, as well as the commercialization of its lead program, motixafortide, during 2024, it cannot determine with reasonable certainty if and when it will become profitable on a current basis. Management believes that the Company&#8217;s current cash and other resources will be sufficient to fund its projected cash requirements into the first half of 2027. However, in the event that the Company does not begin to generate sustainable cash flows from its operating activities in the future, the Company will need to carry out significant cost reductions and/or raise additional funding. See also Note 1c regarding the material uncertainty that may cast significant doubt about the Company&#8217;s ability to continue as a going concern.</span></span></div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value of financial instruments</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-indent:36pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The different levels of valuation of financial instruments are defined as follows:</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:72pt">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

            <tr>
              <td style="width:8%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1</span></span></div>
              </td>
              <td style="width:auto;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:8%;vertical-align:top">&#160;</td>
              <td style="width:auto;vertical-align:top">&#160;</td>
            </tr>
            <tr>
              <td style="width:8%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2</span></span></div>
              </td>
              <td style="width:auto;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inputs, other than quoted prices included within level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices).</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:8%;vertical-align:top">&#160;</td>
              <td style="width:auto;vertical-align:top">&#160;</td>
            </tr>
            <tr>
              <td style="width:8%;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3</span></span></div>
              </td>
              <td style="width:auto;vertical-align:top">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inputs for the asset or liability that are not based on observable market data (unobservable inputs).</span></span></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk, in its assessment of fair value. The fair value of the financial instruments included in the working capital of the Company, as well as the long-term loan, is usually identical or close to their carrying value, as the effect of discounting is immaterial. The fair value of the warrants is based on Level 3 measurements.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the warrants, calculated based on the Black-Scholes model, was $2,174,000 as of December 31, 2025.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;text-indent:-0.05pt;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For more information on the parameters used to value the warrants, see Note 11c.</span></span></div>
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      <div style="margin-top:0px;margin-bottom:0px"></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in financial liabilities with cash flows included in financing activities</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>

        <div>
          <div style="margin-left:72pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Long-term loan</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                      <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Warrants</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                      <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Total</span></span></strong></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">10,168</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">4,509</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">14,677</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during the year 2023:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Principal and interest payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(1,543</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(1,543</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts recognized through profit and loss</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,148</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">11,054</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">12,202</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share premium resulting from exercise of warrants</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(3,631</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(3,631</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">9,773</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">11,932</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">21,705</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during the year 2024:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net proceeds</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">19,223</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">8,724</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">27,947</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Principal and interest payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(22,795</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(22,795</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts recognized through profit and loss</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">7,236</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(18,965</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(11,729</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">13,437</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,691</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">15,128</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during the year 2025:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net proceeds</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">9,082</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">9,082</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Principal and interest payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(5,568</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(5,568</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts recognized through profit and loss</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,070</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(8,599</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(7,529</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">8,939</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">2,174</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">11,113</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>

      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value measurement of warrants using significant unobservable inputs (level 3)</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table presents the changes in level 3 instruments for the years ended December 31, 2023, 2024 and 2025:</span></span></div>
      <div style="line-height:1.25">&#160;</div>

        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2023</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,509</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during 2023:</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercises</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">(3,631</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-14.15pt;margin-left:30.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value through profit and loss</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">11,054</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2023</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">11,932</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during 2024:</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuances</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">8,724</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-14.15pt;margin-left:30.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value through profit and loss</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">(18,965</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2024</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">1,691</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during 2025:</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuances</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">9,082</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value through profit and loss</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">(8,599</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2025</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,174</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract', window );"><strong>Disclosure Of Accounting Judgements And Estimates Explanatory Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS</a></td>
<td class="text">
      <div>
        <div>
          <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4 &#8211; CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS</span></span></div>
          <div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the financial reporting process, Company management is required to make estimates that affect the value of assets, liabilities, income, expenses and certain disclosures included in the Company&#8217;s consolidated financial statements. By their very nature, such accounting estimates are subjective and complex and consequently may differ from actual results. The estimates are continually evaluated and adjusted based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances.</span></span></div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Below are the critical accounting estimates used in the preparation of the financial statements that required Company management to make assumptions involving significant uncertainty.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-indent:-21.25pt;margin-left:70.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Impairment of indefinite-lived intangible assets</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As mentioned in Notes 2e and 2f, the Company performs impairment reviews of intangible assets not subject to amortization on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The recoverable amount is determined using discounted cash flow calculations. The analysis estimates the future cash flows the Company expects to derive from the asset, incorporates expectations about possible variations in the amount or timing of those future cash flows, as well as the uncertainty inherent in the asset, and the risk-adjusted cash flows are then discounted using the Company&#8217;s estimated post-tax weighted average cost of capital (&#8220;WACC&#8221;). The main estimates used in calculating the recoverable amount include the WACC estimation and the amounts and timing of projected future cash flows. Such amounts and timing are influenced by the expected outcome of development activities, the probability of success and timing in gaining regulatory approval, size of the potential market and the Company&#8217;s specific market share, either via direct sales or a potential out-licensing deal.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In light of the Company&#8217;s decision to terminate AGI-134, the value of its intangible asset was written off in its entirety in 2023.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As a result of an impairment review of its remaining rights to motixafortide in solid tumor indications in the fourth quarter of 2024, the Company recorded an impairment loss (see Note 8).</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, the Company has concluded that the value of its intangible assets is higher than their carrying value.</span></span></div>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text">
      <div>
        <div>
          <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 5 &#8211; CASH AND CASH EQUIVALENTS</span></span></div>
          <div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
            <div style="margin-left:54pt">

                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash on hand and in bank</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">944</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">632</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">9,492</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">2,618</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">10,436</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">3,250</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>

            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The short-term bank deposits included in cash and cash equivalents bear interest at annual rates of between 0.7% and 4.9%.</span></span></div>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM BANK DEPOSITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfShortTermBankDepositsAbstract', window );"><strong>Disclosure Of Short Term Bank Deposits Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDepositsFromBanksExplanatory', window );">SHORT-TERM BANK DEPOSITS</a></td>
<td class="text">
      <div>
        <div>
          <div>
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 6 &#8211; SHORT-TERM BANK DEPOSITS</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The short-term bank deposits are primarily in dollars and bear interest at annual rates of between 4.20% and 5.82%.</span></span></div>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfShortTermBankDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfShortTermBankDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDepositsFromBanksExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deposits from banks. [Refer: Deposits from banks]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDepositsFromBanksExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 7 &#8211; PROPERTY AND EQUIPMENT</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Set forth below are the composition of property and equipment and the related accumulated depreciation, grouped by major classifications:</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:54pt">

          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net book value</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:10%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">251</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">42</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">209</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">191</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">41</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">177</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">60</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers and communications equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">467</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">161</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">331</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">291</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">70</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">138</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">223</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">176</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">108</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,571</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,571</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,525</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">26</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,551</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">46</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,036</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,036</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,932</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,036</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,325</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">203</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,147</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,939</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">227</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">179</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,987</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">386</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">160</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>

      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">INTANGIBLE ASSETS</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 8 &#8211; INTANGIBLE ASSETS</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;Intellectual property included the following intangible assets acquired by the Company:</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:51.05pt">&#160;</td>
            <td style="width:19.85pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$6.7 million primarily related to AGI-134. In December 2023, the Company made a decision to terminate the development of AGI-134 and, accordingly, an impairment loss for the full amount of the related intellectual property was recorded in the 2023 financial statements.</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:51.05pt">&#160;</td>
            <td style="width:19.85pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$15.0 million associated with BL-8040 were recorded following an amendment to the in-licensing agreement with Biokine Therapeutics Ltd. (&#8220;Biokine&#8221;). This amendment reduced the payments owed by the Company on sublicense receipts (as defined in the license agreement) from 40% to 20%. This intellectual property is amortized proportionally with the revenues recognized from the licensing transaction with HST and Gloria in Asia (see Note 15), and with Ayrmid for the rest of the world (excluding solid tumors) (see Note 16). During the period of self-commercialization in the U.S. of motixafortide in 2024, this intellectual property was amortized in accordance with the lifespan of the patents in the U.S. In addition, as a result of an impairment review of its remaining rights to motixafortide in solid tumor indications in the fourth quarter of 2024, the Company recorded an impairment loss of $1.0 million. Sensitivity tests on impairment of the remaining rights to motixafortide in solid tumor indications were carried out as of December 31, 2025, by increasing the WACC by 0.5% and by decreasing the annual growth rate of new cases by 0.5%. Such changes, if realized, would not have a material effect on the carrying amount of the motixafortide intellectual property. As of December 31, 2025, the net book value of the intangible assets associated with BL-8040 amounted to $10.2 million.</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:51.05pt">&#160;</td>
            <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$6.0 million associated with the acquisition of GLIX1, pursuant to the collaboration transaction and asset transfer agreement with Hemispherian AS (see Note 17).</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;text-indent:-19.85pt;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, the Company has concluded that the value of its intangible assets is higher than their carrying value.</span></span></div>
      <div style="text-align:justify;text-indent:-19.85pt;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <div></div>
      <div style="text-align:justify;margin-left:51.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Set forth below are the composition of intangible assets and the related accumulated depreciation, grouped by major classifications:</span></span></div>
      <div style="line-height:1.25">&#160;</div>

        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Cost</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation and impairment</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Additions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Disposal</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Additions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Impairment</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Net book value</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">beginning</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">end of</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">beginning</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">end of</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">of year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">of year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">2024</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">2025</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Composition in 2024</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Intellectual property</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">21,342</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">3,323</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">18,019</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">6,799</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">1,010</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">7,809</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">10,210</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Computer software</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">982</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">1</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">185</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">798</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">671</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">73</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">185</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">559</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">239</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">22,324</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">1</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">185</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">3,323</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">18,817</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">7,470</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">73</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">185</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">1,010</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">8,368</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">10,449</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Intellectual property</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">18,019</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">6,000</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">6,700</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">17,319</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">7,809</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">6,700</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">1,109</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">10,210</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">16,210</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Computer software</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">798</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">2</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">4</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">796</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">559</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">82</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">3</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">638</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">239</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">158</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:16%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">18,817</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">6,002</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">6,704</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">18,115</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">8,368</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">82</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">6,703</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">1,747</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">10,449</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">16,368</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">LEASES</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 9 &#8211; LEASES</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right-of-use assets</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:72pt">

          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net book value</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:middle;width:20%;vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">1,551</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">-</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">-</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">1,551</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">810</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">135</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">-</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">945</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">741</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">606</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:middle;width:20%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">456</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">-</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">196</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">260</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">230</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">79</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">139</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">170</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">226</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">90</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:20%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">2,007</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">-</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">196</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">1,811</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">1,040</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">214</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">139</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">1,115</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">967</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">696</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>

      </div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">B.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:72pt">

          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest expense</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange differences</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="22" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:16%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,409</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">176</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">174</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">596</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,163</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">194</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">71</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">10</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">17</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">102</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">48</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:16%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">1,603</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">71</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">186</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">191</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">698</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">1,211</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>

      </div>
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      <div></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">C.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional disclosures</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:71.85pt">&#160;</td>
            <td style="width:21pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company leases its premises in Israel under a lease agreement entered into in August 2014. Payments under the lease commenced in June 2015, and the initial term of the lease expired in June 2020. The lease agreement includes three options to extend the lease through June 30, 2030 in the aggregate, each at a 5% increase to the preceding lease payment amount. The Company exercised its first and second options to extend the lease through June 30, 2028, and is currently making monthly lease payments of approximately $30,000. In addition to the monthly lease payments, the Company also pays building monthly maintenance charges of approximately $9,700.</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:71.85pt">&#160;</td>
            <td style="width:21pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has entered into lease agreements in connection with a number of vehicles. The lease periods are generally for three years. The annual lease fees, linked to the CPI, are approximately $215,000. To secure the terms of the lease agreements, the Company has prepaid two months of lease payments to the leasing companies.</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:71.85pt">&#160;</td>
            <td style="width:21pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3)</span></span></td>
            <td style="width:auto;vertical-align:top;text-align:justify">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, minimum future rental payments (taking into consideration the aforementioned extension periods) under the leases are as follows:</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:72pt">

          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">332</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">106</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">438</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25">348</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25">21</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25">369</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2028</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">348</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">348</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2029-2030</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">523</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">523</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,551</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">127</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,678</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>

      </div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Extension and termination options are included in the property lease. These are used to maximize operational flexibility in terms of managing the assets used in the Company&#8217;s operations. The substantial majority of extension and termination options are exercisable solely by the Company and not by the lessors.</span></span></div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM LOAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract', window );"><strong>Disclosure of detailed information about borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBorrowingsExplanatory', window );">LONG-TERM LOANS</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 10 </span></span>&#8211;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"> LONG-TERM LOAN</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2022, the Company entered into a loan agreement with BlackRock EMEA Venture and Growth Lending (previously Kreos Capital VII Aggregator SCSP) (&#8220;BlackRock&#8221;), with an aggregate principal amount of up to $40 million comprised of three tranches of up to $10 million, $20 million and $10 million. The Company drew down the initial tranche of $10 million following execution of the loan agreement in September 2022, and it drew down the second tranche of $20 million in April 2024, following fulfilment of the requisite milestones. The third tranche was available for drawdown until October 1, 2024, upon the achievement of certain milestones. No drawdown was made by the indicated date, and thus, availably of the third tranche under the facility was cancelled.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Each tranche of the loan carried a pre-defined interest-only payment period, followed by a loan principal amortization period of up to 36 months subsequent to the interest-only period. The interest-only periods were subject to possible extension based on certain pre-defined milestones. Borrowings under the financing bear interest at a fixed annual rate of 9.5% (~11.0%, including associated cash fees). As security for the loan, BlackRock received a first-priority secured interest in all Company assets, including intellectual property, and the Company undertook to maintain a $10 million minimum cash balance. In addition, BlackRock was entitled to mid-to-high single-digit revenue-based payments on motixafortide sales in the U.S., up to a pre-defined cap.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, in connection with the Ayrmid License Agreement, the Company entered into an amendment to the loan Agreement with BlackRock. Pursuant to the amendment: (i) the Company made a payment of $16.5 million as partial repayment of the loan to BlackRock and in lieu of future revenue-based payments, which were fully cancelled, (ii) effective December 1, 2024, the Company began to pay the remaining amounts outstanding under the loan (in principal and interest) over a three-year period ending December 1, 2027, and (iii) the Company&#8217;s minimum cash balance requirement under the Loan Agreement was reduced to $4 million. In addition, pursuant to the amendment, 10% of any future milestone payments received by the Company from its out-licensing agreements through December 1, 2027 will be used to repay outstanding loan principal, and the repayments in (ii) above will be adjusted accordingly. All other terms of the Loan Agreement remain the same.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:49.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above amendment met the criteria in IFRS 9 regarding a substantial modification of the terms of a financial liability. In accordance with this paragraph, such modification is to be accounted for as the extinguishment of the original financial liability and the recognition of a new financial liability, with the&#160;difference between the carrying amount of the derecognized financial liability, versus any consideration paid plus any new liability undertaken, recorded as interest expense or income in the statement of comprehensive loss. Accordingly, the above amendment resulted in approximately $4.0 million of interest expense in the fourth quarter of 2024.&#160;</span></span></div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">EQUITY</a></td>
<td class="text">
    <div>
      <div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 11 &#8211; EQUITY</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share capital</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s share capital is composed of ordinary shares, par value NIS 0.10 per share, as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:90%;width:90%">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of Ordinary Shares</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Authorized share capital</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">5,000,000,000</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">20,000,000,000</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and paid-up share capital</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">1,336,670,575</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">2,610,814,390</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:90%;width:90%">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD and NIS Amounts</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Authorized share capital (in NIS)</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">500,000,000</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">2,000,000,000</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and paid-up share capital (in NIS)</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">133,667,057</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">261,081,439</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and paid-up share capital (in USD)</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">38,096,940</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">73,428,375</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rights related to shares</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ordinary shares confer upon their holders voting and dividend rights and the right to receive assets of the Company upon its liquidation. As of December 31, 2024 and 2025, all outstanding share capital consisted of ordinary shares.</span></span></div>
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in the Company&#8217;s equity</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;1)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2022, the Company completed a registered direct offering of 340,909 ADSs at a price of $44.00 per ADS. The Company also issued to investors in the offering unregistered warrants to purchase 340,909 ADSs. The warrants are exercisable immediately, expire  five years from the date of issuance and have an exercise price of $46.00 per ADS. In addition, the Company granted to the placement agent in the offering, as part of the placement fee, warrants to purchase 17,045 ADSs. These warrants are exercisable immediately, expire  five years from the date of issuance and have an exercise price of $55.00 per ADS. Gross proceeds from the offering totaled $15.0 million, with net proceeds of $13.5 million, after deducting fees and expenses. The offering consideration allocated to the placement agent warrants amounted to $0.4 million.</span></span></div>
                <div>&#160;</div>
                <div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The warrants issued to the investors have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the warrants is computed using the Black-Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 3.62%, and an average standard deviation of 82.5%. The gross consideration initially allocated to the investor warrants amounted to $9.1 million,</span></span></div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">with total issuance costs initially allocated to the warrants amounting to $0.8 million.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the warrants amounted to $24,000 as of December 31, 2025 (December 31, 2024 - $478,000), and was based on the then current price of an ADS, a risk-free interest rate of 3.47%, an average standard deviation of 101.32%, and on the remaining contractual life of the warrants.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The changes in fair value for the years ended December 31, 2024 and 2025 of $11,427,000 and $454,000 respectively, have been recorded as non-operating income in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, 63,636 of these warrants had been exercised.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The placement agent warrants have been classified in shareholders&#8217; equity, with initial recognition at fair value on the date issued, using the same assumptions as the investor warrants.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;2)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In August 2023, the Company entered into a securities purchase&#160;agreement, pursuant to which the Company sold in a private placement an aggregate of 170,728 ADSs of the Company, at a purchase price of $85.44 per ADS. Aggregate gross proceeds from the sale amounted to $14.6 million, with related issuance costs amounting to approximately $0.9 million. Pursuant to IFRS 15, approximately $12.0 million of gross proceeds and $0.7 million of issuance costs were recognized as equity (see Note 15).</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;3)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In April 2024, the Company completed a registered direct offering of 187,500 ADSs at a price of $32.00 per ADS. The Company also issued to investors in the offering unregistered warrants to purchase 187,500 ADSs. The warrants are exercisable immediately, expire  five years from the date of issuance and have an exercise price of $32.00 per ADS. Gross proceeds from the offering totaled $6.0 million, with net proceeds of $5.4 million, after deducting fees and expenses.</span></span></div>&#160;<div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the warrants is computed using the Black-Scholes option pricing model and is determined by using a&#160;level 3&#160;valuation technique. The fair value of the warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 4.21%, and an average standard deviation of 84.7%. The fair value initially allocated to the investor warrants amounted to $6,250,000, with total issuance costs initially allocated to the warrants amounting to $642,000.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Due to a difference between the fair value at initial recognition and the transaction price (&#8220;day 1 loss&#8221;),&#160;upon initial recognition, the fair value of the warrants was adjusted by the amount of $250,000, to reflect the unrecognized day 1 loss. Following initial recognition, the unrecognized day 1 loss of the warrants is being amortized over its contractual life.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the warrants amounted to $171,000 as of December 31, 2025 (December 31, 2024 - $679,000), and was based on the then current price of an ADS, a risk-free interest rate of 3.55%, an average standard deviation of 94%, and on the remaining contractual life of the warrants.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The changes in fair value for the years ended December 31, 2024 and 2025 of 5,571,000 and $298,000 respectively, have been recorded as a non-operating income in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, none of these warrants had been exercised.</span></span>
                    <p style="margin:0pt">&#160;</p>
                  </div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div></div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;4)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, the Company completed a registered direct offering to certain funds associated with Highbridge Capital Management LLC (&#8220;Highbridge&#8221;) of 103,037 ADSs and 308,749 pre-funded warrants to purchase ADSs. Each ADS and pre-funded warrant was sold at a purchase price of $21.86 and $21.85, respectively. The Company also issued to the investors unregistered ordinary warrants to purchase an aggregate of 205,893 ADSs. Gross proceeds from the offering totaled $9.0 million, with net proceeds of $8.9 million, after deducting fees and expenses. See Note 16.</span></span></div>
                <div>&#160;</div>
                <div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The pre-funded warrants are exercisable immediately, do not expire until exercised in full, and have an exercise price of $0.004 per ADS. The ordinary warrants are exercisable immediately, expire  four years from the date of issuance, and have an exercise price of $23.60 per ADS.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A holder of the pre-funded or ordinary warrants cannot exercise such warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the outstanding share capital of the Company immediately after giving effect to such exercise.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ordinary warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The pre-funded warrants have been classified in shareholders&#8217; equity, with initial recognition at fair value on the date issued, using the same assumptions as the ordinary warrants.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the ordinary warrants is computed using the Black-Scholes option pricing model. The fair value of the ordinary warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 4.19%, and an average standard deviation of 84.5%. The gross consideration initially allocated to ordinary warrants amounted to $2,721,000, with total issuance costs initially allocated to the ordinary warrants amounting to $27,000.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the ordinary warrants amounted to $102,000 as of December 31, 2025 (December 31,2024- $745,000) and was based on the then current price of an ADS, a risk-free interest rate of 3.55%, an average standard deviation of 96%, and on the remaining contractual life of the ordinary warrants.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The changes in fair value for the years ended December 31, 2024 and 2025 of $1,976,000 and $643,000 respectively, have been recorded as non-operating income in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, 226,392 of the pre-funded warrants had been exercised, and none of the ordinary warrants had been exercised.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div></div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;5)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2025, the Company completed a registered direct offering to certain institutional investors of 858,303 ADSs and 391,697 pre-funded warrants to purchase ADSs. Each ADS and pre-funded warrant was sold at a purchase price of $8.00 and $7.996, respectively. The Company also issued to investors in the offering unregistered ordinary warrants to purchase an aggregate of 1,250,000 ADSs. The pre-funded warrants are exercisable immediately, do not expire until exercised in full, and have an exercise price of $0.004 per ADS. The ordinary warrants are exercisable immediately, expire  five years from the date of issuance, and have an exercise price of $8.00 per ADS. A holder of the pre-funded or ordinary warrants cannot exercise such warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or 9.99% at the election of the holder) of the outstanding share capital of the Company immediately after giving effect to such exercise.</span></span></div>
                <div>&#160;</div>
                <div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, the Company granted to the placement agent in the offering, as part of the placement fee, warrants to purchase 62,500 ADSs. These warrants are exercisable immediately, expire  five years from the date of issuance and have an exercise price of $10.00 per ADS. The offering consideration allocated to the placement agent warrants amounted to $0.5 million.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross proceeds from the offering totaled $10.0 million, with net proceeds of $8.9 million, after deducting fees and expenses.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The investors&#8217; ordinary warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The pre-funded warrants have been classified in shareholders&#8217; equity. The fair value of the ordinary warrants is computed using the Black-Scholes option pricing model and is determined by using a level 3 valuation technique. The fair value of the ordinary warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 4.41%, and an average standard deviation of 90.2%. The fair value initially allocated to the investor ordinary warrants amounted to $10.4 million, with total issuance costs initially allocated to the ordinary warrants amounting to $0.7 million.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Due to a difference between the fair value at initial recognition and the transaction price (&#8220;Day 1 loss&#8221;), upon initial recognition, the fair value of the ordinary warrants was adjusted by the amount of $1.4 million, to reflect the unrecognized day 1 loss. Following initial recognition, the unrecognized day 1 loss of the warrants is being amortized over its contractual life.</span></span></div>
                </div>
              </td>
            </tr>

        </table>&#160;<div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:67.5pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the ordinary warrants amounted to $1,878,000 as of December 31, 2025, and was based on the then current price of an ADS, a risk-free interest rate of 3.64%, an average standard deviation of 91.0%, and on the remaining contractual life of the warrants.</span></span></div>
                <div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The changes in fair value for the year ended December 31, 2025 of $7,204,000, have been recorded as non-operating income in the statement of comprehensive loss.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, all of the pre-funded warrants had been exercised, and none of the ordinary warrants had been exercised.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with IFRS 2, the placement agent warrants have been classified in shareholders&#8217; equity, with initial recognition at fair value on the date issued, using the same assumptions as the investor warrants.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share purchase agreement</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:70.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2021, the Company entered into an ATM sales agreement with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;), pursuant to which the Company is entitled, at its sole discretion, to offer and sell through HCW, acting as sales agent, ADSs having an aggregate offering price of up to $25.0 million throughout the period during which the ATM facility remains in effect. The Company agreed to pay HCW a commission of 3.0%&#160;of the gross proceeds from the sale of ADSs under the facility. During 2025, 772,264 ADSs were sold under the program for total net proceeds of $5.0 million. From the effective date of the agreement through the issuance date of this report, 825,010 ADSs have been sold under the program for total net proceeds of $9.2 million.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:43.9pt">&#160;</td>
              <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based payments</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:74pt">&#160;</td>
              <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
              <td style="vertical-align:top;text-align:justify;width:auto">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share Incentive plan &#8211; general</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In 2003, the Company adopted the 2003 Share Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the granting of stock options and ordinary shares to the Company&#8217;s employees, directors, consultants and other service providers. Options are issued at the determination of the Board of Directors in accordance with applicable law. The options are generally exercisable for a ten -year period, and the grants generally vest over a four -year period. In 2013, the Company&#8217;s Board of Directors approved amendments to the Plan to take into account changes in laws and regulations that had occurred since its adoption and to extend the term of the plan until November 2023. In 2016, the Board of Directors approved amendments to the Plan to allow for the grant of restricted stock units (&#8220;RSUs&#8221;) and performance stock units (&#8220;PSUs&#8221;). In 2022, the Board approved certain amendments to the Plan in order to conform the Plan to U.S. tax regulations for the benefit BioLineRx USA, Inc. employees.&#160;In November 2023, the Company&#8217;s Board of Directors approved extension of the Plan through May 2024, and subsequently further approved extension of the Plan through May 2044.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PSUs are RSUs that are linked to any one or more performance goals (in addition to, or in lieu of, time-based vesting terms) determined appropriate by the Board of Directors. The specific performance goals, as well as the time period associated with achieving such goals, are approved by the Board and are set forth in the grantee&#8217;s grant agreement. To date, each PSU grant has had between three to five performance goals on which vesting is based, each such goal being either a specified Company milestone and or the success of a specific project, with vesting of 20-40% on the achievement of each goal. The tranche of PSUs associated with a given milestone expires 12 months after the target date established for that milestone. As of December 31, 2025, 8,787,600 PSUs were vested in accordance with their original terms.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, there were 326,757,000 ordinary shares issuable upon the exercise of outstanding equity instruments under the Plan.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Company employees and directors in Israel are granted options under Section 102 of the Israeli Income Tax Ordinance (the &#8220;Ordinance&#8221;), primarily under the &#8220;capital gains&#8221; track. Israeli non-employees of the Company (consultants and other service providers) are granted options under Section 3(i) of the Ordinance. All non-Israeli employees and non-employees of the Company are granted options as non-qualifies.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, there were 233.4 million remaining authorized but unissued ordinary shares in the pool reserved for future share-based incentive grants.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:74pt">&#160;</td>
              <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
              <td style="vertical-align:top;width:auto">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee share incentive plan:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table contains additional information concerning equity instruments granted to employees and directors under the existing share incentive plans.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:99pt">

            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="22" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number<br/>of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise price</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number<br/>of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise price</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number<br/>of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise price</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at beginning of year</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">89,871,858</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.44</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">150,429,825</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.32</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">141,634,245</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.32</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">64,855,380</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.18</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">23,190,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.20</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">212,760,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.01</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expired</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(1,379,640</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.68</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(3,825,990</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.53</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(24,310,920</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.25</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">(2,424,535</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.21</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">(27,389,565</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.23</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">(18,116,325</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.25</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(493,238</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.22</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(770,025</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.14</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">-</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">-</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at end of year*</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">150,429,825</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.32</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">141,634,245</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.32</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">311,967,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.12</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable at end of year</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">51,970,635</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.54</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">88,080,600</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.40</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">81,825,600</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.39</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:99pt">&#160;</td>
              <td style="width:7.05pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, 2024 and 2025 includes 12,219,465, 4,010,670 and 8,126,400 respectively, PSUs at an exercise price of 0.10 NIS (par value of ordinary shares) for which performance obligations have not been met. As of December 31, 2025 includes additional 21,240,000 PSUs at a zero exercise price, for which performance obligations have not been met.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The total consideration received from the exercise of equity instruments during 2023, 2024 and 2025 was not material.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Set forth below is data regarding the range of exercise prices and weighted-average remaining contractual life (in years) for the equity instruments outstanding at the end of each of the years indicated.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">

            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="14" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Range of</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise prices</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Number</span></span></span></span></strong></div>
                        <div style="line-height:1.25;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">of options outstanding</span></span></span></span></strong></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining contractual life (in&#160;yrs.)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Number</span></span></span></span></strong></div>
                        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">of options outstanding</span></span></span></span></strong></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining contractual life (in&#160;yrs.)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Up to 0.49</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">114,352,425</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">8.07</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">288,520,200</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">9.07</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.5-0.99</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25">15,104,100</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25">6.54</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25">12,576,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25">4.96</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.00-2.00</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">11,727,795</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">4.57</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">10,423,800</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">2.82</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.01-3.4</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">449,925</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">3.18</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">447,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">1.17</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">141,634,245</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">7.60</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">311,967,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">8.68</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of equity instruments granted to employees through December 31, 2025 has been determined using the Black-Scholes option-pricing model. These values are based on the following assumptions as of the applicable grant dates:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">

            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="width:41%;vertical-align:bottom;padding-bottom:2px">&#160;</td>
                    <td style="width:20.28%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;padding-bottom:2px">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;padding-bottom:2px">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected dividend yield</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">0%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">0%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">0%</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">69%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">73%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">93%</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">4%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">4%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">4%</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life of options (in years)</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">6</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">6</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">6</div>
                    </td>
                  </tr>

              </table>
            </div>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The remaining unrecognized deferred compensation expense as of December 31, 2025 was $1.2 million. This amount will be expensed over the remaining vesting period of the equity instruments.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:74pt">&#160;</td>
              <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3)</span></span></td>
              <td style="vertical-align:top;width:auto">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock options to consultants</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">From inception through December 31, 2025, the Company has issued to consultants options for the purchase of 17,836,200 ordinary shares at a weighted average exercise price of 0.36 NIS per share.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The options to consultants generally vest over four years and may be exercised for periods of between five and ten years. As of December 31, 2025, 14,790,000 options to consultants were outstanding with a weighted average exercise price of NIS 0.03 per share and a weighted average contractual life of 9.8 years.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Company management estimates the fair value of the options granted to consultants based on the value of services received over the vesting period of the applicable options. The value of such services (primarily in respect of clinical advisory services) is estimated based on the additional cash compensation the Company would need to pay if such options were not granted. The value of services recorded in each of the years 2023, 2024 and 2025 was not material.</span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfIncomeTaxesAbstract', window );"><strong>Disclosure Of Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">TAXES ON INCOME</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 12 &#8211; TAXES ON INCOME</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Corporate taxation</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The taxable income of BioLineRx Ltd. and Tetragon is taxed at the standard Israeli corporate tax rate, which was 23% for all years included in these financial statements.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax loss carryforwards</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2025, the tax loss carryforwards of BioLineRx Ltd. were approximately $381 million. The tax loss carryforwards have no expiration date.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assessments</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with Israeli tax regulations, the tax returns filed by BioLineRx Ltd. through the 2020 tax year are considered final.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical taxes</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has not recognized any deferred tax assets in the financial statements, as it does not expect to generate taxable income in the foreseeable future. The reported tax on the Company&#8217;s income before taxes differs from the theoretical amount that would arise using the weighted average tax rate applicable to income of the consolidated entities as follows:</span></span></div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>

        <div>
          <div style="margin-left:72pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="22" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">23.0</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(60,614</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">23.0</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(9,221</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">23.0</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(2,026</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical tax benefit</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(13,941</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(2,121</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(466</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Disallowed deductions (tax exempt income):</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss (gain) on adjustment of warrants to fair value</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,542</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(4,056</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(1,978</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">534</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">261</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">91</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Impairment of intangible asset</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,542</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">232</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">11</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">11</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">11</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">9,312</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">5,673</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,342</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income for the reported year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">LOSS PER SHARE</a></td>
<td class="text">
      <div>
        <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 13 &#8211; LOSS PER SHARE</span></span></div>
        <div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;text-indent:-21.25pt;margin-left:70.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table contains the data used in the computation of the basic loss per share:</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:54pt">

              <div>
                <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss attributed to ordinary shares</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(60,614</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(9,221</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(2,026</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in thousands</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of shares used in basic calculation</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">963,366</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">1,198,108</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">2,465,273</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(0.06</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(0.01</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(0.00</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                    </tr>

                </table>
              </div>

          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The number of shares used in the 2024 and 2025 basic calculations includes 12,052 and 49,279 pre-funded warrants, respectively.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:49.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding options, RSUs, PSUs and ordinary warrants have been&#160;excluded from the calculation of the diluted loss per share for all years presented, since their effect was anti-dilutive.</span></span></div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract', window );"><strong>Disclosure of commitments and contingent liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 14 &#8211; COMMITMENTS AND CONTINGENT LIABILITIES</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commitments</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Obligation to pay royalties to the State of Israel</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalties may be payable to the State of Israel (represented by the Israel Innovation Authority, or IIA), on proceeds from the sale or license of products whose development was supported by grants from&#160;the IIA. Such royalties are generally 3% in the first three years from initial repayment, 4% of sales in the three subsequent years and 5% of sales in the seventh year until repayment of 100% of the grants (linked to the dollar) received, plus annual interest at the 12-month SOFR rate as published on the first trading day of each calendar year. Under certain circumstances, the royalty rate is calculated according to a formula based on the ratio of participation by the IIA in the project to the project&#8217;s total accumulated costs.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other than motixafortide (see next paragraph), the Company does not have any royalty obligation in respect of products supported by the IIA.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the in-licensing of motixafortide from Biokine Therapeutics Ltd. (&#8220;Biokine&#8221;), and as a condition to IIA consent to the transaction, the Company agreed to abide by any obligations resulting from funds previously received by Biokine from the IIA. The contingent liability to the IIA assumed by the Company relating to this transaction amounts to $2.5 million as of December 31, 2025. In this regard, and in connection with the out-licensing transactions with Gloria (see Note 15) and with Ayrmid (see Note 16), as well as with the direct sales of motixafortide in the U.S. during the period from product launch through the transaction with Ayrmid, the royalty rate agreed with the IIA for motixafortide consideration received is 3.9% for sub-license consideration and 4% for direct product sales. The Company has a full right of offset for amounts payable to the IIA from all payments due to Biokine in the future.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Licensing agreements</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the development of therapeutic compounds, the Company may enter into in-licensing agreements with academic institutions, research institutions and companies (the &#8220;licensors&#8221;). Pursuant to these licensing agreements, the Company generally obtains the rights for one or more therapeutic compounds in pre-clinical and early clinical stages of development, in order to continue development of the compounds through more advanced stages of development and, subsequently, to manufacture, distribute and market the drugs or to out-license the development, manufacturing and commercialization rights to third parties.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div></div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The licenses that have been granted to the Company are broad and comprehensive, and generally include various provisions and usage rights as follows: (i) territorial scope of the license (global); (ii) term of the license (unrestricted but not shorter than the life of the patent); and (iii) development of the therapeutic compound (allowing the Company to perform all development activities on its own, or by outsourcing under Company supervision, as well as out-licensing development under the license to other companies, subject to the provisions of the licensing agreements).</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">According to the provisions of the licensing agreements, the intellectual property rights in the development of any licensed technology, through the date the applicable license agreement is effective, remain with the licensor, while the rights in products and/or other deliverables developed by the Company after the license is granted belong to the Company. In cases where the licensor has a claim to an invention that was jointly developed with the Company, the licensor also co-owns the related intellectual property. In any event, the scope of the license also covers these intellectual property rights.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, the Company generally undertakes in the licensing agreements to protect registered patents resulting from developments under the various licenses, to promote the registration of patents covering new developments in cooperation with the licensor, and to bear responsibility for all related costs. Pursuant to the various agreements, the Company generally works to register the various patents on a broad basis worldwide, and if the Company decides not to initiate or continue a patent registration proceeding in a given country, the Company is required to notify the applicable licensor to this effect, and the licensor is entitled to take action for registration of the patent in such country.</span></span></div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consideration paid pursuant to the licensing agreements generally includes several components that may be payable over the license period and that relate, inter alia, to the progress made in research and development activities, as well as commercial success, as follows: (a) a one-time, up-front payment and/or periodic payments; (b) payments through the early stages of development (i.e., through the end of phase 2); (c) payments upon the achievement of milestones necessary for advancing to phase 3; (d) payments from the end of a successful phase 3 trial through approval of the therapeutic compound; and e) royalties on sales of the final product resulting from development under the license or including any component thereof, generally less than 5% of the Company&#8217;s net sales of the product, although in specific instances (for example, with regard to motixafortide, where the royalty rate on net sales directly commercialized by the Company payable to Biokine is 10%) the royalty rate has been higher or lower than this range. In instances where the Company has out-licensed the product for further development, the Company pays a percentage of the net consideration received from the licensee (&#8220;Sublicense Receipts&#8221;) to the upstream licensor that generally range from 20% to 29.5% of such consideration, although in specific instances the percentage paid has been higher or lower than this range. These Sublicense Receipts generally take the place of most or all of the milestone and royalty payments set forth in (b) through (e) above.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div></div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The license agreements may be cancelled by the licensor only in specific circumstances, generally upon the occurrence of one of the following events: (a) the Company&#8217;s failure to meet certain milestones stipulated in the applicable license agreement and appended timetables; (b) default, insolvency, receivership, liquidation, etc., of the Company that is not imposed and/or lifted within the timeframe stipulated in the license agreement; and (c) fundamental breach of the license agreement that is not corrected within the stipulated timeframe. The Company may generally cancel a license agreement with prior notice of 30 to 90 days, due to unsuccessful development or any other cause.</span></span></div>
      <div style="text-align:justify;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Some of the license agreements have been accompanied by consulting, support and cooperation agreements, pursuant to which the Company may be committed to pay the various licensers a fixed monthly amount over the period stipulated in the agreement for their assistance in the continued research and development under the license.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commitments in respect of Biokine</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with the license agreement of motixafortide with Biokine (as amended), the Company is required to pay Biokine a payment of 20% of amounts received as consideration in connection with any sublicensing or sale of the licensed technology. Biokine is also eligible to receive up to a total of $2.5 million in future milestone payments. Subject to certain limitations, if the Company independently sells products related to motixafortide, the Company will pay Biokine a royalty payment of 10% of net sales.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:70.9pt">&#160;</td>
            <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4)</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase orders</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s outstanding open purchase order commitments as of December 31, 2025 amounted to $2.4 million.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Guarantees</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To secure the Company&#8217;s lease obligation on its Israeli premises, the Company has provided a bank guarantee in the amount of $100,000 for the benefit of the lessor, which remains outstanding as of December 31, 2025.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contingent liabilities</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2024, Biokine Therapeutics Ltd. (&#8220;Biokine&#8221;),&#160;filed a complaint with the District Court of Jerusalem against the Company. The complaint alleged breach of contract and a purported failure to make certain payments to Biokine under the Company&#8217;s in-licensing agreement with Biokine for motixafortide. The lawsuit sought compensatory damages in the amount of approximately $6.5 million and a declaratory judgment in favor of Biokine. The Company filed a statement of defense in November 2024. In November 2024, the Company and Biokine entered into an agreement to refer the dispute to binding arbitration, and the claim was withdrawn. During the first quarter of 2025, Biokine filed an updated complaint under the arbitration, increasing the damages to the amount of approximately $7.2 million.</span></span></div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In February 2026, the arbitrator issued a final decision in the case, denying all claims asserted by Biokine against the Company, and awarding the Company expenses, including legal fees.</span></span></div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract', window );"><strong>License And Securities Purchase Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock', window );">LICENSE AND SECURITIES PURCHASE AGREEMENTS &#8211; HST/GLORIA</a></td>
<td class="text">
        <div>
          <div>
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 15 &#8211; LICENSE AND SECURITIES PURCHASE AGREEMENTS &#8211; HST/GLORIA</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, the Company closed on a license agreement (the &#8220;Gloria License Agreement&#8221;) with Hong Seng Technology Limited (&#8220;HST&#8221;) and Auspex Bioscience (Guangzhou) Co., Ltd. (formerly Guangzhou Gloria Biosciences Co., Ltd.) (&#8220;Gloria&#8221; and together with HST, the &#8220;Gloria Licensee&#8221;), pursuant to which the Company granted HST an exclusive, royalty-bearing, sublicensable license to develop and commercialize motixafortide in Asia (other than Israel and certain other countries) (collectively, the &#8220;Gloria Territory&#8221;) and to engage and authorize Gloria to perform services under the Gloria License Agreement in the Gloria Territory. In addition, the Company granted the Gloria Licensee a first offer right with respect to the grant of certain rights in motixafortide outside of the Gloria Territory.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the terms of the Gloria License Agreement, the Gloria Licensee paid an upfront payment of $15 million, which was received by the Company at closing. The Company is also entitled to up to $49 million based on the achievement of certain development and regulatory milestones in China and Japan, and up to $197 million in sales milestones based on defined sales targets of motixafortide in the Gloria Territory. In addition, the Company is eligible to receive tiered double-digit royalties (ranging from 10-20%), on a country-by-country basis until the longer of (i) fifteen years from the date of the first sale of motixafortide by the Gloria Licensee, (ii) the last to expire valid claim of any licensed patents with respect to motixafortide in such country and (iii) the expiration of motixafortide&#8217;s orphan drug status in such country. The royalties payable by Gloria Licensee are to be reduced by 50% following the end of the initial royalty term and are also to be reduced upon the occurrence of certain events, including, on a country-by-country basis, the entry of a generic product in such country.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, in October 2023, the Company closed on a securities purchase agreement (the &#8220;Gloria Purchase Agreement&#8221;) with HST and Gloria, pursuant to which the Company issued in a private placement an aggregate of 170,728 ADSs of the Company, at a purchase price of $85.44 per ADS. Aggregate gross proceeds from the sale were approximately $14.6 million, with related issuance costs amounting to approximately $0.9 million. No warrants were issued in the transaction.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with IFRS 15, both agreements have been treated as a single unit of account, with the consideration combined and subsequently allocated between the Gloria Purchase Agreement and the Gloria License Agreement. Of the total consideration amounting to $29.6 million, $12.0 million were allocated to the Purchase Agreement, and $17.6 million were allocated to the Gloria License Agreement. Costs in the amount of $0.7 million directly attributable to the Purchase Agreement were recognized as a reduction in equity.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company identified the following performance obligations in the contract, each to be recognized separately: (1) stem-cell mobilization (&#8220;SCM&#8221;) license; (2) SCM support services; and (3) pancreatic cancer (&#8220;PDAC&#8221;) license and related support services.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With regard to PDAC, the Company determined that the license, together with the associated support services, should be combined into a single performance obligation, since the Licensee cannot benefit from the license without the associated support services. The support services are highly specialized for the licensed product in this indication. Licensing rights for other indications and related support were deemed immaterial.</span></span>
              <p style="margin:0pt">&#160;</p>
            </div>
            <div></div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fixed transaction price has been allocated among the performance obligations based on similar price offers received by the Company, with the assistance of a valuation specialist. The variable consideration&#160;related to the performance obligations&#160;was not taken into account in the fixed transaction price due to uncertainty.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue has been recognized in the Company&#8217;s financial statements as follows:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue for the SCM license was recognized in the fourth quarter of 2023, upon transfer of control over the license to the licensee, in the amount of $2.0 million.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue from providing the SCM support services has been recognized using the input method, which is based on costs incurred and labor hours expended, resulting in straight-line revenue recognition for the year ended December 31, 2024 totaling $0.1 million.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue from the PDAC performance obligation has been recognized over time, with the percentage of completion determined based on support hours incurred, with a total amount of $15.5 million recognized through the end of 2024.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Based on the above methodology, as well as the achievement of a specific regulatory milestone, the Company recognized revenues from the license agreement of $4.6 million and $15.0 million for the years ended December 31, 2023 and 2024, respectively. Due to a delay in payment of $2.4 million to be received from the Gloria Licensee during 2024, a provision for doubtful accounts receivable in the amount of $0.8 million was recorded in the fourth quarter of 2024. This amount was subsequently collected in 2025 and the provision was reversed.</span></span></div>
          </div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of license and securities purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract', window );"><strong>Disclosure Of License And Securities Purchase Agreements Ayrmid And Highbridge [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory', window );">LICENSE AND SECURITIES PURCHASE AGREEMENTS &#8211; AYRMID/HIGHBRIDGE</a></td>
<td class="text">
      <div>
        <div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 16 &#8211; LICENSE AND SECURITIES PURCHASE AGREEMENTS &#8211; AYRMID/HIGHBRIDGE</span></span><br/>&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, the Company entered into a license agreement (the &#8220;Ayrmid License Agreement&#8221;) with Ayrmid Pharma Ltd. (the &#8220;Ayrmid Licensee&#8221;), pursuant to which the Company granted the Ayrmid Licensee an exclusive, transferable, royalty-bearing, sublicensable license with respect to the intellectual property rights and know-how associated with motixafortide, to commercialize motixafortide across all indications, except solid tumor indications, in all territories other than Asia (collectively, the &#8220;Ayrmid Territory&#8221;).</span></span><br/>&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the terms of the Ayrmid License Agreement, the Company received a non-refundable $10 million upfront payment and is entitled to up to $87 million of certain commercial and sales milestones based on defined sales targets of motixafortide in the Ayrmid Territory. Additionally, the Company is eligible to receive tiered double-digit royalties (ranging from 18-23%) on aggregate net sales of motixafortide&#160;on a country-by-country basis until the longer of (i) fifteen years from the date of the first sale of motixafortide by the Ayrmid Licensee in such country, (ii) the last to expire of any licensed patents with respect to motixafortide in such country, (iii) the expiration of regulatory exclusivity in such country and (iv) the expiration of motixafortide&#8217;s orphan drug status, if any, in such country, it being noted that such royalties may be subject to reduction in certain specific circumstances.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div></div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the Ayrmid License Agreement, the Company and the Ayrmid Licensee also entered into a manufacturing and supply agreement (the &#8220;Supply Agreement&#8221;), according to which the Company has committed to supply motixafortide to the Ayrmid Licensee during the term, on a cost-plus basis, for both commercial and development supply. Furthermore, the Supply Agreement provides the Ayrmid Licensee with &#8220;step-in rights&#8221; with respect to the manufacture and supply of motixafortide upon the occurrence of certain trigger events.</span></span><br/>&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Ayrmid License Agreement will continue on a country-by-country basis in the Ayrmid Territory until the expiration of the royalty term or earlier termination thereof. The Ayrmid License Agreement may also be terminated by either party in the case of a material breach or bankruptcy.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Concurrent with the above transaction, the Company completed a registered direct offering with gross proceeds of $9.0 million to certain funds associated with&#160;Highbridge, a related party to Ayrmid&#160;(see Note 11c(4)).</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with IFRS 15, both transactions have been treated as a single unit of account, with the consideration combined and subsequently allocated between the Ayrmid License agreement and the registered direct offering. Of the total consideration amounting to $19.0 million, $7.8 million were allocated to the Ayrmid License Agreement, and $11.2 million were allocated to the registered direct offering. Costs in the amount of $0.1 million directly attributable to the registered direct offering were recognized as a reduction in equity. The proceeds allocated to the ordinary warrants in the registered direct offering were measured with reference to their fair value as financial instruments issued to a customer.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consideration allocated to the Ayrmid License Agreement of $7.8 million was attributed to a single material performance obligation &#8211; i.e., the granting of the license to commercialize and develop motixafortide in the Ayrmid Territory. Accordingly, revenue from the license of $7.8 million was recognized during the fourth quarter of 2024, upon transfer of control over the Ayrmid License to the licensee. Sales-based milestone payments and royalties based on motixafortide net sales are subject to the &#8220;royalties exception&#8221; of IFRS 15 and are recognized as revenue when the related sale occurs. Total royalties based on motixafortide net sales in 2025 amounted to $1.2 million.</span></span></div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of license and securities purchase agreements Ayrmid And Highbridge explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementWithCompaniesForDevelopmentAbstract', window );"><strong>Agreement With Companies For Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory', window );">AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1</a></td>
<td class="text">
      <div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 17 &#8211; AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2025, the Company entered into a collaboration transaction with Hemispherian AS, a Norwegian corporation (&#8220;Hemispherian&#8221;), for the development, clinical evaluation and commercialization of GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors. As part of the transaction, (i) the Company and Hemispherian entered into a Collaboration and Shareholders Agreement (the &#8220;Agreement with Hemispherian&#8221;), which governs the ownership, governance, funding, administration, and related operational and commercial terms of a new company (Tetragon) established by the Company and Hemispherian, and (ii) Hemispherian and Tetragon entered into an Asset Transfer Agreement (the &#8220;ATA&#8221;), pursuant to which Hemispherian transferred to Tetragon certain intellectual property, regulatory filings, know-how, and related assets primarily in respect of GLIX1, Hemispherian&#8217;s lead compound (the &#8220;Transferred Assets&#8221;).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In consideration for the transfer of the Transferred Assets, Hemispherian received 60% of the issued share capital of Tetragon. In consideration for the Company&#8217;s commitment to invest $5 million in Tetragon (the &#8220;Threshold Amount&#8221;) within 36 months as of the date of the Agreement with Hemispherian, the Company received 40% of the issued share capital of Tetragon. Such threshold amount is to be paid in tranches according to a development plan, and the 36-month period may be extended by an additional six months upon the occurrence of certain events as specified in the Agreement with Hemispherian (the &#8220;Threshold Term&#8221;). If the Company does not invest the full Threshold Amount by the end of the Threshold Term, Hemispherian will have the right to repurchase, for nominal consideration, a pro rata portion of the Company&#8217;s shares in Tetragon corresponding to the unfunded portion of the Threshold Amount. As of December 31, 2025, the Company had invested $1.2 million of the Threshold Amount.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Following the investment of the Threshold Amount, the Company may make additional investments in Tetragon. For each incremental $1 million invested by the Company beyond the Threshold Amount, the Company will be entitled to an additional 1% equity interest, up to an aggregate maximum ownership of 70%. Following the attainment of a 50% stake by the Company in Tetragon, Hemispherian will have the right to co-invest alongside the Company on the same terms in order to maintain a 50% ownership stake in Tetragon.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furthermore, under the terms of the Agreement with Hemispherian, the Company will be responsible for managing and implementing Tetragon&#8217;s activities and overseeing its operations, budget, and expenses. Following the closing, Tetragon will pay Hemispherian a monthly advisory fee of $80,000 for a period of 24 months or until the termination of the collaboration, whichever occurs first.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Agreement with Hemispherian provides for the establishment of a board of directors of Tetragon as well as a steering committee with joint representation from both the Company and Hemispherian. The Company holds the deciding vote in the event of any deadlock on either of such corporate bodies and, accordingly, is the controlling shareholder of Tetragon. Tetragon has a first-look right, as well as a right of first refusal, on other assets in Hemispherian&#8217;s pipeline for defined periods specified in the ATA.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ATA and the Agreement with Hemispherian contain customary representations and warranties, indemnification and other provisions customary for transactions of this nature. The ATA and Agreement with Hemispherian also include termination events, including failure to fund the Threshold Amount within the Threshold Term, or prolonged inability of Tetragon to operate due to insufficient financial resources.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the ATA and Agreement with Hemispherian, an intangible asset in the amount of $6.0 million was recorded in respect of the GLIX1 molecule at fair value, against a minority interest in the same amount.</span></span></div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementWithCompaniesForDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementWithCompaniesForDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of agreement with hemispherian for development of Glix1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRANSACTIONS AND BALANCES WITH RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</a></td>
<td class="text">
          <div>
            <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 18 &#8211; TRANSACTIONS AND BALANCES WITH RELATED PARTIES</span></span></div>
            <div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-indent:-12.35pt;margin-left:70.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions with related parties</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-indent:-12.35pt;margin-left:70.85pt;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expenses:</span></span></div>
              <div style="margin-left:70.9pt;line-height:1.25">&#160;</div>
              <div style="margin-left:63pt">

                  <div>
                    <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-14.6pt;margin-left:14.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Benefits to related parties:</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                            <div style="text-indent:-13.5pt;margin-left:28.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation and benefits to senior management, including benefit component of equity instrument grants</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">3,155</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">2,396</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">1,398</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-13.5pt;margin-left:28.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation and benefits to directors, including benefit component of equity instrument grants</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">587</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">415</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">473</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>

              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;font-weight:normal;margin-left:60pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Regarding transactions and balances related to Gloria, see Note 15.</span></span></div>
              <div style="text-align:justify;line-height:1.25;margin-left:70pt">&#160;</div>
              <div style="line-height:1.25;font-weight:bold;margin-left:60pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Key management compensation</span></span></div>
              <div style="line-height:1.25;font-weight:bold;margin-left:70pt">&#160;</div>
              <div style="line-height:1.25;font-weight:normal;text-align:justify;margin-left:60pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Key management includes directors and executive officers. The compensation paid or payable to key management for services during each of the years indicated is presented below.</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:63pt">

                  <div>
                    <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-16.35pt;margin-left:16.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and other short-term employee benefits</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">2,425</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">2,018</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">1,425</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Post-employment benefits</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25">256</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25">394</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25">116</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other long-term benefits</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">31</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">29</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">32</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">1,030</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">370</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">298</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">3,742</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">2,811</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">1,871</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>

              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">SEGMENT REPORTING</a></td>
<td class="text">
      <div>
        <div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 19 &#8211; SEGMENT REPORTING</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company operates in a <span style="-sec-ix-hidden:Fxbrl_20250327041154148">single</span> reportable operating segment &#8211; the development and commercialization of therapeutics. Its corporate headquarters and development activities are in Israel, while its revenues stem from activities carried out in the U.S. and Asia (primarily Greater China). In this regard, product sales relate to the Company&#8217;s direct commercialization activities in the U.S. from October 2023 through November 2024, while license revenues relate to outlicensing agreements entered into in Asia and in the U.S. in October 2023 and November 2024, respectively. Set forth below is a breakdown of revenues from external parties by geographic region.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:54pt">

              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">China</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">4,610</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">14,957</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">-</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">190</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">13,983</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">1,180</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">4,800</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">28,940</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">1,180</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>

          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:55.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Substantially all of the Company&#8217;s non-current assets are located in Israel. See Notes 15 and 16 for information on customers representing 10% or more of total revenues.</span></span></div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract', window );"><strong>Disclosure of supplementary financial statement information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text">
    <div>
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE 20 &#8211; SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other receivables</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>

        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2025</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>in USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">Government institutions</div>
                </td>
                <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>455</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>33</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Advance payments</span></p>
                </td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">91</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">-</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>932</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>377</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,478</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>410</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>

          </table>
        </div>

      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>b.</span></span></span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accounts payable and accruals</span></span></span></span></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>

        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2025</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>in USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Accounts payable:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160; Overseas</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,250</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,814</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160; In Israel</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,333</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>679</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5,583</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,493</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Payroll and related expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,993</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>523</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Accrued expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>707</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>372</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:0pt;margin-left:23.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160; Accrual for vacation and recreation pay</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>431</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>310</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Other</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>538</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,131</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,743</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>

      <div style="line-height:1.25">&#160;</div>
      <div style="margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The carrying amounts of accounts payable and accruals approximate their fair value, as the effect of discounting is not material.</span></span></span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenues</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>

        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">License fees and royalties payable to licensor</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,027</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,024</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">230</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Direct costs related to license revenues</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">203</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,605</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of intangible asset</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">450</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,323</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of product sales</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">311</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,692</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,263</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">230</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>

      <div style="text-indent:-21.25pt;margin-left:70.85pt;line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>

        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development services</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,603</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,170</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,118</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payroll and related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,452</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,524</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,982</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lab, occupancy and telephone</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">969</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,102</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">855</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional fees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">935</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">273</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">390</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">760</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">451</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation and amortization</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">583</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">431</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">495</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">217</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">198</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">149</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,519</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,149</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,093</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>

      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales and marketing expenses</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>

        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payroll and related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,868</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,224</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Medical Affairs</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,824</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,891</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,091</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,041</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Travel</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">986</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,506</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office-related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,923</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,477</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Business Analytics</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,005</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,264</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Market Access</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,606</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">701</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional fees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">745</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">627</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">751</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">98</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation and amortization</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">314</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">330</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss on abandonment of right-of-use asset</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">246</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">157</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">200</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25,270</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,605</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>

      <div style="line-height:1.25">&#160;</div>
      <div></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>

        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payroll and related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,117</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,000</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,407</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional fees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,028</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,991</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,290</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Insurance</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">939</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">808</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">603</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">780</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">585</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">292</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">37</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">28</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Provision for doubtful accounts receivable</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">800</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(800</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">409</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">127</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">324</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,310</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,321</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,144</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>

      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-operating income (expenses), net</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>

        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value of warrants</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,054</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,965</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,599</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance costs</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(669</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(702</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">235</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">139</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">180</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(10,819</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,435</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,077</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>

      <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">h.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial income</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>

        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,007</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,820</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,124</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange differences, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">61</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">51</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">340</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,068</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,871</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,464</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>

      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:43.9pt">&#160;</td>
            <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
            <td style="width:auto;vertical-align:top">
              <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial expenses</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>

        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest expense</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,144</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,074</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,251</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank commissions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">45</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">29</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,169</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,119</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,280</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplimentry financial statements information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplementary financial statement information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">
      <div>
        <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk management and strategy</span></span></div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have developed and maintain a cybersecurity risk management program that focuses primarily on securing and safeguarding computer systems, networks, cloud services, business applications and data and that is integrated in our overall risk management strategy and framework. We have implemented protocols to protect against cyber threats and ensure the containment and security of sensitive business data, including ongoing security reviews of critical systems, continuous monitoring of event data, and employee training programs, which processes are aligned with our overall business and operational goals and strategies. Our risk assessment occurs on an ongoing basis and covers identification of risks that could act against the company&#8217;s objectives as well as specific risks related to a compromise to the security of data.</span></span></div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We engage a third party to provide operational support for cybersecurity risks. This forms a critical part of our risk management strategy, facilitating effective management and mitigation of risks, and ensuring adherence to applicable regulatory and industry standards.</span></span></div>
        <div style="text-align:justify;line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Overall, we believe that we have established a robust framework for confidentiality, integrity, and availability of information, adhering to relevant security standards, practices, and compliance requirements. In addition, we maintain insurance to help protect against risks associated with cybersecurity threats. As of the date of this report, we do not believe that any risks from cybersecurity threats have materially affected, or are reasonably likely to materially affect, us, including our business strategy, results of operations, or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have not experienced an undetected cybersecurity incident. For more information about these risks, please see &#8220;Item 3.D. Key Information - Risk Factors - Risks Related to Our Industry - Significant disruptions of our information technology systems or breaches of our data security could adversely affect our business.&#8221; in this Annual Report on Form 20-F.</span></span></div>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Overall, we believe that we have established a robust framework for confidentiality, integrity, and availability of information, adhering to relevant security standards, practices, and compliance requirements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">As of the date of this report, we do not believe that any risks from cybersecurity threats have materially affected, or are reasonably likely to materially affect, us, including our business strategy, results of operations, or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have not experienced an undetected cybersecurity incident.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">
      <div>
        <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Governance</span></span></div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our audit committee oversees our cybersecurity program and helps guide our strategy for managing cybersecurity risks in the context of our overall risk management system.&#160;Our cybersecurity program is managed by our Chief Financial Officer and our internal IT team, who is responsible for leading enterprise-wide cybersecurity strategy, protocols, framework, standards and processes. The Chief Financial Officer reports to our board of directors, as well as our Chief Executive Officer and other members of senior management as appropriate.</span></span></div>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our audit committee oversees our cybersecurity program and helps guide our strategy for managing cybersecurity risks in the context of our overall risk management system.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity program is managed by our Chief Financial Officer and our internal IT team, who is responsible for leading enterprise-wide cybersecurity strategy, protocols, framework, standards and processes.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure of significant accounting policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis of presentation and consolidation</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Basis of preparation</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s consolidated financial statements as of December 31, 2024 and 2025, and for each of the three years in the period ended December 31, 2025, have been prepared in accordance with IFRS<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#174;</sup> Accounting Standards as issued by the International Accounting Standards Board (&#8220;IASB<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#174;</sup>&#8221;) (hereinafter &#8220;IFRS&#8221;). The material<span style="font-weight:bold">&#160;</span>accounting policies described below have been applied on a consistent basis for all years presented.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements have been prepared on the basis of historical cost, subject to adjustment of warrant liabilities to their fair value through profit or loss.</span></span></div>
            <div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity and expenses, as well as the related disclosures of contingent assets and liabilities, in the process of applying the Company&#8217;s accounting policies.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are material<span style="font-weight:bold">&#160;</span>to the consolidated financial statements, are disclosed in Note 4. Actual results may differ materially from estimates and assumptions used by the Company&#8217;s management.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Basis of consolidation</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsidiaries are entities controlled by the Company. Control exists when the Company has power over the investee, is exposed or has rights to variable returns from its involvement with the investee, and has the ability to use its power to affect those returns. Subsidiaries are consolidated from the date on which control is obtained and are deconsolidated from the date control ceases. The financial statements of subsidiaries are prepared for the same reporting period as the parent company using consistent accounting policies.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All intercompany balances, transactions, income and expenses, and unrealized gains and losses arising from intra-group transactions are eliminated in full upon consolidation</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Non-controlling interests</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-controlling interests represent the portion of equity in subsidiaries not attributable, directly or indirectly, to the shareholders of the parent. Non-controlling interests are presented in the consolidated statement of financial position within equity, separately from the equity attributable to the owners of the parent.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in the Company&#8217;s ownership interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Any difference between the amount by which the non-controlling interests are adjusted, and the fair value of the consideration paid or received, is recognized directly in equity and attributed to the owners of the parent.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Functional and reporting currency</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Functional and reporting currency</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The functional and reporting currency in these financial statements is the U.S. dollar (&#8220;dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221;), which is the primary currency of the economic environment in which the Company operates. Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year-end exchange rates are generally recognized in profit or loss.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventory</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inventory</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inventory is measured at the lower of cost or net realizable value. The cost of inventories includes purchase costs, packaging and labeling costs, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price of the inventories in the ordinary course of business, less the estimated costs necessary to make the sale. Inventory is written down for estimated obsolescence based upon management assumptions about future demand, expiration due date and market conditions.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text">
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:43.9pt">&#160;</td>
                    <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment are stated at historical cost less depreciation. Historical cost includes expenditures that are directly attributable to acquisition of the items. Assets are depreciated by the straight-line method over the estimated useful lives of the assets, provided that Company management believes the residual values of the assets to be negligible, as follows:</span></span></div>
              <div style="text-align:justify;margin-left:69.85pt;line-height:1.25">&#160;</div>

                <div>
                  <div style="margin-left:72pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="width:81.77%;vertical-align:middle">&#160;</td>
                          <td style="width:18.23%;vertical-align:middle;border-bottom:2px solid black">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers and communications equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15</span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                </div>

              <div style="text-align:justify;line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:69.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful life of the improvements.</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text">
          <div>
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="vertical-align:top;font-weight:bold;width:43.9pt">&#160;</td>
                    <td style="vertical-align:top;font-weight:bold;width:24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                    <td style="vertical-align:top;text-align:justify;width:auto">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Intangible assets</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies the cost method of accounting for initial and subsequent measurements of intangible assets. Under this method of accounting, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Intellectual property</span></span></span></div>
              <div style="text-align:justify;margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes in its financial statements intellectual property developed by the Company to the extent that the conditions stipulated in paragraph j. below are met. Intellectual property acquired by the Company is initially measured at cost. Intellectual property used by the Company for development purposes and not yet generating revenues is not amortized and is tested annually for impairment. See f. below.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Computer software</span></span></span></div>
              <div style="text-align:justify;margin-left:70.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Acquired computer software licenses are capitalized based on the costs incurred&#160;to acquire and bring to use the specific software. These costs are amortized over the estimated useful lives of the software (5 years).</span></span></div>
            </div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Impairment of non-financial assets</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Impairment of intellectual property is required when the Company decides to terminate or suspend the development of a project based on such intellectual property. In addition, the Company performs impairment reviews on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment. Property and equipment, as well as computer software, are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized equal to the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value, less costs to sell and the asset&#8217;s value in use to the Company. See Note 8 for information about an impairment loss recorded in 2023 in connection with the decision to terminate the AGI-134 project, as well as an impairment loss recorded in 2024 in connection with the remaining rights to motixafortide in solid tumor indications.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory', window );">Warrants</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Receipts in respect of ordinary warrants are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. In the event that the exercise price or the numbers of shares to be issued are not deemed to be fixed, the ordinary warrants are classified as a derivative financial liability. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value at each reporting date. The fair value changes are charged to non-operating income and expense on the statement of comprehensive loss. Issuance costs allocable to ordinary warrants classified as a liability are also recorded as non-operating expense on the statement of comprehensive loss.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pre-funded warrants are classified in shareholders&#8217; equity, with initial recognition at fair value on the date issued, using the same valuation assumptions as ordinary warrants.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory', window );">Borrowings</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">h</span>.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Borrowings</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With respect to the long-term loan (see Note 10), a financial liability was recognized for each tranche upon drawdown. Upon initial recognition, the effective interest rate was calculated by estimating the future cash flows, including loan principal repayments, interest and royalties, if any. The royalty feature did not meet the definition of a derivative, was not classified separately, and was not measured separately, since it was an integral part of the loan terms and conditions and could not be transferred or settled separately from the loan.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Determining the weighted effective interest rate requires certain judgments and estimations regarding the timing and amount of the Company&#8217;s future revenues. The loans are subsequently measured at amortized cost. Furthermore, revisions to the estimated amounts or timing of future cash flows, if necessary, may result in an adjustment of the amortized cost of the loan to reflect the present value of actual and revised estimated contractual cash flows, discounted using the original effective interest rate. This adjustment was recognized in profit or loss as financial income or expense.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months subsequent to the reporting period.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenues</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenues</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for contract revenue in accordance with IFRS 15, &#8220;Revenue from Contracts with Customers.&#8221;</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">IFRS 15 introduces a five-step model for recognizing revenue from contracts with customers, as follows:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">identify the contract with a customer;</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">identify the performance obligations in the contract;</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">determine the transaction price;</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">allocate the transaction price to the performance obligations in the contract; and</span></span></div>
                  </td>
                </tr>

            </table>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:88.25pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">recognize revenue when (or as) the entity satisfies a performance obligation.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Revenues from selling products</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In September 2023, the FDA approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and shortly thereafter, the Company began to independently commercialize motixafortide in the U.S. These activities terminated in November 2024, as a result of the out-licensing transaction entered into with Ayrmid Ltd. (see Note 16) and the shutdown of the Company&#8217;s U.S. commercial operations. The information below relates to the period during which the Company carried out direct sales activities.</span></span></div>
            <div style="text-align:justify;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company sells products mainly to wholesale distributors. Gross revenues are recognized at a point in time when control over the product is transferred to the distributors (upon delivery), at the gross selling price. The net revenues reflect gross revenues, reduced by amounts attributable to distributor fees, as well as accruals of chargebacks, rebates and returns.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The specific considerations the Company uses in estimating these amounts relating to variable consideration are as follows:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:85pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Distribution fees - The Company pays distribution fees to its three main distributors. The distribution fees are paid based on contractually determined rates from the gross consideration. When the service is received and the products sold to distributors, it is recognized as a reduction of revenues in the period the related revenues from the sale of products are recognized.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:85pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rebates and patient discount programs - The Company offers various rebate and patient discount programs, which results in discounted prescriptions to qualified patients. The Company estimates the allowance for these rebates, based on the estimated utilization of the rebate and discount programs, at the time the revenues are recognized. These estimates are recognized as a reduction of revenues.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:85pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Product returns - The Company offers customers a right of return as part of the distributor agreements. The Company estimates the amount of product sales that may be returned by its customers and records this estimate as a reduction of revenues at the time of sale, based on estimates of product returns based on its own sales information, its visibility into the inventory remaining in the distribution channel, and product dating.</span></span></div>
                  </td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>
            <div></div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Revenues from</span><span style="text-decoration:underline"> licensing agreement</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">According to IFRS 15, performance obligations are a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service, either on its own or together with other resources that are readily available to the customer, and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">IFRS 15 defines the &#8216;Transaction Price&#8217; as the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services to a customer.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with IFRS 15, the Company identified a number of performance obligations (components) in the contract &#8211; in respect of which revenue will be recognized separately for each component.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following assumptions were taken into account, as part of the revenue recognition process:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Development milestones: Variable payments, contingent on achieving additional milestones, are included in the transaction price based on the most likely amount method. Amounts included in the transaction price are recognized only when it is highly probable that a material<span style="font-weight:bold">&#160;</span>reversal of cumulative revenues will not occur, usually upon achievement of the specific milestone, in accordance with the relevant agreement.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales-based royalties and sales-based milestones are recognized as the related sale occurs, due to the specific exception of IFRS 15 for sales-based royalties from licensing of intellectual properties.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For more information, see Notes 15 and 16.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development expenses</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">j.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research expenses are charged to profit or loss as incurred. As of December 31, 2025, the Company has not yet capitalized development expenses.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payments</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">k.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based payments</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company operates an equity-settled, share-based compensation plan, under which it grants equity instruments (options, restricted stock units and performance stock units) of the Company as additional consideration for services from employees and service providers. The fair value of the employee services received in exchange for the grant of the equity instruments is recognized as an expense. The total amount to be expensed is determined by reference to the fair value of the equity instruments granted including any market performance conditions (for example, the Company&#8217;s share price).</span></span></div>
            <div style="text-align:justify;margin-right:0.55pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-market performance and service conditions are included in assumptions about the number of equity instruments that are expected to vest. Performance stock unit expenses are recognized only if it is probable that the performance condition will be achieved.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">l.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss per share</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
                  <td style="width:auto;vertical-align:top">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The basic loss per share is calculated by dividing the loss attributable to the holders of ordinary shares by the weighted average number of ordinary shares, including pre-funded warrants, outstanding during the year.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:70.9pt">&#160;</td>
                  <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
                  <td style="width:auto;vertical-align:top">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Diluted</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The diluted loss per share is calculated by adjusting the weighted average number of outstanding ordinary shares, assuming conversion of all dilutive potential shares. The Company&#8217;s dilutive potential shares consist of warrants issued to investors, as well as equity instruments granted to employees and service providers. The dilutive potential shares were not taken into account in computing loss per share in 2023, 2024 and 2025, as their effect would have been anti-dilutive.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The calculation of diluted loss per share for the years ended December 31, 2023, 2024 and 2025 does not include 369,484,579, 568,205,319 and 1,538,622,579 of shares underlying options and warrants, respectively, because the effect would be anti-dilutive.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text">
          <div>
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:43.9pt">&#160;</td>
                    <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">m.</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify">
                      <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leases</span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s leases include property and motor vehicle leases.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date. Simultaneously, the Company recognizes a right-of-use asset in the amount of the lease liability.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since the interest rate implicit in the lease cannot be readily determined, the Company uses the Company&#8217;s incremental borrowing rate.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The lease term is the non-cancellable period for which the Company has the right to use an underlying asset, together with both the periods covered by an option to extend the lease, if the Company is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the Company is reasonably certain not to exercise that option.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">After the commencement date, the Company measures the right-of-use asset applying the cost model, less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets are depreciated by the straight-line method over the estimated useful lives of the right of use assets or the lease period, whichever is shorter, as follows:</span></span></div>
            </div>
            <div>
              <div>
                <div>
                  <div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="margin-left:72pt">

                        <div>
                          <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                              <tr>
                                <td style="width:76.27%;vertical-align:middle">&#160;</td>
                                <td style="width:23.73%;vertical-align:middle;border-bottom:2px solid black">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
                                </td>
                              </tr>
                              <tr>
                                <td style="width:76.27%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                                </td>
                                <td style="width:23.73%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div>
                                </td>
                              </tr>
                              <tr>
                                <td style="width:76.27%;vertical-align:middle">
                                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                                </td>
                                <td style="width:23.73%;vertical-align:middle">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></div>
                                </td>
                              </tr>

                          </table>
                        </div>

                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory', window );">New International Financial Reporting Standards, amendments to standards and new interpretations</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:43.9pt">&#160;</td>
                  <td style="width:24pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">New International Financial Reporting Standards, amendments to standards and new interpretations</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.85pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">New standards and interpretations not yet adopted</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.85pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">IFRS 18, Presentation and Disclosure in the Financial Statements</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">This standard replaces the international accounting standard IAS 1,&#160;&#8220;Presentation of Financial Statements.&#8221; As part of the new disclosure requirements, companies will be required to present new defined subtotals in the statements of income, as follows: (1) operating profit and (2) profit before financing and tax. In addition, income statement items will be classified into three defined categories: operating, investment and financing. The standard also includes a requirement to provide separate disclosure in the financial statements regarding the use of management-defined performance measures (&#8220;non-GAAP measures&#8221;), and specific instructions were added for the grouping and splitting of items in the financial statements and in the notes to the financial statements.&#160;IFRS 18&#160;is effective for annual reporting periods beginning on or after January 1, 2027, with an option for early adoption. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statement disclosures.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for changes in accounting policies and disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DescriptionOfAccountingPolicyForWarrantExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DescriptionOfAccountingPolicyForWarrantExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 164<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_164_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 164<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_164_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure of significant accounting policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory', window );">Schedule of Depreciation Rates</a></td>
<td class="text">
                <div>
                  <div style="margin-left:72pt">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="width:81.77%;vertical-align:middle">&#160;</td>
                          <td style="width:18.23%;vertical-align:middle;border-bottom:2px solid black">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers and communications equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div>
                          </td>
                        </tr>
                        <tr>
                          <td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                          </td>
                          <td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                            <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15</span></span></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory', window );">Schedule of Useful Life of Right of Use Assets</a></td>
<td class="text">
                        <div>
                          <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                              <tr>
                                <td style="width:76.27%;vertical-align:middle">&#160;</td>
                                <td style="width:23.73%;vertical-align:middle;border-bottom:2px solid black">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
                                </td>
                              </tr>
                              <tr>
                                <td style="width:76.27%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                                </td>
                                <td style="width:23.73%;vertical-align:middle;background-color:rgb(204, 238, 255)">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div>
                                </td>
                              </tr>
                              <tr>
                                <td style="width:76.27%;vertical-align:middle">
                                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                                </td>
                                <td style="width:23.73%;vertical-align:middle">
                                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></div>
                                </td>
                              </tr>

                          </table>
                        </div>
                      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about useful lives for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information of useful life of right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory', window );">Schedule of Concentration of Currency Risk</a></td>
<td class="text">
        <div>
          <div style="margin-left:90pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Value on</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sensitive instrument</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">balance sheet</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS-linked balances:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(179</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(94</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,974</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">104</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">219</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short term deposit</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(86</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(45</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">943</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">50</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">105</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(7</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(3</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">72</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">4</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">8</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">19</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">10</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(206</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(11</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(23</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">87</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">46</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(962</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(51</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(107</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total NIS-linked balances</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(166</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(86</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,821</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">96</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">202</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Euro-linked trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(107</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(56</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(1,177</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">62</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">131</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(273</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(142</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">644</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>158</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>333</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:90pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Value on</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income (loss)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sensitive instrument</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% increase</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">balance sheet</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10% decrease</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS-linked balances:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(87</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(45</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">955</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">50</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">106</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(52</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(27</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">568</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">30</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">63</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">115</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">60</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(933</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(67</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(141</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">154</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">81</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(1,495</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(89</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(188</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total NIS-linked balances</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">130</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">69</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(905</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(76</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(160</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Euro-linked trade payables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(83</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(44</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(919</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">48</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">102</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:40%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">47</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(1,824</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(28</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(58</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory', window );">Schedule of Linkage of Monetary Items</a></td>
<td class="text">
        <div>
          <div style="margin-left:90pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding:0px 0px 2px">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dollar</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">currencies</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dollar</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NIS</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currencies</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:middle;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD in thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:middle;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD in thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">9,428</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">955</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">53</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">973</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,974</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">303</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">9,126</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">16,683</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">943</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">819</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">568</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">91</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">338</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">72</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">19,373</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">1,523</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">144</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">17,994</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">2,989</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">303</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liabilities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current liabilities:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current maturities of long-term loan</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">4,479</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">4,479</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accounts payable and accruals:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:0pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">3,549</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">933</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,101</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,993</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">206</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,294</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;vertical-align:bottom">
                    <div style="text-indent:0pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,636</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,495</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">781</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">962</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term loan, net of current maturities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">8,958</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">4,460</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">18,622</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,428</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,101</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">11,713</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,168</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,294</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:28%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net balance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">751</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(905</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(957</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">6,281</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">1,821</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(991</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Schedule of Credit Risk</a></td>
<td class="text">
        <div style="margin-left:72pt">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">10,436</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">3,250</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">9,126</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">17,626</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">2,476</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">46</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,478</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">410</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">23,516</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">21,332</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory', window );">Schedule of Changes in Financial Liabilities With Cash Flows Included in Financing Activities</a></td>
<td class="text">
        <div>
          <div style="margin-left:72pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Long-term loan</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                      <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Warrants</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                      <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Total</span></span></strong></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">10,168</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">4,509</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">14,677</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during the year 2023:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Principal and interest payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(1,543</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(1,543</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts recognized through profit and loss</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,148</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">11,054</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">12,202</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share premium resulting from exercise of warrants</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(3,631</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(3,631</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">9,773</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">11,932</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">21,705</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during the year 2024:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net proceeds</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">19,223</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">8,724</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">27,947</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Principal and interest payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(22,795</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(22,795</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts recognized through profit and loss</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">7,236</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(18,965</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">(11,729</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">13,437</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,691</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">15,128</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during the year 2025:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net proceeds</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">9,082</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">9,082</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Principal and interest payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(5,568</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">(5,568</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts recognized through profit and loss</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,070</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(8,599</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(7,529</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">8,939</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">2,174</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">11,113</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Schedule of Fair Value Measurement of Warrants</a></td>
<td class="text">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2023</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,509</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during 2023:</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercises</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">(3,631</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-14.15pt;margin-left:30.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value through profit and loss</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">11,054</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2023</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">11,932</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during 2024:</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuances</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">8,724</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-14.15pt;margin-left:30.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value through profit and loss</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">(18,965</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2024</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">1,691</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes during 2025:</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:16.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuances</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">9,082</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                  <div style="margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value through profit and loss</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">(8,599</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2025</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,174</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure detailed information about classification of financial assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about concentration of currency risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS13_g91-99_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory', window );">Schedule of Cash And Cash Equivalents</a></td>
<td class="text">
                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash on hand and in bank</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">944</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">632</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">9,492</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">2,618</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">10,436</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">3,250</div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of Composition of Property and Equipment and Related Accumulated Depreciation</a></td>
<td class="text">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net book value</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:10%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">251</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">42</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">209</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">191</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">41</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">177</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">60</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers and communications equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">467</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">161</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">331</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">291</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">70</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">138</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">223</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">176</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">108</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,571</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,571</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,525</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">26</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,551</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">46</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,036</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,036</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,932</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,036</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:10%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,325</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">203</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,147</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,939</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">227</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">179</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,987</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">386</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">160</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Schedule of Intangible Assets</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Cost</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation and impairment</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Additions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Disposal</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Additions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Impairment</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Net book value</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">beginning</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">end of</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">beginning</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">during</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">end of</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">of year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">of year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">year</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">2024</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">2025</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></span></strong></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Composition in 2024</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Intellectual property</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">21,342</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">3,323</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">18,019</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">6,799</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">1,010</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">7,809</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">10,210</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Computer software</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">982</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">1</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">185</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">798</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">671</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">73</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">185</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">559</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">239</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">22,324</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">1</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">185</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">3,323</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">18,817</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">7,470</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">73</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">185</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">1,010</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">8,368</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">10,449</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><strong><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></span></strong></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Intellectual property</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">18,019</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">6,000</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">6,700</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">17,319</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">7,809</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">6,700</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">1,109</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">10,210</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom">
                  <div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt">16,210</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:9pt"><span><span style="font-family:Times New Roman,Times,serif">Computer software</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">798</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">2</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">4</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">796</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">559</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">82</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">3</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">638</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">239</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">158</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:16%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">18,817</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">6,002</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">6,704</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">18,115</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">8,368</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">82</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">6,703</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">-</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">1,747</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">10,449</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:9pt">16,368</span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Schedule of Right-of-use assets</a></td>
<td class="text">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net book value</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;text-align:center">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:middle;width:20%;vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">1,551</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">-</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">-</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">1,551</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">810</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">135</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">-</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">945</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">741</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom">
                  <div style="line-height:1.25">606</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:middle;width:20%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">456</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">-</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">196</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">260</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">230</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">79</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">139</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">170</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">226</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">90</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:20%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">2,007</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">-</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">196</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">1,811</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">1,040</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">214</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">139</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">1,115</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">967</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">696</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory', window );">Schedule of Lease Liabilities</a></td>
<td class="text">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deletions</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest expense</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange differences</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">beginning</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">during</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">end of</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="22" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Composition in 2025</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:16%;vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,409</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">176</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">174</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">596</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">1,163</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:middle;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">194</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">71</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">10</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">17</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">102</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">48</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:16%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">1,603</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">71</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">186</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">191</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">698</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">1,211</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Schedule of Minimum Future Rental Payments</a></td>
<td class="text">
          <div>
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Motor vehicles</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">332</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">106</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">438</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25">348</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25">21</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                    <div style="line-height:1.25">369</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2028</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">348</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">348</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2029-2030</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">523</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">523</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,551</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">127</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,678</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 97<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 124<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_124&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 124<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_124&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of Share Capital</a></td>
<td class="text">
          <div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:90%;width:90%">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of Ordinary Shares</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Authorized share capital</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">5,000,000,000</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">20,000,000,000</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and paid-up share capital</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">1,336,670,575</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">2,610,814,390</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:90%;width:90%">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD and NIS Amounts</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Authorized share capital (in NIS)</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">500,000,000</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">2,000,000,000</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and paid-up share capital (in NIS)</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">133,667,057</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">261,081,439</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:9%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and paid-up share capital (in USD)</span></span></div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">38,096,940</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
                    <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%">
                      <div style="line-height:1.25">73,428,375</div>
                    </td>
                    <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of Amounts Outstanding Under Employee Share Incentive Plan</a></td>
<td class="text">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="22" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number<br/>of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise price</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number<br/>of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise price</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number<br/>of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average exercise price</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at beginning of year</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">89,871,858</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.44</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">150,429,825</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.32</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">141,634,245</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.32</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">64,855,380</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.18</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">23,190,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.20</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">212,760,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.01</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expired</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(1,379,640</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.68</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(3,825,990</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.53</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(24,310,920</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.25</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">(2,424,535</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.21</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">(27,389,565</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.23</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">(18,116,325</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">0.25</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(493,238</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.22</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">(770,025</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">0.14</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">-</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">-</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at end of year*</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">150,429,825</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.32</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">141,634,245</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.32</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">311,967,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.12</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable at end of year</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">51,970,635</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.54</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">88,080,600</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.40</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">81,825,600</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25"></span></span></span></div>
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.39</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of Options Outstanding by Exercise Price Range</a></td>
<td class="text">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="14" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Range of</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise prices</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in NIS)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Number</span></span></span></span></strong></div>
                        <div style="line-height:1.25;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">of options outstanding</span></span></span></span></strong></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining contractual life (in&#160;yrs.)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Number</span></span></span></span></strong></div>
                        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">of options outstanding</span></span></span></span></strong></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining contractual life (in&#160;yrs.)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Up to 0.49</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">114,352,425</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">8.07</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">288,520,200</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">9.07</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.5-0.99</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25">15,104,100</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25">6.54</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25">12,576,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom">
                      <div style="line-height:1.25">4.96</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.00-2.00</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">11,727,795</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">4.57</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">10,423,800</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">2.82</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.01-3.4</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">449,925</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">3.18</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">447,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">1.17</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">141,634,245</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">7.60</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">311,967,000</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">8.68</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Schedule of Assumptions Used to Value Options</a></td>
<td class="text">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="width:41%;vertical-align:bottom;padding-bottom:2px">&#160;</td>
                    <td style="width:20.28%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;padding-bottom:2px">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;padding-bottom:2px">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected dividend yield</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">0%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">0%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">0%</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">69%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">73%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">93%</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">4%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">4%</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-align:center;line-height:1.25">4%</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:41%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life of options (in years)</span></span></div>
                    </td>
                    <td style="width:20.28%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">6</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.09%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">6</div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom">&#160;</td>
                    <td style="width:18.78%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25">6</div>
                    </td>
                  </tr>

              </table>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfIncomeTaxesAbstract', window );"><strong>Disclosure Of Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory', window );">Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income</a></td>
<td class="text">
        <div>
          <div style="margin-left:72pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="22" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">23.0</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(60,614</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">23.0</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(9,221</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">23.0</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(2,026</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical tax benefit</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(13,941</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(2,121</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(466</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Disallowed deductions (tax exempt income):</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss (gain) on adjustment of warrants to fair value</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,542</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(4,056</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">(1,978</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">534</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">261</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">91</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Impairment of intangible asset</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">1,542</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">232</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;vertical-align:bottom">
                    <div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">11</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">11</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25">11</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">9,312</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">5,673</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">2,342</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:28%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income for the reported year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">-</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about weighted average tax rate applicable to income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory', window );">Schedule of Basic Loss Per Share</a></td>
<td class="text">
              <div>
                <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss attributed to ordinary shares</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(60,614</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(9,221</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(2,026</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in thousands</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of shares used in basic calculation</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">963,366</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">1,198,108</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">2,465,273</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(0.06</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(0.01</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25">(0.00</div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </div>
                      </td>
                    </tr>

                </table>
              </div>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about basic loss per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of Transactions With Related Parties</a></td>
<td class="text">
                  <div>
                    <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-14.6pt;margin-left:14.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Benefits to related parties:</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                            <div style="text-indent:-13.5pt;margin-left:28.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation and benefits to senior management, including benefit component of equity instrument grants</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">3,155</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">2,396</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">1,398</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-13.5pt;margin-left:28.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation and benefits to directors, including benefit component of equity instrument grants</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">587</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">415</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">473</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory', window );">Schedule of Key Management Compensation</a></td>
<td class="text">
                  <div>
                    <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                            <div style="line-height:1.25">
                              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                            </div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="text-indent:-16.35pt;margin-left:16.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and other short-term employee benefits</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">2,425</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">2,018</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">1,425</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Post-employment benefits</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25">256</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25">394</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                            <div style="line-height:1.25">116</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other long-term benefits</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">31</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">29</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">32</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">1,030</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">370</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                            <div style="line-height:1.25">298</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">3,742</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">2,811</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                            <div style="line-height:1.25">1,871</div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        </tr>

                    </table>
                  </div>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 18A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_18A&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 229<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_229&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 229<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_229&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory', window );">Schedule of revenues from external parties by geographic region</a></td>
<td class="text">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">China</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">4,610</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">14,957</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">-</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">190</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">13,983</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">1,180</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">4,800</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">28,940</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">1,180</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of geographical information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract', window );"><strong>Disclosure of supplementary financial statement information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory', window );">Schedule of Other Receivables</a></td>
<td class="text">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2025</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>in USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25">Government institutions</div>
                </td>
                <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>455</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>33</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Advance payments</span></p>
                </td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">91</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">-</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other</span></span></span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>932</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>377</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,478</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>410</span></span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory', window );">Schedule of Accounts Payable and Accruals</a></td>
<td class="text">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2025</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>in USD thousands</span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Accounts payable:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160; Overseas</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,250</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,814</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160; In Israel</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,333</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>679</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5,583</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,493</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other:</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Payroll and related expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,993</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>523</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Accrued expenses</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>707</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>372</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:0pt;margin-left:23.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160; Accrual for vacation and recreation pay</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>431</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>310</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Other</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>538</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,131</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,743</span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory', window );">Schedule of Cost of Revenues</a></td>
<td class="text">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">License fees and royalties payable to licensor</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,027</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,024</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">230</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Direct costs related to license revenues</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">203</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,605</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of intangible asset</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">450</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,323</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of product sales</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">311</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,692</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,263</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">230</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory', window );">Schedule of Research and Development Expenses</a></td>
<td class="text">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development services</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,603</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,170</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,118</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payroll and related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,452</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,524</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,982</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lab, occupancy and telephone</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">969</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,102</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">855</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional fees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">935</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">273</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">390</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">760</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">451</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation and amortization</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">583</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">431</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">495</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">217</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">198</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">149</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,519</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,149</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,093</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory', window );">Schedule of Sales and Marketing Expenses</a></td>
<td class="text">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payroll and related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,868</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,224</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Medical Affairs</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,824</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,891</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,091</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,041</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Travel</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">986</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,506</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office-related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,923</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,477</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Business Analytics</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,005</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,264</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Market Access</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,606</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">701</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional fees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">745</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">627</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">751</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">98</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation and amortization</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">314</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">330</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss on abandonment of right-of-use asset</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">246</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">157</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">200</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25,270</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,605</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payroll and related expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,117</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,000</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,407</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional fees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,028</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,991</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,290</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Insurance</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">939</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">808</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">603</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">780</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">585</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">292</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">37</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">28</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Provision for doubtful accounts receivable</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">800</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(800</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">409</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">127</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">324</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,310</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,321</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,144</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory', window );">Schedule of Non-Operating Income (Expenses), Net</a></td>
<td class="text">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value of warrants</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,054</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,965</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,599</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance costs</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(669</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(702</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">235</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">139</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">180</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(10,819</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,435</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,077</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory', window );">Schedule of Financial Income</a></td>
<td class="text">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,007</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,820</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,124</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange differences, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">61</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">51</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">340</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,068</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,871</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,464</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory', window );">Schedule of Financial Expenses</a></td>
<td class="text">
        <div style="margin-left:72pt">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in USD thousands</span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest expense</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,144</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,074</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,251</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank commissions</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">45</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">29</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,169</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,119</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,280</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about accounts payable and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about cost of revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about fnancial income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about non-operating income expenses net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about research and development expenses..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplimentry financial statements information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL INFORMATION (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfGeneralInformationAbstract', window );"><strong>Disclosure of general information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">$ (401,002)<span></span>
</td>
<td class="num">$ (399,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DepositaryShareConversionDescription', window );">Depositary share conversion description</a></td>
<td class="text">Each ADS represents 600 ordinary shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription', window );">Depositary share ratio change description</a></td>
<td class="text">On January 30, 2025, the Company effected a change in the ratio of its ADSs to ordinary shares, from one ADS representing 15 ordinary shares to a new ratio of one ADS representing 600 ordinary shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DepositaryShareConversionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the conversion relationship between one depositary share and the number of ordinary shares it represents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DepositaryShareConversionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DepositaryShareToOrdinaryShareRatioChangeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the change in the ratio of depositary shares to ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DepositaryShareToOrdinaryShareRatioChangeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfGeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfGeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICIES (Narrative) (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted loss per share</a></td>
<td class="nump">2,465,272,604<span></span>
</td>
<td class="nump">1,198,107,761<span></span>
</td>
<td class="nump">963,365,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis=ifrs-full_ComputerSoftwareMember', window );">Computer software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful lives of intangible assets (In years)</a></td>
<td class="text">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember', window );">Share options [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted loss per share</a></td>
<td class="nump">1,538,622,579<span></span>
</td>
<td class="nump">568,205,319<span></span>
</td>
<td class="nump">369,484,579<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of useful life used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICIES (Schedule of Depreciation Rates) (Details) - Net Book Value [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers and communications equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment', window );">Depreciation rates (in %)</a></td>
<td class="text">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment', window );">Depreciation rates (in %)</a></td>
<td class="text">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=blrx_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment', window );">Depreciation rates (in %)</a></td>
<td class="text">15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=blrx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=blrx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICIES (Schedule of Useful Life of Right of Use Assets) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember', window );">Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets', window );">Estimated useful lives or lease period of right of use assets (in Years)</a></td>
<td class="text">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember', window );">Motor vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets', window );">Estimated useful lives or lease period of right of use assets (in Years)</a></td>
<td class="text">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of useful life or lease period of right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Fair value of the warrants</a></td>
<td class="nump">$ 2,174,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity', window );">10% increase effect on net income (loss) and equity</a></td>
<td class="num">$ (273)<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity', window );">5% increase effect on net income (loss) and equity</a></td>
<td class="num">(142)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads', window );">Value on balance sheet</a></td>
<td class="nump">644<span></span>
</td>
<td class="num">(1,824)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity', window );">5% decrease effect on net income (loss) and equity</a></td>
<td class="nump">158<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity', window );">10% decrease effect on net income (loss) and equity</a></td>
<td class="nump">333<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_CashAndCashEquivalentMember', window );">Cash and cash equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity', window );">10% increase effect on net income (loss) and equity</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity', window );">5% increase effect on net income (loss) and equity</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads', window );">Value on balance sheet</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity', window );">5% decrease effect on net income (loss) and equity</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity', window );">10% decrease effect on net income (loss) and equity</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_ShortTermDepositMember', window );">Short Term Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity', window );">10% increase effect on net income (loss) and equity</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity', window );">5% increase effect on net income (loss) and equity</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads', window );">Value on balance sheet</a></td>
<td class="nump">943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity', window );">5% decrease effect on net income (loss) and equity</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity', window );">10% decrease effect on net income (loss) and equity</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_OtherReceivablesMember', window );">Other receivables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity', window );">10% increase effect on net income (loss) and equity</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity', window );">5% increase effect on net income (loss) and equity</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads', window );">Value on balance sheet</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity', window );">5% decrease effect on net income (loss) and equity</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity', window );">10% decrease effect on net income (loss) and equity</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_TradePayablesMember', window );">Trade payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity', window );">10% increase effect on net income (loss) and equity</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity', window );">5% increase effect on net income (loss) and equity</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads', window );">Value on balance sheet</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity', window );">5% decrease effect on net income (loss) and equity</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity', window );">10% decrease effect on net income (loss) and equity</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_OtherPayablesMember', window );">Other payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity', window );">10% increase effect on net income (loss) and equity</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity', window );">5% increase effect on net income (loss) and equity</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads', window );">Value on balance sheet</a></td>
<td class="num">(962)<span></span>
</td>
<td class="num">(1,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity', window );">5% decrease effect on net income (loss) and equity</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity', window );">10% decrease effect on net income (loss) and equity</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_NisLinkedBalancesMember', window );">Total NIS-linked balances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity', window );">10% increase effect on net income (loss) and equity</a></td>
<td class="num">(166)<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity', window );">5% increase effect on net income (loss) and equity</a></td>
<td class="num">(86)<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads', window );">Value on balance sheet</a></td>
<td class="nump">1,821<span></span>
</td>
<td class="num">(905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity', window );">5% decrease effect on net income (loss) and equity</a></td>
<td class="nump">96<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity', window );">10% decrease effect on net income (loss) and equity</a></td>
<td class="nump">202<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_EuroLinkedTradePayablesMember', window );">Euro-linked trade payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity', window );">10% increase effect on net income (loss) and equity</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity', window );">5% increase effect on net income (loss) and equity</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads', window );">Value on balance sheet</a></td>
<td class="num">(1,177)<span></span>
</td>
<td class="num">(919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity', window );">5% decrease effect on net income (loss) and equity</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity', window );">10% decrease effect on net income (loss) and equity</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of a five percent decrease in the given metric on net income (loss) and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of a five percent increase in the given metric on net income (loss) and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of a ten percent decrease in the given metric on net income (loss) and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of a ten percent increase in the given metric on net income (loss) and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the accumulated change in the value of foreign currency basis spreads of financial instruments when excluding them from the designation of these financial instruments as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 9<br> -IssueDate 2025-01-01<br> -Paragraph 6.5.16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=9&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_6.5.16&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_CashAndCashEquivalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_CashAndCashEquivalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_ShortTermDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_ShortTermDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_TradePayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_TradePayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_OtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_OtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_NisLinkedBalancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_NisLinkedBalancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_EuroLinkedTradePayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_EuroLinkedTradePayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Linkage of Monetary Items) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="nump">$ 10,436<span></span>
</td>
<td class="nump">$ 4,255<span></span>
</td>
<td class="nump">$ 10,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">40,905<span></span>
</td>
<td class="nump">38,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Current maturities of long-term loans</a></td>
<td class="nump">4,479<span></span>
</td>
<td class="nump">4,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade</a></td>
<td class="nump">3,493<span></span>
</td>
<td class="nump">5,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived', window );">Long-term loans, net of current maturities</a></td>
<td class="nump">4,460<span></span>
</td>
<td class="nump">8,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">17,560<span></span>
</td>
<td class="nump">25,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=blrx_DollarMember', window );">Dollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">973<span></span>
</td>
<td class="nump">9,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Short term bank deposits</a></td>
<td class="nump">16,683<span></span>
</td>
<td class="nump">9,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">17,994<span></span>
</td>
<td class="nump">19,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Current maturities of long-term loans</a></td>
<td class="nump">4,479<span></span>
</td>
<td class="nump">4,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">3,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived', window );">Long-term loans, net of current maturities</a></td>
<td class="nump">4,460<span></span>
</td>
<td class="nump">8,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,713<span></span>
</td>
<td class="nump">18,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_NetAssetValueOfLinkageMonetaryItems', window );">Net asset value</a></td>
<td class="nump">6,281<span></span>
</td>
<td class="nump">751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=blrx_NisMember', window );">NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Short term bank deposits</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">2,989<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Current maturities of long-term loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other</a></td>
<td class="nump">962<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived', window );">Long-term loans, net of current maturities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">2,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_NetAssetValueOfLinkageMonetaryItems', window );">Net asset value</a></td>
<td class="nump">1,821<span></span>
</td>
<td class="num">(905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=blrx_OtherCurrenciesMember', window );">Other currencies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Short term bank deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Current maturities of long-term loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived', window );">Long-term loans, net of current maturities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_NetAssetValueOfLinkageMonetaryItems', window );">Net asset value</a></td>
<td class="num">$ (991)<span></span>
</td>
<td class="num">$ (957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_NetAssetValueOfLinkageMonetaryItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net asset value of linkage monetary items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_NetAssetValueOfLinkageMonetaryItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current loans received. [Refer: Loans received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=blrx_DollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=blrx_DollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=blrx_NisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=blrx_NisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=blrx_OtherCurrenciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=blrx_OtherCurrenciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Credit Risk) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="nump">$ 10,436<span></span>
</td>
<td class="nump">$ 4,255<span></span>
</td>
<td class="nump">$ 10,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">40,905<span></span>
</td>
<td class="nump">38,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">10,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Short-term bank deposits</a></td>
<td class="nump">17,626<span></span>
</td>
<td class="nump">9,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">$ 21,332<span></span>
</td>
<td class="nump">$ 23,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Changes in Financial Liabilities With Cash Flows) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Balance as of January 1</a></td>
<td class="nump">$ 15,128<span></span>
</td>
<td class="nump">$ 21,705<span></span>
</td>
<td class="nump">$ 14,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes during the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Net proceeds</a></td>
<td class="nump">9,082<span></span>
</td>
<td class="nump">27,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Principal and interest payments</a></td>
<td class="num">(5,568)<span></span>
</td>
<td class="num">(22,795)<span></span>
</td>
<td class="num">(1,543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities', window );">Amounts recognized through profit and loss</a></td>
<td class="num">(7,529)<span></span>
</td>
<td class="num">(11,729)<span></span>
</td>
<td class="nump">12,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SharePremiumResultingFromExerciseOfWarrants', window );">Share premium resulting from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Balance as of December 31</a></td>
<td class="nump">11,113<span></span>
</td>
<td class="nump">15,128<span></span>
</td>
<td class="nump">21,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember', window );">Long-term loans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Balance as of January 1</a></td>
<td class="nump">13,437<span></span>
</td>
<td class="nump">9,773<span></span>
</td>
<td class="nump">10,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes during the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Net proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Principal and interest payments</a></td>
<td class="num">(5,568)<span></span>
</td>
<td class="num">(22,795)<span></span>
</td>
<td class="num">(1,543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities', window );">Amounts recognized through profit and loss</a></td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">7,236<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SharePremiumResultingFromExerciseOfWarrants', window );">Share premium resulting from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Balance as of December 31</a></td>
<td class="nump">8,939<span></span>
</td>
<td class="nump">13,437<span></span>
</td>
<td class="nump">9,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Balance as of January 1</a></td>
<td class="nump">1,691<span></span>
</td>
<td class="nump">11,932<span></span>
</td>
<td class="nump">4,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes during the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Net proceeds</a></td>
<td class="nump">9,082<span></span>
</td>
<td class="nump">8,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Principal and interest payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities', window );">Amounts recognized through profit and loss</a></td>
<td class="num">(8,599)<span></span>
</td>
<td class="num">(18,965)<span></span>
</td>
<td class="nump">11,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SharePremiumResultingFromExerciseOfWarrants', window );">Share premium resulting from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Balance as of December 31</a></td>
<td class="nump">$ 2,174<span></span>
</td>
<td class="nump">$ 1,691<span></span>
</td>
<td class="nump">$ 11,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from amounts recognized through profit and loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SharePremiumResultingFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share premium resulting from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SharePremiumResultingFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 166<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_166&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Value Measurement of Warrants) (Details) - Level 3 of fair value hierarchy [member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FairValueOfWarrants', window );">Balance as of January 1</a></td>
<td class="nump">$ 1,691<span></span>
</td>
<td class="nump">$ 11,932<span></span>
</td>
<td class="nump">$ 4,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IssuancesOfWarrants', window );">Issuances</a></td>
<td class="nump">9,082<span></span>
</td>
<td class="nump">8,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsExercises', window );">Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants', window );">Changes in fair value through profit and loss</a></td>
<td class="num">(8,599)<span></span>
</td>
<td class="num">(18,965)<span></span>
</td>
<td class="nump">11,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FairValueOfWarrants', window );">Balance as of December 31</a></td>
<td class="nump">$ 2,174<span></span>
</td>
<td class="nump">$ 1,691<span></span>
</td>
<td class="nump">$ 11,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ChangesInFairValueThroughProfitAndLossOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value through profit and loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ChangesInFairValueThroughProfitAndLossOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance as of January 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IssuancesOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IssuancesOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_WarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_WarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents', window );">Interest rate on short-term deposits</a></td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents', window );">Interest rate on short-term deposits</a></td>
<td class="nump">4.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate on short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS (Schedule of Cash And Cash Equivalents) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash on hand and in bank</a></td>
<td class="nump">$ 632<span></span>
</td>
<td class="nump">$ 944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term bank deposits</a></td>
<td class="nump">2,618<span></span>
</td>
<td class="nump">9,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="nump">$ 10,436<span></span>
</td>
<td class="nump">$ 4,255<span></span>
</td>
<td class="nump">$ 10,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM BANK DEPOSITS (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_InterestRateOnShortTermDeposits', window );">Interest rate on short-term deposits</a></td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_InterestRateOnShortTermDeposits', window );">Interest rate on short-term deposits</a></td>
<td class="nump">5.82%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_InterestRateOnShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate on short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_InterestRateOnShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Schedule of Composition of Property and Equipment and Related Accumulated Depreciation) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="nump">$ 386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="nump">4,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions during year</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Deletions during year</a></td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="nump">4,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Deletions during year</a></td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [Member] | Computers and communications equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions during year</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Deletions during year</a></td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [Member] | Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="nump">1,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Deletions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="nump">1,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [Member] | Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="nump">2,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Deletions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="nump">2,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="num">(3,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions during year</a></td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Deletions during year</a></td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="num">(3,987)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="num">(191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions during year</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Deletions during year</a></td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member] | Computers and communications equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="num">(291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions during year</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Deletions during year</a></td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member] | Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="num">(1,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions during year</a></td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Deletions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="num">(1,551)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member] | Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="num">(1,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions during year</a></td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Deletions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="num">(2,036)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net Book Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net Book Value [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net Book Value [Member] | Computers and communications equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net Book Value [Member] | Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net Book Value [Member] | Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of year</a></td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of year</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=blrx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=blrx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital', window );">Percentage of increasing weighted average cost of capital (WACC)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfDecreasingAnnualGrowthRate', window );">Percentage of decreasing annual growth rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 16,368,000<span></span>
</td>
<td class="nump">$ 10,449,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net Book Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">16,368,000<span></span>
</td>
<td class="nump">10,449,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Intellectual property [Member] | Net Book Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">16,210,000<span></span>
</td>
<td class="nump">10,210,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=blrx_BL8040Member', window );">BL-8040 [Member] | Net Book Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=blrx_AgalimmuneLtdMember', window );">Agalimmune Ltd. [Member] | Intellectual property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intangible assets acquired</a></td>
<td class="nump">6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=blrx_BiokineTherapeuticsLtdMember', window );">Biokine Therapeutics Ltd [Member] | Intellectual property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intangible assets acquired</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfPaymentToBeMade', window );">Percentage of payment to be made</a></td>
<td class="text">40% to 20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill', window );">Impairment loss</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=blrx_Glix1Member', window );">GLIX1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions through business combinations, intangible assets other than goodwill</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfDecreasingAnnualGrowthRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represets percentage of decreasing annual growth rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfDecreasingAnnualGrowthRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfIncreasingWeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents percentage of increasing weighted average cost of capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfIncreasingWeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfPaymentToBeMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of payment to be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfPaymentToBeMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B67_d_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=blrx_BL8040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=blrx_BL8040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=blrx_AgalimmuneLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=blrx_AgalimmuneLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=blrx_BiokineTherapeuticsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=blrx_BiokineTherapeuticsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=blrx_Glix1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=blrx_Glix1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Schedule of Intangible Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning of year</a></td>
<td class="nump">$ 10,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at end of year</a></td>
<td class="nump">16,368<span></span>
</td>
<td class="nump">$ 10,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning of year</a></td>
<td class="nump">18,817<span></span>
</td>
<td class="nump">22,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions during year</a></td>
<td class="nump">6,002<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsIntangibleAssetsOtherThanGoodwill', window );">Deletions during the year</a></td>
<td class="nump">6,704<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposal during the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at end of year</a></td>
<td class="nump">18,115<span></span>
</td>
<td class="nump">18,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [Member] | Intellectual property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning of year</a></td>
<td class="nump">18,019<span></span>
</td>
<td class="nump">21,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions during year</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsIntangibleAssetsOtherThanGoodwill', window );">Deletions during the year</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposal during the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at end of year</a></td>
<td class="nump">17,319<span></span>
</td>
<td class="nump">18,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [Member] | Computer software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning of year</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions during year</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsIntangibleAssetsOtherThanGoodwill', window );">Deletions during the year</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposal during the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at end of year</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation and impairment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning of year</a></td>
<td class="num">(8,368)<span></span>
</td>
<td class="num">(7,470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions during year</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsIntangibleAssetsOtherThanGoodwill', window );">Deletions during the year</a></td>
<td class="nump">6,703<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment during year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at end of year</a></td>
<td class="num">(1,747)<span></span>
</td>
<td class="num">(8,368)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation and impairment [Member] | Intellectual property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning of year</a></td>
<td class="num">(7,809)<span></span>
</td>
<td class="num">(6,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions during year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsIntangibleAssetsOtherThanGoodwill', window );">Deletions during the year</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment during year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at end of year</a></td>
<td class="num">(1,109)<span></span>
</td>
<td class="num">(7,809)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation and impairment [Member] | Computer software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning of year</a></td>
<td class="num">(559)<span></span>
</td>
<td class="num">(671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions during year</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsIntangibleAssetsOtherThanGoodwill', window );">Deletions during the year</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment during year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at end of year</a></td>
<td class="num">(638)<span></span>
</td>
<td class="num">(559)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net Book Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning of year</a></td>
<td class="nump">10,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at end of year</a></td>
<td class="nump">16,368<span></span>
</td>
<td class="nump">10,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net Book Value [Member] | Intellectual property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning of year</a></td>
<td class="nump">10,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at end of year</a></td>
<td class="nump">16,210<span></span>
</td>
<td class="nump">10,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net Book Value [Member] | Computer software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning of year</a></td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at end of year</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DeletionsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from deletions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DeletionsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LeasePeriod', window );">Lease Period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AnnualLeaseFee', window );">Annual Lease fee</a></td>
<td class="nump">$ 215,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LeaseAgreementMonthlyFee', window );">Lease agreement monthly fee</a></td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AdditionalExtendLeasePeriod', window );">Additional extension period</a></td>
<td class="text">three<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageIncreasePrecedingLeasePaymentAmount', window );">Percentage Increase preceding lease payment amount</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepairsAndMaintenanceExpense', window );">Building maintenance charges</a></td>
<td class="nump">$ 9,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AdditionalExtendLeasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional extend the lease period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AdditionalExtendLeasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AnnualLeaseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Lease fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AnnualLeaseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfLeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfLeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_LeaseAgreementMonthlyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease agreement monthly fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_LeaseAgreementMonthlyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_LeasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_LeasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageIncreasePrecedingLeasePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase preceding lease payment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageIncreasePrecedingLeasePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepairsAndMaintenanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepairsAndMaintenanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Schedule of Right-of-use assets) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of year</a></td>
<td class="nump">$ 967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of year</a></td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of year</a></td>
<td class="nump">2,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsToRightOfUseAssets', window );">Deletions during year</a></td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of year</a></td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [Member] | Property [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of year</a></td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsToRightOfUseAssets', window );">Deletions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of year</a></td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [Member] | Motor vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of year</a></td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsToRightOfUseAssets', window );">Deletions during year</a></td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of year</a></td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of year</a></td>
<td class="num">(1,040)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions during year</a></td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsToRightOfUseAssets', window );">Deletions during year</a></td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of year</a></td>
<td class="num">(1,115)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member] | Property [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of year</a></td>
<td class="num">(810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions during year</a></td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsToRightOfUseAssets', window );">Deletions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of year</a></td>
<td class="num">(945)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [member] | Motor vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of year</a></td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions during year</a></td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsToRightOfUseAssets', window );">Deletions during year</a></td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of year</a></td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net book value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of year</a></td>
<td class="nump">967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of year</a></td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net book value [Member] | Property [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of year</a></td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of year</a></td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember', window );">Net book value [Member] | Motor vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of year</a></td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of year</a></td>
<td class="nump">$ 90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DeletionsToRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deletions to right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DeletionsToRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=blrx_NetBookValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Schedule of Lease Liabilities) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Quantitative Information About Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at beginning of year</a></td>
<td class="nump">$ 1,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AdditionsLeaseLiabilities', window );">Additions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsLeaseLiabilities', window );">Deletions during year</a></td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_InterestExpenseLeaseLiabilities', window );">Interest expense during year</a></td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExchangeDifferencesDuringYear', window );">Exchange differences during year</a></td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PaymentsLeaseLiabilities', window );">Payments during year</a></td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at end of year</a></td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember', window );">Property [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Quantitative Information About Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at beginning of year</a></td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AdditionsLeaseLiabilities', window );">Additions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsLeaseLiabilities', window );">Deletions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_InterestExpenseLeaseLiabilities', window );">Interest expense during year</a></td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExchangeDifferencesDuringYear', window );">Exchange differences during year</a></td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PaymentsLeaseLiabilities', window );">Payments during year</a></td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at end of year</a></td>
<td class="nump">1,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember', window );">Motor vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Quantitative Information About Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at beginning of year</a></td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AdditionsLeaseLiabilities', window );">Additions during year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DeletionsLeaseLiabilities', window );">Deletions during year</a></td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_InterestExpenseLeaseLiabilities', window );">Interest expense during year</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExchangeDifferencesDuringYear', window );">Exchange differences during year</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PaymentsLeaseLiabilities', window );">Payments during year</a></td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at end of year</a></td>
<td class="nump">$ 48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AdditionsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AdditionsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DeletionsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deletions in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DeletionsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ExchangeDifferencesDuringYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excahnge difference in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ExchangeDifferencesDuringYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_InterestExpenseLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense on lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_InterestExpenseLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PaymentsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PaymentsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Schedule of Minimum Future Rental Payments) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">$ 1,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember', window );">Property [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember', window );">Motor vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">2026 [Member] | Property [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">2026 [Member] | Motor vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">2027 [Member] | Property [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">2027 [Member] | Motor vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">2028 [Member] | Property [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">2028 [Member] | Motor vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember', window );">2029-2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember', window );">2029-2030 [Member] | Property [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember', window );">2029-2030 [Member] | Motor vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived', window );">Minimum future rental payments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of undiscounted operating lease payments to be received. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 97<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 124<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_124&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 124<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_124&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM LOAN (Narrative) (Details) - Loan Agreement With BlackRock EMEA Venture and Growth Lending [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AmountOfLoanAgreement', window );">Amount of loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AmountOfIntellectualPropertyAndCashBalance', window );">Amount of intellectual property and cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBondsNotesAndDebentures', window );">Repayment of loan</a></td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_MinimumCashBalanceRequirementUnderLoanAgreement', window );">Minimum cash balance requirement under the Loan Agreement</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfFutureMilestonePayments', window );">Percentage of future milestone payments</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_LoanAgreementWithKreosCapitalMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfAnnualInterestOfCashFees', window );">Percentage of annual interest of cash fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_LoanAgreementWithKreosCapitalMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfAnnualInterestOfCashFees', window );">Percentage of annual interest of cash fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_LoanAgreementWithKreosCapitalMember', window );">First tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AmountOfLoanAgreement', window );">Amount of loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_LoanAgreementWithKreosCapitalMember', window );">Second tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AmountOfLoanAgreement', window );">Amount of loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_LoanAgreementWithKreosCapitalMember', window );">Third Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AmountOfLoanAgreement', window );">Amount of loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AmountOfIntellectualPropertyAndCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents amount of intellectual property and cash balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AmountOfIntellectualPropertyAndCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AmountOfLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents amount of loan agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AmountOfLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_MinimumCashBalanceRequirementUnderLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of minimum cash balance requirement under the Loan Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_MinimumCashBalanceRequirementUnderLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfAnnualInterestOfCashFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents percentage of annual interest of cash fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfAnnualInterestOfCashFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents future milestone payments percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBondsNotesAndDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of bonds, notes and debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBondsNotesAndDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_LoanAgreementWithKreosCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInvestmentPropertyAxis=blrx_LoanAgreementWithKreosCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TrancheAxis=blrx_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TrancheAxis=blrx_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TrancheAxis=blrx_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TrancheAxis=blrx_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TrancheAxis=blrx_ThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TrancheAxis=blrx_ThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Share </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Share </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Share</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454,000<span></span>
</td>
<td class="nump">$ 11,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702,000<span></span>
</td>
<td class="nump">669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,894,000<span></span>
</td>
<td class="nump">$ 16,357,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RemainingAuthorizedUnissuedOrdinaryShares', window );">Remaining authorized unissued ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option outstanding | Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,634,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 4 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Average standard deviation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RemainingUnrecognizedDeferredCompensationExpense', window );">Remaining unrecognized deferred compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,871,000<span></span>
</td>
<td class="nump">$ 2,811,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price outstanding | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=blrx_AmericanDepositarySharesMember', window );">ADSs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExercisePriceOfShareIssued', window );">Exercise Price Of Share Issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=blrx_AmericanDepositarySharesMember', window );">ADSs [Member] | IFRS 15 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RecognizedAsEquity', window );">Recognized as equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=blrx_HCWainwrightAndCoLlcMember', window );">H C Wainwright And Co Llc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SaleOfStockNumberOfSharesIssued', window );">Sale of stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfCommissionOnSalesAgreement', window );">Percentage of commission on sales agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=blrx_HCWainwrightAndCoLlcMember', window );">H C Wainwright And Co Llc [Member] | ADSs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SaleOfStockNumberOfSharesIssued', window );">Sale of stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_ShareIncentivePlanMember', window );">2003 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,757,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Option vested and exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">To date, each PSU grant has had between three to five performance goals on which vesting is based, each such goal being either a specified Company milestone and or the success of a specific project, with vesting of 20-40% on the achievement of each goal.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Option vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,787,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_PerformanceSharesUnitMember', window );">Performance Shares Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option outstanding | Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,219,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,126,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,010,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price outstanding | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_PerformanceSharesUnitTwoMember', window );">Performance Shares Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option outstanding | Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price outstanding | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantFourMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExercisePriceOfShareIssued', window );">Exercise Price Of Share Issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.85<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AmountAllocatedToWarrant', window );">Amount allocated to warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,721,000<span></span>
</td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">478,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.19%<span></span>
</td>
<td class="nump">4.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.47%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Average standard deviation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.50%<span></span>
</td>
<td class="nump">84.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SharesIssuedRegisteredDirectOfferings', window );">Registered direct offerings sales | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,749<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsExpirationPeriod', window );">Warrants expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExercisePriceOfWarrants', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ProceedsFromWarrantIssue', window );">Proceeds from warrant issue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantFourMember', window );">Warrant [Member] | Initial recognition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantFiveMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,571,000<span></span>
</td>
<td class="nump">298,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 679,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Average standard deviation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantSixMember', window );">Warrantt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,000<span></span>
</td>
<td class="nump">745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Average standard deviation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExercisePriceOfShareIssued', window );">Exercise Price Of Share Issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsIssuedToPurchaseShares', window );">Warrants issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsExpirationPeriod', window );">Warrants expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> four years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExercisePriceOfWarrants', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ChangesInFairValueRecordedAsANonoperatingIncome', window );">Changes In Fair Value Recorded As A Non-operating Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 643,000<span></span>
</td>
<td class="nump">$ 1,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_BeneficiallyOwnInExcess', window );">Beneficially Own In Excess</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,836,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Option vested and exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The options to consultants generally vest over four years and may be exercised for periods of between five and ten years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option outstanding | Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price outstanding | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_InvestorsMember', window );">Investors [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsIssuedToPurchaseShares', window );">Warrants issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,893<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_PlacementAgentsDesigneesMember', window );">Placement Agent's Designees [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AmountAllocatedToWarrant', window );">Amount allocated to warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsIssuedToPurchaseShares', window );">Warrants issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsExpirationPeriod', window );">Warrants expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExercisePriceOfWarrants', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ProceedsFromWarrantIssue', window );">Proceeds from warrant issue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_HighbridgeCapitalManagementLlcMember', window );">Highbridge Capital Management Llc [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExercisePriceOfShareIssued', window );">Exercise Price Of Share Issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SharesIssuedRegisteredDirectOfferings', window );">Registered direct offerings sales | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_January2025OfferingMember', window );">January 2025 Offering [Member] | ADSs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExercisePriceOfShareIssued', window );">Exercise Price Of Share Issued | $ / shares</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SharesIssuedRegisteredDirectOfferings', window );">Registered direct offerings sales | shares</a></td>
<td class="nump">858,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsIssuedToPurchaseShares', window );">Warrants issued to purchase shares | shares</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_January2025OfferingMember', window );">January 2025 Offering [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AmountAllocatedToWarrant', window );">Amount allocated to warrant</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">4.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Average standard deviation</a></td>
<td class="nump">90.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount', window );">Fair value of the ordinary warrants was adjusted amount</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ChangesInFairValueRecordedAsANonoperatingIncome', window );">Changes In Fair Value Recorded As A Non-operating Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_January2025OfferingMember', window );">January 2025 Offering [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExercisePriceOfShareIssued', window );">Exercise Price Of Share Issued | $ / shares</a></td>
<td class="nump">$ 7.996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SharesIssuedRegisteredDirectOfferings', window );">Registered direct offerings sales | shares</a></td>
<td class="nump">391,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Exercise price of other equity instruments exercisable | $ / shares</a></td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsExpirationPeriod', window );">Warrants expiration period</a></td>
<td class="text"> five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExercisePriceOfWarrants', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_BeneficiallyOwnInExcess', window );">Beneficially Own In Excess</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_January2025OfferingMember', window );">January 2025 Offering [Member] | Pre Funded Warrants [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ProceedsFromIssuanceOfInitialPublicOffering', window );">Proceeds from public offering, gross</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsIssuedToPurchaseShares', window );">Warrants issued to purchase shares | shares</a></td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsExpirationPeriod', window );">Warrants expiration period</a></td>
<td class="text"> five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ExercisePriceOfWarrants', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantOfferingConsideration', window );">Warrants offering consideration</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses', window );">Proceeds From Exercise Of Warrants After Deducting Fees And Expenses</a></td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WarrantsIssuedToPurchaseShares', window );">Warrants issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AmountAllocatedToWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AmountAllocatedToWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_BeneficiallyOwnInExcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beneficially Own In Excess</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_BeneficiallyOwnInExcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ChangesInFairValueRecordedAsANonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ChangesInFairValueRecordedAsANonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ExercisePriceOfShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ExercisePriceOfShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_FairValueOfOrdinaryWarrantsAdjustedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount fair value of ordinary warrants adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_FairValueOfOrdinaryWarrantsAdjustedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfCommissionOnSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfCommissionOnSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of proceeds from exercise of warrants after deducting fees and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ProceedsFromIssuanceOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ProceedsFromIssuanceOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ProceedsFromWarrantIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from warrant issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ProceedsFromWarrantIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_RecognizedAsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized as equity Pursuant to IFRS 15.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_RecognizedAsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_RemainingAuthorizedUnissuedOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining authorized unissued ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_RemainingAuthorizedUnissuedOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_RemainingUnrecognizedDeferredCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining unrecognized deferred compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_RemainingUnrecognizedDeferredCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SaleOfStockNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SaleOfStockNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SharesIssuedRegisteredDirectOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registered direct offerings sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SharesIssuedRegisteredDirectOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_WarrantOfferingConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tha amount of warrant offering consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_WarrantOfferingConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_WarrantsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_WarrantsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_WarrantsIssuedToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_WarrantsIssuedToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 227<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_227&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 227<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_227&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=blrx_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=blrx_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InitiallyAppliedIFRSsAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InitiallyAppliedIFRSsAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=blrx_HCWainwrightAndCoLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=blrx_HCWainwrightAndCoLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_ShareIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_ShareIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_PerformanceSharesUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_PerformanceSharesUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_PerformanceSharesUnitTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_PerformanceSharesUnitTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInvestmentPropertyAxis=blrx_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInvestmentPropertyAxis=blrx_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_PlacementAgentsDesigneesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInvestmentPropertyAxis=blrx_PlacementAgentsDesigneesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_HighbridgeCapitalManagementLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInvestmentPropertyAxis=blrx_HighbridgeCapitalManagementLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInvestmentPropertyAxis=blrx_January2025OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInvestmentPropertyAxis=blrx_January2025OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=blrx_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=blrx_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=blrx_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY (Schedule of Share Capital) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>ILS (&#8362;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>ILS (&#8362;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_NumberOfOrdinarySharesAbstract', window );"><strong>Number of Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Authorized share capital</a></td>
<td class="nump">20,000,000,000<span></span>
</td>
<td class="nump">20,000,000,000<span></span>
</td>
<td class="nump">5,000,000,000<span></span>
</td>
<td class="nump">5,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid-up share capital</a></td>
<td class="nump">2,610,814,390<span></span>
</td>
<td class="nump">2,610,814,390<span></span>
</td>
<td class="nump">1,336,670,575<span></span>
</td>
<td class="nump">1,336,670,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AuthorizedShareCapitalValue', window );">Authorized share capital | &#8362;</a></td>
<td class="nump">&#8362; 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IssuedAndPaidUpShareCapitalValue', window );">Issued and paid-up share capital</a></td>
<td class="nump">&#8362; 261,081,439<span></span>
</td>
<td class="nump">$ 73,428,375<span></span>
</td>
<td class="nump">&#8362; 133,667,057<span></span>
</td>
<td class="nump">$ 38,096,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AuthorizedShareCapitalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of authorized share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AuthorizedShareCapitalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IssuedAndPaidUpShareCapitalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issued and paid up share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IssuedAndPaidUpShareCapitalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_NumberOfOrdinarySharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_NumberOfOrdinarySharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Schedule of Amounts Outstanding Under Employee Share Incentive Plan) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>Share </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Share </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Share </div>
<div>&#8362; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_NumberOfOptionsAbstract', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of year</a></td>
<td class="nump">141,634,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of year</a></td>
<td class="nump">311,967,000<span></span>
</td>
<td class="nump">141,634,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted average exercise price (in NIS)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding at end of year | &#8362; / shares</a></td>
<td class="nump">&#8362; 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_EmployeesAndDirectorsMember', window );">Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_NumberOfOptionsAbstract', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of year</a></td>
<td class="nump">141,634,245<span></span>
</td>
<td class="nump">150,429,825<span></span>
</td>
<td class="nump">89,871,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted</a></td>
<td class="nump">212,760,000<span></span>
</td>
<td class="nump">23,190,000<span></span>
</td>
<td class="nump">64,855,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired</a></td>
<td class="num">(24,310,920)<span></span>
</td>
<td class="num">(3,825,990)<span></span>
</td>
<td class="num">(1,379,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited</a></td>
<td class="num">(18,116,325)<span></span>
</td>
<td class="num">(27,389,565)<span></span>
</td>
<td class="num">(2,424,535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(770,025)<span></span>
</td>
<td class="num">(493,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of year</a></td>
<td class="nump">311,967,000<span></span>
</td>
<td class="nump">141,634,245<span></span>
</td>
<td class="nump">150,429,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable at end of year</a></td>
<td class="nump">81,825,600<span></span>
</td>
<td class="nump">88,080,600<span></span>
</td>
<td class="nump">51,970,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted average exercise price (in NIS)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding at beginning of year | &#8362; / shares</a></td>
<td class="nump">&#8362; 0.32<span></span>
</td>
<td class="nump">&#8362; 0.32<span></span>
</td>
<td class="nump">&#8362; 0.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Granted | &#8362; / shares</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Expired | &#8362; / shares</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">0.53<span></span>
</td>
<td class="nump">0.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited | &#8362; / shares</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
<td class="nump">0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercised | &#8362; / shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">0.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding at end of year | &#8362; / shares</a></td>
<td class="nump">0.12<span></span>
</td>
<td class="nump">0.32<span></span>
</td>
<td class="nump">0.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable at end of year | &#8362; / shares</a></td>
<td class="nump">&#8362; 0.39<span></span>
</td>
<td class="nump">&#8362; 0.4<span></span>
</td>
<td class="nump">&#8362; 0.54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_NumberOfOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_NumberOfOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_WeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_WeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_v&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_v&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_v&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_v&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=blrx_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Schedule of Options Outstanding by Exercise Price Range) (Details) - Share<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding</a></td>
<td class="nump">311,967,000<span></span>
</td>
<td class="nump">141,634,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual (in yrs.)</a></td>
<td class="text">8 years 8 months 4 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeMember', window );">Up to 0.49 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding</a></td>
<td class="nump">288,520,200<span></span>
</td>
<td class="nump">114,352,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual (in yrs.)</a></td>
<td class="text">9 years 25 days<span></span>
</td>
<td class="text">8 years 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeOneMember', window );">0.5- 0.99 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding</a></td>
<td class="nump">12,576,000<span></span>
</td>
<td class="nump">15,104,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual (in yrs.)</a></td>
<td class="text">4 years 11 months 15 days<span></span>
</td>
<td class="text">6 years 6 months 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeTwoMember', window );">1.00-2.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding</a></td>
<td class="nump">10,423,800<span></span>
</td>
<td class="nump">11,727,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual (in yrs.)</a></td>
<td class="text">2 years 9 months 25 days<span></span>
</td>
<td class="text">4 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeFourMember', window );">2.01-3.4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding</a></td>
<td class="nump">447,000<span></span>
</td>
<td class="nump">449,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual (in yrs.)</a></td>
<td class="text">1 year 2 months 1 day<span></span>
</td>
<td class="text">3 years 2 months 4 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=blrx_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Schedule of Assumptions Used to Value Options) (Details) - Year<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life of options (in years)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">$ 381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TaxLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TaxLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfIncomeTaxesAbstract', window );"><strong>Disclosure Of Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Loss before taxes (Percentage)</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss before taxes</a></td>
<td class="num">$ (2,026)<span></span>
</td>
<td class="num">$ (9,221)<span></span>
</td>
<td class="num">$ (60,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Theoretical tax benefit</a></td>
<td class="num">(466)<span></span>
</td>
<td class="num">(2,121)<span></span>
</td>
<td class="num">(13,941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisallowedDeductionsTaxExemptIncomeAbstract', window );"><strong>Disallowed deductions (tax exempt income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation', window );">Loss (gain) on adjustment of warrants to fair value</a></td>
<td class="num">(1,978)<span></span>
</td>
<td class="num">(4,056)<span></span>
</td>
<td class="nump">2,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation', window );">Share-based compensation</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_WriteoffOfIntangibleAsset', window );">Impairment of intangible asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated', window );">Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created</a></td>
<td class="nump">2,342<span></span>
</td>
<td class="nump">5,673<span></span>
</td>
<td class="nump">9,312<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes on income for the reported year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisallowedDeductionsTaxExemptIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disallowed deductions tax exempt income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisallowedDeductionsTaxExemptIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to gains on adjustments of warrants to fair value, that are exempt from taxation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to share-based compensation that are exempt from taxation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_WriteoffOfIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of write-off of intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_WriteoffOfIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LOSS PER SHARE (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PreFundedWarrants', window );">Pre Funded Warrants</a></td>
<td class="nump">$ 49,279<span></span>
</td>
<td class="nump">$ 12,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represnts of pre funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Loss attributed to ordinary shares</a></td>
<td class="num">$ (2,026)<span></span>
</td>
<td class="num">$ (9,221)<span></span>
</td>
<td class="num">$ (60,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Number of shares used in basic calculation</a></td>
<td class="nump">2,465,272,604<span></span>
</td>
<td class="nump">1,198,107,761<span></span>
</td>
<td class="nump">963,365,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic and diluted loss per ordinary share</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings (loss) per share</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems', window );"><strong>Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RoyaltiesReceivedPercentage', window );">Royalties received percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales', window );">Percentage Of Net Consideration Received For Direct Product Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfNetConsiderationReceivedForSubLicense', window );">Percentage Of Net Consideration Received For Sub License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_BankGuaranteeAmountForBenefitOfLessor', window );">Bank guarantee amount for benefit of lessor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_OpenPurchaseOrderCommitments', window );">Company's outstanding open purchase order commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=blrx_BiokineTherapeuticsLtdMember', window );">Biokine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems', window );"><strong>Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RoyaltiesPaymentPercentage', window );">Royalties payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_MaximumFutureMilestonePayments', window );">Maximum future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ContingentLiability', window );">Value of contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts', window );">Royalties payment percentage if the company independently sell products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LawsuitClaimAmount', window );">Lawsuit claim amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems', window );"><strong>Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RoyaltiesOnSale', window );">Royalties on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfNetConsiderationReceivedFromLicensee', window );">Percentage of net consideration received from the licensee</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems', window );"><strong>Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RoyaltiesOnSale', window );">Royalties on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfNetConsiderationReceivedFromLicensee', window );">Percentage of net consideration received from the licensee</a></td>
<td class="nump">29.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=blrx_FirstThreeYearsMember', window );">First three years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems', window );"><strong>Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RoyaltiesReceivedPercentage', window );">Royalties received percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=blrx_ThreeSubsequentYearsMember', window );">Three subsequent years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems', window );"><strong>Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RoyaltiesReceivedPercentage', window );">Royalties received percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=blrx_SeventhYearMember', window );">Seventh year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems', window );"><strong>Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RoyaltiesReceivedPercentage', window );">Royalties received percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_BankGuaranteeAmountForBenefitOfLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank guarantee amount for benefit of Lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_BankGuaranteeAmountForBenefitOfLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the value of contingent liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_LawsuitClaimAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>lawsuit claim amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_LawsuitClaimAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_MaximumFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the maximum future milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_MaximumFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_OpenPurchaseOrderCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total outstanding open purchase order commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_OpenPurchaseOrderCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfNetConsiderationReceivedForDirectProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net consideration received from the for direct product sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfNetConsiderationReceivedForDirectProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfNetConsiderationReceivedForSubLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net consideration received from the for sub license</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfNetConsiderationReceivedForSubLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfNetConsiderationReceivedFromLicensee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net consideration received from the licensee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfNetConsiderationReceivedFromLicensee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_RoyaltiesOnSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties on sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_RoyaltiesOnSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_RoyaltiesPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the royalties payment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_RoyaltiesPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the royalties payment percentage if the company independently sell products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_RoyaltiesReceivedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties received percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_RoyaltiesReceivedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=blrx_BiokineTherapeuticsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=blrx_BiokineTherapeuticsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=blrx_FirstThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=blrx_FirstThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=blrx_ThreeSubsequentYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=blrx_ThreeSubsequentYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=blrx_SeventhYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=blrx_SeventhYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2023</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Costs related to share purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702<span></span>
</td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ProvisionForDoubtfulAccountsReceivable', window );">Provision for doubtful accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LicenceFeeIncome', window );">Licence fee income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,180<span></span>
</td>
<td class="nump">22,917<span></span>
</td>
<td class="nump">4,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementTypeAxis=blrx_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementTypeAxis=blrx_ScmLicenseMember', window );">SCM license [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementTypeAxis=blrx_ScmSupportServicesMember', window );">SCM support services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementTypeAxis=blrx_PDACPerformanceObligationMember', window );">PDAC performance obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementTypeAxis=blrx_GloriaLicenseAgreementMember', window );">Gloria License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForDevelopmentProjectExpenditure', window );">Development and regulatory entitled amount</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SalesMilestoneAmount', window );">Sales milestone amount</a></td>
<td class="nump">$ 197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementTypeAxis=blrx_GloriaPurchaseAgreementMember', window );">Gloria Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AggregateAmericanDepositaryShares', window );">Aggregate American depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PurchasePricePerADS', window );">Purchase price per ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares', window );">Proceeds from sale or issue of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Share issue related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_CostsIncurrentInOffering', window );">Costs Incurrent In Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementTypeAxis=blrx_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DelayInPayment', window );">Delay in payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Gloria License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RoyaltiesEligibleMargin', window );">Royalties eligible margin</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Gloria License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_RoyaltiesEligibleMargin', window );">Royalties eligible margin</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AggregateAmericanDepositaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about aggregate American depositary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AggregateAmericanDepositaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_CostsIncurrentInOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurrent in offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_CostsIncurrentInOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DelayInPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents delay in payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DelayInPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ProvisionForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount for provision for doubtful accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ProvisionForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PurchasePricePerADS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent about purchase price per ADS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PurchasePricePerADS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_RoyaltiesEligibleMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about royalties eligible margins.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_RoyaltiesEligibleMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SalesMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sales milestone amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SalesMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LicenceFeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LicenceFeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForDevelopmentProjectExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for expenditure related to development projects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForDevelopmentProjectExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale or issuing of treasury shares. [Refer: Sale or issue of treasury shares; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementTypeAxis=blrx_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementTypeAxis=blrx_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementTypeAxis=blrx_ScmLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementTypeAxis=blrx_ScmLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementTypeAxis=blrx_ScmSupportServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementTypeAxis=blrx_ScmSupportServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementTypeAxis=blrx_PDACPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementTypeAxis=blrx_PDACPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementTypeAxis=blrx_GloriaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementTypeAxis=blrx_GloriaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementTypeAxis=blrx_GloriaPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementTypeAxis=blrx_GloriaPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementTypeAxis=blrx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementTypeAxis=blrx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration received</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LicenceFeeIncome', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,180<span></span>
</td>
<td class="nump">$ 22,917<span></span>
</td>
<td class="nump">$ 4,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementTypeAxis=blrx_AyrmidLicenseAgreementMember', window );">Ayrmid License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration received</a></td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LicenceFeeIncome', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Total royalties based on motixafortide net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementTypeAxis=blrx_AyrmidLicenseAgreementMember', window );">Ayrmid License Agreement [Member] | Single Material Performance Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration received</a></td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementTypeAxis=blrx_HighbridgeMember', window );">Highbridge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_GrossProceedsFromOffering', window );">Gross proceeds from offering</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AgreementTypeAxis=blrx_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration received</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_CostsIncurrentInOffering', window );">Costs incurrent in offering</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Ayrmid License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales', window );">Percentage of royalties receivable from aggregate net sales</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Ayrmid License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems', window );"><strong>License And Securities Purchase Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales', window );">Percentage of royalties receivable from aggregate net sales</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_CostsIncurrentInOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurrent in offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_CostsIncurrentInOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_GrossProceedsFromOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross proceeds from offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_GrossProceedsFromOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties receivable from aggregate net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LicenceFeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LicenceFeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementTypeAxis=blrx_AyrmidLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementTypeAxis=blrx_AyrmidLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PerformanceObligationAxis=blrx_SingleMaterialPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PerformanceObligationAxis=blrx_SingleMaterialPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementTypeAxis=blrx_HighbridgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementTypeAxis=blrx_HighbridgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementTypeAxis=blrx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementTypeAxis=blrx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1 (Narrative) (Details) - Hemispherian As [Member] - Asset Transfer Agreement [Member] - Tetragon [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_CollaborationAndShareholdersAgreementLineItems', window );"><strong>Collaboration And Shareholders Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfIssuedShareCapitalReceived', window );">Percentage of issued share capital received</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentProperty', window );">Investment</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths', window );">Percentage of issued share capital received within 36 months</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_IncrementalInvestment', window );">Incremental investment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfAdditionalEquityInterest', window );">Percentage of additional equity interest</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Percentage of aggregate maximum ownership</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PercentageOfOwnershipStake', window );">Percentage of ownership stake</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_MonthlyAdvisoryFee', window );">Monthly advisory fee</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Intangible asset amount</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_CollaborationAndShareholdersAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_CollaborationAndShareholdersAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_IncrementalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of incremental investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_IncrementalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_MonthlyAdvisoryFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly advisory fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_MonthlyAdvisoryFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfAdditionalEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of additional equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfAdditionalEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfIssuedShareCapitalReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of issued share capital received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfIssuedShareCapitalReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of issued share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PercentageOfOwnershipStake">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Perpresents percentage of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PercentageOfOwnershipStake</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property (land or a building - or part of a building - or both) held (by the owner or by the lessee as a right-of-use asset) to earn rentals or for capital appreciation or both, rather than for: (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2025-01-01<br> -Paragraph 76<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_76&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 269<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_269&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 271<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_271_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 269<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_269&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 271<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_271_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_CollaborationTransactionAxis=blrx_HemispherianAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_CollaborationTransactionAxis=blrx_HemispherianAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AgreementTypeAxis=blrx_AssetTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AgreementTypeAxis=blrx_AssetTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=blrx_TetragonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=blrx_TetragonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Transactions With Related Parties) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SeparateManagementEntitiesAxis=blrx_SeniorManagementMember', window );">Senior Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_BenefitsToRelatedPartiesAbstract', window );"><strong>Benefits to related parties:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity', window );">Compensation and benefits to management, including benefit component of equity instrument grants</a></td>
<td class="nump">$ 1,398<span></span>
</td>
<td class="nump">$ 2,396<span></span>
</td>
<td class="nump">$ 3,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SeparateManagementEntitiesAxis=blrx_DirectorsMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_BenefitsToRelatedPartiesAbstract', window );"><strong>Benefits to related parties:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity', window );">Compensation and benefits to management, including benefit component of equity instrument grants</a></td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_BenefitsToRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Benefits to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_BenefitsToRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 229<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_229&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 18A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_18A&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 229<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_229&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SeparateManagementEntitiesAxis=blrx_SeniorManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SeparateManagementEntitiesAxis=blrx_SeniorManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SeparateManagementEntitiesAxis=blrx_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SeparateManagementEntitiesAxis=blrx_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Key Management Compensation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Salaries and other short-term employee benefits</a></td>
<td class="nump">$ 1,425<span></span>
</td>
<td class="nump">$ 2,018<span></span>
</td>
<td class="nump">$ 2,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long-term benefits</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">1,030<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Benefits to key executive personnel</a></td>
<td class="nump">$ 1,871<span></span>
</td>
<td class="nump">$ 2,811<span></span>
</td>
<td class="nump">$ 3,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 227<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_227&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 227<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_227&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_NumberOfSegments', window );">Number of segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_NumberOfSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_NumberOfSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Rvenues from external parties</a></td>
<td class="nump">$ 1,180<span></span>
</td>
<td class="nump">$ 28,940<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Rvenues from external parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,957<span></span>
</td>
<td class="nump">4,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember', window );">U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Rvenues from external parties</a></td>
<td class="nump">$ 1,180<span></span>
</td>
<td class="nump">$ 13,983<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Receivables) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract', window );"><strong>Disclosure of supplementary financial statement information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_InstitutionsCurrentReceivables', window );">Government institutions</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AdvancePayments', window );">Advance payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_Others', window );">Other</a></td>
<td class="nump">377<span></span>
</td>
<td class="nump">932<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">$ 410<span></span>
</td>
<td class="nump">$ 1,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AdvancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AdvancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplimentry financial statements information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_InstitutionsCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Institutions other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_InstitutionsCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_Others">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_Others</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Payable and Accruals) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_AccountsPayableAbstract', window );"><strong>Accounts payable:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TradeAndOtherPayablesToForeignTradeSuppliers', window );">Overseas</a></td>
<td class="nump">$ 2,814<span></span>
</td>
<td class="nump">$ 4,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_TradeAndOtherPayablesToLocalTradeSuppliers', window );">In Israel</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade</a></td>
<td class="nump">3,493<span></span>
</td>
<td class="nump">5,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_OtherPayablesAbstract', window );"><strong>Other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_PayrollAndRelatedExpenses', window );">Payroll and related expenses</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisionsForEmployeeBenefits', window );">Accrual for vacation and recreation pay</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Other</a></td>
<td class="nump">$ 1,743<span></span>
</td>
<td class="nump">$ 3,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_AccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_AccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_OtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_OtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_PayrollAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payroll and related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_PayrollAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TradeAndOtherPayablesToForeignTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to foreign suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TradeAndOtherPayablesToForeignTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_TradeAndOtherPayablesToLocalTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to local suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_TradeAndOtherPayablesToLocalTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Cost of revenues) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract', window );"><strong>Disclosure of supplementary financial statement information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LicenseFeesAndRoyaltiesPayableToLicensor', window );">License fees and royalties payable to licensor</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 3,024<span></span>
</td>
<td class="nump">$ 3,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_CostRelatedToLicenseRevenues', window );">Direct costs related to license revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,605<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Amortization of intangible asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,323<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_CostOfProductSales', window );">Cost of product sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 9,263<span></span>
</td>
<td class="nump">$ 3,692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_CostOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_CostOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_CostRelatedToLicenseRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost related to license revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_CostRelatedToLicenseRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplimentry financial statements information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_LicenseFeesAndRoyaltiesPayableToLicensor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fees and royalties payable to licensor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_LicenseFeesAndRoyaltiesPayableToLicensor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Research and Development Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract', window );"><strong>Disclosure of supplementary financial statement information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Research and development services</a></td>
<td class="nump">$ 3,118<span></span>
</td>
<td class="nump">$ 3,170<span></span>
</td>
<td class="nump">$ 4,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Payroll and related expenses</a></td>
<td class="nump">2,982<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
<td class="nump">4,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommunicationExpense', window );">Lab, occupancy and telephone</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ProfessionalFee', window );">Professional fees</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment', window );">Share based compensation</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">495<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Other</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 8,093<span></span>
</td>
<td class="nump">$ 9,149<span></span>
</td>
<td class="nump">$ 12,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplimentry financial statements information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ProfessionalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fee expense related to professional.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ProfessionalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ShareBasedCompensationRelatedToResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of share based compensation related to research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ShareBasedCompensationRelatedToResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommunicationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommunicationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Sales and Marketing Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract', window );"><strong>Disclosure of supplementary financial statement information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SalesAndMarketingExpensesRelatedToSales', window );">Payroll and related expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,224<span></span>
</td>
<td class="nump">$ 8,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_MedicalAffairs', window );">Medical Affairs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,891<span></span>
</td>
<td class="nump">4,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_MarketingExpenses', window );">Marketing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,041<span></span>
</td>
<td class="nump">4,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TravelExpense', window );">Travel</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SalesAndMarketingPayrollExpense', window );">Office-related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
<td class="nump">1,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_BusinessAnalyticsExpense', window );">Business Analytics</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_MarketAccessExpense', window );">Market Access</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">701<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SalesAndMarketingProfessionalFees', window );">Professional fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">627<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SalesAndMarketingShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SalesAndMarketingDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_LossOnAbandonmentOfRightofuseAsset', window );">Loss on abandonment of right-of-use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_SalesAndMarketingExpensesOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,605<span></span>
</td>
<td class="nump">$ 25,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_BusinessAnalyticsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business analytics expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_BusinessAnalyticsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplimentry financial statements information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_LossOnAbandonmentOfRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of loss on abandonment of rightofuse asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_LossOnAbandonmentOfRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_MarketAccessExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market access expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_MarketAccessExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_MarketingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketing Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_MarketingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_MedicalAffairs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Affairs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_MedicalAffairs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SalesAndMarketingDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SalesAndMarketingDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SalesAndMarketingExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales and marketing expenses Other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SalesAndMarketingExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SalesAndMarketingExpensesRelatedToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales and marketing expenses related to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SalesAndMarketingExpensesRelatedToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SalesAndMarketingPayrollExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payroll and related expenses, including vehicles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SalesAndMarketingPayrollExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SalesAndMarketingProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales and marketing professional fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SalesAndMarketingProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_SalesAndMarketingShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales and marketing Share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_SalesAndMarketingShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TravelExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TravelExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of General and Administrative Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract', window );"><strong>Disclosure of supplementary financial statement information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Payroll and related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,407<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">2,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceExpense', window );">Insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="nump">808<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ProvisionForDoubtfulAccountsReceivable', window );">Provision for doubtful accounts receivable</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,144<span></span>
</td>
<td class="nump">$ 6,321<span></span>
</td>
<td class="nump">$ 6,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplimentry financial statements information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ProvisionForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount for provision for doubtful accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ProvisionForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of share based compensation related to general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Non-Operating Income (Expenses), Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract', window );"><strong>Disclosure of supplementary financial statement information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities', window );">Changes in fair value of warrants</a></td>
<td class="nump">$ 8,599<span></span>
</td>
<td class="nump">$ 18,965<span></span>
</td>
<td class="num">$ (11,054)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Issuance costs</a></td>
<td class="num">(702)<span></span>
</td>
<td class="num">(669)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_OtherNonoperatingIncomeExpenses', window );">Other</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_ProfitLossFromNonOperatingActivities', window );">Non-operating income, net</a></td>
<td class="nump">$ 8,077<span></span>
</td>
<td class="nump">$ 18,435<span></span>
</td>
<td class="num">$ (10,819)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplimentry financial statements information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_OtherNonoperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_OtherNonoperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_ProfitLossFromNonOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non operating profit (loss) from operating activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_ProfitLossFromNonOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Income) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract', window );"><strong>Disclosure of supplementary financial statement information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">$ 1,124<span></span>
</td>
<td class="nump">$ 1,820<span></span>
</td>
<td class="nump">$ 2,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Exchange differences, net</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">$ 1,464<span></span>
</td>
<td class="nump">$ 1,871<span></span>
</td>
<td class="nump">$ 2,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplimentry financial statements information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2025-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract', window );"><strong>Disclosure of supplementary financial statement information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 1,251<span></span>
</td>
<td class="nump">$ 9,074<span></span>
</td>
<td class="nump">$ 2,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Bank commissions</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="nump">$ 1,280<span></span>
</td>
<td class="nump">$ 9,119<span></span>
</td>
<td class="nump">$ 2,169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplimentry financial statements information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>350</ContextCount>
  <ElementCount>427</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>98</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/StatementsOfChangesInEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/ConsolidatedCashFlowStatements</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Disclosure - GENERAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/GeneralInformation</Role>
      <ShortName>GENERAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - MATERIAL ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>MATERIAL ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagement</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/CriticalAccountingEstimatesAndJudgments</Role>
      <ShortName>CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - CASH AND CASH EQUIVALENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/CashAndCashEquivalents</Role>
      <ShortName>CASH AND CASH EQUIVALENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - SHORT-TERM BANK DEPOSITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/Short-termBankDeposits</Role>
      <ShortName>SHORT-TERM BANK DEPOSITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - LONG-TERM LOAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/Long-termLoans</Role>
      <ShortName>LONG-TERM LOAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/Equity</Role>
      <ShortName>EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/TaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LOSSPERSHARE</Role>
      <ShortName>LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTS</Role>
      <ShortName>LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGE</Role>
      <ShortName>LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1</Role>
      <ShortName>AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/TransactionsAndBalancesWithRelatedParties</Role>
      <ShortName>TRANSACTIONS AND BALANCES WITH RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SEGMENTREPORTING</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9960701 - Disclosure - MATERIAL ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>MATERIAL ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9960702 - Disclosure - MATERIAL ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>MATERIAL ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9960703 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagement</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9960704 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>CASH AND CASH EQUIVALENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/CashAndCashEquivalents</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9960705 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/PropertyAndEquipment</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9960706 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/IntangibleAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9960707 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9960708 - Disclosure - EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/EquityTables</Role>
      <ShortName>EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/Equity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9960709 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/TaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/TaxesOnIncome</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9960710 - Disclosure - LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LossPerShareTables</Role>
      <ShortName>LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/LOSSPERSHARE</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9960711 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables</Role>
      <ShortName>TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/TransactionsAndBalancesWithRelatedParties</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9960712 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SEGMENTREPORTINGTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SEGMENTREPORTING</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9960713 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SupplementaryFinancialStatementInformation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9960714 - Disclosure - GENERAL INFORMATION (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/GeneralInformationDetails</Role>
      <ShortName>GENERAL INFORMATION (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/GeneralInformation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9960715 - Disclosure - MATERIAL ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>MATERIAL ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9960716 - Disclosure - MATERIAL ACCOUNTING POLICIES (Schedule of Depreciation Rates) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails</Role>
      <ShortName>MATERIAL ACCOUNTING POLICIES (Schedule of Depreciation Rates) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9960717 - Disclosure - MATERIAL ACCOUNTING POLICIES (Schedule of Useful Life of Right of Use Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails</Role>
      <ShortName>MATERIAL ACCOUNTING POLICIES (Schedule of Useful Life of Right of Use Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9960718 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9960719 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9960721 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Linkage of Monetary Items) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Linkage of Monetary Items) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9960722 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Credit Risk) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Credit Risk) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9960723 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Changes in Financial Liabilities With Cash Flows) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Changes in Financial Liabilities With Cash Flows) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9960724 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Value Measurement of Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Value Measurement of Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9960725 - Disclosure - CASH AND CASH EQUIVALENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails</Role>
      <ShortName>CASH AND CASH EQUIVALENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/CashAndCashEquivalentsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9960726 - Disclosure - CASH AND CASH EQUIVALENTS (Schedule of Cash And Cash Equivalents) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails</Role>
      <ShortName>CASH AND CASH EQUIVALENTS (Schedule of Cash And Cash Equivalents) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/CashAndCashEquivalentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9960727 - Disclosure - SHORT-TERM BANK DEPOSITS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails</Role>
      <ShortName>SHORT-TERM BANK DEPOSITS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/Short-termBankDeposits</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9960728 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Composition of Property and Equipment and Related Accumulated Depreciation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Schedule of Composition of Property and Equipment and Related Accumulated Depreciation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9960729 - Disclosure - INTANGIBLE ASSETS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/IntangibleAssetsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9960730 - Disclosure - INTANGIBLE ASSETS (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/IntangibleAssetsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9960731 - Disclosure - LEASES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>LEASES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/LeasesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9960732 - Disclosure - LEASES (Schedule of Right-of-use assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails</Role>
      <ShortName>LEASES (Schedule of Right-of-use assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/LeasesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9960733 - Disclosure - LEASES (Schedule of Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES (Schedule of Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/LeasesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9960734 - Disclosure - LEASES (Schedule of Minimum Future Rental Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails</Role>
      <ShortName>LEASES (Schedule of Minimum Future Rental Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/LeasesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9960735 - Disclosure - LONG-TERM LOAN (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/Long-termLoansNarrativeDetails</Role>
      <ShortName>LONG-TERM LOAN (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/Long-termLoans</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9960736 - Disclosure - EQUITY (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/EquityNarrativeDetails</Role>
      <ShortName>EQUITY (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/EquityTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9960737 - Disclosure - EQUITY (Schedule of Share Capital) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails</Role>
      <ShortName>EQUITY (Schedule of Share Capital) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/EquityTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9960738 - Disclosure - EQUITY (Schedule of Amounts Outstanding Under Employee Share Incentive Plan) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails</Role>
      <ShortName>EQUITY (Schedule of Amounts Outstanding Under Employee Share Incentive Plan) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/EquityTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9960739 - Disclosure - EQUITY (Schedule of Options Outstanding by Exercise Price Range) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails</Role>
      <ShortName>EQUITY (Schedule of Options Outstanding by Exercise Price Range) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/EquityTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9960740 - Disclosure - EQUITY (Schedule of Assumptions Used to Value Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails</Role>
      <ShortName>EQUITY (Schedule of Assumptions Used to Value Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/EquityTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9960741 - Disclosure - TAXES ON INCOME (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails</Role>
      <ShortName>TAXES ON INCOME (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9960742 - Disclosure - TAXES ON INCOME (Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails</Role>
      <ShortName>TAXES ON INCOME (Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9960743 - Disclosure - LOSS PER SHARE (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LOSSPERSHARENarrativeDetails</Role>
      <ShortName>LOSS PER SHARE (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/LossPerShareTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9960744 - Disclosure - LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails</Role>
      <ShortName>LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/LossPerShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9960745 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9960746 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails</Role>
      <ShortName>LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTS</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9960747 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails</Role>
      <ShortName>LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGE</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9960748 - Disclosure - AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1 (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails</Role>
      <ShortName>AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1 (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9960749 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Transactions With Related Parties) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails</Role>
      <ShortName>TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Transactions With Related Parties) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9960750 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Key Management Compensation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails</Role>
      <ShortName>TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Key Management Compensation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9960751 - Disclosure - SEGMENT REPORTING (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SEGMENTREPORTINGNarrativeDetails</Role>
      <ShortName>SEGMENT REPORTING (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SEGMENTREPORTINGTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9960752 - Disclosure - SEGMENT REPORTING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SEGMENTREPORTINGDetails</Role>
      <ShortName>SEGMENT REPORTING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SEGMENTREPORTINGTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9960753 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Receivables) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Receivables) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9960754 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Payable and Accruals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Payable and Accruals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9960755 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Cost of revenues) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Cost of revenues) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9960756 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Research and Development Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Research and Development Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9960757 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Sales and Marketing Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Sales and Marketing Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9960758 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of General and Administrative Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of General and Administrative Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9960759 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Non-Operating Income (Expenses), Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Non-Operating Income (Expenses), Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9960760 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="zk2634707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9960761 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>blrx-20251231.xsd</File>
    <File>blrx-20251231_cal.xml</File>
    <File>blrx-20251231_def.xml</File>
    <File>blrx-20251231_lab.xml</File>
    <File>blrx-20251231_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="zk2634707.htm">zk2634707.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image0.jpg</File>
    <File>image2.jpg</File>
    <File>image3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="11">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
    <BaseTaxonomy items="967">https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>113
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zk2634707.htm": {
   "nsprefix": "blrx",
   "nsuri": "http://biolinerx.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "blrx-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "blrx-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "blrx-20251231_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "blrx-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "blrx-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2634707.htm"
     ]
    }
   },
   "keyStandard": 263,
   "keyCustom": 164,
   "axisStandard": 27,
   "axisCustom": 4,
   "memberStandard": 35,
   "memberCustom": 61,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2025": 3,
    "http://biolinerx.com/20251231": 3
   },
   "contextCount": 350,
   "entityCount": 1,
   "segmentCount": 98,
   "elementCount": 877,
   "unitCount": 9,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 967,
    "http://xbrl.sec.gov/dei/2025": 42,
    "http://xbrl.sec.gov/cyd/2025": 11,
    "http://xbrl.sec.gov/ecd/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://biolinerx.com/role/DocumentAndEntityInformation",
     "longName": "0001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
     "longName": "0002 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231",
      "name": "ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "longName": "0003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:LicenceFeeIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://biolinerx.com/role/StatementsOfChangesInEquity",
     "longName": "0004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember",
      "name": "ifrs-full:Equity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember",
      "name": "ifrs-full:Equity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://biolinerx.com/role/ConsolidatedCashFlowStatements",
     "longName": "0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:CashFlowsFromUsedInOperatingActivities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://biolinerx.com/role/GeneralInformation",
     "longName": "0006 - Disclosure - GENERAL INFORMATION",
     "shortName": "GENERAL INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://biolinerx.com/role/SignificantAccountingPolicies",
     "longName": "0007 - Disclosure - MATERIAL ACCOUNTING POLICIES",
     "shortName": "MATERIAL ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagement",
     "longName": "0008 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT",
     "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://biolinerx.com/role/CriticalAccountingEstimatesAndJudgments",
     "longName": "0009 - Disclosure - CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS",
     "shortName": "CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://biolinerx.com/role/CashAndCashEquivalents",
     "longName": "0010 - Disclosure - CASH AND CASH EQUIVALENTS",
     "shortName": "CASH AND CASH EQUIVALENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://biolinerx.com/role/Short-termBankDeposits",
     "longName": "0011 - Disclosure - SHORT-TERM BANK DEPOSITS",
     "shortName": "SHORT-TERM BANK DEPOSITS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfDepositsFromBanksExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfDepositsFromBanksExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://biolinerx.com/role/PropertyAndEquipment",
     "longName": "0012 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://biolinerx.com/role/IntangibleAssets",
     "longName": "0013 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://biolinerx.com/role/Leases",
     "longName": "0014 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://biolinerx.com/role/Long-termLoans",
     "longName": "0015 - Disclosure - LONG-TERM LOAN",
     "shortName": "LONG-TERM LOAN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://biolinerx.com/role/Equity",
     "longName": "0016 - Disclosure - EQUITY",
     "shortName": "EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://biolinerx.com/role/TaxesOnIncome",
     "longName": "0017 - Disclosure - TAXES ON INCOME",
     "shortName": "TAXES ON INCOME",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://biolinerx.com/role/LOSSPERSHARE",
     "longName": "0018 - Disclosure - LOSS PER SHARE",
     "shortName": "LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://biolinerx.com/role/CommitmentsAndContingentLiabilities",
     "longName": "0019 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTS",
     "longName": "0020 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA",
     "shortName": "LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGE",
     "longName": "0021 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE",
     "shortName": "LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1",
     "longName": "0022 - Disclosure - AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1",
     "shortName": "AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:AgreementWithHemispherianForDevelopmentOfGlix1Explanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:AgreementWithHemispherianForDevelopmentOfGlix1Explanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedParties",
     "longName": "0023 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES",
     "shortName": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://biolinerx.com/role/SEGMENTREPORTING",
     "longName": "0024 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformation",
     "longName": "0025 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "9960701 - Disclosure - MATERIAL ACCOUNTING POLICIES (Policies)",
     "shortName": "MATERIAL ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://biolinerx.com/role/SignificantAccountingPoliciesTables",
     "longName": "9960702 - Disclosure - MATERIAL ACCOUNTING POLICIES (Tables)",
     "shortName": "MATERIAL ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables",
     "longName": "9960703 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://biolinerx.com/role/CashAndCashEquivalentsTables",
     "longName": "9960704 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)",
     "shortName": "CASH AND CASH EQUIVALENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://biolinerx.com/role/PropertyAndEquipmentTables",
     "longName": "9960705 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://biolinerx.com/role/IntangibleAssetsTables",
     "longName": "9960706 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://biolinerx.com/role/LeasesTables",
     "longName": "9960707 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://biolinerx.com/role/EquityTables",
     "longName": "9960708 - Disclosure - EQUITY (Tables)",
     "shortName": "EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://biolinerx.com/role/TaxesOnIncomeTables",
     "longName": "9960709 - Disclosure - TAXES ON INCOME (Tables)",
     "shortName": "TAXES ON INCOME (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://biolinerx.com/role/LossPerShareTables",
     "longName": "9960710 - Disclosure - LOSS PER SHARE (Tables)",
     "shortName": "LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables",
     "longName": "9960711 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Tables)",
     "shortName": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://biolinerx.com/role/SEGMENTREPORTINGTables",
     "longName": "9960712 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables",
     "longName": "9960713 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://biolinerx.com/role/GeneralInformationDetails",
     "longName": "9960714 - Disclosure - GENERAL INFORMATION (Narrative) (Details)",
     "shortName": "GENERAL INFORMATION (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "ifrs-full:RetainedEarnings",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:DepositaryShareConversionDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "longName": "9960715 - Disclosure - MATERIAL ACCOUNTING POLICIES (Narrative) (Details)",
     "shortName": "MATERIAL ACCOUNTING POLICIES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:AdjustedWeightedAverageShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_ifrsfullComputerSoftwareMember",
      "name": "ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
       "div",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails",
     "longName": "9960716 - Disclosure - MATERIAL ACCOUNTING POLICIES (Schedule of Depreciation Rates) (Details)",
     "shortName": "MATERIAL ACCOUNTING POLICIES (Schedule of Depreciation Rates) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember",
      "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember",
      "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails",
     "longName": "9960717 - Disclosure - MATERIAL ACCOUNTING POLICIES (Schedule of Useful Life of Right of Use Assets) (Details)",
     "shortName": "MATERIAL ACCOUNTING POLICIES (Schedule of Useful Life of Right of Use Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember",
      "name": "blrx:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory",
       "div",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember",
      "name": "blrx:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory",
       "div",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails",
     "longName": "9960718 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Narrative) (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember",
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails",
     "longName": "9960719 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231",
      "name": "blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails",
     "longName": "9960721 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Linkage of Monetary Items) (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Linkage of Monetary Items) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "blrx:DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails",
     "longName": "9960722 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Credit Risk) (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Credit Risk) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails",
     "longName": "9960723 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Changes in Financial Liabilities With Cash Flows) (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Changes in Financial Liabilities With Cash Flows) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20221231",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails",
     "longName": "9960724 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Value Measurement of Warrants) (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Value Measurement of Warrants) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember",
      "name": "blrx:FairValueOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20221231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember",
      "name": "blrx:FairValueOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails",
     "longName": "9960725 - Disclosure - CASH AND CASH EQUIVALENTS (Narrative) (Details)",
     "shortName": "CASH AND CASH EQUIVALENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember",
      "name": "blrx:InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember",
      "name": "blrx:InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails",
     "longName": "9960726 - Disclosure - CASH AND CASH EQUIVALENTS (Schedule of Cash And Cash Equivalents) (Details)",
     "shortName": "CASH AND CASH EQUIVALENTS (Schedule of Cash And Cash Equivalents) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "ifrs-full:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231",
      "name": "ifrs-full:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails",
     "longName": "9960727 - Disclosure - SHORT-TERM BANK DEPOSITS (Narrative) (Details)",
     "shortName": "SHORT-TERM BANK DEPOSITS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember",
      "name": "blrx:InterestRateOnShortTermDeposits",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfDepositsFromBanksExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember",
      "name": "blrx:InterestRateOnShortTermDeposits",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfDepositsFromBanksExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails",
     "longName": "9960728 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Composition of Property and Equipment and Related Accumulated Depreciation) (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Schedule of Composition of Property and Equipment and Related Accumulated Depreciation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails",
     "longName": "9960729 - Disclosure - INTANGIBLE ASSETS (Narrative) (Details)",
     "shortName": "INTANGIBLE ASSETS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "blrx:PercentageOfIncreasingWeightedAverageCostOfCapital",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231",
      "name": "blrx:PercentageOfIncreasingWeightedAverageCostOfCapital",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails",
     "longName": "9960730 - Disclosure - INTANGIBLE ASSETS (Schedule of Intangible Assets) (Details)",
     "shortName": "INTANGIBLE ASSETS (Schedule of Intangible Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://biolinerx.com/role/LeasesNarrativeDetails",
     "longName": "9960731 - Disclosure - LEASES (Narrative) (Details)",
     "shortName": "LEASES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:LeasePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:LeasePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
     "longName": "9960732 - Disclosure - LEASES (Schedule of Right-of-use assets) (Details)",
     "shortName": "LEASES (Schedule of Right-of-use assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails",
     "longName": "9960733 - Disclosure - LEASES (Schedule of Lease Liabilities) (Details)",
     "shortName": "LEASES (Schedule of Lease Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241231",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails",
     "longName": "9960734 - Disclosure - LEASES (Schedule of Minimum Future Rental Payments) (Details)",
     "shortName": "LEASES (Schedule of Minimum Future Rental Payments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231",
      "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://biolinerx.com/role/Long-termLoansNarrativeDetails",
     "longName": "9960735 - Disclosure - LONG-TERM LOAN (Narrative) (Details)",
     "shortName": "LONG-TERM LOAN (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_20220901to20220930_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember",
      "name": "blrx:AmountOfLoanAgreement",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220901to20220930_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember",
      "name": "blrx:AmountOfLoanAgreement",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://biolinerx.com/role/EquityNarrativeDetails",
     "longName": "9960736 - Disclosure - EQUITY (Narrative) (Details)",
     "shortName": "EQUITY (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails",
     "longName": "9960737 - Disclosure - EQUITY (Schedule of Share Capital) (Details)",
     "shortName": "EQUITY (Schedule of Share Capital) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231",
      "name": "blrx:AuthorizedShareCapitalValue",
      "unitRef": "ILS",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails",
     "longName": "9960738 - Disclosure - EQUITY (Schedule of Amounts Outstanding Under Employee Share Incentive Plan) (Details)",
     "shortName": "EQUITY (Schedule of Amounts Outstanding Under Employee Share Incentive Plan) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_20241231",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20221231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails",
     "longName": "9960739 - Disclosure - EQUITY (Schedule of Options Outstanding by Exercise Price Range) (Details)",
     "shortName": "EQUITY (Schedule of Options Outstanding by Exercise Price Range) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails",
     "longName": "9960740 - Disclosure - EQUITY (Schedule of Assumptions Used to Value Options) (Details)",
     "shortName": "EQUITY (Schedule of Assumptions Used to Value Options) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails",
     "longName": "9960741 - Disclosure - TAXES ON INCOME (Narrative) (Details)",
     "shortName": "TAXES ON INCOME (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:TaxLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails",
     "longName": "9960742 - Disclosure - TAXES ON INCOME (Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income) (Details)",
     "shortName": "TAXES ON INCOME (Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://biolinerx.com/role/LOSSPERSHARENarrativeDetails",
     "longName": "9960743 - Disclosure - LOSS PER SHARE (Narrative) (Details)",
     "shortName": "LOSS PER SHARE (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "blrx:PreFundedWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231",
      "name": "blrx:PreFundedWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails",
     "longName": "9960744 - Disclosure - LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details)",
     "shortName": "LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails",
     "longName": "9960745 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:RoyaltiesReceivedPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:RoyaltiesReceivedPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails",
     "longName": "9960746 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA (Narrative) (Details)",
     "shortName": "LICENSE AND SECURITIES PURCHASE AGREEMENTS - HST/GLORIA (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_20241101to20241130",
      "name": "ifrs-full:ConsiderationPaidReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "blrx:DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231001to20231031_blrxAgreementTypeAxis_blrxPurchaseAgreementMember",
      "name": "ifrs-full:ConsiderationPaidReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "blrx:LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
     "longName": "9960747 - Disclosure - LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE (Narrative) (Details)",
     "shortName": "LICENSE AND SECURITIES PURCHASE AGREEMENTS - AYRMID/HIGHBRIDGE (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_20241101to20241130",
      "name": "ifrs-full:ConsiderationPaidReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "blrx:DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember",
      "name": "blrx:UpfrontPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "blrx:DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails",
     "longName": "9960748 - Disclosure - AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1 (Narrative) (Details)",
     "shortName": "AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1 (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember",
      "name": "blrx:PercentageOfIssuedShareCapitalReceived",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "blrx:AgreementWithHemispherianForDevelopmentOfGlix1Explanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember",
      "name": "blrx:PercentageOfIssuedShareCapitalReceived",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "blrx:AgreementWithHemispherianForDevelopmentOfGlix1Explanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails",
     "longName": "9960749 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Transactions With Related Parties) (Details)",
     "shortName": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Transactions With Related Parties) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember",
      "name": "ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember",
      "name": "ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails",
     "longName": "9960750 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Key Management Compensation) (Details)",
     "shortName": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Key Management Compensation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://biolinerx.com/role/SEGMENTREPORTINGNarrativeDetails",
     "longName": "9960751 - Disclosure - SEGMENT REPORTING (Narrative) (Details)",
     "shortName": "SEGMENT REPORTING (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R78": {
     "role": "http://biolinerx.com/role/SEGMENTREPORTINGDetails",
     "longName": "9960752 - Disclosure - SEGMENT REPORTING (Details)",
     "shortName": "SEGMENT REPORTING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:Revenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember",
      "name": "ifrs-full:Revenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails",
     "longName": "9960753 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Receivables) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Receivables) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "blrx:InstitutionsCurrentReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231",
      "name": "blrx:InstitutionsCurrentReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails",
     "longName": "9960754 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Payable and Accruals) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Payable and Accruals) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "blrx:TradeAndOtherPayablesToForeignTradeSuppliers",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20251231",
      "name": "blrx:TradeAndOtherPayablesToForeignTradeSuppliers",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails",
     "longName": "9960755 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Cost of revenues) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Cost of revenues) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:LicenseFeesAndRoyaltiesPayableToLicensor",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:LicenseFeesAndRoyaltiesPayableToLicensor",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails",
     "longName": "9960756 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Research and Development Expenses) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Research and Development Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:ServicesExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:ServicesExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails",
     "longName": "9960757 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Sales and Marketing Expenses) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Sales and Marketing Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:SalesAndMarketingExpensesRelatedToSales",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "blrx:SalesAndMarketingExpensesRelatedToSales",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails",
     "longName": "9960758 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of General and Administrative Expense) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of General and Administrative Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails",
     "longName": "9960759 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Non-Operating Income (Expenses), Net) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Non-Operating Income (Expenses), Net) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails",
     "longName": "9960760 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Income) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Income) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:RevenueFromInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:RevenueFromInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails",
     "longName": "9960761 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Expenses) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:InterestExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20251231",
      "name": "ifrs-full:InterestExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "blrx:DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory",
       "div",
       "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2634707.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ifrs-full_AccountingProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccountingProfit",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss before taxes",
        "verboseLabel": "Loss before taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r195",
      "r196"
     ]
    },
    "blrx_AccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AccountsPayableAbstract",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts payable.",
        "label": "Accounts Payable Abstract",
        "terseLabel": "Accounts payable:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "presentation": [
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and impairment [Member]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r11",
      "r42",
      "r52",
      "r55",
      "r198",
      "r214",
      "r223",
      "r226"
     ]
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation [member]",
        "verboseLabel": "Accumulated depreciation and amortisation [member]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r461",
      "r465",
      "r467",
      "r468"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss"
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails",
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, intangible assets other than goodwill",
        "terseLabel": "Intangible asset amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r215"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "blrx_AdditionalCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AdditionalCommitmentFee",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional commitment fee.",
        "label": "Additional commitment fee"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AdditionalExtendLeasePeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AdditionalExtendLeasePeriod",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional extend the lease period.",
        "label": "Additional Extend Lease Period",
        "terseLabel": "Additional extension period"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AdditionalImpairmentChargesOfDecreasingAnnualGrowthRate",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents additional impairment charges of decreasing annual growth rate.",
        "label": "Additional Impairment Charges Of Decreasing Annual Growth Rate",
        "verboseLabel": "Additional impairment charges of decreasing annual growth rate"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AdditionalImpairmentChargesOfWeightedAverageCostOfCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AdditionalImpairmentChargesOfWeightedAverageCostOfCapital",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represnts additional impairment charges of weighted average cost of capital.",
        "label": "Additional Impairment Charges Of Weighted Average Cost Of Capital",
        "verboseLabel": "Additional impairment charges of weighted average cost of capital"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AdditionsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AdditionsLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition in lease liabilities.",
        "label": "Additions Lease Liabilities",
        "verboseLabel": "Additions during year"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "verboseLabel": "Additions during year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r215"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions during year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r199"
     ]
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "verboseLabel": "Additions during year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r171"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "commentaryGuidance": "The reported value should be tagged twice, with both this element and the element \u2018Basic earnings (loss) per share\u2019 when: (a) basic and diluted earnings per share are equal; and (b) an entity presents one line item to accomplish the dual presentation requirement of paragraph 67 of IAS 33.",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF DILUTED LOSS PER ORDINARY SHARE",
        "totalLabel": "Total diluted earnings (loss) per share",
        "verboseLabel": "Diluted loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "Decrease (increase) in inventory"
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in prepaid expense other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "negatedLabel": "Decrease (increase) in prepaid expenses and other receivables",
        "label": "Adjustments For Decrease Increase In Prepaid Expenses And Other Operating Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade and other receivables",
        "terseLabel": "Decrease (increase) in trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "ifrs-full_AdjustmentsForFairValueGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForFairValueGainsLosses",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments of warrants"
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of property and equipment",
        "label": "Adjustments for gain (loss) on disposals, property, plant and equipment",
        "verboseLabel": "Loss on disposal of property and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 80.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for impairment loss recognised in profit or loss, goodwill",
        "terseLabel": "Intangible assets impairment"
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in contract liabilities",
        "terseLabel": "Increase (decrease) in contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in accounts payable and accruals"
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments required to reflect net cash used in operating activities (see appendix below)",
        "totalLabel": "Total adjustments required to reflect net cash used in operating activities",
        "verboseLabel": "Adjustments required to reflect net cash used in operating activities (see appendix below)"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange differences on cash and cash equivalents"
       }
      }
     },
     "auth_ref": [
      "r317",
      "r472"
     ]
    },
    "blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments Required To Reflect Net Cash Used In Operating Activities Abstract",
        "terseLabel": "Adjustments required to reflect net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AdvancePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AdvancePayments",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance payments.",
        "label": "Advance Payments",
        "verboseLabel": "Advance payments"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AgalimmuneLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AgalimmuneLtdMember",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agalimmune Ltd. [Member]",
        "label": "Agalimmune Ltd. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AggregateAmericanDepositaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AggregateAmericanDepositaryShares",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about aggregate American depositary shares.",
        "label": "Aggregate American Depositary Shares",
        "terseLabel": "Aggregate American depositary shares"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate offering price.",
        "label": "Aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r366",
      "r377",
      "r387",
      "r420"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r369",
      "r380",
      "r390",
      "r423"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "blrx_AgreementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AgreementTypeAxis",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about agreement type .",
        "label": "Agreement Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AgreementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AgreementTypeDomain",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AgreementWithCompaniesForDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AgreementWithCompaniesForDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement With Companies For Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AgreementWithHemispherianForDevelopmentOfGlix1Explanatory",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of agreement with hemispherian for development of Glix1.",
        "label": "Agreement With Hemispherian For Development Of Glix1 Explanatory",
        "terseLabel": "AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r381",
      "r391",
      "r415",
      "r424",
      "r428",
      "r436"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AmericanDepositarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AmericanDepositarySharesMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADSs [Member]",
        "label": "American Depositary Shares Member",
        "terseLabel": "ADSs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AmortisationExpense",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortisation expense",
        "label": "Amortisation expense",
        "terseLabel": "Amortization of intangible asset",
        "totalLabel": "Total depreciation and amortisation expense",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "blrx_AmountAllocatedToWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AmountAllocatedToWarrant",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to warrant.",
        "label": "Amount allocated to warrant"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AmountGrantOfEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AmountGrantOfEquityInstruments",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount granted for equity instruments.",
        "label": "Amount Grant Of Equity Instruments",
        "terseLabel": "Amount granted for equity instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and benefits to management, including benefit component of equity instrument grants"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r205"
     ]
    },
    "blrx_AmountOfIntellectualPropertyAndCashBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AmountOfIntellectualPropertyAndCashBalance",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents amount of intellectual property and cash balance.",
        "label": "Amount Of Intellectual Property And Cash Balance",
        "verboseLabel": "Amount of intellectual property and cash balance"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AmountOfLoanAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AmountOfLoanAgreement",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents amount of loan agreement.",
        "label": "Amount Of Loan Agreement",
        "verboseLabel": "Amount of loan agreement"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AnnualLeaseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AnnualLeaseFee",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Lease fee.",
        "label": "Annual Lease fee"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails",
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate tax rate",
        "verboseLabel": "Loss before taxes (Percentage)"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r196"
     ]
    },
    "blrx_AssetTransferAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AssetTransferAgreementMember",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Transfer Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Default Label]",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r157",
      "r160",
      "r252",
      "r253",
      "r279"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "verboseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r373"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r373"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r373"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "blrx_AuthorizedShareCapitalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AuthorizedShareCapitalValue",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of authorized share capital.",
        "label": "Authorized Share Capital Value",
        "verboseLabel": "Authorized share capital"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_AvailableBalanceUnderFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AvailableBalanceUnderFacility",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available balance under the facility",
        "label": "Available balance under the facility"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "blrx_AyrmidLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "AyrmidLicenseAgreementMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Ayrmid License Agreement.",
        "label": "Ayrmid License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_BL8040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "BL8040Member",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "B L-8040 [Member]",
        "label": "B L-8040 [Member]",
        "terseLabel": "BL-8040 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_BankGuaranteeAmountForBenefitOfLessor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "BankGuaranteeAmountForBenefitOfLessor",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank guarantee amount for benefit of Lessor.",
        "label": "Bank guarantee amount for benefit of lessor"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "LOSS PER ORDINARY SHARE \u2013 BASIC ATTRIBUTABLE TO OWNERS OF THE COMPANY",
        "verboseLabel": "Basic and diluted loss per ordinary share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31"
     ]
    },
    "blrx_BeneficiallyOwnInExcess": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "BeneficiallyOwnInExcess",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficially Own In Excess",
        "label": "Beneficially Own In Excess"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_BenefitsToRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "BenefitsToRelatedPartiesAbstract",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benefits to related parties.",
        "label": "Benefits To Related Parties Abstract",
        "terseLabel": "Benefits to related parties:"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_BiokineTherapeuticsLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "BiokineTherapeuticsLtdMember",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biokine Therapeutics Ltd [Member]",
        "label": "Biokine Therapeutics Ltd [Member]",
        "terseLabel": "Biokine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_BostonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "BostonMember",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Boston",
        "label": "Boston [Member]",
        "verboseLabel": "Boston [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails",
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails",
      "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "verboseLabel": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r91",
      "r108",
      "r123",
      "r189",
      "r320",
      "r321",
      "r476"
     ]
    },
    "blrx_BtigLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "BtigLlcMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BTIG, LLC [Member]",
        "label": "BTIG, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_BusinessAnalyticsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "BusinessAnalyticsExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business analytics expense.",
        "label": "Business Analytics Expense",
        "terseLabel": "Business Analytics"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [Axis]",
        "verboseLabel": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r241"
     ]
    },
    "ifrs-full_BusinessCombinationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BusinessCombinationsDomain",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r132",
      "r241"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r350",
      "r373"
     ]
    },
    "blrx_BvfPartnersLpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "BvfPartnersLpMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BVF Partners L.P. [Member]",
        "label": "Bvf Partners Lp Member",
        "terseLabel": "BVF Partners L.P. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CapitalReserve",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the capital reserves."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "ifrs-full_CapitalReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CapitalReserveMember",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital reserve [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing capital reserves."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails",
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis]",
        "verboseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9",
      "r42",
      "r46",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r131",
      "r141",
      "r142",
      "r198",
      "r201",
      "r214",
      "r218",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r243",
      "r249",
      "r250"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails",
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount [member]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r51",
      "r53",
      "r54",
      "r131",
      "r141",
      "r142",
      "r201",
      "r218",
      "r222",
      "r224",
      "r225",
      "r243",
      "r249",
      "r250"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash on hand and in bank"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "blrx_CashAndCashEquivalentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "CashAndCashEquivalentMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents [Member]",
        "label": "Cash And Cash Equivalent [Member]",
        "terseLabel": "Cash and cash equivalents [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 0.0
      },
      "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails",
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements",
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF YEAR",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR",
        "label": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r62",
      "r81",
      "r190",
      "r276"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in short-term deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r64"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS - FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r64"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS - INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r64"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS - OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashTransferred",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash transferred",
        "terseLabel": "Cash consideration"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r239"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r246"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r246"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails",
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [Axis]",
        "verboseLabel": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r207"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails",
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r207"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "ifrs-full_ChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ChangesInEquityAbstract",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHANGES IN"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ChangesInFairValueRecordedAsANonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ChangesInFairValueRecordedAsANonoperatingIncome",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss.",
        "label": "Changes In Fair Value Recorded As A Non-operating Income"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ChangesInFairValueThroughProfitAndLossOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ChangesInFairValueThroughProfitAndLossOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in fair value through profit and loss.",
        "label": "Changes In Fair Value Through Profit And Loss Of Warrants",
        "terseLabel": "Changes in fair value through profit and loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes during the year:"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes In Operating Assets And Liabilities Abstract",
        "terseLabel": "Changes in operating asset and liability items:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in tax rates or tax laws enacted or announced [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for changes in tax rates or tax laws enacted or announced."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r333"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails",
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails",
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r89",
      "r99",
      "r173",
      "r210",
      "r254"
     ]
    },
    "ifrs-full_ClassesOfAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfAssetsDomain",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails",
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails",
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r89",
      "r99",
      "r173",
      "r210",
      "r254"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [Axis]",
        "verboseLabel": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r143",
      "r144",
      "r145",
      "r249",
      "r251"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r143",
      "r144",
      "r145",
      "r249",
      "r251"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails",
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [Axis]",
        "verboseLabel": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r219"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails",
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r219"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [Axis]",
        "verboseLabel": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r202"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r202"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r258",
      "r289"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r258",
      "r289"
     ]
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClosingForeignExchangeRate",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange rate per dollar"
       }
      },
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "blrx_CollaborationAndShareholdersAgreementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "CollaborationAndShareholdersAgreementLineItems",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration And Shareholders Agreement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_CollaborationAndShareholdersAgreementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "CollaborationAndShareholdersAgreementTable",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration And Shareholders Agreement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_CollaborationTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "CollaborationTransactionAxis",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Transaction [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_CollaborationTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "CollaborationTransactionDomain",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Transaction [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_CommitmentsAndContingentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "CommitmentsAndContingentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment and contingent liabilities.",
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommunicationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CommunicationExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab, occupancy and telephone"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss__1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveTerseLabel": "Comprehensive loss for the year",
        "label": "Comprehensive income",
        "terseLabel": "Comprehensive loss for the year",
        "totalLabel": "Total comprehensive income",
        "verboseLabel": "Loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69",
      "r78",
      "r209",
      "r228",
      "r266",
      "r293",
      "r319"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss__1": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to non-controlling interests",
        "totalLabel": "Total comprehensive income, attributable to non-controlling interests",
        "verboseLabel": "To non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r295"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss__1": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to owners of parent",
        "totalLabel": "Total comprehensive income, attributable to owners of parent",
        "verboseLabel": "To owners of the Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r296"
     ]
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers and communications equipment [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer software [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "ifrs-full_ConsiderationPaidReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ConsiderationPaidReceived",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration paid (received)",
        "terseLabel": "Consideration received"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "blrx_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants [Member]",
        "label": "Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ContingentLiability",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of contingent liability.",
        "label": "Contingent Liability",
        "verboseLabel": "Value of contingent liability"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_CostOfProductSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "CostOfProductSales",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sales.",
        "label": "Cost Of Product Sales",
        "verboseLabel": "Cost of product sales"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "COST OF REVENUES",
        "negatedTerseLabel": "Cost of sales",
        "label": "Cost of sales",
        "totalLabel": "Cost of sales",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r301"
     ]
    },
    "blrx_CostRelatedToLicenseRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "CostRelatedToLicenseRevenues",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost related to license revenues.",
        "label": "Cost Related To License Revenues",
        "verboseLabel": "Direct costs related to license revenues"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_CostsIncurrentInOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "CostsIncurrentInOffering",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurrent in offering.",
        "label": "Costs Incurrent In Offering",
        "terseLabel": "Costs incurrent in offering"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CountryOfDomicileMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CountryOfDomicileMember",
     "presentation": [
      "http://biolinerx.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country of domicile [member]",
        "terseLabel": "U.S. [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the country in which the entity is registered and where it has its legal address or registered office."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "verboseLabel": "Document And Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CreditExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CreditExposure",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exposure to loss resulting from credit risk. [Refer: Credit risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r337",
      "r338"
     ]
    },
    "ifrs-full_CreditRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CreditRiskMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r327"
     ]
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": {
       "parentTag": "ifrs-full_OtherCurrentPayables",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r282",
      "r319"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less current maturities",
        "label": "Current maturities of long-term loans",
        "verboseLabel": "Current maturities of long-term loan"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "terseLabel": "Current maturities of lease liabilities",
        "verboseLabel": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r283",
      "r319"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ifrs-full_CurrentProvisionsForEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentProvisionsForEmployeeBenefits",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": {
       "parentTag": "ifrs-full_OtherCurrentPayables",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for vacation and recreation pay"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r284"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r358",
      "r447"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r358",
      "r447"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r360",
      "r449"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r360",
      "r449"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r362",
      "r451"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r360",
      "r449"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r353",
      "r442"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r354",
      "r443"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r354",
      "r443"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r352",
      "r441"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r352",
      "r441"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r352",
      "r441"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r444"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r357",
      "r446"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r357",
      "r446"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r358",
      "r447"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r361",
      "r450"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r448"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r356",
      "r445"
     ]
    },
    "blrx_DelayInPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DelayInPayment",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents delay in payment.",
        "label": "Delay In Payment",
        "verboseLabel": "Delay in payment"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DeletionsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DeletionsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from deletions.",
        "negatedLabel": "Deletions during the year",
        "label": "Deletions during the year",
        "terseLabel": "Deletions during the year"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DeletionsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DeletionsLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deletions in lease liabilities.",
        "negatedLabel": "Deletions during year",
        "label": "Deletions Lease Liabilities",
        "terseLabel": "Deletions during year"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DeletionsToRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DeletionsToRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deletions to right-of-use assets.",
        "label": "Deletions To Right Of Use Assets",
        "terseLabel": "Deletions during year"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DepositaryShareConversionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DepositaryShareConversionDescription",
     "presentation": [
      "http://biolinerx.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the conversion relationship between one depositary share and the number of ordinary shares it represents.",
        "label": "Depositary Share Conversion Description",
        "terseLabel": "Depositary share conversion description"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DepositaryShareToOrdinaryShareRatioChangeDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DepositaryShareToOrdinaryShareRatioChangeDescription",
     "presentation": [
      "http://biolinerx.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the change in the ratio of depositary shares to ordinary shares.",
        "label": "Depositary Share To Ordinary Share Ratio Change Description",
        "terseLabel": "Depositary share ratio change description"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortisation expense",
        "label": "Depreciation and amortisation expense",
        "totalLabel": "Total depreciation and amortisation expense",
        "verboseLabel": "Depreciation and amortization"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r155",
      "r162",
      "r265",
      "r301",
      "r339"
     ]
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "blrx_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for basis of presentation.",
        "label": "Description Of Accounting Policy For Basis Of Presentation [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for changes in accounting policies and disclosures.",
        "label": "Description Of Accounting Policy For Change In Accounting Policy And Disclosures Explanatory",
        "terseLabel": "New International Financial Reporting Standards, amendments to standards and new interpretations"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for Changes in accounting policies.",
        "label": "Description Of Accounting Policy For Change In Accounting Policy Explanatory",
        "terseLabel": "Changes in accounting policies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional and reporting currency"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of non-amortized non-financial assets",
        "verboseLabel": "Impairment of non-financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for measuring inventories [text block]",
        "terseLabel": "Inventory"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r186"
     ]
    },
    "blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for principles of consolidation.",
        "label": "Description Of Accounting Policy For Principles Of Consolidation And Equity Accounting Explanatory",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Revenues"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "blrx_DescriptionOfAccountingPolicyForWarrantExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DescriptionOfAccountingPolicyForWarrantExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for warrants.",
        "label": "Description Of Accounting Policy For Warrant Explanatory",
        "verboseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents and short-term bank deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r63",
      "r191"
     ]
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility (%)",
        "verboseLabel": "Average standard deviation"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options (in years)"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate (%)",
        "verboseLabel": "Risk-free interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives of intangible assets (In years)"
       }
      },
      "en": {
       "role": {
        "documentation": "Description of useful life used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r213"
     ]
    },
    "blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of useful life or lease period of right of use assets.",
        "label": "Description Of Useful Life Or Lease Period Of Right Of Use Assets",
        "terseLabel": "Estimated useful lives or lease period of right of use assets (in Years)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfUsefulLifePropertyPlantAndEquipment",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation rates (in %)"
       }
      },
      "en": {
       "role": {
        "documentation": "Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option vested and exercised"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r114",
      "r229"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "LOSS PER ORDINARY SHARE \u2013 DILUTED ATTRIBUTABLE TO OWNERS OF THE COMPANY"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31"
     ]
    },
    "blrx_DirectPlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DirectPlacementMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct Placement [Member]",
        "label": "Direct Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DirectorsMember",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Director [Member]",
        "label": "Directors [Member]",
        "terseLabel": "Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisallowedDeductionsTaxExemptIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisallowedDeductionsTaxExemptIncomeAbstract",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disallowed deductions tax exempt income.",
        "label": "Disallowed Deductions Tax Exempt Income Abstract",
        "terseLabel": "Disallowed deductions (tax exempt income):"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/CriticalAccountingEstimatesAndJudgments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Accounting Judgements And Estimates Explanatory Abstract",
        "terseLabel": "Disclosure of critical accounting estimates and judgments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory",
     "presentation": [
      "http://biolinerx.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Composition of Lease Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of additional information about leasing activities of a lessee."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r174"
     ]
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Key Management Compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r205"
     ]
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r205"
     ]
    },
    "ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more, and more than, twelve months after reporting date."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "ifrs-full_DisclosureOfBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBorrowingsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LONG-TERM LOANS"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of cash and cash equivalents [text block]",
        "terseLabel": "CASH AND CASH EQUIVALENTS"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES",
        "terseLabel": "MATERIAL ACCOUNTING POLICIES"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://biolinerx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r258",
      "r289"
     ]
    },
    "blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure detailed information about classification of financial assets and liabilities.",
        "label": "Disclosure Of Classification Of Financial Assets And Liabilities Explanatory",
        "terseLabel": "Schedule of Linkage of Monetary Items"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of commitments and contingent liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of commitments and contingent liabilities [text block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "ifrs-full_DisclosureOfDepositsFromBanksExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDepositsFromBanksExplanatory",
     "presentation": [
      "http://biolinerx.com/role/Short-termBankDeposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHORT-TERM BANK DEPOSITS"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of deposits from banks. [Refer: Deposits from banks]"
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about accounts payable and accruals.",
        "label": "Disclosure Of Detailed Information About Accounts Payable And Accruals Explanatory",
        "terseLabel": "Schedule of Accounts Payable and Accruals"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory",
     "presentation": [
      "http://biolinerx.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about basic loss per share.",
        "label": "Disclosure Of Detailed Information About Basic Loss Per Share Explanatory",
        "terseLabel": "Schedule of Basic Loss Per Share",
        "verboseLabel": "LOSS PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about cash and cash equivalents.",
        "label": "Disclosure Of Detailed Information About Cash And Cash Equivalents Explanatory",
        "terseLabel": "Schedule of Cash And Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about concentration of currency risk.",
        "label": "Disclosure Of Detailed Information About Concentration Of Currency Risk Explanatory",
        "terseLabel": "Schedule of Concentration of Currency Risk"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about cost of revenues.",
        "label": "Disclosure Of Detailed Information About Cost Of Revenues Explanatory",
        "verboseLabel": "Schedule of Cost of Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about financial expenses.",
        "label": "Disclosure Of Detailed Information About Financial Expenses Explanatory",
        "verboseLabel": "Schedule of Financial Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about fnancial income.",
        "label": "Disclosure Of Detailed Information About Financial Income Explanatory",
        "verboseLabel": "Schedule of Financial Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Credit Risk"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r143",
      "r148",
      "r244"
     ]
    },
    "blrx_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about general and administrative expenses.",
        "label": "Disclosure Of Detailed Information About General And Administrative Expenses Explanatory",
        "verboseLabel": "Schedule of General and Administrative Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about income and expense.",
        "label": "Disclosure Of Detailed Information About Income And Expenses Explanatory",
        "terseLabel": "Schedule of Income and Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r47",
      "r219"
     ]
    },
    "blrx_DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about non-operating income expenses net.",
        "label": "Disclosure Of Detailed Information About Non-operating Income Expenses Net Explanatory",
        "verboseLabel": "Schedule of Non-Operating Income (Expenses), Net"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about other receivables.",
        "label": "Disclosure Of Detailed Information About Other Receivables Explanatory",
        "terseLabel": "Schedule of Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Composition of Property and Equipment and Related Accumulated Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r202"
     ]
    },
    "blrx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about research and development expenses..",
        "label": "Disclosure Of Detailed Information About Research And Development Expenses Explanatory",
        "verboseLabel": "Schedule of Research and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfDetailedInformationAboutRevenuesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutRevenuesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about revenues.",
        "label": "Disclosure Of Detailed Information About Revenues Explanatory",
        "verboseLabel": "Schedule of Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about sales and marketing expenses.",
        "label": "Disclosure Of Detailed Information About Sales And Marketing Expenses Explanatory",
        "verboseLabel": "Schedule of Sales and Marketing Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about useful lives for property, plant and equipment.",
        "label": "Disclosure Of Detailed Information About Useful Life Of Property Plant And Equipment Explanatory",
        "terseLabel": "Schedule of Depreciation Rates"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about weighted average tax rate applicable to income.",
        "label": "Disclosure Of Detailed Information About Weighted Average Tax Rate Applicable To Income Explanatory",
        "terseLabel": "Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://biolinerx.com/role/LOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Schedule of Basic Loss Per Share",
        "verboseLabel": "LOSS PER SHARE"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementExplanatory",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Measurement of Warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for fair value measurement."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails",
      "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails",
      "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r143",
      "r148",
      "r244"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesLineItems",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesTable",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r244"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/GeneralInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL INFORMATION"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r271"
     ]
    },
    "blrx_DisclosureOfGeneralInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfGeneralInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of general information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SEGMENTREPORTINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of geographical areas [text block]",
        "terseLabel": "Schedule of revenues from external parties by geographic region"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of geographical information."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasLineItems",
     "presentation": [
      "http://biolinerx.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of geographical areas [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasTable",
     "presentation": [
      "http://biolinerx.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of geographical areas [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to geographical areas."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "TAXES ON INCOME"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "blrx_DisclosureOfIncomeTaxesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfIncomeTaxesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Income Taxes [Abstract]",
        "terseLabel": "Taxes On Income Schedule Of Reconciliation Of Weighted Average Tax Rate Applicable To Income",
        "verboseLabel": "Taxes On Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://biolinerx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions Used to Value Options"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails",
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails",
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r219"
     ]
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105"
     ]
    },
    "blrx_DisclosureOfLeasesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfLeasesLineItems",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.",
        "label": "Disclosure Of Leases [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfLeasesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfLeasesTable",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to leases.",
        "label": "Disclosure Of Leases [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of License And Securities Purchase Agreements Ayrmid And Highbridge [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of license and securities purchase agreements Ayrmid And Highbridge explanatory.",
        "label": "Disclosure Of License And Securities Purchase Agreements Ayrmid And Highbridge Explanatory",
        "terseLabel": "LICENSE AND SECURITIES PURCHASE AGREEMENTS \u2013 AYRMID/HIGHBRIDGE"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Minimum Future Rental Payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r178"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r178"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SUBSEQUENTEVENTREGISTEREDDIRECTOFFERING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [text block]",
        "terseLabel": "SUBSEQUENT EVENT (if relevant)"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]"
       }
      }
     },
     "auth_ref": [
      "r0",
      "r193"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r193"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Amounts Outstanding Under Employee Share Incentive Plan"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r237"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Outstanding by Exercise Price Range"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SEGMENTREPORTING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [text block]",
        "terseLabel": "SEGMENT REPORTING"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r202"
     ]
    },
    "blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of quantitative information about lease liabilities.",
        "label": "Disclosure Of Quantitative Information About Lease Liabilities Explanatory",
        "terseLabel": "Schedule of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Quantitative Information About Lease Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Quantitative Information About Lease Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r99",
      "r173"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r173"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Financial Liabilities With Cash Flows Included in Financing Activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r316"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r316"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of risk management strategy related to hedge accounting [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of risk management strategy related to hedge accounting [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the risk management strategy in relation to hedge accounting."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r247",
      "r262"
     ]
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://biolinerx.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "terseLabel": "EQUITY"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r259",
      "r290"
     ]
    },
    "blrx_DisclosureOfShortTermBankDepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfShortTermBankDepositsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Short Term Bank Deposits Abstract",
        "terseLabel": "Disclosure of short-term bank deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfSupplementaryFinancialStatementInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of supplimentry financial statements information.",
        "label": "Disclosure of supplementary financial statement information [Abstract]",
        "terseLabel": "Supplementary Financial Statement Information Schedule Of Other Receivables",
        "verboseLabel": "Supplementary Financial Statement Information"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfSupplementaryFinancialStatementInformationExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplementary financial statement information.",
        "label": "Disclosure Of Supplementary Financial Statement Information Explanatory",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r238"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Transactions With Related Parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r206"
     ]
    },
    "blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information of useful life of right of use assets.",
        "label": "Disclosure Of Useful Life Of Right Of Use Assets Explanatory",
        "terseLabel": "Schedule of Useful Life of Right of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisposalsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposal during the year",
        "label": "Disposals, intangible assets other than goodwill",
        "terseLabel": "Disposal during the year"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r216"
     ]
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deletions during year",
        "label": "Disposals, property, plant and equipment",
        "terseLabel": "Deletions during year"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r200"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r373"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r373",
      "r416"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "blrx_DollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "DollarMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dollar [Member]",
        "label": "Dollar [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59"
     ]
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee benefit expense"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r265",
      "r301",
      "r339"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Directors [Member]",
        "label": "Employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's Reporting Status Current",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity a Voluntary Filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity a Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "BALANCE",
        "periodStartLabel": "BALANCE",
        "label": "Equity",
        "totalLabel": "Total equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68",
      "r86",
      "r87",
      "r88",
      "r208",
      "r227",
      "r252",
      "r253",
      "r261",
      "r279",
      "r285"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total liabilities and equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent",
        "totalLabel": "Total equity attributable to owners of the Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "ifrs-full_EquityInterestsOfAcquirer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityInterestsOfAcquirer",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity interests of acquirer",
        "terseLabel": "Equity consideration"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r240"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r366",
      "r377",
      "r387",
      "r420"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r363",
      "r374",
      "r384",
      "r417"
     ]
    },
    "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EstimatedFinancialEffectOfContingentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r212"
     ]
    },
    "blrx_EuroLinkedTradePayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "EuroLinkedTradePayablesMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro-linked trade payables [Member]",
        "label": "Euro Linked Trade Payables [Member]",
        "terseLabel": "Euro-linked trade payables [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_EuroPerDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "EuroPerDollarMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro Per Dollar [Member]",
        "label": "Euro Per Dollar Member",
        "terseLabel": "Euro per $1"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ExchangeDifferencesDuringYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ExchangeDifferencesDuringYear",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excahnge difference in lease liabilities.",
        "negatedTerseLabel": "Exchange differences during year",
        "label": "Exchange differences during year",
        "terseLabel": "Exchange differences during year"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ExchangeDifferencesOnLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ExchangeDifferencesOnLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for exchange differences on lease liability to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Exchange differences on lease liability",
        "terseLabel": "Exchange differences on lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "blrx_ExercisableTermOfWarrant": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ExercisableTermOfWarrant",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercisable term of warrant.",
        "label": "Exercisable term of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ExercisePriceOfShareIssued": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ExercisePriceOfShareIssued",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price of shares issued.",
        "label": "Exercise Price Of Share Issued",
        "terseLabel": "Exercise price of shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ExercisePriceOfWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ExercisePriceOfWarrants",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price of warrants.",
        "label": "Exercise price of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over 40.00 [Member]",
        "label": "Exercise Price Range Four Member",
        "terseLabel": "2.01-3.4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ExercisePriceRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ExercisePriceRangeMember",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up to 10.00 [Member]",
        "label": "Exercise Price Range Member",
        "terseLabel": "Up to 0.49 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "10.01-20.00 [Member]",
        "label": "Exercise Price Range One Member",
        "terseLabel": "0.5- 0.99 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "20.01-30.00 [Member]",
        "label": "Exercise Price Range Two Member",
        "terseLabel": "1.00-2.00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield (%)"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "blrx_FairValueOfOrdinaryWarrantsAdjustedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "FairValueOfOrdinaryWarrantsAdjustedAmount",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount fair value of ordinary warrants adjusted.",
        "label": "Fair Value Of Ordinary Warrants Adjusted Amount",
        "terseLabel": "Fair value of the ordinary warrants was adjusted amount"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_FairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "FairValueOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance as of January 1.",
        "periodEndLabel": "Balance as of December 31",
        "periodStartLabel": "Balance as of January 1",
        "label": "Fair Value Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FeeAndCommissionExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank commissions"
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 30.0
      },
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "FINANCIAL EXPENSES",
        "label": "Finance costs",
        "totalLabel": "Financial expenses"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 20.0
      },
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL INCOME",
        "totalLabel": "Financial income"
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently, category [member]",
        "terseLabel": "Initial recognition [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss designated as such upon initial recognition or subsequently category. [Refer: Financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently]"
       }
      }
     },
     "auth_ref": [
      "r149",
      "r245"
     ]
    },
    "blrx_FirstThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "FirstThreeYearsMember",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First three years.",
        "label": "First Three Years [Member]",
        "terseLabel": "First three years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_FirstTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "FirstTrancheMember",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for first tranche.",
        "label": "First Tranche [Member]",
        "verboseLabel": "First tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "FivePercentDecreaseEffectOnNetIncomeLossAndEquity",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effect of a five percent decrease in the given metric on net income (loss) and equity.",
        "label": "Five Percent Decrease Effect On Net Income Loss And Equity",
        "terseLabel": "5% decrease effect on net income (loss) and equity"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "FivePercentIncreaseEffectOnNetIncomeLossAndEquity",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effect of a five percent increase in the given metric on net income (loss) and equity.",
        "label": "Five Percent Increase Effect On Net Income Loss And Equity",
        "terseLabel": "5% increase effect on net income (loss) and equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ForeignCountriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ForeignCountriesMember",
     "presentation": [
      "http://biolinerx.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign countries [member]",
        "terseLabel": "China [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for countries outside the entity's country of domicile. [Refer: Country of domicile [member]]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r381",
      "r391",
      "r424"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r381",
      "r391",
      "r424"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r381",
      "r391",
      "r424"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r381",
      "r391",
      "r424"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r381",
      "r391",
      "r424"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "blrx_GainOnRealizationOfLongtermInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "GainOnRealizationOfLongtermInvestment",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails": {
       "parentTag": "blrx_ProfitLossFromNonOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on realization of long-term investment.",
        "negatedLabel": "Gain on realization of long-term investment",
        "label": "Gain On Realization Of Longterm Investment",
        "terseLabel": "Gain from realization of long-term investment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://biolinerx.com/role/SEGMENTREPORTINGDetails",
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r306",
      "r322",
      "r324",
      "r332"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://biolinerx.com/role/SEGMENTREPORTINGDetails",
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r306",
      "r322",
      "r324",
      "r332"
     ]
    },
    "blrx_Glix1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "Glix1Member",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Glix1 [Member]",
        "terseLabel": "GLIX1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_GloriaLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "GloriaLicenseAgreementMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information related to Gloria License Agreement.",
        "label": "Gloria License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_GloriaPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "GloriaPurchaseAgreementMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member is stand for Gloria Purchase Agreement.",
        "label": "Gloria Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost [Member]",
        "verboseLabel": "Gross carrying amount [member]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42",
      "r52",
      "r55",
      "r131",
      "r142",
      "r144",
      "r198",
      "r214",
      "r223",
      "r226",
      "r250",
      "r251",
      "r328"
     ]
    },
    "blrx_GrossProceedsFromOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "GrossProceedsFromOffering",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gross proceeds from offering.",
        "label": "Gross Proceeds From Offering",
        "terseLabel": "Gross proceeds from offering"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross profit",
        "totalLabel": "GROSS PROFIT"
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "blrx_HCWainwrightAndCoLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "HCWainwrightAndCoLlcMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "H.C. Wainwright &amp; Co., LLC [Member]",
        "label": "H C Wainwright And Co Llc [Member]",
        "terseLabel": "H.C. Wainwright &amp; Co., LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_HemispherianAsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "HemispherianAsMember",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hemispherian As [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_HighbridgeCapitalManagementLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "HighbridgeCapitalManagementLlcMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Highbridge Capital Management LLC [Member]",
        "label": "Highbridge Capital Management Llc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_HighbridgeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "HighbridgeMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Highbridge [Member]",
        "label": "Highbridge [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "IL",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails",
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISRAEL",
        "verboseLabel": "Israel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r373"
     ]
    },
    "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Identifiable intangible assets recognised as of acquisition date",
        "verboseLabel": "Intangible assets acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r334"
     ]
    },
    "blrx_IfrsStatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IfrsStatementLineItems",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ifrs Statement [LineItems]",
        "label": "Ifrs Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_IfrsStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IfrsStatementTable",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ifrs Statement [Table]",
        "label": "Ifrs Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ImpairmentLossOnIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ImpairmentLossOnIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "commentaryGuidance": "This element should be used to tag non-restated comparative information only.",
        "documentation": "Represent the amount of impairment loss on intangible assets.",
        "negatedLabel": "IMPAIRMENT OF INTANGIBLE ASSETS",
        "label": "Impairment Loss On Intangible Assets",
        "verboseLabel": "IMPAIRMENT OF INTANGIBLE ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossGoodwill",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, goodwill",
        "terseLabel": "Impairment loss"
       }
      }
     },
     "auth_ref": [
      "r130",
      "r242"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment during year",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill",
        "terseLabel": "Impairment during year"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r217"
     ]
    },
    "blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IncomeAndExpensesNotInvolvingCashFlowsAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income And Expenses Not Involving Cash Flows Abstract",
        "terseLabel": "Income and expenses not involving cash flows:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "totalLabel": "Taxes on income for the reported year"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r27",
      "r85",
      "r156",
      "r194",
      "r195",
      "r196",
      "r299"
     ]
    },
    "ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseDueToApplicationOfIFRS15Member",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IFRS 15 [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for IFRS 15 Revenue with Contracts with Customers."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents",
        "totalLabel": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r62",
      "r190"
     ]
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInFairValueMeasurementLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails": {
       "parentTag": "blrx_ProfitLossFromNonOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in fair value of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the fair value measurement of liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from amounts recognized through profit and loss.",
        "label": "Increase Decrease Through Amounts Recognized Through Profit And Loss Arising From Financing Activities",
        "terseLabel": "Amounts recognized through profit and loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Employee stock options exercised",
        "label": "Increase (decrease) through exercise of options, equity",
        "terseLabel": "Employee stock options exercised"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "blrx_IncreaseDecreaseThroughExerciseOfOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IncreaseDecreaseThroughExerciseOfOptionsShares",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options, shares.",
        "label": "Increase (Decrease) Through Exercise Of Options, Shares",
        "terseLabel": "Employee stock options exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the increase (decrease) in equity resulting from the exercise of pre-funded warrants.",
        "label": "Increase (Decrease) Through Exercise Of Pre-funded Warrants Equity",
        "verboseLabel": "Pre-funded warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the increase (decrease) in equity resulting from the exercise of pre-funded warrants, shares.",
        "label": "Increase (Decrease) Through Exercise Of Pre-funded Warrants Shares",
        "terseLabel": "Pre-funded warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "verboseLabel": "Warrants exercised"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "blrx_IncreaseDecreaseThroughExerciseOfWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsShares",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants, shares.",
        "label": "Increase (Decrease) Through Exercise Of Warrants, Shares",
        "terseLabel": "Warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IncreaseDecreaseThroughForfeitedAndExpiredOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock options forfeited and expired.",
        "label": "Increase Decrease Through Forfeited And Expired Of Options",
        "terseLabel": "Employee stock options expired"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "verboseLabel": "Share-based compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created.",
        "label": "Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_IncrementalInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IncrementalInvestment",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of incremental investment.",
        "label": "Incremental Investment",
        "terseLabel": "Incremental investment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r381",
      "r391",
      "r415",
      "r424",
      "r428",
      "r436"
     ]
    },
    "blrx_InitialRoyaltyTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "InitialRoyaltyTerm",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about initial royalty term.",
        "label": "Initial Royalty Term",
        "terseLabel": "Initial royalty term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InitiallyAppliedIFRSsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InitiallyAppliedIFRSsAxis",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initially applied IFRSs [axis]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r192"
     ]
    },
    "ifrs-full_InitiallyAppliedIFRSsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InitiallyAppliedIFRSsDomain",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initially applied IFRSs [domain]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r192"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r351",
      "r440"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r351",
      "r440"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r351",
      "r440"
     ]
    },
    "blrx_InstitutionsCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "InstitutionsCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Institutions other receivables.",
        "label": "Institutions Current Receivables",
        "terseLabel": "Government institutions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails",
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "label": "Intangible assets other than goodwill",
        "terseLabel": "Intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r218",
      "r274"
     ]
    },
    "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsWithIndefiniteUsefulLifeAxis",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets with indefinite useful life [Axis]",
        "verboseLabel": "Intangible assets with indefinite useful life [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r220"
     ]
    },
    "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsWithIndefiniteUsefulLifeDomain",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets with indefinite useful life [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets with an indefinite useful life. It also represents the standard value for the 'Intangible assets with indefinite useful life' axis if no other member is used. [Refer: Intangible assets with indefinite useful life]"
       }
      }
     },
     "auth_ref": [
      "r48",
      "r220"
     ]
    },
    "blrx_InterestAndExchangeDifferencesOnRestrictedDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "InterestAndExchangeDifferencesOnRestrictedDeposits",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and exchange differences on restricted deposits.",
        "label": "Interest And Exchange Differences On Restricted Deposits",
        "terseLabel": "Warrant issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_InterestAndExchangeDifferencesOnShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "InterestAndExchangeDifferencesOnShortTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and exchange differences on short-term deposits.",
        "label": "Interest And Exchange Differences On Short Term Deposits",
        "terseLabel": "Interest and exchange differences on short-term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_InterestAndLinkageDifferencesOnBankLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "InterestAndLinkageDifferencesOnBankLoan",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and linkage differences on bank loan.",
        "label": "Interest And Linkage Differences On Bank Loan",
        "terseLabel": "Interest accrued",
        "verboseLabel": "Interest on loan"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "terseLabel": "Interest expense",
        "verboseLabel": "Interest expense, net"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r154",
      "r162"
     ]
    },
    "blrx_InterestExpenseLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "InterestExpenseLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense on lease liabilities.",
        "label": "Interest Expense Lease Liabilities",
        "terseLabel": "Interest expense during year"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense on borrowings",
        "terseLabel": "Interest expense"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ifrs-full_InterestPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestPayable",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": {
       "parentTag": "ifrs-full_OtherCurrentPayables",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payable",
        "terseLabel": "Interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest recognised as a liability."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "blrx_InterestRateOnLongTermBankLoan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "InterestRateOnLongTermBankLoan",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate on long term bank loan.",
        "label": "Interest rate on long term bank loan"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_InterestRateOnShortTermDeposits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "InterestRateOnShortTermDeposits",
     "presentation": [
      "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate on short-term deposits.",
        "label": "Interest Rate On Short Term Deposits",
        "verboseLabel": "Interest rate on short-term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents",
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate on short-term deposits.",
        "label": "Interest Rate On Short Term Deposits Includes Cash And Cash Equivalents",
        "terseLabel": "Interest rate on short-term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current inventories",
        "terseLabel": "Inventory",
        "totalLabel": "Total Inventory"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r187",
      "r275",
      "r342"
     ]
    },
    "ifrs-full_InvestmentProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InvestmentProperty",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment property",
        "terseLabel": "Investment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property (land or a building - or part of a building - or both) held (by the owner or by the lessee as a right-of-use asset) to earn rentals or for capital appreciation or both, rather than for: (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r222",
      "r224",
      "r273"
     ]
    },
    "blrx_InvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "InvestorsMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors [Member]",
        "label": "Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_IssuanceOfShareCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IssuanceOfShareCapital",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents the issuance of share capital, net.",
        "label": "Issuance Of Share Capital",
        "verboseLabel": "Issuance of share capital, net"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_IssuancesOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IssuancesOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuances.",
        "label": "Issuances Of Warrants",
        "terseLabel": "Issuances"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of share capital, net",
        "verboseLabel": "Issuance of share capital, pre-funded warrants and warrants, net"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "blrx_IssuedAndPaidUpShareCapitalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "IssuedAndPaidUpShareCapitalValue",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issued and paid up share capital.",
        "label": "Issued And Paid Up Share Capital Value",
        "verboseLabel": "Issued and paid-up share capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r345"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "blrx_January2025OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "January2025OfferingMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2025 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation cost",
        "totalLabel": "Benefits to key executive personnel"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r204"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationOtherLongtermBenefits",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term benefits"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-employment benefits"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries and other short-term employee benefits"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "blrx_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LandAndBuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LandAndBuildingsMember",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails",
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails",
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property [member]",
        "terseLabel": "Property [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanFiveYearsAndNotLaterThanTenYearsMember",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027-2030 [Member]",
        "terseLabel": "2029-2030 [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years and not later than ten years."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r331",
      "r480"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 [Member]",
        "terseLabel": "2027 [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r113",
      "r329",
      "r331",
      "r480"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026 [Member]",
        "terseLabel": "2029 [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than four years."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r113",
      "r329",
      "r331",
      "r480"
     ]
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 [Member]",
        "terseLabel": "2028 [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than three years."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r113",
      "r329",
      "r331",
      "r480"
     ]
    },
    "blrx_LawsuitClaimAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LawsuitClaimAmount",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "lawsuit claim amount",
        "label": "Lawsuit Claim Amount",
        "verboseLabel": "Lawsuit claim amount"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_LeaseAgreementMonthlyFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LeaseAgreementMonthlyFee",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease agreement monthly fee.",
        "label": "Lease agreement monthly fee"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "label": "Lease liabilities [Default Label]",
        "totalLabel": "Total lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "blrx_LeasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LeasePeriod",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Period.",
        "label": "Lease Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3 of fair value hierarchy [member]",
        "verboseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r87",
      "r211",
      "r253"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r87",
      "r253"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyDomain",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r87",
      "r253"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r157",
      "r161",
      "r252",
      "r253",
      "r279"
     ]
    },
    "ifrs-full_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance as of December 31",
        "periodStartLabel": "Balance as of January 1",
        "label": "Liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r316"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r316"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesDomain",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r316"
     ]
    },
    "ifrs-full_LicenceFeeIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LicenceFeeIncome",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licence fee income",
        "verboseLabel": "License revenues"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "blrx_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for license agreement.",
        "label": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_LicenseAndSecuritiesPurchaseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LicenseAndSecuritiesPurchaseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License And Securities Purchase Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of license and securities purchase agreements.",
        "label": "License And Securities Purchase Agreements Explanatory [Text Block]",
        "terseLabel": "LICENSE AND SECURITIES PURCHASE AGREEMENTS \u2013 HST/GLORIA"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_LicenseAndSecuritiesPurchaseAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LicenseAndSecuritiesPurchaseAgreementsLineItems",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License And Securities Purchase Agreements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_LicenseAndSecuritiesPurchaseAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LicenseAndSecuritiesPurchaseAgreementsTable",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License And Securities Purchase Agreements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_LicenseFeesAndRoyaltiesPayableToLicensor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LicenseFeesAndRoyaltiesPayableToLicensor",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONScheduleOfCostOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License fees and royalties payable to licensor",
        "label": "License Fees And Royalties Payable To Licensor",
        "verboseLabel": "License fees and royalties payable to licensor"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_LoanAgreementWithKreosCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LoanAgreementWithKreosCapitalMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement With Kreos Capital [Member]",
        "label": "Loan Agreement With BlackRock EMEA Venture and Growth Lending [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_LoanTakenForPaymentOfAgreementValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LoanTakenForPaymentOfAgreementValue",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of loan taken for payment of agreement value.",
        "label": "Loan Taken For Payment Of Agreement Value",
        "verboseLabel": "Loan taken from Kreos Capital for the payment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://biolinerx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LongtermBorrowingsMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term loans [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r318"
     ]
    },
    "blrx_LossOnAbandonmentOfRightofuseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "LossOnAbandonmentOfRightofuseAsset",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 10.0
      },
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of loss on abandonment of rightofuse asset.",
        "label": "Loss On Abandonment Of Rightofuse Asset",
        "terseLabel": "Loss on abandonment of right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_MarketAccessExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "MarketAccessExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market access expenses.",
        "label": "Market Access Expense",
        "terseLabel": "Market Access"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_MarketSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "MarketSharePrice",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market price of ordinary shares.",
        "label": "Market Share Price",
        "terseLabel": "Market price of ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_MarketingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "MarketingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing Expenses.",
        "label": "Marketing Expenses",
        "terseLabel": "Marketing"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_MaturitiesOfShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "MaturitiesOfShortTermDeposits",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturities of short-term deposits.",
        "negatedLabel": "Maturities of short-term deposits",
        "label": "Maturities Of Short Term Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r101",
      "r102",
      "r106",
      "r107",
      "r108",
      "r113",
      "r136",
      "r147",
      "r169",
      "r170",
      "r176",
      "r178",
      "r248",
      "r281",
      "r307",
      "r329"
     ]
    },
    "blrx_MaturityDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "MaturityDate",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity date of warrant.",
        "label": "Maturity Date",
        "terseLabel": "Maturity date of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r101",
      "r102",
      "r106",
      "r107",
      "r108",
      "r113",
      "r136",
      "r169",
      "r170",
      "r176",
      "r178",
      "r248",
      "r281",
      "r307",
      "r329",
      "r330"
     ]
    },
    "blrx_MaximumFutureMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "MaximumFutureMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the maximum future milestone payments.",
        "label": "Maximum Future Milestone Payments",
        "terseLabel": "Maximum future milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "blrx_MedicalAffairs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "MedicalAffairs",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 80.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Affairs.",
        "label": "Medical Affairs"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_MinimumCashBalanceRequirementUnderLoanAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "MinimumCashBalanceRequirementUnderLoanAgreement",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of minimum cash balance requirement under the Loan Agreement.",
        "label": "Minimum Cash Balance Requirement Under Loan Agreement",
        "terseLabel": "Minimum cash balance requirement under the Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "blrx_MonthlyAdvisoryFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "MonthlyAdvisoryFee",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of monthly advisory fee.",
        "label": "Monthly Advisory Fee",
        "terseLabel": "Monthly advisory fee"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MotorVehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MotorVehiclesMember",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails",
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails",
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Motor vehicles [member]",
        "terseLabel": "Motor vehicles [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing self-propelled ground vehicles used in the entity's operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "blrx_NetAssetValueOfLinkageMonetaryItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "NetAssetValueOfLinkageMonetaryItems",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net asset value of linkage monetary items.",
        "label": "Net Asset Value Of Linkage Monetary Items",
        "totalLabel": "Net asset value",
        "verboseLabel": "Net asset value"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_NetBookValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "NetBookValueMember",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails",
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails",
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net book value.",
        "label": "Net Book Value [Member]",
        "terseLabel": "Net book value [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetForeignExchangeGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NetForeignExchangeGain",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net foreign exchange gain",
        "terseLabel": "Exchange differences, net"
       }
      }
     },
     "auth_ref": [
      "r463",
      "r482"
     ]
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NetForeignExchangeLoss",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange loss",
        "label": "Net foreign exchange loss",
        "terseLabel": "Exchange differences, net"
       }
      }
     },
     "auth_ref": [
      "r463",
      "r482"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_NisLinkedBalancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "NisLinkedBalancesMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NIS-linked balances [Member]",
        "label": "Nis Linked Balances Member",
        "terseLabel": "Total NIS-linked balances [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_NisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "NisMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NIS [Member]",
        "label": "NIS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_NisPerDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "NisPerDollarMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nis Per Dollar [Member]",
        "label": "Nis Per Dollar Member",
        "terseLabel": "NIS per $1"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r381",
      "r391",
      "r415",
      "r424"
     ]
    },
    "blrx_NonOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "NonOperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-operating expense incurred.",
        "label": "Non operating expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r193"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r193"
     ]
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r70",
      "r72",
      "r277"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interests [member]",
        "verboseLabel": "Non-controlling interest [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r75",
      "r282",
      "r319"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "verboseLabel": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r283",
      "r319"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT LIABILITIES",
        "verboseLabel": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentPortionOfNoncurrentLoansReceived",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveLabel": "Long-term loan, net of current maturities",
        "label": "Long-term loans, net of current maturities",
        "terseLabel": "Long-term portion of loan",
        "verboseLabel": "Long-term bank loan, net of current maturities"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current loans received. [Refer: Loans received]"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 [Member]",
        "terseLabel": "2026 [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r113",
      "r175",
      "r177",
      "r280",
      "r329",
      "r331"
     ]
    },
    "ifrs-full_NumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfEmployees",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of individuals to which this benefit related"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of personnel employed by the entity at a date."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "blrx_NumberOfNewSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "NumberOfNewSharesIssued",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued by the entity.",
        "label": "Number Of New Shares Issued",
        "totalLabel": "Total number of shares issued",
        "verboseLabel": "Issuance of share capital, pre-funded warrants and warrants, net, shares"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_NumberOfOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "NumberOfOptionsAbstract",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options.",
        "label": "Number Of Options Abstract",
        "terseLabel": "Number of options"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_NumberOfOrdinarySharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "NumberOfOrdinarySharesAbstract",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ordinary shares.",
        "label": "Number of Ordinary Shares Abstract",
        "terseLabel": "Number of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option vested"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails",
      "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at end of year",
        "periodStartLabel": "Outstanding at beginning of year",
        "label": "Option outstanding",
        "verboseLabel": "Number of options outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r120",
      "r123",
      "r230",
      "r235"
     ]
    },
    "blrx_NumberOfPremises": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "NumberOfPremises",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of premises.",
        "label": "Number Of Premises",
        "verboseLabel": "Number of premises"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_NumberOfSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "NumberOfSegments",
     "presentation": [
      "http://biolinerx.com/role/SEGMENTREPORTINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments.",
        "label": "Number Of Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable at end of year",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r236"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised",
        "label": "Options exercised",
        "verboseLabel": "Exercised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r233"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired",
        "label": "Number of share options expired in share-based payment arrangement",
        "verboseLabel": "Expired"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r234"
     ]
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r232"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r231"
     ]
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorized share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r255",
      "r286"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "verboseLabel": "Issuance of share capital and warrants, net, shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued and paid-up share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r256",
      "r287"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "BALANCE, shares",
        "periodStartLabel": "BALANCE, shares",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r257",
      "r288"
     ]
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office furniture and equipment [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "blrx_OpenPurchaseOrderCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "OpenPurchaseOrderCommitments",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total outstanding open purchase order commitments.",
        "label": "Open Purchase Order Commitments",
        "terseLabel": "Company's outstanding open purchase order commitments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "verboseLabel": "Other comprehensive loss"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r268",
      "r292",
      "r300"
     ]
    },
    "blrx_OtherComprehensiveIncomeLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "OtherComprehensiveIncomeLossMember",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive income loss [Member]",
        "label": "Other Comprehensive Income Loss [Member]",
        "terseLabel": "Other comprehensive loss [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_OtherCurrenciesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "OtherCurrenciesMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OrbiMed Advisors LLC [Member]",
        "label": "Other Currencies [Member]",
        "terseLabel": "Other currencies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 30.0
      },
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "totalLabel": "Other"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 40.0
      },
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "totalLabel": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r335",
      "r344"
     ]
    },
    "ifrs-full_OtherExpenseByFunction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherExpenseByFunction",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expense, by function",
        "verboseLabel": "Other"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r301",
      "r340"
     ]
    },
    "ifrs-full_OtherExpenseByNature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherExpenseByNature",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expenses, by nature",
        "verboseLabel": "Other"
       }
      }
     },
     "auth_ref": [
      "r301",
      "r339"
     ]
    },
    "ifrs-full_OtherFeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherFeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment fee"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ifrs-full_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails",
      "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual property [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "blrx_OtherNonoperatingIncomeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "OtherNonoperatingIncomeExpenses",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails": {
       "parentTag": "blrx_ProfitLossFromNonOperatingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other nonoperating income (expense).",
        "label": "Other Nonoperating Income Expenses",
        "verboseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": {
       "parentTag": "ifrs-full_OtherCurrentPayables",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other payables",
        "verboseLabel": "Other"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "blrx_OtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "OtherPayablesAbstract",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other payables.",
        "label": "Other Payables Abstract",
        "terseLabel": "Other:"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_OtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "OtherPayablesMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other payables [Member]",
        "label": "Other Payables [Member]",
        "terseLabel": "Other payables [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables [Default Label]",
        "verboseLabel": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r344"
     ]
    },
    "blrx_OtherReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "OtherReceivablesMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other receivables [Member]",
        "label": "Other Receivables [Member]",
        "terseLabel": "Other receivables [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherRevenue",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other revenue",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)",
        "verboseLabel": "Other"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r195"
     ]
    },
    "blrx_Others": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "Others",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other receivables.",
        "label": "Others",
        "verboseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r379",
      "r389",
      "r422"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r371",
      "r382",
      "r392",
      "r425"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r371",
      "r382",
      "r392",
      "r425"
     ]
    },
    "blrx_PDACPerformanceObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PDACPerformanceObligationMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for PDAC performance obligation.",
        "label": "P D A C Performance Obligation [Member]",
        "terseLabel": "PDAC performance obligation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "ifrs-full_PaymentsForDevelopmentProjectExpenditure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsForDevelopmentProjectExpenditure",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for development project expenditure",
        "terseLabel": "Development and regulatory entitled amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for expenditure related to development projects."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for share issue costs",
        "terseLabel": "Share issue related costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "blrx_PaymentsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PaymentsLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of lease liabilities.",
        "negatedLabel": "Payments during year",
        "label": "Payments Lease Liabilities",
        "terseLabel": "Payments during year"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of lease liabilities",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "blrx_PayrollAndRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PayrollAndRelatedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": {
       "parentTag": "ifrs-full_OtherCurrentPayables",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll and related expenses.",
        "label": "Payroll And Related Expenses",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "blrx_PercentageIncreaseDecreaseInExchangeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageIncreaseDecreaseInExchangeRate",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage increase (decrease) in exchange rate.",
        "label": "Percentage Increase Decrease In Exchange Rate",
        "terseLabel": "Percentage increase (decrease) in USD exchange rate"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageIncreasePrecedingLeasePaymentAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageIncreasePrecedingLeasePaymentAmount",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Increase preceding lease payment amount.",
        "label": "Percentage Increase preceding lease payment amount"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfAdditionalEquityInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfAdditionalEquityInterest",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of additional equity interest.",
        "label": "Percentage Of Additional Equity Interest",
        "terseLabel": "Percentage of additional equity interest"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfAnnualInterestOfCashFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfAnnualInterestOfCashFees",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents percentage of annual interest of cash fees.",
        "label": "Percentage Of Annual Interest Of Cash Fees",
        "verboseLabel": "Percentage of annual interest of cash fees"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfCommissionOnSalesAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfCommissionOnSalesAgreement",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on sales agreement.",
        "label": "Percentage of commission on sales agreement"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfDecreasingAnnualGrowthRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfDecreasingAnnualGrowthRate",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represets percentage of decreasing annual growth rate.",
        "label": "Percentage Of Decreasing Annual Growth Rate",
        "verboseLabel": "Percentage of decreasing annual growth rate"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfFutureMilestonePayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfFutureMilestonePayments",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents future milestone payments percentage.",
        "label": "Percentage Of Future Milestone Payments",
        "terseLabel": "Percentage of future milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfIncreasingWeightedAverageCostOfCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfIncreasingWeightedAverageCostOfCapital",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents percentage of increasing weighted average cost of capital.",
        "label": "Percentage Of Increasing Weighted Average Cost Of Capital",
        "verboseLabel": "Percentage of increasing weighted average cost of capital (WACC)"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfIssuedShareCapitalReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfIssuedShareCapitalReceived",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of issued share capital received.",
        "label": "Percentage Of Issued Share Capital Received",
        "terseLabel": "Percentage of issued share capital received"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfIssuedShareCapitalReceivedWithinMonths",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of issued share capital.",
        "label": "Percentage Of Issued Share Capital Received Within Months",
        "terseLabel": "Percentage of issued share capital received within 36 months"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfNetConsiderationReceivedForDirectProductSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfNetConsiderationReceivedForDirectProductSales",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net consideration received from the for direct product sales.",
        "label": "Percentage Of Net Consideration Received For Direct Product Sales"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfNetConsiderationReceivedForSubLicense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfNetConsiderationReceivedForSubLicense",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net consideration received from the for sub license",
        "label": "Percentage Of Net Consideration Received For Sub License"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfNetConsiderationReceivedFromLicensee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfNetConsiderationReceivedFromLicensee",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net consideration received from the licensee.",
        "label": "Percentage of net consideration received from the licensee"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfOwnershipStake": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfOwnershipStake",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Perpresents percentage of ownership.",
        "label": "Percentage Of Ownership Stake",
        "terseLabel": "Percentage of ownership stake"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfPaymentToBeMade": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfPaymentToBeMade",
     "presentation": [
      "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of payment to be made.",
        "label": "Percentage Of Payment To Be Made",
        "verboseLabel": "Percentage of payment to be made"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PercentageOfRoyaltiesReceivableFromAggregateNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PercentageOfRoyaltiesReceivableFromAggregateNetSales",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties receivable from aggregate net sales.",
        "label": "Percentage Of Royalties Receivable From Aggregate Net Sales",
        "terseLabel": "Percentage of royalties receivable from aggregate net sales"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PerformanceObligationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PerformanceObligationAxis",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Obligation [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PerformanceObligationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PerformanceObligationDomain",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Obligation [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PerformanceSharesUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PerformanceSharesUnitMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Shares Unit [Member]",
        "label": "Performance Shares Unit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PerformanceSharesUnitTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PerformanceSharesUnitTwoMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares Unit Two [Member]",
        "terseLabel": "Performance Shares Unit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PlacementAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PlacementAgentMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PlacementAgentsDesigneesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PlacementAgentsDesigneesMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Agent's Designees [Member]",
        "label": "Placement Agent's Designees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "blrx_PreFundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PreFundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represnts of pre funded warrants.",
        "label": "Pre Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Warrants [Member]",
        "label": "Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Net proceeds"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfOptions",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "terseLabel": "Employee stock options exercised"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "terseLabel": "Exercise of warrants",
        "verboseLabel": "Gross proceeds from offering"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of proceeds from exercise of warrants after deducting fees and expenses.",
        "label": "Proceeds From Exercise Of Warrants After Deducting Fees And Expenses",
        "terseLabel": "Proceeds from exercise of warrants after deducting fees and expenses"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ProceedsFromExerciseWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ProceedsFromExerciseWarrants",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the exercise share purchase warrants.",
        "label": "Proceeds From Exercise Warrants",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ProceedsFromIssuanceOfInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ProceedsFromIssuanceOfInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from public offering.",
        "label": "Proceeds From Issuance Of Initial Public Offering",
        "terseLabel": "Proceeds from public offering, gross"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ProceedsFromIssuanceOfInitialPublicOfferingNet",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from public offering, net.",
        "label": "Proceeds From Issuance Of Initial Public Offering Net",
        "terseLabel": "Proceeds from public offering, net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from transaction"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingOtherEquityInstruments",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuing other equity instruments",
        "verboseLabel": "Proceeds from long-term loan, net of issuance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements",
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of share capital and warrants, net of issuance cost",
        "terseLabel": "Issuance of share capital, pre-funded warrants and warrants, net of issuance costs",
        "verboseLabel": "Gross proceeds"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromSaleOrIssueOfTreasuryShares",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale or issue of treasury shares",
        "terseLabel": "Aggregate gross proceeds"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the sale or issuing of treasury shares. [Refer: Sale or issue of treasury shares; Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "blrx_ProceedsFromWarrantIssue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ProceedsFromWarrantIssue",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from warrant issue.",
        "label": "Proceeds From Warrant Issue",
        "terseLabel": "Proceeds from warrant issue, net"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ProfessionalFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ProfessionalFee",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fee expense related to professional.",
        "label": "Professional Fee",
        "terseLabel": "Professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfessionalFeesExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees expense",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements",
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveTerseLabel": "Comprehensive loss for the year",
        "label": "Comprehensive loss for the year",
        "terseLabel": "Comprehensive loss for the year",
        "totalLabel": "LOSS AND COMPREHENSIVE LOSS",
        "verboseLabel": "Loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69",
      "r157",
      "r159",
      "r209",
      "r228",
      "r267",
      "r291",
      "r319",
      "r323"
     ]
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to [abstract]",
        "terseLabel": "ATTRIBUTION OF LOSS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to non-controlling interests",
        "verboseLabel": "Non-controlling interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r294"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss attributed to ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "blrx_ProfitLossFromNonOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ProfitLossFromNonOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 10.0
      },
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non operating profit (loss) from operating activities of the entity.",
        "label": "Profit Loss From Non Operating Activities",
        "terseLabel": "NON-OPERATING INCOME (EXPENSES), NET",
        "totalLabel": "Non-operating income, net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "OPERATING LOSS"
       }
      }
     },
     "auth_ref": [
      "r308",
      "r486"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "label": "Property and equipment, net"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r201",
      "r272"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate",
        "terseLabel": "Percentage of aggregate maximum ownership"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r73"
     ]
    },
    "blrx_ProvisionForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ProvisionForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": -1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount for provision for doubtful accounts receivable.",
        "negatedLabel": "Provision for doubtful accounts receivable",
        "label": "Provision For Doubtful Accounts Receivable",
        "terseLabel": "Provision for doubtful accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents bout purchase agreement.",
        "label": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_PurchaseAgreementPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PurchaseAgreementPeriod",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement period.",
        "label": "Purchase agreement period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible assets",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "blrx_PurchasePricePerADS": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "PurchasePricePerADS",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent about purchase price per ADS.",
        "label": "Purchase Price Per A D S",
        "terseLabel": "Purchase price per ADS"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails",
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails",
      "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]",
        "verboseLabel": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r91",
      "r108",
      "r123",
      "r189",
      "r320",
      "r321",
      "r476"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails",
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails",
      "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r91",
      "r108",
      "r123",
      "r189",
      "r320",
      "r321",
      "r476"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [Axis]",
        "verboseLabel": "Ranges of exercise prices for outstanding share options [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsDomain",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Range [domain]]"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "blrx_RecognizedAsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RecognizedAsEquity",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized as equity Pursuant to IFRS 15.",
        "label": "Recognized As Equity",
        "verboseLabel": "Recognized as equity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r363",
      "r374",
      "r384",
      "r417"
     ]
    },
    "ifrs-full_ReductionOfIssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReductionOfIssuedCapital",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction of issued capital",
        "terseLabel": "Reduction in equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "blrx_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for registered direct offering.",
        "label": "Registered Direct Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_RemainingAuthorizedUnissuedOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RemainingAuthorizedUnissuedOrdinaryShares",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining authorized unissued ordinary shares.",
        "label": "Remaining authorized unissued ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_RemainingUnrecognizedDeferredCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RemainingUnrecognizedDeferredCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining unrecognized deferred compensation expense.",
        "label": "Remaining unrecognized deferred compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepairsAndMaintenanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RepairsAndMaintenanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building maintenance charges"
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "ifrs-full_RepaymentsOfBondsNotesAndDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RepaymentsOfBondsNotesAndDebentures",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of bonds, notes and debentures",
        "terseLabel": "Repayment of loan"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of bonds, notes and debentures."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of loans",
        "negatedTerseLabel": "Principal and interest payments",
        "label": "Repayments of borrowings, classified as financing activities",
        "verboseLabel": "Repayment of loan and Interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "ifrs-full_RepaymentsOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RepaymentsOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of loan",
        "negatedTerseLabel": "Repayments of borrowings",
        "label": "Repayments of non-current borrowings",
        "verboseLabel": "Repayment of loan and Interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      },
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "label": "Research and development expense",
        "totalLabel": "Research and development expenses"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r221"
     ]
    },
    "ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReserveOfChangeInValueOfForeignCurrencyBasisSpreads",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value on balance sheet"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the accumulated change in the value of foreign currency basis spreads of financial instruments when excluding them from the designation of these financial instruments as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r484"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r364",
      "r375",
      "r385",
      "r418"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r365",
      "r376",
      "r386",
      "r419"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r372",
      "r383",
      "r393",
      "r426"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "label": "Accumulated deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r345",
      "r346"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r341"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "terseLabel": "Total revenues",
        "totalLabel": "Total revenues",
        "verboseLabel": "Rvenues from external parties"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r133",
      "r152",
      "r158",
      "r163",
      "r164",
      "r167",
      "r297",
      "r319",
      "r339",
      "r340"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [abstract]",
        "verboseLabel": "REVENUES:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "terseLabel": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r153",
      "r162",
      "r480"
     ]
    },
    "ifrs-full_RevenueFromRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty income",
        "terseLabel": "Total royalties based on motixafortide net sales"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods",
        "verboseLabel": "Product sales, net"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The revised weighted average exercise price of share options exercised in a share-based payment arrangement.",
        "label": "Revised Weighted Average Exercise Price Of Share Options Exercised In Share Based Payment Arrangement 2019",
        "verboseLabel": "Revised weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_RightOfUseAssetWrittenOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RightOfUseAssetWrittenOff",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right Of Use Asset Written Off",
        "label": "Right Of Use Asset Written Off",
        "terseLabel": "Right of use of asset written off"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "label": "Right-of-use assets, net"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r98",
      "r172"
     ]
    },
    "blrx_RoyaltiesEligibleMargin": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RoyaltiesEligibleMargin",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about royalties eligible margins.",
        "label": "Royalties Eligible Margin",
        "terseLabel": "Royalties eligible margin"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_RoyaltiesOnSale": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RoyaltiesOnSale",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties on sale.",
        "label": "Royalties on sale"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_RoyaltiesPaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RoyaltiesPaymentPercentage",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the royalties payment percentage.",
        "label": "Royalties Payment Percentage",
        "terseLabel": "Royalties payment percentage"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the royalties payment percentage if the company independently sell products.",
        "label": "Royalties Payment Percentage If Company Independently Sell Products",
        "terseLabel": "Royalties payment percentage if the company independently sell products"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_RoyaltiesRateOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RoyaltiesRateOnNetSales",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the royalties rate on net sales.",
        "label": "Royalties Rate On Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_RoyaltiesReceivedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "RoyaltiesReceivedPercentage",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties received percentage.",
        "label": "Royalties received percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "blrx_SaleOfStockNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SaleOfStockNumberOfSharesIssued",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock.",
        "label": "Sale Of Stock Number Of Shares Issued",
        "terseLabel": "Sale of stock"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SalesAndMarketingDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SalesAndMarketingDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation and amortization.",
        "label": "Sales And Marketing Depreciation And Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      },
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "SALES AND MARKETING EXPENSES",
        "label": "Sales and marketing expense",
        "totalLabel": "Sales and marketing expenses",
        "verboseLabel": "Sales and marketing expenses"
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "blrx_SalesAndMarketingExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SalesAndMarketingExpensesOther",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and marketing expenses Other.",
        "label": "Sales And Marketing Expenses Other",
        "verboseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SalesAndMarketingExpensesRelatedToSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SalesAndMarketingExpensesRelatedToSales",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and marketing expenses related to sales.",
        "label": "Sales And Marketing Expenses Related To Sales",
        "verboseLabel": "Payroll and related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SalesAndMarketingPayrollExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SalesAndMarketingPayrollExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll and related expenses, including vehicles.",
        "label": "Sales And Marketing Payroll Expense",
        "verboseLabel": "Office-related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SalesAndMarketingProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SalesAndMarketingProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and marketing professional fees.",
        "label": "Sales And Marketing Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SalesAndMarketingShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SalesAndMarketingShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and marketing Share-based compensation.",
        "label": "Sales And Marketing Share Based Compensation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SalesMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SalesMilestoneAmount",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sales milestone amount.",
        "label": "Sales Milestone Amount",
        "terseLabel": "Sales milestone amount"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ScmLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ScmLicenseMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for SCM license.",
        "label": "Scm License [Member]",
        "terseLabel": "SCM license [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ScmSupportServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ScmSupportServicesMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for SCM support services.",
        "label": "Scm Support Services [Member]",
        "terseLabel": "SCM support services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SecondTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SecondTrancheMember",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for second tranche.",
        "label": "Second Tranche [Member]",
        "verboseLabel": "Second tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 30.0
      },
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "GENERAL AND ADMINISTRATIVE EXPENSES",
        "label": "Selling, general and administrative expense",
        "totalLabel": "General and administrative expenses"
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "blrx_SeniorManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SeniorManagementMember",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Management [Member]",
        "label": "Senior Management [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SensitivityAnalysisForEachTypeOfMarketRisk",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Sensitivity Analysis"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_SeparateManagementEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SeparateManagementEntitiesAxis",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Separate management entities [Axis]",
        "verboseLabel": "Separate management entities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r205"
     ]
    },
    "ifrs-full_SeparateManagementEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SeparateManagementEntitiesDomain",
     "presentation": [
      "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for separate entities that provide key management personnel services to the entity. It also represents the standard value for the 'Separate management entities' axis if no other member is used. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r205"
     ]
    },
    "blrx_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A [Member]",
        "label": "Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SeriesBWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SeriesBWarrantMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B [Member]",
        "label": "Series B Warrant [Member]",
        "terseLabel": "Series B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ServicesExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development services"
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "blrx_SeventhYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SeventhYearMember",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seventh year [Member]",
        "label": "Seventh Year [Member]",
        "terseLabel": "Seventh year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of share based compensation related to general and administrative expenses.",
        "label": "Share Based Compensation Related To General And Administrative Expenses",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ShareBasedCompensationRelatedToResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ShareBasedCompensationRelatedToResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of share based compensation related to research and development.",
        "label": "Share Based Compensation Related To Research And Development",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ShareIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ShareIncentivePlanMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2003 Plan [Member]",
        "label": "Share Incentive Plan Member",
        "terseLabel": "2003 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails": {
       "parentTag": "blrx_ProfitLossFromNonOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance costs",
        "label": "Share issue related cost",
        "terseLabel": "Costs related to share purchase agreement"
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "blrx_ShareIssuedAsAdditionalCommitmentFee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ShareIssuedAsAdditionalCommitmentFee",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share issued as additional commitment fee.",
        "label": "Share issued as additional commitment fee"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ShareIssuedOfPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ShareIssuedOfPublicOffering",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten public offering.",
        "label": "Share Issued Of Public Offering",
        "terseLabel": "Underwritten public offering"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ShareIssuedToPurchaseWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ShareIssuedToPurchaseWarrant",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued to purchase warrant.",
        "label": "Share Issued To Purchase Warrant",
        "terseLabel": "Shares issued to purchase warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShareOptionsMember",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share options [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share options."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r345"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share premium [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "blrx_SharePremiumResultingFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SharePremiumResultingFromExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share premium resulting from exercise of warrants.",
        "label": "Share Premium Resulting From Exercise Of Warrants",
        "terseLabel": "Share premium resulting from exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SharePurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SharePurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SharePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SharePurchaseAgreementMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for share purchase agreement.",
        "label": "Share Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SharePurchaseAgreementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SharePurchaseAgreementShares",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement, shares.",
        "label": "Share purchase agreement, shares"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SharesIssuedRegisteredDirectOfferings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SharesIssuedRegisteredDirectOfferings",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered direct offerings sales.",
        "label": "Shares Issued Registered Direct Offerings",
        "terseLabel": "Registered direct offerings sales"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ShortTermDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ShortTermDepositMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term deposit",
        "label": "Short Term Deposit [Member]",
        "terseLabel": "Short term deposit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term deposits, classified as cash equivalents",
        "verboseLabel": "Short-term bank deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term bank deposits",
        "verboseLabel": "Short-term bank deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term employee benefits expense",
        "verboseLabel": "Payroll and related expenses"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term bank deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "blrx_SingleMaterialPerformanceObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SingleMaterialPerformanceObligationMember",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for single material performance obligation .",
        "label": "Single Material Performance Obligation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://biolinerx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r367",
      "r378",
      "r388",
      "r421"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_StockIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "StockIssuedPricePerShare",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering price.",
        "label": "Stock Issued Price Per Share",
        "terseLabel": "Public offering price"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SupplementalInformationOnInterestPaidInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SupplementalInformationOnInterestPaidInCash",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental information on interest paid in cash.",
        "label": "Supplemental Information On Interest Paid In Cash",
        "terseLabel": "Supplemental information on interest paid in cash"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SupplementalInformationOnNoncashTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SupplementalInformationOnNoncashTransactionsAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary non-cash investment.",
        "label": "Supplemental Information On Non-cash Transactions: [Abstract]",
        "terseLabel": "Supplemental information on non-cash transactions:"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on Changes In Right-of-use Asset And Lease Liabilities",
        "label": "Supplementary Information On Changes In Right Of Use Asset And Lease Liabilities",
        "verboseLabel": "Changes in right-of-use asset and lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SupplementaryInformationOnFairValueOfExercisedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SupplementaryInformationOnFairValueOfExercisedWarrants",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of Supplementary information on Fair Value Of Exercised Warrants",
        "label": "Supplementary Information On Fair Value Of Exercised Warrants",
        "verboseLabel": "Fair value of exercised warrants (portion related to accumulated fair value adjustments)"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SupplementaryInformationOnIntangibleAssetAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SupplementaryInformationOnIntangibleAssetAcquired",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of supplementary information on intangible asset acquired.",
        "label": "Supplementary Information On Intangible Asset Acquired",
        "verboseLabel": "Intangible asset acquired in connection with GLIX1 collaboration transaction"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SupplementaryInformationOnInterestReceivedInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SupplementaryInformationOnInterestReceivedInCash",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on interest received in cash.",
        "label": "Supplementary Information On Interest Received In Cash",
        "terseLabel": "Supplemental information on interest received in cash"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplementary Information On Investing And Financing Activities Not Involving Cash Flows Abstract",
        "terseLabel": "Supplementary information on investing and financing activities not involving cash flows:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to gains on adjustments of warrants to fair value, that are exempt from taxation.",
        "label": "Tax Effect Of Gain On Adjustment Of Warrants Fair Value Exempt From Taxation",
        "terseLabel": "Loss (gain) on adjustment of warrants to fair value"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TaxEffectOfShareBasedCompensationExemptFromTaxation",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to share-based compensation that are exempt from taxation.",
        "label": "Tax Effect Of Share Based Compensation Exempt From Taxation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theoretical tax benefit"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r195"
     ]
    },
    "blrx_TaxLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TaxLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax loss carryforwards.",
        "label": "Tax Loss Carryforwards",
        "terseLabel": "Tax loss carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TenPercentDecreaseEffectOnNetIncomeLossAndEquity",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effect of a ten percent decrease in the given metric on net income (loss) and equity.",
        "label": "Ten Percent Decrease Effect On Net Income Loss And Equity",
        "terseLabel": "10% decrease effect on net income (loss) and equity"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TenPercentIncreaseEffectOnNetIncomeLossAndEquity",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effect of a ten percent increase in the given metric on net income (loss) and equity.",
        "label": "Ten Percent Increase Effect On Net Income Loss And Equity",
        "terseLabel": "10% increase effect on net income (loss) and equity"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_TetragonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TetragonMember",
     "presentation": [
      "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tetragon [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ThirdTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ThirdTrancheMember",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for thied tranche.",
        "label": "Third Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ThreeSubsequentYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ThreeSubsequentYearsMember",
     "presentation": [
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three subsequent year [Member]",
        "label": "Three Subsequent Years Member",
        "terseLabel": "Three subsequent years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails",
      "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails",
      "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "verboseLabel": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r91",
      "r108",
      "r123",
      "r189",
      "r320",
      "r321",
      "r476"
     ]
    },
    "blrx_TotalChangeInOperatingAssetAndLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TotalChangeInOperatingAssetAndLiability",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Change in operating asset and liability.",
        "label": "Total Change In Operating Asset And Liability",
        "totalLabel": "Total change in operating asset and liability"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TotalIncomeAndExpenseNotInvolvingCashFlows",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total income and expense not involving cash flows.",
        "label": "Total Income And Expense Not Involving Cash Flows",
        "totalLabel": "Total income and expense not involving cash flows"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accruals:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r343",
      "r485"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesAbstract",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accruals:"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_TradeAndOtherPayablesToForeignTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TradeAndOtherPayablesToForeignTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payment due to foreign suppliers for goods and services used in the entity's business.",
        "label": "Trade And Other Payables To Foreign Trade Suppliers",
        "terseLabel": "Overseas"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_TradeAndOtherPayablesToLocalTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TradeAndOtherPayablesToLocalTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payment due to local suppliers for goods and services used in the entity's business.",
        "label": "Trade And Other Payables To Local Trade Suppliers",
        "terseLabel": "In Israel"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails",
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables [Default Label]",
        "totalLabel": "Trade",
        "verboseLabel": "Trade"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "blrx_TradePayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TradePayablesAbstract",
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade payables.",
        "label": "Trade Payables Abstract",
        "terseLabel": "Trade:"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_TradePayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TradePayablesMember",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade payables [Member]",
        "label": "Trade Payables [Member]",
        "terseLabel": "Trade payables [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r344"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "blrx_TrancheAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TrancheAxis",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.",
        "label": "Tranche [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_TrancheDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TrancheDomain",
     "presentation": [
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for tranche.",
        "label": "Tranche [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_TransferFromLicenseToTheLicenseeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "TransferFromLicenseToTheLicenseeAmount",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer from license to the licensee amount.",
        "label": "Transfer From License To The Licensee Amount",
        "terseLabel": "Transfer from license to the licensee amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TravelExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TravelExpense",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": {
       "parentTag": "ifrs-full_SalesAndMarketingExpense",
       "weight": 1.0,
       "order": 110.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Overseas travel",
        "verboseLabel": "Travel"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsDomain",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_TypesOfInvestmentPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfInvestmentPropertyAxis",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of investment property [axis]",
        "verboseLabel": "Types of investment property [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ifrs-full_TypesOfInvestmentPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfInvestmentPropertyDomain",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/Long-termLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of investment property [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Types of investment property' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [Axis]",
        "verboseLabel": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r109",
      "r110",
      "r111",
      "r112",
      "r134",
      "r139",
      "r140",
      "r203"
     ]
    },
    "ifrs-full_TypesOfRisksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfRisksDomain",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r109",
      "r110",
      "r111",
      "r112",
      "r134",
      "r139",
      "r140",
      "r203"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [Axis]",
        "verboseLabel": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r238"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r238"
     ]
    },
    "blrx_UnderwaterEmployeeStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "UnderwaterEmployeeStockOptionsMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwater Employee Stock Options [Member]",
        "label": "Underwater Employee Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UndiscountedOperatingLeasePaymentsToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum future rental payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of undiscounted operating lease payments to be received. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r178"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "blrx_UniformTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "UniformTaxRate",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uniform tax rate.",
        "label": "Uniform Tax Rate",
        "terseLabel": "Uniform tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "UpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSAYRMIDHIGHBRIDGENarrativeDetails",
      "http://biolinerx.com/role/LICENSEANDSECURITIESPURCHASEAGREEMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payment.",
        "label": "Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_ValueOfServicesRecorded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "ValueOfServicesRecorded",
     "crdr": "debit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of services recorded.",
        "label": "Value of services recorded"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wages and salaries",
        "verboseLabel": "Payroll and related expenses"
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "blrx_WarrantFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WarrantFiveMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Five [Member]",
        "label": "Warrant Five [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_WarrantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WarrantFourMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Four [Member]",
        "label": "Warrant Four [Member]",
        "verboseLabel": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_WarrantOfferingConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WarrantOfferingConsideration",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tha amount of warrant offering consideration.",
        "label": "Warrant Offering Consideration",
        "terseLabel": "Warrants offering consideration"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant [Member]",
        "label": "Warrant One Member",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WarrantReserve",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant reserve",
        "terseLabel": "Warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]"
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "ifrs-full_WarrantReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WarrantReserveMember",
     "presentation": [
      "http://biolinerx.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant reserve [member]",
        "verboseLabel": "Warrants [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments [member]]"
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "blrx_WarrantSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WarrantSixMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant six.[Member]",
        "label": "Warrant Six [Member]",
        "verboseLabel": "Warrantt [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_WarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WarrantThreeMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Three [Member]",
        "label": "Warrant Three [Member]",
        "verboseLabel": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_WarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WarrantTwoMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant One[Member]",
        "label": "Warrant Two [Member]",
        "verboseLabel": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_Warrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "Warrants",
     "crdr": "credit",
     "calculation": {
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The non-current portion of warrants.",
        "label": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_WarrantsExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WarrantsExercises",
     "crdr": "credit",
     "presentation": [
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercises.",
        "label": "Warrants Exercises",
        "terseLabel": "Exercises"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_WarrantsExpirationPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WarrantsExpirationPeriod",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants expiration period.",
        "label": "Warrants expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_WarrantsIssuedToPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WarrantsIssuedToPurchaseShares",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued to purchase shares.",
        "label": "Warrants issued to purchase shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails",
      "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails",
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for warrants."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "blrx_WeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price.",
        "label": "Weighted Average Exercise Price Abstract",
        "terseLabel": "Weighted average exercise price (in NIS)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement",
        "terseLabel": "Exercise price of other equity instruments exercisable"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable at end of year",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r121",
      "r236"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised",
        "verboseLabel": "Weighted average exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r233"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement",
        "verboseLabel": "Expired"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r119",
      "r234"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "Forfeited and expired",
        "terseLabel": "Forfeited"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r117",
      "r232"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price",
        "verboseLabel": "Granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r116",
      "r231"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at end of year",
        "periodStartLabel": "Outstanding at beginning of year",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "terseLabel": "Weighted average exercise price outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r115",
      "r120",
      "r230",
      "r235"
     ]
    },
    "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
     "presentation": [
      "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average incremental borrowing rate on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://biolinerx.com/role/EquityNarrativeDetails",
      "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average contractual life",
        "verboseLabel": "Weighted average remaining contractual (in yrs.)"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "terseLabel": "Number of shares used in basic calculation",
        "verboseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF BASIC LOSS PER ORDINARY SHARE"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "blrx_WithholdingApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WithholdingApplicableTaxRate",
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The applicable withholding income tax rate.",
        "label": "Withholding Applicable Tax Rate",
        "terseLabel": "Withholding income tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "blrx_WriteoffOfIntangibleAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biolinerx.com/20251231",
     "localname": "WriteoffOfIntangibleAsset",
     "crdr": "debit",
     "calculation": {
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of write-off of intangible asset.",
        "label": "Write-off Of Intangible Asset",
        "terseLabel": "Impairment of intangible asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2025-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2025-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "A19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "18A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2025-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_vii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2025-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "130",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iiA",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "86",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2025-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "46",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI",
   "URIDate": "2025-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "C8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_C8_a&doctype=Appendix&subtype=C",
   "URIDate": "2025-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "59",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_59&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "C12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C",
   "URIDate": "2025-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2025-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2025-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "22A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_22A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2025-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "6.5.16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_6.5.16&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2026-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "30A",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "128",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "133",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "164",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "164",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "166",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "168",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "169",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "170",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_170&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "178",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_178&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "190",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "192",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "223",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "227",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "229",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_229&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "230",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "231",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "250",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_250&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "254",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "259",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "264",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_264_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "266",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "269",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "271",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "271",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "273",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "274",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_v&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_e_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "43",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "64A",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "71",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_ii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_c&doctype=Standard&book=b",
   "URIDate": "2025-03-27"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_q&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_r&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Paragraph": "22",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2025-03-27"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2025-03-27"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "191",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_191_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG24_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2025-03-27"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG25",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG25_b&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2025-03-27"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard",
   "URIDate": "2025-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>114
<FILENAME>0001178913-26-001581-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-26-001581-xbrl.zip
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M)ZM,7CH O83^UD)"7P;CF^'<&8V=X?_>CQ:_]0)2#:]+-UY?!]'33B;RF%+
MZ,7T?0LQ#>9?G.O;R2_] "KD<X/H;S>0[ C%=[T<?@"3 <=>$,4I0?3'S7 \
MG-$E9S2^GLSN!OVJ4YJW\"K$2^RYU%+SF.L+AZLI!?,PXJ-"#Z(7QM^KPJ#\
M'\[  !A<7D[NQXO1^(;: K>CR]&P'PR%5 H3;!3&"6'6;TP-Z>+S#,=?[]S0
M7;'))A-3RSIZN?VC*K>=Y38:SQ>S^VPN&XROA)+9:/YO*N#QX(9-=;TXB[6'
M4 1IC[OA,XP33&<S!!+Z5^JOQ$7($%@OP(]5 5[.J+U]61YXP_EB! ,R$^2_
M[J]NF%A[P16"HT8 93K\!Z;:HQL(<E*7:<5R?B:)!4P!X#[[ XRVGP>WO1!*
M2]0Z H\N(IO/;OCU"FUA6YJO3>HRO1#.JT*8?YG,%B=T8;IS/@_&_W:NAFQ[
MVLN@D,&41%M$DA?PYE!EW^Z6'66)GO\75?Y/9Y/I<+;XC0T$& /3?OT0N3^B
MA(4K\#D/XACENB]]U7/]0Y7KH_&"[A9'GV^'SF ^'_;JOF/X+7+CW/SE?^N9
M^[<J<V^'@WEOT0H<C<(5FZ=O(S?,.5O^IN?P]Q*')^.;;,Z^G0SZ'5W!:='I
M9.)?.I<VS+WKJ,S1A?N,XDDX"ND7E#&V_$G/7VD/O!C\2DWNR9C.P)>3NV'/
MZ&*2F,SGU!"8?QG,AGR*$+_HV2QM6:&N0RL[K';/Y9TG=+/!2>X?N(S8'I/^
MNL7N PXH\JAPAS8#ZF4B[T(G=W>CQ<YY<#EA.U'ZV[D=#3Z/;NDFM5\VA1$Q
MNAR.YT/*JOGP\G[&N#.]GUU^H=;%X&8VS'S*?*R8P6HE=B%M4'FK3%J[=IV\
M86?7,@7^,E^<WMQ.9J-!+\)V(AS\-KL;77T9W7SY/!M=W0S;B%2JJQ>QM/UM
M)>*LL]-=;[VD<TD7?/IEM/CR97@WFD^_@+,;SAVNAC\/;R=L7SNYOKD=_7J>
M2;AE';UDI8UUT;H#S3MB^P[MP!%Z@',IUD<OS\+N(W1;XGHLOHLN@)_= .+R
MXU]PLIZA  X)IR[9+9?FX'HI2AOUQ6PPG@\NX> J6S4_#VX'XTLZ1)E49\-;
M=L8X'<SZQ;/D.!PR?_9L.)W,P,K@+L/J5[TTI)T]K^\4#?0,+QB>;K?9#1N7
MO!0'3\6AN'2VVP)>+R3).3"_GTYOV<PWF/TF'%$5Y_#]:;!2@/>?YW3W3_E#
M%P88(S>C^6(X&UY=C6;#2[H*7=.UHQA(AL!ZT4G>AUVS#FO7^0XO'8("].B&
MR7_ULC(ZN6]Q@F]RDO_QXP]G?S^3#$?=8;[S7=YP+S,SF2W<A\!(8ARP45Z2
M.:B75]9L+ZT]HS!$\>U5LU&>DF&X1U!&+V;9'Z8\R!?%J85H%)MD0=:>^??"
MD82C.EX61:,I;Q2,9#6JSZ%[J4A2J1X]BQ*I*6N4AF0(2N?3O2!DYR([G!;9
M7_K2R'3I;"H[M^XY+7$Z.TH5.5WZTLAIZ7@J.V7M.2V[W<2S59'AJH)&ODM'
M4)73UUX \J02Q?$4D?G:)27^*[XWL5\.>"R?RO;<E]7?U(U<&AHM*S7*3=KK
MMW-"]W*5]_X5OW-INZ\N:Y22M,.7G-.](&1!&'N=2R)J6ZM1>-)VOI73NA>L
M)%CYJM@52EP<Q'4WR?+B1E%)6WC%G3+GN[%+(!O$(_HOYSO>="\=,]]GP;J2
MQ-I5:92BM-_7^T-[<>XM3DA&ZJ<!FBRO6"I-S)":P1TF<P$;--(H<LFIH!=Y
MWJ43+1VQ4X?UVNO!_GIP'Z-E&MSB)?U[AE?KA'W*/$3[J(1)>XW:T>IV:ED[
MLOX=0 !^,A3X=R?#HM>6@X]4U*O"@6TT:L4Q[K[VJ\<Q]6 W[.>0UX1R%8/'
MWPU>8AP?H!M&[3;JB^1AVDM?Q,E%P,;)T>G5Z(AJ=!F%'OV0Y6ZC/WG.30 _
MBCH9M-^D5G(D]L%J5<**?>!X.8!8KV!'5## C'Z<+.^B$(''8)2@S7&F*GW3
MC6HE.?8.5BN.$/R9H^0PG'J-.N:419"/D^/-4%)SC9HC.1L/GY 8$OWL<W1=
MR?.+%9#"E2TX$\B36QUG1FK?7:.N'2?4J:1K&9(.#IT"34? TP%$'<#48:CV
M"GE$A;QV,?G9#5)TAUP0*)1.EK_ %BE,CJ.$9ETT*I[DZ3U8\0 QAV'F"*A!
M28Y<KVK&47EJCX A;*/P)0>Q)E*OW]^WEYZP9"C+#81JVD2CK"7/L$;6I74$
M5@C:;_:'T'.O!\:YFVI.>\Q@&R4K>77KTCOU@[A][*WHX]AL>8+HR5(%2O_F
ML2<#STLW*?M3/%4I2?];==:H/I+[MRXJN.Q:*?"#GSF&6<KR'$?VBV/I"&B6
MCIIZ353%&Q>AP%DDL'H":81JE+WDRE7$(/=S1IO(\-T0KI:41=>Z6I,L/TC^
M4X4LQ2&\ZZ@_P&L*.%>/OYJR1DG)"2EX$'H_U)I%L1LI[ SZ)%J>I,J#=7/P
M1H%)GL!<8.)X$MMWW'Y$F8J1_18<4UHAU@$WBE!RL*E$R%H7G62]  T$>$<Q
MWJ2;ZS2AG)T!V<'4?=E(&]P]ZC6*M28/95FLO",GZ\G)NG+ROGH9-Z:OK%G^
M]#"-LFO(<-DOAR87M-2BJ2EK%$E-:LQ>%":B$*)KX,;0I;O%=)Y1R$4/V"@D
MR=^3"ZD44@,M.[SI7F@&0AML(/@RGJ0)O$?MXW!U'_J(##?;('I!B#%TQ )*
MZ#"8!FZHE>S>K36*O_9BI2A^WKTC].\P!)P< ZXA!0X.(-$KBH&B3+;0KRC:
MSR_#9T0\'*,IP1Z:P<FK5CO:-=&H$I(;1Z42O,^22L"#[[Q;A_7KL(Y[-3"9
M+^(XW60\O:<]+B)VYLFYK)\;3&HV"?UODK]'.0_LNH)0;=])(GXVR[OK1=UT
M(UMM8>E!&H4G7S>MWM+N+2YC"0D^'N1%H4<W[SP0]1<$3AGD#QX1<5>(UH*+
M+8/M-L >W"9<1%D+]:(]7MN-.B%YF22=*+F;2NBP\ J.D,,Q<BA*["*/LT,*
MQG^&5J]6#0G9:S:].HA&$<M>J$IV@'[4FR9JV W,SVZ,/;&HXJ5H5:=1A++'
MJ2)"<9"R;ASHQZ$=929W+]G]<O27@V7,X1LE*D=!&27M[\6X;^[WFIEUO[J-
MXI5\6GMF^.\GY]?(^W^(+C2VU:@;<CJP@YX&Z%7DF \&J%7CP#8:54)RK^WS
MID"O"$?*^;2SV,0J,EQY _=:K3<JCYQ\K646*=%X%''*;FODL70<K5ZUCJ-:
M_T8ONQL6$-F(: O0P*%:U=APDT)]+SGY#E$HBHZSP\<1$>I5R2"#64T8=Q-4
MHY#E]WGEK&;]>M)&4EH!&<O%)-M<+PM)%L:)XX3SL&2-R QY"#^R)&]E^1VQ
MP4:9'YJDKG3B!D@X A;]V#V2OO!,2?'4?0'&TN68?B&I&QRN.<U--^J0_(32
M_CJ4H^-P?-B=BARC7I^4;_H(S"YX7;!:X+1XW29.X(3G$85I=?8Y6G.->G/8
MJT[5"SHQNW-+.!*]JAQIZIE1?KC$@ZN85Y2W0<2N.@V?P90^PL)EUGRC*BE>
MF=I;E7*4V-0C(.7D6/6Z=23=FKO42*"2OW/)5P0G&D=3J\:6&S5*OF6ZOT8Q
M;)@Z%?CTRG1L9>+I?\& \3>4PCC)-I"<T0>KE&'[C8HE.5P/4"R.4V8DE;#*
M]:M7KR.IUS@*3^#2KPNC-PLIR8?P&"4':Y=9\XW*)3ED#U N0&F2H\2C:)SO
MBGGKOQV*6*]>1U(O(2V.%*!UQ/::%.@'R0%[@ (5./0A6*^D+$>SEVI;;%08
MV9E[#(7IK2/M'?P8^X@LB M![0-(,I4=<=1<7&L!KQ'WV=D_Y/0)6<L.;]K)
M\W@S@V1*(H^*EDJB%]TN[BN,Z4<?CL^*$1EG^4\(6D->X$<$\7.__WZ>1WZU
MJ*$5WT<8JD43+.YK/)_<CJ[8"5HQ/.=PJG\YN9O.AE^&X_GHYV$6\O?=P/=9
M4W1X7NYXYIS_Q4<F_//@QFB&ELXS^Y)0F)_>Q7A#I]EW_-N:H.5/[QX"\GQR
M<7;Q_?G%A_/?*:GOGS=!#@+-%[KQ]/3T_OF!!.\CLCJ].#O[D.E'E3N\X[P)
MEWA2*T\?6!OG'S]^/&50M!&6G8:.P],<^7>GQR**BJ$M467)V4<259&V)%6T
MRCZ: O>A+4VT"@I>@YH?3]WM%E.S W[2'V$891K.?J/,5G%"=T/[J!Y'/,"&
MUDNRN1!(_+T6(F,-$(8_T6^PCZ)3'0SH=X[+H7YZEY 4&,>@*,(X\A>L'EVH
M&$[OG#BEP#A)X=<-B=)MWBBFS;US0AP$T#%OZE1%1#%3[N)VKQ$2B:B#$(G8
M" F@JV0LW2 ^*AV\J8<LS(.V@QYPTD#=\#E!H<_R'$P9"DH*%5!FHCHZC7IJ
M1INMBPD+75F[9(5B>)C&(Q1OL)K",'4#VL53LH8[)DI*6[9PL*QQ"#<;DT-%
M[;$TS>VY4[D1E)T"\2O8IOS1M]$I#K';#O$=VCP@HB2_#)#1YB?D!/Z*/_G1
MQL7AFX^#N)IR1D&* L::>4LKJO]+X^P2Q75$^,B$6^G\_RE!5#_]?.\Y"'T6
MT5#XP(3(AA)3CMAJQ]@X0W^DF,"57FHO!,A+QBB!O*GWU+P>A06) X\]=D(5
M1;6>'Z4YFQ;_1V!AGFZG1&FEQ);I3;/6K]P ;S9IB&X37Y[:5*6VS6NK%4$K
MN*FZH3UXD'B"9?*DK,[FXQ(]C; E/6/?WIZRR7*)0.-91@,5.14 6]1.-\=0
MS-EOZ'#PC,M2DLI>>?3[R2<?;\#5$C%%-A2/@.85&P1U1.2EYD/GFTQD(HJ*
ML:\HM90 ]D9%1(W/D*X9;)$N@CI4"U*K:A8M/"+>7] &QUMJ9V W+*,^6=X$
M^/F<VB-T&+I)1%[J:&_71E7V"7I./@>1]_7M)LB:65S6Y09 VY:T&G2G*?'6
M+L^HDU_T-B"SIEZ5ZBTO>7.ZYPG5JN&SQUY\J16F$LHZ28(K:Q#080+^_47$
MGPPID5,'TH5EG"%_ _A.EEE:(.'9%XG*>D!K]D4:4YF1P!):HP V+ZD;")GL
M81_#[U!)=)M5>BMYZXB%5)C%FJ&@JU+^9F+4T<#W8Z/P.@78.TQWX@E%3D%.
M/:@U"JH;C<P#R7PW%6]TI< :8C2C#1).LRN*=&M3:)B\&&C!+#-7TV0=$?PG
M\L4TF2Q[F4B1#JH+2\*CBUE5/J^Q+(W7+F1V2DJ6J![.&A75D?I"-MB_I495
M&".-CFK![-)1>+GG)G5AG48HFQ7ISN S"M$2PW2/XC@2:3.$MT::]1,.4 *K
MF22^:H%E)B9+R02W*W"04OMQZ)*0[E%C,1=4B1@#:.LV!ID^0>!8\#)Y"D<A
M-?NI9HETU4$H:($$L6],2A*#"UR\9*_P4S2#VN.;^(RCKSB4-VN5[Y9-=AER
MBS4B[A;1AKQ8Y077@]DV'>#HEB([>U:142ZQ#?/;?YS][4Q&N_39,@6*8'<@
MHUSZ;!G*"5[=!IZ,<_F[;;J1QE1UXW@0NL$+#$!^VBH24 O2!>/C<0F3>XA(
M?+N59:,JM4Q"RM<\)4JT4+915+R*G;],#"EJB8_\03P81V'E-H](9=N:UFBH
M9K,C$[58T_97ZRF)J)5"I0I&Y.[%9BT_FJIVBB&[N 7V2!:0LXN<4=AU;2O:
M8^5=1@ 290U2=-FN8!T%=.<>%QM;,#( P9(&M*S8,9(7T$A;<GFE5R;53SZM
M7V#3DSX@XZ/M$OY"GK#*0;T>[/4):W]F7X>Q='S?!&B746>0/;A$FP%T!SR-
M<',F#: 3^<1746:;>5'P'7"%6U;9;"'<WJ+2&84^VH1XB;VLE"T48$VL0AR#
M/0$)?J@EE3U=?%4.7'Z]+FS1CGJ+6E;K%R5GA%);B-*J/(1/4[/)3[V$99TH
M$2476F-(Z205)]S!M8BXESQ/-52AKAZL(W12H\]+"6%'C'G07H5&-4@'Z+NB
MPGD9A?P(5:"J6F -+9J!1G%&+!*^^GPUB^U>4 O^)HK\)]I^F5#C2IUB@N;*
M@ ;&&A*U.IMAOXC8<\>3Y7W^F+**1A64-51J!5D*"*.KWR/=B<!JCF*/X&W6
MO4"O";B9??]-;*D*PHMH0GP<YC]GT$^VZ3:BU["Z5?07>!4)'R$<'&[KO\!Y
MK!OC&$R#W>7CK&R1QW"6N'%X8U5;^^UC19NHR@0\"JM%[*PTSX@0JX-J7Z'M
MOPX#C\NRKC.I2/; (.3D+?MJ6+MVN\>X*9U?/;P-$,N,(1!+QU 63KJKM!\+
M]^ZA>\SD?O;]^*2J;#D+J+6V3(-;O$03(EQ3GRRU-M]^#=AD%6""/"H@V3LF
ME5CF&\OPFP:NIXZHJRFWCHK8#8+H"?E7"%PR; ?A/@^?T6:;9$=_BM.A5K7L
M.2?9&3+BK/&OU-\Y&H>TBPU=C\2U2,V PUJRE"G%75K!F]I$OKZ.K80*5\PF
M&[1RIW0;M7$;:6VJUBUR:U;7MC4M7%I%$NAWGQUFYB[9)BEK*M@IW\O C>/B
M=$2PK56']LU"W[\YNS7!X%"Q035:M6"GKF19%B&719&"<_ 0I4G]&QS-"G-@
MFW9K31UQTG/&^_-)WU0WV:,,HSM EPS:ZRBCHA"B_0F?;"_9P9KW,L/QUP.X
M9=AH5UDFOO5R")=JV^DF8Z04ROOS1M]4Q]E3)+<_E#F*ACK*FC2AY3.TY8FA
MX-ITN%H@LLGOEAW K79M=Y.!#4]S'# 26[7<3>9QGU'H'\XM?5-=90]=H8
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M?+Q\Q5!3HP"SC!R6FS?=T.D@#5APL3( N4J=:2UK9A/-<61&4#4&1Z)8!NC
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MA- (I,<TFYC5%3O BX7[/*2[(-@+W5#[>1(._/]+XR2+F,Z7EF+9H8O.9IN
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M D E$*&L0\."HKW%66=2TK=Z$+,MP#<53368N9R!6@M5HN9M Q'K\)1B1YL
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M(>TL0)A=<$,Q?"0BGB")+F_$W1R%7Z)H^D2"H('K&F9['\!@>B-BC-$L8=B
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MTR_?%9W4I0\Y+3Z\25I8U%=LC#6(E.C)[S$KW@#M 5HC8^KTV%1QN.'][)A
ME=*.[Y%KC L]''%^6A%G%R4BL+\U>S5NTE2,@':+=AZWUE24@)8_K1"RH$FK
MDA+(6JP'@IE5K\ .TO7*-_U4L+C2PJ!7@K4H9X&MPG8NI37U+J -H58(U208
M];4QSHI>:RIT*9-Q6#9WX19E/<WW<W%,BFY<$:X[XXQB<8XC[L!N9*J^< =4
MCW2E2KWUYWB:B 9HZM_/Q!,7 9C^'BVZ>3C1NZ,1 T"]*[;<NIK'MFOQLEG(
M@U %U\XJ=:JXRPX]RQ,TCX_L7AS>H6<L^Z&)K,Y&"N;9C+3VB"NY<F\F/NL&
MQ7@LWH[TTS<TTA6 R<D4* YM%NU,GQ>3RBH-$S855YLL $B&;@#-TG1QX8C2
M,ZM%UV"^K036?0#-=YK-L!]/9J*V8A)N K ;DVI=?L&MK<4R%K8&GR>IKD"C
MEW5[:AET3[F4B6:SK7B%#F[MA)Z:O13H(GW?$Y%^%N_"\,/."@I;D-AT*4!-
M8-(WRW,4BIG;5-:=X/@)XS!+'/&+GN9SN4*H7H[:F]3?-KTUC5DGQH3(YP#Q
M?Z<536)3LN P%(I:+E)OCWL&W D49:?AXW\PHGS:_9SX\S/,!_*?Y5KW?,Y5
M%)_R]>.-YMEN7_)* !2:U.PUEF>B.+0FA9DD=L.@:D>+OL2Y(]FH#D2JTQV.
M!*OZ81$+=02ZS+<_,=*K&G(DNM6!EUY31T$*BMUQ.<J0+TG#$3U!@>@WS.Y)
M/+_!\GW3:T1%3'#C(?Z!7[ZBD/N",EE9N&[ 7, 2G->8LB@,<5 $N-:.:YX.
MR/UK!G8=J?B\6 ;1"\8G.,0S=<^)7M8%%+ SP:)2F-N9*I7U '4U;89>ZH[+
M*'P4Y]H3GRC7M'5Q]TJ5ZXAQ_2.87 SIB2SJ13T(#SL9"4"M_=%-<KCAWNR>
M0MM2Q!&G9M>DT8D31[R>79-'*U;,O9_=VYZWR7(92!P0?<G2T"A8OZEP$<XB
MFM)S8WQ6OP0 9G-*\$[3:@G35I::.;;6I3;ZQV(2)]+ -P+,8%9/F8#Q="6<
MC9H6LJIA/<7I)=6U>Z:_%LR3_8D*/7NH_=B&@W-#L]HAO<TACFA).S373&FN
MY& *\2SHQ+*/<T2#"]^G"0J@B?/2]V<9M.PNDG^6B!.U#+%<H2=1K]DK:WK0
M"+3U&GTEA-5;7O(E@DY *U8 Y(87[WX.L[&=D$_H*4?,E^.763P3F 7]\F_$
M=!373H"6[S6G[)JD@+I@IH<MA2/>^FXO^]6T,[+M8H!>_,A;4IAT :^,M7W+
M8_>G>4VC%6'"/N-"U2H8:[) X>&/_9DUIDI/F=2S4T!NF+,[((A:N3EH]Q94
MF0K].DWCQN&;(:O71F_J3#OI(T>">[:4V%99CM0HM#SR)@4&Z=77-NYM[0/L
MT%S<6F!KS9'Z=^;AY,:U>283))LF \IRWV*Z(CXV0ZL\MJ>8JKH**]/;=Y&:
M870N9JO% "64.=2+)"1^5HG6?":J";;NM,Z_I]$,,R:%Z#E6@:$:!L@3[O@&
MK4$[73C>;OHU90K6R<N5:)YA4'%>F5#P>_=G'S1I"*VA8"!UW;#]VU-@2T [
MX@988MQ)U#OB#[1F HU&<,0[:,,)VQK(D=+CUF=LI)I MQWN@0@:#6;>51BF
M(WB+ AG1^(KH-RQJQ('Z@#HXZUT(S:2>DIE;RRLORM^UWRO:K-%3,G.G3Q#W
MY*7IN%+>0F-:EF;UE(?<VD1M&1C#J)[>DU.UM5M%>6F3IXT3>_KP\R1A7(@Q
MOA4*7F+BUT0&:L?;^D;:ER\KG*.#8VN@;1*O%H"QS\WJ)E(HAGJ63\;I@,!3
M;M %X]D,$7U%0WF49_F4FS'#IKF5!EHT3+-^I=Y6+*W] #G"6CZ5IUL_-;_;
MZB)N))GHVM+(XDOT^[/U:M2_TL6S4\5N>/>6-##2\(ZX^5V/OVH]..+*=T5;
M:Y XXM-WQ5]AZ3CBX%MB7F-+.>+,6R*L,MI OPK4$=.J;0CZX9_VN%;M4-#O
M]O0HI[9,7-"/]/2OE[>M9E<>YS&G0(U]O4860J>^-J''+YBO@439W'BZ("%A
ML>A_L<(9CM "D#C@&STV -U0T6"R!*"RE'OT*/F4\RNB3<7;U<& RDZJ)IW)
M86GF /HZXR)D"14?E9F@4QW<5S2T/BW:P.KZ2$FW90%]X5&,(=B6@>1'!:?&
MI9P$.T]"7Q/K;IK24[QV7:8I'I.*DH>8;YE_N;?Y6+&FELA@-H@R%6/5H;4?
M%.+9D0A69]3UHMR52%9G$BC$OROAK):X]Z1'7 EZ=>80M>)Q)?+5&7VMFG(E
M%-;EFA@K0H-HV0"TSWG%21GECS"FO1CSRWZ%XS8N9TTY<_K0KNCMR;?=//VX
M?L.DQBYIG O(2]Q^&6S=\_8K__^$RN,P_0;8>C5 ?J94-^+!&9RIF-.(U;?I
M4\[HJ8@F[4E\@U&0)2TGL[P;U>:%1QT/&DWNR8F4LI>SN>9BZD!LF+;'!G4V
MM[C&9+._") M^EZ(HKLOL)^ ZX"ZU64$;=)W)4+S=7>]<=QZ&,CG:E+H3)Z7
M*(T$9*C<X!4.$RQ?A<N^9Z[%0S$>D+'![=6LX\3G9U^^+R[$1"U"ZBD@GNVJ
M\HQ6 Z@/!;+B:X&D]J @O<[52<0!_<P@.R%A5=2[*<6!@$1<?B7,4D*EL8!$
MVSD6W63$IV5$AFU-L-', 92OV[[4P@ZR%-AB"HB>GY4+4./&5+G,*5G=B)^>
M[QQ)+I@BJN5%2*T^3Z.0\3].A6NXUD1L,A/A?XKG_&3(*H6;,R(0N5""S<"\
M5HP'I($4T(WCF)*')$[?XIP\\2/C1W*-:-,C%I9K =)@C9"+%\NC,!85?-*5
M385D0W.]EHN",/#57*N5-O9'[X9:Z9L,^B/OY"I\/!( B7<=?OL_4$L#!!0
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M\$W61U/-0 !QFQ<*-F]P90Q4:%9'";2B@1K)/)ALN_@Q(60:RX'5 JB&D&-
M!U83H!I&CE$=6&F ,AC5S?/ 2@54FU"NP1Y8O8!J*&6V^\8+",B+R=1R:0*M
M*Z,E#;(,_<>!1VCP!W:-E(0H,/W#O4,$- OEN:)7 *PHIPQ.YFD M@=+0^3[
M+X!MP?((*_@\CF"75O:3P!4 RYQ4^@X2N**AX36P[UT!5FFJYJDO>%> %:.J
M;\[W?#/ "E291BYSZ@ K857+BI<Z<J"5N:K&!9%G!UJQJVI(2_ATH%7"JL8
MCJ='5@*K]IP,=^:[4]>QB_7(GD@SQT7A([UUX_SZ](%Y(%ZV&S>D[J05)K<$
M63)D,ERRF+IAB*+P7I#XH3E"I<>FFT/,RR_1Z TH\I_6)@X'TRY9B!/76T7Q
M;B'[*TZ#"J7Y)_+NK<&J$"RL,@ @O/'MGDHTJED=6\T!8<DT$O5\CC!WMD'!
MT,SZ@Q:XOGL"_G2C.2VN'=^IZ$>(2*M[=XJD9XW.0( 2+U3)5IA_O:$ \8!*
M8RLB:XZ":?1*3AF5+"9F%T"8#C>OT'9X(;%[,-U0NXLJUK[&1):_"X+)J^NQ
M NFK#UKM57>SC.DMEEZP1N@*^60NH[#WMB0*B5AXY/2!E-7S$[FS.36<O"!L
MS] ]??"#JF<.COUAMG<58!R\$LUF:$>HNUQZ+IJ,@WMJ>+AW[6?7(\H4"H?(
M"8@V%)*!(EJLGPK+Y ^V%_=(JCN0W]T.1]0%(;KPFZ<'4B92=_+?JY# WV$#
M-U1;L6<QI:>!P$A]99&K^ZOH7T<30*D)F\<S)44.<("E&OWET(,/O%0EGP>?
MJ?D=*]@]];!Q_[U.#%0#Z_I0L5%-'F^:NN,!EX3TI-.%4I4EN3()]4#0!R)R
M&C!U3GA/[AU\/0"-J#0I1E;00(^7*P+]%&R86&70!](PP<:<56:H5/.4A)H=
MU$\[<N9HLO((]ANTQ,AQXXFC,Q\"]MP^X8#(6]'ZR:.@_ EUIB]EM?O*#@74
ME\LE7,^I*QX&D-?LVK/I8[P"BN45!I6&:!5FE;)0BH- PIT*KSF%&DZ6G3Z
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MMN^XME?,P? G^:^';OCKP?;M67S#M*&>2TYZ(4Q57\$5C@)4D671K*>P<D<
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M@3^CRL8F=DMA+_,Z0<)UP-EM[5XWPP5(]01RJ5W]E%+*=2\];-'N?FCF/.'
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M1TH?=;4#MG>Q#'SZIBSA*$"M5"R:]0Q0W!$ Z>E#NI6D9J2\%33*%8P)A7:
MJ+\*HBA8D$.24J=@^F&T!X1F'"S5H>PVUGV\%-B:,FF+ZA,5&:,PHN]N#_PX
M9WU<R%GO^XZWFJ!0N?)3]4$+IJ6#F49DMX>2U4-T&!^Y04,(G>OT+ASY@,T2
M6V0*L8 W-NQ0R0/#O@E:#HIQ)QPP8%)N'=%>=JVR>6@>N$9N&0ECZM;08H+?
MQV&:MO\K+Q)SUM#.&AH$F?2LH9TUM+.&!E]#*ZF#G;6LLY9UUK(@*21G+>NL
M9;5/RSJ\'O6$ W*"1FNBXU'];KE3[B]8Q(3&_D!64_)S6A"QZSBKQ2K^D:##
MR$G<B( 5L0S/DV?'0')0^MJ8?"B@*AF7<#V]3#P,(+'ZVL9X39W7<9X+9\V2
M/^+(#9.?_4E_L;1=G*[V.QR$X<XH,EVOKH^"Y:O*ZRF,#H#P,#BN (K;"Q R
MWO+S)\45J !69R!=A92CS#VBZ"H(?J6)2!P*.2TMS;HYX#<+M/IJ<7XEC03C
M7@;R@U)I"$ /O\@)5C!]J X""/=@.G4=E-.GL(29/0 AHI+NBLCJ.I@X?0PE
M5]S;SP&FK==RFL0= +W,<T]SC>>!1^4;'+S$-B*E6IO\?J *+39Z'D"[ ;CT
M"N%R>UD=.(54NY-)K 6'\6,&X[GMIR&L5ZN0J'A$Z@L6SZX?BSQA.3Z8^01]
MU1D*TXB&N Q"VRO)$'EW^C#UP>WP2KJ_DC%>JD4?N45>CI_'Q1HU;,!6_CI1
MJW$:O*&=1RX/GDB#/Q:,FHH[6-N\&FZ^.:#Q-"4=5PJ8O=W"(I(5[A%5 P3D
MZI#J(,JS(;=(@#T4-2#PV,"S61PS9KY- ^X]4!JVU&P"-I/5Q%1+;"J-YZQJ
M78_-G7&MBE&HIHP*33$G@-^<"0;LP6'4<J%@GCEPO</^X[C[>->_NN]U1Z/>
M>-2&!(&^']G^S"6B:O)<Z+UV. IW!*!1*+OTZ@6?,'L#\KBS#@^I*Y37"3@N
M!?<&OYLN-H[CK#NS/7>Q6/GH/IJ(76:,IH:(N'*#7P3FF-PC]A*M(M<)I=2(
M^AB*H+CSW+>.F(I"$T Q$^87&S3O62Z0[IYGN3!R%P235]?SU.,HE(:"Y(57
M)ES'CZHX&" ^Q!3NDJT29<'O9ZCFY-7]US\^_B$YQPIM=(,ACG9Q@3MNCBL2
M%D[&FZ%06  1DT?'5&A[L#\AJ]J=NE1AV3U'TB<80OI<Q6#:=8A2G21BW)#]
M(H1>>M1B.,6A64,+#HRQ[8=3A/%&W^?,]59;JP/GSJ&VD&B=90%E+,>2Q<OM
M974T0_DXQ\(3P@Y9)/:,6H&2MU+&P15ZL">LI27K0N"#8?CFMJ U!3?+O>\G
MQ08'F/X^NYO%^TAK*.O"C.)8Y'/Z2 LYQGXB=S:G658O1#><H>L@C ;3:WOI
M1C8+1,F1K LSMT[QR^D#,_0H]OV5[9$;_#6:#]F'F$9OZ\+,0[B9S=?V-O-]
M/;?Q+"YJ6H+MI0>T+C[6CTA_.DH.9UT BM[<W'.AP*(O%>7%\9N&/F)=P(G@
MK,81!:@ XC=%QG*1\T-J?S[R:$TN;![/!"9MP$&6(JIUD((OM" FFA$XP3:>
M'PT\B34>K#M<&^BVP1]T5*3AS=C"V$;M4U?;%]"*T$9E,-79TIY01PTH/+:(
M'0C'RP&6WP)TJ9T#[H23.#5K=%0<\(8]8$K1A2JS-\X'L,<-CU[&F<)VJT!^
M2 K.$FA5Y&TI,T(E5\WQLH7AT&E%0&TIL$)G3RL>CM* K>)*DKS]U#K,53Q*
M&2\^'0DO*CBF,E9\/E96B'U=&?POQP2_DJ\LX\C7D^&(V-N6\>/;D?"C'M?:
M1FHZ.C8I^=MR_ <J.+M+Y*;8[.Y?SBDZ@!$?5XK.D07# N7KN2PL7&2ZRZ]"
M@5CQD.=2L<<?]WQ.=3IT-@H</@!(=6J@K.PHF$:O-E9YS(G=Y9Q'!32/JNX0
MR0Z<RTBK/$;%8%JCG[(Z9B*K;Y"'2H/3' %2]=N\U$>U254?!E(56S6C?<5C
MP,PW0-3#/<=3MSY&!7(\-IC"F'!#G<]%;]6+WDJ-$6"C+,[E;\_E;\\AXI "
M8X\Y0/H<(JY@H3E'C,.*&(?D>N]<'C%\\^::8XOW+&'].;;8S[*&H%./!U4R
M^T@"1>N.ZHEKB8>5JNOR;*X%)B=?N1<$V\BZZ$;7*!/%BX<1-:_D_I_:X7.\
M?$,<Q?;-#\B+0OJ_F-Z85O(?:Q01M8DNL3L4S+"]G+N.S7.K"MLW0VUBG2M^
MF^M$$K:O1&V(G-]GP<L'ARJ".#$?9__9T)O^PNK?,XC;_-%40=D@C 3O\NZU
MT8VC./!TE7+K\6(_5I0!M+XY6I#CE'M.[+8S5"(SWN'=&4;Q-GH(_&CNK6\1
M]W3@M3?TCN@FHK@7'^KQYYX0=@-65359%]VW1*45HM($ $0FP4$3UY\E'TO2
M0A)3#(],K4&TGPGE4#ZD0>F#Z8\PN8U_8C<B+!I,ISPJN1VLCIF306%"BQ-H
MJ+)D$H$>#RQ8V]NM(#FSAXC*7F'7GSR0\X?,B.T[J/>V) JU.*Y5U+'H:&[
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M-&8D/N;5N*8QA/79E.M1^9./B+L"]4:Q/AN\6K+K05H"B]W:^FRH-BIS],1
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M]YU@P3TE-(<AY)NY9:^0CZ:N$X?U#E[]/A&#'11R#V!.<ZM3*#AUL(??JI1
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MX\FP/7)*N42N?K#QC+\6.<U-I;#VJ09G>\E7UF.$%SQ"]EMJ)YUR=R;9;^3
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M#HO&UY+#HO'#IV8_130-+URIS6KUC?"4]H4_B297*E39R8!IZ*E5J0=HV S
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M_$W; T*T\94!(=I8RX 0;=Q-&SZ\!,<2]V$U@$<;4\GAT<9+<GBTL;#A*$0
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M=TOC0YME12K)A_0#4881(C!$OC1M/O1OA;?19G']*+51_A[3N7B.3Z"'KW6
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M0')4&L 0^N?N8 B]<7<PA+ZWVL6")R4ZV6C9&:&OK.V,Z)1BMO/<-J5]67D
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M[6F,]DT"+:KXPXP654QC1HLJ]AUCJ!<.Y74 &%64(P=&%<_(@5'%KUTGN)G
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MF$0)BS"^)'W,579>/]7N%KB.Z@ PPFA!"XS2]U,"(\H#8#JYUF(E-RN(?YO
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MA]2'9NV7GYT\*@@02+UE*PA$N0PZ02#UC-#R6B9>_QH"@2K5P67E 1"IIZ0
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MJ!A"4GST3%66N%8?+M^_??>QTBB]](A&Y:.DOB&C\M%PWY!1^:A'O 4:\P7
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M"DB)D9Y2J[4*4?3.%NGJ3.U8+*R"M!CIH^/<KI,XUO)^$YNS=>I*P1_#6*L
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M/R(P?$2,=/SPEICC0A*WQV- X:-A]#YQ;(6Y.A'XF>$1WHK\F;X5<1P(?[*
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M>SVI_?)(B(_>20 F^;9.7BXVH5=[C+VX"M)BI&TH:3%3-UN,5[B3Q"):'51
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M%W=9-N]L'VJ1H\Q*.FY2U DW*)J0B4HOJTCL&25Q0X8.1'UO$YB=A17V[\,
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M#3\ \G +!X IT*M=K=XM\C@+!T#_..V>?RR7EX%7->OGTT__Z%Q>GHXX[?=
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M$ZRMN5I/M5V'YD;MO?&&NC%-UIZKS'[:M;5AT02\+A\\;*=<>O:CG]F4WJ3
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M!1L_NX0V1H[?.3!+([$K@P==-E%R35LZ><V.!:5-^?V9>W %Z<HD0L ;KA:
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M=A[EPO*BA)=%=B#12ZZ='KMJ]F#QYL(SGH;W-BMU<Q\7,KH#/$%((W$'MQ6
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ME*]Q><_/-OJ#?//#D-IN@IIG/!:Q\]T!DG8,:"!=)$'X;06O^]D".2&_L!_
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M^M^.-=\X.0=VI#50HJ-53!)L*8]@$"37!I]S]O<JV;D*7 >YY1I545C1$MS
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MRD,.[G#M9T6CA5\>3-7ZW8HFN#0P ")S4=:4/CGV30L*MQ(!H2^APP>@TX^
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MA$9I4A?'<D/0RF[Q03!)C^6 T)!'Q-?XDL;EYC&SS'I-"*(.@4J$U4*V;GK
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M6[9_GMUEVX2KV@1\#.*T@%,0 VVA('F DB1H,#C;DD>>D'F<!6(HG/ID!*!
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M2S7=[9/LB=(+&37);,\RRD.HL(<@K)\0YOR-E=Q$8YW"R$2@P>/G@*T3<9"
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MX7D3E.**X9HM.G^G00ZQ1>996?U]0U/^9TL/?/CQPQ_???CQIQ]'Q>+<!<,
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M1%9^STUIC/1HB^S!+;#.H^]E75PG>=C"$^2A$HG]LP>-+/%?D)"([LMWK9Z
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MOK:J.^Y^Z:!%2,(416I RH_[ZQ< 'R()9!*DY,E4W_UR^TXY,Y4'2# /2?"
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M[[T>4[*QKAZFU0^,%QN5[=>;<L= ?B>6V3J5_R7BZM\U UU)PQ?LLS8E<\U
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MYWM 0CAX_HGQ?7G>V4]>@0M&<Z9L99=KP#B'&AV0>H5.& &<3XT.2+V&)XP
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M!N4/='; GJZNH/R!3@_8T]5/GL_3V4.4QEE:5O:=.>PG6^WUO4J>BT)# 4C
ML"M=506@ MC!L"M=K06@@BC"H"M5!7[3/$P4L^52Y'FU'#0,/R/PV5+5F#=O
M0%_59TM51?Z\_1W=9TM;)S)='ZZQ@(RI:TE;(]V<_7W9M:2MCV[._E[L6M+6
MAMUI<*OTO:E.V=]^'4/:RNAD[.^RCB%M770R]G=0QY"N*HKJX:ON=J[LQ7M
MG'' C:YB!M! +1-UHZLF' T@I#C@QJ'2/-][ #J'N!>'.O-A@7HNYL6ARGQ8
MH%Z,>1'7V,ME5.AK+R %V#$BKJ Z4Z@3MXR(ZZ/.%.K +2.ZV7^6V_WV:J]S
M$=]D8C[*2$7U-,J4,M2+43>Z"AE  W5FU(VNB@;00)T9=2.K-!'+993,5JM(
M*IT]H '8,R.KI'ZV0*OMFI%5BDS-E)N/UCY'B=F-?R?^M9>E NJ/-!:J\\Y#
MPP&Z[<@X9+,S&B_0D4?&.9_Y!=KXR#ADUXIR6^(L?I1YILK]C(!$G\>4K"I]
M60.]WS4EJRU?UD#7=TVI*N2[*.SC9?N6;+ZZD58K3"<HBDB]E"=(OP<T\$)\
MJ6HH#)>_\8?X4E592&X? ,V[$%_.=?@!T+H+\:72N=.Y?<ZRGS:U:DO$!T#!
MSF-*N'K<K/VMWV-*N#;<K/T-W&-*6/E-LO[6?+ @K(<F1W\C/E@0SGZ3H[_M
M'BS(YEKFYNHDXHHUYDW&0(<%[,GJ ,P?Z*2 /5F-0/D#$FV0/6']-!D#O5 R
MJ)$F1Z#1209U<"O4998DD6J2!?J;:THXLF[60']S35F--=#H7%.RE9:E\YU0
M4>OUN4X;Z'T>6[(:\>8-]$./+5F59(^1*O3\;R*UC9HZ =JBSYALQ/?FY^>K
MV58HN8S2ZD64OO,H#R<NY1866:/4I&$!W7)TI#/"#*B)C8]$5J$3, ,]>G0D
MLJM@E>EW\=1.32,#.CM@3UVG;OY LP?LJ6O.S1]H^X ]O_H!" !@3_;TILJG
M.O-S]I 7*EH6.G^ "0#VU/7OY@\P L">NO[=_ %B -A3U_]<Q3)MKN\M&#@1
M -S(JPE  PB;#;B1UQ:$!F_>@!MUI=TJ8;Z6%'&M(5>3B>;[]E@3$T#K;%00
MZBH,1(HW^J @U!4:B!2G!$%!&%3O5IJ-ZA\ *37'D$$5UAGCE* Q9%!-=<8X
M"6@,J:OB7JS++5<? ,DTQY"Z*EH9XQV^,:2NBD/&@$::8TA=%=5UK+Y\Z<3Q
MAMVWIZX1-W^\*??MJ2IFKK/)TH-P3OVL#M!) \RI1G]NCFZ1Z=H\76F.%:[/
M-C_(J'\ !-0"W=FC\W?70'>RRMN)M"Y_3;^%NLBV6UG4URU__T6=R.8)1^+O
MRZ@3TSGQ]VO4B:JOS-6#_";B:E/>8:GX&[C?FJR>BHT=Q)T2&Y'F\E&4AU:9
MS\IK(( 66H K:U3^IA_@2K9B0E#YJ4" *]GJL:GME3D6K44* "$SOS5MG;FY
M Q3 :TU;36[N0(/W6I/6S/<LS>J7T&4U-U^K?P#4S8;\2.L(Q0,T]@$_TMI"
M\0#M?<"/M-XJL<36@UY W<QO35I;;NZ @IG?FK2./+DCK=NQ9E$S]=45T"'S
MV;*HER9OI!OW;%G42I,WTHE[MJ1U<B>60CYV4T<:L6M.6BV^[)$&[)J3UHPO
M>Z3=NN:DE:.;*: ,5OV9M#),=DB3)&8H.CM UJOZ,]7,UI^*.\>_?P#DO$ '
MJME'$/A;(.A 52$( G\S!!T85I&_+8(.5+NH=$+:-C&2Y2*)"G%0U?P R(#!
M'H0K <3@;Y*P!^%: #'X6R7L0;8:+F<7MT*M,K6UYVH^)'(=F=<4==,'1,.&
M_,CJ:A"/O_$.^9'5V! >0#ALR(^LWH1:ZHMIM#:/6I6YHEZ*\K_7Z9?GY29*
MU\*<A*V! 3T]- !9!88C!'I^: "RF@Q'"'""T !\JO16Z1N<6*;K\BBMDA)4
MI\1] ,3)QD7A4Z\X5H!AC(I"7[GFV/%8EN_CS;F0Q<MU6@@E<@,1(" ASO2S
MB"(#:$F(,_,Y VA*B#/]548GEZ9[LS.D3&F^,E)(YEPBC0P@+"'.+*H11 8H
MK04YLZA&&-D0=T&<.52CW3^2YWJQS-/[R+PW:*2W/@ 2;8'N'"H213?$6%!W
M#E5942G=>,L2^ZJRIV)3\C% ?BW0G</<H>B&J GJSG[NAED)XL[AJ@(I?WX
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M<@4;9,N*<ESSE5#FA75URM@B6VQ$]?_7!]']"@C1!KI3SD00.K!MAKASGSM
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M[]L\1UK<9%%JA"R%?!2Q 80]F@H/1/O@9A1@[,'4B$#G QA[=!4>B/:1^RC
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MU#9^S\PCE406+W9)S.V?\Z]Z-11F^^T[3$-\0L S'(!0'AP8D,T E(G=R)4
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MK&4B(+JQ;(*<-IRD@R%*TG.\1B$6:I#[F@1(*-&A<;U3T)YYQ2.LV1-<\ '
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M )B48]O0P'>MH]S6@>UJZ)^V.H=^^]ZUCFI;'!YUW:8HCW+8IXU>LD2[H:_
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MCMK,7?GNTG5(N%)JI,'BR@0/<TC5&,VGCKN8R@&4 @3T+!9"QS'F=0Z?'#A
MITWVVTD=/&GJVU(!NSBCQ352ROK:ZQRV-W6C[T^8U%5RQ4#IB%O^3%0*9-J0
MR0(!>M9I*-<YY (XISO=M;Z4U,D6DWSZQ_.65.QP;&]_^0RCV,4"0.)3^H_=
M8J7>HUKB&=TO1Y9 ^7U0K%UBD\JC6@,LT&.G0(GT$52 ">BQK?=-I0ZH&D,
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M**CE)%<""^AA5/NB<EYT55[T^U0_CFZ'S[/AX/EN-KS].AW-1\/9Y.OT]LL
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MC=\&>*^]12[6:\9X"V%2#LL!*"9[*D&%Y$;(\1;YK,H# >(OX:4Z' J(AN<
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MT@/\!;&63?ZK%D%="SJ\:..!'[L+U]NE)?#P]]PE%YUL4#5G>F]HE0^OY@(
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M?,-$_[##!6T[,L>6ZR>>(MA<+&_*^4N4A+5^Z,V*-+'8Q)+OX#*!B;$TB>(
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MF#Q>XM=XL7/BF<V)>CD>"2A)/46.A3]UW.D"O-M30Q1.:'LA<B8Q5'"?7$)
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M).YKND/P=0/D54A%WP);CO0EG)/+5C16_^TW N[%CM"__W]02P,$%     @
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MCM_(TX4XA5<V?_WJU?S5R\4B.SI+,_G*K2-)/ *!557?^G_C)YF9N?^<R#G
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M1$5.7JJRK7MX(9@:7/>DK+\E6,N6F::=HBA:[S+3B#-A[+654,07["B=.-C
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MP;=L;IPW[;2,;F+%= T7#]Q5QXSB3!E9MG'1!&[@6MLZ227K,B>KAEFE8\'
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MJ-B)%7])I#"V!-W/)87W_0@,=G!KJ\:ER V0P<N)#+YX,AA;<NMM200X^[E
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MKKC/A-9Y>+K#V%!-;JH[L'EM"29N7P^4((,FI6M)LM+TKKKD=N>FC1.'08T
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M4WK^?[6%U#MP<G8;1VZK>>/_%?P^DI#!-8NQWNCP@EW>$N&+8'K?/.'I=<(
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MOZD5)@(O:L8PPQ%S>K>(I :S<6WM<;,'XV;;VW;:#_@$JTU8L;?AB)?E")9
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MO;S'RAUJ'+!.,'6(.;E?V2OI=,02%4-0O$#I<79&FB4S9.?BP2 7;]Y7I#?
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M L\;8%WFW_A\.G@A=9]/!V^K%WD^;55N1]->^1*N!LV;_A]02P,$%     @
M'3EW7)3JR&O=9@  V)4   H   !I;6%G93 N:G!G[+P+.%1MWS>\2J6HID(*
MF:N0LDF)M,%4LDN:D&0[J607+B%39%5"$5*A=#%)DJ2I[$J8&)LDR3XC9HQ$
MMC.VR\R:M;[3=;_/\Q[/??=\W_V\SWM\]_U^WZWC=)@U:YV;_^;W__W.M5;X
M5YP#K3AH8FX"S9LW#SH!_D%X)V0T]^F_]3/7R7^WCWGX>VCEXOF#8N?$YFV
MYJ^<)[9R'EX)$2%HWL*_G #]CY]Y\\46+%PDOGB)A"0XH6 %-'^>F-C\!6(+
M%RY8 +Z]!+Z'%JQ<N&K]MGV+I*Q<Q3?X2VM?24A?K+3_5;F,=2-/>?O)<U>7
M2*R67;-63F6CZJ;-:CJZ._1V[MIM=,#8Q-3,_*#-4=MC=L?M'4Z==COC[N'I
M%1 8=#Z8>N%B^+6(R*CK-Z)OW[F;F)1\[W[*HXS'F4^RGF8_>YV77U!8].9M
M<06SLJJZYD/MQZ;FEM:V]J\=K!YN[_>^'_T#/P?YXQ.34],SR*Q@;EWS(+%_
M7_HOU[42K&O^@@5B"\3GUC5O?O#<"2L7+%R_;=&J?5;BKOY2&[2O+);>GY#^
MJGR)TG9KGLS)<XT2JY5U>E3X<TO[<V5_W\*N_B^M[-\7]C_7Q8*6BLT#SA-;
M"9$@#-OT*!KZ5_M7^U?[5_M7^U?[5_M7^]_:Z"0DBZ]DA)AR#(*YQ!N:NMY=
MLDQV!\VGX LG[VVK"M;6%BA:WCG\DL+V+(Q_/69]U1SM_+JC\W$#\;[:8^W0
M$!PB_(80<6@_O<H/78D8X="#%$11C6_!'%W\:5.?DWW5A6/&][A; R<D=AX*
M.O@RQV;AL3*E960I&0D;E\]!O'LIYEV&7MN;:O6F.L3G^4=)<P;/*)"8"-J^
MT%1*?YV3R6KIOL-KG@4^;4M=N^MH3'^LAK%$K,.W@@UCI8R]3^D-;.2"^'L<
M$LB$J<.<^ HB^JWQ5U.:I2/WM!;BT "7-X,MI^/0I_ZW.+0BI)(M4-I.0V5,
M<2CY G;IOF"A<5@8#C$_&(KCT)<<OB,.+0A;@4,_?L3_:B"IA1R&2,%%$8?*
M6W%H]@\2ET!]@$,'S@3@T-6G.#0^1FK((_T7YDGBGBB1Q:&,&"8;V<W H>U1
MZ+XQ*7C@YF>89TO$G/MGI]T'9&1FA;^\N.<[40RLT1;)!<.3%L,3 :;H(=FK
M.#3I3P6>$K<#"_D=AZX;</U$*^\W8!(9.%17@D.&GT3S'S%(\*^NUP_GP"()
MA@R#9]I#P'P]<.C&51X%B],BP)Q!'$(_$_GB)98X]&C[+F"%H_!L,*V_@_;P
MJ%W_V"^NC;H52L"A=#MN$;8878]#]?5$_E8721QJK.H90]=1<.@^$_MMY@9C
MTL2=A*C%X]"6"52X?5(B>A/]:T/]_NA-#^?_']P(=W'(ASV[@W"#/:."0X,5
MO%28%"2:'];)&#]+E&*,6N!0:T3/;BQL""T0^.)0;5L/#@GUWI*Q_#^.PQ=%
MJW'H.[N?.'W\!U'PN(?S*%H=^8[=D=CTZ/)?-U(.^,T8V(M#ZRK^"5;^W[+:
M#0;G$2MU.E8HCYYLR>_ ZD-\<$A"6/O@8Z1/6G 5:<$^U='^N.,/ JT_T/1]
M8CN3E\I$C?_$(4F]:A#[\CCTT3<!AS[(B SA\H/P]X]A.CC4!<*U-8]S$+,:
M0JL%'LW72JP_**0O(4V)J=O=M3F/0\??Y%CD3[;2?B9_J1._5DFET,@K(YAV
M*;W?FM2"GEKGJ,@POVFT',U:JRO=M_'V><LB[\)@&B\OU ^']C'0)S^)Z!53
M5(,-1O\"#FTN!A#SFYVX,;PA1(XR,4C#YA''22](>=IL@>P)F'<'I,7'SQ/8
M:K]8D(%Z.'2W2PF';FW"H8@'O;!@&0[UZ9D!YTMP!C*^-N$0[2@.\1:#,^ S
M;HS)+0!:>C8".$A,[?_K,:W^U@[EC::O,D':9^,09R4X!?M4!P\X7\&ABD,D
M'%+?TX#8EX$I/&1C-H'QV-Z,OYZ5>OBC^%,6V"4;''JOA.T3W4\" [X#T''M
M'HP=^WNLH%B=C JR<.BR*1HNW*X)(.$\ -PE6P&@/!\C]9Q!V%@X/&O91)J=
M'_\?)_-B>;1!K-;L%!F'H/A9\>DS *+W#Q.P5:X @.U%*C#3/-03]-> 0YKL
M)0""H^,13ZU8TB3P=]^['A)F91?92&$3AY(!SC;:5M*0T'K2+,!J [C54 ;@
MF'L4L&Q],CRQ;29YN(?OQY6-#_5_-H!I\,6G"U-]>BQ&#LK#P[FK:MR&=Y=%
M>"MTGW_PI.-SYXF2M_%U%QRD?OAZU#T^R_"VZY<=!A95T7+"H5?RP%+-.!3I
M/7F>D1.ZX=.V6=JB+U5G=GYS<;UQ(=*0L#*VLJVJ_?<(LZ?[VNB[$Q5./+"*
M27Q4:(:Y\<EB5^N0UX7R\\(K.+\/B5U-20]G-C&M;/Y0[E,Y>'/]PLT&;BKR
MM:-?K8QE!!=F/U@92T/_![9Y/ 8JG84=RNHEBYII(D?#!?0^149./+*9C-XG
M5].$621!8>@2RD<#^#[)DC"[>Q=!=&L7!<MWLH:SX/T-L[J@G(N29^E87HF:
MM!7(,EI[NK'TD7E_U<1'JZ2M*"QQWJXIRJ_=LY-QFC"[^6*_Z#J+AM'0[92,
M E$L)PN]]146KCU#$IP3'X=C0%C9MX,+PT#,6WX"3$KD@9;\P\G<_V)#IT"U
MSZ%T_:2])-?$#*T-C7E*ZK&;M9[UKRWZA-3S1F5G-YHK^31^&)I87WUNZ_N5
M*,CDBF N0R ! "D.\)T/0:)HN-R>U$=D$^'11%#8AA!_2M4(?(]AN:,]VG[A
M PK_LILS//B(FR$Z*5CB.F#+B[G>=RQ"[K:+T@^^=?9AJ=O1/6DK/%4W%9WN
M/,\:*<MR!FC C@:@HXY#MW># =<W_LV1=B5C>+WS#!Q"*@C+# <0<4@/6PQP
M[<.Z8%0U#)SVD(Z9_62@4:;_\:-3K/3<583L$Z W*0"M5S?#X^)_YXBRE]C=
MS,'C),$")LR)IJ!7VN'_:(O O_H<]*'1F!T\\U*01,"N;&4C&Y(!! :Q>:D(
M';O*F%5Z H)I'?$_?CRG8Q7<)1HV_.^O:M@4U2)&DR9UX#XI)@/-SL!DXZN(
M CG2^(T>-G:T_4XCA0;3%0!B&L/2," ;.P!'S)MEBEP^D 9,[X"RD@=H\T="
M/L,=9LGW+H_O=;;N/\R'._KO5+2_W(-#)Z@N9RM9A3>4-G9,FA]QXQJ]V>1:
M!%TV([G!S*/H18#$8P")X47PQ![*?=I\QG??%GC8"9#.YK0$BEW[_6A^?-6W
M1WGE?89JU/A$#C?#>N>A=W$['RR,C#T8/9&2'EF_V=KF@?GG@PI-%PL;JA!V
M.&*QDF:;38E SI>2<UR3\W-ONR6JNHF[U>MK9+HUNM2E3ZJBNN0:N@#0\O%V
MGCM@T?E_.Q>#1I#Y_'4EP*T9M5PZIF&X!8?ZR\>)@^1%<*,2DXB<^,B8O260
MPN2R>MM%!'C6&]D.Z"F+U/,LS #^,H-#28QPTFPJ/6T@ U,J @5R\H*^+0Y5
M156Q480PI1I.&DCHB4>WNE'0#Y= )5IFPQ_"HAAH ;H6Z(^1L+LHQ#_&Z/6[
M%K:*3[H!9I8_54\6AHRTL]U>OY[ JK@^[N1"'#)I'AG1X(X_']'L$=67A* ,
M;<OQ=^_"-ML-NP\#GJXL^QZ>T8$'W;EJ&%L@1DWD:JU!F)7WW67Y."3'/^9H
MQ'3J)1II<0^K-01\6J80M&439]A PT=CHWM\E>M/[L\>_O$4:?Z*)SG[XS:4
M;JK?7V!6QZ<IO F.&H];5?=JUS'C.WWW;O!7K[K&7QMF?[7\6.I:M[>EYE:)
M3KH2MBH';3(/GWORG=-_>)7G&V-Z.L 3''(F].U]%+T)^C^DB4UD81*U.+0)
M0X"L"@3BT(["C,:TO(7[01*]AC^2R@P!7P2IUMK.XS)B6#BTS3 %'@]\31#^
MIDT7>;P![,'!\ I[W(,:CWTV\<>AYS7B$:#.?#"=?O^K8B=P-9:VX_9/S(Z0
M_B8A/A+_YE!U/V5L H?H@2#$[HPK:N-00A=9*,[$H9]+@<''R8E_DG[135$B
MX_M5A(#]B!<=0HTI<4'"M4)UN'8ACRBJ)PKN(]$,("G=9=$T3 V'\FS3X"'G
M]S4]%#/2K))V@W SCR)X]CG^+S[T(O>^_R?PS;]\^/\G'][!)%KU=[!Y9'K\
MA).E](HL5"UWO'Z#L9POTL'KD@V,L[4+T'Y:N_8D]/T*I0J>;@.@N\\'H++8
M"(R,P&Z N-M39DW8(^M #(#2:==0,8BM&D(Y@A-N.GQ,Y7M0ED/@-ZJ\1I9'
MM:9.'K8Q<:H-$U*41,X"":Z;:<7A#='1B:A)?=]Y%CN2NL^1;#1 &<F5QZZR
MW#%Q$#)\%JDPWT\@Z4E#B-XX5./=_TQ]EBQR2@?3T(5YBXDLD@L-%<9W-Z3#
M_^%$#XS5R!C0? )S+H'07$=/>YKQ/Z\2;P="R+!W)N__<3"@!NTVP5\L*>C\
M>5- WS:\$0T+9(7>)H %%-['H2O3#/1\_M"/BX*3)3>;MT12AG>I'<XJG"[Z
M8>[8(=SCT#7;)5K^AT&P8QK?JJ^OHRC,UQ>[ L+X=B"(]+W$)X XAVV!26G-
M/'7,9,04JZIK$.WZ*3-U*33];X[X!F$X1!+, !UF3EK?JS6[K@6'7H:2L%L5
MT9OHRK-'YKQ*_]K0X8B9:5W&H5$/'&IIJ+1%^BFO:*^+T%N4>3@TMPF63;N>
M W)VVA^N'>/2A;KV_5C!MZ5A,I/ @;>W:^#0:QI@(,^>#PA6@8ZG'V/ZO]KN
M^&=M)"!I.:\9X[$,UA[LISA&IT6THBKM,X!P+01$^:X/ULB>,2--A:);Z#U;
M& U^F<GH'T[)V(?G[X"S2TS@9[1]C%F=;T8@Z:4 -VOSOG85F.&'F'#KO_%W
M]9_1LVEE]^C)7/+L51QZ2Q.]O[B&,!N"0[\#L_(>1:OW->R=.U&T%?S-#YA%
MIVE7*.-Z7J3I+2[PSP8S>LY0'^&OC_0&T&=F<:B]&!:8SQ+6PA]&LT3A@!].
M1H(HN:#Z<2YB%H95AWUDC^\+!=H]P!1[$K:!7K/[;R",#7 J!B/#,G#'LP;2
MU O.*1[],1%-N.\NNHMHB6S=3;_<!8JM0)7/^2=0HG^W8IU=#US85ES\&A28
M8V$M13N"M[.<JG!(PK3N36&*F6H\/"+/B];KT#AT>R/2E5#X\MO-C^>>[\.A
M/23DH+XE#AFM!BX.OP0\>UM=M!+FO)O;K*"P,K"!8"P?K@ "8A<+V\?'(B1*
MW)(.9LK9*K]Q7W0WZ["4IT;[+D]5Y:X7G87M?F^Q8M$\UR54@\JX(S=IZ(&2
M'A<KRTZ1':?=NX!-L0G&5L5+P5^J7H P9!\!FB2:U+.)KR=:ZC"&+9LB8&;/
MU=1Y[&>NI %Y E@(",MQU1GQUW.[0S__LCNDI3(CS^#=I3[ (C6#<6B1( J0
M3BL@C4QO, 9.ML,\OZ?PN+&KE6GK5MKD,O!EN0X.S:Z8/LKH[R*A\TE]W\MZ
M_XY9;!(\D<*NO,0A9",-AS8H?DQ&A7_9("I)_N8+!*<5UT^PIH"-R@^"V'$I
M!Q.@W20-G.5K880@,G:0/I]^G"ZO5WZ"W3IVC4GBCNT'XH5VB1-R05=.:T@O
M$QA<G&H,,).MI1S(X-U'F%ADPRHPGYFC8#[/2#W;^5&B96DJ8/ZCV3A4:UMO
MY:+7\CME4CP"#'X1"+T1H01QXD<R)ADUNTX+W1@&,CL]KY*!&+229M7BD4.H
M*_"I^PV8%_(,'K<-.&HUI2 KFM<#\]+F%)]B110Z"\QZM0<S[2#Q\C P4J,1
MOP&3*<8A'-*8V^FC@<5$$^-@7FX[,*&KDZ[,.-QQWT\D^9*$F /+]KDGB%)!
M9U^6 U\M 687?XL:(J_XAYOMW]YNYU(J)3WE#]U?FH1I\Q6V'.GJV+:_<?!@
ME87:[<><1)N;5^:,)IG1*RN2B;\!(\X(,&]2P3@H&XSOFH#PG/C)F'S25'JL
MY-,QF\2#>>?JM*='UKE(+NWNZMK>/Z&0I9:VT3K-/OFSTTN[),EEJJ?S[0(?
M&&AALJ;56@)U(C E[QT?5 -- /01C?P8++JFDH%N06UPJ,YAXJ Z34C<#"SF
M G3VM>-^V%$ 3J=. SQ1JX-Y49) 8\9;_.)"4D]@Z$D<>O2*KP4FSY &\=E6
MTA1->C5.$\CTL1'C2&"6?:+8.W.W:S2!IQ3 >6J_FI;W*"T<SC<=F7>*QV8F
M%5+6&6ZS[S06T?L<6:@E/[=DY5A[@3FQ+E+31\ER?,^'SJ.^Y\_L.J.,N;6S
M*$O@[S0JC %9']*2(V@8\$MV0V"IO(X>WL[=4J'B]ZL^Q\G%;MY9MK[GPLZW
M^U?Z:E9OJ6?Q#[>;(7&&'[35.@SE9%X[/7E^S,WDH.ZYX75FV1I;MFU6V:VY
M\8[7=.D#9_NI*%2'-B(+1/A,KQVVCJ0 ECD=CWB26%I8S%@U'=T=-K=].4+-
ME<$2A6J4B=$_]X_'*?ZS1 &=29H\_)V">-3-W8(2@5I[]72H$T+O'8LWU&Q$
M@_A[N+*Q.C%^UQRF,_TRD;SJ-&6^8JK?4V:O%L1B/C4Z]=S++JG1I<KGP@6_
M=2W^&C\7MGY2_RWN@BTC4'UV!/1V&*ZM0IJQ#_3K.#2U"_&G?$D,;3MSU_^<
ME?D6,X_;%KX?<$C7\.Y.#46QJK,N1+%KS!-/->YL3$F_EFZQS/CP4:\ <^N,
MQ?L.'G-JZGLW.+=3V4_[W/.+W;E_MB;^G8S*PIB5A? HW+4<%-]X9!^E?P]E
M ,#\0E#6[EICK<09(\94!K;";O9S^[A>/&W\N!MCVO($L)3G'[0AQA<I[- 8
M",*.NL_P5!+GRUP%%A->^_?:W:9>.]2F7E//^$'$N( E;?]6R_BABG' GX!!
MJ=<8S#%XL9^ 2I0Y37QN>,\>7_T&\*Q ML#&TR7'Q9;C-ROI!'_=[2?:G$^W
MI>^10NU^$C_P@/:?&W4IZ3?0B=C-/X<:T;K&&">7D'#(GR(R&+3E^US*Y"5C
MYC, 64:!,LHJ/<C(*8MBC =L;Q"N#R")/':>0#Z#N$LX3,2J=> I^=47=8$B
M^KERUDIP"8<6_(%#=V+X6:($"B@3@P% 5Z6K82$PYPYMW'_N%LMK=2Y)=#A,
MP6Y2A;(M!2ZM0Z7GU _Z7G ,KOU6#7^-40;R2&8_X#,[,=]_-%/[N]C<AE^7
M:1PRT4*VX!#Z*'D:",EBH#]RB;RKC,_G&0DEH:# ,P$TO?8&-"GGT'<<<L8N
MT\;=J<G89Y< (#2+%LT)S>O$;^O_+?9<7KF003/TP2%0968 ,/BG_0 5;!MI
M!O1Q#ISNLFMTX1QG-P/9--Z?=CYL$0[=*J@1A3_!H:8'!Z<<QNEB\ >'7JR\
M&?YIF7DQ]\)7&I=AAIE&Q>,0-1EQG067'U=PG1N-XAD*BM'M2W.W&H%L_#EF
M38_Q_NMH$3E/&@!_WT^#.R2!U!C:QQ2O]F] H^<XYK8,''KZ-:_QZ9SJ-(O_
M&-\\ABCWHW]08DG#T0@8T(86)2-:8C?1^9]$S>S-9M$HA0,*TF/:#_&F/.SP
MC^U8I;TJ=N_9'-NLF?C]GX#Q_=GL_D /(TQ>/"?IBB>7?I,MC2F@2KRR])Q.
M)(Q929,J\>NA00.RQ:*NI/1LAX'S*371!0:JA]^VC@:.J!YE%#6[O@GI>)[?
MM7]PIYSDGAM*DUY8 (/3KS6[E7&--AT<-A^'6G7YTR7+-W_V J8EG.EHE=M:
M:5OW\G7E_@C[@]*#YH=7]MW-N* RYC+D3&#P\L)?=O]&C:H(77NSVJZ.5V*<
MTER7T_M[R\_62M?TW4%G!JVS[&8";@<VY4_FN0\5H?J$:5!K,[Z)$DA\96P9
M/.%I^HMCE+XJ8W@/#E6^[R=.DMUHB"UPK!;EIS=V X>J#*E[L#A9*;B'#E#C
M>RF<21?$X1#S/: 0#(%!0X<4#JTB<P"%V7$7_M711,SI*""04F)_P(T&27#/
M,744= )(E_0L9TRPTPD$>F0)T,FWI[ DQB"8!D%,!(3-P SI-!DU)X534);5
MKP[:S?I;F:*'E@,N<V#:'I")X_1QT$46:M,?SACH\=?#Y,89F$6[P &$Z]A_
MP11$_M9=-2*I#G=,YB2C#EQ/XY/30#W(B*AD(]X?0=G]TS89#!Z/]%4+BP^8
M/@!L=P?1Q:'Z3.*O#L+),M+P7UO7"_Y_U[0#8*D+/40/R^9C+6P>N2&>#23Y
M&:U8]F+8@QUGN!M8T Z'%IN6TP"G6%6REA_"+;K)Z%F#=/!ZJUT 9%RSZV$S
M1[PK#;7X!%2I>P5OFL'-#1 JF99@M;SNJ.?>@*NZ-^O4=3XEQ5"0X/X1("E,
M3(6  7)WA+KAT(\M90!-KZZ /QYCN,'"%R3!9Z+LD&A-SM<Z)"P^]JY;E?V3
M#2_,K]<-EA$CI;1N;I/VLJK8GW9*X4#6C?Q6^X8=.995(='2V04Y">-K<>CZ
MSH;TC=K)$4Z:R:YOV%K<I3KZ^W(?N$]Y]7W]9+A=-\<Q2LVMY:G;QZ,JD9E&
MUWC(/=L'TR]>;,E7?KNY K K4-27HZ)2T@"@,]X,U*3A)@.M:OS5P79!7*,S
M@Z_501))[Z)AJWK@!A 4",P_XKL-1$4(DX0$UI-FB7-!X43AC35T-F,WXZ?!
M6BO/(H"E?7(F_NH@_'0$! 5CCA0?^0$C%D!XD/Z,BGUO:K#8L:4XU-,,RNKW
M2R L9OUA)H/D1Q9HDUAC.+0RKQ?PWFV!OSH8A&7D@YA8);HSIS@ =O=LD45%
M?T:%S*)>HD"O9#L.11UJ!H5^+BI^;8=V4%>8"[%O[,DSQ((H3(D.SL).Y8AT
M-KUPLFML4*D*,?15JE>JK?=VW1J'?BOJPJ%@,D4S9"LMW^(F+ZTYF?EB#2W_
M.V.'=TK.N0 ?CZD?\!5L;L.N'"[2$ZV-&@'BZ?H0'\:A>X.D'I#8OGZ"[006
M$ZRBG3LGD+:U8BG2=JJHQ6%30)-W^,P];$": !,NI?&M1G< L_M5L)'S]8Q9
M*118\Y==M,"_7D(&II*E!$3&@QUSCT 09P4X9&&#J1E4LR=]$$=@CHXB($GA
M5#]TF^I(*HCA&"$9[@F?>TSJ4RJ15TDK#!;):8V ^AA)X()3M8.PZ*-VX,15
MKV[!C;9_P#VK)=%/).XC%.AKDW[@5][0 WA<=7:$JC>M*7J5&V3^_:WH#NP9
M0ZV_]E01OD*43M__@]MZ==&=BF>9T3DK'GZ/4%VSJ%0=6S,V#>A?AKTH ^9]
M"#T$4N@DH[1878)FO%PQ6U6UZO['TOSC&@0R;6J6WR9*#W5SR'B*ZO?<*[S]
MNG[[L?SFYR'$<E5T&WL$8*1)GM $&.H6 D+B4Q615P,#_B#7,"(/EF'$G;MM
M)B,::00X6OF$-R.2>=N.K3SQ9Z#W_3IP_HL=FZ('_0APHV,JL([X_TT\_B?=
M7O+G,:=/B#+S<4C,XSP FKR:FCWJ;^#\DDY'QK4RP\(W,9]:IY;8?(KT(SR^
M4:9G+G4N]L-@K]I[VG!<M$BO@K[H7(/$FZBUE;O"@N+KO4]IGS6QU#?<3HA*
M/RC]:LWPNW5JC:F+?@R:7 C<_)015/W\09L:9A(P.<;]UB])EK2[C)R_Z=D>
M&[3[0I+[QCZY(,^G+*N"E&==,XU;^L?!_)=V"(U!NLU'6L&B\VI(Z*,,;&W>
M= R(LH7\'!Q:YAX'SQI3VG5EYO8^JRBS$T"CSD^>8@L<T';TL)T4W+@V >X)
M VGQ@387,(?BK\$RJ!B_OZJX)JYL#;J?YY(0P(MQ:?:9(J^F:E6F*32_T%U;
MXL:1?QJ(^!7$[OC,<NSP>3ZV1:D@[E@JI^#M_5/;RM6U1B.D[5)OO.#K.ML;
M&[^ILM_17IQ[*83V.4R%CVVO+-N44[5FF+$LR2[G:CDG37;)L5POM34[#ZY,
M2?6V_!A:7WLV]R$@G)]#_^$\[-_YV 1(,_%=<&T$"L1$WCN>+)9-CR\0K6G_
M]1<\3 6N75+)GM:D8:F/PWHFO0$='>F)%]W]"HM,*VD5<\^'E/<+OP#>"?UU
M"WL'ER\F]:E37C-$[421.R%F"KMI"P@<;S]A]F#[,"BL034X9,_DBN ,&=@)
M 61=.0R@G-L6$!*V%[9A!RX9 @#G_]XN>G#H 0XYI&G//:7G1XJZ^D_PG-W_
M<GM#O,Z0,%R-GFCTT=?E^_4470[;3 TFMSYL?ZY#N%ZVG#<6.^FH>:[MLY!<
MV.:C0Y?R9*7&%N;ZN3[S.K_5:^O[Y 3[0;VVQD\ON[XIIT[);+^F9G(D>W'+
MM<3,)56'M1U95K<]<R8].@G7*UW5;2I=O=N8)S=;I"2&&M@WYAX\YIV2ZG#N
M9H_Z#OI:U3.M#<FDGBCX)%T +-X!U!40&3U Q&@?A9G+L2K*)("?U_T80/L*
M&#N=,[A;/5FX!U3)API$3&IN9Y)P2N3%A06;)@!!/$-$OX2^!<F\1R@#-]*P
M.MJ<F%D"^-[M#&Q-\+0:@&*2*)G$!]?BT(0*Q:K1=/H\!8?V[B2A&]-!ZHH+
M6BM!.;?J9R/43Z39A[,!O[K.%-TZ-FP+$ X6;H&Y)%05X/K!LHQ'\</##.SR
M[S!B:034'6$J![#O@8P&!H]_#Y[8-][_J\OB$5?VUQSL)D 5)P#=, )PY5/B
M)5-C8D<'+((X $I2@.#_C3AD!\9N-*7!/;U 8_X([VOXY95$'I/QRDX$Z-4P
ML,1U<#D-A^ZK">*B27FO<4@PKQP86)> [26UO0 3>!0/ IQ9#6"K7KR.]NMK
M?^T@VZEUTK [2)9)L7#@'2\B>AG.=0)S,%:\!.K!35#'4P@+>.[#V4*MT)U\
MP^1>ORA:7O![TCQJ@Y%>EC'?+]R0$*K/8]R8#,_V;+]H\BBP-,2(-Q*7D_5
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M)2NW1\HG>C>L\&3-5&9O?)UGKI7438D4!)4.U;J?+D[-L;S@GP5OIQ7$H^L
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M9-&-V )$ME>2_MM*Y:)SH6J\_L@?*6/?]_JNH?I :J>)9QQ_IU#=*%,,^CA
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MYU9 A=<(#AJ(-!]\9FDU?,P7GO_T/F7QV5=\S(%8_)@%.9('7@R?(H5(*.A
M1HCMN)WNVZ'C\#U0V81#<8WI[T\_,U+XU"6?3JCH-8)2[SX\^DZIKKH/W;T8
M;V92:)!5-_>7CU6]9E.CSI<_#.J@<!#_GQUGJE#.G2UN*0.!-CPW1(R'MK/%
M$:XW[;!=R XIX=D?]OJUF>9P*![E4.HF0;E^Q\[TEG.4 A!<[VCYGMO;<4J]
M1M_WF+G.;_."]R$O\66\9N!=IS@5-I6X2=?7DESQ=$WH$W/417?GL<,]7A7E
MX6604O3L=O_S2[MJR8*:#G(CMRMY TMB=+1.8NU(3%LGQY1_GK*5G);B9/6<
MLVK1Q'+B"YF/A9JB]  X6RY[<]>TY6EU9Z34XWPB5<A>!&?J.>4E=#9G:O2G
M3N[KY6N8'ZY=.<)ULDT:+FS.PA_[GPIZCUYQC9=:LGT#JR_%"E6QQSA@Z\-T
M8KQ)6>'A]D/5(%)H>+\^*]VW7/'15^><"9<3X12Z"=53A5T\3#K^W=>E^:#D
MSK^F"KF)#+JSOSOB1:A5/HO2+=2_YT,>5]O)JD##0<['-4!EK"P=*]*48YYD
MMQQ9A.C?^8\KLZ?DOZ3QB">1W^.:0%Q>:XF"6CH<))A1ESJ &Z+8;5#V:%UO
M.JY4*,>H4=*;/7MH+YRTFM//3&<K3EUHQ\\8W.4?2=FJ?_3!8CEF;_TOLCS.
MV<[%1WT",K?*LA!EFM?!DN@B H%N#[F_X-J6ERV-V9M.H<Z^T]C1O_FT6?/&
M7X_>STK'S&UBAX=33@2& $ (]<RI,U2+X8\?WW<->7.]27M[CA]___[ R^7:
MX&ZF2<_^\35NV=8E3U*(2Q:0/+R3BB@ODIB-5:892]S&B&7XA(&#?01S0 %Y
M+2ZA'Z_M+RI[]S87Q9+*R<D0?>O;(L*G]-4FIR&CI&]Q9I;.-@3#NISWSP 5
M,NB%#E8I+EZ(S(S9;8+5P&Q[8@EO*H,M8^\?L,$*9%=&/6$6=.I7[,!):W*"
M[XZ*1)>*"E!<FINTLYP:ZZOU+,IQJXK,R ?")H5F7%NJE <T=))!;YX:T+#'
MSGR,C [6(6P;()ZF#@XU>]\7S21^>WPB2&&TLG6',&-O%524="&_)X#Q$WB0
M9?8XBZ;BGD#[-J/17@ GMFPO#M!U^!P=9H@<SO]1G%4AQ_Q&A8TZ10L8T0#^
M^E#ZD^P>?24QKKP]M:(. A)G5U65@O@FPG+GG0FC+9FVT'+/.?6Q^>.[-I",
M/9QF@RY.&^2-I6+G;J!J@1Z@!AV _P<.=6^13QA<NV4P/F<H@$MNZ%3N.#':
MR=TFU+I_MWT0)@K.9^0W$D+S+=9O\?:&V]IZ#&"OADO=[Z\6B-*PR-KD5CGF
M -A:<@LH];I.5Q,08QC+0&83>]&8=WBT5)/OJNJ?J0XR8[XE^HO,ZU2:&&MZ
M"LON8YV>5<1[[C U,9<X1_@;."PZ=3-LIP6(E6JT(<I,E$PJDR0$.$(,P Z+
MO3_'LUTJXQA;I%ZU/0]*(&P+$'?8VW') _;$QI+CSB<>OKO&!6Y(=Q#,@J3$
MAX\N"2,*QLM5)+SN*_^\JOJK8-!=Y',YLIH,'G+]3G0="D'>S"QDYO>UC^['
M?-?X<35F/'\(18DH+.7?V8HNUAX@*% M08Y91=]I.#=5+#&:\%9BUJ\#_(\=
MOX\58IL=,IU1:RO'+,M^/JQ8.*4YX8D'4VG]?]I^<!8$X6RQGB7.P.JC!U[@
MW_&DN@MMJECX9^%3P5@1'@IL"J%PRN9$P$-:1 MW.)=-R3\V252M5UW*\X"#
MP2]!UNX)W*MZQ_M^YE!U8.'@U+E9Q;XP4^.F:C97KU'[(*<WR&*E@4.RQ9$]
M'GOV',J/R]KTY,DUK2,8K5\Q&,SJ51,88QB=7-0P\.&M''.R4[)3;34P4=QK
M+#G'%KHB:JB;N&TO2R1.?; Y@=J/MD-9:E]#?F#5$#A$XD3WAYU UBBKP376
M;GNOC2'J9L4I):#=+8AUH/OP4H)-H& FMKJBD$T#FBS3\U('Q/7XV]Y]&8?Z
M0R7*A6FD[9Z>WK<[<U5J]#C+%Y!L!8?_C@JO'9?5V)EY,[A &2>:D"'>!VL*
M)YWHFH(.[_Y 'X+X.EPC&/J#+>AVO?>QG@T.O<!"@R.TGI=>W727HD2JPGO7
M"+^@45LS_)\SL %5JI$AI$JULL4EW0P5^,IG#S"MH5/1,8_&$<?!Q2=.I^'!
MZU)BRJP@T:7K8TWD5=/:JZ.7"ZFA5(5W$\HVZR*N>C5CM^NFWA84>G;),>_F
M^&D-U!B@-*^1',M38*C"[BZ@8Y-:-(+MEN+Y')5QM\N7TGT3'PT]53?>^;K2
M*\T$-^/6:^;M7.=XZ'E5?6TJ*2/^]&]JKLD[!,D[3B2M2UB_3YA@?B1Y1]?N
M1\$/KRWLT+IK3[+0W7$?^^?];<PG[L@7KO#-]-*B(#-^*O<3E]9_U,ST<]+#
M=.6'%UZN/]PJ6G.K^F[H6<_%&IL"-BI(@SE\#@ >4#V%*"=*(FB3C;[Z;T?:
MQ1?@X8A"^E%9^NR^(X#?$.SHSDF@:M!W+#$VM@X,LA=XQ85I@Q^\Z7LG', ;
MR/*^Z>G,S]XI.SCJQC(VAU](!@^0;Z"DT(,YB&\!2CG,:5,I8?2J[0<H_(4<
MDU"0YY _@5]N9W34NQUWMT#OXJET.:;)JO?@O%)2Z#ZSH+-]=.NKH29%3\,B
M? AN)7*,/IX[(#X BR3J=#HT,S4HV0MOFD%'6F6'#]C;<ZCT]_(WS*)Q][2K
M>BWU&OTV^5F0T@VZX]D"X,'D]B<%-LO% Q>.!5Q*$VM?PUO^P.0B(^E*)J+B
M#$TBRBNAHJND)HA'WR]+MS,(V&XPRGIA7.=2^#0L)]J@++8-^:GJ^59O&EF8
M''6Z0+4BYZ/JMI8K!WX1L%:U@O8/ G&Z4A(*@(8&%EIR13Y@-*/S/NR*:1@E
M#Y)'R3&U/@6D=]Z^M$K!^8(PI5B$0+=+GR"UGRF'TIJ&]_K/BNR4JGO*EYZS
M&")%\%0#X_U,1Z*?3GA&^!&SPA!%1 7B)-GIP=F.$*>)@X6S7_B:@[--(_XX
M NC+*:"16G3UWZ=^]78*RYZ<UQ].+LP][A08''SNZZ!/@S&IT]RD=:</29S-
M9TG7I*'V/@/6IV13K%Q%&4)F' [W=NJW'M$WUYN,E:!:B[(9OR+ZYTJ4=69N
M #LZF_7WCJ]<E/+E<ZM:6/A:"CNWZF[B6R7)*@];>[>>;QG&]YT]ZDM[S"<W
M^@I17'JH*O+5J^ZEK>-&5=55-'[DJD/.+TWB$G:>_8GSTJB-"(:QI-JL5N]=
MW64\KAZZ<6HY?NV3N"7P6K#1U&?4,'SW!L@K5NKEI[%9D3X4L?'\H6WF7BOK
M^\DOV5P_9!E!$H8,+IDF<*GB(I@' ?OJ2895(#/>)J1@%U_)*HC+>_>:LZ*,
M4L;YR3XD*&*-I9M/D^#=] UQ?XI.HC=I]35B;Z5X"K5==XG\5.#9;'WY SFF
M\7.L. TNS3GN2^&!3X"S566L.,O4ZM;[^2TY$U;A\;67JI/RF@#ESD?#-FT>
MSWIK#R$_7S=A/RQ]:Z$R"103(93&*6HL1" X_ >\"AOOF6N( L\;I8"*L^:U
MSVZ[P!X%QWG2$P.A-7=JRFFS,S>]M/MU<Q-ZAEP6-]CA* S5^I+J^-\GK]Q0
M[?PRBT*L/$>I3F!!0/J<5+-'_&3 HL/Y4']Y7:!X"JHH?!JH6_[Q3?:3"6YN
M-FC/]_CTX'& =_2'VSZ\ .Q<B$O8Y84")4NOK2]MOM@4O0:*ER$H'N._E&.^
M[Y5C1%OD&+\J(5OFAE]4(/GY7],EX'^3%U,P[?V7,:<L-7#J/]-M.,_(L($<
M(]5;"Z($\I9$ 787%_=R IAX*1YJB[.Y"ADU]-!.MJ.H-I9.%NPSE6*+5#<T
MBG\QZ@\U);^I9F[S:9USU;FHK:E11)KL<$66A\ 9ZM0I*KRQ\CKA3TFVNRQ=
MNNM1U->-WY/8K4'^[%?'0?PG#]^;QS#$J ECR1T 1I=0'(>U-I#5(BIUK#^R
M#LHQ2VV"]3OO7)H!2@@)ZQ-?DS/.D8,VP<=?9R3SG$ _Z>I)(5-DK<-8"S38
M?UN4O?[1A"=NN>Q^N7;OYZA3T21]$@DNJ:A(B=U2E3+J4+<[ 5K:6_+Z&KY!
MZSSLUXAL@(HX.33WAGK] 3I)>/_*%UNB/<B+"4VR]QV8S?A^\61Q=]G532.H
MOZ :+FNU#K2FY-+U\R\$RFP9*)YN2$<M,#/6DI(O/05'2QP971K?+RB'!E%;
M=2V;J"KFQ3HV PD]@C?QC^"B'=/A^2E&T*/7D:MK[YVR"\Z8UUE(&+\OQQ0K
M3;GE)>('0\0GX%W@E7&12,2F.PG82\>_T'B>R8/'3EH-),_NZ;4Y4?#\_=3!
M!X7O55]?6*6(49!^1#$A"Z2TB4HE/KXP5>@HBEJ1)]%A=%86#P5<I&0:E$12
MN=M:K8*:O7U$=?51H/#++[_!E[5F[W^<T@S@:7;$U#T,V+X(+^@O#0K^[( D
MLXH)4UB)"=!@@ZPX*E63W4&T_7DKZ 9KQO/A*/>;^HZMOC:0VJ"P(J,9L8/"
M^+>/00=KS#>W+?;2C6XG42K<=N7ZBZLOI04%G5%[%_H_"N?)@FA4B]$5N_U-
M5DF<FI9C*$39\7IS]IPM^RLLRR;R.URY1J,LD3(T.GHF350 DIKZR:L9V^AN
M<(Y?UC#='.J0]<=3(*4VW9E$T[*,@G?E$;2BZ= Q"]K4YZJ$I0_3C_KN&SUR
M!J, KWC(>=X)1ZJ(4^28;-'"OV+&%+1QI'79R,^1LD><,0E#28X1/%FX7"7X
M*\!5L#V8(<2VL1+(:HB*U A\\V"4$$]<94-Z !LTV*WN%F[U#<2MA52E5I?N
MGU-;.41ZVJ/,9D][&YMN;S6^OWN>9B+*2R?^J&,^@AX)6P;ZBPU;B2?9J&<N
MF8OR.MA;ZY@]_EA(O8G;45JB'4)W@!N$*H''I('"QW/MP:'G'-Z[^6?JE%?7
M5-_>#^8R'U)V^Y%L.Q9 X&)'U.Z=#IV!-V!%ID(U;L;H0(L<LPA!@:'Z-\(R
M3FR]8HN HSC!7<$">1[0XBLQK%&JS@$;^\OY3L%"$F=%!SXF5*5FT;G0#F,O
M:/^KKTZ/21G42:M_!S'(^H5^Y^3OYL1WI<@;^U;\_-.P9<B0,>B%J RB/WX-
MCD<W+0K>">H)_)IF;F:JP-N(C<3X:CF&.>MRJM57?\#&29N]XK'@F(UU4.X[
M;_^T[<SEQ2^#35_/837/+;W5MN;\&U351D<=@& 6M!@K,I1C'(= HARCZL4$
MOD<X2G<I2IR +K%4#<4E'BC9]7VK!'[VE6,D9HS7@ [Q'),)J!+/=E[SU<I
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M7<T=+OM>^U88^HO,Z%_^!RA_R]_RM_PM?\O?\K?\+?\=14D^^&]02P,$%
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MB+NP!(;ED?BTOL[K_I'^,_.]JFJ@:(;ZLT1]E"_MOT'B6E5I8(6_*_WC&T9
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M"5%1AJ$WNPZ")SC[NHZV 46UQRIBYV#*YC<$F)BK%<M)9GU9' K 2A?X'RY
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MV3%XIWJA[E!/X5DY%16W0A^70LM;U9:XZMX EZ\Z7[H4%NY;VS(2Q9"MWOM
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MIL$=K4?X <XZ,X0066MV*WC54]C8I4#GY+U4W9WDG2&X+H$I?7;*KQ^X[J=
MO(&3_:_.-BLQ\C=#\K^R-B(Y=[V]87OQ1_RQY  PF4W\HYG0_0_\ 5)OU-5Y
M\QOQA$S6+P;(4ZQGK)5/L)[,+@0VV!E, 29[8G9]P.8[.YB^$$-4P#RDVE,L
M&Z>=6.L_2-#ZTYNGYP'ZQLZC4Y(P=&C6+&)<X,U1%1R? \V&LTJT'CS%FF"H
M8-;<PDA\Z0D..2,NY\BF@4)/V<%&[N>,H'D6-/SMS%*285H=TV?F>O&9L7IG
MJH@<I= =\XOQ^Z'$0T=[%8L3]*+;5-#J<*O7R^';ZQ\/G=BF7QL9&16M><_F
M%Z.T/-SKPR'[% ^JGO2\&YSY^'W(*PV7)SJ[G<V]<J=:/M@PW;Y;%:H-&#??
M%+2E(9WHEUV@,C8R*>F1V3U!8(IVX5FSF!K7N-AVP;$3THQI7#/R@1ILU2R)
MTAAY=/!XXY5!8US@01G_VT]WH5*+VP@[OT%E<,?!!#*VF1<,D@%6+T89;PK2
MV:Q>6IY(@=M&1[T+G7NM?HD -<V+[$;)X/>"%?UE.N!U[NB2Z637?HS@5V6"
M(A7%1D!SB/O"85!!> 5S,7#_J"%ND'>Q'31EVM-+3_"HQ)X-_# >!M!63[")
M&<=HBG'UWG38;E-H]I;*J@KGG9GLS_W=UJ:TKN> .<,?FG;G2Y/ &$AO7\=^
MIW<<2N+=81]_X-4\(2.&V(Y[V_/6OH;8OJU/'(_7]K-H/U7SP"=MV($NK?JV
M:C[0Z$&EZACQT,?%9,?-P]?5N8O(!RIW!P\,*YW%6S<$90U]B8U6D"IQ[1W/
M4' M.J%;II#ZA6V,[&N%H2IL--SU>H*>K43T!#=Y7FG_[/L9M0]OA]/)Z<L0
M2:N%$7=!<TG<0QA97+CAW3C=F%71K^A'_CA'[N[90^HF/;R2*<%A=ZREP87P
MD?!5E4R=R5E5TR>B=[<G3=9AO430-6=^+9O,_^4]]A14NFWEUAP%+#!_*41X
M3PJ.A["O\G\3:,,48NJ_Q60PR1GD^ *-;N"*PP)XIS)<:_\H+J$*&SW+'/,8
M-Q5#Y(=)'Z!?NK+?I,>O1'K7;R8ZS9Q?YG26,*Z,%;=5VY&:&;8CMQGPP(%Q
MXM<?(6Y/'F+,X7.OD#&)UO&,XP/L%>>8U2ZCX?:6$("S<V1P&?G=>. J=&7V
M5SKZ$,.=HWX<PW/T=?;>UVIQR0YEQ!B$>ED0:^E /CI]=N\=.DQ9=!@_C%+I
M^AEGTPF>?"0P$9:;0M/%D&<)W0&1;,)+(8H#[4$H+FG]:MDI:@GE8C@L>C(A
MN^L8& /-L=;$$KNWKG_/H(96@_9NP"<Q),N4O/+.-)*?2U8>NLI%V(/Q_-^Q
MPUX *@V_731&HZ 8&%60%@AR ;X?E]7C;/)22P&8(-,QTRJGP;&Y3A.)T'$^
M,-.3U%F0OD8-KG3@%,A+1)[F$]QOW**4*FS.ZM:RSWOOM3PEU^&+E:^_#%QU
M"_<J=;2>=BW<.5IXB)V6IC+H5[K/66T@AQ>O:XB=^'SE6,7\FV.%(5G5=[S[
M@BLRJQW+8G)>&WL_&'ME=%QS7T>7J]H<B):Z^P9[B85XU7Y'I]_K50UU1TCA
MV-:DA@EOK!:VP.I-TLF-0\B!IZ#3PYS"XMZH*QLVDK"=$H':'@]+(<@*O('A
M;BWEY^V@/S A=9,66F_NP\TH</<'6F]QPG GD^<"KK[4TI\0:$,SS7P%)FPU
M@X\ FW(S8U5:944P"^'.X_M"'7+8%XA-K-SSPLI0\&Q'#,_R?0-M+A@X*W"R
MO&)IOBJO])JVMXR-^ZV >SSN^^1PUI_3'>FBM.4AO!%.7Z*$^UCIUB:@*^?%
M4"@:6,N/"X^S\OM.GU+V*IGH?-)L8^) .KOD=ZT^6/9EV!Z]]XM3L=OU=Q_Z
MTXYB,EX;5.KGJ1CN&?UDPL>O+N*\MI<[PY644;EKXQ%I.-W5X[G1+D^BR8/L
M3>,8K44;"W;)CZ>N!>D:>J^7/%X;71ZZC'Q>IF'$V7<Q,JLO=H=KT>7/WC>&
MC1*5]..:J&;JBNLMQ5Q9I%V"679M?IER,0?1;V4RYT(.X7H["PL/C62\S,.P
M[5=6G^)\7H#>A"HFUK,+_@$_A9(Z!UPHF6QZBE:?$5Q";WL/#F"46;,!.HP9
M+-&^@_MPD2 LUH[$)8/:0$[/,1K@?E^@!\QWB]0P-UER(BCN%'@\Z%%8D9]U
M'E#<SYRB%XV;#>_#&;^- ^N_87["T@-? (B43U-49[:_K)[?E%1&7%6+_\Q?
M4466PJ^/'ZL)'?%#=H6AJH[&T=CGCI7^7H,UYGX1N1Z?V3=*Y4*W1YB-JT<\
M\,0>M49]/G[ILN+EY]?BW=)E%&SDO1K,<VHY5_5'/38(<AN["DURKR.)LONN
MP1ND;C0E[F(,RLB=KK#RL7>LW-=1KS\&!/=9[B!R8#E$BB),T=H"IP*>Y'Y"
MA;GK],S0%/##74@PC^_OB]T%4PB[@E,E\JYRE3.X_39<PZ:YTF [2GK_&> [
M'9K.+$I]-HL[U<1MR5M?LM:Y'94H69Y0YV?/P19H:IQTUV$,H3NP0: J.D$=
MBVH0>,?,$95%HVZ@ J-KQ[.IIW83^E1H _:J_Y3!)F;'S =[=JG=6L"4F=X'
M>+(0X]K^7/CV<07_"LG HL;=-:/9[6:MRYXX]LY3<<$KP-NJ:O2MY,((;U<'
M[6L+NAMB""/AM=+N'5IEWKFDC!XQY.)H_<V*!R'M2,5&5:2<QO:<@:.#ANR'
M<E8AJB"[_))<S+V%.( 2O,OC_0(R !>ZD+#R$PEG#MBOL.>'$-TB=8!'Y*!W
MX3#"RE7K0Z -^W-QQ>*L1<N$:4P>36$>:,O87-6PL;Q&#N7XB& SX$5Z-_-:
MPR5R.? 6^-!U>W+KU&(ERA2I5B<PFQ#IB=Z(X(!R.> _=QMDL<60U>VAG!G8
M=-$4!]J+8,+8];0<VD6, IC/G.'] ;)C#&C97;JX:SE]EH?)G.LR["(:P!GC
M.!?DXA!7E6\1YJ]C',;C)53]R2[XD06M-ZU! 2.UQ^<_>(DA3$)ZK7N]M([:
MVVH7LGZMKOO=ZKXG2F8N)A]+;:WWU?;9%H?B]R^T7#D[II0S/_"<LL3*1NR6
M1<[K#Q]5JIJB!U]!T@V'O/9V744K%7'TYHX$-WHT[AE</%\$U;QOHR00@ <0
M-XD V=H<IS>"\^4C%U%R#5UR OUQG W?2S2 5^1^6J!? QIRYEE2I S!0;ZG
MZ$W@OHG-X=UA71;<N^L@#Y9I?7"\ZU?#IAK!KW=ZO40&+P#K&Z1 85EI7UO,
M=78.8M>7#IV5_KFUZ87?A)544YJFR !W:(P:RC7G0;G=DR*U2 #[\UH Z!0^
M/PP!@U^*%$9P#C'  #2W3',$?V") *6L9264J7#1C"@")C_ I8>_M?=QJVCV
M.PE1.W'GX833L)*:Q00OKMKQF<1/7.,3PP,?AJH%'1ER*]77#W'<X(DA'&MM
M?[4 X&MX9G5.GUM_]3RV)OV APEB986L3RX]9<0NL4B:;FL<+#S[0C:[/).-
M+-9P@O>'/-3-Z VY79LGT 18?W1)+=(4:2'#2A$2/J[ ]9\38%J(# -S.I.5
M+I)Q !9XU\#PFDA8<T;^Q3'J=B %PYW*%6F#&"^ E6EM$J:.SOE6;_Y29$D#
M&HC<9U%V,_0BRX3L>I?2H"T;/K)SJ*V?-A-C-Z:@M;,9[ 36/!OWI&CGT0IP
MMH YFU?!51YE$O0N)>R59^?%>([-/[]EL.D<O?1CM3ZZQ:GX.7\'=8&=0=>4
M87O=J/I28L9KK@^([-+EHO($KAR,_'#050Y"$=O<N]79UU0?Z<?H\'I0L>AP
MT,'4#U\:7!EN>?%.15@2OO!QN.7UHOM/F?ZV@UFO12V.CZMJKE*1EQO='QZN
MX^:HP2=)=FD6XV>[!J*/NI I"_CU!\6#L:BLY1QC:H]:&K)[/H3^+EJUVZWO
M/.!3Y:(P;]:GM/'*QN#5%>0+V7LC/HDAJC64HV?J2^R-? :&O$EYU5G?(HX\
MIJ9PW_[/G[KT7]ZV;=[,/D(>'*[:=>3Q'__:K)/_7:%*?FJ&^&]S-AQ+/BY#
M9,L50\@M!%,L5@SYGD5(A_WI:JNT\C#HGS(^_XD%JWY7@YV^)>@60RR>,+V<
MG\P\V[@6/?CF%>VWGB'6JX ?>I4_*%V21MW_=X_9_\GSX!*=)5I$@?S=HGL"
MJVK*_ CJ VI+@4!D3'I:6Z(V-\60Q1+6)+%P,'\"]9+V[>..$5NEZO^)6?YO
M8U++VQ5=,<7$,_^<T,1]__<I10-<//^T:$@,D:&>1*1*Q,9;S"]X3;!FECG)
M(^P&ESFT/P0'.3LOK04;3W\8K(C<XA&K^J,2]AC[O>$-*C'.45TD_/8&GJ7^
M/5.@QS<1_(-KGS(7258&8VRX@9WLR NM3OWM7*V".:CJDOHAZ?!#5RK'G*IG
MF'VMPXK5QX,4[-C9Q(\LG@?HS8<C! HOZ"R*>2]J.J8?U4IF2"*T1J\6$J:R
MN98AANSZ-IQ/@/W*+<[&V<Q'G3@[2>%W!FZ@IP30R,>]E?W:;SK90O_3X_4"
MV^IWV/N'B&X3C\<SEAYJ%+*YB4@NMIIS_>%5=9]='D<O5\ WC52K)NLJCW/@
M[A6.=W6#EOSO/_>LFE<:5'WCM/'UR)LF'_TW9=NVHZ57246<9L=WN3BN/-VM
M9ZXFZ/+7/:2T2J_.B F]\XN80CO3:CMWW/K=_6(((5XBKXBR CU42CW.E2O5
MK:7Q',RJ\0LC0%<W_WXSU1(I.CZY"=W_+DPDE^-*:[O#8%8"'2W'2O#9;6T)
MJ/"45VF"+]_1;'(F'L)]6LVI5^B>/0X0<LS(/R^QWFF9CR+-.%$J 1-(C884
MRU*57B_U@-4)5D;+N<FV@_P3WMEO-HYM%.@8.;3]*$<KX:2XL!NTN5M;,2OS
M3W'!HW@UK J/3P%LZ\G]D9W&"YQMD26$3(%*S?*4>5-8TM>V1XN3Q>9;8X/*
M#QX;9CWU>]^R,/U-UN+%?6%VS$Q,'ZO9ZX88LOT"6/D$BV&+:CDQDAEI.79C
M#I'AQ2/((678,@XM4 5L#H/I%XF2WXSY.:Q+D6O.4*/4[FS85!H7>-=&SAX<
M-]L9U'C'B](V8:9Y"D8F2GO>53PZ5HOT(,'/5&;E'AV]FOC^2@G\LLNSE)*'
M\/'<6K\'5[Y_K@A='V__FAMQG+,X0DI).S)5C9&VO/=7L@6P/&PD5VI7Y?@X
M=1ZN&++/:EE;>7'L"I7P>&!>(,N%OH0I4%"@@T@=7.AF[1&8\68ZS45[8=NP
M#VRY%S.$%><&BB=A3.;VK^5!O!F=.*<7&$HB;V6@V2[M#]2?6U*]PS/)/%?A
M8S'D B$#12GN7]N!'[?>)6P@N@'U[_T2>E@[!>93UHH@Z[=12NU,%A51C56>
M'9WJ*U.[+:'83,_.-\_K?75F*(.Z7_>/4!$F]F9BR.>8E5(.;<9]CBQ0H/6A
M*-^[$04LJ$ 7&)LC]:[MC4@00W[:C$E31V5+,09M.)*%2<IZT(?:8Z9[@0O+
MF/W.]XU[$2#3[5#N?.S&'FI&;Y)A&[:8E_B6?7RRW#+'^"4JTA]167P^6!\S
MWG2[;^KUT=N5B>>*X*5AG,; /NLI6<?"3_#;-57KX\GGL9PRF,(NM,[KJ2;Z
MYY:-T_KS-T1O7_8CZ"$6[R8_I0?I*T4H=%^,E$<%Y]0&7.F[>Z1#,%Z\Z1DJ
M&5CUC+SXF/16K>/ ]>^,*"F'UJG-88@O^,#V.;<AISS0[)GOLE];6E#G]027
MT>A9WE!4B\;@SDL+D2]"LD--&+!&\L)W-JGOG89HESS?#S^BO([%=+]*%D-^
M>0^&<V.<Q9"TM)JEHZ -_;L?*:U+#5OK0.&FDQ^%)VR]&M%?,ZR_M)G3N<V&
M-JG3ZCMC-[)F)FUP*60#,5W,6Q4V?!5#(L60Z0SV6I[H^#)+TUH!__8,MD1O
M*-136%C7)24X./XQI6>0W%#.MP+%$,\1Y*_<$YSH8K9F&"J]Y?K5WEDYX#KU
MRHRS0IC?QZ368HZ,+U'Z_,*NB:.;U=KI P"XQ67 1^XNH7_2QQ^$GJI45[HL
M^!;>@\ON3#)\[- ],/JI!A=_(\W1M,E4S]&'NJ!0%+20BDVT4PRZ[S[8>(_J
MK&]W.%W7G>Q5;W8\J!$LN##C>5"FVVD+7>?!163 &%=!*S.AO, _\K$?MFBA
MYU7-N[;,5<%QPO7DRG?+&U]N7JVF/PY<2KI63O*+>.97G]>[F;;ZQ*2SMX[;
M+V!]P;3IK+* [_.3-^+YKCAW(H\P2NZR"@1=YN=(?6O3,6X ;65Y'@4A7 H
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M28EUI@11AE#&_[NS$_]K,QKMM[C-HEW;^,&B49;<06$%WAC_!M;<OW*K!IO
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M?'CR+]$;%("&,65Z\/O5%_ID57@R0#PM%2^SC('B-$/X%C@(,$GDQ.S#LOR
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MP[T&FNZ+E$MZSG&;Z8X/=>Z%@-BY\+F@5Z=>Y-:X>EIU'4ZS! F1WLR^G#;
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M%2-1UC+%'T^6JXY6" F%K !R!3I&\A+:P QTU&&&L"H);,WTKH0#*8RNI C
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M_@O,;/IO/!/*30 9Q?DB=)Q#Z!VG8HUG$_DMPGLW5+&$:DW*$D N#NDAQ!T
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M:B%A).^HP\H_Y=9K#= SZC#PV,O[Q\+<Y?*>$B-C X)^$D!PN$:KWRRT,)=
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MY2!IO\7!HM1>MUN]-@G3:5^37#5ZQ&.1;:9AYZN3@*\'2'#);E65P.\&@((
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MPYU3HKX%"2_[_L?6=?6[,$"P ?W$W%&ZO0MCR/'LB-^+RP1P84;O+]R%E=7
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M^5CVK<GZ'?/XOH!CK:^!G=SFU':C._?9<Z);J,.SEVK0$7Y0H4-3<^;ZHBO
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M/$@KFT<7$#-UH@9-5MR!G;Q:EJ.*>SC'5O6N_;4/]GXC#>/J0,6(8\N.=\O
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MS<X]B_H=)1KLG1I3W:[QOO&P@EP?@].'/8#(E;';%<OSLB!QC09\YV ?\,7
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MHC_B+IOWKRM<!-9ZSRU&5L3Z!W8]D= V.XQ: Q"VCA\?N.9;H?'IR'U#DQ\
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MM]!A =*6+6EATVAUP;C!\H3;SRNUTD>U+D4:X#D31-.9,PV#_WT$_%/O7J9
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M84.U,W51W_1-TX]8.+=,]!J,?XI$C$0"Z#S&9C#(FJ<<NC0;T-CG8'^@@;I
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MSC.P>R 7[Z>\KL F9J,4D(?0RFHR54=3><I8_K=2V5<XM8(14M3VPVHAMC>
MOH'\8Y!Z[,!MW=;W>"UH3T2RE)HB-L?O "W:JJ"T/J9ZYZ@$-<=2#($0'#1,
MIK!DRSPPZ>"=1*S^O!I)E8V@@3.T/0>J^5XW]??<."88SN1M;H=OP^7S-<I?
M7S]P.\FHRKE!8D5VZ9BT3F/EKB5G-R?"?ULB&$-M#2&A'*$75VT.5O!CIAO6
M0]C:4OPQQ09=R .\4863=0)4@=UI)0RQ20*#XJ+J79-CJ=SVAAEF-Q!'YO;7
M71"L;H8(HXA\55P1_TL&]DII"U0&M*U$B;JEC7C$Q5;Z'<A=Y @E7V:US2_;
MT 9,N+;Y!'A0--<O[WU(]SO:S*3GRT#ZW?LI8:%>A[QKJ,OO017":)GTAV>4
MR6R/3.:U[0N',6SM&^_W[>W!B3HWZVK2Z_1&#0>[/C.S?]M<SR';CF.7H.84
M+_VO"X;W_%*4:]FOST%[@.@8N]G;L6)'PBLP9M8"W/RE2$C16YS= EUU@,W1
MM&1O].'C23QM>;[?%15?C<AV\ ;L10> DFPB4,:W8677/ .,..L*A:B=^+WI
M:4D)PB6$"G?PUJ\'6T;=!2;H\R)K* 5U77+T I^5RX7?X .%A:AH[&X:.^RB
MF,]BPZ;)_77Z-_'I#Y?06DEQ1F>D5&(,7#LTB"JW((#7/ZL*4/)\!IYK=FT:
M%<? E%\T*AO*=&."98S9?0 Z6Z:%WQ]K_ $@+D\WX@;9VE.YQ'-R2 WH!U(6
M2^'7"?I0U"G0:"5,'(F9\L Q=2$2\.SYS[7QM9NWS;QNK,VS.6\NV[QP2 ,/
MO3W&5R)I0D(1^_KE@#ZF'02+$X8%]+#@LOV04X!YAUB4(WW,M,&4\I97@:S=
M<97=(&KY&S#<:TQUK>&>4'K9=\YQ8C@O.9'\S'?7M7F,!3HJ[.6WMKIL4>C8
MF4^RH8(8/.!6$5OZ8A0=_/KCD-EO[0[78NY7[#M4I^6R.'UKT7CJ+J'M+D,]
M)H!ZW 8UOA94J+:D;M##PV^##/7KL"I-\AH-ES8_>^@B)&66>K+FAA6@#4Q=
M'/D84(O-A:L1,3"-<IV316RN5SXJ.L[+!3TM%CD"&J\6+D0^@A[CQN9:8^R*
M,VOVMT*N0*&R?)2"1E%R 9S^"_>,HTW-Q/L*PFS["5I06AR [9$'B>Y'G3<9
MMG.4+.YDW:,!/F47WEB:CX<_A.G*]4__G@,WH$!FB9MPL 0O"@9"QB[%#=2%
MZVT?\RGSDM.EER^$V8_<#ZYF.X0!%_NY[ND&_6@ZXCKC:(H KA6KOZ?MT O1
M\/0WV;86X-!PG\M<3=VFOS%<V$ (7.EM4]/';X:]$S?F^8^^'=O\2QKT)2>!
M\R-X*S*_<_F[M?A9$YJ/8A-S6GD#8GO\;K#C;F=\**;"1DJ7'<3(#D*@. 1C
M&T .2$8JCCD8-H:_5W(]UUJUI/$T8-52-3^3ZV>$,?9S\T:O6%)?^+L>,?0Y
M0KQ$TW7635MKI(I#K!*+2HQLZ_9$C-TUN,41VXTO"HOMZ ^J[OOT#,(*:ZM,
M=A9:9/F 0-+!BT^Q:L;G)_#G\<K2LDN2_7A'V#*-G^[+OY9=Y9JFL3+,?G]H
M1M0*4K-94>L*:C,#E9 =>@>QUP&Y;X&HP;I,TG..$RK'-YD%<-#;B%&VDY?Q
M5I>0<&?'[VD_T1L)*C%=3')L V$8U78X7Z"C%QD*:&4QO/F(C9(CXTRMC@8P
MUNDQ2.[SXL(%N:VCZ%X12H45]7Z[GM&<U_(W?CE!@-@D.075P0O:5[336+HS
M,9/ SSN+7?N#DT15]?@@,&F@+TU91["E2<":87L\03QRBIQS3+=&S9@*Y35D
MG*KO*,)5>73:PEMHRV'I*J44[JPNN#VZR^&:CV=GY 7%K#(_N>#: CQ_P&$J
M'#&*-VZ6;)U<KJ&_0=KB@R<<C+$"VG35G'+W+;*:SKK"=4J;%QN#75>(YI%N
M-[X)QD4)C?HH],4,[PIP4R)H(YU?B3>G^H=^:4I+L CT;'RZ>'RQVO9'ZNNF
M@T<]JO^)  Y]Z'>CEGT:$=W!+7]\X0[WGJHK?/4NO3&]?#O$):GE5PUY:603
MIW<O1/YQUS! E:]O\A(ZUQ@=O]GKP&,H"4B=\27F:*.6G<4VMK=LEM"_29R9
MT#%AN4Y/"66K1#O<'77S?[J5#N^W:RY2+FRHE=B/K:Z@8A SZ'[8E5F#UFY@
M.(>Q$<Q-[-X>%N9K![N!WL$PK?;BDS():N/(/9@N?XJ0LCV$\*9B>W8PX+*B
M;4;0&XP5PK7P;F]DZC@W,5N;5-C.FX'U(PU&"!H2-2@B);(6TQ70B[@YNP^D
ML'7L:Q^,VX09C>^=1&X;HG+1BTPUB /:SC7Q,AF& JRB1#O_-*L;>EHM40>]
M\JWE<!,.\3AKULGQZ!#)M76%&Z6$D0#NY2(!=("1QE,C#,W:@BJ5ZJ6$<L3T
MF'/SOI"RACB7_N0 GGX3C;GO[8QL0N1K3=G*U,1[0>D1#]&2)' 9:>@<HH3.
M)CY>5^A)CV+#-[,NZIU8^!K,Q<NQ0KBBV?]^]6(LG8(-LS<^%QG;X%:=<E!L
MDORHWGBJ]L/C77'GU(7!E^^.QSK9]J(P6M*ZTCK7M$N?2O,3_[7<S1AMC![8
MELE4K3 IQK.U3%B+'./7>ZK-G'<D)?_57"M\S$B^_?+(2]1(IT3MF^C^Y+I"
M+&R:RD:I,B(K@W!H@>?M)ERV' XX".6%:VMW[0YG"%>WA9LSFVHP:HMKKUFU
MBX?]1>3@Z#BW>7_&G2\_FF=P"B92&EJ>'IQGFC8&2"F$HQ"YI]2SJE*"!!$K
MOD)[7G;7M<=D[R42WQ'.=^G!;@V)K3!V?]JLYY NU'-A!U,*"$:]K;?C0/L^
M@F7[;9]/>T:(?S: C6*8N]+]3]8'?1,Q3FI&VQ&I)IBSB03CD+<O/<N?5E\.
M27!/EA%P9<5_MGHB!8UM%KT,%258F7_B'ZH\B\ <MIK#4QK&GS?]P]1+$1OK
M/]L[.]G4_2COX$-&!O__YZ=#_O^[L<J'Y7W8HT(XA-LH"."D8V7;P'6%S;K0
ML!B&UX6D@B&O?K0&<C,NN==?_S# +!:8XR/[[(9[NX_/]P4KSU__TO[[UZW(
M_OS:A=N&U>4U3ZR'[-T>CZTK/+23$*0=#LFH7)GEX@O^$BJ'G#JUG#+7M%%
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M&,Y/9X?G[2D:X,FK=OG".KDJ-WQ<&JEXA]U!^B&6Z82'A1/18_4*+9D3D%G
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MA9>?MG7U/7"?J\0?3*YY+2TQ(:5@.DOON+^^ON]PC3-R)?+FBY&]1=&9HNP
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MJ]K:BC?,YJM/CR\LB<OW+G$-=89;O+0NH(V@&9KB[=UYD@'8UOYT5H_:S=J
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M<%_S&,-:]&(AOI7,]Y*\@4R DE_D50I[@JLD&<H'M.#;"+AN@68<:>ND["1
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M);#'.P]*\Y I+X&]02^KBO>G_+U3Y>N_Q!]0T&F"BO3T5NE_<E+9\QDHKA)
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M_,_G1DO'C([:NL\&!#X(53_CYNJ$F$3\S^'8_8C4P%BRTD\%X5T@\1U*ZP+
MZMSCAGDO/H9/024A=E&LH: ZO&NGG%>W!JK+RH=@>=E2N1J/<VQK'FD6H;I:
M-4)FR$%1F[^4RC73!O_ZF,78+#YAS=,EI1H2=* \U2Y=!MPTLXZPS>"6I1LB
MZRGA$%V1TMO/C2?M0#XP?D&SI&]N>0&68ET^M.1;ZN!0:?U_#7+O@>%(=>"W
MGR]T @GI;P@O\O,.!*N]<\VAOBE5MW6]\MHVW/EU=X'K.B)A=TW;FVS"FT;F
M<)5O6UG/B<JO+F7..>'-V,,ZBU7#I8')OO<IQX*<FX^\KAQ))$V-_\\STT7-
M(,*$L8 ID[6#X ^V=J SB7#(C1<6W4?:0G &T4R2&D3B+&>&CJWT+>%L4YE:
M1J--6+3<PM#\NLG#JO#U"W&>9=?7UB]2$DB7&B8GT<>($ZA%58'S5P8,>5@\
M%(B$0KG4),9.NMJD4)]!%JOT)B+W0G!/**=<Z W* S/)54(=\200[:N:%3V]
M_XL34M#56O-TCK].S*O].FZ"J[*O[-B0#D6^>C!JYEP773V>HI$G/,*:/*_C
M6;AU\';&%0^KNK-G7#*N["2N'1V-.H],Q]@^.G:\69=GJ&:M^=#E-1 1F6K1
M??'/K"L(_8J;Q1J1CZJY])>93,Z\R^T'7]_5!H0XF]X3,QC_TXYYE(826 I=
M0$HB39;+V #Y=2-1[5 JEY)&5 :6$PFJP"RWIYUK\9*2HJ4Z9!G"[5O0LQU_
MA0!NXS/D#)EQM?GOJLH@BYZB R ZN2G[J, /;$VEG2C^^#6_B-HG=(%,01*;
ME'9,J /6<+RZR$E:1T:,XDGRWG@LEWR+A@:D<TUU!O&R?<1H*N#:@"UX,>_)
MO*FYU;O2)_,M*NN/3 9"C+\]K/3MM4"'1.V.LV,BMQ6B@Q%UYBQ:L\Z?#L:^
M9:;.3W+,;)S/97$.OZA\/FUAX3U?NF*Y;N'5G6![_UV1&0VMO]W?S;/H9&0'
M]R@GTO@()]PU97^9AG>&<9@#[<B;S <'>*Z.;H*$_W'_KH8F -D>U 8.9(K*
M7#60"[<'&6S2;3H2.H>_\L.=%H'JF+%@@#L+GX31]VD499=FHA6FT)R:M9':
ME>&:L*O=>J6^"Z;D Z]E1HCF$MAM'.$WR*9*Z(W)9FDR0EF)17#("20.LXT'
MNLC*X0AUFCV'I$EP+WC%1\DO"XW9$7 .I@.=1E&\$O2>@*B>TRAZP44H$I
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MP,DZEM]Z+/BOG&9&VZ?";ZRFZJDK=<ZX'/)B#!#6]+,I"L=-+'%D=P'A7QG
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M_O?^P%M:.P'*DBH;DU9D!M)OA8 -:UUK]%/W.3T/N0'H[L"M]'K 1-HF%7V
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M60SAT8GR7R'31)K1.&'E0W"01[\^:@ 7Q$>*_D%<RA B'"_Y<%9_7YS7-5'
M(T;0(^?J!?14EG*Z3@XJ4+]SLH"E+,=B>.805,]E7%>@_A[+X(181/OT57VU
MPAHJ:>Y,-A :B9/4IR-DLDAM[]$&\&V2L"K(_19O4.=R'++9+J>FR"G^4>A-
M@%S2.)AF^IT)QWFU\6&E<$)V,A 3K"I!=/KG-@#EL1\XIT!%PO7RM7S8 1#5
M$D0/E$!-J 5$*^5*S7 ]7[Z6 =^19<@U!%-,^"BG"WC&>4H07_)Y;:_U1*/X
M8+;>(W5OY%EBFU?KV3];[3F:Z9W%F:TGKT>=#&UA8U6)%G<*=;:7[@F,,>7O
MUCOL?P[\5N7[;'..Y1Y:<*"WW7K_:HK'7Z?!(?N_O7VC<W3JPKIX9\+/WH@\
M4V+W9U)1H,&?^3.$GQS:-@LX.TWXZ<UC$2\TO6*/ _U$*FES_)7#DXQ:XO0&
M[-0(%"V15PD;C= :%#%QR%F$3:.I4XH=X>[2YF+^IL EA9/BW,3S;-/) ;WL
M6Z*76G7.:GZNLMT@+M.*GDI;!<;1$8*4/H4U@+VXH]N[\>]N.,;);H@C-_)]
M>VG]AJSY[8Y14O-WU-GDS^)-N7^TVY?I'$;L8&6M+>N6%9,M..09=8IQ"^%)
M7"K5;S&(TB&1%HEP(U[BR+$,^K2)LOMQ[8(587J;GX ;OS=[<I8B+OABD6#-
M.T<Q(:E0<W"6.$PXV%U+5IFPPV2W<_VJ_/8WP@EB[!#Y"FW5(%N/J@I;@))6
MW$-G,:#\TE5L ]B4]T<HICXO^]KF1A%1Y<NP3O7"YJ*R\;S-1<!#?-'I"\.1
MT]*LAX$!/G^%-/1N,[TQO1'Z_@;OX&S1Y+RM8%70OGK+C3$1 _>>K+\D!'N3
MPO^Z_#SS*/>Y.*'15@?L_W#(H[_Y=+F]5?#41^_,A>I@>G;(FM\N!+;GHU>_
MN[P]&ZMA<':S9C%1PQF=3$G:9ML_L=4DK4CO?%Y)=JN']UW'@= 'Z3]V3?X?
M;^)XX??5/DQ4,RD28'!C@/"[LD\'/?RKE'69':A'F%L"G4)F[+< 4M+8?D,/
M+=?]R___=GCE?1T8$F:+/X^NLGRX=F13KZ/F^V.7#_WRTMQEPS^\J.2@PCLZ
M);$FV05 @G;E8,_04$" 8S!9SO[J3-ETU^*44+X@^O,05F4L5CC+E##DJ\86
M492E<M5+8(<$,RU9C$6B84C,R&#CX ^0;=/H,A#-Y:1?3KF*[%NT#*6I]6VL
M!^=3J'M$(T>8%E-S(WLC7NX[.FIQM,N[LQ0X2Q*,#^=4E(5?KAH;NL!?(]QU
MCK/[;4WEYT?.-S_V__'&Y#+L_]2';?=LKVV.Q:FR[N9M@;_D/2@71L5&K<][
MU^!:HG>A]+AVA6>IR_>!*KOHTN,%UIXE'GM,MB[N+NO]]/F\?TT<2URLC;DX
M$KEI6,:4E0)")F<)31/&-,NMX:6/*5AIH?/,B'$SX0F'YT=818&LZN (":"U
MF;FYR+(TRBBE,G^DT=#JKI[J%E$BUXM4JV_QN^SF.5K]>_\1W_LW)\2JH4,#
MUO%I04EZCKN/<(^\+GF?J+WD??M]:WD< WV3W\QY8D[C-\08:4(FN5.3"M3R
M>3@6'.9*!,FSSOJJ"E1V3M0[2EL$21M^Z5OKI-]*V]1C7+N]O2)@E.1$OC^Q
M<#S?H.? N5OO:1.(JBS/?I_R#!=EQ83SZ%3.,S2/F>YU&3.E0"T>H)0*T2W$
MH?EF]MX^JD8QLA,<3"+CJF(4**V)!MI?&19M+YD)-P^[')"DANLUIJ1N9L<O
M4FHG#<UG"W%@;\HW>\/5M="[>SJD'/&NI+\^]W#Y.]Y$ZZUCWG1[E5 8H ?;
M[]O:Y[U0MRF_)2'P=F.AF4?4]LS@V7L[;G>]_=LG.>RN9-0KY]/)[7-1=2"\
MY^SZ7"_==.]C-EBUZ]Z95F9[/#['FO6WNI8<7TLN="\PBY;G5UM651E_K_[Z
M:UW&'Z7Y4=LNM#=F:\?]\_KE7V#%O5M=>C]&I)FP2()-'"8FXEBJ(*D5,,"Q
M7" ,-U!ML):N0O+U"Z00?AL\]AG0"4_;AODC?Z_'=<=U+)T!EVV/YQ<*"\X]
MBD8*$!*4THK^A;I4J6NNRIL'!3KV[A!=5#]5M'B<]M:.W,Q)PYOW;^JGNA1]
MD=OW(4?G 77K&0W'-&8I6"?-):\^N.E *6E\=$-BS_#;YLK9SKVS<=)',CI5
M>W$#[2VG)J= Q->$>]MHN^&4Q=_E_,"-<!&DVL;>R!ZT9FK##SJ.0-JW_%L&
MSPF&AJUP9>'KO,?#S\;Z(!TC%9,U%F\82_(N).N;2(D:=]LQ[IJIF1>TRH43
M+86X55Y+<\^>C/((V7;([KF3_>;@0WW<X_<F'-8VIM\6EG@2NEA+A!SU,]%?
M5]/7ALQ&F[;:.]T-]@E!\TW>C*I8=8!4PIT0YL[VL^O5-[R*-FC8WAQ"\6$9
MZK:O>])5DN)>E9RSN8KPY75$JD7?/E[W_LQ)/5;/IJ-OAX:O%MS&G#-\K'Y<
M?<E#YXRX/+^80DSAVD>AZTZ&/5"WW9"SO56B_E#;\O[V/;K:\"HP7FB3IBS(
M';!HT8\R)BV$QGC.!<9"3AM?@ZH+AX%^+>P='# [5ZBVE%MO>U$:N*'O7.V<
MC^E [ WR!K_/1^1#9<,1.S_4?=P:%/8(PCX9;":L1RQAY0Q>?AQ6$5D$M0HP
M+,?[B#G8GLQ:LODE1.()UK \Q+LJ88!G:Z3:/</>3B'S(5ON],&>0;>>V:VL
M>%'H"J:H[VE !%>ZPW]XZ%T[7(A)@[PKSWH6W]X2[--&T+W:_'G=FXV3@E6.
M^AY]55>\_7H\"E<\+D%7'7=-OU4U]=CDJ'=(X1+PLQ/W7H)=X29/'GQ55*\"
M"C!1.)4>X<3L-WHP[RYCM7##M8[=SZHOY]A=\M_-7+J-N_;;MGUZ[]+<2W,2
MXE>9/9\@L K7PF,@2;RB*+*$@A'SN8SUX;F%^OT_11<EHHUF-,"LIFZ]3V&>
M (TXXMV15K*#XDM6 2IM"\=+A;)HMR.=U3?$&:J-*JXY(R<3G3V^(#L@S2:\
M-9B;0DT0H?5@+YY\!43UC9%K0LE)S/'+I<GV+NI/_LBY;#^\XD5(K$U^Y:&*
M@%?:[-S-C.@+>9D]K8;YQWK:])'VNL:]XI_;\2%<&Z".!*L_D?!U8=5VX)F2
M)AI3. =DI83PZ76"MA2)(",$NW:6N2;<#IC.%T7(S%LTP_-<[K256S)%X[&"
M3-/CO76<S#\G+RM0>=WR&CBCB6#(7OMS :<");P'_$+[-8*&9T,AO "R!).)
MUT"\4B2VK61]Q/CO+GO#170X>R\<#QGSY@O-(.I3ZG)X!N1R1PT@[!4@1(&Z
MQEX-C5!U0$%K?F2$]'K7Z;R1YH6XY"GYX(TX(.4']DVIU*ETF/::@(F-1V?[
M!N=.R2!<(/B,&2OZ@!/+JAA<#B8";S1HKRLV)!UJZ*Z=P6[RFA_V+!'1M;PC
M&B+>#4_\[1]F]^%1^3GCQ&_F=XR:Q71]RMYFO<TOQ"1="I/+U@;GDZF$,KB&
M=WDL-;9@KV-/+4XU;&U=6X5X7Z!<+E:-)#CTGCJ<IT!Y--PTUS_2Q_K^(#$"
M>0,([[!Q?7*#,,8S?NK<S%"--%;VT!Y30K6"T:(9#*(*SY3"#DI)KC8'8&",
M1-""36*K06KL A%NJ/=8WGQ[X4IR-MZD?XZLX2BJ"@>T"H[/>T(AJ6<&[W>?
M9QU8'%(VB0=HRINVY1) 5WXFQR 6.]+1C%UG31]R%!.;^4F%6K)LN:H_I5>Z
M&QR<JA/M6]JFEWO5W@0*DJC\)*+7IAL8V74CG4%B3-NT,]=.P(6IN@\IUYQ
M/W\-87SD9>'' (%(OA\X=<'_0.PR6\_>0_OJWNQX[_?^X.2F7<T[5VW,V[KV
M]LVMQL$QL28^*T\=^76P\ NP7KX.SL.EW*)$BT.NS'VA6;P+;RAM>14#Z(1>
MODD]W&MEKM4WU^C8K!:6L!-^T'ZD]V'VHMO+[JQ/C5F53XC1FZ+^R12\32XN
MIA#$7E,5D/$A^-7B[\IZ\L>OIFXFH6G\+(E J3^QRZS(OPQQBX:H/J!*&N:
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MG5O.9>$; QP.O(P?LAP^8NPSE>E6\::K76J;;!\'1K1C3]6 Y$RV+J6)\O)
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M82&:C81WH-K=,@I7]9%B >P*4M@)-!9/QPF/](O-*F$=MSY2%(#-+-0;/+^
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M.P.@==_X36L)\W=1RWUQH4WZ"1B- Q%[LZRB*@YG&RG[WK'J?^@U;74"W_-
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MU*"WCIJ%D].LLRQ=XKR <+4N8RZ8;45-2VG+VL8[1][2*U8&9MXA^=2T#HF
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MS%%,&+%/C9948+0AE'1(_A?9$!R2QD%FJ\=]9+A^,G[5B>P!%0$JTB00GJ-
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MBHU-;B0F[#5A7 6##J(,VNDO>$>L6D6R%=JY(L4C488DT2\E$Z,F@-9@[O7
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MQQK8P1ULKF&"1TJ;MB_>272C-Z2VZ109=T:>I4#YC4"V0J?.)F 0GX#44,9
M(DT$AK(N<D$U\GEP/T/T"DU\/A.T"51-W L\YAKUS"_A]<DN0Q/]Y.OP=J3.
MK& JV2H*L0EM6_(EZ,O(3"_YH#R38DI"P(=7+/R#  T^V52>P]U/Z1[;8W>C
M4K0C29+)"7M&"I6X]2_A69#?IR^D2YN6".6\9B[B1K7.FZL62_[E-Q$F=-H8
M[XU\U/Z%PQKL@OPU+Z1Y9_>^[^UOAGZM[>,:$NR&TJ+(&T#4.0"?Q,)GQ(5F
M/"<?'91%B(OL6X>4BN5,AIB W!J1)93C.QHG,^CX@/KE.P$9<F/O^EH!<41=
M2LTXS>W_AO86^9N-VG>N>/,S<C9$8M4HEC,\W<).P>3M,!'#X.<ZR)8ZX4;-
M0&1U5@L+I]$GZ%\B%%L:7S;U/)@[?V=FP1Q5P8:"6[$ ;CR3:P!M!F.%(=_3
MN#N4*XB$;DF/]D;?>N<>IK3Z@T/8NI>D ^3(E:+VL2UWI-NM'87O))!3P1".
M<V_)+4+.,$KC$HW94/,J7.8.YBQHB'$"%7[!5#*]F)B&V0AZ)Y'W8@Z2_2!L
M/(,4.C01PFM#&<PT=K6/)R%<H;X6A&CL9 $O64(^1/:HF!60/2(P)GT=#RIC
M""JNRA"BOLU O*; A\@ '\H0%A83[R@<S"V!NGQ /0;H_RMG$*U33B((N]LE
MVI'Y@M!\T0ZR2<WH'.)&TL3HR<4V+<B__:^ <.YAHT,I)W);AZ3LLZ1RJ^3Z
M5__(\KMH;'C;'%/3$=6&2AW3RF@_2LIIX?W63S&5V4-".H3L*%8;5!P@Q0H_
M\FK(Z$&KG TCJ':S"&N-/\8=/W'\)ZJ[MY*,^.V(KI2K,I=J/XAZUNWU*_R=
M-5BM=SI9'UQ/8G:X3[@;_ *ZM-!RL'#RS7+(0*F.=#F!2C/1%@'21<Q$,N$Z
MPY]4)S8<SR"?$*WF/IWV7A"A$ 3!@ZQKU5"5R'Z$N,['9S2@;'O<U/P[I4RE
M37BW28:'SC?+BY;&-\B,<B>RDFFB6QK71=:2-.ZNSS)]4'('Q<H*E;CFMA9<
MS0)Z9\4MBFU-42Y\FSJ9>\, VO/9B+^ 1./'66?FVZ8T3479+@Q5<&D.7JU+
M7>E80G>B7JSB$!"6S'&+C0=UG.N@<OJTWDK*GQ3CUHFLV"ZD&OKH<U)*QYA.
M'V6WN[#9O@6S>Y",,LJ*7X-MMDEX0GH;CS^C^#A@8>)&&#$H8\<F42,D:C/4
M.N;\ D@3[_L'NG4!$BN!*.F\8*88#J1DR2Y8X_Y;>PN3+)<D\@$A;4O$V!'P
MP@)IL*#=;D-B1F500'USQ7UV_DKSU\>Q-'U2J72/O)QS42Q7[Z"8@MV):.]K
M0F+:N(',,4J4LTT6!@TP< S(1)2?I-A-(K:M.&<!]+- _10?FY +Z;UK#S)Z
MP>F1:3;6LS,6++8LSJT<#;=IB%N#]?Y#>:^PIR8@7S#Y)=4DMU6B]!(8VV)!
M[6([K\%\%6\'YA5Z9/,A-%RTG;,;*]W<Q'O-&:@WM;2Z/'@E>E.-U=\%_C.L
MN3RWT^HNHS)R@X)WZ"A&C]*/W\#1$!I>)#L^(YGQO?SHG=T"56<@)9FB0=:#
MNH-O:F9-P'5QMT3-;EW%*LK D+DF/9Q (<G:S7\\BW+XU:<K9(U@4;RK?RG#
MW+OV-.KPO]=6\=K4Q].HVRZ"JNE1)="^4I+J!"T;LQ-:=8*BP.#S]^;.0$FV
M6>9H;X;L1+^YE857=^N87F]]H$F;U.XJ6U1DW!H75=;(>D.MQ!=FW*C_L=B.
M0?13+ZW!,KW78/KUO#3>.IF]B)GJ-[605RGX3 X:4@;3H\4;J\$U)?L W1TT
MS<#I8MM>RH[9AGR>KLPDON)S5XULMQN/#<W]RBL>;[.KYS2>'MK;)B_"7F)F
MQO'F;X&$7SBTMJ"=@VNP"-2P[83J';1Q.>%[W"3MII!!:%NAMC-.RCDQ81'"
MZH9/C(H&4)H>Q8A^M5QT1N 38^: <^NSC-+>7%1*F N[RHV4]M'SOJE^P6R0
M-W*WDQZLP42ACT3N\"Z*7K\,#C:UTS9R;$MFUF :E$/04 =VZSB_>&<#N.]C
M\Q.2B]*5;S%H?^D><LG:/F?;M%_HHQJWB?@C&JH^H',I_3/4W29Y)M<RZ90D
M;949(XWV@YU9^FU'A23.)33!^$M%<?0.D<N=<Y&#X@MV]_M.&Q7IIW2DR/9J
M$ZX6J$6$^8>\P&[H6MU)]NKMSEC8"[!;\<@9;RI+2>+*\@G$RP*@(8 JVO_(
M-HV[?=IH:W]7LN* S *X"\+;1KW_!<^+6PI"Z-GSF'TD?,#KN@&#EOP"W28"
MID.T!AO.$!';49\S%#OZ.L=UNE,Q9I@L8>$/<GS5+&5OO\4DZ)*@V#6#U%9^
M]TB,V>TEID%DHS/M6DD$9F,CE/)U1G%L@%7M#7($4>RTFLM]=S&!MC/QQ+X@
M6M_P#7A +S6R^W9<9WGI= ]$#^BU;B9TV2 U+O:@_0&Q*/;V<C.J"_$Q!9DJ
MLQ<JD6Q:<02XFE!)VB_N:+3*B)VHSMDNF/;"6/\FY6YK'$3MN3=Z? 8;11VN
MC7:W;[\Q9C<8$Z_OV4L^)W+S7X-IR@Y#M:++.:U<C?XA9U"_W<$9"R<9>-!.
M01?#*NL$([*S T]?0O%5]?5+!2YI1&&?I(S]@WA6GH8Q)DWQ:3KD#:(LE+#K
M-@>Y>@+*:?%"[JAO0F:MP9"\<&:&C7+=,7H^-K5/E-:^"\_:F!];/E=L >IG
M6M8L%9I- CEWK,:3@K;Z6IMMY^XC5<R=RFV+IR50UBL&>!HR1^%X:MP6:AT[
M37:3KNBVP\\/4PF5I(3.H,U -,*;GZ-'*)#PX6F"&S0A+TG ZI1XO !M2E6S
M%=H1/23\B;K&%R]P:N2?[W1>2'%W&+>?*5^HR1\<;%B#Q?I/(]TCUF#UJ)9X
M_TZI M8KN]&871LK"N=HA3%\2<2.[WA-)ODZ-B6WXRQ)[YWH"P9)3?*F'"L\
M<1<E!F+8F5]!L[\%-0^(NHRN)%*W0@VUBIZA;B)[@!XM"&X]N)DUGE*\'TJ:
MB$?@5607@* BT/E=6ZS=U2*F'\FL@[(+^B/Z0S0I^,+ O+EB5P#I!GSK&V!0
MJS(RZ/C+'G,KA\A;\$- ROP)4/UGJ"H&I^4^@3,@N4Y)'_/DY=_0@?%@K/1^
MC_ZO \O^/] QU\M(1*EO#]D3WMJ$WSK#TPIK3.%S,4,<JLB:!91]>B?";H3J
M+C04CY_]D3N!FF\%"5*:/(,:QK#UXD*Q0I0ZR5'Z!_3U"=EV@#6^%2H]/R0+
M%#$SC30'R!K"(; S 9OP?&E\/>E6V]:Q60T&)D,$3\U7F#\RC[%7QVVZG^NJ
M8;I,=,,W5#;;<0=[GF #8_#91H8]U+#5-9@ [E';SUJ#P97AUK#$&'\HC6RP
MJTEXWNA8TL" IPSA0,W<LKG#LX*L3QDNO8P:EO^M4=>5V0\6T3_V-K&3<;H0
M=M4S$-56=-U77O&<Q4OAZ7(V@T;CPM@LLN%$LTK'V*ZF?F4RDY885.$H_;9L
M<QD]DTP5J?-T2?;M HTE1&A.E$B]TC(*?3KVRH?R\.]UOI%D%TA7/)XQOIFR
MB;P+O%R,^(1&T>>XJESH1Y20N1/J7O!CIE",9G*J(KAZ@%YS&72]-6YA2/H]
M>XFI%H G?->GK.^W<D"\E4ZV:;B=/>2'W 315C5)Z=A41$,S4#S25GP,@&>C
M'2:N@V:M>)9^)U-@X@EZE8J[DXV.!OJWC%D!^IW[!F2Q(%PXE![-VS*[HLBC
MDYAN_2AO?C=]YL8#RK9^B^5FK^^XO*N\P7&+F/&7(\]N16.5EH)?S4,6/N3N
M):GCH!-E,FV(!JIWO"!E\/';T,=!_Y]!?3XNK7@'H,EIK'A40XIU[^5@*Z"X
MQ7/]''LF9-QNTX#=-@7&#R;H90GG&-;,H&<R9_ES"9.C(7)WE$8!V%2N"=D1
M2,D@6PMY>A"\@Z>A.$)"=E#TV.#&Q]9S_G/=L+FQGWK0^".S<98HJR(7[YRV
M8GA!J[7;*W3@,U(.[I-,70PO[)J/6/4IS-&#"OK$SKFEI"8/R!"D"^FW+6LP
M)DJ92DO#(&QSN#8R+)0FI&X0R$*5?BL"-.C@_C^3O[Q'_Z%MO<?L1WT[1>3L
M/UQ]WO%FC8DL>\#E&N,E=]=?K-\T_\WGC\(/WA_)[[]G\_'\'^6P:_,EA!^F
MW-+K75H3_F/MQ_7Q%],_Z$U_M)<_:.M'_2/S>Z3<9C^Z+RZY5G^+]U[U\-T&
MM;/N9??S1+^8%3;YX5RUUQ%5^;?.G7^Z[-[^:P]W?SC]>/IQ8$<E=?I!.\,?
MXNS->YC-F[_X!ET^MNWSG[#=F^(%_S,D\=;'75Y;FB]<(_,A==J"E.8C=7R;
M-U^N<5U>8U=K^-;&-\]TOE#%=Z O#_UG:)-/"'3U@*]R,O)4[C*?%NZQJ%/*
M4V7B5.4^DZ!S[]XX+5)J.G/&:563)T/PBP5\X?^$U[/47WC\,/Z/1DG_/Y_%
M:/QUJ[I,/H,6Q0.;3-X!3^L?6GUP_\MG![H%O-WC/\.34_88(J]6+/:WW_^/
M??V7K:/&CQH_:ORH\:/&CQH_:ORH\:/&CQH_:CP%QB]/7/'RU])-<2^G7ZOJ
MG=-ZS7HW]XR\MW,7)TW2\L_[Y')4ULLB7#5"-$? -88*"\Q&<1?#_YL 4$L#
M!!0    ( !TY=US/ACXH-"P  #(Q   *    :6UA9V4S+FIP9^UZ>UA2Z=ON
MZFCE&)FIDY;\.EJ9TL%#*<&4DU:.4IKG U..*9HQI28I0FJ>,Z:L+)TD,S6/
MI(&6!TCQ4#E&G@U3!*8\H+E6*:YD 9OY?K_][>_:>[[K^KZ]_]UP<7'QKO=Z
MUGN_[_,\]WT#ZD'U*+#FA,-Q!V#1HD7 SYHGH!X"[/_Z]/_T^"O(_VN,1>J7
M@.X*@ #4+%FT&5BLNVB)[B)U"X &@$7+_CD!^-=CT>(E2Y<MUUJQ<I6V9@)G
M#;!XT9(EBY<N6;9LZ5+-U3C-=6"I[K*UF_8>7JYWZHS6YHOK]L7?S%^QY4A5
MD[YK%[AU_]E+"2M7&1A^O]YHVW;3'3MW65I9VQPX:&O_XU$'QV/'3[B==O?P
M]/+V"?PEZ%QP""DT(C+J<C3E2DSBM:3DE-2T]%M9M^_<S;YW/^=1P>/"HN(G
M):75S]B<FMKG+^J:^2VM;>VO7K_I[NGMZQ\8?"\42Z1_?OPT-CXQ"7WY.CLG
MGX>_+?R%:Q&PY-^A_RTN70VNQ4N7+EFJ]1>N18NC_YJ@NW39IKW+UQX^I77F
MHM[F??$KUAVYF5_5M'++?E=0_^REKE4&6RW%VZ"_H/T;LO\:L(3_*V3_#NQ_
MX1("WRU9I#F\);H 'E")J4<KQW&ZH.J%1& 05N>8C#479Z+=(,,TJI/$W*'C
M**@&4AKPC]X32L)L/[THGW0;(@E=&(\G^@=L%O**Z1'DH#-!Y$-]O=#A=;<P
M;T0@2!_44S$8<KP::+D+8]1 )R=4#339/]HB7Z1\X=+5/A6K^"DOI;:);!SK
M.1AP7#6.,&#/_NX;J_)6WS75(^C[N%<=R-'-_.[HAGT)?->FWDM9)==:#]8Q
M?4([WC^Y1!SYY,<S=)?N"MQUYM>^/;V!CCI)K(.>_+Z6-P4M?:UNI]*+,YIW
MA6JO&A:Q(Z)PS<F\=71^DQKXF;" PP^J 36PUG>4IP:L>_]^N&].55@98KL[
M<W55Q;CPIXX"F<GF$([YB3=M_[83O@3BFK#R;+<?^8[O<CV[L[UZ7RD,[@GS
M\C#!5T>&5H:3LNLNUQ9-++S-C#M3%K+ R2PJ+@RM"^HU7+A07"1JVMAW([]8
MY--04UMC4U/=&D&*#M]=,[_':<.[5U!=%='K#7T<M5<-\.\:OE$#7W>I6..>
M?<_"\4/[5,ROYBUS']5 2:T_30V8XZPUBTE4O63.4NE5:D"UM;:)K@I_\G>#
M9=/TK6H@DN:([/A"F'?\D][,(-^AOS,)U$S>C<E6GFA@BO[<EMS)5@/G.^KH
M?]3J*44+N5=XO,]P@<H$I5A,[X)4[6H OB5:I@:^U?SM(*NT$HD8]<=[FJ!Y
M$//:><ZG?DO&ZLRU,RT^AVHJJ8<E.K8*SW>1FXHZ+V<7>_7//MCOVF>9N<=>
M/NSDTC/#.O\P1]A])5!&S5)V?4.#!;+U!.6B3Q@>LO,,E:4&]K&(O%=TCW\N
M<>$_++&#D(X7CZJ!IZ9*-'J*K@;2S$&B&L@-_?M1Q:JOGEV1TTZ.71P=XO&J
M?NR1^:X0(_>/RL*:PLKC13Y6JD(31B"V)*J$R_R9$4N]>\JE_V[JP/Y4L:O4
M\S5^&'U3#:PZQ'53 S]<8:@V/.42YW;-*9#$R?<US.G[=,*WNQ)ZO1IP(]O,
M?R-!C@@6+5^J!@JD2H8:@+9QM35G&O[WHT2B*"QG]?W2\1R#0DW>T5Y(@GLW
M@R.9<27>/J'<?V0=?Q;NZ,[XL:<XQZ[3>[;SD(\:..FTXH+1FTZ?R3^/ A8Z
MGK[O(M>S?>,B?+K8).1X^5'QS.JFTDF/F$BAG&>5J2I>G?*H_<IN3&F8'JG.
MH_C)T2*O\OEJKXG:>=*BA+>28X+R(/RLUKU9-7#_KF&'JM _2H'\MMLZO%AQ
MCMBC"GK._"Q2G1LASWSI^1,%4_!3*]6 8[L"K08D3E1#-?!)R/C;46XE.'8=
MT9=JW<*O@'G-W)V42/IJ./D7\!/OL8QL$"]1')Q#KPR[97$_*M+-$7)@AD?0
MQ</.5ZO[IZ;'ZGI,7R3LW!CEZ]'EYIO")Y21S"1VF;ND?HG\:7I(W8>%;87#
M%4DC5:MO!QE^(7G4SO=[>!HE_-#_F_^P<,AI7^?%M0?GKA>KKGY%(P?/4'F3
M[@.:-,)5Y-+?_4],:J!WJ%.I!J+;F7_7N-!_-QC'^I/YF?%*#20%PG2_=U3O
M I)J"UA96T#)Y@O9:%(W1X2:]/!YFUDR1*:HNHHG<R('K&U^NW*S@1;._N+8
MN#'Z@NNBZ2_,A25_T,&/25]XR)M&34G_P^O\D"KQ/Q:Z[U_Y_=M_*[^U%<2C
MJ@]JX%JP@GA<\Y:E,%-$JW350*V0?H%^-HZEP"N"%::="KK<<T@-O..Q:0(Y
M@:/)QBLCT:\],=LY/146')TCDOZVYC9A;,>0['4!AZVAE[3B%W5U+WY_;"WO
M!PLZL5]MCZX[UGWL3?JQ_W(U,/X[U? +R6;A7&/A1-VGE"<DX=NT\@EY3 VC
MG&1S>>%&=NE$3&9#= ZML&C2@&Q5*&?&D2QM/*+O/G,B1Y%W1S1M:9EL4P.W
MZ'7X+:IUL=3_6@*T_NU9QZ*:&4*M4<-VYK2FUYWB;>"BD&#-OKHIS%1K&; [
M>FV#(62HTN5-BZ;14X2_)OUHU1BH0"LT+T_5&U67PD:>(O<HD!/LIFQPGO57
M3!4%7_!BH@F\?8L:T%$J?LHL8 S.RXT.H>B9>/#D##FTVPS#2FE[F[DAW.BY
MWR%;Z([?.9/&@Q&!>^Z1CIQ,7H+"I.CNW+DKO7-KCP-!<21YRY)5<T_=2\Y6
MZ?'?6#Z] \YMZ4AHD10<Z,W#ZZ$S5C^23,C6UY\PWU(!IB#I 9JBK(K^40WT
M!%6LH]BKCF(T^SU8_X@^4=V?#D?,%%3/$F]FJH%E:Q/)B-Z\?/S@!7P@2WA^
M=A;>*0TDGE4RAWF[ON%5J\Q-\*-,?.V99DAAK.HI_@*;2NFABBUOY,0.-5!!
M=/2H1;:.^FLZ0&".1>.>]_C9>M+@M]#3=#%Q@R;;;EYV'ZHT.Z &$M7 XK%6
M-#MZBC_*2MT'9TE7=L_YJH%4E2'L+HU#\7,N9SRFQ'A 2Y_!3JWR?@,C1I:X
MC&D0-L 3QKQE1CU\%,8,[<)$IFKZEC8]B!2P![Y32)D1^QLWX=FTK.)QH[9L
M]/3&@@ JOEL-C/X>@TELP!01$=<>+)I<.&E@9)*I..(=@.#8.:B5&BYSZ<G7
M17Y@M!B9E'-1MUY_KER>%($KL1J3$=)5!ZF&H&EZ=A/."BX<1:^D%*AT*YS:
M]$BX+9#UG8+C@>**'6;#DPL5;?D7R<&/?1NT8Z\45Y9<).$JBL?SMO>RG[#.
M8\TD3@_,WCI.)RD.?>@0=\0M:<W;#/6-I2,'8R7#: )\!BR0S+?Z_T2A._.>
M]ECIV'OVX(PIVJT^*<FM-_)+27>S+W.WU'2SPL=ZS[OZ_F+SZY6\P"=YM;6Q
MIF75Q$>U9+>^S(/FYJ9AE[O\[6(.Q;E][1EE&L#!\M>U[^@AZ._@B),PERX^
M GL&@&/-,[I.)?"ST_TX#(F^CK;KL$2A!O1(U4WEI&BZ'C48[)!3JTRTNX,Y
M S]#RW.EC:Y?AIK2\N&>J8&[5,.,2+1P/0Z%72 P>*'3P2>ZN;M@"5GG,%HC
MJH2\EW7%:>>+X;A"QV(XQK?13%K;(AC2^@%\V#^-.)8@.(C7PD)1BIL-3+#/
M<YTA7I)%@YX:6&&YEM8&&TH8\:IM@^.VK/BYC?;$K@8GL1-Q?8APUL00<F>E
M5%IFU$^P154"B8Z]/;M+(PGT!T5#?CZR@"6]K KLQ8?.9%M9WL8>I&351*>4
MM6((^:&':^!<MHORU0.\S)$J\4<4RXM$(2 CA=.HQ:]KJU 6U9@7')4?"FY9
MV,@<-.W=TOL9-RS/\-TY'<XRK0WHPK.5<;*)VNRL'E^SN?I3)%9T<*R/W43<
MG,\P(HK#ZU_ &BN.C3/7(J<DA!2NH3+?$I4Z8@<-3+6S CZ$U:J!-59J8/4(
M7PU\5R5]A1 "I62](:\)WDI.I@V?:6ALW]7@O<[G\DUQIX5JH_7;C5J'W^&K
M(U^94>S;B;J6X[1-E%C^.]I G@UDG:'8KA(LU-Y0;:!\;<6SMV=(G>@9(]MA
M9E@^<@PR3#G[HK:7MLUK0EYWWF;A1J--DV*%I3+0H0MK7TC]1^^LR-;\A$!>
MZP)Y)F#)Y=0CH,Z#CS<:2RA&8\Z@J.708IE+W:T! K,UX/L>Q#FPD)BAV-H3
M=8Q#T);EQ$UU^3C%G3=GW17.=]SKN,!!EH ,<7!S6;A#AYC.)Z2(=*;FKHS6
M]55@EXR*5L.XH=,O.)F2FN>]/X/RW.*CL8<:7(]O6/OA<?71#3=N5I?M,1-N
M[2L4\3SIK9.*C.P&7]A#%G2AEN=(]H_N@9R:N4N5CRYH6D42U[2N1X6C)+:9
M:,,,Q<_C/&WJ*<D#8WE\CV6'W<98L4M\"56KCWKXD68#")D< 8IBUA*PH]=G
MT!FBM^3P!O.=6$NI1_JWY/(7DN,+9W.LXQ6'X82.9A_3)!;^_+#=RQAYE<(D
MA*E/;H@H14+?(=%!TF''EKI6YK1^A-@YL*7'%YXY#.[&Z=5W$UMS9I*"G\'>
M13)M\_D$5L7#:L,UM#^O!'1\H\^5W8!F;C1L =OY;A1^NU'U>-[&VKZ&_?F=
M3Y2);KTUH7E[(1QC5*0C5&8=J^K%Y"H<6W)4647?)D+[Y?0P11#27[/&;_C(
MSD(V4QIW2\3Y[9NOPG8\NUG5)_]6'PY/?$M4G+57^/N2C QN:JQ(\\C^=^QA
MPR8TVR17/&T_&MV*RM#4+]99LB@8C/:O@>ET:#41]LQ;W1O),+3FD?,[Q6<N
M2M FDSZ,#+*%4!"0Y<E.F/>04/U'"<+-/:Z0%O^0B52>U4]#$Y%S\%E>6"_5
M"0KVX36 Q=?I@8RTIU3GI(:X*T\Z)<M ,F)^K.$ V7(0.6R81-THE65:FQL(
M^,*6_M\\IS%WIGC9:L#G^0P*EC7C=D(8!A:=']H1)\$D^]1DY,-2%\7RXC!E
M6BDEA6_D>)T=2^2,> T-3A+/@R/UA:$!M)M1=#)9SJH:=EZ&&%H_[2F+I@7W
M\ AW1XAQ+?F_9)MUV4WW%<<MA&:S[L,98'^/E)&H0DV8?$_74O5:J_31*-Y9
MQO+=AM9,3@ 3SW?VP0#(:0[<(S'#KZ3HL(G7A?(4C7Y:/QCR-,QD*7R&!6\?
M.NT FN10CQ=2#SBMJ#Q8AEJJZK->6)XFO6>)%VY1&>:J7C'7-1@:IG)\,1GS
M"]>,/B<JCGUPC"WP;X^5&#?:HM8-(P;/^CCDQ?9EE(>A(Q9]&OG>*,:LE=$P
M67S:YJR%-5\:L[^H =FIC[$8C;[K+YS6O_5I*-PD-Y0[;5-=9_\Q^OWGW+[+
MQ^=D XW9FK;"CK.3!K%I:PEKX0)Y+82>4@/H5M%ZS<D[Q8GQR4PV@\]*LRYE
M+J<RES)0$]RM, N*E=<.X-9W0H;3T0,1</^82]<9J$'>/[!PGJ>=7W.CIX>Z
M<Y21)D0C>@6C,TGFCV$^.-!FZ\Q*T&OYC1+V$G>@#TLOG+C+M56<*RR"LYIX
M**S;*/ZZA]"D $@8:.T$LWUKX?@S^<,C 2%WZY(2B+[."UM&11FX)7!\)<S@
M<W5Y?7.Q,RMDN.W@6&IE>R*5%"B>MFG!H?HJ9@EKQC&23B=^#4W_>?_Y*.TG
MU$:+'N_GW-[=U&%?YX2O)VKSY&8T-)P[BEE'"K >L'2F:5>8B@5I5&\QRHCH
M?*:4!([3_@'NUX?<;_.$'@;D:(-;A_>%&L4,3]3NTAX<\7NX>]DI,UE=V#0I
M-OS/BN+@WH#.^I#9BS&79.&YXT.?HB_W=PTBNTWTE/GFD@P)EJ:M+)L5I<XH
M["AN+AD>1H)VQO<RFTXQ9FA-J,G6'G.KE9$$'=F>]E)D/=NV/06[4BK2(>'7
MSE#WQH1;=6 ,*/TS 9!I:IQ=:S<U"GHPDVF%UI_@<4JI^I!A"UVH$0B']C?3
MC.&Q(HK0W]$#IH.]R)(,?] C-SA(HB!<RW89L56]>8>U?^R-V#V#?JDFT?4B
M92L")*_Q)*JIQ%FK':</"C(;S*EUQ<G8,V*E<2MN0Z^JXTJ0LN AG.A2T\?.
MF*D*M>[/22H6SBKJ8QG5(A^?$=]O>>Z:QE/0UJCUKT+,ME4%CW&Y=;X!=7'\
MC[(W,Y6U/@&B0[97"D6$5ZBK(QO@IH?4(\H<VJIA2D;[@F,2BZ9%U8;5@'3C
MDE,#U*.%H5QMM YMK4TS0P_9'F?QU=6W L5?$+24T(PHN9[@G<X[%<D5E_)L
MGZK:,J>B8M\H@Q7X>IJ[3LHUZMY"F5 -I$<*=&"Z"X1/EW2-0HZI4Y9Q.$$
MM-7$)&%RZ(<48M_T=$&O52K;+DPV%&=RR$'RT?*5Q>='U6L<+^[BSO\+1J75
M[1@5S2?\X_R"[BZ__JX*JUH+Y?PWZIWY'O24:OJ;9WO RD25]3*%\_5:=-7
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M+#G#D&97!UE]>B$1I."L>Z(8:&?(6.R9P:F(=H/TIXL'\!M4RZ@!<))B.TV
M1C&2"XT$"5&,!(V(-.*NHVC[@\3TK1 ^"<&(8Q\8$L&4Y$HZ:3D4S!=L0.G
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MP#4=[:8_;BO(;-]<#)K@-,%M'\%IKX0F3DV<6TJ<>Z=T+CW+7-/4#K@ MX*
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MGR(;5FEW'#DY4\K8[[FSTF!X @Q?/2"AW_C -G>P/E$^$G*F=% P6$+.87?
M?'X]HN8=.P**YV4834_PH.)_2TA[UQ#9;RZRA).5&B+[G7PRBXM,]K'YW0X'
M'=?B?=NU0_XMX'#3I=WG^]"U\3ESW8:NAEO$82JE4PD?^*M:4L5N7=C)V *_
ML/T@E#].V/&25#ON P]"7!5E-2;FN\?<UKW/.5[%C?G5YQX8M2,[9,Y6XTL5
MQU5K(6W>Z=58AMD]=R&5M?WT4JX>NY6CTNESL4O/5$NKQNXA@%(CYC6(*<]
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M>TOW$NA+;F)Y]^CM"$Z7T<<RGNV.1M2KY9*J> ;\KB+8S[W/:?:X0/%F?W:
MI-FE;<)"\OB6K=YJ0>J3LY';.6\^JV< U:-RZ?E%ON"9<F79#& Y$/@K\$,J
M#4MWPS^^VJX]C(8'!I G/PDK\SY>IS<?\9^9E=+06P+TV \-O<6@EUZIPX4>
M*$!/0>\F\LT!VR/)-V-"6PR"%=1[38&@,A<$77,HR7%W]WUR#EN[U>LX9#%W
MJ[O1:.3Y89?[#U@D?Z>W/'<NJ]_Z;3I+L?#6WYRWSE)FWG7/L>^I!O#N(N")
M*1T4$*HQ$)YB]_MCYF[.P'W^MF^<]>MMWR-JK\7*'6W[FG;Q%2OW?%UI57QR
M8=MHCZPB;0\]WRC>'WZYH][@5T,@<FVQ_YW+;KQO0\Z"R.<?[<"K5<HG[^&:
M>EQ=4O_&YS\6<E[V%WSW+XJ3Q*^U[ ?8O_27KZ(A]UGH^2_\\M3S^.,Y=[VA
M[>:]5BXO16_FO3?SBG?9T<^=.# 1/K6,<A_@S^>M8E?@:NI]PK(3%Y_YQLQ^
M9-^'EU[PMF#&=)]>Y.D7?NN>S\0@7'OVRY:#P2>^O'48_),S/W^/\<H3B_C.
M_O$>!N:!,.3!1_KG@#.+N!U\_>//^#_ 8WX> /L.QPYP[Y[GP_7WKN?R#^+O
MHYX7AM[P?7GTPP@\Q[:,GL/,[^IJZ(W>UR8N#3@F KPOET8_/I@>,./W_]6G
M__O0@\OWOA>YUE'V K*Q(P;FK/L>N';(_0]#YM_;[I'#^^%[%H6>^H&2#,0O
M4P^]>4?3D=,2?ZF937_!L5U^I,9Z7*E_Z ,[/7H4/_0\QWKS\;__5[E1^B!6
M:SEO_#D8,5>]@2[WV=!VQN_O0+@%QA5_-&X]L.Z+].]B  R_G_=48/^'XPH#
M1_EVU;EKGQO=N]9=&S@LWOKQYY[_;N93-7RJVS[[=MNYZ[2[1NOJW&C_<?:E
M=?6Y;9Q=?_W:Z78[UU?J5>H_JUR$U'1>L4(??V]UOW2N/M]=7Q6-\^.S8Z-2
MJM=.)R<R-9^0]1QNF-QQ1LS"WIF_O"F]H7_#K:;Z=\Z0_C$QIG\4#3$J@X;U
M(3NW#X^V%0[@S]+?%?D %3AL%/#WZH\TJ!'[BH!*]']OE$J0: :AGZ@)^$]+
MC3/UL0?NA[;)'/E>H-DWZ8>R.SJY?SE4H)22,*T*O4N/9/G#>@'0/DQB?BY!
M" 2]!GT7U[=?C9^!RP+[)$EBF\3$+Y K"Y]5M5*NE,O-2K/1 $2Y##5FB]OO
MSSTS4IHL($_H=;>\GY_ ]@9TQJ,+8NC)IZ;P/0/MF]B\)6"J('] 4IW+AOX5
M!6!5C*?@L4*V\_8K\[\;UR[_Z4E6\[Q%V9XI+@3KZFDE']:W_-X.0I]\U=T0
M3!O2A9_&N4&N[O"7-_:/\'W?_L$M&+(3<%RJTY-:[<,D#1BW[<^=[MUMZPX$
MF!")7]M7=\;-M]ONMQ;\<7=M@.2CJ^7*V]Y/QO6M\?8>_G-AW'UI&RFI&$O$
MUMD=7BZ?5FOKV=X9_&V%NWM]>]C K=5/:HT\X+9<-\*Z/QAU>QE>0S]2<&U,
MP[5U=?6M=0FHO;F^G8'2*D*T7']K'3I(+SS?" ?<Z-L!R!UC# :0P?&\W6(R
MMUZOGE3R]OB&G"IMX7-Y[B9;\,S1$!X9X(N/+#8^PH$=<??-0M [+55.&[7T
ML,XBW^=8'PUGB5;>\D:&@SKGIO"FH;LIB\;B0@MY6JXV*KE</AGR!?P2+*;'
M5.K3>LQ">LW.X_G F>YII7Q:SV6Z=SYS ZJR]AK&^X2B #K"5;=#+%9S7XW6
MI]':F.#3"JW= 7><,V\(;QJO$*_=+^W+2_3.W+2N_EP4LEZ?)&:7FY%/10^-
M]@]S@&FC1LL,\?(^0Q:E)LZ1/\"G#9__.[+Q !PLB1T8 6X;;!3M&US$C=O7
MA9A^-N..4XI5&/-=0P2:C+[O#>4R&'_%_V>$7NI?^[IH0-)#.\!P(VB<#C?<
MB-2FA9@%:$B59II9M"F,> 'ON:+7+*(;E?"0;[U2J6Z50C37R]9XQ:(OLJZU
M2O6D.KVNRKW@AE=P99&U_61[ES"QVQ_&96@=SUS@[4/EVYPWX]_O\5"D;;[Y
MV/[!@+/C"B'K2U;&8,#S1MS$@+MEV*YAAX$!LL /,2A.[UZ3]VHNL+*36=DR
MDHKID#\JNTS__;^:E?+)AT"LH.T"JVN[]XX=#)ZS."^;[?0"BL"$B!7$,8F]
MBU'43J?<R2+H.!&"K,1Q1O^^][94-/#__;3<F,&FU<Q:\^2T-LWA.J[I^:"B
M)![4,R]R0W]\YEG/]0P<!=Q\SZU[YH]\[\$4[T'70"?P&7>>*VWR'/<YFUQ9
M3\A@,7C!IP\06_7J:9[T;%F6SX- _@?%8GDAUXWQA7UEDE^R,0R]&_J<AU/X
MH5#TT^.KE$K5DWIYYOC.X,]K_\Y[=!<9W5?/LN78;'=R2!))"XWIM-DXG3FF
M&R\ WOW_VJ,%R?#C2?GDI'GR,L];I52N-_/42K5 @I)?P@TD$\ 7+Y<1/"^P
MF$^I2R#"-6D5;_\)9G9@V:;2*^PTVS; S/+\>^;:_Z%_/ZEN[2AGW:']DI2#
M6S7R8;/L$7,,_H.;46@_H +=QV-6+]JHQ6/7JS?1-BMXX*]*HYGQ])[!1\!,
MN>%^X+DN=Q8SV_Z"1S,<CRNA%:<SPQV?H@#6 ]DA?4.E,=\,;,<>&:UCH\M]
M9UHFD)CZ?Q::3K52.CG)3 >'Y'.VF!1XU31.3RI3KL&WS9\6DQ_5DU(SHP!<
M>D"Y-P//7=@M\:K!-VJ5HU,P+5ZQ]K63D]+I/"A=L!^+NUA@-6GUY,"FY++Q
MML_,P 9BX#\MKL?4JQ-B>G*,[2&S';EL*U[R$< ^^%\]VT,FX?\X-M&A]T(%
M#7:NTLPQ3EZD0+YJ5DO7/<NE^FFSM!3=\U436Y+:6BXW:O7*LM365\WH51IO
MN5(YJ9V\7N-]S0Q6HRSOCD,197/1N.,.'Z&@*!KM(V1?!G.M=Z#17B@&J1SD
M\+N1TJMD9,R0BVH()K@5'L<5KFHJXN:3;Y'[W$(#(/2,'D__-HK\($+_+%R!
MI\A0$)EI,GC7,L/WRUZF@_4K[IWCY\X.'1'D9.; ,+%4XIZ:E?NU;U<R0$/;
MQE50'FC_<6##+PF#V&&ORWI64I7_-)+ZGX8XS584J^OS$?P##W*Z]T:C5 (V
M#'P.;POD;2/F&P_8"-*XZG2-TG&YA %P<7E/J>E5V[M2N@@L]F]#5GDU,+&>
M/YF7L0$:6-[^[! RUG(T:,?9T;5F+KO%7/[':KV[BTQX>^V8_W'EA6@ 8VX8
M&@<?0$5QQI@^8J(G2Y@KCW8X(%/%3QWS0>5FMF@^7K9]/'<)38<S'W,*!NH4
M,1Y;)K-$_EL=<J8%*TS#=L3N^5'/Y^S[$>O#"-XSYY&-@Q30IPY1'PD*H4/0
MD]^G(]-X)645R>E4DD/3PN[).30M#:)W\4A3T]Y"$+W:&+Y/&\/KA<[VY&W2
M2"QNRFCB>VPUA8$,_N;CE>?&H@0]GF]CJY!JYQ^"EP5YE#"= "8^-^S 8#*K
M%]5^+RZ5EX^Q=+:TQMCV8FP#IP,ZK@4R+.2$#>GCA%E[48A5^U$H2E4O-N<E
MCNP@B+@?)Q2:HHT%7C6E @*8-;WAT,.A>>9W3-&$JZ"6P$N:1:-2JC3>*S_Y
MA<\$5O,=Y=73B4-9PMU]1J_OXMN%X+U.AIWC-F^4JJ7F&P/KA]"/LBJ, 9"P
MA\P)?GG3N;K('EZ %3FR/$(-WO+F8Z78*)>*S7*M6#V-(WUJ]!\GC>_]ATUO
M;)@##KL[Q$/B=C^C*0$;(D[UR!WGZ+OK/<+G. N UBR)GR*BPN)]VQ5IN[<1
M4%VM5,\YV_%<QK5+;.I/N$$>C1&#3/_O8K&D6JU9STE_^QV6_E=<^:Y<^ ZM
M^R+AXRMO*F <'_3=5UCWQ?$9(5H)O"[\/SPE;0@S01TA$7<4 ;.+$X+KJ7,Z
M ':0SW3P0KPHR!?<5?SJ<PX[:0J932'U:K69DU_XF^=$+AIO>'[%7^A<[P%2
M!EC*W#@RSA#BXI091MA^&*SG/7"PD1U'PMNQ.?P@3IW%X%\QZNDD%]YH^RE=
M.#!(P8/?O8"KMS_/-M^I+9HADQ\''(V&27[TMOR3,0#AB]MA&0SV3^U)>K-Z
M7-X [WS%_EB1KT S\KG)2:\L5PPZP!\8;^%]:.($$:B&P<##4SOJD%XX8.'D
MV!]9, TI>EC.X:<B!>K?5L0<>YS#HD:]?\$,\'ZZ%1["4<CW4 LMX0O"0;(@
M-$Y+AL7&ZP+,!FRC!9AFI51NY"5ERS(.M\H$Q4,;B]5$^!.UXGSFF</8KSPC
M/C*LR1:@CW &) _M, 3L<P<0[7LN.JB=,1X%!M.C@T!"@P3X\#D+F7$A.&Z&
MJI-WI%EP6OV^Y?>1/$/6/;HSWN(2GGRH5"O'L7YNTQF[$7SNIU63N!@O4?7(
M ^)4),R#GPZ<0$] \<\[4A6# #$@Z543Z,H)E Q>A_D@ 9EI H'ZV%64H(K6
MKIO[*^A.[E'.!0\3S@P03NA6OS?N?>\Q'*AC_9CKS87Q;*N8!/IC*J4/L[Y/
ME\L?U&VS;T ZDS?-^+JZ4QGMY4KOJ*+T@;02L'3R/(STKDI]EV*/E_F 6Y0W
MQ&'')R+!.[4F+;T:"PJS>JE:+9?K]9-ZN5;..2-)EKGLU?RB$X"BSCUM@BE?
M@\G-5WE<]Z6F_5[N6CN?^2_D<*E6:B?UG/1V]<[/]$J90;V*JD+;>K!M,X[-
MV8J$4,!!:Q]1H =+9X!.P5S39@Y\3Q8T#5#4 [6 _,/V7"(OXMMQ]]CXW&K=
M/,,3BB8,&2Y <>@S NT^"D0 "M9(U#S,*=8CPDDC9XP3H(_CT%V8-5SQ^8,=
M$ 6K<>-((Y$522$AYEL!Z2RU#P96!K"M61'YZEOV4ZXBL_>:[AV62>+^4*E^
MSUE<I0_ZO,_] !<4MR<:8:%&$>PA)Q(NZD7\GE;RGJ[:)..3!__!%R 0<^\X
M\RR[CV##_:*,%:,U\FW'J&-8L5S1/KZ$TJ1_3X4T<,% MV=@^B-EXP+*E88O
M,M%*/@[J4D@WP)\4/?!^GY-1Z<H#,#;Q!=@!ESG$PGW/,3P0<"FT)(D*PB&K
M**U6JJ5.@G29WV/PVJ/K'PX?D_OP;;E.'.;LV#BI-/#8R$\*0YFTFIX#,BB%
MR;[M#S-,C?)Q) AQQ"RR[%".ZW@A85:I-FJ5S.G CMGW6_@>SV\EJWGAL+S0
M\\IEV>XBN@\F5^P]AKUZ[O&AF9(G312Y\LR;#M*YIA-9(A0M'I,^XKY#KF/X
M">2?S^,2""A4?5\D>XV03WI1@!F$ FIY7]U_*?($CT*Q0"N/41FQ>,F:*@2D
M=HGH.'8%(B,S/?)S K]RQH$=R%(4J.,_\*,>0U&%F@)W R9CM2:'2R1_XJ^G
M]SUF>)/%$4"0I?R:/F@M#R*<)8<@=9,T3*6;M(:IT.='9<#J? 93 P930S][
MN7)2SBW!">*R&P[#-B[56;Q2FM$L"Y:85@>H$4!*29$<81H%PALMQ<ILUI)E
M)'8@.8D^ZOBR-B\[93/'-M&2_3TGK^U+DM-2:L/!BWJCU,SE>8G:K[3^14(7
M':&((GL$<DS,C#A,F=@04UX>H.ZLE9)]V1Q+9;G^H=W"^C6)]%?@?'_]+=*&
MIA52QG&<C$ "2(@'4'9&H/APE"LR>DIJI/'O"-0@0-\<!=>F(.B4_ $;AP_G
MN5TP9P)XM?=X;%R]:^UK_%2,K(-K43Z9DSTF[FCNOV(N8_:9M,8G$AGG13FS
M1<;?YF3RS@P*[F_0?GZBXI6WF.N\5*OE);RGJ_&_7OF?[M@S?U.2/Q;:I<RY
MU%JI]&&^TIE92WW@34[[OQT=@2+#'>L]*"1D4QS=P9Y_H*2>]\:H___U/&M\
M/ B''S#9!W["@PY_KYR7JO _E>I=Z>1]O?*^"MCK(L"-TH\2H.3THM;Z8%R/
MR.9^;_SQ]?(&"PEX)KKUCHX^%FB+Z2A,0?P-_TD:2:8MBDF+ P']'U:QFOU>
MG3?JU5[MI,%[S7JY4:OTJOURQ:SW6,80>6_@1AF3Q)6U0@RQM@8MKC%I>1BQ
MZ6&DJ-\@X\,0RVRDS8_8XIC2OXS3^G&U 9^84,*,K!8V@]\8BJT;:6HPB!R,
M-#T8XJ#V7>O391N;JYQ=7]VUK^ZZ8N]32M+T &O'C5K.^&11Z<S\8RT?-U*\
M--:XEKH$4[/-DO#NSR=W]WYFQL!'[OM?-ZW;N\Z;C_@?HP.RC7U<S<3+3\[<
M]QZ1:__RIOSF.:N@=BL]VMFO>L'(4Q]8&P23_>G<M;^6\P3[Q(:FKT\>%S12
MYP7Q?49Y0DXN^O!Q//[..=!\Y^Y/Y #GG=OVV=WU;;=H=-M7G>M;XVOKJO59
M='C$)L:M\]\ZW?9MW 19@VP+0599-LBF@IF+/AV/__KBHGU+W4([W;O.F>J(
M?0-H:Y\;=YVO;9)"&E9;#*OJLF%5?37O^K7]I]&YPJ[0U(Y6PV>+X5-;-GQJ
MQ\8+ 92"3,*AKJCWH&S_MG(D5>L:2J^S9:;PU5HRP.*QU5HO!=JWJ]MV]_KR
M-Y!Q(/LNT,3Z^E686"O&5Z.I\?5B5I7KFWL-JZJ_7H&Z:6/+]:O/I#E==*Y:
M5V<=ZFO]6Z?]._UX<WO=185*@VNKP=58-K@:KP;7DV9?^^O-Y?6?[?;JH75R
MJJ'U8FB=+!M:)Z^&UM?6/P%.W2^MV_:7Z\OS]JTP_6[;ERVT_-!9]:?H%-VB
MYKIK\"R4M!;_<H@UEPVQYJLAE@C#M9J"I9J&T8MA=+IL&)V^&D9H_0DW%3*H
M2_1377U> XRT(?@*=WIIZ?[TTJN!U#H_[R +6CM#:F@DO1Q)RX_,E%^-I/_]
MK86A&<#/;VWB2O##I?KW>:=[=GG=_7;;1M_5U];MK^T[X[;3_77U2"MK^^\5
M2%MZ>&;ZL-GS+<!V]^RV<X.,"N. W?;9MUM@8NVN<0UR\1:$8^O*:/_O;Q@G
M3"YJI&TWTI8>L2E7EX"TB]:WR[MN$1C8;QA[/@>+\/:VW;IM?6X+X_"\?=FY
M^M_?VJ#4KP-C%6T/O@)C2P_KE*<*2+[ Z7#7OD6#\.OU>>>B<T8*6->XNR8E
M_[;S^<M=-\7F_C32KHEO74J&NKF]/FNWSS7^MAQ_2_?5EU_OK,=$NMOKRZYR
MRY^UST%-TU#:<B@MW3-??KUK_O\ ;MJWO[7/_^\:T%/1Z%EN3+K<6%E0&E[]
M4G 9K6_GG3N*17?N[MKME <54[)NUQ!!U%A; =8^K0YKGUZ,M;/K<]*GVG=?
M.F<:6#L)K+/5 >OLQ<"ZN>T S[H!IM4Z.[O^=G77NKHS+MK2AD2AV3E;B\ZE
M ;=TP)VO#G#G+P9<^X_VUQMA25[<7G\E6U*&B3"[Z^J\=7L.EZYO)^7K- B3
MQ5HV&*L:C,L&8WMU8&R_G/M]NSW[TNJVR8\QY9@U/OU)\.QTN]]D0+-U<=&Y
M[(BD"_ELSC$.#<P= N;%ZH!Y\7)][TOKZC,@[\JX;7\&[G@+8EG6-NH:9V!<
M="[^I#3&6&BO041K\"T=?)]7![[/+T[L/[N^O;F^!29G?+[^K7V+5NT:SA1I
M>"T?7E]6!Z\O+^9M7SM7;:/;NFB#L$W"[VL F$XU6SK .JL#6.?% $OE=(#T
M!'L")258%.W.YROCGZ#<=<\[9S*8]:5U!S9P^S?,T>Y<4>9_;O[LZE0ZC<K7
MH_(I"$Z@]I]Q9.&?\H0_[;:<3\[-5]W..>9OW+8(2S?7EQT155\]/'1BX]KA
M\6L,CU^?A@?<?/;G)[ "911\E0),8^%9<<GG;?N)VO43VG0U8B$'IFY-@CUX
M'+\MCR/JK=_)K6^JK6\^2>]-O?5[M?6G:NM/G]QZN+7]QY?.I\YJMUOGGZ^B
M/%>REUVP EIWF$GTYF/R]RIW-/\PIJR.:J1*LQFFPX+@ES>?;F\N;M@]_X1U
M[5KP/_'FB()U!E6L,U(E\ZCN6OR++)IGR*IYL]\=OW>JC)ZAZNC-K)]GE-3W
M8%EDU;QL:3>U*5@Y;Z)TVP=CJGA><BDUR3?OE(*=.XDOG%E414SM'/VG@+7V
M;FZOL6$&WG45#7O<O^4!#_]^>7;[]_+?__YWK(Q7F(4M66MR46@M;.!B/MOY
MM[/,09;4Y&8SM4P1Q9G#CDF"?K3APUB1K]I 9.2\]'=.)?J9T;.]T8#Y0V;R
MB& =5P*E<OA8*=FQ^_R(BG[*>NH^&]D\*-BNX;FX?_=CZD;BXQLM.^ LX,&Q
M<1UA]Q _" TVPE8]V C"]ZP(>SVT;KZT_SAOP=1.:A^,MT,OM'^P/E9WMOA/
MHI/B W>,$1_A+W%#WQ! &JI&)D'(AT=8MK P]'JV8_]'-I*!D02>8UM&& T]
M/RBJ+D.J-BK>)!M#?'-MK*.+;6^Y:!N,+Z5:B$;FI7B)12'.%6OZ4E^CD</<
M,'[=,')">^3PPG#,'6_(BEA<M<=QQ2P.<_%&V/; I9X&0^YCI5_[/Z),=6OL
M#V&X-[0-QF5H'5/+2/GSVWO'ZV%?V*+!?V#I2'QE*[#93_2Z5A2,^ _CD^T%
MILVQH]/;SQ%LU7\&7O13X<R#=^$;C;=81!3 .#;BR\9G(#V;I9[%GCSR@9]H
M#/*.MS!!^N2QH8#C!)[!K >L62R+[,MIJNW)[&D!%W $BT5E]6E# &,F;J=M
M&B9VHO)I.AZ5J4WOG^%%88 @@'?B&(X7)!O%=Y=*-AW7Z (F.?(4+-%9!W1Q
M@S@&U<O%?DFBB&5/,@&!%4;-'@HT\2]\: <CF*8-F&QU:9W3OR'\KSS_D=_C
M#4"?(3>3)E]]SZ3V!?#F8,@(IPXWL4JO7$5!GT3,@'U%.:G-*19,F!F1.G]@
M3I2031J:3/5&^7S9^:-<S(PP;K0!O-HR+#^ZQX];-C:)PM$3U<-B'A''Q@DR
MIS@YW!![36(E]L+Y5<NPV!"8=5)%&P!W[]A>#UX0$C4A&#]]+:9 (N8;Y.+A
M%5N\$G8K7HH<$:2H[3)_; 0#:M,V8 ]<%!,'H!!M>X(WW0'_:SW U[NA9WXO
MJ+++M!)WK6Z[*-LPX;W!> CB2-4J_W1Y^X<J51Y@2Q7C@O?\"#]:*95.Y!K"
M6%I4+AA =LY'7F"'>$>7AB48T'D7_L@.D%L%.;XK%ECLW\89R((0H/25^=]Y
M2,^)*T7!(^8-LI@=Y3\C!T=(I_ZV?TN_N0XUST(L/MH$65%ZV\*9.Z*#FF"J
MU$]&S-KV+N%5MS_4U NX,O*BK @]V=XW"B9_>>0Y#7YA0S/-V_"K\>>D5(&M
M[@0^XXZM^(D @QT&!1/H#MDNM= ,HA[P7)OY-DKRV[RI3 !9?KNH+B-X)G][
M9#Z6'0]R1D\O 9(F,*FUB>>!BS3QO:*$IWJGD/OIMQ2)FX@^9R@]@9?%Z[%1
M(0(B%#LEJH52JI!8D\<!=\4&BH9%'E'JQ7DKUJ(*Q'!3:Y>1M//?,R&CY;>%
M>F-9MNR2D2A* 0G\S#XX-FC( 2^P>Y_+-CDDUJ2Z@N.26@,+1',O<>%2/&>T
MU'/I6Z<N9C>/;A5MN]*B-1["M& MJJ^?99Z(W[\3+":7[J@OC86S\J<(;.+G
M@GJD>Q[?F<+-WV(Z]*EMA4G=Y<VXLU96.T:X"'DA7I++WZXZW8F77O''@N(Y
MW0'_SIWG,13U'F]:=A;!2@ UTC=0B^$2J=0>,6FF8;NB>#YJ7T(4=2[PE%I.
M'QB277BU^/(N,N(=K>ZG8P.[</8CUY3/X)*-8-!<V@R%R=66W#]N-95I[(!*
MP05,!,3CT46LU(W!5#9$I]5S;@JEM%HN2L54WM02[[F=?@^:*"1_4I#:";J8
M)WI3<Q&JMR,8&2XSH--@0]RZH"#W(M7;:_9""0S*E\$341 W%L-6&_+-U>/R
M*2+U;^7C4JDH&^'*7AETG]C*!%2?F/N]  \+\L O3NWBXMOQ^K6?^8;7_.^U
M:_R3N:1[5DL2F85'U8&4.@'*)9(F.3%J7%)24$'$$_%/*,U]WQO">G&\ 9=5
M["5N2KD^=3/99-@#-WFU>+*0>;)1*DT^>HP0H&\,/ =X1U!,#5$.>\"$9 K8
M4,T*V0?#CQP!H>+_#\?8?!>>%P,.1HX='ALM4!)Q%(*9"F1YH]@8DXI-FH,9
MSP)MHKC[//0]%LM2"[=<M ]*M<2$U; B$YLYD\>,^#TNOQ*]-IGK0;Q1.),1
MB ,N&QC!T"*'VJ_CY@@61LSOV)A'K[D3*639G<\4%Z41I2:&+D0Q$QR2RW'7
M0A@0&)ER'HMJ>J\EEESO(,P!MM$ZNO2\[U):R-:":_#]56:QSZXWY$KJI)H=
MIBPUU<4322/$QL-21&.+I4+UV/B5CT$D)K@\,F[MX+MQ ?N$'K<)<X4:,]6.
M,T]((U(*O1R#@!ZJ'QO7(X[TY@J--VX&5[CE#S;0-/YXXWND*F;L"M S..C
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M(R:B%R"Y9@J[0+F<R>1D*?L"W5XV[28LJ2M3C-6;9[V/@(S! C4>,,+_'8D
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M3(.=E,W*R<FI6:XU*\W3:JU7J9:J8/KW:V99<X]E.8IBY4D<X0U"%6=1IZQ
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M\<9-^\F&MF4Y?/$F%IE5?,$S+W4$+OXMZ3!<R0!G^AH7'^#OH@8&4F-$KL8
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M:U&8-=YT$A:>M@J$'23B?[AJJ'F0%6G[0P*X+?$-[Z,T]-*'S&OIM_('BEL
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M=;I-EJ:1W2(2_Z3,VIJ1"+,+7I19738+"W793",O.0J1<.9L66^\6Q554AJ
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MOPP*"3+\4X4]*&18*E%NPY*:0 L<_,AR[E2<V8!?>=-8I$/[=D'=2+"FJVV
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M?)+F[((M[-%NZ'8=:!&"&6*K$;C1L/<?6"M=3QQ0G8<C#A=@^,YMT8(-L>]
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MH-N"EB084)3(%@2TL'!E*KQDME#K^%'"PP_ ^Y-QXH?#=BLB["W&)?<:]*%
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ML'=M!=%=;@N+"D84Z>3K1/T<>M'E_5Z$*@HBW82C@0,[E6G=(S)8SI*.C0,
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MKG@_@.43E@6C&?4B'/5>:'SG&+"%.[F_ Q+>P0&K81A!4;.7$L1,;'C<QJH
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M0/]Z4AE$4):_K,W<5 8FNS2B72%M0N;,DF]_SM9JL3C<E1G=0I-FLQ :0P[
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MN@LV;^<M?-I";A8QSYLT,LX7X%8><"LM9.!)2UX4\][3*7/67,"]X (X/.2
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MK@4_"H0J<_P@#/I"S39W2!V'4J2]WXK1YHW(R(& X0A2L"YR,NDOKGUW)C$
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MVK.PSNGBR1+[L8&+:B5RE<#C+/^G[ TYQH.5J^I5_XU=<HX$TO]L%FAH@K6
M'8*N0*#_;W;%/9', S:HB0$>R;8SS)QLN&+%9I*Z;7XP:S'M6S0N1JS?^+A+
MM)-<>_1^'Y6:]HZ1IXUY$J"L99A1\:Z8+<0(<82S=(D/27?R0'ADOY!]0^J'
M-KAB K7,<%XZO #]Q)6V"*&B9SWC'=$OY+O[?+3Q_Z_*FXV@?DA=8E&>GITX
M!1RKC6B+EU72#=Z]^4IH(81:Q<R'FT/8_OY610B_/WYWF+.XK+C92C>&N'UC
MBLWHAM'8*9T)VX1T(5-%'0TIP+@P/S_.5,>]A6H?2:?S+2-4TG1PV;*%54&'
M>RY-&M+AI*[F+C7"(!F)TYD:EIL(/QD7U^Q9HM^S=L38[[KIGO[B+G'1J7-@
M[Y=E,\Z'C( *''\Z%5=Y.>4K"RF4<BR&L_](\0YM83-U#Y2.8X8"QD$AG=%<
M7#.QZ!-KPLH-WK/"N@O%&0@WK[E3!@%^B^=6<N,$Z:&)^^9*'2'.#,Y!G(&^
M7W+-BEOEK@8)4T9 /M-_[%W(!P.-G?GH1MY([P^TGAP7A6]K(KKKZ2^]\8I%
MH5:P>*>O_RUG8CF3_6\YDSN^7WZ_A_CX1>_^WO[>EQ <>K6J(YHN&*W3XA(0
MQ, #,0V4I3JU3.G 5R"YY&\E(2DU8Z#+MX4S0]4JTP;%CG ]'Y+E-J0_R?[F
M_B^6(+<[E:DV?<_MF7%0-V_+N27(Z6;%M3>6#FE)/E6V;(WLT#O'JRF4VE7.
ME2:,LR0?1.I.[*%! V:O_H;UVK=B)[$-&S4;&?@E6<C]]+R4.&A@!B3L^<Q[
M]N(,#L*B@EN%JMX9J^BQ>K5UV;R5D4E^C6G.L0#68SHG^Q<!&W"Q 2'5@*4>
M&U,,\Y77LP,$N0%R-AZDHC<N@?%)2.6CCY+KB!?&Q)DK%J_3(E:LL&T%;Z&Y
M+++DX!YNA)@&7>LXWA67*BNM*VK:Y.:5+S*T6RT ?)L[R- CN-P3*2/KLN1@
M-M(!BG[&:H:O)#;1%:C !H:&_$9D^RYXYL^7TLR&S&0R?Z0UI]R=0;?6A&P(
M0<?0HZ9:R><B'0;.MSSC$#5/S"J%QI=].P=\#-P"+=1:J;A,V(NH!$&]Y( ;
M5LX!&2X)K=O*L>\+P<'FZ6%D;LY1S6 Y:?1H=B*8KQ%X<%8BEV-DM^A,\$-+
M ;70AQD9<UT4;[\ZE'>(0#[J*-WQCF:[!"RON2:?3ZPT+RSJNKRL+/Z=+J9#
MH9B0G_L&#S7&P"Z>20-^@R@%F;(%78DKJ?R@'[ZZ.,W"T"XD0CHE9>G)"J=F
M6@I7<-#CRC7FXB?57+ 1<,JA1,G&ZLCZ3Y_B]V_CV(4-+W>]+C"@%GIIF[H%
MY.TZKRV3[B\+$N/5G$8B26"A4-SP17RM+;\RZ!.XPP_]GE:K7@WS9M<Q)([\
MXKB".4X-)_\BCVTIR0E,/]"Z<[\4D]P0E_(DP7%;?M],:0:^&;?6_B.=BWA^
MBOP><3X^* [0[P(<:1T-K=O5EBTR5"SR6PI,LF%*<TDD*.?_6J'W$#S_J2;$
M5++"F(%[@3QFDH\25E2.; U3A33B^>(-A$E +GU48DKWFMSR;IEC'N/\[ES"
M!5AI2=^)^E>G@01Z8.V7U?-(0G'+-K@_BUA <MW/ED1H4]A:O./N)93($2DQ
MF4)5V][(BB7^+*+6CD1=[ !M,LBV# WR5$@!FW3G^>O372W*HV?1OS)I1H5A
MX&_T$_776EL3+)'3)K)*NL$)'S;)OM@@W7KC>AG6Y<#7[>(>+Z2#*107NU&E
M%F&-"@]GX,_F:WX(&BRR8U97:[HGE92*G*^&.U&!"XV')5'-Q?)+4?J_W_!^
MRGU=.7Y ,J+$KNGKJEZ.JVE9?1G3O]V=YZN:Z7/UVI=^;<NMNPY]4K"<='S
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M8]A5$V>P)0,>FOAH,Q$9V?YBE%8_$9&@_Z;4T'#K<"OQVPBAV"G)0WD_\B6
MAB'T>9(D;]?S=4*KPV%XU).+T63.+$";G:P326"?X'J8@JMYI2D/UUEPV4_
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M%+A6",4QR[86,K$=ZP1<_+F.YZVC8J\EQ7J7$)(3OO,$#WC,_2(><,!+V@*
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M_P)B&+=&7''NZ M AOT4%'_=I0+4WG..]2HL2DMW?GI\MIMMS7&)LDO@:*)
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MA1)XLSF'H<*GX8%'!6BO,?0 &3,E$TSK3[YS*-"F+\IA7?UDW*Y%/G.W^)0
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MA"G&.?KQU4EFOV6Y5N<=KB,?:?%):9;%P@?B8T\AS2,48B-?1HNUM,55D;K
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M54V;6(TV!X5W215&B"*0G6=M2D_L!!W! JT'4U,G:1@@%XLA^F:_(  %J%X
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MD1EV#Z6C5,Q-.0'?$V15\"7 0Z^UU2()GN&,UCU=YN]!7(E0$""^:3[JWJ>
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M%QW5]/S\N/T4"GS.[WON''9.O,*=EW'#A6^-$;&SX-13!$ICR:2@.K_A$?A
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M&W>W./=@A_ZWVZ#PCI<5/I9ZC9(RCNJS=\@E<(A/L#O9C&4=O_X'E"A%,-,
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M\*%D/=AG0S>V"S_=V&E%W>(LJG*^9$<2CZMGR%W:KBC]T%)H]/WENG:K\KZ
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MFYJ;<5FIM+.@)7"9/A.^AL3K\J']I:S77 67Q=>U=TN/-Z1=(NS^%+?GTY'
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M9&[1G00K/U2;D+ %R_ =3>@2\O0Y<9J)X1KL8C8%:T*+EQ[E3>QS? J9;3*
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M]/Z=G8>WIIFQ51%!ZA-QF?K;T7HX^XM%G4B:?$,B O9YDH\*[X!2)*,A'\Y
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MP--]6/O3JPL$J_#J !)_2&O(K@EI)YV_.WM]>.+^YO_9V3F9CVZJ>F?GK^)
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MMX,%K$NTO]"U%?VH^R<VS\3:*?2:W.Q!H0?W;Q-66[L,9VMW^&8Y"/$YK18
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MM<UR98J%7OGG##3;?P[,?JQRCL,M,>9Z9FWO^'T&<L9@C;V4P..7#]]]Z%8
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MH1?&!9E<YI+DVOA2)./>27LD.0=)<2W>\Q5V\A(;LDG]AY'P]&%Z1_K@HWK
M9YX)2'X: 2&AK&'#RH2-T(._1.\@X6/@DZ=@"K[G5"-I,;:WM#!7GULNJ3PI
MD1)74H%L"H%ZH;)21E'B)T_97TR >.4R*0V%]\P7B9] _>;E^"+2<#35A%0F
M?8,K/^-I-BD7C%E-9.OV'V<!/YKD3Y4).'ZX-F@UERJ7:<-D)'-2 -][FBW1
M1Y-DXCC#SU$;-_I &0XA3@B)A)E)%+T;OFI%1?%S?)0<&VG WIK;BQ$-S^!#
M]"DT=/!#\P0,V"FX?%3<'\%?@S_#YI)%N8C7B9Y/X6C+'/-[*VO:\#M>PB,,
M7ITMUR*$H,0+6\B'Q<BB\(=*T ;QOXXB+6(3<&(XR24S'(V@ Y"75J!;6PDE
MC\+#,=/G\ RJ"0\/=0%]?$)KL ?1V)!DN!(-0>8*1MX_2##]1R+N,OR:OT^.
MU0I\'42"Z;=^,H-7JL(5%FSWO3HU8'K<I"L8XN +F^<26XY<*1(?7>%\[7P%
M))%D?F:*LU!$/M9V)@&:$MH4\<)_2G#X= X_,BM([/B37OL$[T9H(XG0%PN]
M2$[\@)^A"*=HX[?.2C\'?R99K;15:)MTSK7K4QP9<(EA#!.H(@:M,I6IBO?*
MZ(T:JWGRPZCU/4NJ,;HAV>QS+V'UV%$!SSDLO"T&-<T! E @)2,[B<86?A$Q
M8FHG[C3EOZYY 1\++JX9IFW<&2X;"-8T^4[<F+J!J^0$"->"^$Q/^XW$Y;S$
M^H$3XCZG)UTX4A[$:/ XA(I3BA/-*:%CED_DQ-'H -D?N:.UNPO@.(SCZ>VN
MP=MC'7;+!K5YNRRWV:/P53E/QIL,OVWK3_CZHF"SEZ:BAMZA7/'[R)KT1[)&
MXL!YIVSR"<[KP&#((@/!W)#HM+C:Z109#">X+C!"0'$>988RD/I7JXB^Z-5.
MNB@J)VD9'N8ZPW^;@*-]F>*_SEY<8/H, [\T.JMJ'3KW5R[ /T?OZ")),1I#
M4303%^ML+DF>++62H/],*"SNCYS7Q/$3$Y"7H/6G[M0^GEV\Q/M[IXJI^@_7
M06<4C$HU7(L?=O.L.=]B;<8?%*HX^BX:-Q0!$Z<:C&P\L;K=U^Y4=C65R6QT
MUXU(%2YS*2'B<-^/*BA_ER*@QQ2,KRE9C;/&D'_$$L12"[_,(:R.H@_9$@Q0
MT?%OH'2X5*I]2K=I:-#4.9$14>83GF'1Z(\&,=,751CI/S#P5VAWS3_V![UF
MJX5J&#_(<L \BQP9^@;E'TAL1E)^AFRA4P%RLGD?0Q6F5*L97R2H;SEE$"R.
M0WB0B*=8:345E-M9\@>:%:MP$_@QL";F[ 509$^< DZP(_6I=)-%B36O..S'
M",@<O_5<"O(.L&C+0'DZ*]#*RP<BW<\GFU2&V>5H]J0B-UQ%WHUVTW20:+QB
MQ+9/-+8N,J"986-T.KJ%:-J=UC:B85%6(9M(Q8YL<);J[703/)+"[S571W()
MM D<A@56%"J0L@B*G\L!8'GFX,E=)OIOV "&&Y7D5.U- EU'80WJK7?9[;4:
MH]9ME]D;>'?I30^M?>2@VQATAY&[$// Z>U4$-^="K9*#V-^179!&@:UAT!Q
MA9.[1$J\6Z1<ZXI,B>XJ4RA5055QNYFQU>O?)L'[/B]&]WX+[I7OQ('-0T"]
M-J#>_:XQ.9^,*/7K]V]3B:?#1A]8;#<;=COU8C3%";7L1!1U*BVR$C26$.Y!
MDGZQ=?8%A/4D%7\PCOY6@NVT^HW34?<6@NUTFX,[$FP4JOS8YAP,V#UBFF^U
M1EJGC6'O-FL$#<O>;FLD<IP)AS$Z[<3W8(Z@O[N/(N2XE'E3CVFP9QAY@8W.
M&.MNY]Y1X9BD<CZ_C1&]+=^)#:/[9L,[.TEXWE$=#6PS'38C*H^:?/I2%O5;
MOFY7*8U.O]5HW:I43N^L4[Z,14?MQF TO&53P^9H-*C9%>8B*D0<X6CV!_<3
M:A@S#A@SVH<Q*P:Y;2F+P9;!3K!:=ZBSAV70-LYRM)>S?._*O2)3HD=3[:$
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M#X!GOHY^''E14:\<!(Y3WJ$9_X-^;0)DKU,&#<$OO&X^;U+1'2$GOSKI@F&
M1:P,CR9%*&,UQAYN/9_%>3E'"USN0&HO81=X!^;,>_#$W1MZ"!S,^RKQ>X-F
MDR7$HF(W?0L RE6&ZVPRG&(M#C^&KTMO&SDK\>7;EV?Q/^$/B$6%O/9+GMW
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MMW*T3!XL4]5"_\7$CKC*B/J"<[T\=>$Q*)44<G,1]^D03!$R^PCK7)9D0Z=
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M4A:Q.'@<!BN PQL\B<-J&LI:8T)(3Q&GN!$OM%"?E[ML1.SN3C@0PI,@4:'
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MRK5]-*(03:.N]@_-)--\=A0,1#O>P*SN4HNM 83&7]![N*H=;=I&+V4H;?!
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M"(+O0Q!\B>XXNU)YEL87DZL;E:_^%+D0'[6/GX@>?5QSXK3[1([AJYH3"N>
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MP]GX5$U.3Y]BW\;M.*+[WL)=Y\'O0:?WL*O]Y,*^0*@[%GKM02*8MC2!H/)
MM]ZI8JK^$Y]+5_9;PE6E]E<UPXG=U$T]Q]YTAMOBAEAL=1M+N8+=C^U]:VZ>
MYWYB>NOAWL[=7_3E':=]YR:%>R+;KT2,G8<@QGU;;,_BA?;'JQ*6HO3.K[3>
M NE[(*"G1$![!62_%@$ACI!."^[Z/=#1MT1'>T7FOA8=,9 L#V;+T@1TFL-E
M!H+Z,G/N07#JN(O:L^9"4.Y=W6T-:82.KD#I@Y5WC<@1!9W#EEZIN$@0[M-!
M5;4'S?@5XL&\56OXL36".PG^# OE9N7:-6Q3!77D.U 465$>_W>5EBJG)4YQ
MB;/R$HZ)?MRR B&]U;=M4(<^_VUC/<3@^6^U1KR*=WIUD^6?P)Q/)YO;&. V
M+!HQ_&+X&1N!Q3[J L@KOLAFJQO$S;A8%RN]***/B*T!^V*\ +CBUQ_IH0E"
M;SC8M#'<,4+ZY$K0AK$O'!XZC\^N@;X(33%+IXB ['8G^ *%Y_S$:EYD!K88
MJ2%%$-6E=+X6D5KA2Z@\<\>".V,0DQ4<Q#Q##D'D#H3H@'>^@7>_TFIJBEPO
M7I[3I__1O&CZ #(O$%2%64XQC,D[,T*7CXEQG/F%&I%"I-7Y/":2O09W>ZT5
M@BZLW"(KH/TB_EW1!*L5HH:]:)[#(>)N_@/W!_9LX1\'@C0HPBQ.9@C-RZ=J
M(%>4P%E=98CPI>+GS8M),V+$)MR:!Y1"R$C_TK#NM4*@,9!7!8(?T2$!B\#-
MYO;LW1/T)$NS13(I!&V=5B>4ES4_$A$O?M%9?JF]M_(6^ )8B*\@@-ZJH(FN
M$8O8<5(GJI<(.Z7.>T+Y!1X<P_$1&N^6;P-;PFW3^A4!=,%$;GQU9'W^-@/C
M,*X,/MG!H<-MP?)MP>ZAIYBOQ_M^O35JWGIFYJ;HH)[K69;KZ-\9CQJV6"+^
MFR&WZ<5RGJW93]LB5N)0K" DWQS(TC(Z(2YJV#%^YI_(?.]S723D2LK+-2.W
M*@D-=ZBW,-$J_F]=%'J.E>__2RV6S]S/.(M -#'ZGGB6<,$3?8, 95=96>AS
M L4N"*4T3T5"1&\8U['IG<0=F1GTHN/$L0$$99@\^8IA0X.VKR\UH\6DBG&1
MHK,)B%_@X/AB!9Z,#Q 8LN8!A$5 6$Y;WSL(RU.4U)OMB\9$C$%81W7F6TTS
MG(AK9RMUVF(^O=+C7'[7'E;LITX+U#2J9%J^(JE#211M0Y%NQBPJXQI121S<
M0> 0,YJ#S=/--5&GQVEIW(*%97-G#@GL8R3HJ!](FKV(X9H2FG$!HNZC!AO@
M?8AV^SJ=PHWE*"#(>'J=D@1>X"0LG&[@+8%O7M%/]+:_\(KO\XQ .M\0=34B
M[RWF@MSJ0Y<2+JEF<_-:61,$B'C*:BG-KAD]$2<  %G &Y.1B<0/DM5[?& &
M>:)S<H7S5%;YFB%&T_BM_P%",Z1B#)P*P:=",*D-0HIE*\<8K=^*85/?V;?%
MJV(WP/5]^8%4#SR,>0?HM">G+@_?0IR.(@W)T5&V1\.^H?,(#1;&+/,)K4[%
M-^)?Q6"G1[UV9/%/^&N9&UA9=+LJVT.<,X9>1:QASZO&=>D]H^ ]2<'C@)Z$
M(='BHW?_NG@9GRU /TQ4^O/[-_]S7%F"C UV/=#62"O0OS1+0Z$0"+Y%4T/P
MY! QD"Z(L*3S2R#FB:-:I^%_U\F?V <!KP_DLBI7Q#<7DT3#S30V*'OWPS[J
MR56*['P2/HY^3PS [+*=G=@GN%H7Z!_8Y_X*DA0TJ^=CP$/_KO,285L7)%G<
M))?@/ S_,C>:!T:['VA@;N$,&>::]I3,LR*#K=$@:3Z?I\VP09><L&DC]OP0
MP2JNX<LC)CG$A<UI?I#\I4$@OG(\"ZU2;R[(N0Q[ 6FO;A R=I7,!6,0YQ8A
MN/6Q49;EG#1E!X\V(E,Z#$R=483\W 2B.(3A!SW=G_B)"$/,TTS(W@UD4?7A
MKUW4ZZV->D75)]H]LN\,Y[CQ6#XX]_#G&KZ?7V@]%8W'3_+QO;N,*;K](=$[
M'#(%=@G.![TT$E*.$<P&L2U RE%DB.'3S0;=<R>>[(7UD?=$\'Q\\\^?XW?_
M?//+L7U4J\./:H_LHSSK9UMP#)[\J_I3YRKVWO@(T2AU#D<G?_M%IQK,@>(8
M?1ZC@<60*'!:EP1W&F8H*KNYB)/,5DS4'HWD55N=AJ<8KA5\N"SJ+99ZDZ00
M1]##TB[<6 3?N'.O:U1 .[)[V'$BM.A;Q+N&]^/%1$79EV@WO(C<]H?4[5R\
MK,@\LH^/Q$=[-%KOZE6"+DZ86?.E_N,-CK!ME\21+S@-<&?#/-:]WMLF[8@>
M!%XEJ/3$#QHUR'7Z%ZB[1OR/B[.G+5B?_[W2/5CG-VP7KLS2-J;;9ID@G]\I
MY5@<H8*3]1&D^1JY !@N,+ZB2C0#J0H'"\Q-L%$T/"TM,4Z<1Y70_#EBGRMT
M:B:?"MC'&QY/ KH0N3C-TA-&/A=;X$\#/RMS!5@]7#+G1V-5) 6?  T "%\
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M?+A9"9XED +61&#K":+&K58,1S#'@@<2C//$G"]\K>12\ZE:4*W 1%&Z@?]
M3B7HVW*^0A6M8K3K6>5-2[X>+$9G349GOU(4QUQEU!FX2.&H#%O13O?>J'Q.
M_D[>)U%K9#9/>8@<:0,[#Z_I0,<N_&)CN)0!%!8VOW,'D*1%F1.D M6A6^[>
MX Q^#/%5=8EHSR7V%!:F3*7"]YN>]*!Y#JZO)S"DO-W3VKBSEPQ)H=%/YBF'
M[S&&3/65)R!^A)200+VM8F!3;A!8R01_^2UC$2JUOO-7UF3!2?GC&\7UKYS(
MGENMH'[>CRSX2+4+&$<F%B'YA%%PHB^)/*G+2Q2S8!EA3[8/J1;=8%]'0JRI
M6'P'Q.B'K?WT*[(P>L=+:[=BRB'&GMVI\P.[[8:H!F(#VMLT PI!]A)((EAA
M':D%VJ_H(=C=Y#I9@&=2T >XZ7%)D5R6+!/03=0S@KW)G%1%>B=%4HK0LZA*
M4P[VKRA$!X9H-OT"\7T(XY@P3O=[#^/< ;=7S<:S4;O7G\XFP]Y(#Y2:=6:=
M=G<\ZHU.A^W)#V;-R6Q%C_T,(-_; 'J#<]N*UEO%XF-"W0*R+.]IJ1GNX//0
M".\!P1!>UB*/N\.\++$G#._DA[N^H?E][4O689_;'71N74MHW#Q2;@@?'1>@
MF:?;=O,ER-VUJNY"S14'#F:@S1L[;N/SUR"8Q8)LD0=Y/N50LA1LS.(.E#%+
M]Z(*<(P0.048G*3D3:Z6]TDJ!V*]PT6_QV9)L"D?A(IR\ 1SKJMXD.=G2UM/
M\3#/ITA@ 4XKYJO'.M6S9/5-, 1M:P< [AU4TKU@X3X0<]["AX//?NP7$U(E
M]'E$?D-6%M@ZC3X!07M.<1) 7M2C^GXMBMI_4LA=!6>-I7A^_O+EJU?6;!H.
M?KK#R,/Y_ YN5,.X\%*!WNX:;^?KFCK&0/QIW_D9^^LV]-3VVMN.B[AUVW?9
M4%HN'FH_/N_E2!5VBZ,[D%"[T1GU[V8>?R7>_%I7=*#HOQ9%]X?#[X"> W/F
MJV#(]YNCSPL/NG2*R\-PCYX7(^18FX0&5U>8/MU,9)E8X^XX(&I%$^S+"4=9
M8UGE;(ZI<%ZXL+5CY]+BI_"SD^PR3?[44P+Y*Q%-V,!!%RNUDGCZ7L'(SXO6
MWB'6,YETVM/)Y'0ZZ_9[_7%;C5OM]E2W^K-V?S#4IT\_UE-Q^%!,MAHQ_M_Q
M(WA][Y2 W;V7*N6_7/CGD0^88D#K_UV4RVW[IF=3Q"]\HO$?@#-_CHN%FL\Q
M3DH#L>!I?ZL*^Z?LA!YHZ,MH*"-A_-R$'>Z/F#H'8OK>B.FY!'/OCXBZ!R+Z
MWHCHGVI>HGWZ(,%6:C,X>8Z8$@_R_*"F[_[8H+>%#6XQA?WBNYJ_QT$B^,!4
M?V&F0@?N-TPT?$M4WS\(_^^-3C_B"()O01X)(=Y'[NL>RS&>L&_]$.GJ_>9-
M_G6R:(]!F[?GUSJG=P@E5Z=?WLVBV=)>=4BV?;>IB<YH\$TF&PX4^KU0Z*A[
M(- #@3YA FWW3@\4>J#0)TRA",E\(- #@3Y9 NT<=/R!0)\R@0YZWZ8(O==0
MQN?$*][" WB0^>=$*E[9:J?'C50\"',]"@<]L"EL"G<?+<#WZ-+Z0"K[D4I_
M>*"4 Z7L0RG#KV4<'BCE&Z>4=N= *0=*N8O#>5^E0$^C$NA ?M\(^74'K2=)
M*D\V[?UR/E?Q19:K]+/\2'_LY2'G_;T'<SJ=;S.8<Z#0[X5"^Z,#@1X(] D3
MZ.DA87,@T*=,H%\M%' @T .!?G\1B /5'ZC^LP(?HZ^5]GD"V":?#Z4Q;G?T
MZ>1T-AF-Q[U3^'=;3R:#X; ]&7<' X32D%7W1\X(L&.E562"31G+ D[-_.MV
MA(VMH!JR ",VU\2$[J4CY][7.FH?[[V<*E?9YS;1[!KR<";(,,55=I,2F L"
MMEA\& 67]E.,<]SC@A KX"\X6(6F 2"H.@%'C]<>Q)K=CH6 QCEL.6+,$([-
M?TH<QLH#B'"M9][C$0O^1N<:H:A3 IF9"C)-DN,H6-C>',-I1:QG,]A?P@/3
MS$3 K,Q75V8!\_QF5=>%P<:[@055((/NP%;=7F_8Z4Q..Y/^N#>83D?MUK#3
M5J-A:S:<C3JM UO=&UMUCN\-X/CK,*$, ZC@>0@HOT5M7ZHU0RX)5I,=]OK:
MHOW;>3P-NQ\UO<8_36/D6\:=PGG414-8UDTZ"(<&+!GWU7SX6LF781<RF'-2
M+G7N_1*'>*13)<,?>$)0X@_N^)(CBGV%]F4\_#G<.^V.)X/>I-N9MH>]V70X
M:K5[[='TM#<8GDY[JO<]<.^F!'QP3N[6]VQ^':Y\L3DV(<4!\P)[;96E&>23
MZP6.W"G*,4T9$R[ET3X*YSS8W7A(:W88F __%A-Z-W@?S(J;@_*:]7SP6410
M9^$_GOR_ZV7NM=87GM"35'*];TW)G3/:+EEK#H_08 RB^J Y5R=H#4Y#=L#Q
M[6FAS33+"NO875E40IIG!!_*]15J,3 2YUEQ-ZC";X/6OBK%]1]"&-<LM/\1
MD-5DX5&"84L5XZF@C2VR<3+7)[E,(!:RVIR@O(W W#-P FB!W@T(]\M<X> N
M/=?+JRS5#?1GDDE\I=4<O)'0JKI", 2UMGB@3I!_B5USWP..X@<9FW3FS;FK
MFVPGL\]%RUZ"%8PCO1>:9Z)>Z3D!D0*3=AK5B4DYS6)+5G/V%R>JN HE" B$
M'[NM!F)2+&D(6UK"G?W8;G3@-R@7:+:9*-K<T[]F>84S!Z<T]BABF'#X^K!S
MQR]?)\H1"G[V.IGJ#*?N@=,+- +/',B&</)G,DEXHA>>EYE[B*CEZ&8C.?W8
MI5?"SR](CA57R1)?EG;D-B(.\G-C2+A98S(@C(%@T0\W@\LJPWKKOHH3HB(<
M88(/,"*=)KSAA?1;/\57</\:A:Z2>>Q9KB\S/!*:?(+?XYWBRCQ-"F\0'T'C
MI^CATXRL,/W'A,(-\)B%^B-9E N[)K@?R"@17#W.F<O1*7+4P=-+P?8F]L;_
MPFF6A<P8Q.<97X7Y'H,0'_1E.5<\/.+H0SGG7PE:;S"JC":SB7[Z8 9H41PD
M0[0+V8T]M>,&3[3%K^VS-/Q-S^B"W2=NKC)8S)N&CL?]!H?13>F3'W.:3AS_
M5JYPO#%NA)>1Q9OQB_U",XW-*7QT(Q*B 8>26;G3_\EP[\87>.8P1FJ>1;4?
M\)]X?T&?^-5V91\994^3'-$&R?'//_;ZQ$UXJ1.:[LMS$:NRQ(Q+J[()RJ0Z
M-GF1-^,S$'3PU8O)U0WL\T]BNTC%/XY.<4E6X_H_9;):[[)_2-9L_13HH53.
M#I<T:X7@RX=1:F:46N]['Z5V/UH=^<P'-0?U- &91T,U2D.N%0::8S2D<%,P
M3R*.>7&WW4WJ]-@&7%!EN"X.ON05PDF;L,*MTZ:;=G3Q789?/M1$R5S&BN)P
M11K^FV;P"V#I2P%:AW,FC042,D7Q7L1CO;K18!&4.&.8%2R:%:!LIPT9P;W>
M&"_9,%X4SR[B#[M!CC2=7@*0<;G$S^)(U]2:42R69<XCRF&G:&7BLEC/CSJB
M^[Q9'9'ZJ /#-[3"8XXR/IN@PI/IOL[=04/B#4WL)0O+3LP1 AJ7X._HHHB2
M MP[LC5D+$!-> I,C[K?TY1G_8?.)TG!@U&7V8WA:?S;2GWBWZL)&T#6FD0+
ML%CJ"4VQG<_7D:?MJIX$+U\S+T&1D5$L,1*!H5\D=F(.M08==X*.V2*<N4MC
MGN%$$V /]$KLMV5R<00G :9G4EPYIZ;N/%[6;P;\(;"&)6+. XMRM&Z,+55,
M<$):9LV+S4<W3+P1C5^:W.!F9F^9D%X[5-V,,-X\M4<=NQW0*I[ &7I%:([#
M(9P5!69,>.1Q_?%$"UC/#'JBR-.*7/<5V+W7[)(C92W +V$OI=WRSY:C![A\
MC5_!_H.7YXB/DAG>P7$S/C=BG#86U;#"Q N'T2OOP3Y7*&XU"V3C)YFAW*%'
MS,*=WN@MV(+_@O\F!;B,1N/BP2\UG;[]E@F9\'N]4\54_8?<"GQ_\H$>E13^
M0=O:20,XW&O!MCZ<#'XT#"9$QB&'+P:A!PPNH#@[*R^17L WZ%9C#$?>D6X2
M Y *7SVQ-8D+PUKL6I%-IGE*<@0RX_*2F(_^>$(^"HTL!TE!_C!^NIY>Z"U3
M^,*<4F[+K"!9UB :@$-;725,-LC-*X1DC5,RIC<?1ZE". [RRS!^ ENO$UYG
M0F5;(C-"?,&!CC68O&0$<LBFQVI%8U$!R;,<1.F)^]%G66]V#@FD99+[U@<=
ME#?#7'[KFR',&36'>). ;AFSX%?5!S$[X7)(6BF="I_FEA=W&Z5@Q9:7DRLU
MF]B;D/ H"]E;!,YH,H]OW5'=5:",XZ_C+&[8 (VL+"=@$Q5HN^.L[OG:J:(&
M?!J8JY"S3LN<SIB"/?8ES#$A'2;PO/H(JC4IR':EA^9Z00% "LK(P9-4 U67
MC%$1:CC31Q4TOVW$%@T_JT5&5.DSM"J$#HJ?/V_3=\A"]]N]8?=TVM*3<:NG
M3GOCTU%7STYG8P6_[P_[WUP6>I%,IW-]YPP;N6!?,_=!JG'PE?*7Q#\DNU[[
M<B&<5DE!I>M<7:E%_#:;3ZZR!FGZ#VJ1Q"]43FS_"XB&\^Q*PZV3Y$.18)B.
M1(+=TJ:NC+?I2JSWTE9C@FP??O$\\<_/F1T(:#<!W4)!SYM_1T<9(Y@<R7Y!
M)+2\ I,V_C6;@9N7/"SQG#Z[93CS@8 >EX!NH: +N+U<Q>]5JA>UH6Y+5A=7
M*EN7Z(IX!.5HR".L+R*HP3UF\&OSKU]@6;SFS$(^I7RP[W,OEIQ,NE;)G.P!
M>"],EL$JF *Y5BL-EEI1PBM'[)]Y?KZX:N2B44I#,F9LE] 2.<9A<Q-)G$G]
MH/L:;X8'4AH;;IEG:"/BQ].,0X!P 8X:(DX=@HQ04[.6[PU3%:&$WRC55WUW
M+INJ=]S1+@5*OLIRJ@Z!+6&>9H'>75W(QUFFM%4MY5G&!J=P*.VAR!9@;"7Y
MI%Q@('6")[9A,F,H2EX9LZ+I-,&RQO"18>ASO,8CB_RGF/Q6A8*_P+0]Y&Y,
M[J9_R-W<ESP"%V-7 (UX07S#C6A(M,6)/2;QA3(>RX;324(.]=8(IHNR)2R9
MZ@(62<&N85  P!^,0A__*J--2RBU<'4%$J_>&CZJC0J X(17$Y'()9Y4]P.4
MF$W]D$2T-21Q! ?".7O^._Z,H;PQ)F^HL!J];LJCV1H,)4>W!N]<F^7KSH4R
M,;"AL<;_11\[LN46X3'%DEN_[1A<K"&%J[U+J,$4V!$11U=4X5)<:?>R\&N@
MTYVA\L</,=;%+[;P!@8+;4"6 D;P#__(-RB34Q"DC$F142C>#5:FK!T7'W#4
M>8EV7*&;\3^J6C]W=2*@WNPR$:G6VY]("M9%I6[0@1QC>X\J.-3F18MLZP!E
M"F= 8]QX0 ]+M"EN*SX!RS?HME6$I3]<MX$/PZ\E$_SHFBP!BDEYR4S\C,DP
M^=M=8.F4!+'JQD\WXU\ME=%M@#%H["<T'K+R\FJ^CFPQZ%1J7FH&60O3SKF.
M9F(&89.-0R4LP-!ZC/\)YW:C[Z2)=]F><0_WT^))86K^]+09@> U9&,>4T<P
M&X3"<49SA7CMDTH9^38J)<L=#KPA02PCOS&1S+'9U7HIUP@6ESD-_QCPYV*2
MR:?P+W/]!Z;>X;.8+<Y,.\C=$A@W.I+W=,D93&,[TC1V,GVL2%;[,<P=MF""
M)A'^D0O/;E_@,075K;4-5)?$=8I!!9^I>8BVBCH5R]= ^Z 306X_G7XV)[)
MJR6>;#Z_YJR)3@@$:R.M2#HN6I9CV*ZAL@9==5:N?*WB&B@P1<HY8%1#ZM_@
M&JR8,JE>DA0RLS'6^+F2P<3&;#'/4E NHQF_PK(QH )PLL"3,2^-(CHQAOU\
MS4K9_E248\I&HA# =.O.EXO#EQ.G8N7L$N*OX!RC+>=H,QH5;MSO%G9MAL3
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M*X2H[FH?58?^TUAOH7(,CR7W\TBV1U,EBPBAQNF8J9>(9YS01LBJ-/;1+MU
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MV%-VW@XH<LP8Z+ ^"06.=T_X\A1RH4$-G?Y/CVJKOR2K0$*5=;;H9:Y2J:[
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M]H_&AP?'^\/1Y/!H>!*/QN/3\< YOC\#]WGV'.M9AF@S:^[X\MF8+##*-1C
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M15!?T5%UU99:R$Y-)&F%^63L]V5]\ZG"MOL$##!FDEW%FNW #4H+K[MYLRE
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M3A&$(<!-MJUPJ.K&WGZV.K,RI9YAMGF+[_W'Y;F-1<+WS+<YP;LF>/!A3_#
MHOZQR))@L#\X<NN<V\J'P\N+%TU-J2G()X2P[N AB/UK2<U-=!P1"KZVQI*4
M/*=#-ZEL>%'@]PEG,B+A;EQVU!9-AX5'G6%OSA%LN$:)[-430B4$>>782KQ.
ME+,F@?DJ^E12?V78]DH'6::=DH(F)<D2OIZB0J*HC:9-FN#8F (& G1T3BP
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M8'"\=:-N*6;K1GTLI?<-O#[\WTERDSXD</'^MFSO>U5KUB6LP^CD\#C:W^8
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M0+T;DSK@D4F<3M'_ ^K&+/Z4&"ME'B^9E<(7.D\6\Z0^97MLA:'25%/QS:I
M6? ,))XE: ?E(JU U4KAIL!,0:'*%[!/-']R<(&A8GPV$MF-9V@OD?+AZN3!
M7XY[1ZJ2R]K&"=R)@M_RQV)\I9;0)+YA]44F2,X4W?I2^2YI5<F$K*#<T67[
M;/P<DC[K:KB'$>OY$I3TW5Z9LSGP=P$OYE2!<5K.%Q5M>UP,TZH0;9&3;]"*
M &HE_1KW=%S$MV!QO%P4XA6#>1=P\O]:P*BL%F(<,PIJ%)6%BSG+1DL;QFST
M!TZS$1!+J>_7[1>SNF/[P[^<] ;&(MKDY8)#>94,"XKJ<AZ$N\+<9#7$L#5
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M-W:[.[P[OP()Y2-Q.@&U8R_>:;S1)E2_LQM!4K^FRWKHUC/O,?^+DC'2D=7
M D\#4^QQIU(Z,IA$]5^[K77<@;QB;46N1-%/'H(BS^ -8T19!QONFEOY!#$(
MI669*G81*'[)#8B+G8N7OYQ_V)7J[E[X#I0XYNRE/PS!GYE@E6%9U,?(@&?R
MLT8PW29#X%L$3.,5G]+6CY.1*& _L9L-=_^'O]_>WO;*9-2[RF\,9A5."N>@
M$^..=&7N^F[,U$0Y?7UY_I7S6-[V9O%5%O?2,L;I]-*IS"A0=\/'\\N+ME&N
MJVK^TU__BFL!&1OW*F#KO5$.;]AL4G3IN"!!7M^@P&8_;:0.,]'13,"?0ZP6
MFMNK\5<,+"$'3[*SRUAR]$ _^+PDQ4\+\KVT%LJU9P-B EH?NHU9\J&^G,M?
M,2KG7$.!;;O>Q" N>9OZI]J+QM4^2;U-&0'#7"AVZ%YJ:B[]^G@GWN5_UFXG
M?TA7%.<&.Y:!)0&WAL0N:F\PTZ!UUVH>Y/L/2#=_4=@]B/R]Z9A,+;FK/B]N
M+5!2H()350EHZR8IEM;!7:H3DU%^3(+2,9;B=LW8-Z(")W'+G(G-YO:(R/>T
M1HJ2,66U59-N78YHO>>6HFK<"AO+<>K^=(G9.C$Y\&$O\+6B,H^HQR'7>J";
MSFUI1I:,0<=HG_GFDY@,D*6:L\G_S]Z;=Z>MI.NC__M3Z.3</IV<*]@:&)/N
MO7X$XX1N!]Q ]NY][[K+2X;"5@<D6A)VW)_^UEN#!A!8#!J .JM/MFV$5*IZ
MY^%Y-\JZN(9_D$\/I@UW=WYB^30O<P$7#GH$Q&!; 3HEJZ@Q2$\+P8\B.H!R
M"E^$#Q$0+@N7( ]$Z0BKHQ:-K]/("@AOXN5I2NFF?/4[FUSE8TZ%[XVEAX-<
MUP<.V'PCR;5GB)X[J8<QB  A^PS?8$"WXWQMGRY-JS/,B]#^%]4V%!%;/V);
M%Q';S/GE;^45CJ=M52# 7Z6O5!L6E74RWBK*%X! T1UUOJDJ_LM_E4HM:XR-
M@5+I5T:\\)FDJF7I']];O5%WU!IU?^M(K=[U%?[#+?_]NCMLW_:'WP<=J=^3
MOK4&?^^,I$%W^/<\]QK\ ] P6)--B#T::R" 3E\X,%J;VC7X&R!D,;W0 KGN
MS6!(RCN"H@KB2+2&G\O2[]PZIL5-I KK&6I^:<VP8[H_UK$LH9+3]9&>'Y8N
M7KH;'@Y+(:! 09)L)4D[!W-S:?\PW%H.BB/\64+DSS,3VU83('GXG1I,=#8/
M_3S2$/> 9O8+>94 0XRF1,.-SRZ]-X&/I*!G_Z&5,\8$FXGX4VJ"N[S-AK_6
M>F80;"H8RDA WX<(V@7P^^@<(^G-$V,E+,3 ]DT -'/1"T7??E/QTTEA4VJ7
M\HT(92O(:;+,=.C-8YGU /),A:D'<-[X/;J<6 9 +#>SY9AU(^3-D$%UD$N!
M"$F,W\0JS)R]\L)$F98G@H?P#"AYU,"_"DU >S"L'S!K$2*@+B%>DHRAPYIY
M 7_PK-(C@.)%H/4"JYZP.;:J^.]X$<L%/7P_-1]N68"QU,@A5+DP%N DSVT+
MO?(.63;JF<RR!A?*@@7\ @50P:^KPY)I41/=!PB^_XMZL\$$7;^DBEBIY#O0
MTP+0QOB8D?., M>/.\YSXR>PJ3_(GJ4 &&X:;RLG3J"]<C(<L,W%QTP2+A:=
MD$EF4)'\(9<K!([U:O5D5X0BVQGRI0GU0J<!2=*C"@FW2)6:0>$1Z K912L3
MA4/]R5<^G/7**S$:L0 -B[9/<R[' AT?(I'YI'3GT29]NOY88C?V;M=+/]P5
M(LN BJ[6OT22J_CU9)8:&!N.0V+A=,U0N$/-/9HYP8='HR@!KC.YL"QU20$/
MB3U@23DFZ4?P]%<?QE8#X,/!N 6B4M;D7%2YA XGY^P!KVAF\^P"1QL$7=ZR
M;*5(9GW\'I\#2>MM0V.D7M 50)(;80;C\'$A-80LE_9-];I#*E%>"%^12/.3
MR:JE:6B'@<OSA\'A8T>$3KI" -EF4I!CEC4D?7K=X14S3J9+3"J4,JT@=<UN
M-;9=O]N9#51B*>"NZQAH)OD ]71$'>-+!_D-<I(%9<]DUOM\ 0.9F97 9C\3
M9O%O' RI9D&S9X3?SPTDE=]QO?1*F/YALK,?6RQ-\.4S>T&%I>, L80,/>.5
MM^E-V&S&R*Y>T46%'TAWAF)V!\\*WYC&U#"]V&3\-)J$%%KPH% HU9>+G@]S
MA&DEQ'17U'!<305"3(Z6;+'#\%<*=BN]#U%@0<T#>SC!EJ6R)\S;?I=;>!2E
MZ\\%OPK1$!7#+-C"1W9'C@UB0(&]ALF2AG']BCB:Q>"Q5H .1R^YQLIN2/C3
M9!-/34!GYT/1D?5(>JV"?7W%?O3DT6^C,&A)XQ49Y<;(GAP1L[^"C?"E+*6F
MMW>?G6T0R0UFF 5G[$L#,B*=B0"R&IN.DPQQ-3$N7 +!# MQ0P-I>$$B'Q8S
M(_%>#^3+T@WBPYP.UHU]5@.YC\+8W"FVE_^J;?-?-:RP.\/VH'LWZF('M7\#
MX>#O@^ZHVQE*_='7SD :?6WUKCK_^-X=_1'Z,$_EU\*+!C-QZ)N)(G)!R_*P
M,4<D, O\#^##PFZ.B(CZ$=&&B(AFWQ99EOK$'A!B9&5GKJ$2#Y,FY*RN:2@!
MO.\A*9[*<X^&B, !>D\T-D>;L-WEG 8'L,JUY_[$)E\U@__)"TFN6&0$6_L.
MHE5%QAQF='XV[5O\O,%/F00</D,4!7\%&/8/V_DA?4.S&>U(F?@;(O.^_.O0
MG[CK36O2R*\LU\RL!G-.S!$^81(LFMQKT:Y)=^,B7#(':\KSJ#LLPLKW!WQ*
M".B :JM!,VA\ 34['32Y\O/;@;TXPAY9ZQDOCU8&P#W(0=^BY=S$_Y:HUT;"
MP&V\7'MB&H&9'IPR+?LAJR(S)<!IZQGNQ/AWOH!DI*_2F?,C7*=U_BIXZ4&,
MB'V#<_Q5B.,'#&GB?>MZP."V0L> ]P9N1/P"TE@%T2>65R?I #]3#!N*?CZ9
M#R9OC=N>R9;:]H*%BN)?)%I=19LK27>L28>+1,\]..XMO"U+'#\,?U]55'R=
M@Y47%GL>?JHG7_'KY>";JJ(U:OGV]A-@4R+>@G/+N<Z"=$U %(>0%P*_"OQ
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M]B7G9*7%U(8(JHRU2K6N&=5ZM=FH5:K:0\-HUG75J%7JS;JJ5"8GU\RP6Q:
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M./HWIO2D9:5,!-)#&.E!NW2DA]2([/"^#^@UHY:7#]HB1U&A*',![ PT1WF
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M:5PNZ4"_&,ES^Z(P!"SW@&F*(N-#$3R$=F]*:ID(T  P,_:;!%_5G-&\/H^
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MGVW#F<!;7YL.&GNV0P,V9$CC$SXGY)#)R"F%R+<$@6J*KC947=4JFJ[58H)
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M3_@!^*F/+.YET,(8?X4A:\7T7JDM@*93*'/"JXW?3')-X,3.U[-$X;U8XYC
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ML"9K%>"7)C/6PG8P9DE3*K*DZ0W\3[7ZX4 "R?Z,6Z0N=(>3/> @#]B_PPV
M%)^=VGNG(T[%,8AC..-CV%^^GYKL;G\?#&!R0FLX[(PVC1X^L@P_-<LU0X86
M6R.VYB#YPQ!K*W_*P-),7SA!':./Q ?MC,_&+ YV,1TYQ7*#!VWEP614B$6$
M/$L'CI^MJID%E7W*L&*$_;M+9"O7HTU'TA:"Y JQB#SI/LW*P1O'H#TBI"Q$
M4S15592:JE:J6E-K-.[]Z4_FU'%+T^5L]A%D<<N:P'\Z@2".*2*L4,S?I672
M/WX?7N-=QMN ;Z>_DR9H;,Z-F?O7=R7\&[2G&("'_=/[:"WGI8GME=@5[WY5
M%;FBUWC-(5^S8$?!CA?&CNH![%@]&COJLE95SH\;CV%K%Y&T0O;,\,EVO!+T
M]4H/AO4#'SK!:\[:C$Y=-F4O=T[.M%VK@,_CS%/6DX+."J.[FO?:NNXBX@BD
M4==Z1@QYN#V#GD?HD6JY6=J835G5<C Q!5M<.%OH:;#%\6P]M2[73HTO1-"4
M_#MR "O306.$*>5AAD2P-#\OE97A',--+<#>B/"&"&\<K@MYHW)%T34=_Z=:
M51J:=I_(<B2R;1"(ME1-0TVNU$7TL1"<48A%"/9\RX)-P)[',U$K9\B;%Q"+
MO(.Q529@U"^0Y69NG9Z#$[QJ5>;S3B):<3G1BDI, HJ"EC-V[C!N3M4@JU3T
MTXI(%(TT!>WO2OM-Y;YZ .T?S]K1%/6T:%]$X\B_?0)#*:)Q%^FUY9#?U13C
M5"@L5I DYMOXH;XG3JR%6,1EQ#G6%7UM7=$3Z<VT?59A1U6NU!OG%]HX14XH
MQ"(NE1WKA[#C$<.,JJAYC#7.DR,J%,46A[H*R[.=UXPMI QQ0O)XYI;(9)'?
M/&6]E<>K1Y%'\",9Z@A(#T66X'^YZ*D#EE4X1;6>'].TIIXL?<T%D)FR":G+
M>!79:RW!>8+SBL!Y,9GI[9QWQ# MYKP<G+?"P!MM-0^/[Z\0RC<M&*+X46N4
M]>K"RQZ->V3#?!P^Q-?($ QIV_D7PF\NV+IVLU3/;@>SU[N%V,)$2K @9+F/
M_C[O,%!C8_J5PLZE6P):EU6E4@A]+KA></VE<+UZW]R=ZX]HQ.MRK9%#N44.
M7)]BP6GQJY5$S::H6]NS;DV<DSBG;*7L.0)']_J]4AX I(7(ZQ=B$:)7]?3.
MK!"+2*4JI0!;(^A&T,UI^EM%J;*Y<V!HM_=*@'L!LW<!2":R9"%/]/JE9.86
MMQZ]7H0S%^Y4MG269^10C<&NY2+I;F987LN:=+A42K<*IW%B $I%(T]!__O0
M?PQ8["[T?T0,L5H.E=-Y&V>GFI8)J>P!/*ID3TM+%[%RECRLM]/V!XKJ*A77
M4FR>"GV)$,'YTGVNFCNF8IS(8GN*)7$&U2[-6OW\6IU.D0,*L8C+9$/M7HTI
M'T_ AL>SFVM-@6P6:UN?8L>A9UB/YL,L3T.ZR$UXJ<JIH]-+#E9QHZ#$(GJX
M,M.VY]3#%:-N8[#E K%)U2WI^Q\]&=87VYZ\F+-9ZF/'*LU"E'\*UA.LER+K
MQ4#;[<-ZQPP9RWI-]$]>8O\D/N^2Z*$L_KI$#Z7HIA+=5">FZ&.@[7JV-<ZL
MCU)5Y8:B%4*O"\X7G'\IG*_?JS$H>@DX_ZB#Y#3M,CJH4[#Z*SN'+)-8]-DW
M^E 3OPAF_98=34V6I_G,Y.9XH=X\6V6:R:M'M0U^I#2QEY#Y*500:\=UG8**
MBT$(R<"DQ2JCJ>20J!4<)C@L:PZ+0>/(P'2L*)C#\H>Q/)3#<JXJ/H]BI$(L
M0C1+G]Z9%6(1%][T>HI'5HA%7#C=Y-\LG7VDY-8T'LR9Z9GX<MY [64]L"!U
MRLE!0^?S3J+S<E?))LZI2 \XT7,ZC4[.[+4+!]NZ[;8^=V^[HVY'(&X))U(X
M Z>PB MW!D[QR JQB NGF_R=R/2U.BN;G1O>TJ&NHSV59K;U6,+Z98Y_,BSA
M0:9D\!:W=0P&5^9_Z,*SRI;0\DP4:C'86TPX?;8=QWXQK4>W94W8W^YL!^[6
MGP85:<%EJ2;O*W*EGD.'EV"0BV:0RKT6 \YU1 8Y8N[]]!CD-&(^J6O]UGB,
MU^^YTL)X-0CP@#61C/'86>*3_RBB/2+:([SV$UC$A7OMIWADA5C$A=/-!41[
MZ$OO]^_(,2:H"%&!2W9 <@@%:<I#$4Y=N+H7Y.K&H%D2\8/=6P(JPGU<ZJ:X
M(YM\.EPN%C,3.>G&?ZIRM:&?EGM;-)H53+$/4\1@2Q[(%,>+^>ARI7EB3%',
MF$^X!U>ME+4\0'76;3^)$)@( )V!/R8,S;0\RL0ZA!-&<=Y'<$Q1H_,);8,8
M(,PXFR#=KF99U7.8?"["B05=Q&4R8_5>BX'&3,B,1\3.D>N5' QR$:,]V S:
M4)&'#!=)LZ##JP@QN4L.!5S E",1<BH G>6JR6*P'YEXN@5Y%&HX33?DJN6
M_RBH_]*I/P;_,#GU'\^4T_0<,!#S-M(R@3#/W+;[W7 <P\H;Q[ P^+ %6]=.
MTX#.,@2KJN,3)LV"1F4+1N4"G;G@^B*)==*XU_U^F8>9\_,CURSI0K'+M68.
M$5Z!Q"YX_8)YO7FOJTEY_8A>AZS6!?;Z >Y*$<EM:Y''#J7 !)*=3US*+RA]
M.=-)$XQ+*LR;BQF#A5*-191#"0-P,>CL/ "74>19K<J5 B"U"UX3O):N.ZG%
MX+0GXK4CEBQ@DU/+H6:A@ ,\B^$S7OHB1 /VZ9U9(19QX8VTIWADA5C$A=--
M_L5]V:/J]OJ]4O[(NN=0=R) VXO\@!,% R_:-HIS*J33592@_FT$MU66+.1!
M\?AXK:3\5!KM"F&^%-6R*W =4=;PL<*E*>@B+K,)K'FOQT"8!$B<,>"<MUA@
MNP,T1N8SFJ2:TVC(S6KC_%K#3I$["K&(BV71&$"5@UCTJ!"Z->7\6/0R*VUN
M<V[=+'*M2-95^R=G26?=\RD*#T3A0;9:. :Z)*1RLVPS566E48SR=L%R@N52
M9+D8@)*=6.YXAFZS7C]YACN9=M<PMJ#6*.O5/, %:>TX/N]2(>O'"Q$-*-BZ
M=JM#/[L=%"UCHF7LI'2\KBCW>@QT2TC'9V51*[*BYS +2K"_8/_+9O\8[)JD
M['\\Z[XJ5_1BV/>G$-D^V9HA4>4GJL=.NGJL:-LHSNF4JOS"8962JI<AK#(W
MG$?3*LW0%-L"]$_YUYJW^]^^=4??.KW14&KUKJ5VOS?J]K[D6WI>#&.WF';L
M698&5DZ%P$3=T0D2?EK4R[]5<M&X9/XL/9D3+/ _WOQ\<&;@--447:UC'TQ1
M&DJ]<A_CD37XEK&1.AOH7Q"\(/CS(/CFN1!\(<K6"I2\*U3"[DQ+V03@DRA,
MN:C"%&8CK46MLTI5:56Y4JD6(E@MF$PP68I,%H/TE!G$4UVNYM'84,"*KXOW
MA@JQ" 'Q='IG5HA%7#A4SRD>62$6<>%T<XD03YU_?.^._A"(3BFEI@N<ZE*+
M<.BB!N*L:B"*MHWBG KI(^8:B @KOW\O3>]5,CS/,1^6'@R^ECQ;LE\LY)#!
MQMX3DMKV'%_[^O%4*@,*87$)[U=X,04@G$OT8D[QR JQB NGF^R]WW#5@+):
MEUHM-_(H(N@[$],RG%?)?3*<S$L(SL$.%DT017[ N<U"AZ1A15E/&G9==XDF
M;6-A>L8LU=P\%KY*,X=&,D'V%TWVZGU%W9WLCY<MK^MR1<L!J3-O$R?=%IVB
MF$%#L'ZDA8/FYG(N(A\B\B$\V!-8Q"6"Y1)-&(-G3238'15@Z=I_55VN-7,8
M#2C8L*"+N%@VC,&L?H,-CV>/ZEI=KC9R& HOXG)9&*2_&XYC6)X(R(F W-D>
MU(E&)GC3I:;H2D5M8G6@*,V8.G[&P@.$;_:,4K7)JK)>$R&Y8C_@# E?KU8;
M,=AF;Q+^$:T@N=:HG1;ABZ!<8H@<&M:5'$I((BPGPG(B'G "B[C8>$#,] PF
MP[(P J&?LY*#%2CXL*"+N%@^C!FI\28?'K&ONBHWU1R,4A&8RZ1@SGM"#CZ=
M^<)!3\ARS6<DS6Q7!.I$H.YL#ZKX\8KWB52#=E^)F<30&H^7\^7,\-"$,'<[
MS-M="[-ZJG:;Y.)-Q)?!R+-*'GHC.5<4I8_I@Q"VE\S#,2''_7CX:#:?X.',
M>#@E_,=T(ZIJI:SE8:R&V )3\]0<FU[^()&%\,L+MBXQU4V,=1)CG?8Q1.*M
MAC P<D-I5AM*HUY;!T:.=P@&R#/P<R8=P[$PV:0*=1E8#GJS*3>TN/AMH87R
M849&Z,(3LD?@% I]*$)(G9>0BO%X$@BI%-R;BJ+*BJ()(77B0BK?6+ZJE:MK
M@YERBN=3%'VT S*."#Z)2/^Y'E3QHX1O:M(ZUJ2:IE<KC35-&E^B05&Q6B'6
M']E]POC]Z9T!(UK3+=O0Y4I-+7+(L/@4+%CDB"P24SVQ%XL<L:*B(:O-0D?5
M,YM3=*J5.R&+JV=;)2 6QY[A9S]*)M@&R!61Z4*N2T2F161:!'V*(D:3:?8J
MMDX3&K]8&(=D<9>)XJ.&O*?F3S0I_0<Y]KM?2X48-R.D@9 &0AK$V/G)I<'Q
MC/NJK%::%R$64G()]H_#YCRZE 9=\S?[\S!(BV&N%^;-Q4#%0BG$4U%VZZG2
M:@PV*HU>G6405_"7X*\,^4N_K\: L&[DK^,9B9HNZV<P$#@%"["2>O'R)BLQ
M^^%M:Q/O)<.:%,*,// 44I/$>:\KN3F:]TI3V<%LU6YAMC"J _&RI(F]A)*:
MDPL8I;#V4U#R,?BR+ 5L3;:/)S_JG(&FDD/25_"_X/]+Y_\88-N$_'\\D[^B
M8/[/W^3/@O\#M^"*_ (%-O#[=OK@]V$[L&:^1\RN ACO3T@RQF-:0PMU'Y;M
M@07OX#];I CDT<'6_<)P/%YPBZF+.,^D?W%J6H8U-O$EKH?_,,?OY9836?U_
M6?"%LX)CSUZ$\4382<-?$KY96'Y ]?*GU>WB9[.(/G_;[25Z?XD^('K#&#LZ
MNG8]>!MX.;J(&ZDD56 -8=)8&(^H]. @XT?)F.(;?31F+\:KB\_JR>'7,!E(
M64+!##">(<,!FGYB3R&"$3YA;*,H?_K$J M\9,HE_ZV0_UMG'_Y!]!TT6/0O
M_-C>(/\U^LUAI/1GT[[%RQK\E&Z]24)23(^CTX=C[/>&_=ON=6O4N9:&(_R?
M;YW>:"CU;Z1V_]O=H/.UTQMV?^M(M_WAD#X.]$OD,_@(W_6_2B7,].,GVY%*
MI4U;=H0-I(7\8S2;,:G^UW?*._([B&3^>\RF_'EE5_Z<F#V).(B2>< C[WPI
M3_63LZ>RRC#>>L1':6\\*FIZL=UCX=/=$YT[]/$445WVL';,J24QWZ3",6E;
M$127G.+^P#I>0M8$VUK7:(SF#\B1=%4^#R+<&GF_<+F;]RL47HX(Q;6#&-$4
M33\/F2$([E0(KB((3A!<E@17/0^"$U:1L(J$=Y6)T# MZ?OP6O*>[*5K6)-=
M\*+/5X!X]B(U/CLUN9"A$#CZUF1^CF)?Q+ZDL"_'L8?2+<<LJ7IY#3R)_BE_
M+3?H_-;I?>\,/V93CIEF"<F;+E&.Y2L%*T@2QR".01R#.(9BM\]6M:/.'XI7
MN:EKV%L3N[0NDASTC*PE$G.'<D;PRJ'N2*W*$@R9R/_@!5Q<ML26/8Q$5=&U
MFJJKFJXWM,8]_W,%_UF':E^U45?T570)5;N/:<,EDFN,;M#F@2RZHBJJ9\-/
MQZLCEFNJ<EK8<44C9\$O*?.+?A_35IN 7RH^OQRO[T;3Y*::PQA9P3""879@
MF)@6M00,4_49YHCHI++:.#$%<YPX9^!693Y0JRC>V)UC3Y9C3W(QW;BR9"&!
M8EK(=0D44X%;*' +3\L>:"I*Y2"'<T!#9#>./1]B^=R??K'M25S3:AINI]K,
MP280,D/(#"$S#G&Z$\N,-%SOFDQJYX74$%)#2(W"2HV8R$-BJ7&$^,/EP:D?
M.UJQ?]A!K90;"6NO,@+#$VG@HP4"\GDG$>$^]PCW :YK9BG2AG)B$>RBD:O@
MAV/QPS:W+*L4:$-N5@1#%/L!%\00FST.D>(\VQ1GH?L\VOWA"("_>+^'R'H6
M<5V;160NDT5S*)75E/$)DV:LJ$NLQE; \(KYBB((>_9!V/?)C!]-46N59-YQ
MVW:]_A0BK5EE<W6YUM3.,-B:F"Y"%^9A/H=$^H><D!.$^!/B+W/Q%QL,V2[^
MT@B(-&6M=HZ):2'^A/@3XJ_(XB\F]+5=_*41_L)+%,+OK(1?<4H*"AWF^S+H
M#X?2W:!_TQV)"@-187"N!W4N"20-_Z(DBZ%\<6S7O7/LJ>EE51$OJTKCM))(
M12-9P1/'XHE8QWH[3Z3A6*M-N587S=;%?L %,46,N[6=*=)PMYK5"Z\UN.#"
M@D%GV&D-VE^E5N]:NN[ Q+ [&#,F=?YYU^D-,Z\T*$9HJYA1J_,L&)B<"H45
MM#I <$R.')-A"#=A';N+#&?\U+(FU^@9S>P%S&WM_%P AF%6?J<F5]5F]A9%
M3HQ=H!#LJ7-R(19QH>)D0QO ;N(DG5RX6A'21$B3TUS$Q4J3V!Z*W:1)&K&.
MAJPT<ZBL$=)$9(-WWMYAZ[8S)(&9;ZW!WSNC;N]+7F$9$4LN0JADEP'EV<9H
M\P^#" HMDO;7U[4_*2##JO^;X?Q GFD]9AN5T*JR5B]TGN/4M7K1&$MP[CZ<
M6SF(<U-!!]#EFE(5G"LX]S(Y-Q'C5NZK!S'NZ0.EB8*"0CBM7SJ]SJ!U2]S6
MUO6W;J\[' U:H^YO'5%2<($QR%S\Y.FI4%A!?6G!,9<9M:_<UV*,"#3#2WS\
M@BSD&#-L3;0F<],R7<\Q//,99>O%UV0]C^%B(GQ_ZAQ=B$5<K%BI'U&LI ,$
MKVNJ$"M"K)SD(BY6K#2.*%;2*#;09;52$6+EO(H-8G "SC24T_UVU^H.2#=(
M_T;J]D:MWI?NY]N.U!H..Z,"8%"F+M4S?.9.V)$G%Y-I%)18LA^?D[XED@3<
M)@=3Y(!E%<\666_PK.H5=1L2P,/,^?FQ.U\8I@-5C[>VZ_:MKN49UJ/Y,$,M
MUT5>1NB*DHLW%U\&?D]=*0;.6 KV2.C"$S)=I(PPQ(0<NB Y%&KNV%<.I1!V
M">20*BMYA'6%'!)R2,BA(U2CK(SX4QI57:W4#A4YIU^3<F0WI/AE*OD'+?IW
M'2@WZ7V1;OM#46J27RAZ%8SOM/<FY4#!:6^.R&'LG\-HKN<P*/@3J$D8<-M?
M(,A=6(\M?)]GTS.S&L(0F.>5IEQKBD2&R(^>YB(N5+94[]48A)A]A$NJOK^F
MR)4\<$J%<#EUOB[$(BY7N,3@Q>PC7%(HO @%%A59:^2 ]RJ$2W'P'O*/2?3Z
MO5(0E^CVVOUO'>D];X?Y($N]CH#[OT1 A\<BG'I!FU $A>:?5M05'6M]K5*K
M-AIJ/1+/CZKZGFT5($Z!M7TC#^3)R]'D1>,UP<R)<W.:HBM5S'QU';OS^C%X
M.94!#0VYHA<:[*'X-"N88F?XA-J]6CD&2Z0$67AJ(TM$HOIM%7S3[;5Z[6[K
MECF$(G!W.8&[7)S-IU.AL((ZI()CSBW4G=0TB(%6NC$MPQJCKC6VYYE!&,I*
M[>039>?!"H58Q,7R8PQ*R5O\F(JO*C?J)X\:<!ZL4(A%7"P_QL![O,6/:3C*
MJERIG7R56OK.]/'[B7/TG7/"%!3-Z$<CGCQ<8;.@Y%)0SU>T;9U\VU:RJJ[Z
MO1J#J<-T>=MVL^I0QZZN6LLAD2L:0C?OKV@(%9+E(,D2T^GRAF1):9Q@'B4B
M0K((R2(D2SJ218MI<WE#LJ03?M : L3B="1+RG&5"CZ("YX# =WW9 A$N__M
M;M#YVND-809$#DWYQSV7U.(Y>:]K2^M^P5::R@YFBP18F"V,V@9X6=+$7C[,
M4-0X* A=;K5K4EC[21@_6]OP,@<45.2:FD,.)G5)<,F&4A$.1<@\(?,"F1<S
M7'ZKS$L5P* I:WD,CQ B3X@\(?(N0^0U[K68B=I;15ZJL J:K&@U(?+.2N1E
M!-)0_.ZV+-OG5B,M^;R3Z',\4I^C."=Q3N*<SNV<BM_-&LT*5<J5U:P0_5/^
M6:'6:#3H?OX^ZO9[,%.J.$FB8GAIQ?"_!'+SB9Q9(1:12M=+ ;9&T(V@&T$W
MQ5O$A=--OEB:84,3&Y5:C%&9N@TYLB7[Q4*.*]E3R7M"4MN>X[^_"D@S$7XZ
MUX,J/LS6=B#)FJ*K=551&DJUJ=37YM,U[[68'F+@:P<](<LUGUDG<<OS'/-A
MZ1D/,S2R^T0,]*=WAH,)^5)J75)(9Q0H1U%DAA0<?TR.C^DT/)SCS['20S"\
M8/AS8/B8!L##&3[=\1&R6B\T&.VI,WP&V";I9EMR=((Q29: '1Q[AA__*)G@
MRR'7<_,'MRA$)*9@ZTK>7Y/W2E/9P6S[:PJSA8EZ;PM"EONT#6=1=EF<8KO(
M'6*>OE7PKM\AA04FL] :>ET_5A"F9ULA+=3E2BB=:,QN\[RW*+XLJK^%O!3R
M,@]YF?5DD;?ERCZAGN1RY0@QG]WDBA <0G (P7'4F-$FR;%/S"BYY$@U>-2H
MYM\5>'Q)<H)6>V%;9&+ZF;+VZ<_MF;NAF!3FS;-''\E8(6]JV\Q;V^ZXKA-0
MI?#_U?V=^TNIHCB(,R]9"0H9)&30WC(H62#@0NHZA @2(DB(H*Q%4+*(PN4B
M:@@1E$0$";2,'$KD1+M"D1]PHMW]1=M&<4[BG$[YG [4C)Z]R')VPWD^:EUG
M%O ]T^'[8[ZHLHU(,YFJL=%R7C_A_,%=3$O"GE!.3OZ1J2Z#5%_:,$!:N;8*
M T3_E#^E$-R?N\Y Z@^NN[W6X ]I^+4UZ$C_\]\-[*]_DCZWAMTV 0:Z[MY^
M'W6N)0X<U/I\V]F-PDYQ?R@]TG^E45_J_][K#(: F#3ZVB%@2:W>'V*,1A'7
ME7AT:CHBH #C557]A"E3C $1^-"G$^W6%5U5%:U:5W5=K:P'MJ_-V=)#DX[A
M6)CJ7("*OD/.\,EP=L[SWR^0<\^^R4+=2CC4K26-="<%O(YYG<^&:XX+]3)*
M68F+VA<@C"^J_@J8;12R7LCZ@V6]KM;P @Z4]5OK*3*7]3&OLXNLS^9EL*R/
M*Q(1LE[(>B'KA:Q/1=97U7HU9O++;K)^:^%*YK*^=IBLS^9EL*R/&^4L9/T9
MR7I1PB-*>$3)P3F4'!1M&\4YB7,ZY7,2R>\T#9C?.]TO7TE.^[?.H/6E(_6^
M?_L,N? ;F@4?2M^'^--N3VJW;MO?;ULP+>>R<MXL\XUW9+T28$/MP GG',\X
MP2BRX2(;?C+$*J)F18^:;0Z:N7[SEP:!(46OJ^MQIM;D7TO70Y/?R3+1I(5?
MT7A$)&"T&V =_TI<D$G9'F1*@*6UY17R77JSILMZK2I7M3A4Y+.+C@E))R1=
MP26=4J]78K*GNTJZS1G4]"7=AE?(=^FJK#8;,EZ;7*]=1-97R#HAZPHGZX*&
M_FJE6E-K,1!&NTJZS?G#HTNZ9. #^2Y<DRO8GM/JFEQ3XE"8+D#.!='.*_(+
M@$C"[W]9\#6S>)EG+SXJ0?B,+9$0/K_K@GSQL#ZM3V\_;@L3[O7M#5PJ43:5
M")_N>N.C7SYZ0I(Q'M-ACS#PPK(]O%Q,^Q*^#4R_>'2,F;0P'(]/AL1,1)KR
M#,Q?TM2T#&MLXDM<#_]ACH_#+2<*SJ1_H)Q^8A[X]I>OWI+:"1; >6&Q.UVL
MT-_Z!D4?IT=IE"J.&ZDD58%]PJ^QP.*P]. @XT?)F.(;?31F+\:KBPGGR>'7
M,,5(Y8>"I<5XA@P'!, 3>PK1EO )DS&*\J=/;&^@29"*E/]6R/^MRQK^0?0=
M-%CT+V'Y%QP=_>%PJDE%U7XV[5O\X,%/Z=:;K!%_#/6M&P!;2/7MMTSEI8:C
MUJCSK=,;D0ZY]M=6[TMG"/F3SC^^=T=_T)N"1F8?=7OT _R\_RJ5L/ 8/]F.
M5"H=50JL;Q11+-(8S69,R1'M#+^#AN*_Q[S\GU?>_L^)&1 R/"L4'G#!.U_I
M476]DN?;W/D</*^)'U? SO($CX(RM*2]W6SK6'_WEJ=N2\$E8/Z-QQVB]I7-
M3RPTFL?)9G3^O32]5\D(X6U+7J[SF+-"&XCN>_KTN8T\$ZPEMW<3^URH?=Y:
MRI&$L<"H O.)R+T5>9*"0$]PTT!R;X#@.#1)O/*6.Y2^KJC\HW[M^%HD0[W1
M=_ Y&\ZKY))815[M&FLL$T?E>=&U=N)T?=($2F)HTL)!<W,Y%^1YAN1YB53]
MN^$XAK731%A!T*="T"=-F6UC87K&3,+& '*>D2#0(A/H25-:WWM"CC0.0WS_
MY<'YY=>9[0JY6&BRNT2YV!J/E_/EC"2L)FAJCDU/$&F1B?2DJ:UG6Z70J$22
M1(59B>=#<ON%W-(CP"UT=;0&[..Z0UN[BU) K"TDHXQL;*P6FBO>CLWN$0H^
MFVQ?=LF^RU0DIL4BNQ+>.X+B6_^4EW5]-OCC^@[XXX)L]T<LE[PG>^D:UN1,
M*'9/0<\K0_Z412/FJ10\?&[=MGKMCM0:27]K];Y#N[&*=T#1LF[K+$8)??&*
MX^M%)M>TJ?/-ROFF6M,U16_68@K/>\OY W+Z4UH^WE]ZKH=E()9#,<7G&I2<
MW\-WX:M0X&-;4#_;G]**H-9/T_4_[KKN$DU8A/<;@J=LKE;?:5[>KTU-DYO5
MYIMUZ45EQI1;;X20$$+B[98:+!"4BJ8H5:6I59NK,S)KS7M5B>D\IHR>KFS8
M>Y#FKUI=5F,A^X0D$)) 2(*])$%=P9) 2TL2$#O@CA;<'%$0Z/@,F_4<1ND*
M25#010A)D%@2:$I=T_6X-MOC\#RK1QK0HH\C<KTJ5Y2&X/DBL%LA%B%X_CC:
M/P9[_#B2@'D *4B"BEROQ:$3"5$@1,$EBX+M$P<2R(*8@5R'R8*'F?.35.>U
MP\5Y76MLSQ%, 3B>5 B _;&AH)Z\<W""U+<O@O^I2Y]"+$*(P".(0!6+P!B8
MLN.80P/D&7CC_(DN:8@^76O*S:8FA)\0?D+X79[P2X"R5M=J>K5:32WYT[.M
M4+5QEQ4;'R#LIN9/-"G]!SGVNU]+IR[8SH/="K$(P?.'AW_ WHF9U;9=$APE
MA%-5Y$8E#G3UQ-E9U.4=L7\T0/F"8KR/Q[:JDO2-9"SJ3G1)J<CBPFU;%K!'
M!3S< BY)T%MQ5GD)2Q+T5IQ57L*2!+T59Y67L"1!;\59Y24L2=!;<59Y"4L2
M]%:<55["D@2]%6>5E[ D06]'@<,.HO!GE!X*!=3#@[>A2<^PQ@@ _0FLAS2F
MY;JR9*%=P*&.D95)/5&9?1+R/"DH43-Z5564AM^,#A6@?A\Z?@3M#:<]HF\/
MM2U /[JJ5>1F]>UR\SQX).4B \&71>;+),4^S6J]TFC>\S_K^,\J_G_,HIA5
M[U?+!#2]TJC55\L$*M5[@"D*L3-7'@Q8@K%=5MQ\0..HK%5R*(X4K"M8-S_6
M53-EW91:OE6H%ZH+UBWT P3K[L&Z&N;42K5:R91+C]6DG7-QKN!.P9TY*=;:
MO:YERK+'ZJ86+"M8]F)95L^$9=-K>A;,*YCW8IDW6Q/Y>.VZ@FD%TYXZT_(_
MUS55:30R9<1SZR@5_"CX,2<E6K_7JT?AW6/!>"F-MW&^"\6 QR@N*6Z+9Y8%
M*'QNK81^(F=LNF@B4#-$!WW>%)JHP*6&_[^^XHU88P<9+KI&]+^C)[Q]CT\=
M1MO]*2=W7HIR H4O^*C5QMOI\J*RJ0#@$.*C..9;1:UIS34[3=6K-55;&\^@
MW-=B8#D2RYB-^!T%*\=1947,<R@&,Q=B$4*BI"E18A#?<Y,H*54)5>5J@L%1
M0J (@2($2C*!HJF52AU+D0+)CC.I71)"HZ"+$$(C-2M$O:\U"B1)SJ2D2DB2
M@BY"2)(T)4G,N-O,)<G95GH)F5+010B9DJ),J2L%D"EG5X F9$E!%R%DR?ZR
M)"B(JVMQ&.JYB8US*Y<3TJ.@BQ#2(S5+1+NO9Q%Q/4K.I7:>.1>!(I6DB*\S
M7\SL5X3P#>WQ#\E>P.'G5](GRIQ/A(:2E=EI]:I6VZW,KD\I\(2J["I-/>\2
M.]&1(%AU]YE2JM*LU1IQ/0;[N$.,<4^@:.UM=A4,*ABTT RZ3RG8T1DTI1JP
MRMM(C8(_!7_FSI]06:56&GH16/%,2JH$&PHVW&,8_ 8]V;C7]RE6.CIS'JM*
M:<O4^!P&L2;GU1.DNSR'P0N!5&3".$P>[5/R=#1Y=+:U3L)L$%QZ1"ZM[%-$
M='2KX6RJAP1W"N[</=]>JU3UQCXY]*,SXKG5XPA^%/QX-&W9O*^DRJ1'B2AK
M)S9W0&!4I5[>LC =@5<E"@[SI];2J1"AJ,85S%$,:T1M5AHJ%)?%62-:DG*S
M&]N9(DS-DY8UZ5!=4-P"%E&^7SA>+<0BA, XBL#0BR,PT@)5RJ&@1DB-@BY"
M2(U="GST:J-:((OB3,I\A' HZ"*$<$A<=K31IJ@J]Y5$T-+9B(STBX].W[PX
M00K-LT!)B$DA)@_UO$!*5O.7DF=;$B5,K((N0LB.H\B.1%W%V5A89U.H)61&
M01<A9,8NA6-536L42#R<6_F8D!(%7820$D>Q+.KIBP[!]0*M::]R-I(@+#U@
M.H0SG"^PNVK ^8L.-5'-6X3B,E%:+HAQ=UU<K]94O;FFB]7[2O+V;2(9B6"\
M,U[GV!@?.086CF-1TB785+!IRFR:O*LY(S8]3B&5X%+!I:?%I5"RI%64:N$8
M\DP*EP1+"I8\HN*L)@<:R(A/TZH6^E63=:W0($7%YR?!L#DSK'9?3=[KG#+#
MGFWABN!8P;''Y%BM*!Q[=N4B@E,%I^Y3GE&O*87S3\^M2$/PIN#-8VK1Y"#7
M!S+LI3J;QZA_6!B3"99>)?K!1VWQ\](J?S:4341\)&F&W2.@'PF[3](K,IR,
MD^3'/:8CUJ[9S@0YH65)KCTS)Q*L19$E^-^'HA:XI;STG7@AH.+0U[9_,?5I
M7>$[Q#Q\*P/$\<'QI$*12F" OPO-[BE;<$(R"<GT_[/WKMMM(TFZZ/]Y"IR:
MW6?LM2@-KKS8,UY+MN1J[>.2O"U5]YY?7!"9E-"F #8 VE8__8G(3-Q(4"(I
M7!)D5'>5S1N0R(SX,BY?1A R-85,VYGDENF4F.36V+'73?*26'#'J4\$U@36
M!-8$UET':Z=AL&Z# $=835A-6$U8W0&L1IZD,1B-FH;E=FB0!,P$S 3,!,QJ
M W-*$-!MJZRG2*W 7!7OE8"9@)F F8#YD(#YA>B&/78&#:&U*J1GPFW"[:/'
M[;:J+F^ H<'8*:D64*O16!V3>W-QY;[>ZQMV\URVVB&G;FM!G<UUE_+,RF\?
MA,DJ8S+9TNVK^U9!CH%NV7K3^U7+AQRZ#'MD-1-"'Z+5/!R7U0K9"X7([B6[
MMQZ[=X^S,7&P:+TPJ'CU4USH+IA/ZY[PCV=?SJX^76AGM]KYQ:>+/SY>?-,L
M R04-%2%0I!T%E"]8U(O6JLCHV^9IM$?E!RDOUJBY7@]XVRSZ'H91['K(WR6
M[1;5<8W%[?8\&VCT]&&_YPQ'K[%7VSXMJ)K6D%K6?437 E4TX-\^-J6TQVOF
MG3Z$OZR:=P-C;.@ER1FA<?4JZ?ZG=V'+LMKH*4<*20I9MT*:H) E89]J%+*F
M]M&@C#U[:))"*GT#4LAG%!+^.["&CEU2QJ(:U:N*V%MBKMKZD%1/Z1N0ZNV]
M%Y8$'ZM1R-H*F1J#GJ[KI)%*W^ 8-/+YN/_>*FF4U"1^G4K6Q]K;G#Z ;=/H
MJZRD'12X?6/[*@,%(9&B2&0!$I4< JG&.&B"N&>-]%Y?)PPB#&K]!L> 0=NQ
MK@QS9)?4S:D&5:B&K+HJ0#JF9@P M_F2Q/+S"EF-'V_U3*1%=$FKB BSG67P
MZ:]G5[]?W&B75\A]L=]5;2@4GZYVQ%'P=CO#7:./^]I-2L$)I_6E]:7U[>Z$
MT_K2^M+Z=G?":7UI?6E]NSOAM+ZTOK2^U?<<JOX$)9]:SY\R/WYW8CBG0P=F
MX=$-[SW_9,YF\;OD/:5#I;EH5+X3$7+F77_"M&"F14C7U2:"J-33%B$[F<$\
MLJGV4[ )(\WULQ<]S6=QPRDO-0XAJWF^^&@[:VUU9*QO6[J=,MV1 I2>%H-;
MB!-<X@!)293?3D\6VZJ<&AO8/<M\F0.OJCXVNN,WH[ ='5*;B-+!JB_=..J^
M56;4 5 ;&2L'$W3XW![V!ZN94=L96R5,3 YQ"?@UA9S[)UGMWL"H'S2;00*"
M4%6&U VCK#VFY<Y 4T*TK EHZCFBF&-=]O1^'8<S6H283@AFK;S,CL*4@D,B
MXY.,SV(7',=VRCI)U@3_M1V3[??ZSLNXWPT@(D-3E2$17!)<;F-"]\=6"8FY
M)@Q5KE6-0@A T*G*D @Z"3JWA,Z2HBP50V<'^L8HA 4$HJH,B4"40'1+$&W.
MAZ_N\#R!Y\$@E8)#(O \-O!,C_F;ACXLJ;)9$R"JVU9%(?4F7%1E2(2+QX:+
M^QF5@['EO!I#*TGN#'N6?F0LHBJH^8?)/LZSZ;^64.;9+Q9.O(A-J3K4=C<X
MBLHUNYB02%\?F:.A:1?HZY?^)&1NQ,Z9^//V ?3__N%"RMOU#*11"*/,<D<)
MX[P#_/:!W1M12Q326]7T]L76=F"_&);3-\Q5^Z6OC_O]$OOE)2U.E+<K%&NS
MI^LO*RZI*JFJTJI:TJ6H-56MJ8]*GWJH*'Z#8]#3+=K%(B_4'O3+ZB^WII-U
M,4>SHP-FKS\R5%;0#@H;E6LF%*K<6C#&_;+D3EO(U X?DPP%4E&E5;2DLU/C
M*JH*[X^4E915964=E%4::&L_;8M?1DI*2JI"CQ+XGZY2X)K:FJBK-:26+>^=
MYGC01)3LR-1,S<*42LOP!H;,Q>-B'CPQ!A<,)M^U8(&+WQY)ANI)=J)TD8J$
M''V0:]VV'2'G6DA[EV@X@_J+6*C*\%98:Y48!$''#EWH'-/H.^M49T,?]?O#
M,JKS/AZ7Q)<.<(1:R&L2CB@Z",*1.G%D'QY3Y3A2$X%IBPI;!",$(P0CV\$(
MLJP,>UA6_J1QQ*B*7M5RT(G00M%!$%KL5,!Y)ZMC.+;VX4-5CB%5$:$V4S3M
M%@XZ*%[,^; YG(2;A)MU.6L F_MPU"J#S8,EIY$1IN@@"$QJ!!-['PY=Y3;8
MP9#G"$04'02!R"YD/LL<#EJU,@Z5Q4?XH.@@"!]J,S)&8WL?LN'66%)-KKF%
M0^Y4C4MIKN'""ZD<%S&NRR7H1 7!(/K_$0OC5ANU;?3-?G&C-D;VT+#ZYGKI
M3-BHS6VHJI^#<,9 \*9G_O1"P*2ZK+(.GR=03:U(;Y756TL=O:V+Q651N3BU
M;T#:^XSV(FW*<H:.0AOL@9"G2$=)1_<A*^VRQ3KZ>+M37,UH;OV4)<5WVPY*
M)=64([AJR"% M'+:1ZN#90J1Q4$JW( *]]M7X8/CYY#JDNKNPX<9#1Q='74\
M-%8,:25I90,;ZJ!^#3XRY:.*5U6Q4'C6Y.0.Y!#7\'$!SI*+ZT\GEX@'V+:<
M-LUU(9*LHH,@Y=C%/''LD;UNG@R<OF&-ULP38VQO?QJ:;Q9\K_CJ/CV"FW ;
MNK!?3(B!0VC2G4$0FM2))ML?WVD(3:KA!1&8**?'2@R"P.258(($)5!M1SG<
M.!":$B&'HH,@Y*C1#'&V+R_0$)S4Q9WZ8/0,RR%<44&EE1@$X4IMN&*.G>U/
M%->,*P?+<B)@4700!"QU HNI"K <'/>* $7101"@[,(%<VQ]A]I(#8'$H3'"
M""L4'01A19W&Q_9%]5^)*Q3QJ)?4MG"G4P#B$_'!.W/QZY!D?P.'K> !:W-P
M?E%^-'".M2?FA@VSB+9?@@J1.0BG+,S=4HN"N3?54$+UGH;_;P6:7S&LG>0S
MDZS<SY[_8>UM&O-7*+GYLT)9)IO5::I*O#W4N=94L&:CC9" D."XD>!9:]71
M+1,,4DMW;&N46:N)$=LW=-L9KANQENF4&+'6V+'7C=B2V'C':8H$I02E!*4$
MI?5"J=,PE+;!T20D)20E)"4D?362(H/5&(Q&38-F.P15@DV"38)-@LVM8-.&
MMSETVL.A7I*\KA4?JV+<$CX2/A(^$CXJXZ#;8V?0$):JPC(F5"54;1Q5FRX1
M72E(#,9.26&'6@VNZAC#FPM$CWK@;C?/_7D5'M2]J:NS!^Y28+I5W"; )#/T
M",W0A$P^U/71J.2(;*W;0\M<<56AB$S( T;$3IN0PW%958Z],(*,0#("=T;>
M/0CQ<;#H1(E7\>JGN-!=,)_6O2@?S[Z<77VZT,YNM?.+3Q=_?+SXIED&S $H
M:%?*;-)9I@,[R[2+V3HR^I9IF:9=$OJ\6J()>3WC-*+H>AE'L>LC5)=M3-51
M/,7M]C[$9%G]7G^@O\9P[<*QIBYJJ!*#()C8X<AC'YY\.%JW;/4A_&75LAT8
M8T,OP1&! /6"QO[''F%I]='@\,X]=E$WE1@$ 41M &$"0)2D3ZH!B)HZ55N.
MU>N/+ ((%713B4$00+P2(."_ VOHV"7U$:J!@JHXO.MMZWM6GVP%);10B4$0
M%-1J*Y3$R:L!B/K*Q@YZCDT(H81R*C$(0HAM$FQ[0X11DFY_'434Q\W<G'DS
M>K;1[SIH=% H]\VO=1V4E!@$(6-]R&@!,I;4U*[&>&J"D&J-1KVAV7E#JH/B
M2)A(F-B^$&Y%MS3Z3K^DP'<U*$<U>,E#))U71>?W-X-V!HAJXD!6S^ZW0*94
ML)HND0<W6%>?_GIV]?O%C79YA7Q!YUW5QE;QZ91 P(X.J1:(5F[:7KO1=W1Q
M%1P2R9LZHSR&(9&\J3/*8Q@2R9LZHSR&(9&\J3/*8Q@2R9LZHSR&(9&\J3/*
M8Q@2R9LZHSR&(9&\5=S0;K<(.Y]^SY\R/WYW8MBG)DS"HQO>>_[)G,WB=X9S
M.G3@/:6S2[G >[[+'1XK=/T)TX*9%N$)(FTBN,$];1&RDQDL(YMJ/\6!@DAS
M_>Q%3_-9W#!#HO9,:/-9S@/*8.9D;*N3]WU'[V<G[Y%YFAZZAUN(@_#BW&M)
MLM)):\$XBAR^'PV&/<MN_>A]&RP&TDN5]7*K[KZZW1^M]J#0X7-[V!^L,@ML
M9VR5,,^Y;B5:UY3*[D]2, <]<]#"R5924%+0/2C0.VMH"0.Z)@VMY^QY1H<V
MS1X8#2IK:@>EKDVF,\&1RH*Q-QJ9 #ZV4]8SM2;@J>^DN]X">Y$, ]+$NBWW
M_M@JH037I)[M-$LBO22][*)>EM2#J5@O56F\0QI*&MI%#6W.L*WND#%I)FEF
M9S0S/=MJFK;9G+8=VF%74CI2NKJWP\'8*NE-OJ."5E25T#'L;BE9%226ZH^2
MYDDMSFF_0Y26KR5<%?:+A1,O8E.JXD$G^ML6T*WX,"/'&HR&!3X,^.8A<R-V
MSL2?MP\P??</%U*VKV<@^4+P92@\2B@L'2#,F".G-]1?AFY5%99*@Q"0M&Z]
MI<W9;,,QG5<V9[/&6?)N3_SI"OMGV-.=X>%5*.FBGBLQ" *;G5I!5H0VCF)H
M4S>3"0R> 96Z/2ZR$T$K06L]T(J$*V,P&JF&HG71LG*,T)XQ- E'"4<)1X\/
M1_>!41O>YE!J#X=98Q5%\/) >'+DVRHZ" *.I@-I]M@9* (R!TOZ([A1=! $
M-TW#S6#LO#9O2 Q&@IEN#8)@9B=&Y6"4=0M1!",.C7=)4*'H( @JFK9(AF.G
MJ2@+ 84"1=*4EOI<T#I?_.SB<3$/GAB#"P:3[UJPP,5'XNC""QNGC1)_OB,2
M=**"8-!ACB,6QJT.<\ V;.AKN_70L/KF^F&.T=C>RC?X'(0S!H(W/?.G%P(F
MKV?7 C>5H_S1(2S2V\/76TL=O:V'//?![.EMM$(F_27]K49_D:8%'K&CT!9;
M%4.+]EC2495T=,M2FKMLLHX^MK<Z%-.,YE;%%7J.6ZGX?MM!N:1BFP18#3D%
MB%=;$<+KQ:N#I1V1S4$JW( *]]M7X8.C\I#JDNKN09VQ[/Y0@1WU4%DSI)6D
ME0ULJ%OQ\5^GP4>F?&I6,5-:LC<P47CFY.0.Y!#7\'$!SI*+ZT\G+(DGV+:<
M-LUW(1*MHH,@Y=C%/,%\G[G.EG7Z1@E;UAC;PY)BJN4V"M\L^%[QU7UZ!#?A
M-G1AOY@0"X?0I#N#(#2I$TU&JJ%)-=P@ A/E]%B)01"8O!),D*)DVKJC'&X<
M"%&)D$/101!RU&B&.&5-PEN%D[K84Q^L4>?+>AZ&0BLQ"$*5VE#%'#MEC<U;
M096#Y3@1L"@Z" *6.H&EK#-RJ^;*P3"O"% 4'00!RBY,,!NPHJ\:2!P:'XRP
M0M%!$%;4:7R4M7^O!5<HWD%EDUY#5H/]YB2WX6B>W''H6!M1>%4@D!&?G(1Q
M9]O>MBP;4Q9U\+B^AL',BS$@>!;'H7>WC-V[.;L--ACN1.$B?29]5D6?2Q@1
MK>GS09"H2)U)G6M5YV>X3*UI[H'0F$AW27=;VXK+V$2M*?2!M&PCA2:%;DFA
MRXD\C2OTP7)X2+5)M=M3[1(J36M[]<&P:$BE2:5?K=(OD5E:4]/*>2QK2>M^
M3]=U4ENE;T!J6_%.7,(KJ5S%CU4[JR",+-SI%&;[1'SPSES\.C8ZU0:>2<$A
MT^8@K2@_&OAJVA-SPX99!=4N4X6$P""<LC W+"T*YMY4P['H/0W__U95UF#-
M0]])%S(ISOWL^1_6K0R%*Y3<_%D%*-.#ZE!!)<X0ZK?2ZEZSJ4?(1,A$R-04
M,FU%_MZM5ZXU=NQU([TD'MUQ9AAA.&$X83AA^(%BN-,PAK?!!B0()P@G""<(
M[RZ$(SO4&(Q&3:-U.PQ0PFO":\)KPFNU\=K6+8'9]G"HE]#V:P7F=IB\!,P$
MS 3,!,QJ _-^L1![[ P: G%5V-L$YP3G1P_GU0/5FQK0:3!V2FHTU&IB5D=
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M]0)-+5XE 8UB0-/13@W*U(A<A,$/;\JFVMV3]D86C'P+_TH-:[EBI!K!1ZI
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M:PC-Y\N?=UUWVY2-^ANY$IX<+9Z45/>K!$]J=8A:J:M\C(!RK$F-SZX7:N"
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M"CX2/A ^'#4^#,>.4S4^U)-E-=JH\=P"/M21B3TVYXY7HVS1L5,$=%4%U*Z
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M>&3V>()F#'R&9&5YQ<)04(;%<+P(_.N?_+%BUX]A"!RC^/V9%L'3,/X[!K^
MVV%L5WL3,0;/, ]^OCV%I];0?,)["(1,I@^N+'WS.(0)1$^>RQ7,)OB$>+%;
M!OIR#V.#B8PF'H)U5-P3DF]D6X*K39+KKTRTV SP;S=L 7-P!S=!F>>3L@K(
M&Q&7)XWY;21(GW"0[@'0AA&>?S^9S&%%>J L+NP\T:/+)QIVB258DZ";]PQ[
M7FKG5V?:U'V$GX*610O8>Q@.[7[N!7=P 7!373Z( "%> YR:@"KG9I9_>!7$
M3#,&;X]!\RY7ULWJI?*J?0X"L:>?A\M[[6SZ"$L3Q3*EG\C*Y_.S#,P7BS#
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M:\G=D_;UT]GU1XTS9$%9H[>)5JV.5M27?RJ@$5S.U>[S6V&2Q'ZQ\$$N [M
M$B_?$:)H^2CFNJA#0C6>N:V(4@4\MBFR,B)H4HB6B"@I"*(,<F=T@V 93X)'
M)J"'1VK363\&]<E@+%UM/&(0I5,ILKF%XR@3>?C,\[?;2F"!>IHWDP=\F)_@
M%[R+PLK74EXRV1[QKAZ(! ^$\T38'4]QX0]!$"/!7.#YZEL>0$?ESD?/P5)_
M"'YB5+"W0:0XVDXPL@>*C7H:W,62_\U/,_%]#VXM)1AK?H@PW"P)W>5B?9>%
MC4M$_(M7%W.87#V-E^^R)</\_6? N4LKT]9#DP%AP9?9=L'[S@45>48*Y@R>
M<"X"FMBMK:XL#[E=;;A=ZT&G@W*[1!L4(?T@L_S\S/G-\VT&%77 G,9JT[Y\
MJ'=@@P,U&CY[J/<VN):G</G+;SC_8CEV/.1[[6O_V_4Y-\/2$Q)*'C@93ZUP
M(LHD76^^!25KCOB(Z\Y=DN+9X)[T?'Q6/$C,Z2+.VMEHSDKR8=[2:Y?^LN00
M\NGJ*63M##84/BJ>JP/37KS@SFSBVZ*Q^+PU%+(X#%QYM%\:,-PVPMV3^V\K
M.I"=VTWG3>QTS W!)P$;<2I3@)OO3]#??>A?/\MU4-!_QD_.NMP<>]&[Z,2&
MD.];GLN^)!O$L+$-XG:;2G4K<9GT\/H3TOOP8.=T/9ZE_>1F>7+F&<G>\(N/
M 1+)X'+G*:T ?(H_W'#RH!DI6X]';6"Z1-4*GM)F/*XAKP)[CQ?"HR3CXE>5
M&\F#QV;:Q2]P$'A8[%IP&;+3T/SSM'!5\ODSU<RRHEI%S%>A4E^;*6^#4MX=
M2;U2RIM2WMNEO(LE*%_T'6S=L2QST'^^>&#:O_)L(HX)^/=?8;N9@'WZ^FJ!
MQ7J!RE0,--/D^A^P'-]P8<X^?;K^\^KV\NIW[2NLVZ?+B\WU'_<R.5XN]]@W
M^I@6& U&*]Y>ZL1=SU86Z>ES$'[$),OU[*OPB7C 2'QV"\OU<1Y,ON^]>.L+
M*(Q5=;V(@I68'W*X^AWQ]HY^Q8:?\5J(6S@:+95'W##J5Q1)7->!1A[U8Y)/
M7.2$719F2HSDE]KTY(9?.E%%?Z-$GE9\C_6IV!(.5G_V0F"J/VK0[RC\B@]L
MRB:R(=*[)1X,PF$4%P3/!I;-_D9'[["FK#33^:+KYO+96W7/;"[3(OZ&?T./
MCB?\I4<5/X1,^'<I,V,!HPBFF]R]7EE2S_-YT?1PRM,XXM3CYV\W_Q4M4T-D
M%1UPOA$B"C.:@VU>VPS-*UB^@0W+!]?ZH&6;%I+>13:3A\VB:)DYGY=HF/FN
M//%9^AOAGR;5NR[/;CY6/MBT'M@;3%S!DJ$3DY3PQ.E)OB 8Y$DZ^ 5*7R+-
M7!?<[-$6TM+2IGR3O\/9X*7<<J=@%PM^$@J!C@N4%\6<UL!5+RD;)61!PB)[
MIOSW 6O?7IGM5:;* TQO$/)2J\B9Z>4Y"5G.&K\I>U)K\ZS!NR:X'LA&R/I0
M)TG311C,/)XF18+0;BN4#TB=F#B+*U&ID7EJE$]V)Y<RMYWDDKS%Q13M^Y#Y
MA3GG%+Z2]'64)S5Q>M%WIN%1;%19L#C_L9S>2PSV)<%A(2@?*8TC=Y($QA.$
M/((ODP9(:L)F)7"EG #TDA0X+X_V:X$UX:)"63-Q,<'QF*9N6"1CIP@*O X9
MO[0XCYJ_>@+V83#AQVQF'!Z>DKSU&C-D'6E40(8F&11GO+"$.-S)3_* AM\C
MNPL/[S*>?$DD@6?>80;G[!<L(<_)R[(4@L.0$Q&^O(DL<7;#/AN!9(:]B%L]
M39:20VEALAQAS#3[%+;)&$O')6=#46JG'HAMF#^SQ?-NN>&NR#NOBY?$;E<D
M*-.A8Q.<G4W@9UV0XYBSFWPE=%'?//82NAZON;$F:>( -WR4D.@X!2F?SD!J
M\B+XB?5_?S"1V0!U!G%FK(=4'H!9KA6@KOC5K/(G4@AYI")D\3+T<PR>_%GO
M]&Q_=E%^.%=B=8Y<M\1ZO'$R&+0'DOT![I_<Y%1;FX2B?B?,-I'Z]65-93D_
M^#R"Z"0KTG/%9\]<(?DAIPS)8XV;DD31ZLA2*RA)&47N8[+7\4U#.!5R*O"K
MHD8H7Y=E)&E^B45*N\V',U[!%8 WF:2$P=S+5V,5!6*0UKAB)G"6JZ"BP:+P
MR@C"!I",\E#PRH0<P[J[)YB#612N+?1N[CW*2AFP66#,5ULN G_',,EAK<VV
M@'X5^"?Y$D%\/0$9UE+71^):;9R/C(@C29-I<5]I!,O"RBGD( ?8C6/P<Y<\
MA-:3Q]?GO( !,JW%JY[TH_+%W],LMT"A4VWSL"2R14D!M'4C*X7%HG/!655)
M066L[<4? X/3W!EAB2G%*3S2SL\]3C)JK/J_-MYCDYJO!6]7 )W+-[I' "(Y
M]4EUJD=8K@=9PBA!QI"EDRM8LYNF5I 'Q.?^)J'H\2H#@JCE1:F]+(5CX\\P
M8B"\ABG#DQ]9W>EC6T^9)MQX8N*GY$&G<\?#B[G>%\*MEB<!),V??X7+AW1_
MT9+A*R],"6F9@/TAU2V_T8G*)\+;P:)R:8&RW$$UL#6%??7\*O-;2CY?5IH_
M%\/)-8WTII*5#>+G<:L3JRV"Y$ZY-0HO@GN?[]\IN*50(DRZK:3Z)0%;ZTBZ
M1G^1'[1,@LFDNKPN1%'BUT@ISQ6J*.I-FV0;D\@V'2%]$-F&R#:[U9=8@]J7
MMO9MJCOL1$#)"CSL-(YR#LK&:@Q;\E-LO9_Q4W*,HA=(*O!_&)O_B9^TG3S=
MXCXN2O1503)*MQCBJ3S[LU9Y*B_7+=\PZN[Q5#XO_4E2N9A7;DP":A,I_P?)
M4&F<&3][:9I?.-HCV\WQTJ-3K!T=IMP"\5+F^GM)_O_/FW/Y%MK]\LW_E76:
M2_OCB20=]N]\R@8C[?NTCBCS?WA@%CS*@^B9HY(VEN('0#&J*^$SN]9:Q"^6
MB)JT8XJ+\Y/^4$1M^3AD;TG>;2A*CB9-^8N$9U)PMY)!I#]<"U *MRX-4?(0
M#HOC>1IKB9;XB(6Q^[F(=IQM"Z)1H<]$X<S2="CXY#B169BS.$F>>"AD1IPP
M'F<M/B],VKUHO<M;,:5N&Y8YWRE5O[4K5A-EU#&'=DF-E9>VY#^8&RVQ8,FE
MCP48 PS1T0Y\R#OPRY6?-HRZ>SMP(M,'N],V6/I>SB3N:X\<,[*#K'.1EYUQ
MKA3B)?:ID/4H4/-Y]$PD)<4W9CS-*M$FJ6(1:8ME". <B6^!D@,X?'?O>>05
M,=_%&CX\V1@E-;:3T'$4YPI7 73?(:(E6US^7BDU*\E9\'*\.?ZPJ+R+Q6K7
M'R'9TQ,2!98MD@TD )?3^&#QV41L+SF;#/@;1OR;60%8K(>[<EWQ1#[C-6W#
MIY2Y)+*S<X8UG'(+\C/TXICYHILCIXFF5PKNH@!N,!&Q41=3Y#P'F*-%%2@M
M=UA>75:#GK)'7A:$_5IX,MHY7<J,,R\JS\N=YRJAM[E'KM[JQ8,QEC.R=,/9
MPXW]BC7PP_CI*_9Y/?.G%_]<>KS 5E5>;-DNVH5]M&0GW;B7[KV;JK:?OES2
M8^.X7[VCMK"G)L(ODGF)Y&^YP6[:8LLWV35Q*MUH]]YJU4VSE<^Q*(XF>X_$
MJQQEL8U,,1F/3=_Y)O;7E:^D.RUGFP!H<])I6DPO356MYK/="8Q!9L6330[<
M9TR^29^,[Q;RUAF["VLDX4R=X*R!V1 _!-.,OY5M4LN(806FN?<C\SH37BV>
M3?>FO-0\#+.D5&&NLI^L?8]<2+YAKUP,'P4;.+![6&:/4P^PI0IO5Q.]VT*$
M*Y&7Y^3Q94?/<,#5LU;.!N8.<IYC3<TYFU[ZHAHF+-D9[NE_\BG^XLT8'A*L
M??]*9JM4U7.S6+!GS;5\7OH3(8HBHY;N>EOL@@)GA["3[537>,L$(0Y[(S)O
M>/N9#3'Y>&67&!JG@\%?5O>)1V\ZG;.7-\L-%S6&IZ:UX:+O9>92YH',Q2_9
MV/IN#A;YQ@>6=RK7$9E+;00^_[+U;B2'_.SDE>],V<16MYCK*=[P_NZ-J=L]
MS;2P\(;CO-UA]IMAA  @+],.*-@Q;.DGK>OW, ^V69"=I;G266U)ILNV!D!B
M ZSTOF$XCFY:ICXVRX[YY[V9;!O8N F\C/QCO#A>^Y,;\I9$9YQG<Y85C#[/
MF2'P(:R*:,T"][G$7I,AW@A>_!X&4;1RE5]>-,9M#3SPCT'P_6^XD?_!#S)F
M]YWCAAX]LY/QJZ1?ES*:?BHN]]L'RUIU03N*'*JA@JC8H\V6H>^E/?640(/#
MT'1C; Y(T]<U7<C=FI[W#T3-NV@@?''OD%Z/D4HE .!XS $ B2&!1 82>)5,
M&M= PG!:0XE-D;*R8)?XJ'0HY3&%34%V^?'S(8V#"*=]P5-QO!FG]\A+'<H3
MWR%GB(,T_FO;D%7T@.>_PR2L-.<5NN&-1RW8&-.:98FAW-VW.#JPGCW9E"Y9
M2840V;M^LK=%9.^.D(Z)[$UD;R)[[T_V-L&B[._!++OT8]?G:1:1)+I&KL;M
M@^O_'@13[.Y1(^?[N++GVQ<WWR/#WHG*Z=N->[<*ZGEA:IBUEBB.S%L>?')]
MH+?1[5#45(ODF<XH3JW]6;Z(!>\DY'N\#Q"O>;Z\B]@_E[Q)GN#!I94UO-6%
M.]7^Q(H"XK1QV=5[Z[\1Q4+ !_9$FC_+[?,QYYHR2M\EHZ^M?L%+?6M)S7[9
MZ:AHO=OKI;)E>0<L,SB?,U$W:2'#!MN6=MB5I=G<X^?%.R6S<Q8BEJS94$"M
M9":2KI%KA7J2P\KPS*+B@Z2 9AQ N+:W2 00CT>'[GWH+AZT?YS*JH:\4!:+
M3[7211!DDW#]SEZ4Z.'\J4!!10W9=+&2JE9<H_-=,1?+$&L'R5Z= 1X6B.6A
M (X (18-0#*))XM7I#$#W@@4 (2)%C"^OQ25MA R4MT[U6X8TV;RZ4D%$Q5,
MLG):%,SBGR 4W5>_LT1T)ZO/IH%1S.O[2'CG+>%$W(ES<@,_W88R)K-8Z81_
M);-HG-J<%*+B,:D%FV"'R?1>68_':"W*M27Y*AWVFY<\A(&AFP.G[PRWSSR_
MZ!CL$')>O=;?O?CATL<R'0 5++MG:3[X1CYE$@%>"P"+@JIO]XK5M7H:"/[I
M6\X>/EN*6M>SJ\!/-PPQN71(MS#DPSTB-#NB(T*9C0S8A\5A,BMI)^^+S@YM
M-\7E]B:OF2,WS[7:C]C#?2H/[[!0G/7$A$NTC)#&+$ZLY@PZ=+&2KM+9_LI/
MG9;>G7=$1]A!7"SV.H3/D4<;Y7TIL <]]I,WQ7)]:?6)TM&\6BSLM6#NA<)'
MQ+H_,UYU"EW$4#8'%&6+O1!<-6SL/&&Y#M-NKN]LWH@LYX07J@JO61VB9*PT
M3XM6*9]E;+V[T^ R>U\F:9,22[RQ;8!D;.YWP'51JK$XTZH7NE(>"9[$G2=>
M15F])JZ$N:[AQ?NR7Q-L]<[=F]R-Y<?BS-GZ^\E!+ED$F+>F7[E15O9)'M 2
MUA0,-.*S+<6N^"-Y2LP7MEE0K'"*7@ OV#N4,864H"U/7;GK<X5##Z?"DX*-
MU9+EKGW1+CVK6HH:$N$[!17!3\Y^OSPQ+#M1AX*\O'Q#>],-0_8H^S!GE58?
M@]C[Y<[0U)SR61"DX7CY*.OZ35[N8RP@\1"+6JU#[4;LWC\ENHETWVJJU*94
M:4=2=I0JI53IKJG2$L0N?8M2JCGWW+8L?;!3?[>_BSXCY((7AGRX+OC]\;C@
M4K3)T7[M1'[#$K0+4= X9!@7%O65D^(3LE>1C$$C:=:;>:)W?5)9MS2[\\1;
M[,C ,;?W\8MIM0Y7FWF_X#+^DG<;PP)/6+%;MJ62'[)?+ 0?A8E2&=SCYG?Z
M44@C%;^5D"K%A:/<E<5!7MDY#)\&?<\I8X^BG.X=$W?M%8MO///\6-HY]'ZX
MO!]U%@%*ZDP]H2<)3F/ZNIB-ROFS\" \U9:K&NQG?1IDJBP.W0EW0KD%D!3K
M*F:7YT^K]8_C_%7A%:^DG94[PQO(S@_9UQ*7GC\QS-V]F"",<XFZ8J($\FH;
M@F30A1+IQ0K=O":6=@E+P!O'R63#'.NIR%/CZ_.^.N?9=/(LQ3P*,@?4C59&
MN>/0%"C-W:3N?PW9R6S)^_YM$G/TR'.E]&74(JUOSWW[A.D@)5I$)^)-XBP4
ML)<K)\=;A^ 796 C7UHF6I<(Q8NJ67K?'.R11OD8A&'P$]ZAE$EQR&W8:_4G
MN=>MI <IT,=CQ&4B3V9<95/)$7R3F9&/4&/!-4S=9S4U5Z@$I]K*50N&1IY-
MDW$%!*_FF?8*O $A1M_?;+K_VS10#E=G8B?(Q>"?J[>9415D_RE)3;C+GB-7
MQ93WX!*-0V3C"4&W.S8S /D/J>TOK?EYX-^?\$-*\P N^29*$A&&_K;'#?0U
M<Q<VZ,+JI*V'<84G<$U>0VX:NC^QY-RI]B>^++$=>IM6!ZNO\IL ODTD6^SN
M*6&E),LJZ]!-W.A!FV&1GIXL881?X \#?@(,?<'ONG"?9*/$]#:\('#PY,YE
MXTQ,]#S)K!!_^TF;,5<4N_,$^>N1,5D#5Y!(9,VCO(/0XR/'+^>LJZP]D"A-
MF'PEU:W\%T!P)UA#B7\+TS PX/L04Y)N&*>GR_ !<=VB8G'"Y.5R/DUR;ESQ
M0$5#T0%/E-N=EK8LPJL>FU:<,Y$42^1*;(;HE6Z0S+1[[ 3V8!>PJ=@G-A%3
M7(N0W;OA-+ERC!W71+U*"7-R,5=;Y4C13KB%0B9Q;7:$Y\_+$.E3F'3N\<QT
M)+K7!BLLK[1C;9B,$9M>E>C7+"L[V>-IW5R7'G^E^;',V>8&5)1==.=F\Z1[
M;E)R,VVFXXHTO*C:#2-GTT()3.$FXS?R \0&J-(KSO _"#T0+/CFA@65[GMN
M]"L M[[]N'F^K/20$06%%WIL&K1B/10=>5%JN]@#>^FG94WS+3SAUDL_13*$
M[22<!'#+PI5"X5R2TCU)!D'PT&VL&286!H\?HCPA7TK]:NO*XTPX=_1@K4/9
MXHYD+2E;3-EB.EB[?Q;8,D>.\5(9IY+HXK?,O[J>?1,&) 47#SD9[!U/'%'*
M,T41*SWI*D!$9&33_*/T/;EG-\&L&T_D\330Y>=O-V"*I2V/Y*J(*,(G>8%(
M?/<3/"@X1V%T*EL@'9EK).>*MV(/IDOD2V-,[0<[B6*V "]ERN9\XA-W,W>F
M4$SHI#BADV1"=RM/O>^L'B[4#X?PZ'M@O3%L+I'$=::_IC--XGLM.]84CS#,
MGHJ,!R[>;BK@+R.%'&25($_B3N)>K[C+,T-\-PWN8%0R4NSY!6T@Z2?I/PSI
MG\KT"EMM%REH?"3H).B'(>B"WAAOD/,D_; M_F/BBU2#5.,@5"/-I::N+3_&
M_09S=M%;D8P&$RE^TK#T<S3C?7DWJ,HV-7*D>"L7_/%\- 7?G9@&%\5"5&)D
MGAIEM6BDXN!5WO&Z,)-6"_,D(3@1G,A:7&)P8_V4QI$$>7SMABUB7BB&G\06
MS*;/YV=81@ZK.D]+SC_#]SFNPD>8PY:EVG@>&_1X'MP'RTCL(\@2CK./'[&!
M]@)0^O&)S6$TV@(^$]PF?DH RU#/N;<1,IZM+%8MN&/W@GZ!TH@E$@2/!+OS
MX/D*7GEH?;AI%W11/@BWMA\BF9\>*>=$B2NL82WGP>X))K\DB<B<?;#$^ME8
M\(@3-'(;9>'  P\'G#W!M:<\TY>GIO4SZF#TL(QY9],-5!H^YNS99,-TT:W\
MEO=CS4[:BPID(9OS[M_9AHT$PRGO@UW2@3VIQH>']$6//-Z$-<I-T6Y\D-<5
M6E=41?(!9P2-*(4,#6L%S/GIHI\/V(T6)@]Y/*+)8!#".O'*_UFE-3=D*VQ7
M+(OA^9R&%,-=Q>["3:E@GJ.*BCOR^@XY2IQ<Y_PMM3>"PLBP[E7XA$1(P5*Z
MYR,I-/858B2:&LL!)KRF^\*XD8&%$6#.94P85ZO-%'.CT&:,1<62#)-)N'3G
M_*R3.*^#A 5^X3O1L)Z3I>)E^'(=A4/#X-M\L3-8^@AP2RIZ05V7D:AA4B23
M1BQ=$:[^LHK:#S?TA#V<OZ XCT3!]]?8XJH;XD:K2=5::*X)LG S J!%.]'R
MJ+QPGZ(,?M(OH9V %5P>0MA]$:I7L/DV#YWIKU!#%JZ7*V"88VS.L6B3# I-
M.0,SRAC( C,+^G:J_3TI^@3/\@.=:7$\@'D_9)W-'+Q'6%EFNH*ER%U=/50@
M31/\C:1Q9[4\_?S6+UB#@H8>%LS?I.,Z_CB]?7%[ZI*[0GC3&MZ8!X<WWW(V
MB7104GHV*LM]Z#ZN8E" )XDBONVB\R/,FN>OT),FN? QN.KF2.#(*D_H4AS+
ML*"8H"8G3M-I800)Q5P8#1C2^\GC#S-QVCQBB:W5*]9FS55,C3-G3OHDN><H
M&;\T+;GA*KY=:N<FGE<VPE4[>".>$081!FVAL=;!8=!7Z?%)GZ@<;5)&#:H/
M/W# 50=_@3J5/W25]\[<^Y#);EW/(4AZSB?Q/D5P@!>UP ,TO"8BWDOXA6AK
MY0;$_3ED7T6B34!R\>>,ESR>8%$,%UO9IV"5#2\WIF1^TF_A,#"H(@:;BY'T
M^$=XD"@I=>%+_]GSL5H'=G+,RO]).ZI@'V+1"9_-1:PJ&<"4NURMX)02QS8R
M)2@_NI%\_OKC&\5G;N$(1Y^.<'3D* $=X: C'!45_%/G*,?+8WFNA8;RUNG>
M;<+V;@&VZPD(/*ZP]65?;5F^=$@A36<^)R_R0NKTSWKN<-'J9?>+T:N<=4Z0
M:<O?:EFR,;79CS-/?<8/<LC<1GJ*8Q,CB6<YT$)_]$3!<LQD8S;8Y0:]YV.&
M*PAD30D1E^4U_?!NPK\H?"_*?1&3>OPMGK"6[PFG*"W8E_P6W[B#]<2:%3PI
M'&!F>_V2JQ0J#4_&S6$\XL<XGO7?\%MZ478W^/L$C,08 RYG:\\G9X.'ES.J
M>O$"PE5,/YNXF%CV&98/R*+<Q>OV-.;QA\JY7AAP"NX9?SOWV"&+@F58F"T8
M[M3#BH _7&^>)!+S8^BE,7+!LDF3X[G%33*B9<-;O1X^;ZYZB.0WBTP9?T0Q
M5'GUM84YMM1D<@:(UXR1<0&^!/WWMSGVPU?,)B=U]]S5\$$Q \F3Y0D305*G
ML/C$)$[*7_(WYX*3 3L%K_0HHIA)ZCLICY'*=(EVY*7\Z);MF9-O^8QR(OX8
M@LV5.=T$JV^P'&7@8^#H[1ID)19NL49K$N&6U#EO/D]::<C0;[Z43U*,*;W-
ML:T;+W+*4_-\R\\5F?S)L.&)^YWYLJ:J./G86PWS)3.=KW/)RYE%E.PO#'F[
MP+=8?*5#W\;;0PM]G^=:'L&W&6 X[#WOM+\EE):L(!JB#\@7+ZN#F/?@L1]<
M=:9I(9[L"CU9=I#['M,$P-;I[H7LV"-O4^M]1X!*>@*)"GS:F:3=O'S%E717
M@*0Q3O02F7ULUP/O@)[>"1N(FT<:QKKAB><O1!@2V>2KC_H?1D@6A'U7-,S%
MHE%IA)TC,-JHP62R#+'"K6 U<-*8F+]"E:*4EY1.8Z_L7+7D&; ?+OPT=54H
M>4<8MAV%X. P[ :S3R<"2=)"C<)ES'V285-)1CS/W1%,'519K!2W3-V:5#VQ
M7]@BR:<E5CL:5%'I0+BKDP47-K2OVXK_F^IBZRJLIDWW.6F=5TA%)H3P"-<)
MQ<+HJUXSW'9T9X^:X=]8Q-QP\G#F3W,;^X4H-TAEQ M#/MQ*/_\XIDH_0N %
M:2IGR\H2FU0"J+(93F9TM0W(>LG3K%[X&0_OGK.)..MC&3T\[[,2&'F018Z?
M6%QH:EZVG,=9A?.EMH]M\C0&Q-/H"%^ >!K$TZ!2F_N7VK1UPS;W*+5Y@_V2
MN%/X5<32<MD<ZNU3'/+A&N7?C\<HYP(OPR!)^/@P[7"SC7/1XF@ZCW#)OFLG
MLE='3_1FDU./F3TPFD4F&%&FIW&ZB\P3>GCPF+=XDWT;/1^VZJ5H4/$F$+DP
M/#.,I.P)#XS%P>0[7,.3'2SRJ<O<9V]7SMAS$GJ6(RAFJ&?Y/#*/E+''Q3QX
M8JQ ^DA()<E1PGPO.7&SY&?9U=*3?VNI;7Y^T,T"[R43L'X&T$_;-O 1Q$&,
M;2=$ED+FTL7G4\[SR$XNWB'5/6E])&.))>-?'P,?(Q]_TJX&9Q,$\#MX2OG)
MSW5U><,3N[]<F U6<+-2,@<7$9$K>?OJB@-2&_AYB'?ZJ5-6F:1KNG85^"<E
MDYR7QGP;G94T5Z%;X1U6>\BZC^):EZQSRM 1U SA5O]@V)GE:ZF*%7WQU627
M-Y.IKF*.:[6J5/H,*5- IJ2J:W513W#4P9KG_=WML LWQ-,F$<PIWZ'(]"H,
M^7!-K_GQF%Y?, 2WP!XX*.$=,KH.5V/V3 DGM;\ZRFQI. 7\T8V\28?$?7N[
M9U.]M]K<C#N<2A'+3X&$TYT+31;A ;RT89T(_*^4*,(/9)?H0@-YV7W][JG8
M1<\%&7+O\Y;2RB_R;1L7ZXVJ>UA9*XK!2N-]S)<I;_6)N35R4@FWVL6MJMDL
MC5?;F2]!^@FYJD"NJ9C,%[%+='!<Z^-9@D Y1%E#(^[HX2?@.B /,.GQ"KX4
M'PA2 1=!C*1O=RY_52@!D'KD&[\N8B6B(6:"<_ XT5*XB'B4/A)5BW+5WYX)
M),!OMHJN;!X0IT9CLG:='HW.+X:<EK%HK%M< U\6O,1RC_S6(@\LJ%=>*'MN
M:C]Y0]H'6 IP2!EV"XV]DV0X*C#4&Q?J1'2E>&V0\22LA9L=B #?&5?3[JNS
MKTT#)C+O,GZ1>-^?0TFH+4^#.*/!4%]WO\^X5K'IWZ4^G0EUXJYV5.)@6ZF#
M;:&#/<8KX85NGQ8L @<>5CY9^,M,EL]^>5'Z57[M:Q%L^8,_ZV\\/L)ODMP8
MW':<=!CQE$V\1W<>\1>"'P8/\"M^!QI_,@WXP4#\PF\?K/ZH9P_MGC,8)=&-
M9%(^])Z?)ANFR38LRS1UHXS"M>LTV>DTV<I-D],?]DS=Z5G&^C1Q,=MJIFSX
M3W_T^IE:B=@H-5-&S[&&O;YIEHH4K[\B %8<2'WB.TX21?3S5JX\[P,/@3W
M[]C$748LUR%=0BB&\W;!SL,DSKRB?6W9L?XV>39#XMETA.]!/!OBV>Q>#^4E
M1%Z#GWWF[640K+MX0[6DH-49;WJVRK:F/5E&?=TR!H:MV[8S,/;(;GUA;L3J
MI!-1G9M:ZMS4H'"/6^:[ZLAXM9'SXI*_90AM4Q"M/(Q6<WT>94G_95&J.9_F
M-%8@CZT]<??D,<!2ES_8@P=6J/SF-J?9#FW>SF)9I^'Q$=D^_.C"U(V+3!SM
M$>9G&<H*'WRRM+GGRD*9"5,#/L=?%SA"XKL)I:Y8!X>74><_=L4]3[4;#UO
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MZ&Z.UF!L*<47KU%5<YQQ7:6P/CE4*_.MU$(06*D#5L.QI0;GO1&4&K16=I-
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M1X[D@6F?@D?XZ9,&RA5HCZ[GQ_!OI$W<Z$%S_:GX"P.U_0&ZZ,=I?2;-\[6
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MSD/4,^)E)@#B!?&"#@)JWG%H'CH(J';H(!394VJG@U!+<.*(@LOAHR;!'.X
MA.&\<AN7%@!$-G3:#$3^N+M@:;3^DS/W#'LL"E!$:3*'FHJ:VNX@=*12-58+
MJT<?@@WJ=7OLI<]U/77CE$WL($3U.F&+%>(DX23A).$DX23A).$D'?,DE>M!
M[^H=\_63:8]A[?3V9+ \8<9S'.5^7;FL02S,)T;];G/UFEV]UC9"&R@X%!P*
M#@6'@CL&P97KKH3GC/H_5!KZ6^O<*+W:G)L5Y4.::8LKAI\MV'#6E*,2K9&%
M+BO#?C];<)-IV;D]9O^Y7*K8QIX5]Z\SUK'BB^E]7;:H"+*'2NQ(,>AHS96^
M$W;A+1@(!!M.JS"I#ON#:C%Y8Y;9(F:@YU6S1C@*I/^"#:=5<-2&@YR:U&7"
MD>>;+5.X2H2FWEB3=D1F*X?3*F3JPX&\!S+U)IS7'B)2< @(-IQ6(;(['"C5
M(K)<UU7N#'J--7! 0+9R.*T"9&^X+"E>#2"K<UY5Z0AL956Q\);'N>^>'-<_
M\:D[)0^&_1749N9X9D-A[AHIKDGZJI>:%&DXT++4Q">>S?M%..,WCA^5[J+C
M<T_4F+2L=)LBJV9]! 1'%>"0AP.](7#LY6%/S!<Z/OF'NLZ;=R<(" 1$68!0
MAH-N0X HS<-%<" X*@&'.ASTJ@!'$Q%2N=OI]AM;^"$Z#@\=VG"0D^-2"SI*
MWFC7$!>(BS)QD9-G4@LNT*6J+Q*8<V[_"!)EN881EXXH:.J#5;@P3KF:4:[L
MJV_BNJ+LLQAC+MKGM?R'J(J!]2&\RE(PU]TO2]45),C9EP>"-'[="T>U>2T(
M?@3_&O!W ?PYZ4OE@+_<A8?>%:7E,R(?D=]ZY/< ^3EI4N4@O[I\C(&,)( D
M@"10#@GT@01R4K,*D$ 347E510\ P8_@+PG\ P!_3O)3.> OU_?O*0A\!#X"
MOQ3@JQ( /R>QJQS@']:N2J/PKW$SID;H-WOW0I@5GE1J)@P5"",G\2VH"2W(
MQH \Z*C-G6L4I8(^HJR]*-, 93D9=/N@K.R#BKJ""$.$M19A;*L[)PMO'X15
M%^F6M<8.!2/6$&ME8"TGLV\EUAI)\^YU!@-$&:*LM2CK#F4Y)WEK'Y25ZS,J
MG4%?I(PM1!@B;"N$]0!A.1E2^R#L(*M5M*0S6SV%FIOIT79M&@^F9?J@4[5V
MG!"L-HY@PZFD5(]0XL)24*A?J%^'.AS4K^9'>,C#0?UJ?H2'/!S4K^9'>,C#
M0?VJ;<F^ZW)<L*:05M/K]!J5KDG\-?V86)H$YU-0(>-\XGSB?(HK9)Q/G$^<
MSS9N_0E2>BI::TP-?^[RI09Q)L1R[,>@H+WE&#;N$8HRG#:U\U#[0UG.:[ 3
M:-Q[QW6=9]-^]%ASC^"]SX[++G<[N7'L4?IK@IP?T3I:K[%$)0S]M7(XK8+M
M &";UX:G5MBVOZX_0K65PVD35#4)H)I3F:%>J![606Z$;2N'TRK8R@#;G+H*
M)<*VB4,RZ!BW ">"#:=5L%4 MCG5#>J%+3K&"%6$ZB:HJ@#5G!()]4(5'6.Q
MHODMC]2?CT8@?=\C,^.5U=TBACTFQFCDSD%I,#\(]\/:(&2<3YQ/G$]QA8SS
MB?.)\RFND'$^15I1U)4?)#6VZ+AWC3'%_!]1AM.J( RK.91318^KU+D]YN&1
MS\%:UKMW^-MW\]G,,JDK2K*/VM$UW-,0'!2"#:=5&&55BW*J[U6(T9*[3*N-
M%3)">+9R.*V"9W\H*SEE^RJ$9X5U:CNRU%A3-@1K*X?3*K . *PY%0!W!6LC
MA6X[@P$:5,%!(=APVH1170*,YIQ)J1"C)9?)E;H(3['Q(-AP6@?/G+,G%<*S
M2G]7::YF/&;K-!LWYVJ%.3FU[T&514PO#Z[%5\R2"JOFGC90!UIO50?DB)$$
M"5K+G:[:F)> &[#M5_ZT59;!*J]J +R?[I?==TP;Z*CXJ/AE*;X"BK^J >Y^
MBG]8N>&H^X>G^QKH?LX1BDVZWT34LM=O;%\!-?_P-%\'S<_)6RE!\TO>^^XJ
MJ/:H]F6I?1?4/B<5I 2U1V?G\%)2&RR/?>/8)Z-LB6S,4A5E.%CIOOD1'O)P
M4+^:'^$A#P?UJ_D1'O)P4+^:'^$A#P?UJ_D1'O)P4+]J6\X7;P2_W^J]OLR8
MZT1I^0ZQJ<\JSH\R=>@;6<\7EW<E^KI'7_MZ\+W' *N*6PZ&LIIS1F99QRNG
MM-<UJ)[WA8ZH^8V.!4G;Z7<&>K^IH&91O:_-\"(0VP;$K@1 S#G_4C40VU\1
M$\&'X-L7?#* +^=@2]7@.ZRM/00B G%?("H Q)Q$\;V V% Y]ZZ$0$0@MA6(
M*@ Q)VN]:B"B.XK@0_!I +Z<S/FJP8?NJ&C1:L%V!,0?82$TBS'F/2E)O//G
M71UH*Z?%R_4RRU"08+'<[W25QM*_RT11DUZ$&#!"Z(L _2Y /^>\T][0+[G^
M2T=31-HD0M@C[%L-^Q[ /N>PU]ZP/] ZBD@!2 &'1@%]H("<@V_K*:"1ZHQR
MIR<W5IX1H8_0/T#H:SFY8WM#O^RZ-G(7G7Z$/<*^'-CW)(!]3J;:WK _T&*2
MC5) 37L5VAZ9]6DM/./)\,_!&P^.-:[F&#SUR8-A&?:HF09-Q058/7_"S<G8
MF;.NN()NRVXYPJJ83P'F6Z0),LIZ"VIT[GG4_].PYO1V<FW:7XU'^LFQJ6^X
MKU<^G8JRY]'310E[K-3UIAP<!%_#X/NI$/I40)]:#_I*78$0#\0#7WOS;B U
M5F!S+PSN,*6Y/]E(PN7;^9\+6G<F;Z$F KE').[1@'NT>KBGLF50C(?T'O(0
M\A#RD$ \5(B&=* AO00::F+_I=M1FJLTBTL0A-_^\.L"_+KUP*_L/9"^@MA#
M[(F)O6(N> _ UZL'?'6XX(-VXA%=\&*;+-^EOL *0,>_D[I%XF6D&#?S*8Q\
MM'A[K< B9HA?)_:#L%R1[\S>2C#AX<M0!>"=P +2EY$U'\<&&K_$R**&RW3C
MZ2QQ-3]S-3\QZ;_.BDP5">:*\,DZ2\YXG*M&%/#L9F\9'U.@)1_)"6%6;_;N
MUR<W&D+(;0$8F"0R3\4)CWT2 D:2?C@+)<WV[H(-N^\E_D]V)R_Z8 9,=/+@
M4N/KB3&! ;\UK&?CU4N-6TX-7(5Q__)N*;!-<CXKJ/QQ ;**56=I1$7:,]OZ
MYLM)*CZ[F>EDD/9=QWZL O?O30=, _WR0J[]\6F:!*+[[O#HAR'W\K=6;^\O
M[\C]+;G__9)\N+VYN[V^NCB_O[P@'Z]NSF\^7)U?D[M[>./3Y<W]77H^LI)X
MFY)4/FD6V50.1_]C:O@_)L=?@4BROTKL;S.)$97\ZWOPTN6SF)BN;N[NO_S!
MY43.;^("_')U]S_DT_G-^6]<C"22'__W3\SI.<W8NSRS5Y;0<LP/\T^8V2,C
M:EFAT_'O-](;_IIY%='K'&EF[[;6/L2H.HVX!"TG[%+21&=->"P=HCC$@I%H
MZND@KK19KV%UK@7@_FR9%;)PM[>TG3']BM(VM'S]W5NYC0RG;ONXP0"-N>_D
M>(L)%R1A8S<H3$93Y(H$L '=GPSW*_6)"TN,!$K)%C"-""\MV:SK>2R*O.N(
MXKJVZAIIJ<8L3L*1YXYZY#,G76^!F2_NFF>U9R&[X,H]:;T"9'Z@,,L! \N*
MOA+L*1GX;!PAF_O<X:7UB,UG!4/^:)@N^<9B%JQTZ\2T#7MD&A8Q;?!%8<EG
M^YNKMZ8?,ZFQ"_5,:FNZG&WPZ'_-/=^<O"8*V@Z44UG/K6F[89FY\W4KD/.Y
MQ^1[04<\?$-4N4-8^*=#_">:+W;V??;A!V<*-WQEL2//]'B%75B.G\#"T?QF
M^.8W2@P6=_*(88_C373(3S/7A.>%H9%GQ_T*,"<C8V;Z[#8L'-4A8SIS/-.'
MO]AOH[J]_#J)TK[>S_ -CSP#8?#_&JYKL!&.++BU.3'IF+UM+.[^FC'"9<]0
MBV;^/Z;_1%SZ:+ACXCO%YJY#'N%#F\T_P--FA91IJ"H)O*Y6'M/FAF ,?V1G
MWR./U*:N88%JC"S'@VNYQ&3EI!D+L5$&-Q[!1+^R7QI39V[[7 G8+>ED0D=<
M$\>F-V(?L2_!9<WIU "M@<&@!JS4 ";!E1"*0+B<U06HF-&EY,;Q*9'ET2E)
M738%V?BWI:UF(RHL'AG/W><#_8YZ_ ZU?7['Y0N8'F UIKG3Y9J$$R%\V7BD
MC,<85ESJ3- %*4'D5]R>$&=FVFQ?"]@[<BV6 @^,3'Q"8'Z>G\S14\(7 :JG
M; *9??'(TL]PJ07\S^DH(++1:W 5&DXW-R'L1C "1GD/SC=:E)R0<T3B'*U]
MG'/%HLP47&@7E#01 D%>V4.L618A8P>^;CM^L&@!=Q?<T+3L&4D\,*X)',:%
M<QE=[LFQQMYBB0(DQ/S4F/L+EN(7A_FHWA.96,XS>$]@3MA-HTL"(1G<4P6F
M>0!/]\FP'RESC9.C\9" \M"Z*=J6)2 MEWWJ.4+WL#'NNQ<=K0ZH5@$HEXY-
M7PB""JQ0Z?RT\K+52I,Y*P%+@>OA)]C&HM^H=4KNGZ@7T),7.C/<EV$<PT,D
M[ _Z]QQ6[Q9;9G?(@V%_C<51?-<8P^]YY5/>9CL(K3C,CXV_7=+R^ "FYWXY
M"7S+L7?F<3%W,L+FDO2>'-</EKD)T;/Y3$?7M$#X+,Y&GH'OHR_#[#^SM?,3
M/!ES6KG+.C7^ FMRY;D&M4S^NS].[T[Y3;Q3$OK.Z8&&OG3@-8]BB@:+>@=6
M[XM;^5ROPC.^'M-#ETYA;8YZD*,'"Z\!!.4SQ+Z8T_ETL8;@B(S).O CP'N8
M.!;S ]Z6:LX3V4]!,N#+@VOQ\S.2RL[02%UUH&LY98<N3(]%UV#(MY,+ZANF
M1<=7=I"2!UIS_N#,_8]1G.=J&;R#M3'HB>$[[FM>RJ D2[+O1,F#;PCU1L:,
M3:8[IS'CE9-P%4RJDDZ)RAJ5P(<)TI,6[DL!=R;,V@279*O-T8+95FSX&>N<
MW:+=MIX \U$:J4M>R4V[&VZ:S*<-)R@L]K%/3\*=4BVSJ73-%&"(6PY!SD:)
M7C'\L%"C(&IVV.X&$WCH:!%:.1D&43/S-5,_=,U$'L^Y*7H_.Z#%M,D?=Q>P
M1G7F'BQ\B[9K/G;D1"I58U&\>O2!GV-;NXPN?:[K*8^XT<L3HDBCL#4Y&YXD
M[NT<V0R52U7ASG+WAYT)*9$@-$@E!RG::;^^7<=5,?E&*BC6>&2[R</8-9<X
M8#6=<SHZL*D_M\?L/Y?+>=^^P%'T0;!#Q-XOL\J!U-'4;E/'JINM:8!HJ (-
M T!#SBY#831LJ#50*1K4CJ(WUH)8;%-<Y?I!''-]MV+?MA%K+887*=APUI1@
M$:[L>U\:RGI.MP>N94S)+D+UNG'\#XL,^W-/;)=AT)&5QCP&85>=@L%$L.&T
M"K4RH#:G6</^J&W2M9%[G>XQP!9#$2M3E]))?QB":.VB*YG;):N:.I"U[K"@
M_\$UX<M2$01S,)2.UL.0!**C:G2LL/,%T-&D(==:#HVJ#'2Y'=A:9-=OTUG[
M(C1GP@9X^XSYX!K@]17@6B7+M5QWQ?5$9/!$L \FT@#20$DTH (-J#O10*,N
ME]S8IM A=,+<Y*JUKQ/FO>,;E@AN%M;A;T$/C+X.K*=E62](8!3,Y5'4CBXW
MML3$OA>(M_WQU@6\Z5O@K4G?0I$[JJH<'-ZPOX.X_1T4[._0DCX#V-^A&;F7
M+F_L[X#]'19F[+"KG[>K(-?H@ IR79M_STWP4%_KJ<G5YC(^.<4 IPXX\X[K
M$=>Q+%8H&MQV.C*\3(GS15DE:REO"M?]!K=S@@),#X9G\I\9K%:U.>,5EN(E
M %F)*$J_>D%=6=/VX?_\E\MK+JHP&3ZK6<X*?\$WX 5<V9M/)G!=7GH6+D"I
MSTL0V92.2RX3*.;TG5OL%/!CLMKKD\$$,QJ!$(*"XD'U<%[TVP7QV7.XX,1U
MIB!.6(:Q.BHP0\[</[%,,/T>^Y[O&K87+,&\1#%Y7CG+F<+B@U5!,O_AI9'8
M[YG<P5T>DYGK/+K&M .*Y)LO!FB/;XYIAXSG+KMR4.C+]$$-;%;]<4Q9*B$(
M*ZB\!5ZQY]BA"7"9.H *F!.N*<]/U&:_?#9A+ \4AD'9W29F8#)@',N"W%SS
M3LFGI5X_4,ND3#>Y\N3I<?3;1?VXJ Z<Y\Q=IH'AC5-J-P$/GS\^C.6OH'PE
MOX++3KFY-"KP'I82GYBNY\,<61,F-9!&[Y3\[CS#R-P."96?39*?&>>R3.<#
M?63?=**992/RF*P"N2WQQ6>9#<V911K )O5;T'$@O-MDOJQ7']V*/RF#45!/
MSW5?F8+P%I0F/+K!I.2P@IQT/ ^T)"KPZ1JF1PFSW.QMP^+B@1N?DCL*[UN>
M$U8Y'X7%T+FZ/2TKBY*YO9QY+H.I\<H>*GE[%E[Q647B>?YDAE78^?@=5O%^
M3H.2[8\.+Z[OL+O8311T0P>G"0<GN[IKKX,C0A>8W<QFF"BD=E.)0OR-V@H7
MCLW)A'*JY^X$]U"8.!?&++])A\%K4L)G0?>'2NH7%JL"V):*?RE\K>LN%HRL
MG\FNRP/<QN!X!6L*[G?*.S5:VX-:&GC2_YT[S(69N29S>7Z:V\:8F3PZ_IDY
M#-Q]B%H., S$.]&$W7'@O5ASG'4F=K7,MFU.MU9]"O5[VS Q1?N]'82>*T>@
MYU?V;,YJ0 =./CB:-OD[H?J+GDQL80*J'RP]Y< G9;; >6"K7<[$# ?,"^4(
MB /@M4.HR>\PAK7 R+=>R4^&%][B9][(R5Y^PCM-P1VYWQY^!_'3/ORH1X.?
M-9J_! I?LQJL_0QSKY:H"1O7C W?8(8F]HG)+UZ2[L<V!5(M..L*"2E-E.6>
M^S -_\!WEZZM3T=/MOGW/(J"\%K=\!T^@W./+R<RLQ T>3+MS#=S9BQJF ;R
M8.[US/$\$SX-*KOSQ?^R6#CO1$?=F>&"KL0JA/,P"*\1#RKE>3QXPWSRQ:*'
MU_W?J;4>[^66:J^7#&IF@EW)/FT=%G6<>W/>K63I^+#&)KPQ7[87'Q_A5JWX
M5CS=H@<=?'L!II!NR)0:K' Y?^+& I^U:OEJ ;%6!-9H'K2V6DB*?>.]98R^
MGMR-GAP++CYUQM3JP,\\\E\%TFE4=HHPFTRSJ A_O71YSWVV0O^3#:YHELTY
M:,+8M.;,NX[5ED_DW?PG?,"U63=2/.M&VGC"4.YI'5@ 9O)NF,+F=4"M4[D2
M1XND4RG=W;#.2/M'@/C4<1G/+3H"1&H%# 9*X3-.FWM!R#10S*16)MI![BC&
M MDUF.R3F^RC8K)/2Y).,-D'DWTPV0>3?7 OK*K]HVP?J_;NA7U8MHG,-N$V
M^::]_Q3?$X^O!\-?)+;%!=DY*]+(2N^J>D[!U7@CJR^4[72#++C'>CN)KU)@
ML0V/_M%UIA\C.9POQ%!>5ZN$K(IVN6K/'E>**U8P1@96.=@_G+X.V)]G5]\@
M_/=U(NJTPGZOCHF&#]G.?@]B*7"A$^;Y(]MJ<5Q,H7>]YMX:7^#&:R"QTZ\+
MK62VO'#I7X]B<@A1A&B9$,U<=67DJXV(Y*&6RC"YY==SBQ@LHD&'#63L2I9W
M4PG=5VQ+5B-T@A5K5ZNW"G0]:O$^.+X3[B?^MV'/#?>5!+N)1=)D2E,$P2J!
M"S:<5A4F[PUEO9N->Q6.;>4$M)3$IGSA*R7VY]FBG:W9WSNNZSS#]];OU&_=
MH$CN-E:#3_R">V+ 2+#AM K5?4!UKTI4EYUJLV7QO(XN#1"_8@-&L.&T"K\#
MP&_.;M3>^"W'?&J=;J]W^/"K9%72KA5'M",<'CAG27BOU'#Y@J/6+LG8S:#>
MQ\3N%#B?@@H9YU,88U97,PRY>]JO*SO],U@Z5E['XN=L3!8%IIY/9L9KL6(
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M%3A 5T#T-'$L*H79;0>1W2;K0[DO-5?/HT7+Q5Y'4;L'EVF'4#\$J!=SS+J
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M&^L\! [G*_LJN'O,L8W?!Q[^$63"_G3I(Y,!+,R(,8-?@E\&'B(@*C+/2X(
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MR"W]<!8BG>6D!XGHWTO\GVR&>O3!S'BD)P\N-;Z>&!,8\%O#>C9>O=2XY=3
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M@=]NX%.;=?A"X"/P$?@""13C>P)-!F(?L7]0V$=O'X&/P!=.H A\468"@8_
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MT-B6XZLFN*0/M7;G<)?C['0DJ2< \:Q$2S.N#()7>/ >8/[S(>0Q(Y 1R%L
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MW2"I*N*>DS$E7'92)8'Z3X[ON.0;?3)'5KVU]5;5JM]3]E7P7J'$;#'&O)I
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M54EY"]S5 1C:- #WL^F#\22 C@=P7( ,HH)9<5]CQIT!CQ@N)8_4IJYA 5$
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M/<C[4&= I@738TBH9M9(A]'&]1GQ2-EU*C@PXN=/ Z/7!QPYE*I[2Y8Q,Q_
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MW1[RS'Q,OTLA_:XD0FTI&[MR['WEYZ'QO$/RZ;7(6/?>J3WO(>$8VU?/=]
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MVXO$R%QON9P#9B%7H2?'6;\D^JDR(>C8DW/[QF!DV-63<Z^!>X1D'/].//P
M[^9F^A$N[Y\(J)OIKT$PB6["6Q)^0S?O5SXY.LMN?F4W>45G1'^!XP03-49W
M+==@+["YVS,[JV.N*_(L.Z7KB=S<\I;1LX;K=J@3&7D-7<UQZOF1^I-SD=@J
M#IC#GC%2.-#9":0'PH&!X@-'G^ZYSW2 3?*BAOJ\JZ'3/*A!?P"=!+0SV-B?
MD,5$>_')?-)0^O46(K AH-4:HU##5V0;]T.)0B? =<6A=1F!&H8;@?4HT=0D
M*IF=J&1VP8OT985.)%#0\#TNK*P_R=K@32K[D'X\(&.L=7<-2\NNH8MY/W3:
M0)=2%$&ARUITJ1"L74,7ZWXH2?O?'UU*!E]WT*5%D=M!<?HMF'NQ/_?CET.+
MTH,CLB3+_8I$X]"GR(KI:PPF_TQ <D1)V1\=D_<U+ 8/>]7V_5"2[=S(5;<B
MY0;VZ5WU6A%VV*MV[H>2]-=&KKH5"35JYJJ55<C%V%<_^NMB&A*B^8A&)(JU
MT(N)L@K=^Z$D>3!'& B[CP"Z:PZYKP"X(PH\YSQU_1,R#=W[D23KK"&<:45R
MGBG.G)!]V+\?23*5&L*95D1P,SCSNHQ$.IXW,Y[ZC;_0,"\DJC^E]R2-QL']
M2)*,D\-NAL28?+.O[/QO3+01.&UD4=K89"NVFIEWQI;B\'XD2X;8YW[7R[G7
M=+\=,0]']R.)LWNO^UTODXY\ORI!;=\$M70T_6H1DG'PN(!5)W"/4Q*&!&GG
M:4D6D4?QC7S'OQ.>#U;.3GN&+_Y/#20U3?O>[">N2:R*_2E)[_PC<XXK?HSW
MF5-\8(?8"DW_N+U*L+2?Q=(+=U,56,\J(:H&H)W#7S"9SH\T[PETTUA[A@^U
M!R* --$"8 8T:2Z%\3=0!?&_2YH>)I+JRFF!O382ZBC[(-_'\]4D1PR5C<6J
M<\)RZ)2GKV4==*R;4\8Y(J<4GH*!O^&?Q,&24\)'[4)SS'_\??GS/V:A. )/
MW6"<VEA^?S>> ]]"[CSC*]!T:?R&<W/#^/$=!P/6.>?SY$H&B?ABZ3V2BX>0
M>']=>%,X\$_>_-E[B0KG-@L'M^'<?_\Y!5CFJ\PO,R]=D\"+27GOBEQ#8,IR
MZ\W32ZI_N](6=7$8+![;X&V_^,$GP.6OW[5/\:1$3F+?'5[]/.#>.+P_W]Q]
MN-7N;K2[WSYH[V\^W]Y\NKZZO/MPI7V\_GSY^?WUY2?M]@X^^/W#Y[O;XGV4
M(?%3 5(Y25T4W54,;*L4UQ(?,N40V1M<Y:=R:5L(3<TTM7__MR'(S7?:A__[
MQ_7=?VL"7O3/-RC_>B5C5&Z3M@TBJ=!I?]N\R&'YT#63H'<62QD)423TU#V5
MEMM0T8-"IV0%E/36-7Z4C*U1_]#<WV)G+V>-#ITN7[!>@!G)7FE+R&40FY_*
M<C905?TM?OB9I,Q]E_=C)_)6<;#&2LNB<![]JD_)(% &7V,OOH&%4,ON@A5W
M++T7JE9R2&E%UK'&[I)#5&9S%4PKF;U56]+5X_I4*1?*;/&[G1G!EE4/&UD!
M9VXYU"KPK!(L2ZZ%@5--Q'40W!RV),CLD@#:[8!K*)#9+<T?^S8.QG\EKMTX
M0&,R6LUC+Z62*NHHOV61*C*(6J"&,W(@? R#)S!;QX3"<7W9FD[-7#3BO<4+
MK6'SHVC%JMXR@$_N RQR^L1R%8[AU]0-7\>M8!GWYD#BO!9%Y)0G1M=T;YF;
M.M?@Z^YEB?V]KA=HM"/[_!(&8+?'+TDGK_?IT>5]_*(M.\X,]*'=URU)U;D&
M:H2_\,(7+:(+:UZL>=HSKY#5/%8BJQ'>6TS#HK_MP";Q"1<*<'.-RS@P\Z[#
MZP7]D J=+TSF7(8AMCC#OZZIQRT$!QJ"__6GVWOX]3VO_I=Y*#=F5O;LLI-2
M^WQ]B^X;=@^M^&FZ2.F;J[A-RP4LVI1_\4_F /N*+B]69HDM\ZJP9HN6?+M@
M#'6"RN6 ]D@6@/CS^0OUVS%_WC18A2P,J'F+B?;DO3"?'R.-"65=S+M'?:0/
M)'[&<MVI_XW0!V+"HXB]HL-9NY1[5?5Z-.P ]"5I8?OV.VV "V[;=DL?C QI
MZXUU]_1,0KC#] 6U9S^>U6./2,VUP-N_-VNT)ZI@D9D+V(E--GDMC3!'HYS6
MES)&BNN2&QBGO1N2 'M5#3?<@6F:?6=DVO#WHS?]W GL:_M+C'JE]A();W@=
M8D6HA/"%Q[!?0P'QA$T%6#^"7/^$.,.K,XT3LKP@U\T@>3#B=?M:R OWT^",
M/"23Z7/ -Z2=$S(KKL:S=-DWP%  B/"^H [#)A'FD.#/Q@!&M'<T;_+-CP+4
MW_@S;T$'3EYVDC\W&JVX*3PW]J)9/@B75:6?@]5\HBT(@P.8^9K/CR; 1'GC
M(H@%O(JOD0$,>JHF>'[BX0(,$$S4H7)&I9%#"3L)]N'">/[0]^952)OY1_)7
M2<!UHQ,8?U/!+?K J0>F8UG&P')E22RYC@\ 57+G?=^_24.V.</F8%K;];G,
M=VPEON.[R__WX5:[^:Q=?WY_\_N'JEO:EK%TV=&2=1T5G2SEO#2[-ZIRLI33
MM1PXE<29<9 ;]DJDMO&\Z%Z1G+?D<2EY.]M^E_=!N PP?5V+O>^4P6UTOQ1?
M-^]Z23A.SNVR/6K7EY@# Y'G<"D;""@D.Y]R,&34^6 G9=%W!/2?1]1F(WP
M5;"8,G2J!7GA1+N.0H_,?6!YF1N@E02Z]CSS000@AU\_@2%BQKL-*M30=(V1
M8TI<")>)' 5.BTFPA\J2KIP<D3NU)%FJSJE;R=.URCIU.7.7VIA@EG+9#&B
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M-)ICO.=2Q-@:<<D\/W\K_, #I,C^IO#.N7\* 'U>/9'0'[./DU](OOW'4H"
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M&,Y$!RFW&!-\T@\U,IW"[<#^>*#8OZ!KP6557U6A57?:5EO:M7M39^[\CZH
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M$>_V)3&); _R]\'3DQ\_ 51P,"FKHGZ$?WWRO0=_[L<^B?;O/I[M.5[9_/^
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M[ ,0@N<%S0QZ>$'S.@I6(;)M;47CU&+%: 4+,CCFHA3Y($AV(_9\%C)HO]/
M:N)&H4Z!0A!:7%8.K'G&\?95!$4OL\'^^L#1>>@TAAL"R&)* SP(MX>1'(;V
MW"E>P#&\9GY50']D/%N 7'U$5TTF8#3!6!#^Q5LNX<=4^(O[3<Z \1Y6K4/I
M,R1/F.J0./6$OTS7GF?^G&3=7-2!Q:/A0 Q_1Z\719D)F?O8>O<!@V#\X.7
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MX90WL+6XRQO<.*.D;CFM95MI5>XA)*35*47\RYA^S!R OLH!.)%8M,H!4#D
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M/LK,MGA44ZQ:"?4E$;OXW6O'?G"63N PMG4,L?T!E1 D ( U S!]*E$&HC4
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M20ONIMKF O<NO[O:7D!>R*FF?/UBGJJ+D_>NS&K)-9+DD2;QQT([H=/=)E-
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M*_[K*7A>?OI_4$L! A0#%     @ '3EW7-G.Z+#P*@  >Q4" !$
M     ( !     &)L<G@M,C R-3$R,S$N>'-D4$L! A0#%     @ '3EW7&F&
M1X/P$P  XR,! !4              ( !'RL  &)L<G@M,C R-3$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( !TY=UQ"TU77^D0  !_%!  5              "
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M:6)I=%\Q,BTQ+FAT;5!+ 0(4 Q0    ( !TY=UQ?B"18! D  )PS   0
M          "  9&! @!E>&AI8FET7S$R+3(N:'1M4$L! A0#%     @ '3EW
M7.P?$?<<!0  7A$  !               ( !PXH" &5X:&EB:71?,3,M,2YH
M=&U02P$"% ,4    "  =.7=<5!KVLA4%  !2$0  $               @ $-
MD ( 97AH:6)I=%\Q,RTR+FAT;5!+ 0(4 Q0    ( !TY=UQ#<*X$+P0   ,,
M   0              "  5"5 @!E>&AI8FET7S$U+3$N:'1M4$L! A0#%
M  @ '3EW7/11;R":*   !LP   \              ( !K9D" &5X:&EB:71?
M,BTR+FAT;5!+ 0(4 Q0    ( !TY=UPV2IL8UP,  -P/   /
M  "  73" @!E>&AI8FET7S@M,2YH=&U02P$"% ,4    "  =.7=<E.K(:]UF
M  #8E0  "@              @ %XQ@( :6UA9V4P+FIP9U!+ 0(4 Q0    (
M !TY=UPTYZ3%V(@" 'P= P *              "  7TM P!I;6%G93(N:G!G
M4$L! A0#%     @ '3EW7,^&/B@T+   ,C$   H              ( !?;8%
M &EM86=E,RYJ<&=02P$"% ,4    "  =.7=<5(O6G0NC! "H;#4 #0
M        @ '9X@4 >FLR-C,T-S W+FAT;5!+!08     $0 1 !L$   /A@H
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>zk2634707_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:blrx="http://biolinerx.com/20251231"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="blrx-20251231.xsd" xlink:type="simple"/>
    <context id="C_20250101to20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20260308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
        </entity>
        <period>
            <instant>2026-03-08</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">blrx:OtherComprehensiveIncomeLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AssetTransferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="blrx:CollaborationTransactionAxis">blrx:HemispherianAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:TetragonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="C_20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AssetTransferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="blrx:CollaborationTransactionAxis">blrx:HemispherianAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:TetragonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="C_20251231_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AssetTransferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="blrx:CollaborationTransactionAxis">blrx:HemispherianAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:TetragonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:SeniorManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:SeniorManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:SeniorManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SeparateManagementEntitiesAxis">blrx:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullBusinessCombinationsAxis_blrxAgalimmuneLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">blrx:AgalimmuneLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullBusinessCombinationsAxis_blrxBiokineTherapeuticsLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullBusinessCombinationsAxis_blrxBiokineTherapeuticsLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullBusinessCombinationsAxis_blrxGlix1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">blrx:Glix1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_blrxBL8040Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">blrx:BL8040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:TradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:OtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:NisLinkedBalancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:EuroLinkedTradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:TradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:OtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:EuroLinkedTradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:DollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:NisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:OtherCurrenciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:DollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:NisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">blrx:OtherCurrenciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:NisLinkedBalancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:ShortTermDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">blrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_ifrsfullComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20220901to20220930_blrxTrancheAxis_blrxFirstTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:TrancheAxis">blrx:FirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20220901to20220930_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20210901to20220930_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20210901to20220930_ifrsfullRangeAxis_ifrsfullTopOfRangeMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20220901to20220930_blrxTrancheAxis_blrxSecondTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:TrancheAxis">blrx:SecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20220901to20220930_blrxTrancheAxis_blrxThirdTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:TrancheAxis">blrx:ThirdTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20240401to20240430_blrxTrancheAxis_blrxSecondTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:TrancheAxis">blrx:SecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241101to20241130_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20241001to20241231_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:LoanAgreementWithKreosCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxHighbridgeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:HighbridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20241101to20241130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxRegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_blrxPerformanceObligationAxis_blrxSingleMaterialPerformanceObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="blrx:PerformanceObligationAxis">blrx:SingleMaterialPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20241001to20241231_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:AyrmidLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">blrx:NetBookValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20201231to20201231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20201231to20201231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20240601to20240630_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullMaturityAxis_blrxFirstThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">blrx:FirstThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241101to20241130_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">blrx:BiokineTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullMaturityAxis_blrxThreeSubsequentYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">blrx:ThreeSubsequentYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullMaturityAxis_blrxSeventhYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">blrx:SeventhYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxShareIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:ShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxShareIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:ShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20200930_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:HCWainwrightAndCoLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:HCWainwrightAndCoLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20200901to20200930_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:HCWainwrightAndCoLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:PerformanceSharesUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:PerformanceSharesUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:PerformanceSharesUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:PlacementAgentsDesigneesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:PlacementAgentsDesigneesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">blrx:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullInitiallyAppliedIFRSsAxis_ifrsfullIncreaseDecreaseDueToApplicationOfIFRS15Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="C_20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxHighbridgeCapitalManagementLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:HighbridgeCapitalManagementLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxHighbridgeCapitalManagementLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:HighbridgeCapitalManagementLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_ifrsfullCategoriesOfFinancialLiabilitiesAxis_ifrsfullFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20250131_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="C_20250131_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="C_20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">blrx:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">blrx:January2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">blrx:HCWainwrightAndCoLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">blrx:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">blrx:PerformanceSharesUnitTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:GloriaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:GloriaLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:GloriaLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:GloriaPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_20231001to20231231_blrxAgreementTypeAxis_blrxScmLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:ScmLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_blrxAgreementTypeAxis_blrxScmSupportServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:ScmSupportServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_blrxAgreementTypeAxis_blrxPDACPerformanceObligationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:PDACPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_blrxAgreementTypeAxis_blrxLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231_blrxAgreementTypeAxis_blrxLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20241001to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20231001to20231031_blrxAgreementTypeAxis_blrxPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001498403</identifier>
            <segment>
                <xbrldi:explicitMember dimension="blrx:AgreementTypeAxis">blrx:GloriaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <unit id="ILS">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="ILS_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>blrx:Segment</measure>
    </unit>
    <unit id="Share">
        <measure>blrx:Share</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Year">
        <measure>blrx:Year</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_20250101to20251231"
      id="Fdei_EntityCentralIndexKey20211006175904255">0001498403</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_20250101to20251231"
      id="Fdei_AmendmentFlag20211006180939012">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_20250101to20251231"
      id="Fdei_DocumentFiscalPeriodFocus20211006181124979">FY</dei:DocumentFiscalPeriodFocus>
    <blrx:NumberOfSegments
      contextRef="C_20250101to20251231"
      decimals="0"
      id="Fxbrl_20250327041154148"
      unitRef="Segment">1</blrx:NumberOfSegments>
    <blrx:CommitmentsAndContingentLiabilities
      contextRef="C_20251231"
      id="Fxbrl_20260317100008074_20211006114529300_39"
      unitRef="USD"
      xsi:nil="true"/>
    <blrx:CommitmentsAndContingentLiabilities
      contextRef="C_20241231"
      id="Fxbrl_20260317100008074_20211006114529300_38"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211828660">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211839260">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211845746">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211855372">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211902964">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211913620">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211921956">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211926964">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211936228">001-35223</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211942373">BioLineRx Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211948794">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321211953973">2 HaMa&#x2019;ayan Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212003751">Modi&#x2019;in</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212009869">7177871</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212015828">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20230321212022686">Philip A. Serlin</dei:ContactPersonnelName>
    <dei:CityAreaCode
      contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20230321212032077">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20230321212037083">642-9100</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212047709">972 (8) 642-9101</dei:ContactPersonnelFaxNumber>
    <dei:ContactPersonnelEmailAddress
      contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20230321212053828">phils@biolinerx.com</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1
      contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20230321212100284">2 HaMa&#x2019;ayan Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20230321212105980">Modi&#x2019;in</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20230321212116452">7177871</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20250101to20251231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20230321212122747">IL</dei:EntityAddressCountry>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20260308"
      decimals="INF"
      id="Fxbrl_20230321212139620"
      unitRef="Shares">2610814390</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212144853">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212153388">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212201628">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212207485">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250331155751411">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212324757">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212236424">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_20250101to20251231"
      id="Fxbrl_20240324220112714">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212256084">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230321212304420">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250327095952259">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260320004533678">
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk management and strategy&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;We have developed and maintain a cybersecurity risk management program that focuses primarily on securing and safeguarding computer systems, networks, cloud services, business applications and data and that is integrated in our overall risk management strategy and framework. We have implemented protocols to protect against cyber threats and ensure the containment and security of sensitive business data, including ongoing security reviews of critical systems, continuous monitoring of event data, and employee training programs, which processes are aligned with our overall business and operational goals and strategies. Our risk assessment occurs on an ongoing basis and covers identification of risks that could act against the company&#x2019;s objectives as well as specific risks related to a compromise to the security of data.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;We engage a third party to provide operational support for cybersecurity risks. This forms a critical part of our risk management strategy, facilitating effective management and mitigation of risks, and ensuring adherence to applicable regulatory and industry standards.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Overall, we believe that we have established a robust framework for confidentiality, integrity, and availability of information, adhering to relevant security standards, practices, and compliance requirements. In addition, we maintain insurance to help protect against risks associated with cybersecurity threats. As of the date of this report, we do not believe that any risks from cybersecurity threats have materially affected, or are reasonably likely to materially affect, us, including our business strategy, results of operations, or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have not experienced an undetected cybersecurity incident. For more information about these risks, please see &#x201c;Item 3.D. Key Information - Risk Factors - Risks Related to Our Industry - Significant disruptions of our information technology systems or breaches of our data security could adversely affect our business.&#x201d; in this Annual Report on Form 20-F.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    </cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260320004838858">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260320004918603">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260320005006364">Overall, we believe that we have established a robust framework for confidentiality, integrity, and availability of information, adhering to relevant security standards, practices, and compliance requirements.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260320005027903">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260320005108004">As of the date of this report, we do not believe that any risks from cybersecurity threats have materially affected, or are reasonably likely to materially affect, us, including our business strategy, results of operations, or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have not experienced an undetected cybersecurity incident.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260320005147955">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260320004541710">
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Governance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Our audit committee oversees our cybersecurity program and helps guide our strategy for managing cybersecurity risks in the context of our overall risk management system.&#160;Our cybersecurity program is managed by our Chief Financial Officer and our internal IT team, who is responsible for leading enterprise-wide cybersecurity strategy, protocols, framework, standards and processes. The Chief Financial Officer reports to our board of directors, as well as our Chief Executive Officer and other members of senior management as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    </cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260320004637955">Our audit committee oversees our cybersecurity program and helps guide our strategy for managing cybersecurity risks in the context of our overall risk management system.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260320004709368">Our cybersecurity program is managed by our Chief Financial Officer and our internal IT team, who is responsible for leading enterprise-wide cybersecurity strategy, protocols, framework, standards and processes.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260320004744690">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <dei:AuditorFirmId
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230320174828660">1309</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260318131242326">
      &lt;div&gt;
        &lt;div style="line-height:1.25;font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;We have audited the accompanying consolidated statements of financial position of BioLineRx Ltd. and its subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2025 and 2024, and the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2025, including the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024 and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Substantial Doubt about the Company&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1(c) to the consolidated financial statements, the Company has suffered recurring losses from operations and has cash outflows from operating activities that indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) about its ability to continue as a going concern. Management&#x2019;s plans in regard to these matters are also described in Note&#160;1(c). The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    </dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_20250101to20251231"
      id="Fxbrl_20220305175717733">Kesselman &amp; Kesselman</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_20250101to20251231"
      id="Fxbrl_20220305175738918">Tel Aviv, Israel</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529288_0"
      unitRef="USD">10436000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529288_1"
      unitRef="USD">3250000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529289_2"
      unitRef="USD">9126000</ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529289_3"
      unitRef="USD">17626000</ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents>
    <ifrs-full:TradeReceivables
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240323024550822_20211006114529289_2"
      unitRef="USD">2476000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20240323024550822_20211006114529289_3"
      unitRef="USD">46000</ifrs-full:TradeReceivables>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529289_4"
      unitRef="USD">443000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529290_5"
      unitRef="USD">201000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentReceivables
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529290_6"
      unitRef="USD">1478000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529290_7"
      unitRef="USD">410000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:Inventories
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240323024552293_20211006114529289_2"
      unitRef="USD">3145000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20240323024552293_20211006114529289_3"
      unitRef="USD">2148000</ifrs-full:Inventories>
    <ifrs-full:CurrentAssets
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529290_8"
      unitRef="USD">27104000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529291_9"
      unitRef="USD">23681000</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529291_10"
      unitRef="USD">386000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529291_11"
      unitRef="USD">160000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529291_12"
      unitRef="USD">967000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529292_13"
      unitRef="USD">696000</ifrs-full:RightofuseAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529292_14"
      unitRef="USD">10449000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529292_15"
      unitRef="USD">16368000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NoncurrentAssets
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529292_16"
      unitRef="USD">11802000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529293_17"
      unitRef="USD">17224000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529293_18"
      unitRef="USD">38906000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529293_19"
      unitRef="USD">40905000</ifrs-full:Assets>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529293_20"
      unitRef="USD">4479000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529294_21"
      unitRef="USD">4479000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529294_22"
      unitRef="USD">5583000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529294_23"
      unitRef="USD">3493000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:OtherCurrentPayables
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529294_24"
      unitRef="USD">3131000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529295_25"
      unitRef="USD">1743000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529295_26"
      unitRef="USD">522000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529295_27"
      unitRef="USD">234000</ifrs-full:CurrentLeaseLiabilities>
    <blrx:Warrants
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529298_30"
      unitRef="USD">1691000</blrx:Warrants>
    <blrx:Warrants
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529299_31"
      unitRef="USD">2174000</blrx:Warrants>
    <ifrs-full:CurrentLiabilities
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529295_28"
      unitRef="USD">15406000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529298_29"
      unitRef="USD">12123000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529299_32"
      unitRef="USD">8958000</ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived>
    <ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529299_33"
      unitRef="USD">4460000</ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529299_34"
      unitRef="USD">1081000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529299_35"
      unitRef="USD">977000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529300_36"
      unitRef="USD">10039000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529300_37"
      unitRef="USD">5437000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529300_38"
      unitRef="USD">25445000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529300_39"
      unitRef="USD">17560000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529300_40"
      unitRef="USD">38097000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529301_41"
      unitRef="USD">73428000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529301_42"
      unitRef="USD">353693000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529301_43"
      unitRef="USD">327584000</ifrs-full:SharePremium>
    <ifrs-full:WarrantReserve
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20220304191450099"
      unitRef="USD">5367000</ifrs-full:WarrantReserve>
    <ifrs-full:WarrantReserve
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20220304191435587"
      unitRef="USD">3686000</ifrs-full:WarrantReserve>
    <ifrs-full:CapitalReserve
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529301_44"
      unitRef="USD">17547000</ifrs-full:CapitalReserve>
    <ifrs-full:CapitalReserve
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529301_45"
      unitRef="USD">15916000</ifrs-full:CapitalReserve>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529302_46"
      unitRef="USD">-1416000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529302_47"
      unitRef="USD">-1416000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:RetainedEarnings
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20260318095808764_20211006114529302_46"
      unitRef="USD">-399827000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20260318095808764_20211006114529302_47"
      unitRef="USD">-401002000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20260317095223548_20211006114529301_44"
      unitRef="USD">13461000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20260317095223548_20211006114529301_45"
      unitRef="USD">18196000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20260317095225412_20211006114529301_44"
      unitRef="USD">0</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20260317095225412_20211006114529301_45"
      unitRef="USD">5149000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529302_50"
      unitRef="USD">13461000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529303_51"
      unitRef="USD">23345000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006114529303_52"
      unitRef="USD">38906000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006114529303_53"
      unitRef="USD">40905000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250326131233828_xbrl_20240323025118703_20211006114529312_0"
      unitRef="USD">4610000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250326131233828_xbrl_20240323025118703_20211006114529313_1"
      unitRef="USD">22917000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20250326131233828_xbrl_20240323025118703_20211006114529313_2"
      unitRef="USD">1180000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250326131239004_xbrl_20240323025118703_20211006114529312_0"
      unitRef="USD">190000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250326131239004_xbrl_20240323025118703_20211006114529313_1"
      unitRef="USD">6023000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20250326131239004_xbrl_20240323025118703_20211006114529313_2"
      unitRef="USD">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:Revenue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240323025118703_20211006114529312_0"
      unitRef="USD">4800000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240323025118703_20211006114529313_1"
      unitRef="USD">28940000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240323025118703_20211006114529313_2"
      unitRef="USD">1180000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240323025120164_20211006114529312_0"
      unitRef="USD">3692000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240323025120164_20211006114529313_1"
      unitRef="USD">9263000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240323025120164_20211006114529313_2"
      unitRef="USD">230000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240323025122020_20211006114529312_0"
      unitRef="USD">1108000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240323025122020_20211006114529313_1"
      unitRef="USD">19677000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240323025122020_20211006114529313_2"
      unitRef="USD">950000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006114529312_0"
      unitRef="USD">12519000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006114529313_1"
      unitRef="USD">9149000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006114529313_2"
      unitRef="USD">8093000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006114529313_3"
      unitRef="USD">25270000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006114529313_4"
      unitRef="USD">23605000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006114529314_5"
      unitRef="USD">0</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006114529314_6"
      unitRef="USD">6310000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006114529314_7"
      unitRef="USD">6321000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006114529314_8"
      unitRef="USD">3144000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <blrx:ImpairmentLossOnIntangibleAssets
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240323025125341_20211006114529312_0"
      unitRef="USD">-6703000</blrx:ImpairmentLossOnIntangibleAssets>
    <blrx:ImpairmentLossOnIntangibleAssets
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240323025125341_20211006114529313_1"
      unitRef="USD">-1010000</blrx:ImpairmentLossOnIntangibleAssets>
    <blrx:ImpairmentLossOnIntangibleAssets
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20250326130853146"
      unitRef="USD">0</blrx:ImpairmentLossOnIntangibleAssets>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006114529314_9"
      unitRef="USD">-49694000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006114529315_10"
      unitRef="USD">-20408000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006114529315_11"
      unitRef="USD">-10287000</ifrs-full:ProfitLossFromOperatingActivities>
    <blrx:ProfitLossFromNonOperatingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230311024658817"
      unitRef="USD">-10819000</blrx:ProfitLossFromNonOperatingActivities>
    <blrx:ProfitLossFromNonOperatingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220305101734013"
      unitRef="USD">18435000</blrx:ProfitLossFromNonOperatingActivities>
    <blrx:ProfitLossFromNonOperatingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006114529316_14"
      unitRef="USD">8077000</blrx:ProfitLossFromNonOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006114529316_15"
      unitRef="USD">2068000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006114529316_16"
      unitRef="USD">1871000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006114529316_17"
      unitRef="USD">1464000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006114529317_18"
      unitRef="USD">2169000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006114529317_19"
      unitRef="USD">9119000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006114529317_20"
      unitRef="USD">1280000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006114529317_21"
      unitRef="USD">-60614000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006114529317_22"
      unitRef="USD">-9221000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006114529318_23"
      unitRef="USD">-2026000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20260317100805907_20211006114529319_27"
      unitRef="USD">-60614000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20260317100805907_20211006114529319_28"
      unitRef="USD">-9221000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20260317100805907_20211006114529319_29"
      unitRef="USD">-1175000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20260317100808373_20211006114529319_27"
      unitRef="USD">0</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20260317100808373_20211006114529319_28"
      unitRef="USD">0</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20260317100808373_20211006114529319_29"
      unitRef="USD">-851000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20260317100810085_20211006114529319_27"
      unitRef="USD">-60614000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20260317100810085_20211006114529319_28"
      unitRef="USD">-9221000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20260317100810085_20211006114529319_29"
      unitRef="USD">-2026000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20230311025713314"
      unitRef="USD_per_Share">-0.06</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_20230101to20231231"
      decimals="2"
      id="F20211006114529318_24"
      unitRef="USD_per_Share">-0.06</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_20240101to20241231"
      decimals="2"
      id="Fxbrl_20230311025731625"
      unitRef="USD_per_Share">-0.01</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_20240101to20241231"
      decimals="2"
      id="F20211006114529318_25"
      unitRef="USD_per_Share">-0.01</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_20250101to20251231"
      decimals="2"
      id="Fxbrl_20230311025751753"
      unitRef="USD_per_Share">-0</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_20250101to20251231"
      decimals="2"
      id="F20211006114529318_26"
      unitRef="USD_per_Share">-0</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="C_20230101to20231231"
      decimals="0"
      id="Fxbrl_s_20260317225120371"
      unitRef="Shares">963365525</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_20230101to20231231"
      decimals="0"
      id="Fxbrl_20260317225120371"
      unitRef="Shares">963365525</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="C_20240101to20241231"
      decimals="0"
      id="Fxbrl_s_20260317225107745"
      unitRef="Shares">1198107761</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_20240101to20241231"
      decimals="0"
      id="Fxbrl_20260317225107745"
      unitRef="Shares">1198107761</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="C_20250101to20251231"
      decimals="0"
      id="Fxbrl_20260317105456167"
      unitRef="Shares">2465272604</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_20250101to20251231"
      decimals="0"
      id="F20211006114529319_29"
      unitRef="Shares">2465272604</ifrs-full:WeightedAverageShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163203969"
      unitRef="Shares">922959000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20220304200509259_20211006114529369_101"
      unitRef="USD">27100000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20220304200509259_20211006114529370_102"
      unitRef="USD">338976000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20220304220723367"
      unitRef="USD">1408000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20220304200509259_20211006114529370_103"
      unitRef="USD">14765000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20220304200509259_20211006114529370_104"
      unitRef="USD">-1416000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220304200509259_20211006114529371_105"
      unitRef="USD">-329992000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20221231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172635551"
      unitRef="USD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220304200509259_20211006114529371_106"
      unitRef="USD">50841000</ifrs-full:Equity>
    <blrx:NumberOfNewSharesIssued
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163510089"
      unitRef="Shares">124955000</blrx:NumberOfNewSharesIssued>
    <blrx:IssuanceOfShareCapital
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529345_30"
      unitRef="USD">3242000</blrx:IssuanceOfShareCapital>
    <blrx:IssuanceOfShareCapital
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529345_31"
      unitRef="USD">10847000</blrx:IssuanceOfShareCapital>
    <blrx:IssuanceOfShareCapital
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304221454554"
      unitRef="USD">0</blrx:IssuanceOfShareCapital>
    <blrx:IssuanceOfShareCapital
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_32"
      unitRef="USD">0</blrx:IssuanceOfShareCapital>
    <blrx:IssuanceOfShareCapital
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_33"
      unitRef="USD">0</blrx:IssuanceOfShareCapital>
    <blrx:IssuanceOfShareCapital
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_34"
      unitRef="USD">0</blrx:IssuanceOfShareCapital>
    <blrx:IssuanceOfShareCapital
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172957489_xbrl_20260317172721088"
      unitRef="USD">0</blrx:IssuanceOfShareCapital>
    <blrx:IssuanceOfShareCapital
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20260317172957489_xbrl_20230311031510191_xbrl_20220304200234867_20211006114529347_35"
      unitRef="USD">14089000</blrx:IssuanceOfShareCapital>
    <blrx:IncreaseDecreaseThroughExerciseOfWarrantsShares
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163616374"
      unitRef="Shares">38182000</blrx:IncreaseDecreaseThroughExerciseOfWarrantsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529360_66"
      unitRef="USD">1000000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529360_67"
      unitRef="USD">5559000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20260317172941629_xbrl_20220304221447611"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529361_68"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529361_69"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529361_70"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172941629_xbrl_20260317172727206"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20260317172941629_xbrl_20220304200135612_20211006114529362_71"
      unitRef="USD">6559000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <blrx:IncreaseDecreaseThroughExerciseOfOptionsShares
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163627526"
      unitRef="Shares">493000</blrx:IncreaseDecreaseThroughExerciseOfOptionsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20220304200109668_20211006114529347_36"
      unitRef="USD">13000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20220304200109668_20211006114529347_37"
      unitRef="USD">45000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20220304221441483"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20220304200109668_20211006114529348_38"
      unitRef="USD">-31000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20220304200109668_20211006114529348_39"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220304200109668_20211006114529348_40"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172645381"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304200109668_20211006114529349_41"
      unitRef="USD">27000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20220304194813627_20211006114529349_42"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20220304194813627_20211006114529349_43"
      unitRef="USD">55000</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20220304221435852"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20220304194813627_20211006114529350_44"
      unitRef="USD">-55000</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20220304194813627_20211006114529350_45"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220304194813627_20211006114529350_46"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172652286"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304194813627_20211006114529350_47"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20220304194756139_20211006114529351_48"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20220304194756139_20211006114529351_49"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20220304221424059"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20220304194756139_20211006114529351_50"
      unitRef="USD">2321000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20220304194756139_20211006114529352_51"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220304194756139_20211006114529352_52"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172657609"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304194756139_20211006114529352_53"
      unitRef="USD">2321000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20220304194732539_20211006114529353_54"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20220304194732539_20211006114529353_55"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20220304221417995"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20260317172604341"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20220304194732539_20211006114529354_57"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220304194732539_20211006114529357_58"
      unitRef="USD">-60614000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20230101to20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172703408"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304194732539_20211006114529358_59"
      unitRef="USD">-60614000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163221672"
      unitRef="Shares">1086589000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529371_107"
      unitRef="USD">31355000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529372_108"
      unitRef="USD">355482000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031621434_xbrl_20220304220738543"
      unitRef="USD">1408000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529372_109"
      unitRef="USD">17000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529372_110"
      unitRef="USD">-1416000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529373_111"
      unitRef="USD">-390606000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20231231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172712944"
      unitRef="USD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230311031621434_xbrl_20220304194708304_20211006114529373_112"
      unitRef="USD">13223000</ifrs-full:Equity>
    <blrx:NumberOfNewSharesIssued
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163643048"
      unitRef="Shares">174322000</blrx:NumberOfNewSharesIssued>
    <ifrs-full:IssueOfEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529345_30"
      unitRef="USD">4712000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529345_31"
      unitRef="USD">-3060000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031510191_xbrl_20220304221454554"
      unitRef="USD">6650000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_32"
      unitRef="USD">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_33"
      unitRef="USD">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529346_34"
      unitRef="USD">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172721088"
      unitRef="USD">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230311031510191_xbrl_20220304200234867_20211006114529347_35"
      unitRef="USD">8302000</ifrs-full:IssueOfEquity>
    <blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163929824"
      unitRef="Shares">74989000</blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20220304200135612_20211006114529360_66"
      unitRef="USD">2009000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20220304200135612_20211006114529360_67"
      unitRef="USD">682000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20220304221447611"
      unitRef="USD">-2691000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20220304200135612_20211006114529361_68"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20220304200135612_20211006114529361_69"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220304200135612_20211006114529361_70"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172727206"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304200135612_20211006114529362_71"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <blrx:IncreaseDecreaseThroughExerciseOfOptionsShares
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163907944"
      unitRef="Shares">770000</blrx:IncreaseDecreaseThroughExerciseOfOptionsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529347_36"
      unitRef="USD">21000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529347_37"
      unitRef="USD">50000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031521651_xbrl_20220304221441483"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529348_38"
      unitRef="USD">-49000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529348_39"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529348_40"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172732879"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230311031521651_xbrl_20220304200109668_20211006114529349_41"
      unitRef="USD">22000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529349_42"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529349_43"
      unitRef="USD">539000</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031541626_xbrl_20220304221435852"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529350_44"
      unitRef="USD">-539000</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529350_45"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529350_46"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172739750"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230311031541626_xbrl_20220304194813627_20211006114529350_47"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529351_48"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529351_49"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031554946_xbrl_20220304221424059"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529351_50"
      unitRef="USD">1135000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529352_51"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529352_52"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172754079"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230311031554946_xbrl_20220304194756139_20211006114529352_53"
      unitRef="USD">1135000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_54"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_55"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304221417995"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20250326133054396_xbrl_20240323031148809"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529354_57"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529357_58"
      unitRef="USD">-9221000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20240101to20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172800990"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250326133054396_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529358_59"
      unitRef="USD">-9221000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163232247"
      unitRef="Shares">1336670000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529371_107"
      unitRef="USD">38097000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_108"
      unitRef="USD">353693000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031623889_xbrl_20220304220738543"
      unitRef="USD">5367000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_109"
      unitRef="USD">17547000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_110"
      unitRef="USD">-1416000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529373_111"
      unitRef="USD">-399827000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172816562"
      unitRef="USD">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20230311031623889_xbrl_20220304194708304_20211006114529373_112"
      unitRef="USD">13461000</ifrs-full:Equity>
    <blrx:NumberOfNewSharesIssued
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163650647"
      unitRef="Shares">978340000</blrx:NumberOfNewSharesIssued>
    <ifrs-full:IssueOfEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529345_30"
      unitRef="USD">27273000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529345_31"
      unitRef="USD">-22260000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031504698_xbrl_20220304221454554"
      unitRef="USD">501000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529346_32"
      unitRef="USD">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529346_33"
      unitRef="USD">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529346_34"
      unitRef="USD">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172822424"
      unitRef="USD">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230311031504698_xbrl_20220304200234867_20211006114529347_35"
      unitRef="USD">5514000</ifrs-full:IssueOfEquity>
    <blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163953798"
      unitRef="Shares">295804000</blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares>
    <blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_54"
      unitRef="USD">8058000</blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity>
    <blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_55"
      unitRef="USD">-5876000</blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity>
    <blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304221417995"
      unitRef="USD">-2182000</blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity>
    <blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20250326133041525_xbrl_20240323031148809"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity>
    <blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529354_57"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity>
    <blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529357_58"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity>
    <blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172827962"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity>
    <blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20250326133041525_xbrl_20230311031610458_xbrl_20220304194732539_20211006114529358_59"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughExerciseOfPrefundedWarrantsEquity>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529349_42"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529349_43"
      unitRef="USD">2027000</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031545210_xbrl_20220304221435852"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529350_44"
      unitRef="USD">-2027000</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529350_45"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529350_46"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172834685"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230311031545210_xbrl_20220304194813627_20211006114529350_47"
      unitRef="USD">0</blrx:IncreaseDecreaseThroughForfeitedAndExpiredOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_48"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_49"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031558522_xbrl_20220304221424059"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_50"
      unitRef="USD">396000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_51"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_52"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172841456"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_53"
      unitRef="USD">396000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_48"
      unitRef="USD">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_49"
      unitRef="USD">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304221424059"
      unitRef="USD">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529351_50"
      unitRef="USD">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_51"
      unitRef="USD">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_52"
      unitRef="USD">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317174334351_xbrl_20260317172841456"
      unitRef="USD">6000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20260317174334351_xbrl_20230311031558522_xbrl_20220304194756139_20211006114529352_53"
      unitRef="USD">6000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_54"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20230311031610458_xbrl_20220304194732539_20211006114529353_55"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20230311031610458_xbrl_20220304221417995"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20240323031148809"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20230311031610458_xbrl_20220304194732539_20211006114529354_57"
      unitRef="USD">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230311031610458_xbrl_20220304194732539_20211006114529357_58"
      unitRef="USD">-1175000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20250101to20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172846676"
      unitRef="USD">-851000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230311031610458_xbrl_20220304194732539_20211006114529358_59"
      unitRef="USD">-2026000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20260319163250639"
      unitRef="Shares">2610814000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember"
      decimals="-3"
      id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529371_107"
      unitRef="USD">73428000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullSharePremiumMember"
      decimals="-3"
      id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_108"
      unitRef="USD">327584000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullWarrantReserveMember"
      decimals="-3"
      id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304220738543"
      unitRef="USD">3686000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullCapitalReserveMember"
      decimals="-3"
      id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_109"
      unitRef="USD">15916000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_blrxOtherComprehensiveIncomeLossMember"
      decimals="-3"
      id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529372_110"
      unitRef="USD">-1416000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529373_111"
      unitRef="USD">-401002000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20251231_ifrsfullComponentsOfEquityAxis_ifrsfullNoncontrollingInterestsMember"
      decimals="-3"
      id="Fxbrl_20260317172851782"
      unitRef="USD">5149000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20250326132953618_xbrl_20230311031623889_xbrl_20220304194708304_20211006114529373_112"
      unitRef="USD">23345000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555428_85"
      unitRef="USD">-60614000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555428_84"
      unitRef="USD">-9221000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555427_83"
      unitRef="USD">-2026000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555389_0"
      unitRef="USD">38006000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555420_59"
      unitRef="USD">-34652000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555440_112"
      unitRef="USD">-6048000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555390_1"
      unitRef="USD">-22608000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555391_2"
      unitRef="USD">-43873000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555391_3"
      unitRef="USD">-8074000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555392_4"
      unitRef="USD">-47588000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555392_5"
      unitRef="USD">-26350000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555393_6"
      unitRef="USD">-36644000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <blrx:MaturitiesOfShortTermDeposits
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555393_7"
      unitRef="USD">-49329000</blrx:MaturitiesOfShortTermDeposits>
    <blrx:MaturitiesOfShortTermDeposits
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555393_8"
      unitRef="USD">-55778000</blrx:MaturitiesOfShortTermDeposits>
    <blrx:MaturitiesOfShortTermDeposits
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555394_9"
      unitRef="USD">-28126000</blrx:MaturitiesOfShortTermDeposits>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555427_82"
      unitRef="USD">116000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555428_86"
      unitRef="USD">53000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555427_81"
      unitRef="USD">25000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555395_10"
      unitRef="USD">181000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555395_11"
      unitRef="USD">1000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555429_87"
      unitRef="USD">2000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555421_67"
      unitRef="USD">1444000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555429_88"
      unitRef="USD">29374000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555421_66"
      unitRef="USD">-8545000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555396_12"
      unitRef="USD">14089000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555396_13"
      unitRef="USD">16357000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555397_14"
      unitRef="USD">13894000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220305015204602_20230320171555396_12"
      unitRef="USD">2928000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220305015204602_20230320171555396_13"
      unitRef="USD">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220305015204602_20230320171555397_14"
      unitRef="USD">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220305015152596_20230320171555396_12"
      unitRef="USD">27000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220305015152596_20230320171555396_13"
      unitRef="USD">22000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220305015152596_20230320171555397_14"
      unitRef="USD">0</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromIssuingOtherEquityInstruments
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230311040859398_xbrl_20220305015152596_20230320171555396_12"
      unitRef="USD">0</ifrs-full:ProceedsFromIssuingOtherEquityInstruments>
    <ifrs-full:ProceedsFromIssuingOtherEquityInstruments
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230311040859398_xbrl_20220305015152596_20230320171555396_13"
      unitRef="USD">19223000</ifrs-full:ProceedsFromIssuingOtherEquityInstruments>
    <ifrs-full:ProceedsFromIssuingOtherEquityInstruments
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230311040859398_xbrl_20220305015152596_20230320171555397_14"
      unitRef="USD">0</ifrs-full:ProceedsFromIssuingOtherEquityInstruments>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555397_15"
      unitRef="USD">1543000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555397_16"
      unitRef="USD">14433000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555398_17"
      unitRef="USD">4498000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555422_68"
      unitRef="USD">445000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555398_18"
      unitRef="USD">511000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555399_19"
      unitRef="USD">512000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555399_20"
      unitRef="USD">15056000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555400_21"
      unitRef="USD">20658000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555400_22"
      unitRef="USD">8884000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555401_23"
      unitRef="USD">-6108000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555430_89"
      unitRef="USD">6159000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555422_69"
      unitRef="USD">-7735000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="F20230320171555401_24"
      unitRef="USD">10587000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="F20230320171555402_25"
      unitRef="USD">4255000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20241231"
      decimals="-3"
      id="F20230320171555402_26"
      unitRef="USD">10436000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555403_27"
      unitRef="USD">-224000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555403_28"
      unitRef="USD">22000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555432_90"
      unitRef="USD">549000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="F20230320171555403_29"
      unitRef="USD">4255000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20241231"
      decimals="-3"
      id="F20230320171555404_30"
      unitRef="USD">10436000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20251231"
      decimals="-3"
      id="F20230320171555404_31"
      unitRef="USD">3250000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555405_32"
      unitRef="USD">1384000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555405_33"
      unitRef="USD">4065000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555406_34"
      unitRef="USD">523000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20260317110115810_20230320171555405_32"
      unitRef="USD">0</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20260317110115810_20230320171555405_33"
      unitRef="USD">0</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20260317110115810_20230320171555406_34"
      unitRef="USD">-25000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555423_72"
      unitRef="USD">224000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555423_71"
      unitRef="USD">-22000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555423_70"
      unitRef="USD">-549000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555406_35"
      unitRef="USD">11054000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555406_36"
      unitRef="USD">-18965000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555438_106"
      unitRef="USD">-8599000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555407_37"
      unitRef="USD">2321000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555407_38"
      unitRef="USD">1135000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555408_39"
      unitRef="USD">396000</ifrs-full:AdjustmentsForSharebasedPayments>
    <blrx:InterestAndExchangeDifferencesOnShortTermDeposits
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555408_40"
      unitRef="USD">15000</blrx:InterestAndExchangeDifferencesOnShortTermDeposits>
    <blrx:InterestAndExchangeDifferencesOnShortTermDeposits
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555409_41"
      unitRef="USD">185000</blrx:InterestAndExchangeDifferencesOnShortTermDeposits>
    <blrx:InterestAndExchangeDifferencesOnShortTermDeposits
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555412_42"
      unitRef="USD">18000</blrx:InterestAndExchangeDifferencesOnShortTermDeposits>
    <blrx:InterestAndLinkageDifferencesOnBankLoan
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555413_43"
      unitRef="USD">1148000</blrx:InterestAndLinkageDifferencesOnBankLoan>
    <blrx:InterestAndLinkageDifferencesOnBankLoan
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555413_44"
      unitRef="USD">-1126000</blrx:InterestAndLinkageDifferencesOnBankLoan>
    <blrx:InterestAndLinkageDifferencesOnBankLoan
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555414_45"
      unitRef="USD">0</blrx:InterestAndLinkageDifferencesOnBankLoan>
    <blrx:InterestAndExchangeDifferencesOnRestrictedDeposits
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555414_46"
      unitRef="USD">0</blrx:InterestAndExchangeDifferencesOnRestrictedDeposits>
    <blrx:InterestAndExchangeDifferencesOnRestrictedDeposits
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555414_47"
      unitRef="USD">669000</blrx:InterestAndExchangeDifferencesOnRestrictedDeposits>
    <blrx:InterestAndExchangeDifferencesOnRestrictedDeposits
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555415_48"
      unitRef="USD">702000</blrx:InterestAndExchangeDifferencesOnRestrictedDeposits>
    <blrx:ExchangeDifferencesOnLeaseLiability
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555415_49"
      unitRef="USD">-42000</blrx:ExchangeDifferencesOnLeaseLiability>
    <blrx:ExchangeDifferencesOnLeaseLiability
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555416_50"
      unitRef="USD">-31000</blrx:ExchangeDifferencesOnLeaseLiability>
    <blrx:ExchangeDifferencesOnLeaseLiability
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555438_107"
      unitRef="USD">177000</blrx:ExchangeDifferencesOnLeaseLiability>
    <ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240323031911019_20230320171555415_49"
      unitRef="USD">6703000</ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240323031911019_20230320171555416_50"
      unitRef="USD">1010000</ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240323031911019_20230320171555438_107"
      unitRef="USD">0</ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill>
    <blrx:LossOnAbandonmentOfRightofuseAsset
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250326142825154_20230320171555415_49"
      unitRef="USD">0</blrx:LossOnAbandonmentOfRightofuseAsset>
    <blrx:LossOnAbandonmentOfRightofuseAsset
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250326142825154_20230320171555416_50"
      unitRef="USD">246000</blrx:LossOnAbandonmentOfRightofuseAsset>
    <blrx:LossOnAbandonmentOfRightofuseAsset
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20250326142825154_20230320171555438_107"
      unitRef="USD">0</blrx:LossOnAbandonmentOfRightofuseAsset>
    <blrx:TotalIncomeAndExpenseNotInvolvingCashFlows
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555426_80"
      unitRef="USD">22807000</blrx:TotalIncomeAndExpenseNotInvolvingCashFlows>
    <blrx:TotalIncomeAndExpenseNotInvolvingCashFlows
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555424_73"
      unitRef="USD">-12834000</blrx:TotalIncomeAndExpenseNotInvolvingCashFlows>
    <blrx:TotalIncomeAndExpenseNotInvolvingCashFlows
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555439_108"
      unitRef="USD">-7307000</blrx:TotalIncomeAndExpenseNotInvolvingCashFlows>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240323031913211_20230320171555415_49"
      unitRef="USD">-358000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240323031913211_20230320171555416_50"
      unitRef="USD">-2118000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240323031913211_20230320171555438_107"
      unitRef="USD">2430000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240323031916787_20230320171555415_49"
      unitRef="USD">-1953000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240323031916787_20230320171555416_50"
      unitRef="USD">-1192000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240323031916787_20230320171555438_107"
      unitRef="USD">997000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <blrx:AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555416_51"
      unitRef="USD">959000</blrx:AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables>
    <blrx:AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555417_52"
      unitRef="USD">43000</blrx:AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables>
    <blrx:AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555440_111"
      unitRef="USD">-1310000</blrx:AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555439_109"
      unitRef="USD">5512000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555425_75"
      unitRef="USD">-5508000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555424_74"
      unitRef="USD">-3478000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240323031920060_20230320171555415_49"
      unitRef="USD">12957000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240323031920060_20230320171555416_50"
      unitRef="USD">-12957000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240323031920060_20230320171555438_107"
      unitRef="USD">0</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <blrx:TotalChangeInOperatingAssetAndLiability
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555439_110"
      unitRef="USD">15199000</blrx:TotalChangeInOperatingAssetAndLiability>
    <blrx:TotalChangeInOperatingAssetAndLiability
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555425_77"
      unitRef="USD">-21818000</blrx:TotalChangeInOperatingAssetAndLiability>
    <blrx:TotalChangeInOperatingAssetAndLiability
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555425_76"
      unitRef="USD">1259000</blrx:TotalChangeInOperatingAssetAndLiability>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555426_79"
      unitRef="USD">38006000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220305021341935_20230320171555425_77"
      unitRef="USD">-34652000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555441_113"
      unitRef="USD">-6048000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <blrx:SupplementaryInformationOnInterestReceivedInCash
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555417_53"
      unitRef="USD">2020000</blrx:SupplementaryInformationOnInterestReceivedInCash>
    <blrx:SupplementaryInformationOnInterestReceivedInCash
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555417_54"
      unitRef="USD">1992000</blrx:SupplementaryInformationOnInterestReceivedInCash>
    <blrx:SupplementaryInformationOnInterestReceivedInCash
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555418_55"
      unitRef="USD">1153000</blrx:SupplementaryInformationOnInterestReceivedInCash>
    <blrx:SupplementalInformationOnInterestPaidInCash
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240323031939880"
      unitRef="USD">1111000</blrx:SupplementalInformationOnInterestPaidInCash>
    <blrx:SupplementalInformationOnInterestPaidInCash
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555419_57"
      unitRef="USD">10387000</blrx:SupplementalInformationOnInterestPaidInCash>
    <blrx:SupplementalInformationOnInterestPaidInCash
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555419_58"
      unitRef="USD">1268000</blrx:SupplementalInformationOnInterestPaidInCash>
    <blrx:SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555434_96"
      unitRef="USD">149000</blrx:SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities>
    <blrx:SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555434_95"
      unitRef="USD">327000</blrx:SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities>
    <blrx:SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555434_94"
      unitRef="USD">-57000</blrx:SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities>
    <blrx:SupplementaryInformationOnFairValueOfExercisedWarrants
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20230320171555437_105"
      unitRef="USD">3631000</blrx:SupplementaryInformationOnFairValueOfExercisedWarrants>
    <blrx:SupplementaryInformationOnFairValueOfExercisedWarrants
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20230320171555437_104"
      unitRef="USD">0</blrx:SupplementaryInformationOnFairValueOfExercisedWarrants>
    <blrx:SupplementaryInformationOnFairValueOfExercisedWarrants
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20230320171555437_103"
      unitRef="USD">0</blrx:SupplementaryInformationOnFairValueOfExercisedWarrants>
    <blrx:SupplementaryInformationOnIntangibleAssetAcquired
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20260317110118755_20230320171555405_32"
      unitRef="USD">0</blrx:SupplementaryInformationOnIntangibleAssetAcquired>
    <blrx:SupplementaryInformationOnIntangibleAssetAcquired
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20260317110118755_20230320171555405_33"
      unitRef="USD">0</blrx:SupplementaryInformationOnIntangibleAssetAcquired>
    <blrx:SupplementaryInformationOnIntangibleAssetAcquired
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20260317110118755_20230320171555406_34"
      unitRef="USD">6000000</blrx:SupplementaryInformationOnIntangibleAssetAcquired>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250327032729591">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 1 &#x2013; GENERAL INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;width:24pt;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;BioLineRx Ltd. (&#x201c;BioLineRx&#x201d;), headquartered in Modi&#x2019;in, Israel, was incorporated and commenced operations in April 2003. BioLineRx and its subsidiaries (collectively, the &#x201c;Company&#x201d;) are engaged in the development (primarily in clinical stages) and commercialization of therapeutics, with a focus on the fields of oncology and hematology.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;) are traded on the NASDAQ Capital Market, and its ordinary shares are traded on the Tel Aviv Stock Exchange. Each ADS represents 600 ordinary shares.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has one wholly owned subsidiary, BioLineRx USA, Inc., incorporated in the U.S., which had been engaged in commercialization activities associated with the launch of motixafortide for stem-cell mobilization in the U.S., and which is now substantially inactive since the end of 2024 (see below). In addition, the Company is the controlling shareholder of Tetragon Biosciences Ltd. (&#x201c;Tetragon&#x201d;), a company incorporated in Israel in September 2025 for the development and commercialization of GLIX1, a clinical-stage, first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers (see below and Note 17).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In September 2023, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company began to independently commercialize motixafortide in the U.S.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In October 2023, the Company out-licensed the rights to motixafortide for all indications in substantially all of Asia, and in November 2024, the Company out-licensed the global rights (other than in Asia) to motixafortide for all indications, other than solid tumors. In connection with the November 2024 transaction, the Company shut down its independent commercialization activities in the U.S., and entered into an agreement to repay a substantial portion of its outstanding debt, as well as restructure the remaining debt balance. Following these actions, the Company refocused its operations on development activities in Israel in the fields of oncology (including solid tumors) and rare diseases, at a significantly reduced annual cash burn rate.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-top:0px;margin-bottom:0px"&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;font-weight:bold;width:24pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;War in Israel&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On October 7, 2023, an unprecedented invasion was launched against Israel from the Gaza Strip by terrorists from the Hamas terrorist organization that infiltrated Israel&#x2019;s southern border and other areas within the country, attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli civilian population. These attacks resulted in extensive deaths, injuries and the kidnapping of civilians and soldiers. In response, the Security Cabinet of the State of Israel declared war against Hamas, with commencement of a military campaign against the terrorist organization, in parallel to its continued rocket and terror attacks. Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement controlling parts of Yemen, and with Iran. It is also possible that other terrorist organizations, including Palestinian military organizations in the West Bank, will join the hostilities. On October 9, 2025, Israel, Hamas, the US, and other counties in the region agreed to a framework for a ceasefire in Gaza between Israel and Hamas.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In addition, in response to ongoing Iranian aggression and support of proxy attacks against Israel, on June 13, 2025, Israel conducted a series of preemptive defensive air strikes in Iran targeting Iran&#x2019;s nuclear program and military commanders. While a ceasefire was reached in June 2025 following 12 days of hostilities, on February 28, 2026, the United States and Israel launched coordinated military strikes against Iran, including attacks on strategic military infrastructure and leadership targets, with the stated aim of degrading Iran&#x2019;s capacity to conduct or support hostile operations against them. In response, Iran has fired missiles and drones toward population centers and military installations in Israel&lt;span style="font-weight:bold"&gt;, &lt;/span&gt;Europe and neighboring countries in the Gulf region, and also launched counter-strikes against U.S. forces and allied bases throughout the Gulf region. Continued military escalation, retaliatory actions, or broader regional involvement may adversely affect economic conditions, disrupt markets, and create uncertainty that could negatively impact our business, financial condition and results of operations.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The length and severity of the current conflicts in Gaza, Lebanon, Iran and the broader region is unknown at this time, and there can be no assurance that certain ceasefires will hold or that military activities and hostilities will not continue to exist at varying levels of intensity. Any or all of these situations may potentially escalate in the future to more violent events or a greater regional conflict.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s headquarters and principal development operations are located in the State of Israel. In addition, all of its key employees, officers and directors are residents of Israel. The ongoing war and other hostilities in Israel have not, to date, materially impacted the Company&#x2019;s business or operations. Nevertheless, since these are events beyond the Company&#x2019;s control, their continuation or cessation may affect the Company&#x2019;s operations. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employees.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-top:0px;margin-bottom:0px"&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;font-weight:bold;width:24pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Going concern&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has incurred accumulated losses in the amount of $401&#160;million through December 31, 2025,&#160;and it expects to continue incurring losses and negative cash flows from operations until the cash flows from its strategic partnerships reach a level to offset its ongoing development costs. In this regard, Company management monitors rolling forecasts of the Company&#x2019;s liquidity reserves on the basis of anticipated cash flows and seeks to maintain liquidity balances at levels that are sufficient to meet its needs. Management believes that the Company&#x2019;s current cash and other resources will be sufficient to fund its projected cash requirements into the first half of 2027.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s cash flow projections are subject to various risks and uncertainties concerning their fulfilment, and these factors and the risks inherent in the Company&#x2019;s operations indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) on the Company&#x2019;s ability to continue as a going concern. These consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Management&#x2019;s plans include the realization of capital inflows from its strategic partnerships and, if and when required, raising capital through the issuance of debt or equity securities. There are no assurances, however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in realizing the potential cash flows from its strategic partnerships and/or in raising capital, it may need to reduce activities, or curtail or cease operations.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;font-weight:bold;width:24pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change in ratio of ADSs&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On January 30, 2025, the Company effected a change in the ratio of its ADSs to ordinary shares, from one ADS representing 15 ordinary shares to a new ratio of one ADS representing 600 ordinary shares. All ADSs and per ADSs amounts in these financial statements have been retroactively adjusted as if the change in ratio had been effected at the earliest date of these financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="vertical-align:top;font-weight:bold;width:24pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Approval of consolidated financial statements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;text-indent:0pt;margin-left:70.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The consolidated financial statements of the Company for the year ended December 31, 2025 were approved by the Board of Directors on March 18, 2026, and signed on its behalf by the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
    &lt;/div&gt;
  </ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <blrx:DepositaryShareConversionDescription
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317182607060">Each ADS represents 600 ordinary shares</blrx:DepositaryShareConversionDescription>
    <ifrs-full:RetainedEarnings
      contextRef="C_20251231"
      decimals="-6"
      id="Fxbrl_20260318094408173"
      unitRef="USD">-401000000</ifrs-full:RetainedEarnings>
    <blrx:DepositaryShareToOrdinaryShareRatioChangeDescription
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317174817980">On January 30, 2025, the Company effected a change in the ratio of its ADSs to ordinary shares, from one ADS representing 15 ordinary shares to a new ratio of one ADS representing 600 ordinary shares.</blrx:DepositaryShareToOrdinaryShareRatioChangeDescription>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317140533276">
      &lt;div&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 2 &#x2013; MATERIAL ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Basis of preparation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s consolidated financial statements as of December 31, 2024 and 2025, and for each of the three years in the period ended December 31, 2025, have been prepared in accordance with IFRS&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;&#xae;&lt;/sup&gt; Accounting Standards as issued by the International Accounting Standards Board (&#x201c;IASB&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;&#xae;&lt;/sup&gt;&#x201d;) (hereinafter &#x201c;IFRS&#x201d;). The material&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;accounting policies described below have been applied on a consistent basis for all years presented.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The consolidated financial statements have been prepared on the basis of historical cost, subject to adjustment of warrant liabilities to their fair value through profit or loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity and expenses, as well as the related disclosures of contingent assets and liabilities, in the process of applying the Company&#x2019;s accounting policies.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are material&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;to the consolidated financial statements, are disclosed in Note 4. Actual results may differ materially from estimates and assumptions used by the Company&#x2019;s management.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Basis of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Subsidiaries are entities controlled by the Company. Control exists when the Company has power over the investee, is exposed or has rights to variable returns from its involvement with the investee, and has the ability to use its power to affect those returns. Subsidiaries are consolidated from the date on which control is obtained and are deconsolidated from the date control ceases. The financial statements of subsidiaries are prepared for the same reporting period as the parent company using consistent accounting policies.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;All intercompany balances, transactions, income and expenses, and unrealized gains and losses arising from intra-group transactions are eliminated in full upon consolidation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Non-controlling interests&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-controlling interests represent the portion of equity in subsidiaries not attributable, directly or indirectly, to the shareholders of the parent. Non-controlling interests are presented in the consolidated statement of financial position within equity, separately from the equity attributable to the owners of the parent.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in the Company&#x2019;s ownership interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Any difference between the amount by which the non-controlling interests are adjusted, and the fair value of the consideration paid or received, is recognized directly in equity and attributed to the owners of the parent.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt"&gt;&#160;&lt;/p&gt;
        &lt;div&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Functional and reporting currency&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The functional and reporting currency in these financial statements is the U.S. dollar (&#x201c;dollar&#x201d;, &#x201c;USD&#x201d; or &#x201c;$&#x201d;), which is the primary currency of the economic environment in which the Company operates. Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year-end exchange rates are generally recognized in profit or loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Inventory is measured at the lower of cost or net realizable value. The cost of inventories includes purchase costs, packaging and labeling costs, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price of the inventories in the ordinary course of business, less the estimated costs necessary to make the sale. Inventory is written down for estimated obsolescence based upon management assumptions about future demand, expiration due date and market conditions.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;

            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment are stated at historical cost less depreciation. Historical cost includes expenditures that are directly attributable to acquisition of the items. Assets are depreciated by the straight-line method over the estimated useful lives of the assets, provided that Company management believes the residual values of the assets to be negligible, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="margin-left:72pt"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle"&gt;&#160;&lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle;border-bottom:2px solid black"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers and communications equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Office furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

              &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful life of the improvements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;

        &lt;/div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt"&gt;&#160;&lt;/p&gt;
        &lt;div&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-weight:bold;width:43.9pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;font-weight:bold;width:24pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
                      &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company applies the cost method of accounting for initial and subsequent measurements of intangible assets. Under this method of accounting, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="margin-left:70.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company recognizes in its financial statements intellectual property developed by the Company to the extent that the conditions stipulated in paragraph j. below are met. Intellectual property acquired by the Company is initially measured at cost. Intellectual property used by the Company for development purposes and not yet generating revenues is not amortized and is tested annually for impairment. See f. below.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="margin-left:70.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Computer software&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Acquired computer software licenses are capitalized based on the costs incurred&#160;to acquire and bring to use the specific software. These costs are amortized over the estimated useful lives of the software (5 years).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Impairment of non-financial assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Impairment of intellectual property is required when the Company decides to terminate or suspend the development of a project based on such intellectual property. In addition, the Company performs impairment reviews on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment. Property and equipment, as well as computer software, are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized equal to the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value, less costs to sell and the asset&#x2019;s value in use to the Company. See Note 8 for information about an impairment loss recorded in 2023 in connection with the decision to terminate the AGI-134 project, as well as an impairment loss recorded in 2024 in connection with the remaining rights to motixafortide in solid tumor indications.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt"&gt;&#160;&lt;/p&gt;
        &lt;div&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;g.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Receipts in respect of ordinary warrants are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. In the event that the exercise price or the numbers of shares to be issued are not deemed to be fixed, the ordinary warrants are classified as a derivative financial liability. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value at each reporting date. The fair value changes are charged to non-operating income and expense on the statement of comprehensive loss. Issuance costs allocable to ordinary warrants classified as a liability are also recorded as non-operating expense on the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pre-funded warrants are classified in shareholders&#x2019; equity, with initial recognition at fair value on the date issued, using the same valuation assumptions as ordinary warrants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;h&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Borrowings&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;With respect to the long-term loan (see Note 10), a financial liability was recognized for each tranche upon drawdown. Upon initial recognition, the effective interest rate was calculated by estimating the future cash flows, including loan principal repayments, interest and royalties, if any. The royalty feature did not meet the definition of a derivative, was not classified separately, and was not measured separately, since it was an integral part of the loan terms and conditions and could not be transferred or settled separately from the loan.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Determining the weighted effective interest rate requires certain judgments and estimations regarding the timing and amount of the Company&#x2019;s future revenues. The loans are subsequently measured at amortized cost. Furthermore, revisions to the estimated amounts or timing of future cash flows, if necessary, may result in an adjustment of the amortized cost of the loan to reflect the present value of actual and revised estimated contractual cash flows, discounted using the original effective interest rate. This adjustment was recognized in profit or loss as financial income or expense.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months subsequent to the reporting period.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt"&gt;&#160;&lt;/p&gt;
        &lt;div&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;i.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Revenues&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for contract revenue in accordance with IFRS 15, &#x201c;Revenue from Contracts with Customers.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;IFRS 15 introduces a five-step model for recognizing revenue from contracts with customers, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:88.25pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;identify the contract with a customer;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:88.25pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;identify the performance obligations in the contract;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:88.25pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;determine the transaction price;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:88.25pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:88.25pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25;font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Revenues from selling products&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In September 2023, the FDA approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and shortly thereafter, the Company began to independently commercialize motixafortide in the U.S. These activities terminated in November 2024, as a result of the out-licensing transaction entered into with Ayrmid Ltd. (see Note 16) and the shutdown of the Company&#x2019;s U.S. commercial operations. The information below relates to the period during which the Company carried out direct sales activities.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company sells products mainly to wholesale distributors. Gross revenues are recognized at a point in time when control over the product is transferred to the distributors (upon delivery), at the gross selling price. The net revenues reflect gross revenues, reduced by amounts attributable to distributor fees, as well as accruals of chargebacks, rebates and returns.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The specific considerations the Company uses in estimating these amounts relating to variable consideration are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:85pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Distribution fees - The Company pays distribution fees to its three main distributors. The distribution fees are paid based on contractually determined rates from the gross consideration. When the service is received and the products sold to distributors, it is recognized as a reduction of revenues in the period the related revenues from the sale of products are recognized.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:85pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Rebates and patient discount programs - The Company offers various rebate and patient discount programs, which results in discounted prescriptions to qualified patients. The Company estimates the allowance for these rebates, based on the estimated utilization of the rebate and discount programs, at the time the revenues are recognized. These estimates are recognized as a reduction of revenues.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:85pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Product returns - The Company offers customers a right of return as part of the distributor agreements. The Company estimates the amount of product sales that may be returned by its customers and records this estimate as a reduction of revenues at the time of sale, based on estimates of product returns based on its own sales information, its visibility into the inventory remaining in the distribution channel, and product dating.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt"&gt;&#160;&lt;/p&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25;font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Revenues from&lt;/span&gt;&lt;span style="text-decoration:underline"&gt; licensing agreement&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;According to IFRS 15, performance obligations are a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service, either on its own or together with other resources that are readily available to the customer, and the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;IFRS 15 defines the &#x2018;Transaction Price&#x2019; as the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services to a customer.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In accordance with IFRS 15, the Company identified a number of performance obligations (components) in the contract &#x2013; in respect of which revenue will be recognized separately for each component.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following assumptions were taken into account, as part of the revenue recognition process:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Development milestones: Variable payments, contingent on achieving additional milestones, are included in the transaction price based on the most likely amount method. Amounts included in the transaction price are recognized only when it is highly probable that a material&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;reversal of cumulative revenues will not occur, usually upon achievement of the specific milestone, in accordance with the relevant agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sales-based royalties and sales-based milestones are recognized as the related sale occurs, due to the specific exception of IFRS 15 for sales-based royalties from licensing of intellectual properties.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For more information, see Notes 15 and 16.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;j.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research expenses are charged to profit or loss as incurred. As of December 31, 2025, the Company has not yet capitalized development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt"&gt;&#160;&lt;/p&gt;
        &lt;div&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;k.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company operates an equity-settled, share-based compensation plan, under which it grants equity instruments (options, restricted stock units and performance stock units) of the Company as additional consideration for services from employees and service providers. The fair value of the employee services received in exchange for the grant of the equity instruments is recognized as an expense. The total amount to be expensed is determined by reference to the fair value of the equity instruments granted including any market performance conditions (for example, the Company&#x2019;s share price).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-right:0.55pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-market performance and service conditions are included in assumptions about the number of equity instruments that are expected to vest. Performance stock unit expenses are recognized only if it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;l.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The basic loss per share is calculated by dividing the loss attributable to the holders of ordinary shares by the weighted average number of ordinary shares, including pre-funded warrants, outstanding during the year.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Diluted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The diluted loss per share is calculated by adjusting the weighted average number of outstanding ordinary shares, assuming conversion of all dilutive potential shares. The Company&#x2019;s dilutive potential shares consist of warrants issued to investors, as well as equity instruments granted to employees and service providers. The dilutive potential shares were not taken into account in computing loss per share in 2023, 2024 and 2025, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The calculation of diluted loss per share for the years ended December 31, 2023, 2024 and 2025 does not include 369,484,579, 568,205,319 and 1,538,622,579 of shares underlying options and warrants, respectively, because the effect would be anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt"&gt;&#160;&lt;/p&gt;
        &lt;div&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;m.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s leases include property and motor vehicle leases.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date. Simultaneously, the Company recognizes a right-of-use asset in the amount of the lease liability.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Since the interest rate implicit in the lease cannot be readily determined, the Company uses the Company&#x2019;s incremental borrowing rate.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The lease term is the non-cancellable period for which the Company has the right to use an underlying asset, together with both the periods covered by an option to extend the lease, if the Company is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the Company is reasonably certain not to exercise that option.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;After the commencement date, the Company measures the right-of-use asset applying the cost model, less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets are depreciated by the straight-line method over the estimated useful lives of the right of use assets or the lease period, whichever is shorter, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                    &lt;div style="margin-left:72pt"&gt;

                        &lt;div&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                              &lt;tr&gt;
                                &lt;td style="width:76.27%;vertical-align:middle"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:23.73%;vertical-align:middle;border-bottom:2px solid black"&gt;
                                  &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="width:76.27%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td style="width:23.73%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                                  &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="width:76.27%;vertical-align:middle"&gt;
                                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Motor vehicles&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td style="width:23.73%;vertical-align:middle"&gt;
                                  &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;

                          &lt;/table&gt;
                        &lt;/div&gt;

                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;i.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;New International Financial Reporting Standards, amendments to standards and new interpretations&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.85pt;line-height:1.25;font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;New standards and interpretations not yet adopted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.85pt;line-height:1.25;font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;IFRS 18, Presentation and Disclosure in the Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;This standard replaces the international accounting standard IAS 1,&#160;&#x201c;Presentation of Financial Statements.&#x201d; As part of the new disclosure requirements, companies will be required to present new defined subtotals in the statements of income, as follows: (1) operating profit and (2) profit before financing and tax. In addition, income statement items will be classified into three defined categories: operating, investment and financing. The standard also includes a requirement to provide separate disclosure in the financial statements regarding the use of management-defined performance measures (&#x201c;non-GAAP measures&#x201d;), and specific instructions were added for the grouping and splitting of items in the financial statements and in the notes to the financial statements.&#160;IFRS 18&#160;is effective for annual reporting periods beginning on or after January 1, 2027, with an option for early adoption. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statement disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

      &lt;/div&gt;
    </ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <blrx:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162027979">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Basis of preparation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s consolidated financial statements as of December 31, 2024 and 2025, and for each of the three years in the period ended December 31, 2025, have been prepared in accordance with IFRS&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;&#xae;&lt;/sup&gt; Accounting Standards as issued by the International Accounting Standards Board (&#x201c;IASB&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;&#xae;&lt;/sup&gt;&#x201d;) (hereinafter &#x201c;IFRS&#x201d;). The material&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;accounting policies described below have been applied on a consistent basis for all years presented.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The consolidated financial statements have been prepared on the basis of historical cost, subject to adjustment of warrant liabilities to their fair value through profit or loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity and expenses, as well as the related disclosures of contingent assets and liabilities, in the process of applying the Company&#x2019;s accounting policies.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are material&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;to the consolidated financial statements, are disclosed in Note 4. Actual results may differ materially from estimates and assumptions used by the Company&#x2019;s management.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Basis of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Subsidiaries are entities controlled by the Company. Control exists when the Company has power over the investee, is exposed or has rights to variable returns from its involvement with the investee, and has the ability to use its power to affect those returns. Subsidiaries are consolidated from the date on which control is obtained and are deconsolidated from the date control ceases. The financial statements of subsidiaries are prepared for the same reporting period as the parent company using consistent accounting policies.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;All intercompany balances, transactions, income and expenses, and unrealized gains and losses arising from intra-group transactions are eliminated in full upon consolidation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Non-controlling interests&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-controlling interests represent the portion of equity in subsidiaries not attributable, directly or indirectly, to the shareholders of the parent. Non-controlling interests are presented in the consolidated statement of financial position within equity, separately from the equity attributable to the owners of the parent.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in the Company&#x2019;s ownership interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Any difference between the amount by which the non-controlling interests are adjusted, and the fair value of the consideration paid or received, is recognized directly in equity and attributed to the owners of the parent.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </blrx:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162040679">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Functional and reporting currency&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The functional and reporting currency in these financial statements is the U.S. dollar (&#x201c;dollar&#x201d;, &#x201c;USD&#x201d; or &#x201c;$&#x201d;), which is the primary currency of the economic environment in which the Company operates. Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year-end exchange rates are generally recognized in profit or loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162052843">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Inventory is measured at the lower of cost or net realizable value. The cost of inventories includes purchase costs, packaging and labeling costs, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price of the inventories in the ordinary course of business, less the estimated costs necessary to make the sale. Inventory is written down for estimated obsolescence based upon management assumptions about future demand, expiration due date and market conditions.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317135930159">
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment are stated at historical cost less depreciation. Historical cost includes expenditures that are directly attributable to acquisition of the items. Assets are depreciated by the straight-line method over the estimated useful lives of the assets, provided that Company management believes the residual values of the assets to be negligible, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="margin-left:72pt"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle"&gt;&#160;&lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle;border-bottom:2px solid black"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers and communications equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Office furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

              &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:69.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful life of the improvements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <blrx:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326161520539">
                &lt;div&gt;
                  &lt;div style="margin-left:72pt"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle"&gt;&#160;&lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle;border-bottom:2px solid black"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers and communications equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Office furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="width:81.77%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td style="width:18.23%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                            &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </blrx:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"
      id="F20211006115502320_26">33</ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"
      id="F20211006115502321_27">6</ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"
      id="F20211006115502321_28">15</ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162206163">
          &lt;div&gt;
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;font-weight:bold;width:43.9pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;font-weight:bold;width:24pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
                      &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company applies the cost method of accounting for initial and subsequent measurements of intangible assets. Under this method of accounting, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="margin-left:70.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company recognizes in its financial statements intellectual property developed by the Company to the extent that the conditions stipulated in paragraph j. below are met. Intellectual property acquired by the Company is initially measured at cost. Intellectual property used by the Company for development purposes and not yet generating revenues is not amortized and is tested annually for impairment. See f. below.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="margin-left:70.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Computer software&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Acquired computer software licenses are capitalized based on the costs incurred&#160;to acquire and bring to use the specific software. These costs are amortized over the estimated useful lives of the software (5 years).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullIntangibleAssetsWithIndefiniteUsefulLifeAxis_ifrsfullComputerSoftwareMember"
      id="Fxbrl_20250327102756586">5</ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162222635">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Impairment of non-financial assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Impairment of intellectual property is required when the Company decides to terminate or suspend the development of a project based on such intellectual property. In addition, the Company performs impairment reviews on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment. Property and equipment, as well as computer software, are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized equal to the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value, less costs to sell and the asset&#x2019;s value in use to the Company. See Note 8 for information about an impairment loss recorded in 2023 in connection with the decision to terminate the AGI-134 project, as well as an impairment loss recorded in 2024 in connection with the remaining rights to motixafortide in solid tumor indications.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <blrx:DescriptionOfAccountingPolicyForWarrantExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162243307">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;g.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Receipts in respect of ordinary warrants are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. In the event that the exercise price or the numbers of shares to be issued are not deemed to be fixed, the ordinary warrants are classified as a derivative financial liability. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value at each reporting date. The fair value changes are charged to non-operating income and expense on the statement of comprehensive loss. Issuance costs allocable to ordinary warrants classified as a liability are also recorded as non-operating expense on the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pre-funded warrants are classified in shareholders&#x2019; equity, with initial recognition at fair value on the date issued, using the same valuation assumptions as ordinary warrants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </blrx:DescriptionOfAccountingPolicyForWarrantExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162306275">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;h&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Borrowings&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;With respect to the long-term loan (see Note 10), a financial liability was recognized for each tranche upon drawdown. Upon initial recognition, the effective interest rate was calculated by estimating the future cash flows, including loan principal repayments, interest and royalties, if any. The royalty feature did not meet the definition of a derivative, was not classified separately, and was not measured separately, since it was an integral part of the loan terms and conditions and could not be transferred or settled separately from the loan.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Determining the weighted effective interest rate requires certain judgments and estimations regarding the timing and amount of the Company&#x2019;s future revenues. The loans are subsequently measured at amortized cost. Furthermore, revisions to the estimated amounts or timing of future cash flows, if necessary, may result in an adjustment of the amortized cost of the loan to reflect the present value of actual and revised estimated contractual cash flows, discounted using the original effective interest rate. This adjustment was recognized in profit or loss as financial income or expense.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months subsequent to the reporting period.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162329517">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;i.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Revenues&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for contract revenue in accordance with IFRS 15, &#x201c;Revenue from Contracts with Customers.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;IFRS 15 introduces a five-step model for recognizing revenue from contracts with customers, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:88.25pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;identify the contract with a customer;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:88.25pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;identify the performance obligations in the contract;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:88.25pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;determine the transaction price;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:88.25pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:88.25pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25;font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Revenues from selling products&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In September 2023, the FDA approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and shortly thereafter, the Company began to independently commercialize motixafortide in the U.S. These activities terminated in November 2024, as a result of the out-licensing transaction entered into with Ayrmid Ltd. (see Note 16) and the shutdown of the Company&#x2019;s U.S. commercial operations. The information below relates to the period during which the Company carried out direct sales activities.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company sells products mainly to wholesale distributors. Gross revenues are recognized at a point in time when control over the product is transferred to the distributors (upon delivery), at the gross selling price. The net revenues reflect gross revenues, reduced by amounts attributable to distributor fees, as well as accruals of chargebacks, rebates and returns.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The specific considerations the Company uses in estimating these amounts relating to variable consideration are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:85pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Distribution fees - The Company pays distribution fees to its three main distributors. The distribution fees are paid based on contractually determined rates from the gross consideration. When the service is received and the products sold to distributors, it is recognized as a reduction of revenues in the period the related revenues from the sale of products are recognized.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:85pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Rebates and patient discount programs - The Company offers various rebate and patient discount programs, which results in discounted prescriptions to qualified patients. The Company estimates the allowance for these rebates, based on the estimated utilization of the rebate and discount programs, at the time the revenues are recognized. These estimates are recognized as a reduction of revenues.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:85pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Product returns - The Company offers customers a right of return as part of the distributor agreements. The Company estimates the amount of product sales that may be returned by its customers and records this estimate as a reduction of revenues at the time of sale, based on estimates of product returns based on its own sales information, its visibility into the inventory remaining in the distribution channel, and product dating.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt"&gt;&#160;&lt;/p&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25;font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Revenues from&lt;/span&gt;&lt;span style="text-decoration:underline"&gt; licensing agreement&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;According to IFRS 15, performance obligations are a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service, either on its own or together with other resources that are readily available to the customer, and the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;IFRS 15 defines the &#x2018;Transaction Price&#x2019; as the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services to a customer.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In accordance with IFRS 15, the Company identified a number of performance obligations (components) in the contract &#x2013; in respect of which revenue will be recognized separately for each component.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following assumptions were taken into account, as part of the revenue recognition process:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Development milestones: Variable payments, contingent on achieving additional milestones, are included in the transaction price based on the most likely amount method. Amounts included in the transaction price are recognized only when it is highly probable that a material&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;reversal of cumulative revenues will not occur, usually upon achievement of the specific milestone, in accordance with the relevant agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sales-based royalties and sales-based milestones are recognized as the related sale occurs, due to the specific exception of IFRS 15 for sales-based royalties from licensing of intellectual properties.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For more information, see Notes 15 and 16.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162345055">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;j.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research expenses are charged to profit or loss as incurred. As of December 31, 2025, the Company has not yet capitalized development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162401427">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;k.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company operates an equity-settled, share-based compensation plan, under which it grants equity instruments (options, restricted stock units and performance stock units) of the Company as additional consideration for services from employees and service providers. The fair value of the employee services received in exchange for the grant of the equity instruments is recognized as an expense. The total amount to be expensed is determined by reference to the fair value of the equity instruments granted including any market performance conditions (for example, the Company&#x2019;s share price).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-right:0.55pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-market performance and service conditions are included in assumptions about the number of equity instruments that are expected to vest. Performance stock unit expenses are recognized only if it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162532956">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;l.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The basic loss per share is calculated by dividing the loss attributable to the holders of ordinary shares by the weighted average number of ordinary shares, including pre-funded warrants, outstanding during the year.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Diluted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The diluted loss per share is calculated by adjusting the weighted average number of outstanding ordinary shares, assuming conversion of all dilutive potential shares. The Company&#x2019;s dilutive potential shares consist of warrants issued to investors, as well as equity instruments granted to employees and service providers. The dilutive potential shares were not taken into account in computing loss per share in 2023, 2024 and 2025, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The calculation of diluted loss per share for the years ended December 31, 2023, 2024 and 2025 does not include 369,484,579, 568,205,319 and 1,538,622,579 of shares underlying options and warrants, respectively, because the effect would be anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember"
      decimals="0"
      id="Fxbrl_20250326162459780"
      unitRef="Shares">369484579</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember"
      decimals="0"
      id="Fxbrl_20240324133220155"
      unitRef="Shares">568205319</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullShareOptionsMember"
      decimals="0"
      id="Fxbrl_20240324133441369"
      unitRef="Shares">1538622579</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317140445716">
          &lt;div&gt;
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;m.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                      &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s leases include property and motor vehicle leases.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date. Simultaneously, the Company recognizes a right-of-use asset in the amount of the lease liability.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Since the interest rate implicit in the lease cannot be readily determined, the Company uses the Company&#x2019;s incremental borrowing rate.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The lease term is the non-cancellable period for which the Company has the right to use an underlying asset, together with both the periods covered by an option to extend the lease, if the Company is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the Company is reasonably certain not to exercise that option.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;After the commencement date, the Company measures the right-of-use asset applying the cost model, less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets are depreciated by the straight-line method over the estimated useful lives of the right of use assets or the lease period, whichever is shorter, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                    &lt;div style="margin-left:72pt"&gt;

                        &lt;div&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                              &lt;tr&gt;
                                &lt;td style="width:76.27%;vertical-align:middle"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:23.73%;vertical-align:middle;border-bottom:2px solid black"&gt;
                                  &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="width:76.27%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td style="width:23.73%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                                  &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="width:76.27%;vertical-align:middle"&gt;
                                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Motor vehicles&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td style="width:23.73%;vertical-align:middle"&gt;
                                  &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;

                          &lt;/table&gt;
                        &lt;/div&gt;

                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <blrx:DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317140511131">
                        &lt;div&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                              &lt;tr&gt;
                                &lt;td style="width:76.27%;vertical-align:middle"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:23.73%;vertical-align:middle;border-bottom:2px solid black"&gt;
                                  &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="width:76.27%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td style="width:23.73%;vertical-align:middle;background-color:rgb(204, 238, 255)"&gt;
                                  &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="width:76.27%;vertical-align:middle"&gt;
                                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Motor vehicles&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td style="width:23.73%;vertical-align:middle"&gt;
                                  &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;

                          &lt;/table&gt;
                        &lt;/div&gt;
                      </blrx:DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory>
    <blrx:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      id="F20211006115502322_29">11</blrx:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets>
    <blrx:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      id="F20211006115502322_30">3</blrx:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets>
    <blrx:DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326162724866">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;i.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;New International Financial Reporting Standards, amendments to standards and new interpretations&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.85pt;line-height:1.25;font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;New standards and interpretations not yet adopted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.85pt;line-height:1.25;font-style:italic"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;IFRS 18, Presentation and Disclosure in the Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;This standard replaces the international accounting standard IAS 1,&#160;&#x201c;Presentation of Financial Statements.&#x201d; As part of the new disclosure requirements, companies will be required to present new defined subtotals in the statements of income, as follows: (1) operating profit and (2) profit before financing and tax. In addition, income statement items will be classified into three defined categories: operating, investment and financing. The standard also includes a requirement to provide separate disclosure in the financial statements regarding the use of management-defined performance measures (&#x201c;non-GAAP measures&#x201d;), and specific instructions were added for the grouping and splitting of items in the financial statements and in the notes to the financial statements.&#160;IFRS 18&#160;is effective for annual reporting periods beginning on or after January 1, 2027, with an option for early adoption. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statement disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </blrx:DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20240324113143639">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 3 &#x2013; FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin:0px 0px 0px 44.6pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Based on assessments by Company management, the Company&#x2019;s exposure to credit risk as of December 31, 2025, is immaterial (see Note 3b). The activities of the Company expose it to market risk, primarily as a result of currency risk.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin:0px 0px 0px 44.6pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s Finance Department is responsible for carrying out risk management activities in accordance with policies approved by its Board of Directors. In this regard, the Finance Department identifies, defines and assesses financial risk in close cooperation with other Company departments. The Board of Directors provides written guidelines for overall risk management, as well as written policies dealing with specific areas, such as exchange rate risk, interest rate risk, credit risk, use of financial instruments and investment of excess cash.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Market risk&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:21pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Concentration of currency risk&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s activities are partly denominated in non-dollar currencies (primarily the New Israeli Shekel, or &#x201c;NIS,&#x201d; and the Euro), which exposes the Company to risks resulting from changes in exchange rates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The effect of fluctuations in various exchange rates on the Company&#x2019;s income and equity is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="margin-left:90pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Value on&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sensitive instrument&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10% increase&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5% increase&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;balance sheet&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5% decrease&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10% decrease&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NIS-linked balances:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(179&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(94&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,974&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;104&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;219&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="margin-left:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Short term deposit&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(86&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(45&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;943&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;50&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;105&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(7&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(3&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;72&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;8&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;19&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;10&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(206&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(11&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(23&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;87&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;46&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(962&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(51&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(107&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total NIS-linked balances&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(166&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(86&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,821&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;96&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;202&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Euro-linked trade payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(107&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(56&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,177&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;62&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;131&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(273&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(142&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;333&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:90pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Value on&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sensitive instrument&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10% increase&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5% increase&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;balance sheet&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5% decrease&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10% decrease&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NIS-linked balances:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(87&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(45&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;955&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;50&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;106&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(52&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(27&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;568&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;30&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;63&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;115&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;60&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(933&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(67&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(141&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;154&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;81&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,495&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(89&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(188&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total NIS-linked balances&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;130&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;69&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(905&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(76&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(160&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Euro-linked trade payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(83&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(44&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(919&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;48&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;102&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,824&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(28&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(58&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company also maintains cash and cash equivalent balances in other currencies in amounts that are not material.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-top:0px;margin-bottom:0px"&gt;&lt;/div&gt;
      &lt;div style="margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Set forth below is information on the linkage of monetary items:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="margin-left:92.15pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="margin-left:90pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding:0px 0px 2px"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dollar&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NIS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;currencies&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dollar&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NIS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currencies&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:middle;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD in thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:middle;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD in thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,428&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;955&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;53&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;973&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,974&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;303&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,126&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;16,683&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;943&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;819&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;568&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;91&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;338&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;72&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;19,373&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,523&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;144&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;17,994&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,989&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;303&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current maturities of long-term loan&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4,479&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4,479&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accounts payable and accruals:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:0pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;3,549&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;933&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,101&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,993&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;206&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,294&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:0pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,636&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,495&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;781&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;962&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Long-term loan, net of current maturities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;8,958&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4,460&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;18,622&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,428&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,101&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11,713&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,168&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,294&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net balance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;751&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(905&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(957&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;6,281&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,821&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(991&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-top:0px;margin-bottom:0px"&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2025, the financial instruments of the Company consist of non-derivative assets and liabilities (primarily working capital items, deposits, and current and long-term loans), as well as warrants classified as a liability.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;With regard to non-derivative assets and liabilities, given their nature, the fair value of the financial instruments included in working capital is generally close or identical to their carrying amount, as the effect of discounting is immaterial.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;With regard to the warrants classified as a current financial liability, see Note 11c. With regard to long-term loans, see Note 10.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-indent:-21.25pt;margin-left:92.15pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exposure to market risk and management thereof&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In the opinion of Company management, the market risk to which the Company is exposed is primarily related to currency risk exposure, as mentioned above.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest rate risk&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Company management does not consider interest rate risk to be material, as the Company holds deposits whose fair value and/or cash flows are not materially affected by changes in interest rates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Credit risk&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Credit risk is managed at the Company level. These risks relate to cash and cash equivalents, bank deposits, trade receivables, and other receivables.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s cash, cash equivalents and short-term bank deposits at December 31, 2024, and 2025 were deposited with highly rated major Israeli and U.S. banks. In the Company&#x2019;s opinion, the credit risk associated with these balances is remote.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company considers its maximum exposure to credit risk to be as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div style="margin-left:72pt"&gt;
          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;10,436&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;3,250&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,126&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;17,626&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,476&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;46&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,478&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;410&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;23,516&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;21,332&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-top:0px;margin-bottom:0px"&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Liquidity risk&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Company management monitors rolling forecasts of the Company&#x2019;s liquidity reserves on the basis of anticipated cash flows and seeks to maintain the liquidity balances at a level that is sufficient to meet its needs.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Although the Company has succeeded in generating revenues from a number of out-licensing transactions, as well as the commercialization of its lead program, motixafortide, during 2024, it cannot determine with reasonable certainty if and when it will become profitable on a current basis. Management believes that the Company&#x2019;s current cash and other resources will be sufficient to fund its projected cash requirements into the first half of 2027. However, in the event that the Company does not begin to generate sustainable cash flows from its operating activities in the future, the Company will need to carry out significant cost reductions and/or raise additional funding. See also Note 1c regarding the material uncertainty that may cast significant doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-indent:36pt;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The different levels of valuation of financial instruments are defined as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:72pt"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

            &lt;tr&gt;
              &lt;td style="width:8%;vertical-align:top"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:8%;vertical-align:top"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:8%;vertical-align:top"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Inputs, other than quoted prices included within level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:8%;vertical-align:top"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:8%;vertical-align:top"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Inputs for the asset or liability that are not based on observable market data (unobservable inputs).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk, in its assessment of fair value. The fair value of the financial instruments included in the working capital of the Company, as well as the long-term loan, is usually identical or close to their carrying value, as the effect of discounting is immaterial. The fair value of the warrants is based on Level 3 measurements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of the warrants, calculated based on the Black-Scholes model, was $2,174,000 as of December 31, 2025.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;text-indent:-0.05pt;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For more information on the parameters used to value the warrants, see Note 11c.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-top:0px;margin-bottom:0px"&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in financial liabilities with cash flows included in financing activities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="margin-left:72pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Long-term loan&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;10,168&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4,509&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;14,677&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during the year 2023:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Principal and interest payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,543&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,543&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts recognized through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,148&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11,054&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;12,202&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share premium resulting from exercise of warrants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(3,631&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(3,631&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,773&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11,932&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;21,705&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during the year 2024:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net proceeds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;19,223&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;8,724&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;27,947&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Principal and interest payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(22,795&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(22,795&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts recognized through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;7,236&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(18,965&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(11,729&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;13,437&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,691&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;15,128&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during the year 2025:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net proceeds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,082&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,082&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Principal and interest payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(5,568&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(5,568&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts recognized through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,070&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(8,599&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(7,529&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;8,939&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,174&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11,113&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fair value measurement of warrants using significant unobservable inputs (level 3)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table presents the changes in level 3 instruments for the years ended December 31, 2023, 2024 and 2025:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,509&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during 2023:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercises&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;(3,631&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-14.15pt;margin-left:30.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in fair value through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;11,054&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;11,932&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during 2024:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issuances&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;8,724&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-14.15pt;margin-left:30.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in fair value through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;(18,965&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,691&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during 2025:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issuances&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;9,082&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="margin-left:15.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in fair value through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;(8,599&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

    &lt;/div&gt;
  </ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <blrx:DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326191859313">
        &lt;div&gt;
          &lt;div style="margin-left:90pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Value on&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sensitive instrument&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10% increase&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5% increase&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;balance sheet&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5% decrease&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10% decrease&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NIS-linked balances:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(179&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(94&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,974&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;104&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;219&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="margin-left:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Short term deposit&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(86&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(45&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;943&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;50&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;105&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(7&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(3&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;72&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;8&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;19&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;10&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(206&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(11&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(23&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;87&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;46&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(962&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(51&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(107&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total NIS-linked balances&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(166&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(86&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,821&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;96&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;202&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Euro-linked trade payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(107&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(56&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,177&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;62&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;131&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(273&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(142&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;333&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:90pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Value on&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sensitive instrument&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10% increase&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5% increase&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;balance sheet&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5% decrease&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10% decrease&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="18" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NIS-linked balances:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(87&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(45&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;955&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;50&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;106&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(52&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(27&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;568&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;30&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;63&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;115&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;60&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(933&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(67&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(141&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;154&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;81&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,495&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(89&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(188&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total NIS-linked balances&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;130&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;69&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(905&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(76&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(160&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Euro-linked trade payables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(83&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(44&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(919&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;48&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;102&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:40%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,824&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(28&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(58&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"
      decimals="-3"
      id="Fxbrl_20210923050317609_20211006115502390_8"
      unitRef="USD">-179000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"
      decimals="-3"
      id="Fxbrl_20210923050317609_20211006115502399_9"
      unitRef="USD">-94000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"
      decimals="-3"
      id="Fxbrl_20210923050317609_20211006115502405_10"
      unitRef="USD">1974000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"
      decimals="-3"
      id="Fxbrl_20210923050317609_20211006115502406_11"
      unitRef="USD">104000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"
      decimals="-3"
      id="Fxbrl_20210923050317609_20211006115502408_12"
      unitRef="USD">219000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember"
      decimals="-3"
      id="Fxbrl_20260317204521940_xbrl_20210923050317609_20211006115502390_8"
      unitRef="USD">-86000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember"
      decimals="-3"
      id="Fxbrl_20260317204521940_xbrl_20210923050317609_20211006115502399_9"
      unitRef="USD">-45000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember"
      decimals="-3"
      id="Fxbrl_20260317204521940_xbrl_20210923050317609_20211006115502405_10"
      unitRef="USD">943000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember"
      decimals="-3"
      id="Fxbrl_20260317204521940_xbrl_20210923050317609_20211006115502406_11"
      unitRef="USD">50000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxShortTermDepositMember"
      decimals="-3"
      id="Fxbrl_20260317204521940_xbrl_20210923050317609_20211006115502408_12"
      unitRef="USD">105000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317629_20211006115502409_13"
      unitRef="USD">-7000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317629_20211006115502410_14"
      unitRef="USD">-3000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317629_20211006115502412_15"
      unitRef="USD">72000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317629_20211006115502428_16"
      unitRef="USD">4000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317629_20211006115502429_17"
      unitRef="USD">8000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317654_20211006115502430_18"
      unitRef="USD">19000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317654_20211006115502431_19"
      unitRef="USD">10000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317654_20211006115502433_20"
      unitRef="USD">-206000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317654_20211006115502437_21"
      unitRef="USD">-11000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317654_20211006115502438_22"
      unitRef="USD">-23000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317678_20211006115502439_23"
      unitRef="USD">87000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317678_20211006115502440_24"
      unitRef="USD">46000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317678_20211006115502442_25"
      unitRef="USD">-962000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317678_20211006115502443_26"
      unitRef="USD">-51000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317678_20211006115502444_27"
      unitRef="USD">-107000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"
      decimals="-3"
      id="Fxbrl_20260317101507687_xbrl_20210923050317678_20211006115502439_23"
      unitRef="USD">-166000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"
      decimals="-3"
      id="Fxbrl_20260317101507687_xbrl_20210923050317678_20211006115502440_24"
      unitRef="USD">-86000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"
      decimals="-3"
      id="Fxbrl_20260317101507687_xbrl_20210923050317678_20211006115502442_25"
      unitRef="USD">1821000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"
      decimals="-3"
      id="Fxbrl_20260317101507687_xbrl_20210923050317678_20211006115502443_26"
      unitRef="USD">96000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"
      decimals="-3"
      id="Fxbrl_20260317101507687_xbrl_20210923050317678_20211006115502444_27"
      unitRef="USD">202000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317731_20211006115502463_33"
      unitRef="USD">-107000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317731_20211006115502478_34"
      unitRef="USD">-56000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317731_20211006115502479_35"
      unitRef="USD">-1177000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317731_20211006115502480_36"
      unitRef="USD">62000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"
      decimals="-3"
      id="Fxbrl_20210923050317731_20211006115502482_37"
      unitRef="USD">131000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20260317101621151_xbrl_20210923050317731_20211006115502463_33"
      unitRef="USD">-273000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20260317101621151_xbrl_20210923050317731_20211006115502478_34"
      unitRef="USD">-142000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20260317101621151_xbrl_20210923050317731_20211006115502479_35"
      unitRef="USD">644000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20260317101621151_xbrl_20210923050317731_20211006115502480_36"
      unitRef="USD">158000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20260317101621151_xbrl_20210923050317731_20211006115502482_37"
      unitRef="USD">333000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"
      decimals="-3"
      id="F20211006115502390_8"
      unitRef="USD">-87000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"
      decimals="-3"
      id="F20211006115502399_9"
      unitRef="USD">-45000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"
      decimals="-3"
      id="F20211006115502405_10"
      unitRef="USD">955000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"
      decimals="-3"
      id="F20211006115502406_11"
      unitRef="USD">50000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember"
      decimals="-3"
      id="F20211006115502408_12"
      unitRef="USD">106000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"
      decimals="-3"
      id="F20211006115502409_13"
      unitRef="USD">-52000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"
      decimals="-3"
      id="F20211006115502410_14"
      unitRef="USD">-27000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"
      decimals="-3"
      id="F20211006115502412_15"
      unitRef="USD">568000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"
      decimals="-3"
      id="F20211006115502428_16"
      unitRef="USD">30000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherReceivablesMember"
      decimals="-3"
      id="F20211006115502429_17"
      unitRef="USD">63000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"
      decimals="-3"
      id="F20211006115502430_18"
      unitRef="USD">115000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"
      decimals="-3"
      id="F20211006115502431_19"
      unitRef="USD">60000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"
      decimals="-3"
      id="F20211006115502433_20"
      unitRef="USD">-933000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"
      decimals="-3"
      id="F20211006115502437_21"
      unitRef="USD">-67000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxTradePayablesMember"
      decimals="-3"
      id="F20211006115502438_22"
      unitRef="USD">-141000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"
      decimals="-3"
      id="F20211006115502439_23"
      unitRef="USD">154000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"
      decimals="-3"
      id="F20211006115502440_24"
      unitRef="USD">81000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"
      decimals="-3"
      id="F20211006115502442_25"
      unitRef="USD">-1495000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"
      decimals="-3"
      id="F20211006115502443_26"
      unitRef="USD">-89000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxOtherPayablesMember"
      decimals="-3"
      id="F20211006115502444_27"
      unitRef="USD">-188000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"
      decimals="-3"
      id="F20211006115502445_28"
      unitRef="USD">130000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"
      decimals="-3"
      id="F20211006115502446_29"
      unitRef="USD">69000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"
      decimals="-3"
      id="F20211006115502447_30"
      unitRef="USD">-905000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"
      decimals="-3"
      id="F20211006115502448_31"
      unitRef="USD">-76000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxNisLinkedBalancesMember"
      decimals="-3"
      id="F20211006115502449_32"
      unitRef="USD">-160000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"
      decimals="-3"
      id="F20211006115502463_33"
      unitRef="USD">-83000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"
      decimals="-3"
      id="F20211006115502478_34"
      unitRef="USD">-44000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"
      decimals="-3"
      id="F20211006115502479_35"
      unitRef="USD">-919000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"
      decimals="-3"
      id="F20211006115502480_36"
      unitRef="USD">48000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxEuroLinkedTradePayablesMember"
      decimals="-3"
      id="F20211006115502482_37"
      unitRef="USD">102000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240324115437139_xbrl_20210923050317755_20211006115502483_38"
      unitRef="USD">47000</blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity>
    <blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240324115437139_xbrl_20210923050317755_20211006115502484_39"
      unitRef="USD">25000</blrx:FivePercentIncreaseEffectOnNetIncomeLossAndEquity>
    <ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240324115437139_xbrl_20210923050317755_20211006115502490_40"
      unitRef="USD">-1824000</ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreads>
    <blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240324115437139_xbrl_20240324115048940"
      unitRef="USD">-28000</blrx:FivePercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20240324115437139_xbrl_20240324115058793"
      unitRef="USD">-58000</blrx:TenPercentDecreaseEffectOnNetIncomeLossAndEquity>
    <blrx:DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20240324120631670">
        &lt;div&gt;
          &lt;div style="margin-left:90pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding:0px 0px 2px"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dollar&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NIS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;currencies&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dollar&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NIS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid;vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currencies&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;padding:0px 0px 2px"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:middle;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD in thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:middle;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD in thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,428&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;955&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;53&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;973&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,974&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;303&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,126&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;16,683&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;943&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;819&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;568&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;91&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;338&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;72&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;19,373&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,523&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;144&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;17,994&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,989&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;303&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current maturities of long-term loan&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4,479&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4,479&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accounts payable and accruals:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:0pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;3,549&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;933&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,101&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,993&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;206&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,294&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:0pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,636&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,495&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;781&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;962&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:18pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:27pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Long-term loan, net of current maturities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;8,958&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4,460&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;18,622&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,428&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,101&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11,713&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,168&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,294&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net balance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;751&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(905&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(957&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;6,281&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,821&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(991&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502512_88"
      unitRef="USD">9428000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502513_89"
      unitRef="USD">955000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502514_90"
      unitRef="USD">53000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502515_91"
      unitRef="USD">973000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502516_92"
      unitRef="USD">1974000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502517_93"
      unitRef="USD">303000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502520_94"
      unitRef="USD">9126000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502521_95"
      unitRef="USD">0</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502522_96"
      unitRef="USD">0</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502523_97"
      unitRef="USD">16683000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502524_98"
      unitRef="USD">943000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502524_99"
      unitRef="USD">0</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:OtherReceivables
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502525_100"
      unitRef="USD">819000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502526_101"
      unitRef="USD">568000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502527_102"
      unitRef="USD">91000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502528_103"
      unitRef="USD">338000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502529_104"
      unitRef="USD">72000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502530_105"
      unitRef="USD">0</ifrs-full:OtherReceivables>
    <ifrs-full:Assets
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502533_106"
      unitRef="USD">19373000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502534_107"
      unitRef="USD">1523000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502535_108"
      unitRef="USD">144000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502535_109"
      unitRef="USD">17994000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502536_110"
      unitRef="USD">2989000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502537_111"
      unitRef="USD">303000</ifrs-full:Assets>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502538_112"
      unitRef="USD">4479000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502539_113"
      unitRef="USD">0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502540_114"
      unitRef="USD">0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502541_115"
      unitRef="USD">4479000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502542_116"
      unitRef="USD">0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502543_117"
      unitRef="USD">0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502546_118"
      unitRef="USD">3549000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502547_119"
      unitRef="USD">933000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502548_120"
      unitRef="USD">1101000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502549_121"
      unitRef="USD">1993000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502550_122"
      unitRef="USD">206000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502550_123"
      unitRef="USD">1294000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:OtherPayables
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="Fxbrl_20240324174939473"
      unitRef="USD">1636000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502551_124"
      unitRef="USD">1495000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502552_125"
      unitRef="USD">0</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502554_127"
      unitRef="USD">781000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502555_128"
      unitRef="USD">962000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502556_129"
      unitRef="USD">0</ifrs-full:OtherPayables>
    <ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502559_130"
      unitRef="USD">8958000</ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived>
    <ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502560_131"
      unitRef="USD">0</ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived>
    <ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502561_132"
      unitRef="USD">0</ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived>
    <ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502562_133"
      unitRef="USD">4460000</ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived>
    <ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502563_134"
      unitRef="USD">0</ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived>
    <ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502564_135"
      unitRef="USD">0</ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived>
    <ifrs-full:Liabilities
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502565_136"
      unitRef="USD">18622000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502566_137"
      unitRef="USD">2428000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502567_138"
      unitRef="USD">1101000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502568_139"
      unitRef="USD">11713000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502568_140"
      unitRef="USD">1168000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502570_141"
      unitRef="USD">1294000</ifrs-full:Liabilities>
    <blrx:NetAssetValueOfLinkageMonetaryItems
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502572_142"
      unitRef="USD">751000</blrx:NetAssetValueOfLinkageMonetaryItems>
    <blrx:NetAssetValueOfLinkageMonetaryItems
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502573_143"
      unitRef="USD">-905000</blrx:NetAssetValueOfLinkageMonetaryItems>
    <blrx:NetAssetValueOfLinkageMonetaryItems
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502574_144"
      unitRef="USD">-957000</blrx:NetAssetValueOfLinkageMonetaryItems>
    <blrx:NetAssetValueOfLinkageMonetaryItems
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxDollarMember"
      decimals="-3"
      id="F20211006115502575_145"
      unitRef="USD">6281000</blrx:NetAssetValueOfLinkageMonetaryItems>
    <blrx:NetAssetValueOfLinkageMonetaryItems
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxNisMember"
      decimals="-3"
      id="F20211006115502576_146"
      unitRef="USD">1821000</blrx:NetAssetValueOfLinkageMonetaryItems>
    <blrx:NetAssetValueOfLinkageMonetaryItems
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_blrxOtherCurrenciesMember"
      decimals="-3"
      id="F20211006115502577_147"
      unitRef="USD">-991000</blrx:NetAssetValueOfLinkageMonetaryItems>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20240324120639549">
        &lt;div style="margin-left:72pt"&gt;
          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;10,436&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;3,250&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,126&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;17,626&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade receivables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,476&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;46&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-9pt;margin-left:24.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,478&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;410&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;23,516&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;21,332&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"
      decimals="-3"
      id="F20211006115502578_148"
      unitRef="USD">10436000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"
      decimals="-3"
      id="F20211006115502579_149"
      unitRef="USD">3250000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"
      decimals="-3"
      id="F20211006115502580_150"
      unitRef="USD">9126000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"
      decimals="-3"
      id="F20211006115502581_151"
      unitRef="USD">17626000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:TradeReceivables
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"
      decimals="-3"
      id="Fxbrl_20240324113439146_20211006115502580_150"
      unitRef="USD">2476000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"
      decimals="-3"
      id="Fxbrl_20240324113439146_20211006115502581_151"
      unitRef="USD">46000</ifrs-full:TradeReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"
      decimals="-3"
      id="F20211006115502582_152"
      unitRef="USD">1478000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"
      decimals="-3"
      id="F20211006115502583_153"
      unitRef="USD">410000</ifrs-full:OtherReceivables>
    <ifrs-full:Assets
      contextRef="C_20241231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"
      decimals="-3"
      id="F20211006115502585_154"
      unitRef="USD">23516000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_20251231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember"
      decimals="-3"
      id="F20211006115502586_155"
      unitRef="USD">21332000</ifrs-full:Assets>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="C_20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="0"
      id="F20211006115502380_1"
      unitRef="USD">2174000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20240324120656358">
        &lt;div&gt;
          &lt;div style="margin-left:72pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Long-term loan&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;10,168&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4,509&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;14,677&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during the year 2023:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Principal and interest payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,543&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,543&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts recognized through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,148&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11,054&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;12,202&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share premium resulting from exercise of warrants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(3,631&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(3,631&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,773&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11,932&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;21,705&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during the year 2024:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net proceeds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;19,223&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;8,724&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;27,947&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Principal and interest payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(22,795&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(22,795&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts recognized through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;7,236&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(18,965&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(11,729&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;13,437&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,691&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;15,128&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during the year 2025:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net proceeds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,082&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,082&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Principal and interest payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(5,568&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(5,568&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts recognized through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,070&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(8,599&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(7,529&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;8,939&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,174&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11,113&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20221231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="F20211006115502587_156"
      unitRef="USD">10168000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20221231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="F20211006115502588_157"
      unitRef="USD">4509000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20221231"
      decimals="-3"
      id="F20211006115502589_158"
      unitRef="USD">14677000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20230101to20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="F20211006115502590_159"
      unitRef="USD">1543000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="F20211006115502591_160"
      unitRef="USD">0</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115502592_161"
      unitRef="USD">1543000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities
      contextRef="C_20230101to20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="F20211006115502597_165"
      unitRef="USD">1148000</blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities>
    <blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities
      contextRef="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="F20211006115502599_166"
      unitRef="USD">11054000</blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities>
    <blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115502601_167"
      unitRef="USD">12202000</blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities>
    <blrx:SharePremiumResultingFromExerciseOfWarrants
      contextRef="C_20230101to20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="Fxbrl_20240324115004996"
      unitRef="USD">0</blrx:SharePremiumResultingFromExerciseOfWarrants>
    <blrx:SharePremiumResultingFromExerciseOfWarrants
      contextRef="C_20230101to20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="Fxbrl_20240324114917970_xbrl_20220305103524791_xbrl_20220304191819962_20211006115502613_178"
      unitRef="USD">-3631000</blrx:SharePremiumResultingFromExerciseOfWarrants>
    <blrx:SharePremiumResultingFromExerciseOfWarrants
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240324114917970_xbrl_20220305103524791_xbrl_20220304191819962_20211006115502614_179"
      unitRef="USD">-3631000</blrx:SharePremiumResultingFromExerciseOfWarrants>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20231231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="F20211006115502602_168"
      unitRef="USD">9773000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20231231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="F20211006115502603_169"
      unitRef="USD">11932000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20231231"
      decimals="-3"
      id="F20211006115502604_170"
      unitRef="USD">21705000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20240101to20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="Fxbrl_20250326192916872_20211006115502608_174"
      unitRef="USD">19223000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="Fxbrl_20250326192916872_20211006115502609_175"
      unitRef="USD">8724000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250326192916872_20211006115502610_176"
      unitRef="USD">27947000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20240101to20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="F20211006115502611_177"
      unitRef="USD">22795000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="F20211006115502613_178"
      unitRef="USD">0</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115502614_179"
      unitRef="USD">22795000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities
      contextRef="C_20240101to20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="F20211006115502615_180"
      unitRef="USD">7236000</blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities>
    <blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities
      contextRef="C_20240101to20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="F20211006115502616_181"
      unitRef="USD">-18965000</blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities>
    <blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115502617_182"
      unitRef="USD">-11729000</blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20241231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="F20211006115502618_183"
      unitRef="USD">13437000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20241231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="F20211006115502619_184"
      unitRef="USD">1691000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115502620_185"
      unitRef="USD">15128000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20250101to20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="F20211006115502608_174"
      unitRef="USD">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="F20211006115502609_175"
      unitRef="USD">9082000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115502610_176"
      unitRef="USD">9082000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20250101to20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="Fxbrl_20240324114900770_20211006115502611_177"
      unitRef="USD">5568000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="Fxbrl_20240324114900770_20211006115502613_178"
      unitRef="USD">0</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324114900770_20211006115502614_179"
      unitRef="USD">5568000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities
      contextRef="C_20250101to20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="Fxbrl_20240324114908957_20211006115502615_180"
      unitRef="USD">1070000</blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities>
    <blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities
      contextRef="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="Fxbrl_20240324114908957_20211006115502616_181"
      unitRef="USD">-8599000</blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities>
    <blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324114908957_20211006115502617_182"
      unitRef="USD">-7529000</blrx:IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20251231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullLongtermBorrowingsMember"
      decimals="-3"
      id="Fxbrl_20240324114934398_20211006115502618_183"
      unitRef="USD">8939000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="-3"
      id="Fxbrl_20240324114934398_20211006115502619_184"
      unitRef="USD">2174000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20240324114934398_20211006115502620_185"
      unitRef="USD">11113000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317101400566">
        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,509&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during 2023:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercises&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;(3,631&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-14.15pt;margin-left:30.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in fair value through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;11,054&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;11,932&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during 2024:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issuances&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;8,724&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-14.15pt;margin-left:30.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in fair value through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;(18,965&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,691&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes during 2025:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:16.8pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issuances&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;9,082&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="margin-left:15.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in fair value through profit and loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;(8,599&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance as of December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <blrx:FairValueOfWarrants
      contextRef="C_20221231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"
      decimals="-3"
      id="F20211006115502621_186"
      unitRef="USD">4509000</blrx:FairValueOfWarrants>
    <blrx:WarrantsExercises
      contextRef="C_20230101to20231231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"
      decimals="-3"
      id="Fxbrl_20220304192105656"
      unitRef="USD">-3631000</blrx:WarrantsExercises>
    <blrx:ChangesInFairValueThroughProfitAndLossOfWarrants
      contextRef="C_20230101to20231231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"
      decimals="-3"
      id="F20211006115502623_188"
      unitRef="USD">11054000</blrx:ChangesInFairValueThroughProfitAndLossOfWarrants>
    <blrx:FairValueOfWarrants
      contextRef="C_20231231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"
      decimals="-3"
      id="F20211006115502628_192"
      unitRef="USD">11932000</blrx:FairValueOfWarrants>
    <blrx:IssuancesOfWarrants
      contextRef="C_20240101to20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"
      decimals="-3"
      id="Fxbrl_20250326192810721_20211006115502622_187"
      unitRef="USD">8724000</blrx:IssuancesOfWarrants>
    <blrx:ChangesInFairValueThroughProfitAndLossOfWarrants
      contextRef="C_20240101to20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"
      decimals="-3"
      id="F20211006115502627_191"
      unitRef="USD">-18965000</blrx:ChangesInFairValueThroughProfitAndLossOfWarrants>
    <blrx:FairValueOfWarrants
      contextRef="C_20241231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"
      decimals="-3"
      id="F20211006115502632_196"
      unitRef="USD">1691000</blrx:FairValueOfWarrants>
    <blrx:IssuancesOfWarrants
      contextRef="C_20250101to20251231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"
      decimals="-3"
      id="F20211006115502622_187"
      unitRef="USD">9082000</blrx:IssuancesOfWarrants>
    <blrx:ChangesInFairValueThroughProfitAndLossOfWarrants
      contextRef="C_20250101to20251231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"
      decimals="-3"
      id="F20211006115502631_195"
      unitRef="USD">-8599000</blrx:ChangesInFairValueThroughProfitAndLossOfWarrants>
    <blrx:FairValueOfWarrants
      contextRef="C_20251231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember"
      decimals="-3"
      id="Fxbrl_20240324120123228"
      unitRef="USD">2174000</blrx:FairValueOfWarrants>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20240323034353643">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 4 &#x2013; CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As part of the financial reporting process, Company management is required to make estimates that affect the value of assets, liabilities, income, expenses and certain disclosures included in the Company&#x2019;s consolidated financial statements. By their very nature, such accounting estimates are subjective and complex and consequently may differ from actual results. The estimates are continually evaluated and adjusted based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Below are the critical accounting estimates used in the preparation of the financial statements that required Company management to make assumptions involving significant uncertainty.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-indent:-21.25pt;margin-left:70.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of indefinite-lived intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As mentioned in Notes 2e and 2f, the Company performs impairment reviews of intangible assets not subject to amortization on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The recoverable amount is determined using discounted cash flow calculations. The analysis estimates the future cash flows the Company expects to derive from the asset, incorporates expectations about possible variations in the amount or timing of those future cash flows, as well as the uncertainty inherent in the asset, and the risk-adjusted cash flows are then discounted using the Company&#x2019;s estimated post-tax weighted average cost of capital (&#x201c;WACC&#x201d;). The main estimates used in calculating the recoverable amount include the WACC estimation and the amounts and timing of projected future cash flows. Such amounts and timing are influenced by the expected outcome of development activities, the probability of success and timing in gaining regulatory approval, size of the potential market and the Company&#x2019;s specific market share, either via direct sales or a potential out-licensing deal.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In light of the Company&#x2019;s decision to terminate AGI-134, the value of its intangible asset was written off in its entirety in 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As a result of an impairment review of its remaining rights to motixafortide in solid tumor indications in the fourth quarter of 2024, the Company recorded an impairment loss (see Note 8).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2025, the Company has concluded that the value of its intangible assets is higher than their carrying value.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20240323034651084">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 5 &#x2013; CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div&gt;
            &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:54pt"&gt;

                &lt;div&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash on hand and in bank&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;944&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;632&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;9,492&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;2,618&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;10,436&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;3,250&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:49.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The short-term bank deposits included in cash and cash equivalents bear interest at annual rates of between 0.7% and 4.9%.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <blrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326163654597">
                &lt;div&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash on hand and in bank&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;944&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;632&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;9,492&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;2,618&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;10,436&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;3,250&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              </blrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory>
    <ifrs-full:Cash
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115502655_1"
      unitRef="USD">944000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115502655_2"
      unitRef="USD">632000</ifrs-full:Cash>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115502655_3"
      unitRef="USD">9492000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115502655_4"
      unitRef="USD">2618000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115502656_5"
      unitRef="USD">10436000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115502656_6"
      unitRef="USD">3250000</ifrs-full:CashAndCashEquivalents>
    <blrx:InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents
      contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember"
      decimals="3"
      id="Fxbrl_20230311051437007"
      unitRef="Pure">0.007</blrx:InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents>
    <blrx:InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents
      contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember"
      decimals="3"
      id="Fxbrl_20230311051447312"
      unitRef="Pure">0.049</blrx:InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents>
    <ifrs-full:DisclosureOfDepositsFromBanksExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20240323034902050">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 6 &#x2013; SHORT-TERM BANK DEPOSITS&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:49.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The short-term bank deposits are primarily in dollars and bear interest at annual rates of between 4.20% and 5.82%.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </ifrs-full:DisclosureOfDepositsFromBanksExplanatory>
    <blrx:InterestRateOnShortTermDeposits
      contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember"
      decimals="4"
      id="Fxbrl_20230311051710899"
      unitRef="Pure">0.042</blrx:InterestRateOnShortTermDeposits>
    <blrx:InterestRateOnShortTermDeposits
      contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember"
      decimals="4"
      id="Fxbrl_20230311051643701"
      unitRef="Pure">0.0582</blrx:InterestRateOnShortTermDeposits>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317141712300">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 7 &#x2013; PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:49.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Set forth below are the composition of property and equipment and the related accumulated depreciation, grouped by major classifications:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:54pt"&gt;

          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net book value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:10%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Composition in 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:10%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Office furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers and communications equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;331&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:10%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:10%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,932&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:10%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,939&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,987&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;

      &lt;/div&gt;
    &lt;/div&gt;
  </ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317141723430">
          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net book value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;width:10%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="14" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:10%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Composition in 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:10%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Office furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;177&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers and communications equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;331&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:10%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:10%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,932&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:10%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,939&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,987&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:6%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502681_1"
      unitRef="USD">251000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502682_2"
      unitRef="USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502683_3"
      unitRef="USD">42000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502684_4"
      unitRef="USD">209000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502685_5"
      unitRef="USD">-191000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502686_6"
      unitRef="USD">27000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502686_7"
      unitRef="USD">-41000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509500_xbrl_20210923022737036_20211006115502681_11"
      unitRef="USD">-177000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509500_20211006115502726_91"
      unitRef="USD">60000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullOfficeEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509500_20211006115502726_92"
      unitRef="USD">32000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502689_11"
      unitRef="USD">467000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502689_12"
      unitRef="USD">25000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502690_13"
      unitRef="USD">161000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502691_14"
      unitRef="USD">331000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502692_15"
      unitRef="USD">-291000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502693_16"
      unitRef="USD">70000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502694_17"
      unitRef="USD">-138000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509525_xbrl_20210923022737062_20211006115502689_111"
      unitRef="USD">-223000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509525_20211006115502727_93"
      unitRef="USD">176000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509525_20211006115502727_94"
      unitRef="USD">108000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502698_21"
      unitRef="USD">1571000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502699_22"
      unitRef="USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502699_23"
      unitRef="USD">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502700_24"
      unitRef="USD">1571000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502701_25"
      unitRef="USD">-1525000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502702_26"
      unitRef="USD">26000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502703_27"
      unitRef="USD">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509556_xbrl_20210923022737088_20211006115502698_211"
      unitRef="USD">-1551000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509556_20211006115502728_95"
      unitRef="USD">46000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_blrxLaboratoryEquipmentMember"
      decimals="-3"
      id="Fxbrl_20210923024509556_20211006115502729_96"
      unitRef="USD">20000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"
      decimals="-3"
      id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502705_31"
      unitRef="USD">2036000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"
      decimals="-3"
      id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502705_32"
      unitRef="USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"
      decimals="-3"
      id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502706_33"
      unitRef="USD">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"
      decimals="-3"
      id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502707_34"
      unitRef="USD">2036000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"
      decimals="-3"
      id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502708_35"
      unitRef="USD">-1932000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"
      decimals="-3"
      id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502709_36"
      unitRef="USD">104000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"
      decimals="-3"
      id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502710_37"
      unitRef="USD">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"
      decimals="-3"
      id="Fxbrl_20210923024509587_xbrl_20210923022737117_20211006115502705_311"
      unitRef="USD">-2036000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"
      decimals="-3"
      id="Fxbrl_20210923024509587_20211006115502730_97"
      unitRef="USD">104000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullLeaseholdImprovementsMember"
      decimals="-3"
      id="Fxbrl_20210923024509587_20211006115502733_98"
      unitRef="USD">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502713_41"
      unitRef="USD">4325000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502714_42"
      unitRef="USD">25000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502714_43"
      unitRef="USD">203000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502715_44"
      unitRef="USD">4147000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember"
      decimals="-3"
      id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502716_45"
      unitRef="USD">-3939000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember"
      decimals="-3"
      id="Fxbrl_20230314125758233"
      unitRef="USD">227000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember"
      decimals="-3"
      id="Fxbrl_20210923024520812_xbrl_20210923022749221_20211006115502718_47"
      unitRef="USD">-179000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember"
      decimals="-3"
      id="Fxbrl_20230314125810560"
      unitRef="USD">-3987000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember"
      decimals="-3"
      id="Fxbrl_20210923024520812_20211006115502734_99"
      unitRef="USD">386000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember"
      decimals="-3"
      id="Fxbrl_20210923024520812_20211006115502734_100"
      unitRef="USD">160000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20240323035623011">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 8 &#x2013; INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:49.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;Intellectual property included the following intangible assets acquired by the Company:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:51.05pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:19.85pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$6.7 million primarily related to AGI-134. In December 2023, the Company made a decision to terminate the development of AGI-134 and, accordingly, an impairment loss for the full amount of the related intellectual property was recorded in the 2023 financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:51.05pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:19.85pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$15.0 million associated with BL-8040 were recorded following an amendment to the in-licensing agreement with Biokine Therapeutics Ltd. (&#x201c;Biokine&#x201d;). This amendment reduced the payments owed by the Company on sublicense receipts (as defined in the license agreement) from 40% to 20%. This intellectual property is amortized proportionally with the revenues recognized from the licensing transaction with HST and Gloria in Asia (see Note 15), and with Ayrmid for the rest of the world (excluding solid tumors) (see Note 16). During the period of self-commercialization in the U.S. of motixafortide in 2024, this intellectual property was amortized in accordance with the lifespan of the patents in the U.S. In addition, as a result of an impairment review of its remaining rights to motixafortide in solid tumor indications in the fourth quarter of 2024, the Company recorded an impairment loss of $1.0 million. Sensitivity tests on impairment of the remaining rights to motixafortide in solid tumor indications were carried out as of December 31, 2025, by increasing the WACC by 0.5% and by decreasing the annual growth rate of new cases by 0.5%. Such changes, if realized, would not have a material effect on the carrying amount of the motixafortide intellectual property. As of December 31, 2025, the net book value of the intangible assets associated with BL-8040 amounted to $10.2 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:51.05pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$6.0 million associated with the acquisition of GLIX1, pursuant to the collaboration transaction and asset transfer agreement with Hemispherian AS (see Note 17).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;text-indent:-19.85pt;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2025, the Company has concluded that the value of its intangible assets is higher than their carrying value.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;text-indent:-19.85pt;margin-left:70.9pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:51.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Set forth below are the composition of intangible assets and the related accumulated depreciation, grouped by major classifications:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accumulated depreciation and impairment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Disposal&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net book value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Composition in 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;21,342&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;3,323&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;18,019&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;6,799&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;1,010&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;7,809&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;10,210&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computer software&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;982&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;1&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;185&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;798&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;671&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;73&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;185&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;559&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;239&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;22,324&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;1&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;185&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;3,323&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;18,817&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;7,470&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;73&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;185&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;1,010&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;8,368&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;10,449&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Composition in 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:16%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;18,019&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;6,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;6,700&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;17,319&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;7,809&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;6,700&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;1,109&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;10,210&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;16,210&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computer software&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;798&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;2&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;4&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;796&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;559&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;82&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;3&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;638&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;239&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;158&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:16%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;18,817&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;6,002&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;6,704&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;18,115&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;8,368&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;82&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;6,703&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;1,747&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;10,449&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;16,368&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

    &lt;/div&gt;
  </ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="C_20251231_ifrsfullBusinessCombinationsAxis_blrxAgalimmuneLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-5"
      id="Fxbrl_20250326175306079"
      unitRef="USD">6700000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="C_20251231_ifrsfullBusinessCombinationsAxis_blrxBiokineTherapeuticsLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-5"
      id="Fxbrl_20250326175427881"
      unitRef="USD">15000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <blrx:PercentageOfPaymentToBeMade
      contextRef="C_20250101to20251231_ifrsfullBusinessCombinationsAxis_blrxBiokineTherapeuticsLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      id="Fxbrl_20250326175541026">40% to 20%</blrx:PercentageOfPaymentToBeMade>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill
      contextRef="C_20250101to20251231_ifrsfullBusinessCombinationsAxis_blrxBiokineTherapeuticsLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-5"
      id="Fxbrl_20250326182401084"
      unitRef="USD">1000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <blrx:PercentageOfIncreasingWeightedAverageCostOfCapital
      contextRef="C_20251231"
      decimals="3"
      id="Fxbrl_20250328203717154"
      unitRef="Pure">0.005</blrx:PercentageOfIncreasingWeightedAverageCostOfCapital>
    <blrx:PercentageOfDecreasingAnnualGrowthRate
      contextRef="C_20251231"
      decimals="3"
      id="Fxbrl_20250328203724794"
      unitRef="Pure">0.005</blrx:PercentageOfDecreasingAnnualGrowthRate>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_blrxBL8040Member"
      decimals="-2"
      id="Fxbrl_20260319164858920"
      unitRef="USD">10200</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullBusinessCombinationsAxis_blrxGlix1Member"
      decimals="-5"
      id="Fxbrl_20260317113438748"
      unitRef="USD">6000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326175052192">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accumulated depreciation and impairment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Disposal&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Impairment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net book value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Composition in 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;21,342&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;3,323&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;18,019&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;6,799&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;1,010&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;7,809&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;10,210&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computer software&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;982&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;1&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;185&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;798&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;671&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;73&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;185&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;559&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;239&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;22,324&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;1&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;185&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;3,323&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;18,817&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;7,470&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;73&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;185&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;1,010&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;8,368&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;10,449&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;strong&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Composition in 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:16%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;18,019&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;6,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;6,700&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;17,319&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;7,809&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;6,700&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;1,109&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;10,210&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;16,210&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none"&gt;&lt;span style="font-size:9pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computer software&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;798&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;2&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;4&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;796&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;559&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;82&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;3&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;638&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;239&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;158&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:16%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;18,817&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;6,002&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;6,704&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;18,115&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;8,368&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;82&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;6,703&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;-&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;1,747&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;10,449&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:4%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:9pt"&gt;16,368&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-weight:normal;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-size:9pt;font-style:normal;font-variant:normal;text-transform:none;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250326180837730"
      unitRef="USD">21342000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250326181014441"
      unitRef="USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250326184206862"
      unitRef="USD">0</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250326181035360"
      unitRef="USD">3323000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250326181108746"
      unitRef="USD">18019000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250326181128651"
      unitRef="USD">-6799000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250326181334161"
      unitRef="USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250326184431684"
      unitRef="USD">0</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250326181413186"
      unitRef="USD">-1010000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250326181436154"
      unitRef="USD">-7809000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250326181614360"
      unitRef="USD">10210000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326180843674"
      unitRef="USD">982000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326180938994"
      unitRef="USD">1000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326184232596"
      unitRef="USD">185000</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326181042635"
      unitRef="USD">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326181059298"
      unitRef="USD">798000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326181122562"
      unitRef="USD">-671000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326181244586"
      unitRef="USD">73000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326184438035"
      unitRef="USD">185000</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326181358386"
      unitRef="USD">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326181431017"
      unitRef="USD">-559000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326181601650"
      unitRef="USD">239000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20250326180851354"
      unitRef="USD">22324000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20250326180858905"
      unitRef="USD">1000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20250326184301714"
      unitRef="USD">185000</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20250326181047651"
      unitRef="USD">3323000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20250326181054418"
      unitRef="USD">18817000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20231231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-3"
      id="Fxbrl_20250326181117137"
      unitRef="USD">-7470000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-3"
      id="Fxbrl_20250326181154419"
      unitRef="USD">73000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-3"
      id="Fxbrl_20250326184452938"
      unitRef="USD">185000</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-3"
      id="Fxbrl_20250326181346674"
      unitRef="USD">-1010000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-3"
      id="Fxbrl_20250326181420202"
      unitRef="USD">-8368000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember"
      decimals="-3"
      id="Fxbrl_20250326181453779"
      unitRef="USD">10449000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20210924003137540_20211006115502773_1"
      unitRef="USD">18019000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20210924003137540_20211006115502774_2"
      unitRef="USD">6000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250328205521418"
      unitRef="USD">6700000</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20210924003137540_20211006115502775_3"
      unitRef="USD">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20210924003137540_20211006115502775_4"
      unitRef="USD">17319000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20210924003137540_20211006115502776_5"
      unitRef="USD">-7809000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20210924003137540_20211006115502777_6"
      unitRef="USD">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20250328205547986"
      unitRef="USD">6700000</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20210924003137540_20211006115502777_7"
      unitRef="USD">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20210924003137540_20211006115502773_11"
      unitRef="USD">-1109000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20210924003137540_20211006115502773_15"
      unitRef="USD">10210000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember"
      decimals="-3"
      id="Fxbrl_20210924003137540_20211006115502773_19"
      unitRef="USD">16210000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20210924003137581_20211006115502782_11"
      unitRef="USD">798000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20210924003137581_20211006115502782_12"
      unitRef="USD">2000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326184313276"
      unitRef="USD">4000</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20210924003137581_20211006115502783_13"
      unitRef="USD">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20210924003137581_20211006115502783_14"
      unitRef="USD">796000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20210924003137581_20211006115502784_15"
      unitRef="USD">-559000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20210924003137581_20211006115502785_16"
      unitRef="USD">82000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20250326184501541"
      unitRef="USD">3000</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20210924003137581_20211006115502785_17"
      unitRef="USD">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20210924003137581_20211006115502782_111"
      unitRef="USD">-638000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20210924003137581_20211006115502782_115"
      unitRef="USD">239000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullComputerSoftwareMember"
      decimals="-3"
      id="Fxbrl_20210924003137581_20211006115502782_119"
      unitRef="USD">158000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_21"
      unitRef="USD">18817000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_22"
      unitRef="USD">6002000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20250326184333780"
      unitRef="USD">6704000</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_23"
      unitRef="USD">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502788_24"
      unitRef="USD">18115000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-3"
      id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502789_25"
      unitRef="USD">-8368000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-3"
      id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502789_26"
      unitRef="USD">82000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <blrx:DeletionsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-3"
      id="Fxbrl_20250326184507195"
      unitRef="USD">6703000</blrx:DeletionsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-3"
      id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502790_27"
      unitRef="USD">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-3"
      id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_211"
      unitRef="USD">-1747000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember"
      decimals="-3"
      id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_215"
      unitRef="USD">10449000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember"
      decimals="-3"
      id="Fxbrl_20210924003209514_xbrl_20210923214622329_20211006115502787_219"
      unitRef="USD">16368000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326191254510">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 9 &#x2013; LEASES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Right-of-use assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:72pt"&gt;

          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net book value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Composition in 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:middle;width:20%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,551&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,551&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;810&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;135&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;945&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;741&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;606&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:middle;width:20%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Motor vehicles&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;456&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;196&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;260&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;230&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;79&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;139&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;170&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;226&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;90&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:20%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;2,007&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;196&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,811&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,040&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;214&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;139&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,115&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;967&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;696&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

      &lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:72pt"&gt;

          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange differences&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="22" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Composition in 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:16%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,409&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;176&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;174&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;596&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,163&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Motor vehicles&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;194&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;71&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;10&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;17&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;102&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;48&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:16%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,603&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;71&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;186&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;191&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;698&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,211&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;

      &lt;/div&gt;
      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;C.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additional disclosures&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:71.85pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:21pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company leases its premises in Israel under a lease agreement entered into in August 2014. Payments under the lease commenced in June 2015, and the initial term of the lease expired in June 2020. The lease agreement includes three options to extend the lease through June 30, 2030 in the aggregate, each at a 5% increase to the preceding lease payment amount. The Company exercised its first and second options to extend the lease through June 30, 2028, and is currently making monthly lease payments of approximately $30,000. In addition to the monthly lease payments, the Company also pays building monthly maintenance charges of approximately $9,700.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:71.85pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:21pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has entered into lease agreements in connection with a number of vehicles. The lease periods are generally for three years. The annual lease fees, linked to the CPI, are approximately $215,000. To secure the terms of the lease agreements, the Company has prepaid two months of lease payments to the leasing companies.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:71.85pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:21pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2025, minimum future rental payments (taking into consideration the aforementioned extension periods) under the leases are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:72pt"&gt;

          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Motor vehicles&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;332&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;106&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;438&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;348&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;21&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;369&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;348&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;348&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2029-2030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;523&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;523&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,551&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;127&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,678&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;

      &lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Extension and termination options are included in the property lease. These are used to maximize operational flexibility in terms of managing the assets used in the Company&#x2019;s operations. The substantial majority of extension and termination options are exercisable solely by the Company and not by the lessors.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
    &lt;/div&gt;
  </ifrs-full:DisclosureOfLeasesExplanatory>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326191348973">
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net book value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                  &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="14" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Composition in 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:middle;width:20%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,551&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,551&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;810&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;135&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;945&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;741&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;606&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:middle;width:20%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Motor vehicles&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;456&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;196&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;260&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;230&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;79&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;139&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;170&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;226&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;90&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:20%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;2,007&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;196&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,811&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,040&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;214&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;139&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;1,115&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;967&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:5%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;696&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        </ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="F20211006115502851_26"
      unitRef="USD">1551000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="F20211006115502852_27"
      unitRef="USD">0</ifrs-full:AdditionsToRightofuseAssets>
    <blrx:DeletionsToRightOfUseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="F20211006115502853_28"
      unitRef="USD">0</blrx:DeletionsToRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="F20211006115502853_29"
      unitRef="USD">1551000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="F20211006115502854_30"
      unitRef="USD">-810000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="F20211006115502855_31"
      unitRef="USD">135000</ifrs-full:AdditionsToRightofuseAssets>
    <blrx:DeletionsToRightOfUseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="F20211006115502856_32"
      unitRef="USD">0</blrx:DeletionsToRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="F20211006115502851_261"
      unitRef="USD">-945000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="F20211006115502851_265"
      unitRef="USD">741000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="F20211006115502851_269"
      unitRef="USD">606000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="F20211006115502859_36"
      unitRef="USD">456000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="F20211006115502859_37"
      unitRef="USD">0</ifrs-full:AdditionsToRightofuseAssets>
    <blrx:DeletionsToRightOfUseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="F20211006115502860_38"
      unitRef="USD">196000</blrx:DeletionsToRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="F20211006115502861_39"
      unitRef="USD">260000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="F20211006115502862_40"
      unitRef="USD">-230000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="F20211006115502862_41"
      unitRef="USD">79000</ifrs-full:AdditionsToRightofuseAssets>
    <blrx:DeletionsToRightOfUseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="F20211006115502863_42"
      unitRef="USD">139000</blrx:DeletionsToRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="F20211006115502859_361"
      unitRef="USD">-170000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="F20211006115502859_365"
      unitRef="USD">226000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="F20211006115502859_369"
      unitRef="USD">90000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="F20211006115502865_46"
      unitRef="USD">2007000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="F20211006115502865_47"
      unitRef="USD">0</ifrs-full:AdditionsToRightofuseAssets>
    <blrx:DeletionsToRightOfUseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="F20211006115502866_48"
      unitRef="USD">196000</blrx:DeletionsToRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember"
      decimals="-3"
      id="F20211006115502866_49"
      unitRef="USD">1811000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember"
      decimals="-3"
      id="F20211006115502867_50"
      unitRef="USD">-1040000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember"
      decimals="-3"
      id="F20211006115502868_51"
      unitRef="USD">214000</ifrs-full:AdditionsToRightofuseAssets>
    <blrx:DeletionsToRightOfUseAssets
      contextRef="C_20250101to20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember"
      decimals="-3"
      id="F20211006115502868_52"
      unitRef="USD">139000</blrx:DeletionsToRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullAccumulatedDepreciationAndAmortisationMember"
      decimals="-3"
      id="F20211006115502865_461"
      unitRef="USD">-1115000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember"
      decimals="-3"
      id="F20211006115502865_465"
      unitRef="USD">967000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="C_20251231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember"
      decimals="-3"
      id="F20211006115502865_469"
      unitRef="USD">696000</ifrs-full:RightofuseAssets>
    <blrx:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326191404133">
          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deletions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange differences&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;beginning&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;during&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;end of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="22" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Composition in 2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:16%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,409&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;176&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;174&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;596&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,163&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:middle;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.6pt;margin-left:5.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Motor vehicles&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;194&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;71&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;10&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;17&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;102&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;48&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:16%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,603&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;71&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;186&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;191&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;698&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,211&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        </blrx:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory>
    <ifrs-full:LeaseLiabilities
      contextRef="C_20241231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="Fxbrl_20210924024124710_20211006115502837_11"
      unitRef="USD">1409000</ifrs-full:LeaseLiabilities>
    <blrx:AdditionsLeaseLiabilities
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="Fxbrl_20240326121702366"
      unitRef="USD">0</blrx:AdditionsLeaseLiabilities>
    <blrx:DeletionsLeaseLiabilities
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="Fxbrl_20210924024124710_20211006115502836_9"
      unitRef="USD">0</blrx:DeletionsLeaseLiabilities>
    <blrx:InterestExpenseLeaseLiabilities
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="Fxbrl_20210924024124710_20211006115502835_8"
      unitRef="USD">176000</blrx:InterestExpenseLeaseLiabilities>
    <blrx:ExchangeDifferencesDuringYear
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="Fxbrl_20230314032624262"
      unitRef="USD">174000</blrx:ExchangeDifferencesDuringYear>
    <blrx:PaymentsLeaseLiabilities
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="Fxbrl_20210924024124710_20211006115502833_6"
      unitRef="USD">596000</blrx:PaymentsLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="Fxbrl_20210924024124710_20211006115502833_5"
      unitRef="USD">1163000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_20241231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="Fxbrl_20210924024124734_20211006115502845_18"
      unitRef="USD">194000</ifrs-full:LeaseLiabilities>
    <blrx:AdditionsLeaseLiabilities
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="Fxbrl_20210924024124734_20211006115502842_17"
      unitRef="USD">0</blrx:AdditionsLeaseLiabilities>
    <blrx:DeletionsLeaseLiabilities
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="Fxbrl_20210924024124734_20211006115502841_16"
      unitRef="USD">71000</blrx:DeletionsLeaseLiabilities>
    <blrx:InterestExpenseLeaseLiabilities
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="Fxbrl_20210924024124734_20211006115502840_15"
      unitRef="USD">10000</blrx:InterestExpenseLeaseLiabilities>
    <blrx:ExchangeDifferencesDuringYear
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="Fxbrl_20230314032632460"
      unitRef="USD">17000</blrx:ExchangeDifferencesDuringYear>
    <blrx:PaymentsLeaseLiabilities
      contextRef="C_20250101to20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="Fxbrl_20210924024124734_20211006115502839_13"
      unitRef="USD">102000</blrx:PaymentsLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="Fxbrl_20210924024124734_20211006115502838_12"
      unitRef="USD">48000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20210924024132837_20211006115502850_25"
      unitRef="USD">1603000</ifrs-full:LeaseLiabilities>
    <blrx:AdditionsLeaseLiabilities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20210924024132837_20211006115502850_24"
      unitRef="USD">0</blrx:AdditionsLeaseLiabilities>
    <blrx:DeletionsLeaseLiabilities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20210924024132837_20211006115502849_23"
      unitRef="USD">71000</blrx:DeletionsLeaseLiabilities>
    <blrx:InterestExpenseLeaseLiabilities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20210924024132837_20211006115502848_22"
      unitRef="USD">186000</blrx:InterestExpenseLeaseLiabilities>
    <blrx:ExchangeDifferencesDuringYear
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230314032641700"
      unitRef="USD">191000</blrx:ExchangeDifferencesDuringYear>
    <blrx:PaymentsLeaseLiabilities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20210924024132837_20211006115502847_20"
      unitRef="USD">698000</blrx:PaymentsLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20210924024132837_20211006115502846_19"
      unitRef="USD">1211000</ifrs-full:LeaseLiabilities>
    <blrx:AdditionalExtendLeasePeriod
      contextRef="C_20250101to20251231_srtStatementGeographicalAxis_countryIL"
      id="Fxbrl_20230314033314848">three</blrx:AdditionalExtendLeasePeriod>
    <blrx:PercentageIncreasePrecedingLeasePaymentAmount
      contextRef="C_20250101to20251231_srtStatementGeographicalAxis_countryIL"
      decimals="2"
      id="Fxbrl_20230314033321512"
      unitRef="Pure">0.05</blrx:PercentageIncreasePrecedingLeasePaymentAmount>
    <blrx:LeaseAgreementMonthlyFee
      contextRef="C_20250101to20251231_srtStatementGeographicalAxis_countryIL"
      decimals="-3"
      id="Fxbrl_20230314033341560"
      unitRef="USD">30000000</blrx:LeaseAgreementMonthlyFee>
    <ifrs-full:RepairsAndMaintenanceExpense
      contextRef="C_20250101to20251231_srtStatementGeographicalAxis_countryIL"
      decimals="-3"
      id="Fxbrl_20230314033410465"
      unitRef="USD">9700000</ifrs-full:RepairsAndMaintenanceExpense>
    <blrx:LeasePeriod
      contextRef="C_20250101to20251231"
      id="Fxbrl_20230314035606134">P3Y</blrx:LeasePeriod>
    <blrx:AnnualLeaseFee
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230314035626037"
      unitRef="USD">215000000</blrx:AnnualLeaseFee>
    <ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326191426838">
          &lt;div&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Motor vehicles&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;332&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;106&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;438&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;348&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;21&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;369&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;348&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;348&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2029-2030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;523&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;523&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,551&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;127&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,678&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember"
      decimals="-3"
      id="F20211006115502888_121"
      unitRef="USD">332000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember"
      decimals="-3"
      id="F20211006115502889_122"
      unitRef="USD">106000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullMaturityAxis_ifrsfullNotLaterThanOneYearMember"
      decimals="-3"
      id="F20211006115502890_123"
      unitRef="USD">438000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-3"
      id="F20211006115502891_124"
      unitRef="USD">348000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-3"
      id="F20211006115502891_125"
      unitRef="USD">21000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-3"
      id="F20211006115502894_126"
      unitRef="USD">369000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-3"
      id="Fxbrl_20250326193055625"
      unitRef="USD">348000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-3"
      id="F20211006115502895_128"
      unitRef="USD">0</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-3"
      id="F20211006115502896_129"
      unitRef="USD">348000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember"
      decimals="-3"
      id="F20211006115502899_133"
      unitRef="USD">523000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember"
      decimals="-3"
      id="F20211006115502900_134"
      unitRef="USD">0</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullMaturityAxis_ifrsfullLaterThanFiveYearsAndNotLaterThanTenYearsMember"
      decimals="-3"
      id="F20211006115502900_135"
      unitRef="USD">523000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember"
      decimals="-3"
      id="F20211006115502901_136"
      unitRef="USD">1551000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231_ifrsfullClassesOfAssetsAxis_ifrsfullMotorVehiclesMember"
      decimals="-3"
      id="F20211006115502902_137"
      unitRef="USD">127000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115502903_138"
      unitRef="USD">1678000</ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived>
    <ifrs-full:DisclosureOfBorrowingsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317115816245">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 10 &lt;/span&gt;&lt;/span&gt;&#x2013;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt; LONG-TERM LOAN&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In September 2022, the Company entered into a loan agreement with BlackRock EMEA Venture and Growth Lending (previously Kreos Capital VII Aggregator SCSP) (&#x201c;BlackRock&#x201d;), with an aggregate principal amount of up to $40 million comprised of three tranches of up to $10 million, $20 million and $10 million. The Company drew down the initial tranche of $10 million following execution of the loan agreement in September 2022, and it drew down the second tranche of $20 million in April 2024, following fulfilment of the requisite milestones. The third tranche was available for drawdown until October 1, 2024, upon the achievement of certain milestones. No drawdown was made by the indicated date, and thus, availably of the third tranche under the facility was cancelled.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Each tranche of the loan carried a pre-defined interest-only payment period, followed by a loan principal amortization period of up to 36 months subsequent to the interest-only period. The interest-only periods were subject to possible extension based on certain pre-defined milestones. Borrowings under the financing bear interest at a fixed annual rate of 9.5% (~11.0%, including associated cash fees). As security for the loan, BlackRock received a first-priority secured interest in all Company assets, including intellectual property, and the Company undertook to maintain a $10 million minimum cash balance. In addition, BlackRock was entitled to mid-to-high single-digit revenue-based payments on motixafortide sales in the U.S., up to a pre-defined cap.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2024, in connection with the Ayrmid License Agreement, the Company entered into an amendment to the loan Agreement with BlackRock. Pursuant to the amendment: (i) the Company made a payment of $16.5 million as partial repayment of the loan to BlackRock and in lieu of future revenue-based payments, which were fully cancelled, (ii) effective December 1, 2024, the Company began to pay the remaining amounts outstanding under the loan (in principal and interest) over a three-year period ending December 1, 2027, and (iii) the Company&#x2019;s minimum cash balance requirement under the Loan Agreement was reduced to $4 million. In addition, pursuant to the amendment, 10% of any future milestone payments received by the Company from its out-licensing agreements through December 1, 2027 will be used to repay outstanding loan principal, and the repayments in (ii) above will be adjusted accordingly. All other terms of the Loan Agreement remain the same.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:49.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The above amendment met the criteria in IFRS 9 regarding a substantial modification of the terms of a financial liability. In accordance with this paragraph, such modification is to be accounted for as the extinguishment of the original financial liability and the recognition of a new financial liability, with the&#160;difference between the carrying amount of the derecognized financial liability, versus any consideration paid plus any new liability undertaken, recorded as interest expense or income in the statement of comprehensive loss. Accordingly, the above amendment resulted in approximately $4.0 million of interest expense in the fourth quarter of 2024.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
    &lt;/div&gt;
  </ifrs-full:DisclosureOfBorrowingsExplanatory>
    <blrx:AmountOfLoanAgreement
      contextRef="C_20220901to20220930_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="-6"
      id="Fxbrl_20230314043327229"
      unitRef="USD">40000000</blrx:AmountOfLoanAgreement>
    <blrx:AmountOfLoanAgreement
      contextRef="C_20220901to20220930_blrxTrancheAxis_blrxFirstTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="-6"
      id="Fxbrl_20230314043315425"
      unitRef="USD">10000000</blrx:AmountOfLoanAgreement>
    <blrx:AmountOfLoanAgreement
      contextRef="C_20220901to20220930_blrxTrancheAxis_blrxSecondTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="-6"
      id="Fxbrl_20250327033702837"
      unitRef="USD">20000000</blrx:AmountOfLoanAgreement>
    <blrx:AmountOfLoanAgreement
      contextRef="C_20220901to20220930_blrxTrancheAxis_blrxThirdTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="-6"
      id="Fxbrl_20250327033707132"
      unitRef="USD">10000000</blrx:AmountOfLoanAgreement>
    <blrx:AmountOfLoanAgreement
      contextRef="C_20220901to20220930_blrxTrancheAxis_blrxFirstTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="-6"
      id="Fxbrl_20250327033842837"
      unitRef="USD">10000000</blrx:AmountOfLoanAgreement>
    <blrx:AmountOfLoanAgreement
      contextRef="C_20240401to20240430_blrxTrancheAxis_blrxSecondTrancheMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="-6"
      id="Fxbrl_20250327033853147"
      unitRef="USD">20000000</blrx:AmountOfLoanAgreement>
    <blrx:PercentageOfAnnualInterestOfCashFees
      contextRef="C_20210901to20220930_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="3"
      id="Fxbrl_20230314043952511"
      unitRef="Pure">0.095</blrx:PercentageOfAnnualInterestOfCashFees>
    <blrx:PercentageOfAnnualInterestOfCashFees
      contextRef="C_20210901to20220930_ifrsfullRangeAxis_ifrsfullTopOfRangeMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="3"
      id="Fxbrl_20230314044017731"
      unitRef="Pure">0.11</blrx:PercentageOfAnnualInterestOfCashFees>
    <blrx:AmountOfIntellectualPropertyAndCashBalance
      contextRef="C_20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="-6"
      id="Fxbrl_20250327034015884"
      unitRef="USD">10000000</blrx:AmountOfIntellectualPropertyAndCashBalance>
    <ifrs-full:RepaymentsOfBondsNotesAndDebentures
      contextRef="C_20241101to20241130_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="-5"
      id="Fxbrl_20250327034456542"
      unitRef="USD">16500000</ifrs-full:RepaymentsOfBondsNotesAndDebentures>
    <blrx:MinimumCashBalanceRequirementUnderLoanAgreement
      contextRef="C_20241101to20241130_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="-6"
      id="Fxbrl_20260317121137642"
      unitRef="USD">4000000</blrx:MinimumCashBalanceRequirementUnderLoanAgreement>
    <blrx:PercentageOfFutureMilestonePayments
      contextRef="C_20241101to20241130_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="2"
      id="Fxbrl_20260317121151702"
      unitRef="Pure">0.10</blrx:PercentageOfFutureMilestonePayments>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="C_20241001to20241231_ifrsfullTypesOfInvestmentPropertyAxis_blrxLoanAgreementWithKreosCapitalMember"
      decimals="-5"
      id="Fxbrl_20260317121206469"
      unitRef="USD">4000000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20220304153940278">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25;font-weight:bold;margin-top:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 11 &#x2013; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share capital&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s share capital is composed of ordinary shares, par value NIS 0.10 per share, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:90%;width:90%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of Ordinary Shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Authorized share capital&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;5,000,000,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;20,000,000,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issued and paid-up share capital&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;1,336,670,575&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;2,610,814,390&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:90%;width:90%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In USD and NIS Amounts&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Authorized share capital (in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;500,000,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;2,000,000,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issued and paid-up share capital (in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;133,667,057&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;261,081,439&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issued and paid-up share capital (in USD)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;38,096,940&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;73,428,375&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Rights related to shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:70.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The ordinary shares confer upon their holders voting and dividend rights and the right to receive assets of the Company upon its liquidation. As of December 31, 2024 and 2025, all outstanding share capital consisted of ordinary shares.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in the Company&#x2019;s equity&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:67.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In September 2022, the Company completed a registered direct offering of 340,909 ADSs at a price of $44.00 per ADS. The Company also issued to investors in the offering unregistered warrants to purchase 340,909 ADSs. The warrants are exercisable immediately, expire  five years from the date of issuance and have an exercise price of $46.00 per ADS. In addition, the Company granted to the placement agent in the offering, as part of the placement fee, warrants to purchase 17,045 ADSs. These warrants are exercisable immediately, expire  five years from the date of issuance and have an exercise price of $55.00 per ADS. Gross proceeds from the offering totaled $15.0 million, with net proceeds of $13.5 million, after deducting fees and expenses. The offering consideration allocated to the placement agent warrants amounted to $0.4 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
                &lt;div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The warrants issued to the investors have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of the warrants is computed using the Black-Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 3.62%, and an average standard deviation of 82.5%. The gross consideration initially allocated to the investor warrants amounted to $9.1 million,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;with total issuance costs initially allocated to the warrants amounting to $0.8 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of the warrants amounted to $24,000 as of December 31, 2025 (December 31, 2024 - $478,000), and was based on the then current price of an ADS, a risk-free interest rate of 3.47%, an average standard deviation of 101.32%, and on the remaining contractual life of the warrants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The changes in fair value for the years ended December 31, 2024 and 2025 of $11,427,000 and $454,000 respectively, have been recorded as non-operating income in the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2025, 63,636 of these warrants had been exercised.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The placement agent warrants have been classified in shareholders&#x2019; equity, with initial recognition at fair value on the date issued, using the same assumptions as the investor warrants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:67.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In August 2023, the Company entered into a securities purchase&#160;agreement, pursuant to which the Company sold in a private placement an aggregate of 170,728 ADSs of the Company, at a purchase price of $85.44 per ADS. Aggregate gross proceeds from the sale amounted to $14.6 million, with related issuance costs amounting to approximately $0.9 million. Pursuant to IFRS 15, approximately $12.0 million of gross proceeds and $0.7 million of issuance costs were recognized as equity (see Note 15).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:67.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;3)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In April 2024, the Company completed a registered direct offering of 187,500 ADSs at a price of $32.00 per ADS. The Company also issued to investors in the offering unregistered warrants to purchase 187,500 ADSs. The warrants are exercisable immediately, expire  five years from the date of issuance and have an exercise price of $32.00 per ADS. Gross proceeds from the offering totaled $6.0 million, with net proceeds of $5.4 million, after deducting fees and expenses.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&#160;&lt;div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of the warrants is computed using the Black-Scholes option pricing model and is determined by using a&#160;level 3&#160;valuation technique. The fair value of the warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 4.21%, and an average standard deviation of 84.7%. The fair value initially allocated to the investor warrants amounted to $6,250,000, with total issuance costs initially allocated to the warrants amounting to $642,000.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Due to a difference between the fair value at initial recognition and the transaction price (&#x201c;day 1 loss&#x201d;),&#160;upon initial recognition, the fair value of the warrants was adjusted by the amount of $250,000, to reflect the unrecognized day 1 loss. Following initial recognition, the unrecognized day 1 loss of the warrants is being amortized over its contractual life.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of the warrants amounted to $171,000 as of December 31, 2025 (December 31, 2024 - $679,000), and was based on the then current price of an ADS, a risk-free interest rate of 3.55%, an average standard deviation of 94%, and on the remaining contractual life of the warrants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The changes in fair value for the years ended December 31, 2024 and 2025 of 5,571,000 and $298,000 respectively, have been recorded as a non-operating income in the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2025, none of these warrants had been exercised.&lt;/span&gt;&lt;/span&gt;
                    &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:67.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;4)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2024, the Company completed a registered direct offering to certain funds associated with Highbridge Capital Management LLC (&#x201c;Highbridge&#x201d;) of 103,037 ADSs and 308,749 pre-funded warrants to purchase ADSs. Each ADS and pre-funded warrant was sold at a purchase price of $21.86 and $21.85, respectively. The Company also issued to the investors unregistered ordinary warrants to purchase an aggregate of 205,893 ADSs. Gross proceeds from the offering totaled $9.0 million, with net proceeds of $8.9 million, after deducting fees and expenses. See Note 16.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
                &lt;div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The pre-funded warrants are exercisable immediately, do not expire until exercised in full, and have an exercise price of $0.004 per ADS. The ordinary warrants are exercisable immediately, expire  four years from the date of issuance, and have an exercise price of $23.60 per ADS.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A holder of the pre-funded or ordinary warrants cannot exercise such warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the outstanding share capital of the Company immediately after giving effect to such exercise.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The ordinary warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The pre-funded warrants have been classified in shareholders&#x2019; equity, with initial recognition at fair value on the date issued, using the same assumptions as the ordinary warrants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of the ordinary warrants is computed using the Black-Scholes option pricing model. The fair value of the ordinary warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 4.19%, and an average standard deviation of 84.5%. The gross consideration initially allocated to ordinary warrants amounted to $2,721,000, with total issuance costs initially allocated to the ordinary warrants amounting to $27,000.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of the ordinary warrants amounted to $102,000 as of December 31, 2025 (December 31,2024- $745,000) and was based on the then current price of an ADS, a risk-free interest rate of 3.55%, an average standard deviation of 96%, and on the remaining contractual life of the ordinary warrants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The changes in fair value for the years ended December 31, 2024 and 2025 of $1,976,000 and $643,000 respectively, have been recorded as non-operating income in the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2025, 226,392 of the pre-funded warrants had been exercised, and none of the ordinary warrants had been exercised.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:67.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;5)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In January 2025, the Company completed a registered direct offering to certain institutional investors of 858,303 ADSs and 391,697 pre-funded warrants to purchase ADSs. Each ADS and pre-funded warrant was sold at a purchase price of $8.00 and $7.996, respectively. The Company also issued to investors in the offering unregistered ordinary warrants to purchase an aggregate of 1,250,000 ADSs. The pre-funded warrants are exercisable immediately, do not expire until exercised in full, and have an exercise price of $0.004 per ADS. The ordinary warrants are exercisable immediately, expire  five years from the date of issuance, and have an exercise price of $8.00 per ADS. A holder of the pre-funded or ordinary warrants cannot exercise such warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or 9.99% at the election of the holder) of the outstanding share capital of the Company immediately after giving effect to such exercise.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
                &lt;div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In addition, the Company granted to the placement agent in the offering, as part of the placement fee, warrants to purchase 62,500 ADSs. These warrants are exercisable immediately, expire  five years from the date of issuance and have an exercise price of $10.00 per ADS. The offering consideration allocated to the placement agent warrants amounted to $0.5 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross proceeds from the offering totaled $10.0 million, with net proceeds of $8.9 million, after deducting fees and expenses.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The investors&#x2019; ordinary warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The pre-funded warrants have been classified in shareholders&#x2019; equity. The fair value of the ordinary warrants is computed using the Black-Scholes option pricing model and is determined by using a level 3 valuation technique. The fair value of the ordinary warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 4.41%, and an average standard deviation of 90.2%. The fair value initially allocated to the investor ordinary warrants amounted to $10.4 million, with total issuance costs initially allocated to the ordinary warrants amounting to $0.7 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Due to a difference between the fair value at initial recognition and the transaction price (&#x201c;Day 1 loss&#x201d;), upon initial recognition, the fair value of the ordinary warrants was adjusted by the amount of $1.4 million, to reflect the unrecognized day 1 loss. Following initial recognition, the unrecognized day 1 loss of the warrants is being amortized over its contractual life.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;&#160;&lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:67.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of the ordinary warrants amounted to $1,878,000 as of December 31, 2025, and was based on the then current price of an ADS, a risk-free interest rate of 3.64%, an average standard deviation of 91.0%, and on the remaining contractual life of the warrants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The changes in fair value for the year ended December 31, 2025 of $7,204,000, have been recorded as non-operating income in the statement of comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2025, all of the pre-funded warrants had been exercised, and none of the ordinary warrants had been exercised.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In accordance with IFRS 2, the placement agent warrants have been classified in shareholders&#x2019; equity, with initial recognition at fair value on the date issued, using the same assumptions as the investor warrants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share purchase agreement&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:70.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In September 2021, the Company entered into an ATM sales agreement with H.C. Wainwright &amp;amp; Co., LLC (&#x201c;HCW&#x201d;), pursuant to which the Company is entitled, at its sole discretion, to offer and sell through HCW, acting as sales agent, ADSs having an aggregate offering price of up to $25.0 million throughout the period during which the ATM facility remains in effect. The Company agreed to pay HCW a commission of 3.0%&#160;of the gross proceeds from the sale of ADSs under the facility. During 2025, 772,264 ADSs were sold under the program for total net proceeds of $5.0 million. From the effective date of the agreement through the issuance date of this report, 825,010 ADSs have been sold under the program for total net proceeds of $9.2 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:74pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:top;width:18pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share Incentive plan &#x2013; general&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In 2003, the Company adopted the 2003 Share Incentive Plan (the &#x201c;Plan&#x201d;). The Plan provides for the granting of stock options and ordinary shares to the Company&#x2019;s employees, directors, consultants and other service providers. Options are issued at the determination of the Board of Directors in accordance with applicable law. The options are generally exercisable for a ten -year period, and the grants generally vest over a four -year period. In 2013, the Company&#x2019;s Board of Directors approved amendments to the Plan to take into account changes in laws and regulations that had occurred since its adoption and to extend the term of the plan until November 2023. In 2016, the Board of Directors approved amendments to the Plan to allow for the grant of restricted stock units (&#x201c;RSUs&#x201d;) and performance stock units (&#x201c;PSUs&#x201d;). In 2022, the Board approved certain amendments to the Plan in order to conform the Plan to U.S. tax regulations for the benefit BioLineRx USA, Inc. employees.&#160;In November 2023, the Company&#x2019;s Board of Directors approved extension of the Plan through May 2024, and subsequently further approved extension of the Plan through May 2044.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;PSUs are RSUs that are linked to any one or more performance goals (in addition to, or in lieu of, time-based vesting terms) determined appropriate by the Board of Directors. The specific performance goals, as well as the time period associated with achieving such goals, are approved by the Board and are set forth in the grantee&#x2019;s grant agreement. To date, each PSU grant has had between three to five performance goals on which vesting is based, each such goal being either a specified Company milestone and or the success of a specific project, with vesting of 20-40% on the achievement of each goal. The tranche of PSUs associated with a given milestone expires 12 months after the target date established for that milestone. As of December 31, 2025, 8,787,600 PSUs were vested in accordance with their original terms.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2025, there were 326,757,000 ordinary shares issuable upon the exercise of outstanding equity instruments under the Plan.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Company employees and directors in Israel are granted options under Section 102 of the Israeli Income Tax Ordinance (the &#x201c;Ordinance&#x201d;), primarily under the &#x201c;capital gains&#x201d; track. Israeli non-employees of the Company (consultants and other service providers) are granted options under Section 3(i) of the Ordinance. All non-Israeli employees and non-employees of the Company are granted options as non-qualifies.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2025, there were 233.4 million remaining authorized but unissued ordinary shares in the pool reserved for future share-based incentive grants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:74pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:top;width:18pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:top;width:auto"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Employee share incentive plan:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table contains additional information concerning equity instruments granted to employees and directors under the existing share incentive plans.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:99pt"&gt;

            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="22" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;br/&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;br/&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;br/&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;89,871,858&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.44&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;150,429,825&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.32&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;141,634,245&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.32&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;64,855,380&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.18&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;23,190,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.20&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;212,760,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.01&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expired&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(1,379,640&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.68&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(3,825,990&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.53&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(24,310,920&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.25&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(2,424,535&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.21&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(27,389,565&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.23&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(18,116,325&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.25&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(493,238&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.22&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(770,025&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.14&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at end of year*&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;150,429,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;141,634,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;311,967,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercisable at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;51,970,635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;88,080,600&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;81,825,600&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:99pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:7.05pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023, 2024 and 2025 includes 12,219,465, 4,010,670 and 8,126,400 respectively, PSUs at an exercise price of 0.10 NIS (par value of ordinary shares) for which performance obligations have not been met. As of December 31, 2025 includes additional 21,240,000 PSUs at a zero exercise price, for which performance obligations have not been met.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The total consideration received from the exercise of equity instruments during 2023, 2024 and 2025 was not material.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Set forth below is data regarding the range of exercise prices and weighted-average remaining contractual life (in years) for the equity instruments outstanding at the end of each of the years indicated.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:90pt"&gt;

            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="14" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Range of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise prices&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;of options outstanding&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining contractual life (in&#160;yrs.)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;of options outstanding&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining contractual life (in&#160;yrs.)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Up to 0.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;114,352,425&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;8.07&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;288,520,200&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;9.07&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.5-0.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;15,104,100&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;6.54&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;12,576,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;4.96&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.00-2.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;11,727,795&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;4.57&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;10,423,800&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;2.82&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.01-3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;449,925&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;3.18&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;447,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;1.17&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;141,634,245&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;7.60&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;311,967,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;8.68&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of equity instruments granted to employees through December 31, 2025 has been determined using the Black-Scholes option-pricing model. These values are based on the following assumptions as of the applicable grant dates:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:90pt"&gt;

            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:41%;vertical-align:bottom;padding-bottom:2px"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:20.28%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;padding-bottom:2px"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.09%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;padding-bottom:2px"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.78%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:41%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td style="width:20.28%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;0%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.09%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;0%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.78%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;0%&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:41%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td style="width:20.28%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;69%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.09%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;73%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.78%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;93%&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:41%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td style="width:20.28%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;4%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.09%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;4%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.78%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;4%&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:41%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life of options (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td style="width:20.28%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;6&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.09%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;6&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.78%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;6&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The remaining unrecognized deferred compensation expense as of December 31, 2025 was $1.2 million. This amount will be expensed over the remaining vesting period of the equity instruments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:74pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:top;width:18pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:top;width:auto"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock options to consultants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;From inception through December 31, 2025, the Company has issued to consultants options for the purchase of 17,836,200 ordinary shares at a weighted average exercise price of 0.36 NIS per share.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The options to consultants generally vest over four years and may be exercised for periods of between five and ten years. As of December 31, 2025, 14,790,000 options to consultants were outstanding with a weighted average exercise price of NIS 0.03 per share and a weighted average contractual life of 9.8 years.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Company management estimates the fair value of the options granted to consultants based on the value of services received over the vesting period of the applicable options. The value of such services (primarily in respect of clinical advisory services) is estimated based on the additional cash compensation the Company would need to pay if such options were not granted. The value of services recorded in each of the years 2023, 2024 and 2025 was not material.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20251231"
      decimals="2"
      id="Fxbrl_20260318014401116"
      unitRef="ILS_per_Share">0.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250327035205202">
          &lt;div&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:90%;width:90%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of Ordinary Shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Authorized share capital&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;5,000,000,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;20,000,000,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issued and paid-up share capital&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;1,336,670,575&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;2,610,814,390&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:90%;width:90%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In USD and NIS Amounts&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Authorized share capital (in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;500,000,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;2,000,000,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issued and paid-up share capital (in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;133,667,057&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;261,081,439&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:76%"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issued and paid-up share capital (in USD)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;38,096,940&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:9%"&gt;
                      &lt;div style="line-height:1.25"&gt;73,428,375&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="C_20241231"
      decimals="INF"
      id="F20211006115502956_7"
      unitRef="Shares">5000000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="C_20251231"
      decimals="INF"
      id="F20211006115502957_8"
      unitRef="Shares">20000000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="C_20241231"
      decimals="INF"
      id="F20211006115502958_9"
      unitRef="Shares">1336670575</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="C_20251231"
      decimals="INF"
      id="F20211006115502959_10"
      unitRef="Shares">2610814390</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <blrx:AuthorizedShareCapitalValue
      contextRef="C_20241231"
      decimals="0"
      id="F20211006115502960_11"
      unitRef="ILS">500000000</blrx:AuthorizedShareCapitalValue>
    <blrx:AuthorizedShareCapitalValue
      contextRef="C_20251231"
      decimals="0"
      id="F20211006115502961_12"
      unitRef="ILS">2000000000</blrx:AuthorizedShareCapitalValue>
    <blrx:IssuedAndPaidUpShareCapitalValue
      contextRef="C_20241231"
      decimals="0"
      id="F20211006115502961_13"
      unitRef="ILS">133667057</blrx:IssuedAndPaidUpShareCapitalValue>
    <blrx:IssuedAndPaidUpShareCapitalValue
      contextRef="C_20251231"
      decimals="0"
      id="F20211006115502962_14"
      unitRef="ILS">261081439</blrx:IssuedAndPaidUpShareCapitalValue>
    <blrx:IssuedAndPaidUpShareCapitalValue
      contextRef="C_20241231"
      decimals="0"
      id="F20211006115502963_15"
      unitRef="USD">38096940</blrx:IssuedAndPaidUpShareCapitalValue>
    <blrx:IssuedAndPaidUpShareCapitalValue
      contextRef="C_20251231"
      decimals="0"
      id="F20211006115502964_16"
      unitRef="USD">73428375</blrx:IssuedAndPaidUpShareCapitalValue>
    <blrx:SharesIssuedRegisteredDirectOfferings
      contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="INF"
      id="Fxbrl_20230314052424711"
      unitRef="Shares">340909</blrx:SharesIssuedRegisteredDirectOfferings>
    <blrx:ExercisePriceOfShareIssued
      contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="2"
      id="Fxbrl_20230314052436524"
      unitRef="USD_per_Share">44</blrx:ExercisePriceOfShareIssued>
    <blrx:WarrantsIssuedToPurchaseShares
      contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember"
      decimals="INF"
      id="Fxbrl_20230314052447987"
      unitRef="Shares">340909</blrx:WarrantsIssuedToPurchaseShares>
    <blrx:WarrantsExpirationPeriod
      contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      id="Fxbrl_20230314052500179"> five years</blrx:WarrantsExpirationPeriod>
    <blrx:ExercisePriceOfWarrants
      contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="2"
      id="Fxbrl_20230314052515116"
      unitRef="USD_per_Share">46</blrx:ExercisePriceOfWarrants>
    <blrx:WarrantsIssuedToPurchaseShares
      contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember"
      decimals="INF"
      id="Fxbrl_20230314052524982"
      unitRef="Shares">17045</blrx:WarrantsIssuedToPurchaseShares>
    <blrx:WarrantsExpirationPeriod
      contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember"
      id="Fxbrl_20230314052535780"> five years</blrx:WarrantsExpirationPeriod>
    <blrx:ExercisePriceOfWarrants
      contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember"
      decimals="2"
      id="Fxbrl_20230314052545374"
      unitRef="USD_per_Share">55</blrx:ExercisePriceOfWarrants>
    <blrx:AggregateOfferingPrice
      contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember"
      decimals="-5"
      id="Fxbrl_20230314052556205"
      unitRef="USD">15000000</blrx:AggregateOfferingPrice>
    <blrx:ProceedsFromWarrantIssue
      contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember"
      decimals="-5"
      id="Fxbrl_20230314052604326"
      unitRef="USD">13500000</blrx:ProceedsFromWarrantIssue>
    <blrx:AmountAllocatedToWarrant
      contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxPlacementAgentsDesigneesMember"
      decimals="-5"
      id="Fxbrl_20230314052615678"
      unitRef="USD">400000</blrx:AmountAllocatedToWarrant>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="4"
      id="Fxbrl_20230314053247964"
      unitRef="Pure">0.0362</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="3"
      id="Fxbrl_20230314053323669"
      unitRef="Pure">0.825</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="-5"
      id="Fxbrl_20230314053502057"
      unitRef="USD">9100000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <blrx:AmountAllocatedToWarrant
      contextRef="C_20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="-5"
      id="Fxbrl_20230314053603648"
      unitRef="USD">800000</blrx:AmountAllocatedToWarrant>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="0"
      id="Fxbrl_20230314053958904"
      unitRef="USD">24000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="0"
      id="Fxbrl_20240324164651993"
      unitRef="USD">478000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="4"
      id="Fxbrl_20230314053901242"
      unitRef="Pure">0.0347</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="4"
      id="Fxbrl_20230314053913105"
      unitRef="Pure">1.0132</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20240101to20241231"
      decimals="0"
      id="Fxbrl_20230314054038616"
      unitRef="USD">11427000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20250101to20251231"
      decimals="0"
      id="Fxbrl_20240324164703256"
      unitRef="USD">454000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <blrx:WarrantsIssuedToPurchaseShares
      contextRef="C_20250101to20251231_ifrsfullTypesOfAntidilutiveInstrumentsAxis_ifrsfullWarrantsMember"
      decimals="INF"
      id="Fxbrl_20240324164715248"
      unitRef="Shares">63636</blrx:WarrantsIssuedToPurchaseShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember"
      decimals="INF"
      id="Fxbrl_20240324165003117"
      unitRef="Shares">170728</ifrs-full:NumberOfSharesIssued>
    <blrx:ExercisePriceOfShareIssued
      contextRef="C_20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember"
      decimals="2"
      id="Fxbrl_20240324165109745"
      unitRef="USD_per_Share">85.44</blrx:ExercisePriceOfShareIssued>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember"
      decimals="-5"
      id="Fxbrl_20240324165340844"
      unitRef="USD">14600000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember"
      decimals="-5"
      id="Fxbrl_20240324170202505"
      unitRef="USD">900000</ifrs-full:ShareIssueRelatedCost>
    <blrx:RecognizedAsEquity
      contextRef="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullInitiallyAppliedIFRSsAxis_ifrsfullIncreaseDecreaseDueToApplicationOfIFRS15Member"
      decimals="-5"
      id="Fxbrl_20240324170219715"
      unitRef="USD">12000000</blrx:RecognizedAsEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20230801to20230831_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullInitiallyAppliedIFRSsAxis_ifrsfullIncreaseDecreaseDueToApplicationOfIFRS15Member"
      decimals="-5"
      id="Fxbrl_20240324170358812"
      unitRef="USD">700000</ifrs-full:ShareIssueRelatedCost>
    <blrx:SharesIssuedRegisteredDirectOfferings
      contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="INF"
      id="Fxbrl_20250327053040964"
      unitRef="Shares">187500</blrx:SharesIssuedRegisteredDirectOfferings>
    <blrx:ExercisePriceOfShareIssued
      contextRef="C_20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="2"
      id="Fxbrl_20250327053051289"
      unitRef="USD_per_Share">32</blrx:ExercisePriceOfShareIssued>
    <blrx:WarrantsIssuedToPurchaseShares
      contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember"
      decimals="INF"
      id="Fxbrl_20250327053107408"
      unitRef="Shares">187500</blrx:WarrantsIssuedToPurchaseShares>
    <blrx:WarrantsExpirationPeriod
      contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      id="Fxbrl_20250327053120897"> five years</blrx:WarrantsExpirationPeriod>
    <blrx:ExercisePriceOfWarrants
      contextRef="C_20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="2"
      id="Fxbrl_20250327053135547"
      unitRef="USD_per_Share">32</blrx:ExercisePriceOfWarrants>
    <blrx:AggregateOfferingPrice
      contextRef="C_20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="-5"
      id="Fxbrl_20250327053205601"
      unitRef="USD">6000000</blrx:AggregateOfferingPrice>
    <blrx:ProceedsFromWarrantIssue
      contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="-5"
      id="Fxbrl_20250327053215472"
      unitRef="USD">5400000</blrx:ProceedsFromWarrantIssue>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="4"
      id="Fxbrl_20250327053453803"
      unitRef="Pure">0.0421</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="3"
      id="Fxbrl_20250327053512791"
      unitRef="Pure">0.847</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20240401to20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="0"
      id="Fxbrl_20250327053529465"
      unitRef="USD">6250000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <blrx:AmountAllocatedToWarrant
      contextRef="C_20240430_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="0"
      id="Fxbrl_20250327053547144"
      unitRef="USD">642000</blrx:AmountAllocatedToWarrant>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="C_20251231_ifrsfullCategoriesOfFinancialLiabilitiesAxis_ifrsfullFinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="0"
      id="Fxbrl_20260317140828916"
      unitRef="USD">250000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="C_20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember"
      decimals="0"
      id="Fxbrl_20250327053654403"
      unitRef="USD">171000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember"
      decimals="0"
      id="Fxbrl_20260317140422075"
      unitRef="USD">679000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember"
      decimals="4"
      id="Fxbrl_20250327053715577"
      unitRef="Pure">0.0355</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember"
      decimals="2"
      id="Fxbrl_20250327053730690"
      unitRef="Pure">0.94</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember"
      decimals="0"
      id="Fxbrl_20260318021638236"
      unitRef="USD">5571000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFiveMember"
      decimals="0"
      id="Fxbrl_20250327054903591"
      unitRef="USD">298000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <blrx:SharesIssuedRegisteredDirectOfferings
      contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxHighbridgeCapitalManagementLlcMember"
      decimals="INF"
      id="Fxbrl_20250327055310808"
      unitRef="Shares">103037</blrx:SharesIssuedRegisteredDirectOfferings>
    <blrx:SharesIssuedRegisteredDirectOfferings
      contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="INF"
      id="Fxbrl_20250327055336152"
      unitRef="Shares">308749</blrx:SharesIssuedRegisteredDirectOfferings>
    <blrx:ExercisePriceOfShareIssued
      contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxHighbridgeCapitalManagementLlcMember"
      decimals="2"
      id="Fxbrl_20250327055414991"
      unitRef="USD_per_Share">21.86</blrx:ExercisePriceOfShareIssued>
    <blrx:ExercisePriceOfShareIssued
      contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="2"
      id="Fxbrl_20250327055419007"
      unitRef="USD_per_Share">21.85</blrx:ExercisePriceOfShareIssued>
    <blrx:WarrantsIssuedToPurchaseShares
      contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxInvestorsMember"
      decimals="INF"
      id="Fxbrl_20250327055505325"
      unitRef="Shares">205893</blrx:WarrantsIssuedToPurchaseShares>
    <blrx:AggregateOfferingPrice
      contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="-5"
      id="Fxbrl_20250327055518647"
      unitRef="USD">9000000</blrx:AggregateOfferingPrice>
    <blrx:ProceedsFromWarrantIssue
      contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="-5"
      id="Fxbrl_20250327055530087"
      unitRef="USD">8900000</blrx:ProceedsFromWarrantIssue>
    <blrx:ExercisePriceOfShareIssued
      contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"
      decimals="3"
      id="Fxbrl_20250327055706384"
      unitRef="USD_per_Share">0.004</blrx:ExercisePriceOfShareIssued>
    <blrx:WarrantsExpirationPeriod
      contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"
      id="Fxbrl_20250327055750895"> four years</blrx:WarrantsExpirationPeriod>
    <blrx:ExercisePriceOfWarrants
      contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"
      decimals="2"
      id="Fxbrl_20260317141350007"
      unitRef="USD_per_Share">23.6</blrx:ExercisePriceOfWarrants>
    <blrx:BeneficiallyOwnInExcess
      contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"
      decimals="4"
      id="Fxbrl_20250327055923090"
      unitRef="Pure">0.0499</blrx:BeneficiallyOwnInExcess>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="4"
      id="Fxbrl_20250327060326785"
      unitRef="Pure">0.0419</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="3"
      id="Fxbrl_20250327060339417"
      unitRef="Pure">0.845</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20241101to20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="0"
      id="Fxbrl_20250327060353217"
      unitRef="USD">2721000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <blrx:AmountAllocatedToWarrant
      contextRef="C_20241130_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantFourMember"
      decimals="0"
      id="Fxbrl_20250327060405329"
      unitRef="USD">27000</blrx:AmountAllocatedToWarrant>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember"
      decimals="0"
      id="Fxbrl_20250327060452136"
      unitRef="USD">102000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember"
      decimals="0"
      id="Fxbrl_20260317135635140"
      unitRef="USD">745000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember"
      decimals="4"
      id="Fxbrl_20250327060524128"
      unitRef="Pure">0.0355</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantSixMember"
      decimals="2"
      id="Fxbrl_20250327060611666"
      unitRef="Pure">0.96</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <blrx:ChangesInFairValueRecordedAsANonoperatingIncome
      contextRef="C_20240101to20241231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"
      decimals="0"
      id="Fxbrl_20260317135618497"
      unitRef="USD">1976000</blrx:ChangesInFairValueRecordedAsANonoperatingIncome>
    <blrx:ChangesInFairValueRecordedAsANonoperatingIncome
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"
      decimals="0"
      id="Fxbrl_20250327060654888"
      unitRef="USD">643000</blrx:ChangesInFairValueRecordedAsANonoperatingIncome>
    <blrx:WarrantsIssuedToPurchaseShares
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember"
      decimals="INF"
      id="Fxbrl_20250327060723548"
      unitRef="Shares">226392</blrx:WarrantsIssuedToPurchaseShares>
    <blrx:SharesIssuedRegisteredDirectOfferings
      contextRef="C_20250101to20250131_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="INF"
      id="Fxbrl_20260317143223196"
      unitRef="Shares">858303</blrx:SharesIssuedRegisteredDirectOfferings>
    <blrx:SharesIssuedRegisteredDirectOfferings
      contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="INF"
      id="Fxbrl_20260317143257916"
      unitRef="Shares">391697</blrx:SharesIssuedRegisteredDirectOfferings>
    <blrx:ExercisePriceOfShareIssued
      contextRef="C_20250131_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="2"
      id="Fxbrl_20260317144033649"
      unitRef="USD_per_Share">8</blrx:ExercisePriceOfShareIssued>
    <blrx:ExercisePriceOfShareIssued
      contextRef="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="3"
      id="Fxbrl_20260317144040498"
      unitRef="USD_per_Share">7.996</blrx:ExercisePriceOfShareIssued>
    <blrx:WarrantsIssuedToPurchaseShares
      contextRef="C_20250101to20250131_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="INF"
      id="Fxbrl_20260317144348705"
      unitRef="Shares">1250000</blrx:WarrantsIssuedToPurchaseShares>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="3"
      id="Fxbrl_20260317144336937"
      unitRef="USD_per_Share">0.004</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <blrx:WarrantsExpirationPeriod
      contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      id="Fxbrl_20260317144423706"> five years</blrx:WarrantsExpirationPeriod>
    <blrx:ExercisePriceOfWarrants
      contextRef="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="2"
      id="Fxbrl_20260317144444209"
      unitRef="USD_per_Share">8</blrx:ExercisePriceOfWarrants>
    <blrx:BeneficiallyOwnInExcess
      contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="4"
      id="Fxbrl_20260317144524376"
      unitRef="Pure">0.0499</blrx:BeneficiallyOwnInExcess>
    <blrx:WarrantsIssuedToPurchaseShares
      contextRef="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="INF"
      id="Fxbrl_20260317144642236"
      unitRef="Shares">62500</blrx:WarrantsIssuedToPurchaseShares>
    <blrx:WarrantsExpirationPeriod
      contextRef="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      id="Fxbrl_20260317144727824"> five years</blrx:WarrantsExpirationPeriod>
    <blrx:ExercisePriceOfWarrants
      contextRef="C_20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="2"
      id="Fxbrl_20260317144745816"
      unitRef="USD_per_Share">10</blrx:ExercisePriceOfWarrants>
    <blrx:WarrantOfferingConsideration
      contextRef="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="-5"
      id="Fxbrl_20260317144815608"
      unitRef="USD">500000</blrx:WarrantOfferingConsideration>
    <blrx:ProceedsFromIssuanceOfInitialPublicOffering
      contextRef="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="-5"
      id="Fxbrl_20260317145157752"
      unitRef="USD">10000000</blrx:ProceedsFromIssuanceOfInitialPublicOffering>
    <blrx:ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses
      contextRef="C_20250101to20250131_ifrsfullCategoriesOfRelatedPartiesAxis_blrxPlacementAgentMember_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="-5"
      id="Fxbrl_20260317145543439"
      unitRef="USD">8900000</blrx:ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="4"
      id="Fxbrl_20260317145722430"
      unitRef="Pure">0.0441</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="3"
      id="Fxbrl_20260317145815077"
      unitRef="Pure">0.902</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="-5"
      id="Fxbrl_20260317145833957"
      unitRef="USD">10400000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <blrx:AmountAllocatedToWarrant
      contextRef="C_20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="-5"
      id="Fxbrl_20260317145902029"
      unitRef="USD">700000</blrx:AmountAllocatedToWarrant>
    <blrx:FairValueOfOrdinaryWarrantsAdjustedAmount
      contextRef="C_20250101to20250131_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="-5"
      id="Fxbrl_20260317150419004"
      unitRef="USD">1400000</blrx:FairValueOfOrdinaryWarrantsAdjustedAmount>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="0"
      id="Fxbrl_20260317150511045"
      unitRef="USD">1878000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="4"
      id="Fxbrl_20260317150548692"
      unitRef="Pure">0.0364</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="3"
      id="Fxbrl_20260317150614356"
      unitRef="Pure">0.91</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <blrx:ChangesInFairValueRecordedAsANonoperatingIncome
      contextRef="C_20250101to20251231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantOneMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxJanuary2025OfferingMember"
      decimals="0"
      id="Fxbrl_20260317150659436"
      unitRef="USD">7204000</blrx:ChangesInFairValueRecordedAsANonoperatingIncome>
    <blrx:AggregateOfferingPrice
      contextRef="C_20200930_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember"
      decimals="-5"
      id="Fxbrl_20220305140438613"
      unitRef="USD">25000000</blrx:AggregateOfferingPrice>
    <blrx:PercentageOfCommissionOnSalesAgreement
      contextRef="C_20200930_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember"
      decimals="3"
      id="Fxbrl_20220304150237043"
      unitRef="Pure">0.03</blrx:PercentageOfCommissionOnSalesAgreement>
    <blrx:SaleOfStockNumberOfSharesIssued
      contextRef="C_20250101to20251231_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember"
      decimals="INF"
      id="Fxbrl_20260317150843891"
      unitRef="Shares">772264</blrx:SaleOfStockNumberOfSharesIssued>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_20250101to20251231_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember_ifrsfullClassesOfShareCapitalAxis_blrxAmericanDepositarySharesMember"
      decimals="-5"
      id="Fxbrl_20260317150912371"
      unitRef="USD">5000000</ifrs-full:ProceedsFromIssuingShares>
    <blrx:SaleOfStockNumberOfSharesIssued
      contextRef="C_20200901to20200930_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember"
      decimals="INF"
      id="Fxbrl_20220304150321792"
      unitRef="Shares">825010</blrx:SaleOfStockNumberOfSharesIssued>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="C_20240101to20241231_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHCWainwrightAndCoLlcMember"
      decimals="-5"
      id="Fxbrl_20220304150309000"
      unitRef="USD">9200000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement
      contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxShareIncentivePlanMember"
      id="Fxbrl_20260318020210320">To date, each PSU grant has had between three to five performance goals on which vesting is based, each such goal being either a specified Company milestone and or the success of a specific project, with vesting of 20-40% on the achievement of each goal.</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxShareIncentivePlanMember"
      decimals="INF"
      id="F20211006115503102_157"
      unitRef="Pure">8787600</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxShareIncentivePlanMember"
      decimals="INF"
      id="F20211006115503103_158"
      unitRef="Shares">326757000</ifrs-full:NumberOfSharesIssued>
    <blrx:RemainingAuthorizedUnissuedOrdinaryShares
      contextRef="C_20251231"
      decimals="-5"
      id="F20211006115503110_163"
      unitRef="Shares">233400000</blrx:RemainingAuthorizedUnissuedOrdinaryShares>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250327041531143">
            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="22" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;br/&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;br/&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;br/&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;89,871,858&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.44&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;150,429,825&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.32&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;141,634,245&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.32&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;64,855,380&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.18&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;23,190,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.20&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;212,760,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.01&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expired&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(1,379,640&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.68&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(3,825,990&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.53&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(24,310,920&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.25&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(2,424,535&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.21&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(27,389,565&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.23&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(18,116,325&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.25&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(493,238&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.22&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;(770,025&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;0.14&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at end of year*&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;150,429,825&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;141,634,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;311,967,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercisable at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;51,970,635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;88,080,600&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;81,825,600&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:1.25"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          </ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20221231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502965_17"
      unitRef="Share">89871858</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20221231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502966_18"
      unitRef="ILS_per_Share">0.44</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502967_19"
      unitRef="Share">150429825</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502967_20"
      unitRef="ILS_per_Share">0.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502971_21"
      unitRef="Share">141634245</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502972_22"
      unitRef="ILS_per_Share">0.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502973_23"
      unitRef="Share">64855380</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502974_24"
      unitRef="ILS_per_Share">0.18</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502975_25"
      unitRef="Share">23190000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502975_26"
      unitRef="ILS_per_Share">0.2</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502976_27"
      unitRef="Share">212760000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502977_28"
      unitRef="ILS_per_Share">0.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="Fxbrl_20250327115544603_20211006115502973_23"
      unitRef="Share">1379640</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="Fxbrl_20250327115544603_20211006115502974_24"
      unitRef="ILS_per_Share">0.68</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="Fxbrl_20250327115544603_20211006115502975_25"
      unitRef="Share">3825990</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="Fxbrl_20250327115544603_20211006115502975_26"
      unitRef="ILS_per_Share">0.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="Fxbrl_20250327115544603_20211006115502976_27"
      unitRef="Share">24310920</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="Fxbrl_20250327115544603_20211006115502977_28"
      unitRef="ILS_per_Share">0.25</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502978_29"
      unitRef="Share">2424535</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502979_30"
      unitRef="ILS_per_Share">0.21</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502980_31"
      unitRef="Share">27389565</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502981_32"
      unitRef="ILS_per_Share">0.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502981_33"
      unitRef="Share">18116325</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502982_34"
      unitRef="ILS_per_Share">0.25</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502983_35"
      unitRef="Share">493238</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="C_20230101to20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502986_36"
      unitRef="ILS_per_Share">0.22</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="Fxbrl_20240324173832656"
      unitRef="Share">770025</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502987_38"
      unitRef="ILS_per_Share">0.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="Fxbrl_20240324173750102"
      unitRef="Share">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="C_20250101to20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="0"
      id="Fxbrl_20240324173515688"
      unitRef="ILS_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502990_41"
      unitRef="Share">150429825</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502991_42"
      unitRef="ILS_per_Share">0.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502992_43"
      unitRef="Share">141634245</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502993_44"
      unitRef="ILS_per_Share">0.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502993_45"
      unitRef="Share">311967000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502994_46"
      unitRef="ILS_per_Share">0.12</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502995_47"
      unitRef="Share">51970635</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502996_48"
      unitRef="ILS_per_Share">0.54</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115502997_49"
      unitRef="Share">88080600</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115502998_50"
      unitRef="ILS_per_Share">0.4</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="INF"
      id="F20211006115503000_51"
      unitRef="Share">81825600</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember"
      decimals="2"
      id="F20211006115503001_52"
      unitRef="ILS_per_Share">0.39</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember"
      decimals="INF"
      id="Fxbrl_20220304152435700"
      unitRef="Share">12219465</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember"
      decimals="INF"
      id="Fxbrl_20220304152442682"
      unitRef="Share">4010670</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember"
      decimals="INF"
      id="Fxbrl_20220304152449442"
      unitRef="Share">8126400</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember"
      decimals="2"
      id="Fxbrl_20220305192307100"
      unitRef="ILS_per_Share">0.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember"
      decimals="2"
      id="Fxbrl_20220305192045655"
      unitRef="ILS_per_Share">0.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitMember"
      decimals="2"
      id="Fxbrl_20220304152502892"
      unitRef="ILS_per_Share">0.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitTwoMember"
      decimals="INF"
      id="Fxbrl_20260317154353940"
      unitRef="Share">21240000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20251231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxPerformanceSharesUnitTwoMember"
      decimals="0"
      id="Fxbrl_20260317154421051"
      unitRef="ILS_per_Share">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250327041553087">
            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="14" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Range of&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise prices&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(in NIS)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;of options outstanding&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining contractual life (in&#160;yrs.)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;of options outstanding&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining contractual life (in&#160;yrs.)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Up to 0.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;114,352,425&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;8.07&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;288,520,200&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;9.07&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.5-0.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;15,104,100&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;6.54&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;12,576,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;4.96&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.00-2.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;11,727,795&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;4.57&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;10,423,800&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;2.82&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.01-3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;449,925&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;3.18&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;447,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;1.17&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;141,634,245&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;7.60&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;311,967,000&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:15.5%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;8.68&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.75%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          </ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember"
      decimals="INF"
      id="Fxbrl_20240324164459671_20211006115503003_55"
      unitRef="Share">114352425</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember"
      id="Fxbrl_20240324164459671_20211006115503004_56">P8Y25D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember"
      decimals="INF"
      id="Fxbrl_20240324164459671_20211006115503005_57"
      unitRef="Share">288520200</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember"
      id="Fxbrl_20240324164459671_20211006115503006_58">P9Y25D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember"
      decimals="INF"
      id="F20211006115503003_55"
      unitRef="Share">15104100</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember"
      id="F20211006115503004_56">P6Y6M14D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember"
      decimals="INF"
      id="F20211006115503005_57"
      unitRef="Share">12576000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeOneMember"
      id="F20211006115503006_58">P4Y11M15D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember"
      decimals="INF"
      id="F20211006115503015_67"
      unitRef="Share">11727795</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember"
      id="F20211006115503016_68">P4Y6M25D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember"
      decimals="INF"
      id="F20211006115503017_69"
      unitRef="Share">10423800</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeTwoMember"
      id="F20211006115503018_70">P2Y9M25D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember"
      decimals="INF"
      id="Fxbrl_20240324164501865_20211006115503003_55"
      unitRef="Share">449925</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20240101to20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember"
      id="Fxbrl_20240324164501865_20211006115503004_56">P3Y2M4D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember"
      decimals="INF"
      id="Fxbrl_20240324164501865_20211006115503005_57"
      unitRef="Share">447000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20250101to20251231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeFourMember"
      id="Fxbrl_20240324164501865_20211006115503006_58">P1Y2M1D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20241231"
      decimals="INF"
      id="F20211006115503025_79"
      unitRef="Share">141634245</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20240101to20241231"
      id="F20211006115503026_80">P7Y7M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20251231"
      decimals="INF"
      id="F20211006115503028_81"
      unitRef="Share">311967000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20250101to20251231"
      id="F20211006115503029_82">P8Y8M4D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250327041607903">
            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:41%;vertical-align:bottom;padding-bottom:2px"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:20.28%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;padding-bottom:2px"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.09%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;padding-bottom:2px"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.78%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:41%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td style="width:20.28%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;0%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.09%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;0%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.78%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;0%&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:41%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td style="width:20.28%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;69%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.09%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;73%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.78%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;93%&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:41%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td style="width:20.28%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;4%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.09%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;4%&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.78%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;4%&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:41%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life of options (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td style="width:20.28%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;6&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.09%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;6&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18.78%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;6&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          </ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="C_20230101to20231231"
      decimals="2"
      id="F20211006115503030_83"
      unitRef="Pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="C_20240101to20241231"
      decimals="2"
      id="F20211006115503031_84"
      unitRef="Pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="C_20250101to20251231"
      decimals="2"
      id="F20211006115503032_85"
      unitRef="Pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20230101to20231231"
      decimals="2"
      id="F20211006115503032_86"
      unitRef="Pure">0.69</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20240101to20241231"
      decimals="2"
      id="F20211006115503033_87"
      unitRef="Pure">0.73</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="C_20250101to20251231"
      decimals="2"
      id="F20211006115503034_88"
      unitRef="Pure">0.93</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_20230101to20231231"
      decimals="2"
      id="F20211006115503035_89"
      unitRef="Pure">0.04</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_20240101to20241231"
      decimals="2"
      id="F20211006115503035_90"
      unitRef="Pure">0.04</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="C_20250101to20251231"
      decimals="2"
      id="F20211006115503036_91"
      unitRef="Pure">0.04</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="C_20230101to20231231"
      decimals="0"
      id="F20211006115503037_92"
      unitRef="Year">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="C_20240101to20241231"
      decimals="0"
      id="F20211006115503038_93"
      unitRef="Year">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="C_20250101to20251231"
      decimals="0"
      id="F20211006115503039_94"
      unitRef="Year">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <blrx:RemainingUnrecognizedDeferredCompensationExpense
      contextRef="C_20250101to20251231"
      decimals="-5"
      id="F20211006115503113_166"
      unitRef="USD">1200000</blrx:RemainingUnrecognizedDeferredCompensationExpense>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_20231231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember"
      decimals="INF"
      id="F20211006115503120_172"
      unitRef="Shares">17836200</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_20230101to20231231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember"
      decimals="2"
      id="F20211006115503120_173"
      unitRef="ILS_per_Share">0.36</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement
      contextRef="C_20250101to20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember"
      id="F20211006115503125_179">The options to consultants generally vest over four years and may be exercised for periods of between five and ten years.</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="C_20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember"
      decimals="INF"
      id="F20211006115503124_178"
      unitRef="Share">14790000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember"
      decimals="2"
      id="F20211006115503126_180"
      unitRef="ILS_per_Share">0.03</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="C_20250101to20251231_ifrsfullTypesOfInvestmentPropertyAxis_blrxConsultantsMember"
      id="Fxbrl_20211011164913211">P9Y9M18D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317142207252">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 12 &#x2013; TAXES ON INCOME&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Corporate taxation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The taxable income of BioLineRx Ltd. and Tetragon is taxed at the standard Israeli corporate tax rate, which was 23% for all years included in these financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2025, the tax loss carryforwards of BioLineRx Ltd. were approximately $381 million. The tax loss carryforwards have no expiration date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax assessments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In accordance with Israeli tax regulations, the tax returns filed by BioLineRx Ltd. through the 2020 tax year are considered final.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Theoretical taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has not recognized any deferred tax assets in the financial statements, as it does not expect to generate taxable income in the foreseeable future. The reported tax on the Company&#x2019;s income before taxes differs from the theoretical amount that would arise using the weighted average tax rate applicable to income of the consolidated entities as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div&gt;
          &lt;div style="margin-left:72pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="22" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss before taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;23.0&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(60,614&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;23.0&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(9,221&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;23.0&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(2,026&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Theoretical tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(13,941&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(2,121&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(466&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Disallowed deductions (tax exempt income):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss (gain) on adjustment of warrants to fair value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,542&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(4,056&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,978&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;534&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;261&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;91&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Impairment of intangible asset&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,542&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;232&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,312&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;5,673&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,342&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Taxes on income for the reported year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;

    &lt;/div&gt;
  </ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:ApplicableTaxRate
      contextRef="C_20240101to20241231"
      decimals="2"
      id="Fxbrl_s_20230320181509413"
      unitRef="Pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="C_20250101to20251231"
      decimals="2"
      id="Fxbrl_20230320181509414"
      unitRef="Pure">0.23</ifrs-full:ApplicableTaxRate>
    <blrx:TaxLossCarryforwards
      contextRef="C_20250101to20251231"
      decimals="-6"
      id="F20211006115503157_4"
      unitRef="USD">381000000</blrx:TaxLossCarryforwards>
    <blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317142220573">
        &lt;div&gt;
          &lt;div style="margin-left:72pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="22" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss before taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;23.0&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(60,614&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;23.0&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(9,221&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;23.0&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(2,026&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Theoretical tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(13,941&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(2,121&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(466&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Disallowed deductions (tax exempt income):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss (gain) on adjustment of warrants to fair value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,542&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(4,056&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;(1,978&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;534&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;261&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;91&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Impairment of intangible asset&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;1,542&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;232&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-13.5pt;margin-left:25.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;11&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;9,312&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;5,673&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;2,342&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.65pt;margin-left:11.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Taxes on income for the reported year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory>
    <ifrs-full:ApplicableTaxRate
      contextRef="C_20230101to20231231"
      decimals="3"
      id="F20211006115503157_6"
      unitRef="Pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:AccountingProfit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503158_9"
      unitRef="USD">-60614000</ifrs-full:AccountingProfit>
    <ifrs-full:ApplicableTaxRate
      contextRef="C_20240101to20241231"
      decimals="3"
      id="F20211006115503157_7"
      unitRef="Pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:AccountingProfit
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503158_10"
      unitRef="USD">-9221000</ifrs-full:AccountingProfit>
    <ifrs-full:ApplicableTaxRate
      contextRef="C_20250101to20251231"
      decimals="3"
      id="F20211006115503158_8"
      unitRef="Pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:AccountingProfit
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503158_11"
      unitRef="USD">-2026000</ifrs-full:AccountingProfit>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503159_12"
      unitRef="USD">-13941000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503159_13"
      unitRef="USD">-2121000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503159_14"
      unitRef="USD">-466000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <blrx:TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503159_15"
      unitRef="USD">2542000</blrx:TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation>
    <blrx:TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240323053527621"
      unitRef="USD">-4056000</blrx:TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation>
    <blrx:TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230314152311676"
      unitRef="USD">-1978000</blrx:TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation>
    <blrx:TaxEffectOfShareBasedCompensationExemptFromTaxation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20260317142144620"
      unitRef="USD">534000</blrx:TaxEffectOfShareBasedCompensationExemptFromTaxation>
    <blrx:TaxEffectOfShareBasedCompensationExemptFromTaxation
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503160_19"
      unitRef="USD">261000</blrx:TaxEffectOfShareBasedCompensationExemptFromTaxation>
    <blrx:TaxEffectOfShareBasedCompensationExemptFromTaxation
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503160_20"
      unitRef="USD">91000</blrx:TaxEffectOfShareBasedCompensationExemptFromTaxation>
    <blrx:WriteoffOfIntangibleAsset
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240323053554820_20211006115503160_18"
      unitRef="USD">1542000</blrx:WriteoffOfIntangibleAsset>
    <blrx:WriteoffOfIntangibleAsset
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240323053554820_20211006115503160_19"
      unitRef="USD">232000</blrx:WriteoffOfIntangibleAsset>
    <blrx:WriteoffOfIntangibleAsset
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240323053554820_20211006115503160_20"
      unitRef="USD">0</blrx:WriteoffOfIntangibleAsset>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503161_21"
      unitRef="USD">11000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503161_22"
      unitRef="USD">11000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503161_23"
      unitRef="USD">11000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <blrx:IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503161_24"
      unitRef="USD">9312000</blrx:IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated>
    <blrx:IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503162_25"
      unitRef="USD">5673000</blrx:IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated>
    <blrx:IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503162_26"
      unitRef="USD">2342000</blrx:IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503162_27"
      unitRef="USD">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503162_28"
      unitRef="USD">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20250326193719808"
      unitRef="USD">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326194950231">
      &lt;div&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 13 &#x2013; LOSS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;text-indent:-21.25pt;margin-left:70.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table contains the data used in the computation of the basic loss per share:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:54pt"&gt;

              &lt;div&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss attributed to ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(60,614&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(9,221&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(2,026&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of shares used in basic calculation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;963,366&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;1,198,108&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;2,465,273&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(0.06&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(0.01&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(0.00&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;

          &lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:49.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The number of shares used in the 2024 and 2025 basic calculations includes 12,052 and 49,279 pre-funded warrants, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:49.65pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding options, RSUs, PSUs and ordinary warrants have been&#160;excluded from the calculation of the diluted loss per share for all years presented, since their effect was anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <blrx:DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326193350587">
              &lt;div&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss attributed to ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(60,614&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(9,221&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(2,026&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of shares used in basic calculation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;963,366&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;1,198,108&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;2,465,273&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(0.06&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(0.01&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;(0.00&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
            </blrx:DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503174_1"
      unitRef="USD">-60614000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503174_2"
      unitRef="USD">-9221000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503174_3"
      unitRef="USD">-2026000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:WeightedAverageShares
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172633227_20211006115503174_1"
      unitRef="Shares">963366000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172633227_20211006115503174_2"
      unitRef="Shares">1198108000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172633227_20211006115503174_3"
      unitRef="Shares">2465273000</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20230311055749004"
      unitRef="USD_per_Share">-0.06</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_20230101to20231231"
      decimals="2"
      id="F20211006115503174_7"
      unitRef="USD_per_Share">-0.06</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_20240101to20241231"
      decimals="2"
      id="Fxbrl_20230311055803379"
      unitRef="USD_per_Share">-0.01</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_20240101to20241231"
      decimals="2"
      id="F20211006115503174_8"
      unitRef="USD_per_Share">-0.01</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_20250101to20251231"
      decimals="2"
      id="Fxbrl_20230311055817891"
      unitRef="USD_per_Share">-0</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_20250101to20251231"
      decimals="2"
      id="F20211006115503175_9"
      unitRef="USD_per_Share">-0</ifrs-full:BasicEarningsLossPerShare>
    <blrx:PreFundedWarrants
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20260317154957402"
      unitRef="USD">12052000</blrx:PreFundedWarrants>
    <blrx:PreFundedWarrants
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20250326194937641"
      unitRef="USD">49279000</blrx:PreFundedWarrants>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317145024567">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 14 &#x2013; COMMITMENTS AND CONTINGENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Commitments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Obligation to pay royalties to the State of Israel&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Royalties may be payable to the State of Israel (represented by the Israel Innovation Authority, or IIA), on proceeds from the sale or license of products whose development was supported by grants from&#160;the IIA. Such royalties are generally 3% in the first three years from initial repayment, 4% of sales in the three subsequent years and 5% of sales in the seventh year until repayment of 100% of the grants (linked to the dollar) received, plus annual interest at the 12-month SOFR rate as published on the first trading day of each calendar year. Under certain circumstances, the royalty rate is calculated according to a formula based on the ratio of participation by the IIA in the project to the project&#x2019;s total accumulated costs.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other than motixafortide (see next paragraph), the Company does not have any royalty obligation in respect of products supported by the IIA.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In connection with the in-licensing of motixafortide from Biokine Therapeutics Ltd. (&#x201c;Biokine&#x201d;), and as a condition to IIA consent to the transaction, the Company agreed to abide by any obligations resulting from funds previously received by Biokine from the IIA. The contingent liability to the IIA assumed by the Company relating to this transaction amounts to $2.5 million as of December 31, 2025. In this regard, and in connection with the out-licensing transactions with Gloria (see Note 15) and with Ayrmid (see Note 16), as well as with the direct sales of motixafortide in the U.S. during the period from product launch through the transaction with Ayrmid, the royalty rate agreed with the IIA for motixafortide consideration received is 3.9% for sub-license consideration and 4% for direct product sales. The Company has a full right of offset for amounts payable to the IIA from all payments due to Biokine in the future.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Licensing agreements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In connection with the development of therapeutic compounds, the Company may enter into in-licensing agreements with academic institutions, research institutions and companies (the &#x201c;licensors&#x201d;). Pursuant to these licensing agreements, the Company generally obtains the rights for one or more therapeutic compounds in pre-clinical and early clinical stages of development, in order to continue development of the compounds through more advanced stages of development and, subsequently, to manufacture, distribute and market the drugs or to out-license the development, manufacturing and commercialization rights to third parties.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The licenses that have been granted to the Company are broad and comprehensive, and generally include various provisions and usage rights as follows: (i) territorial scope of the license (global); (ii) term of the license (unrestricted but not shorter than the life of the patent); and (iii) development of the therapeutic compound (allowing the Company to perform all development activities on its own, or by outsourcing under Company supervision, as well as out-licensing development under the license to other companies, subject to the provisions of the licensing agreements).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;According to the provisions of the licensing agreements, the intellectual property rights in the development of any licensed technology, through the date the applicable license agreement is effective, remain with the licensor, while the rights in products and/or other deliverables developed by the Company after the license is granted belong to the Company. In cases where the licensor has a claim to an invention that was jointly developed with the Company, the licensor also co-owns the related intellectual property. In any event, the scope of the license also covers these intellectual property rights.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In addition, the Company generally undertakes in the licensing agreements to protect registered patents resulting from developments under the various licenses, to promote the registration of patents covering new developments in cooperation with the licensor, and to bear responsibility for all related costs. Pursuant to the various agreements, the Company generally works to register the various patents on a broad basis worldwide, and if the Company decides not to initiate or continue a patent registration proceeding in a given country, the Company is required to notify the applicable licensor to this effect, and the licensor is entitled to take action for registration of the patent in such country.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The consideration paid pursuant to the licensing agreements generally includes several components that may be payable over the license period and that relate, inter alia, to the progress made in research and development activities, as well as commercial success, as follows: (a) a one-time, up-front payment and/or periodic payments; (b) payments through the early stages of development (i.e., through the end of phase 2); (c) payments upon the achievement of milestones necessary for advancing to phase 3; (d) payments from the end of a successful phase 3 trial through approval of the therapeutic compound; and e) royalties on sales of the final product resulting from development under the license or including any component thereof, generally less than 5% of the Company&#x2019;s net sales of the product, although in specific instances (for example, with regard to motixafortide, where the royalty rate on net sales directly commercialized by the Company payable to Biokine is 10%) the royalty rate has been higher or lower than this range. In instances where the Company has out-licensed the product for further development, the Company pays a percentage of the net consideration received from the licensee (&#x201c;Sublicense Receipts&#x201d;) to the upstream licensor that generally range from 20% to 29.5% of such consideration, although in specific instances the percentage paid has been higher or lower than this range. These Sublicense Receipts generally take the place of most or all of the milestone and royalty payments set forth in (b) through (e) above.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The license agreements may be cancelled by the licensor only in specific circumstances, generally upon the occurrence of one of the following events: (a) the Company&#x2019;s failure to meet certain milestones stipulated in the applicable license agreement and appended timetables; (b) default, insolvency, receivership, liquidation, etc., of the Company that is not imposed and/or lifted within the timeframe stipulated in the license agreement; and (c) fundamental breach of the license agreement that is not corrected within the stipulated timeframe. The Company may generally cancel a license agreement with prior notice of 30 to 90 days, due to unsuccessful development or any other cause.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Some of the license agreements have been accompanied by consulting, support and cooperation agreements, pursuant to which the Company may be committed to pay the various licensers a fixed monthly amount over the period stipulated in the agreement for their assistance in the continued research and development under the license.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Commitments in respect of Biokine&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In accordance with the license agreement of motixafortide with Biokine (as amended), the Company is required to pay Biokine a payment of 20% of amounts received as consideration in connection with any sublicensing or sale of the licensed technology. Biokine is also eligible to receive up to a total of $2.5 million in future milestone payments. Subject to certain limitations, if the Company independently sells products related to motixafortide, the Company will pay Biokine a royalty payment of 10% of net sales.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:70.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Purchase orders&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:92.15pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s outstanding open purchase order commitments as of December 31, 2025 amounted to $2.4 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Guarantees&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;To secure the Company&#x2019;s lease obligation on its Israeli premises, the Company has provided a bank guarantee in the amount of $100,000 for the benefit of the lessor, which remains outstanding as of December 31, 2025.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Contingent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In June 2024, Biokine Therapeutics Ltd. (&#x201c;Biokine&#x201d;),&#160;filed a complaint with the District Court of Jerusalem against the Company. The complaint alleged breach of contract and a purported failure to make certain payments to Biokine under the Company&#x2019;s in-licensing agreement with Biokine for motixafortide. The lawsuit sought compensatory damages in the amount of approximately $6.5 million and a declaratory judgment in favor of Biokine. The Company filed a statement of defense in November 2024. In November 2024, the Company and Biokine entered into an agreement to refer the dispute to binding arbitration, and the claim was withdrawn. During the first quarter of 2025, Biokine filed an updated complaint under the arbitration, increasing the damages to the amount of approximately $7.2 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In February 2026, the arbitrator issued a final decision in the case, denying all claims asserted by Biokine against the Company, and awarding the Company expenses, including legal fees.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
    &lt;/div&gt;
  </ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <blrx:RoyaltiesReceivedPercentage
      contextRef="C_20250101to20251231_ifrsfullMaturityAxis_blrxFirstThreeYearsMember"
      decimals="2"
      id="Fxbrl_20240324071913871"
      unitRef="Pure">0.03</blrx:RoyaltiesReceivedPercentage>
    <blrx:RoyaltiesReceivedPercentage
      contextRef="C_20250101to20251231_ifrsfullMaturityAxis_blrxThreeSubsequentYearsMember"
      decimals="2"
      id="Fxbrl_20260317151021093"
      unitRef="Pure">0.04</blrx:RoyaltiesReceivedPercentage>
    <blrx:RoyaltiesReceivedPercentage
      contextRef="C_20250101to20251231_ifrsfullMaturityAxis_blrxSeventhYearMember"
      decimals="2"
      id="Fxbrl_20260317151023551"
      unitRef="Pure">0.05</blrx:RoyaltiesReceivedPercentage>
    <blrx:RoyaltiesReceivedPercentage
      contextRef="C_20250101to20251231"
      decimals="2"
      id="F20211006115503180_1"
      unitRef="Pure">1</blrx:RoyaltiesReceivedPercentage>
    <blrx:ContingentLiability
      contextRef="C_20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember"
      decimals="-5"
      id="Fxbrl_20230322125255995"
      unitRef="USD">2500000</blrx:ContingentLiability>
    <blrx:PercentageOfNetConsiderationReceivedForSubLicense
      contextRef="C_20250101to20251231"
      decimals="3"
      id="Fxbrl_20260317160834623"
      unitRef="Pure">0.039</blrx:PercentageOfNetConsiderationReceivedForSubLicense>
    <blrx:PercentageOfNetConsiderationReceivedForDirectProductSales
      contextRef="C_20250101to20251231"
      decimals="2"
      id="Fxbrl_20260317160847298"
      unitRef="Pure">0.04</blrx:PercentageOfNetConsiderationReceivedForDirectProductSales>
    <blrx:RoyaltiesOnSale
      contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember"
      decimals="2"
      id="Fxbrl_20260317151249446"
      unitRef="Pure">0.05</blrx:RoyaltiesOnSale>
    <blrx:RoyaltiesOnSale
      contextRef="C_20250101to20251231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember"
      decimals="2"
      id="Fxbrl_20260317161352027"
      unitRef="Pure">0.10</blrx:RoyaltiesOnSale>
    <blrx:PercentageOfNetConsiderationReceivedFromLicensee
      contextRef="C_20201231to20201231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember"
      decimals="2"
      id="F20211006115503181_8"
      unitRef="Pure">0.20</blrx:PercentageOfNetConsiderationReceivedFromLicensee>
    <blrx:PercentageOfNetConsiderationReceivedFromLicensee
      contextRef="C_20201231to20201231_ifrsfullRangeAxis_ifrsfullTopOfRangeMember"
      decimals="3"
      id="F20211006115503182_9"
      unitRef="Pure">0.295</blrx:PercentageOfNetConsiderationReceivedFromLicensee>
    <blrx:RoyaltiesPaymentPercentage
      contextRef="C_20250101to20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember"
      decimals="2"
      id="Fxbrl_20220304151524036"
      unitRef="Pure">0.20</blrx:RoyaltiesPaymentPercentage>
    <blrx:MaximumFutureMilestonePayments
      contextRef="C_20250101to20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember"
      decimals="-5"
      id="Fxbrl_20240324072004311"
      unitRef="USD">2500000</blrx:MaximumFutureMilestonePayments>
    <blrx:RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts
      contextRef="C_20250101to20251231_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember"
      decimals="2"
      id="Fxbrl_20220304151535337"
      unitRef="Pure">0.10</blrx:RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts>
    <blrx:OpenPurchaseOrderCommitments
      contextRef="C_20251231"
      decimals="-5"
      id="F20211006115503182_10"
      unitRef="USD">2400000</blrx:OpenPurchaseOrderCommitments>
    <blrx:BankGuaranteeAmountForBenefitOfLessor
      contextRef="C_20250101to20251231"
      decimals="0"
      id="F20211006115503182_11"
      unitRef="USD">100000</blrx:BankGuaranteeAmountForBenefitOfLessor>
    <blrx:LawsuitClaimAmount
      contextRef="C_20240601to20240630_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember"
      decimals="-5"
      id="Fxbrl_20230320180909657"
      unitRef="USD">6500000</blrx:LawsuitClaimAmount>
    <blrx:LawsuitClaimAmount
      contextRef="C_20241101to20241130_deiLegalEntityAxis_blrxBiokineTherapeuticsLtdMember"
      decimals="-5"
      id="Fxbrl_20260317150140874"
      unitRef="USD">7200000</blrx:LawsuitClaimAmount>
    <blrx:LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock
      contextRef="C_20250101to20251231"
      id="Fxbrl_20240324114158606">
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 15 &#x2013; LICENSE AND SECURITIES PURCHASE AGREEMENTS &#x2013; HST/GLORIA&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In October 2023, the Company closed on a license agreement (the &#x201c;Gloria License Agreement&#x201d;) with Hong Seng Technology Limited (&#x201c;HST&#x201d;) and Auspex Bioscience (Guangzhou) Co., Ltd. (formerly Guangzhou Gloria Biosciences Co., Ltd.) (&#x201c;Gloria&#x201d; and together with HST, the &#x201c;Gloria Licensee&#x201d;), pursuant to which the Company granted HST an exclusive, royalty-bearing, sublicensable license to develop and commercialize motixafortide in Asia (other than Israel and certain other countries) (collectively, the &#x201c;Gloria Territory&#x201d;) and to engage and authorize Gloria to perform services under the Gloria License Agreement in the Gloria Territory. In addition, the Company granted the Gloria Licensee a first offer right with respect to the grant of certain rights in motixafortide outside of the Gloria Territory.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to the terms of the Gloria License Agreement, the Gloria Licensee paid an upfront payment of $15 million, which was received by the Company at closing. The Company is also entitled to up to $49 million based on the achievement of certain development and regulatory milestones in China and Japan, and up to $197 million in sales milestones based on defined sales targets of motixafortide in the Gloria Territory. In addition, the Company is eligible to receive tiered double-digit royalties (ranging from 10-20%), on a country-by-country basis until the longer of (i) fifteen years from the date of the first sale of motixafortide by the Gloria Licensee, (ii) the last to expire valid claim of any licensed patents with respect to motixafortide in such country and (iii) the expiration of motixafortide&#x2019;s orphan drug status in such country. The royalties payable by Gloria Licensee are to be reduced by 50% following the end of the initial royalty term and are also to be reduced upon the occurrence of certain events, including, on a country-by-country basis, the entry of a generic product in such country.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In addition, in October 2023, the Company closed on a securities purchase agreement (the &#x201c;Gloria Purchase Agreement&#x201d;) with HST and Gloria, pursuant to which the Company issued in a private placement an aggregate of 170,728 ADSs of the Company, at a purchase price of $85.44 per ADS. Aggregate gross proceeds from the sale were approximately $14.6 million, with related issuance costs amounting to approximately $0.9 million. No warrants were issued in the transaction.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In accordance with IFRS 15, both agreements have been treated as a single unit of account, with the consideration combined and subsequently allocated between the Gloria Purchase Agreement and the Gloria License Agreement. Of the total consideration amounting to $29.6 million, $12.0 million were allocated to the Purchase Agreement, and $17.6 million were allocated to the Gloria License Agreement. Costs in the amount of $0.7 million directly attributable to the Purchase Agreement were recognized as a reduction in equity.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company identified the following performance obligations in the contract, each to be recognized separately: (1) stem-cell mobilization (&#x201c;SCM&#x201d;) license; (2) SCM support services; and (3) pancreatic cancer (&#x201c;PDAC&#x201d;) license and related support services.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;With regard to PDAC, the Company determined that the license, together with the associated support services, should be combined into a single performance obligation, since the Licensee cannot benefit from the license without the associated support services. The support services are highly specialized for the licensed product in this indication. Licensing rights for other indications and related support were deemed immaterial.&lt;/span&gt;&lt;/span&gt;
              &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
            &lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fixed transaction price has been allocated among the performance obligations based on similar price offers received by the Company, with the assistance of a valuation specialist. The variable consideration&#160;related to the performance obligations&#160;was not taken into account in the fixed transaction price due to uncertainty.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Revenue has been recognized in the Company&#x2019;s financial statements as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Revenue for the SCM license was recognized in the fourth quarter of 2023, upon transfer of control over the license to the licensee, in the amount of $2.0 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Revenue from providing the SCM support services has been recognized using the input method, which is based on costs incurred and labor hours expended, resulting in straight-line revenue recognition for the year ended December 31, 2024 totaling $0.1 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Revenue from the PDAC performance obligation has been recognized over time, with the percentage of completion determined based on support hours incurred, with a total amount of $15.5 million recognized through the end of 2024.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Based on the above methodology, as well as the achievement of a specific regulatory milestone, the Company recognized revenues from the license agreement of $4.6 million and $15.0 million for the years ended December 31, 2023 and 2024, respectively. Due to a delay in payment of $2.4 million to be received from the Gloria Licensee during 2024, a provision for doubtful accounts receivable in the amount of $0.8 million was recorded in the fourth quarter of 2024. This amount was subsequently collected in 2025 and the provision was reversed.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </blrx:LicenseAndSecuritiesPurchaseAgreementsExplanatoryTextBlock>
    <blrx:UpfrontPayment
      contextRef="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember"
      decimals="-6"
      id="Fxbrl_20240324114350435"
      unitRef="USD">15000000</blrx:UpfrontPayment>
    <ifrs-full:PaymentsForDevelopmentProjectExpenditure
      contextRef="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember"
      decimals="-6"
      id="Fxbrl_20240324120125798"
      unitRef="USD">49000000</ifrs-full:PaymentsForDevelopmentProjectExpenditure>
    <blrx:SalesMilestoneAmount
      contextRef="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember"
      decimals="-6"
      id="Fxbrl_20240324120149766"
      unitRef="USD">197000000</blrx:SalesMilestoneAmount>
    <blrx:RoyaltiesEligibleMargin
      contextRef="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="Fxbrl_20240324120208549"
      unitRef="Pure">0.10</blrx:RoyaltiesEligibleMargin>
    <blrx:RoyaltiesEligibleMargin
      contextRef="C_20231001to20231012_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember_srtRangeAxis_srtMaximumMember"
      decimals="2"
      id="Fxbrl_20240324120328382"
      unitRef="Pure">0.20</blrx:RoyaltiesEligibleMargin>
    <blrx:AggregateAmericanDepositaryShares
      contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember"
      decimals="INF"
      id="Fxbrl_20240324120750045"
      unitRef="Shares">170728</blrx:AggregateAmericanDepositaryShares>
    <blrx:PurchasePricePerADS
      contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember"
      decimals="2"
      id="Fxbrl_20240324120850549"
      unitRef="USD_per_Share">85.44</blrx:PurchasePricePerADS>
    <ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares
      contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember"
      decimals="-5"
      id="Fxbrl_20240324120938500"
      unitRef="USD">14600000</ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember"
      decimals="-5"
      id="Fxbrl_20240324121010839"
      unitRef="USD">900000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember"
      decimals="-5"
      id="Fxbrl_20250327102008077"
      unitRef="USD">29600000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxPurchaseAgreementMember"
      decimals="-5"
      id="Fxbrl_20250327102035988"
      unitRef="USD">12000000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaLicenseAgreementMember"
      decimals="-5"
      id="Fxbrl_20250327102100125"
      unitRef="USD">17600000</ifrs-full:ConsiderationPaidReceived>
    <blrx:CostsIncurrentInOffering
      contextRef="C_20231001to20231031_blrxAgreementTypeAxis_blrxGloriaPurchaseAgreementMember"
      decimals="-5"
      id="Fxbrl_20250327102118071"
      unitRef="USD">700000</blrx:CostsIncurrentInOffering>
    <ifrs-full:OtherRevenue
      contextRef="C_20231001to20231231_blrxAgreementTypeAxis_blrxScmLicenseMember"
      decimals="-5"
      id="Fxbrl_20240324122524826"
      unitRef="USD">2000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="C_20240101to20241231_blrxAgreementTypeAxis_blrxScmSupportServicesMember"
      decimals="-5"
      id="Fxbrl_20240324122550628"
      unitRef="USD">100000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="C_20240101to20241231_blrxAgreementTypeAxis_blrxPDACPerformanceObligationMember"
      decimals="-5"
      id="Fxbrl_20240324122622293"
      unitRef="USD">15500000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="C_20230101to20231231_blrxAgreementTypeAxis_blrxLicenseAgreementMember"
      decimals="-5"
      id="Fxbrl_20250327094309125"
      unitRef="USD">4600000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="C_20240101to20241231_blrxAgreementTypeAxis_blrxLicenseAgreementMember"
      decimals="-5"
      id="Fxbrl_20250327094313532"
      unitRef="USD">15000000</ifrs-full:OtherRevenue>
    <blrx:DelayInPayment
      contextRef="C_20240101to20241231_blrxAgreementTypeAxis_blrxLicenseAgreementMember"
      decimals="-5"
      id="Fxbrl_20250328211831684"
      unitRef="USD">2400000</blrx:DelayInPayment>
    <blrx:ProvisionForDoubtfulAccountsReceivable
      contextRef="C_20241001to20241231"
      decimals="-5"
      id="Fxbrl_20250327100724372"
      unitRef="USD">-800000</blrx:ProvisionForDoubtfulAccountsReceivable>
    <blrx:DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250327055235567">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 16 &#x2013; LICENSE AND SECURITIES PURCHASE AGREEMENTS &#x2013; AYRMID/HIGHBRIDGE&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2024, the Company entered into a license agreement (the &#x201c;Ayrmid License Agreement&#x201d;) with Ayrmid Pharma Ltd. (the &#x201c;Ayrmid Licensee&#x201d;), pursuant to which the Company granted the Ayrmid Licensee an exclusive, transferable, royalty-bearing, sublicensable license with respect to the intellectual property rights and know-how associated with motixafortide, to commercialize motixafortide across all indications, except solid tumor indications, in all territories other than Asia (collectively, the &#x201c;Ayrmid Territory&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to the terms of the Ayrmid License Agreement, the Company received a non-refundable $10 million upfront payment and is entitled to up to $87 million of certain commercial and sales milestones based on defined sales targets of motixafortide in the Ayrmid Territory. Additionally, the Company is eligible to receive tiered double-digit royalties (ranging from 18-23%) on aggregate net sales of motixafortide&#160;on a country-by-country basis until the longer of (i) fifteen years from the date of the first sale of motixafortide by the Ayrmid Licensee in such country, (ii) the last to expire of any licensed patents with respect to motixafortide in such country, (iii) the expiration of regulatory exclusivity in such country and (iv) the expiration of motixafortide&#x2019;s orphan drug status, if any, in such country, it being noted that such royalties may be subject to reduction in certain specific circumstances.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div&gt;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In connection with the Ayrmid License Agreement, the Company and the Ayrmid Licensee also entered into a manufacturing and supply agreement (the &#x201c;Supply Agreement&#x201d;), according to which the Company has committed to supply motixafortide to the Ayrmid Licensee during the term, on a cost-plus basis, for both commercial and development supply. Furthermore, the Supply Agreement provides the Ayrmid Licensee with &#x201c;step-in rights&#x201d; with respect to the manufacture and supply of motixafortide upon the occurrence of certain trigger events.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Ayrmid License Agreement will continue on a country-by-country basis in the Ayrmid Territory until the expiration of the royalty term or earlier termination thereof. The Ayrmid License Agreement may also be terminated by either party in the case of a material breach or bankruptcy.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Concurrent with the above transaction, the Company completed a registered direct offering with gross proceeds of $9.0 million to certain funds associated with&#160;Highbridge, a related party to Ayrmid&#160;(see Note 11c(4)).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In accordance with IFRS 15, both transactions have been treated as a single unit of account, with the consideration combined and subsequently allocated between the Ayrmid License agreement and the registered direct offering. Of the total consideration amounting to $19.0 million, $7.8 million were allocated to the Ayrmid License Agreement, and $11.2 million were allocated to the registered direct offering. Costs in the amount of $0.1 million directly attributable to the registered direct offering were recognized as a reduction in equity. The proceeds allocated to the ordinary warrants in the registered direct offering were measured with reference to their fair value as financial instruments issued to a customer.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The consideration allocated to the Ayrmid License Agreement of $7.8 million was attributed to a single material performance obligation &#x2013; i.e., the granting of the license to commercialize and develop motixafortide in the Ayrmid Territory. Accordingly, revenue from the license of $7.8 million was recognized during the fourth quarter of 2024, upon transfer of control over the Ayrmid License to the licensee. Sales-based milestone payments and royalties based on motixafortide net sales are subject to the &#x201c;royalties exception&#x201d; of IFRS 15 and are recognized as revenue when the related sale occurs. Total royalties based on motixafortide net sales in 2025 amounted to $1.2 million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </blrx:DisclosureOfLicenseAndSecuritiesPurchaseAgreementsAyrmidAndHighbridgeExplanatory>
    <blrx:UpfrontPayment
      contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember"
      decimals="-6"
      id="Fxbrl_20250327055339574"
      unitRef="USD">10000000</blrx:UpfrontPayment>
    <blrx:UpfrontPayment
      contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember"
      decimals="-6"
      id="Fxbrl_20250327055352233"
      unitRef="USD">87000000</blrx:UpfrontPayment>
    <blrx:PercentageOfRoyaltiesReceivableFromAggregateNetSales
      contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember"
      decimals="2"
      id="Fxbrl_20250327055429844"
      unitRef="Pure">0.18</blrx:PercentageOfRoyaltiesReceivableFromAggregateNetSales>
    <blrx:PercentageOfRoyaltiesReceivableFromAggregateNetSales
      contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_ifrsfullRangeAxis_ifrsfullTopOfRangeMember"
      decimals="2"
      id="Fxbrl_20250327055449918"
      unitRef="Pure">0.23</blrx:PercentageOfRoyaltiesReceivableFromAggregateNetSales>
    <blrx:GrossProceedsFromOffering
      contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxHighbridgeMember"
      decimals="-5"
      id="Fxbrl_20250327055641307"
      unitRef="USD">9000000</blrx:GrossProceedsFromOffering>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="C_20241101to20241130"
      decimals="-5"
      id="Fxbrl_20250327055729114"
      unitRef="USD">19000000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember"
      decimals="-5"
      id="Fxbrl_20250327055800636"
      unitRef="USD">7800000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxRegisteredDirectOfferingMember"
      decimals="-5"
      id="Fxbrl_20250327055813830"
      unitRef="USD">11200000</ifrs-full:ConsiderationPaidReceived>
    <blrx:CostsIncurrentInOffering
      contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxRegisteredDirectOfferingMember"
      decimals="-5"
      id="Fxbrl_20250327055844464"
      unitRef="USD">100000</blrx:CostsIncurrentInOffering>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="C_20241101to20241130_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember_blrxPerformanceObligationAxis_blrxSingleMaterialPerformanceObligationMember"
      decimals="-5"
      id="Fxbrl_20250327055914455"
      unitRef="USD">7800000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_20241001to20241231_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember"
      decimals="-5"
      id="Fxbrl_20250327055951963"
      unitRef="USD">7800000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:RevenueFromRoyalties
      contextRef="C_20250101to20251231_blrxAgreementTypeAxis_blrxAyrmidLicenseAgreementMember"
      decimals="-5"
      id="Fxbrl_20260317161059174"
      unitRef="USD">1200000</ifrs-full:RevenueFromRoyalties>
    <blrx:AgreementWithHemispherianForDevelopmentOfGlix1Explanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317193423560">
      &lt;div&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 17 &#x2013; AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In September 2025, the Company entered into a collaboration transaction with Hemispherian AS, a Norwegian corporation (&#x201c;Hemispherian&#x201d;), for the development, clinical evaluation and commercialization of GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors. As part of the transaction, (i) the Company and Hemispherian entered into a Collaboration and Shareholders Agreement (the &#x201c;Agreement with Hemispherian&#x201d;), which governs the ownership, governance, funding, administration, and related operational and commercial terms of a new company (Tetragon) established by the Company and Hemispherian, and (ii) Hemispherian and Tetragon entered into an Asset Transfer Agreement (the &#x201c;ATA&#x201d;), pursuant to which Hemispherian transferred to Tetragon certain intellectual property, regulatory filings, know-how, and related assets primarily in respect of GLIX1, Hemispherian&#x2019;s lead compound (the &#x201c;Transferred Assets&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In consideration for the transfer of the Transferred Assets, Hemispherian received 60% of the issued share capital of Tetragon. In consideration for the Company&#x2019;s commitment to invest $5 million in Tetragon (the &#x201c;Threshold Amount&#x201d;) within 36 months as of the date of the Agreement with Hemispherian, the Company received 40% of the issued share capital of Tetragon. Such threshold amount is to be paid in tranches according to a development plan, and the 36-month period may be extended by an additional six months upon the occurrence of certain events as specified in the Agreement with Hemispherian (the &#x201c;Threshold Term&#x201d;). If the Company does not invest the full Threshold Amount by the end of the Threshold Term, Hemispherian will have the right to repurchase, for nominal consideration, a pro rata portion of the Company&#x2019;s shares in Tetragon corresponding to the unfunded portion of the Threshold Amount. As of December 31, 2025, the Company had invested $1.2 million of the Threshold Amount.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Following the investment of the Threshold Amount, the Company may make additional investments in Tetragon. For each incremental $1 million invested by the Company beyond the Threshold Amount, the Company will be entitled to an additional 1% equity interest, up to an aggregate maximum ownership of 70%. Following the attainment of a 50% stake by the Company in Tetragon, Hemispherian will have the right to co-invest alongside the Company on the same terms in order to maintain a 50% ownership stake in Tetragon.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Furthermore, under the terms of the Agreement with Hemispherian, the Company will be responsible for managing and implementing Tetragon&#x2019;s activities and overseeing its operations, budget, and expenses. Following the closing, Tetragon will pay Hemispherian a monthly advisory fee of $80,000 for a period of 24 months or until the termination of the collaboration, whichever occurs first.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Agreement with Hemispherian provides for the establishment of a board of directors of Tetragon as well as a steering committee with joint representation from both the Company and Hemispherian. The Company holds the deciding vote in the event of any deadlock on either of such corporate bodies and, accordingly, is the controlling shareholder of Tetragon. Tetragon has a first-look right, as well as a right of first refusal, on other assets in Hemispherian&#x2019;s pipeline for defined periods specified in the ATA.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The ATA and the Agreement with Hemispherian contain customary representations and warranties, indemnification and other provisions customary for transactions of this nature. The ATA and Agreement with Hemispherian also include termination events, including failure to fund the Threshold Amount within the Threshold Term, or prolonged inability of Tetragon to operate due to insufficient financial resources.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In connection with the ATA and Agreement with Hemispherian, an intangible asset in the amount of $6.0 million was recorded in respect of the GLIX1 molecule at fair value, against a minority interest in the same amount.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    </blrx:AgreementWithHemispherianForDevelopmentOfGlix1Explanatory>
    <blrx:PercentageOfIssuedShareCapitalReceived
      contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"
      decimals="2"
      id="Fxbrl_20260317193503072"
      unitRef="Pure">0.60</blrx:PercentageOfIssuedShareCapitalReceived>
    <ifrs-full:InvestmentProperty
      contextRef="C_20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"
      decimals="-6"
      id="Fxbrl_20260317193508882"
      unitRef="USD">5000000</ifrs-full:InvestmentProperty>
    <blrx:PercentageOfIssuedShareCapitalReceivedWithinMonths
      contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"
      decimals="2"
      id="Fxbrl_20260317193533712"
      unitRef="Pure">0.40</blrx:PercentageOfIssuedShareCapitalReceivedWithinMonths>
    <ifrs-full:InvestmentProperty
      contextRef="C_20251231_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"
      decimals="-5"
      id="Fxbrl_20260317193602468"
      unitRef="USD">1200000</ifrs-full:InvestmentProperty>
    <blrx:IncrementalInvestment
      contextRef="C_20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"
      decimals="-6"
      id="Fxbrl_20260317193635912"
      unitRef="USD">1000000</blrx:IncrementalInvestment>
    <blrx:PercentageOfAdditionalEquityInterest
      contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"
      decimals="2"
      id="Fxbrl_20260317193701920"
      unitRef="Pure">0.01</blrx:PercentageOfAdditionalEquityInterest>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"
      decimals="2"
      id="Fxbrl_20260317193721402"
      unitRef="Pure">0.70</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <blrx:PercentageOfOwnershipStake
      contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"
      decimals="2"
      id="Fxbrl_20260317193732807"
      unitRef="Pure">0.50</blrx:PercentageOfOwnershipStake>
    <blrx:PercentageOfOwnershipStake
      contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"
      decimals="2"
      id="Fxbrl_20260317193747080"
      unitRef="Pure">0.50</blrx:PercentageOfOwnershipStake>
    <blrx:MonthlyAdvisoryFee
      contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"
      decimals="0"
      id="Fxbrl_20260317193756880"
      unitRef="USD">80000</blrx:MonthlyAdvisoryFee>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember"
      decimals="-5"
      id="Fxbrl_20260317193833840"
      unitRef="USD">6000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326173517101">
          &lt;div&gt;
            &lt;div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 18 &#x2013; TRANSACTIONS AND BALANCES WITH RELATED PARTIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-indent:-12.35pt;margin-left:70.85pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Transactions with related parties&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-indent:-12.35pt;margin-left:70.85pt;line-height:1.25;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expenses:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="margin-left:70.9pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="margin-left:63pt"&gt;

                  &lt;div&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-14.6pt;margin-left:14.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Benefits to related parties:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-13.5pt;margin-left:28.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Compensation and benefits to senior management, including benefit component of equity instrument grants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;3,155&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;2,396&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;1,398&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-13.5pt;margin-left:28.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Compensation and benefits to directors, including benefit component of equity instrument grants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;587&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;415&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;473&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;

              &lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="line-height:1.25;font-weight:normal;margin-left:60pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Regarding transactions and balances related to Gloria, see Note 15.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="text-align:justify;line-height:1.25;margin-left:70pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="line-height:1.25;font-weight:bold;margin-left:60pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Key management compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;font-weight:bold;margin-left:70pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="line-height:1.25;font-weight:normal;text-align:justify;margin-left:60pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Key management includes directors and executive officers. The compensation paid or payable to key management for services during each of the years indicated is presented below.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="margin-left:63pt"&gt;

                  &lt;div&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-16.35pt;margin-left:16.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Salaries and other short-term employee benefits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;2,425&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;2,018&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;1,425&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Post-employment benefits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;256&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;394&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;116&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other long-term benefits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;31&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;29&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;32&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;1,030&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;370&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;298&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;3,742&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;2,811&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;1,871&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;

              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326173412246">
                  &lt;div&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-14.6pt;margin-left:14.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Benefits to related parties:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-13.5pt;margin-left:28.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Compensation and benefits to senior management, including benefit component of equity instrument grants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;3,155&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;2,396&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;1,398&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-13.5pt;margin-left:28.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Compensation and benefits to directors, including benefit component of equity instrument grants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;587&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;415&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;473&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                </ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity
      contextRef="C_20230101to20231231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember"
      decimals="-3"
      id="F20211006115503191_2"
      unitRef="USD">3155000</ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity>
    <ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity
      contextRef="C_20240101to20241231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember"
      decimals="-3"
      id="F20211006115503194_3"
      unitRef="USD">2396000</ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity>
    <ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity
      contextRef="C_20250101to20251231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember"
      decimals="-3"
      id="F20211006115503194_4"
      unitRef="USD">1398000</ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity>
    <ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity
      contextRef="C_20230101to20231231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember"
      decimals="-3"
      id="F20211006115503195_8"
      unitRef="USD">587000</ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity>
    <ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity
      contextRef="C_20240101to20241231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember"
      decimals="-3"
      id="F20211006115503195_9"
      unitRef="USD">415000</ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity>
    <ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity
      contextRef="C_20250101to20251231_ifrsfullSeparateManagementEntitiesAxis_blrxDirectorsMember"
      decimals="-3"
      id="F20211006115503196_10"
      unitRef="USD">473000</ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity>
    <ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326173500950">
                  &lt;div&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="text-indent:-16.35pt;margin-left:16.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Salaries and other short-term employee benefits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;2,425&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;2,018&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;1,425&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Post-employment benefits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;256&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;394&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;116&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other long-term benefits&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;31&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;29&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;32&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;1,030&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;370&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;298&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;3,742&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;2,811&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;1,871&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  &lt;/div&gt;
                </ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503197_15"
      unitRef="USD">2425000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503197_16"
      unitRef="USD">2018000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503197_17"
      unitRef="USD">1425000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503197_18"
      unitRef="USD">256000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503197_19"
      unitRef="USD">394000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503197_20"
      unitRef="USD">116000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503198_21"
      unitRef="USD">31000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503198_22"
      unitRef="USD">29000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503198_23"
      unitRef="USD">32000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503198_24"
      unitRef="USD">1030000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503198_25"
      unitRef="USD">370000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503199_26"
      unitRef="USD">298000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503199_27"
      unitRef="USD">3742000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503199_28"
      unitRef="USD">2811000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503199_29"
      unitRef="USD">1871000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250327040723759">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 19 &#x2013; SEGMENT REPORTING&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company operates in a &lt;span style="-sec-ix-hidden:Fxbrl_20250327041154148"&gt;single&lt;/span&gt; reportable operating segment &#x2013; the development and commercialization of therapeutics. Its corporate headquarters and development activities are in Israel, while its revenues stem from activities carried out in the U.S. and Asia (primarily Greater China). In this regard, product sales relate to the Company&#x2019;s direct commercialization activities in the U.S. from October 2023 through November 2024, while license revenues relate to outlicensing agreements entered into in Asia and in the U.S. in October 2023 and November 2024, respectively. Set forth below is a breakdown of revenues from external parties by geographic region.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:54pt"&gt;

              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;China&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;4,610&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;14,957&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;U.S.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;190&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;13,983&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;1,180&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;4,800&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;28,940&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;1,180&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;

          &lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:55.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Substantially all of the Company&#x2019;s non-current assets are located in Israel. See Notes 15 and 16 for information on customers representing 10% or more of total revenues.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <ifrs-full:DisclosureOfGeographicalAreasExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317170227955">
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;China&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;4,610&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;14,957&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;-&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;U.S.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;190&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;13,983&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;1,180&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;4,800&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;28,940&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;1,180&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            </ifrs-full:DisclosureOfGeographicalAreasExplanatory>
    <ifrs-full:Revenue
      contextRef="C_20230101to20231231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember"
      decimals="-3"
      id="Fxbrl_20250327040836299_33"
      unitRef="USD">4610000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_20240101to20241231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember"
      decimals="-3"
      id="Fxbrl_20250327040836299_37"
      unitRef="USD">14957000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_20250101to20251231_ifrsfullGeographicalAreasAxis_ifrsfullForeignCountriesMember"
      decimals="-3"
      id="Fxbrl_20250327040836299_311"
      unitRef="USD">0</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_20230101to20231231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember"
      decimals="-3"
      id="Fxbrl_20250327040836299_43"
      unitRef="USD">190000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_20240101to20241231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember"
      decimals="-3"
      id="Fxbrl_20250327040836299_47"
      unitRef="USD">13983000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_20250101to20251231_ifrsfullGeographicalAreasAxis_ifrsfullCountryOfDomicileMember"
      decimals="-3"
      id="Fxbrl_20250327040836299_411"
      unitRef="USD">1180000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250327040836299_53"
      unitRef="USD">4800000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250327040836299_57"
      unitRef="USD">28940000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20250327040836299_511"
      unitRef="USD">1180000</ifrs-full:Revenue>
    <blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20240324122047540">
    &lt;div&gt;
      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;NOTE 20 &#x2013; SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div&gt;&#160;&lt;/div&gt;

        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;Government institutions&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;455&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Advance payments&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;91&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;-&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;932&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;377&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;410&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accounts payable and accruals&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div&gt;&#160;&lt;/div&gt;

        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Accounts payable:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:28.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160; Overseas&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4,250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,814&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:28.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160; In Israel&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,333&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;679&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5,583&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,493&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Payroll and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,993&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;523&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;707&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;372&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:0pt;margin-left:23.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160; Accrual for vacation and recreation pay&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;310&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Other&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;538&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,131&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,743&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div style="margin-left:70.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The carrying amounts of accounts payable and accruals approximate their fair value, as the effect of discounting is not material.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost of revenues&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;License fees and royalties payable to licensor&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Direct costs related to license revenues&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of intangible asset&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost of product sales&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,692&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;div style="text-indent:-21.25pt;margin-left:70.85pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div&gt;&#160;&lt;/div&gt;

        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development services&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,603&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Payroll and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,524&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,982&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lab, occupancy and telephone&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;855&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,093&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sales and marketing expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Payroll and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Medical Affairs&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,824&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,891&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketing&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Travel&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Office-related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,923&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Business Analytics&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,005&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Market Access&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;751&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss on abandonment of right-of-use asset&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;25,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Payroll and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Insurance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;939&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;808&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;603&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;780&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Depreciation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Provision for doubtful accounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;409&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;324&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;g.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-operating income (expenses), net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in fair value of warrants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(11,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;18,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,599&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issuance costs&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(702&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(10,819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;18,435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,077&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;h.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,007&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange differences, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
      &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

          &lt;tr&gt;
            &lt;td style="width:43.9pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="width:24pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;i.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width:auto;vertical-align:top"&gt;
              &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,074&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Bank commissions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

    &lt;/div&gt;
  </blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory>
    <blrx:DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326205132294">
        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;Government institutions&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;455&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Advance payments&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;91&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;-&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;932&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;377&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;410&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory>
    <blrx:InstitutionsCurrentReceivables
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115503214_4"
      unitRef="USD">455000</blrx:InstitutionsCurrentReceivables>
    <blrx:InstitutionsCurrentReceivables
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115503214_5"
      unitRef="USD">33000</blrx:InstitutionsCurrentReceivables>
    <blrx:AdvancePayments
      contextRef="C_20241231"
      decimals="-3"
      id="Fxbrl_20260319170221167_20211006115503214_4"
      unitRef="USD">91000</blrx:AdvancePayments>
    <blrx:AdvancePayments
      contextRef="C_20251231"
      decimals="-3"
      id="Fxbrl_20260319170221167_20211006115503214_5"
      unitRef="USD">0</blrx:AdvancePayments>
    <blrx:Others
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115503215_6"
      unitRef="USD">932000</blrx:Others>
    <blrx:Others
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115503216_7"
      unitRef="USD">377000</blrx:Others>
    <ifrs-full:OtherCurrentReceivables
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115503216_8"
      unitRef="USD">1478000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115503217_9"
      unitRef="USD">410000</ifrs-full:OtherCurrentReceivables>
    <blrx:DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326205152300">
        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Accounts payable:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:28.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160; Overseas&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4,250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,814&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:28.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160; In Israel&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,333&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;679&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5,583&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,493&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Payroll and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,993&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;523&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;707&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;372&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:0pt;margin-left:23.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160; Accrual for vacation and recreation pay&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;310&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Other&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;538&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,131&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,743&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory>
    <blrx:TradeAndOtherPayablesToForeignTradeSuppliers
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115503217_10"
      unitRef="USD">4250000</blrx:TradeAndOtherPayablesToForeignTradeSuppliers>
    <blrx:TradeAndOtherPayablesToForeignTradeSuppliers
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115503218_11"
      unitRef="USD">2814000</blrx:TradeAndOtherPayablesToForeignTradeSuppliers>
    <blrx:TradeAndOtherPayablesToLocalTradeSuppliers
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115503218_12"
      unitRef="USD">1333000</blrx:TradeAndOtherPayablesToLocalTradeSuppliers>
    <blrx:TradeAndOtherPayablesToLocalTradeSuppliers
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115503219_13"
      unitRef="USD">679000</blrx:TradeAndOtherPayablesToLocalTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115503223_14"
      unitRef="USD">5583000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115503223_15"
      unitRef="USD">3493000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <blrx:PayrollAndRelatedExpenses
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115503224_16"
      unitRef="USD">1993000</blrx:PayrollAndRelatedExpenses>
    <blrx:PayrollAndRelatedExpenses
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115503225_17"
      unitRef="USD">523000</blrx:PayrollAndRelatedExpenses>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115503225_18"
      unitRef="USD">707000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115503226_19"
      unitRef="USD">372000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115503226_20"
      unitRef="USD">431000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115503227_21"
      unitRef="USD">310000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:OtherPayables
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115503227_22"
      unitRef="USD">0</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115503228_23"
      unitRef="USD">538000</ifrs-full:OtherPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="C_20241231"
      decimals="-3"
      id="F20211006115503228_24"
      unitRef="USD">3131000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="C_20251231"
      decimals="-3"
      id="F20211006115503229_25"
      unitRef="USD">1743000</ifrs-full:OtherCurrentPayables>
    <blrx:DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326205236196">
        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;License fees and royalties payable to licensor&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Direct costs related to license revenues&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of intangible asset&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost of product sales&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,692&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfDetailedInformationAboutCostOfRevenuesExplanatory>
    <blrx:LicenseFeesAndRoyaltiesPayableToLicensor
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250326213035798"
      unitRef="USD">3027000</blrx:LicenseFeesAndRoyaltiesPayableToLicensor>
    <blrx:LicenseFeesAndRoyaltiesPayableToLicensor
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250326213052598"
      unitRef="USD">3024000</blrx:LicenseFeesAndRoyaltiesPayableToLicensor>
    <blrx:LicenseFeesAndRoyaltiesPayableToLicensor
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20250326213103518"
      unitRef="USD">230000</blrx:LicenseFeesAndRoyaltiesPayableToLicensor>
    <blrx:CostRelatedToLicenseRevenues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240324142706720_xbrl_20220304172035907_20211006115503242_44"
      unitRef="USD">203000</blrx:CostRelatedToLicenseRevenues>
    <blrx:CostRelatedToLicenseRevenues
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240324142706720_xbrl_20220304172035907_20211006115503242_45"
      unitRef="USD">2605000</blrx:CostRelatedToLicenseRevenues>
    <blrx:CostRelatedToLicenseRevenues
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324142706720_xbrl_20220304172035907_20211006115503243_46"
      unitRef="USD">0</blrx:CostRelatedToLicenseRevenues>
    <ifrs-full:AmortisationExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20260317202838350"
      unitRef="USD">450000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240324142859214_xbrl_20240324142702400_xbrl_20220304172035907_20211006115503242_45"
      unitRef="USD">3323000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324142859214_xbrl_20240324142702400_xbrl_20220304172035907_20211006115503243_46"
      unitRef="USD">0</ifrs-full:AmortisationExpense>
    <blrx:CostOfProductSales
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240324142700553_xbrl_20220304172035907_20211006115503242_44"
      unitRef="USD">12000</blrx:CostOfProductSales>
    <blrx:CostOfProductSales
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240324142700553_xbrl_20220304172035907_20211006115503242_45"
      unitRef="USD">311000</blrx:CostOfProductSales>
    <blrx:CostOfProductSales
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324142700553_xbrl_20220304172035907_20211006115503243_46"
      unitRef="USD">0</blrx:CostOfProductSales>
    <ifrs-full:CostOfSales
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240324142658592_xbrl_20220304172035907_20211006115503242_44"
      unitRef="USD">3692000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240324142658592_xbrl_20220304172035907_20211006115503242_45"
      unitRef="USD">9263000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324142658592_xbrl_20220304172035907_20211006115503243_46"
      unitRef="USD">230000</ifrs-full:CostOfSales>
    <blrx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326205320884">
        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development services&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,603&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Payroll and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,524&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,982&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lab, occupancy and telephone&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;855&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,093&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory>
    <ifrs-full:ServicesExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172035875_20211006115503229_26"
      unitRef="USD">4603000</ifrs-full:ServicesExpense>
    <ifrs-full:ServicesExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172035875_20211006115503230_27"
      unitRef="USD">3170000</ifrs-full:ServicesExpense>
    <ifrs-full:ServicesExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172035875_20211006115503231_28"
      unitRef="USD">3118000</ifrs-full:ServicesExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172035879_20211006115503231_29"
      unitRef="USD">4452000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172035879_20211006115503232_30"
      unitRef="USD">3524000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172035879_20211006115503232_31"
      unitRef="USD">2982000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:CommunicationExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172035890_20211006115503233_32"
      unitRef="USD">969000</ifrs-full:CommunicationExpense>
    <ifrs-full:CommunicationExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172035890_20211006115503233_33"
      unitRef="USD">1102000</ifrs-full:CommunicationExpense>
    <ifrs-full:CommunicationExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172035890_20211006115503234_34"
      unitRef="USD">855000</ifrs-full:CommunicationExpense>
    <blrx:ProfessionalFee
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172035894_20211006115503234_35"
      unitRef="USD">935000</blrx:ProfessionalFee>
    <blrx:ProfessionalFee
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172035894_20211006115503235_36"
      unitRef="USD">273000</blrx:ProfessionalFee>
    <blrx:ProfessionalFee
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172035894_20211006115503238_37"
      unitRef="USD">390000</blrx:ProfessionalFee>
    <blrx:ShareBasedCompensationRelatedToResearchAndDevelopment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240326125243135_xbrl_20220304172035894_20211006115503234_35"
      unitRef="USD">760000</blrx:ShareBasedCompensationRelatedToResearchAndDevelopment>
    <blrx:ShareBasedCompensationRelatedToResearchAndDevelopment
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240326125243135_xbrl_20220304172035894_20211006115503235_36"
      unitRef="USD">451000</blrx:ShareBasedCompensationRelatedToResearchAndDevelopment>
    <blrx:ShareBasedCompensationRelatedToResearchAndDevelopment
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240326125243135_xbrl_20220304172035894_20211006115503238_37"
      unitRef="USD">104000</blrx:ShareBasedCompensationRelatedToResearchAndDevelopment>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172035899_20211006115503239_38"
      unitRef="USD">583000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172035899_20211006115503239_39"
      unitRef="USD">431000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172035899_20211006115503240_40"
      unitRef="USD">495000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:OtherExpenseByNature
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172035903_20211006115503240_41"
      unitRef="USD">217000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172035903_20211006115503241_42"
      unitRef="USD">198000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172035903_20211006115503241_43"
      unitRef="USD">149000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172035907_20211006115503242_44"
      unitRef="USD">12519000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172035907_20211006115503242_45"
      unitRef="USD">9149000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172035907_20211006115503243_46"
      unitRef="USD">8093000</ifrs-full:ResearchAndDevelopmentExpense>
    <blrx:DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260317172622660">
        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Payroll and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Medical Affairs&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,824&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,891&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketing&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Travel&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Office-related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,923&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Business Analytics&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,005&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Market Access&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;751&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Depreciation and amortization&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss on abandonment of right-of-use asset&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-13.7pt;margin-left:13.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;25,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfDetailedInformationAboutSalesAndMarketingExpensesExplanatory>
    <blrx:SalesAndMarketingExpensesRelatedToSales
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240324122600862_20211006115503243_47"
      unitRef="USD">8868000</blrx:SalesAndMarketingExpensesRelatedToSales>
    <blrx:SalesAndMarketingExpensesRelatedToSales
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240324122600862_20211006115503244_48"
      unitRef="USD">12224000</blrx:SalesAndMarketingExpensesRelatedToSales>
    <blrx:SalesAndMarketingExpensesRelatedToSales
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324122600862_20211006115503245_49"
      unitRef="USD">0</blrx:SalesAndMarketingExpensesRelatedToSales>
    <blrx:MedicalAffairs
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240324122557657_20211006115503243_47"
      unitRef="USD">4824000</blrx:MedicalAffairs>
    <blrx:MedicalAffairs
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240324122557657_20211006115503244_48"
      unitRef="USD">2891000</blrx:MedicalAffairs>
    <blrx:MedicalAffairs
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324122557657_20211006115503245_49"
      unitRef="USD">0</blrx:MedicalAffairs>
    <blrx:MarketingExpenses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503243_47"
      unitRef="USD">4091000</blrx:MarketingExpenses>
    <blrx:MarketingExpenses
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503244_48"
      unitRef="USD">2041000</blrx:MarketingExpenses>
    <blrx:MarketingExpenses
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503245_49"
      unitRef="USD">0</blrx:MarketingExpenses>
    <ifrs-full:TravelExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503247_53"
      unitRef="USD">986000</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503247_54"
      unitRef="USD">1506000</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503248_55"
      unitRef="USD">0</ifrs-full:TravelExpense>
    <blrx:SalesAndMarketingPayrollExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240324122605063_20211006115503243_47"
      unitRef="USD">1923000</blrx:SalesAndMarketingPayrollExpense>
    <blrx:SalesAndMarketingPayrollExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240324122605063_20211006115503244_48"
      unitRef="USD">1477000</blrx:SalesAndMarketingPayrollExpense>
    <blrx:SalesAndMarketingPayrollExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324122605063_20211006115503245_49"
      unitRef="USD">0</blrx:SalesAndMarketingPayrollExpense>
    <blrx:BusinessAnalyticsExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240326130835955"
      unitRef="USD">1005000</blrx:BusinessAnalyticsExpense>
    <blrx:BusinessAnalyticsExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240326130857435"
      unitRef="USD">1264000</blrx:BusinessAnalyticsExpense>
    <blrx:BusinessAnalyticsExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240326130914203"
      unitRef="USD">0</blrx:BusinessAnalyticsExpense>
    <blrx:MarketAccessExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240326130818740"
      unitRef="USD">1606000</blrx:MarketAccessExpense>
    <blrx:MarketAccessExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240326130848771"
      unitRef="USD">701000</blrx:MarketAccessExpense>
    <blrx:MarketAccessExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240326130904171"
      unitRef="USD">0</blrx:MarketAccessExpense>
    <blrx:SalesAndMarketingProfessionalFees
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240324122611470_20211006115503243_47"
      unitRef="USD">745000</blrx:SalesAndMarketingProfessionalFees>
    <blrx:SalesAndMarketingProfessionalFees
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240324122611470_20211006115503244_48"
      unitRef="USD">627000</blrx:SalesAndMarketingProfessionalFees>
    <blrx:SalesAndMarketingProfessionalFees
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324122611470_20211006115503245_49"
      unitRef="USD">0</blrx:SalesAndMarketingProfessionalFees>
    <blrx:SalesAndMarketingShareBasedCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240324122607991_20211006115503243_47"
      unitRef="USD">751000</blrx:SalesAndMarketingShareBasedCompensation>
    <blrx:SalesAndMarketingShareBasedCompensation
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240324122607991_20211006115503244_48"
      unitRef="USD">98000</blrx:SalesAndMarketingShareBasedCompensation>
    <blrx:SalesAndMarketingShareBasedCompensation
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324122607991_20211006115503245_49"
      unitRef="USD">0</blrx:SalesAndMarketingShareBasedCompensation>
    <blrx:SalesAndMarketingDepreciationAndAmortization
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240324122613792_20211006115503243_47"
      unitRef="USD">314000</blrx:SalesAndMarketingDepreciationAndAmortization>
    <blrx:SalesAndMarketingDepreciationAndAmortization
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240324122613792_20211006115503244_48"
      unitRef="USD">330000</blrx:SalesAndMarketingDepreciationAndAmortization>
    <blrx:SalesAndMarketingDepreciationAndAmortization
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324122613792_20211006115503245_49"
      unitRef="USD">0</blrx:SalesAndMarketingDepreciationAndAmortization>
    <blrx:LossOnAbandonmentOfRightofuseAsset
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250326213653806"
      unitRef="USD">0</blrx:LossOnAbandonmentOfRightofuseAsset>
    <blrx:LossOnAbandonmentOfRightofuseAsset
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250326213702631"
      unitRef="USD">246000</blrx:LossOnAbandonmentOfRightofuseAsset>
    <blrx:LossOnAbandonmentOfRightofuseAsset
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20250326213724679"
      unitRef="USD">0</blrx:LossOnAbandonmentOfRightofuseAsset>
    <blrx:SalesAndMarketingExpensesOther
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240324122616608_20211006115503243_47"
      unitRef="USD">157000</blrx:SalesAndMarketingExpensesOther>
    <blrx:SalesAndMarketingExpensesOther
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20240324122616608_20211006115503244_48"
      unitRef="USD">200000</blrx:SalesAndMarketingExpensesOther>
    <blrx:SalesAndMarketingExpensesOther
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20240324122616608_20211006115503245_49"
      unitRef="USD">0</blrx:SalesAndMarketingExpensesOther>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503248_56"
      unitRef="USD">25270000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503249_57"
      unitRef="USD">23605000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503249_58"
      unitRef="USD">0</ifrs-full:SalesAndMarketingExpense>
    <blrx:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326205430333">
        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Payroll and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Professional fees&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Insurance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;939&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;808&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;603&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;780&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Depreciation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Provision for doubtful accounts receivable&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;409&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;324&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatory>
    <ifrs-full:WagesAndSalaries
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172054808_20211006115503250_59"
      unitRef="USD">2117000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172054808_20211006115503252_60"
      unitRef="USD">2000000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172054808_20211006115503253_61"
      unitRef="USD">1407000</ifrs-full:WagesAndSalaries>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172054813_20211006115503254_62"
      unitRef="USD">2028000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172054813_20211006115503254_63"
      unitRef="USD">1991000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172054813_20211006115503255_64"
      unitRef="USD">1290000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:InsuranceExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172054815_20211006115503255_65"
      unitRef="USD">939000</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172054815_20211006115503256_66"
      unitRef="USD">808000</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172054815_20211006115503256_67"
      unitRef="USD">603000</ifrs-full:InsuranceExpense>
    <blrx:ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172054810_xbrl_20220304164546030_20211006115503254_62"
      unitRef="USD">780000</blrx:ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses>
    <blrx:ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172054810_xbrl_20220304164546030_20211006115503254_63"
      unitRef="USD">585000</blrx:ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses>
    <blrx:ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172054810_xbrl_20220304164546030_20211006115503255_64"
      unitRef="USD">292000</blrx:ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses>
    <ifrs-full:DepreciationExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172054818_20211006115503257_68"
      unitRef="USD">37000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172054818_20211006115503257_69"
      unitRef="USD">10000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172054818_20211006115503258_70"
      unitRef="USD">28000</ifrs-full:DepreciationExpense>
    <blrx:ProvisionForDoubtfulAccountsReceivable
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20250326221617246"
      unitRef="USD">0</blrx:ProvisionForDoubtfulAccountsReceivable>
    <blrx:ProvisionForDoubtfulAccountsReceivable
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20250326221623649"
      unitRef="USD">-800000</blrx:ProvisionForDoubtfulAccountsReceivable>
    <blrx:ProvisionForDoubtfulAccountsReceivable
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20250326221807521"
      unitRef="USD">800000</blrx:ProvisionForDoubtfulAccountsReceivable>
    <ifrs-full:OtherExpenseByFunction
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172054822_20211006115503258_71"
      unitRef="USD">409000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172054822_20211006115503259_72"
      unitRef="USD">127000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172054822_20211006115503259_73"
      unitRef="USD">324000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304172054824_20211006115503260_74"
      unitRef="USD">6310000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304172054824_20211006115503260_75"
      unitRef="USD">6321000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20220304172054824_20211006115503261_76"
      unitRef="USD">3144000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <blrx:DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326205450620">
        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in fair value of warrants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(11,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;18,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,599&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issuance costs&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(702&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(10,819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;18,435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,077&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfDetailedInformationAboutNonoperatingIncomeExpensesNetExplanatory>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230314130955334"
      unitRef="USD">-11054000</ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304165334042"
      unitRef="USD">18965000</ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503264_82"
      unitRef="USD">8599000</ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503261_77"
      unitRef="USD">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503262_78"
      unitRef="USD">669000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230314112239673"
      unitRef="USD">702000</ifrs-full:ShareIssueRelatedCost>
    <blrx:OtherNonoperatingIncomeExpenses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20220304165312882"
      unitRef="USD">235000</blrx:OtherNonoperatingIncomeExpenses>
    <blrx:OtherNonoperatingIncomeExpenses
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503269_87"
      unitRef="USD">139000</blrx:OtherNonoperatingIncomeExpenses>
    <blrx:OtherNonoperatingIncomeExpenses
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503269_88"
      unitRef="USD">180000</blrx:OtherNonoperatingIncomeExpenses>
    <blrx:ProfitLossFromNonOperatingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230314130616343"
      unitRef="USD">-10819000</blrx:ProfitLossFromNonOperatingActivities>
    <blrx:ProfitLossFromNonOperatingActivities
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20220304165326367"
      unitRef="USD">18435000</blrx:ProfitLossFromNonOperatingActivities>
    <blrx:ProfitLossFromNonOperatingActivities
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503271_91"
      unitRef="USD">8077000</blrx:ProfitLossFromNonOperatingActivities>
    <blrx:DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326205511453">
        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,007&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange differences, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfDetailedInformationAboutFinancialIncomeExplanatory>
    <ifrs-full:RevenueFromInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230314105745668_20211006115503273_95"
      unitRef="USD">2007000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230314105745668_20211006115503273_96"
      unitRef="USD">1820000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230314105745668_20211006115503274_97"
      unitRef="USD">1124000</ifrs-full:RevenueFromInterest>
    <ifrs-full:NetForeignExchangeGain
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230314105743628_20211006115503273_95"
      unitRef="USD">61000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230314105743628_20211006115503273_96"
      unitRef="USD">51000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230314105743628_20211006115503274_97"
      unitRef="USD">340000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:FinanceIncome
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503273_95"
      unitRef="USD">2068000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503273_96"
      unitRef="USD">1871000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503274_97"
      unitRef="USD">1464000</ifrs-full:FinanceIncome>
    <blrx:DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory
      contextRef="C_20250101to20251231"
      id="Fxbrl_20250326205529363">
        &lt;div style="margin-left:72pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;in USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest expense&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,074&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                  &lt;div style="text-indent:-18.2pt;margin-left:18.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Bank commissions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </blrx:DisclosureOfDetailedInformationAboutFinancialExpensesExplanatory>
    <ifrs-full:InterestExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230314105810997_20211006115503281_107"
      unitRef="USD">2144000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="Fxbrl_20230314105810997_20211006115503281_108"
      unitRef="USD">9074000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="Fxbrl_20230314105810997_20211006115503282_109"
      unitRef="USD">1251000</ifrs-full:InterestExpense>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503277_104"
      unitRef="USD">25000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503278_105"
      unitRef="USD">45000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503280_106"
      unitRef="USD">29000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FinanceCosts
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20211006115503281_107"
      unitRef="USD">2169000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_20240101to20241231"
      decimals="-3"
      id="F20211006115503281_108"
      unitRef="USD">9119000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_20250101to20251231"
      decimals="-3"
      id="F20211006115503282_109"
      unitRef="USD">1280000</ifrs-full:FinanceCosts>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
